<SEC-DOCUMENT>0001538210-23-000007.txt : 20230328
<SEC-HEADER>0001538210-23-000007.hdr.sgml : 20230328
<ACCEPTANCE-DATETIME>20230328161316
ACCESSION NUMBER:		0001538210-23-000007
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230328
DATE AS OF CHANGE:		20230328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NexImmune, Inc.
		CENTRAL INDEX KEY:			0001538210
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40045
		FILM NUMBER:		23769720

	BUSINESS ADDRESS:	
		STREET 1:		9119 GAITHER ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		301-825-9810

	MAIL ADDRESS:	
		STREET 1:		9119 GAITHER ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nexi-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:1d01bc3b-109a-450d-9ee6-f84eb8561d2c,g:e7038408-d172-479b-b01e-e62e0cc0d235,d:5091247d182148eaaadd80685b94df97--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:nexi="http://nex.com/20221231" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nexi-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="f-32">2022</ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="f-33">FY</ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-34">false</ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityCentralIndexKey" id="f-35">0001538210</ix:nonNumeric><ix:nonNumeric contextRef="i81a07e7e0c0f4c6086be99b99cd79cdc_D20200101-20201231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="f-147">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i8cde262665d140a4aa955aed31f5920a_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-546">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nexi-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i373e3231b3f840a68e2e1b764ca2c76a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ife75d305cc1f4ff48462a16aa940d5bb_I20230301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia325791ead244863998b1f8f312ad14c_I20210211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea9cb688d3fe4d64b5fd77adc7e14243_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37d7504e32234f1795742c55cbc6b155_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff21ea6215e44aaf8825b8629943e25d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesATwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied4b640b66f4431e8a9ab05b2c296a7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesAThreeRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5ee39eb5c7c429d8d549dd5e1664fe4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7c755cb14bd427e8793ab33dac3fd7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie510bed0d8e14fc599909e739c5e7d89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dca16917b304e32b75b202c42131f15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida3374a79ddc4d3cb5ad2f1dc1e8a42a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81a07e7e0c0f4c6086be99b99cd79cdc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b987d568d844b0b874f7c2bca5b1c71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02d7650fa3c34b7c9124b8138bfa5e7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i323e4338ce04403fb958b956a6ebd5c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f8c709c7614cd892e0ff95fd765294_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c885db91fa648a29884e7d59755d5ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesATwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i362e074aa71542d3be5f2ac89ce168f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesAThreeRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcf18312a9b849779921e6320f8c96e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d72f5c306cd45b3a45cc5043d61410b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i245c6670d41d42a9b3fa719e42f16d0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbbf1a64b75d4fce82cd179c3bd44da8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesATwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b3409c2a62435692c6df71b1354eaa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesAThreeRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i736ffb84dab44fb0b3e163c0502409b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52a135ff906f46e9bab66d63a940f8e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia891e7526d504d8fadb55664f61f3e46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0445e2ff34a46f185f60587d785bf3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79d26598eacc4a57ba2e44555e59db4b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82f02bb4e976485b911d7b3e40c78b45_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i087599b8fe8e4804833ffb19d54c95d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc09a4b59e0b4de088c1ee9a6f9b937b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23dd0eac814249f3a9f87f2d470e24a0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2f44e04246d4f92ae9eaa55d8242626_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nexi:segment</xbrli:measure></xbrli:unit><xbrli:context id="i87575f3a4a8d47e0b099f6f2d5697f3c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ae3ce8c146e4b3a8647cdb069d847f0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14beae652b44f86850981cbd7bea2fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9cf8573a7849487689779272da2d03b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ec5ac6a0fb4bc1994df10d0b09682c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb99aa2cda304c0e9bea4f6fc09c71fa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i174925bbb76f4a498cf99885a1362415_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5ab7a1dbd54ea8861c3ef82c751c0b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i791c94e47b51427dbee42f8cc8773959_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a0838ebfff413db2e9ad8c231fef39_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4f8973765ad4bc8be9332ad3594c082_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i074eae8be4554fceb16fac6998ae3c9a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ba9051f6c594a37b6e8e5e56c95af66_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieca80fa7685c4607ad5fef70aa7ce16e_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i403fdc2b033c4c1b88c48004e7a37ed6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b550a9ae7a2446e8c50991ec5a09571_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic044d50d4b384932ab18201e6f0b8da8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie253db02491d4a9fb3f8cad4afeb89c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a167d620d684558850204ae675e061c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02e707e70eb144e8a9764dbe72b5e376_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9482c390e2874f69bdd95e842f27cb9a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294000fb786942f083924e218896237f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia62f066291d846ab9d346921a55d6947_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25ad398f6533421f95d670a14ced26ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4421505cb3f46938fada27cf31ab63a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i403ec125cb5f41cb813253079b7b88b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2e473ef2ced4a76af90569c4e60acd9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebce9dddcdbc4c0aa95432c1635a3c49_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1965187e11b4cd7be206e7c49075e52_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24e448c466c94c3bbfea9fb4d64de651_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ffac7d5bf164513a7108afdd83a49dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c5920ce6d144e6ca4a4780bbb323bfb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4ed377902824f8ba0190be0190253f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i906f22664a64466f86557348630d1046_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d5098de97364db3825058bb650872b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaa2d70a7c5a44e0b33c4306131e12a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec4224fbcf36436d982945a277e0bbaf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16f5c36a4c3e45f1bbeaada8cda374f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a0b0ffb5bd4c57ab7546cae1b3e6f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53fe34a4932b4e8087a347be3b55c58e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c590145da4b44288c802fc50a344e72_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>nexi:employee</xbrli:measure></xbrli:unit><xbrli:context id="ie321f805cc7f4133a42ae2ffef7ab78f_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie19a45c8600b4fbba9f92e595547ba14_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe540e5b2e574273bb15fd4fe0b096b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97ccdc3f285040bd876d4fa408564bf9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbc1c26d23f6405c928044ee7980345e_I20120523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:MarylandBiotechnologyCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:TranslationalResearchAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dc71e39107c4d2e888729d888bb4e8b_D20130523-20130523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2013-05-23</xbrli:startDate><xbrli:endDate>2013-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69c37fb252ac488eb687ac1d9ffa59fe_I20130523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:MarylandBiotechnologyCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:TranslationalResearchAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5deb40f57714a11a917ea127c6f7c9f_D20130523-20130523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:MarylandBiotechnologyCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:TranslationalResearchAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-05-23</xbrli:startDate><xbrli:endDate>2013-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64dedfdb14784525a0d5de1ec201e691_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:MarylandBiotechnologyCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:TranslationalResearchAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3294ba19efb4f899898ab09f55e6853_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:MarylandBiotechnologyCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:TranslationalResearchAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6719abe720c5406d8c6c8df3e56df15a_D20170101-20170101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nexi:MilestonesAxis">nexi:ClinicalTrialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id205558188da4f4faaf0ec195c63003f_D20170101-20170101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nexi:MilestonesAxis">nexi:TherapeuticFieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c23fd7809674603b59c0f27fb6a073b_D20170101-20170101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nexi:MilestonesAxis">nexi:RegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6fc5f4226364570a5d62f606626c0ab_D20170101-20170101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nexi:MilestonesAxis">nexi:NonclinicalFieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i432594ce07a346698a0597e5adf392f0_D20170101-20170101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2735225fb3054df286cd15e9d84e3203_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3562b2fa26c44aba06d2f7770d6feb4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0e4cc0109264b539acd8b2cbc12a65b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd3d3cf5f9f6420abe32fd8826ce546d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i073d07654a3240e784df7ae6097d2764_I20200423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nexi:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e206dd327124b4b8af59ef1f3ab5579_I20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64dc0ef29e704fa49df23a5b74b93453_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nexi:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2aff3fdd4ae40b29ed8bab59335a89b_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb6c8b0ddc244a308e9bd3ecbb524199_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i225885d205f04fb9b33ee53d4cfb8f44_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff48a09a554472b8be106abefa1d461_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i873c597d2cf845d493f5de5873c03e05_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf7c9ea8fe8d4438993e95ae15b3887d_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8342e5909c548198f1f8f812c6ccc2a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54b8bf4223dd408ba5dfb81b3157f859_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869076cb5c1441619748ef3b03caf454_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74ebc54878b1455ba9248d3203abce2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibee929c3ceb949d69a3628128e96a111_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i370d6d24e959405ba7d21d7a1ef23d52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic87f7845ea6d43edb990474d68bfd9b9_D20210211-20210211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if353ba0711344094942f5e91286b8497_D20210211-20210211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26259b22e3b94e8c8e38c181c55cf7e8_I20210211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ab94587a7134bc29507a4735e3b4bb5_D20210211-20210211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f4fa39048644fd7896c3a33c09994df_I20210211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77a57977aaa446e78a28a3a70e9a899c_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c929ab7b9c4820bc56af8cd2f474ab_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5835f11998cf40f68d148e445724cb8b_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id09449ea526a48e0b9e20fb9696883ab_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nexi:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81c0f51abc5407c9f1bea1bc4bfb1a9_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nexi:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i606c2339afea414788b70bdaefc16503_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nexi:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9d3dab50aea4a7f8d84d00874e49e4e_I20170301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nexi:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i275a48529a1a4c3885fad3563305e566_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30203c7ac84149eda4226a53b00d5520_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nexi:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ab04e02de714324a031d507a830df05_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9d66ae0c7a46f68c98ad662da4fd70_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nexi:The2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4928ff38b944471a2f040e95d09d31b_I20230301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cde262665d140a4aa955aed31f5920a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief18b08960f540d7b60fdafa452c819e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e219dda5744914b465aec9d485e6e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b3cec944184d4f8af71eef16bd69a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b304823751d4c239cbf3f21b62ab9a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea423a341804ae2b054938793d90352_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa6115f303b4a3fbf9b708fedfe989b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda403dc84674bf3b38163cc09604d2e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05746f41db1943c1bec2cd0749ac1f49_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c755e4c19e14dd3b1b1970081b2809e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c1c88b03e284ba5a4f2d5abe7153e3f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff7fdf8fd69c490e8f4f46d8e7a75f7c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3333ea4033604cef87ae7f2a775a3bca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b6232ae6cb64482b9ec1943b0fe3126_I20230322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2d06934bf864579a4979bf7aa1310c1_I20230322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nexi:EmployeesExcludingExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c4097a670b849ad990fb5d2224c365b_I20230322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JeromeZeldisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d28adc4141b4bbfb5dd66693b958745_I20230322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id386af48387549ec98b66a7ea05efd78_I20230322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ea14e11723c4f1f804456e484f29855_I20230322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0692d5e0603d41138cf06daaf012d2ef_I20230322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3e2d6cfd7a944f3927adf427e2f02ea_I20230322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001538210</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JeromeZeldisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5091247d182148eaaadd80685b94df97_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number&#160;<ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityFileNumber" id="f-6">001-40045</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityRegistrantName" id="f-7">NEXIMMUNE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="f-9">45-2518457</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="f-10">9119 Gaither Road</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="f-11">Gaithersburg</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="f-12">MD</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="f-13">20877</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:CityAreaCode" id="f-14">301</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:LocalPhoneNumber" id="f-15">825-9810</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160; registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:Security12bTitle" id="f-16">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:TradingSymbol" id="f-17">NEXI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> &#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation&#160;S-T&#160;(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> &#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;No &#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a&#160;non-accelerated&#160;filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">o</span></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">x</ix:nonNumeric></span></td></tr><tr style="height:1pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-26">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.   </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).   </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2&#160;of the Exchange Act). Yes &#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the common stock held by&#160;non-affiliates&#160;of the registrant, based on the closing price of a share of common stock on June 30, 2022, as reported by The Nasdaq Global Market on such date was approximately $<ix:nonFraction unitRef="usd" contextRef="i373e3231b3f840a68e2e1b764ca2c76a_I20220630" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="f-29">28.7</ix:nonFraction> million.  This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of Registrant&#8217;s Common Stock outstanding as of March 1, 2023 was <ix:nonFraction unitRef="shares" contextRef="ife75d305cc1f4ff48462a16aa940d5bb_I20230301" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">26,078,451</ix:nonFraction>.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true">None.</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_13">PART I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_16">Item 1. Business.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_22">Item 1A. Risk Factors.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_25">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_25">Item 1B. Unresolved Staff Comments.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_28">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_28">Item 2. Properties.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_28">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_31">Item 3. Legal Proceedings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_31">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_34">Item 4. Mine Safety Disclosures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_34">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_37">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_37">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_40">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_40">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_43">Item 6. Selected Financial Data.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_43">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_46">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_46">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_64">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_64">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_67">Item 8. Financial Statements and Supplementary Data.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_67">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_70">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_70">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_73">Item 9A. Controls and Procedures.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_73">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_76">Item 9B. Other Information.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_76">105</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_79">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_79">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_82">Item 10. Directors, Executive Officers and Corporate Governance.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_82">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_85">Item 11. Executive Compensation.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_85">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_88">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_88">122</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_91">Item 13. Certain Relationships and Related Transactions, and Director Independence.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_91">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_94">Item 14. Principal Accounting Fees and Services.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_94">126</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_97">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_97">128</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_100">Item 15. Exhibits, Financial Statement Schedules.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_100">128</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_103">Item 16. Form&#160;10-K&#160;Summary.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_103">129</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form&#160;10-K&#160;contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form&#160;10-K&#160;are forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to execute successfully on our strategic realignment announced in November 2022, including with respect to our realigned focus on the development of the AIM INJ platform;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to obtain and maintain regulatory approval of our potential product candidates, including any potential product candidates developed using our AIM INJ platform or any of NEXI-001, NEXI-002 or NEXI-003;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to successfully commercialize and market our potential product candidates, including any potential product candidates developed using our AIM INJ platform or any of NEXI-001, NEXI-002 or NEXI-003, in each case if approved;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to contract with third-party suppliers, manufacturers and other service providers and their ability to perform adequately;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential market size, opportunity and growth potential for our potential product candidates, including any potential product candidates developed using our AIM INJ platform or any of NEXI-001, NEXI-002, and NEXI-003, in each case if approved;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize our potential product candidates, including any potential product candidates developed using our AIM INJ platform or any of NEXI-001, NEXI-002 or NEXI-003, in each case if approved;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to obtain funding for our operations;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of anticipated regulatory filings;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of availability of data from our clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the impact of the ongoing COVID-19 pandemic and our response to it;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to advance product candidates into, and successfully complete, clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to recruit and enroll suitable patients in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing or likelihood of the accomplishment of various scientific, clinical, regulatory and other product development objectives;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the pricing and reimbursement of our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the rate and degree of market acceptance of our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the implementation of our business model and strategic plans for our business, product candidates and technology;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developments relating to our competitors and our industry;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the accuracy of our estimates regarding expenses, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the development of major public health concerns, including the novel coronavirus outbreak or other pandemics arising globally, and the future impact of it and COVID-19 on our clinical trials, business operations and funding requirements; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our financial performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form&#160;10-K.&#160;Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report on Form&#160;10-K&#160;may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable as of the date of this Form&#160;10-K,&#160;we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form&#160;10-K&#160;to conform these statements to new information, actual results or to changes in our expectations, except as required by law.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report on Form&#160;10-K&#160;and the documents that we reference in this Annual Report on Form&#160;10-K&#160;and have filed with the Securities and Exchange Commission, or SEC, as exhibits to this Annual Report on Form&#160;10-K&#160;with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form&#160;10-K&#160;includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Such data involves a number of assumptions and limitations and contains projections and estimates of the future performance of the markets in which we operate and intend to operate that are subject to a high degree of uncertainty. We caution you not to give undue weight to such projections, assumptions and estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form&#160;10-K&#160;contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork and other visual displays, may appear without the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i5091247d182148eaaadd80685b94df97_16"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company developing a novel approach to immunotherapy designed to employ the body&#8217;s own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The backbone of our approach is our proprietary Artificial Immune Modulation, or AIM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, nanoparticle technology platform. The AIM technology enables the rational construction of nanoparticles, or artificial antigen presenting cells, that function as synthetic dendritic cells. Like natural dendritic cells, the AIM nanoparticles employ natural signaling proteins, antigen presentation and co-stimulation, to deliver precise instructions to specific T cells directing a desired immune response.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe this is a revolutionary approach to directing antigen-specific T cell function specific to each disease, with several key advantages over other technologies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Our platform is designed to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Deliver </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">either &#8220;upregulatory&#8221; or &#8220;downregulatory&#8221; messages</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to targeted T cells (or T cell populations) to direct an antigen-specific therapeutic response without impairing healthy tissue or immune function. The artificial antigen-presenting cell, or aAPC, nanoparticle employing the activating co-stimulatory signal is used to activate and expand antigen-specific T cells that are intended to fight cancers and infectious diseases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aAPC nanoparticle constructed with a suppressor or apoptotic co-stimulatory signal is intended to engage or suppress antigen specific autoreactive T cells to treat autoimmune diseases.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Simultaneously </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">target T cells directed at multiple antigens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in a single product. We believe this is critical for addressing tumor escape mechanisms in cancer resulting in a durable response or for addressing diverse populations of autoreactive T cells.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Be an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8220;off-the-shelf&#8221; injectable product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">which creates substantial new benefits in terms of ability to scale and commercialize T cell targeting therapies, with advantages in cost, reimbursement, logistics, administration and time to patient delivery. Additionally, this modality unlocks significant potential in autoimmune applications. Taken together, this enables products based on the AIM technology as a way to reach broader populations more effectively than other T cell therapies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This technology was originally developed at Johns Hopkins University.  It has been further developed and optimized by NexImmune following its formation in 2011. The technology translates into two product modalities that include multi-antigen targeted adoptive cell therapies and multi-antigen targeted injectable off the shelf products. The most advanced programs, NEXI-001 and NEXI-002, are adoptive cell therapies which are currently in Phase 1/II trials. Importantly, these two modalities share the same mechanism of action in engaging and directing the function of antigen specific T cells.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Scientific Context</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directing antigen-specific immune responses is one of the top priorities in immunology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It has been demonstrated by multiple modalities ways that harnessing the power of the immune system can be a powerful factor in fighting cancers, infectious diseases and autoimmune disorders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While advances have been made, new modalities are needed to accelerate progress.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The search for a way to successfully amplify the potential benefits of antigen-specific therapies without impacting the broader immune system has gone on for many years, if not decades.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Some of the greatest progress has been in blood cancers, where novel technologies like CAR-Ts and bi-specific T cell engagers (BiTEs) have been able to target well-characterized surface antigen targets, like CD-19 or BCMA with several approved modalities.  However, opportunities remain to address tumor escape, durability as well as significant toxicity and scale-up issues, particularly in the case of autologous cell therapies.  In solid tumors, checkpoint inhibitors (CPIs) such as PD-L1 and CTLA-4 antibodies are considered the most significant breakthrough in immune-oncology and are well-established in many indications as the standard of care.  Yet achieving the next wave of immuno-therapy breakthroughs in solid tumors has been challenging, with a lack of progress in &#8220;I/O-I/O combinations&#8221;. Increasing the numbers effective tumor-specific T cells to clear tumors, establishing immunologic memory combined with broad scalability remain challenges.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In autoimmune disorders, these learnings from oncology are now being applied to create new possibilities for immune-based treatment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like in solid tumors, most treatments are systemic (e.g., TNF or CD20 antibodies) and not antigen-specific for the disease in question.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The emerging opportunity is to target the antigen specific autoreactive T cells directly and leave healthy tissue alone.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The AIM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Platform</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AIM technology enables the rational construction of nanoparticles that function as synthetic dendritic cells.  These synthetic dendritic cells interact with specific populations of T cells (defined both by antigen specificity and phenotype specificity) to direct a specific T cell function.  Typically, this is either a message of activation or suppression.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following graphic illustrates the critical parts and functions of the nanoparticle (the core and conjugated proteins) as well as the relative size of the nanoparticle to a T cell:</span></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><img src="nexi-20221231_g1.jpg" alt="nexi-20221231_g1.jpg" style="height:347px;margin-bottom:5pt;vertical-align:text-bottom;width:648px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that one of the critical advantages of the AIM technology platform is the modular design enabling the ability to rapidly customize it for new therapeutics. We have developed a rapid antigen peptide loading method that can be used to create new potential products with different antigen targets in months. Some of our collaborations, such as with the target-identifying AI company Zephyr, highlight the potential to validate targets and create therapeutics. We have also developed protein conjugation techniques so that nanoparticles can be customized quickly for different therapeutic goals by changing core materials, Signal 1(HLA alleles) and Signal 2 messages. It is even possible to add additional signals or homing proteins. This gives the platform tremendous flexibility and application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">One of the most significant points of flexibility is that this nanoparticle platform can be used for two therapeutic modalities creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ex vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">adoptive cell therapy products or directly-injectable, off-the-shelf, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> T cell therapy products.  We call the adoptive cell therapy modality AIM ACT, and the direct-injectable off-the-shelf modality AIM INJ. Both modalities share the same mechanism of action in engaging and directing antigen specific T cell responses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have two programs currently in clinical trials using the AIM ACT modality:  NEXI-001 in acute myeloid leukemia, or AML, patients that have relapsed post allo-stem cell transplant, and NEXI-002 in relapsed refractory multiple myeloma, or MM, both with potential to move into earlier diseases (lower tumor burden) and combine with emerging SOC in select patient populations. Both these clinical trials have been paused due to resource constraints, but the available data is reviewed in the &#8220;Preliminary Data&#8221; sections of the product reviews below and we expect to be able to provide the full data sets from these trials around an upcoming conference in 2023. Assuming successful final results from these Phase I/II clinical trials, we expect to discuss with the U.S. Federal Drug Administration, or the FDA, plans to progress both programs into registration trials designed to support potential approval of both product candidates in the United States. In parallel, we plan to explore partnering opportunities for further clinical development and, if approved, commercialization in these indications. While our first AIM </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ACT program in solid tumors, NEXI-003 (HPV-related malignancies), has also been paused due to resource constraints we are evaluating the potential to advance our HPV strategy using the AIM INJ modality.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AIM INJ modality is a next-generation opportunity to revolutionize multi-antigen-specific T cell therapy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are injecting our antigen-peptide-loaded nanoparticles directly into the body, our products are customizable and off-the-shelf.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Importantly, we can deliver up-regulatory or down-regulatory instructions directly to targeted T cells (or T cell populations) regardless of host dendritic cell function without impairing healthy tissue or immune function.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the consistent ability to target multiple antigens in a single product, there is powerful potential to change the course of treatment in oncology, infectious diseases and autoimmune disorders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in preclinical development of this technology in multiple diseases (see Pipeline section below) but expect to progress these technologies into clinical trials.</span></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><img src="nexi-20221231_g2.jpg" alt="nexi-20221231_g2.jpg" style="height:332px;margin-bottom:5pt;vertical-align:text-bottom;width:648px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to engineer AIM nanoparticles using our platform is expected to also enable rapid new multi-antigen product development. Our nanoparticles are manufactured &#8220;unloaded,&#8221; meaning that while the Signal 1 and Signal 2 proteins are conjugated to the nanoparticle, the specific antigen peptides are not yet loaded into the HLA molecules. The nanoparticles in this form can be stored for significant periods of time. Then, when antigen peptide targets have been identified and validated, they are "&#8221;loaded&#8221;, a process that takes hours. The nanoparticle can then be vialed and is ready for delivery to the patient. Effectively, this means that the time to product creation depends only on the time to identify and produce the relatively simple antigen-specific peptide (or mix of peptides for multiple targets). This can reduce the time for new multi-antigen-specific product development from years to months.  The AIM nanoparticles themselves can be used as a preclinical tool for target validation to expedite the process.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In summary, our AIM nanoparticle technology is designed to bypass the dendritic cells and deliver the right kind of instructions directly to T cells using natural biology. In essence, we create nano-sized synthetic dendritic cells. These nano-sized synthetic dendritic cells are designed to deliver precise instructions to a specific set of targeted T cells, and these instructions will be different depending on the therapeutic goal. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Our Pipeline</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline consists of programs using both the AIM ACT and AIM INJ modality.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two product candidates in human clinical trials, NEXI-001 in patients with AML and NEXI-002 in patients with MM.  Both of these programs are in Phase I/II trials.  Enrollment is both of these programs is currently paused for resource reasons, with a discussion of the available data below.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Phase I/II trials, the trials consist of two parts. In the first part of the trials, the initial safety evaluation phase, we will assess the safety and tolerability of NEXI-001 or NEXI-002 T cells. In the second part of the trials, the expansion phase, we will further define safety and will also evaluate the initial efficacy of each product candidate at the dose and regimen established in the safety evaluation phase. We have completed enrollment and dosing of patients in the safety evaluation phase of the trial for NEXI-001 and NEXI-002, and we expect to be able to provide the full data sets from these trials in the first half of 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next adoptive cell therapy product candidate, NEXI-003, is our first product candidate targeted at solid tumors.  The IND has been accepted by the FDA, but this program has also been paused due to resource constraints.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have combined the learning from our adoptive cell therapies and INJ pre-clinical efforts which include: </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt"> Ability to expand healthy, fit, antigen-specific T cells from late-stage, heavily pre-treated patients providing insight  into the potential to activate healthy, fit, specific T cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt"> AIM nanoparticles expand antigen-specific T cells with important subtypes known to be associated with anti-tumor activity and immunologic memory regardless of modality or stage. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt"> AIM nanoparticle-expanded T cells proliferate, traffic to tumor site and persist.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt"> No obvious off-tissue toxicity.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt"> Potential synergistic effects when combining AIM-activated antigen-specific T cells with other IO mechanisms suggesting a increased durable response.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have completed substantial non-clinical work to advance the AIM INJ modality towards a potential investigational new drug application, or IND, filing, including preparing appropriate IND-enabling experiments in support of a planned clinical program focusing on solid tumors. Subject to regulatory feedback and an IND filing, we anticipate a second clinical program that would target autoimmune disease and which would be the first AIM product candidate to suppress, rather than activate, T cell function. In support of this potential program, we have generated and published pre-clinical data in which we observed that AIM nanoparticles engaged and suppressed auto-reactive T cells.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are developing the AIM platform for potential clinical application in patients suffering from specific infectious disease. In non-clinical studies, we have been able to expand CD8+ T cells directed against viral antigens including Epstein-Barr virus, Cytomegalovirus, and Human Papillomavirus.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our pipeline as well as many of our key collaborators:</span></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><img src="nexi-20221231_g3.jpg" alt="nexi-20221231_g3.jpg" style="height:339px;margin-bottom:5pt;vertical-align:text-bottom;width:648px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Team and Corporate History</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We were founded in 2011, with the exclusive licensing of the core AIM technology from The Johns Hopkins University, or Johns Hopkins. In 2017, attracted by the promise of this technology, Dr. Sol Barer, the co-founder and former Chairman and Chief Executive Officer of Celgene Corporation, and the current Chairman of Teva Pharmaceutical Industries Ltd., led the acquisition and recapitalization of our company. Dr. Barer currently serves as Chairman of our board of directors, and has led the recruitment of the management team whose members have decades of experience in the biotechnology industry. Our President and Chief Executive Officer, Kristi Jones, brings over 25 years of biotech leadership in product development, business and strategy roles at Genentech, MedImmune and AstraZeneca PLC. Dr. Jerome (Jerry) Zeldis, M.D., Ph.D., our Executive Vice President of Research &amp; Development brings his experience as the former Chief Medical Officer of Celgene and Chief Executive Officer and Chief Medical Officer of Celgene Global Health. Our Chief Financial Officer, John Trainer, has nearly 20 years in various senior financial, operational, strategic and transactional roles across the biotech and pharmaceutical industry including significant time spent at MedImmune and AstraZeneca. Mathias Oelke, our Chief Science Officer and scientific co-founder, transitioned from his faculty position with Johns Hopkins to his current position as our Senior Vice President for preclinical immune therapy and platform development.  Our Chief Medical Officer, Bob Knight, has over 25 years of clinical development experience and joined us from Kite Pharmaceuticals, where he led the clinical development program for Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Approach</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to immunotherapy employs the body&#8217;s own T cells and is designed to generate a specific, potent and durable immune response that mimics natural biology. We believe the key attributes of this platform are:</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">Ability to target specific T cell populations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AIM nanoparticles are programmed to be antigen-specific. That antigen can either be on the T cell itself (in the case of autoreactive T cells) or on a target cell (in the case of oncology or infectious diseases).  Importantly, this means that the activation or suppression message is NOT delivered to other cells.  The message is for a particular T cell only and does not impact healthy tissue or benign cells.  Other T cell technologies can be specific to particular antigens (e.g., CAR-T or TCR therapies), but they cannot also deliver the other major benefits listed here.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">Ability to target multiple T cell populations simultaneously. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While a single AIM nanoparticle is directed at a single antigen, it is preferred to mix nanoparticles targeted at different antigens into a nanoparticle cocktail for administration and use, thereby creating a product which can address multiple targets at the same time.  Our current clinical programs target five (5) antigens simultaneously, but we have tested higher numbers successfully.  This ability to target multiple antigens simultaneously is a powerful tool against tumor escape in oncology, as well as a practical approach to addressing diverse autoreactive T cell populations in autoimmune disorders.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:23.5pt">No genetic engineering.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  The AIM technology works by delivering natural signaling to T cells from the natural repertoire. In ACT, there is no need to genetically alter the T cell offering a more streamline manufacturing process and potential for improved tolerability as a cell therapy. As an INJ therapy, no patient specific manufacturing is required. This has clear benefits for cost, simplicity, and scalability.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:23.5pt">&#8220;Off-the-shelf&#8221; manufacturing and administration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The AIM INJ modality is scalable and simple to administer.  Nanoparticles can be manufactured ahead of time and stored, enabling a significant cost and scalability advantage over most other T cell therapies.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:23.5pt">Rapid new product development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In addition to these core principles of differentiation, we believe the modular design of the AIM platform facilitates the rapid design of new product candidates based on synergies derived from interchangeable components, specifically antigen peptides, signaling proteins and core material, as well as shared methods for nanoparticle construction, protein conjugation, peptide loading, and a platform manufacturing system for T cell therapy products. Specifically, we can customize and load new sets of antigen targets and signaling proteins to efficiently create new products for new indications and new therapeutic areas.  Rather than having to create a fully-new biologic molecule, like an antibody, against the target, the peptides can simply be loaded onto the nanoparticles for immediate testing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are many technology platforms and product candidates in development across the biotechnology industry focused on influencing T cell activity, there is no platform that can deliver this combination of attributes besides the AIM platform.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. We believe that in the long term, our AIM technology has the potential to be a core component of many immunotherapy combinations used to treat a variety of immune-mediated diseases. Our ultimate goal is to develop and bring to patients, independently or working with partners, a portfolio of off-the-shelf T cell products with specific application to a wide range of cancers, autoimmune disorders and infectious diseases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key elements of our strategy include:</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:23.5pt">Advance the AIM INJ program candidates into clinical trials.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that one of the most significant advantages presented by our AIM technology is the potential for an &#8220;off-the-shelf,&#8221; injectable form of the AIM nanoparticle. Our first program is likely to be in oncology, and our next program likely in the autoimmune disorder space.  The specific timing for the start of the clinical trials will depend on resource availability but the development of the AIM INJ product candidates remains our top priority.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:23.5pt">Advance NEXI-001 and NEXI-002 to registrational trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  While enrollment in both these programs is currently paused due to resource constraints, we have been generating meaningful proof-of-concept data in both safety and efficacy. Life Cycle Development Plans to move into earlier lines of therapy and evaluate novel IO/IO combinations in specific populations based on emerging pre-clinical data have also been paused.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:23.5pt">Drive forward NEXI-003, our first solid tumor product candidate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our first solid tumor product candidate, NEXI-003 represents a powerful new expansion of the capability and utility of the AIM platform to advance potential IO/IO breakthroughs. Also, given the large number of potential antigen combinations in solid tumors, we expect licensing and partnerships to be a core element of our strategy as we establish the broader applicability of our AIM technology.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:23.5pt">Leverage partnerships to drive new product development in autoimmune disorders and infectious diseases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The AIM INJ modality will be constructed to deliver either &#8220;suppressive&#8221; or &#8220;apoptotic&#8221; co-stimulation signals directly to auto-reactive T cell populations, which is critical for addressing autoimmune disorders. In addition to autoimmune disorders, we believe that there may be significant opportunities to address virally-mediated infectious diseases via either the AIM ACT or AIM INJ modality. We also believe that the AIM technology may be applicable to the treatment of, and preparation for, future virally-mediated epidemics and pandemics. While we believe that our AIM technology platform is well-suited to address these new therapeutic opportunities, we expect that we would partner with experienced biopharmaceutical companies with deep capabilities in these areas to advance new therapies in these potential indications. Our collaboration with Yale University in Type 1 Diabetes is an example of the kinds of partnerships we will establish to help drive this technology forward for patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we intend to establish our own internal capabilities to develop and commercialize our product candidates, we will also explore strategic collaborations or partnerships that may accelerate our development timelines, broaden the therapeutic reach of our AIM technology platforms and maximize the full potential of both the AIM ACT and AIM INJ modalities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Clinical-Stage Product Candidates</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have two programs in clinical&#160;trials:&#160;NEXI-001&#160;for&#160;AML patients&#160;and&#160;NEXI-002&#160;for&#160;MM patients, with enrollment in both currently paused due to resource constraints.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NEXI-001</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NEXI-001 is an allogeneic cell therapy in Phase I/II development for the treatment of patients with AML who have relapsed disease after receiving allo-HSCT. Allo-HSCT is currently the only therapeutic procedure with established curative potential for intermediate and high risk AML patients. However, of the approximately 20,000 patients diagnosed with AML in the United States in 2019, approximately 50% were young or healthy enough to qualify for allo-HSCT. Of those patients who do receive allo-HSCT, fewer than half are cured. Patients who relapse after allo-HSCT face a dismal prognosis and are left with very limited treatment options. Most will succumb to their disease within one year of relapse and the two-year survival rate is less than 15%. Many of these patients fail to respond to further salvage treatments with an even worse prognosis. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treatment Paradigm for AML</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are currently no approved therapies for this relapsed patient population, donor lymphocyte infusion, or DLI, is employed as the standard-of-care treatment. DLI is a procedure in which non-selected and non-disease specific T cells are collected from an AML patient&#8217;s original stem cell donor by apheresis. The T cells are then infused directly into the AML patient with the hope that some populations of the infused T cells will recognize and kill the patient&#8217;s leukemia cells, directing a graft versus leukemia, or GvL, effect. Unfortunately, this blunt approach works in only approximately 15% to 20% of patients. Making matters worse, approximately 50% to 60% of patients that receive DLI therapy experience life-threatening toxicities associated with non-leukemia specific T cells from the donor attacking healthy cells in the patient, a condition referred to as Graft Versus Host Disease, or GvHD. Currently, there is no way for a treating physician to &#8220;de-couple&#8221; the benefits of GvL from the toxicities of GvHD. They are not able to separate the &#8220;good&#8221; T cells from the &#8220;bad.&#8221; Because each NEXI-001 infusion contains high proportions of T cells that are directed to specifically recognize and attack only a patient&#8217;s leukemia cells and are comprised of very few T cell subtypes capable of eliciting a GvHD response, we believe therapy with NEXI-001 offers the potential to enhance the benefits of GvL while significantly reducing the risk of GvHD.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AIM technology is used to produce the NEXI-001 product candidate. As illustrated in the graphic below, AIM nanoparticles are loaded with AML-specific peptides from the WT 1, PRAME and Cyclin A1 antigens, which are used to enrich and expand AML-specific T cells. These AML-specific T cells recognize and attack these specific antigen peptide targets, which are commonly over-expressed on both leukemic blasts and leukemic stem cells</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><img src="nexi-20221231_g4.jpg" alt="nexi-20221231_g4.jpg" style="height:311px;margin-bottom:5pt;vertical-align:text-bottom;width:233px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The T cells&#160;in&#160;NEXI-001&#160;are&#160;designed to be highly potent and highly selective in their ability to distinguish leukemia cells from healthy cells, and to contain key T cell subtypes that promote immunologic memory and long-term T cell persistence. We believe this combination of attributes has the potential to deliver deep and durable clinical responses for these AML patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Phase I/II Clinical Trial Design</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our clinical trial with NEXI-001 is a prospective, multi-center, open-label, single-arm, dose-escalating Phase I/II trial that aims to enroll between 22 and 26 patients. The primary objective is to assess the safety and tolerability of a single infusion of NEXI-001 T cells in patients with AML who have either minimum residual disease, or MRD, or morphologically detectable disease after an HLA-matched allo-HSCT. As a practical point, the NEXI-001 trial enrolls patients who have not achieved a remission to salvage therapy after relapse following the transplant. Secondary objectives include signals of immunologic responses and preliminary anti-tumor activity, including evaluations of the following clinical endpoints: overall response rate, or ORR, which includes complete response, or CR, progression free survival, or PFS, and overall survival, or OS. Additional analysis will assess the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> persistence, proliferation, functionality and TCR repertoire of NEXI-001 T cells as measured in blood and bone marrow samples. Our clinical endpoints have been recognized as appropriate measurements of safety and clinical response.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This trial consists of two parts. The initial safety evaluation phase assesses the safety and tolerability of a single infusion of NEXI-001 at escalating dose levels. In the second part of the trial, the dose expansion phase, investigators further characterize safety and will also evaluate the initial efficacy of NEXI-001 T cells at the dose established in the safety evaluation phase. Once the recommended dose and regimen have been determined, evaluations of safety, tolerability and initial clinical response will become the objectives of the second part of the trial, the expansion phase. We are currently in the safety evaluation phase of the trial. The City of Hope Cancer Center is the lead clinical trial site for this trial, with additional trial sites at the Dana Farber Cancer Center, the M.D. Anderson Cancer Center, the Memorial Sloan Kettering Cancer Center, the Karmanos Cancer Institute, the Ohio State University Comprehensive Cancer Center, and the Advent Hospital in Orlando, Florida.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The schema for this trial (and current enrollment) is shown below:</span></div><div style="margin-top:12pt;text-align:center"><img src="nexi-20221231_g5.jpg" alt="nexi-20221231_g5.jpg" style="height:321px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Preliminary Data from the Phase I/II Clinical Trial</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At this point, we have completed enrollment and dosing in the dose escalation phase, with a total enrollment of 11 patients.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have reported data from six patients across Dose Level 1, Dose Level 2 and Dose Level 3 safety cohorts to date.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are still collecting data from existing patients and that data will be shared at an appropriate scientific forum.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each of these patients has been closely monitored for safety and early signs of clinical activity. In addition, biomarkers were analyzed to assess early signs of immunologic response; clinical lab reports and patient charts were used to measure myeloid activity (neutrophils counts, platelet counts, Red Blood Cell counts, transfusion burden); and validated clinical endpoints were incorporated to measure early signs of clinical activity. It is important to note that we are early in the safety evaluation and dose-finding part of the Phase I/II trial, and that the results reported here represent data from the first five patients only and are not statistically significant.  Additional data from all safety cohorts is expected to be announced in 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Safety and tolerability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The NEXI-001 therapy has been well tolerated without dose limiting toxicities, observed after a single infusion of NEXI-001 T cells at doses of 50M, 100M and 200M total T cells. This includes no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&gt; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">grade 3 cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or ICANS, or infusion-related reactions, or IRRs at any Grade Level (Grade 1-4).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Immunological responses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first six patients, treated we have observed initial indicators of immunologic response after the infusion of NEXI-001 T cells, including (i) early lymphocyte reconstitution to baseline levels after administration of lymphodepleting therapy with rapid and robust recovery of the CD4+ T cell compartment; (ii) the proliferation and persistence of NEXI-001 antigen-specific T cells as measured by multimer-staining of peripheral blood when adequate samples were available for analysis; (iii) clonal expansion and persistence of NEXI-001 T cells in both peripheral blood and bone marrow as measured by TCR sequencing when data was available; and (iv) the presence of T cell subtypes that support anti-tumor activity, T cell proliferation, self-renewal and long-term persistence as measured by phenotype staining of NEXI-001 antigen-specific T cells in peripheral blood over time when adequate samples were available for analysis. It is important to note that we are early in the safety evaluation and dose-finding part of the Phase I/II trial, and that these results are not statistically significant.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Patient Characteristics</span></div><div style="margin-top:12pt;text-align:center"><img src="nexi-20221231_g6.jpg" alt="nexi-20221231_g6.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Summary of Patient Experience</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed above, we have reported clinical data in six patients for NEXI-001&#8217;s initial clinical trial.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Importantly, this has been part of a dose-ascending clinical plan where the first patient received a single dose of 50M T cells, the next three patients received a single dose of 100M T cells, and the next patients received two doses of 200M cells after Day 30 for a total of 400M cells.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The next and final planned dose level will be 200M cells administered weekly for three weeks, followed by a week of rest, followed by a repeat of the 200M cells administered weekly for three weeks, a total of 1.2 billion T cells.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The data from the initial dose levels reported to date is encouraging and supports progression into the higher doses.  Specifically, we have observed:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">NEXI-001 is well-tolerated.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">As previously described, there have been no grade &#8805;3 SAEs observed.  One case of Grade 2 CRS was reported, which resolved within 24 hours.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">NEXI-001 generates a robust immune response across all dose levels reported to date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">:</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rapid recovery of absolute lymphocyte counts (ALC) following the pre-therapy lymphodepleting chemotherapy regimen including reconstitution of both CD8+ and CD4+ T cell subtypes, despite the fact that NEXI-001 contains CD8+ T cells only. Expansion and persistence of antigen-specific T cells in both the peripheral blood and bone marrow.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">The phenotypes of the antigen-specific T cells in the NEXI-001 product candidate, including stem-cell-like memory and central memory T cell populations, are maintained in blood and the bone marrow over time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Signals of NEXI-001 of clinical activity across all dose levels reported to date: </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In particular, patients are seeing some or all of the following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Evidence of marrow recovery based on improved donor chimerism (i.e., granulocytes, T cells, bone marrow) and where relevant, reduced transfusion burden</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Improved ECOG performance.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Evidence of reduced tumor burden based on decreases in peripheral blasts and a decrease in bone marrow blasts (in Dose Level 3). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following chart summarizes the clinical experience of the patients at the various dosing levels disclosed here: </span></div><div style="margin-top:12pt;text-align:center"><img src="nexi-20221231_g7.jpg" alt="nexi-20221231_g7.jpg" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described above, we have completed enrollment and dosing of patients in Dose Level 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are still collecting data on these patients and expect to share this data at an appropriate scientific forum.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At this time, further enrollment is paused due to resource constraints.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">NEXI-002</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEXI-002 is an autologous cell therapy in Phase I/II clinical development to treat patients with relapsed and/or refractory MM who have failed at least three prior lines of therapy.  We have currently paused enrollment in this trial due to resource constraints.  MM accounts for around 10% to 15% of all hematologic malignancies and primarily affects older individuals, with approximately 32,000 new cases a year in the United States. While significant progress has been made in the treatment of MM, there is currently no cure for the condition.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Treatment Paradigm for MM</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently several T cell therapies under clinical investigation for this patient population. Among them, anti-B-cell maturation antigen, or BCMA, transduced CAR T therapies have demonstrated early and impressive initial clinical results across multiple Phase II/III clinical trials, with objective responses rates, or ORR, greater than 90% in patients reported within some individual trials, and progression free survival, or PFS, rates of approximately 11 months. As clinical trial experience grows and initial data sets mature, certain and common limitations of these therapies are also becoming evident, with many directly attributable to the technology itself.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR T therapy, by design, uses an antibody to target a single protein, such as BCMA, expressed on the surface of a plasma cell. These surface proteins are not critical to the survival of the plasma cell and can be down-regulated when under immune pressure, such as from the CAR T cellular therapy. As a result, the tumor cell can avoid detection by the CAR T cell in a process known as tumor escape. We also believe that a primary driver of tumor relapse following CAR T therapy is the loss of CAR T cells from a patient&#8217;s body: the CAR T cells do not persist. Due to the way CAR T cells are manufactured, they contain highly potent T cells, but do not contain the natural T cell subtypes that support self-renewal, immunologic memory and long-term persistence. When the CAR T cells die out, the cancer can relapse.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEXI-002&#160;was designed to address these emerging limitations of CAR T therapy.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:23.5pt">Tumor escape</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Each infusion of NEXI-002 contains populations of T cells directed to recognize and attack multiple antigen targets on each malignant plasma cell, as shown in the figure below. These targets represent a combination of cell surface antigen proteins, such as CS-1 and CD138, and endogenously presented survival antigen proteins, such as WT-1 and NY-ESO. We believe that by targeting multiple antigen proteins that are over-expressed on each malignant plasma cell, some of which are necessary for tumor cell survival, NEXI-002 has the potential to effectively address tumor escape as an immune evasion mechanism.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Tumor relapse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The AIM technology has been optimized to consistently produce product candidates that contain T cell subtypes that support anti-tumor potency, self-renewal, immunologic memory and long-term T cell persistence. We believe the combination of these T cell characteristics has the potential to effectively address disease relapse due to short-term T cell survival.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When taken together, we believe these attributes of&#160;NEXI-002&#160;give it the potential to improve the durability of clinical responses observed with current BCMA-transduced CAR T products, extend PFS rates and improve the toxicity profile reported to date when using these genetically engineered T cell modalities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with&#160;NEXI-001,&#160;our AIM technology is used to produce each&#160;NEXI-002&#160;infusion. AIM nanoparticles loaded with&#160;MM-specific&#160;antigen peptides, enriched and expanded by the E+E system, generate populations of T cells that are directed to recognize and attack the specific antigen targets, as illustrated in the graphic below.</span></div><div style="margin-top:12pt;text-align:center"><img src="nexi-20221231_g8.jpg" alt="nexi-20221231_g8.jpg" style="height:312px;margin-bottom:5pt;vertical-align:text-bottom;width:235px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The T cells in each&#160;NEXI-002&#160;infusion are designed to be highly potent and highly selective in their ability to distinguish malignant plasma cells from healthy plasma cells, and to contain key T cell subtypes that promote anti-tumor potency, immunologic memory and long-term T cell persistence. We believe this combination of attributes has the potential to deliver deep and durable clinical responses for MM patients who have failed at least three lines of prior therapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Phase I/II Clinical Trial Design</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our clinical trial with NEXI-002 is a prospective, multi-center, open-label, single-arm, dose-escalating Phase I/II clinical trial that aims to enroll between 19 and 23 patients. This trial consists of two phases. The initial safety evaluation phase assessed the safety and tolerability of a single infusion of NEXI-002 within a single dose range. In the second part of the trial, the expansion phase, investigators will further define safety and will also evaluate the initial efficacy of each product candidate at the dose established in the safety evaluation phase. We are currently in the expansion phase of the trial. The trial&#8217;s primary objective is to assess the safety and tolerability of a single infusion of NEXI-002 T cells in patients with MM who have failed at least three prior lines of therapy. Secondary objectives include signals of anti-tumor activity, ORR (which includes CR), OS and PFS. Additional biomarker analysis will assess the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> persistence, proliferation, functionality and TCR repertoire of NEXI-002 T cells as measured in blood and bone marrow samples. Our clinical endpoints have been recognized as appropriate measurements of safety and clinical response. The clinical trial sites include City of Hope Cancer Center, the M.D. Anderson Cancer Center, the Memorial Sloan Kettering Cancer Center, the Karmanos Cancer Institute, the Ohio State University Comprehensive Cancer Center, the Dana Farber Cancer Center, and the Advent Hospital in Orlando, Florida.</span></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><img src="nexi-20221231_g9.jpg" alt="nexi-20221231_g9.jpg" style="height:339px;margin-bottom:5pt;vertical-align:text-bottom;width:648px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Preliminary Data from the Phase I/II Clinical Trial</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Enrollment in this clinical trial has been paused with seven patients enrolled and dosed.  We have reported data on a total of five patients, of which three patients were treated in the Safety Evaluation Phase and two patients were treated in the Expansion Phase.  The remaining data is being collected and will be shared in an appropriate scientific forum.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Safety and tolerability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The NEXI-002 therapy has been well tolerated without dose limiting toxicities observed after a single infusion of NEXI-002 T. This includes no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&gt; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">grade 3 cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or ICANS, or infusion-related reactions, or IRRs at any Grade Level (Grade 1-4).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Immunological responses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  TCR sequencing showed that NEXI-002 product contains T cell clones that were undetectable in the peripheral blood of patients at baseline.  The product contains CD8+ antigen specific T cells with memory phenotypes.  Upon dosing, patients saw a rapid lymphocyte recovery with reconstitution of both CD4 and CD8+ T cells. NEXI-002 cells were detected in the peripheral blood and bone marrow and persist and proliferate over time.  The quality and functionality of the NEXI-002 T cells is comparable to those expanded from healthy donors.  Strategies to yield higher product doses have been implemented as the trial progresses and the NEXI-002 protocol has been amended to include patients with smoldering multiple myeloma (an early stage of multiple myeloma). Analyses of immunologic and clinical activity are ongoing. We expect to announce additional data  in 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Patient Characteristics</span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><img src="nexi-20221231_g10.jpg" alt="nexi-20221231_g10.jpg" style="height:325px;margin-bottom:5pt;vertical-align:text-bottom;width:636px"/></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Summary of Patient Experience</span></div><div style="margin-top:12pt;text-align:center"><img src="nexi-20221231_g11.jpg" alt="nexi-20221231_g11.jpg" style="height:352px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Opportunities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moving forward, our strategy is to focus on the development of the AIM INJ modality, with the expectation that we will be able to advance it through IND approval and into a Phase I/II clinical trial, resources permitting. We believe the data we have already collected is validating of the AIM platform&#8217;s mechanism, which gives us a favorable risk profile as we seek to establish the technology in solid tumors, infectious diseases and autoimmune disorders.  We have generated a significant body </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of combined clinical and non-clinical data to support this approach, which we use to prioritize our clinical development efforts and to identify potential disease areas and indications to pursue.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:23.5pt">Solid Tumors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Our IND for NEXI-003 in HPV-associated malignancies has been accepted by the FDA, but the planned Phase I/II clinical trial has been paused due to resource constraints.  HPV-associated malignancies remains a disease area of high interest for the AIM INJ platform, and there are many more opportunities for the AIM technology in the solid tumor space. The scientific community has identified, robustly characterized and clinically evaluated over 75 specific antigen targets across multiple solid tumor types, and we plan to use this data to inform our next wave of product development in oncology. Additionally, combinations of multi-antigen specific AIM therapeutics with CPI&#8217;s remain a potential IO/IO breakthrough.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:22.8pt">Hematology (Blood Cancers).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The AIM multi-antigen approach has the potential to pursue a broader set of targets to address escape and durability. Combined, early clinical data is consistent with pre-clinical results demonstrating antigen specific cells proliferate, traffic and persist at the site of tumor. Additionally, opportunity exists to move into earlier disease to halt progression. Recent pre-clinical data suggests potential novel IO/IO combinations with Bispecific T cell engagers (e.g. CD3/BCMA, CD3/Flt-3) offers the potential to achieve synergistic, superior potency and durability in select populations. </span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:23.5pt">Autoimmune Disorders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We believe that our AIM technology will enable us to target autoimmune conditions using either the AIM ACT or AIM INJ modality. For most autoimmune disorders like Type 1 Diabetes, autoreactive (or self-destructive) T cells become the cells targeted for therapeutic intervention. For these conditions, AIM nanoparticles can be loaded with Signal 1 antigen peptides that autoreactive T cells recognize, and Signal 2 peptides that deliver a suppressive or apoptotic signal that either tolerizes or eliminates the disease-causing T cells. In conditions like multiple sclerosis, or MS, the Epstein-Barr virus, or EBV, plays a critical role in mediating the disease process. Eliminating EBV-infected cells with EBV-specific T cells has been shown by others to impact disease progression for patients with Primary Progressive MS and could be done using the AIM ACT approach. We believe that EBV-specific AIM ACT or AIM INJ product candidates can be developed for clinical evaluation in various forms of MS.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:23.5pt">Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We believe that there may be significant opportunities to address other viral-mediated diseases using the AIM platform to develop either AIM ACT or AIM INJ product candidates. We also believe that the AIM technology may offer a novel approach to the rapid treatment of, and preparation for, future viral-epidemics and pandemics.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:23.5pt">Expanding to new HLA allele subtype populations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We are also developing additional HLA allele subtypes. NEXI-001 and NEXI-002 currently use the HLA-A2 allele, which is the most prevalent allele in the North American population. However, the additional HLA subtypes we plan to develop, including HLA-A1, HLA-A3, HLA-A11, HLA-A24 and HLA-B7, would broaden the patient eligibility of future product candidates. We believe the modular AIM platform will facilitate the rapid development of nanoparticles that exchange the current HLA-A2 for new HLA subtypes, which will then be used for all AIM product candidates in development.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we continually survey the scientific and industry landscape for opportunities to license, partner or acquire technologies that may help us advance current or new T cell therapies for the benefit of patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to receiving marketing approvals, we expect to commence commercialization activities by building a focused commercial organization in the United States to market, sell and distribute our products. We believe that such an organization can efficiently address the community of hematologists and oncologists who are the key specialists treating the patient populations for which our most advanced product candidates are being developed. Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties to support any of our product candidates that obtain marketing approval.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our potential to generate novel product candidates with potential to address a wide variety of cancers, autoimmune and infectious diseases, we may also consider opportunistically entering into strategic partnerships focused on certain targets, product candidates, disease areas or geographies. These collaborations could advance and accelerate our current clinical and platform development programs in ways that could maximize product availability and value creation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are initially developing product candidates to address hematological malignancies, which will be followed by an expansion into solid tumors, autoimmune disorders and infectious diseases. Accordingly, we may face competitors from multiple biotechnology or biopharmaceutical companies, many of which have access to greater resources, technical expertise and broader collaborations that could result in faster development, exclusive access to novel enabling technologies, biomarker-based differentiation or commercialization. These competitors also compete for recruiting and retaining talent in critical areas of research, development, manufacturing, regulatory and commercial functions. If&#160;NEXI-001,&#160;NEXI-002&#160;or any of our future product candidates do not offer sustainable advantages over competing products, we may not be able to successfully compete against current and future competitors.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The field of immuno-oncology is rapidly evolving, and we expect to compete with companies developing other approaches to direct T cell function. These include but are not limited to, the following modalities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genetically Engineered T Cells</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These include both&#160;CAR-T&#160;and TCR engineered cell therapies being developed as treatments for MM and AML.&#160;CAR-T&#160;cell therapies generally target single cell surface antigen proteins and are mostly limited to blood tumors, including products and product candidates being developed at companies such as Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences, Inc., Fate Therapeutics, Inc. and Mustang Bio, Inc. We also expect to compete with TCR engineered cell therapies, which employ high affinity TCR&#8217;s against a single endogenously presented antigen peptide, including products and product candidates being developed by companies such as Adaptimmune Therapeutics plc, GlaxoSmithKline plc, Gilead Sciences, Inc. and Immatics N.V.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-engineered&#160;T Cells</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These are cell therapy approaches that employ the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;activation and expansion of&#160;non-genetically&#160;engineered endogenous T cells, including TIL products, such as those being developed by Iovance Biotherapeutics, Inc., and antigen presenting cell, or APC, based systems,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;activation and expansion systems, such as those being developed by Atara Biotherapeutics, Inc. and Marker Therapeutics, Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cancer Vaccines</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer vaccine approaches rely on host antigen presenting cells as intermediaries to process and present specific signals that direct a targeted T cell function, including products and product candidates being developed at companies like SQZ Biotechnologies Company, BioNTech SE and Moderna, Inc.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antibody Platforms</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These modalities employ modified antibodies to redirect T cell function and include bispecific T cell engagers, or BiTEs, and dual-affinity&#160;re-targeting&#160;proteins, or DARTs, including products and product candidates being developed at companies like Amgen Inc., GlaxoSmithKline plc, Johnson&#160;&amp; Johnson and MacroGenics, Inc.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may obtain regulatory approval for their products more rapidly than we may, or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products. These competitors may also be more successful in manufacturing and marketing their products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Johns Hopkins License Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2011, we entered into an exclusive license agreement with Johns Hopkins, which was subsequently amended and then superseded in January 2017 by an amended and restated exclusive license agreement, which we refer to as the A&amp;R Johns Hopkins License Agreement. Pursuant to the A&amp;R Johns Hopkins License Agreement, we have (i)&#160;an exclusive license to make, have made, use, import, offer for sale and sell artificial antigen presenting cells (AIM nanoparticles) covered by patent rights owned by Johns Hopkins in therapeutic, diagnostic and&#160;non-clinical&#160;fields, (ii)&#160;an exclusive license to make have made, use, import, offer for sale and sell fusion proteins covered by patent rights owned by Johns Hopkins in the therapeutic field, (iii)&#160;a&#160;non-exclusive&#160;license to make, have made, use, import, offer for sale and sell fusion proteins covered by patent rights owned by Johns Hopkins in diagnostic and&#160;non-clinical&#160;fields and (iv)&#160;a&#160;non-exclusive&#160;right to use Johns Hopkins&#8217;s&#160;know-how&#160;to develop, make, have made and sell products covered by patent rights owned by Johns Hopkins and to develop and provide services covered by the patent rights owned by Johns Hopkins. The rights licensed to us are worldwide and include the right to grant sublicenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johns Hopkins retains rights to practice the patent rights and&#160;know-how&#160;for itself and other&#160;non-profit&#160;academic and&#160;non-profit&#160;research institutions for any&#160;non-profit,&#160;non-commercial&#160;research or other&#160;non-commercial&#160;purpose. The United States government may have a&#160;non-exclusive,&#160;non-transferable,&#160;irrevocable,&#160;paid-up&#160;license to practice or have practiced for or on behalf of the United States throughout the world the inventions described in the patent rights owned by Johns Hopkins that were supported by federal funding. We may be obligated to manufacture the products sold or used in the United States that are covered by patent rights supported by federal funding substantially in the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the 2011 license agreement and the A&amp;R Johns Hopkins License Agreement, Johns Hopkins was entitled to an&#160;up-front&#160;license fee of $155,000 and we issued them 26,918 shares of our common stock. Johns Hopkins was also entitled to milestone fees of $75,000 in connection with clinical trial milestones. For the first licensed product or licensed service in the therapeutic field, we may be required to pay Johns Hopkins additional aggregate milestone fees of $1.6&#160;million for clinical and regulatory milestone fees. We may be required to pay Johns Hopkins reduced milestone fees for the second and third licensed products or licensed services in the therapeutic field in connection with clinical and regulatory milestones. In the diagnostic field, we may be required to pay Johns Hopkins aggregate milestone fees of $400,000 for the first licensed product or licensed service and reduced milestone fees for the second and third licensed products or licensed services. We may be required to pay Johns Hopkins aggregate milestone fees of $100,000 for commercial milestones for the first licensed product or licensed service in the&#160;non-clinical&#160;field. In the aggregate, we may be required to pay Johns Hopkins additional milestone fees of up to $4.2&#160;million for all clinical, regulatory and commercial milestones for all licensed products or licensed services in the therapeutic field, the diagnostic field and the&#160;non-clinical&#160;field. We may also be required to pay royalties in the low to upper single digits on net sales of licensed products and licensed services in the therapeutic field, diagnostic field and&#160;non-clinical&#160;field that are covered by the patent rights owned by Johns Hopkins or use&#160;know-how&#160;of Johns Hopkins. We are required to make minimum annual royalty payments of $100,000 to Johns Hopkins for the remainder of the term of the A&amp;R Johns Hopkins License Agreement; the amount of the minimum annual royalty payment started in the low five figures in the first year of the agreement and increased to $100,000 in the third year of the agreement and for each subsequent year of the agreement. We may also be required to pay Johns Hopkins a low double digit percentage, not to exceed 15%, of any&#160;non-royalty&#160;sublicense consideration we receive. We are also required to use commercially reasonable efforts to meet certain clinical and technical diligence milestones.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must make minimum royalty payments, which began upon the 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> anniversary of the agreement and upon every anniversary thereafter during the term of the agreement, which offset future royalties per above owed to John Hopkins.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event Johns Hopkins or another party provides us with clinical or other evidence demonstrating the practicality of a particular market or use within the therapeutic, diagnostic or&#160;non-clinical&#160;fields that we are not developing or commercializing, we are required to use commercially reasonable efforts to start development or attempt to sublicense to a suitable third party for that particular market or use. If we fail to use commercially reasonable efforts to commence development or do not grant a sublicense to a suitable third party, all rights to that particular use will revert back to Johns Hopkins at no cost and Johns Hopkins will be able to license that particular use to third parties. We are not required to cause development of any licensed product or licensed service for a particular market or use if we reasonably demonstrate to Johns Hopkins that developing such licensed products or licensed services or granting a sublicense for such market or use would a have a potentially adverse commercial effect upon licensed products or licensed services being developed or sold by us, our affiliates or our existing sublicensees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier in accordance with the agreement, the A&amp;R Johns Hopkins License Agreement and the royalty obligations thereunder will continue on a licensed&#160;product-by-licensed&#160;product or licensed&#160;service-by-licensed&#160;service and&#160;country-by-country&#160;basis until the expiration date of the&#160;last-to-expire&#160;patent or, if no patents issue, until the tenth anniversary of the agreement, at which time the licenses will become fully paid up and royalty-free.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or Johns Hopkins may terminate the A&amp;R Johns Hopkins License Agreement if the other party files for insolvency or if there is an uncured breach of obligations or failure to perform by the other party. We may terminate the A&amp;R Johns Hopkins License Agreement upon giving Johns Hopkins 90 days&#8217; written notice.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zephyr Joint Research Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we entered into a Joint Research Agreement, or JRA, with Zephyr AI, Inc., or Zephyr, focused on the joint collaboration, identification and validation of certain targets in order to facilitate further research, development and potential commercialization of immunotherapies.  Pursuant to the JRA , Zephyr will identify suitable antigens or combinations thereof for validation and testing by NexImmune. The Joint Steering Committee provided for by the JRA, or the JSC, will then determine which identified candidates shall be subject to further analysis. We will validate which, if any, of the identified antigens are suitable for T-cell engagement and killing function, which antigens are referred to as the Final Candidates. The JSC will make a good-faith determination as to whether the data supports the further IND-targeted development by us of any of the Final Candidates. We and Zephyr will jointly own any Final Candidates, including the intellectual property related thereto. Each of the company and Zephyr shall be responsible for payment of their own respective costs and expenses in connection with the performance of their respective obligations under the JRA. If a Final Candidate is to be further developed, then we and Zephyr shall engage in good-faith negotiations to agree on the terms and conditions of an agreement with respect to the further development and commercialization of such Final Candidate. If such an agreement is not executed within the prescribed negotiation period, then neither the we nor Zephyr may further develop such Final Candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the company and Zephyr can terminate the JRA (i) for any reason upon 90 days&#8217; written notice, and (ii) upon the other&#8217;s breach or default of any of the terms and conditions thereof, subject to 30 days&#8217; notice and cure period. Absent early termination or mutual extension, the JRA shall terminate two (2) years after the effective date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our patents and patent applications, and other proprietary rights, that we own or control through licensing, are important to our business and competitive position. In addition to patents, we rely on trade secrets,&#160;know-how,&#160;and continuing technological innovations to develop, maintain and strengthen our competitive position. We seek to protect these, in part, through confidentiality agreements with certain employees, consultants, advisors and other parties. Our success will depend in part on our ability, and the ability of our licensor, to obtain, maintain (including making periodic filings and payments) and enforce our patents, including those patents and applications to which we have exclusive rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have exclusively licensed seven issued United States patents and eight pending patent applications for the United States (including U.S. provisional applications). We also have 80 issued or allowed foreign patents and 46 pending foreign patent applications (including pending PCT Applications) intended to protect the intellectual property underlying our technology. In addition to the United States, we have patents issued or applications pending in Australia, Brazil, Canada, China, Europe (EPO), Hong Kong, India, Israel, Japan, South Korea, Mexico, Russian Federation, and Singapore. Our patent applications describe and claim certain features of our technologies, including our T cell activation and expansion platform, our cell therapy product candidates, and our drug candidates based on injectable artificial antigen presenting cells. We currently control issued patents in the United States, Australia, Canada, China, Europe (through the European Patent Convention), Hong Kong, India, Israel, Japan, Mexico, Singapore, South Korea, and Russian Federation, which relate to the technology for generating our cell therapy products (NEXI-001 and NEXI-002) from allogeneic or autologous T cells. Applications relating to our NEXI-001 and NEXI-002 programs remain pending in all jurisdictions for which we have filed patent applications, including more recent patent applications that relate in part to the NEXI-001 and NEXI-002 composition of matter. In addition, we control issued or allowed patents in the United States, Australia, Brazil, China, Israel, India, Japan, South Korea, Mexico, and Europe (through the European Patent Convention) that relate to our AIM INJ programs, including patents covering compositions of matter and methods of use. Applications relating to our AIM INJ programs remain pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, Russian Federation, South Korea, Singapore, and United States. We have and will continue to actively protect our intellectual property, including filing patent applications for our innovations, prosecuting our pending patent applications, and maintaining and enforcing our issued patents. We currently have one pending PCT Application and one pending U.S. provisional application relating to both our cell therapy and AIM INJ technology. No assurances can be given that pending patent applications will result in the issuance of a patent or that the examination process will not require us to narrow our claims. In addition, issued patents may be circumvented by third parties, or found unenforceable or invalid if contested before a court or administrative agency. Thus, we may not be able to successfully enforce our patent rights against third parties. No assurance can be given that others will not independently develop a similar or competing technology or design around any patents that may be issued to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our patents, if and when granted, will generally have a term of 20 years from its earliest,&#160;non-provisional&#160;filing date, subject to available extensions. Our patents and, if granted, patent applications have expiry dates ranging from 2034 to 2044.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more comprehensive risks related to our proprietary technology and processes, please see the section of this filing on Form&#160;10-K&#160;captioned &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors&#8212;Risks Related to Intellectual Property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutic products are subject to rigorous regulation by the FDA and other governmental agency regulations in the United States and in foreign countries. Noncompliance with applicable requirements can result in import detentions, fines, civil penalties, injunctions, suspensions or losses of regulatory approvals or clearances, recall or seizure of products, operating restrictions, denial of export applications, governmental prohibitions on entering into supply contracts, and criminal prosecution. Failure to obtain regulatory approvals or the restriction, suspension or revocation of regulatory approvals or clearances, as well as any other failure to comply with regulatory requirements, would have a material adverse effect on our business, financial condition and results of operations. In connection with therapeutic approval, we will have to comply with the many requirements associated with preclinical and clinical trials, the FDA application process, the terms of any&#160;pre-certification&#160;protocols and agreements, FDA manufacturing requirements for prototypes, and testing. Upon approval of a Biologics License Application, or BLA and similar approvals in other jurisdictions, there will be additional regulation relating to the packaging, distribution, marking, marketing and claims of our potential products. These later regulations are not only found in federal regulation but many states and, of course, foreign countries.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The U.S. FDA Process</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the clinical testing and design of therapeutics to ensure that medical products distributed in the United States are safe and effective for their intended uses. The application process for a new therapeutic is highly regulated.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation by relevant authorities. Our potential products will be regulated as biologics. With this classification, commercial production of our potential products will need to occur in registered and licensed facilities in compliance with current good manufacturing practices, or cGMP, established by the FDA for biologics. The FDA categorizes human cells, tissues, or cellular or tissue-based products, or HCT/Ps, as either minimally manipulated or more than minimally manipulated, and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a BLA for marketing authorization.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States (at the federal, state and local levels) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in a foreign country. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Product Development Process</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates pharmaceutical and biological products under the Federal Food, Drug and Cosmetic Act, or FDCA, the Public Health Services Act, or PHSA, and their respective implementing regulations. Products are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The FDA has limited experience with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial development of T cell therapies for cancer, including direct-injectable technologies such as AIM INJ. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">completion of nonclinical laboratory tests and animal studies according to good laboratory practice, or GLP, and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">approval by an independent institutional review board, or IRB, or ethics committee at each clinical trial site before each clinical trial may be initiated;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practice, or GCP, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity, and potency from results of nonclinical testing and clinical trials;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, compliance with the FDA&#8217;s current good tissue practice, or cGTP, for the use of human cellular and tissue products;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential FDA audit of the trial and clinical trial sites that generated the data in support of the BLA;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">review of the product candidate by an FDA advisory committee, where appropriate or if applicable; and</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">FDA review and approval, or licensure, of the BLA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical studies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any biological product candidate, including our product candidates, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product candidate&#8217;s biological characteristics, chemistry, toxicity, stability and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLP. The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human clinical trials in support of a BLA</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the biological product candidate to human research subjects under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a clinical trial involving a biological product candidate at any time before or during the trial due to safety concerns or non-compliance. If the FDA imposes a clinical hold, the trial may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin or that, once begun, issues will not arise that suspend or terminate such trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical trial will be conducted, and the IRB must conduct continuing review and reapprove the study at least annually. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent form that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. In certain cases, clinical trials also must be reviewed by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about certain clinical trials, including details of the protocol and eventually study results, also must be submitted within specific timeframes to the National Institutes of Health for public dissemination on the ClinicalTrials.gov data registry. Information related to the investigational product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years after the date of completion of the trial. Failure to timely register a covered clinical trial or to submit trial results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. The NIH&#8217;s Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and both NIH and FDA have recently begun enforcing those requirements against non-compliant clinical trial sponsors.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Phase I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The product candidate is initially introduced into human subjects to test for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Phase II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The biological product candidate is evaluated in a limited patient population to identify possible safety risks (adverse effects), optimize dosing and preliminarily evaluate the efficacy of the product candidate for specific targeted diseases.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Phase III</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Clinical trials are undertaken in an expanded patient population to further evaluate dosage, clinical efficacy, and safety, often at geographically dispersed trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval clinical trials, sometimes referred to as Phase IV clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety&#160;follow-up.&#160;In certain instances, the FDA may mandate the performance of Phase IV clinical trials as a condition of approval of a BLA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events, or SAEs, occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the clinical protocol, GCP, or other IRB requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor known as the data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a new drug or biological product, sponsors have the opportunity to meet with the FDA at certain points, including prior to submission of an IND, at the end of Phase II, and before submission of a BLA. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II meeting to discuss their Phase II clinical results with the agency and to present their plans for the pivotal Phase III studies that they believe will support approval of the new drug or biological product.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human immunotherapy products are a new category of therapeutics. Because this is a relatively new and expanding area of novel therapeutic interventions, there can be no assurance as to the length of the trial period, the number of subjects the FDA will require to be enrolled in the trials in order to establish the safety, efficacy, purity and potency of immunotherapy products, or that the data generated in these trials will be acceptable to the FDA to support marketing approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological drug candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Review and Approval Processes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the product&#8217;s chemistry, manufacturing, and controls and proposed labeling, are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. A BLA in particular must contain sufficient evidence of the biological product candidate&#8217;s safety, purity, potency and efficacy for its proposed indication or indications. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, as amended, or PDUFA, each BLA must be accompanied by a significant user fee, and the sponsor of an approved BLA is also subject to an annual program fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a&#160;non-orphan&#160;indication.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the goals and policies for original BLAs agreed to by the FDA under PDUFA, the FDA has ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority review. For all original BLAs, the ten and six-month time periods run from the filing date; for all other submissions, including resubmissions, efficacy supplements and other supplements, the FDA&#8217;s stated review time periods, ranging from two to ten month, run from the submission date. Despite these review goals, it is not uncommon for FDA review of a BLA to extend beyond the goal date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an&#160;in-depth&#160;substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. Most such applications are meant to be reviewed within ten months from the date it is accepted for filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months from the date the application is accepted for filing. The review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making final decisions on approval. The FDA likely will&#160;re-analyze&#160;the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug or biological product. The REMS could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a&#160;case-by-case&#160;basis. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will typically conduct a pre-approval inspection of the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For cell- or tissue-based immunotherapy products, the FDA also will not approve the product if the manufacturer is not in compliance with the cGTP, to the extent applicable. The FDA&#8217;s cGTP regulations and guidance documents govern the methods used in, and the facilities and controls used for, the manufacture of HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the cGTP requirements is to ensure that cellular tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP, cGTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. A sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration is required to submit an initial Pediatric Study Plan, or PSP, within sixty days of an&#160;end-of-Phase&#160;II meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase III or Phase II/III clinical trial. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from&#160;pre-clinical&#160;studies, early phase clinical trials or other clinical development programs. Unless otherwise required by regulation, the PREA does not apply to any product for an indication for which orphan designation has been granted. However, if only one indication for a product has orphan designation, a pediatric assessment may still be required for any applications to market that same product for the&#160;non-orphan&#160;indication(s).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval or may require additional clinical or other data and information. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. On the basis of the FDA&#8217;s evaluation of the BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue either an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase III clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant may choose to either resubmit the BLA addressing all of the deficiencies identified in the letter, or withdraw the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in response to an issued CRL in either two or six months depending on the type of information included. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product receives regulatory approval from the FDA, the approval is limited to the conditions of use (e.g., patient population, indication) described in the application. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase IV clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track, Breakthrough Therapy and Priority Review Designations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, Breakthrough Therapy Designation and priority review designation and regenerative medicine advanced therapy designation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the BLA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor and the FDA agree on a schedule for the submission of the application sections and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA. In addition, fast track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging from the clinical trial process.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, with the enactment of FDASIA in 2012, Congress created a new regulatory program for product candidates designated by FDA as &#8220;breakthrough therapies&#8221; upon a request made by the IND sponsors. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biologics designated as breakthrough therapies are also eligible for accelerated approval of their respective marketing applications. The FDA must take certain actions with respect to breakthrough therapies, such as holding timely meetings with and providing advice to the product sponsor, which are intended to expedite the development and review of an application for approval of a breakthrough therapy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, the FDA may designate a product for priority review if it is a drug or biologic that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a&#160;case-by-case&#160;basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months for an original BLA from the date of filing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, breakthrough therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the 21st Century Cures Act, congress created an accelerated approval pathway for regenerative medicine advanced therapies, or RMATs, which includes therapeutic tissue engineered products, human cell and tissue products, cell therapies and combination products using any such therapies. The program is intended to facilitate efficient development and expedite review of regenerative medicine therapies that are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may request a RMAT designation from the FDA concurrently with or any time after the IND submission. The FDA has 60 calendar days to determine if the drug product meets the required criteria. Preliminary clinical evidence that the product has the potential to address a serious unmet need or condition is expected, is not required to indicate that the drug product may offer significant improvement over current therapies. The RMAT designation provides the same benefits of the fast track and breakthrough designation programs and programs may be eligible for priority review. Products with the RMAT designation may also be eligible for accelerated approval if&#160;pre-agreed&#160;criteria are met.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accelerated Approval Pathway</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a drug or biologic when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint, and the product may be subject to expedited withdrawal procedures. Drugs and biologics granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval when the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate long-term clinical benefit of a drug.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase IV or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm the predicted clinical benefit of the product during post-marketing studies, would allow the FDA to withdraw approval of the drug. All promotional materials for product candidates being considered and approved under the accelerated approval program are subject to prior review by the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation and Exclusivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use will be disclosed publicly by the FDA; the posting will also indicate whether the drug or biologic is no longer designated as an orphan drug. More than one product candidate may receive an orphan drug designation for the same indication. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to seven years of orphan product exclusivity. During the seven-year exclusivity period, the FDA may not approve any other applications to market a product containing the same active moiety for the same disease, except in very limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. A product is clinically superior if it is safer, more effective or makes a major contribution to patient care. Thus, orphan drug exclusivity could block the approval of one of our potential products for seven years if a competitor obtains approval of the same product as defined by the FDA and we are not able to show the clinical superiority of our product candidate or if our product candidate&#8217;s indication is determined to be contained within the competitor&#8217;s product orphan indication. In addition, the FDA will not recognize orphan drug exclusivity if a sponsor fails to demonstrate upon approval that the product is clinically superior to a previously approved product containing the same active moiety for the same orphan condition, regardless of whether or not the previously approved product was designated an orphan drug or had orphan drug exclusivity. A product that has received orphan drug designation may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received the designation. Orphan exclusivity does not prevent the FDA from approving a different drug or biological product for the same disease or condition, or the same product for a different disease or condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period of orphan exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the disease or condition for which the product has been designated. In September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; in the statute means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the Agency to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; It is unclear how this court decision will be implemented by the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Restoration</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA approval of our biological products, some of our US patents may be eligible for limited patent term extension. These patent term extensions permit a patent restoration term of up to five years as compensation for any patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally&#160;one-half&#160;the time between the effective date of an IND, and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension, and the extension must be applied for prior to expiration of the patent. The USPTO in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric exclusivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is a type of&#160;non-patent&#160;marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. This&#160;six-month&#160;exclusivity may be granted if a sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. The issuance of a Written Request does not require the sponsor to undertake the described studies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reference Product Exclusivity for Biological Products</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the Patient Protection and Affordable Care Act, or ACA, was enacted in the United States and included the Biologics Price Competition and Innovation Act of 2009, or the BPCIA. The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an&#160;FDA-licensed&#160;reference biological product. To date, the FDA has approved a number of biosimilars, and numerous biosimilars have been approved in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe. The FDA has also issued several guidance documents outlining its approach to reviewing and approving biosimilars and interchangeable biosimilars.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biosimilar product is defined as one that is highly similar to a reference product notwithstanding minor differences in clinically inactive components and for which there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product. An interchangeable product is a biosimilar product that can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product, although to date no such products have been approved for marketing in the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biosimilar applicant must demonstrate that the product is biosimilar based on data from (1)&#160;analytical studies showing that the biosimilar product is highly similar to the reference product; (2)&#160;animal studies (including toxicity); and (3)&#160;one or more clinical studies to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity and potency.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed. If pediatric studies are performed and accepted by the FDA as responsive to a Written Request, the&#160;12-year&#160;exclusivity period will be extended for an additional six months. In addition, the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a supplement for the reference product for a subsequent application filed by the same sponsor or manufacturer of the reference product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a&#160;case-by-case&#160;basis with data submitted by the sponsor.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA is complex and is still being interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the&#160;12-year&#160;reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any potential products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for&#160;direct-to-consumer&#160;advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as&#160;off-label&#160;use), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available medical products for&#160;off-label&#160;uses, if the physicians deem such uses to be appropriate in their professional medical judgment, it is FDA&#8217;s position that manufacturers may not market or promote such&#160;off-label&#160;uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of&#160;off-label&#160;uses, and a company that is found to have improperly promoted&#160;off-label&#160;uses may be subject to significant liability. If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or a supplement, which may require the applicant to develop additional data or conduct additional&#160;pre-clinical&#160;studies and clinical trials. The FDA may also place other conditions on approvals including the requirement for a REMS to assure the safe use of the product. A REMS </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for&#160;non-compliance&#160;with regulatory standards or if problems occur following initial marketing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the quality and long-term stability of the product. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP and cGTP requirements and satisfy the FDA or comparable foreign regulatory authorities before any product is approved and our commercial products can be manufactured. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP and cGTP regulations. These third-party manufacturers must comply with cGMP and cGTP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP and cGTP. Manufacturers, including third-party manufacturers, and other entities involved in the manufacture and distribution of approved biologics and HCT/Ps are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, cGTP, and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP and cGTP compliance, as applicable. Future inspections by the FDA and other regulatory agencies may identify compliance issues at the facilities of our CMOs that may disrupt production or distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these rules, including failure to conform to cGMP or cGTP regulations, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, voluntary recall and regulatory sanctions as described below.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other post-approval requirements applicable to biological products, include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval or clearance of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product approvals;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure or detention, or refusal to permit the import or export of products;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties; and</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. Furthermore, the the Drug Supply Chain Security Act, or DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10-year period that is expected to culminate in November 2023. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Outside of the United States</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations within the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products outside of the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the&#160;28-member&#160;European Union, before we may commence clinical trials or market products in those countries or areas. It is not yet clear how the United Kingdom&#8217;s withdrawal from the European Union will affect the approval of medicinal products in the UK. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union drug development, review and approval</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, our product candidates also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. Similar to the United States, the various phases of&#160;pre-clinical&#160;and clinical research in the European Union are subject to significant regulatory controls.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new Clinical Trials Regulation (EU) No 536/2014, which became effective in January 2022, aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the &#8220;EU portal&#8221;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. Any substantial changes to the trial protocol or other information submitted with the CTA must be notified to or approved by the relevant competent authorities and ethics committees. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation. Investigational medicinal products used in clinical trials must be manufactured in accordance with good manufacturing practices. Other national and EU-wide regulatory requirements may also apply.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain a marketing authorization of a drug in the European Union, we may submit marketing authorization applications, or MAA, either under the&#160;so-called&#160;centralized or national authorization procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ATMP review and approval in the EU</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, medicinal products, including advanced therapy medicinal products, or ATMPs, are subject to extensive pre- and post-market regulation by regulatory authorities at both the EU and Member State levels. Regulated in accordance with Regulation (EC) No 1394/2007, ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products. Gene therapy products deliver genes into the body that lead to a therapeutic, prophylactic or diagnostic effect. We anticipate that our NEXI-001 and NEXI-002 product candidates will be regulated as ATMPs in the EU.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain regulatory approval of an ATMP under EU regulatory systems, we must submit a marketing authorization application, or MAA, under the centralized procedure administered by the European Medicines Agency, or EMA. The application used to submit a BLA in the United States is similar to the required application process in the EU, with the exception of, among other things, certain specific requirements set out in the ATMP Regulation, for example certain additional product characteristic information that must be included in the MAA. The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across all of the EU. As provided for in the ATMP Regulation, the scientific evaluation of MAAs for ATMPs is primarily performed by a specialized scientific committee called the Committee for Advanced Therapies, or CAT. The CAT prepares a draft opinion on the quality, safety and efficacy of the ATMP which is the subject of the MAA, which is sent for final approval to the Committee for Medicinal Products for Human Use, or CHMP. The CHMP recommendation is then sent to the European Commission, which adopts a decision binding in all EU Member States. The maximum timeframe for the evaluation of a MAA for an ATMP is 210 days from receipt of a valid MAA, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CAT and/or CHMP. Clock stops may extend the timeframe of evaluation of a MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, which makes and issues the final decision to grant a marketing authorization within 67 days of receipt of the EMA&#8217;s recommendation.  Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the timeframe of 210 days for assessment will be reduced to 150 days (excluding clock stops), but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Now that the United Kingdom (which comprises Great Britain and Northern Ireland) has left the EU, Great Britain will no longer be covered by centralized marketing authorizations (under the Northern Irish Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland). All medicinal products with a current centralized marketing authorization were automatically converted to Great Britain marketing authorizations on January, 1 2021. For a period of two years from January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, the United Kingdom medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate application will, however, still be required.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Conditional approval</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In specific circumstances, E.U. legislation (Article 14(7) Regulation (EC) No 726/2004 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1)&#160;the risk-benefit balance of the product candidate is positive, (2)&#160;it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3)&#160;the product fulfills unmet medical needs and (4)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric studies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining a marketing authorization in the EU, applicants have to demonstrate compliance with all measures included in an&#160;EMA-approved&#160;Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the elderly population.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union regulatory exclusivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the&#160;pre-clinical&#160;and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU. The&#160;ten-year&#160;market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union orphan designation and exclusivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an orphan medicinal product in the European Union, are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2)&#160;either (a) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (b)&#160;the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify investment; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;ten-year&#160;market exclusivity in the EU may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if:</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the applicant consents to a second orphan medicinal product application; or</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the applicant cannot supply enough orphan medicinal product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRIME designation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation, where the marketing authorization application will be made through the centralized procedure. Eligible products must target conditions for which where is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated Agency contact and rapporteur from the CHMP or CAT are appointed early in PRIME scheme facilitating increased understanding of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the product at EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Periods of authorization and renewals</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a&#160;re-evaluation&#160;of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the&#160;so-called&#160;sunset clause).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brexit and the regulatory framework in the United Kingdom</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the electorate in the United Kingdom voted in favor of leaving the European Union (commonly referred to as &#8220;Brexit&#8221;). Thereafter, in March 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom formally left the European Union on January 31, 2020. A transition period began on February 1, 2020, during which EU pharmaceutical law remained applicable to the United Kingdom. This transition period ended on December 31, 2020. Since the regulatory framework in the United Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the United Kingdom as United Kingdom legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for product candidates and products in the United Kingdom in the long-term. The MHRA, the United Kingdom medicines and medical devices regulator, has recently published detailed guidance for industry and organizations to follow from January 1, 2021 now that the transition period is over, which will be updated as the United Kingdom&#8217;s regulatory position on medicinal products evolves over time. On June 28, 2021, the European Commission issued a decision that the United Kingdom ensures an adequate level of protection for personal data transferred under the GDPR from the European Union to the United Kingdom.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of the world regulation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage, Pricing and Reimbursement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of pharmaceutical products approved by the FDA will depend in significant part on the availability of third-party coverage and reimbursement for the products. Third-party payors include government healthcare programs in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Further, there is no uniform policy for coverage and reimbursement in the United States. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development. Our product candidates may not be considered cost-effective. It is time consuming and expensive to seek reimbursement from third-party payors. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, coverage and reimbursement for products can differ significantly from payor to payor. One payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. In the United States, the principal decisions about reimbursement for new medicines are typically made by the U.S. Centers for Medicare &amp; Medicaid Services, or CMS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. Payment methodologies may also be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. There also has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. By way of example, in August 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated, or the impact of the IRA on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of our product candidate to currently available therapies (so-called health technology assessment, or HTA) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Other Member States allow companies to fix their own prices for drug products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally tend to be priced significantly lower.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution (arbitrage between low-priced and high-priced member states) can further reduce prices. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other U.S. Health Care Laws and Regulations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently do not have any products on the market, our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors expose us to broadly applicable healthcare regulation and enforcement by the U.S. federal government and the states and foreign governments in which we conduct our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business, such as fraud and abuse, transparency and health information privacy rules and regulations. These laws include, without limitation:</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal anti-kickback statute, prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal false claims laws, including the False Claims Act provides for civil whistleblower or qui tam actions, and the civil monetary penalties law, which among other things prohibit individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any health care benefit program or making false statements relating to health care matters;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information, for covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their business associates and covered subcontractors that provide services to, or on behalf of, the covered entity that involve individually identifiable health information;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal transparency requirements under the Physician Payments Sunshine Act require certain manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to the Department of Health and Human Services, or DHS, information related to payments and other transfers of value to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate family members. Beginning in 2022, applicable manufacturers will also be required to report information related to payments and other transfers of value provided in the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives;</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws and regulations pertaining to our financial relationships and interactions with foreign government officials, which prohibit U.S. companies and their employees, officers, and representatives from paying, offering to pay, promising, or authorizing the payment of anything of value to any foreign government official (including, potentially, healthcare professionals in countries in which we operate or may sell our products), government staff member, political party, or political candidate to obtain or retain business or to otherwise seek favorable treatment; and</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by nongovernmental third-party payors, including private insurers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the DHHS finalized significant changes to the regulations implementing the AKS, as well as the Physician Self-Referral Law (Stark Law) and the civil monetary penalty rules regarding beneficiary inducements, with the goal of offering the healthcare industry more flexibility and reducing the regulatory burden associated with those fraud and abuse laws, particularly with respect to value-based arrangements among industry participants.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines, or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures to the extent that those laws impose requirements that are more stringent than the Physician Payments Sunshine Act. In addition, state and local laws may require the registration of pharmaceutical sales representatives. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of any of such laws or any other governmental regulations that apply to us, may subject us to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of&#160;non-compliance&#160;with these laws, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Reform in the United States and Potential Changes to Health Care Laws</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously mentioned, a primary trend in the U.S. health care industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other health care funding. As previously mentioned, a primary trend in the U.S. health care industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other health care funding and applying new payment methodologies. For example, in March 2010, the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#8217; outpatient drugs coverage under Medicare Part D; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the Act. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact health care laws and regulations or our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, presidential executive orders and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical and biologic products. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other health care funding and applying new payment methodologies. In addition to the sweeping reforms contained in the ACA, other legislative changes have been proposed and adopted in the United States that may affect health care expenditures. For example, the 2020 Consolidated Appropriations Act (P.L. 116-94) included a piece of bipartisan legislation called the Creating and Restoring Equal Access to Equivalent Samples Act, or the CREATES Act. The CREATES Act aims to address the concern articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS program for certain products, to deny generic product developers access to samples of brand products. Because generic product developers need samples to conduct certain comparative testing required by the FDA, some have attributed the inability to timely obtain samples as a cause of delay in the entry of generic products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221; Whether and how generic product developments will use this new pathway, as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as the likely outcome of any legal challenges to provisions of the CREATES Act, remain highly uncertain and its potential effects on our future commercial products are unknown.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biden Administration, which assumed control of the Executive Branch on January 20, 2021, has indicated that lowering prescription drug prices is a priority. For example, in July 2021, President Biden issued a sweeping executive order on promoting competition in the American economy that includes several mandates pertaining to the pharmaceutical and health care insurance industries. Among other things, the executive order directs the FDA to work towards implementing a system for importing drugs from Canada (following on a Trump administration notice-and-comment rulemaking on Canadian drug importation that was finalized in October 2020). The Biden order also called on HHS to release a comprehensive plan to combat high prescription drug prices, and it includes several directives regarding the Federal Trade Commission&#8217;s oversight of potentially anticompetitive practices within the pharmaceutical industry. The drug pricing plan released by HHS in September 2021 in response to the executive order makes clear that the Biden Administration supports aggressive action to address rising drug prices, including allowing HHS to negotiate the cost of Medicare Part B and D drugs, but such significant changes will require either new legislation to be passed by Congress or time-consuming administrative actions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that federal, state and local governments in the United States will continue to consider legislation directed at lowering the total cost of health care. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate pharmaceutical benefit managers, or PBMs, and other members of the health care and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize any product that is ultimately approved, if approved. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employees and Human Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;1, 2023, we had 50 full-time employees. Of these employees, 36 were engaged in research and development activities. Substantially all of our employees are based in Gaithersburg, Maryland. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We have no collective bargaining agreements with our employees, and we have not experienced any work stoppages. We consider our relations with our employees to be good.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in 2011. Our principal executive offices are located at 9119 Gaither Road, Gaithersburg, MD 20877, and our telephone number is (301)&#160;825-9810.&#160;Our website address is</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;www.neximmune.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and the information contained in, or that can be accessed through, our website is not part of this annual report and should not be considered part of this annual report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934 (Exchange Act). The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also make available free of charge on our Internet website at</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;www.neximmune.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;our annual reports on Form&#160;10-K,&#160;quarterly reports on Form&#160;10-Q,&#160;current reports on Form&#160;8-K,&#160;and, if applicable, amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. These reports are available through the &#8220;Investor Relations&#8212;Financials and Filings&#8212;SEC Filings&#8221; section of our website.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our code of ethics, other corporate policies and procedures, and the charters of our Audit Committee, Compensation Committee and Nominating and Governance Committee are available through our Internet website at&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.neximmune.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i5091247d182148eaaadd80685b94df97_19"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance&#160;Sheet Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented we did not have, nor do we currently have, any&#160;off-balance&#160;sheet arrangements as defined under SEC rules.</span></div><div id="i5091247d182148eaaadd80685b94df97_22"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, the section of this Annual Report Form&#160;10-K&#160;entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation&#8221; and our financial statements and related notes, before investing in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business, operating results and prospects could be materially harmed. In that event, the price of our common stock could decline, and you could lose part or all of your investment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our Risk Factors:</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">We require substantial additional funding. If we are unable to raise capital, we expect to be compelled to delay, reduce or eliminate our product candidate development programs and may be unable to further develop our AIM nanoparticle technology.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">Pursuant to our recently announced strategic realignment announced in November 2022, we have paused clinical trials for our AIM ACT cell therapy product candidates in order to realign our focus on our AIM INJ preclinical programs. If we fail to execute successfully on this realigned strategic focus, our business and prospects may be adversely affected.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">Our shares of common stock could be delisted from the Nasdaq Global Market which could result in, among other things, a decline in the price of our common stock and less liquidity for holders of shares of our common stock.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We have incurred significant operating losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If we are unable to successfully obtain approval for and commercialize&#160;our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Initial success in our ongoing clinical trials may not be indicative of results obtained when these trials are completed.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We plan to initially target a small number of patients with our product candidates, and the market opportunities for these product candidates, if and when approved, may be limited to those patients who are ineligible for established therapies or have failed prior treatments and, accordingly, the opportunities may be small.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The AIM technology is a novel immunotherapy platform and therapies derived from it have not been tested in humans before. As a result, only limited human study data is available and it remains not fully known as to what kind of cytokines may be released.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If we are not able to obtain, or if there are delays in obtaining, required marketing approvals, we will not be able to commercialize our product candidates, if approved, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our product candidates are biologics and the manufacturing process for our product candidates is complex, generally more costly than traditional small molecule chemical compounds, and more difficult to reproduce. If we or any of our third-party manufacturers encounter manufacturing difficulties, our ability to provide or secure supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We rely on, and expect to continue to rely on, third parties to conduct our clinical trials for our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our product candidates, and our business could be substantially harmed.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The third parties upon which we rely for the supply of the source materials, are our sole sources of supply and have limited capacity, and the loss of any of these suppliers could harm our business.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.</span></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If we are unable to obtain and maintain intellectual property protection for our technology and products, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A detailed discussion of the above Risk Factors follows below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company that was formed in June 2011. We have no products approved for commercial sale and have not generated any revenue. We are focused on developing immunotherapy products in which the body&#8217;s immune system is orchestrates a targeted T cell response against disease-relevant cells. Although there have been significant advances in cell-based immunotherapy, our T cell technologies are new and largely unproven. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential product candidates, undertaking preclinical studies, and conducting clinical trials. If one of our product candidates received regulatory approval, we will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. In addition, our limited operating history, particularly in light of the rapidly evolving cancer immunotherapy field, may make it difficult to evaluate our current business and predict our future performance. Our short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses in for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not profitable and have incurred significant losses in each period since our inception, including net losses of $62.5 million and $50.9 million for the years ended December&#160;31, 2022 and 2021, respectively. We have not commercialized any products and have never generated any revenue from product sales. We expect these losses to increase as we continue to incur significant research and development and other expenses related to our ongoing operations, seek regulatory approvals for our product candidates,&#160;scale-up&#160;manufacturing capabilities and hire additional personnel to support the development of our product candidates and to enhance our operational, financial and information management systems.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A critical aspect of our strategy is to invest significantly in our technology platform to improve the efficacy and safety of our product candidates. To become and remain profitable, we must develop and eventually commercialize products with significant market potential, which we may never achieve. Even if we succeed in commercializing one or more of these product candidates, we will continue to incur losses for the foreseeable future relating to our substantial research and development expenditures to develop our technologies. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Further, the net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a period to period comparison of our results of operations may not be a good indication of our future performance. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our discovery and preclinical development efforts, expand our business or continue our operations and may require us to raise additional capital that may dilute your ownership interest. A decline in the value of our company could also cause you to lose all or part of your investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. Biopharmaceutical drug development is a highly speculative undertaking and involves a substantial degree of risk. We were incorporated in June 2011, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential product candidates, undertaking nonclinical studies and conducting clinical trials. We have not yet demonstrated our ability to successfully obtain marketing approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Typically, it takes several years to develop one new drug from the time it is discovered to when it is available for treating patients. In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated any revenue from product sales and our ability to generate revenue from product sales and become profitable depends significantly on our success in a number of factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale, have not generated any revenue from product sales, and do not anticipate generating any revenue from product sales until sometime after we have received regulatory approval for the commercial sale of a product candidate. Our ability to generate revenue and achieve profitability depends significantly on our success in many factors, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">completing research regarding, and nonclinical and clinical development of, our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining regulatory approvals and marketing authorizations for product candidates for which we complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developing a sustainable and scalable manufacturing process for our product candidates, including establishing and maintaining commercially viable supply relationships with third parties and establishing our own manufacturing capabilities and infrastructure;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">launching and commercializing product candidates for which we obtain regulatory approvals and marketing authorizations, either directly or with a collaborator or distributor;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining market acceptance of our product candidates as viable treatment options;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">addressing any competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">identifying, assessing, acquiring and/or developing new product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and&#160;know-how;&#160;and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">attracting, hiring, and retaining qualified personnel.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the U.S. Food and Drug Administration, or the FDA, or other regulatory agencies, domestic or foreign, or other comparable foreign authorities, to perform preclinical studies or clinical trials in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of any of our product candidates, our expenses could increase and revenue could be further delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies, domestic or foreign, to change our manufacturing processes or assays, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate. If we are successful in obtaining regulatory approvals to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price, and whether w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;own the commercial rights for that territory. If the number of our addressable disease patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are not able to generate revenue from the sale of any approved products, we may never become profitable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain additional financing on acceptable terms or at all, we may be unable to complete the development and commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have required substantial amounts of cash since inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our product candidates. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We would have to spend substantial amounts to conduct research and development and preclinical or nonclinical testing and studies and clinical trials, to build a supply chain, to seek regulatory approvals for any product candidates we may develop. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company in the United States.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $34.6 million in cash, cash equivalents, and available-for-sale marketable securities. In February 2021, we completed the IPO for net proceeds of $114.6 million after deducting underwriting discounts and commissions and offering expenses. We believe that, based upon our current operating plan, our existing capital resources will be sufficient to meet our anticipated cash requirements for at least twelve months from the issuance of these financial statements. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because the length of time and activities associated with successful research and development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. In addition, our future capital requirements will depend on many factors, and could increase significantly as a result of many factors, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope, progress, results and costs of nonclinical development, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope, prioritization and number of our research and development programs;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to establish collaboration arrangements for the development of our product candidates on favorable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the extent to which we acquire or&#160;in-license&#160;other product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs associated with being a public company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that additional funding will be available on acceptable terms, or at all. Our ability to raise additional funding will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. In addition, our ability to obtain future funding when needed through equity financings, debt financings or strategic collaborations may be particularly challenging in light of the continued uncertainties and circumstances regarding the coronavirus, or&#160;COVID-19,&#160;pandemic. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Our license and collaboration agreements may also be terminated if we are unable to meet the payment obligations under the agreements. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a shelf registration statement effective and an existing &#8220;at-the-market&#8221; offering facility, however, our ability to raise capital under this registration statement and through our &#8220;at-the-market&#8221; offering facility may be limited by, among other things, SEC rules and regulations impacting the eligibility of smaller companies to use Form S-3 for primary offerings of securities. Based on our public float, as of the date of the filing of this Annual Report on Form 10-K, we are only permitted to utilize a shelf registration statement, including the registration statement under which our &#8220;at-the-market&#8221; offering facility is operated, subject to Instruction I.B.6 to Form S-3, which is referred to as the &#8220;baby shelf&#8221; rule. For so long as our public float is less than $75.0 million, we may not sell more than the equivalent of one-third of our public float during any 12 consecutive months pursuant to the baby shelf rules. Although alternative public and private transaction structures may be available, these may require additional time and cost, may impose operational restrictions on us, and may not be available on attractive terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pursuant to our announced strategic realignment announced in November 2022, we have paused clinical trials for our AIM ACT cell therapy product candidates in order to realign our focus on our AIM INJ preclinical programs. If we fail to execute successfully on this realigned strategic focus, our business and prospects may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we announced that we are pausing our clinical trials for NEXI-001 and NEXI-003, and that our clinical trial for NEXI-002 will remain paused, in order to realign our focus on development of the AIM INJ platform. We believe this realigned strategic focus is the best way to optimize our financial and other resources to advance our business. However, there is no assurance that we will be successful at executing on this strategy, and we cannot currently specify when, if ever, we will be able to resume clinical development of NEXI-001, NEXI-002 or NEXI-003. If we are unable to execute successfully on this realigned strategic focus, our business and prospects may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our chief executive officer and certain other key executives and to attract, retain and motivate qualified personnel.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the experience of Kristi Jones, our President and Chief Executive Officer, as well as certain other principal members of our management, scientific and R&amp;D teams. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we implemented a strategic realignment that reduced our workforce by approximately 30%. The uncertainty inherent in this ongoing restructuring may be difficult to manage, may cause concerns from third parties with whom we do business, and may increase the likelihood of turnover of other key officers and employees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are have undertaken internal realignment activities that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that our strategic realignment will achieve the cost savings, operating efficiencies or other benefits that we may initially expect. Realignment activities may also result in a loss of continuity, accumulated knowledge and inefficiency during transitional periods and thereafter. In addition, internal realignments can require a significant amount of time and focus from management and other employees, which may divert attention from operations. Further, our realignment may result in unexpected expenses or liabilities and/or write-offs. If our strategic realignment fails to achieve some or all of the anticipated benefits, our cash resources may not last as long as estimated and our business, results of operations and financial condition could be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our costs and expenses to increase as we continue to develop our product candidates and progress our current clinical programs and costs associated with being a public company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents, and marketable securities of $34.64 million as of December&#160;31, 2022, which we believe that should be sufficient to fund our operating plan into the fourth quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Pursuant to the requirements of ASC 205-40, Presentation of Financial Statements - Going Concern, and as a result of our financial condition and other factors described herein, there is substantial doubt about our ability to continue as a going concern for a period of at least twelve months from the date of the financial statements. Our ability to continue as a going concern will depend on our ability to obtain additional funding, as to which no assurances can be given. Our future success depends on our ability to raise capital and/or execute our current operating plan. However, we cannot be certain that these initiatives or raising additional capital, whether through issuing additional debt or equity securities or obtaining a line of credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of our common stock, and our current shareholders may experience dilution. If we are unable to obtain funds when needed or on acceptable terms, we may be required to curtail our current development programs, cut operating costs, forego future development and other opportunities or even terminate our operations, which may involve seeking bankruptcy protection.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with more substantial enterprises.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition. As a result, our actual or proposed immunotherapies could become obsolete before we recoup any portion of our related research and development and commercialization expenses. Competition in the biopharmaceutical industry is based significantly on scientific and technological factors. These factors include the availability of patent and other protection for technology and products, the ability to commercialize technological developments and the ability to obtain governmental approval for testing, manufacturing and marketing. We compete with specialized biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations. Many biopharmaceutical companies have focused their development efforts in the human therapeutics area, including cancer. Many major pharmaceutical companies have developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies. These companies, as well as academic institutions, governmental agencies and private research organizations, also compete with us in recruiting and retaining highly qualified scientific personnel and consultants. Our ability to compete successfully with other companies in the pharmaceutical field will also depend to a considerable degree on the continuing availability of capital to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of certain investigational new drugs under development or approved products by competitors that are used for the prevention, diagnosis, or treatment of certain diseases we have targeted for drug development. Various companies are developing biopharmaceutical products that have the potential to directly compete with our immunotherapies even though their approach may be different. The competition comes from both biotechnology firms and from major pharmaceutical companies. Many of these companies have substantially greater financial, marketing, and human resources than us. We also experience competition in the development of our immunotherapies from universities, other research institutions and others in acquiring technology from such universities and institutions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our immunotherapies may be subject to competition from investigational new drugs and/or products developed using other technologies, some of which have completed numerous clinical trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful development of immunotherapies is highly uncertain.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of biopharmaceuticals is highly uncertain and depends on numerous factors, many of which are beyond our control. Immunotherapies that appear promising in the early phases of development may fail to reach the market for several reasons including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinical study results that may show the immunotherapy to be less effective than expected (e.g., the study failed to meet its primary endpoint) or to have unacceptable side effects;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused by slow enrollment in clinical studies, length of time to achieve study endpoints, additional time requirements for data analysis, or preparation of Biologics License Application, or BLA, discussions with the FDA, an FDA request for additional preclinical or clinical data, or unexpected safety or manufacturing issues;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">manufacturing costs, formulation issues, pricing or reimbursement issues, or other factors that make the immunotherapy uneconomical; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the proprietary rights of others and their competing products and technologies that may prevent the immunotherapy from being commercialized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical and early clinical studies does not ensure that large-scale clinical studies will be successful. Clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. The length of time necessary to complete clinical studies and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one immunotherapy to the next and may be difficult to predict.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in getting market approval, commercial success of any of our product candidates will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and managed care organizations, which may be affected by existing and future health care reform measures designed to reduce the cost of health care. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other health care payors were not to provide adequate coverage and reimbursement levels for any of our products once approved, market acceptance and commercial success would be reduced.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our technology platform, including our proprietary Artificial Immune Modulation, or AIM, technology is a new approach to treat cancer and other immune-related diseases that presents significant challenges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concentrated our research and development efforts on advancing a new generation of immunotherapies based on the AIM technology, and our future success is highly dependent on the successful development of our product candidates, which target cancer and other immune-related diseases. Our technology platform is the foundation for our innovative approach to immunotherapy in which the body&#8217;s immune system orchestrates a targeted T cell response against disease-relevant cells. Central to the AIM technology are synthetic dendritic cells that present antigens to T cells eliciting a targeted therapy driven by the patient&#8217;s immune system. Because this is a new approach to immunotherapy and for the treatment of cancer and other immune-related diseases generally, developing and commercializing our product candidates subjects us to a number of challenges, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">educating medical personnel about the administration of the AIM product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">educating medical personnel regarding the potential side effect profile of our product candidates, such as the potential adverse side effects related to cytokine release syndrome, neurotoxicity or autoimmune or rheumatologic disorders. As the AIM technology is a novel immunotherapy platform and therapies derived from it have not been tested in humans before, only limited human study data is available, and it remains not fully known as to what kind of cytokines may be released. Medical personnel will need to continue to monitor on an ongoing basis;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">administering chemotherapy to patients in advance of administering our product candidates, which may increase the risk of adverse side effects;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sourcing clinical and, if approved, commercial, supplies for the materials used to manufacture and process our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">manufacturing the proteins necessary for the cell therapy and injections and issues with our facility, quality control or general production process may arise, which could delay the development of our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developing AIM INJ, a direct-injectable modality of the AIM technology that has not previously been demonstrated and may not work as originally contemplated;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potentially moving the development of AIM INJ into the clinic, and addressing uncertainty around the regulatory requirements that may need to be met in connection with such an investigational new drug application, or IND;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">managing the risk in relying on one single source for the production of AIM nanoparticles, including the risk that if that source is unable to provide us with the necessary particles that may result in significant delays to our clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developing a robust and reliable T cell manufacturing process, including efficiently managing shipment of patient cells from and to clinical sites, minimizing potential contamination to the cell product and effectively scaling manufacturing capacity to meet demand;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">managing costs of inputs and other supplies while scaling production;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">using medicines to manage adverse side effects of our product candidates, which may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining regulatory approval from the FDA;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">addressing the broader uncertainty around the regulatory requirements and pathway for the approval of an adoptive cell therapy;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be sure that our AIM technology will yield satisfactory products that are safe and effective, scalable, or profitable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are a cell therapy company our technology could become subject to many of the challenges and risks that gene therapies face, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the future.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA could recommend&#160;follow-up&#160;observation period of up to 15 years for all patients who receive our treatment. We may need to adopt such an observation period for our product candidates.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinical trials using genetically modified cells conducted at institutions that receive funding for recombinant DNA research from the U.S. National Institutes of Health, or the NIH, are subject to review by the NIH Office of Biotechnology Activities&#8217; Recombinant DNA Advisory Committee, or the RAC. Although the FDA decides whether individual protocols may proceed, the RAC review process can impede the initiation of a clinical trial, even if the FDA has reviewed the study and approved its initiation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, public perception of therapy safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to subscribe to the novel treatment mechanics. Physicians, hospitals and third-party payors often are slow to adopt new products, technologies and treatment practices that require additional upfront costs and training. Physicians may not be willing to undergo training to adopt this novel and personalized therapy, may decide the therapy is too complex to adopt without appropriate training and may choose not to administer the therapy. Based on these and other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our near-term ability to generate product revenue is dependent on the success of one or more of our product candidates, each of which are at an early-stage of development and will require significant additional clinical testing before we can seek regulatory approval and begin commercial sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our near-term ability to generate product revenue is highly dependent on our ability to obtain regulatory approval of and successfully commercialize one or more of our product candidates. All of our product candidates are in the early stages of development and will require additional clinical and nonclinical development, regulatory review and approval in each </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdiction in which we intend to market the products, substantial investment, access to sufficient commercial manufacturing capacity, and significant marketing efforts before we can generate any revenue from product sales. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety, purity, and potency of the product candidates in humans. We cannot be certain that any of our product candidates will be successful in clinical trials and they may not receive regulatory approval even if they are successful in clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can generate any revenues from sales of our lead product candidates, we must complete the following activities for each of them, any one of which we may not be able to successfully complete:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">conduct additional preclinical and clinical development with successful outcomes;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">manage preclinical, manufacturing and clinical activities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtain regulatory approval from the FDA and other comparable foreign regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish manufacturing relationships for the clinical and post-approval supply of the applicable drug candidate in compliance with all regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">build a commercial sales and marketing team, either internally or by contract with third parties;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish and maintain patent and trade secret protection or regulatory exclusivity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">develop and implement marketing strategies for successful commercial launch of our product candidates, if and when approved;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">secure and maintain acceptance of our products, if and when approved, by patients, from the relevant medical communities and from third-party payors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">compete effectively with other therapies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish and maintain adequate health care coverage and reimbursement from third-party payors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ensure continued compliance with any post-marketing requirements imposed by regulatory authorities, including any required post-marketing clinical trials or the elements of any post-marketing Risk Evaluation and Mitigation Strategy, or REMS, that may be required by the FDA or comparable requirements in other jurisdictions to ensure the benefits of the product outweigh its risks;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain continued acceptable safety profile of the product candidates following approval; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">invest significant additional cash in each of the above activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to address one or more of these factors in a timely manner or at all, we could experience significant delays in the successful commercialization of, or an inability to successfully commercialize, our product candidates, which would materially harm our business. If we do not receive regulatory approvals for one or more of our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to manufacture and market our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because&#160;NEXI-001&#160;and&#160;NEXI-002&#160;are clinical-stage candidates, and because our other product candidates are based on similar technology, if&#160;NEXI-001&#160;and&#160;NEXI-002&#160;were to encounter safety or efficacy problems, developmental delays, regulatory issues, or other problems, our development plans and business could be significantly harmed. Further, competitors who are developing products with similar technology may experience problems with their products that could identify problems that would potentially harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely completion of clinical development include:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation of clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in reaching a consensus with regulatory agencies on trial design;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA may not allow us to use the clinical trial data from a research institution to support an IND if we cannot demonstrate the comparability of our product candidates with the product candidate used by the relevant research institution in its clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our INDs have been approved in a timely manner thus far, however the FDA may not agree with our approach and strategy, which could result in potential delays, and changes to our regulatory strategy;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be required to complete additional preclinical studies in HLAs before we can proceed with our INDs;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in obtaining required Institutional Review Board, or IRB, approval at each clinical trial site;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical trial operations or trial sites; developments on clinical trials conducted by competitors for related technology that raises FDA concerns about risk to patients of the technology broadly; or if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in recruiting suitable patients to participate in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">difficulty collaborating with patient groups and investigators;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure by our CROs, other third parties, or us to adhere to clinical trial requirements;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure to perform in accordance with the FDA&#8217;s current good clinical practice regulations, or cGCPs, requirements, or similar applicable regulatory guidelines in other countries;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in having patients complete participation in a trial or return for post-treatment&#160;follow-up;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">patients dropping out of a trial;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of clinical trials of our product candidates being greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in developing our manufacturing processes and transferring to new third-party facilities to support future development activities and commercialization that are operated by contract manufacturing organizations, or CMOs, in a manner compliant with all regulatory requirements; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval for our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional trials to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of any of our product candidates may be delayed, and our business will be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we provide timing estimates regarding the initiation of clinical trials and clinical development milestones, and the expected availability of data resulting from these trials for certain of our product candidates. We expect to continue to estimate the timing of these types of development milestones and our expected timing for the accomplishment of various other scientific, clinical, regulatory and other product development objectives. However, the achievement of many of these milestones and events may be outside of our control. All of these timing estimations are based on a variety of assumptions we make which may cause the actual timing of these events to differ from the timing we expect, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our available capital resources and our ability to obtain additional funding as needed;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the rate of progress, costs and results of our clinical trials and research and development activities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our receipt of approvals by the FDA, European Medicines Agency, or EMA, and other regulatory authorities and the timing of these approvals;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to access sufficient, reliable and affordable supplies of materials used in the manufacture of our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the efforts with respect to the commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the securing of, costs related to, and timing issues associated with, manufacturing our therapeutic</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">candidates and, if any of our product candidates are approved, associated with sales and marketing activities and the commercial manufacture of our product candidates; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">circumstances arising from or relating to the&#160;COVID-19&#160;pandemic, including potential effects on the global supply chain, our manufacturers and the availability of raw materials needed for the research and development of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to achieve announced milestones in the timeframes we expect, the commercialization of any of our product candidates may be delayed, and our business and results of operations may be harmed and our stock price may decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully identify, develop and commercialize additional therapeutics or product candidates could impair our ability to grow.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a substantial amount of our efforts will focus on the continued preclinical and clinical testing and potential approval of our product candidates in our current pipeline, we expect to continue to innovate and potentially expand our portfolio. Because we have limited financial and managerial resources, research programs to identify product candidates may require substantial additional technical, financial and human resources, whether or not any new potential product candidates are ultimately identified. Our success may depend in part upon our ability to identify, select and develop promising product candidates and therapeutics. We may expend resources and ultimately fail to discover and generate additional product candidates suitable for further development. All product candidates are prone to risks of failure typical of biotechnology product development, including the possibility that a product candidate may not be suitable for clinical development as a result of its harmful side effects, limited efficacy or other characteristics indicating that it is unlikely to receive approval by the FDA, the EMA and other comparable foreign regulatory authorities and achieve market acceptance. If we do not successfully develop and commercialize new product candidates we have identified and explored, our business, prospects, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to health, pandemics, epidemics and outbreaks, including the&#160;COVID-19&#160;pandemic, which could significantly disrupt our preclinical studies and clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide, our business may be adversely affected. The&#160;COVID-19&#160;pandemic has impacted the global economy and may continue to impact our operations, including the potential interruption of our clinical trial activities, regulatory reviews and our supply chain. For example, the&#160;COVID-19&#160;pandemic may delay enrollment in our clinical trials due to prioritization of hospital resources toward the outbreak or other factors, and some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay our ability to conduct clinical trials or release clinical trial results and could delay our ability to obtain regulatory approval and commercialize our product candidates. Furthermore, the spread of the virus may affect the operations of key governmental agencies, such as the FDA, which may delay the development or approval process for our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At present, we are not experiencing significant impact or delays from&#160;COVID-19&#160;on our business or operations. However, the enrollment of patients in, and the conduct of, our clinical trials have been, and we expect may continue to be, affected by the&#160;COVID-19&#160;pandemic. In particular, the trial start date for our&#160;NEXI-002&#160;clinical trial was delayed from April to September 2020. We have also experienced delays in transporting blood products from donors to manufacturing sites in California and in planned technology transfer in connection with our manufacturing process. The global outbreak of&#160;COVID-19&#160;may further delay enrollment in our planned or ongoing clinical trials due to prioritization of hospital resources toward the outbreak, the protection of the health of patients and investigators at the clinical trial sites, and restrictions on work and travel. In addition, some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. These and other factors could significantly delay our ability to conduct clinical trials or release clinical trial results. We will continue to monitor carefully the situation with respect to each of our clinical trials and follow guidance from local and federal health authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19&#160;may also affect employees of third-party contract research organizations that we rely upon to carry out our clinical trials. The spread of&#160;COVID-19,&#160;or another infectious disease, could also negatively affect the operations at our CMOs, which could result in delays or disruptions in the supply of our product candidates. In addition, we have taken precautionary measures, and may take additional measures, intended to help minimize the risk of the virus to our employees, including temporarily requiring certain employees to work remotely, suspending all&#160;non-essential&#160;travel worldwide for our employees, and discouraging employee attendance at industry events and&#160;in-person&#160;work-related meetings, which could negatively affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot presently predict the extent to which current or future business shutdowns and disruptions may impact or limit our ability or the ability of any of the third parties with which we engage to conduct business in the manner and on the timelines presently planned. Any such impacts or limitations could have a material adverse impact on our business and our results of operation and financial condition. While the potential economic impact brought by and the duration of the coronavirus outbreak may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of&#160;COVID-19&#160;could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant outbreak of other infectious diseases in the future also could result in a widespread health crisis that could adversely affect the economies and financial markets worldwide, resulting in an economic downturn that could impact our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA or comparable foreign regulatory authorities may disagree with our regulatory plans and we may fail to obtain regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA standard for approval of a biologic generally requires two well-controlled Phase III studies or one large and robust, well-controlled Phase III study in the patient population being studied that provides substantial evidence that a biologic is safe and effective for its proposed indication. Phase III clinical trials typically involve hundreds of patients, have significant costs and take years to complete. Product candidates studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA usually requires a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals. Although we intend to request accelerated approval status for&#160;NEXI-001&#160;and&#160;NEXI-002,&#160;we can provide no assurance that the FDA will grant such designation for either product candidate, nor can we provide any assurance that even if the FDA grants such designation that it will improve the likelihood that the agency will ultimately approve either product candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its marketing authorization process, the EMA may grant marketing authorizations on the basis of less complete data than is normally required, when, for certain categories of medicinal products, doing so may meet unmet medical needs of patients and serve the interest of public health. In such cases, it is possible for the Committee for Medicinal Products for Human Use, or CHMP, to recommend the granting of a marketing authorization, subject to certain specific obligations to be reviewed annually, which is referred to as a conditional marketing authorization. This may apply to medicinal products for human use that fall under the jurisdiction of the EMA, including those that aim at the treatment, the prevention, or the medical diagnosis of seriously debilitating diseases or life-threatening diseases and those designated as orphan medicinal products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A conditional marketing authorization may be granted when the CHMP finds that, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, all the following requirements are met:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the risk-benefit balance of the medicinal product is positive;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">it is likely that the applicant will be in a position to provide the comprehensive clinical data;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unmet medical needs will be fulfilled; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The granting of a conditional marketing authorization is restricted to situations in which only the clinical part of the application is not yet fully complete. Incomplete nonclinical or quality data may only be accepted if duly justified and only in the case of a product intended to be used in emergency situations in response to public-health threats.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditional marketing authorizations are valid for one year, on a renewable basis. The holder is required to complete ongoing studies or to conduct new studies with a view to confirming that the benefit-risk balance is positive. In addition, specific obligations may be imposed in relation to the collection of pharmacovigilance data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The granting of a conditional marketing authorization  allows medicines to reach patients with unmet medical needs earlier than might otherwise be the case and ensure that additional data on a product are generated, submitted, assessed and acted upon. Although we may seek a conditional marketing authorization for one or more of our product candidates by the EMA, the EMA or CHMP may ultimately not agree that the requirements for such conditional marketing authorization have been satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial results may also not support approval, whether accelerated approval, conditional marketing authorizations, or regular approval. The results of preclinical studies and clinical trials may not be predictive of the results of later-stage clinical trials, and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through preclinical studies and initial clinical trials. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be unable to demonstrate that our product candidates&#8217; risk-benefit ratios for their proposed indications are acceptable;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be unable to demonstrate that the clinical and other benefits of our product candidates outweigh their safety risks;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, our own manufacturing facilities, or a third-party manufacturer&#8217;s facilities with which we contract for clinical and commercial supplies; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, failure to obtain approval for any of the above reasons may be made more likely due to the novel nature of our AIM technology. Failure to obtain regulatory approval to market any of our product candidates would significantly harm our business, results of operations, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trials of our product candidates are, and the manufacturing and marketing of our products will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. In particular, because our product candidates are subject to regulation as biological products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. The risk/benefit profile required for product licensure will vary depending on these factors and may include not only the ability to show tumor shrinkage, but also adequate duration of response, a delay in the progression of the disease, and/or an improvement in survival. For example, response rates from the use of our product candidates may not be sufficient to obtain regulatory approval unless we can also show an adequate duration of response. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of studies in one set of patients or line of treatment may not be predictive of those obtained in another. We expect there may be greater variability in results for products processed and administered on a&#160;patient-by-patient&#160;basis, as anticipated for our product candidates which involve personalized T cell therapy, than for&#160;&#8220;off-the-shelf&#8221;&#160;products, like small molecule drugs which are not personalized for each patient. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if our clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most biological products, use of our product candidates could be associated with side effects or adverse events, which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. Undesirable side effects or unacceptable toxicities caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or comparable foreign regulatory authorities could delay or deny approval of our product candidates for any or all targeted indications and negative side effects could result in a more restrictive label for any product that is approved. Side effects such as toxicity or other safety issues associated with the use of our product candidates could also require us or our collaborators to perform additional studies or halt development or sale of these product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or could result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, as toxicities resulting from personalized T cell therapy are not normally encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using our product candidates to understand their potential side effect profiles, both for our planned clinical trials and upon any commercialization of any product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in adverse effects to patients, including death. Any of these occurrences may materially harm our business, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, including during any long-term&#160;follow-up&#160;observation period recommended or required for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory authorities may withdraw or limit their approvals of such products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory authorities may require the addition of labeling statements, specific warnings or a contraindications;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be required to create a Risk Evaluation and Mitigation Strategy, or REMS, plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be required to change the way such products are distributed or administered, or change the labeling of the products;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA or a comparable foreign regulatory authority may require us to conduct additional clinical trials or costly post-marketing testing and surveillance to monitor the safety and efficacy of the products;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may decide to recall such products from the marketplace after they are approved;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we could be sued and held liable for harm caused to individuals exposed to or taking our products; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our reputation may suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, adverse side effects caused by any therapeutics that may be similar in nature to our product candidates could delay or prevent regulatory approval of our product candidates, limit the commercial profile of an approved label for our product candidates, or result in significant negative consequences for our product candidates following marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the size and nature of the patient population;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the patient eligibility criteria defined in the protocol;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the proximity of patients to trial sites;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the design of the trial;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">competing clinical trials for similar therapies or other new therapeutics not involving T cell based immunotherapy;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to obtain and maintain patient consents; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the risk that patients enrolled in clinical trials will not complete a clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic cell transplantation, rather than enroll patients in any future clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials are expensive, time-consuming and difficult to design and implement, and our clinical trial costs may be higher than for more conventional therapeutic technologies or drug products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our product candidates are based on new technologies and manufactured on a&#160;patient-by-patient&#160;basis, we expect that they will require extensive research and development and have substantial manufacturing costs. In addition, costs to treat patients with relapsed/refractory cancer and to treat potential side effects that may result from our product candidates can be significant. Accordingly, our clinical trial costs are likely to be significantly higher per patient than those of more conventional therapeutic technologies or drug products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, one of our early-stage product candidates that is currently in preclinical development is for a novel class of injectable biologics. Development of the underlying technology may be affected by unanticipated technical, regulatory, manufacturing or other problems, among other research and development issues, and the possible insufficiency of funds needed in order to complete development of this product candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proposed personalized product candidates involve several complex and costly manufacturing and processing steps, the costs of which will be borne by us. Depending on the number of patients we ultimately enroll in our trials, and the number of trials we may need to conduct, our overall clinical trial costs may be higher than for more conventional treatments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development of biopharmaceutical products is inherently risky. We may not be successful in our efforts to use and enhance our AIM technology platform to create a pipeline of product candidates and develop commercially successful products, or we may expend our limited resources on programs that do not yield a successful product candidate and fail to capitalize on product candidates or diseases that may be more profitable or for which there is a greater likelihood of success. If we fail to develop additional product candidates, our commercial opportunity will be limited.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing clinical development of product candidates developed employing our AIM technology. We are at an early stage of development and our technology platform has not yet led, and may never lead, to approved or commercially successful products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in continuing to build our pipeline, obtaining regulatory approvals and commercializing additional product candidates will require substantial additional funding beyond the net proceeds of this transaction and are prone to the risks of failure inherent in medical product development. Investment in biopharmaceutical product development involves significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide you any assurance that we will be able to successfully advance any of these product candidates through the development process. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development or commercialization for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our platform may not be successful in identifying additional product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our product candidates may not succeed in preclinical or clinical testing;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">competitors may develop alternatives that render our product candidates obsolete or less attractive;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the market for a product candidate may change during our program so that the continued development of that product candidate is no longer reasonable;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive FDA approval to market additional product candidates, whether for the treatment of cancers or other diseases, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketplace or more effective than other commercially available alternatives. Further, because of our limited financial and managerial resources, we are required to focus our research programs on certain product candidates and on specific diseases. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. For additional information regarding the factors that will affect our ability to achieve revenue from product sales, see the risk factor above &#8220;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have never generated any revenue from product sales and our ability to generate revenue from product sales and become profitable depends significantly on our success in a number of factors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are biologics and the manufacture of our product candidates is complex and we may encounter difficulties in production, particularly with respect to process development or&#160;scaling-out&#160;of our manufacturing capabilities. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are biologics and the process of manufacturing our products is complex, highly-regulated and subject to multiple risks. The manufacture of our product candidates involves complex processes, including harvesting T cells from patients, enriching and expanding T cells&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ultimately infusing the T cells back into a patient&#8217;s body. As a result of the complexities, the cost to manufacture biologics in general, and our modified cell product candidates in particular, is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce. Our manufacturing process will be susceptible to product loss or failure due to logistical issues associated with harvesting T cells, or starting material, from the patient, shipping such material to the manufacturing site, shipping the final product back to the patient, and infusing the patient with the product, manufacturing issues associated with the differences in patient starting materials, interruptions in the manufacturing process, contamination, equipment or reagent failure, improper installation or operation of equipment, vendor or operator error, inconsistency in cell growth, and variability in product characteristics. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If for any reason we lose a patient&#8217;s starting material or later-developed product at any point in the process, the manufacturing process for that patient may need to be restarted and the resulting delay may adversely affect that patient&#8217;s outcome. Our product candidate relies on donor&#8217;s providing their blood, which is used to harvest&#160;T-cells.&#160;If issues arise with the product candidate, the donor may need to wait three months before they are able to donate again. This could result in the patient not being treated. Additionally, if microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Because our product candidates are manufactured for each particular patient, we will be required to maintain a chain of identity with respect to materials as they move from the patient to the manufacturing facility, through the manufacturing process, and back to the patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in adverse patient outcomes, loss of product, or regulatory action including withdrawal of our products from the market. Further, as product candidates are developed through preclinical to late stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. As a result of the complexities of our manufacturing process, we have in the past encountered difficulties in producing our product candidates. For example, our manufacturer has in prior instances produced batches of the active ingredient in our product candidate that did not meet the dosing requirement of our clinical trial protocol.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing strategy involves the use of one or more CMOs, and we expect in the future to establish our own capabilities and infrastructure, including a manufacturing facility. We expect that development of our own manufacturing facility will provide us with enhanced control of material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes, and allow for better long-term margins. However, we have no experience as a company in developing a manufacturing facility and may never be successful in developing our own manufacturing facility or capability. We may establish multiple manufacturing facilities as we expand our commercial footprint to multiple geographies, which may lead to regulatory delays or prove costly. Even if we are successful, our manufacturing capabilities could be affected by cost-overruns, unexpected delays, equipment failures, labor shortages, natural disasters, power failures and numerous other factors that could prevent us from realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the manufacturing process for any products that we may develop is subject to FDA and foreign regulatory authority approval process, and we will need to contract with manufacturers who can meet all applicable FDA and foreign regulatory authority requirements on an ongoing basis. If we or our CMOs are unable to reliably produce products to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specifications acceptable to the FDA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to manufacture our clinical product supplies, and we intend to rely on third parties for at least a portion of the manufacturing process of our product candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product or fail to do so at acceptable quality levels or prices, or fail to maintain or achieve satisfactory regulatory compliance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and currently rely on a single source vendor to manufacture supplies and process our product candidates, which is and will need to be done on a&#160;patient-by-patient&#160;basis. We have not yet caused our product candidates to be manufactured or processed on a commercial scale and may not be able to do so for any of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although in the future we do intend to develop our own manufacturing facility, we also intend to use third parties as part of our manufacturing process and may, in any event, never be successful in developing our own manufacturing facility. Our anticipated reliance on a limited number of third-party manufacturers exposes us to the following risks:</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA must approve any manufacturers. This approval would require new testing and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">GMP and current good tissue practices, or cGTP compliance inspections by FDA, as applicable.  In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our manufacturers may have little or no experience with autologous cell products, which are products made from a patient&#8217;s own cells, and therefore may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our product candidates.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our third-party manufacturers might be unable to timely manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Contract manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our future contract manufacturers may not perform as agreed, may not devote sufficient resources to our products, or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with current cGMP, or cGTP, if applicable and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our third-party manufacturers could breach or terminate their agreement with us.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well as natural or&#160;man-made&#160;disasters.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates. In addition, we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will rely on third parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA could place significant restrictions on our company until deficiencies are remedied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In complying with the manufacturing regulations of the FDA and other comparable foreign regulatory authorities, we and our third-party suppliers must spend significant time, money and effort in the areas of design and development, testing, production, record-keeping and quality control to assure that the products meet applicable specifications and other regulatory requirements. Although our agreements with our CMOs require them to perform according to certain cGMP and, if applicable, cGTP requirements such as those relating to quality control, quality assurance and qualified personnel, we cannot control the conduct of our CMOs to implement and maintain these standards. If any of our CMOs cannot successfully manufacture material that conforms to our specifications and the regulatory requirements of the FDA, EMA or other comparable foreign authorities, we would be prevented from obtaining regulatory approval for our drug candidates unless and until we engage a substitute CMO that can comply with such requirements, which we may not be able to do. In addition, our CMOs are subject to inspection and approval by regulatory authorities before we can commence the manufacture and sale of any of our product candidates, and thereafter are subject to ongoing inspection from time to time. Our CMOs may not be able to comply with applicable cGMP or cGTP regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in regulatory actions, such as the issuance of FDA Form 483 notices of observations, warning letters or sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such failure by us or any of our CMOs would significantly impact our ability to develop, obtain regulatory approval for or market our drug candidates, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of biologic products often encounter difficulties in production, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process (including the absence of contamination). These problems include logistics and shipping, difficulties with production costs and yields, quality control, including stability of the product, product testing, operator error, availability of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability failures or other issues relating to the manufacture of our product candidates will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our product candidate to patients in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our third-party manufacturers may be unable to successfully scale up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing any approved product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing partners may be unable to successfully increase the manufacturing capacity for our product candidates in a timely or cost-effective manner, or at all, as needed for our development efforts or, if our product candidates are approved, our commercialization efforts. Quality issues may also arise during&#160;scale-up&#160;activities. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of our product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting therapeutic may be delayed or not obtained, which could significantly harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell-based therapies rely on the availability of reagents, specialized equipment, and other specialty materials, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment, and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing our product candidates will require many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. We currently depend on a limited number of vendors for certain materials and equipment used in the manufacture of our product candidates. Some of these suppliers may not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be&#160;ill-equipped&#160;to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some of these reagents, equipment, and materials, we rely and may in the future rely on sole source vendors or a limited number of vendors. An inability to continue to source product from any of these suppliers, which could be due to regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands, or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to develop and scale our manufacturing process, we expect that we will need to obtain rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to obtain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and will rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend and will depend upon independent investigators and collaborators to conduct our clinical trials under agreements with universities, medical institutions, CROs, strategic partners, and others. We expect to have to negotiate budgets and contracts with CROs and trial sites, which may result in delays to our development timelines and increased costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely and will rely heavily on third parties over the course of our clinical trials, and as a result will have limited control over the clinical investigators and limited visibility into their&#160;day-to-day&#160;activities, including with respect to how they are providing and administering T cell therapy. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory, and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with good clinical practices, or GCP, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional nonclinical or clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the applicable GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMP, and likely cGTP regulations and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical, and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed, or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any agreements governing our relationships with CROs or other contractors with whom we currently engage or may engage in the future may provide those outside contractors with certain rights to terminate a clinical trial under specified circumstances. If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for our product candidates, if and when approved, may be limited to those patients who are ineligible for established therapies or have failed prior treatments and may be small.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer therapies are sometimes characterized as first line, second line, or third line, and the FDA often approves new therapies initially only for third line use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, hormone therapy, surgery, or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules, or a combination of these. Third line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies, more invasive forms of surgery, and new technologies. We expect to initially seek approval of our product candidates as a third line therapy for patients who have failed other approved treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval as a second line therapy and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved, would be approved for second line or first line therapy. In addition, we may have to conduct additional clinical trials prior to gaining approval for second line or first line therapy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive third line therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, we expect to initially target a small patient population with our product candidates.&#160;NEXI-001&#160;is being developed for the treatment of AML or MDS patients with relapsed disease after an allogeneic hematopoietic cellular transplant and&#160;NEXI-002&#160;is being developed for the treatment of MM patients that have failed at least three prior lines of therapy. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, including use as a first or second line therapy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market opportunities may also be limited by competitor treatments that may enter the market. See the risk factor below &#8220;&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We plan to seek orphan drug status for some or all of our product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and&#160;user-fee&#160;waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our drug candidates receives orphan exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek orphan drug designation for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products, including AML or MDS and MM, but exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition. In addition, although we intend to seek orphan drug designation for other product candidates, we may never receive such designations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We plan to seek but may fail to obtain breakthrough therapy designation for some or all of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the enactment of Food and Drug Administration Safety and Innovation Act, or FDASIA, in 2012, the Congress established a &#8220;breakthrough therapy&#8221; designation which is intended to expedite the development and review of products that treat serious or life-threatening diseases when &#8220;preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.&#8221; The designation of a product candidate as a breakthrough therapy provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate and ensure collection of appropriate data needed to support approval; more frequent written correspondence from FDA about such things as the design of the proposed clinical trials and use of biomarkers; intensive guidance on an efficient drug development program, beginning as early as Phase I; organizational commitment involving senior managers; and eligibility for rolling review and priority review.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy is within the discretion of the FDA, and such designation does not change the standards for product approval. We intend to seek breakthrough therapy designation for some or all of our product candidates for the treatment of AML or MDS and MM, but there can be no assurance that we will receive breakthrough therapy designation. Even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to grant such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even after a product candidate qualifies as a breakthrough therapy, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The review processes of regulatory authorities are lengthy, time consuming, expensive and inherently unpredictable. If we are unable to obtain approval for our product candidates from applicable regulatory authorities, we will not be able to market and sell those product candidates in those countries or regions and our business could be substantially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug and biological products are, and will remain, subject to extensive regulation by the FDA in the United States and by the respective regulatory authorities in other countries, where regulatory requirements for such products differ. We are not permitted to market any of our biological product candidates in the United States until we receive approval of a BLA from the FDA, or in any foreign countries until we receive the requisite approval from the respective regulatory authorities in such countries. The time required to obtain approval, if any, by the FDA, EMA and comparable foreign authorities is unpredictable, but typically takes many years following the commencement of clinical trials, if approval is obtained at all, and depends upon numerous factors, including the substantial discretion of the regulatory authorities and the type, complexity and novelty of the product candidates involved. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical studies or clinical trials. We have not submitted a marketing application such as a BLA to the FDA, an MAA to the EMA, or any similar application to any other jurisdiction. We have limited experience in planning and conducting the clinical trials required for marketing approvals, and we have and expect to continue to rely on third-party CROs to assist us in this process. Obtaining marketing approval requires the submission of extensive nonclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process, and in many cases the inspection of manufacturing, processing, and packaging facilities by the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use, or there may be deficiencies in cGMP compliance by us or by our CMOs that could result in the candidate not being approved. Moreover, we have not obtained regulatory approval for any drug candidate in any jurisdiction and it is possible that none of our existing drug candidates or any drug candidates we may seek to develop in the future will ever obtain regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our biological product candidates could fail to receive, or could be delayed in receiving, regulatory approval for many reasons, including any one or more of the following:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be unable to demonstrate to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">upon review of our clinical trial sites and data, the FDA or comparable foreign regulatory authorities may find our record keeping or the record keeping of our clinical trial sites to be inadequate;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies may fail to meet the requirements of the FDA, EMA or comparable foreign regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FDA, EMA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we contemplate developing internally or with partners; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the change of the medical standard of care or the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner that renders our clinical data insufficient for approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time and expense of the approval process, as well as the unpredictability of future clinical trial results and other contributing factors, may result in our failure to obtain regulatory approval to market, in one or more jurisdictions, any drug candidates we are developing or may seek to develop in the future, which would significantly harm our business, results of operations and prospects. In such case, we may also not have the resources to conduct new clinical trials and/or we may determine that further clinical development of any such product candidate is not justified and may discontinue any such programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we were to obtain regulatory approval in one or more jurisdictions, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve prices we may propose to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that drug candidate. Any of the foregoing circumstances could materially harm the commercial prospects for our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales, marketing, or commercial product distribution capabilities and have no experience in marketing products. We intend to develop an&#160;in-house&#160;marketing organization and sales force, which will require significant capital expenditures, management resources, and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train, and retain marketing and sales personnel.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable or decide not to establish internal sales, marketing and commercial distribution capabilities for any or all products we develop, we will likely pursue collaborative arrangements regarding the sales and marketing of our products. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to develop&#160;in-house&#160;sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product in the United States or overseas, and as a result, we may not be able to generate product revenue.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with operating our business internationally could materially adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we, and any potential collaborators in those jurisdictions, will be subject to additional risks related to operating in foreign countries, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">differing regulatory requirements and reimbursement regimes in foreign countries;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls, and other regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">difficulties staffing and managing foreign operations;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign laws;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">business interruptions resulting from&#160;geo-political&#160;actions, including war and terrorism; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">deteriorating relations between the United States and Russia resulting from the current situation involving Russia and Ukraine, including tariffs, economic sanctions and import-export restrictions imposed by either nation, and retaliatory actions by other nations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with our planned international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry, and the rapidly evolving market for developing T cell therapies in particular, is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities, and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations as well as established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized, or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we face competition from companies developing T cell therapies such as Cue Biopharma, Atara Biotherapeutics, Iovance Biotherapeutics and Parvus Therapeutics. Even if we obtain regulatory approval of our product candidates, we may not be the first to market and that may affect the price or demand for our product candidates. Additionally, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. Additionally, a competitor could obtain orphan product exclusivity from the FDA with respect to such competitor&#8217;s product. If such competitor product is determined to be the same product as one of our product candidates, that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may prevent us from obtaining approval from the FDA for such product candidate for the same indication for seven years, except in limited circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, particularly our chief executive officer, Kristi Jones, who is an&#160;at-will&#160;employee, and our scientific and medical personnel. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in product development and harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our operations at our facility in Gaithersburg, Maryland, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we will need to recruit talent from outside of our region, and doing so may be costly and difficult.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided restricted stock and stock option grants that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for&#160;at-will&#160;employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key man&#8221; insurance policies on the lives of all of these individuals or the lives of any of our other employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;1, 2023, we had 50 employees, most of whom are full-time. As our development and commercialization plans and strategies develop, and as we transition into operating as a public company, we must add a significant number of additional managerial, operational, sales, marketing, financial, and other personnel. Future growth will impose significant added responsibilities on members of management, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">identifying, recruiting, integrating, maintaining, and motivating additional employees;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">improving our operational, financial and management controls, reporting systems, and procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from&#160;day-to-day&#160;activities in order to devote a substantial amount of time to managing these growth activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development, and commercialization goals.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form or seek strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur&#160;non-recurring&#160;and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, collaborations involving our product candidates, such as our collaborations with third-party research institutions, are subject to numerous risks, which may include the following:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">collaborators may own or&#160;co-own&#160;intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, if we enter into collaboration agreements and strategic partnerships or license our products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition, and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">increased operating expenses and cash requirements;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the assumption of additional indebtedness or contingent liabilities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to achieve desired efficiencies, synergies or other anticipated benefits from such acquisitions or strategic partnerships;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large&#160;one-time&#160;expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate substantial revenue from product sales, if ever, we expect to finance our cash needs through a combination of public and private equity offerings, debt financings, strategic partnerships, and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. If we are unable to raise additional capital through equity or debt financings when needed (including if we are unable to do so as a result of the&#160;COVID-19&#160;pandemic), we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we, our CROs or our CMOs use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by us or third parties, such as CROs and CMOs. We and such third parties are subject to federal, state, and local laws and regulations in the United States governing the use, manufacture, storage, handling, and disposal of medical and hazardous materials. Although we believe that our and such third parties&#8217; procedures for using, handling, storing, and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state, or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition, or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our future CROs and other contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also engage third-party vendors and service providers to store and otherwise process some of our data, including sensitive and personal information. Our vendors and service providers may also be the targets of the risks described above, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">including cyberattacks, ransomware, malicious software, phishing schemes, and fraud. From time to time, we get notifications that such vendors experienced cyber security breaches. Our ability to monitor our vendors and service providers&#8217; data security is limited, and, in any event, third parties may be able to circumvent those security measures, resulting in the unauthorized access to, misuse, disclosure, loss or destruction of our data, including sensitive and personal information, and disruption of our or third-party service providers&#8217; systems. We and our third-party service providers may face difficulties in identifying, or promptly responding to, potential security breaches and other instances of unauthorized access to, or disclosure or other loss of, information. Any hacking or other attack on our or our third-party service providers&#8217; or vendors&#8217; systems, and any unauthorized access to, or disclosure or other loss of, information suffered by us or our third-party service providers or vendors, or the perception that any of these have occurred, could result in legal claims or proceedings, loss of intellectual property, liability under laws that protect the privacy of personal information, negative publicity, disruption of our operations and damage to our reputation, which could divert our management&#8217;s attention from the operation of our business and materially and adversely affect our business, revenues and competitive position. Moreover, we may need to increase our efforts to train our personnel to detect and defend against cyber- or phishing-attacks, which are becoming more sophisticated and frequent, and we may need to implement additional protective measures to reduce the risk of potential security breaches, which could cause us to incur significant expenses. Although we take reasonable steps to help protect confidential and other sensitive information from unauthorized access or disclosure, we also could be the target of phishing attacks seeking confidential information regarding our employees. Furthermore, while we have implemented data privacy and security measures in an effort to comply with applicable laws and regulations relating to privacy and data protection, some PHI and other PII or confidential information may be transmitted to us by third parties, who may not implement adequate security and privacy measures, and it is possible that laws, rules and regulations relating to privacy, data protection, or information security may be interpreted and applied in a manner that is inconsistent with our practices or those of third parties who transmit PHI and other PII or confidential information to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we or these third parties are found to have violated such laws, rules or regulations or that any disruption or security breach were to result in a loss of, or damage to, our or our third-party vendors&#8217;, collaborators&#8217; or other contractors&#8217; or consultants&#8217; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability including litigation exposure, penalties and fines, we could become the subject of regulatory action or investigation, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Any of the above could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, and those of our third-party research institution collaborators, CROs, CMOs, suppliers, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, and other natural or&#160;man-made&#160;disasters or business interruptions, for which we are predominantly self-insured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates on a&#160;patient-by-patient&#160;basis. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a&#160;man-made&#160;or natural disaster or other business interruption. All of our operations including our corporate headquarters are located in a single facility in Gaithersburg, Maryland. Damage or extended periods of interruption to our corporate, development or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business may be seriously harmed by such delays and interruption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in securities litigation that could divert management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the past, securities litigation has often followed certain significant business events, such as the announcement of a strategic restructuring or realighment. We may be exposed to such litigation even if no wrongdoing occurred. Litigation is usually expensive and diverts management&#8217;s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential partnership or other opportunities, or the ultimate value our stockholders receive in any such partnership or other opportunity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing any approved products, these claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities (or the manufacturing processes and facilities of our third-party manufacturer) or our marketing programs, a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">decreased demand for our products;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injury to our reputation;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">withdrawal of clinical trial participants and inability to continue clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">initiation of investigations by regulators;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">costs to defend the related litigation;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">exhaustion of any available insurance and our capital resources;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inability to commercialize any product candidate; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a decline in our share price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Although we currently carry $10,000,000 of clinical trial insurance, the amount of such insurance coverage may not be adequate, we may be unable to maintain such insurance, or we may not be able to obtain additional or replacement insurance at a reasonable cost, if at all. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislation or other changes in U.S. tax law could adversely affect our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, legislation enacted in 2017 informally titled, the Tax Cuts and Jobs Act, or the TCJA, made significant changes to corporate taxation, including the reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses from taxable years beginning after December&#160;31, 2017 to 80% of current year taxable income and the elimination of net operating loss carrybacks generated in taxable years ending after December&#160;31, 2017 (though any such net operating losses may be carried forward indefinitely) and the modification or repeal of many business deductions and credits. In addition, on March&#160;27, 2020, former President Trump signed into law the &#8220;Coronavirus Aid, Relief, and Economic Security Act&#8221; or the CARES Act, which included certain changes in tax law intended to stimulate the U.S. economy in light of the&#160;COVID-19&#160;public health emergency, including providing temporary relief from certain aspects of the TCJA that had imposed limitations on the utilization of certain losses, interest expense deductions, and minimum tax credits and provided temporary deferral of certain payroll taxes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It cannot be predicted whether, when, in what form or with what effective dates new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our or our shareholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our U.S. net operating loss carryforwards and certain other U.S. tax attributes may be limited.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to use our U.S. federal and state net operating losses to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unused losses for the tax year beginning before January&#160;1, 2018, and prior tax years will carry forward to offset future taxable income, if any, until such unused losses expire. Unused losses generated in tax years beginning after December&#160;31, 2017, under the TCJA will not expire and may be carried forward indefinitely, and generally may not be carried back to prior taxable years, except that, under the CARES Act, net operating losses generated in 2018, 2019 and 2020 may be carried back five taxable years. Additionally, for taxable years beginning after December&#160;31, 2020, the deductibility of such U.S. federal net operating losses generated in tax years beginning after December&#160;31, 2017, is limited to 80% of our taxable income. In addition, both our current and our future unused losses and other tax attributes may be subject to limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if we undergo an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future, some of which are outside our control. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA regulatory approval process is lengthy, time-consuming, and inherently unpredictable, and we may experience significant delays in the clinical development and regulatory approval, if any, of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, import, export, adverse event reporting, record keeping, advertising, promotion, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug product in the United States until we receive a Biologics License from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, pure, potent, and effective for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing, and controls for the product, and the manufacturing facilities must complete a successful&#160;pre-license&#160;inspection. We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of T cell therapies for cancer. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive, and lengthy, and approval may not be obtained.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining regulatory approval to begin a trial, if applicable;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the availability of financial resources to begin and complete the planned trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining approval at each clinical trial site by an independent institutional review board, or IRB;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">recruiting suitable patients to participate in a trial in a timely manner;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">having patients complete a trial or return for post-treatment&#160;follow-up;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinical trial sites deviating from trial protocol, not complying with GCP, or dropping out of a trial;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">addressing any patient safety concerns that arise during the course of a trial;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">addressing any conflicts with new or existing laws or regulations;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adding new clinical trial sites; or</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">manufacturing qualified materials under cGMP for use in clinical trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is a significant factor in the timing of clinical trials and is affected by many factors. See the risk factor above&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;&#8212;If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for additional information on risks related to patient enrollment. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted, the Data Safety Monitoring Committee for such trial, or the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party research institution collaborators may also experience similar difficulties in completing ongoing clinical trials and conducting future clinical trials of product candidates. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post- marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, and comparable foreign regulatory authority, requirements, including ensuring that quality control and manufacturing procedures conform to cGMP, and in certain cases cGTP, regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and cGTP and adherence to commitments made in any BLA, other marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient&#160;follow-up,&#160;a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, we will have to comply with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements including submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP, cGTP, and GCP for any clinical trials that we conduct post-approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in the following among other things:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the manufacturing of the product, the approved manufacturers or the manufacturing process;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the labeling or marketing of a product;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on product distribution or use;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">withdrawal of the product from the market;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product recalls;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">warning or untitled letters from the FDA or comparable notice of violations from foreign regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal of the FDA or other applicable regulatory authority to approve pending applications or</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">supplements to approved applications;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, restitution or disgorgement of profits or revenues;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">suspension of any of our ongoing clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure or detention or refusal to permit the import or export of products; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">consent decrees, injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of&#160;off-label&#160;uses, and a company that is found to have improperly promoted&#160;off-label&#160;uses may be subject to significant liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compliance&#160;with European Union requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with the European Union&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we were able to obtain accelerated approval of any of our product candidates, the FDA would require us to conduct a confirmatory study to verify the predicted clinical benefit and additional safety studies. The results from the confirmatory study may not support the clinical benefit, which would result in the approval being withdrawn. While operating under accelerated approval, we will be subject to certain restrictions that we would not be subject to upon receiving regular approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers, and others in the medical community.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of modified T cells as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers, and others in the medical community. For example, certain of the product candidates that we will be developing target a cell surface marker that may be present on cancer cells as well as&#160;non-cancerous&#160;cells. It is possible that our product candidates may kill these&#160;non-cancerous&#160;cells, which may result in unacceptable side effects, including death. Additional factors will influence whether our product candidates are accepted in the market, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the clinical indications for which our product candidates are approved;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">physicians, hospitals, cancer treatment centers, and patients considering our product candidates as a safe and effective treatment;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential and perceived advantages of our product candidates over alternative treatments;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the prevalence and severity of any side effects;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">any restrictions on concomitant us of other medications</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">limitations or warnings contained in the labeling approved by the FDA;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the size of the market for such drug candidate, based on the size of the patient subsets that we are targeting, in their territories for which we gain regulatory approval and have commercial rights;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the safety of the drug candidate as demonstrated through broad commercial rights;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the adequacy of supply of our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of market introduction of our product candidates as well as competitive products;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of treatment in relation to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the amount of upfront costs or training required for physicians to administer our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the availability of adequate coverage, reimbursement, and pricing by third-party payors and government authorities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the willingness of patients to pay&#160;out-of-pocket&#160;in the absence of coverage and reimbursement by third-party payors and government authorities;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">support from patient advocacy groups</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the effectiveness of our sales and marketing efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we are not utilizing embryonic stem cells or replication competent vectors, adverse publicity due to the ethical and social controversies surrounding the therapeutic use of such technologies, and reported side effects from any clinical trials using these technologies or the failure of such trials to demonstrate that these therapies are safe and effective may limit market acceptance our product candidates. If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to negotiate, secure and maintain third-party coverage and reimbursement for our product candidates may be affected by political, economic and regulatory developments in the United States, the European Union and other jurisdictions. Governments continue to impose cost containment measures, and third-party payors are increasingly challenging prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. These and other similar developments could significantly limit the degree of market acceptance of any product candidate of ours that receives marketing approval in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are and will be subject to stringent privacy laws, cybersecurity laws, regulations, policies and contractual obligations related to privacy and security, and changes in such laws, regulations, policies or how they are interpreted or changes in related contractual obligations could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, processing, storage and use of personally-identifying information including comprehensive regulatory systems in the United States and European Union, which, among other things, impose certain requirements relating to the privacy, security and transmission of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations by us or third parties to whom we contract certain types of work (like clinical trials) could result in enforcement action against us or such third parties, including fines, imprisonment of company officials </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to the US federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to properly protect the privacy and security of protected health information or other personal, sensitive, or confidential information in our possession, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face significant administrative, civil and criminal penalties. Enforcement activity can also result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal and outside resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some U.S. state governments have enacted or are considering enacting more stringent laws and regulations protecting personal information and data. For instance, California passed the California Data Privacy Protection Act of 2018 (the &#8220;CCPA&#8221;), which went into effect in January 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact certain of our business activities. In addition, the California Consumer Rights Act (&#8220;CPRA&#8221;) was recently enacted to strengthen elements of the CCPA and becomes effective January 1, 2023. A number of other states have considered similar privacy proposals, with states like Virginia and Colorado enacting their own privacy laws (also scheduled to come into effect in January 1, 2023 and July 1, 2023, respectively). These privacy laws may impact our business activities and exemplify the vulnerability of our business to the evolving regulatory environment related to personal data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, we may be subject to the General Data Protection Regulation (GDPR) which went into effect in May 2018 and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR applies to any company established in the European Economic Area, or EEA, (which includes the EU Member States plus Iceland, Liechtenstein, and Norway) and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR establishes stringent requirements applicable to the processing of personal data, including strict requirements relating to the validity of consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct data protection impact assessments for &#8220;high risk&#8221; processing, limitations on retention of personal data, special provisions affording greater protection to and requiring additional compliance measures for &#8220;special categories of personal data&#8221; including health and genetic information of data subjects, mandatory data breach notification (in certain circumstances), &#8220;privacy by design&#8221; requirements, and direct obligations on service providers acting as processors. The GDPR also prohibits the international transfer of personal data from the EEA to countries outside of the EEA unless made to a country deemed to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place.If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR may also impose additional compliance obligations relating to the transfer of data between us and our subsidiaries or other business partners. For example, on July 16, 2020, the Court of Justice of the European Union (CJEU), issued a landmark opinion in the case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Maximilian Schrems vs. Facebook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Case C-311/18), called </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Schrems II.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This decision (a) calls into question commonly relied upon data transfer mechanisms as between the EU Member States and the United States (such as the Standard Contractual Clauses) and (b) invalidates the EU-U.S. Privacy Shield on which many companies had relied as an acceptable mechanism for transferring such data from the EU to the United States. The CJEU is the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">highest court in Europe and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Schrems II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision heightens the burden on data importers to assess U.S. national security laws on their business and future actions of EU data protection authorities are difficult to predict. Some customers or other service providers may respond to these evolving laws and regulations by asking us to make certain privacy or data-related contractual commitments that we are unable or unwilling to make. This could lead to the loss of current or prospective customers or other business relationships.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to address the implications of the recent changes to EU data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EU and elsewhere and carries with it the potential for significant penalties if we are found to be&#160;non-compliant.&#160;Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful sales of our product candidates, if approved, depend on the availability of adequate coverage and reimbursement from third-party payors. In addition, because our product candidates represent new approaches to treat cancer and other immune-related diseases, we cannot accurately estimate the potential revenue from our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors are critical to new product acceptance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a covered benefit under its health plan;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">safe, effective and medically necessary;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">appropriate for the specific patient;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">cost-effective; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">neither experimental nor investigational.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a&#160;payor-by-payor&#160;basis, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require&#160;co-payments&#160;that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term&#160;follow-up&#160;evaluations required following the use of our products. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Because our product candidates have a higher cost of goods than conventional therapies, and may require long-term follow up evaluations, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future health care reform measures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and the Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;) was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. The ACA continues to significantly impact the United States&#8217; pharmaceutical industry. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the Act. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013, and, due to subsequent legislative amendments, will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. The CARES Act and other COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through June 30, 2022 (a 1% sequester will apply from April 1, 2022 through June 30, 2022). In January 2013, the American Taxpayer Relief Act of 2012, was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace from February 15, 2021 through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to health care, including, among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. In addition, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs and review the relationship between pricing and manufacturer patient programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. Payment methodologies may also be subject to changes in healthcare legislation and regulatory initiatives. For example, Centers for Medicare and Medicaid Services may develop new payment and delivery models, such as bundled payment models. There also has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. By way of example, in August 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated, or the impact of the IRA on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, particularly as a result of the new presidential administration. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the demand for our product candidates, if we obtain regulatory approval;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to set a price that we believe is fair for our products;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the level of taxes that we are required to pay; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the availability of capital.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any denial in coverage or reduction in reimbursement from Medicare or other government programs may result in a similar denial or reduction in payments from private payors, which may adversely affect our future profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with applicable laws and regulations of the FDA and other similar foreign regulatory bodies; provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials, which could result in significant regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with prescribers, purchasers, third-party payors and patients will be subject to applicable anti-kickback, fraud and abuse and other health care laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, upon commercialization of our drug candidates, if approved, we will be subject to additional health care statutory and regulatory requirements and oversight by federal and state governments in the United States as well as foreign governments in the jurisdictions in which we conduct our business. Physicians, other health care providers and third-party payors will play a primary role in the recommendation, prescription and use of any product candidates for which we obtain marketing approval. Our future arrangements with such third parties may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain our business or financial arrangements and relationships through which we market, sell and distribute any products for which we may obtain marketing approval. Restrictions under applicable domestic and foreign health care laws and regulations include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recommendation of, any good or service, for which payment may be made under a federal health care program such as Medicare and Medicaid; a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">U.S. federal false claims, false statements and civil monetary penalties laws, including the U.S. False Claims Act, which impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; actions may be brought by the government or a whistleblower and may include an assertion that a claim for payment by federal health care programs for items and services which results from a violation of the federal Anti-Kickback Statue constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any health care benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for health care benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">analogous state and foreign laws and regulations relating to health care fraud and abuse, such as state anti-kickback and false claims laws, that may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by&#160;non-governmental&#160;third-party payors, including private insurers;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the FCPA and other anti-corruption laws and regulations pertaining to our financial relationships and interactions with foreign government officials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the U.S. federal physician payment transparency requirements, sometimes referred to as the &#8220;Sunshine Act,&#8221; which requires manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to physician payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as the ownership and investment interests of physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding its relationships with physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwives during the previous year;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">analogous state and foreign laws that require pharmaceutical companies to track, report and disclose to the government and/or the public information related to payments, gifts, and other transfers of value or remuneration to physicians and other health care providers, marketing activities or expenditures, or product pricing or transparency information, or that require pharmaceutical companies to implement compliance programs that meet certain standards or to restrict or limit interactions between pharmaceutical manufacturers and members of the health care industry;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the U.S. federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under federal health care programs;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HIPAA, which imposes obligations on certain covered entity health care providers, health plans, and health care clearinghouses and their business associates that perform certain services involving the use or disclosure of individually identifiable health information as well as their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">state and foreign laws that govern the privacy and security of health information in certain circumstances, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal Anti-Kickback and criminal healthcare fraud statutes. As a result of such amendment, a person or entity no longer needs to have actual knowledge of these statutes or specific intent to violate them in order to have committed a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">violation. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. If any of the physicians or other health care providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from federal health care programs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on intellectual property licensed from third parties, in particular from Johns Hopkins, and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on patents,&#160;know-how,&#160;and proprietary technology, both our own and licensed from others. Any termination of these licenses, in particular from Johns Hopkins, could result in the loss of significant rights and could harm our ability to commercialize our product candidates. See the sections of this Annual Report on Form&#160;10-K&#160;captioned &#8220;Business&#8212;Intellectual Property and &#8220;Business&#8212;Johns Hopkins License Agreement&#8221; for additional information regarding our license agreements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including those relating to:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">whether we are complying with our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the allocation of ownership of inventions and&#160;know-how&#160;resulting from the joint creation or use of intellectual property by our licensors and by us and our partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend, in part, on our licensors to file, prosecute, maintain, defend, and enforce patents and patent applications that are material to our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have significant control over the filing, prosecution, and maintenance of our patents licensed from Johns Hopkins, our filing, prosecution, and maintenance of these licensed patents is subject to approval of the licensor. We generally have the first right to enforce our patent rights, although our ability to settle such claims often requires the consent of the licensor. If our licensors or any future licensees having rights to file, prosecute, maintain, and defend our patent rights fail to conduct these activities for patents or patent applications covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, or selling competing products. We cannot be certain that such activities by our licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of such license agreements, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and, even if we are permitted to pursue such enforcement or defense, we cannot ensure the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. In addition, even when we have the right to control patent prosecution of licensed patents and patent applications, enforcement of licensed patents, or defense of claims asserting the invalidity of those patents, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to or after our assuming control.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our product development pipeline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or license from third parties certain intellectual property rights necessary to develop our product candidates. The growth of our business may depend in part on our ability to acquire or&#160;in-license&#160;additional proprietary rights. For example, our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties. We may be unable to acquire or&#160;in-license&#160;any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be&#160;non-exclusive,&#160;which may allow our competitors access to the same technologies licensed to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be unsuccessful in obtaining or maintaining adequate patent protection for one or more of our products or product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will file additional patent applications both in the United States and in other countries, as appropriate. However, we cannot predict:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">if and when any patents will issue;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the degree and range of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">whether others will apply for or obtain patents claiming aspects similar to those covered by our patents and patent applications; or</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">whether we will need to initiate litigation or administrative proceedings to defend our patent rights, which may be costly whether we win or lose.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Composition of matter patents for biological and pharmaceutical products are generally considered to be the strongest form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain, however, that the claims in our pending patent applications covering the composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office, or the USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products&#160;&#8220;off-label&#8221;&#160;for those uses that are covered by our method of use patents. Although&#160;off-label&#160;prescriptions may infringe or contribute to the infringement of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">method of use patents, the practice is common and such infringement is difficult to prevent or prosecute. Many of our issued patents cover methods for making our cell therapy products. Method of making patents protect the process by which a product is made. This type of patent does not prevent a competitor from marketing a product that is similar to our product, if the competitor&#8217;s product is made by a process not covered by our patents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field can be uncertain, and evaluating the scope of such patents involves complex legal and scientific analyses. The patent applications that we own or&#160;in-license&#160;may fail to result in issued patents with claims that cover our product candidates, methods of making our product candidates, or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability, or scope thereof, which may result in such patents being narrowed, invalidated, or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, this could dissuade companies from collaborating with us to develop, and could threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March&#160;16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For U.S. applications containing a claim not entitled to priority before March&#160;16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the U.S. patent laws, including new procedures for challenging pending patent applications and issued patents.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary&#160;know-how&#160;that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our product discovery and development processes that involve proprietary&#160;know-how,&#160;information, or technology that is not covered by patents. Trade secrets, however, may be difficult to protect. We seek to protect our proprietary processes, in part, by entering into confidentiality agreements with our employees, consultants, outside scientific advisors, contractors, and collaborators. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, outside scientific advisors, contractors, and collaborators might intentionally or inadvertently disclose our trade secret information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or misappropriation of our intellectual property by third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement against us or our collaborators may prevent or delay our product discovery and development efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Recently, due to changes in U.S. law referred to as patent reform, procedures including inter parties review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have conducted analyses of the patent landscape with respect to our product candidates, and based on these analyses, we believe that we will be able to commercialize our product candidates, third parties may nonetheless assert that we infringe their patents, or that we are otherwise employing their proprietary technology without authorization, and may sue us. While we are aware of at least one third-party U.S. patent that is relevant to our planned products, it will expire prior to our currently planned commercial launch. There may be other third-party patents of which we are currently unaware with claims to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compositions, methods of manufacture, or methods of use or treatment that cover our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies or the manufacture, use, or sale of our product candidates infringes upon these patents. If any such third-party patents were held by a court of competent jurisdiction to cover our technologies or product candidates, the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties asserting their patent rights against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, maintaining and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can have a different scope and strength than do those in the United States. To date, in addition to the United States, we have filed patent applications in Australia, Brazil, Canada, China, Europe (via European Patent Office, or EPO), Hong Kong, India, Israel, Japan, Russian Federation, South Korea, Mexico, and Singapore. In addition, the laws of some foreign countries, such as China, Brazil, Russia, and India, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement against importation of infringing products is challenging or legal remedies are insufficient. These products may compete with our products and our patents or other intellectual property rights may not be effective or adequate to prevent them from competing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, such as China, Brazil, Russia, and India, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biopharmaceutical products, which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, or the marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore such proceedings could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or misappropriation against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming, and unsuccessful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensors. To cease such infringement or unauthorized use, we may be required to file patent infringement claims, which can be expensive and time- consuming. In addition, in an infringement proceeding or a declaratory judgment action against us, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to, or the correct inventorship of, our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation, interference, or derivation proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign authority.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post-grant review, and equivalent proceedings in foreign jurisdictions, such as opposition or derivation proceedings. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves, both technological and legal complexity, and is therefore costly, time-consuming, and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the U.S. Supreme Court held that certain claims to naturally-occurring substances are not patentable. Although we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. Although an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits,&#160;non-payment&#160;of fees, and failure to properly legalize and submit formal documents. In any such event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The lives of our patents may not be sufficient to effectively protect our products and business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States and most foreign jurisdictions, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilars. Our issued patents will expire on dates ranging from 2034 to 2039, subject to any patent extensions that may be available for such patents. If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2034 to 2042. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face competition from biosimilars, which may have a material adverse impact on the future commercial prospects of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in achieving regulatory approval to commercialize a product candidate faster than our competitors, we may face competition from biosimilars. The Patient Protection and Affordable Care Act, which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. While certain biosimilar products have been approved by the FDA for use in the United States, none of these have been cell therapy products and none have been interchangeable biosimilars. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Additional guidance is expected to be finalized by the FDA in the near term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that the product is &#8220;highly similar&#8221; to the reference product notwithstanding minor differences in clinically inactive components and that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and, for products administered multiple times, that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own&#160;non-clinical&#160;data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are not currently experiencing any claims challenging the inventorship of our patents or ownership of our intellectual property, we may in the future be subject to claims that former employees, collaborators, or other third parties have </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an interest in our patents or other intellectual property as an inventor or&#160;co-inventor.&#160;For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Product Candidates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale including, among others, cost overruns, potential problems with process&#160;scale-up,&#160;process reproducibility, stability issues, lot consistency and timely availability of raw materials. There is no assurance that our manufacturers will be successful in establishing a larger-scale commercial manufacturing process for&#160;our product candidates that achieves our objectives for manufacturing capacity and cost of goods. Even if we could otherwise obtain regulatory approval for any product candidate, there is no assurance that our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities of the approved product for commercialization, our commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics carry unique risks and uncertainties, which could have a negative impact on future results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful discovery, development, manufacturing and sale of biologics is a long, expensive and uncertain process. There are unique risks and uncertainties with biologics. For example, access to and supply of necessary biological materials, such as cell lines, may be limited and governmental regulations restrict access to and regulate the transport and use of such materials. In addition, the development, manufacturing and sale of biologics is subject to regulations that are often more complex and extensive than the regulations applicable to other pharmaceutical products. Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies. Such manufacturing also requires facilities specifically designed and validated for this purpose and sophisticated quality assurance and quality control procedures. Biologics are also frequently costly to manufacture because production inputs are derived from living animal or plant material, and some biologics cannot be made synthetically. Failure to successfully discover, develop, manufacture and sell our biological product candidates would adversely impact our business and future results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates for which we intend to seek approval may face generic or biosimilar competition sooner than anticipated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in achieving regulatory approval to commercialize a product candidate ahead of our competitors, our product candidates may face competition from biosimilar products. In the United States, our AIM technology-based product candidates are expected to be regulated by the FDA as biological products and we intend to seek approval for these product candidates pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for FDA approval of biosimilar and interchangeable biological products based on a previously licensed reference product. Under the BPCIA, an application for a biosimilar biological product cannot be approved by the FDA until 12 years after the original reference biological product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the&#160;12-year&#160;period of exclusivity available to reference biological products. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference biological products pursuant to its interpretation of the exclusivity provisions of the BPCIA for competing products, potentially creating the opportunity for generic&#160;follow-on&#160;biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for&#160;non-biological&#160;products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing including whether a future competitor seeks an interchangeability designation for a biosimilar of one of our products. Under the BPCIA as well as state pharmacy laws, only interchangeable biosimilar products are considered substitutable for the reference biological product without the intervention of the health care provider who prescribed the original biological product. However, as with all prescribing decisions made in the context of a patient-provider </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relationship and a patient&#8217;s specific medical needs, health care providers are not restricted from prescribing biosimilar products in an&#160;off-label&#160;manner. In addition, a competitor could decide to forego the abbreviated approval pathway available for biosimilar products and to submit a full BLA for product licensure after completing its own preclinical studies and clinical trials. In such a situation, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its biological product as soon as it is approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, if approved, our future products may become subject to competition from such biosimilars, whether or not they are designated as interchangeable, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any of our product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or health care reform initiatives, which would harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug and biological products vary widely from country to country. Current and future legislation may change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product marketing approval is granted and, in some markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and reimbursement for these product candidates and related treatments will be available from government authorities, private health insurers and other organizations. In the United States, reimbursement varies from payor to payor. Reimbursement agencies in Europe may be more conservative than federal health care programs or private health plans in the United States. For example, a number of cancer drugs are generally covered and paid for in the United States, but have not been approved for reimbursement in certain European countries. A primary trend in the U.S. health care industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of payments for particular products. For example, payors may limit coverage to specific drug or biological products on an approved list, also known as a formulary, which might not include all of the&#160;FDA-approved&#160;drugs or biologics for a particular indication. Payors may require use of alternative therapies or a demonstration that a product is medically necessary for a particular patient before use of a product will be covered. Additionally, payors may seek to control utilization by imposing prior authorization requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for products. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if coverage is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. Patients are unlikely to use our products, if they are approved for marketing, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such products. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs and biologics, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by federal health care programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. In the European Union, reference pricing systems and other measures may lead to cost containment and reduced prices. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there have been, and may continue to be, legislative and regulatory proposals at the U.S. federal and state levels and in foreign jurisdictions directed at broadening the availability and containing or lowering the cost of healthcare. In addition, existing legislation aimed at patient affordability in the United States such as the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACAmay be repealed or replaced. The continuing efforts of the government, insurance companies, managed care organizations and other third-party payors to contain or reduce costs of healthcare may adversely affect our ability to set prices for our products that would allow us to achieve or sustain profitability. In addition, governments may impose price controls on any of our products that obtain marketing approval, which may adversely affect our future profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some foreign countries, particularly the member states of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can be a long and expensive process after the receipt of marketing approval for a product candidate. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between&#160;low-priced&#160;and high-priced member states, can further reduce prices. In some countries, we may be required to conduct additional clinical trials that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount in a particular country, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability for sales of any of our product candidates that are approved for marketing in that country and our business could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no experience selling, marketing or distributing products and currently have no internal marketing and sales force. If we are unable to establish effective marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively market and sell our product candidates, if approved, or generate product revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales, marketing or distribution capabilities and have no experience as a company in the sale or marketing of pharmaceutical products. There can be no assurance that we will be able to market and sell our products in the United States or overseas. In order to commercialize any product candidates, we must build on a&#160;territory-by-territory&#160;basis marketing, sales, distribution, managerial and other&#160;non-technical&#160;capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. Therefore, with respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either globally or on a&#160;territory-by-territory&#160;basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If so, our success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities, such collaborators&#8217; strategic interest in the products under development and such collaborators&#8217; ability to successfully market and sell any such products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to enter into such arrangements when needed on acceptable terms or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. Further, to the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we decide not to, or are unable to, enter into collaborative arrangements with respect to the sales and marketing of our products, we may in the future need to establish an internal sales and marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which could be expensive, time-consuming and requiring significant attention of our executive officers to manage. Further, we may not have sufficient resources to allocate to the sales and marketing of our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure or delay in the development of sales, marketing and distribution capabilities, through collaboration with one or more third parties or through internal efforts, would adversely impact the commercialization of any of our products that we obtain approval to market. As a result, our future product revenue will suffer and we may incur significant additional losses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we fail to maintain the listing of our common stock with a United States national securities exchange, the liquidity of our common stock could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 25, 2022, we received a deficiency letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying us that, for the last 30 consecutive business days, the bid price for our common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the &#8220;Minimum Bid Price Requirement&#8221;). The Nasdaq deficiency letter has no immediate effect on the listing of our common stock, and our common stock will continue to trade on the Nasdaq Global Select Market under the symbol &#8220;NEXI&#8221; at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the &#8220;Compliance Period Rule&#8221;), we have been provided a period of 180 calendar days, or until April 24, 2023 (the &#8220;Compliance Date&#8221;), to regain compliance with the Minimum Bid Price Requirement. If, at any time ending April 24, 2023, the bid price for our common stock closes at $1.00 or more for a minimum of ten consecutive business days, as required under the Compliance Period Rule, the Staff will provide written notification to us that we have regained compliance with the Minimum Bid Price Requirement and our common stock will continue to be eligible for listing on the Nasdaq Global Select Market, unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we do not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, we may be eligible for an additional 180 calendar day compliance period. To qualify, we would need to transfer the listing of our common stock to The Nasdaq Capital Market, provided that we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and would need to provide written notice to Nasdaq of our intention to cure the deficiency during the additional compliance period. To effect such a transfer, we would also need to pay an application fee to Nasdaq and provide written notice to the Staff of our intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. As part of its review process, the Staff will make a determination of whether it believes we will be able to cure the deficiency. Should the Staff conclude that we will not be able to cure the deficiency, the Staff will provide written notification to us that our common stock will be subject to delisting. At that time, we may appeal the Staff&#8217;s delisting determination to a Nasdaq Listing and Hearing Review Panel. However, there can be no assurance that, if we receive a delisting notice and appeal the delisting determination by the Staff to the panel, such appeal would be successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We intend to monitor the closing bid price of our common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, which could include seeking to effect a reverse stock split. However, there can be no assurance that we will be able to regain compliance with the Minimum Bid Price Requirement, secure a second period of 180 days to regain compliance, or maintain compliance with any of the other Nasdaq continued listing requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on the OTC Bulletin Board or another over-the-counter market. Any such alternative would likely result in it being more difficult for us to raise additional capital through the public or private sale of equity securities and for investors to dispose of, or obtain accurate quotations as to the market value of, our common stock. In addition, there can be no assurance that our common stock would be eligible for trading on any such alternative exchange or markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this section and many others beyond our control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form&#160;10-K,&#160;these factors include:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the enrollment, completion or results of our Phase I/II clinical trials for&#160;NEXI-001&#160;and&#160;NEXI-002;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">any delay in identifying and advancing a clinical candidate for our other programs;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adverse results or delays, suspensions or terminations in future preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adverse regulatory decisions, including failure to receive regulatory approval of&#160;NEXI-001,&#160;NEXI-002&#160;or any other product candidate or the failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in laws or regulations applicable to any of our product candidate, including but not limited to clinical trial requirements for approvals;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">adverse developments concerning our manufacturers;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to establish collaborations, if needed;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our failure to commercialize our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unanticipated serious safety concerns related to the use of any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">introduction of new products or services offered by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to effectively manage our growth;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our cash position;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">publication of research reports about us or our industry, or product candidates in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the structure of the healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">overall performance of the equity markets;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in accounting practices;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ineffectiveness of our internal controls;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">general political and economic conditions;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. </span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by affected countries and others could exacerbate market and economic instability; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market has experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders and their affiliates, if they choose to act together, will continue to have the ability to exercise significant influence over all matters submitted to stockholders for approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers and directors, combined with our stockholders who own more than 5% of our outstanding common stock, in the aggregate, beneficially own shares representing a majority of our outstanding capital stock. As a result, if these stockholders were to choose to act together, they would be able to influence our management and affairs and the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or substantially all of our assets. This concentration of ownership control may adversely affect the market price of our common stock by:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delaying, deferring or preventing a change in control;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">entrenching our management and the board of directors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">impeding a merger, consolidation, takeover or other business combination involving us that other stockholders may desire; and/or</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company, or EGC, as defined in the Jumpstart Our Business Startups Act, or the JOBS Act, enacted in April 2012. For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this Annual Report on Form&#160;10-K&#160;and our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an EGC for up to five years following the year in which we complete the IPO, although circumstances could cause us to lose that status earlier. We will remain an EGC until the earlier of (a)&#160;the last day of the fiscal year (i)&#160;following the fifth anniversary of the completion of the IPO, (ii)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion or (iii)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by&#160;non-affiliates&#160;to exceed $700.0&#160;million as of the prior June 30th, and (b)&#160;the date on which we have issued more than $1.0&#160;billion in&#160;non-convertible&#160;debt during the prior three-year period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by&#160;non-affiliates&#160;plus the proposed aggregate amount of gross proceeds from the IPO was less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K&#160;and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of reduced reporting burdens in this Annual Report on Form&#160;10-K.&#160;In particular, we have not included all of the executive compensation information that would be required if we were not an EGC. We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the JOBS Act, EGCs can also delay adopting new or revised accounting standards until such time as those standards apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We previously identified a material weakness in our internal control over financial reporting, which has been remediated. If we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and stock price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected in a timely basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot assure you that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent or avoid potential future material weaknesses. In connection with the implementation of the necessary procedures </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and practices related to internal control over financial reporting, we may identify material weaknesses that we may not be able to remediate in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. In addition, we may encounter problems or delays in completing the implementation of any improvements and receiving a favorable attestation by our independent registered public accounting firm, if and when required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to achieve and maintain an effective internal control environment in our disclosure controls or internal control over financial reporting, the accuracy and timing of our financial reporting may be adversely affected; our liquidity, our access to capital markets and our ability to complete acquisitions may be adversely affected; we may be unable to maintain or regain compliance with applicable securities laws, The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) listing requirements, and the covenants under certain agreements regarding the timely filing of periodic reports; we may be subject to regulatory investigations and penalties; investors may lose confidence in our financial reporting; and our stock price may decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there are 26,078,451 shares of common stock outstanding. Sales of stock by these stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have registered on&#160;Form&#160;S-8&#160;all shares of common stock that are issuable under our 2021 Equity Incentive Plan. As a consequence, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less&#160;than&#160;two-thirds&#160;of&#160;all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a requirement of approval of not less&#160;than&#160;two-thirds&#160;of&#160;all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers and employees to us or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our bylaws (in each case, as they may be amended from time to time) or (iv)&#160;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein; provided, however, that this exclusive forum provision will not apply to any causes of action arising under Exchange Act. Our bylaws further provide that, unless we consent in writing to an alternative forum, the United States District Court for the District of Maryland will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. We have chosen the United States District Court for the District of Maryland as the exclusive forum for such Securities Act causes of action because our principal executive offices are located in Gaithersburg, Maryland. In addition, our amended and restated bylaws will provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions. We recognize that the forum selection clause in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the State of Maryland, as applicable. Additionally, the forum selection clause in our bylaws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. The Court of Chancery of the State of Delaware or the United States District Court for the District of Maryland may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the applicability of the exclusive forum provision is limited to the extent permitted by applicable law, we do not intend that the exclusive forum provision would apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. We also acknowledge that Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder and that there is uncertainty as to whether a court would enforce an exclusive forum provision for actions arising under the Securities Act.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules, and any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factor</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, and particularly after we are no longer an &#8220;emerging growth company,&#8221; we will incur significant legal, accounting and other expenses that we did not incur as a private company. Sarbanes-Oxley, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our issuance of additional capital stock in connection with potential future financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity awards to employees, directors and consultants under our stock incentive plans. We may also raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary companies, products or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline.</span></div><div id="i5091247d182148eaaadd80685b94df97_25"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B. Unresolved Staff Comments.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i5091247d182148eaaadd80685b94df97_28"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Properties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters is located in Gaithersburg, Maryland, where we lease a total of approximately 22,800 square feet of office and laboratory space under a lease that is due to expire on June&#160;30, 2027. We lease an additional 6,440 square feet of office space in Gaithersburg, Maryland that is set to expire February 29, 2024. We anticipate that we will require additional office and laboratory space for our planned operations prior to the expiration of our current lease.</span></div><div id="i5091247d182148eaaadd80685b94df97_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Legal Proceedings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div id="i5091247d182148eaaadd80685b94df97_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i5091247d182148eaaadd80685b94df97_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;12, 2021, our common stock began trading on The Nasdaq Global Market under the symbol &#8220;NEXI&#8221;. Prior to that time, there was no public market for our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Our Common Stock</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there were approximately 67 holders of record of shares of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, our financial condition, our capital requirements, general business conditions, our future prospects and other factors that our board of directors may deem relevant. Our ability to pay cash dividends on our capital stock in the future may also be limited by the terms of any preferred securities we may issue or agreements governing any additional indebtedness we may incur. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Equity Securities</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not sell any of our unregistered securities during the year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from Initial Public Offering</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial public offering of common stock, or the IPO, was effected through a Registration Statement on&#160;Form&#160;S-1&#160;(File&#160;No.&#160;333-&#160;252220) that was declared effective by the SEC on February&#160;11, 2021. We issued and sold in aggregate 7,441,650 shares of common stock, which included 970,650 shares of our common stock issued pursuant to the underwriters&#8217; option to purchase additional shares, at a public offering price of $17.00 per share, for net proceeds of $114.6 million after deducting underwriting discounts and commissions and other offering costs. None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10% or more of our common stock or to any of our affiliates. We have invested the net proceeds from the IPO in a money market fund and available-for-sale marketable securities. There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on February&#160;11, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i5091247d182148eaaadd80685b94df97_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Selected Financial Data.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i5091247d182148eaaadd80685b94df97_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this filing on&#160;Form&#160;10-K&#160;and our final prospectus for our initial public offering filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, or the Securities Act, on February&#160;11, 2021, or the Prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this Form&#160;10-K,&#160;including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the &#8220;Risk Factors&#8221; section of this Form&#160;10-K,&#160;our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investors and others should note that we routinely use the Investor Relations section of our website to announce material information to investors and the marketplace. While not all of the information that we post on the Investor Relations section of our website is of a material nature, some information could be deemed to be material. Accordingly, we encourage investors, the media, and others interested in us to review the information that it shares on the Investor Relations section of our website, www.neximmune.com.</span></div><div id="i5091247d182148eaaadd80685b94df97_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company developing a novel approach to immunotherapy designed to employ the body&#8217;s own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we announced that, following a strategic review of our pipeline, indications, timelines and cash position, we are implementing a strategic realignment initiative, which is designed to reduce costs and reallocate resources towards our AIM INJ preclinical development programs. As part of this strategy, we will focus on developing AIM INJ nanoparticle constructs and modalities for potential clinical evaluation in oncology and autoimmune disorders. We will also pause development of our current adoptive cell therapy, or AIM ACT, product candidates, NEXI-001 and NEXI-003. As previously disclosed, the NEXI-002 trial in Multiple Myeloma will remain paused. We intend to explore external opportunities that may permit us to continue to advance these clinical programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The backbone of our approach is our proprietary Artificial Immune Modulation, or AIM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. One of the critical advantages of the AIM technology platform is the ability to rapidly customize it for new therapeutics, in a modular, Lego-like manner. NexImmune has developed protein conjugation techniques so that nanoparticles can be customized quickly for different antigens, HLA alleles and Signal 2 messages. It is even possible to add additional signals or homing proteins. This gives the platform tremendous flexibility and application in oncology and infectious disease (where up-regulatory messages are delivered to targeted T cells) but also autoimmune disorders (where down-regulatory or apoptopic messages are delivered to targeted T cells). These conjugation techniques also apply to both the ex vivo adoptive cell therapy modality, called AIM ACT, and the in vivo directly-injectable modality, called AIM INJ.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AIM INJ modality is designed to enable AIM nanoparticles to engage CD8+ T cells directly inside the body without the need for ex vivo expansion and manufacturing, which we believe will result in a greater ease of administration and a less complex and less expensive manufacturing process. We have completed substantial non-clinical work to advance the AIM INJ modality towards a potential investigational new drug application, or IND, filing, including preparing appropriate IND-enabling experiments in support of a planned clinical program focusing on solid tumors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware on June&#160;7, 2011. In June 2011, we exclusively licensed the core AIM technology from The Johns Hopkins University, or Johns Hopkins. See &#8220;Business&#8212;Johns Hopkins License Agreement&#8221; for information about this license.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, identifying and developing product candidates, enhancing our intellectual property portfolio, undertaking research, conducting preclinical studies and clinical trials, and securing manufacturing for our development programs. We do not have any products approved for sale and have not generated any revenue from product sales.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have funded our operations primarily with proceeds from private placement of convertible preferred stock, our convertible promissory notes and the IPO. In February 2021, we completed the IPO and issued and sold an aggregate 7,441,650 shares of common stock, which included 970,650 shares of our common stock issued pursuant to the underwriters&#8217; option to purchase additional shares, at a public offering price of $17.00 per share, for net proceeds of $114.6 million after deducting underwriting discounts and commissions and other offering costs. In the year ended December&#160;31, 2022, we sold an aggregate of 3,184,900 shares through our &#8220;at-the-market&#8221; offering facility resulting in net proceeds of $5.1 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses since our inception, which are mainly attributed to research and development costs and employee payroll expense. Our net loss was $62.5 million and $50.9 million for the years ended December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022, we had an accumulated deficit of $190.2 million. Our operating losses may fluctuate significantly from&#160;quarter-to-quarter&#160;and&#160;year-to-year&#160;as a result of several factors, including the timing of our preclinical studies and clinical trials and our expenditures related to other research and development activities. We expect to continue to incur operating losses for the foreseeable future. We anticipate these losses will increase substantially as we advance our product candidates through preclinical and clinical development, develop additional product candidates and seek regulatory approvals for our product candidates. We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more product candidates. In addition, if we obtain marketing approval for any product candidate, we expect to incur&#160;pre-commercialization&#160;expenses and significant commercialization expenses related to marketing, sales, manufacturing and distribution. We may also incur expenses in connection with the&#160;in-licensing&#160;of additional product candidates. Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations, compliance and other expenses that we did not incur as a private company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through public or private equity offerings, debt financings, collaborations and licensing arrangements or other capital sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our updated corporate strategy announced in November 2022, we are initiated a workforce reduction plan to reduce headcount by approximately 30%, primarily affecting the clinical development, manufacturing and administrative staff that had been needed to support the AIM ACT adoptive cell therapy clinical programs. The plan will reduce our workforce from 74 full-time employees prior to the announcement to approximately 50 full-time employees. We  incurred $0.5 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. Management communicated the workforce reduction on November 14, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash and cash equivalents of $34.6 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nasdaq Delisting Notification</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 25, 2022, we received a deficiency letter from the Listing Qualifications Department (the &#8220;Staff&#8221;) of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying us that, for the last 30 consecutive business days, the bid price for our common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the &#8220;Minimum Bid Price Requirement&#8221;). The Nasdaq deficiency letter has no immediate effect on the listing of our common stock, and our common stock will continue to trade on the Nasdaq Global Select Market under the symbol &#8220;NEXI&#8221; at this time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the &#8220;Compliance Period Rule&#8221;), we have been provided a period of 180 calendar days, or until April 24, 2023 (the &#8220;Compliance Date&#8221;), to regain compliance with the Minimum Bid Price Requirement. If, at any time ending April 24, 2023, the bid price for our common stock closes at $1.00 or more for a minimum of ten consecutive business days, as required under the Compliance Period Rule, the Staff will provide written notification to us that we have regained compliance with the Minimum Bid Price Requirement and our common stock will continue to be eligible for listing on the Nasdaq Global Select Market, unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, we may be eligible for an additional 180 calendar day compliance period. To qualify, we would need to transfer the listing of our common stock to The Nasdaq Capital Market, provided that we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and would need to provide written notice to Nasdaq of our intention to cure the deficiency during the additional compliance period. To effect such a transfer, we would also need to pay an application fee to Nasdaq and provide written notice to the Staff of our intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. As part of its review process, the Staff will make a determination of whether it believes we will be able to cure the deficiency. Should the Staff conclude that we will not be able to cure the deficiency, the Staff will provide written notification to us that our common stock will be subject to delisting. At that time, we may appeal the Staff&#8217;s delisting determination to a Nasdaq Listing and Hearing Review Panel. However, there can be no assurance that, if we receive a delisting notice and appeal the delisting determination by the Staff to the panel, such appeal would be successful.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to monitor the closing bid price of our common stock and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement, which could include seeking to effect a reverse stock split. However, there can be no assurance that we will be able to regain compliance with the Minimum Bid Price Requirement, secure a second period of 180 days to regain compliance, or maintain compliance with any of the other Nasdaq continued listing requirements.</span></div><div id="i5091247d182148eaaadd80685b94df97_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future, if at all.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our research and development expenses have related primarily to development of&#160;NEXI-001&#160;and&#160;NEXI-002 and related clinical trials,&#160;preclinical studies and other preclinical activities related to our portfolio. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses also include the accrual of minimum royalties under our Johns Hopkins license.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">salaries, payroll taxes, employee benefits and stock-based compensation charges for those individuals involved in research and development efforts;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">external research and development expenses incurred under agreements with contract research organizations, or CROs, and consultants to conduct our preclinical, toxicology and other preclinical studies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">laboratory supplies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">costs related to manufacturing product candidates, including fees paid to third-party manufacturers and raw material suppliers;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">license fees and research funding; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, maintenance of facilities, insurance, equipment and other supplies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. We outsource a substantial portion of our clinical trial activities, utilizing external entities such as CROs, independent clinical investigators and other third-party service providers to assist us with the execution of our clinical trials. We also expect to incur additional expenses related to milestone and royalty payments payable to Johns Hopkins.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue the development of our product candidates and seek to discover and develop new product candidates,  we will likely require substantial funds to continue such activities. Due to the inherently unpredictable nature of preclinical and clinical development, we cannot determine with certainty the timing of the initiation, duration or costs of future clinical trials and preclinical studies of product candidates. Clinical and preclinical development timelines, the probability of success and the amount of development costs can differ materially from expectations. We anticipate that we will make determinations as to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which product candidates and development programs to pursue and how much funding to direct to each product candidate or program on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#8217;s commercial potential. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future clinical development costs may vary significantly based on factors such as:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">per-patient&#160;trial costs;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of trials required for regulatory approval;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of sites included in the trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the countries in which the trials are conducted;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of patients that participate in the trials;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of doses that patients receive;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the&#160;drop-out&#160;or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential additional safety monitoring requested by regulatory agencies;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the duration of patient participation in the trials and&#160;follow-up;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the phase of development of the product candidate; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the efficacy and safety profile of the product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for personnel in our executive, finance and other administrative functions. Other significant costs include facility-related costs, legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services and insurance costs. We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities,&#160;pre-commercialization&#160;activities and, if any product candidates receive marketing approval, commercialization activities. We also anticipate increased expenses related to audit, legal, regulatory and&#160;tax-related&#160;services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs associated with operating as a public company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our cash equivalents and marketable securities during the period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of interest accrued on the convertible notes and interest recognized upon the amortization of the beneficial conversion feature, debt issuance costs and bifurcated derivative liability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Derivative Liability</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of derivative liability consists entirely of the&#160;mark-to-market&#160;adjustment of the bifurcated derivative liability related to the convertible notes. As a result of our IPO, the derivative liability was settled.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Extinguishment of Debt</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The gain on the extinguishment of debt is the result of our PPP Loan being forgiven by our lending institution through the application of the CARES Act.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Years Ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,827&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,827)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,354&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,777)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,505)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,901)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,604)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Research and development expenses were $47.1 million and $37.5 million for the years ended December&#160;31, 2022 and 2021, respectively. The increase of $9.7 million was due primarily to increases of $3.6&#160;million on research and preclinical manufacturing, an increase of $0.6 million on clinical trial expenses, increases to salary and benefits of $4.1&#160;million resulting from increased headcount including a $0.5 million restructuring charge, $0.9 million in stock compensation expense, and $0.5 million in facility and consulting fees. We have not historically tracked internal research and development expenses by product candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;General and administrative expenses were $15.9 million and $15.8 million for the years ended December&#160;31, 2022 and 2021, respectively. The increase of $0.1 million was due primarily to increases of $1.4 million in legal and professional fees, offset by a an decrease in salary and benefits of $0.1 million from decreased head count and reduction of $1.0 million in stock compensation expense.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interest Income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest income was $0.6 million and $0.1 million for the years ended December&#160;31, 2022 and 2021, respectively. The increase is due to increasingly favorable interest rates on fixed income securities held as cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Change in Fair Value of Derivative Liability.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The change in fair value of derivative liability was $0 and $2.4 million for the year ended December&#160;31, 2022 and 2021, respectively. The decrease reflected the remeasurement of the derivative liability immediately before the conversion of the convertible notes into shares of common stock upon the completion of the IPO in February 2021. Following the IPO there are no derivative instruments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on Extinguishment of Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The gain on extinguishment of debt was $0.8 million for the year ended December&#160;31, 2021. The increase was due to the PPP Loan forgiveness of $0.8 million. The was no debt extinguishment for the year ended December&#160;31, 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interest Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;Interest expense was $0 and $0.9 million for the years ended December&#160;31, 2022 and 2021, respectively. The increase is due to the issuance of convertible debt during the period from April 2020 into January 2021. The convertible notes were converted into shares of common stock upon the completion of the IPO in February 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December&#160;31, 2021 and 2020:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,851&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,404&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain om extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income / (expense)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,354&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,015)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,901)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,866)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,035)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses were $37.5 million and $17.8 million for the years ended December 31, 2021 and 2020, respectively. The increase of $19.6 million was due primarily to increases of $10.5 million on research and preclinical manufacturing, an increase of $1.9 million on clinical trial expenses, increases to salary and benefits of $3.7 million resulting from increased headcount, $2.6 million in stock compensation expense, and $0.9 million in consulting fees. We have not historically tracked internal research and development expenses by product candidate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General and administrative expenses were $15.8 million and $10.0 million for the years ended December 31, 2021 and 2020, respectively. The increase of $5.8 million was due primarily to increases of $1.7 million in salary and benefits resulting from increased headcount, $2.2 million in stock compensation expense, an increase of $2.5 million in professional fees and Directors and Officers insurance as a result of operating as public company, partially offset by a $0.6 million decrease in legal and consulting fees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Derivative Liability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The change in fair value of derivative liability was an increase of $2.4 million and a decrease of $0.4 million for the years ending December 31, 2021 and 2020, respectively. The increase reflected the remeasurement of the derivative liability immediately before the conversion of the convertible notes into shares of common stock upon the completion of the IPO in February 2021. Upon completion of the IPO, the derivative liability was settled and there is no future remeasurement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on Extinguishment of Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The gain on extinguishment of debt was $0.8 million for the year ended December 31, 2021. The increase was due to the PPP Loan forgiveness of $0.8 million. The was no debt extinguishment for the years ended December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest expense was $0.9 million and $1.7 million for the years ended December 31, 2021 and 2020, respectively. The decrease is due to the conversion of the convertible notes into shares of common stock upon the completion of the IPO in February 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of December&#160;31, 2022, we had cash and cash equivalents of $34.6 million.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash and cash equivalents will be sufficient to fund our activities into the fourth quarter of 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our research and development activities mature and develop over the next year, we will likely require substantial funds to continue such activities, depending upon events that are difficult to predict at this time. In this regard, management plans to raise additional capital through financing activities that may include public offerings and private placements of our common stock, preferred stock offerings, collaborations and licensing arrangements and issuances of debt and convertible debt instruments. In the absence of additional capital, the Company plans to strategically manage its uncommitted spend, execute its priorities and implement cost saving measures to reduce research and development and general and administrative expenditures which could include minimizing staff costs and delaying or terminating manufacturing and clinical trial costs. There are inherent uncertainties associated with fundraising activities and activities to manage our uncommitted spending and the successful execution of these activities may not be within our control. There are no assurances that such additional funding will be obtained and that the Company will succeed in its future operations. If we cannot successfully raise additional capital and implement our strategic development plan, our liquidity, financial condition and business prospects will be materially and adversely affected. We are continually looking into further capital planning and the evaluation of strategic alternatives. There is substantial doubt about our ability to continue as a going concern.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations principally through private placements of our convertible preferred stock, our convertible promissory notes, the IPO, and an "at-the-market" offering facility.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock Financing</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From December 2017 through August 2018, we issued an aggregate of 121,735,303 shares of our Series A Redeemable Convertible Preferred Stock at a purchase price of $0.2951 per share for aggregate consideration of $25.0 million plus conversion of convertible notes.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019 and February 2019, we issued an aggregate of 22,047,361 shares of our Series A-2 Preferred Stock at a purchase price of $0.3523 per share for aggregate consideration of $7.8 million.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019 and December 2019, we issued an aggregate of 31,209,734 shares of our Series A-3 Preferred Stock at a purchase price of $0.3523 per share for aggregate consideration of $11.0 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Note Financing</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From April 2020 through December 31, 2020, we issued $21,618,286 aggregate principal amount of convertible notes, which carried an interest at the rate of 6% per annum until converted into common shares upon completion of our IPO.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we issued an additional $9,031,480 aggregate principal amount of convertible notes, which carried an interest at the rate of 6% per annum until converted into common shares upon completion of our IPO.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;23, 2020, we entered into an unsecured loan agreement with JPMorgan Chase Bank, or Chase, under the terms of which Chase loaned us $843,619, or the PPP Loan, pursuant to the Paycheck Protection Program, or PPP, under the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act. In accordance with the requirements of the CARES Act, we used the proceeds primarily for payroll costs and other eligible expenses. The PPP Loan had a maturity date of April&#160;23, 2022 and accrued interest at an annual rate of 0.98%. Interest and principal payments were deferred for the first six months of the loan. Thereafter, monthly interest and principal payments were due until the loan is fully satisfied. The promissory note evidencing the PPP Loan contains customary events of default resulting from, among other things, default in the payments. The use of loan proceeds must be for payroll costs, payment of interest on covered mortgage obligations, rent and utility costs over either an eight-week or&#160;24-week&#160;period, at our option, following our receipt of the loan proceeds. We elected to use the proceeds over a&#160;24-week&#160;period. We treated the PPP loan as debt under ASC&#160;470,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. We submitted the PPP Loan forgiveness application in March 2021 and received full forgiveness of the $843,619 PPP Loan in July 2021. The Company recognized the $843,619 forgiveness as a gain on extinguishment of debt for the year ended December 31, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Initial Public Offering</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we completed an IPO and issued and sold an aggregate 7,441,650 shares of common stock, which included 970,650 shares of our common stock issued pursuant to the underwriters&#8217; option to purchase additional shares, at a public offering price of $17.00 per share, for net proceeds of $114.6 million after deducting underwriting discounts and commissions and other offering costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"At-the-market" offering facility</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, we sold an aggregate of 3,184,900 shares through our &#8220;at-the-market&#8221; offering facility resulting in net proceeds of $5.1 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the net cash flow activity for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December&#160;31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase in cash, cash equivalents and restricted cash</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $51.2 million and $45.8&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. The net cash used in operating activities for the year ended December&#160;31, 2022 was primarily due to our net loss of $62.5 million, resulting from R&amp;D expenditures of $47.1 million as we continue to our preclinical and clinical program and $15.9 million of administrative expenses for salary and related expenses and professional fees. Our net loss is partially offset by $11.3 million in&#160;non-cash&#160;expenses and working capital changes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash used in operating activities for the year ended December&#160;31, 2021 was primarily due to our net loss of $50.9 million, consisting of $37.5 million for R&amp;D expenses primarily in&#160;pre-clinical&#160;research expenses as we prepared for our clinical program and began ramping up our clinical programs, and $15.8 million in administrative expenses for salary and related expenses and profession fees. These are partially offset by $5.1 million in&#160;non-cash&#160;expenses and working capital changes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $50.3 million for the year ended December&#160;31, 2022 and used in was $53.8 million for the year ended December&#160;31, 2021. The net cash provided by investing activities for the year ended December&#160;31, 2022 was primarily due to the maturities of $73.0 million in&#160;available-for-sale&#160;marketable securities partially offset by the purchase of $21.5 million in available-for-sale marketable securities and by the purchase of property and equipment of $1.3 million.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash used in investing activities for the year ended December&#160;31, 2021 was primarily due to purchase of $90.5 million in available-for-sale marketable securities partially offset maturities of $39.0 million in&#160;available-for-sale&#160;marketable securities and the purchase of property and equipment for $2.4 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $5.2 million for the year ended December&#160;31, 2022 primarily due to the net proceeds of $5.1 million from the "at-the-market" offering facility. Net cash provided by financing activities was $124.9 million for the year ended December&#160;31, 2021 primarily due to the net proceeds of $114.7 million from the IPO,$9.0 million from the issuance of convertible debt, and $1.2 million from the exercise of stock options. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing cash and cash equivalents and marketable securities, together with the net proceeds from our IPO, will be sufficient to meet our anticipated cash requirements into the fourth quarter of 2023. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. If we are not able to raise additional funding, we may not be able to enter into successful collaborations under favorable terms. As a result, we may be unable to realize value from our assets and discharge our liabilities in the normal course of business.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the initiation, progress, timing, costs and results of drug discovery, preclinical studies and clinical trials of our product candidates;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number and characteristics of product candidates that we pursue;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the outcome, timing and costs of seeking regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of manufacturing our product candidates for clinical trials in preparation for marketing approval and in preparation for commercialization;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the emergence of competing therapies and other adverse market developments;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the extent to which we in-license or acquire other products and technologies; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs of operating as a public company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues to support our capital requirements, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations and licensing arrangements or other capital sources. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may need to relinquish valuable rights to our product candidates, future revenue streams or research programs or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings as and when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note 3, &#8220;Summary of significant accounting policies,&#8221; we believe the following accounting policies and estimates to be most critical to the preparation of our financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses &amp; Prepayment of Services</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments, if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from&#160;contract-to-contract&#160;and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span></div><div id="i5091247d182148eaaadd80685b94df97_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Company Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Operating Loss and Research and Development Carryforwards and Other Income Tax Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had federal and state net operating loss carryforwards of $135.2 million and federal research credit carryforwards of $0.3 million. Approximately $10.5 million of the federal NOL was generated prior to 2018 and will expire in increments through 2037 beginning in 2035, while the remaining $124.7 million will be carried forward indefinitely. The state NOL will expire in increments through 2037, beginning expiring in 2035. The federal research and development tax credit carryforwards, if not utilized, will expire beginning in 2037.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that it is more likely than not that we will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December&#160;31, 2022. Management reevaluates the positive and negative evidence at each reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not completed a Section&#160;382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation due to the complexity and cost associated with such a study and the fact that there may be additional such ownership changes in the future. Pursuant to Sections 382 and 383 of the Internal Revenue Code, annual use of our net operating loss and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. We will remain an emerging growth company until the earlier of (1)&#160;December&#160;31, 2026, (2) the last day of the fiscal year in which we have total annual gross revenues of at least $1.07&#160;billion, (3)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, or (4)&#160;the date on which we have issued more than $1.0&#160;billion in&#160;non-convertible&#160;debt securities during the prior three-year period. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company,</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may present only two years of audited financial statements, plus unaudited condensed financial statements for any interim period, and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in this filing.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may provide reduced disclosure about our executive compensation arrangements; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may not require stockholder non-binding advisory votes on executive compensation or golden parachute arrangements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this filing is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. Until the date that we are no longer an emerging growth company or affirmatively and irrevocably opt out of the exemption provided by Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, upon issuance of a new or revised accounting standard that applies to our financial statements and that has a different effective date for public and private companies, we will disclose the date on which we will adopt the recently issued accounting standard.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by&#160;non-affiliates&#160;plus the proposed aggregate amount of gross proceeds to us as a result of the IPO was less than $700.0&#160;million and our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. After the IPO we may continue to be a smaller reporting company if either (1)&#160;the market value of our stock held by&#160;non-affiliates&#160;is less than $250.0&#160;million or (2)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by&#160;non-affiliates&#160;is less than $700.0&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K&#160;and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recently issued and adopted accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 3, &#8220;Summary of significant accounting policies&#8221;.</span></div><div id="i5091247d182148eaaadd80685b94df97_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate risks, foreign currency exchange rate risks and inflation risks. Periodically, we maintain deposits in accredited financial institutions in excess of federally insured limits. We deposit our cash in financial institutions that we believe have high credit quality and have not experienced any significant losses on such accounts and do not believe we are exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash consists of cash in readily-available checking accounts and short-term money market fund investments. Such interest-earning instruments carry a degree of interest rate risk and the returns from such instruments will vary as short-term interest rates change. While historical fluctuations in interest income have not been significant, in a financial environment with extremely low or negative interest rates, we could experience a significant reduction in the interest earned from such instruments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our employees and our operations are currently located in the United States. We have, from&#160;time-to-time,&#160;engaged in contracts with contractors or other vendors in a currency other than the U.S. dollar. To date, we have had minimal exposure to fluctuations in foreign currency exchange rates as the time period between the date that transactions are initiated and the date of payment or receipt of payment is generally of short duration. Accordingly, we believe we do not have a material exposure to foreign currency risk.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented.</span></div><div id="i5091247d182148eaaadd80685b94df97_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and related financial statement schedules required to be filed are listed in the Index to Financial Statements and are incorporated in Item 15 of Part IV of this Annual Report on Form&#160;10-K.</span></div><div id="i5091247d182148eaaadd80685b94df97_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i5091247d182148eaaadd80685b94df97_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A. Controls and Procedures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and&#160;15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer), evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2022. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an assessment of the evaluation of the effectiveness of our internal control over financial reporting as of December&#160;31, 2022 based on the criteria set forth in &#8220;Internal Control - Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form&#160;10-K&#160;does not include an attestation report of our registered public accounting firm due to a transition period established by rules of the SEC for newly public companies. Additionally, our independent registered public accounting firm will not be required to opine on our internal control over financial reporting until we are no longer an emerging growth company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the period covered by this Annual Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i5091247d182148eaaadd80685b94df97_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item&#160;9B. Other Information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)       On March 23, 2023, Jerome Zeldis, M.D., Ph.D., Executive Vice President of Research and Development, entered into a Consulting Agreement with the Company (the &#8220;Consulting Agreement&#8221;) effective as of March 31, 2023 (the &#8220;Transition Date&#8221;).  Pursuant to the Consulting Agreement and effective as of the Transition Date, the exiting Employment Agreement, dated January 4, 2021, by and between the Company and Dr. Zeldis is terminated, Dr. Zeldis will have resigned from the Company, and Dr. Zeldis will transition to providing consulting and advisory services to the Company for a period ending on March 31, 2024 (the &#8220;Consulting Period&#8221;).  Pursuant to the terms of the Consulting Agreement, in consideration for, among other things, his compliance with certain restrictive covenants, including customary non-compete and non-solicitation covenants, and a typical release of claims, Dr. Zeldis will be paid $200.00 per hour for services provided to the Company and vested options to purchase 100,000 shares of common stock of the Company held by Dr. Zeldis (a portion of the grant received by Dr. Zeldis on February 11, 2021) are eligible to participate in the Option Repricing (as defined herein), with the exercise price for such options reduced to the level set for executive officers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing description of the material terms of the Consulting Agreement is not complete and is qualified in its entirety by the full text of the Consulting Agreement, which is attached hereto as Exhibit 10.7.1, and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)       On March 22, 2023, in order to retain and motivate employees and other key contributors of the Company, our board of directors approved a one-time stock option repricing (the &#8220;Option Repricing&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Option Repricing, the exercise price of all of the below stock options to purchase shares of the Company&#8217;s common stock previously granted under our 2017 Equity Incentive Plan, 2018 Equity Incentive Plan and 2021 Equity Incentive Plan (the &#8220;Repriced Options&#8221;) will be amended as of April 4, 2023 (the &#8220;Effective Date&#8221;) to reduce the exercise prices of such options to a price equal to or greater than the closing price per share of the Company&#8217;s common stock on The Nasdaq Stock Market on the Effective Date (the &#8220;Nasdaq Market Price&#8221;), on the terms described below; provided, however, that if the closing price per share on the Effective Date is less than $0.40, the Nasdaq Market Price will be deemed to be $0.40 for purposes of the Option Repricing:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.567%"><tr><td style="width:1.0%"></td><td style="width:32.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Repriced Options</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Terms of Repriced Options vested or vesting within six months following the Effective Date </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Terms of Repriced Options vesting more than six months following the Effective Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All options held by employees other than our executive officers, in good standing on the Effective Date</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to 2.5 times the Nasdaq Market Price </span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to the Nasdaq Market Price</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All options held by our current executive officers and 100,000 options held by Jerome Zeldis, our former EVP and Head of Research &amp; Development</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to 3.0 times the Nasdaq Market Price</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to 2.0 times the Nasdaq Market Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All options held by our directors</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to 4.0 times the Nasdaq Market Price</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to 3.0 times the Nasdaq Market Price</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Repriced Options include the following options held by our President and Chief Executive Officer, our Chief Financial Officer and our other named executive officer.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:1.0%"></td><td style="width:60.168%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Position</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares Underlying Repriced Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price of Repriced Options ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristi Jones, President and Chief Executive Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Trainer, Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jerome Zeldis, former EVP and Head of Research &amp; Development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company does not expect that the Option Repricing will have a material impact on its statement of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i5091247d182148eaaadd80685b94df97_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Board of Directors</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our executive officers and directors as of March&#160;1, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Officers:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristi Jones</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President,&#160;Chief&#160;Executive Officer and Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Trainer, M.B.A.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jerome (Jerry) Zeldis, M.D., Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President of Research and Development</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert (Bob) Knight, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mathias Oelke, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Science Officer</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Employee&#160;Directors:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sol J. Barer, Ph.D.(2)(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alan S. Roemer, M.B.A., M.P.H.(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tim Bertram, Ph.D.(1)(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul D&#8217;Angio, R.P.H., M.S.J.(1)(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zhengbin (Bing) Yao, Ph.D.(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant Verstandig(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leena Gandhi, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Member of the Audit Committee.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Member of the Compensation Committee.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Member of the Nominating and Governance Committee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Kristi Jones </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as our President and Chief Executive Officer and as a member of our board of directors since February 2022.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> She </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">served as our Chief Operating Officer from March 2018 to February 2022, our Chief Business Officer from June 2017 to March 2018, and as a consultant to the Company from September 2015 to February 2017. Prior to joining us, from 2013 to 2015, Ms. Jones served as Vice President of Portfolio Strategy at AstraZeneca. From November 2011 to July 2013 she served as Vice President of Global Strategic Marketing at MedImmune. Prior to that, Ms. Jones held multiple leadership roles with increasing responsibility at Genentech where she worked for 16 years, including Head of Immunology and Ophthalmology Global Product Strategy, Life Cycle Lead and Franchise Management. Ms. Jones has held roles in Strategy, Business Development, Commercial Operations, Managed Care, Marketing and Sales. Ms. Jones serves on the Life Science Panel for Springboard Enterprises focused on start-up companies led by women and on the Cell Therapy Committee for the Alliance of Regenerative Medicine. Ms. Jones received her Pharmacy degree from the University of Texas, College of Pharmacy and her B.S. in Biology from Texas Tech University. We believe that Ms. Jones&#8217; qualifications to serve on the board of directors include her extensive executive leadership in the life sciences industry and her knowledge of our business, having previously served in several senior positions with the company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">John Trainer&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Chief Financial Officer since January 2020. Before joining us, Mr.&#160;Trainer served as Vice President and Head of Partnering and Strategy of MedImmune from February 2017 to July 2019. Prior to MedImmune, Mr.&#160;Trainer served as Vice President, Corporate Development of AstraZeneca from April 2015 to February 2017, as well as the global commercial leader for AstraZeneca&#8217;s infection, neuroscience and gastrointestinal therapeutic areas from May 2013 to April 2015. Mr.&#160;Trainer previously served on the boards of directors of several private biotechnology companies, including Corvidia Therapeutics, Inc., Archigen Biotech Limited and Fujifilm Kyowa Kirin Biologics Co., Ltd. Prior to joining AstraZeneca, Mr.&#160;Trainer was a strategy consultant at Monitor Group, where he provided strategic planning in healthcare and other industries. Mr.&#160;Trainer received his M.B.A. from Harvard Business School and his A.B. from Harvard College.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Jerome B. Zeldis, M.D., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;has served as our Executive Vice President of Research and Development since January 2021. He was Chief Medical Officer and President of Clinical Research, Regulatory, and Safety at Sorrento Therapeutics, and Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, Summit, NJ. Prior to that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">he was Celgene&#8217;s Senior Vice President of Clinical Research and Medical Affairs and has been at Celgene since February 1997. He attended Brown University for an A.B., M.S., followed by Yale University for an M.Phil., M.D., Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry). Dr.&#160;Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Prior to working at Celgene, Dr.&#160;Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He is currently on the board of PTC Therapeutics, Soligenix, Immodulon, NexGel, and was previously on the board of BioSig Technologies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Robert Knight, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as our Chief Medical Officer since January 2021. He previously served as the Vice President of Clinical Development at Kite Pharmaceuticals, a Gilead company, from June 2020 to January 2021. Dr.&#160;Knight also led the cancer immunotherapy development program at Sorrento Therapeutics as Senior Vice President and Head of Clinical Research from July 2017 to May 2020. Prior to that, from 2001 to June 2017, Dr.&#160;Knight spent 16 years at Celgene Corporation in positions of increasing seniority, including most recently as a Vice President in Clinical Research. During his tenure at Celgene, he helped lead the development of the company&#8217;s IMiD and targeted therapy programs, including thalidomide, lenalidomide, and enasidenib. Dr.&#160;Knight is board certified in internal medicine, hematology, and oncology. Dr.&#160;Knight received his B.S. from United States Military Academy at West Point, New York and he received his M.D. from the State University of New York Downstate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:106%">Mathias Oelke, Ph.D. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">has served as our Chief Scientific Officer since April 2022. Dr. Oelke has more than 20 years of research experience in cancer immunotherapy and has a long-standing track record of developing methods for antigen-specific stimulation of T cells for therapeutic use. Prior to his promotion, he served as Senior Vice President, Preclinical Immunotherapy and Head of Cell Biology of NexImmune since 2017. Dr. Oelke has numerous peer-reviewed publications and is a co-inventor on more than 25 patents and patent applications describing NexImmune&#8217;s proprietary aAPC technology, with additional pending patent applications in related fields of cancer immunotherapy. Previously, he was a member of the faculty at the Johns Hopkins University for over 11 years. Dr. Oelke, who is a chemist by training, received his Ph.D. in Biology from University of Freiburg, where he first became interested in the critical role of antigen presenting cells and their use in immunotherapy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee&#160;Directors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Sol J. Barer, Ph.D.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as the Chairman of our board of directors since November 2019. Dr.&#160;Barer has served as Chairman of the Hackensack Meridian Health Center for Discovery&#160;&amp; Innovation since June 2018 and as a member of Barer&#160;&amp; Son Capital, an investment fund focused on capitalizing early-stage breakthrough biotechnology companies, since 2017. Dr.&#160;Barer also serves on the boards of directors of several public companies, including Teva Pharmaceutical Industries Limited as Chairman and ContraFect Corporation as lead Director. Dr.&#160;Barer previously served as Chairman and director of InspireMD, Inc. from 2011 to 2017, and as a director of Amicus Therapeutics, Inc. from 2009 to 2017 and Aegerion Pharmaceuticals, Inc. from 2011 to 2016. From 1987 to 2011, Dr.&#160;Barer held various leadership positions at Celgene. He served as Chairman of Celgene from January 2011 to June 2011, Executive Chairman from June 2010 to January 2011, and Chairman and Chief Executive Officer from May 2006 to June 2010. He was previously President of Celgene from 1993 to May 2016 and Chief Operating Officer from 1994 to May 2006. Dr.&#160;Barer was the founder of the biotechnology group at the Celanese Research Company that was subsequently spun off as Celgene. Dr. Barer also served as the Chairman and director of Edge Therapeutics from 2011 to 2019 and as the Chairman of Aevi Genomic Medicine from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2012 to 2021. Dr.&#160;Barer received his Ph.D. in organic and physical chemistry from Rutgers University and his B.S. in chemistry from Brooklyn College of the City University of New York. We believe that Dr.&#160;Barer&#8217;s qualifications to serve on our board of directors include his significant scientific, executive and board leadership experience in the biopharmaceutical industry.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Alan S. Roemer, M.B.A., M.P.H.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">served as a member of our board of directors since February 2017 and served as chair of our board of directors from December 2017 to November 2019. He has served as chair and a member of the board of directors of IN8bio, Inc., a public biotechnology company, since September 2020; chair and a member of the board of directors of UTILITY therapeutics Ltd., a private biotechnology company, since March 2020; a member of the board of directors of Bit.Bio Ltd., a private synthetic biology company, since August 2021; and a member of the board of trustees of the Helene Fuld College of Nursing since June 2014. Mr. Roemer was a founding leadership team member and senior vice president of Roivant Sciences, Inc., a private biopharmaceutical company, from the company&#8217;s inception May 2014 to August 2019, where he held various senior management roles responsible for finance, operations and corporate development. From March 2015 to August 2015, he also served as principal financial and accounting officer of Axovant Sciences Ltd., a public biopharmaceutical company, and a founding leadership team member and chief financial officer of its wholly owned subsidiary, Axovant Sciences, Inc. Prior to Roivant and Axovant, Mr. Roemer served in various executive roles, including managing director of the Trout Group LLC and Trout Capital LLC from 2009 to 2014, chief financial officer and treasurer of Zelos Therapeutics, Inc. from 2008 to 2009, and vice president of Pharmasset, Inc. 1999 to 2008, which was subsequently acquired by Gilead Sciences, Inc. Mr. Roemer has also served as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> a member of the board of directors of Envisagenics, Inc., a private artificial intelligence </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">from September 2021 to February 2023, and as a member of the board of directors of SomPharmaceuticals SA, a private biopharmaceutical company, from August 2012 to May 2016, until its acquisition by Amryt Pharma plc. Mr. Roemer received a B.S. in Business Administration from Georgetown University and his MBA and MPH degrees from Emory University&#8217;s Goizueta Business School and Rollins School of Public Health. We believe that Mr. Roemer&#8217;s qualifications to serve on our board include significant executive and board leadership experience in the biopharmaceutical industry.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Tim Bertram, Ph.D.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as a member of our board of directors since January 2017. Dr. Bertram currently serves as Chief Executive Officer and board member of ProKidney. Since May 2016, Dr. Bertram served as Chief Executive Officer and as a member of the board of directors of inRegen, a clinical-stage cellular therapeutics company focused on the treatment of chronic renal disease. Mr. Bertram also is a member of the board of directors of Twin City Bio LLC, a contract development and manufacturing service for pharmaceutical and biotech companies focused on cell-based therapies. Prior to that, he served as Chief Executive Officer of RegenMed Therapeutics. He served as Chief Scientific Officer of Tengion Inc. from 2004 to 2014 after serving as President of Research and Development where he brought four cell-based therapeutic products from discovery through Phase 2 clinical development. Dr. Bertram was involved in the development and registration of eight medical products while serving as a senior executive at Pfizer Inc., SmithKline Beecham Pharmaceuticals, and The Procter &amp; Gamble Company. He was a faculty member at the University of Illinois, and a visiting scientist at the National Institutes of Health. Tengion Inc. filed a voluntary chapter 7 bankruptcy petition in December 2014. Dr. Bertram received his D.V.M. and Ph.D. in Cellular Pathology from Iowa State University and was board certified in Veterinary Pathology in 1984. We believe that Dr. Bertram&#8217;s qualifications to serve on our board of directors include his leadership experience in drug development at public and private biotechnology companies, along with his leadership in the innovation of cellular therapeutics.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paul D&#8217;Angio, R.P.H., M.S.J.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as a member of our board of directors since January 2017. Mr.&#160;D&#8217;Angio served as Vice President, Head of Manufacturing of PDS Biotechnology Corporation, a clinical-stage immunotherapy company, from March 2019 through June 2020. He also has served as President of PDA Pharmaceutical Services LLC since September 2016. From December 2017 to March 2019, Mr.&#160;D&#8217;Angio served as Vice President, Head of Development of Edge Therapeutics, Inc., a biopharmaceutical company. From December 1998 to August 2016, he served as Senior Director, Senior Vice President, Global Head of Technical Operations of Celgene, where he gained extensive cross-functional and technical leadership experience in building and operating a global pharmaceutical manufacturing and supply chain organization. Mr.&#160;D&#8217;Angio is a registered pharmacist and received his BSc in Pharmacy from Duquesne University and MSJ in Healthcare Law from Seton Hall University Law School. We believe that Mr.&#160;D&#8217;Angio&#8217;s qualifications to serve on our board of directors include his substantial experience in the pharmaceutical industry, specifically in commercial manufacturing, drug product development, risk management operations and investigational materials supply.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Zhengbin (Bing) Yao, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;has served as a member of our board of directors since January 2017. Dr. Yao brings more than 20 years&#8217; experience in the biopharmaceutical industry. Dr. Yao is currently CEO and Chairman of ArriVent BioPharma. He has served as Chief Executive Officer of Viela Bio, Inc., a clinical-stage biotechnology company focused on autoimmune and severe inflammatory diseases, from February 2018 and as Chairman of its board of directors from January 2019 to March 2021. From October 2010 to February 2018, Dr. Yao served in various leadership roles at MedImmune, most recently as Senior Vice President, Head of Respiratory, Inflammation, Autoimmune iMED. Dr. Yao also served as Senior Vice President, Head of Immuno-Oncology Franchise, of AstraZeneca. Prior to his tenure at MedImmune and AstraZeneca, Dr. Yao served as Head of PTL for Immunology, Infectious Diseases, Neuroscience, and Metabolic Disease of Genentech. Previously, Dr. Yao was Vice President and Head of Research of Tanox, Inc., before it was acquired by Genentech in 2007. Dr. Yao serves on the board of directors of Immune-Onc Therapeutics, Inc., a private biotechnology company developing biotherapies for cancer. Dr. Yao received his M.S. in Immunology from Anhui Medical University in Anhui, China and his Ph.D. in Microbiology and Immunology from the University of Iowa. We believe that Dr. Yao&#8217;s qualifications to serve on our board of directors include his significant experience in the biopharmaceutical industry, particularly in autoimmune disease, and his experience serving as a chief executive officer of a publicly-traded biotechnology company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Grant Verstandig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> has served as a member of our board of directors since January 2021. Mr. Verstandig is a Co-Founder and has served as the Chairman of Red Cell Partners, an investment and incubation firm that backs, builds, and scales early stage technology-led companies in the healthcare and national security sectors since October 2020. Mr. Verstandig was the founder and served as the CEO of Rally Health, Inc., a consumer centric digital health company acquired by UnitedHealth Group from April 2009 to July 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">He has also served as the Executive Chairman of Epirus, a venture-backed directed energy company that creates counter-UAS systems and power management solutions for multiple applications from since November 2022 and served as Executive Chairman from June 2018 to April 2022 and later co-founded Spycraft Entertainment, a content and entertainment production company focused on intelligence and military operations, in June 2018. Mr. Verstandig has also served on the National Council for the American Enterprise Institute since April 2016 and is a founding member of the Greater Washington Partnership where he has been a director since January 2017. Mr. Verstandig has served as an advisor to several organizations in the health, defense, foreign policy and intelligence spaces, and has served as a senior advisor to the National Security Agency on advanced analytics, technology and artificial intelligence since 2017. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mr. Verstandig attended Brown </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">University. We believe that Mr. Verstandig&#8217;s qualifications to serve on our board of directors include his healthcare industry experience, along with his leadership in the innovation of technology-enabled health services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Leena Gandhi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> has served as a member of our board of directors since May 2022. Dr. Gandhi has served as the Chief Medical Officer of NextPoint Therapeutics since January 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">She has served as Director of the Center for Cancer Therapeutic Innovation at the Dana-Farber Cancer Institute from June 2020 until January 2023; and previously served and prior to that as Vice President of Immuno-Oncology Development at Eli Lilly from June 2018 to May 2020, where she led the development of novel immune-oncology agents across cancer types. From June 2016 to June 2018, Dr. Gandhi served as the Director of Thoracic Medical Oncology at New York University where she focused her research on novel drug development and biomarkers for selection in lung cancer with a particular focus on immuno-oncology. Dr. Gandhi received her Ph.D. from the University of California, Berkeley, and her M.D. from New York University, and her B.S. from the University of Utah, Salt Lake City. Dr. Gandhi completed her postgraduate training at Massachusetts General Hospital in addition to Dana-Farber Cancer Institute in Boston, where she was later a clinical fellow and faculty member in the Thoracic Oncology program. Dr. Gandhi&#8217;s qualifications to serve on the board of directors include her significant experience as a clinical investigator and medical professional and her insight and expertise with respect to clinical trials and drug development.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Composition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">                </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2023, our board of directors consisted of eight members, all of whom are members pursuant to the board composition provisions of our existing sixth amended and restated certificate of incorporation. Our board of directors may consider a broad range of factors relating to the qualifications and background of nominees, which may include diversity, which is not only limited to race, gender or national origin. We have no formal policy regarding board diversity. Our board of directors&#8217; priority in selecting board members is identification of persons who will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape and professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their death, resignation or removal. Our sixth amended and restated certificate of incorporation and amended and restated by-laws provides that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rule 5605 of the Nasdaq Listing Rules requires a majority of a listed company&#8217;s board of directors to be comprised of independent directors within one year of listing. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act. Under Rule 5605(a)(2), a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of our board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the board of directors, the audit committee or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our board of directors has determined that all members of our board of directors, except Kristi Jones, are independent directors, including for purposes of the rules of The Nasdaq Stock Market and relevant federal securities laws and regulations. There are no family relationships among any of our directors or executive officers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Staggered Board</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our board of directors is divided into three staggered classes of directors of the same or nearly the same number, and each is assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2022 for Class I directors, 2023 for Class II directors, and 2024 for Class III directors:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our Class I directors are Mr. D&#8217;Angio and Dr. Zhengbin (Bing) Yao;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our Class II directors are Mr. Roemer, Dr. Bertram and Mr. Verstandig; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our Class III directors are Dr. Barer, Ms. Jones and Dr. Gandhi.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committees of Our Board of Directors and Meetings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Our Audit committee has three members, Alan S. Roemer (Chairman), Tim Bertram, and Paul D&#8217;Angio. Our board of directors has determined that each member of the Audit committee meets the independence requirements of Rule&#160;10A-3&#160;under the Exchange Act and the applicable Nasdaq Listing Rules, and has sufficient knowledge in financial and auditing matters to serve on the Audit committee. Our board of directors has determined that Alan S. Roemer is an &#8220;audit committee financial expert,&#8221; as the Securities and Exchange Commission has defined that term in Item 407 of Regulation&#160;S-K.&#160;The Audit committee&#8217;s responsibilities include:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">selecting a firm to serve as the independent registered public accounting firm to audit our financial statements;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ensuring the independence of the independent registered public accounting firm;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and that firm, our interim and&#160;year-end&#160;operating results;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing procedures for employees to anonymously submit concerns about questionable accounting or audit matters;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">considering the effectiveness of our internal controls and internal audit function;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reviewing material related-party transactions or those that require disclosure; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">approving or, as permitted,&#160;pre-approving&#160;all audit and&#160;non-audit&#160;services to be performed by the independent registered public accounting firm.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Audit committee&#8217;s written charter is publicly available on our website at&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">https://ir.neximmune.com/investors/corporate-governance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Our Compensation committee has three members, Tim Bertram (Chairman), Sol Barer, and Paul D&#8217;Angio. Our Compensation committee&#8217;s role and responsibilities are set forth in the Compensation committee&#8217;s written charter and includes reviewing, approving and making recommendations regarding our compensation policies, practices and procedures to ensure that legal and fiduciary responsibilities of our board of directors are carried out and that such policies, practices and procedures contribute to our success. Our Compensation committee also administers our 2021 Equity Incentive Plan. The Compensation committee is responsible for recommending to the Board the compensation for our chief executive officer, and conducts its deliberations or voting with respect to that issue without the chief executive officer present. All members of the Compensation committee qualify as independent under the definition promulgated by the Nasdaq Listing Rules.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the Compensation committee&#8217;s process involves the establishment of corporate goals and objectives for the current year and determination of compensation levels. For executives other than the Chief Executive Officer, the compensation committee solicits and considers evaluations and recommendations submitted to the committee by the Chief Executive Officer. In the case of the Chief Executive Officer, the evaluation is conducted by the Compensation committee, which recommends any adjustments to his compensation levels and arrangements for approval by the board of directors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation committee has the sole authority to obtain, at our expense, advice and assistance from compensation consultants, legal counsel, experts and other advisors that the Compensation committee deems advisable in the performance of its duties. The Compensation committee has the sole authority to approve any such consultants&#8217; or advisors&#8217; fees and other retention terms. The Compensation committee may select any such consultant, counsel, expert or adviser to the Compensation committee, only after taking into consideration factors that bear upon the adviser&#8217;s independence. The Compensation committee&#8217;s independent compensation consultant during fiscal year 2021 was The Radford Group (&#8220;Radford&#8221;). Radford is engaged by, and reports directly to, the Compensation committee, which has the sole authority to hire or fire Radford and to approve fee arrangements for work performed. Radford assists the Compensation committee in fulfilling its responsibilities under its charter, including advising on proposed compensation packages for executive officers, compensation program design and market practices generally. The Compensation committee has authorized Radford to interact with management on behalf of the Compensation committee, as needed in connection with advising the Compensation committee, and Radford is included in discussions with management and, when applicable, the Compensation committee&#8217;s outside legal counsel on matters being brought to the Compensation committee for consideration.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Compensation committee&#8217;s written charter is publicly available on our website at&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">https://ir.neximmune.com/investors/corporate-governance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nominating and Governance committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Our Nominating and Governance committee (&#8220;Nominating Committee&#8221;) has three members, Sol Barer, Ph.D. (Chairman), Zhengbin (Bing) Yao, Ph.D., and Grant Verstandig. Our Board of Directors has determined that all members of the Nominating Committee qualify as independent under the definition promulgated by the Nasdaq Stock Market. The Nominating Committee&#8217;s responsibilities are set forth in the Nominating Committee&#8217;s written charter and include:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">evaluating and making recommendations to the full Board as to the composition, organization and governance of our board of directors and its committees,</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">evaluating and making recommendations as to director candidates,</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">evaluating current Board members&#8217; performance</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">overseeing the process for CEO and other executive officer succession planning, and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developing and recommending governance guidelines for the Company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, our Nominating Committee considers candidates recommended by stockholders as well as from other sources such as other directors or officers, third party search firms or other appropriate sources. Once identified, the Nominating Committee will evaluate a candidate&#8217;s qualifications in accordance with our Nominating and Governance Committee Policy Regarding Qualifications of Directors appended to our Nominating Committee&#8217;s written charter. Threshold criteria include: personal integrity and sound judgment, business and professional skills and experience, independence, knowledge of our industry, possible conflicts of interest, diversity, the extent to which the candidate would fill a present need on our board of directors, and concern for the long-term interests of our stockholders. Our Nominating Committee has not adopted a formal diversity policy in connection with the consideration of director nominations or the selection of nominees. However, the Nominating Committee will consider issues of diversity among its members in identifying and considering nominees for director, and strive where appropriate to achieve a diverse balance of backgrounds, perspectives, experience, age, gender, ethnicity and country of citizenship on our board of directors and its committees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a stockholder wishes to propose a candidate for consideration as a nominee for election to our board of directors, it must follow the procedures described in our Bylaws. In general, persons recommended by stockholders will be considered in accordance with our Policy on Stockholder Recommendation of Candidates for Election as Directors appended to our Nominating Committee&#8217;s written charter. Any such recommendation should be made in writing to the Nominating and Governance Committee, care of our Corporate Secretary at our principal office and should be accompanied by the following information concerning each recommending stockholder and the beneficial owner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;if any, on whose behalf the nomination is made:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">all information relating to such person that would be required to be disclosed in a proxy statement;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">certain biographical and share ownership information about the stockholder and any other proponent, including a description of any derivative transactions in the Company&#8217;s securities;&#160;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a description of certain arrangements and understandings between the proposing stockholder and any beneficial owner and any other person in connection with such stockholder nomination; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a statement whether or not either such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy to holders of voting shares sufficient to carry the proposal.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recommendation must also be accompanied by the following information concerning the proposed nominee:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">certain biographical information concerning the proposed nominee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">all information concerning the proposed nominee required to be disclosed in solicitations of proxies for election of directors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">certain information about any other security holder of the Company who supports the proposed nominee;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a description of all relationships between the proposed nominee and the recommending stockholder or any beneficial owner, including any agreements or understandings regarding the nomination; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">additional disclosures relating to stockholder nominees for directors, including completed questionnaires and disclosures required by our Bylaws.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Nominating Committee&#8217;s written charter, including its appendices, is publicly available on our website at&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">https://ir.neximmune.com/investors/corporate-governance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the members of our Compensation committee has at any time during the last fiscal year been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or Compensation committee of any entity that has one or more executive officers serving on our board of directors or Compensation committee. For a description of transactions between us and members of our Compensation committee and affiliates of such members, please see the &#8220;Certain Relationships and Related Party Transactions&#8221; section of this Annual Report on Form&#160;10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Leadership Structure</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The positions of our chairman of the board and chief executive officer are separated, with Ms.&#160;Jones serving as our Chief Executive Officer and Dr.&#160;Barer serving as the chairman of our board of directors. Separating these positions allows Ms. Jones, as our Chief Executive Officer, to focus on our&#160;day-to-day&#160;business, while allowing the chairman of the board to lead the board of directors in its fundamental role of providing advice to and independent oversight of management. Our board of directors recognizes the time, effort and energy that Ms.&#160;Jones, as our Chief Executive Officer, must devote to her position in the current business environment, as well as the commitment required to serve as our chairman, particularly as the board of directors&#8217; oversight responsibilities continue to grow. Our board of directors also believes that this structure ensures a greater role for the independent directors in the oversight of our company and active participation of the independent directors in setting agendas and establishing priorities and procedures for the work of our board of directors. Our board of directors believes its administration of its risk oversight function has not affected its leadership structure. Our board of directors believes that having separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Role in Risk Oversight</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors oversees the management of risks inherent in the operation of our business and the implementation of our business strategies. Our board of directors performs this oversight role by using several different levels of review. In connection with its reviews of our operations and corporate functions, our board of directors addresses the primary risks associated with those operations and corporate functions. In addition, our board of directors reviews the risks associated with our business strategies periodically throughout the year as part of its consideration of undertaking any such business strategies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our board committees also oversees the management of our risks that fall within the committee&#8217;s areas of responsibility. In performing this function, each committee has full access to management, as well as the ability to engage advisors. Our Chief Executive Officer reports risk management controls and methodologies to the Audit committee and is responsible for identifying, evaluating and implementing risk management controls and methodologies to address any identified risks. In connection with its risk management role, our Audit committee meets privately with representatives from our independent registered public accounting firm and our Chief Executive Officer. The Audit committee oversees the operation of our risk management program, including the identification of the primary risks associated with our business and periodic updates to such risks, and reports to our board of directors regarding these activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Delinquent Section 16(a) Reports</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Section 16(a) of the Exchange Act requires directors, executive officers, and persons owning more than 10% of any class of a company&#8217;s equity securities registered under Section 12 of the Exchange Act to file reports on a timely basis on the initiation of their status as a reporting person and any changes with respect to their beneficial ownership of such equity securities with the SEC. Executive officers, directors and greater than 10% stockholders are required by SEC regulations to furnish those companies copies of all Section 16(a) forms they file.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our records reflect that all reports which were required to be filed pursuant to Section 16(a) of the Exchange Act were filed on a timely basis during the year ended December 31, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of business conduct and ethics that applies to all of our employees. The text of the code of business conduct and ethics is posted on the &#8220;Investor Relations &#8212; Corporate Governance&#8221; section of our website at&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">https://ir.neximmune.com/investors/corporate-governance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to disclose any amendments to, or waivers from, provisions of the code of business conduct and ethics that apply to our directors, principal executive and financial officers in a Current Report on Form&#160;8-K&#160;within four business days following the date of the amendment or waiver, unless website posting or the issuance of a press release of such amendments or waivers is then permitted by Nasdaq rules.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i5091247d182148eaaadd80685b94df97_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11. Executive Compensation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the total compensation paid or accrued during the last two fiscal years ended December&#160;31, 2022 and 2021 to our Chief Executive Officer and President, our two next most highly compensated executive officers and our Chief Financial Officer, each of whom earned more than $100,000 during the fiscal years ended December&#160;31, 2022 and 2021, and was serving as an executive officer as of such date.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Principal Position</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salary<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bonus<br/>($)(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br/>Awards<br/>($)(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">All Other<br/>Compensation<br/>($)(3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristi Jones</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Carmer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,587,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,301,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Trainer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jerome Zeldis (4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EVP, Head of Research &amp; Development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,935,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,341,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mathias Oelke (6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Science Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The amount represents Bonuses earned for 2021 and 2020 then paid in 2022 and 2021, respectively.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">These amounts represent the aggregate grant date fair value for option granted and RSUs awarded during the fiscal years ended December&#160;31, 2022 and 2021, computed in accordance with FASB ASC Topic 718.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The amounts in this column include our 401(k) match contribution for each named executive officer, medical insurance for Mr. Zeldis, and life insurance premium paid for Mr. Oelke.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Mr.&#160;Zeldis joined the Company in 2021. On March 23, 2023, Mr. Zeldis resigned as EVP, Head of Research &amp; Development effective as of March 31, 2023 and has agreed to act as a consultant to the Company effective as of April 1, 2023.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Mr. Carmer resigned as President and Chief Executive Officer and as a director of the Company effective as of February 12, 2022.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:15.34pt">Mr. Oelke was appointed Chief Science Officer in April 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annual Base Salary</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Base salaries of our named executive officers (other than our Chief Executive Officer) are reviewed annually and recommended to our compensation committee by our chief executive officer, and the base salary for each named executive officer is recommended by our compensation committee and approved by our board of directors. Adjustments to base salaries are based on the scope of a named executive officer&#8217;s responsibilities, individual contribution, experience and performance. Decisions regarding salary increases may consider the named executive officer&#8217;s current salary, equity ownership and the amounts paid to individuals in comparable positions at our company and at our peer companies provided by the Radford Group.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annual Cash Bonus Opportunities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under our annual bonus program for 2022, each named executive officer was eligible to be considered for an annual bonus based by our compensation committee assessment of our performance in 2021.&#160;Each named executive officer was assigned a target bonus expressed as a percentage of their base salary, which was 50% for Ms.&#160;Jones, 45% for Mr. Zeldis, 40% for Mr.&#160;Trainer and Mr. Oelke.&#160;These may be  adjusted for company performance for the year based on an assessment by the compensation committee. Our board of directors approved performance bonuses for the named executive officers as reflected in the column of the Summary Compensation Table above entitled &#8220;Bonus.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2022, the board approved a modification to the annual bonus program for 2022, whereby each employee was guaranteed a bonus payout in the amount of 70% of their target bonus for the fiscal year 2022. The board also approved a modification and bifurcation of the annual bonus program for 2023, including a guaranteed payout in the amount of 70% of each target bonus in the first half of fiscal year 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Equity Incentives</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity grant program is intended to align the interests of our named executive officers with those of our stockholders and to motivate them to make important contributions to our performance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into executive employment agreements with each of our named executive officers in connection with their employment with us, the material terms of which are described below. These executive employment agreements provide for &#8220;at will&#8221; employment, subject to certain notice and severance requirements. Each of the named executive officers was also required to enter into restrictive covenant agreements which obligate each named executive officer to refrain from disclosing any of our proprietary information received during the course of employment and to assign to us any inventions conceived or developed during the course of employment. Such restrictive covenant agreements also contain&#160;non-competition&#160;and&#160;non-solicitation&#160;protections in our favor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kristi Jones</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an employment agreement dated as of March 8, 2022 with Ms. Jones with respect to her service as our President and Chief Executive Officer. Under the terms of the agreement, Ms. Jones will receive an annual base salary of $538,000, subject to increase by our board of directors in its discretion. Ms. Jones is also eligible to receive an annual cash bonus with a target of fifty percent (50%) of her annual salary over the time period covered by the bonus in the sole discretion of our board of directors and based on such factors that our board of directors deems appropriate. Ms. Jones is also eligible to participate in our equity incentive plans and received on April 5, 2022, an option to acquire up to 456,000 shares of our common stock under the 2021 Plan at an exercise price equal to the Fair Market Value (as defined in the 2021 Plan) of a share of the Company&#8217;s Common Stock on the grant determined in accordance with the terms of the 2021 Plan. 25% of the shares subject to the new option will vest on the first anniversary of the grant date and the remaining shares will vest in equal monthly installments over the next 36 months. Ms. Jones is also entitled to participate in our health insurance and other employee benefit plans and to receive reimbursement for business expenses and up to $15,000 of attorney&#8217;s fees incurred in connection with the negotiation of her employment agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ms. Jones&#8217;s employment agreement provides that in the event that (1) Ms. Jones&#8217;s employment is terminated other than for cause, or (2) Ms. Jones terminates her own employment as a result of a material breach of her employment agreement by us, including any material diminution in the nature or scope of Ms. Jones&#8217;s authorities, powers, functions, duties or responsibilities, following a cure period (a &#8220;Constructive Termination&#8221;), she is entitled to receive the following severance benefits: (i) a severance payment equal to 12 months of her then-current salary paid in installments; (ii) a severance payment equal to the ProRata Bonus (as defined in the employment agreement); and (iii) eligibility for at least 12 months of healthcare coverage through COBRA. If Ms. Jones&#8217;s employment is terminated other than for cause or Ms. Jones terminates her own employment as a &#8220;Constructive Termination&#8221; in connection with the closing of a Change in Control (as defined in the employment agreement) or during the 12 month period following such closing, she is entitled to receive the following severance benefits: (i) a severance payment equal to 1.5 times the sum of her then-current base salary and target bonus, paid in a single lump sum; (ii) accelerated vesting and exercisability of then-unvested portion of the outstanding option awards along with any other restricted stock, stock options or other equity subject to forfeiture or rights of repurchase held by Ms. Jones; (iii) a severance payment equal to the ProRata Bonus (as defined in the employment agreement), and (iv) eligibility for 18 months of healthcare coverage through COBRA. All severance benefits are conditioned upon Ms. Jones&#8217;s execution of a release of claims in our favor. If as a result of a termination of her employment Ms. Jones becomes subject to the excise tax imposed by Section 4999 of the Internal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue Code, Ms. Jones is subject to a modified cutback of the payments and benefits she would otherwise receive in connection with a change in control, such that she would retain the higher of the net amount she would receive if such payments were reduced to avoid payment of the excise tax and the net amount she would receive if she received such payments in full and paid the excise tax. On any termination of Ms. Jones&#8217;s employment, including due to her death or disability, she or her beneficiary is entitled to payment of all accrued and unpaid base salary, any earned but unpaid bonus, payment for all accrued but unused vacation time for the then-current annual period and all unreimbursed business expenses incurred through the date of termination. In the event of termination of her employment due to death or disability, she or her beneficiary, or if no such person is designated, her estate or personal representative, is also entitled to the ProRata Bonus (as defined in the employment agreement).</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the 2022 fiscal year, Ms.&#160;Jones was paid an annual bonus of $148,800, and was also granted options to purchase 456,000 shares of our common stock. For the 2021 fiscal year,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ms.&#160;Jones was paid an annual bonus of $142,898 and was also granted options to purchase 84,207 shares of our common stock. Ms.&#160;Jones&#8217;s 2022 and 2021 options grant is subject to a four-year vesting schedule, with 25% vesting one year after the vesting commencement date and the balance vesting monthly over the remaining three years, subject to Ms.&#160;Jones&#8217;s continued service through each vesting date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">John Trainer</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an employment agreement dated as of January&#160;6, 2020 with Mr.&#160;Trainer with respect to his service as our Chief Financial Officer. Under the terms of the agreement, Mr.&#160;Trainer was entitled to an initial annual base salary of $345,000, subject to increase by our board of directors. Mr.&#160;Trainer was entitled to receive options to purchase 164,719 shares of our common stock, such that his unvested stock options at that time would represent 1.2% of the fully diluted equity of the Company. Pursuant to the terms of the agreement, Mr.&#160;Trainer is also entitled to receive an annual cash bonus of up to 40% of his then-current base salary in the sole discretion of our board of directors and based on such factors that our board of directors deems appropriate. Mr.&#160;Trainer is also eligible to participate in our equity incentive plans and is entitled to participate in our health insurance and other employee benefit plans and to receive reimbursement for business expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr.&#160;Trainer&#8217;s employment agreement provides that in the event that (1)&#160;Mr.&#160;Trainer&#8217;s employment is terminated other than for cause, (2)&#160;Mr.&#160;Trainer terminates his own employment as a result of a material breach of his employment agreement by the Company, including any material diminution in the nature or scope of Mr.&#160;Trainer&#8217;s authorities, powers, functions, duties or responsibilities, following a cure period (a &#8220;Constructive Termination&#8221;), or (3)&#160;a change of control of the Company occurs, he is entitled to receive the following severance benefits: (i)&#160;a severance payment equal to 12 months of his then-current salary and a&#160;pro-rata&#160;share of Mr.&#160;Trainer&#8217;s bonus target (40% of then-current salary) paid in installments; (ii)&#160;accelerated vesting and, if applicable, exercisability of the then-unvested portion of each of his outstanding equity awards; and (iii)&#160;eligibility for at least 18 months of healthcare coverage through COBRA. These severance benefits are conditioned upon Mr.&#160;Trainer&#8217;s execution of a release of claims in favor of the Company. In the event that Mr.&#160;Trainer&#8217;s employment is terminated due to his death or disability, he or his beneficiary is entitled to payment of all accrued and unpaid base salary, payment for all accrued but unused vacation time for the then-current annual period, all unreimbursed business expenses incurred through the date of termination and a&#160;pro-rata&#160;portion of his annual bonus.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2022 fiscal year, Mr.&#160;Trainer was paid an annual bonus of $146,000, and was also granted options to purchase 78,100 shares of our common stock. For the 2021 fiscal year, Mr.&#160;Trainer was paid an annual bonus of $138,000, and was granted options to purchase 28,987 shares of our common stock. The options granted to Mr.&#160;Trainer are subject to a four-year vesting schedule, with 25% vesting one year after the vesting commencement date and the balance vesting monthly over the remaining three years, subject to Mr. Trainer&#8217;s continued service through each vesting date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jerome Zeldis</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an employment agreement dated as of January 4, 2021 with Mr. Zeldis with respect to his service as our Executive Vice President, Head of Research and Development. Under the terms of the agreement, Mr. Zeldis was entitled to an initial annual base salary of $385,000, subject to increase by our board of directors. Mr. Zeldis was entitled to receive options to purchase 351,016 shares of our common stock. Pursuant to the terms of the agreement, Mr. Zeldis is also entitled to receive an annual cash bonus of up to 45% of his then-current base salary in the sole discretion of our board of directors and based on such factors that our board of directors deems appropriate. Mr. Zeldis is also eligible to participate in our equity incentive plans and is entitled to participate in our health insurance and other employee benefit plans and to receive reimbursement for business expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Zeldis&#8217;s employment agreement provides that in the event that (1) Mr. Zeldis&#8217;s employment is terminated other than for cause, (2) Mr. Zeldis terminates his own employment as a result of a material breach of his employment agreement by the Company, including any material diminution in the nature or scope of Mr. Zeldis&#8217;s authorities, powers, functions, duties or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsibilities, following a cure period (a &#8220;Constructive Termination&#8221;), or (3) a change of control of the Company occurs, he is entitled to receive the following severance benefits: (i) a severance payment equal to 12 months of his then-current salary and a pro-rata share of Mr. Zeldis&#8217;s bonus target (45% of then-current salary) paid in installments; (ii) accelerated vesting and, if applicable, exercisability of the then-unvested portion of each of his outstanding equity awards; and (iii) eligibility for at least 18 months of healthcare coverage through COBRA. These severance benefits are conditioned upon Mr. Zeldis&#8217;s execution of a release of claims in favor of the Company. In the event that Mr. Zeldis&#8217;s employment is terminated due to his death or disability, he or his beneficiary is entitled to payment of all accrued and unpaid base salary, payment for all accrued but unused vacation time for the then-current annual period, all unreimbursed business expenses incurred through the date of termination and a pro-rata portion of his annual bonus.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2022 fiscal year, Mr.&#160;Zeldis was paid an annual bonus of $173,250, and was also granted options to purchase 80,100 shares of our common stock. For the 2021 fiscal year, Mr. Zeldis was granted options to purchase 351,016 shares of our common stock. The options granted to Mr. Zeldis are subject to a two-year vesting schedule, with 50% vesting one year after the vesting commencement date and the balance vesting monthly over the remaining one year, subject to Mr. Zeldis&#8217;s continued service through each vesting date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mathias Oelke </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an employment agreement dated as of April 5, 2022, and subsequently amended as of August 11, 2022, with Mr. Oelke with respect to his service as our Chief Scientific Officer. Under the terms of the agreement, Mr. Oelke was entitled to an initial annual base salary of $360,400, subject to increase by our board of directors. Mr. Oelke was entitled to receive options to purchase 60,000 shares of our common stock. Pursuant to the terms of the agreement, Mr. Oelke is also entitled to receive an annual cash bonus of up to 40% of his then-current base salary in the sole discretion of our board of directors and based on such factors that our board of directors deems appropriate. Mr. Oelke is also eligible to participate in our equity incentive plans and is entitled to participate in our health insurance and other employee benefit plans to receive reimbursement for business expenses, and to receive a reimbursement for a personal life insurance policy premium of up to $20,000 per year. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Oelke&#8217;s employment agreement provides that in the event that (1) Mr. Oelke&#8217;s employment is terminated other than for cause, (2) Mr. Oelke&#8217;s terminates his own employment as a result of a material breach of his employment agreement by the Company, including any material diminution in the nature or scope of Mr. Knight&#8217;s authorities, powers, functions, duties or responsibilities, following a cure period (a &#8220;Constructive Termination&#8221;), he is entitled to receive the following severance benefits: (i) a severance payment equal to 12 months of his then-current salary paid in installments; (ii) a severance payment equal to the ProRata Bonus (as defined in the employment agreement); and (iii) eligibility for at least 18 months of healthcare coverage through COBRA. If Mr. Oelke&#8217;s employment is terminated other than for cause or Mr. Oelke terminates his own employment as a &#8220;Constructive Termination&#8221; in connection with the closing of a Change in Control (as defined in the employment agreement) or during the 12 month period following such closing, he is entitled to receive, in addition to the aforementioned benefits, accelerated vesting and exercisability of then-unvested portion of the outstanding option awards along with any other restricted stock, stock options or other equity subject to forfeiture or rights of repurchase held by Mr. Oelke. These severance benefits are conditioned upon Mr. Oelke&#8217;s execution of a release of claims in favor of the Company. On any termination of Mr. Oelke&#8217;s employment, including due to his death or disability, him or his beneficiary is entitled to payment of all accrued and unpaid base salary, any earned but unpaid bonus, payment for all accrued but unused vacation time for the then-current annual period, and all unreimbursed business expenses incurred through the date of termination. In the event of termination of his employment due to death or disability, him or his beneficiary, or if no such person is designated, her estate or personal representative, is also entitled to the ProRata Bonus (as defined in the employment agreement).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2022 fiscal year, Mr.&#160;Oelke was paid an annual bonus of $115,500, and was also granted options to purchase 60,000 shares of our common stock. The options granted to Mr. Oelke are subject to a four-year vesting schedule, with 25% vesting one year after the vesting commencement date and the balance vesting monthly over the remaining three years, subject to Mr. Oelke&#8217;s continued service through each vesting date.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at 2022 Fiscal&#160;Year-End</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows grants of stock options outstanding on the last day of the year ended December&#160;31, 2022 to each of the executive officers named in the Summary Compensation Table.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option Grants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option&#160;Exercise<br/>Price ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Option<br/>Expiration&#160;Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Awards:<br/>Number of<br/>Unearned<br/>Units or Other<br/>Rights That Have<br/>Not Vested</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market Value of Unearned Shares, Units or Other Rights That Have Not Vested (3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristi Jones</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/02/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07/30/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/24/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/18/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/17/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/10/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/04/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,700</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Carmer (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Trainer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,337&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,612&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/04/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/10/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/04/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,200</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jerome Zeldis (2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,626&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/10/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/04/2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mathias Oelke</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,379&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/02/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/02/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07/30/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/24/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/18/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/10/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/04/2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Mr. Carmer resigned as President and Chief Executive Officer and as a director of the Company effective as of February 12, 2022.</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;On March 23, 2023 Mr. Zeldis resigned as EVP, Head of Research &amp; Development effective as of March 31, 2023 and</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">           has agreed to act as as consultant to the Company effective as of April 1, 2023.</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The market values of RSUs and restricted stock are determined by multiplying the number of shares by $0.24, the closing price of our common stock on the NASDAQ on December 30, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Potential Payments upon Termination or&#160;Change-In-Control</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Severance Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the named executive officers is a participant in the Severance Plan.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Severance Plan, if we terminate a participant&#8217;s employment without &#8220;Cause&#8221; at any time other than during the &#8220;Change in Control Period&#8221;, then the participant is eligible to receive the following benefits:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We will pay for company contribution for continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, or COBRA, during the severance period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Severance Plan, if we terminate a participant&#8217;s employment without &#8220;Cause&#8221; or participant resigns for &#8220;Good Reason&#8221;, during the &#8220;Change in Control Period&#8221;, then the participant is eligible to receive the following benefits:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We shall reimburse the participant for all reasonable and necessary attorney&#8217;s fees incurred by such participant in connection with pursuing benefits under the Severance Plan.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A participant&#8217;s rights to any severance benefits under the Severance Plan are conditioned upon the participant executing and not revoking a valid separation and general release of claims agreement in a form provided by us.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following terms have the following meanings under the Severance Plan:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a participant&#8217;s: (i)&#160;failure to substantially perform his/her duties and obligations to us (other than failure resulting from the participant&#8217;s incapacity because of disability), including one or more acts of gross negligence or insubordination or a material breach of our policies and procedures, which failure is not cured within fifteen (15)&#160;days after a written demand for cure is received by participant from us; (ii)&#160;material breach of our code of conduct, equal opportunity and anti-harassment policies, or compliance policies (which may include, but not be limited to, a code of business conduct, an anti-bribery policy, a competition policy, and a policy on healthcare business ethics); (iii) commission, indictment, conviction, or entry of a plea of guilty or nolo contendere to, a felony or any other crime involving fraud, dishonesty, theft, breach of trust or moral turpitude; (iv)&#160;engagement in misconduct which results in, or could reasonably be expected to result in, material injury to our financial condition, reputation, or ability to do business; (v)&#160;material breach of a written agreement with us, including any confidentiality, invention assignment,&#160;non-competition,&#160;non-solicitation&#160;or&#160;non-disparagement&#160;agreement; (vi)&#160;violation of state or federal securities laws or regulations; or (vii)&#160;willful failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by us to cooperate, willful destruction or failure to preserve documents or other materials relevant to such investigation, or willful inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of any of the following without participant&#8217;s prior consent: (i)&#160;a material decrease in participant&#8217;s base salary or bonus opportunity; (ii)&#160;a material diminution in the aggregate employee benefits and material perquisites provided to participant; (iii)&#160;a material diminution in participant&#8217;s title, reporting relationship, duties or responsibilities; (iv)&#160;a relocation of participant&#8217;s primary office by more than thirty-five (35)&#160;miles from participant&#8217;s then-current location; and (v)&#160;the failure by any successor to us or any acquiring corporation to explicitly assume the Severance Plan and our obligations thereunder and maintain the Severance Plan in effect for a period of at least twenty-four (24)&#160;months.</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; is defined as a transaction or a series of related transactions in which: (i)&#160;all or substantially all of our assets are transferred to any &#8220;person&#8221; or &#8220;group&#8221; (as such terms are defined in the Exchange Act); (ii) any person or group, other than person or group who prior to such acquisition is a &#8220;beneficial owner&#8221; (as defined under the Exchange Act), directly or indirectly, of any of our equity, becomes the &#8220;beneficial owner&#8221;, directly or indirectly, of our outstanding equity representing more than 50% of the total voting power of our then-outstanding equity; (iii)&#160;we undergo a merger, reorganization or other consolidation in which the holders of our outstanding equity immediately prior to such merger, reorganization or consolidation directly or indirectly own less than 50% of the surviving entity&#8217;s voting power immediately after the transaction; or (iv)&#160;if within any rolling twelve month period, the persons who were our directors at the beginning of such twelve month period, or the incumbent directors, cease to constitute at least a majority of such board of directors; provided that any director who was not a director at the beginning of such twelve (12)&#160;month period will be deemed to be an incumbent director if that director was elected to the board of directors by, or on the recommendation of or with the approval of, a majority of the directors who then qualified as incumbent directors. Any of (i)&#160;through (iv) above may constitute a Change in Control, provided that the Change in Control meets all of the requirements of a &#8220;change in the ownership of a corporation,&#8221; a &#8220;change in the effective ownership of a corporation,&#8221; or &#8220;a change in the ownership of a substantial portion of the corporation&#8217;s assets,&#8221; each within the meaning of Treasury Regulation&#160;&#167;1.409A-3(i)(5).</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control Period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means: (i)&#160;the twenty-four (24)&#160;month period beginning on the date of a Change in Control; (ii)&#160;any such time prior to a Change in Control where the successor or acquiring entity in the Change in Control requests for the termination of a participant&#8217;s employment without Cause; or (iii)&#160;any such time prior to a Change in Control where we terminate a participant&#8217;s employment without Cause in connection with or in anticipation of a Change in Control.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the total compensation paid during the fiscal year ended December&#160;31, 2022 to each of our directors, other than Mr.&#160;Carmer and Ms. Jones who did not receive compensation for their service as a director.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.304%"><tr><td style="width:1.0%"></td><td style="width:84.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sol J. Barer, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alan S. Roemer, M.B.A., M.P.H.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tim Bertram, Ph.D.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul D&#8217;Angio, R.P.H., M.S.J.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zhengbin (Bing) Yao, Ph.D.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant Verstandig</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leena Gandhi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the aggregate grant date fair value for option awards granted during the fiscal year ended December&#160;31, 2022, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 3 to our financial statements for the fiscal year ended December&#160;31, 2022 included elsewhere in this Annual Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:68.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Stock Options<br/>Held at<br/>Fiscal Year-End</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sol J. Barer, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,680.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alan S. Roemer, M.B.A., M.P.H.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,680.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tim Bertram, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,680.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul D&#8217;Angio, R.P.H., M.S.J.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,680.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zhengbin (Bing) Yao, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,680.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant Verstandig</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,680.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leena Gandhi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,038.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee&#160;Director Compensation Policy</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a policy with respect to the compensation payable to our&#160;non-&#160;employee directors. Under this policy, each&#160;non-employee&#160;director will be eligible to receive compensation for his or her service consisting of annual cash retainers and equity awards. Our&#160;non-employee&#160;directors will receive the following annual retainers for their service:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retainer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board Chairperson</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Committee Chair</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation Committee Chair</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction Committee Chair</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technical Operations Committee Chair</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Science and Technical Committee Chair</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nominating and Governance Committee Chair</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board Member</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Committee Member</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation Committee Member</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction Committee Member</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technical Operations Committee Member</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Science and Technical Committee Member</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nominating and Governance Committee Member</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity awards for&#160;non-employee&#160;directors will consist of consist of an annual equity award consisting of options to purchase 61,678 shares of common stock annual, vesting 12 months after the grant date.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directors may be reimbursed for travel, food, lodging and other expenses directly related to their service as directors. Directors are also entitled to the protection provided by their indemnification agreements and the indemnification provisions in our third amended and restated certificate of incorporation and amended and restated bylaws.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan and Other Benefit Plans</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2017 Equity Incentive Plan, or the 2017 Plan, was approved by our board of directors and stockholders in January 2017, and was subsequently amended in April 2017. The 2017 Plan provides for the issuance of up to 660,838 shares of our common stock. The 2017 Plan allows us to make grants of stock options, restricted stock, restricted stock units and stock appreciation rights to our employees, directors and consultants. As of January&#160;31, 2021, under the 2017 Plan, options to purchase 509,605 shares of our common stock were outstanding, 148,454 shares of our common stock had been issued and were outstanding pursuant to the exercise of options granted under the 2017 Plan, and 2,671 shares of our common stock were available for future awards under the 2017 Plan, which shares are no longer available for issuance.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2018 Equity Incentive Plan, or the 2018 Plan, was approved by our board of directors in June 2018 and our stockholders in July 2018, and was subsequently amended in July 2018. The 2018 Plan and 2017 Plan are collectively referred to as the &#8220;Equity Plans.&#8221; The 2018 Plan provides for the issuance of up to 1,806,984 shares of our common stock. The 2018 Plan allows us to make grants of stock options, restricted stock, restricted stock units and stock appreciation rights to our employees, directors and consultants. As of January&#160;31, 2021, under the 2018 Plan, options to purchase 1,543,089 shares of our common stock were outstanding, 2,138 shares of our common stock had been issued and were outstanding pursuant to the exercise of options granted under the 2018 Plan, and 263,895 shares of our common stock were available for future awards under the 2018 Plan, which shares are no longer available for issuance.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2021 Equity Incentive Plan, or the 2021 Plan, was approved by our board of directors in January 2021 and our stockholders in February 2021. The 2021 Plan, the 2018 Plan and the 2017 Plan are collectively referred to as the &#8220;Equity Plans.&#8221; The 2021 Plan provides for the issuance of up to 2,757,241 shares of our common stock, which includes 266,566 shares of common stock previously reserved for issuance pursuant to future awards under our 2017 Plan and our 2018 Plan, which shares will cease to be available for issuance under the 2017 Plan and the 2018 Plan. In addition, the 2021 Plan contains an &#8220;evergreen&#8221; provision, which allows for an annual increase in the number of shares of our common stock available for issuance under the 2021 Plan on the first day of each calendar year beginning in calendar year 2022. The annual increase in the number of shares shall be equal to the lower of (i) 5.0% of the number of shares of our common stock outstanding on the date of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable increase or (ii)&#160;a lesser amount determined by our board of directors. The 2021 Plan allows us to make grants of stock options, restricted stock, restricted stock units and stock appreciation rights to our employees, directors and consultants.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Equity Plans, in the event there is a specified type of change in our capital structure, such as a recapitalization or stock split, appropriate adjustments will be made to (i)&#160;the class(es) and maximum number of securities subject to the Equity Plans, (ii)&#160;the class(es) and maximum number of securities that may be issued pursuant to the exercise of incentive stock options, and (iii)&#160;the class(es) and number of securities and price per share of stock subject to outstanding stock awards under the Equity Plans.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Equity Plans also provide that in the event of a corporate transaction (as defined in the Equity Plans and described below), and except as otherwise stated in a stock option or other award agreement, our board of directors will take one or more of the following actions with respect to outstanding stock awards: (i)&#160;arrange for the surviving corporation or acquiring corporation to assume or substitute for the outstanding stock awards; (ii)&#160;accelerate the vesting of outstanding stock awards, with such awards terminating if not exercised prior to the effective time of the corporate transaction, (iii)&#160;terminate or cancel outstanding stock awards to the extent not vested or exercised prior to the effective time of the corporate transaction; or (iv)&#160;make a payment equal to the excess of the value the holder would receive upon exercise of the award over the exercise price payable by the holder</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Equity Plans, a corporate transaction is generally the consummation of: (i)&#160;a sale or other disposition of all or substantially all of the assets of the Company and its subsidiaries; (ii)&#160;a sale or other disposition of at least 90% of the securities of the Company; (iii)&#160;a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of our common stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</span></div><div id="i5091247d182148eaaadd80685b94df97_88"></div><div style="margin-bottom:5pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of March&#160;1, 2023, for (a)&#160;the executive officers named in the Summary Compensation Table on page 113 of this filing on&#160;Form&#160;10K,&#160;(b)&#160;each of our directors and director nominees, (c)&#160;all of our current directors and executive officers as a group and (d)&#160;each stockholder known by us to own beneficially more than 5% of our common stock. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. We deem shares of common stock that may be acquired by an individual or group within 60 days of March&#160;1, 2023, pursuant to the exercise of options to be outstanding for the purpose of computing the percentage ownership of such individual or group, but those shares are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them based on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information provided to us by these stockholders. Percentage of ownership is based on <ix:nonFraction unitRef="shares" contextRef="ife75d305cc1f4ff48462a16aa940d5bb_I20230301" decimals="0" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-36">26,078,451</ix:nonFraction> shares of common stock outstanding on March&#160;1, 2023.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Beneficially&#160;Owned</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Address**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than 5% stockholders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B&amp;S NexImmune Holdco LLC and Joshua Barer (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louise Brady (2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert E. Long Jr. (3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Piedmont Capital Partners LLC (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,381,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors and executive officers:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sol J. Barer, Ph.D.(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alan S. Roemer, M.B.A., M.P.H. (6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tim Bertram, Ph.D. (7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul D&#8217;Angio, R.P.H., M.S.J. (8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zhengbin (Bing) Yao, Ph.D. (9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant Verstandig (10)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,133,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leena Gandhi, M.D., Ph.D. (11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristi Jones (12)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Trainer, M.B.A.(13)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jerome Zeldis, M.D., Ph.D. (14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Knight, M.D. (15)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mathias Oelke, Ph.D. (16)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All directors and current executive officers as a group (12)&#160;persons</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,929,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">*&#160;&#160;&#160;&#160;Represents beneficial ownership of less than 1% of the outstanding shares of our common stock.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">**&#160;&#160;&#160;&#160;Unless otherwise indicated, the address for each beneficial owner listed is c/o NexImmune, Inc., 9119 Gaither Road, Gaithersburg, MD 20877.</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:15.34pt">Consists of (a)&#160;1,538,013 shares of our common stock held by B&amp;S NexImmune Holdco, LLC, and (b) 346,577 shares of our common stock Joshua Barer. Joshua Barer is the sole manager of B&amp;S NexImmune Holdco LLC and has sole voting and dispositive control over the shares held by B&amp;S NexImmune Holdco LLC. Mr. Barer may be considered the beneficial owner of the shares held by B&amp;S NexImmune Holdco LLC and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Sol J. Barer, Ph.D., one of our directors and the father of Joshua Barer, is a member of Barer &amp; Son Capital, LLC, which is a member of B&amp;S NexImmune Holdco LLC, but Sol J. Barer, Ph.D. does not have voting or dispositive control over the shares held by B&amp;S NexImmune Holdco LLC. The principal business address of B&amp;S NexImmune Holdco LLC and Mr. Barer is 2 Barer Lane, Mendham, New Jersey 07945.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:15.34pt">Consists of 1,563,124 shares of common stock owned by Ms. Brady.</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:15.34pt">Consists of 1,510,664 shares of common stock owned by Mr.. Long.</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.34pt">Piedmont Capital Partners, LLC,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> a North Carolina limited liability company, has the right to receive dividends from, and the proceeds from the sale of, 1,381,938 shares of the common stock of the issuer over which Louise F. Brady has sole voting power. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Piedmont Capital Partners</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, LLC, a North Carolina limited liability company, has the right to receive dividends from, and the proceeds from the sale of, 1,381,938 shares of the common stock of the issuer over which Robert E. Long, Jr. has the sole power of disposition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The principal business address of Piedmont Capital Partners, LLC  is 300 North Greene Street, Suite 1750, Greensboro, North Carolina 27401. This information is based solely on a Schedule 13G filed by Louise F. Brady and Robert E. Long Jr. with the SEC on February 22, 2022 and February 14, 2022, respectively, which reported ownership as of December 31, 2021.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:15.34pt">Consists of 1,817,814 shares of common stock and 175,012 shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Dr. Barer. Does not include the securities held by B&amp;S NexImmune Holdco LLC discussed in footnote 1, as Dr. Barer has no voting or dispositive control over such securities.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:15.34pt">Consists of 195,641 shares of common stock and 34,605 shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Mr. Roemer. Does not include the securities held by the Alan S. Roemer 2015 Family Trust, as Mr. Roemer has no voting or dispositive control over such securities.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:15.34pt">Consists of 78,199 shares of common stock and 45,312 shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Dr. Bertram.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Consists of of 27,847 shares of common stock and 45,312shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Mr. D&#8217;Angio.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:15.34pt">Consists of 12,634 shares of common stock and 32,678 shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Dr. Yao.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.34pt">Consists of 1,105,495 shares of common stock and 28,236 shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Mr. Verstandig.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.34pt">Consists of 24,733 shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Ms. Gandhi.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.34pt">Consists of 73,078 shares of common stock and 309,764 shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Ms. Jones.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">Consists of 61,769 shares of common stock and 103,858 shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Mr. Trainer.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">Consists of 5,882 shares of common stock and 371,041 shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Dr. Zeldis.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">Consists of 130,467 shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Dr. Knight.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(16)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.34pt">Consists of 7,923 shares of common stock and 225,707 shares of common stock underlying options that are exercisable as of March 1, 2023 or will become exercisable within 60 days after such date held by Mr. Oelke. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Incentive Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain aggregate information with respect to all of the Company&#8217;s equity compensation plans in effect as of March&#160;1, 2023.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:50.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>securities&#160;to<br/>be<br/>issued upon<br/>exercise of<br/>outstanding<br/>options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise<br/>price of<br/>outstanding<br/>options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities<br/>remaining available<br/>for future issuance<br/>under equity<br/>compensation<br/>plans (excluding<br/>securities reflected<br/>in column(a))</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by Security holders(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,419,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439,424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Consist of options to purchase 291,742 shares of our common stock outstanding under 2017 Equity Incentive Plan as of March&#160;1, 2023.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">No additional stock awards will be granted under the 2017 Plan and the shares remaining available for the grant of future stock awards under the 2017 Plan, are available for the grant of stock awards under the 2021 Plan.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Consist of options to purchase 869,095 shares of our common stock outstanding under the 2018 Equity Incentive Plan as of March&#160;1, 2023.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">No additional stock awards will be granted under the 2018 Plan and the shares remaining available for the grant of future stock awards under the 2018 Plan, are available for the grant of stock awards under the 2021 Plan.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Consist of options to purchase 2,701,140 shares of our common stock outstanding and the right to receive 1,558,000 RSUs of common stock under the 2021 Equity Incentive plan as of March&#160;1, 2023.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Represents shares of common stock reserved for issuance upon the exercise of options granted or RSUs awarded under the 2021 Plan as of March&#160;1, 2023.</span></div><div id="i5091247d182148eaaadd80685b94df97_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Audit committee reviews and approves in advance all related-party transactions. In addition to the director and executive officer compensation arrangements discussed above in &#8220;Executive Officer and Director Compensation,&#8221; during the fiscal year ended December&#160;31, 2022, we have engaged in the following transactions in which the amount involved exceeded $120,000 and in which any director, executive officer or holder of more than 5% of our voting securities, whom we refer to as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our principal stockholders, or affiliates or immediately family members of our directors, executive officers and principal stockholders, had or will have a material interest. We believe that all of these transactions were on terms as favorable as could have been obtained from unrelated third parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreements with Stockholders</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated Investors&#8217; Rights Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Second Amended and Restated Investors&#8217; Rights Agreement, dated as of November&#160;27, 2019, or the Investors&#8217; Rights Agreement, with certain holders of our capital stock. With the completion of the IPO, the holders of <ix:nonFraction unitRef="shares" contextRef="ia325791ead244863998b1f8f312ad14c_I20210211" decimals="0" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-37">10,144,041</ix:nonFraction>&#160;shares of our common stock, including shares issued upon the automatic conversion of our convertible preferred stock, or their permitted transferees, which we refer to as our registrable securities, are entitled to rights with respect to the registration of these securities under the Securities Act. These shares also may be sold under Rule&#160;144 under the Securities Act, depending on their holding period and subject to restrictions in the case of shares held by persons deemed to be our affiliates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Investors&#8217; Rights Agreement, holders of registrable shares can demand that we file a registration statement or request that their shares be included on a registration statement that we are otherwise filing, in either case, registering the resale of their shares of common stock. These registration rights are subject to conditions and limitations, including the right, in certain circumstances, of the underwriters of an offering to limit the number of shares included in such registration and our right, in certain circumstances, not to effect a registration upon demand of the holders of registrable shares within 90 days following the effective date of any registration statement that we file covering a firm commitment underwritten public offering in which the holders of registrable shares were entitled to join and in which we effectively registered all registrable shares that were requested to be registered.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Demand Registration Rights</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning on August&#160;11, 2021, the holders of at least 25% of registrable securities then outstanding under the Investors&#8217; Rights Agreement may require us to file a registration statement under the Securities Act on a&#160;Form&#160;S-1&#160;at our expense, subject to certain exceptions, with respect to at least 40% of the registrable securities then outstanding, and we are required to effect the registration as soon as practicable, and in any event within 60 days. Any time after we are eligible to use a registration statement on&#160;Form&#160;S-3,&#160;the holders of at least 20% of our registrable securities under the Investors&#8217; Rights Agreement may require us to file a registration statement on&#160;Form&#160;S-3&#160;at our expense, subject to certain exceptions, with respect to the resale of their registrable shares, and we are required to effect the registration as soon as practicable, and in any event within 45 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Piggyback Registration Rights</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we propose to file a registration statement under the Securities Act for the purposes of a public offering of our securities (including, but not limited to, registration statements relating to a secondary offering of our securities but excluding (i)&#160;a registration statement relating to the sale of securities to employees pursuant to a stock option, stock purchase, or similar plan; (ii)&#160;with respect to any corporate reorganization or transaction under Rule&#160;145 of the Securities Act; (iii)&#160;a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the registrable securities; or (iv)&#160;a registration in which the only common stock being registered is common stock issuable upon conversion of debt securities that are also being registered. The underwriters of the offering will have the right to limit the number of shares to be included in such registration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expenses of Registration</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all registration expenses, other than underwriting discounts and commissions, related to any demand or piggyback registration. The amended and restated investors&#8217; rights agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling stockholders, in the event of misstatements or omissions in the registration statement attributable to us except in the event of fraud, and they are obligated to indemnify us for misstatements or omissions attributable to them.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expiration of Registration Rights</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration rights will terminate upon the earliest to occur of the closing of certain liquidation events, such time when all of the holder&#8217;s registrable securities may be sold without limitation (and without the requirement for us to be in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compliance with the current public information requirement) under Rule 144 of the Securities Act and the fifth anniversary of the closing date of our initial public offering.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Agreements with Officers and Directors and Directors&#8217; and Officers&#8217; Liability Insurance</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our initial public offering, we entered into, and intend to continue to enter into, indemnification agreements with each of our executive officers and directors. The indemnification agreements, our third amended and restated certificate of incorporation and our amended and restated bylaws became effective upon completion of our initial public offering and require us to indemnify our directors to the fullest extent not prohibited by Delaware law. Subject to certain limitations, our amended and restated bylaws require us to advance expenses incurred by our directors and officers. We also maintain a general liability insurance policy, which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policies and Procedures for Related Party Transactions</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our initial public offering, we adopted a written policy that requires all future transactions between us and any director, executive officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of them, or any other related persons, as defined in Item 404 of Regulation&#160;S-K,&#160;or their affiliates, in which the amount involved is equal to or greater than $120,000, be approved in advance by our Audit committee. Any request for such a transaction must first be presented to our Audit committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit committee will consider the relevant facts and circumstances available and deemed relevant to the Audit committee, including, but not limited to, the extent of the related party&#8217;s interest in the transaction, and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third party under the same or similar circumstances.</span></div><div id="i5091247d182148eaaadd80685b94df97_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14. Principal Accounting Fees and Services.</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents fees for professional audit services rendered by Ernst&#160;&amp; Young LLP for the years ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit fees (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Audit fees relate to professional services rendered in connection with the audit of NexImmune&#8217;s annual financial statements, quarterly review of financial statements, and audit services provided in connection with other statutory and regulatory filings, including fees related to our initial public offering, registration statement filings and consents, comfort letters. There were no audit-related, tax or other fees incurred for the years ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All fees described above were&#160;pre-approved&#160;by our Audit committee. We have furnished the foregoing disclosure to Ernst&#160;&amp; Young LLP.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy on Audit committee&#160;Pre-Approval&#160;of Audit and Permissible&#160;Non-Audit&#160;Services of Independent Public Accountant</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with SEC policies regarding auditor independence, the Audit committee has responsibility for appointing, setting compensation and overseeing the work of our independent registered public accounting firm. In recognition of this responsibility, the Audit committee has established a policy to&#160;pre-approve&#160;all audit and permissible&#160;non-audit&#160;services provided by our independent registered public accounting firm.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to engagement of an independent registered public accounting firm for the next year&#8217;s audit, management will submit an aggregate of services expected to be rendered during that year for each of four categories of services to the Audit </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">committee for approval. Management and our independent registered public accounting firm will each confirm to our Audit Committee that each non-audit service is permissible under all applicable legal requirements.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:19.5pt">Audit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;services include audit work performed in the preparation of financial statements, as well as work that generally only an independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial accounting and/or reporting standards.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:19.5pt">Audit-Related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;services are for assurance and related services that are traditionally performed by an independent registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:19.5pt">Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;services include all services performed by an independent registered public accounting firm&#8217;s tax personnel except those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning, and tax advice.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:19.5pt">Other Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;are those associated with services not captured in the other categories. The Company generally does not request such services from our independent registered public accounting firm.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to engagement, the Audit committee&#160;pre-approves&#160;these services by category of service. During the year, circumstances may arise when it may become necessary to engage our independent registered public accounting firm for additional services not contemplated in the original&#160;pre-approval.&#160;In those instances, the Audit committee requires specific&#160;pre-approval&#160;before engaging our independent registered public accounting firm.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit committee may delegate&#160;pre-approval&#160;authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any&#160;pre-approval&#160;decisions to the Audit committee at its next scheduled meeting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i5091247d182148eaaadd80685b94df97_100"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15. Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The financial statements filed as part of this Annual Report on Form&#160;10-K&#160;are listed in the Index to Financial Statements. Certain schedules are omitted because they are not applicable, or not required, or because the required information is included in the financial statements or notes thereto. The Exhibits are listed in Item 15(b) below.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Exhibit Index.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated&#160;by<br/>Reference&#160;herein<br/>from Form or<br/>Schedule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Registration<br/>Number</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form of Sixth Amended and Restated Certificate of Incorporation.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/18/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-40045</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restated Bylaws of NexImmune, Inc.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/18/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-40045</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form of Common Stock Certificate.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second Amended and Restated Investors&#8217; Rights Agreement, by and between the Company and the stockholders of the Company listed therein, dated November&#160;27, 2019.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form of Convertible Promissory Note, as amended.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Description of Securities.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/31/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-40045</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form of Indemnification Agreement.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2017 Equity Incentive Plan, as amended.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form of Stock Option Agreement under the 2017 Equity Incentive Plan, as amended.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Equity Incentive Plan, as amended.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form of Stock Option Agreement under the 2018 Equity Incentive Plan, as amended.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 Equity Incentive Plan.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form of Stock Option Agreement under the 2021 Equity Incentive Plan.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employment Agreement, by and between the Company and Scott Carmer, dated February&#160;3, 2021.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employment Agreement, by and between the Company and John Trainer, M.B.A., dated January&#160;6, 2020.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employment Agreement, by and between the Company and Jerome Zeldis, M.D., Ph.D., dated January&#160;4, 2021.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7.2+#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nexi-20221231x10xkxex1072.htm">Consultation</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nexi-20221231x10xkxex1072.htm"> Agreement, by and between the Company and Jerome Zeldis, M.D., Ph.D., dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nexi-20221231x10xkxex1072.htm">March </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nexi-20221231x10xkxex1072.htm">23</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nexi-20221231x10xkxex1072.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nexi-20221231x10xkxex1072.htm">3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employment Agreement, by and between the Company and Kristi Jones, dated February&#160;27, 2017.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated&#160;by<br/>Reference&#160;herein<br/>from Form or<br/>Schedule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Registration<br/>Number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employment Agreement, by and between the Company and Kristi Jones, dated March&#160;8, 2022.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/09/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-40045</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employment Agreement, by and between the Company and Robert Knight, M.D., dated January&#160;6, 2021.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/17/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-40045</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-Employee&#160;Director Compensation Policy.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/08/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amended and Restated Exclusive License Agreement, by and between the Johns Hopkins University and the Company, dated June&#160;21, 2011.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01/19/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Agreement, by and between the Company and W. M. Rickman Construction Co., LLC, dated June&#160;30, 2017.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01/19/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease Agreement, by and between the Company and Modavar Pharmaceuticals LLC, dated December&#160;11, 2017.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01/19/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-252220</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joint Research Agreement, by and between Zephyr AI, Inc. and NexImmune, Inc., dated March 16, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/12/22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-40045</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nexi-20221231x10kxex231.htm">Consent of Ernst&#160;&amp; Young LLP</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nexi-20221231x10kxex311.htm">Certification of the Principal Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nexi-20221231x10kxex312.htm">Certification of the Principal Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nexi-20221231x10kxex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nexi-20221231x10kxex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (&#8220;[***]&#8221;) because the identified confidential portions (i)&#160;are not material and (ii)&#160;would be competitively harmful if publicly disclosed.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Denotes management compensation plan or contract.</span></div><div id="i5091247d182148eaaadd80685b94df97_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16. Form&#160;10-K&#160;Summary.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NEXIMMUNE, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March&#160;28, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kristi Jones</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristi Jones, R.P.H.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Kristi Jones</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(principal executive officer)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristi Jones, R.P.H.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ John Trainer</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal accounting officer and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">principal financial officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Trainer, M.B.A.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Sol J. Barer</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sol J. Barer, Ph.D.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Alan S. Roemer</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alan S. Roemer, M.B.A., M.P.H.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Tim Bertram</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tim Bertram, Ph.D.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Paul D&#8217;Angio</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul D&#8217;Angio, R.P.H., M.S.J.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Zhengbin (Bing) Yao</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zhengbin (Bing) Yao, Ph.D.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Grant Verstandig</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant Verstandig</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Leena Gandhi</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leena Gandhi, M.D., Ph.D.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:92.991%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2022 and 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_112">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID: <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:AuditorFirmId" id="f-38">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_112">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_112">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_115">Balance Sheets as of </a>December&#160;31, 2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_115"> and </a>2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_115">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_115">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_118">Statements of Operations for the Years Ended </a>December&#160;31, 2022 <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_118">and </a>2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_118">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_118">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_121">Statements of Comprehensive Loss for the Years Ended </a>December&#160;31, 2022 <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_121"> and </a>2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_121">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_121">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_124">Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#8217; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_124">Equity</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_124"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_124"> for the Years Ended </a>December&#160;31, 2022 <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_124"> and </a>2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_124">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_124">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_127">Statements of Cash Flows for the Years Ended</a> December&#160;31, 2022<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_127"> and </a>2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_127">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_127">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_130">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_130">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i5091247d182148eaaadd80685b94df97_130">8</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of NexImmune, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of NexImmune, Inc. (the Company) as of December&#160;31, 2022 and 2021, the related statements of operations, comprehensive loss, changes in redeemable convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for the years then ended, and the related notes&#160;(collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's Ability to Continue as a Going Concern </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations, has negative cash flows from operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:AuditorName" id="f-39">Ernst&#160;&amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditors since 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="dei:AuditorLocation" id="f-40">Tysons, Virginia</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;28, 2023</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEXIMMUNE, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BALANCE SHEETS</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-41">34,642,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-42">30,326,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale&#160;marketable&#160;securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="0" id="f-43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-44">51,491,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="0" id="f-45">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="0" id="f-46">67,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-47">2,671,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-48">4,394,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-49">37,368,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-50">86,280,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-51">4,459,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-52">4,427,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-53">967,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="0" id="f-54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other&#160;non-current&#160;assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-55">264,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-56">324,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-57">43,059,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-58">91,032,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-59">2,377,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-60">1,045,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-61">7,357,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-62">6,170,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-63">599,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-65">10,333,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-66">7,215,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-67">425,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="0" id="f-68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred rent, net of current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredRentCreditNoncurrent" format="ixt:fixed-zero" scale="0" id="f-69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredRentCreditNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-70">55,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-71">10,759,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-72">7,271,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and contingencies</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-73"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-74"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-75"><ix:nonFraction unitRef="usdPerShare" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-76">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-77"><ix:nonFraction unitRef="shares" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-78">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-79"><ix:nonFraction unitRef="shares" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-80">26,078,451</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-81"><ix:nonFraction unitRef="shares" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-82">22,828,904</ix:nonFraction></ix:nonFraction> issued and outstanding as of December&#160;31, 2022 and 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-83">2,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-84">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional&#160;paid-in-capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-85">222,547,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-86">211,498,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-87">190,249,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-88">127,743,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="0" id="f-89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-90">3,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-91">32,300,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-92">83,760,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-93">43,059,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-94">91,032,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEXIMMUNE, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-95">47,148,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-96">37,456,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-97">15,934,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-98">15,799,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-99">63,082,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-100">53,255,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-101">63,082,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-102">53,255,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-103">664,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="f-104">52,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="0" id="f-105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="0" id="f-106">2,424,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="f-107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="f-108">843,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="0" id="f-109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="f-110">905,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-111">87,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-112">61,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-113">576,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-114">2,354,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea9cb688d3fe4d64b5fd77adc7e14243_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-115">62,506,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-116">50,901,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated dividends on Redeemable Convertible Preferred Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:fixed-zero" scale="0" id="f-117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:num-dot-decimal" scale="0" id="f-118">377,562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common stockholders&#8217;</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-119">62,506,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-120">51,279,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss available to common stockholders per common share</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-121"><ix:nonFraction unitRef="usdPerShare" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-122">2.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-123"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-124">2.54</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average number of common shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-125"><ix:nonFraction unitRef="shares" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-126">24,059,104</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-127"><ix:nonFraction unitRef="shares" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-128">20,186,127</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i5091247d182148eaaadd80685b94df97_121"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-129">62,506,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-130">50,901,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on&#160;available-for-sale&#160;marketable securities, net of tax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-131">3,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-132">3,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-133">62,509,211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-134">50,898,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="padding-right:-4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2022 and 2021</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.376%"><tr><td style="width:1.0%"></td><td style="width:12.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.050%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.830%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Redeemable Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series&#160;A-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series&#160;A-3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income/ (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January&#160;1, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i37d7504e32234f1795742c55cbc6b155_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-135">121,735,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d7504e32234f1795742c55cbc6b155_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="f-136">35,047,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff21ea6215e44aaf8825b8629943e25d_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-137">22,047,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff21ea6215e44aaf8825b8629943e25d_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="f-138">7,685,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied4b640b66f4431e8a9ab05b2c296a7c_I20201231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-139">31,209,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied4b640b66f4431e8a9ab05b2c296a7c_I20201231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="f-140">10,887,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5ee39eb5c7c429d8d549dd5e1664fe4_I20201231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-141">1,256,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5ee39eb5c7c429d8d549dd5e1664fe4_I20201231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-142">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7c755cb14bd427e8793ab33dac3fd7b_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-143">8,206,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie510bed0d8e14fc599909e739c5e7d89_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-144">77,582,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dca16917b304e32b75b202c42131f15_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida3374a79ddc4d3cb5ad2f1dc1e8a42a_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-146">69,374,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-147">Cumulative effect of adoption of accounting standard</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b987d568d844b0b874f7c2bca5b1c71_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-148">2,277,332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d7650fa3c34b7c9124b8138bfa5e7c_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-149">740,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i323e4338ce04403fb958b956a6ebd5c2_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-150">1,537,274</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of Series A redeemable preferred stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54f8c709c7614cd892e0ff95fd765294_D20210101-20211231" decimals="0" name="nexi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-151">145,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f8c709c7614cd892e0ff95fd765294_D20210101-20211231" decimals="0" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-152">1,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of preferred stock into common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i54f8c709c7614cd892e0ff95fd765294_D20210101-20211231" decimals="0" name="nexi:TemporaryEquityStockConvertedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-153">121,880,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54f8c709c7614cd892e0ff95fd765294_D20210101-20211231" decimals="0" name="nexi:TemporaryEquityStockConvertedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="f-154">35,048,885</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2c885db91fa648a29884e7d59755d5ad_D20210101-20211231" decimals="0" name="nexi:TemporaryEquityStockConvertedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-155">22,047,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c885db91fa648a29884e7d59755d5ad_D20210101-20211231" decimals="0" name="nexi:TemporaryEquityStockConvertedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="f-156">7,685,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i362e074aa71542d3be5f2ac89ce168f3_D20210101-20211231" decimals="0" name="nexi:TemporaryEquityStockConvertedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-157">31,209,734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i362e074aa71542d3be5f2ac89ce168f3_D20210101-20211231" decimals="0" name="nexi:TemporaryEquityStockConvertedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="f-158">10,887,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-159">10,144,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-160">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-161">53,621,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-162">53,622,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Conversion of convertible debt into common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231" decimals="0" name="nexi:StockIssuedDuringPeriodSharesConversionOfConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="f-163">3,669,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231" decimals="0" name="nexi:StockIssuedDuringPeriodValueConversionOfConvertibleDebt" scale="0" id="f-164">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231" decimals="0" name="nexi:StockIssuedDuringPeriodValueConversionOfConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="f-165">30,251,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="nexi:StockIssuedDuringPeriodValueConversionOfConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="f-166">30,252,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the initial public offering. net of transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-167">7,441,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="f-168">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-169">114,550,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-170">114,551,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-171">314,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="f-172">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-173">1,165,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-174">1,166,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231" decimals="0" name="nexi:NumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-175">2,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-176">5,979,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-177">5,979,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized gain on marketable available-for-sale securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcf18312a9b849779921e6320f8c96e3_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-178">3,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-179">3,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d72f5c306cd45b3a45cc5043d61410b_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-180">50,901,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-181">50,901,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i245c6670d41d42a9b3fa719e42f16d0f_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245c6670d41d42a9b3fa719e42f16d0f_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="f-183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbbf1a64b75d4fce82cd179c3bd44da8_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbbf1a64b75d4fce82cd179c3bd44da8_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="f-185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44b3409c2a62435692c6df71b1354eaa_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b3409c2a62435692c6df71b1354eaa_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="f-187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i736ffb84dab44fb0b3e163c0502409b6_I20211231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-188">22,828,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736ffb84dab44fb0b3e163c0502409b6_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-189">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a135ff906f46e9bab66d63a940f8e2_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-190">211,498,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia891e7526d504d8fadb55664f61f3e46_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-191">127,743,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0445e2ff34a46f185f60587d785bf3c_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-192">3,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-193">83,760,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December&#160;31, 2022 and 2021 (Continued)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.809%"><tr><td style="width:1.0%"></td><td style="width:14.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series&#160;A-2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series&#160;A-3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income/ (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January&#160;1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i245c6670d41d42a9b3fa719e42f16d0f_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245c6670d41d42a9b3fa719e42f16d0f_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="f-195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbbf1a64b75d4fce82cd179c3bd44da8_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbbf1a64b75d4fce82cd179c3bd44da8_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="f-197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44b3409c2a62435692c6df71b1354eaa_I20211231" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b3409c2a62435692c6df71b1354eaa_I20211231" decimals="0" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="0" id="f-199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i736ffb84dab44fb0b3e163c0502409b6_I20211231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-200">22,828,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736ffb84dab44fb0b3e163c0502409b6_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-201">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a135ff906f46e9bab66d63a940f8e2_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-202">211,498,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia891e7526d504d8fadb55664f61f3e46_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-203">127,743,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0445e2ff34a46f185f60587d785bf3c_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-204">3,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-205">83,760,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from "at-the-market" offering facility, net of transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-206">3,184,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="f-207">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d26598eacc4a57ba2e44555e59db4b_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-208">5,145,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-209">5,145,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-210">12,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="f-211">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d26598eacc4a57ba2e44555e59db4b_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-212">33,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-213">33,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cashless exercise of options for common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231" decimals="0" name="nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-214">51,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231" decimals="0" name="nexi:StockIssuedDuringPeriodValueCashlessCommonStockExercised" scale="0" id="f-215">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79d26598eacc4a57ba2e44555e59db4b_D20220101-20221231" decimals="0" sign="-" name="nexi:StockIssuedDuringPeriodValueCashlessCommonStockExercised" scale="0" id="f-216">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="nexi:StockIssuedDuringPeriodValueCashlessCommonStockExercised" format="ixt:fixed-zero" scale="0" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d26598eacc4a57ba2e44555e59db4b_D20220101-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-218">5,870,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-219">5,870,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized loss on marketable available-for-sale securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82f02bb4e976485b911d7b3e40c78b45_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-220">3,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-221">3,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea9cb688d3fe4d64b5fd77adc7e14243_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-222">62,506,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-223">62,506,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i087599b8fe8e4804833ffb19d54c95d2_I20221231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-224">26,078,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087599b8fe8e4804833ffb19d54c95d2_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-225">2,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc09a4b59e0b4de088c1ee9a6f9b937b_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-226">222,547,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23dd0eac814249f3a9f87f2d470e24a0_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-227">190,249,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2f44e04246d4f92ae9eaa55d8242626_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-229">32,300,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEXIMMUNE, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-230">62,506,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-231">50,901,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="f-232">994,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="f-233">870,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion income on available-for-sale marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="0" id="f-234">1,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="0" id="f-235">32,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on asset disposal</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="0" id="f-236">21,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="0" id="f-237">8,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-238">5,870,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-239">5,979,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="nexi:LeaseExpenseNoncash" format="ixt:num-dot-decimal" scale="0" id="f-240">500,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="nexi:LeaseExpenseNoncash" format="ixt:fixed-zero" scale="0" id="f-241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash&#160;interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="0" id="f-242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="0" id="f-243">903,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="f-244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-245">2,424,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="f-246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="f-247">843,619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-248">1,723,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-249">2,053,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-250">59,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-251">300,726</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="f-252">1,387,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="0" id="f-253">1,002,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-254">1,258,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-255">4,011,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-256">498,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-258">51,190,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-259">45,785,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-260">1,255,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-261">2,350,416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from disposal of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-262">80,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" format="ixt:fixed-zero" scale="0" id="f-263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases&#160;of&#160;available-for-sale&#160;marketable&#160;securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="0" id="f-264">21,509,940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="0" id="f-265">90,456,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities&#160;of&#160;available-for-sale&#160;marketable&#160;securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-266">71,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-267">39,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from redemption of available-for-sale marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="0" id="f-268">1,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="0" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-270">50,315,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-271">53,807,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from initial offering, net of transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="0" id="f-272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="0" id="f-273">114,721,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from "at-the-market" offering facility, net of transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="f-274">5,145,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="0" id="f-275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-276">33,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-277">1,166,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on capital leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:fixed-zero" scale="0" id="f-278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" format="ixt:num-dot-decimal" scale="0" id="f-279">12,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of convertible notes from related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:fixed-zero" scale="0" id="f-280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:num-dot-decimal" scale="0" id="f-281">56,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the issuance of convertible notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="0" id="f-282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="f-283">8,974,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance costs associated with convertible notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="0" id="f-284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="f-285">19,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-286">5,178,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-287">124,887,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-288">4,303,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-289">25,295,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash, cash equivalents and restricted cash at beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-290">30,393,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida3374a79ddc4d3cb5ad2f1dc1e8a42a_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-291">5,098,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash, cash equivalents and restricted cash at end of period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-292">34,697,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-293">30,393,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during the year for interest</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="0" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:InterestPaidNet" scale="0" id="f-295">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of debt from forgiveness of PPP Loan</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:fixed-zero" scale="0" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="0" id="f-297">843,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment purchases included in accounts payable and accrued expenses</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="f-298">5,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="f-299">131,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_130"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div></div><div><span><br/></span></div><div id="i5091247d182148eaaadd80685b94df97_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-300" continuedAt="i593013759e6f492892e963cba9255d19" escape="true">Description of the Business</ix:nonNumeric></span></div><ix:continuation id="i593013759e6f492892e963cba9255d19" continuedAt="i924f0afb4bfe4544b29f0143f316a9b7"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NexImmune, Inc. (the &#8220;Company&#8221; or &#8220;NexImmune&#8221;), a Delaware corporation headquartered in Gaithersburg, Maryland, was incorporated on June&#160;7, 2011. The Company is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The AIM nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body&#8217;s own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are artificial AIM nanoparticles, which act as synthetic dendritic cells. These AIM nanoparticles can be programmed to present specific antigens to specific T cells orchestrating a highly targeted immune response. These AIM nanoparticles can be rapidly engineered to elicit an immune attack that can be directed toward any foreign substance or cell type in a patient&#8217;s body. The Company&#8217;s first two products, both for the treatment of different types of cancer, entered clinical trials in 2020. Following a strategic review of the Company's corporate strategy, including with respect to its adoptive cell therapy programs, the Company paused investments in its cell therapy studies, NEXI-001, NEXI-002, and NEXI-003 which is designed to reduce costs and reallocate resources towards our AIM INJ preclinical development programs. As part of this strategy, we will focus on developing AIM INJ nanoparticle constructs and modalities for potential clinical evaluation in oncology and autoimmune disorders. The Company is exploring several external opportunities to continue to advance these programs. As a result, the Company will focus its existing resources on its injectable platform in oncology and autoimmune diseases.</span></div><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="nexi:SubstantialDoubtForGoingConcernPolicyTextBlock" id="f-301" continuedAt="i3124e807700b4e0d9784138d779a3719" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements - Going Concern ("ASC 205-40"), requires management to assess the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements are issued. Under ASC 205-40, management has the responsibility to evaluate whether conditions and/or events raise substantial doubt about the Company&#8217;s ability to meet future financial obligations as they become due within one year after the date that the financial statements are issued. As required by this standard, management&#8217;s evaluation shall initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring operating losses and negative cash flows from operations. The financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-302">190.2</ix:nonFraction> million, negative cash flows from operating activities for the period ended December&#160;31, 2022, and significant ongoing research and development expenses. While we have <ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="f-303">no</ix:nonFraction> outstanding debt and $<ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-304">34.6</ix:nonFraction> million in cash and cash equivalents as of December&#160;31, 2022, the Company expects its negative cash flows from operating activities to continue and thus has determined that its losses and negative cash flows from operations and uncertainty in generating sufficient cash to meet our obligations and sustain our operations raise substantial doubt about the Company&#8217;s ability to continue as a going concern for at least one year from the issuance date of these financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s research and development activities mature and develop over the next year, the Company will likely require substantial funds to continue such activities, depending upon events that are difficult to predict at this time. In this regard, management plans to raise additional capital through financing activities that may include public offerings and private placements of its common stock, preferred stock offerings, collaborations and licensing arrangements and issuances of debt and convertible debt instruments. In the absence of additional capital, the Company plans to strategically manage its uncommitted spend, execute its priorities and implement cost saving measures to reduce research and development and general and administrative expenditures which could include minimizing staff costs and delaying or terminating manufacturing and clinical trial costs.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Description of the Business (continued)</span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i924f0afb4bfe4544b29f0143f316a9b7"><ix:continuation id="i3124e807700b4e0d9784138d779a3719">There are inherent uncertainties associated with fundraising activities and activities to manage the Company&#8217;s uncommitted spending and the successful execution of these activities may not be within the Company&#8217;s control. There are no assurances that such additional funding will be obtained and that the Company will succeed in its future operations. If the Company cannot successfully raise additional capital, its liquidity, financial condition and business prospects will be materially and adversely affected. The Company is continually looking into further capital planning and the evaluation of strategic alternatives. There is substantial doubt about the Company&#8217;s ability to continue as a going concern.</ix:continuation></ix:continuation></span></div><div id="i5091247d182148eaaadd80685b94df97_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:BasisOfAccounting" id="f-305" continuedAt="i5586490ca7bb4bea8e478e575c49e4b2" escape="true">Basis of Presentation and Liquidity</ix:nonNumeric></span></div><ix:continuation id="i5586490ca7bb4bea8e478e575c49e4b2"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-306" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Updates (&#8220;ASU&#8221;) of the FASB.</span></div></ix:nonNumeric></ix:continuation><div id="i5091247d182148eaaadd80685b94df97_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-307" continuedAt="if5c528b20fc94dfc9718eddc536ad853" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="if5c528b20fc94dfc9718eddc536ad853" continuedAt="i2c899cf6575c4a7c848baa6256c71c86"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:UseOfEstimates" id="f-308" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the recoverability of long-lived assets, stock-based compensation, the valuation of financial instruments, and the valuation of deferred tax assets and liabilities. The Company&#8217;s estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Although actual results could differ from those estimates, management does not believe that such differences would be material.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="f-309" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to credit risk consist principally of cash and marketable debt securities. All cash is held in United States financial institutions that are federally insured. At times, the Company may maintain cash balances in excess of the federally insured amount. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk. The Company&#8217;s investments in marketable debt securities have been issued by corporate entities and government-sponsored enterprises with high credit ratings. The Company mitigates investment risks by investing in highly-rated securities with relatively short maturities that the Company believes do not subject it to undue investment or credit risk. If any of these financial institutions fail to perform their obligations under the terms of these financial instruments, the Company&#8217;s maximum exposure to potential losses would be equal to the amounts reported on the balance sheet.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-310" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographic Information</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations as and manages its business in <ix:nonFraction unitRef="segment" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-311">one</ix:nonFraction> operating segment operating exclusively in the United States.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-312" continuedAt="i338e37d2444b410c9c96774b83aedac4" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Summary of Significant Accounting Policies (continued)</span></div></div><ix:continuation id="i2c899cf6575c4a7c848baa6256c71c86" continuedAt="ib26709a48825432f981c8b53dd6c1ec1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i338e37d2444b410c9c96774b83aedac4">months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</ix:continuation></span></div><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="f-313" continuedAt="ic817129b1a7448e98d439daa69c15e27" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities with maturities greater than three months from the date of purchase that include commercial paper and corporate notes. Classification of marketable securities between current and&#160;non-current&#160;is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. There were <ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:MarketableSecurities" format="ixt:fixed-zero" scale="0" id="f-314">no</ix:nonFraction> outstanding marketable securities as of December&#160;31, 2022. As of December&#160;31, 2021, all marketable securities were classified as current.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and dividend income are recorded when earned and included in interest income in the statement of operations. Premiums and discounts, if any, on marketable securities are amortized or accreted to maturity and included in interest income in the statement of operations. The specific identification method is used in computing realized gains and losses on the sale of the Company&#8217;s marketable securities.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic817129b1a7448e98d439daa69c15e27">The Company classifies its marketable securities as&#160;available-for-sale.&#160;The Company determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date.&#160;Marketable securities that are classified as&#160;available-for-sale&#160;are measured at fair value on the balance sheet, and unrealized gains and losses on marketable securities are reported as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity (deficit) until realized. Marketable securities are evaluated periodically to determine whether the carrying value of a marketable security exceeds its fair value and the decline in value is determined to be other-than-temporary. Management reviews criteria, such as the general market conditions, magnitude and duration in which the fair value has been less than the carrying value, the investment issuer&#8217;s financial condition and business outlook, as well as the Company&#8217;s ability to hold the securities until the recovery of its amortized cost basis, to determine whether the decline in value is other-than-temporary. If a decline in value is determined to be other-than-temporary, the value of the marketable security is reduced, and the impairment is recorded as other expense in the statement of operations. As of December&#160;31, 2021, any decline in value of marketable securities was concluded not to be other-than-temporary. As of December&#160;31, 2022, no assessment was required.</ix:continuation> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted cash</span></div><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-315" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-316">34,642,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-317">30,326,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-318">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-319">67,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-320">34,697,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-321">30,393,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent amounts required as collateral on corporate credit cards.</span></div><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-322" continuedAt="id230e87cfe584ba980c2e1a6c774016e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, marketable securities, accounts payable, accrued expenses, convertible notes and derivative liabilities. The fair values of the cash and cash equivalents, accounts payable and accrued expenses approximated their carrying values as of December&#160;31, 2022 and 2021, due to their short-term maturities. For a description of the fair value of marketable securities, refer to Note 4. The Convertible Notes as discussed in Note 10 contained embedded derivative features that were required to be bifurcated and remeasured to fair value at each reporting period.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Summary of Significant Accounting Policies (continued)</span></div></div><ix:continuation id="ib26709a48825432f981c8b53dd6c1ec1" continuedAt="i18428f48dd16432184ef89415d682702"><ix:continuation id="id230e87cfe584ba980c2e1a6c774016e"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, Fair Value Measurements (&#8220;ASC 820&#8221;). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt">Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt">Fair value is determined by using inputs, other than Level&#160;1 quoted prices that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt">Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant judgments to be made by a reporting entity.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div></ix:continuation><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-323" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation and amortization. Major replacements and improvements that extend the useful lives of assets are capitalized, while general repairs and maintenance are charged to expense as incurred. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the related lease term, whichever is shorter. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses.</span></div><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-324" continuedAt="i1b52dcf21e80433193fea479f1b10ca1" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property, plant and equipment by major category are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87575f3a4a8d47e0b099f6f2d5697f3c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-325">7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5ae3ce8c146e4b3a8647cdb069d847f0_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-326">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib14beae652b44f86850981cbd7bea2fb_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-327">7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-328" continuedAt="if4550a37bf3043cd9a6aeebf274c6ac2" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of its long-lived asset group for potential impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoverability is determined by comparing future undiscounted cash flows associated with such assets to the related carrying value. An impairment loss may be recognized when the estimated undiscounted future cash flow is less than the carrying amount of the asset. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured as the amount by </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Summary of Significant Accounting Policies (continued)</span></div></div><ix:continuation id="i18428f48dd16432184ef89415d682702" continuedAt="ieffebfb47e5e4722b003503a32c1e1a5"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if4550a37bf3043cd9a6aeebf274c6ac2">which the carrying value of the asset group exceeds the fair value of the asset group.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-329"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-330">No</ix:nonFraction></ix:nonFraction> impairments were recognized for the years ended December&#160;31, 2022 or 2021.</span></div><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="nexi:TemporaryEquityPolicyPolicyTextBlock" id="f-331" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable convertible preferred stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s redeemable convertible preferred stock was classified outside of stockholders&#8217; equity because the shares contained deemed liquidation rights that represented a contingent redemption feature not solely within the control of the Company.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="f-332" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible instruments and embedded derivatives</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that contain conversion options and other embedded features. The Company bifurcates embedded features from their host instruments and accounts for them as free-standing derivative financial instruments according to certain criteria.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any change to the Company&#8217;s debt arrangements, the Company evaluates the amendment to determine whether a debt modification or extinguishment has occurred, including whether the amendment should be accounted for as a troubled debt restructuring.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s derivative instrument related to certain features embedded within the Company&#8217;s Convertible Notes as discussed in Note 10. The derivative was accounted for as a derivative liability and remeasured to fair value as of each balance sheet date. The related remeasurement adjustments are recognized in the accompanying statements of operations and were settled upon the conversion of the Convertible Notes during the year ended December 31, 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-333" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including share-based compensation, as well as costs for third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, based on its estimates of services performed and costs incurred. These estimates include the level of services performed by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="nexi:ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock" id="f-334" continuedAt="i55c7887ac2ab4654931550b008158988" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial and contract development and manufacturing organization expenses </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes payments in connection with clinical trials and contract development and manufacturing organizations (&#8220;CDMO&#8221;) under contracts with contract research organizations that support conducting and managing clinical trials and the manufacturing of materials utilized in clinical and preclinical activities. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of the obligation to make payments under these contracts depends on factors such as the successful enrollment, treatment of patients, the completion of other clinical trial milestones, or completion of manufacturing milestones. Termination clauses within the agreements require notification for a certain number of days prior to completing work, payments for costs incurred through the termination date, and termination penalty, if applicable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Expenses related to development and manufacturing are accrued based on estimates and/or representations from service providers regarding work performed, including progress in the development of processes through technology transfers to manufacture the Company&#8217;s clinical material and completion of the manufactured clinical material. Other incidental costs related to patient enrollment or </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Summary of Significant Accounting Policies (continued)</span></div></div><ix:continuation id="ieffebfb47e5e4722b003503a32c1e1a5" continuedAt="i0bfa638eb54c44b49612886ca3d87c1f"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i55c7887ac2ab4654931550b008158988">treatment are accrued when reasonably certain. If the amounts the Company is obligated to pay under clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.</ix:continuation></span></div><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-335" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records compensation expense associated with stock options and other forms of equity compensation based on the estimated fair value at the grant date. Compensation expense related to awards to employees and non-employees with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the requisite service period of the award, which is generally the vesting term. The Company&#8217;s policy is to account for forfeitures as they occur. The Company uses the Black-Scholes-Merton option pricing (Black-Scholes) model to estimate the fair value of stock options. The Black-Scholes model requires input-based assumptions that are highly subjective, judgmental and sensitive in the determination of stock-based compensation cost.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted after the Company&#8217;s IPO are issued at the fair market value of the Company&#8217;s common stock at the date the grant is approved by the Board.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected volatility was based on the historical volatility of comparable public companies from a representative peer group selected based on industry and market capitalization data. The historical volatility is calculated based on a period of time commensurate with the expected term assumption.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate was based on the continuous rates provided by the U.S. Treasury with a term approximating the expected term of the option.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected dividend yield was <ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-336">0</ix:nonFraction>% because the Company has not historically paid and does not expect to pay any dividends for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based-Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 for a further discussion on stock-based compensation.</span></div><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-337" continuedAt="i90ee16ae0d5b412cad3e65ed8234dd33" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes it is&#160;more-likely-than-not&#160;that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results,&#160;on-going&#160;tax planning and forecasts of future taxable income on a&#160;jurisdiction-by-jurisdiction&#160;basis. The Company recorded a valuation allowance against all estimated net deferred tax assets as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered&#160;more-likely-than-not&#160;to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Recognized income tax positions are measured at the largest amount that is greater than&#160;more-likely-than-not&#160;of being realized. Changes in the recognition or measurement are reflected in the period in </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Summary of Significant Accounting Policies (continued)</span></div></div><ix:continuation id="i0bfa638eb54c44b49612886ca3d87c1f" continuedAt="i8c7d79cb850c4851bb831f5bb0379050"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i90ee16ae0d5b412cad3e65ed8234dd33">which the change in estimate occurs. Interest and penalties related to uncertain tax positions are recorded in the provision of income taxes.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-338"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-339"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-340"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-341"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-342"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-343">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> uncertain tax positions nor income tax related interest and penalties recorded as of or for the years ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-344" continuedAt="iaaf6525620ce4291ac02a47aca54bfff" escape="true">Net Loss Per Share Attributable to Common Stockholders</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaaf6525620ce4291ac02a47aca54bfff">Basic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock and common stock equivalents outstanding for the period. The Company adjusts net loss to arrive at the net loss attributable to common stockholders to reflect the amount of dividends accumulated during the period on the Company&#8217;s redeemable convertible preferred stock. Such dividends are only payable if and when declared by the Board of Directors (Note 11). The treasury stock method is used to determine the dilutive effect of the Company&#8217;s stock option grants and warrants and the&#160;if-converted&#160;method is used to determine the dilutive effect of the Company&#8217;s redeemable convertible preferred stock and Convertible Notes. For the years ended December&#160;31, 2022 and 2021, the Company had a net loss attributable to common stockholders, and as such, all outstanding stock options, shares of redeemable convertible preferred stock, and warrants were excluded from the calculation of diluted loss per share. Under the if-converted method, convertible instruments that are in the money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of bifurcated derivatives is added back to the numerator of the diluted net loss per share calculation if the conversion of the Convertible Notes is dilutive.</ix:continuation>&#160;<ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-345" continuedAt="i269e28b12d584095a6546e86188ce9d3" escape="true">The following table sets forth the computation of basic and diluted earnings per share for the years ended December&#160;31, 2022 and 2021:</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="i269e28b12d584095a6546e86188ce9d3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-346">62,506,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-347">50,901,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated dividends on Redeemable Convertible Preferred Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:fixed-zero" scale="0" id="f-348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:TemporaryEquityDividendsAdjustment" format="ixt:num-dot-decimal" scale="0" id="f-349">377,562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-350"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="0" id="f-351">62,506,199</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-352"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="0" id="f-353">51,279,070</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-354"><ix:nonFraction unitRef="usdPerShare" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-355">2.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-356"><ix:nonFraction unitRef="usdPerShare" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-357">2.54</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-358"><ix:nonFraction unitRef="shares" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-359">24,059,104</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-360"><ix:nonFraction unitRef="shares" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-361">20,186,127</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-362" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following potentially dilutive securities have been excluded from the computation of diluted weighted average common shares outstanding at December&#160;31, 2022 and 2021, as the effect would be anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cf8573a7849487689779272da2d03b6_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-363">3,965,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3ec5ac6a0fb4bc1994df10d0b09682c_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-364">3,305,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb99aa2cda304c0e9bea4f6fc09c71fa_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-365">1,558,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i174925bbb76f4a498cf99885a1362415_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec5ab7a1dbd54ea8861c3ef82c751c0b_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i791c94e47b51427dbee42f8cc8773959_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-368">1,164,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4a0838ebfff413db2e9ad8c231fef39_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4f8973765ad4bc8be9332ad3594c082_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-370">506,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i074eae8be4554fceb16fac6998ae3c9a_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ba9051f6c594a37b6e8e5e56c95af66_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-372">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-373">5,523,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-374">4,976,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of redeemable convertible preferred stock also participate in dividends with shares of common stock (if and when declared) and therefore are deemed participating securities. The holders of redeemable convertible preferred stock do not contractually share in losses and therefore no additional net loss per share has been disclosed under the&#160;two-class&#160;method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging growth company status</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an &#8220;emerging growth company&#8221; (EGC), as defined in the Jumpstart Our Business Startups Act (JOBS Act), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section&#160;107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. Summary of Significant Accounting Policies (continued)</span></div></div><ix:continuation id="i8c7d79cb850c4851bb831f5bb0379050"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transition period for complying with new or revised accounting standards, and as a result of this election, the financial statements may not be comparable to companies that comply with public company FASB standards&#8217; effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an IPO offering or such earlier time that it is no longer an EGC.</span></div><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-375" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting standards and pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as subsequently amended (collectively &#8220;ASC 842&#8221;). The guidance amends the existing accounting standards for lease accounting, including requirements for lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expanding disclosure requirements regarding leasing arrangements. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting ASC 842 in which entities can elect to apply the new guidance using a modified retrospective approach at the beginning of the year in which the new lease standard is adopted. In November 2019, the FASB issued ASU 2019-10 deferring the effective date for private entities for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the FASB issued ASU 2020-05 which further defers the effective date for private entities for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As an EGC, the Company adopted the new leasing guidance on January 1, 2022. The Company combined lease and non-lease components as a single component for all underlying asset classes. ASC 842 provides a number of optional practical expedients in transition. The Company applied the &#8216;package of practical expedients&#8217; which allows the Company to not reassess i) whether existing or expired arrangements contain a lease, ii) the lease classification of existing or expired leases, or iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. The Company completed its evaluation and recognized $<ix:nonFraction unitRef="usd" contextRef="ieca80fa7685c4607ad5fef70aa7ce16e_I20220101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-376">1.5</ix:nonFraction> million in operating right-of-use assets and $<ix:nonFraction unitRef="usd" contextRef="ieca80fa7685c4607ad5fef70aa7ce16e_I20220101" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-377">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieca80fa7685c4607ad5fef70aa7ce16e_I20220101" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-378">1.0</ix:nonFraction> million in operating lease liabilities, current and non-current, respectively, on January 1, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU&#160;2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for&#160;available-for-sale&#160;debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for fiscal year beginning after December&#160;15, 2022, and interim periods beginning after December&#160;15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company&#8217;s investment portfolio, current market conditions and historical credit loss activity, the adoption of ASU&#160;2016-13&#160;is not expected to have a material impact on its financial position, results of operations or the related disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i5091247d182148eaaadd80685b94df97_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="f-379" continuedAt="ib545c7975e0b45fb99d01c7deca0a819" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ib545c7975e0b45fb99d01c7deca0a819" continuedAt="iffd81e92a40e4752b739b7d3f18109a7"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-380" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403fdc2b033c4c1b88c48004e7a37ed6_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-381">23,722,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b550a9ae7a2446e8c50991ec5a09571_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic044d50d4b384932ab18201e6f0b8da8_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie253db02491d4a9fb3f8cad4afeb89c0_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-384">22,124,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a167d620d684558850204ae675e061c_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02e707e70eb144e8a9764dbe72b5e376_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9482c390e2874f69bdd95e842f27cb9a_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294000fb786942f083924e218896237f_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-388">7,979,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia62f066291d846ab9d346921a55d6947_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ad398f6533421f95d670a14ced26ca_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4421505cb3f46938fada27cf31ab63a_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-391">56,991,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i403ec125cb5f41cb813253079b7b88b1_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e473ef2ced4a76af90569c4e60acd9_I20221231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-393">23,722,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebce9dddcdbc4c0aa95432c1635a3c49_I20221231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-394">7,979,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1965187e11b4cd7be206e7c49075e52_I20221231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e448c466c94c3bbfea9fb4d64de651_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-396">22,124,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ffac7d5bf164513a7108afdd83a49dc_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="f-397">56,991,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c5920ce6d144e6ca4a4780bbb323bfb_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. Fair Value Measurements (continued)</span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iffd81e92a40e4752b739b7d3f18109a7">During the years ended December&#160;31, 2022 and 2021, the Company did not have any transfers between levels. There were no Level&#160;3 recurring fair value measurements as of December&#160;31, 2022 or 2021.</ix:continuation> </span></div><div id="i5091247d182148eaaadd80685b94df97_148"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="nexi:PrepaidExpensesAndOtherCurrentAssetsTextBlock" id="f-399" continuedAt="i34fb649322324f9e8ea8d44e9219db07" escape="true">Prepaid Expenses and Other Current Assets</ix:nonNumeric></span></div><ix:continuation id="i34fb649322324f9e8ea8d44e9219db07"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-400" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following at December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="nexi:PrepaidResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="0" id="f-401">1,176,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="nexi:PrepaidResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="0" id="f-402">3,375,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid maintenance agreements</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="nexi:PrepaidMaintenanceAgreements" format="ixt:num-dot-decimal" scale="0" id="f-403">369,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="nexi:PrepaidMaintenanceAgreements" format="ixt:num-dot-decimal" scale="0" id="f-404">132,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="0" id="f-405">403,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="0" id="f-406">479,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-407">245,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="f-408">308,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-409">74,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:InterestReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-411">401,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-412">99,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-413">2,671,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-414">4,394,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5091247d182148eaaadd80685b94df97_151"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-415" continuedAt="ibec3cf91192a4209a48858e9f33a8da1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="ibec3cf91192a4209a48858e9f33a8da1"><ix:continuation id="i1b52dcf21e80433193fea479f1b10ca1"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following at December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ed377902824f8ba0190be0190253f8_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-416">6,803,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906f22664a64466f86557348630d1046_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-417">5,943,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d5098de97364db3825058bb650872b0_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-418">516,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa2d70a7c5a44e0b33c4306131e12a5_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-419">486,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec4224fbcf36436d982945a277e0bbaf_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-420">47,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f5c36a4c3e45f1bbeaada8cda374f9_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-421">47,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a0b0ffb5bd4c57ab7546cae1b3e6f4_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-422">319,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53fe34a4932b4e8087a347be3b55c58e_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-423">230,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-424">7,688,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-425">6,708,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-426">3,229,592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-427">2,281,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-428">4,459,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-429">4,427,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="0" id="f-430">994,792</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="0" id="f-431">870,285</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div id="i5091247d182148eaaadd80685b94df97_866"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-432" continuedAt="ifa208d3a1e8d4b479030aed3595f1faa" escape="true">Restructuring Activities</ix:nonNumeric></span></div><ix:continuation id="ifa208d3a1e8d4b479030aed3595f1faa" continuedAt="i4ae14aeae91b4360a4a6bc2df1848e3b"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company announced that, following a strategic review of its pipeline, indications, timelines and cash position, it implemented a strategic realignment initiative, which was designed to reduce costs and reallocate resources towards its AIM INJ preclinical development programs. As part of this strategy, the Company initiated a workforce reduction plan to reduce headcount by <ix:nonFraction unitRef="number" contextRef="i7c590145da4b44288c802fc50a344e72_D20221101-20221130" decimals="2" name="nexi:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-433">30</ix:nonFraction>%, primarily affecting the clinical development, manufacturing and administrative staff that had been needed to support the AIM ACT adoptive cell therapy clinical programs. This plan will reduce the Company&#8217;s workforce from <ix:nonFraction unitRef="employee" contextRef="i7c590145da4b44288c802fc50a344e72_D20221101-20221130" decimals="INF" name="nexi:RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations" scale="0" id="f-434">74</ix:nonFraction> full-time employees to approximately <ix:nonFraction unitRef="employee" contextRef="i7c590145da4b44288c802fc50a344e72_D20221101-20221130" decimals="INF" name="nexi:RestructuringAndRelatedCostNumberOfPositionsAfterEliminations" scale="0" id="f-435">50</ix:nonFraction> full-time employees. The Company estimates that it will incur approximately $<ix:nonFraction unitRef="usd" contextRef="ie321f805cc7f4133a42ae2ffef7ab78f_I20221130" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="f-436">0.7</ix:nonFraction> million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. These one-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued salaries at December 31, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="ie19a45c8600b4fbba9f92e595547ba14_I20221231" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-437">0.4</ix:nonFraction> million in severance expenses related to the November 2022 restructuring. The Company communicated the workforce reduction on November 14, 2022 and recognized $<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="f-438">0.5</ix:nonFraction> million in <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="nexi:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" id="f-439">costs associated with the restructuring</ix:nonNumeric> during the year ended December 31, 2022. The Company expects to complete the restructuring in the second quarter of 2023. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div></div><ix:continuation id="i4ae14aeae91b4360a4a6bc2df1848e3b"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-440" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges related to the restructuring activities as of December&#160;31, 2022. There were no restructuring expenses during the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued Restructuring Expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued Restructuring Expenses</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance, benefits and related costs due to workforce reduction</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe540e5b2e574273bb15fd4fe0b096b5_I20211231" decimals="0" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="0" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97ccdc3f285040bd876d4fa408564bf9_D20220101-20221231" decimals="0" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="0" id="f-442">531,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97ccdc3f285040bd876d4fa408564bf9_D20220101-20221231" decimals="0" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="0" id="f-443">149,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19a45c8600b4fbba9f92e595547ba14_I20221231" decimals="0" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="0" id="f-444">382,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Totals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="0" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="0" id="f-446">531,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="0" id="f-447">149,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="0" id="f-448">382,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i5091247d182148eaaadd80685b94df97_154"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-449" continuedAt="ic3e48cdd06914611a734d36ef00faac4" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="ic3e48cdd06914611a734d36ef00faac4"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-450" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the components of accrued expenses is as follows as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="nexi:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-451">3,210,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="nexi:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-452">2,611,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-453">267,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-454">384,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued salaries, benefits and related expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-455">3,855,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-456">3,143,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-457">23,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-458">31,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-459">7,357,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-460">6,170,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5091247d182148eaaadd80685b94df97_157"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-461" continuedAt="iaff5b4b568e14d6a811f54960eeeb88b" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="iaff5b4b568e14d6a811f54960eeeb88b" continuedAt="i72e0f175dd01422ab7392e8f55623072"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a Translational Research Award Agreement effective May&#160;23, 2012 with the Department of Business&#160;&amp; Economic Development with the State of Maryland, Maryland Biotechnology Center (&#8220;MBC&#8221;). The mission of MBC is to integrate entrepreneurial strategies to stimulate the transformation of scientific discovery and intellectual assets into capital formation and business development. Under the agreement, MBC provided $<ix:nonFraction unitRef="usd" contextRef="icbc1c26d23f6405c928044ee7980345e_I20120523" decimals="0" name="nexi:ResearchAndDevelopmentArrangementContractToPerformForOthersLiability" format="ixt:num-dot-decimal" scale="0" id="f-462">200,000</ix:nonFraction> to NexImmune for research on its artificial aAPC for cancer immunotherapy. In 2013, an amendment increased the amount by $<ix:nonFraction unitRef="usd" contextRef="i0dc71e39107c4d2e888729d888bb4e8b_D20130523-20130523" decimals="0" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="0" id="f-463">125,000</ix:nonFraction> for a total grant of $<ix:nonFraction unitRef="usd" contextRef="i69c37fb252ac488eb687ac1d9ffa59fe_I20130523" decimals="0" name="nexi:ResearchAndDevelopmentArrangementContractToPerformForOthersLiability" format="ixt:num-dot-decimal" scale="0" id="f-464">325,000</ix:nonFraction>. This grant was recorded as income in 2012 and 2013, as the Company incurred the expenses which qualified it for the grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must repay the funds through annual payments calculated at <ix:nonFraction unitRef="number" contextRef="ie5deb40f57714a11a917ea127c6f7c9f_D20130523-20130523" decimals="2" name="nexi:ResearchAndDevelopmentArrangementAnnualPaymentPercentage" scale="-2" id="f-465">3</ix:nonFraction>% of annual revenues for the preceding year. Payments shall continue for <ix:nonNumeric contextRef="ie5deb40f57714a11a917ea127c6f7c9f_D20130523-20130523" name="nexi:ResearchAndDevelopmentArrangementContractualPaymentPeriod" format="ixt-sec:duryear" id="f-466">10</ix:nonNumeric> years after the first payment date and may total up to <ix:nonFraction unitRef="number" contextRef="ie5deb40f57714a11a917ea127c6f7c9f_D20130523-20130523" decimals="2" name="nexi:ResearchAndDevelopmentArrangementContractualPaymentPercentage" scale="-2" id="f-467">200</ix:nonFraction>% of the total grant amount. The end date of the agreement is defined as January&#160;31, 2024, or when any and all repayments due to MBC have been made. If the Company does not earn any revenue, the grant does not need to be repaid. Through December&#160;31, 2022, <ix:nonFraction unitRef="usd" contextRef="i64dedfdb14784525a0d5de1ec201e691_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-468">no</ix:nonFraction> revenue has been recorded, therefore, <ix:nonFraction unitRef="usd" contextRef="ie3294ba19efb4f899898ab09f55e6853_I20221231" decimals="0" name="nexi:ResearchAndDevelopmentArrangementContractToPerformForOthersLiability" format="ixt:fixed-zero" scale="0" id="f-469">no</ix:nonFraction> payments to MBC are due.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Johns Hopkins University Exclusive License Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into an Exclusive License Agreement with Johns Hopkins University (&#8220;JHU&#8221;) effective June 2011, which was amended and restated in January 2017, referred to as the A&amp;R JHU License Agreement, under which there are license fees, royalties, and milestone payments. As part of the agreement, the Company acquired a perpetual, exclusive license from JHU covering its invention related to Antigen Specific T cells.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JHU was also entitled to milestone fees of $<ix:nonFraction unitRef="usd" contextRef="i6719abe720c5406d8c6c8df3e56df15a_D20170101-20170101" decimals="0" name="nexi:MilestoneFees" format="ixt:num-dot-decimal" scale="0" id="f-470">75,000</ix:nonFraction> in connection with clinical trial milestones. For the first licensed product or licensed service in the therapeutic field, the Company may be required to pay JHU additional aggregate milestone fees of $<ix:nonFraction unitRef="usd" contextRef="id205558188da4f4faaf0ec195c63003f_D20170101-20170101" decimals="-5" name="nexi:MilestoneFees" format="ixt:num-dot-decimal" scale="6" id="f-471">1.6</ix:nonFraction> million for clinical and regulatory milestone fees. The Company may be required to pay JHU reduced milestone fees for the second and third licensed products or licensed services in the therapeutic field in connection with clinical and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. Commitments and Contingencies (continued)</span></div></div><ix:continuation id="i72e0f175dd01422ab7392e8f55623072"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory milestones. In the diagnostic field, the Company may be required to pay JHU aggregate milestone fees of $<ix:nonFraction unitRef="usd" contextRef="i2c23fd7809674603b59c0f27fb6a073b_D20170101-20170101" decimals="-5" name="nexi:MilestoneFees" scale="6" id="f-472">0.4</ix:nonFraction> million for the first licensed product or licensed service and reduced milestone fees for the second and third licensed products or licensed services in connection with regulatory and commercial milestones. The Company may be required to pay JHU aggregate milestone fees of $<ix:nonFraction unitRef="usd" contextRef="ia6fc5f4226364570a5d62f606626c0ab_D20170101-20170101" decimals="0" name="nexi:MilestoneFees" format="ixt:num-dot-decimal" scale="0" id="f-473">100,000</ix:nonFraction> for commercial milestones for the first licensed product or licensed service in the&#160;non-clinical&#160;field. In the aggregate, the Company may be required to pay JHU additional milestone fees of up to $<ix:nonFraction unitRef="usd" contextRef="i432594ce07a346698a0597e5adf392f0_D20170101-20170101" decimals="-5" name="nexi:MilestoneFees" format="ixt:num-dot-decimal" scale="6" id="f-474">4.2</ix:nonFraction> million for all clinical, regulatory and commercial milestones for all licensed products or licensed services in the therapeutic field, the diagnostic field and the non-clinical field. The Company may also be required to pay royalties in the low to upper&#160;single&#160;digits on net sales of licensed services in therapeutic products, diagnostic products and&#160;non-clinical&#160;products. The Company is required to make minimum annual royalty payments of $<ix:nonFraction unitRef="usd" contextRef="i2735225fb3054df286cd15e9d84e3203_D20220101-20221231" decimals="0" name="nexi:MinimumAnnualRoyaltyPayments" format="ixt:num-dot-decimal" scale="0" id="f-475">100,000</ix:nonFraction> to JHU under the A&amp;R JHU License Agreement, which started in the low five figures in the first year of the agreement and increased to $<ix:nonFraction unitRef="usd" contextRef="i2735225fb3054df286cd15e9d84e3203_D20220101-20221231" decimals="0" name="nexi:MinimumAnnualRoyaltyPayments" format="ixt:num-dot-decimal" scale="0" id="f-476">100,000</ix:nonFraction> in the third year and for each subsequent year of the agreement. The Company may also be required to pay JHU a low double digit percentage, not to exceed <ix:nonFraction unitRef="number" contextRef="i2735225fb3054df286cd15e9d84e3203_D20220101-20221231" decimals="2" name="nexi:SublicenseConsiderationPaymentPercentMaximum" scale="-2" id="f-477">15</ix:nonFraction>%, of any&#160;non-royalty&#160;sublicense consideration the Company receives.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will record a liability when such events become probable. The Company has not reached any of the milestones or transacted its first commercial sale as of December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must make minimum royalty payments, which began upon the fourth anniversary of the agreement and upon every anniversary thereafter during the term of the agreement, which offset future royalties per above owed to JHU. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred $<ix:nonFraction unitRef="usd" contextRef="ib3562b2fa26c44aba06d2f7770d6feb4_I20221231" decimals="0" name="nexi:CumulativeMinimumRoyalties" format="ixt:num-dot-decimal" scale="0" id="f-478">525,000</ix:nonFraction> in cumulative minimum royalties from inception. Future annual minimum royalties consist of $<ix:nonFraction unitRef="usd" contextRef="i2735225fb3054df286cd15e9d84e3203_D20220101-20221231" decimals="0" name="nexi:MinimumAnnualRoyaltyPayments" format="ixt:num-dot-decimal" scale="0" id="f-479">100,000</ix:nonFraction> due each year during the remaining term of the agreement. The Company records milestones, royalties and minimum royalties at the time when payments become probable. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="ia0e4cc0109264b539acd8b2cbc12a65b_D20210101-20211231" decimals="0" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="0" id="f-480"><ix:nonFraction unitRef="usd" contextRef="icd3d3cf5f9f6420abe32fd8826ce546d_D20220101-20221231" decimals="0" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="0" id="f-481">100,000</ix:nonFraction></ix:nonFraction> related to minimum royalties owed in the years ended December&#160;31, 2022 and 2021 and is included in research and development expenses on the accompanying statement of operations. The Company has accrued royalties of $<ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-482"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-483">50,000</ix:nonFraction></ix:nonFraction> as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;23, 2020, the Company applied for an unsecured $<ix:nonFraction unitRef="usd" contextRef="i073d07654a3240e784df7ae6097d2764_I20200423" decimals="0" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-484">843,619</ix:nonFraction> loan under the Paycheck Protection Program (the &#8220;PPP Loan&#8221;). The Paycheck Protection Program (or &#8220;PPP&#8221;) was established under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) and is administered by the U.S. Small Business Administration (&#8220;SBA&#8221;). On May&#160;1, 2020, the PPP loan was approved and funded. The Company entered into a promissory note of $<ix:nonFraction unitRef="usd" contextRef="i6e206dd327124b4b8af59ef1f3ab5579_I20200501" decimals="0" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-485">843,619</ix:nonFraction>, which is recorded within other current liabilities in the accompanying balance sheet. The Company treats the PPP loan as debt under ASC 470. The use of loan proceeds must be for payroll costs, payment of interest on covered mortgage obligations, rent and utility costs over either an eight-week or&#160;24-week&#160;period, at the Company&#8217;s option.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company submitted the PPP Loan forgiveness application to the SBA in March 2021 and received full forgiveness of the $<ix:nonFraction unitRef="usd" contextRef="i64dc0ef29e704fa49df23a5b74b93453_D20210701-20210731" decimals="0" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="0" id="f-486">843,619</ix:nonFraction> PPP Loan in July 2021. The Company did not carry a PPP loan balance as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. As of December&#160;31, 2022 and 2021, the Company was not involved in any material legal proceedings.</span></div></ix:continuation><div id="i5091247d182148eaaadd80685b94df97_160"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="f-487" continuedAt="i7550a855959e47e3981bb85a610fe971" escape="true">Convertible Notes</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7550a855959e47e3981bb85a610fe971" continuedAt="i08d6da158d77447194ff56f1532ac98b">In April 2020, the Company entered into Convertible Note Purchase Agreement (&#8220;Agreement&#8221;) for the sale of up to  $<ix:nonFraction unitRef="usd" contextRef="ie2aff3fdd4ae40b29ed8bab59335a89b_I20200430" decimals="0" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-488">15,000,000</ix:nonFraction> of convertible promissory notes with <ix:nonFraction unitRef="number" contextRef="ie2aff3fdd4ae40b29ed8bab59335a89b_I20200430" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-489">6</ix:nonFraction>% interest rate (&#8220;Convertible Notes&#8221;). The Agreement specified an initial closing date of April&#160;23, 2020 and allowed additional closings within <ix:nonNumeric contextRef="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430" name="nexi:DebtInstrumentAdditionalClosingLockInPeriod" format="ixt-sec:durday" id="f-490">90</ix:nonNumeric> days of the initial closing. The Convertible Notes were scheduled to mature on April&#160;23, 2021.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. Convertible Notes (continued)</span></div></div><ix:continuation id="i08d6da158d77447194ff56f1532ac98b"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Convertible Notes required a mandatory conversion upon certain qualified financing events (&#8220;Mandatory Conversion&#8221;) and allowed for conversion at the option of the holder upon certain&#160;non-qualified&#160;financing events (&#8220;Optional Conversion 1&#8221;). Upon Mandatory Conversion and Optional Conversion 1, the outstanding principal amount and all accrued and unpaid interest would have automatically converted into the Company&#8217;s preferred stock of the same series issued in such equity financing and will be equal to the number of preferred stock obtained by dividing (a)&#160;all principal and accrued but unpaid interest under such Convertible Note by (b)&#160;the price per share paid by the other purchasers of the preferred stock sold in such equity financing multiplied by <ix:nonFraction unitRef="number" contextRef="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430" decimals="2" name="nexi:DebtInstrumentConvertiblePricePercentage" scale="-2" id="f-491">80</ix:nonFraction>%.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Mandatory Conversion and Optional Conversion 1 did not occur by the maturity date, the outstanding principal amount plus all accrued and unpaid interest would be converted at the option of the holder into Company&#8217;s common stock at the price per share obtained by dividing $<ix:nonFraction unitRef="usd" contextRef="ie2aff3fdd4ae40b29ed8bab59335a89b_I20200430" decimals="-6" name="nexi:DebtInstrumentFullyDilutedCapitalization" format="ixt:num-dot-decimal" scale="6" id="f-492">85</ix:nonFraction> million by the Company&#8217;s fully-diluted capitalization (&#8220;Optional Conversion 2&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company (i)&#160;consummates a change in control or (ii)&#160;the Company&#8217;s common stock becomes publicly listed on a stock exchange, the outstanding principal amount plus all accrued and unpaid interest would be automatically converted into shares of the Company&#8217;s most senior series of capital stock outstanding at the time of such change in control or public listing, at a price equal to the lower of (a) <ix:nonFraction unitRef="number" contextRef="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="f-493">90</ix:nonFraction>% of the price per share paid by the purchasers of such stock in such a transaction and (b)&#160;the price per share obtained by dividing $<ix:nonFraction unitRef="usd" contextRef="ie2aff3fdd4ae40b29ed8bab59335a89b_I20200430" decimals="-6" name="nexi:DebtInstrumentRedemptionAmount" format="ixt:num-dot-decimal" scale="6" id="f-494">125</ix:nonFraction> million by the Company&#8217;s fully-diluted capitalization (&#8220;Change in Control&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement was amended in July 2020 to allow the sale of up to $<ix:nonFraction unitRef="usd" contextRef="ifb6c8b0ddc244a308e9bd3ecbb524199_I20200731" decimals="0" name="nexi:DebtInstrumentRedemptionAmount" format="ixt:num-dot-decimal" scale="0" id="f-495">50,000,000</ix:nonFraction> convertible notes and to allow for additional closings within <ix:nonNumeric contextRef="i225885d205f04fb9b33ee53d4cfb8f44_D20200701-20200731" name="nexi:DebtInstrumentAdditionalClosingLockInPeriod" format="ixt-sec:durday" id="f-496">150</ix:nonNumeric> days of the initial closing date. The Agreement was amended in September 2020 to allow for additional closings within <ix:nonNumeric contextRef="i8ff48a09a554472b8be106abefa1d461_D20200901-20200930" name="nexi:DebtInstrumentAdditionalClosingLockInPeriod" format="ixt-sec:durday" id="f-497">190</ix:nonNumeric> days of the initial closing date. In addition, the provisions of Mandatory Conversion and Optional Conversion 1 were amended to allow for conversion upon an equity financing at a price equal to the lower of (a) <ix:nonFraction unitRef="number" contextRef="i8ff48a09a554472b8be106abefa1d461_D20200901-20200930" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="f-498">80</ix:nonFraction>% of the price per share paid by the purchasers of such stock in such a transaction and (b)&#160;the price per share obtained by dividing $<ix:nonFraction unitRef="usd" contextRef="i873c597d2cf845d493f5de5873c03e05_I20200930" decimals="0" name="nexi:DebtInstrumentRedemptionAmount" format="ixt:num-dot-decimal" scale="0" id="f-499">125,000,000</ix:nonFraction> by the Company&#8217;s fully-diluted capitalization. The Company evaluated the amendments and concluded that the amendments represented a debt modification.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Agreement was further amended to allow additional closings through December&#160;31, 2020, and in January 2021 it was amended again to allow closings through January 31, 2021. In January 2021, the Company issued convertible notes with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="idf7c9ea8fe8d4438993e95ae15b3887d_D20210101-20210131" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="f-500">9.0</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Convertible Notes and determined that the Mandatory Conversion feature, Optional Conversion 1 feature and Change in Control meet the definition of an embedded derivative liability that is required to be bifurcated from the host instrument and measured at fair value. The fair value of the derivative liability for the convertible notes issued in January 2021 was $<ix:nonFraction unitRef="usd" contextRef="ic8342e5909c548198f1f8f812c6ccc2a_D20220101-20221231" decimals="-5" name="nexi:FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance" scale="6" id="f-501">0.7</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company amortized the debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ic8342e5909c548198f1f8f812c6ccc2a_D20220101-20221231" decimals="-5" name="nexi:DebtIssuanceCosts" scale="6" id="f-502">0.3</ix:nonFraction> million and debt discount of $<ix:nonFraction unitRef="usd" contextRef="ic8342e5909c548198f1f8f812c6ccc2a_D20220101-20221231" decimals="-5" name="nexi:DebtDiscount" scale="6" id="f-503">4.2</ix:nonFraction> million, comprising of the initial value of the derivative liability of $<ix:nonFraction unitRef="usd" contextRef="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430" decimals="-5" name="nexi:FairValueOfDerivativeLiabilityOfConvertibleNotes" scale="6" id="f-504">2.0</ix:nonFraction> million and the BCF of $<ix:nonFraction unitRef="usd" contextRef="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430" decimals="-5" name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" scale="6" id="f-505">2.2</ix:nonFraction> million, prior to the adoption of ASU 2020-06, over the term of the Convertible Notes using the effective interest method. Upon adoption of this standard, the beneficial conversion feature was no longer separately accounted. As a result of applying the modified retrospective method, the Company recognized a transition adjustment of $<ix:nonFraction unitRef="usd" contextRef="i54b8bf4223dd408ba5dfb81b3157f859_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-506">0.7</ix:nonFraction> million recorded in accumulated deficit, a reduction of additional paid-in capital of $<ix:nonFraction unitRef="usd" contextRef="i869076cb5c1441619748ef3b03caf454_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-507">2.3</ix:nonFraction> million and an increase to the carrying value of the convertible notes of $<ix:nonFraction unitRef="usd" contextRef="i74ebc54878b1455ba9248d3203abce2c_I20211231" decimals="-5" name="us-gaap:ConvertibleNotesPayable" scale="6" id="f-508">1.5</ix:nonFraction> million on January 1, 2021. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt issuance costs and debt discount amortization expense for the years ended December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ibee929c3ceb949d69a3628128e96a111_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="f-509">0.6</ix:nonFraction> million  and is included in interest expense in the accompanying statements of operations. The interest expense at <ix:nonFraction unitRef="number" contextRef="i370d6d24e959405ba7d21d7a1ef23d52_I20211231" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-510">6</ix:nonFraction>% of the Convertible Notes&#8217; principal amount for the years ended December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ibee929c3ceb949d69a3628128e96a111_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-511">0.2</ix:nonFraction> million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed an IPO on February 11, 2021, which triggered the mandatory conversion of all the outstanding Convertible Notes plus accrued interest into <ix:nonFraction unitRef="shares" contextRef="ic87f7845ea6d43edb990474d68bfd9b9_D20210211-20210211" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-512">3,669,010</ix:nonFraction> shares of common stock (Note 11). Upon conversion of the Convertible Notes, the outstanding Convertible notes principal plus accrued interest thereon, net of unamortized debt discounts totaling $<ix:nonFraction unitRef="usd" contextRef="ic87f7845ea6d43edb990474d68bfd9b9_D20210211-20210211" decimals="-5" name="nexi:DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts" scale="6" id="f-513">30.3</ix:nonFraction> million was reclassified to stockholders&#8217; equity.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_163"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="nexi:RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" id="f-514" continuedAt="ia346c27ab8ca4279a23eb01717b9ddbb" escape="true">Series A Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit</ix:nonNumeric></span></div><ix:continuation id="ia346c27ab8ca4279a23eb01717b9ddbb"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2021, the Company completed its IPO, pursuant to which it issued and sold <ix:nonFraction unitRef="shares" contextRef="if353ba0711344094942f5e91286b8497_D20210211-20210211" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-515">7,441,650</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i26259b22e3b94e8c8e38c181c55cf7e8_I20210211" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-516">17.00</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6ab94587a7134bc29507a4735e3b4bb5_D20210211-20210211" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-517">114,551,315</ix:nonFraction>, after deducting underwriting discounts and commissions and other offering expenses. Upon the closing of the IPO, all of the <ix:nonFraction unitRef="shares" contextRef="ia325791ead244863998b1f8f312ad14c_I20210211" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-518">&#8212;</ix:nonFraction> outstanding shares of the Company&#8217;s Redeemable Convertible Preferred Stock automatically converted into <ix:nonFraction unitRef="shares" contextRef="ia325791ead244863998b1f8f312ad14c_I20210211" decimals="0" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-519">10,144,041</ix:nonFraction> shares of common stock after giving effect to the reverse stock split, and all of the outstanding convertible debt and accrued but unpaid interest thereon of $<ix:nonFraction unitRef="usd" contextRef="ic87f7845ea6d43edb990474d68bfd9b9_D20210211-20210211" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="0" id="f-520">31,272,183</ix:nonFraction> converted to <ix:nonFraction unitRef="shares" contextRef="ic87f7845ea6d43edb990474d68bfd9b9_D20210211-20210211" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-521">3,669,010</ix:nonFraction> shares of common stock. Upon completion of the offering on February 11, 2021, the Company&#8217;s authorized capital stock consists of <ix:nonFraction unitRef="shares" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-522"><ix:nonFraction unitRef="shares" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-523">250,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-524"><ix:nonFraction unitRef="usdPerShare" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-525">0.0001</ix:nonFraction></ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-526"><ix:nonFraction unitRef="shares" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-527">10,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i8f4fa39048644fd7896c3a33c09994df_I20210211" decimals="4" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-528">0.0001</ix:nonFraction> per share, all of which shares of preferred stock are undesignated.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, <ix:nonFraction unitRef="shares" contextRef="i77a57977aaa446e78a28a3a70e9a899c_I20210131" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-529">145,000</ix:nonFraction> warrants were exercised at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i85c929ab7b9c4820bc56af8cd2f474ab_I20210131" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-530">0.01</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5835f11998cf40f68d148e445724cb8b_D20210101-20210131" decimals="0" name="nexi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-531"><ix:nonFraction unitRef="shares" contextRef="i77a57977aaa446e78a28a3a70e9a899c_I20210131" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-532">145,000</ix:nonFraction></ix:nonFraction> shares of Series A redeemable convertible stock were issued and then converted into common stock upon the closing of the IPO. The remaining outstanding warrants outstanding as of December 31, 2020 were exercised and settled in January 2021 with <ix:nonFraction unitRef="shares" contextRef="i85c929ab7b9c4820bc56af8cd2f474ab_I20210131" decimals="0" name="nexi:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-533">2,896</ix:nonFraction> shares of common stock issued in a cashless exercise.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and BTIG, LLC (together, the &#8220;Agents&#8221;), pursuant to which the Company may offer and sell shares of its common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id09449ea526a48e0b9e20fb9696883ab_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-534">0.0001</ix:nonFraction> par value per share, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="ia81c0f51abc5407c9f1bea1bc4bfb1a9_D20220601-20220630" decimals="-5" name="nexi:SaleOfStockAggregateOfferingApproval" scale="6" id="f-535">50.0</ix:nonFraction> million (the "Shares") from time to time through the Agents (the "Offering"). Subject to the terms and conditions of the Sales Agreement, any such sales made through the Agents can be made, based upon the Company's instructions, by methods deemed an &#8220;at-the-market" offering as defined in Rule 415(a)(4) promulgated under the Securities Act. The Company agreed to pay the Agents a commission of <ix:nonFraction unitRef="number" contextRef="id09449ea526a48e0b9e20fb9696883ab_I20220630" decimals="4" name="nexi:SaleOfStockCommissionPercentage" scale="-2" id="f-536">3.0</ix:nonFraction>% of the gross proceeds of any sales of shares sold pursuant to the Sales Agreement. During the year ended December&#160;31, 2022, the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i606c2339afea414788b70bdaefc16503_D20220101-20221231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-537">3,184,900</ix:nonFraction> shares through our &#8220;at-the-market" offering facility resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i606c2339afea414788b70bdaefc16503_D20220101-20221231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-538">5.1</ix:nonFraction> million.</span></div></ix:continuation><div id="i5091247d182148eaaadd80685b94df97_166"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-539" continuedAt="i1b60d4113dd94b9ba27fa884551d0132" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i1b60d4113dd94b9ba27fa884551d0132" continuedAt="ib7d1e0fb9dca4c8b8b4154143543c7fc"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During January 2017, the Company adopted the 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;), which provides for granting of restricted stock, options to purchase shares of common stock and other awards to employees, directors and consultants. In March 2017, the Company amended the 2017 Plan to increase the number of available shares to <ix:nonFraction unitRef="shares" contextRef="ie9d3dab50aea4a7f8d84d00874e49e4e_I20170301" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-540">660,838</ix:nonFraction>. In September 2018, the Company adopted the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) which provides for granting of restricted stock, options to purchase shares of common stock, and other awards to employees, directors and consultants, and reserved <ix:nonFraction unitRef="shares" contextRef="i275a48529a1a4c3885fad3563305e566_I20180930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-541">1,741,770</ix:nonFraction> shares for this purpose. The 2018 Plan was amended in July 2018 to increase the number of available shares to <ix:nonFraction unitRef="shares" contextRef="i30203c7ac84149eda4226a53b00d5520_I20180731" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-542">1,809,143</ix:nonFraction>. In February 2021, the Company adopted the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;) and reserved <ix:nonFraction unitRef="shares" contextRef="i8ab04e02de714324a031d507a830df05_I20210228" decimals="0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-543">2,757,556</ix:nonFraction> shares under the plan. No further shares will be issued under the 2017 and 2018 plans. In addition, the 2021 Plan contains an &#8220;evergreen&#8221; provision, which allows for an annual increase in the number of shares of our common stock available for issuance under the 2021 Plan on the first day of each calendar year beginning in calendar year 2022. The annual increase in the number of shares shall be equal to the lower of (i) <ix:nonFraction unitRef="number" contextRef="ibf9d66ae0c7a46f68c98ad662da4fd70_D20210101-20211231" decimals="2" name="nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock" scale="-2" id="f-544">5.0</ix:nonFraction>% of the number of shares of our common stock outstanding on the date of the applicable increase or (ii) a lesser amount determined by our board of directors. Following the annual increase in the number of shares of our common stock available for issuance under the 2021 Plan, there are <ix:nonFraction unitRef="shares" contextRef="if4928ff38b944471a2f040e95d09d31b_I20230301" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-545">1,439,424</ix:nonFraction> shares available for issuance under the 2021 plan as of  March 1, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of options to be granted under the 2021 Plan, the option exercise prices, and other terms of the options are determined by the Board of Directors in accordance with the terms of the 2021 Plan. Generally, stock options are granted at fair value, become exercisable over a period of <span style="-sec-ix-hidden:f-546">one</span> to <ix:nonNumeric contextRef="ief18b08960f540d7b60fdafa452c819e_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-547">four years</ix:nonNumeric>, expire in <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-548">ten years</ix:nonNumeric> or less and are subject to the employee&#8217;s continued employment. Restricted stock units awarded in November 2022 vest after an <ix:nonNumeric contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="f-549">18</ix:nonNumeric>-month service period. No restricted stock units were awarded in the year ended December 31, 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. Stock-Based Compensation (continued)</span></div></div><ix:continuation id="ib7d1e0fb9dca4c8b8b4154143543c7fc" continuedAt="i850d8e1677cf4c868d1f7f282d0992a6"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-550" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was recorded in the following financial statement line items within the statement of operations for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02e219dda5744914b465aec9d485e6e6_D20220101-20221231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-551">3,812,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b3cec944184d4f8af71eef16bd69a0_D20210101-20211231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-552">2,918,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b304823751d4c239cbf3f21b62ab9a6_D20220101-20221231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-553">2,057,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea423a341804ae2b054938793d90352_D20210101-20211231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-554">3,061,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-555">5,870,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-556">5,979,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-557" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of option activity under the Company&#8217;s Stock Option Plans:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January&#160;1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-558">3,305,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-559">9.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-560">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-561">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-562">1,628,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-563">3.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-564">362,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-565">2.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-566">255,701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" name="nexi:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" scale="0" id="f-567">8.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-568">349,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-569">15.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-570">3,965,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-571">7.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-572">8.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="6" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-574">3,965,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-575">7.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-576">8.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="6" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-578">1,852,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-579">8.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-580">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="6" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares unvested as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-582">2,113,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-583">6.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-584">9.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="6" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of the options granted during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-586">2.42</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-587">11.16</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-588" continuedAt="ib3aa71899b064f40ad35dd2c4c7a7a7c" escape="true">The options were valued using the Black-Scholes option-pricing model for the years ended December&#160;31, 2022 and 2021 with the following assumptions:</ix:nonNumeric></span></div><div style="margin-top:12pt"><ix:continuation id="ib3aa71899b064f40ad35dd2c4c7a7a7c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-589">78.6</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-590">83.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-591">78.7</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-592">81.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-593">1.5</ix:nonFraction>%&#160;to&#160;<ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-594">3.80</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-595">0.5</ix:nonFraction>%&#160;to&#160;<ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-596">1.40</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-597">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-598">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8cde262665d140a4aa955aed31f5920a_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-599">5.5</ix:nonNumeric>&#160;to&#160;<ix:nonNumeric contextRef="ief18b08960f540d7b60fdafa452c819e_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-600">6.1</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3fa6115f303b4a3fbf9b708fedfe989b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-601">5.4</ix:nonNumeric>&#160;to&#160;<ix:nonNumeric contextRef="idda403dc84674bf3b38163cc09604d2e_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-602">6.1</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of stock options vested during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-603">9.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="f-604">1.4</ix:nonFraction> million, respectively. The intrinsic value of stock options exercised for the years ended December&#160;31, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-605">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-606">2.1</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-607">8.0</ix:nonFraction> million of total unrecognized compensation expense related to unvested options that will be recognized over a weighted average period of <ix:nonNumeric contextRef="i05746f41db1943c1bec2cd0749ac1f49_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-608">2.4</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A restricted stock unit (&#8220;RSU&#8221;) represents the right to receive one of the Company&#8217;s common stock upon vesting of the RSU. The fair value of each RSU is based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. Stock-Based Compensation (continued)</span></div></div><ix:continuation id="i850d8e1677cf4c868d1f7f282d0992a6"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="f-609" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the 2021 Plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.233%"><tr><td style="width:1.0%"></td><td style="width:63.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.881%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of restricted units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c755e4c19e14dd3b1b1970081b2809e_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-610">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c755e4c19e14dd3b1b1970081b2809e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-612">1,558,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-613">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding  as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c1c88b03e284ba5a4f2d5abe7153e3f_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-618">1,558,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c1c88b03e284ba5a4f2d5abe7153e3f_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-619">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i2c1c88b03e284ba5a4f2d5abe7153e3f_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-620">0.7</ix:nonFraction> million of unrecognized compensation expense related to unvested RSUs, which are expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-621">1.4</ix:nonNumeric> years.</span></div></ix:continuation><div id="i5091247d182148eaaadd80685b94df97_169"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-622" continuedAt="icb889a840d9a422180c1373c1396da02" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="icb889a840d9a422180c1373c1396da02" continuedAt="ie99dbb055c8f406c85046ffc4e430145"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-623" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s provision for income taxes consists of the following for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax provision:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax benefit:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-630">12,339,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-631">10,606,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-632">7,370,113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-633">3,291,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-634">4,969,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="f-635">13,898,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" format="ixt:num-dot-decimal" scale="0" id="f-636">4,969,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" format="ixt:num-dot-decimal" scale="0" id="f-637">13,898,469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision (benefit) for income taxes</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-640" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory U.S. income tax rate to the effective income tax rate as of December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal statutory rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-641">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-642">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-643">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-644">6.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-645">0.58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-646">0.13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-647">0.02</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-648">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-649">12.61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="-2" id="f-650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-651">7.96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-652">27.41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-653">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-654">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. Income Taxes (continued)</span></div></div><ix:continuation id="ie99dbb055c8f406c85046ffc4e430145"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-655" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-656">28,477,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="f-657">31,758,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="0" id="f-658">575,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="0" id="f-659">701,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-660">1,913,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="f-661">1,445,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="0" id="f-662">291,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="0" id="f-663">291,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-664">7,838,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="0" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="nexi:DeferredTaxAssetsOperatingLeases" format="ixt:num-dot-decimal" scale="0" id="f-666">216,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="nexi:DeferredTaxAssetsOperatingLeases" format="ixt:fixed-zero" scale="0" id="f-667">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="f-668">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="f-669">52,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-670">39,316,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="f-671">34,249,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-672">38,857,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="f-673">33,886,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-674">458,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-675">363,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="0" id="f-676">204,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:fixed-zero" scale="0" id="f-677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-678">253,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-679">363,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-680">458,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-681">363,427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="0" id="f-682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="0" id="f-683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company had net operating loss (NOL) carryforwards for income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="iff7fdf8fd69c490e8f4f46d8e7a75f7c_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-684">135.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3333ea4033604cef87ae7f2a775a3bca_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-685">115.4</ix:nonFraction> million, respectively, which are available to offset future federal taxable income, if any. Approximately $<ix:nonFraction unitRef="usd" contextRef="iff7fdf8fd69c490e8f4f46d8e7a75f7c_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-686">10.5</ix:nonFraction> million of the federal NOL was generated prior to 2018 and will be expiring in increments through 2037 beginning in 2035, while the remaining $<ix:nonFraction unitRef="usd" contextRef="iff7fdf8fd69c490e8f4f46d8e7a75f7c_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-687">124.7</ix:nonFraction> million will be carried forward indefinitely. The state NOL will expire in increments through 2037, beginning in 2035. The federal research and development tax credit carryforwards, if not utilized, will expire beginning in 2037.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Section&#160;382 of the Internal Revenue Code imposes substantial restrictions on the utilization of net operating losses and Section 383 of the Internal Revenue Code imposes restrictions on the utilization of tax credits in the event of a corporations&#8217; ownership change. The Company believes that the future use of net operating losses and tax credits presented above may be limited as a result of past ownership changes and a formal study has not yet been completed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions more likely than not of being sustained. At December&#160;31, 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="f-688">no</ix:nonFraction> gross unrecognized tax benefits and did <ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="6" id="f-689">not</ix:nonFraction> recognize any interest or penalties related to uncertain tax positions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December&#160;31, 2022, the Company provided a <ix:nonFraction unitRef="number" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="2" name="nexi:DeferredTaxAssetValuationAllowancePercent" scale="-2" id="f-690">100</ix:nonFraction>% valuation allowance on its net deferred tax assets because realization of any future tax benefit cannot be reasonably assured. The Company&#8217;s valuation allowance increased due to the pre-tax losses generated in the current year.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income taxation by both federal and state taxing authorities. Income tax returns for the years ended December 31, 2021, 2020, and 2019 are open to audit by federal and state taxing authorities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Cuts and Jobs Act of 2017, research and development costs are no longer fully deductible and are required to be capitalized and amortized for US Tax purposes over five or fifteen years effective January 1, 2022. The mandatory capitalization requirement increased our deferred tax assets as of December 31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i5091247d182148eaaadd80685b94df97_172"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2020 and 2019</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-691" continuedAt="ib22c9ec9cdd14a57a87889891c9d3839" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="ib22c9ec9cdd14a57a87889891c9d3839" continuedAt="ie510b70a685643519880bc8bc02c2828"><div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space and laboratory space. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company does not recognize right-of-use assets or lease liabilities for leases determined to have a term of 12 months or less. Options to extend a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the operating lease liability is recorded at the present value of future lease payments over the expected remaining lease term using the discount rate implicit in the lease, if it is readily determinable, or the Company&#8217;s incremental borrowing rate. The right-of-use asset is measured as the lease liability and adjusted for prepaid rent, initial direct costs, and incentives. The Company's leases contain variable non-lease components such as maintenance, taxes, insurance, and similar costs for the spaces it occupies. For new and amended leases beginning in 2022 and after, the Company has elected the practical expedient not to separate these non-lease components of leases for classes of all underlying assets and instead account for them as a single lease component for all leases. The Company recognizes the net fixed payments of operating leases on a straight-line basis over the lease term. Variable executory costs, as it relates to net leases, are to be excluded from the calculation of the lease liability and the Company expenses the variable lease payments in the period in which it incurs the obligation to pay such variable amounts and will be included in variable lease costs in the leases footnote disclosure.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease payments are not included in the Company's calculation of its right-of-use assets or lease liabilities. Variable lease costs were immaterial for the year ended December&#160;31, 2022. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="f-692" continuedAt="idc8e5741023542c1bc9c0cf322362340" escape="true">The components of lease cost under ASC 842 for the year ended December&#160;31, 2022 are as follows:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="idc8e5741023542c1bc9c0cf322362340"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:27.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline">Lease costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Statement of Operations Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses: research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02e219dda5744914b465aec9d485e6e6_D20220101-20221231" decimals="0" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-693">379,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses: general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b304823751d4c239cbf3f21b62ab9a6_D20220101-20221231" decimals="0" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-694">207,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-695">586,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="f-696" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information and weighted average remaining lease term and discount rate related to leases were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:69.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline">Other information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" decimals="0" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="0" id="f-697">584,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term &#8212; operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-698">1.8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate &#8212; operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-699">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-700" continuedAt="i6de0e95ff6eb476bb512133e16e0f8a0" escape="true">Future fixed lease payments for operating leases in effect as of December&#160;31, 2022, are payable as follows:</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i5091247d182148eaaadd80685b94df97_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NexImmune, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. Leases (continued)</span></div></div><ix:continuation id="ie510b70a685643519880bc8bc02c2828"><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i6de0e95ff6eb476bb512133e16e0f8a0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:69.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Maturity of lease liabilities for the years ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-701">617,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-702">469,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:fixed-zero" scale="0" id="f-703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="0" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="0" id="f-705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="0" id="f-706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="f-707">1,087,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="f-708">63,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-709">1,024,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the year ended December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="f-710">0.4</ix:nonFraction> million in accordance with ASC 840.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i5091247d182148eaaadd80685b94df97_175"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-711" continuedAt="i01a4c80a0a624b019fe045e1e1ac669c" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i01a4c80a0a624b019fe045e1e1ac669c"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 16, 2022, the Company and Zephyr AI, Inc. (&#8220;Zephyr&#8221;) entered into a Joint Research Agreement (the &#8220;JRA&#8221;) focused on the joint collaboration, identification and validation of certain targets in order to facilitate further research, development and potential commercialization of immunotherapies. Zephyr is owned by a holding company with multiple Board members from the Company. The JRA term is two years unless mutually extended.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the JRA, Zephyr will identify suitable antigens or combinations thereof for validation and testing by NexImmune. The Joint Steering Committee (the &#8220;JSC&#8221;) provided for by the JRA will then determine which identified candidates shall be subject to further analysis. NexImmune will validate which, if any, of the identified antigens are suitable for T-cell engagement and killing function (the &#8220;Final Candidates&#8221;). The JSC will make a good-faith determination as to whether the data supports the further IND-targeted development by NexImmune of any of the Final Candidates. The Company and Zephyr will jointly own any Final Candidates, including the intellectual property related thereto. Each of the Company and Zephyr shall be responsible for payment of their own respective costs and expenses in connection with the performance of their respective obligations under the JRA. If a Final Candidate is to be further developed, then the Company and Zephyr shall engage in good-faith negotiations to agree on the terms and conditions of an agreement with respect to the further development and commercialization of such Final Candidate. If such an agreement is not executed within the prescribed negotiation period, then neither the Company nor Zephyr may further develop such Final Candidate. The expenses related to the JRA for the year ended December&#160;31, 2022 were not material.</span></div></ix:continuation><div id="i5091247d182148eaaadd80685b94df97_178"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="f-712" continuedAt="i3b1348b8d3824581ab2807d006eedd46" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i3b1348b8d3824581ab2807d006eedd46" continuedAt="ia8ec5e54ab814fc7aacb74a87bf0112e">On March 22, 2023, in order to retain and motivate employees and other key contributors of the Company, the board of directors approved a one-time stock option repricing (the &#8220;Option Repricing&#8221;). Pursuant to the Option Repricing, the exercise price of all of the below stock options to purchase shares of the Company&#8217;s common stock previously granted under our 2017 Equity Incentive Plan, 2018 Equity Incentive Plan and 2021 Equity Incentive Plan (the &#8220;Repriced Options&#8221;) will be amended as of April 4, 2023 (the &#8220;Effective Date&#8221;) to reduce the exercise prices of such options to a price equal to or greater than the closing price per share of the Company&#8217;s common stock on The Nasdaq Stock Market on the Effective Date (the &#8220;Nasdaq </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia8ec5e54ab814fc7aacb74a87bf0112e"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Market Price&#8221;), on the terms described below; provided, however, that if the closing price per share on the Effective Date is less than $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b6232ae6cb64482b9ec1943b0fe3126_I20230322" decimals="2" name="nexi:ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold" scale="0" id="f-713">0.40</ix:nonFraction>, the Nasdaq Market Price will be deemed to be $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b6232ae6cb64482b9ec1943b0fe3126_I20230322" decimals="2" name="nexi:ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold" scale="0" id="f-714">0.40</ix:nonFraction> for purposes of the Option Repricing:</span></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.567%"><tr><td style="width:1.0%"></td><td style="width:32.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Repriced Options</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Terms of Repriced Options vested or vesting within six months following the Effective Date </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Terms of Repriced Options vesting more than six months following the Effective Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All options held by employees other than our executive officers, in good standing on the Effective Date</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to <ix:nonFraction unitRef="number" contextRef="ie2d06934bf864579a4979bf7aa1310c1_I20230322" decimals="2" name="nexi:ShareBasedPaymentArrangementOptionRepricingMultiple" scale="0" id="f-715">2.5</ix:nonFraction> times the Nasdaq Market Price </span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to the Nasdaq Market Price</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All options held by our current executive officers and <ix:nonFraction unitRef="shares" contextRef="i7c4097a670b849ad990fb5d2224c365b_I20230322" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-716">100,000</ix:nonFraction> options held by Jerome Zeldis, our former EVP and Head of Research &amp; Development</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to <ix:nonFraction unitRef="number" contextRef="i3d28adc4141b4bbfb5dd66693b958745_I20230322" decimals="2" name="nexi:ShareBasedPaymentArrangementOptionRepricingMultiple" scale="0" id="f-717">3.0</ix:nonFraction> times the Nasdaq Market Price</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to <ix:nonFraction unitRef="number" contextRef="id386af48387549ec98b66a7ea05efd78_I20230322" decimals="2" name="nexi:ShareBasedPaymentArrangementOptionRepricingMultiple" scale="0" id="f-718">2.0</ix:nonFraction> times the Nasdaq Market Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All options held by our directors</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to <ix:nonFraction unitRef="number" contextRef="i4ea14e11723c4f1f804456e484f29855_I20230322" decimals="2" name="nexi:ShareBasedPaymentArrangementOptionRepricingMultiple" scale="0" id="f-719">4.0</ix:nonFraction> times the Nasdaq Market Price</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to <ix:nonFraction unitRef="number" contextRef="i0692d5e0603d41138cf06daaf012d2ef_I20230322" decimals="2" name="nexi:ShareBasedPaymentArrangementOptionRepricingMultiple" scale="0" id="f-720">3.0</ix:nonFraction> times the Nasdaq Market Price</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On March 23, 2023, Jerome Zeldis, M.D., Ph.D., Executive Vice President of Research and Development, entered into a Consulting Agreement with the Company (the &#8220;Consulting Agreement&#8221;) effective as of March 31, 2023 (the &#8220;Transition Date&#8221;).  Pursuant to the Consulting Agreement and effective as of the Transition Date, the exiting Employment Agreement, dated January 4, 2021, by and between the Company and Dr. Zeldis is terminated, Dr. Zeldis will have resigned from the Company, and Dr. Zeldis will transition to providing consulting and advisory services to the Company for a period ending on March 31, 2024 (the &#8220;Consulting Period&#8221;).  Pursuant to the terms of the Consulting Agreement, in consideration for, among other things, his compliance with certain restrictive covenants, including customary non-compete and non-solicitation covenants, and a typical release of claims, Dr. Zeldis will be paid $<ix:nonFraction unitRef="usd" contextRef="ia3e2d6cfd7a944f3927adf427e2f02ea_I20230322" decimals="2" name="nexi:RelatedPartyTransactionHourlyRate" scale="0" id="f-721">200</ix:nonFraction> per hour for services provided to the Company and vested options to purchase <ix:nonFraction unitRef="shares" contextRef="i7c4097a670b849ad990fb5d2224c365b_I20230322" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-722">100,000</ix:nonFraction> shares of common stock of the Company held by Dr. Zeldis (a portion of the grant received by Dr. Zeldis on February 11, 2021) are eligible to participate in the Option Repricing (as defined above), with the exercise price for such options reduced to the level set for executive officers.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7 2
<SEQUENCE>2
<FILENAME>nexi-20221231x10xkxex1072.htm
<DESCRIPTION>EX-10.7 2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i833c623b5cc844ea91859ef33ae3bf57_1"></div><div style="min-height:61.92pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONSULTING AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Consulting Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), effective as of April 1, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), is entered by and between NexImmune, Inc., a Delaware corporation with its principal place of business at 9119 Gaither Road, Gaithersburg, Maryland 20877 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">NexImmune</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and Jerome Zeldis, M.D., Ph.D, an individual (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Consultant was previously employed by the Company under the Employment Agreement with the Company, dated January 4, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Consultant resigned employment with the Company effective as of March 31, 2023 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Resignation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the Employment Agreement was terminated effective as of the Resignation Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Consultant has agreed to perform the Services (as defined herein) for NexImmune.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, for and in consideration of the mutual promises and covenants herein, and other good and valuable consideration, the receipt and sufficiency of which hereby are acknowledged, the parties hereto agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Engagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  Subject to the terms and conditions of this Agreement, NexImmune engages Consultant to perform certain services as more fully described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  All Services will be performed in a competent fashion in accordance with applicable standards of the profession and all Services are subject to final approval by a representative of the NexImmune prior to payment.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; As compensation for the Services, NexImmune agrees to pay Consultant the amounts set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.   </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Developments and Deliverables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">Consultant acknowledges and agrees that as part of their engagement with NexImmune, Consultant is expected to make new contributions of value to NexImmune.  All work performed, formulations, formula(s), design(s), model(s), drawing(s), photograph(s), invention(s), ideas, concepts, discoveries, developments, know-how, trade secrets, techniques, methodologies, modifications, improvements, works of authorship, documentation, analyses, data, writings, transcripts, audio and video tapes, reports, records and other deliverables,  (and all intellectual property rights therein whether or not protectable under state, federal, or foreign patent, trademark, copyright, trade secret or similar laws), made, conceived, reduced to practice or authored by Consultant, either solely or jointly with others, prior to or during the performance of this Agreement or arising out of the Services or any other work performed by Consultant (including prior to this Agreement as an employee of NexImmune or otherwise) or with the use of information, materials, equipment, or facilities, or at the expense of NexImmune during any period in which Consultant provided services to NexImmune or its successor in business (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Developments and Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be promptly disclosed to NexImmune in writing. Developments and Inventions shall be the sole property of NexImmune.  Consultant hereby assigns to NexImmune, without the payment of additional compensation, the entire right, title, and interest (including, without limitation, intellectual property rights) for the entire world in and to all Developments and Inventions.  For the avoidance of doubt, all Developments and Inventions developed during Consultant&#8217;s employment with the NexImmune shall be the sole property of NexImmune. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Inventions, if any, patented or unpatented, which Consultant made prior to Consultant&#8217;s service with the Company are excluded from the scope of this Agreement. To preclude any possible uncertainty, Consultant has set forth on Exhibit B attached hereto a complete list of all inventions </font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that Consultant has, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of Consultant&#8217;s affiliation with the Company, that Consultant considers to be Consultant&#8217;s property or the property of third parties, and that Consultant wishes to have excluded from the scope of this Agreement (collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  If disclosure of any such Prior Invention would cause Consultant to violate any prior confidentiality agreement, Consultant understands that Consultant is not to list such Prior Inventions in Exhibit B but is only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason. A space is provided on Exhibit B for such purpose.  If no such disclosure is attached, Consultant represents that there are no Prior Inventions. To the extent Consultant incorporates any Prior Invention into any Developments and Inventions or the use of the Prior Invention is required for NexImmune&#8217;s manufacture, use or sale of the Developments and Inventions, Consultant hereby grants to NexImmune a royalty-free, worldwide, perpetual, irrevocable, non-exclusive license, with the right to sublicense, under the Prior Invention to manufacture, use, modify, reproduce and sell the Developments and Inventions and any products and services including, without limitation, any Developments and Inventions.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">Without additional compensation to Consultant, Consultant shall sign, execute, and acknowledge or cause to be signed, executed, and acknowledged, any and all documents and shall perform such acts as may be necessary, useful, or convenient for the purpose of securing to NexImmune or its nominees, patent, trademark, or copyright protection throughout the world upon all such Developments and Inventions.  NexImmune shall reimburse Consultant for any reasonable out-of-pocket expenses incurred by Consultant in connection with Consultant&#8217;s execution of such confirmatory documentation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Consultant acknowledges that NexImmune from time to time may have agreements with the other persons or entities or with the United States Government, or agencies thereof, which impose obligations or restrictions on NexImmune regarding inventions made during the course of work under such agreements or regarding the sensitive nature of such work (including but not limited to the use or assignment of or rights to such inventions). Consultant agrees to be bound by all such obligations and restrictions which are made known to Consultant and to take all action necessary to discharge the obligations of NexImmune under such agreements.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Confidential Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; Consultant has previously and will continue to have access to, or NexImmune has previously and will continue to disclose or otherwise make available to Consultant, certain proprietary or confidential information (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">NexImmune Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  By way of illustration, but not limitation, &#8220;NexImmune Information&#8221; includes&#58; (a) developments, trade secrets, work product, inventions, mask works, ideas, processes, formulas, source and object codes, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques, all Developments and Inventions&#59; (b) information regarding plans for research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers&#59; (c) information regarding the skills and compensation of employees and consultants of NexImmune, and the amounts invested by various investors&#59; and (d) confidential or propriety information received from third parties pursuant to a duty on NexImmune&#8217;s part to maintain the confidentiality of such information and use it only for certain limited purposes.  All NexImmune Information disclosed to Consultant or otherwise in Consultant&#8217;s possession shall be held in strict confidence, and shall not be disclosed by Consultant to any third party during the Term and thereafter&#59; provided, however, that this disclosure restriction shall lapse following the five (5) year anniversary of the termination of Consultant&#8217;s service, except with respect to (x) Developments and Inventions, in which case such restrictions shall apply indefinitely, and (y) NexImmune Information that qualifies that as a trade secret, in which case such restrictions shall continue to apply so long as such NexImmune Information qualifies as a trade secret. Consultant shall not use any NexImmune Information except for the limited purpose of performing the Services. All NexImmune Information, including all copies and derivation thereof, are and shall remain the sole </font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and exclusive property of NexImmune.  Upon request by NexImmune, Consultant shall return all NexImmune Information to NexImmune.  In the event Consultant is asked or subpoenaed by a court of law or governmental agency to provide NexImmune Information, Consultant shall promptly inform NexImmune and shall reasonably cooperate with NexImmune to obtain any and all protection that may be afforded such NexImmune Information, prior to disclosing it, if such disclosure is ultimately required.  </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Company Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consultant agrees and covenants that Consultant shall not remove or copy any computer programs, documents or other materials including NexImmune Information or otherwise pertaining to the business of NexImmune without the express written consent of NexImmune, who in all events shall be considered to be the owner and possessor of all such programs, documents, and materials. Consultant covenants and agrees that Consultant shall in no way utilize any such programs, documents, and materials or NexImmune Information in Consultant's possession for the gain or advantage of Consultant and&#47;or to the detriment of NexImmune.  Upon a termination of this Agreement, or at such earlier date as NexImmune may request, Consultant shall deliver to NexImmune all such programs, programs, documents, and materials (including all copies thereof) which are then in Consultant's possession or control.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">DTSA Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; Consultant&#160;is hereby notified in accordance with the Defend Trade Secrets Act of 2016 that Consultant&#160; will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If Consultant&#160;files a lawsuit for retaliation against NexImmune for reporting a suspected violation of law, Consultant&#160;may disclose the NexImmune's trade secrets to Consultant&#8217;s attorney and use the trade secret information in the court proceeding if Consultant&#160;files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Consultant agrees that during the period of Consultant&#8217;s engagement and for the one (1) year period after the date Consultant&#8217;s engagement ends for any reason, including but not limited to voluntary termination by Consultant or involuntary termination by the NexImmune, Consultant will not, as an officer, director, employee, consultant, owner, partner, or in any other capacity, either directly or through others, except on behalf of NexImmune&#58;</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.7pt">solicit, induce, encourage, or participate in soliciting, inducing, or encouraging any employee of NexImmune to terminate his or her relationship with NexImmune&#59;</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.65pt">hire, employ, or engage in business with or attempt to hire, employ, or engage in business with any person employed by NexImmune or who has left the employment of NexImmune within the preceding three (3) months of any such prohibited activity or discuss any potential employment or business association with such person, even if Consultant did not initiate the discussion or seek out the contact&#59;</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:1.6pt">solicit, induce or attempt to induce any Customer or Potential Customer, or any consultant or independent contractor with whom Consultant had direct or indirect contact during Consultant&#8217;s service with NexImmune or whose identity Consultant learned as a result of Consultant&#8217;s service with NexImmune, to terminate, diminish, or materially alter in a manner harmful to NexImmune its relationship with NexImmune. For clarity, Consultant shall be permitted to contact consultants and independent contractors of NexImmune so long as such contact is not intended to, and&#47;or does not result in, terminating, diminishing, or </font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">materially altering in a manner harmful to NexImmune, the relationship between NexImmune and such consultant or independent contractor&#59; or</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:2.2pt">solicit, perform, provide or attempt to perform or provide any Conflicting Services (as defined below) for a Customer or Potential Customer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties agree that for purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Customer or Potential Customer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; is any person or entity who or which, at any time during the one (1) year prior to the date Consultant&#8217;s engagement with NexImmune ends, (i) contracted for, was billed for, or received from NexImmune any product, service or process with which Consultant worked directly or indirectly during Consultant&#8217;s service for NexImmune or about which Consultant acquired NexImmune Information&#59; or (ii) was in contact with Consultant or in contact with any other employee, owner, or agent of NexImmune, of which contact Consultant was or should have been aware, concerning any product, service or process with which Consultant worked directly or indirectly during Consultant&#8217;s service with NexImmune or about which Consultant acquired NexImmune Information&#59; or (iii) was solicited by NexImmune in an effort in which Consultant was involved or of which Consultant was or should have been aware.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Consultant agrees that for the one (1) year period after the date Consultant&#8217;s engagement with NexImmune ends for any reason, including but not limited to voluntary termination by Consultant or involuntary termination by NexImmune, Consultant will not, directly or indirectly, as an officer, director, employee, consultant, owner, partner, or in any other capacity solicit, perform, or provide, or attempt to perform or provide Conflicting Services, nor will Consultant assist another person to solicit, perform or provide or attempt to perform or provide Conflicting Services. The parties agree that for purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Conflicting Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any product, service, or process or the research and development thereof, of any person or organization other than NexImmune that directly competes with a product, service, or process, including the research and development thereof, of NexImmune with which Consultant worked directly or indirectly during Consultant&#8217;s service with NexImmune or about which Consultant acquired NexImmune Information during Consultant&#8217;s relationship with NexImmune.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt;text-decoration:underline">Reasonableness of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.7pt">Consultant agrees that Consultant has read this entire Agreement and understands it.  Consultant agrees that this Agreement does not prevent Consultant from earning a living or pursuing Consultant&#8217;s career. Consultant agrees that the restrictions contained in this Agreement are reasonable, proper, and necessitated by NexImmune&#8217;s legitimate business interests.  Consultant represents and agrees that Consultant is entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.65pt">In the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, Consultant and NexImmune agree that the court shall read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law.</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:1.6pt">If the court declines to enforce this Agreement in the manner provided in Section 7(c), Consultant and NexImmune agree that this Agreement will be automatically modified to provide NexImmune with the maximum protection of its business interests allowed by law and Consultant agrees to be bound by this Agreement as modified.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Legal and Equitable Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.7pt">Consultant agrees that it may be impossible to assess the damages caused by Consultant&#8217;s violation of this Agreement or any of its terms.  Consultant agrees that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to the Company and the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach or threatened breach of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.65pt">Consultant agrees that if the Company is successful in whole or in part in any legal or equitable action against Consultant under this Agreement, the Company shall be entitled to payment of all costs, including reasonable attorney&#8217;s fees, from Consultant. </font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:1.6pt">In the event the Company enforces this Agreement through a court order, Consultant agrees that the restrictions of Sections 7(a) and (b) shall remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Independent Contractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; In all matters relating to this Agreement, Consultant shall be acting as an independent contractor and not an employee of NexImmune or any of its subsidiaries or affiliates. Consultant at no time shall hold itself out as an agent or affiliate of NexImmune or create any obligation, express or implied, on behalf of NexImmune for any purpose and shall have no authority to bind NexImmune to any obligation. Consultant further acknowledges that Consultant is liable for any and all federal, state, local, social security, unemployment and other taxes assessed on, against or in connection with the Services Fees to be paid hereunder, and that NexImmune will not withhold any amounts from such Service Fees. Consultant acknowledges that Consultant shall not have the right or entitlement, and hereby waives any right or entitlement (retrospectively or prospectively), to any of the pension, retirement or other benefit programs now or hereafter available to the NexImmune&#8217;s regular employees.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Non-Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consistent with the parties' intent that the relationship created by this Agreement be that of service recipient and independent contractor, Consultant shall have the right to perform services for others during the Term, provided that such performance is not rendered for a competitor of NexImmune. For the purposes of this Agreement, a &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#34; is defined as any company, partnership, business organization or other entity or individual that engages in the sale of, service of, or production of product(s) or services that are substantially the same or similar to those of, or offered by, NexImmune.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  Consultant represents and warrants to NexImmune that&#58; (a) he shall perform the Services with the degree of skill and the standard of care observed by nationally reputable firms performing the same or similar services&#59; (b) he has the requisite knowledge and expertise to provide the Services&#59; (c) he shall perform the Services in compliance with all applicable laws and regulations&#59; (c) all Services performed hereunder shall comply with the description of the Services approved by NexImmune&#59; (d) any qualifications, experience and expertise held by Consultant with respect to the Services so represented by Consultant to NexImmune are true and accurate&#59; (e) the Services performed hereunder, or any Developments and Inventions, or other  materials, software, documents or services provided therewith or utilized in the provision of Services, shall not violate or infringe the rights, other than patent rights, of any third parties&#59; (f) to the best of Consultant&#8217;s knowledge, the Services performed hereunder, or any Developments and Inventions, or other  materials, software, documents or services provided therewith or utilized in the provision of Services, shall not violate or infringe the patent rights of any third parties, and (g) Consultant&#8217;s service to NexImmune on the terms and conditions set forth herein and Consultant&#8217;s execution and performance of this Agreement do not constitute a breach or violation of any other agreement, obligation or understanding with any third party.</font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consultant shall indemnify, defend and hold harmless NexImmune and its directors, officers, employees and agents, from and against any and all claims, demands, suits, losses, damages, costs, and expenses (including without limitation reasonable attorney&#8217;s fees) which may arise or result from&#58; (a) claims against NexImmune for bodily injury or property damage caused by Consultant&#59; (b) any material breach by Consultant of its obligations under this Agreement, including without limitation its representation and warranties set forth in this Agreement&#59; and (c) Consultant&#8217;s negligence or willful misconduct.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each party will carry insurance in such amounts and types as may be <br>reasonably required by the other party and as appropriate to the activities of each party.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; Consultant shall not enter into a subcontract with respect to the subject matter of this Agreement without the prior written consent of NexImmune. Consultant shall be responsible for all work performed by, and for acts, omissions, or negligence of any permitted subcontractors and for compliance of any permitted subcontractors with the requirements of this Agreement, and all applicable laws, rules, and regulations to the same extent that Consultant would be responsible if Consultant were doing such work directly.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Term and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Consulting Agreement shall commence on the Effective Date and shall continue until March 31, 2024, unless earlier terminated in accordance with the terms hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The Term may be extended by mutual agreement of the parties. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be terminated by either party without cause upon fifteen (15) days&#8217; written notice to the other party.  Upon notice of termination, Consultant shall cease performance of all activities hereunder, except as may be necessary to carry out such cancellation.  Consultant shall take all reasonable actions for the purpose of winding down its performance, as directed by NexImmune.  If this Agreement is so terminated, NexImmune shall be liable only for payment for Services actually performed and non-cancelable approved Expenses actually incurred prior to the effective date of termination.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt;text-decoration:underline">Effects of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  At the end of the Term or upon earlier termination of this Agreement, Consultant shall deliver to NexImmune any and all works in progress, drawings, reports, notes, memoranda, specifications, formulas, documents, together with all copies thereof and any other material containing or disclosing Developments and Inventions or NexImmune Information.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The respective rights and obligations of the parties hereunder shall survive the termination or expiration of this Consulting Agreement to the extent necessary for the intended preservation of such rights and obligations.  Without limiting the generality of the foregoing, the rights or obligations of the parties set forth in Sections 3, 4, 5, 7, 8, 9, 10, 11, 14(c), and 22 hereof shall survive any termination or expiration of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  Any notices, requests, demands or other communication required or permitted under this Agreement shall be given in writing and shall be hand delivered or mailed by certified mail, return receipt requested, postage prepaid, or sent by facsimile, addressed as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to NexImmune&#58; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9119 Gaither Road</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gaithersburg, MD 20877</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58; Chief Financial Officer</font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Consultant&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the last address the Company has on file</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each party may designate by notice in writing pursuant to the provisions of this Section 15, a new address to which any notices may thereafter be delivered, given or sent. Documents delivered by hand shall be deemed to have been received upon delivery&#59; documents sent by facsimile shall be deemed to have been received upon confirmation thereof&#59; and documents sent by mail shall be deemed to have been received upon their receipt, or at such time as delivery is refused by the addressee upon presentation.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;   Neither this Agreement, nor any obligations hereunder, may be assigned by Consultant without the prior written consent of NexImmune.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Amendments and Non-Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  No amendment or modification of this Agreement shall be effective unless made in writing and signed by each of the parties.  No waiver of any of the provisions of this Agreement shall be valid unless the same is in writing and signed by the party against whom it is sought to be enforced. Any waiver of any breach of this Agreement shall not be considered to be a continuing waiver or consent to any subsequent breach on the part of either party.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  This Agreement and any Exhibits hereto constitute the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings between the parties relating to the subject matter hereof. In the event of a conflict between the terms of this Agreement and any Exhibit hereto, the terms of this Agreement shall control.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  If any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby and shall remain in full force to the fullest extent permitted by law.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Governing Law&#59; Venue&#59; Equitable Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any controversy out of or relating to this Agreement shall be governed by the law of the State of Maryland, without giving effect to the principles of conflicts of law thereof.  The parties agree that any litigation between them regarding the subject matter of this Agreement may only be brought in courts located within Maryland, and each party consents to the jurisdiction of those courts&#59; provided, however, that NexImmune may bring an action to compel specific performance of Consultant&#8217;s obligations pursuant to Sections 3, 4, 5, and 7 hereunder in any court that has jurisdiction.  Consultant acknowledges and agrees that any breach of Sections 3, 4, 5, or 7 of this Agreement may cause substantial and irreparable harm to NexImmune, such that payment of money would not adequately compensate NexImmune for the damages it would suffer as a result of such a breach.  Accordingly, Consultant agrees that, in addition to any other available remedies, NexImmune shall have the right to seek equitable remedies, including without limitation an injunction, for such breaches.  </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Release.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">Consultant acknowledges that, as of the Resignation Date&#58; (a) Consultant was deemed to have resigned from each and every office, position or responsibility in which Consultant served for Company and each of its affiliates, subsidiaries or divisions&#59; and (b) Consultant is not now and shall not in the future be entitled to any other compensation from Company or any of its affiliates, subsidiaries or divisions, including, without limitation, other wages, commissions, bonuses, </font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">equity, stock options, carve out, paid time off, severance (including, without limitation under the Employment Agreement), or any other form of compensation or benefit, except as otherwise provided in Exhibit A.  For the avoidance of doubt, Consultant shall not be eligible for any severance benefits under Section 3.F of the Employment Agreement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Consultant previously executed an Employee Proprietary Information, Inventions, Non-Competition and Non-Solicitation Agreement, dated as of January 4, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Restrictions Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The Restrictions Agreement remains in full force and effect and Consultant shall honor and abide by the terms and provisions of the Restrictions Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">In consideration for Consultant signing and returning this Agreement within twenty-one (21) days of receipt and not revoking this Agreement during the seven (7) day revocation period after it is signed and returned, the Company will pay Consultant a bonus for 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Pro Rated Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) based on the Company&#8217;s performance for 2023, which bonus will be prorated for the number of days Consultant remained employed with the Company during 2023 (e.g., through the Resignation Date).  The Pro Rated Bonus shall be payable on the later of (x) the first payroll date following the date that this Agreement and this Section 22 becomes effective and irrevocable and (y) the date that 2023 bonuses are paid to executives of the Company, but in all cases in the 2023 calendar year.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Consultant agrees and acknowledges that by signing this Agreement and accepting the benefits hereunder, including, without limitation, the payment under Section 22(c) and the benefits set forth in Exhibit A, and for other good and valuable consideration provided for in this Agreement, Consultant is waiving and Consultant&#8217;s right to assert any form of legal claim against Company, any of the Company&#8217;s affiliates and all of the foregoing entities&#8217; owners, shareholders, partners, directors, officers, employees, trustees, agents, successors and assigns (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) whatsoever for any alleged action, inaction or circumstance existing or arising from the beginning of time through the Effective Date.  Consultant&#8217;s waiver and release herein is intended to bar any form of legal claim, charge, complaint or any other form of action (jointly referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) against Company or any of the Company Parties seeking any form of relief including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages or any other form of monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional distress damages, punitive damages, attorneys&#8217; fees and any other costs) against Company or any Company Party, for any alleged action, inaction or circumstance existing or arising through the Effective Date. Without limiting the generality of the foregoing, Consultant specifically waives and releases Company and the Company Parties from any waivable claim arising from or related to Consultant&#8217;s employment relationship with Company through the Effective Date including, without limitation&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i) &#160;&#160;&#160;&#160;Claims under any Maryland, New Jersey, or any other state or federal discrimination, fair employment practices, or other employment related statute, regulation or executive order (as amended through the Effective Date), including but not limited to the Age Discrimination in Employment Act and the Older Workers Benefit Protection Act (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">29 U.S.C. &#167; 621 et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Civil Rights Acts of 1866 and 1871 and Title VII of the Civil Rights Act of 1964 and the Civil Rights Act of 1991 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">42 U.S.C. &#167; 2000e et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Equal Pay Act (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">29 U.S.C. &#167; 201 et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Genetic Information Non-Discrimination Act (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">42 U.S.C. &#167;2000ff et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Uniformed Services Employment and Reemployment Rights Act of 1994 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">38 U.S.C. &#167; 4301 et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Equal Pay Act (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">29 U.S.C. &#167; 201 et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.), the Lily Ledbetter Fair Pay Act, the Americans with Disabilities Act of 1990 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">42 U.S.C. &#167;&#160;12101 et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Rehabilitation Act of 1973, the Maryland Fair Employment Practices Act, the Maryland Anti-Discrimination Law, the Maryland Medical Information Discrimination Law, the Maryland Reasonable Accommodations for Disabilities Due to Pregnancy Act, the Maryland Deployment of Family Members in the Armed Forces Act, New&#160;Jersey&#160;Law Against Discrimination, the&#160;New&#160;Jersey&#160;Conscientious Employee </font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Protection Act, the&#160;New&#160;Jersey&#160;Wage Payment Law, the&#160;New&#160;Jersey&#160;Wage and Hour Law, the&#160;New&#160;Jersey&#160;Security and Financial Empowerment Act, and any other similar federal, state or local statute.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii) &#160;&#160;&#160;&#160;Claims under any Maryland, New Jersey, or any other state or federal employment related statute, regulation or executive order (as amended through the Effective Date) relating to wages, hours or any other terms and conditions of employment, including but not limited to the National Labor Relations Act (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">29 U.S.C. &#167; 151 et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Family and Medical Leave Act (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">29 U.S.C. &#167;2601 et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Employee Retirement Income Security Act of 1974 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">29 U.S.C. &#167; 1000 et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), COBRA (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">29 U.S.C. &#167; 1161 et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Worker Adjustment and Retraining Notification Act (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">29 U.S.C. &#167; 2101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), the Maryland Equal Pay for Equal Work Law, the Maryland WARN Law, the Maryland Flexible Leave Act, the Maryland Lien for Unpaid Wages, the&#160;New&#160;Jersey&#160;Equal Pay Act, the&#160;New&#160;Jersey&#160;Warn Act, or other federal, state or local statute, and specifically including Claims related to salary, overtime, commissions, vacation pay, holiday pay, sick leave pay, dismissal pay, bonus pay, severance pay, or retaliation.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii) &#160;&#160;&#160;&#160;Claims under any Maryland, New Jersey, or any other state or federal common law theory, including, without limitation, wrongful discharge, breach of express or implied contract, breach of the implied covenant of good faith and fair dealing, privacy violations, invasion of privacy, promissory estoppel, unjust enrichment, breach of a covenant of good faith and fair dealing, wrongful termination in violation of public policy, defamation, interference with contractual relations, intentional or negligent infliction of emotional distress, fraudulent inducement, misrepresentation, deceit, fraud or negligence, rehire or reemployment rights or any claim to attorneys&#8217; fees under any applicable statute or common law theory of recovery. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Claims under any Maryland, New Jersey, or any other state or federal statute, regulation, or executive order (as amended through the Effective Date) relating to whistleblower protections, violation of public policy, or any other form of retaliation or wrongful termination, including but not limited to the Sarbanes-Oxley Act of 2002 or other federal, state or local statute.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Claims under any Company employment, compensation, bonus, benefit, stock option, incentive compensation, restricted stock unit, and&#47;or equity plan, program, policy, practice, or agreement, including, without limitation, any equity award or plan, or employment agreement, including the Employment Agreement&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;Any other Claim arising under other local, state, or federal law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">Notwithstanding the foregoing, this Section 22 does </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i) &#160;&#160;&#160;&#160;Release Company or any Company Party from any obligation expressly set forth in this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Waive or release any rights Consultant may have to vested benefits under the Company-sponsored employee benefit plans in which Consultant participated, including the Company&#8217;s 401(k) plan.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Waive or release any legal claims which Consultant may not waive or release by law, including obligations under workers&#8217; compensation laws.</font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv) &#160;&#160;&#160;&#160;Waive or release any legal claims to indemnification under the Indemnification Agreement dated as of February 9, 2021 between Consultant and Company or under Company&#8217;s director and officers&#8217; insurance policies in effect from time to time&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;Prohibit Consultant from (i) filing a charge with, or participating in or assisting with an investigation or proceeding conducted by, any governmental, regulatory and&#47;or administrative entity or agency (including the Securities Exchange Commission, the Equal Employment Opportunity Commission, the Maryland Commission for Civil Rights, and&#47;or OSHA)&#59; (ii) filing and, including as provided for under Section 21F of the Securities Exchange Act of 1934 (and Regulation 21F thereunder), maintaining the confidentiality of, a claim with a governmental, regulatory and&#47;or administrative entity or agency that is responsible for enforcing a law&#59; or (iii) providing truthful information to a governmental, regulatory and&#47;or administrative entity or agency, law enforcement, or court, in response to compulsory legal process or as otherwise required by law or legal process or as permitted by Section 21F of the Securities Exchange Act of 1934 (or Regulation 21F thereunder)&#59; provided, however, Consultant waives the right to recover any personal damages or other personal relief based on any claim, cause of action, demand, lawsuit or similar that is waived pursuant to this Agreement and brought by Consultant or on Consultant by any third party, including as a member of any class or collective action, except that Consultant does not waive any right to receive and fully retain any monetary award from a government-administered whistleblower award program for providing information to a government agency, including but not limited to damages or relief that may be available to Consultant pursuant to such a program under the Securities Exchange Act of 1934.  Consultant is not required to inform the Company that Consultant has engaged in any of the activities described in this Section.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.59pt">Consultant understands and expressly agrees that this release extends to all claims of every nature and kind, known or unknown, suspected, or unsuspected, past, present, or future, arising from or attributable to any conduct of Company or any Company Party, whether set forth in any pleading or demand referred to in this Agreement or not. Consultant acknowledges that Consultant may later discover facts in addition to or different from those which Consultant now believes to be true with respect to the matters released in this Section.  Consultant, however, agrees that Consultant has taken that possibility into account in reaching this Agreement, and that the release in this Agreement will remain in effect as a full and complete release notwithstanding the discovery or existence of additional or different facts.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Consultant acknowledges and agrees that, but for providing this waiver and release, Consultant would not be receiving the benefits provided to Consultant under the terms of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Consultant understands and agrees that with respect to any possible claim arising under the Age Discrimination in Employment Act of 1967 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">ADEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) Consultant&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Has had the opportunity to consider this Agreement for a full twenty-one (21) calendar days before executing it (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Review Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and if signing this Agreement before the end of the Review Period, Consultant has voluntarily waived the remainder of the Review Period&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">Has carefully read and fully understands all of the provisions of this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">Is, through this Agreement, releasing Company and all of the Company Parties from any and all claims Consultant may have against them&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">Knowingly and voluntarily agrees to all of the terms set forth in this Agreement&#59;</font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Knowingly and voluntarily intends to be legally bound by the terms of this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">Was advised and hereby is advised in writing to consider the terms of this Agreement and to consult with an attorney of Consultant&#8217;s choice prior to executing this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.08pt">Understands that rights or claims under the ADEA that may arise due to acts or omissions that occur after the Effective Date are not waived&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.03pt">Understands that Consultant has had a period of seven (7) calendar days after the date that Consultant signs this Agreement to revoke Consultant&#8217;s acceptance of the terms of this Agreement by actually completing delivery of (not merely dispatching) a written notification by e-mail to Karen Haslbeck, Director, Human Resources at khaslbeck&#64;neximmune.com.  If Consultant revokes this Agreement, all of its provisions shall be void and unenforceable.  This Agreement shall become effective on the eighth day after Consultant signs it, so long as Consultant has not exercised Consultant&#8217;s right to revoke it.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:4.25pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which, when taken together, shall constitute one and the same instrument.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#91;Signature page next page.&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">NEXIMMUNE, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">CONSULTANT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Kristi Jones&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Kristi Jones</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jerome Zeldis, M.D., Ph.D&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Jerome Zeldis, M.D., Ph.D</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Services and Service Fees</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company is primarily focused on Oncology and auto-immune applications. However, there is a biologic rationale and significant opportunity to advance applications amenable to virally driven Infectious Diseases (ID) while potentially providing non-dilutive funding. As such, Consultant will be working in collaboration with the Company on the&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Evaluation and development of scientific proposals and plans for the Infectious Disease application of the AIM platfor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">m. The current project under evaluation is a &#91;***&#93; and funding mechanisms to determine interest and potential path for a combination therapy targeting Ebola (filoviruses). Other viral infectious diseases may be explored pending initial feedback and results. &#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Feedback and input into R&#47;D plans and data review.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Feedback on the INJ strategic plans including responses from the FDA on the pre-IND briefing and other applications&#47;interactions with the FDA or other competent authorities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Participation in advisory discussions (e.g. RRC, expert&#160;calls, SABs, and&#160;potential other forums as needed).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Weekly or bi-monthly 1&#58;1 meetings with CEO and others as needed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consultant is expected to provide approximately 20 hours per week of service during the Term. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consultant will attend meetings, by teleconference or on-site at NexImmune&#8217;s facility at 9119 Gaither Road Gaithersburg, MD 20877, as reasonably requested by NexImmune.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Service Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As compensation for the Services, NexImmune agrees to pay Consultant $200 per hour, payable bi-weekly in arrears, and Consultant hereby agrees to accept such amounts (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Service Fees&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Consultant will submit a weekly invoice to the Company within two business days following the end of the week setting forth the time worked, the total number of hours worked and tasks performed in the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Option Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consultant was previously awarded options under the Company&#8217;s 2021 Equity Incentive Plan and the award agreements described in the table below (such options, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Consultant acknowledges and agrees that, other than with respect to the Repriced Options (as defined below)&#58; (a) Consultant&#8217;s Continuous Service (as defined in the Plan) terminated effective as of the Resignation Date&#59; (b) vesting of the Options ceased as of the Resignation Date&#59; and (c) the right to exercise the Options shall expire on the three (3) month anniversary of the Resignation Date.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to approval by the Board of Directors and any other necessary approvals, up to 100,000 shares subject to the Options, in accordance with the proposed allocations below, shall be eligible to participate in the option repricing program currently contemplated by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Option Repricing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (any  Options repriced under the Option Repricing Program, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Repriced Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).&#160; </font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Award </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Grant</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Date</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"># of Shares </font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subject to Option</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exercise Price at Grant </font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(Per Share)</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Vested Shares as of Resignation Date</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Shares Eligible for Option Repricing Program</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Stock Option Award Notice</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">2&#47;11&#47;2021</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">351,016</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">$17.00</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">351,016</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">100,000</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Stock Option Award Notice</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">4&#47;05&#47;2022</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">80,100</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">$4.22</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">0</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">0</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consultant shall be reimbursed for all reasonable and necessary expenses incurred by Consultant while performing the Services, subject to the prior written approval by Company of any such expense.  Consultant will provide Company with all documentation requested by Company for any such expense.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PRIOR INVENTIONS </font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TO&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FROM&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DATE&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-54pt"><font><br></font></div><div style="padding-left:57.6pt;text-align:justify;text-indent:-57.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SUBJECT&#58;&#160;&#160;&#160;&#160;Prior Inventions </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Except as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter of my employment by NexImmune, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company&#58;</font></div><div style="text-align:justify;text-indent:28.8pt"><font><br></font></div><div style="text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;No inventions or improvements.</font></div><div style="text-align:justify;text-indent:28.8pt"><font><br></font></div><div style="text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;See below&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div style="padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Due to a prior confidentiality agreement, I cannot complete the disclosure under Section&#160;1 above with respect to inventions or improvements generally listed below, the proprietary rights and duty of confidentiality with respect to which I owe to the following party(ies)&#58;</font></div><div style="text-align:justify;text-indent:28.8pt"><font><br></font></div><div style="text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Invention or Improvement&#160;&#160;&#160;&#160;Party(ies)&#160;&#160;&#160;&#160; Relationship</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;</font></div><div style="padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font><br></font></div><div style="padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font></div><div style="padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font><br></font></div><div style="padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font></div><div style="padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font><br></font></div><div style="padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div style="height:122.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Portions of this Exhibit, indicated by the mark &#8220;&#91;***&#93;,&#8221; were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div><div id="i833c623b5cc844ea91859ef33ae3bf57_4"></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Hours Worked Template</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Send by Mail&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Controller</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9119 Gaither Road</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gaithersburg, MD 20877  USA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Send By Email&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">To NexImmune Accounts Payable at accountspayable&#64;neximmune.com or other as designated by NexImmune CFO from time to time</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Day&#47;Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Time Worked</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Services Performed</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total hours worked for the week ending &#91;Date&#93;&#58;  _________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature&#58; ________________________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Printed name&#58;_ ____________________________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;  ____________________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NexImmune, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting Agreement</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>nexi-20221231x10kxex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib1f1d08f32a34b0bae5bb603afbce6c2_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:18pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Exhibit 23.1</font></div><div style="margin-bottom:18pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Consent&#160;of Independent Registered Public Accounting Firm</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We&#160;consent&#160;to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-253527) pertaining to the 2017 Equity Incentive Plan, as amended, the 2018 Equity Incentive Plan, as amended, and the 2021 Equity Incentive Plan of NexImmune, Inc.,</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement (Form S-3 No. 333-263399) of NexImmune, Inc., and </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-263400) pertaining to the 2021 Equity Incentive Plan of NexImmune, Inc.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our report dated March&#160;28, 2023, with respect to the financial statements of NexImmune, Inc. included in this Annual Report (Form 10-K) of NexImmune, Inc. for the year ended December&#160;31, 2022.</font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tysons, Virginia</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;28, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>nexi-20221231x10kxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4db7232caec8431a8755b789bcb5c722_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION UNDER SECTION 302</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kristi Jones, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this annual report on Form&#160;10-K&#160;of NexImmune, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and&#160;15d-15(f))&#160;for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;28, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Kristi Jones</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kristi Jones</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>nexi-20221231x10kxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i34026e1d54ef4e8295046466c1fc41cf_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION UNDER SECTION 302</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Trainer, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this annual report on Form&#160;10-K&#160;of NexImmune, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and&#160;15d-15(f))&#160;for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;28, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;John Trainer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Trainer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>nexi-20221231x10kxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i839ee522e8944ae1b047108ed3c60cd0_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION UNDER SECTION 906</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of NexImmune, Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge that&#58;</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Report for the year ended December&#160;31, 2022 (the &#8220;Form&#160;10-K&#8221;)&#160;of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form&#160;10-K&#160;fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;28, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Kristi Jones</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kristi Jones</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>nexi-20221231x10kxex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5b89e370a3e94b0ba122e4c25f5a4ebf_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION UNDER SECTION 906</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of NexImmune, Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge that&#58;</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Report for the year ended December&#160;31, 2022 (the &#8220;Form&#160;10-K&#8221;)&#160;of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form&#160;10-K&#160;fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;28, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;John Trainer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Trainer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>nexi-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1d01bc3b-109a-450d-9ee6-f84eb8561d2c,g:e7038408-d172-479b-b01e-e62e0cc0d235-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nexi="http://nex.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://nex.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nexi-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nexi-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nexi-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nexi-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://nex.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://nex.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://nex.com/role/BalanceSheets">
        <link:definition>0000003 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://nex.com/role/BalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfOperations" roleURI="http://nex.com/role/StatementsOfOperations">
        <link:definition>0000005 - Statement - Statements Of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfComprehensiveLoss" roleURI="http://nex.com/role/StatementsOfComprehensiveLoss">
        <link:definition>0000006 - Statement - Statements Of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity" roleURI="http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity">
        <link:definition>0000007 - Statement - Statements Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfCashFlows" roleURI="http://nex.com/role/StatementsOfCashFlows">
        <link:definition>0000008 - Statement - Statements Of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://nex.com/role/DescriptionoftheBusiness">
        <link:definition>0000009 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandLiquidity" roleURI="http://nex.com/role/BasisofPresentationandLiquidity">
        <link:definition>0000010 - Disclosure - Basis of Presentation and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://nex.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://nex.com/role/FairValueMeasurements">
        <link:definition>0000012 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssets" roleURI="http://nex.com/role/PrepaidExpensesandOtherCurrentAssets">
        <link:definition>0000013 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://nex.com/role/PropertyandEquipment">
        <link:definition>0000014 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivities" roleURI="http://nex.com/role/RestructuringActivities">
        <link:definition>0000015 - Disclosure - Restructuring Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://nex.com/role/AccruedExpenses">
        <link:definition>0000016 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://nex.com/role/CommitmentsandContingencies">
        <link:definition>0000017 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotes" roleURI="http://nex.com/role/ConvertibleNotes">
        <link:definition>0000018 - Disclosure - Convertible Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesARedeemableConvertiblePreferredStockandStockholdersDeficit" roleURI="http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficit">
        <link:definition>0000019 - Disclosure - Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://nex.com/role/StockBasedCompensation">
        <link:definition>0000020 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://nex.com/role/IncomeTaxes">
        <link:definition>0000021 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://nex.com/role/Leases">
        <link:definition>0000022 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://nex.com/role/RelatedPartyTransactions">
        <link:definition>0000023 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://nex.com/role/SubsequentEvents">
        <link:definition>0000024 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://nex.com/role/FairValueMeasurementsTables">
        <link:definition>0000027 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://nex.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>0000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://nex.com/role/PropertyandEquipmentTables">
        <link:definition>0000029 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivitiesTables" roleURI="http://nex.com/role/RestructuringActivitiesTables">
        <link:definition>0000030 - Disclosure - Restructuring Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://nex.com/role/AccruedExpensesTables">
        <link:definition>0000031 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://nex.com/role/StockBasedCompensationTables">
        <link:definition>0000032 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://nex.com/role/IncomeTaxesTables">
        <link:definition>0000033 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://nex.com/role/LeasesTables">
        <link:definition>0000034 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessDetails" roleURI="http://nex.com/role/DescriptionoftheBusinessDetails">
        <link:definition>0000035 - Disclosure - Description of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails" roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails">
        <link:definition>0000037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Restricted Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails" roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails">
        <link:definition>0000038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Lives of Property Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails" roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails">
        <link:definition>0000039 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails" roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails">
        <link:definition>0000040 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail" roleURI="http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail">
        <link:definition>0000041 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail" roleURI="http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>0000042 - Disclosure - Prepaid Expenses And Other Current Assets - Summary of Prepaid Expenses And Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentSummaryofPropertyAndEquipmentDetail" roleURI="http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail">
        <link:definition>0000043 - Disclosure - Property and Equipment - Summary of Property And Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetail" roleURI="http://nex.com/role/PropertyandEquipmentAdditionalInformationDetail">
        <link:definition>0000044 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivitiesDetails" roleURI="http://nex.com/role/RestructuringActivitiesDetails">
        <link:definition>0000045 - Disclosure - Restructuring Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails" roleURI="http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails">
        <link:definition>0000046 - Disclosure - Restructuring Activities - Summary of Charges Related to Restructuring Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesSummaryofComponentsofAccruedExpensesDetail" roleURI="http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail">
        <link:definition>0000047 - Disclosure - Accrued Expenses - Summary of Components of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000048 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails" roleURI="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails">
        <link:definition>0000049 - Disclosure - Commitments and Contingencies - Additional Information, Maryland Biotechnology Center Grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails" roleURI="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails">
        <link:definition>0000050 - Disclosure - Commitments and Contingencies - Additional Information, Johns Hopkins University Exclusive License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails" roleURI="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails">
        <link:definition>0000051 - Disclosure - Commitments and Contingencies - Additional Information, Paycheck Protection Program Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesAdditionalInformationDetail" roleURI="http://nex.com/role/ConvertibleNotesAdditionalInformationDetail">
        <link:definition>0000052 - Disclosure - Convertible Notes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail" roleURI="http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail">
        <link:definition>0000053 - Disclosure - Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://nex.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>0000054 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail" roleURI="http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail">
        <link:definition>0000055 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofOptionActivityDetail" roleURI="http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail">
        <link:definition>0000056 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail" roleURI="http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail">
        <link:definition>0000057 - Disclosure - Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRSUActivityDetails" roleURI="http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails">
        <link:definition>0000058 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofProvisionForIncomeTaxesDetails" roleURI="http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails">
        <link:definition>0000059 - Disclosure - Income Taxes - Schedule of Provision For Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>0000060 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000061 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://nex.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000062 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseCostDetails" roleURI="http://nex.com/role/LeasesComponentsofLeaseCostDetails">
        <link:definition>0000063 - Disclosure - Leases - Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofCashFlowSupplementalDisclosuresDetails" roleURI="http://nex.com/role/LeasesScheduleofCashFlowSupplementalDisclosuresDetails">
        <link:definition>0000064 - Disclosure - Leases - Schedule of Cash Flow, Supplemental Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureFixedLeasePaymentsDetails" roleURI="http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails">
        <link:definition>0000065 - Disclosure - Leases - Future Fixed Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://nex.com/role/SubsequentEventsDetails">
        <link:definition>0000066 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nexi_DebtDiscount" abstract="false" name="DebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_SublicenseConsiderationPaymentPercentMaximum" abstract="false" name="SublicenseConsiderationPaymentPercentMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nexi_DeferredTaxAssetValuationAllowancePercent" abstract="false" name="DeferredTaxAssetValuationAllowancePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="nexi_LeaseExpenseNoncash" abstract="false" name="LeaseExpenseNoncash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_TherapeuticFieldMember" abstract="true" name="TherapeuticFieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="nexi_DebtInstrumentAdditionalClosingLockInPeriod" abstract="false" name="DebtInstrumentAdditionalClosingLockInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nexi_SaleOfStockAggregateOfferingApproval" abstract="false" name="SaleOfStockAggregateOfferingApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nexi_MarylandBiotechnologyCenterMember" abstract="true" name="MarylandBiotechnologyCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nexi_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nexi_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations" abstract="false" name="RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nexi_SaleOfStockCommissionPercentage" abstract="false" name="SaleOfStockCommissionPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nexi_TwoThousandEighteenEquityIncentivePlanMember" abstract="true" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_RelatedPartyTransactionHourlyRate" abstract="false" name="RelatedPartyTransactionHourlyRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_TemporaryEquityStockConvertedDuringPeriodValue" abstract="false" name="TemporaryEquityStockConvertedDuringPeriodValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_MilestoneFees" abstract="false" name="MilestoneFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_TemporaryEquityStockConvertedDuringPeriodShares" abstract="false" name="TemporaryEquityStockConvertedDuringPeriodShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nexi_ShareBasedPaymentArrangementOptionRepricingMultiple" abstract="false" name="ShareBasedPaymentArrangementOptionRepricingMultiple" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent" abstract="false" name="RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nexi_EmployeesExcludingExecutiveOfficerMember" abstract="true" name="EmployeesExcludingExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_CumulativeMinimumRoyalties" abstract="false" name="CumulativeMinimumRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_The2021PlanMember" abstract="true" name="The2021PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_SubstantialDoubtForGoingConcernPolicyTextBlock" abstract="false" name="SubstantialDoubtForGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nexi_MinimumAnnualRoyaltyPayments" abstract="false" name="MinimumAnnualRoyaltyPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations" abstract="false" name="RestructuringAndRelatedCostNumberOfPositionsAfterEliminations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nexi_PrepaidMaintenanceAgreements" abstract="false" name="PrepaidMaintenanceAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesAThreeRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage" abstract="false" name="ResearchAndDevelopmentArrangementAnnualPaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts" abstract="false" name="DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold" abstract="false" name="ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="nexi_TemporaryEquityPolicyPolicyTextBlock" abstract="false" name="TemporaryEquityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt" abstract="false" name="StockIssuedDuringPeriodSharesConversionOfConvertibleDebt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised" abstract="false" name="StockIssuedDuringPeriodValueCashlessCommonStockExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_ClinicalTrialMilestonesMember" abstract="true" name="ClinicalTrialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt" abstract="false" name="StockIssuedDuringPeriodValueConversionOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage" abstract="false" name="ResearchAndDevelopmentArrangementContractualPaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nexi_ExclusiveLicenseAgreementMember" abstract="true" name="ExclusiveLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock" abstract="false" name="ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nexi_DebtInstrumentFullyDilutedCapitalization" abstract="false" name="DebtInstrumentFullyDilutedCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_DebtInstrumentConvertiblePricePercentage" abstract="false" name="DebtInstrumentConvertiblePricePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="nexi_PrepaidResearchAndDevelopmentExpenses" abstract="false" name="PrepaidResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" abstract="false" name="RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nexi_WeightedAverageRemainingContractualTermInYearsAbstract" abstract="true" name="WeightedAverageRemainingContractualTermInYearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes" abstract="false" name="FairValueOfDerivativeLiabilityOfConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_JohnsHopkinsUniversityMember" abstract="true" name="JohnsHopkinsUniversityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_JeromeZeldisMember" abstract="true" name="JeromeZeldisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod" abstract="false" name="ResearchAndDevelopmentArrangementContractualPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nexi_DebtInstrumentRedemptionAmount" abstract="false" name="DebtInstrumentRedemptionAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_SeriesATwoRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesATwoRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_NonclinicalFieldMember" abstract="true" name="NonclinicalFieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_PaycheckProtectionProgramLoanMember" abstract="true" name="PaycheckProtectionProgramLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance" abstract="false" name="FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_RegulatoryAndCommercialMilestonesMember" abstract="true" name="RegulatoryAndCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_NumberOfWarrantsExercised" abstract="false" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nexi_SeriesARedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesARedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract" abstract="true" name="RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nexi_DebtIssuanceCosts" abstract="false" name="DebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_TranslationalResearchAwardAgreementMember" abstract="true" name="TranslationalResearchAwardAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_DeferredTaxAssetsOperatingLeases" abstract="false" name="DeferredTaxAssetsOperatingLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nexi_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nexi_TwoThousandSeventeenEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" abstract="false" name="RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="nexi_MilestonesAxis" abstract="true" name="MilestonesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nexi_MilestonesDomain" abstract="true" name="MilestonesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>nexi-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1d01bc3b-109a-450d-9ee6-f84eb8561d2c,g:e7038408-d172-479b-b01e-e62e0cc0d235-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://nex.com/role/BalanceSheets" xlink:type="simple" xlink:href="nexi-20221231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://nex.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ef51a532-1380-4d6f-8509-e0a0cdbde3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_33d669a6-5754-4fe5-b4b3-a74be8571dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ef51a532-1380-4d6f-8509-e0a0cdbde3d0" xlink:to="loc_us-gaap_AssetsCurrent_33d669a6-5754-4fe5-b4b3-a74be8571dac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1736eb24-88c4-4097-9c17-745e1e5e30b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ef51a532-1380-4d6f-8509-e0a0cdbde3d0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1736eb24-88c4-4097-9c17-745e1e5e30b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d96efa3e-9c4f-4da3-9082-4c0ff5f34940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ef51a532-1380-4d6f-8509-e0a0cdbde3d0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d96efa3e-9c4f-4da3-9082-4c0ff5f34940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_63c84610-496e-4806-bdd5-26c53e35cd86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ef51a532-1380-4d6f-8509-e0a0cdbde3d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_63c84610-496e-4806-bdd5-26c53e35cd86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0871a249-73d9-49b8-84d0-8c6b9ba27a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5c71b399-34ce-4fae-985a-e23ec54cc860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0871a249-73d9-49b8-84d0-8c6b9ba27a40" xlink:to="loc_us-gaap_CommonStockValue_5c71b399-34ce-4fae-985a-e23ec54cc860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5e52ab28-4fb2-4d4c-b3c1-0b05628eab53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0871a249-73d9-49b8-84d0-8c6b9ba27a40" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5e52ab28-4fb2-4d4c-b3c1-0b05628eab53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c798333b-8dd2-4cd5-83c5-1b35d026478f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0871a249-73d9-49b8-84d0-8c6b9ba27a40" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c798333b-8dd2-4cd5-83c5-1b35d026478f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_80eaeac2-f22c-4ab5-bdf2-552e4934ff09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0871a249-73d9-49b8-84d0-8c6b9ba27a40" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_80eaeac2-f22c-4ab5-bdf2-552e4934ff09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e5847524-c7b6-4528-a491-73f23f8ebec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e9af99be-3c23-4284-89eb-942f2cfbab4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e5847524-c7b6-4528-a491-73f23f8ebec8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e9af99be-3c23-4284-89eb-942f2cfbab4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2ef3adc9-e648-47e1-a263-515d42ae8916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e5847524-c7b6-4528-a491-73f23f8ebec8" xlink:to="loc_us-gaap_AccountsPayableCurrent_2ef3adc9-e648-47e1-a263-515d42ae8916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cdb77992-8c06-44b8-8e4f-81c4ba24906c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e5847524-c7b6-4528-a491-73f23f8ebec8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cdb77992-8c06-44b8-8e4f-81c4ba24906c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_84ae6288-8eb4-453f-a2cf-bb9985d0128d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_a58ceaf8-e77b-4391-a7c7-bac79d70b3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_84ae6288-8eb4-453f-a2cf-bb9985d0128d" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_a58ceaf8-e77b-4391-a7c7-bac79d70b3aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5314c6ee-c365-4810-b040-d93b30d85ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_84ae6288-8eb4-453f-a2cf-bb9985d0128d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5314c6ee-c365-4810-b040-d93b30d85ef3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_88b71751-340b-41ed-b964-fecd335905c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_84ae6288-8eb4-453f-a2cf-bb9985d0128d" xlink:to="loc_us-gaap_LiabilitiesCurrent_88b71751-340b-41ed-b964-fecd335905c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7500bde6-146f-4009-8a93-2438075ad03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f2ce120e-376c-47e3-aa6b-34757d36af00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7500bde6-146f-4009-8a93-2438075ad03d" xlink:to="loc_us-gaap_StockholdersEquity_f2ce120e-376c-47e3-aa6b-34757d36af00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9fe22a52-6d3c-47c8-b329-dbdec54cee1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7500bde6-146f-4009-8a93-2438075ad03d" xlink:to="loc_us-gaap_Liabilities_9fe22a52-6d3c-47c8-b329-dbdec54cee1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c129ba7e-2d21-44dc-bf97-0e75985d7631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f26917c6-1fc6-4398-bfdb-4f4782bed90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c129ba7e-2d21-44dc-bf97-0e75985d7631" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f26917c6-1fc6-4398-bfdb-4f4782bed90c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1f02b7cd-b983-4333-bf43-41ae05cd5764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c129ba7e-2d21-44dc-bf97-0e75985d7631" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1f02b7cd-b983-4333-bf43-41ae05cd5764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_2c2c888a-db2c-4a68-a046-e17e35b1133a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c129ba7e-2d21-44dc-bf97-0e75985d7631" xlink:to="loc_us-gaap_RestrictedCashCurrent_2c2c888a-db2c-4a68-a046-e17e35b1133a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_781d060d-2cc4-4386-ad49-c4859115ddc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c129ba7e-2d21-44dc-bf97-0e75985d7631" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_781d060d-2cc4-4386-ad49-c4859115ddc0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/StatementsOfOperations" xlink:type="simple" xlink:href="nexi-20221231.xsd#StatementsOfOperations"/>
  <link:calculationLink xlink:role="http://nex.com/role/StatementsOfOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a4de3c3-f5c5-4473-90c3-1065faaad2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0307b2e0-a3d1-4cf9-ac82-2bbbccdd44f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1a4de3c3-f5c5-4473-90c3-1065faaad2f8" xlink:to="loc_us-gaap_OperatingIncomeLoss_0307b2e0-a3d1-4cf9-ac82-2bbbccdd44f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3baff2f6-2c2f-43a4-ab7f-4c9b5db9ad81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1a4de3c3-f5c5-4473-90c3-1065faaad2f8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3baff2f6-2c2f-43a4-ab7f-4c9b5db9ad81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0c5f5ee9-141e-4e43-8fec-af801ba5aff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2ac35b4b-1e14-4d0e-b9fa-06571d643c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0c5f5ee9-141e-4e43-8fec-af801ba5aff4" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2ac35b4b-1e14-4d0e-b9fa-06571d643c77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7476528d-3b94-49b1-8f22-ce3ff9d0a7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0c5f5ee9-141e-4e43-8fec-af801ba5aff4" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7476528d-3b94-49b1-8f22-ce3ff9d0a7dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_bda26fbc-7b38-4532-b9fb-a38c08332e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0c5f5ee9-141e-4e43-8fec-af801ba5aff4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_bda26fbc-7b38-4532-b9fb-a38c08332e90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_30e30d8d-6cf5-4f53-b7bc-20920267bc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0c5f5ee9-141e-4e43-8fec-af801ba5aff4" xlink:to="loc_us-gaap_InterestExpense_30e30d8d-6cf5-4f53-b7bc-20920267bc7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_1a0d7d87-e0a0-4515-b1bc-365e34d8a189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0c5f5ee9-141e-4e43-8fec-af801ba5aff4" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_1a0d7d87-e0a0-4515-b1bc-365e34d8a189" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_92f0f6d8-e43f-4c8b-9954-501380669439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1787b9d1-32c9-468d-ae4a-8944d47b02c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_92f0f6d8-e43f-4c8b-9954-501380669439" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1787b9d1-32c9-468d-ae4a-8944d47b02c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_22bc497b-93ec-4f6e-ba5a-eb8b86e06dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_92f0f6d8-e43f-4c8b-9954-501380669439" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_22bc497b-93ec-4f6e-ba5a-eb8b86e06dce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b56423a2-4c0d-4faa-adf5-c413a8feb28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_218afb86-f521-42e2-b598-689d40ac04e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b56423a2-4c0d-4faa-adf5-c413a8feb28d" xlink:to="loc_us-gaap_NetIncomeLoss_218afb86-f521-42e2-b598-689d40ac04e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_8f8ec5a0-a4ee-4b20-ac5d-178af1bb5b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b56423a2-4c0d-4faa-adf5-c413a8feb28d" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_8f8ec5a0-a4ee-4b20-ac5d-178af1bb5b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0f2d4721-0a33-4fc5-b55c-febd04aaf876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6b5a3322-ac95-4831-baf7-127043cafaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0f2d4721-0a33-4fc5-b55c-febd04aaf876" xlink:to="loc_us-gaap_OperatingExpenses_6b5a3322-ac95-4831-baf7-127043cafaf0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/StatementsOfComprehensiveLoss" xlink:type="simple" xlink:href="nexi-20221231.xsd#StatementsOfComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://nex.com/role/StatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf0a47d6-f2e4-4b67-a61c-6d937e8d0cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e5900ef-6987-43fb-b1f0-f20a1d659116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf0a47d6-f2e4-4b67-a61c-6d937e8d0cdd" xlink:to="loc_us-gaap_NetIncomeLoss_3e5900ef-6987-43fb-b1f0-f20a1d659116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_123a0721-2113-4067-96e3-c98b60fe1f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf0a47d6-f2e4-4b67-a61c-6d937e8d0cdd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_123a0721-2113-4067-96e3-c98b60fe1f29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/StatementsOfCashFlows" xlink:type="simple" xlink:href="nexi-20221231.xsd#StatementsOfCashFlows"/>
  <link:calculationLink xlink:role="http://nex.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9178a66-3e1f-4f9e-b246-03f2d32be54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_cb6f9b28-8715-4823-a429-f09b97d559f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9178a66-3e1f-4f9e-b246-03f2d32be54c" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_cb6f9b28-8715-4823-a429-f09b97d559f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6b85135c-efed-46f4-8e9e-6a1c27c969e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9178a66-3e1f-4f9e-b246-03f2d32be54c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6b85135c-efed-46f4-8e9e-6a1c27c969e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3e4686fe-a6a3-43cf-9e93-1b3767ff4f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9178a66-3e1f-4f9e-b246-03f2d32be54c" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3e4686fe-a6a3-43cf-9e93-1b3767ff4f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_0c621d12-1bd9-4436-937d-97e0e103381a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9178a66-3e1f-4f9e-b246-03f2d32be54c" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_0c621d12-1bd9-4436-937d-97e0e103381a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3f639ac3-c2e6-41e1-a67e-bfc91a2991f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b9178a66-3e1f-4f9e-b246-03f2d32be54c" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3f639ac3-c2e6-41e1-a67e-bfc91a2991f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59f9b689-b516-439c-8bf3-25756c882a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4b695854-dc11-40c7-a5da-d666449489d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59f9b689-b516-439c-8bf3-25756c882a43" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4b695854-dc11-40c7-a5da-d666449489d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_dfb443e0-0da4-418a-9f22-4a7380fa301e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59f9b689-b516-439c-8bf3-25756c882a43" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_dfb443e0-0da4-418a-9f22-4a7380fa301e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9631bb3f-5e69-4c78-8920-9ebeb7ecad87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59f9b689-b516-439c-8bf3-25756c882a43" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9631bb3f-5e69-4c78-8920-9ebeb7ecad87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_e86b2447-044e-422f-a1a0-94754270b371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59f9b689-b516-439c-8bf3-25756c882a43" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_e86b2447-044e-422f-a1a0-94754270b371" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_14ad5499-7808-4976-a99b-1a2998fb3d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59f9b689-b516-439c-8bf3-25756c882a43" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_14ad5499-7808-4976-a99b-1a2998fb3d67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_48871de1-5776-4622-b8bc-70f2c8e50ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59f9b689-b516-439c-8bf3-25756c882a43" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_48871de1-5776-4622-b8bc-70f2c8e50ce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1b3aa611-9ab1-47b6-ba56-74346d91a9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59f9b689-b516-439c-8bf3-25756c882a43" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1b3aa611-9ab1-47b6-ba56-74346d91a9a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_84c0e416-a997-4849-bfa8-0af8b7619a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2123b785-89df-448a-98f3-280dec5d3bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_84c0e416-a997-4849-bfa8-0af8b7619a8a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2123b785-89df-448a-98f3-280dec5d3bd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8c4ebca-95e5-4767-a9ed-ff586473e1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_84c0e416-a997-4849-bfa8-0af8b7619a8a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b8c4ebca-95e5-4767-a9ed-ff586473e1de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44218cd3-faef-486e-b926-9cf1a1ab2633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_84c0e416-a997-4849-bfa8-0af8b7619a8a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44218cd3-faef-486e-b926-9cf1a1ab2633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_LeaseExpenseNoncash_2a0ccacc-27b6-46bc-90a2-7bee79e52094" xlink:href="nexi-20221231.xsd#nexi_LeaseExpenseNoncash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_nexi_LeaseExpenseNoncash_2a0ccacc-27b6-46bc-90a2-7bee79e52094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fb046788-d866-4edd-996c-207907d7368c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_NetIncomeLoss_fb046788-d866-4edd-996c-207907d7368c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_ff65906a-99ca-4a46-b4c1-99fb5eabf743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_ff65906a-99ca-4a46-b4c1-99fb5eabf743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e499b000-4b1f-4329-861c-bd5160608bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e499b000-4b1f-4329-861c-bd5160608bd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_a74861ad-f535-4ddf-908f-644f4db48ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_a74861ad-f535-4ddf-908f-644f4db48ad2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_95911003-91fb-412a-89fe-b0acf8f80388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_PaidInKindInterest_95911003-91fb-412a-89fe-b0acf8f80388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bd3515fa-590c-4f9a-8df0-14407f08c71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bd3515fa-590c-4f9a-8df0-14407f08c71f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_28de5ff7-a7da-4766-86d1-6974267f569a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_ShareBasedCompensation_28de5ff7-a7da-4766-86d1-6974267f569a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_853b99ad-37e5-415a-8815-c00c24a964e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_853b99ad-37e5-415a-8815-c00c24a964e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_52963fd4-3a45-42f6-bd24-22fcc0fc2ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_52963fd4-3a45-42f6-bd24-22fcc0fc2ebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_23167f06-0f5f-45f3-866a-2978c4ad88d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_23167f06-0f5f-45f3-866a-2978c4ad88d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_b6503ce5-a67a-45f9-9078-7db310264ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_GainLossOnInvestments_b6503ce5-a67a-45f9-9078-7db310264ce6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3f146bc0-7905-4846-91fd-3eff36bfa21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3f146bc0-7905-4846-91fd-3eff36bfa21f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2329414f-5f71-400a-9225-ba133fb658b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8eb6f64b-ed6f-49d3-9e74-73ecf0d97380" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2329414f-5f71-400a-9225-ba133fb658b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1908cfc-41c3-4319-a381-cd952ca437a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b841810d-c1c3-43ef-9e0e-bb4dd4e6b82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1908cfc-41c3-4319-a381-cd952ca437a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b841810d-c1c3-43ef-9e0e-bb4dd4e6b82f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_f0fb0132-1145-469b-b61b-77f29551de00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1908cfc-41c3-4319-a381-cd952ca437a9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_f0fb0132-1145-469b-b61b-77f29551de00" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"/>
  <link:calculationLink xlink:role="http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_406a5c27-cffe-40c8-8453-5b090c4a1c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ad34a674-66a2-449d-8ec3-89a05d9e2e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_406a5c27-cffe-40c8-8453-5b090c4a1c1d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ad34a674-66a2-449d-8ec3-89a05d9e2e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d0823924-b69f-43ac-8dbf-1bd0a20b9fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_406a5c27-cffe-40c8-8453-5b090c4a1c1d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d0823924-b69f-43ac-8dbf-1bd0a20b9fda" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail"/>
  <link:calculationLink xlink:role="http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ff3bd39-36fa-4511-817c-29702fcf2d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9b191987-1cca-4e07-b52e-38119c58b536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ff3bd39-36fa-4511-817c-29702fcf2d84" xlink:to="loc_us-gaap_OtherAssetsCurrent_9b191987-1cca-4e07-b52e-38119c58b536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_32079f41-c9a9-4ffe-ba45-16a3f2d1329b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ff3bd39-36fa-4511-817c-29702fcf2d84" xlink:to="loc_us-gaap_InterestReceivableCurrent_32079f41-c9a9-4ffe-ba45-16a3f2d1329b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_PrepaidResearchAndDevelopmentExpenses_2ac14594-7698-41ee-8db6-c606237d86b9" xlink:href="nexi-20221231.xsd#nexi_PrepaidResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ff3bd39-36fa-4511-817c-29702fcf2d84" xlink:to="loc_nexi_PrepaidResearchAndDevelopmentExpenses_2ac14594-7698-41ee-8db6-c606237d86b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_87a774d2-9c1f-4516-ae2a-9ffda98d9282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ff3bd39-36fa-4511-817c-29702fcf2d84" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_87a774d2-9c1f-4516-ae2a-9ffda98d9282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_86b3f43a-a001-437e-9dd1-9a5cb7fc3549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ff3bd39-36fa-4511-817c-29702fcf2d84" xlink:to="loc_us-gaap_PrepaidInsurance_86b3f43a-a001-437e-9dd1-9a5cb7fc3549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_PrepaidMaintenanceAgreements_ada910ca-bd65-4f94-8e32-741fbbded628" xlink:href="nexi-20221231.xsd#nexi_PrepaidMaintenanceAgreements"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1ff3bd39-36fa-4511-817c-29702fcf2d84" xlink:to="loc_nexi_PrepaidMaintenanceAgreements_ada910ca-bd65-4f94-8e32-741fbbded628" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#PropertyandEquipmentSummaryofPropertyAndEquipmentDetail"/>
  <link:calculationLink xlink:role="http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_677cf85f-8e44-4d0b-8489-a525427bbba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ba51cd2b-d8b6-4931-8a31-a22c859fbee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_677cf85f-8e44-4d0b-8489-a525427bbba1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ba51cd2b-d8b6-4931-8a31-a22c859fbee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_423f519d-385a-441e-817f-72cb8b3a2b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_677cf85f-8e44-4d0b-8489-a525427bbba1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_423f519d-385a-441e-817f-72cb8b3a2b26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#AccruedExpensesSummaryofComponentsofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_015aa461-b055-4bae-a120-52865ee98eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_582fdb9f-fcf8-419d-b768-49a15af35f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_015aa461-b055-4bae-a120-52865ee98eaa" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_582fdb9f-fcf8-419d-b768-49a15af35f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9207ca97-459e-4919-a300-3c20465eb07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_015aa461-b055-4bae-a120-52865ee98eaa" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9207ca97-459e-4919-a300-3c20465eb07f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6b7979ee-5297-4a01-bacd-c32de11c5d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_015aa461-b055-4bae-a120-52865ee98eaa" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6b7979ee-5297-4a01-bacd-c32de11c5d00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_AccruedResearchAndDevelopmentCostsCurrent_fa4dd8aa-7b83-4b3f-833b-0209a9dbecb4" xlink:href="nexi-20221231.xsd#nexi_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_015aa461-b055-4bae-a120-52865ee98eaa" xlink:to="loc_nexi_AccruedResearchAndDevelopmentCostsCurrent_fa4dd8aa-7b83-4b3f-833b-0209a9dbecb4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b94e5e98-d85e-455c-b514-b6660b3da045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_c63119cc-d00c-4515-b1aa-8e8103e017d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b94e5e98-d85e-455c-b514-b6660b3da045" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_c63119cc-d00c-4515-b1aa-8e8103e017d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0518f14d-415a-41d8-8721-3e38232af56f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b94e5e98-d85e-455c-b514-b6660b3da045" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0518f14d-415a-41d8-8721-3e38232af56f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_576bab2b-5447-48c1-af85-53541850e632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b94e5e98-d85e-455c-b514-b6660b3da045" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_576bab2b-5447-48c1-af85-53541850e632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_835dcef5-712e-46f3-9a0d-e7392fd09d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_915f2010-fd79-4289-9b06-968344a9d260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_835dcef5-712e-46f3-9a0d-e7392fd09d72" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_915f2010-fd79-4289-9b06-968344a9d260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0c3cd3c6-4722-4ce5-a6ae-aae77ff606d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_835dcef5-712e-46f3-9a0d-e7392fd09d72" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0c3cd3c6-4722-4ce5-a6ae-aae77ff606d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f15b45ea-04b2-449f-8167-1581c6434338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7dd7730a-fceb-45b3-ba13-173b883a87b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f15b45ea-04b2-449f-8167-1581c6434338" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7dd7730a-fceb-45b3-ba13-173b883a87b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_183f4dc8-06af-4627-b402-02114eaf68b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f15b45ea-04b2-449f-8167-1581c6434338" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_183f4dc8-06af-4627-b402-02114eaf68b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fb6ffb7e-1a1e-4bbf-9782-5bf53f02b806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4c3b561e-eeee-42e0-ad11-df708cd95da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fb6ffb7e-1a1e-4bbf-9782-5bf53f02b806" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4c3b561e-eeee-42e0-ad11-df708cd95da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_df263072-3b2e-4916-8752-b12590b9816e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fb6ffb7e-1a1e-4bbf-9782-5bf53f02b806" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_df263072-3b2e-4916-8752-b12590b9816e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d98ef264-2031-4e82-8358-81588eb933a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fb6ffb7e-1a1e-4bbf-9782-5bf53f02b806" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d98ef264-2031-4e82-8358-81588eb933a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f8334d37-3f2c-4236-900b-2b2fa92f26a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fb6ffb7e-1a1e-4bbf-9782-5bf53f02b806" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f8334d37-3f2c-4236-900b-2b2fa92f26a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b5a16a7c-c80f-490a-a079-5942756ebb95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fb6ffb7e-1a1e-4bbf-9782-5bf53f02b806" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b5a16a7c-c80f-490a-a079-5942756ebb95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ad76b352-621d-4c1d-92e2-f8667c80c56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fb6ffb7e-1a1e-4bbf-9782-5bf53f02b806" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ad76b352-621d-4c1d-92e2-f8667c80c56a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_595371a4-91e7-4168-af42-8a17444870ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_798484f1-2fda-477e-899f-2aae7f8c13e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_595371a4-91e7-4168-af42-8a17444870ed" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_798484f1-2fda-477e-899f-2aae7f8c13e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d5b1901d-61cf-4851-b41d-87d893676fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_595371a4-91e7-4168-af42-8a17444870ed" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d5b1901d-61cf-4851-b41d-87d893676fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a7d7aa66-e38b-4072-bc76-0d2bb375a7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d6374d5d-2eb2-4c15-ad42-9f45c8b76b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a7d7aa66-e38b-4072-bc76-0d2bb375a7fc" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d6374d5d-2eb2-4c15-ad42-9f45c8b76b2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4fd2f928-9eb8-4c81-bb12-54b58b4bedac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a7d7aa66-e38b-4072-bc76-0d2bb375a7fc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4fd2f928-9eb8-4c81-bb12-54b58b4bedac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DeferredTaxAssetsOperatingLeases_4084b322-3bd1-4c52-89cb-a170726bdf4a" xlink:href="nexi-20221231.xsd#nexi_DeferredTaxAssetsOperatingLeases"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a7d7aa66-e38b-4072-bc76-0d2bb375a7fc" xlink:to="loc_nexi_DeferredTaxAssetsOperatingLeases_4084b322-3bd1-4c52-89cb-a170726bdf4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_f89a41bd-b3f9-4767-a93f-567c04110e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a7d7aa66-e38b-4072-bc76-0d2bb375a7fc" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_f89a41bd-b3f9-4767-a93f-567c04110e88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_bbea4a14-13b0-49f8-b7b7-84cdea284e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a7d7aa66-e38b-4072-bc76-0d2bb375a7fc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_bbea4a14-13b0-49f8-b7b7-84cdea284e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_14ef4cb3-0217-47d8-9d97-8eb0eab49380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a7d7aa66-e38b-4072-bc76-0d2bb375a7fc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_14ef4cb3-0217-47d8-9d97-8eb0eab49380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_244280b5-a887-4535-b36d-7d997a2c1bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a7d7aa66-e38b-4072-bc76-0d2bb375a7fc" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_244280b5-a887-4535-b36d-7d997a2c1bf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_18627411-a09d-4e3e-a166-7503e0396184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d83063ea-0bbe-47e5-8705-441d003cdbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_18627411-a09d-4e3e-a166-7503e0396184" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d83063ea-0bbe-47e5-8705-441d003cdbdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_19bd6103-5caa-438a-a22a-ac9cfc406210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_18627411-a09d-4e3e-a166-7503e0396184" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_19bd6103-5caa-438a-a22a-ac9cfc406210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7aecad7c-a700-4c89-ad2e-5bc061974cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ae91b0c3-12ef-4c09-a3fe-f0e7d12ba4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7aecad7c-a700-4c89-ad2e-5bc061974cd1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ae91b0c3-12ef-4c09-a3fe-f0e7d12ba4eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1e48fb29-db53-40fd-85f0-fe19cec6a6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_7aecad7c-a700-4c89-ad2e-5bc061974cd1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1e48fb29-db53-40fd-85f0-fe19cec6a6e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#LeasesFutureFixedLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f778406-1343-4efe-b523-39e7fa111ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_656670f9-081f-4a3f-9bb0-2f5c44bdbe62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f778406-1343-4efe-b523-39e7fa111ab9" xlink:to="loc_us-gaap_OperatingLeaseLiability_656670f9-081f-4a3f-9bb0-2f5c44bdbe62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f4068ab1-05ae-4d8a-8df4-895c428251ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5f778406-1343-4efe-b523-39e7fa111ab9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f4068ab1-05ae-4d8a-8df4-895c428251ad" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>nexi-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1d01bc3b-109a-450d-9ee6-f84eb8561d2c,g:e7038408-d172-479b-b01e-e62e0cc0d235-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity" xlink:type="simple" xlink:href="nexi-20221231.xsd#StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"/>
  <link:definitionLink xlink:role="http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity" xlink:type="extended" id="icebab20ba632408d9b52d4f73ae3c2c6_StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ff318db0-55e2-4b3c-8731-c1e10050e684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ff318db0-55e2-4b3c-8731-c1e10050e684" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7f9947f4-fe08-42db-8131-335eba67f7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7f9947f4-fe08-42db-8131-335eba67f7f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6fde220f-ca7e-41ca-8d43-2aaa45a2e133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6fde220f-ca7e-41ca-8d43-2aaa45a2e133" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c45f858d-dfaf-45a9-ac8c-610c47b751c8" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c45f858d-dfaf-45a9-ac8c-610c47b751c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5adb8cd3-d2b2-40b7-bf23-f70c1c9c7a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5adb8cd3-d2b2-40b7-bf23-f70c1c9c7a45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityStockConvertedDuringPeriodShares_e9f80cbc-4be9-4a92-b4b2-24935c71e631" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityStockConvertedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_nexi_TemporaryEquityStockConvertedDuringPeriodShares_e9f80cbc-4be9-4a92-b4b2-24935c71e631" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityStockConvertedDuringPeriodValue_770460d5-db35-45a7-a486-157ea5f60f0e" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityStockConvertedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_nexi_TemporaryEquityStockConvertedDuringPeriodValue_770460d5-db35-45a7-a486-157ea5f60f0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_87428272-f4ce-4d49-b1b5-9c0bddb222b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f58ac608-0f8b-4636-a170-d3fa61f20113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ff318db0-55e2-4b3c-8731-c1e10050e684" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_128cf141-5898-4c85-b3dc-0f2875f12dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_SharesOutstanding_128cf141-5898-4c85-b3dc-0f2875f12dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_32f19208-5b8d-4e9c-8c57-2c7a4e94bcde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockholdersEquity_32f19208-5b8d-4e9c-8c57-2c7a4e94bcde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_5e0a6c6f-a5af-4cd4-a5c1-5efbb25caa20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_5e0a6c6f-a5af-4cd4-a5c1-5efbb25caa20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c663d337-e1a0-4615-92d0-a6fbb326157b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c663d337-e1a0-4615-92d0-a6fbb326157b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_4cc2b640-2d1a-4e08-a7c5-e00e96d855b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_4cc2b640-2d1a-4e08-a7c5-e00e96d855b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt_304ca6b7-1de4-4003-9be0-8d50b17b9d70" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt_304ca6b7-1de4-4003-9be0-8d50b17b9d70" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt_43ab68d5-523d-4076-bd2f-256cb38b97e7" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt_43ab68d5-523d-4076-bd2f-256cb38b97e7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c9d41ebe-817f-4125-94b1-61ef3db979d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c9d41ebe-817f-4125-94b1-61ef3db979d3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_48092de5-692d-4337-8504-ae7f3de243e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_48092de5-692d-4337-8504-ae7f3de243e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_865428c2-fdfc-44a6-bcfe-8603e87a4137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_865428c2-fdfc-44a6-bcfe-8603e87a4137" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f5932228-5cd9-4035-a09d-a2257c8254dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f5932228-5cd9-4035-a09d-a2257c8254dc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod_65969f42-0fa7-4020-826f-a270977cad54" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod_65969f42-0fa7-4020-826f-a270977cad54" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised_481d0bee-4898-44cc-bf07-b449c7fd2fcb" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised_481d0bee-4898-44cc-bf07-b449c7fd2fcb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_NumberOfWarrantsExercised_9783faa6-641d-4028-8218-54ca7965471c" xlink:href="nexi-20221231.xsd#nexi_NumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_nexi_NumberOfWarrantsExercised_9783faa6-641d-4028-8218-54ca7965471c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c6d3c97d-3054-41ff-8e57-70c50aaef6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c6d3c97d-3054-41ff-8e57-70c50aaef6c0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_387cd492-8e7c-463a-9ed0-fb4d22d4e648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_387cd492-8e7c-463a-9ed0-fb4d22d4e648" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_990d43cb-1bcd-4092-bfa6-65d1d729a13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_NetIncomeLoss_990d43cb-1bcd-4092-bfa6-65d1d729a13e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_924293f8-af4e-404f-95d7-286ea7fc847d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_10a97021-185f-4ec8-82eb-31c44b300621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2e4f68da-3720-49d6-baa5-ac8d3ff71ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ff318db0-55e2-4b3c-8731-c1e10050e684" xlink:to="loc_us-gaap_StatementTable_2e4f68da-3720-49d6-baa5-ac8d3ff71ad4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3f9cf9ed-efdf-418b-927a-46413f31bfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2e4f68da-3720-49d6-baa5-ac8d3ff71ad4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3f9cf9ed-efdf-418b-927a-46413f31bfb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3f9cf9ed-efdf-418b-927a-46413f31bfb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f9cf9ed-efdf-418b-927a-46413f31bfb9" xlink:to="loc_us-gaap_EquityComponentDomain_3f9cf9ed-efdf-418b-927a-46413f31bfb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f9cf9ed-efdf-418b-927a-46413f31bfb9" xlink:to="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_aadae989-2db2-470c-9027-cb5f7848966d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:to="loc_us-gaap_CommonStockMember_aadae989-2db2-470c-9027-cb5f7848966d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8273d6e8-985a-41b5-af5d-c18c85bc2d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8273d6e8-985a-41b5-af5d-c18c85bc2d56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f0659bee-6818-4c16-8dcc-e650dc44a3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:to="loc_us-gaap_RetainedEarningsMember_f0659bee-6818-4c16-8dcc-e650dc44a3e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_43a4764c-5bb7-47c8-ac49-6000d31bcdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_43a4764c-5bb7-47c8-ac49-6000d31bcdec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_73def146-1e56-480d-b7be-ca5150ce02c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2e4f68da-3720-49d6-baa5-ac8d3ff71ad4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_73def146-1e56-480d-b7be-ca5150ce02c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_73def146-1e56-480d-b7be-ca5150ce02c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73def146-1e56-480d-b7be-ca5150ce02c1" xlink:to="loc_us-gaap_ClassOfStockDomain_73def146-1e56-480d-b7be-ca5150ce02c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2a09a242-03c1-4957-8f01-bd3821efd836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73def146-1e56-480d-b7be-ca5150ce02c1" xlink:to="loc_us-gaap_ClassOfStockDomain_2a09a242-03c1-4957-8f01-bd3821efd836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SeriesARedeemableConvertiblePreferredStockMember_c53f76d1-61cc-4cd0-9333-814e6541856b" xlink:href="nexi-20221231.xsd#nexi_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a09a242-03c1-4957-8f01-bd3821efd836" xlink:to="loc_nexi_SeriesARedeemableConvertiblePreferredStockMember_c53f76d1-61cc-4cd0-9333-814e6541856b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember_a511b1fa-2d19-4545-99d8-de1f97bbae08" xlink:href="nexi-20221231.xsd#nexi_SeriesATwoRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a09a242-03c1-4957-8f01-bd3821efd836" xlink:to="loc_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember_a511b1fa-2d19-4545-99d8-de1f97bbae08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember_59e70615-f94a-4fd7-b29a-b08ae0bedc6b" xlink:href="nexi-20221231.xsd#nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a09a242-03c1-4957-8f01-bd3821efd836" xlink:to="loc_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember_59e70615-f94a-4fd7-b29a-b08ae0bedc6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e921694-3f47-40e4-b9b9-111bf10fdaaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2e4f68da-3720-49d6-baa5-ac8d3ff71ad4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e921694-3f47-40e4-b9b9-111bf10fdaaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8e921694-3f47-40e4-b9b9-111bf10fdaaf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e921694-3f47-40e4-b9b9-111bf10fdaaf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8e921694-3f47-40e4-b9b9-111bf10fdaaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d38444c9-bd4b-4f15-9abc-1fc57ce7d378" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e921694-3f47-40e4-b9b9-111bf10fdaaf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d38444c9-bd4b-4f15-9abc-1fc57ce7d378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_77c2b215-f043-4a78-93b1-5f23c61d358a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d38444c9-bd4b-4f15-9abc-1fc57ce7d378" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_77c2b215-f043-4a78-93b1-5f23c61d358a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="ie0a369eb5a304d9cadb31b4bba1015ef_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a394301a-ebcb-4529-a608-7480025057e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a394301a-ebcb-4529-a608-7480025057e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_c9db03b6-90b3-45e4-8339-a6aa23b9fabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_MarketableSecurities_c9db03b6-90b3-45e4-8339-a6aa23b9fabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9abba3b7-6331-4161-a674-39fa2e12a10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9abba3b7-6331-4161-a674-39fa2e12a10a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f939d8ca-e3f2-4ba1-bd93-54041363a583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f939d8ca-e3f2-4ba1-bd93-54041363a583" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_74750ee4-53c3-4ab5-976c-105980320d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_74750ee4-53c3-4ab5-976c-105980320d3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7fa6f086-3f03-41aa-96b3-20000b493b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7fa6f086-3f03-41aa-96b3-20000b493b9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d449cd2c-31e8-4bbf-bdef-8a396b354f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d449cd2c-31e8-4bbf-bdef-8a396b354f0b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_43fa4421-32fc-4139-80b4-4137638ddcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_43fa4421-32fc-4139-80b4-4137638ddcf5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d0ed6cb2-0602-40f7-a7fe-54f8e7a066e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d0ed6cb2-0602-40f7-a7fe-54f8e7a066e0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4b7455ec-961f-4ab7-8a2e-c304d7075eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4b7455ec-961f-4ab7-8a2e-c304d7075eac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cf3aea4-509a-4239-8e52-e49bb57dfa02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cf3aea4-509a-4239-8e52-e49bb57dfa02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b000c4f3-50f1-49a1-b6d4-e1e1722884d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cf3aea4-509a-4239-8e52-e49bb57dfa02" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b000c4f3-50f1-49a1-b6d4-e1e1722884d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b000c4f3-50f1-49a1-b6d4-e1e1722884d3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b000c4f3-50f1-49a1-b6d4-e1e1722884d3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b000c4f3-50f1-49a1-b6d4-e1e1722884d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_080de70a-efc5-485c-9400-8fa99271b9b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b000c4f3-50f1-49a1-b6d4-e1e1722884d3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_080de70a-efc5-485c-9400-8fa99271b9b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_636b79ec-3c5a-4939-a1e5-657827fc7233" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_080de70a-efc5-485c-9400-8fa99271b9b6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_636b79ec-3c5a-4939-a1e5-657827fc7233" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c5085c5a-0f96-46fb-a95a-0af2ab750dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cf3aea4-509a-4239-8e52-e49bb57dfa02" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c5085c5a-0f96-46fb-a95a-0af2ab750dff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c5085c5a-0f96-46fb-a95a-0af2ab750dff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5085c5a-0f96-46fb-a95a-0af2ab750dff" xlink:to="loc_us-gaap_EquityComponentDomain_c5085c5a-0f96-46fb-a95a-0af2ab750dff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14a25be2-1ab4-4ee0-aa1e-3b243fde187b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5085c5a-0f96-46fb-a95a-0af2ab750dff" xlink:to="loc_us-gaap_EquityComponentDomain_14a25be2-1ab4-4ee0-aa1e-3b243fde187b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_32b6dbcc-8447-42c6-a0cf-3aff9f71bffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14a25be2-1ab4-4ee0-aa1e-3b243fde187b" xlink:to="loc_us-gaap_RetainedEarningsMember_32b6dbcc-8447-42c6-a0cf-3aff9f71bffa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1315538c-ea57-4b37-92d1-d54297b95c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14a25be2-1ab4-4ee0-aa1e-3b243fde187b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1315538c-ea57-4b37-92d1-d54297b95c2b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i11a0fa6793da4bb094df219522a6adce_SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e422213-0208-44b7-a0eb-4ff283cfff41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_13add06d-67e7-44b2-90b5-d502640eba0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e422213-0208-44b7-a0eb-4ff283cfff41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_13add06d-67e7-44b2-90b5-d502640eba0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdbd6533-ad17-482e-8eb8-03bd00a3f293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e422213-0208-44b7-a0eb-4ff283cfff41" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdbd6533-ad17-482e-8eb8-03bd00a3f293" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_710104a7-fc9c-4630-8d62-bfe193c8efde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdbd6533-ad17-482e-8eb8-03bd00a3f293" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_710104a7-fc9c-4630-8d62-bfe193c8efde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_710104a7-fc9c-4630-8d62-bfe193c8efde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_710104a7-fc9c-4630-8d62-bfe193c8efde" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_710104a7-fc9c-4630-8d62-bfe193c8efde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60f0aed5-8e99-4d73-9e10-08bc8c74a642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_710104a7-fc9c-4630-8d62-bfe193c8efde" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60f0aed5-8e99-4d73-9e10-08bc8c74a642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_LaboratoryEquipmentMember_434755c4-3f2f-4559-8ffb-f567e4fe10ec" xlink:href="nexi-20221231.xsd#nexi_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60f0aed5-8e99-4d73-9e10-08bc8c74a642" xlink:to="loc_nexi_LaboratoryEquipmentMember_434755c4-3f2f-4559-8ffb-f567e4fe10ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ComputerEquipmentAndSoftwareMember_60a20f58-c68c-44dc-ae6c-f5838631fdfc" xlink:href="nexi-20221231.xsd#nexi_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60f0aed5-8e99-4d73-9e10-08bc8c74a642" xlink:to="loc_nexi_ComputerEquipmentAndSoftwareMember_60a20f58-c68c-44dc-ae6c-f5838631fdfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c0ef5236-10ee-4a90-b10c-5c53b1f329de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60f0aed5-8e99-4d73-9e10-08bc8c74a642" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c0ef5236-10ee-4a90-b10c-5c53b1f329de" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails" xlink:type="extended" id="iac4e8757e720496bb9e04f651a661ce4_SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3791867f-7ef6-460e-98c2-7541a29871d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_78d736ad-50bd-475d-b665-bd69f25ae49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3791867f-7ef6-460e-98c2-7541a29871d2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_78d736ad-50bd-475d-b665-bd69f25ae49c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_904b7a97-74e1-408a-9968-71aa116c0144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3791867f-7ef6-460e-98c2-7541a29871d2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_904b7a97-74e1-408a-9968-71aa116c0144" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e9d715c-e0bc-4590-9c2d-badda72695a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_904b7a97-74e1-408a-9968-71aa116c0144" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e9d715c-e0bc-4590-9c2d-badda72695a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e9d715c-e0bc-4590-9c2d-badda72695a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e9d715c-e0bc-4590-9c2d-badda72695a5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9e9d715c-e0bc-4590-9c2d-badda72695a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e9d715c-e0bc-4590-9c2d-badda72695a5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_597395ed-482c-4fd4-8131-38d178759fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:to="loc_us-gaap_EmployeeStockOptionMember_597395ed-482c-4fd4-8131-38d178759fdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_14fdaf6f-b4a4-4b50-8569-dcabf9ab9345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_14fdaf6f-b4a4-4b50-8569-dcabf9ab9345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_23132799-8e11-4462-9db2-2288077d6d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_23132799-8e11-4462-9db2-2288077d6d2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_2b5aee4d-6018-4e06-ac43-ee14af5eb429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_2b5aee4d-6018-4e06-ac43-ee14af5eb429" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_798c5db0-285a-4aeb-be22-a527bbd7e469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:to="loc_us-gaap_WarrantMember_798c5db0-285a-4aeb-be22-a527bbd7e469" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail" xlink:type="extended" id="i94e0b8d61fef4d76b83648c412951680_FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ef57d5-803d-4f72-9c2a-45bef555b6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_df3be17c-00f5-478e-818d-80b942026b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ef57d5-803d-4f72-9c2a-45bef555b6e1" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_df3be17c-00f5-478e-818d-80b942026b72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bcbf5d0d-b876-47fa-8807-462bdb471cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_df3be17c-00f5-478e-818d-80b942026b72" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bcbf5d0d-b876-47fa-8807-462bdb471cb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d07b5520-1c56-42d0-b681-e1e381062fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_df3be17c-00f5-478e-818d-80b942026b72" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d07b5520-1c56-42d0-b681-e1e381062fda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5173332b-3051-49d6-9853-6476bb94e15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_df3be17c-00f5-478e-818d-80b942026b72" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5173332b-3051-49d6-9853-6476bb94e15a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4bb5e6c-d897-41fd-ba7f-dfd754ada8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ef57d5-803d-4f72-9c2a-45bef555b6e1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4bb5e6c-d897-41fd-ba7f-dfd754ada8f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a796ec13-39eb-4c50-9188-e4ee40678437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4bb5e6c-d897-41fd-ba7f-dfd754ada8f6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a796ec13-39eb-4c50-9188-e4ee40678437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a796ec13-39eb-4c50-9188-e4ee40678437_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a796ec13-39eb-4c50-9188-e4ee40678437" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a796ec13-39eb-4c50-9188-e4ee40678437_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfd7230e-ec10-434f-8a1b-e184153259cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a796ec13-39eb-4c50-9188-e4ee40678437" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfd7230e-ec10-434f-8a1b-e184153259cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_02ca74ca-ca50-4136-bcd1-99e0c06cf8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfd7230e-ec10-434f-8a1b-e184153259cc" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_02ca74ca-ca50-4136-bcd1-99e0c06cf8a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_94f81486-b630-4313-b9e7-d45dd006f3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfd7230e-ec10-434f-8a1b-e184153259cc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_94f81486-b630-4313-b9e7-d45dd006f3d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4b3cffa4-6d91-4fb7-abad-64746ef70cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfd7230e-ec10-434f-8a1b-e184153259cc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4b3cffa4-6d91-4fb7-abad-64746ef70cca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_caaae815-a2be-4fe7-9563-64885cc6e2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4bb5e6c-d897-41fd-ba7f-dfd754ada8f6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_caaae815-a2be-4fe7-9563-64885cc6e2db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_caaae815-a2be-4fe7-9563-64885cc6e2db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_caaae815-a2be-4fe7-9563-64885cc6e2db" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_caaae815-a2be-4fe7-9563-64885cc6e2db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_77f30c1b-1ab3-4e46-a93b-e38ae8252c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_caaae815-a2be-4fe7-9563-64885cc6e2db" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_77f30c1b-1ab3-4e46-a93b-e38ae8252c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9dd8a12c-b3d0-4b65-a6aa-316df2c56421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_77f30c1b-1ab3-4e46-a93b-e38ae8252c1f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9dd8a12c-b3d0-4b65-a6aa-316df2c56421" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e2bf35d8-5d6f-48c4-9f5f-d165632cec9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4bb5e6c-d897-41fd-ba7f-dfd754ada8f6" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e2bf35d8-5d6f-48c4-9f5f-d165632cec9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e2bf35d8-5d6f-48c4-9f5f-d165632cec9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e2bf35d8-5d6f-48c4-9f5f-d165632cec9c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e2bf35d8-5d6f-48c4-9f5f-d165632cec9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_69425cc9-e19e-44a0-b753-a5d7df14ca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e2bf35d8-5d6f-48c4-9f5f-d165632cec9c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_69425cc9-e19e-44a0-b753-a5d7df14ca3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d049fd73-b904-4807-8755-6a54a8c68725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_69425cc9-e19e-44a0-b753-a5d7df14ca3f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d049fd73-b904-4807-8755-6a54a8c68725" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_d200ec64-8a2d-4957-9581-d1ff0bc80297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_69425cc9-e19e-44a0-b753-a5d7df14ca3f" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_d200ec64-8a2d-4957-9581-d1ff0bc80297" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#PropertyandEquipmentSummaryofPropertyAndEquipmentDetail"/>
  <link:definitionLink xlink:role="http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail" xlink:type="extended" id="ic768e03483b04313ad8e530562f3101e_PropertyandEquipmentSummaryofPropertyAndEquipmentDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40d30834-68b4-4107-ad50-9512b34b8a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f033a520-d19e-4804-bfac-2ffd41853d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40d30834-68b4-4107-ad50-9512b34b8a03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f033a520-d19e-4804-bfac-2ffd41853d52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_855e6005-712e-4992-842d-390734182607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40d30834-68b4-4107-ad50-9512b34b8a03" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_855e6005-712e-4992-842d-390734182607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12dc357d-5b47-4fa7-a7dd-3a44f9e2a2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40d30834-68b4-4107-ad50-9512b34b8a03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12dc357d-5b47-4fa7-a7dd-3a44f9e2a2bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_12e5205a-03b5-4356-9be6-3f2cd194f4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40d30834-68b4-4107-ad50-9512b34b8a03" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_12e5205a-03b5-4356-9be6-3f2cd194f4a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cdbfbfe0-19a7-4657-a4e8-e25db4d2da3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_12e5205a-03b5-4356-9be6-3f2cd194f4a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cdbfbfe0-19a7-4657-a4e8-e25db4d2da3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cdbfbfe0-19a7-4657-a4e8-e25db4d2da3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cdbfbfe0-19a7-4657-a4e8-e25db4d2da3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cdbfbfe0-19a7-4657-a4e8-e25db4d2da3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cdbfbfe0-19a7-4657-a4e8-e25db4d2da3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_LaboratoryEquipmentMember_60382c00-dc84-410d-b926-f82f1c35e640" xlink:href="nexi-20221231.xsd#nexi_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:to="loc_nexi_LaboratoryEquipmentMember_60382c00-dc84-410d-b926-f82f1c35e640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ComputerEquipmentAndSoftwareMember_296631ea-cc56-42b9-b09d-02179f01906a" xlink:href="nexi-20221231.xsd#nexi_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:to="loc_nexi_ComputerEquipmentAndSoftwareMember_296631ea-cc56-42b9-b09d-02179f01906a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_17754905-430e-4df3-9cd4-fab3800b6dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_17754905-430e-4df3-9cd4-fab3800b6dfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c790f114-f810-4bfc-b912-fa9c459905ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c790f114-f810-4bfc-b912-fa9c459905ee" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/RestructuringActivitiesDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#RestructuringActivitiesDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/RestructuringActivitiesDetails" xlink:type="extended" id="i8ee2b6e460d74dc088d63028700ef1ab_RestructuringActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent_ccbdcb79-4893-4adf-9a57-c5885369016f" xlink:href="nexi-20221231.xsd#nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent_ccbdcb79-4893-4adf-9a57-c5885369016f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations_dba46f6e-6e41-4c3e-80aa-fbfe85ce5618" xlink:href="nexi-20221231.xsd#nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations_dba46f6e-6e41-4c3e-80aa-fbfe85ce5618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations_2310fbad-3323-4c17-a2ea-fdf30c9abb94" xlink:href="nexi-20221231.xsd#nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations_2310fbad-3323-4c17-a2ea-fdf30c9abb94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_9018618a-2279-43b2-a98a-a0e62b2155d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_9018618a-2279-43b2-a98a-a0e62b2155d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_0b7ca0af-7583-464c-b2e1-9475b7c785c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_us-gaap_RestructuringReserve_0b7ca0af-7583-464c-b2e1-9475b7c785c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_29191fc0-36ac-4810-89ca-ad931fce1c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_29191fc0-36ac-4810-89ca-ad931fce1c1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_05ed8e63-266c-40e2-b20f-9ff1e20a5146" xlink:href="nexi-20221231.xsd#nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_05ed8e63-266c-40e2-b20f-9ff1e20a5146" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b26974db-44c8-40c8-beb3-bce44c0af53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b26974db-44c8-40c8-beb3-bce44c0af53f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_56f1733f-52d5-453d-b939-20a2b4465dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b26974db-44c8-40c8-beb3-bce44c0af53f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_56f1733f-52d5-453d-b939-20a2b4465dc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_56f1733f-52d5-453d-b939-20a2b4465dc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_56f1733f-52d5-453d-b939-20a2b4465dc4" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_56f1733f-52d5-453d-b939-20a2b4465dc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e017273e-1922-4668-8089-7261d2198dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_56f1733f-52d5-453d-b939-20a2b4465dc4" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e017273e-1922-4668-8089-7261d2198dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_2ad39a73-460a-4c0c-995b-d9e1fc1862bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e017273e-1922-4668-8089-7261d2198dea" xlink:to="loc_us-gaap_EmployeeSeveranceMember_2ad39a73-460a-4c0c-995b-d9e1fc1862bf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails" xlink:type="extended" id="iddb0511daa1342e996362d7b2b15dde0_RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bd3fc8b1-570a-496b-b7a5-67a773dc05d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_31201539-8413-49d3-92f0-4b9b7b5de7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bd3fc8b1-570a-496b-b7a5-67a773dc05d8" xlink:to="loc_us-gaap_RestructuringReserveRollForward_31201539-8413-49d3-92f0-4b9b7b5de7ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_729771c5-c65c-46a1-a992-83cc522824c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31201539-8413-49d3-92f0-4b9b7b5de7ef" xlink:to="loc_us-gaap_RestructuringReserve_729771c5-c65c-46a1-a992-83cc522824c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a9eaef6b-8e77-4511-a837-85ef65e143e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31201539-8413-49d3-92f0-4b9b7b5de7ef" xlink:to="loc_us-gaap_RestructuringCharges_a9eaef6b-8e77-4511-a837-85ef65e143e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_483bf03a-f802-4d7c-9d84-529a556eb77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31201539-8413-49d3-92f0-4b9b7b5de7ef" xlink:to="loc_us-gaap_PaymentsForRestructuring_483bf03a-f802-4d7c-9d84-529a556eb77e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_1c19642e-7733-44f5-a74d-3f5a19e800d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3fa943c-1d70-4b1c-96b3-bcb9d20cd09c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bd3fc8b1-570a-496b-b7a5-67a773dc05d8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3fa943c-1d70-4b1c-96b3-bcb9d20cd09c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2ace02cd-81d1-47ee-88ae-8e1f641e64b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3fa943c-1d70-4b1c-96b3-bcb9d20cd09c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2ace02cd-81d1-47ee-88ae-8e1f641e64b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2ace02cd-81d1-47ee-88ae-8e1f641e64b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2ace02cd-81d1-47ee-88ae-8e1f641e64b6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2ace02cd-81d1-47ee-88ae-8e1f641e64b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a90f34a4-f6cf-44d6-bf86-0ed24b8a93e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2ace02cd-81d1-47ee-88ae-8e1f641e64b6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a90f34a4-f6cf-44d6-bf86-0ed24b8a93e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_a4ac3096-55fd-4059-a001-a6a998d0540d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a90f34a4-f6cf-44d6-bf86-0ed24b8a93e4" xlink:to="loc_us-gaap_EmployeeSeveranceMember_a4ac3096-55fd-4059-a001-a6a998d0540d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails" xlink:type="extended" id="i957fa263e86b4e489cdfb454203c9da7_CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability_2eff3a27-92a6-43d2-8d5e-d96dc802c43d" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability_2eff3a27-92a6-43d2-8d5e-d96dc802c43d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6c2a4cf3-9613-4699-bb89-418e1eb4cdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6c2a4cf3-9613-4699-bb89-418e1eb4cdc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage_ace3f885-48eb-4c8c-991f-41c8016b1a38" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage_ace3f885-48eb-4c8c-991f-41c8016b1a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod_2c86fb4a-9322-4674-a395-92f1a56ccbbf" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod_2c86fb4a-9322-4674-a395-92f1a56ccbbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage_e80a4227-b421-43cd-97f2-189b87bcf32c" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage_e80a4227-b421-43cd-97f2-189b87bcf32c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6eb544ef-f6a7-41ae-8909-f0ca7576c31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6eb544ef-f6a7-41ae-8909-f0ca7576c31d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentTable_8181f5d5-02a6-4c28-a855-b820731d937a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_us-gaap_SupplyCommitmentTable_8181f5d5-02a6-4c28-a855-b820731d937a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_70cb74f6-a8db-420c-8c09-3ab5e973cae5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SupplyCommitmentTable_8181f5d5-02a6-4c28-a855-b820731d937a" xlink:to="loc_srt_CounterpartyNameAxis_70cb74f6-a8db-420c-8c09-3ab5e973cae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70cb74f6-a8db-420c-8c09-3ab5e973cae5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_70cb74f6-a8db-420c-8c09-3ab5e973cae5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_70cb74f6-a8db-420c-8c09-3ab5e973cae5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd535406-89e7-4d43-8c53-8e53ff61329f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_70cb74f6-a8db-420c-8c09-3ab5e973cae5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd535406-89e7-4d43-8c53-8e53ff61329f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MarylandBiotechnologyCenterMember_9b51ff94-93dc-4f84-9b2a-174c09975726" xlink:href="nexi-20221231.xsd#nexi_MarylandBiotechnologyCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd535406-89e7-4d43-8c53-8e53ff61329f" xlink:to="loc_nexi_MarylandBiotechnologyCenterMember_9b51ff94-93dc-4f84-9b2a-174c09975726" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc9bac69-69df-4764-97db-1107d6c4ab01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SupplyCommitmentTable_8181f5d5-02a6-4c28-a855-b820731d937a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc9bac69-69df-4764-97db-1107d6c4ab01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc9bac69-69df-4764-97db-1107d6c4ab01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc9bac69-69df-4764-97db-1107d6c4ab01" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc9bac69-69df-4764-97db-1107d6c4ab01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d0c57ed-bb3d-4b4b-86e4-34b2ded093ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc9bac69-69df-4764-97db-1107d6c4ab01" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d0c57ed-bb3d-4b4b-86e4-34b2ded093ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TranslationalResearchAwardAgreementMember_2cd76059-2819-4fa8-9261-993bb9a794ee" xlink:href="nexi-20221231.xsd#nexi_TranslationalResearchAwardAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d0c57ed-bb3d-4b4b-86e4-34b2ded093ed" xlink:to="loc_nexi_TranslationalResearchAwardAgreementMember_2cd76059-2819-4fa8-9261-993bb9a794ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails" xlink:type="extended" id="i9d5ec07869d04be2bc18f288310aedb5_CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MilestoneFees_2eaa5989-33a9-4b08-a443-7b70fd556d53" xlink:href="nexi-20221231.xsd#nexi_MilestoneFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_nexi_MilestoneFees_2eaa5989-33a9-4b08-a443-7b70fd556d53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MinimumAnnualRoyaltyPayments_63110329-2a9d-44f5-ae2e-def0897937d6" xlink:href="nexi-20221231.xsd#nexi_MinimumAnnualRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_nexi_MinimumAnnualRoyaltyPayments_63110329-2a9d-44f5-ae2e-def0897937d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SublicenseConsiderationPaymentPercentMaximum_fe02b7a4-8b25-49a3-abe0-124cdd82cac5" xlink:href="nexi-20221231.xsd#nexi_SublicenseConsiderationPaymentPercentMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_nexi_SublicenseConsiderationPaymentPercentMaximum_fe02b7a4-8b25-49a3-abe0-124cdd82cac5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_CumulativeMinimumRoyalties_3850e115-fa4a-4702-a65d-6df71c249431" xlink:href="nexi-20221231.xsd#nexi_CumulativeMinimumRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_nexi_CumulativeMinimumRoyalties_3850e115-fa4a-4702-a65d-6df71c249431" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_0014c3e6-4d9c-4055-9672-596488777f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_us-gaap_RoyaltyExpense_0014c3e6-4d9c-4055-9672-596488777f9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_9b027a21-84fc-4ebc-ba03-fb6a5350dab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_9b027a21-84fc-4ebc-ba03-fb6a5350dab4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d8e473f9-004f-4e20-9a48-bf0533d6b012" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:to="loc_srt_CounterpartyNameAxis_d8e473f9-004f-4e20-9a48-bf0533d6b012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8e473f9-004f-4e20-9a48-bf0533d6b012_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d8e473f9-004f-4e20-9a48-bf0533d6b012" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8e473f9-004f-4e20-9a48-bf0533d6b012_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c073eac-2169-479e-b047-4a60cf6690d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d8e473f9-004f-4e20-9a48-bf0533d6b012" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c073eac-2169-479e-b047-4a60cf6690d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_JohnsHopkinsUniversityMember_9e768ef5-f054-4011-94db-fbfccb29619c" xlink:href="nexi-20221231.xsd#nexi_JohnsHopkinsUniversityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c073eac-2169-479e-b047-4a60cf6690d8" xlink:to="loc_nexi_JohnsHopkinsUniversityMember_9e768ef5-f054-4011-94db-fbfccb29619c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d017ef67-8bbf-4ed2-aea0-a4edfcfa8533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d017ef67-8bbf-4ed2-aea0-a4edfcfa8533" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d017ef67-8bbf-4ed2-aea0-a4edfcfa8533_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d017ef67-8bbf-4ed2-aea0-a4edfcfa8533" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d017ef67-8bbf-4ed2-aea0-a4edfcfa8533_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_537300b4-201a-48f3-860e-cd81597e8c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d017ef67-8bbf-4ed2-aea0-a4edfcfa8533" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_537300b4-201a-48f3-860e-cd81597e8c24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ExclusiveLicenseAgreementMember_8175463b-9dc5-4bcb-b2e6-2fdebd3b5017" xlink:href="nexi-20221231.xsd#nexi_ExclusiveLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_537300b4-201a-48f3-860e-cd81597e8c24" xlink:to="loc_nexi_ExclusiveLicenseAgreementMember_8175463b-9dc5-4bcb-b2e6-2fdebd3b5017" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MilestonesAxis_ec65a8d0-7c41-4d8b-ad8a-a064ed8d7be5" xlink:href="nexi-20221231.xsd#nexi_MilestonesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:to="loc_nexi_MilestonesAxis_ec65a8d0-7c41-4d8b-ad8a-a064ed8d7be5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MilestonesDomain_ec65a8d0-7c41-4d8b-ad8a-a064ed8d7be5_default" xlink:href="nexi-20221231.xsd#nexi_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nexi_MilestonesAxis_ec65a8d0-7c41-4d8b-ad8a-a064ed8d7be5" xlink:to="loc_nexi_MilestonesDomain_ec65a8d0-7c41-4d8b-ad8a-a064ed8d7be5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:href="nexi-20221231.xsd#nexi_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nexi_MilestonesAxis_ec65a8d0-7c41-4d8b-ad8a-a064ed8d7be5" xlink:to="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ClinicalTrialMilestonesMember_b9bc72f1-8269-424b-8e7b-e2f9f7006676" xlink:href="nexi-20221231.xsd#nexi_ClinicalTrialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:to="loc_nexi_ClinicalTrialMilestonesMember_b9bc72f1-8269-424b-8e7b-e2f9f7006676" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TherapeuticFieldMember_aad770c0-dd17-47c0-ad53-338af27562ed" xlink:href="nexi-20221231.xsd#nexi_TherapeuticFieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:to="loc_nexi_TherapeuticFieldMember_aad770c0-dd17-47c0-ad53-338af27562ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RegulatoryAndCommercialMilestonesMember_f57368c1-2a00-4a1e-b6a0-6f5274fdfa0f" xlink:href="nexi-20221231.xsd#nexi_RegulatoryAndCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:to="loc_nexi_RegulatoryAndCommercialMilestonesMember_f57368c1-2a00-4a1e-b6a0-6f5274fdfa0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_NonclinicalFieldMember_a30b6edf-a318-4c0b-928e-05332079d1a5" xlink:href="nexi-20221231.xsd#nexi_NonclinicalFieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:to="loc_nexi_NonclinicalFieldMember_a30b6edf-a318-4c0b-928e-05332079d1a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28de1ac5-f790-4fca-b168-6756a3a44beb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:to="loc_srt_RangeAxis_28de1ac5-f790-4fca-b168-6756a3a44beb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_28de1ac5-f790-4fca-b168-6756a3a44beb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_28de1ac5-f790-4fca-b168-6756a3a44beb" xlink:to="loc_srt_RangeMember_28de1ac5-f790-4fca-b168-6756a3a44beb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7464b4f9-9123-4ade-97ec-73679e83ddbc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_28de1ac5-f790-4fca-b168-6756a3a44beb" xlink:to="loc_srt_RangeMember_7464b4f9-9123-4ade-97ec-73679e83ddbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7ac151ec-da44-48ab-914a-5e6c1af84091" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7464b4f9-9123-4ade-97ec-73679e83ddbc" xlink:to="loc_srt_MinimumMember_7ac151ec-da44-48ab-914a-5e6c1af84091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8e631d2f-c20e-4d40-a958-49269206b91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8e631d2f-c20e-4d40-a958-49269206b91e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8e631d2f-c20e-4d40-a958-49269206b91e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8e631d2f-c20e-4d40-a958-49269206b91e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8e631d2f-c20e-4d40-a958-49269206b91e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b1fa3e17-e290-407b-a77c-5fe5e2089687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8e631d2f-c20e-4d40-a958-49269206b91e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b1fa3e17-e290-407b-a77c-5fe5e2089687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a062573-af96-4d8a-a275-44e1f3ad49ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b1fa3e17-e290-407b-a77c-5fe5e2089687" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a062573-af96-4d8a-a275-44e1f3ad49ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails" xlink:type="extended" id="i88ae830103dc44a2bed9944a16913518_CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_5839df64-b793-423a-81bf-8a3a02289f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1b0f9c37-7181-4387-bca7-e00f69ada9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5839df64-b793-423a-81bf-8a3a02289f16" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1b0f9c37-7181-4387-bca7-e00f69ada9bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_bbf74b9a-d8ce-4570-b49b-638432bf3baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5839df64-b793-423a-81bf-8a3a02289f16" xlink:to="loc_us-gaap_NotesPayableCurrent_bbf74b9a-d8ce-4570-b49b-638432bf3baf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_132d0539-9ecd-477c-9342-457c13db0d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5839df64-b793-423a-81bf-8a3a02289f16" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_132d0539-9ecd-477c-9342-457c13db0d1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_a1a8b38c-5ab9-4299-b02f-777aae1ee8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5839df64-b793-423a-81bf-8a3a02289f16" xlink:to="loc_us-gaap_OtherCommitmentsTable_a1a8b38c-5ab9-4299-b02f-777aae1ee8dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c7f8bac2-ec55-4064-bece-53cbd30e6b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_a1a8b38c-5ab9-4299-b02f-777aae1ee8dc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c7f8bac2-ec55-4064-bece-53cbd30e6b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c7f8bac2-ec55-4064-bece-53cbd30e6b6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c7f8bac2-ec55-4064-bece-53cbd30e6b6f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c7f8bac2-ec55-4064-bece-53cbd30e6b6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1279e012-ae19-495c-aa63-d7d669f47f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c7f8bac2-ec55-4064-bece-53cbd30e6b6f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1279e012-ae19-495c-aa63-d7d669f47f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_PaycheckProtectionProgramLoanMember_f6baa3a5-c67a-4a85-8a45-3ca21883293f" xlink:href="nexi-20221231.xsd#nexi_PaycheckProtectionProgramLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1279e012-ae19-495c-aa63-d7d669f47f9d" xlink:to="loc_nexi_PaycheckProtectionProgramLoanMember_f6baa3a5-c67a-4a85-8a45-3ca21883293f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1c00f2cf-6239-4526-b429-ef246d7a4bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_a1a8b38c-5ab9-4299-b02f-777aae1ee8dc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1c00f2cf-6239-4526-b429-ef246d7a4bdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1c00f2cf-6239-4526-b429-ef246d7a4bdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c00f2cf-6239-4526-b429-ef246d7a4bdf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1c00f2cf-6239-4526-b429-ef246d7a4bdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e7a26984-dfe2-4894-8f43-bd3d0dcf3e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c00f2cf-6239-4526-b429-ef246d7a4bdf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e7a26984-dfe2-4894-8f43-bd3d0dcf3e42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_c13cdcd4-246b-403e-9851-832e378e0b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e7a26984-dfe2-4894-8f43-bd3d0dcf3e42" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_c13cdcd4-246b-403e-9851-832e378e0b61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/ConvertibleNotesAdditionalInformationDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#ConvertibleNotesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://nex.com/role/ConvertibleNotesAdditionalInformationDetail" xlink:type="extended" id="i6f90f257cfa442d9b0079d49619c2466_ConvertibleNotesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8013a1e4-598b-4fc5-83af-841e7a9a9ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8013a1e4-598b-4fc5-83af-841e7a9a9ee0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd485f5a-e9a0-4abd-b3d2-74b8ab4cf358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd485f5a-e9a0-4abd-b3d2-74b8ab4cf358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentAdditionalClosingLockInPeriod_a39fb58d-e855-4ae4-8a23-c913b5eb3e02" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentAdditionalClosingLockInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtInstrumentAdditionalClosingLockInPeriod_a39fb58d-e855-4ae4-8a23-c913b5eb3e02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentConvertiblePricePercentage_c457f318-9aa3-45a8-86ae-6e68fe23be3c" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentConvertiblePricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtInstrumentConvertiblePricePercentage_c457f318-9aa3-45a8-86ae-6e68fe23be3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentFullyDilutedCapitalization_33c87b2b-c604-4000-852c-adcaac118626" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentFullyDilutedCapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtInstrumentFullyDilutedCapitalization_33c87b2b-c604-4000-852c-adcaac118626" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_1f5fdc8a-2e9f-4e10-9ea8-34b74c6fb2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_1f5fdc8a-2e9f-4e10-9ea8-34b74c6fb2c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentRedemptionAmount_99d2fb2c-2a6a-4050-b5a3-e39431403c3a" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentRedemptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtInstrumentRedemptionAmount_99d2fb2c-2a6a-4050-b5a3-e39431403c3a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0665a9ed-7769-48ac-9c3d-32d03c7bbc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0665a9ed-7769-48ac-9c3d-32d03c7bbc97" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance_d647efe3-a6e0-4a29-abac-3ce01f6492fa" xlink:href="nexi-20221231.xsd#nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance_d647efe3-a6e0-4a29-abac-3ce01f6492fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes_3b358edf-4c2a-477c-a84c-bef96e44a34d" xlink:href="nexi-20221231.xsd#nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes_3b358edf-4c2a-477c-a84c-bef96e44a34d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtDiscount_3fda7515-f574-4983-97c2-fee404e8cef0" xlink:href="nexi-20221231.xsd#nexi_DebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtDiscount_3fda7515-f574-4983-97c2-fee404e8cef0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtIssuanceCosts_849a9cd5-ae4a-470d-a394-c04e027813ae" xlink:href="nexi-20221231.xsd#nexi_DebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtIssuanceCosts_849a9cd5-ae4a-470d-a394-c04e027813ae" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_99c10262-8c7b-4052-8c52-205b303358f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_99c10262-8c7b-4052-8c52-205b303358f7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_af71fd45-7802-445c-8ded-f0bd99a68398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_StockholdersEquity_af71fd45-7802-445c-8ded-f0bd99a68398" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_920d5800-0685-4fb2-b196-b34fc3bd5326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_ConvertibleNotesPayable_920d5800-0685-4fb2-b196-b34fc3bd5326" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_667a5d56-4538-4d3b-b0d7-5bbcbc379476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_667a5d56-4538-4d3b-b0d7-5bbcbc379476" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3885c5f8-b347-4564-b9ec-5502aab9f337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_InterestExpenseDebt_3885c5f8-b347-4564-b9ec-5502aab9f337" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_d0bf0601-131a-4ec5-9c8b-576fd6634f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_d0bf0601-131a-4ec5-9c8b-576fd6634f22" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts_9060af63-5cb3-40ef-9c38-1fb479b992d4" xlink:href="nexi-20221231.xsd#nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts_9060af63-5cb3-40ef-9c38-1fb479b992d4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_36b497a0-4abf-4640-98ea-dceea90de49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_DebtInstrumentTable_36b497a0-4abf-4640-98ea-dceea90de49d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_30cfcff8-451b-448f-a79f-c004fdf87ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_36b497a0-4abf-4640-98ea-dceea90de49d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_30cfcff8-451b-448f-a79f-c004fdf87ea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_30cfcff8-451b-448f-a79f-c004fdf87ea5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_30cfcff8-451b-448f-a79f-c004fdf87ea5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_30cfcff8-451b-448f-a79f-c004fdf87ea5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d29c23a1-ac45-4bb3-a80d-7141a0dbb5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_30cfcff8-451b-448f-a79f-c004fdf87ea5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d29c23a1-ac45-4bb3-a80d-7141a0dbb5da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_ebfe5c04-d174-483c-b08e-b23616fb3400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d29c23a1-ac45-4bb3-a80d-7141a0dbb5da" xlink:to="loc_us-gaap_ConvertibleDebtMember_ebfe5c04-d174-483c-b08e-b23616fb3400" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_408a10e5-5241-4aca-9126-aa5e2f53b116" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_36b497a0-4abf-4640-98ea-dceea90de49d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_408a10e5-5241-4aca-9126-aa5e2f53b116" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_408a10e5-5241-4aca-9126-aa5e2f53b116_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_408a10e5-5241-4aca-9126-aa5e2f53b116" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_408a10e5-5241-4aca-9126-aa5e2f53b116_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_78720c29-3aa6-495d-bb7d-ee41d8d733f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_408a10e5-5241-4aca-9126-aa5e2f53b116" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_78720c29-3aa6-495d-bb7d-ee41d8d733f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fde60de2-8d22-44ed-b73f-b2e3dfab468a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_78720c29-3aa6-495d-bb7d-ee41d8d733f8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fde60de2-8d22-44ed-b73f-b2e3dfab468a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_370fd730-2d06-4c5a-8f09-fc0534a2023e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_36b497a0-4abf-4640-98ea-dceea90de49d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_370fd730-2d06-4c5a-8f09-fc0534a2023e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_370fd730-2d06-4c5a-8f09-fc0534a2023e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_370fd730-2d06-4c5a-8f09-fc0534a2023e" xlink:to="loc_us-gaap_EquityComponentDomain_370fd730-2d06-4c5a-8f09-fc0534a2023e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_85868a74-e956-4657-b885-0bdd4da6e6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_370fd730-2d06-4c5a-8f09-fc0534a2023e" xlink:to="loc_us-gaap_EquityComponentDomain_85868a74-e956-4657-b885-0bdd4da6e6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2d9caafd-4600-42ac-94d2-49f64de4bcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_85868a74-e956-4657-b885-0bdd4da6e6d6" xlink:to="loc_us-gaap_RetainedEarningsMember_2d9caafd-4600-42ac-94d2-49f64de4bcc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_be18cf3e-ab3f-4a14-b78a-9c17a084e852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_85868a74-e956-4657-b885-0bdd4da6e6d6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_be18cf3e-ab3f-4a14-b78a-9c17a084e852" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail" xlink:type="extended" id="i7f7bcfb0a0614c118af5f6250f4b4043_SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fe61b0d4-1a4d-47cb-a28b-b0f17c0f4bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fe61b0d4-1a4d-47cb-a28b-b0f17c0f4bc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_717ba982-5444-4d95-9686-3fc45c857bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_717ba982-5444-4d95-9686-3fc45c857bbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_875d6eca-f280-4775-a224-0376762740cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_875d6eca-f280-4775-a224-0376762740cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_321b50ec-b21a-46e2-bb26-b664a8ca3167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_321b50ec-b21a-46e2-bb26-b664a8ca3167" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_79fdbcbb-593c-4e21-a8bf-60f306a46829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_79fdbcbb-593c-4e21-a8bf-60f306a46829" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_9ce35eaf-2e63-4585-adec-7edf43507430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_9ce35eaf-2e63-4585-adec-7edf43507430" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c359457d-ad83-4ca4-9040-bf1746b4d35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c359457d-ad83-4ca4-9040-bf1746b4d35e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_dc280747-0f63-4459-9656-e54ab405642d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_dc280747-0f63-4459-9656-e54ab405642d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_53f9459b-c9bd-47e2-a969-cf91e592cf17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_53f9459b-c9bd-47e2-a969-cf91e592cf17" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7df38cc4-f401-457f-ad10-b9b639083183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7df38cc4-f401-457f-ad10-b9b639083183" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7331cb77-5959-4d0c-b600-2ae53926e00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7331cb77-5959-4d0c-b600-2ae53926e00b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3bfb4022-d8bc-41c9-818b-d82d7bb9a369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3bfb4022-d8bc-41c9-818b-d82d7bb9a369" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0d7a9b6e-56dc-4d50-8b63-57e601754a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0d7a9b6e-56dc-4d50-8b63-57e601754a20" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_212de097-5b66-4a80-9b29-0c1e5cadfd61" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_212de097-5b66-4a80-9b29-0c1e5cadfd61" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodSharesWarrantsExercised_08a24253-fe61-46f8-8881-4f232c71060c" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_nexi_StockIssuedDuringPeriodSharesWarrantsExercised_08a24253-fe61-46f8-8881-4f232c71060c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SaleOfStockAggregateOfferingApproval_cc4393be-55a2-493e-8670-7d11592a1fa4" xlink:href="nexi-20221231.xsd#nexi_SaleOfStockAggregateOfferingApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_nexi_SaleOfStockAggregateOfferingApproval_cc4393be-55a2-493e-8670-7d11592a1fa4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SaleOfStockCommissionPercentage_b23a23ea-4757-402b-bd5c-9a24c0479b01" xlink:href="nexi-20221231.xsd#nexi_SaleOfStockCommissionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_nexi_SaleOfStockCommissionPercentage_b23a23ea-4757-402b-bd5c-9a24c0479b01" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbfa3ffd-47c1-43f6-8df4-dd5d541c7a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbfa3ffd-47c1-43f6-8df4-dd5d541c7a5d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9e272d2b-8810-4355-9c08-874b1eedf2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9e272d2b-8810-4355-9c08-874b1eedf2c7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c3b63d8f-fbe7-4c6f-886f-87090a1b9664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c3b63d8f-fbe7-4c6f-886f-87090a1b9664" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_66b1bc58-5739-44ca-b1db-b0d117733965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c3b63d8f-fbe7-4c6f-886f-87090a1b9664" xlink:to="loc_us-gaap_StatementClassOfStockAxis_66b1bc58-5739-44ca-b1db-b0d117733965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_66b1bc58-5739-44ca-b1db-b0d117733965_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_66b1bc58-5739-44ca-b1db-b0d117733965" xlink:to="loc_us-gaap_ClassOfStockDomain_66b1bc58-5739-44ca-b1db-b0d117733965_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_781285aa-cd8f-4338-8516-bdc230681680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_66b1bc58-5739-44ca-b1db-b0d117733965" xlink:to="loc_us-gaap_ClassOfStockDomain_781285aa-cd8f-4338-8516-bdc230681680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_a08e0d57-cbff-476c-9fac-a33e1470e77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_781285aa-cd8f-4338-8516-bdc230681680" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_a08e0d57-cbff-476c-9fac-a33e1470e77d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5ca21416-257b-4927-8c60-7c4e1bb3a91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_781285aa-cd8f-4338-8516-bdc230681680" xlink:to="loc_us-gaap_CommonClassAMember_5ca21416-257b-4927-8c60-7c4e1bb3a91a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SeriesARedeemableConvertiblePreferredStockMember_ef8ceb6b-5981-496b-80ce-1a02ccf6e9ec" xlink:href="nexi-20221231.xsd#nexi_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_781285aa-cd8f-4338-8516-bdc230681680" xlink:to="loc_nexi_SeriesARedeemableConvertiblePreferredStockMember_ef8ceb6b-5981-496b-80ce-1a02ccf6e9ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_872d8e22-5dd0-49c3-b3ae-d970360c33ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c3b63d8f-fbe7-4c6f-886f-87090a1b9664" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_872d8e22-5dd0-49c3-b3ae-d970360c33ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_872d8e22-5dd0-49c3-b3ae-d970360c33ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_872d8e22-5dd0-49c3-b3ae-d970360c33ec" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_872d8e22-5dd0-49c3-b3ae-d970360c33ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97680404-1099-43c2-97ef-80a089b6ce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_872d8e22-5dd0-49c3-b3ae-d970360c33ec" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97680404-1099-43c2-97ef-80a089b6ce7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_8a02c538-39a5-44b2-82c3-3fb98e059853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97680404-1099-43c2-97ef-80a089b6ce7c" xlink:to="loc_us-gaap_IPOMember_8a02c538-39a5-44b2-82c3-3fb98e059853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_AtTheMarketOfferingMember_33618cab-97f6-46d3-abc5-a2b7d3146fd7" xlink:href="nexi-20221231.xsd#nexi_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97680404-1099-43c2-97ef-80a089b6ce7c" xlink:to="loc_nexi_AtTheMarketOfferingMember_33618cab-97f6-46d3-abc5-a2b7d3146fd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a385143f-8825-4738-82f1-7ff8c1fbab2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c3b63d8f-fbe7-4c6f-886f-87090a1b9664" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a385143f-8825-4738-82f1-7ff8c1fbab2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a385143f-8825-4738-82f1-7ff8c1fbab2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a385143f-8825-4738-82f1-7ff8c1fbab2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a385143f-8825-4738-82f1-7ff8c1fbab2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01b0e82a-dc49-4726-b6b7-43718d379210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a385143f-8825-4738-82f1-7ff8c1fbab2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01b0e82a-dc49-4726-b6b7-43718d379210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_eeb1f58b-d11f-4bac-a24d-452263e4c197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_01b0e82a-dc49-4726-b6b7-43718d379210" xlink:to="loc_us-gaap_ConvertibleDebtMember_eeb1f58b-d11f-4bac-a24d-452263e4c197" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://nex.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="ic1cdb269a7724da7b8ce86fa6930f856_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_047f2a5d-4600-4ebd-8f33-8a2231353420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_047f2a5d-4600-4ebd-8f33-8a2231353420" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock_0e1d918e-8fdb-4fdd-b66f-e6422b1f118f" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock_0e1d918e-8fdb-4fdd-b66f-e6422b1f118f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f14e6512-edbc-400a-a2e3-413f5a1a2fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f14e6512-edbc-400a-a2e3-413f5a1a2fe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d9f27f96-1a08-46b8-8d4e-0734ea22508e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d9f27f96-1a08-46b8-8d4e-0734ea22508e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5a8f22e6-90c3-4def-b8ac-e7a81996527f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5a8f22e6-90c3-4def-b8ac-e7a81996527f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0551b2eb-c89e-4c07-9b94-c412c8e2f21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0551b2eb-c89e-4c07-9b94-c412c8e2f21c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_201a0c68-422a-4d40-8d86-180f9b886004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_201a0c68-422a-4d40-8d86-180f9b886004" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b19f8618-aff1-4122-ab0a-65b3fd9f345d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b19f8618-aff1-4122-ab0a-65b3fd9f345d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c5de40da-0c87-405e-9148-e8ae2cdad34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c5de40da-0c87-405e-9148-e8ae2cdad34e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c27d4d03-d60f-408e-a0f6-989ef08471c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c27d4d03-d60f-408e-a0f6-989ef08471c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5ad7aca5-97c7-492c-a1c5-e80f96792f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:to="loc_us-gaap_PlanNameAxis_5ad7aca5-97c7-492c-a1c5-e80f96792f59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5ad7aca5-97c7-492c-a1c5-e80f96792f59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5ad7aca5-97c7-492c-a1c5-e80f96792f59" xlink:to="loc_us-gaap_PlanNameDomain_5ad7aca5-97c7-492c-a1c5-e80f96792f59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7d5256c4-5907-4158-aa29-759db5878bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5ad7aca5-97c7-492c-a1c5-e80f96792f59" xlink:to="loc_us-gaap_PlanNameDomain_7d5256c4-5907-4158-aa29-759db5878bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TwoThousandSeventeenEquityIncentivePlanMember_52a0aaa8-934b-4428-ae70-c600ba959937" xlink:href="nexi-20221231.xsd#nexi_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7d5256c4-5907-4158-aa29-759db5878bb3" xlink:to="loc_nexi_TwoThousandSeventeenEquityIncentivePlanMember_52a0aaa8-934b-4428-ae70-c600ba959937" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TwoThousandEighteenEquityIncentivePlanMember_052908c1-1698-43a3-be37-4822ad4acd63" xlink:href="nexi-20221231.xsd#nexi_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7d5256c4-5907-4158-aa29-759db5878bb3" xlink:to="loc_nexi_TwoThousandEighteenEquityIncentivePlanMember_052908c1-1698-43a3-be37-4822ad4acd63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_The2021PlanMember_7c08681e-c865-4efc-b53a-c46cfe918135" xlink:href="nexi-20221231.xsd#nexi_The2021PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7d5256c4-5907-4158-aa29-759db5878bb3" xlink:to="loc_nexi_The2021PlanMember_7c08681e-c865-4efc-b53a-c46cfe918135" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f8d45e16-39c6-41d1-b7e9-dd9a6ea45832" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:to="loc_srt_RangeAxis_f8d45e16-39c6-41d1-b7e9-dd9a6ea45832" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8d45e16-39c6-41d1-b7e9-dd9a6ea45832_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f8d45e16-39c6-41d1-b7e9-dd9a6ea45832" xlink:to="loc_srt_RangeMember_f8d45e16-39c6-41d1-b7e9-dd9a6ea45832_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6394e98-358a-405b-92f6-faad4562b72e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f8d45e16-39c6-41d1-b7e9-dd9a6ea45832" xlink:to="loc_srt_RangeMember_b6394e98-358a-405b-92f6-faad4562b72e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e3809c5b-2f2b-4c2f-ad53-50773b8760da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b6394e98-358a-405b-92f6-faad4562b72e" xlink:to="loc_srt_MinimumMember_e3809c5b-2f2b-4c2f-ad53-50773b8760da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_623e2aca-f299-477e-a2ad-7f38281ecc4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b6394e98-358a-405b-92f6-faad4562b72e" xlink:to="loc_srt_MaximumMember_623e2aca-f299-477e-a2ad-7f38281ecc4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e1f96841-cade-4efb-9b1d-cdea2704fd52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:to="loc_us-gaap_AwardTypeAxis_e1f96841-cade-4efb-9b1d-cdea2704fd52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1f96841-cade-4efb-9b1d-cdea2704fd52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e1f96841-cade-4efb-9b1d-cdea2704fd52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e1f96841-cade-4efb-9b1d-cdea2704fd52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82761907-72f1-43e4-8426-3981153ad270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e1f96841-cade-4efb-9b1d-cdea2704fd52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82761907-72f1-43e4-8426-3981153ad270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0c5097b1-67bb-4c37-b225-e9ab84677182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82761907-72f1-43e4-8426-3981153ad270" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0c5097b1-67bb-4c37-b225-e9ab84677182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9b11a2c8-3607-4465-86a7-f9c1fd366dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82761907-72f1-43e4-8426-3981153ad270" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9b11a2c8-3607-4465-86a7-f9c1fd366dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_36d27554-ac4c-4664-a79a-f07b5eadf0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_36d27554-ac4c-4664-a79a-f07b5eadf0cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_36d27554-ac4c-4664-a79a-f07b5eadf0cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_36d27554-ac4c-4664-a79a-f07b5eadf0cf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_36d27554-ac4c-4664-a79a-f07b5eadf0cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f273733c-185d-48cb-829e-9ad9109f9a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_36d27554-ac4c-4664-a79a-f07b5eadf0cf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f273733c-185d-48cb-829e-9ad9109f9a1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d3940426-8a11-4a87-9363-1e30aac9d043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f273733c-185d-48cb-829e-9ad9109f9a1e" xlink:to="loc_us-gaap_SubsequentEventMember_d3940426-8a11-4a87-9363-1e30aac9d043" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail" xlink:type="extended" id="i634d0695dfa54f498344a70f530a3d69_StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5c81f676-9c7f-4b02-b5e9-f4fa964ad76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b8474357-337d-4242-99fb-ca8fb6473e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5c81f676-9c7f-4b02-b5e9-f4fa964ad76f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b8474357-337d-4242-99fb-ca8fb6473e8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7fffbb9e-c754-4242-a02c-cb87a8e9eef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5c81f676-9c7f-4b02-b5e9-f4fa964ad76f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7fffbb9e-c754-4242-a02c-cb87a8e9eef0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d66c15d3-12b2-41f1-9ac5-7531d4db40ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7fffbb9e-c754-4242-a02c-cb87a8e9eef0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d66c15d3-12b2-41f1-9ac5-7531d4db40ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d66c15d3-12b2-41f1-9ac5-7531d4db40ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d66c15d3-12b2-41f1-9ac5-7531d4db40ea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d66c15d3-12b2-41f1-9ac5-7531d4db40ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3234386f-9fc0-46a3-9f83-e2885233cf31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d66c15d3-12b2-41f1-9ac5-7531d4db40ea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3234386f-9fc0-46a3-9f83-e2885233cf31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8dba6c02-12a1-4702-9a27-492ea78982e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3234386f-9fc0-46a3-9f83-e2885233cf31" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8dba6c02-12a1-4702-9a27-492ea78982e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8998f295-24c3-47a9-a59f-f07e98072d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3234386f-9fc0-46a3-9f83-e2885233cf31" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8998f295-24c3-47a9-a59f-f07e98072d33" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail"/>
  <link:definitionLink xlink:role="http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail" xlink:type="extended" id="i8b3f600ae21345a297af1c22645a178b_StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d1e8bb9b-7c32-4252-a33d-344d238d1d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d1e8bb9b-7c32-4252-a33d-344d238d1d70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_423d6d0d-4d74-4ff4-9ee9-b7fc6a018408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_423d6d0d-4d74-4ff4-9ee9-b7fc6a018408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bcca9e0d-2762-46c0-bd8e-18ebb62c554e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bcca9e0d-2762-46c0-bd8e-18ebb62c554e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13aa9f47-223b-4739-8770-f6e58754794a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13aa9f47-223b-4739-8770-f6e58754794a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cae9a199-a786-45da-916e-f2faabf824e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cae9a199-a786-45da-916e-f2faabf824e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_748abde2-d912-4779-a60f-b0db515520d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_748abde2-d912-4779-a60f-b0db515520d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fb8e7f01-7053-4187-b777-3ee70812b949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fb8e7f01-7053-4187-b777-3ee70812b949" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_53f58bf2-259a-4bb9-82ea-bb22b376f857" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fb8e7f01-7053-4187-b777-3ee70812b949" xlink:to="loc_srt_RangeAxis_53f58bf2-259a-4bb9-82ea-bb22b376f857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53f58bf2-259a-4bb9-82ea-bb22b376f857_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_53f58bf2-259a-4bb9-82ea-bb22b376f857" xlink:to="loc_srt_RangeMember_53f58bf2-259a-4bb9-82ea-bb22b376f857_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e840582-02a3-4667-a33d-72ede81d8424" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_53f58bf2-259a-4bb9-82ea-bb22b376f857" xlink:to="loc_srt_RangeMember_3e840582-02a3-4667-a33d-72ede81d8424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7db2ef40-21f4-49ef-b2cf-90d302a754a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3e840582-02a3-4667-a33d-72ede81d8424" xlink:to="loc_srt_MinimumMember_7db2ef40-21f4-49ef-b2cf-90d302a754a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1a655a8-f69d-47aa-898b-760b34c1ca5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3e840582-02a3-4667-a33d-72ede81d8424" xlink:to="loc_srt_MaximumMember_b1a655a8-f69d-47aa-898b-760b34c1ca5d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#StockBasedCompensationSummaryofRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="extended" id="i8f80176fa3cd4e88b6fb2d32ef9e522f_StockBasedCompensationSummaryofRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8fa291e3-2100-41cd-96fa-b1f4f645e387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8fa291e3-2100-41cd-96fa-b1f4f645e387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85dd64eb-70fc-457a-b5df-a1ec2151275b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85dd64eb-70fc-457a-b5df-a1ec2151275b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a1c8d6c8-196d-467d-a3cd-eb3df224c619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a1c8d6c8-196d-467d-a3cd-eb3df224c619" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a2c130fc-cdfb-41af-96ea-45ee740733ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a2c130fc-cdfb-41af-96ea-45ee740733ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8cacad2d-bd8e-4222-a4f5-b83f172c1a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3a883ffd-0020-405a-b0e6-30f3b67e2e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3a883ffd-0020-405a-b0e6-30f3b67e2e31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eb55b00d-2196-44fa-8e8a-dda6dc47e494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eb55b00d-2196-44fa-8e8a-dda6dc47e494" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5d062f15-8a2e-4e04-9b5b-f639fa3511e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5d062f15-8a2e-4e04-9b5b-f639fa3511e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_343c113d-98db-409b-9c08-54fe44b41ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_343c113d-98db-409b-9c08-54fe44b41ae0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_46c0ecf7-17ca-4462-bf00-25569e8b82e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2bebfd9c-91dc-4a61-bc65-ca9262996045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2bebfd9c-91dc-4a61-bc65-ca9262996045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32200123-e29e-4530-a13e-47ef8b97ddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32200123-e29e-4530-a13e-47ef8b97ddf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4872a8b-531b-453f-8a03-25dcc3797a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4872a8b-531b-453f-8a03-25dcc3797a5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a14fac0a-3bff-447e-9716-b8b74cb8071e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4872a8b-531b-453f-8a03-25dcc3797a5a" xlink:to="loc_us-gaap_AwardTypeAxis_a14fac0a-3bff-447e-9716-b8b74cb8071e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a14fac0a-3bff-447e-9716-b8b74cb8071e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a14fac0a-3bff-447e-9716-b8b74cb8071e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a14fac0a-3bff-447e-9716-b8b74cb8071e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b029718-51f9-4d1d-973a-bc7ebb7ab633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a14fac0a-3bff-447e-9716-b8b74cb8071e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b029718-51f9-4d1d-973a-bc7ebb7ab633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8a901f7b-e9a2-4e66-8ee2-9330a962b3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b029718-51f9-4d1d-973a-bc7ebb7ab633" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8a901f7b-e9a2-4e66-8ee2-9330a962b3d2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="icd3f4bdfcb284352b7310b56a3a412f6_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_20c5d160-e822-4aa2-a4db-a4ee59a1ca04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_20c5d160-e822-4aa2-a4db-a4ee59a1ca04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_bad90bc9-0388-4cc9-88fb-2b313be21ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_bad90bc9-0388-4cc9-88fb-2b313be21ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_56c714e1-0002-43ff-97a4-78070335b84f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_56c714e1-0002-43ff-97a4-78070335b84f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_27ee94f5-d7e4-4f52-b43e-c646a3680f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_27ee94f5-d7e4-4f52-b43e-c646a3680f1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_972106b7-9953-4f9b-a0c9-60f8f771e4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_972106b7-9953-4f9b-a0c9-60f8f771e4f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DeferredTaxAssetValuationAllowancePercent_fe069082-7a9d-4b32-a385-4d966f267a24" xlink:href="nexi-20221231.xsd#nexi_DeferredTaxAssetValuationAllowancePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_nexi_DeferredTaxAssetValuationAllowancePercent_fe069082-7a9d-4b32-a385-4d966f267a24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_dd147b91-4342-4530-a7e9-fa081e5d48ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_dd147b91-4342-4530-a7e9-fa081e5d48ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3caf0db8-97d7-44cc-98c2-ac52293d9897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_dd147b91-4342-4530-a7e9-fa081e5d48ac" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3caf0db8-97d7-44cc-98c2-ac52293d9897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3caf0db8-97d7-44cc-98c2-ac52293d9897_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3caf0db8-97d7-44cc-98c2-ac52293d9897" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3caf0db8-97d7-44cc-98c2-ac52293d9897_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_aab31f7a-8dd8-4200-a35d-f8b49399436c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3caf0db8-97d7-44cc-98c2-ac52293d9897" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_aab31f7a-8dd8-4200-a35d-f8b49399436c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_490ff7cc-24ba-4b0e-ad5f-c1a70821fe79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aab31f7a-8dd8-4200-a35d-f8b49399436c" xlink:to="loc_us-gaap_DomesticCountryMember_490ff7cc-24ba-4b0e-ad5f-c1a70821fe79" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/LeasesComponentsofLeaseCostDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#LeasesComponentsofLeaseCostDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/LeasesComponentsofLeaseCostDetails" xlink:type="extended" id="i412f3dfef26642fda953e5527ab6e904_LeasesComponentsofLeaseCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_196a60eb-b199-4704-971b-1b93baf1a034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cab5dba9-6088-43ef-b50a-e9b0b1168323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_196a60eb-b199-4704-971b-1b93baf1a034" xlink:to="loc_us-gaap_OperatingLeaseCost_cab5dba9-6088-43ef-b50a-e9b0b1168323" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ab17fdff-1de8-46c7-9def-9498dc93282d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_196a60eb-b199-4704-971b-1b93baf1a034" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ab17fdff-1de8-46c7-9def-9498dc93282d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b207f76-1818-4362-87b0-f4cc666db5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ab17fdff-1de8-46c7-9def-9498dc93282d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b207f76-1818-4362-87b0-f4cc666db5d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3b207f76-1818-4362-87b0-f4cc666db5d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b207f76-1818-4362-87b0-f4cc666db5d4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3b207f76-1818-4362-87b0-f4cc666db5d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_91756aa6-229e-4c65-9e39-a4d647b133c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b207f76-1818-4362-87b0-f4cc666db5d4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_91756aa6-229e-4c65-9e39-a4d647b133c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_868f6866-f8d4-4e8d-855d-e14fedcfdcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_91756aa6-229e-4c65-9e39-a4d647b133c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_868f6866-f8d4-4e8d-855d-e14fedcfdcbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9bfb3fbd-758f-4a4c-92be-c8436322b0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_91756aa6-229e-4c65-9e39-a4d647b133c4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9bfb3fbd-758f-4a4c-92be-c8436322b0d4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://nex.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://nex.com/role/SubsequentEventsDetails" xlink:type="extended" id="i24fc34d1e60746f483db483c25b30702_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold_159ed597-5859-4f61-83cf-862a632a7b5d" xlink:href="nexi-20221231.xsd#nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:to="loc_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold_159ed597-5859-4f61-83cf-862a632a7b5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple_6fb07ef4-446d-4c13-b449-afb6f9f94893" xlink:href="nexi-20221231.xsd#nexi_ShareBasedPaymentArrangementOptionRepricingMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:to="loc_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple_6fb07ef4-446d-4c13-b449-afb6f9f94893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RelatedPartyTransactionHourlyRate_29a9f128-353c-4bad-a7a6-5d6b12d64105" xlink:href="nexi-20221231.xsd#nexi_RelatedPartyTransactionHourlyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:to="loc_nexi_RelatedPartyTransactionHourlyRate_29a9f128-353c-4bad-a7a6-5d6b12d64105" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bb73230f-e5c0-489d-9d19-ef783c6704a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bb73230f-e5c0-489d-9d19-ef783c6704a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:to="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b73c615c-2426-4791-9013-0b235cd3f015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b73c615c-2426-4791-9013-0b235cd3f015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b73c615c-2426-4791-9013-0b235cd3f015_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b73c615c-2426-4791-9013-0b235cd3f015" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b73c615c-2426-4791-9013-0b235cd3f015_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_abe25de6-97e2-4983-932d-6a7799e5e392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b73c615c-2426-4791-9013-0b235cd3f015" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_abe25de6-97e2-4983-932d-6a7799e5e392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_13c92121-49c4-4a13-bf75-52018a4070c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_abe25de6-97e2-4983-932d-6a7799e5e392" xlink:to="loc_us-gaap_SubsequentEventMember_13c92121-49c4-4a13-bf75-52018a4070c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7f46a0c0-ddd6-4c58-9648-3a540b8b5c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:to="loc_us-gaap_VestingAxis_7f46a0c0-ddd6-4c58-9648-3a540b8b5c0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7f46a0c0-ddd6-4c58-9648-3a540b8b5c0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_7f46a0c0-ddd6-4c58-9648-3a540b8b5c0e" xlink:to="loc_us-gaap_VestingDomain_7f46a0c0-ddd6-4c58-9648-3a540b8b5c0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e13130b6-ed91-4a56-bb76-3563642f5c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_7f46a0c0-ddd6-4c58-9648-3a540b8b5c0e" xlink:to="loc_us-gaap_VestingDomain_e13130b6-ed91-4a56-bb76-3563642f5c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_482e847a-1f74-497d-a39d-329c0f5749b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e13130b6-ed91-4a56-bb76-3563642f5c36" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_482e847a-1f74-497d-a39d-329c0f5749b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_689add63-cf1d-49dc-9247-50fcdaa22bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e13130b6-ed91-4a56-bb76-3563642f5c36" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_689add63-cf1d-49dc-9247-50fcdaa22bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8c27546b-0041-4e16-987a-dffcafd11641" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:to="loc_srt_TitleOfIndividualAxis_8c27546b-0041-4e16-987a-dffcafd11641" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8c27546b-0041-4e16-987a-dffcafd11641_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_8c27546b-0041-4e16-987a-dffcafd11641" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8c27546b-0041-4e16-987a-dffcafd11641_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53183332-dbfc-4a53-b58c-acea5e90540d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_8c27546b-0041-4e16-987a-dffcafd11641" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53183332-dbfc-4a53-b58c-acea5e90540d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_29c6db41-5298-4768-95dc-4e94954bcf80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53183332-dbfc-4a53-b58c-acea5e90540d" xlink:to="loc_srt_ExecutiveOfficerMember_29c6db41-5298-4768-95dc-4e94954bcf80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_968c801a-a695-4c84-984b-a37cf899dcbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53183332-dbfc-4a53-b58c-acea5e90540d" xlink:to="loc_srt_DirectorMember_968c801a-a695-4c84-984b-a37cf899dcbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_EmployeesExcludingExecutiveOfficerMember_a03e8b62-d071-49ff-b5ec-d39a87f210fa" xlink:href="nexi-20221231.xsd#nexi_EmployeesExcludingExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53183332-dbfc-4a53-b58c-acea5e90540d" xlink:to="loc_nexi_EmployeesExcludingExecutiveOfficerMember_a03e8b62-d071-49ff-b5ec-d39a87f210fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c8b43d6-84b9-48c4-b2bc-6578d516febf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c8b43d6-84b9-48c4-b2bc-6578d516febf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2c8b43d6-84b9-48c4-b2bc-6578d516febf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c8b43d6-84b9-48c4-b2bc-6578d516febf" xlink:to="loc_us-gaap_RelatedPartyDomain_2c8b43d6-84b9-48c4-b2bc-6578d516febf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9dde9121-2310-4c99-bce9-933876daf89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c8b43d6-84b9-48c4-b2bc-6578d516febf" xlink:to="loc_us-gaap_RelatedPartyDomain_9dde9121-2310-4c99-bce9-933876daf89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_2d6bb2c3-0b2b-4ace-9acd-7a182bb11930" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9dde9121-2310-4c99-bce9-933876daf89f" xlink:to="loc_srt_AffiliatedEntityMember_2d6bb2c3-0b2b-4ace-9acd-7a182bb11930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3862c97d-55fc-4f15-b714-9afc3ce11115" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:to="loc_srt_CounterpartyNameAxis_3862c97d-55fc-4f15-b714-9afc3ce11115" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3862c97d-55fc-4f15-b714-9afc3ce11115_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3862c97d-55fc-4f15-b714-9afc3ce11115" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3862c97d-55fc-4f15-b714-9afc3ce11115_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1e59ab99-3634-4748-9306-47c300d6a548" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3862c97d-55fc-4f15-b714-9afc3ce11115" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1e59ab99-3634-4748-9306-47c300d6a548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_JeromeZeldisMember_c2c2e49f-3e5f-4ce0-accf-e2d2d3945ca9" xlink:href="nexi-20221231.xsd#nexi_JeromeZeldisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1e59ab99-3634-4748-9306-47c300d6a548" xlink:to="loc_nexi_JeromeZeldisMember_c2c2e49f-3e5f-4ce0-accf-e2d2d3945ca9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>nexi-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1d01bc3b-109a-450d-9ee6-f84eb8561d2c,g:e7038408-d172-479b-b01e-e62e0cc0d235-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ea2e94cf-8eaf-42c2-b003-4d163be51d31_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f11f469-3ebd-479e-89c3-eb6b3072da89_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_e4c8e2c2-c6dc-4f04-8ebb-a7999a5b04b2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement contract to perform for others compensation earned</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8d40c240-18e2-4d79-a865-aa86edfbcf82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_1792d6df-7c47-42d4-bde8-1ce3fc64cbce_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_73bc3692-c9b0-4037-9c59-07b249a6d15f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion income on available-for-sale marketable securities, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_10116b14-b3a2-4910-bb03-e02e8009970a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_NumberOfWarrantsExercised_20421c2d-43b9-4571-86d8-a2ebfdd7fd17_terseLabel_en-US" xlink:label="lab_nexi_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_nexi_NumberOfWarrantsExercised_label_en-US" xlink:label="lab_nexi_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:label id="lab_nexi_NumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_nexi_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_NumberOfWarrantsExercised" xlink:href="nexi-20221231.xsd#nexi_NumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_NumberOfWarrantsExercised" xlink:to="lab_nexi_NumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember_d949778f-57f8-46b3-bc2d-38ad89e834bc_terseLabel_en-US" xlink:label="lab_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;A-2</link:label>
    <link:label id="lab_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Two Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Two Redeemable Convertible Preferred Stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:href="nexi-20221231.xsd#nexi_SeriesATwoRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:to="lab_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a188434a-8906-44bd-9d38-0d4611836694_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_54d4e264-5496-43d4-90f4-4c57f7d69e3e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_bc901895-d064-424e-ad4a-0de510538fd6_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Expenses, beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_23287c32-2143-4fa8-a060-ac608d2b5406_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Expenses, ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2a829018-d681-4462-be79-6940af3d5104_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional&#160;paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_37069b88-73fa-4cd2-a41f-9fd0299535f0_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_884a8c37-039a-4d9e-a16c-dd80c889ad2a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_663acf2f-ec7b-4118-9753-8ab0fd743d77_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_cd0577dc-feed-44dc-a2f0-fd98f6574941_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_SaleOfStockAggregateOfferingApproval_5eaa0252-05d0-4278-b482-4064cb652237_terseLabel_en-US" xlink:label="lab_nexi_SaleOfStockAggregateOfferingApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price</link:label>
    <link:label id="lab_nexi_SaleOfStockAggregateOfferingApproval_label_en-US" xlink:label="lab_nexi_SaleOfStockAggregateOfferingApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Aggregate Offering Approval</link:label>
    <link:label id="lab_nexi_SaleOfStockAggregateOfferingApproval_documentation_en-US" xlink:label="lab_nexi_SaleOfStockAggregateOfferingApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Aggregate Offering Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SaleOfStockAggregateOfferingApproval" xlink:href="nexi-20221231.xsd#nexi_SaleOfStockAggregateOfferingApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_SaleOfStockAggregateOfferingApproval" xlink:to="lab_nexi_SaleOfStockAggregateOfferingApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_MilestonesAxis_9eeeded1-567b-4d8b-9945-d5068df314f8_terseLabel_en-US" xlink:label="lab_nexi_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_nexi_MilestonesAxis_label_en-US" xlink:label="lab_nexi_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_nexi_MilestonesAxis_documentation_en-US" xlink:label="lab_nexi_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MilestonesAxis" xlink:href="nexi-20221231.xsd#nexi_MilestonesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_MilestonesAxis" xlink:to="lab_nexi_MilestonesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5fdf8554-fdd4-4088-ae38-121aae877b7f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate &#8212; operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_58c0c861-9b04-40c3-bb46-0ba2aea8951a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a99de4d6-0f85-4092-8a05-90a3c276d407_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock into common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_af2aa3fa-0d14-4828-af9a-40e6aaad58c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_DeferredTaxAssetsOperatingLeases_51882ad9-d95b-4018-8760-dbb8a6cc8c43_terseLabel_en-US" xlink:label="lab_nexi_DeferredTaxAssetsOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_nexi_DeferredTaxAssetsOperatingLeases_label_en-US" xlink:label="lab_nexi_DeferredTaxAssetsOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Leases</link:label>
    <link:label id="lab_nexi_DeferredTaxAssetsOperatingLeases_documentation_en-US" xlink:label="lab_nexi_DeferredTaxAssetsOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DeferredTaxAssetsOperatingLeases" xlink:href="nexi-20221231.xsd#nexi_DeferredTaxAssetsOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_DeferredTaxAssetsOperatingLeases" xlink:to="lab_nexi_DeferredTaxAssetsOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_cb3d9650-8341-4363-880a-c8d79086af87_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentLineItems_908998b0-079e-46d9-b37c-989794437513_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentLineItems" xlink:to="lab_us-gaap_SupplyCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_DebtInstrumentRedemptionAmount_a6a799a0-d04d-41ba-9a97-566636d679bd_terseLabel_en-US" xlink:label="lab_nexi_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note redemption amount</link:label>
    <link:label id="lab_nexi_DebtInstrumentRedemptionAmount_label_en-US" xlink:label="lab_nexi_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Redemption Amount</link:label>
    <link:label id="lab_nexi_DebtInstrumentRedemptionAmount_documentation_en-US" xlink:label="lab_nexi_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentRedemptionAmount" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentRedemptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_DebtInstrumentRedemptionAmount" xlink:to="lab_nexi_DebtInstrumentRedemptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_66089e2f-5d90-4f5f-8688-823cf4636f87_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_9ed05e74-2ff0-4b42-892d-d99b51bd8479_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_02c3f163-2fa1-4812-9af1-81fadc887e32_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_JeromeZeldisMember_7b91d938-8001-44b6-8be9-23e5aeda9d90_terseLabel_en-US" xlink:label="lab_nexi_JeromeZeldisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jerome Zeldis</link:label>
    <link:label id="lab_nexi_JeromeZeldisMember_label_en-US" xlink:label="lab_nexi_JeromeZeldisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jerome Zeldis [Member]</link:label>
    <link:label id="lab_nexi_JeromeZeldisMember_documentation_en-US" xlink:label="lab_nexi_JeromeZeldisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jerome Zeldis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_JeromeZeldisMember" xlink:href="nexi-20221231.xsd#nexi_JeromeZeldisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_JeromeZeldisMember" xlink:to="lab_nexi_JeromeZeldisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_46517b51-2675-4e30-a1ea-b133c7feb470_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5bf2e330-dc72-4d24-ae23-2ff2c025be3e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_7ebf16e4-381c-4695-bea9-7f7c5811242e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b305061b-68fa-44ae-953b-98bc381c65cd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_376846f2-0843-492c-aa76-990651932cd5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_f8c95920-4347-4559-97be-ae93e46bfa96_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ae5039c4-88e5-49cb-bdb3-e15bde7a1a3c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_74d9f9ae-d2c5-4830-8835-91e9b3640aba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2bbb2c6a-3f88-4f4c-9cf1-89416676d256_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_7f7fb707-53ca-4d2a-85ce-a391d0fe5562_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_59f91f14-4555-4810-9697-49a22d51c69f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_c56063ed-dcdb-4eb0-b53f-d594db6003d9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_cfa061f4-e7a9-420d-a60c-e3b3483aa44a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_72963101-9a84-41fb-ad0f-0eaea8ebbd2e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_ddecc1c7-cda7-4a7c-8300-50cfff54de51_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_0857956b-8e96-4191-b888-46e2824bf2d3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_cd04bb36-935e-4176-97fe-c9701b2f287b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_229be459-d0f0-4d65-b5a7-f947b4b17d72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f0e13fce-85dc-4813-93ad-be597adbce63_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_684a0563-690a-450f-985d-91199f7c07f6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_148cb005-8df8-4471-b578-9c52eba10735_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSU activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7f90d156-d721-47dc-bcdc-cbeeaf6ca4d5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_1b37039a-17a9-43c7-bf6e-384659fc5c1d_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d5a428b2-d76e-45ae-8605-41c918ef1965_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e14b9a0c-60cb-48b9-8d19-83ffe1716a8b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_fa749aa5-1088-4ca8-b2f7-0327ff1cb417_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax benefit:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_c33a9bec-0423-451a-9be4-5d63fcb3a0b6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c922fb42-8fb8-4425-af95-6cbc6b14d8b8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_cca2b46c-daa3-4400-b15c-d1a50a677619_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20db8549-a7a4-47c3-98e3-f259a9e3dd2a_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding as of end of period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_78aadcdc-cc2b-43ac-8ee7-4970d9c5e6aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d1387d1d-4fd6-4641-bbae-44c6a592edbe_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_31211192-0f47-4e66-9b68-fb4c32db889a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_906172b1-1685-4d88-8150-64a9446b5774_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_96706e15-0f4b-440f-848b-ed51c3f80a13_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_RelatedPartyTransactionHourlyRate_5817482c-8af4-4910-962d-96ad51191660_terseLabel_en-US" xlink:label="lab_nexi_RelatedPartyTransactionHourlyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance cost, hourly rate (in dollars)</link:label>
    <link:label id="lab_nexi_RelatedPartyTransactionHourlyRate_label_en-US" xlink:label="lab_nexi_RelatedPartyTransactionHourlyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Hourly Rate</link:label>
    <link:label id="lab_nexi_RelatedPartyTransactionHourlyRate_documentation_en-US" xlink:label="lab_nexi_RelatedPartyTransactionHourlyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Hourly Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RelatedPartyTransactionHourlyRate" xlink:href="nexi-20221231.xsd#nexi_RelatedPartyTransactionHourlyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_RelatedPartyTransactionHourlyRate" xlink:to="lab_nexi_RelatedPartyTransactionHourlyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b21b1fa8-22ca-46f2-aa27-0fbba84b8ee3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1493fa9a-1ebb-4ea9-b9f6-938e9aabb7be_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1f38aca4-bc60-42dd-87bc-f85021e912d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_90df6ebc-66fd-48e5-9fd3-183ce7c5d664_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a6359f9d-e258-4cf1-9c9d-c104eed852b3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_1faff8f0-57b3-43f1-8ee9-cca7cb9ee4a7_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock_c7bee56b-dee3-4392-a707-8f1ff976c89c_terseLabel_en-US" xlink:label="lab_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Going Concern</link:label>
    <link:label id="lab_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock_label_en-US" xlink:label="lab_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Doubt For Going Concern [Policy Text Block]</link:label>
    <link:label id="lab_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock_documentation_en-US" xlink:label="lab_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Doubt For Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock" xlink:href="nexi-20221231.xsd#nexi_SubstantialDoubtForGoingConcernPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock" xlink:to="lab_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_bd558ca6-1923-4f2f-a84a-7dd7144664d6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bfd5757e-37f8-42de-bd59-5ca4ffcc6b5d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term &#8212; operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_50d87687-92a8-4afd-a5fc-f62761d6f310_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_95ca1d8e-ebff-4aac-9550-391a4c38751e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of transaction costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_579e8da2-ea29-4555-8a80-3986516c5522_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_72ab5ceb-29d6-40a7-bfb8-c87ddeec4df3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ce40c6cb-d06a-41ce-9a72-0fee3d2fcbb2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ca91e07c-483c-411b-ab21-7ea122e7f3f2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated useful lives of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_584691f9-1428-49f4-9034-0ba2dca36880_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_67a347fc-165e-4423-aaf6-f762b7d63cb1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_90763df0-3311-40f4-8b8a-42328fff209e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f8c591a6-79f9-46bd-b5d4-7764b1ab63c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of restricted units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_d9a95495-46c5-4458-89bd-7af0bef454a5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_0287c88d-68a2-4d32-99e2-71ab47d6701b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f9dc3373-910e-4cc5-8bf8-b4481eba0a47_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0e94cf30-14d8-4fc1-a15d-6590a32c53fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_25e5666e-d441-4ef1-a092-e7579d966668_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_49fc16b3-5bb9-4a4a-8584-2688a90b3b8d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5eb2208c-8691-41af-b3f3-d44829066984_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_611f622e-45ad-4e7f-b13f-40b716223ea0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cbfa207d-d5e2-4fea-82e2-09a20fb00141_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_98a70a9f-a1db-48cf-94c4-8c4131c18109_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt_415d506a-4b4e-4e95-8147-8f26257820f3_terseLabel_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible debt into common stock</link:label>
    <link:label id="lab_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt_label_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Conversion Of Convertible Debt</link:label>
    <link:label id="lab_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt_documentation_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period value conversion of convertible debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt" xlink:to="lab_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9f7057fc-7265-4ba8-ad00-8e6cb856e5c9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7358aaef-96cf-4a89-b98b-90f244ceee14_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b6e66d44-b493-4692-baf8-f7a928a2bd96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_c31fecfb-56e5-4a75-88bd-cd8a559a8ece_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_TemporaryEquityPolicyPolicyTextBlock_e5640388-e7cc-44e7-9ca3-6f952da2a74b_terseLabel_en-US" xlink:label="lab_nexi_TemporaryEquityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock</link:label>
    <link:label id="lab_nexi_TemporaryEquityPolicyPolicyTextBlock_label_en-US" xlink:label="lab_nexi_TemporaryEquityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Policy [Policy Text Block]</link:label>
    <link:label id="lab_nexi_TemporaryEquityPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_nexi_TemporaryEquityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityPolicyPolicyTextBlock" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_TemporaryEquityPolicyPolicyTextBlock" xlink:to="lab_nexi_TemporaryEquityPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod_e5890ff5-50a9-434f-95f1-dc1e75702e50_terseLabel_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement contractual payment period</link:label>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod_label_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contractual Payment Period</link:label>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod_documentation_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement contractual payment period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod" xlink:to="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_1f9cd868-bc5d-4eae-8705-e891e91095df_negatedLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated dividends on Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_8bd06bd7-2a22-4819-a601-753dae67004a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated dividends on Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityDividendsAdjustment_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividends, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDividendsAdjustment" xlink:to="lab_us-gaap_TemporaryEquityDividendsAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_The2021PlanMember_80e8f82f-b4f0-4c9f-8014-789a00c95c79_terseLabel_en-US" xlink:label="lab_nexi_The2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2021 Plan</link:label>
    <link:label id="lab_nexi_The2021PlanMember_label_en-US" xlink:label="lab_nexi_The2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2021 Plan [Member]</link:label>
    <link:label id="lab_nexi_The2021PlanMember_documentation_en-US" xlink:label="lab_nexi_The2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2021 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_The2021PlanMember" xlink:href="nexi-20221231.xsd#nexi_The2021PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_The2021PlanMember" xlink:to="lab_nexi_The2021PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability_ce3c43ed-a893-4be3-9a43-35f88ac35494_terseLabel_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement contract to perform for others liability</link:label>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability_label_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Liability</link:label>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability_documentation_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement contract to perform for others liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability" xlink:to="lab_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_70ae81e4-0746-46dc-ac4d-6f1a146c2403_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1f7db38f-d15d-4c75-b53a-e5f3ab480c45_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_DebtInstrumentConvertiblePricePercentage_fd6a5682-09c2-4774-89f1-e7861e662175_terseLabel_en-US" xlink:label="lab_nexi_DebtInstrumentConvertiblePricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note price percentage</link:label>
    <link:label id="lab_nexi_DebtInstrumentConvertiblePricePercentage_label_en-US" xlink:label="lab_nexi_DebtInstrumentConvertiblePricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Price Percentage</link:label>
    <link:label id="lab_nexi_DebtInstrumentConvertiblePricePercentage_documentation_en-US" xlink:label="lab_nexi_DebtInstrumentConvertiblePricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, price percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentConvertiblePricePercentage" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentConvertiblePricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_DebtInstrumentConvertiblePricePercentage" xlink:to="lab_nexi_DebtInstrumentConvertiblePricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e9d13fe2-3b20-4bc0-88b5-7fc0e46f5d3c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_StockIssuedDuringPeriodSharesWarrantsExercised_325e3b47-a36b-4723-a2cc-789356cae4ab_terseLabel_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued (in shares)</link:label>
    <link:label id="lab_nexi_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_nexi_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_nexi_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4746d568-8c47-45b9-8f71-0b9b55ae04ed_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9d45579e-bca1-44c0-afd8-73d1cfbe3905_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_30ab93e6-572e-4909-971b-18ec4f1adf8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ffb8ea26-96ff-4396-b2cd-c0188be14953_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_62cb590e-aaf0-4983-b59d-666a64eaa483_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_b88febe9-1e19-4a29-bfd6-7792613ab161_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_04c09f84-acb7-43ba-97f5-9f7d5426365c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember_933228ad-b729-42ca-8240-9cedc6441c8b_terseLabel_en-US" xlink:label="lab_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;A-3</link:label>
    <link:label id="lab_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Three Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Three Redeemable Convertible Preferred Stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember" xlink:href="nexi-20221231.xsd#nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember" xlink:to="lab_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_d15be9c4-45b6-40a3-bb77-ff8244f3b2f9_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayable" xlink:to="lab_us-gaap_ConvertibleNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_673af60b-f41e-40a5-abcc-590275d5155f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued salaries, benefits and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_873ea1a3-0c0b-485a-9161-b31ed54d4c33_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5255c2b9-6efd-42a1-92dc-034db3fd5e3a_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ce75f245-fe7d-45fc-bfdd-e5b574b53a1c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c7636cbf-d61a-411c-9780-9ce6e5bf032a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2ffc9797-9c7e-4b68-89ae-1bad3f118e73_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_00f66bbf-dea9-4ad1-92c9-e1ac27b50b4b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_65bb8df4-7e86-44ca-90e3-4dd60d6e4dbe_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs and discounts</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_DebtInstrumentAdditionalClosingLockInPeriod_5f5a3d0c-c2c1-4a53-bd22-31ea24c2e7c4_terseLabel_en-US" xlink:label="lab_nexi_DebtInstrumentAdditionalClosingLockInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional closing period (in days)</link:label>
    <link:label id="lab_nexi_DebtInstrumentAdditionalClosingLockInPeriod_label_en-US" xlink:label="lab_nexi_DebtInstrumentAdditionalClosingLockInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Additional Closing Lock In Period</link:label>
    <link:label id="lab_nexi_DebtInstrumentAdditionalClosingLockInPeriod_documentation_en-US" xlink:label="lab_nexi_DebtInstrumentAdditionalClosingLockInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, additional closing lock in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentAdditionalClosingLockInPeriod" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentAdditionalClosingLockInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_DebtInstrumentAdditionalClosingLockInPeriod" xlink:to="lab_nexi_DebtInstrumentAdditionalClosingLockInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ClinicalTrialMilestonesMember_7e7c4372-9644-45bb-82b3-ffe143aa86ab_terseLabel_en-US" xlink:label="lab_nexi_ClinicalTrialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial Milestones</link:label>
    <link:label id="lab_nexi_ClinicalTrialMilestonesMember_label_en-US" xlink:label="lab_nexi_ClinicalTrialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial Milestones [Member]</link:label>
    <link:label id="lab_nexi_ClinicalTrialMilestonesMember_documentation_en-US" xlink:label="lab_nexi_ClinicalTrialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">clinical Trial Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ClinicalTrialMilestonesMember" xlink:href="nexi-20221231.xsd#nexi_ClinicalTrialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ClinicalTrialMilestonesMember" xlink:to="lab_nexi_ClinicalTrialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_48406c14-4eb8-43b3-855f-3b5968eee6b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of black-scholes option pricing model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_060bf655-3f8b-498a-aceb-36c852a0032f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_42a2140f-a752-47a3-bd2b-e8adbb5b4a58_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a3fa6a1f-90b7-4a9a-bc9f-600b255b0385_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_381956c7-2773-464d-b05b-1f77de5c34ad_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d555a9bd-2e8a-4b91-a367-543214d6b7cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6c4e44f5-631c-464c-b5de-0da4fade1175_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3f91b0b9-1ae3-43a8-b663-199845c62826_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_JohnsHopkinsUniversityMember_7fbb078a-8a0a-4661-b8b7-b99e11a858ce_terseLabel_en-US" xlink:label="lab_nexi_JohnsHopkinsUniversityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johns Hopkins University</link:label>
    <link:label id="lab_nexi_JohnsHopkinsUniversityMember_label_en-US" xlink:label="lab_nexi_JohnsHopkinsUniversityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johns Hopkins University [Member]</link:label>
    <link:label id="lab_nexi_JohnsHopkinsUniversityMember_documentation_en-US" xlink:label="lab_nexi_JohnsHopkinsUniversityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johns Hopkins University.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_JohnsHopkinsUniversityMember" xlink:href="nexi-20221231.xsd#nexi_JohnsHopkinsUniversityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_JohnsHopkinsUniversityMember" xlink:to="lab_nexi_JohnsHopkinsUniversityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_892d758f-2300-46cb-a35f-90e94461ac34_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0b064de8-590a-4511-839d-f6d69e76917a_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_41770711-1931-4606-b02d-c691eefd3abe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_902c2474-5a07-468d-be3a-b4fdb7dd3b3e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable as of end of period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent_9a99b460-64fa-4ac5-88b5-c35fd5821a6e_terseLabel_en-US" xlink:label="lab_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in headcount, percentage</link:label>
    <link:label id="lab_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Expected Number Of Positions Eliminated, Period Percent</link:label>
    <link:label id="lab_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent_documentation_en-US" xlink:label="lab_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Expected Number Of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent" xlink:href="nexi-20221231.xsd#nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_011a7718-9ada-456e-b912-b52c0292b835_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ae313714-f0f6-4e27-a1d7-4b83e8230c05_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer, including assessed tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_31de911c-3839-4e92-8b42-3603be37e4ee_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Liquidity</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_53cdf784-5bc4-4eb8-9169-a79e29fdd2f9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4378a129-ffec-494d-9b6f-024badca1726_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of transaction costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_04b79a02-4c56-4c53-b69f-78e8154eff42_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_f7134cd6-da8a-46f6-a191-dc8e62cddeb5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_94011583-dfbc-4d77-a4c2-8494ffe65233_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_ea731767-c1d1-421f-b758-8b05140c709b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a0c1b212-497e-437c-b01e-7a4a810e9313_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_AtTheMarketOfferingMember_d4e901d8-87e0-4d40-ad02-22c3c59f4c1e_terseLabel_en-US" xlink:label="lab_nexi_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:label id="lab_nexi_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_nexi_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:label id="lab_nexi_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_nexi_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_AtTheMarketOfferingMember" xlink:href="nexi-20221231.xsd#nexi_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_AtTheMarketOfferingMember" xlink:to="lab_nexi_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_bdf203b5-519e-416c-a6e0-d4ebd3759644_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_800c9c06-0c20-4f8d-a6a7-9ac6b90aadea_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e5757ed9-8cce-487d-b8b1-38c7ece7d578_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_TherapeuticFieldMember_abb238bc-7212-44b2-b663-6b258aaf282c_terseLabel_en-US" xlink:label="lab_nexi_TherapeuticFieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Therapeutic Field</link:label>
    <link:label id="lab_nexi_TherapeuticFieldMember_label_en-US" xlink:label="lab_nexi_TherapeuticFieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Therapeutic Field [Member]</link:label>
    <link:label id="lab_nexi_TherapeuticFieldMember_documentation_en-US" xlink:label="lab_nexi_TherapeuticFieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Therapeutic field.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TherapeuticFieldMember" xlink:href="nexi-20221231.xsd#nexi_TherapeuticFieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_TherapeuticFieldMember" xlink:to="lab_nexi_TherapeuticFieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ef7e6462-cff9-4ed6-b5fb-9bd72399f480_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_da9800e9-ca57-4632-beaa-5b14e499bf93_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations_ed5d7df6-624a-4bb8-8cc8-d23f6df81073_terseLabel_en-US" xlink:label="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions after eliminations</link:label>
    <link:label id="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations_label_en-US" xlink:label="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Number Of Positions, After Eliminations</link:label>
    <link:label id="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations_documentation_en-US" xlink:label="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Number Of Positions, After Eliminations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations" xlink:href="nexi-20221231.xsd#nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations" xlink:to="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f76c7c73-b926-4d70-a1d7-29556cb4d4c6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_72fd488b-a26a-42cd-a915-75d5423f1c19_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_3506ebbe-6637-4370-8cf5-c3fe37f8ce01_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_6c8f0480-28e0-4e8e-b5fa-fb623438c31a_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c155b6c9-cfa2-4a87-870b-0eb1643d84ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_a52605e4-7b1a-4837-8a9a-b94430ff7fcd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e6ff4d44-7179-4955-9e0b-b296aa0f50fb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_230147aa-04ed-424d-bb2b-3b19e31ba392_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ExclusiveLicenseAgreementMember_504aa359-8438-4b16-8e5b-c72519b09a30_terseLabel_en-US" xlink:label="lab_nexi_ExclusiveLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive License Agreement</link:label>
    <link:label id="lab_nexi_ExclusiveLicenseAgreementMember_label_en-US" xlink:label="lab_nexi_ExclusiveLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive License Agreement [Member]</link:label>
    <link:label id="lab_nexi_ExclusiveLicenseAgreementMember_documentation_en-US" xlink:label="lab_nexi_ExclusiveLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive License Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ExclusiveLicenseAgreementMember" xlink:href="nexi-20221231.xsd#nexi_ExclusiveLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ExclusiveLicenseAgreementMember" xlink:to="lab_nexi_ExclusiveLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_ae6d583e-8619-4ca2-8d67-bb38aa7e4c66_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a3ac47a8-5d37-4b3f-acec-5e282fb21374_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_97467908-7998-463d-b7dc-5d42a16781be_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_MilestonesDomain_22d0ca29-10fd-4ff6-8852-dfb1400fa5e6_terseLabel_en-US" xlink:label="lab_nexi_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_nexi_MilestonesDomain_label_en-US" xlink:label="lab_nexi_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_nexi_MilestonesDomain_documentation_en-US" xlink:label="lab_nexi_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MilestonesDomain" xlink:href="nexi-20221231.xsd#nexi_MilestonesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_MilestonesDomain" xlink:to="lab_nexi_MilestonesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_4c8ba6a4-f0e2-469e-a022-53ea29247019_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_04a666e6-fa31-4fb7-a3b3-9f8de47d19e7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible instruments and embedded derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ca43d1cb-076b-40f1-98f1-e28f214b53e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e66c3ed9-0ea1-4692-abc2-0eaa36cc4da1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c99387ac-383d-4110-a4ee-09b7b3f0aefd_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_85a92184-40e2-4506-ae11-71bae61f9e36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest by period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e9e6ccfa-4541-47ab-8481-5457e291f64e_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_68df2b16-5ab4-4aaf-b1e5-670983882922_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7302cd74-2103-4a7b-8a00-9e8a55a1b68f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6d5b773e-f5f9-4f6e-9f51-36bf33c7e073_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_NonclinicalFieldMember_de645f7c-345b-4fae-9474-63ab615dfdd6_terseLabel_en-US" xlink:label="lab_nexi_NonclinicalFieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-clinical field</link:label>
    <link:label id="lab_nexi_NonclinicalFieldMember_label_en-US" xlink:label="lab_nexi_NonclinicalFieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonclinical Field [Member]</link:label>
    <link:label id="lab_nexi_NonclinicalFieldMember_documentation_en-US" xlink:label="lab_nexi_NonclinicalFieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">non-clinical field</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_NonclinicalFieldMember" xlink:href="nexi-20221231.xsd#nexi_NonclinicalFieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_NonclinicalFieldMember" xlink:to="lab_nexi_NonclinicalFieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e9172afe-e451-431a-a305-3e7e4ff733bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_967bcf5f-34a2-4cdf-b992-88b932ab5ba7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3787fe49-f16a-4250-b472-fcb84cdef55a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_TemporaryEquityStockConvertedDuringPeriodValue_88ee6340-fb8f-46ea-9160-7da054735088_negatedTerseLabel_en-US" xlink:label="lab_nexi_TemporaryEquityStockConvertedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock into common stock</link:label>
    <link:label id="lab_nexi_TemporaryEquityStockConvertedDuringPeriodValue_label_en-US" xlink:label="lab_nexi_TemporaryEquityStockConvertedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Stock Converted During Period Value</link:label>
    <link:label id="lab_nexi_TemporaryEquityStockConvertedDuringPeriodValue_documentation_en-US" xlink:label="lab_nexi_TemporaryEquityStockConvertedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity stock converted during period value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityStockConvertedDuringPeriodValue" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityStockConvertedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_TemporaryEquityStockConvertedDuringPeriodValue" xlink:to="lab_nexi_TemporaryEquityStockConvertedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_38365b35-9ea0-4ed4-99d3-e27eb00aa9e4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_4bf14bc9-9d92-4bca-8e2d-9d98ded242ca_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0d717c2b-064b-4791-b622-e8c4228f074f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss attributable to common stockholders per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e099ce8b-f065-4401-8746-e38034b2e971_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_ddad855e-f27b-4acf-810d-ec03118aae9e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b9d60bc6-ef1e-47cf-99a7-c71636949f9a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5969c4a8-fe5d-472a-9f9b-84f9c0b434c4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f8408a09-9b23-492f-8a2f-6ca3fa0043cc_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_86d54a14-9606-4389-b8dc-fc70fc30de27_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_74d60bac-77c1-4f03-a5c0-2f79d8687188_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition adjustment recorded in accumulated deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_079b47ce-a523-4d92-a3c5-5a4091b4fb11_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance_9b1ebcf1-3c42-4ec9-9141-8a0bb5943ede_terseLabel_en-US" xlink:label="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability of convertible notes at issuance</link:label>
    <link:label id="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance_label_en-US" xlink:label="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Derivative Liability Of Convertible Notes At Issuance</link:label>
    <link:label id="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance_documentation_en-US" xlink:label="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Derivative Liability Of Convertible Notes At Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance" xlink:href="nexi-20221231.xsd#nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance" xlink:to="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f6d311c7-d595-4ec2-91ef-519fdc90fafc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_1cd92212-4627-42cb-9349-11ae79121cde_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_EmployeesExcludingExecutiveOfficerMember_f93726e1-e962-4ef2-9c60-4a87f72e9863_terseLabel_en-US" xlink:label="lab_nexi_EmployeesExcludingExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees, Excluding Executive Officer</link:label>
    <link:label id="lab_nexi_EmployeesExcludingExecutiveOfficerMember_label_en-US" xlink:label="lab_nexi_EmployeesExcludingExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees, Excluding Executive Officer [Member]</link:label>
    <link:label id="lab_nexi_EmployeesExcludingExecutiveOfficerMember_documentation_en-US" xlink:label="lab_nexi_EmployeesExcludingExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees, Excluding Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_EmployeesExcludingExecutiveOfficerMember" xlink:href="nexi-20221231.xsd#nexi_EmployeesExcludingExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_EmployeesExcludingExecutiveOfficerMember" xlink:to="lab_nexi_EmployeesExcludingExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_01a56059-55a1-4bbd-bf1b-4bdb114afe89_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_19bfe6ea-c577-4f58-82e2-e7015be1c7f7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3e4ab652-27f0-4ead-a01b-4607f3ecd9bd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8648a91f-0edb-46f6-8d1f-183f35846d88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_91cf7c70-4065-4314-9626-abb58b821e56_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_d9bc129f-8f20-4bd9-bd90-ca44053dd668_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_54687d82-b3fb-4af0-897a-c9d7b39f5e87_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from redemption of available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f355e3cb-ad82-4884-997b-862c891dc4f3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5dae0464-65fe-4798-a344-4406fbd87db0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage_f991aa43-886d-45af-ab26-823f1fddfe37_terseLabel_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement annual payment percentage</link:label>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage_label_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Annual Payment Percentage</link:label>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage_documentation_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Annual Payment Percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage" xlink:to="lab_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5274e852-afa6-49b0-a6f3-ab2a3af6c16e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4d217384-87ab-4bce-87fb-63633e0558af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_c8e0ca06-dbc7-417b-bb46-a8f9f4912a0a_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_42908aae-fc06-47d3-8577-06157c8c85ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_45ae973d-1d27-4d44-9ecf-7515fcf6411d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1c02d74d-9828-48e0-aa98-07f6da863670_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue_aeb188e6-0830-472c-bb52-1dbd1492f86d_terseLabel_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares unvested as of December&#160;31, 2022</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Outstanding Aggregate Intrinsic Value</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue" xlink:to="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_537982ad-5023-4dcb-8273-e77685f658cf_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ccd0e94b-8364-47a1-a810-6ed6a4e7870f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_aa0a58d8-d166-42c1-93c3-aaa041059071_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax provision:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d1367868-60ba-40bc-8de0-8988414a3abd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_04fd85b4-49cb-4933-895b-bef7ca554042_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note redemption price, percentage of principal amount redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_86c8b001-b370-4ffe-b31f-eecf5bc0c66c_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2570945b-bcdc-41b5-a268-b0506147dca5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d8484152-ebf2-4ef3-8a1a-898ae376c71e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ef7b3797-e545-4f52-8a65-54db96cf165d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d878dd4c-f40d-413f-98b6-3dfdbb664b8c_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1c308e8f-74da-4c35-8cb3-7edc87884cc2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_69241774-5e7b-46d9-b4b9-c16064aad010_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_b4b0063b-d390-4d9e-b858-a90916ec5aef_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_dd26da22-adbc-4b24-b71f-939ed5822d1f_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ad5c1da1-7288-442c-b337-380d16da4210_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_b313e22c-bbc0-4995-bb40-99bd9022c2b2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Converted common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_ae83f740-9be4-49d4-8c95-4c31d2a7911d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_af101951-a5ed-4834-966c-a5d699ebe407_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases&#160;of&#160;available-for-sale&#160;marketable&#160;securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fd084502-e5a8-42cd-a599-d59958d76fe5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_02876251-56a5-4277-8dd5-ec732d7c8bed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_addbc6a0-2e59-42e6-9cb6-1d6d1ac09077_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable as of end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_44bc9443-6bab-45b3-bd4d-78bf65ce1198_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_974078e6-17b9-4277-b884-4d0e3f9880b9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and geographic information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7c3d969d-ee2d-45d8-bb6b-9b7142e7c212_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6593dc17-c3ac-41b5-9904-2dab786a3e36_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_2e19fe66-65e9-491d-824a-b470a911cb57_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_LaboratoryEquipmentMember_b4c90d41-e381-442e-9cfe-68cf0285a927_terseLabel_en-US" xlink:label="lab_nexi_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_nexi_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_nexi_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_nexi_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_nexi_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_LaboratoryEquipmentMember" xlink:href="nexi-20221231.xsd#nexi_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_LaboratoryEquipmentMember" xlink:to="lab_nexi_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_119e620b-01d5-4969-a0cf-d2ae7633adde_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a3c71cfc-e978-42cf-b724-d104171e8456_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e1a3431f-0563-45d8-8566-23f41720b925_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod_760eb8b5-563b-46e1-8e37-fea8687651bc_terseLabel_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cashless exercise of options for common stock (in shares)</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod_label_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Common Stock, Cashless, Exercised in Period</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod_documentation_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Common Stock, Cashless, Exercised in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod" xlink:to="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_ec5bfb6f-a696-4850-b0db-4ce97b2f3c48_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_02add578-b020-488a-be5f-45b09486568b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_249cabfc-d4cb-4691-b3ab-50d0bf6e530c_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9d2c3b88-279e-4eaf-92c5-04e6ab8abba3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_fed2b08d-1ef9-431a-b891-38c10f6edbdf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from disposal of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_328c4de5-03e6-4bc3-9582-87201be6f1bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/ (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_TwoThousandEighteenEquityIncentivePlanMember_aee10387-2c37-4103-99e1-84e69f10a86c_terseLabel_en-US" xlink:label="lab_nexi_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2018 Plan</link:label>
    <link:label id="lab_nexi_TwoThousandEighteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_nexi_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_nexi_TwoThousandEighteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_nexi_TwoThousandEighteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TwoThousandEighteenEquityIncentivePlanMember" xlink:href="nexi-20221231.xsd#nexi_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="lab_nexi_TwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_6ca0c7e0-dd38-43f4-b849-d8f811211870_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_7ffbdd56-7b67-4c1c-abdc-c64c764ad8c8_terseLabel_en-US" xlink:label="lab_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A redeemable preferred stock upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label id="lab_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity stock issued during period shares new issues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_90dcff7d-9c0d-49a0-b669-dfdf11071de0_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_DebtInstrumentFullyDilutedCapitalization_7e381185-2332-417d-bd50-a63c709fde47_terseLabel_en-US" xlink:label="lab_nexi_DebtInstrumentFullyDilutedCapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note fully diluted capitalization</link:label>
    <link:label id="lab_nexi_DebtInstrumentFullyDilutedCapitalization_label_en-US" xlink:label="lab_nexi_DebtInstrumentFullyDilutedCapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Fully Diluted Capitalization</link:label>
    <link:label id="lab_nexi_DebtInstrumentFullyDilutedCapitalization_documentation_en-US" xlink:label="lab_nexi_DebtInstrumentFullyDilutedCapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument fully diluted capitalization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentFullyDilutedCapitalization" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentFullyDilutedCapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_DebtInstrumentFullyDilutedCapitalization" xlink:to="lab_nexi_DebtInstrumentFullyDilutedCapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b614f655-f834-4920-b946-b9b61a00b7c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest as of end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_67fbbc3f-1ab9-42d2-9f5b-19784ee17739_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a0b6442c-eac3-43c9-9cd2-c840280282f8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ed2d81d6-704e-4ace-902d-86741e4498ad_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_63e7d7f4-d8b8-4a20-815e-fab3cf5542fa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial conversion feature</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6f7b35e4-cc86-4553-8601-661989ee16fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_679b9675-67de-46e9-9936-f0203e0567bd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a42f7a04-060e-4853-8f4c-d512f6c1e519_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting standards and pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_bfedff60-8b54-4235-9824-cec74672997e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes outstanding converted into common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_c620f72d-09c9-49d1-8d80-1c150c07ab9b_terseLabel_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:to="lab_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d0d5f00f-2964-4082-a377-a9b39e7a47d4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dec7548a-b4fa-466d-aa68-b38f04977f36_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_423398fd-2097-43bd-86cb-1855c08dc40c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_a9d4b3e1-39e4-45cf-8898-0cb37fe14f24_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef9ea71c-3b11-4f52-aec2-682dcb98b07a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_SeriesARedeemableConvertiblePreferredStockMember_859041b4-d083-4e7f-b742-80b849b70934_terseLabel_en-US" xlink:label="lab_nexi_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_nexi_SeriesARedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_nexi_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_nexi_SeriesARedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_nexi_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SeriesARedeemableConvertiblePreferredStockMember" xlink:href="nexi-20221231.xsd#nexi_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="lab_nexi_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_31bc8dc8-6140-454d-bc80-a608aa4da25f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_AccruedResearchAndDevelopmentCostsCurrent_75a51a45-4bf1-426b-b41d-356ea5ad1526_terseLabel_en-US" xlink:label="lab_nexi_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development costs</link:label>
    <link:label id="lab_nexi_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_nexi_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:label id="lab_nexi_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_nexi_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="nexi-20221231.xsd#nexi_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_nexi_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_629e34d7-1457-4ab5-8574-e6b06c68bd3a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_TemporaryEquityStockConvertedDuringPeriodShares_ba0e966f-a89c-427e-9f3a-c9d42879fb40_negatedTerseLabel_en-US" xlink:label="lab_nexi_TemporaryEquityStockConvertedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock into common stock (in shares)</link:label>
    <link:label id="lab_nexi_TemporaryEquityStockConvertedDuringPeriodShares_label_en-US" xlink:label="lab_nexi_TemporaryEquityStockConvertedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Stock Converted During Period Shares</link:label>
    <link:label id="lab_nexi_TemporaryEquityStockConvertedDuringPeriodShares_documentation_en-US" xlink:label="lab_nexi_TemporaryEquityStockConvertedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity stock converted during period shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityStockConvertedDuringPeriodShares" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityStockConvertedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_TemporaryEquityStockConvertedDuringPeriodShares" xlink:to="lab_nexi_TemporaryEquityStockConvertedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_DebtDiscount_b388a486-4cd0-4862-a08a-af02f4b7a246_terseLabel_en-US" xlink:label="lab_nexi_DebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_nexi_DebtDiscount_label_en-US" xlink:label="lab_nexi_DebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Discount</link:label>
    <link:label id="lab_nexi_DebtDiscount_documentation_en-US" xlink:label="lab_nexi_DebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtDiscount" xlink:href="nexi-20221231.xsd#nexi_DebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_DebtDiscount" xlink:to="lab_nexi_DebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_83e74544-b720-4f23-941e-5e35b6453419_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total provision (benefit) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_179b0324-82dc-4a03-989d-10472273eb62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d67ac35-757b-420d-93d7-2e5d5e4a060b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fcc30574-9feb-4b7b-86cd-daef71efc9bd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a7be3b79-5e3a-4a2f-9904-e136e54fb995_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_687fddc7-a71d-4a8b-9dec-e14d1f90f52d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d454d3b1-1de6-465b-baef-168721f926e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_8f6de097-c9e2-4f92-83af-80aef21d8a9e_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_00d813c5-102a-496d-bcdc-9ce69cb41f3a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_72f1cdee-2636-4ab3-bde5-99c394068f4f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9fcab9a7-223f-4b04-a92d-a2faea9d8152_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_1e06c50c-407d-4d9c-9c68-fc2d5bfb05b9_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9fae87e0-562c-48be-a045-8a71ccbe10a3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e51009fd-2f2d-4a11-96fc-b994cd74f194_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_SaleOfStockCommissionPercentage_60122caf-5e9f-48db-a35e-6246a90b1d3e_terseLabel_en-US" xlink:label="lab_nexi_SaleOfStockCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission percentage</link:label>
    <link:label id="lab_nexi_SaleOfStockCommissionPercentage_label_en-US" xlink:label="lab_nexi_SaleOfStockCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commission Percentage</link:label>
    <link:label id="lab_nexi_SaleOfStockCommissionPercentage_documentation_en-US" xlink:label="lab_nexi_SaleOfStockCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Commission Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SaleOfStockCommissionPercentage" xlink:href="nexi-20221231.xsd#nexi_SaleOfStockCommissionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_SaleOfStockCommissionPercentage" xlink:to="lab_nexi_SaleOfStockCommissionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_TranslationalResearchAwardAgreementMember_997f9909-bf4c-43ce-afaa-3c2d78b3dc1a_terseLabel_en-US" xlink:label="lab_nexi_TranslationalResearchAwardAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translational Research Award Agreement</link:label>
    <link:label id="lab_nexi_TranslationalResearchAwardAgreementMember_label_en-US" xlink:label="lab_nexi_TranslationalResearchAwardAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translational Research Award Agreement [Member]</link:label>
    <link:label id="lab_nexi_TranslationalResearchAwardAgreementMember_documentation_en-US" xlink:label="lab_nexi_TranslationalResearchAwardAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translational Research Award Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TranslationalResearchAwardAgreementMember" xlink:href="nexi-20221231.xsd#nexi_TranslationalResearchAwardAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_TranslationalResearchAwardAgreementMember" xlink:to="lab_nexi_TranslationalResearchAwardAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_17757d8e-0fd4-4c29-ac3e-3a8d948dd4ad_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ea88e088-4256-4860-ac9e-76f2abf1af79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b1ed248f-d892-428e-b7a6-6f65efa483b3_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ef6bbe4e-513e-480b-a46f-117fd798d3ba_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_e0153cbd-1ba0-455e-8863-cc357844022b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, current</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_636ed9ad-6108-4242-9d8e-5d7dc3b87f0f_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_5cb9be40-8e59-42cb-9f86-da66a521b552_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_5c3f3564-f835-46ea-a489-f9adf2f5ccf4_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment positions in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock_80a1277e-9950-4936-9b44-9396807f4df1_terseLabel_en-US" xlink:label="lab_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial and contract development and manufacturing organization expenses</link:label>
    <link:label id="lab_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial, Contract Development, and Manufacturing Organization Expenses, Policy [Policy Text Block]</link:label>
    <link:label id="lab_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Trial, Contract Development, and Manufacturing Organization Expenses, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock" xlink:href="nexi-20221231.xsd#nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock" xlink:to="lab_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_44102239-4cc9-4cc4-a61c-38e1121b03b5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $0.0001 par value, 250,000,000 shares authorized as of December&#160;31, 2022 and 2021, 26,078,451 and 22,828,904 issued and outstanding as of December&#160;31, 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_MilestoneFees_177410f5-4a6a-4937-be40-cfa03be52928_terseLabel_en-US" xlink:label="lab_nexi_MilestoneFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone fees</link:label>
    <link:label id="lab_nexi_MilestoneFees_label_en-US" xlink:label="lab_nexi_MilestoneFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Fees</link:label>
    <link:label id="lab_nexi_MilestoneFees_documentation_en-US" xlink:label="lab_nexi_MilestoneFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MilestoneFees" xlink:href="nexi-20221231.xsd#nexi_MilestoneFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_MilestoneFees" xlink:to="lab_nexi_MilestoneFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_c8b8424d-f690-4e1b-9d64-f9eedbaddf95_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_47200319-6840-455e-95f0-6101b8b6c91f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_73c23137-e7e8-4061-950e-307fa37c31aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of antidilutive securities outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_17dcf0af-92f6-47d2-b53d-53d08cddbaf9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value assets and liabilities measured on recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_6e3a5893-0b13-4c8a-abd5-f6f2de1b6481_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4a70f631-fb45-42be-826f-967e678eff22_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable as of December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d5ab1ee3-3083-46a6-916f-9d055b1a2dec_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6a83db9e-8c03-4a43-a415-d03a120caa03_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bb20daa9-10f1-4897-af8b-35380375736b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22db75c3-4a78-43f7-aa84-0cf20f9e85e6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_LeaseExpenseNoncash_045b10ab-ec79-45a8-8522-d4711c712eb1_terseLabel_en-US" xlink:label="lab_nexi_LeaseExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_nexi_LeaseExpenseNoncash_label_en-US" xlink:label="lab_nexi_LeaseExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expense, Noncash</link:label>
    <link:label id="lab_nexi_LeaseExpenseNoncash_documentation_en-US" xlink:label="lab_nexi_LeaseExpenseNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Expense, Noncash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_LeaseExpenseNoncash" xlink:href="nexi-20221231.xsd#nexi_LeaseExpenseNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_LeaseExpenseNoncash" xlink:to="lab_nexi_LeaseExpenseNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cecb2d41-3e09-4de4-bfa1-9107f32bafca_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_730c4c87-08d2-4e79-89c5-8195ad6ba33f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_56ca5a18-6400-4c64-b8b0-7b23d7dae749_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_fb83737f-d13e-46e4-9780-1d94e60f9f62_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2ed6f585-541d-44db-b86e-953d74fc2dd4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss available to common stockholders&#8217;</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_cc7441de-b4b9-448d-8409-d003d170d5f4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1_a2a8c3e4-282d-48c8-8c13-9751206e873b_terseLabel_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares unvested as of end of period (in years)</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Options Non Vested Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1_documentation_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Options Non Vested Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a41be83c-a534-4627-8246-66389f554d90_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8d2cdd70-7abb-4e76-b7b8-4a174a287f65_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest as of end of period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_DebtIssuanceCosts_457396dc-1877-49cb-b62e-2d4f17a42bee_terseLabel_en-US" xlink:label="lab_nexi_DebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_nexi_DebtIssuanceCosts_label_en-US" xlink:label="lab_nexi_DebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_nexi_DebtIssuanceCosts_documentation_en-US" xlink:label="lab_nexi_DebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtIssuanceCosts" xlink:href="nexi-20221231.xsd#nexi_DebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_DebtIssuanceCosts" xlink:to="lab_nexi_DebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f28abc50-fc50-4764-b14c-5bb007df1b2d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment purchases included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_40998fa1-4061-45d3-b913-91203ce3d63b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4914d50a-1fa9-46b9-88b8-253c2720cb20_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7288d6fa-5c34-46d3-a553-8ce2bcd1280c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_651af549-174e-4345-9c33-628bb0920fed_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_f2ea3564-3c97-437b-b208-6a631cf54e7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_002ddda3-ae81-4435-844f-5c6ce5639cf8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6210e40c-5069-4c13-9b24-4b958e16ec5b_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_f1acbb38-399d-4622-abbd-035c024e7972_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock_29ab5433-7bb1-443a-878c-7c6b9d6d875d_terseLabel_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding stock maximum</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock_label_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Increase In Authorized Shares by Percentage of Outstanding Stock</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock_documentation_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Increase In Authorized Shares by Percentage of Outstanding Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock" xlink:to="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_36f13c33-2c1b-430d-b81e-54e913838c6e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_501f3463-4a65-4ca0-bebb-4bfb2ccee47e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;non-current&#160;assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_0240eb99-891a-41c8-a8ae-7a078b2be2e7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_225d0700-1aa9-4a34-80c3-c6cb725a4d41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_06fb14df-6cb2-4b66-9572-9043b5e46281_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable as of period end (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_DeferredTaxAssetValuationAllowancePercent_f7971341-c402-4eae-9a32-3be6585d717e_terseLabel_en-US" xlink:label="lab_nexi_DeferredTaxAssetValuationAllowancePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_nexi_DeferredTaxAssetValuationAllowancePercent_label_en-US" xlink:label="lab_nexi_DeferredTaxAssetValuationAllowancePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance, Percent</link:label>
    <link:label id="lab_nexi_DeferredTaxAssetValuationAllowancePercent_documentation_en-US" xlink:label="lab_nexi_DeferredTaxAssetValuationAllowancePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DeferredTaxAssetValuationAllowancePercent" xlink:href="nexi-20221231.xsd#nexi_DeferredTaxAssetValuationAllowancePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_DeferredTaxAssetValuationAllowancePercent" xlink:to="lab_nexi_DeferredTaxAssetValuationAllowancePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_613d2db8-49b6-4825-8324-9603127b8073_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_de1f9a69-9e42-4382-93cf-60a2630ec5ab_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_6bf741a7-d633-44dc-a179-39a90205ab5b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_39bb3877-8b4c-40c5-86c8-7fc9196c26ee_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7c771251-5e0a-4230-98da-2e57c999e04b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding as of beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2edcec17-2f6d-4a68-abb6-281f49bc3c79_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding as of end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4c717b0e-ee98-4c83-9438-7e62cb591250_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_c035db22-8639-41a3-b7ca-2ad5b433a53f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_efe0ca0d-d563-475d-a2d2-566940662ca4_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_952c3b4f-bfdd-4b9a-b97c-1ebc07b754cc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a19ccced-a22d-4ca3-b06b-42656966e0af_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a1556835-b414-4a36-9c44-d8402599bcdb_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_436dfc27-850e-4c21-8fb3-be8e352db101_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_474b36a6-df59-4e9e-933f-8a384677884b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_191fe5e9-1aec-4526-9c8d-4ed4c171bf94_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_6c2eabc9-db97-42c3-a731-334cb222b863_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_PrepaidMaintenanceAgreements_4315b886-e4fc-43a2-96e4-9c3979350a70_terseLabel_en-US" xlink:label="lab_nexi_PrepaidMaintenanceAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid maintenance agreements</link:label>
    <link:label id="lab_nexi_PrepaidMaintenanceAgreements_label_en-US" xlink:label="lab_nexi_PrepaidMaintenanceAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance Agreements</link:label>
    <link:label id="lab_nexi_PrepaidMaintenanceAgreements_documentation_en-US" xlink:label="lab_nexi_PrepaidMaintenanceAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid maintenance agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_PrepaidMaintenanceAgreements" xlink:href="nexi-20221231.xsd#nexi_PrepaidMaintenanceAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_PrepaidMaintenanceAgreements" xlink:to="lab_nexi_PrepaidMaintenanceAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_32df4c22-abd5-49ad-946e-b3e75c578396_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_209d79c5-d941-49e0-9e33-e73fd75be002_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_72d857a2-c275-486c-b5da-159d07272604_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c5991fb7-eefd-416d-9c01-4a84cf439d48_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fd4675bf-0418-4407-ad4f-59f87266f986_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_241ea424-52ea-4cd9-bffa-2d15c0c0cd1a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1dcf1b64-bb49-4ac6-8124-92fad24218e7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes_c8820169-c731-4cfb-b877-4287c5996e4d_terseLabel_en-US" xlink:label="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability of convertible notes</link:label>
    <link:label id="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes_label_en-US" xlink:label="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative Liability of Convertible Notes</link:label>
    <link:label id="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes_documentation_en-US" xlink:label="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability of convertible notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes" xlink:href="nexi-20221231.xsd#nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes" xlink:to="lab_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f7ca992a-72fe-4c5a-a78a-66fa1211d48d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_8f160005-c907-4da8-87bc-1a2f8a1161c6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Activities</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_edadfc30-ede5-4528-a646-a5f73cb90b8e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_2c72970e-9cf8-46a3-8a83-97ca32d541ed_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e33f622f-d9c6-4fe7-af11-4e1dbb5d18c8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1a068617-0d3f-49aa-9473-19aba21821b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentTable_53461f0c-a6a4-47d9-8873-e374b60e3683_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentTable_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentTable" xlink:to="lab_us-gaap_SupplyCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_CumulativeMinimumRoyalties_6c7a7527-41e6-4c1d-b7de-2b7046d48a0b_terseLabel_en-US" xlink:label="lab_nexi_CumulativeMinimumRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative minimum royalties</link:label>
    <link:label id="lab_nexi_CumulativeMinimumRoyalties_label_en-US" xlink:label="lab_nexi_CumulativeMinimumRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Minimum Royalties</link:label>
    <link:label id="lab_nexi_CumulativeMinimumRoyalties_documentation_en-US" xlink:label="lab_nexi_CumulativeMinimumRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative minimum royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_CumulativeMinimumRoyalties" xlink:href="nexi-20221231.xsd#nexi_CumulativeMinimumRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_CumulativeMinimumRoyalties" xlink:to="lab_nexi_CumulativeMinimumRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_7dbc5b58-de27-4d5e-9f09-bb2e64544d24_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_32b096ae-9d9f-43df-82af-f492105a9e39_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_252069b0-2de6-4a6d-855d-0736b592cb50_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_af837408-2609-4971-a506-cf03a5bae683_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_be18241f-c684-413d-b33b-ae952bd3fda6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_cf123ba0-c8c0-4fa1-b806-1ed3587db37b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_f7000be9-ea83-4aa1-a731-fe4608c1b46c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_bf0ec12d-10fc-426a-809c-70ed05706bb5_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_10727224-c8f6-494b-8210-0c48c19bd5d0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ComputerEquipmentAndSoftwareMember_be28e64b-ed18-4f3f-a612-6d24c0b9bd9f_terseLabel_en-US" xlink:label="lab_nexi_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_nexi_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_nexi_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_nexi_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_nexi_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ComputerEquipmentAndSoftwareMember" xlink:href="nexi-20221231.xsd#nexi_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ComputerEquipmentAndSoftwareMember" xlink:to="lab_nexi_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_6347313d-4168-4c27-bf96-914d5ee8c273_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f0e941f7-43ef-4ca9-9576-49a5e98f8944_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_8ae0e1ed-c095-4c40-bae8-2fc5336215c1_terseLabel_en-US" xlink:label="lab_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:href="nexi-20221231.xsd#nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1aa1e117-8491-4064-9575-678378e5f3c3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_6035a04a-82ba-466e-bc22-3f67bb1372fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_0db5e2da-a204-46d6-bb6c-b90037715166_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash&#160;interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c230ab0b-c7c7-4261-808b-4d80724cffac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding as of December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage_c9717881-b7d4-458d-ab66-1660e7d6c61d_terseLabel_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement, contractual payment percentage</link:label>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage_label_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contractual Payment Percentage</link:label>
    <link:label id="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage_documentation_en-US" xlink:label="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development arrangement contractual payment percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage" xlink:to="lab_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_1e0eae32-5358-465b-bdf2-6b1dd9b91d26_negatedTerseLabel_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_label_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period</link:label>
    <link:label id="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_documentation_en-US" xlink:label="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:to="lab_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_2a34ba19-e3c9-4971-8b99-04cc31ca9117_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_66e4d099-230e-4990-aaff-e1dc95c555e1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_d8083a83-974e-4686-ae1e-158fdcee85a0_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income debt securities</link:label>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember" xlink:to="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_46897f75-4e65-4e06-a842-fbd2b24eac5d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt_2c2a3c7c-d00c-42cd-aa32-3a59c62d2785_terseLabel_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible debt into common stock (in shares)</link:label>
    <link:label id="lab_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt_label_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Convertible Debt</link:label>
    <link:label id="lab_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt_documentation_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period shares conversion of convertible debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt" xlink:to="lab_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_aa65d7c3-0ea3-440e-8a39-0cd8777c9420_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock_d3a0d0a6-fa7f-49ab-83f4-c167095da7f9_terseLabel_en-US" xlink:label="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit</link:label>
    <link:label id="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock_label_en-US" xlink:label="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock And Stockholders Equity Disclosure [Text Block]</link:label>
    <link:label id="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock_documentation_en-US" xlink:label="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock and Stockholders Equity Disclosure [Text Block].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xlink:href="nexi-20221231.xsd#nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xlink:to="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_65bfc8bd-1a0f-4c98-95f3-43090d15f5d4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_197c713f-d7e5-4b77-b267-1a1094c11d4b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs associated with convertible notes</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_fb886778-f2bd-427b-b8dd-be0912563898_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock_a989c0e2-f539-4e61-9e8b-1af5955e559f_terseLabel_en-US" xlink:label="lab_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
    <link:label id="lab_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock_documentation_en-US" xlink:label="lab_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="nexi-20221231.xsd#nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="lab_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b0e4598a-255c-4617-849a-b8f8737f0452_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract_label_en-US" xlink:label="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock And Stockholders Equity Disclosure [Abstract]</link:label>
    <link:label id="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract_documentation_en-US" xlink:label="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock and Stockholders Equity Disclosure [Abstract].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract" xlink:href="nexi-20221231.xsd#nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract" xlink:to="lab_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e6ac5050-a86f-4aec-99c1-311f77d3a064_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_acc8546e-1d2c-4661-aad4-2eb9497be562_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e4c6894-a97b-4f3d-bf5c-657f093eb4c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold_7ff19e8d-f8bf-4af2-9f53-7d2d37a574b4_terseLabel_en-US" xlink:label="lab_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing share price minimum threshold (dollars per share)</link:label>
    <link:label id="lab_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold_label_en-US" xlink:label="lab_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Repricing, Closing Share Price Minimum Threshold</link:label>
    <link:label id="lab_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold_documentation_en-US" xlink:label="lab_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Repricing, Closing Share Price Minimum Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold" xlink:href="nexi-20221231.xsd#nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold" xlink:to="lab_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_debf0f46-6b18-48ed-b5e0-78882eb54919_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2c43fd16-6fca-41c1-9889-d77f92efce6d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_c1cf4b3c-f057-4e6b-a7dc-0bbfbc312e49_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9c6ec4cf-5d34-412b-9bb2-3c0327faef7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5a9832fc-ae91-42b2-96d0-7d2acb6f1c7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest as of December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_PrepaidResearchAndDevelopmentExpenses_4fb9bf5e-5fde-4ea1-9d16-7acb9976946a_terseLabel_en-US" xlink:label="lab_nexi_PrepaidResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_nexi_PrepaidResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_nexi_PrepaidResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development Expenses</link:label>
    <link:label id="lab_nexi_PrepaidResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_nexi_PrepaidResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_PrepaidResearchAndDevelopmentExpenses" xlink:href="nexi-20221231.xsd#nexi_PrepaidResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_PrepaidResearchAndDevelopmentExpenses" xlink:to="lab_nexi_PrepaidResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_PaycheckProtectionProgramLoanMember_0cbe0896-5d99-4d31-a79a-d0d724cdd975_terseLabel_en-US" xlink:label="lab_nexi_PaycheckProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program Loan</link:label>
    <link:label id="lab_nexi_PaycheckProtectionProgramLoanMember_label_en-US" xlink:label="lab_nexi_PaycheckProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program Loan [Member]</link:label>
    <link:label id="lab_nexi_PaycheckProtectionProgramLoanMember_documentation_en-US" xlink:label="lab_nexi_PaycheckProtectionProgramLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program Loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_PaycheckProtectionProgramLoanMember" xlink:href="nexi-20221231.xsd#nexi_PaycheckProtectionProgramLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_PaycheckProtectionProgramLoanMember" xlink:to="lab_nexi_PaycheckProtectionProgramLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_c86d5729-4e9a-485a-ab5b-0e7bdd76fd26_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_5c98423c-8bf6-4207-9e80-110f69d1a277_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_dbe1ca10-3d16-452b-b541-7f4f612f7259_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_71830f0c-eef2-4bd5-ab2a-da0f37d01568_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from "at-the-market" offering facility, net of transaction costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3a01ac98-7e3f-4597-84c0-27244cdc3f53_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_d0284713-057a-4900-aa1a-409a525aa65c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_07a39d01-88cb-4ebd-a448-4b539a483c97_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0c5742c5-6cf3-49a0-b3d8-320c1f4a42cf_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c85910e7-ca15-4eb3-8e23-daa7c25d0c57_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c9d4016-a0dc-4361-a8e4-3f83cd9c8ffd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding as of beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b91d320c-38c8-42b1-978e-b11e3b98a508_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding as of end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_e683ff1d-0667-4975-9bee-830b8ce8accd_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on asset disposal</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_TwoThousandSeventeenEquityIncentivePlanMember_00689f82-fac1-4218-8a7e-cda83ed1157d_terseLabel_en-US" xlink:label="lab_nexi_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The 2017 Plan</link:label>
    <link:label id="lab_nexi_TwoThousandSeventeenEquityIncentivePlanMember_label_en-US" xlink:label="lab_nexi_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_nexi_TwoThousandSeventeenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_nexi_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TwoThousandSeventeenEquityIncentivePlanMember" xlink:href="nexi-20221231.xsd#nexi_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="lab_nexi_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_ba13aa87-f73c-4f52-871f-dcb3b4d2c267_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6bfe867d-7329-4b6b-b585-ce9dfe55edf5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_a50c00bf-15de-4ae5-ac1b-1b32cefcfe4a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8c0032bd-3408-45b5-af3d-348bf9d6a449_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock into common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_d4694398-48b4-47be-8834-8cf1f7887ea2_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7d99bcac-654d-4d5e-a1f3-f2ecf07bc62d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_0e82a7a3-d71c-4fae-a8fc-c5a9fb33c203_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_4180f7f0-69eb-46a0-95ef-bccf5375d68f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_6410f7a5-9e6e-476c-8ee9-ca664cbc1460_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f003cfe3-f4fc-483f-9331-7a05fe0a6e33_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations_3b594151-ee5a-47ef-b826-9d5b5026db9c_terseLabel_en-US" xlink:label="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions before eliminations</link:label>
    <link:label id="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations_label_en-US" xlink:label="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Number Of Positions, Before Eliminations</link:label>
    <link:label id="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations_documentation_en-US" xlink:label="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Number Of Positions, Before Eliminations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations" xlink:href="nexi-20221231.xsd#nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations" xlink:to="lab_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_SublicenseConsiderationPaymentPercentMaximum_9642e157-8c75-4d9c-9b18-6e0010b8cf16_terseLabel_en-US" xlink:label="lab_nexi_SublicenseConsiderationPaymentPercentMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense consideration payment, maximum percent</link:label>
    <link:label id="lab_nexi_SublicenseConsiderationPaymentPercentMaximum_label_en-US" xlink:label="lab_nexi_SublicenseConsiderationPaymentPercentMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Consideration Payment, Percent, Maximum</link:label>
    <link:label id="lab_nexi_SublicenseConsiderationPaymentPercentMaximum_documentation_en-US" xlink:label="lab_nexi_SublicenseConsiderationPaymentPercentMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicense Consideration Payment, Percent, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SublicenseConsiderationPaymentPercentMaximum" xlink:href="nexi-20221231.xsd#nexi_SublicenseConsiderationPaymentPercentMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_SublicenseConsiderationPaymentPercentMaximum" xlink:to="lab_nexi_SublicenseConsiderationPaymentPercentMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2c638bb9-6f8e-425d-b349-d387229d2a93_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares unvested as of end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_dd01b1a9-ccc9-4db8-91cc-bd05130e4f02_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_f090a311-1021-4956-a7c9-c4d1b2b7531d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, incurred cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_8be0c075-8e15-45e5-aada-3703c656c089_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_MinimumAnnualRoyaltyPayments_9940d0b4-6e1b-40a4-8a4a-e40d02de66f3_terseLabel_en-US" xlink:label="lab_nexi_MinimumAnnualRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum annual royalty payments</link:label>
    <link:label id="lab_nexi_MinimumAnnualRoyaltyPayments_label_en-US" xlink:label="lab_nexi_MinimumAnnualRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Annual Royalty Payments</link:label>
    <link:label id="lab_nexi_MinimumAnnualRoyaltyPayments_documentation_en-US" xlink:label="lab_nexi_MinimumAnnualRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum annual royalty payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MinimumAnnualRoyaltyPayments" xlink:href="nexi-20221231.xsd#nexi_MinimumAnnualRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_MinimumAnnualRoyaltyPayments" xlink:to="lab_nexi_MinimumAnnualRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d13ab426-a7c6-4376-829f-ae2caf82d590_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_97ffbdff-f050-4e5d-a5c9-eb47bc6081b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0ebfd6aa-b2f8-44ae-a6cc-97dc7b1f27d2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49d4a56b-b56c-48dd-b19c-ab3897c9b210_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_aec93517-2cf5-4df4-bc1c-6e307b01ae78_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple_ace121f0-2f2f-4064-b3b6-4e4292582b65_terseLabel_en-US" xlink:label="lab_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repricing multiple</link:label>
    <link:label id="lab_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple_label_en-US" xlink:label="lab_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Repricing Multiple</link:label>
    <link:label id="lab_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple_documentation_en-US" xlink:label="lab_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Repricing Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple" xlink:href="nexi-20221231.xsd#nexi_ShareBasedPaymentArrangementOptionRepricingMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple" xlink:to="lab_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_af8b52a0-9966-46ae-8a7e-8df3753f8042_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of debt from forgiveness of PPP Loan</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_909c6784-6142-4e5e-97c4-cfeb0a37018b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9c91d633-2fad-40da-8ef4-6f02c088c429_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_34f5a095-f454-43de-9c0b-b656b89c53c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2518e910-80ec-4875-880b-8d86b4ca8eec_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a09bdaa2-ba62-42aa-8745-87c81b3107d4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e1c30b4e-a03c-473c-9827-14119b347671_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51643a6c-47a9-425a-a443-2803aca56bb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_c6259ceb-aa5b-4d79-b832-2b5b7f478d48_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale&#160;marketable&#160;securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_dd5df95b-b785-4273-b96d-82a735b6569f_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_da33fcd4-35af-4035-bce8-10ae7944c41b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b37335f0-8f37-4847-b583-c632883716b2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss attributable to common stockholders per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3edca445-d0a9-4e8f-89a8-a615c49a5f23_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_154b04f3-28ab-4a06-8290-f56fa9901c2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d19a98ca-92ca-4207-85c8-38bde0cb3efd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cb9b0780-4c4f-41e1-b5b4-662b62132cdc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_AuditorInformationAbstract_label_en-US" xlink:label="lab_nexi_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_nexi_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_nexi_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_AuditorInformationAbstract" xlink:href="nexi-20221231.xsd#nexi_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_AuditorInformationAbstract" xlink:to="lab_nexi_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_dd7ce23d-5eb1-40f6-9e1e-bdc92c055993_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_7c9c57f0-7107-4c0d-bfb5-8205202af79c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8584e4e4-4fa8-4eed-88d9-ae4e6ca65bae_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_4d4bb750-9903-462c-a39d-090962dfa9dd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_ee5e644d-2fd5-4465-8f7c-0fcd46f0926f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_328a57a5-b5d7-4253-aaff-3f5ecc0ff44f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_799f6354-1320-4a60-bc33-43ad6ebbb1e7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_095fccc5-dc6c-4a11-941a-cfb7ff525cd3_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_6cf69b29-f255-4978-bb96-0e426cf45a54_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d37f802c-522a-40f2-957b-e77bd54a9ea9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_cfe4ba21-8f82-44bb-9e5a-09783c7ad74b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect of adoption of accounting standard</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_968bcd20-4673-45f0-bd3e-6a0e7455eac9_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_b0ca04c2-c49d-4a85-9d7f-4c5cb17201e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9a358d89-e91f-43e6-a8e4-e1c2b6a98d5a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Fixed Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ffc96598-2696-4bbe-a6f0-8cf80adf9224_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_275afcde-2c74-4deb-bfe5-f875232a1344_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_06450c39-3ae1-4606-aa20-378d498a23b5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_6bcd504b-60b9-4951-8dcd-8806aea28615_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_b554026f-e3e7-485b-97e2-8334152ad26b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in state tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_ec04f44e-045a-410d-aa05-f2e845209e35_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on capital leases</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_64f49801-5dd1-4dc8-9d5f-c5b760c01758_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A redeemable preferred stock upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_42b37c50-0d04-43a4-a6ce-88e89cafa6d3_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_RegulatoryAndCommercialMilestonesMember_def047d5-5d4d-40d3-9f1e-8a5c17550a2a_terseLabel_en-US" xlink:label="lab_nexi_RegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and Commercial Milestones</link:label>
    <link:label id="lab_nexi_RegulatoryAndCommercialMilestonesMember_label_en-US" xlink:label="lab_nexi_RegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and Commercial Milestones [Member]</link:label>
    <link:label id="lab_nexi_RegulatoryAndCommercialMilestonesMember_documentation_en-US" xlink:label="lab_nexi_RegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RegulatoryAndCommercialMilestonesMember" xlink:href="nexi-20221231.xsd#nexi_RegulatoryAndCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_RegulatoryAndCommercialMilestonesMember" xlink:to="lab_nexi_RegulatoryAndCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5d81a8c3-8767-4c6d-a3ed-c598cf38970d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on&#160;available-for-sale&#160;marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_712a91a3-0201-468b-82b5-dc3cc1aedb64_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_6c74d93e-d694-46a4-b559-91e3bfc7cdd0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40769b4d-615d-475d-a1fa-c0dd0264fc4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the components of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_771e656e-11e2-4e0b-95a4-da893d6cf830_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1d41c1a8-66f9-40e1-b281-d9e9bf6b5689_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0a392024-e63f-46ac-8323-8b2bbea108a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_79fd5ba9-1665-4834-b122-eb487cefa502_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_a8c5f7cc-2ac2-4e93-8675-5d5b6a161b08_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (millions)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised_cb2870f7-1299-4250-b238-88016060c669_terseLabel_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cashless exercise of options for common stock</link:label>
    <link:label id="lab_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised_label_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Cashless, Common Stock Exercised</link:label>
    <link:label id="lab_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised_documentation_en-US" xlink:label="lab_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Cashless, Common Stock Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised" xlink:to="lab_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_171f861e-bc8b-4d33-be5c-47e37171ed81_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_WeightedAverageRemainingContractualTermInYearsAbstract_6b7c345f-2f5d-403c-9657-5d06a439e9d8_terseLabel_en-US" xlink:label="lab_nexi_WeightedAverageRemainingContractualTermInYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_nexi_WeightedAverageRemainingContractualTermInYearsAbstract_label_en-US" xlink:label="lab_nexi_WeightedAverageRemainingContractualTermInYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) [Abstract]</link:label>
    <link:label id="lab_nexi_WeightedAverageRemainingContractualTermInYearsAbstract_documentation_en-US" xlink:label="lab_nexi_WeightedAverageRemainingContractualTermInYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_WeightedAverageRemainingContractualTermInYearsAbstract" xlink:href="nexi-20221231.xsd#nexi_WeightedAverageRemainingContractualTermInYearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_WeightedAverageRemainingContractualTermInYearsAbstract" xlink:to="lab_nexi_WeightedAverageRemainingContractualTermInYearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e9ce3f03-58b0-4b69-ad8b-985ebec180e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_96ef1c82-08a1-4175-9c8e-9308dad84bff_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_0071d1fe-e40e-4085-8161-d7756f37d558_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Charges Related to Restructuring Activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_88493516-48a3-4907-a0a5-fe52bc540aec_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b82bb351-6428-4459-8aaa-1b099f4efbe1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_117cc24e-c210-40c6-a826-f686f643f108_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4b8420a7-6681-432e-9764-79aa25298d60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_3225c066-0f68-4a92-afad-81f96fa4f910_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7c63d91a-79cf-4d93-bb82-84a4caaa3448_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9d1d5f5f-b5bb-4004-b80e-db7fb19d2d2d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_e474221d-50a0-4464-9625-28d770dd4b32_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_46456b12-557e-4d1e-8f23-03aaf95512ac_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_6fec8da9-7f62-448b-9fcf-e0452fae8ebc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_27b8d455-a823-4018-a479-3928c9094db5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4702405c-8b6f-42cf-b70f-6a6abc29f3b0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_bdb893b6-c83d-4328-9bde-660e3eecf4b2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_d6373bf4-d070-40e1-8b4c-78a4f4ba368d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_098e9c09-e3c3-414d-9244-5071d8a1269b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares unvested as of period end (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_99a9a68f-619c-4a57-b318-9189ef9846d6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_48a4971a-a020-42bb-95fd-97d4f6c20a31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6ba09f75-c9f4-4ba5-9ab1-8132e7e9b286_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities&#160;of&#160;available-for-sale&#160;marketable&#160;securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_MarylandBiotechnologyCenterMember_1925fd93-20e0-4733-a12d-458fe4557d8c_terseLabel_en-US" xlink:label="lab_nexi_MarylandBiotechnologyCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maryland Biotechnology Center</link:label>
    <link:label id="lab_nexi_MarylandBiotechnologyCenterMember_label_en-US" xlink:label="lab_nexi_MarylandBiotechnologyCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maryland Biotechnology Center [Member]</link:label>
    <link:label id="lab_nexi_MarylandBiotechnologyCenterMember_documentation_en-US" xlink:label="lab_nexi_MarylandBiotechnologyCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maryland Biotechnology Center.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MarylandBiotechnologyCenterMember" xlink:href="nexi-20221231.xsd#nexi_MarylandBiotechnologyCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_MarylandBiotechnologyCenterMember" xlink:to="lab_nexi_MarylandBiotechnologyCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40e71a34-24cf-4428-b8bc-2f971e91d81f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0d898d56-6c8c-4a82-b630-023dd15bfb7e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial offering, net of transaction costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ba815642-d430-4c9f-8680-327f7044fc20_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_9bd877c1-0fb7-40d7-849a-86848f422f1f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_bf35bea2-dc99-4054-8bb6-dc24f9a41caa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e815fac0-2ee9-4d34-a9b3-6d8e1ab9557b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_546dcd4c-ac7f-44ed-b2ec-bc8b1ee6de45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6a5c090e-421b-4863-940d-41cc17bc8b8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of the options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_7d23cb6a-37e8-43c9-8199-1cfa1a309250_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial conversion feature</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8131e830-7fe9-4d54-8fd9-6eddc738d08e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_914f0f40-2b36-4e4b-a15f-e2c50b569463_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts_6ba72202-6f8c-47a0-9fab-1f0a1f1bea8c_terseLabel_en-US" xlink:label="lab_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes outstanding, net of unamortized discounts, reclassified to stockholders' equity</link:label>
    <link:label id="lab_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts_label_en-US" xlink:label="lab_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Converted Instrument Net Of Amortization Of Debt Discounts</link:label>
    <link:label id="lab_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts_documentation_en-US" xlink:label="lab_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion converted instrument net of amortization of debt discounts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts" xlink:href="nexi-20221231.xsd#nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts" xlink:to="lab_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9c0ee208-7e22-4585-804a-f8ac79cc743b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_e7a490a9-7166-4603-a3ce-24f4a76f388b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of convertible notes from related parties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_3307813e-d01d-4eff-9b29-ee7d368c9a03_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_340e8f41-af1b-457f-906e-05f9ad042d05_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_81bd0dde-f0ce-4a25-85d4-0bf5903605d1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>nexi-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1d01bc3b-109a-450d-9ee6-f84eb8561d2c,g:e7038408-d172-479b-b01e-e62e0cc0d235-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://nex.com/role/Cover" xlink:type="simple" xlink:href="nexi-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://nex.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_89dcf14e-0065-4a54-9916-aeddfa1ff08f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_DocumentType_89dcf14e-0065-4a54-9916-aeddfa1ff08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_2371fdc2-ddca-47d4-935a-2f359232a64d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_DocumentAnnualReport_2371fdc2-ddca-47d4-935a-2f359232a64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0e5be83c-1996-4a4c-9ce1-f39776cd235b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_DocumentPeriodEndDate_0e5be83c-1996-4a4c-9ce1-f39776cd235b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_51240673-fca7-4904-a6e0-9870adc47f1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_CurrentFiscalYearEndDate_51240673-fca7-4904-a6e0-9870adc47f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e66df776-2acc-4c17-8bfb-d62a4b832b1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_DocumentTransitionReport_e66df776-2acc-4c17-8bfb-d62a4b832b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e866c46f-9b7a-468e-93d7-5280e8bcc7ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityFileNumber_e866c46f-9b7a-468e-93d7-5280e8bcc7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_77972912-ee7b-4250-9234-e75d44573a5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityRegistrantName_77972912-ee7b-4250-9234-e75d44573a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_272d8245-07a6-408c-86a4-973e279ee09b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityIncorporationStateCountryCode_272d8245-07a6-408c-86a4-973e279ee09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f2f4f78a-ed0c-46ec-be00-7dc861940b71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityTaxIdentificationNumber_f2f4f78a-ed0c-46ec-be00-7dc861940b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c78d911f-e5ec-4080-b881-9967366ef5db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityAddressAddressLine1_c78d911f-e5ec-4080-b881-9967366ef5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0febd016-0fa5-4d09-9514-0852a0110595" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityAddressCityOrTown_0febd016-0fa5-4d09-9514-0852a0110595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_443b0008-2a92-41da-a868-d3563767b01d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityAddressStateOrProvince_443b0008-2a92-41da-a868-d3563767b01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4f3c041a-f2cf-46c8-bf5e-bb94ea32a92e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityAddressPostalZipCode_4f3c041a-f2cf-46c8-bf5e-bb94ea32a92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_da0e959f-1db7-46a1-bcd5-554760b55caf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_CityAreaCode_da0e959f-1db7-46a1-bcd5-554760b55caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cf178729-3a01-4c99-80eb-4ea4beff7547" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_LocalPhoneNumber_cf178729-3a01-4c99-80eb-4ea4beff7547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_edaaba36-f4e5-4139-8714-f8eea58d453b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_Security12bTitle_edaaba36-f4e5-4139-8714-f8eea58d453b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_70f2d52c-096f-4af3-8f16-4012813a4cf6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_TradingSymbol_70f2d52c-096f-4af3-8f16-4012813a4cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c49ea8cc-e4ca-42d0-8c10-30c4f09129b7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_SecurityExchangeName_c49ea8cc-e4ca-42d0-8c10-30c4f09129b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0f58a884-abe2-4124-93ac-8512112a4693" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0f58a884-abe2-4124-93ac-8512112a4693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_bf6e9f99-a030-4090-8b86-31a2d77ac83f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityVoluntaryFilers_bf6e9f99-a030-4090-8b86-31a2d77ac83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e4fa59fa-4b44-40ec-b99b-468d5d82c4a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityCurrentReportingStatus_e4fa59fa-4b44-40ec-b99b-468d5d82c4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a1719b87-6b5b-4473-98bc-9e6a2558b226" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityInteractiveDataCurrent_a1719b87-6b5b-4473-98bc-9e6a2558b226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_40b16038-10a8-43b4-909e-65f6dbb594e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityFilerCategory_40b16038-10a8-43b4-909e-65f6dbb594e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_141d3132-bfa3-423b-86c6-8e9262d6c0fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntitySmallBusiness_141d3132-bfa3-423b-86c6-8e9262d6c0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e1847716-f36f-4983-ae87-8dc1d5009ac7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityEmergingGrowthCompany_e1847716-f36f-4983-ae87-8dc1d5009ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_355a34e4-63f8-480b-a577-48d9d178e1fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityExTransitionPeriod_355a34e4-63f8-480b-a577-48d9d178e1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_c904257b-2c69-448e-b3dc-5174a23ab591" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_IcfrAuditorAttestationFlag_c904257b-2c69-448e-b3dc-5174a23ab591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8706b43b-c780-4aec-b815-0a66747c3a9b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityShellCompany_8706b43b-c780-4aec-b815-0a66747c3a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_bcc11d33-a5af-4468-9107-69548533af99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityPublicFloat_bcc11d33-a5af-4468-9107-69548533af99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3792a7bd-b74b-4b84-ac23-47c5d01156c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3792a7bd-b74b-4b84-ac23-47c5d01156c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_14d499e7-382e-4ff0-9e31-d72b274135e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_14d499e7-382e-4ff0-9e31-d72b274135e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0f8cbbd9-b0a3-4563-9c1c-3832a79929d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_DocumentFiscalYearFocus_0f8cbbd9-b0a3-4563-9c1c-3832a79929d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9e75b3ed-3f28-404a-9af8-67be01034c94" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9e75b3ed-3f28-404a-9af8-67be01034c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2fda8b9d-d0d2-42e5-8900-7d5e60100553" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_AmendmentFlag_2fda8b9d-d0d2-42e5-8900-7d5e60100553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_64b16300-eba4-411f-ae99-847e66c239bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c11baf93-a284-4e3f-ae57-9aceded9efde" xlink:to="loc_dei_EntityCentralIndexKey_64b16300-eba4-411f-ae99-847e66c239bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/AuditInformation" xlink:type="simple" xlink:href="nexi-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://nex.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nexi_AuditorInformationAbstract_b64bc91b-8069-40b0-beed-d38af2e48e00" xlink:href="nexi-20221231.xsd#nexi_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_b2f8eee9-28af-4497-836f-fb712064fbc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_AuditorInformationAbstract_b64bc91b-8069-40b0-beed-d38af2e48e00" xlink:to="loc_dei_AuditorFirmId_b2f8eee9-28af-4497-836f-fb712064fbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_a5baf1ab-3c35-4462-a109-90db6d805ca9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_AuditorInformationAbstract_b64bc91b-8069-40b0-beed-d38af2e48e00" xlink:to="loc_dei_AuditorName_a5baf1ab-3c35-4462-a109-90db6d805ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_eba063bd-bf0c-439e-8f7a-1e793c34c642" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_AuditorInformationAbstract_b64bc91b-8069-40b0-beed-d38af2e48e00" xlink:to="loc_dei_AuditorLocation_eba063bd-bf0c-439e-8f7a-1e793c34c642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/BalanceSheets" xlink:type="simple" xlink:href="nexi-20221231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://nex.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7de0aa56-bf9b-4f19-ba1c-666b36f883b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_bf84a09a-09ab-4bf2-ba63-0e29e7c63c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7de0aa56-bf9b-4f19-ba1c-666b36f883b1" xlink:to="loc_us-gaap_AssetsAbstract_bf84a09a-09ab-4bf2-ba63-0e29e7c63c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_69f4f9d0-3711-4a2c-aa5f-863eca488a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf84a09a-09ab-4bf2-ba63-0e29e7c63c0d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_69f4f9d0-3711-4a2c-aa5f-863eca488a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_397d6022-e165-405b-9839-9fa15ae8083e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69f4f9d0-3711-4a2c-aa5f-863eca488a5a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_397d6022-e165-405b-9839-9fa15ae8083e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_dbc1fff7-45b4-41c9-9e3e-928afc2bc8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69f4f9d0-3711-4a2c-aa5f-863eca488a5a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_dbc1fff7-45b4-41c9-9e3e-928afc2bc8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_a6af7136-50bf-44c5-b641-a5cadd4b071b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69f4f9d0-3711-4a2c-aa5f-863eca488a5a" xlink:to="loc_us-gaap_RestrictedCashCurrent_a6af7136-50bf-44c5-b641-a5cadd4b071b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7730356-7d23-4935-8b7d-015bfd71e1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69f4f9d0-3711-4a2c-aa5f-863eca488a5a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7730356-7d23-4935-8b7d-015bfd71e1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f446d8d1-2b78-468b-8b1e-f7e9bb058bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_69f4f9d0-3711-4a2c-aa5f-863eca488a5a" xlink:to="loc_us-gaap_AssetsCurrent_f446d8d1-2b78-468b-8b1e-f7e9bb058bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6b461915-a98f-4db2-88bf-36cf297efec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf84a09a-09ab-4bf2-ba63-0e29e7c63c0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6b461915-a98f-4db2-88bf-36cf297efec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_14e66546-eaf6-47bb-927f-ae1ca966907e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf84a09a-09ab-4bf2-ba63-0e29e7c63c0d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_14e66546-eaf6-47bb-927f-ae1ca966907e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d751c618-976c-4e9f-9c87-93f78927ea1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf84a09a-09ab-4bf2-ba63-0e29e7c63c0d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d751c618-976c-4e9f-9c87-93f78927ea1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_39bb654f-7ca9-4bdd-b55a-1aa5bfb39790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bf84a09a-09ab-4bf2-ba63-0e29e7c63c0d" xlink:to="loc_us-gaap_Assets_39bb654f-7ca9-4bdd-b55a-1aa5bfb39790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42b64575-1d42-4f23-9d2e-022d7a698539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7de0aa56-bf9b-4f19-ba1c-666b36f883b1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42b64575-1d42-4f23-9d2e-022d7a698539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c06b99f2-88ef-4a1f-bd5d-61fb018e72ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42b64575-1d42-4f23-9d2e-022d7a698539" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c06b99f2-88ef-4a1f-bd5d-61fb018e72ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e22c7caf-ad13-489a-b524-42979b6f9ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c06b99f2-88ef-4a1f-bd5d-61fb018e72ad" xlink:to="loc_us-gaap_AccountsPayableCurrent_e22c7caf-ad13-489a-b524-42979b6f9ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c18054d0-2ca1-4a01-baed-19d9f5a3e2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c06b99f2-88ef-4a1f-bd5d-61fb018e72ad" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c18054d0-2ca1-4a01-baed-19d9f5a3e2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_268f2f7e-410d-4f52-ab83-8ba893398e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c06b99f2-88ef-4a1f-bd5d-61fb018e72ad" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_268f2f7e-410d-4f52-ab83-8ba893398e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_32972134-6fd2-455b-8e32-41fa013ab91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c06b99f2-88ef-4a1f-bd5d-61fb018e72ad" xlink:to="loc_us-gaap_LiabilitiesCurrent_32972134-6fd2-455b-8e32-41fa013ab91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ca0134ff-0562-4c61-9e91-699c6e39dc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42b64575-1d42-4f23-9d2e-022d7a698539" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ca0134ff-0562-4c61-9e91-699c6e39dc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_dbd6a541-8f71-41db-9708-25cb4a28804d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42b64575-1d42-4f23-9d2e-022d7a698539" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_dbd6a541-8f71-41db-9708-25cb4a28804d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9783deb9-1db2-4a70-b934-6abed5e890ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42b64575-1d42-4f23-9d2e-022d7a698539" xlink:to="loc_us-gaap_Liabilities_9783deb9-1db2-4a70-b934-6abed5e890ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_68791684-b84e-4eee-9b6b-4fc06cd64451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42b64575-1d42-4f23-9d2e-022d7a698539" xlink:to="loc_us-gaap_CommitmentsAndContingencies_68791684-b84e-4eee-9b6b-4fc06cd64451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_00222872-fedb-4c51-b34d-d2caa15af1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42b64575-1d42-4f23-9d2e-022d7a698539" xlink:to="loc_us-gaap_StockholdersEquityAbstract_00222872-fedb-4c51-b34d-d2caa15af1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dffba235-9cc1-467c-8ca0-27d5f1882d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_00222872-fedb-4c51-b34d-d2caa15af1a3" xlink:to="loc_us-gaap_CommonStockValue_dffba235-9cc1-467c-8ca0-27d5f1882d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c62b8bda-80c4-4e94-9fc5-fba805d03d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_00222872-fedb-4c51-b34d-d2caa15af1a3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c62b8bda-80c4-4e94-9fc5-fba805d03d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70132147-4046-4440-b437-635b57b5364e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_00222872-fedb-4c51-b34d-d2caa15af1a3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_70132147-4046-4440-b437-635b57b5364e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_122b9694-9117-4abc-9fc2-3ae820181cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_00222872-fedb-4c51-b34d-d2caa15af1a3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_122b9694-9117-4abc-9fc2-3ae820181cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6a5e0a04-5333-40ac-b68c-752bf9e9efc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_00222872-fedb-4c51-b34d-d2caa15af1a3" xlink:to="loc_us-gaap_StockholdersEquity_6a5e0a04-5333-40ac-b68c-752bf9e9efc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c233e4ab-3aea-4485-900e-e2d8d05a381f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_42b64575-1d42-4f23-9d2e-022d7a698539" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c233e4ab-3aea-4485-900e-e2d8d05a381f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="nexi-20221231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://nex.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_93424064-e4ed-4724-971a-7b9eedbb14e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_92c9609e-3c57-430d-b649-66cbea30cbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93424064-e4ed-4724-971a-7b9eedbb14e4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_92c9609e-3c57-430d-b649-66cbea30cbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_694dc558-8d1a-4a44-84a3-8310780ac37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93424064-e4ed-4724-971a-7b9eedbb14e4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_694dc558-8d1a-4a44-84a3-8310780ac37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5f6c172b-1549-4cd8-829c-f6f61d1d28af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93424064-e4ed-4724-971a-7b9eedbb14e4" xlink:to="loc_us-gaap_CommonStockSharesIssued_5f6c172b-1549-4cd8-829c-f6f61d1d28af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b5e56f2c-210d-471b-90e0-6f20b4926058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_93424064-e4ed-4724-971a-7b9eedbb14e4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b5e56f2c-210d-471b-90e0-6f20b4926058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/StatementsOfOperations" xlink:type="simple" xlink:href="nexi-20221231.xsd#StatementsOfOperations"/>
  <link:presentationLink xlink:role="http://nex.com/role/StatementsOfOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_37bdac5f-06d1-4b25-863e-a8f00e02e00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4ca2f6f1-47c8-4e57-abcc-4fe2b39c5478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_37bdac5f-06d1-4b25-863e-a8f00e02e00c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4ca2f6f1-47c8-4e57-abcc-4fe2b39c5478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_434318f1-9320-45d8-8378-fca921b38a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ca2f6f1-47c8-4e57-abcc-4fe2b39c5478" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_434318f1-9320-45d8-8378-fca921b38a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_855fd11c-df71-42ac-b405-4c52d56d00d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ca2f6f1-47c8-4e57-abcc-4fe2b39c5478" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_855fd11c-df71-42ac-b405-4c52d56d00d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8aeba32d-b3df-4170-b5ec-131f9309a1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4ca2f6f1-47c8-4e57-abcc-4fe2b39c5478" xlink:to="loc_us-gaap_OperatingExpenses_8aeba32d-b3df-4170-b5ec-131f9309a1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b01bb0e2-f767-4a17-a61e-63a66e5e1525" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_37bdac5f-06d1-4b25-863e-a8f00e02e00c" xlink:to="loc_us-gaap_OperatingIncomeLoss_b01bb0e2-f767-4a17-a61e-63a66e5e1525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5fb74320-05a6-4051-b8f6-23fd94a92b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_37bdac5f-06d1-4b25-863e-a8f00e02e00c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5fb74320-05a6-4051-b8f6-23fd94a92b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_05b4a4cd-6392-42c2-b3c5-d9e3f0e5bf72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5fb74320-05a6-4051-b8f6-23fd94a92b68" xlink:to="loc_us-gaap_InvestmentIncomeInterest_05b4a4cd-6392-42c2-b3c5-d9e3f0e5bf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_2dd7c4f4-9cf3-44df-bbeb-6f307c808c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5fb74320-05a6-4051-b8f6-23fd94a92b68" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_2dd7c4f4-9cf3-44df-bbeb-6f307c808c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a1afe806-a7fa-470d-a56d-436c109e9954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5fb74320-05a6-4051-b8f6-23fd94a92b68" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a1afe806-a7fa-470d-a56d-436c109e9954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1817797e-e00d-456e-b0a7-904e20a59d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5fb74320-05a6-4051-b8f6-23fd94a92b68" xlink:to="loc_us-gaap_InterestExpense_1817797e-e00d-456e-b0a7-904e20a59d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_271bbaf2-6dcb-4e05-9e55-37802550061b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5fb74320-05a6-4051-b8f6-23fd94a92b68" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_271bbaf2-6dcb-4e05-9e55-37802550061b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ad12c45b-26ee-48c7-9779-5d4f6d779652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5fb74320-05a6-4051-b8f6-23fd94a92b68" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ad12c45b-26ee-48c7-9779-5d4f6d779652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d89e8f40-20e2-49e5-8155-5589a9f0bf0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_37bdac5f-06d1-4b25-863e-a8f00e02e00c" xlink:to="loc_us-gaap_NetIncomeLoss_d89e8f40-20e2-49e5-8155-5589a9f0bf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_02945a2f-5f91-457e-aa00-205b9ffad881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_37bdac5f-06d1-4b25-863e-a8f00e02e00c" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_02945a2f-5f91-457e-aa00-205b9ffad881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_93fb4a8a-e612-432a-bf32-745cb6a5f49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_37bdac5f-06d1-4b25-863e-a8f00e02e00c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_93fb4a8a-e612-432a-bf32-745cb6a5f49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_08300f0f-0a13-498c-b1f6-65f9d4e68b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_37bdac5f-06d1-4b25-863e-a8f00e02e00c" xlink:to="loc_us-gaap_EarningsPerShareBasic_08300f0f-0a13-498c-b1f6-65f9d4e68b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5fb85408-d571-47df-b862-ac41f809a23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_37bdac5f-06d1-4b25-863e-a8f00e02e00c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5fb85408-d571-47df-b862-ac41f809a23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ac237e7f-9619-4154-afea-8eaa6bed81ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_37bdac5f-06d1-4b25-863e-a8f00e02e00c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ac237e7f-9619-4154-afea-8eaa6bed81ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd173b49-3211-4678-923e-902379a0c8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_37bdac5f-06d1-4b25-863e-a8f00e02e00c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd173b49-3211-4678-923e-902379a0c8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/StatementsOfComprehensiveLoss" xlink:type="simple" xlink:href="nexi-20221231.xsd#StatementsOfComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://nex.com/role/StatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d3ffcaeb-f03f-4db4-a2e7-f5e35f14ae81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f14b62a-1d65-456f-bb9d-20f18c0b8c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d3ffcaeb-f03f-4db4-a2e7-f5e35f14ae81" xlink:to="loc_us-gaap_NetIncomeLoss_2f14b62a-1d65-456f-bb9d-20f18c0b8c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7bb880f8-bbdb-408b-b02c-d3eb7a93862f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d3ffcaeb-f03f-4db4-a2e7-f5e35f14ae81" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7bb880f8-bbdb-408b-b02c-d3eb7a93862f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4944fa2f-8c18-4562-8aa7-a06be44eb421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7bb880f8-bbdb-408b-b02c-d3eb7a93862f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4944fa2f-8c18-4562-8aa7-a06be44eb421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d2a5d19-2799-4c04-82fd-8ad716a8b1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d3ffcaeb-f03f-4db4-a2e7-f5e35f14ae81" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d2a5d19-2799-4c04-82fd-8ad716a8b1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity" xlink:type="simple" xlink:href="nexi-20221231.xsd#StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"/>
  <link:presentationLink xlink:role="http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_85ef984e-c336-44dd-8c66-d7d987047a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2e4f68da-3720-49d6-baa5-ac8d3ff71ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_85ef984e-c336-44dd-8c66-d7d987047a88" xlink:to="loc_us-gaap_StatementTable_2e4f68da-3720-49d6-baa5-ac8d3ff71ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3f9cf9ed-efdf-418b-927a-46413f31bfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e4f68da-3720-49d6-baa5-ac8d3ff71ad4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3f9cf9ed-efdf-418b-927a-46413f31bfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3f9cf9ed-efdf-418b-927a-46413f31bfb9" xlink:to="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_aadae989-2db2-470c-9027-cb5f7848966d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:to="loc_us-gaap_CommonStockMember_aadae989-2db2-470c-9027-cb5f7848966d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8273d6e8-985a-41b5-af5d-c18c85bc2d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8273d6e8-985a-41b5-af5d-c18c85bc2d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f0659bee-6818-4c16-8dcc-e650dc44a3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:to="loc_us-gaap_RetainedEarningsMember_f0659bee-6818-4c16-8dcc-e650dc44a3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_43a4764c-5bb7-47c8-ac49-6000d31bcdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2b645828-bd3c-465b-aadb-17864423cd2c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_43a4764c-5bb7-47c8-ac49-6000d31bcdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_73def146-1e56-480d-b7be-ca5150ce02c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e4f68da-3720-49d6-baa5-ac8d3ff71ad4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_73def146-1e56-480d-b7be-ca5150ce02c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2a09a242-03c1-4957-8f01-bd3821efd836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73def146-1e56-480d-b7be-ca5150ce02c1" xlink:to="loc_us-gaap_ClassOfStockDomain_2a09a242-03c1-4957-8f01-bd3821efd836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SeriesARedeemableConvertiblePreferredStockMember_c53f76d1-61cc-4cd0-9333-814e6541856b" xlink:href="nexi-20221231.xsd#nexi_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a09a242-03c1-4957-8f01-bd3821efd836" xlink:to="loc_nexi_SeriesARedeemableConvertiblePreferredStockMember_c53f76d1-61cc-4cd0-9333-814e6541856b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember_a511b1fa-2d19-4545-99d8-de1f97bbae08" xlink:href="nexi-20221231.xsd#nexi_SeriesATwoRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a09a242-03c1-4957-8f01-bd3821efd836" xlink:to="loc_nexi_SeriesATwoRedeemableConvertiblePreferredStockMember_a511b1fa-2d19-4545-99d8-de1f97bbae08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember_59e70615-f94a-4fd7-b29a-b08ae0bedc6b" xlink:href="nexi-20221231.xsd#nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a09a242-03c1-4957-8f01-bd3821efd836" xlink:to="loc_nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember_59e70615-f94a-4fd7-b29a-b08ae0bedc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e921694-3f47-40e4-b9b9-111bf10fdaaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e4f68da-3720-49d6-baa5-ac8d3ff71ad4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e921694-3f47-40e4-b9b9-111bf10fdaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d38444c9-bd4b-4f15-9abc-1fc57ce7d378" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8e921694-3f47-40e4-b9b9-111bf10fdaaf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d38444c9-bd4b-4f15-9abc-1fc57ce7d378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_77c2b215-f043-4a78-93b1-5f23c61d358a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d38444c9-bd4b-4f15-9abc-1fc57ce7d378" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_77c2b215-f043-4a78-93b1-5f23c61d358a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ff318db0-55e2-4b3c-8731-c1e10050e684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e4f68da-3720-49d6-baa5-ac8d3ff71ad4" xlink:to="loc_us-gaap_StatementLineItems_ff318db0-55e2-4b3c-8731-c1e10050e684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ff318db0-55e2-4b3c-8731-c1e10050e684" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7f9947f4-fe08-42db-8131-335eba67f7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7f9947f4-fe08-42db-8131-335eba67f7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6fde220f-ca7e-41ca-8d43-2aaa45a2e133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6fde220f-ca7e-41ca-8d43-2aaa45a2e133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c45f858d-dfaf-45a9-ac8c-610c47b751c8" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c45f858d-dfaf-45a9-ac8c-610c47b751c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5adb8cd3-d2b2-40b7-bf23-f70c1c9c7a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_5adb8cd3-d2b2-40b7-bf23-f70c1c9c7a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityStockConvertedDuringPeriodShares_e9f80cbc-4be9-4a92-b4b2-24935c71e631" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityStockConvertedDuringPeriodShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_nexi_TemporaryEquityStockConvertedDuringPeriodShares_e9f80cbc-4be9-4a92-b4b2-24935c71e631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityStockConvertedDuringPeriodValue_770460d5-db35-45a7-a486-157ea5f60f0e" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityStockConvertedDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_nexi_TemporaryEquityStockConvertedDuringPeriodValue_770460d5-db35-45a7-a486-157ea5f60f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_87428272-f4ce-4d49-b1b5-9c0bddb222b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_87428272-f4ce-4d49-b1b5-9c0bddb222b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f58ac608-0f8b-4636-a170-d3fa61f20113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_92c0d4c6-3103-42b9-bab1-e7a71e7a83ae" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f58ac608-0f8b-4636-a170-d3fa61f20113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ff318db0-55e2-4b3c-8731-c1e10050e684" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_128cf141-5898-4c85-b3dc-0f2875f12dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_SharesOutstanding_128cf141-5898-4c85-b3dc-0f2875f12dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_32f19208-5b8d-4e9c-8c57-2c7a4e94bcde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockholdersEquity_32f19208-5b8d-4e9c-8c57-2c7a4e94bcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_5e0a6c6f-a5af-4cd4-a5c1-5efbb25caa20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_5e0a6c6f-a5af-4cd4-a5c1-5efbb25caa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c663d337-e1a0-4615-92d0-a6fbb326157b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c663d337-e1a0-4615-92d0-a6fbb326157b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_4cc2b640-2d1a-4e08-a7c5-e00e96d855b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_4cc2b640-2d1a-4e08-a7c5-e00e96d855b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt_304ca6b7-1de4-4003-9be0-8d50b17b9d70" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt_304ca6b7-1de4-4003-9be0-8d50b17b9d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt_43ab68d5-523d-4076-bd2f-256cb38b97e7" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt_43ab68d5-523d-4076-bd2f-256cb38b97e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c9d41ebe-817f-4125-94b1-61ef3db979d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c9d41ebe-817f-4125-94b1-61ef3db979d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_48092de5-692d-4337-8504-ae7f3de243e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_48092de5-692d-4337-8504-ae7f3de243e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_865428c2-fdfc-44a6-bcfe-8603e87a4137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_865428c2-fdfc-44a6-bcfe-8603e87a4137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f5932228-5cd9-4035-a09d-a2257c8254dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f5932228-5cd9-4035-a09d-a2257c8254dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod_65969f42-0fa7-4020-826f-a270977cad54" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod_65969f42-0fa7-4020-826f-a270977cad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised_481d0bee-4898-44cc-bf07-b449c7fd2fcb" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised_481d0bee-4898-44cc-bf07-b449c7fd2fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_NumberOfWarrantsExercised_9783faa6-641d-4028-8218-54ca7965471c" xlink:href="nexi-20221231.xsd#nexi_NumberOfWarrantsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_nexi_NumberOfWarrantsExercised_9783faa6-641d-4028-8218-54ca7965471c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c6d3c97d-3054-41ff-8e57-70c50aaef6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c6d3c97d-3054-41ff-8e57-70c50aaef6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_387cd492-8e7c-463a-9ed0-fb4d22d4e648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_387cd492-8e7c-463a-9ed0-fb4d22d4e648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_990d43cb-1bcd-4092-bfa6-65d1d729a13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_NetIncomeLoss_990d43cb-1bcd-4092-bfa6-65d1d729a13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_924293f8-af4e-404f-95d7-286ea7fc847d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_SharesOutstanding_924293f8-af4e-404f-95d7-286ea7fc847d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_10a97021-185f-4ec8-82eb-31c44b300621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_37680a3c-34ce-4308-903e-aeb35e87ccf0" xlink:to="loc_us-gaap_StockholdersEquity_10a97021-185f-4ec8-82eb-31c44b300621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/StatementsOfCashFlows" xlink:type="simple" xlink:href="nexi-20221231.xsd#StatementsOfCashFlows"/>
  <link:presentationLink xlink:role="http://nex.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b41bcd46-ca86-438f-b0e5-8323695d44bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4d5e0b13-cca7-4904-9a09-6d3573bd3245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b41bcd46-ca86-438f-b0e5-8323695d44bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4d5e0b13-cca7-4904-9a09-6d3573bd3245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b589f4ae-fc05-4125-96fd-33b407b9b035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4d5e0b13-cca7-4904-9a09-6d3573bd3245" xlink:to="loc_us-gaap_NetIncomeLoss_b589f4ae-fc05-4125-96fd-33b407b9b035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca38a7d9-6b03-4af9-88d5-3b2ee84fc70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4d5e0b13-cca7-4904-9a09-6d3573bd3245" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca38a7d9-6b03-4af9-88d5-3b2ee84fc70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2a3031a4-468a-4f04-a13f-342399525afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca38a7d9-6b03-4af9-88d5-3b2ee84fc70f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2a3031a4-468a-4f04-a13f-342399525afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_071188c2-2602-4195-809e-9eb81636142f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca38a7d9-6b03-4af9-88d5-3b2ee84fc70f" xlink:to="loc_us-gaap_GainLossOnInvestments_071188c2-2602-4195-809e-9eb81636142f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_214ca0f4-9b45-4aa4-b35e-236815697319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca38a7d9-6b03-4af9-88d5-3b2ee84fc70f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_214ca0f4-9b45-4aa4-b35e-236815697319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_319dc0ed-ae11-4d12-87d1-a45cb355dfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca38a7d9-6b03-4af9-88d5-3b2ee84fc70f" xlink:to="loc_us-gaap_ShareBasedCompensation_319dc0ed-ae11-4d12-87d1-a45cb355dfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_LeaseExpenseNoncash_8abd0c9f-3620-41d9-816a-3b095661e9b3" xlink:href="nexi-20221231.xsd#nexi_LeaseExpenseNoncash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca38a7d9-6b03-4af9-88d5-3b2ee84fc70f" xlink:to="loc_nexi_LeaseExpenseNoncash_8abd0c9f-3620-41d9-816a-3b095661e9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_4bd1c2a4-6820-432c-9af8-d9a3d99ace6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca38a7d9-6b03-4af9-88d5-3b2ee84fc70f" xlink:to="loc_us-gaap_PaidInKindInterest_4bd1c2a4-6820-432c-9af8-d9a3d99ace6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_ed9101ff-fdf6-4ff4-846f-7a0303321a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca38a7d9-6b03-4af9-88d5-3b2ee84fc70f" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_ed9101ff-fdf6-4ff4-846f-7a0303321a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1b1ac439-03b8-4507-b948-1e96a7877a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca38a7d9-6b03-4af9-88d5-3b2ee84fc70f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1b1ac439-03b8-4507-b948-1e96a7877a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a545959-3b2d-40ec-a733-04ce2cacf468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ca38a7d9-6b03-4af9-88d5-3b2ee84fc70f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a545959-3b2d-40ec-a733-04ce2cacf468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5903bfbe-ee08-491b-bb8c-8984322a35f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a545959-3b2d-40ec-a733-04ce2cacf468" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5903bfbe-ee08-491b-bb8c-8984322a35f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1de07d84-c639-48fe-bd4d-41e5d52efd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a545959-3b2d-40ec-a733-04ce2cacf468" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1de07d84-c639-48fe-bd4d-41e5d52efd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_87495b50-501c-4452-acfe-67d8eef596da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a545959-3b2d-40ec-a733-04ce2cacf468" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_87495b50-501c-4452-acfe-67d8eef596da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_75608d80-391a-4498-8bdb-e91fd70f8f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a545959-3b2d-40ec-a733-04ce2cacf468" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_75608d80-391a-4498-8bdb-e91fd70f8f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_493f489d-f6d7-4fb2-a6ae-b430887763ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a545959-3b2d-40ec-a733-04ce2cacf468" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_493f489d-f6d7-4fb2-a6ae-b430887763ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ccb09f46-382d-4e09-800e-d4b3c6202b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4d5e0b13-cca7-4904-9a09-6d3573bd3245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ccb09f46-382d-4e09-800e-d4b3c6202b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1773520e-001c-41ef-a4d2-17e70de0a081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b41bcd46-ca86-438f-b0e5-8323695d44bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1773520e-001c-41ef-a4d2-17e70de0a081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5cc3e42f-03c0-4769-b879-f462d483788c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1773520e-001c-41ef-a4d2-17e70de0a081" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5cc3e42f-03c0-4769-b879-f462d483788c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_e082223a-6b84-4b34-9498-4b047f8d16f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1773520e-001c-41ef-a4d2-17e70de0a081" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_e082223a-6b84-4b34-9498-4b047f8d16f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fb61ffd3-adfc-4e89-b691-862113b8e26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1773520e-001c-41ef-a4d2-17e70de0a081" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fb61ffd3-adfc-4e89-b691-862113b8e26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_f4abef3a-4339-4581-a6c2-afa44e2f054f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1773520e-001c-41ef-a4d2-17e70de0a081" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_f4abef3a-4339-4581-a6c2-afa44e2f054f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6c7baa4a-fbc6-4d8d-a963-01dc185de9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1773520e-001c-41ef-a4d2-17e70de0a081" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6c7baa4a-fbc6-4d8d-a963-01dc185de9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4eca1283-0078-4fc5-b4b6-fe6a3a779298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1773520e-001c-41ef-a4d2-17e70de0a081" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4eca1283-0078-4fc5-b4b6-fe6a3a779298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4ca2df6-827c-4ae9-9653-59bcd3c38622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b41bcd46-ca86-438f-b0e5-8323695d44bf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4ca2df6-827c-4ae9-9653-59bcd3c38622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_6dc184dd-b464-484d-b903-c9c282393e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4ca2df6-827c-4ae9-9653-59bcd3c38622" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_6dc184dd-b464-484d-b903-c9c282393e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f1261308-0a10-4457-865a-4d6f2612f7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4ca2df6-827c-4ae9-9653-59bcd3c38622" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f1261308-0a10-4457-865a-4d6f2612f7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_57dcd96c-7887-4e21-aa66-ff109aea80b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4ca2df6-827c-4ae9-9653-59bcd3c38622" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_57dcd96c-7887-4e21-aa66-ff109aea80b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_7eb66f3c-a9ff-4b1a-826b-44b41d44fe93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4ca2df6-827c-4ae9-9653-59bcd3c38622" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_7eb66f3c-a9ff-4b1a-826b-44b41d44fe93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_3cca16ea-4bc7-4124-9a86-05b0c82afd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4ca2df6-827c-4ae9-9653-59bcd3c38622" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_3cca16ea-4bc7-4124-9a86-05b0c82afd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_b9d43e50-0fc4-4a1c-8bdf-88470cd44b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4ca2df6-827c-4ae9-9653-59bcd3c38622" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_b9d43e50-0fc4-4a1c-8bdf-88470cd44b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_067ffc13-1312-44d8-b8c5-51b2b0422350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4ca2df6-827c-4ae9-9653-59bcd3c38622" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_067ffc13-1312-44d8-b8c5-51b2b0422350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1fdfafb4-ca17-4ea7-82d7-20fdc09aa15e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4ca2df6-827c-4ae9-9653-59bcd3c38622" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1fdfafb4-ca17-4ea7-82d7-20fdc09aa15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7b72b05a-6f6c-4d63-ba17-cf639c6500cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b41bcd46-ca86-438f-b0e5-8323695d44bf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7b72b05a-6f6c-4d63-ba17-cf639c6500cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_331c2194-ae90-4fc5-9fbb-b64d3deb2218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b41bcd46-ca86-438f-b0e5-8323695d44bf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_331c2194-ae90-4fc5-9fbb-b64d3deb2218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_167b7e0a-0b95-4409-a4c8-898a7380aa73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b41bcd46-ca86-438f-b0e5-8323695d44bf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_167b7e0a-0b95-4409-a4c8-898a7380aa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2f922e04-19d2-4a29-a950-00c4ff71a1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b41bcd46-ca86-438f-b0e5-8323695d44bf" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2f922e04-19d2-4a29-a950-00c4ff71a1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_2af74179-bbb0-4bd4-89bf-e61bad98dfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2f922e04-19d2-4a29-a950-00c4ff71a1b8" xlink:to="loc_us-gaap_InterestPaidNet_2af74179-bbb0-4bd4-89bf-e61bad98dfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_de9fddec-c9d0-4ee8-b6f2-991d6226456e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b41bcd46-ca86-438f-b0e5-8323695d44bf" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_de9fddec-c9d0-4ee8-b6f2-991d6226456e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_ee5a6b36-e11d-4333-8078-2a112555db50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_de9fddec-c9d0-4ee8-b6f2-991d6226456e" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_ee5a6b36-e11d-4333-8078-2a112555db50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b3122a4b-58a0-484c-b885-77c50e992a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_de9fddec-c9d0-4ee8-b6f2-991d6226456e" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b3122a4b-58a0-484c-b885-77c50e992a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="nexi-20221231.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://nex.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d55c3ce-476a-4188-8467-4cea9e590dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_be41fdb5-d75d-4d41-b24c-3690b629a2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d55c3ce-476a-4188-8467-4cea9e590dec" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_be41fdb5-d75d-4d41-b24c-3690b629a2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/BasisofPresentationandLiquidity" xlink:type="simple" xlink:href="nexi-20221231.xsd#BasisofPresentationandLiquidity"/>
  <link:presentationLink xlink:role="http://nex.com/role/BasisofPresentationandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cd50c9c7-f96b-4ab8-9c19-6300c8995686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_94fde637-5a08-44cd-a38d-36529797268a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cd50c9c7-f96b-4ab8-9c19-6300c8995686" xlink:to="loc_us-gaap_BasisOfAccounting_94fde637-5a08-44cd-a38d-36529797268a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bf00d07e-fcc0-44c5-bb13-6e26d9cbdd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_eaac8a8d-a6a0-4c3e-ab1f-d4899a39d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf00d07e-fcc0-44c5-bb13-6e26d9cbdd1d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_eaac8a8d-a6a0-4c3e-ab1f-d4899a39d7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nexi-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://nex.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_12b68b10-7ce3-4f3a-99f1-89526797dc03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_bb373c91-94ac-4b53-90b8-2a470c092755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_12b68b10-7ce3-4f3a-99f1-89526797dc03" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_bb373c91-94ac-4b53-90b8-2a470c092755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="simple" xlink:href="nexi-20221231.xsd#PrepaidExpensesandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://nex.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_af1b9d0b-a945-4041-ad80-6d4942dd44e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock_6946e35a-8cd0-4515-8ebf-4733a9a02532" xlink:href="nexi-20221231.xsd#nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_af1b9d0b-a945-4041-ad80-6d4942dd44e6" xlink:to="loc_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock_6946e35a-8cd0-4515-8ebf-4733a9a02532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="nexi-20221231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://nex.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6f54404a-c5e2-4238-8f85-fd3cb12d90d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bba098b1-438a-461d-80da-bcd8c93abc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6f54404a-c5e2-4238-8f85-fd3cb12d90d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bba098b1-438a-461d-80da-bcd8c93abc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/RestructuringActivities" xlink:type="simple" xlink:href="nexi-20221231.xsd#RestructuringActivities"/>
  <link:presentationLink xlink:role="http://nex.com/role/RestructuringActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d48881cb-0b56-4f85-8ffb-dafdd24ae61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_60ecb90c-c9a8-4ec7-9680-ecd7468f441b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d48881cb-0b56-4f85-8ffb-dafdd24ae61b" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_60ecb90c-c9a8-4ec7-9680-ecd7468f441b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/AccruedExpenses" xlink:type="simple" xlink:href="nexi-20221231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://nex.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b69f1330-7d79-4c1a-ba72-473f72ee6862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0bf0bf7e-b427-42cc-b75c-4a61072bad0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b69f1330-7d79-4c1a-ba72-473f72ee6862" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0bf0bf7e-b427-42cc-b75c-4a61072bad0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nexi-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://nex.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_701b5e80-540b-474e-a058-7f7c3a2c4b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e090c5b2-5dde-4cd2-a088-e33a877d8bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_701b5e80-540b-474e-a058-7f7c3a2c4b55" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e090c5b2-5dde-4cd2-a088-e33a877d8bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/ConvertibleNotes" xlink:type="simple" xlink:href="nexi-20221231.xsd#ConvertibleNotes"/>
  <link:presentationLink xlink:role="http://nex.com/role/ConvertibleNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5fa23311-722a-4426-b541-44ab7ca86139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_d2ebe82d-9b73-4b68-ba64-9517fb54884f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5fa23311-722a-4426-b541-44ab7ca86139" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_d2ebe82d-9b73-4b68-ba64-9517fb54884f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficit" xlink:type="simple" xlink:href="nexi-20221231.xsd#SeriesARedeemableConvertiblePreferredStockandStockholdersDeficit"/>
  <link:presentationLink xlink:role="http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract_85793280-3b02-454b-91e6-cb55f7bce984" xlink:href="nexi-20221231.xsd#nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock_a42b4fe5-f655-4432-b99d-21bea6c813e7" xlink:href="nexi-20221231.xsd#nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract_85793280-3b02-454b-91e6-cb55f7bce984" xlink:to="loc_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock_a42b4fe5-f655-4432-b99d-21bea6c813e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nexi-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://nex.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be8d4acc-367d-432b-a414-2e3f1fefd7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04533d2e-1b33-4727-a723-60665842062a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be8d4acc-367d-432b-a414-2e3f1fefd7e4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_04533d2e-1b33-4727-a723-60665842062a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/IncomeTaxes" xlink:type="simple" xlink:href="nexi-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://nex.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_132c9e57-e728-4ac9-80fe-355d8fe9ced2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1a686ed7-e89c-4925-a444-fe3e855d6ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_132c9e57-e728-4ac9-80fe-355d8fe9ced2" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1a686ed7-e89c-4925-a444-fe3e855d6ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/Leases" xlink:type="simple" xlink:href="nexi-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://nex.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e2b844e6-87a4-4b20-a4ec-f9011a61a7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_d6ed5052-4705-44d0-97c6-51f5041c7cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e2b844e6-87a4-4b20-a4ec-f9011a61a7ed" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_d6ed5052-4705-44d0-97c6-51f5041c7cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="nexi-20221231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://nex.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_d25f6de1-3793-4774-8ea9-475a0c56d912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3554387c-27f2-4857-a149-5dc8d43629c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_d25f6de1-3793-4774-8ea9-475a0c56d912" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3554387c-27f2-4857-a149-5dc8d43629c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SubsequentEvents" xlink:type="simple" xlink:href="nexi-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://nex.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f85ab38e-c45a-44af-9930-7cee7c4f27d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_749a96f7-b130-48c0-8cec-bb3fa082944b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f85ab38e-c45a-44af-9930-7cee7c4f27d4" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_749a96f7-b130-48c0-8cec-bb3fa082944b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock_1ee403f5-9077-4f1e-8b51-3a1b25ecb862" xlink:href="nexi-20221231.xsd#nexi_SubstantialDoubtForGoingConcernPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock_1ee403f5-9077-4f1e-8b51-3a1b25ecb862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_555b01cf-81da-4d2e-b773-8128fcc6e5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_555b01cf-81da-4d2e-b773-8128fcc6e5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_168d7b25-83f6-4a0d-bb81-d09302aadca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_UseOfEstimates_168d7b25-83f6-4a0d-bb81-d09302aadca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e9979a61-aeae-47a2-9bc0-efb8c1e94e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e9979a61-aeae-47a2-9bc0-efb8c1e94e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_f7b2ae33-11fd-4922-b66a-209b66e8d0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_f7b2ae33-11fd-4922-b66a-209b66e8d0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_314ff341-8f2c-4e8d-9465-10dc97100077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_314ff341-8f2c-4e8d-9465-10dc97100077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_53144fe3-5f2a-448c-9045-d8dd5087316b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_53144fe3-5f2a-448c-9045-d8dd5087316b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_396ab96e-9b12-4b2f-87e6-6ea1c875cf0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_396ab96e-9b12-4b2f-87e6-6ea1c875cf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_36d0d9d2-2653-4642-908f-e64d2d04f40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_36d0d9d2-2653-4642-908f-e64d2d04f40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_af20db88-8be0-45c1-9b91-81f45472dc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_af20db88-8be0-45c1-9b91-81f45472dc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityPolicyPolicyTextBlock_1122cf85-a142-420f-b515-3f9957605a37" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_nexi_TemporaryEquityPolicyPolicyTextBlock_1122cf85-a142-420f-b515-3f9957605a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_fb15ef03-6b8e-4b4a-9d12-9f969e5ac04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_fb15ef03-6b8e-4b4a-9d12-9f969e5ac04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_21917a27-fe53-48b6-b58b-a109239e1291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_21917a27-fe53-48b6-b58b-a109239e1291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock_2e1b37d6-160f-47a8-9ce6-f0f931cc405e" xlink:href="nexi-20221231.xsd#nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock_2e1b37d6-160f-47a8-9ce6-f0f931cc405e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_75897ebf-31d0-49d6-81da-a3efed0d45c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_75897ebf-31d0-49d6-81da-a3efed0d45c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_35c7c3fb-56a0-4e85-9cd2-0a06b2183c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_35c7c3fb-56a0-4e85-9cd2-0a06b2183c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_ae711d19-dc6e-47ce-998e-984838f23b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_ae711d19-dc6e-47ce-998e-984838f23b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92faf6ac-ea39-45ec-b98e-e7dd2fcb4d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c4c9b6-1213-4d52-b223-85e4efe22fcf" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92faf6ac-ea39-45ec-b98e-e7dd2fcb4d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4896af32-8a97-4e0b-a3e2-6a367c3f2487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_96349dc1-5187-4edc-a255-73099bbc3755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4896af32-8a97-4e0b-a3e2-6a367c3f2487" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_96349dc1-5187-4edc-a255-73099bbc3755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_425240ae-d4a9-4aca-8c49-35d312d35e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4896af32-8a97-4e0b-a3e2-6a367c3f2487" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_425240ae-d4a9-4aca-8c49-35d312d35e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_08893237-9686-44bd-b1e7-f43bb35c2edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4896af32-8a97-4e0b-a3e2-6a367c3f2487" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_08893237-9686-44bd-b1e7-f43bb35c2edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_40a8f691-4b3a-4021-9bdf-17e2afc2ad01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4896af32-8a97-4e0b-a3e2-6a367c3f2487" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_40a8f691-4b3a-4021-9bdf-17e2afc2ad01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nexi-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://nex.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6c898fc0-113d-4e5e-947b-a1fdfc4dd441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_095bc1d8-3dcd-4464-8b94-e5fe1b05cfd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6c898fc0-113d-4e5e-947b-a1fdfc4dd441" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_095bc1d8-3dcd-4464-8b94-e5fe1b05cfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="nexi-20221231.xsd#PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://nex.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_6fdc58f1-8238-4591-97e6-4649d0468a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_9f106b4f-d45b-44d3-a69f-c58269854a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_6fdc58f1-8238-4591-97e6-4649d0468a5c" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_9f106b4f-d45b-44d3-a69f-c58269854a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="nexi-20221231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://nex.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_84b5448c-9fa5-4030-8f57-dbaa3873d57a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_447af85f-223a-4567-90d3-8c91bf1cc2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_84b5448c-9fa5-4030-8f57-dbaa3873d57a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_447af85f-223a-4567-90d3-8c91bf1cc2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/RestructuringActivitiesTables" xlink:type="simple" xlink:href="nexi-20221231.xsd#RestructuringActivitiesTables"/>
  <link:presentationLink xlink:role="http://nex.com/role/RestructuringActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2cdefc02-67ab-4fb9-a648-df0a6d29053f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_157adb64-3bec-48dc-9be7-914056e3b2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2cdefc02-67ab-4fb9-a648-df0a6d29053f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_157adb64-3bec-48dc-9be7-914056e3b2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="nexi-20221231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://nex.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7d4ed482-533f-4d85-8ac4-6b8823680294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d0e0c8dd-cc61-429e-acb4-8359c52e7f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7d4ed482-533f-4d85-8ac4-6b8823680294" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d0e0c8dd-cc61-429e-acb4-8359c52e7f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nexi-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://nex.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6957b25-2b76-4ccd-8214-140c709fa0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3ffd3399-8e56-437c-b282-6790bcd622cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6957b25-2b76-4ccd-8214-140c709fa0aa" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3ffd3399-8e56-437c-b282-6790bcd622cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_38ad5533-cea6-4b7b-ba74-e658d8802b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6957b25-2b76-4ccd-8214-140c709fa0aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_38ad5533-cea6-4b7b-ba74-e658d8802b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_59caca35-52ed-4a11-80cc-94a985012492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6957b25-2b76-4ccd-8214-140c709fa0aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_59caca35-52ed-4a11-80cc-94a985012492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_75470c10-8d14-4f60-a747-291f330d508f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c6957b25-2b76-4ccd-8214-140c709fa0aa" xlink:to="loc_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_75470c10-8d14-4f60-a747-291f330d508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="nexi-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://nex.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_61b2b415-9dbb-46fe-908f-9ce405d2b2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b7c3cf24-9968-4632-a3f6-c44e4fb66ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_61b2b415-9dbb-46fe-908f-9ce405d2b2f9" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b7c3cf24-9968-4632-a3f6-c44e4fb66ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b2f24a6f-f07e-486e-9937-76fa51308f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_61b2b415-9dbb-46fe-908f-9ce405d2b2f9" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b2f24a6f-f07e-486e-9937-76fa51308f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ee17571e-de26-41a1-badc-7d6484deba27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_61b2b415-9dbb-46fe-908f-9ce405d2b2f9" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ee17571e-de26-41a1-badc-7d6484deba27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/LeasesTables" xlink:type="simple" xlink:href="nexi-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://nex.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a2581e5e-e678-4b90-b84f-6d510c70992d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_a21fb092-9321-4636-9a3a-e8211856df1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2581e5e-e678-4b90-b84f-6d510c70992d" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_a21fb092-9321-4636-9a3a-e8211856df1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_23238689-329f-45dd-afa4-31a31ce0699e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2581e5e-e678-4b90-b84f-6d510c70992d" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_23238689-329f-45dd-afa4-31a31ce0699e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_43d305e3-a68b-4b8f-9378-53b9f65850ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2581e5e-e678-4b90-b84f-6d510c70992d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_43d305e3-a68b-4b8f-9378-53b9f65850ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/DescriptionoftheBusinessDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#DescriptionoftheBusinessDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/DescriptionoftheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3504d761-4ab9-4ed5-9fbb-1d0627b43192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae3dc1df-b147-4669-99dd-b03411121611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3504d761-4ab9-4ed5-9fbb-1d0627b43192" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae3dc1df-b147-4669-99dd-b03411121611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7c287dcf-06de-49b4-9597-eadec643c1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3504d761-4ab9-4ed5-9fbb-1d0627b43192" xlink:to="loc_us-gaap_LongTermDebt_7c287dcf-06de-49b4-9597-eadec643c1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36f01467-0360-4e90-baf7-72957aeaf8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3504d761-4ab9-4ed5-9fbb-1d0627b43192" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36f01467-0360-4e90-baf7-72957aeaf8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6c523927-1fdf-4d3e-8c01-c3807df03b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cf3aea4-509a-4239-8e52-e49bb57dfa02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c523927-1fdf-4d3e-8c01-c3807df03b66" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cf3aea4-509a-4239-8e52-e49bb57dfa02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b000c4f3-50f1-49a1-b6d4-e1e1722884d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cf3aea4-509a-4239-8e52-e49bb57dfa02" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b000c4f3-50f1-49a1-b6d4-e1e1722884d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_080de70a-efc5-485c-9400-8fa99271b9b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_b000c4f3-50f1-49a1-b6d4-e1e1722884d3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_080de70a-efc5-485c-9400-8fa99271b9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_636b79ec-3c5a-4939-a1e5-657827fc7233" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_080de70a-efc5-485c-9400-8fa99271b9b6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_636b79ec-3c5a-4939-a1e5-657827fc7233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c5085c5a-0f96-46fb-a95a-0af2ab750dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cf3aea4-509a-4239-8e52-e49bb57dfa02" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c5085c5a-0f96-46fb-a95a-0af2ab750dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14a25be2-1ab4-4ee0-aa1e-3b243fde187b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c5085c5a-0f96-46fb-a95a-0af2ab750dff" xlink:to="loc_us-gaap_EquityComponentDomain_14a25be2-1ab4-4ee0-aa1e-3b243fde187b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_32b6dbcc-8447-42c6-a0cf-3aff9f71bffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14a25be2-1ab4-4ee0-aa1e-3b243fde187b" xlink:to="loc_us-gaap_RetainedEarningsMember_32b6dbcc-8447-42c6-a0cf-3aff9f71bffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1315538c-ea57-4b37-92d1-d54297b95c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14a25be2-1ab4-4ee0-aa1e-3b243fde187b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1315538c-ea57-4b37-92d1-d54297b95c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7cf3aea4-509a-4239-8e52-e49bb57dfa02" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a394301a-ebcb-4529-a608-7480025057e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a394301a-ebcb-4529-a608-7480025057e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_c9db03b6-90b3-45e4-8339-a6aa23b9fabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_MarketableSecurities_c9db03b6-90b3-45e4-8339-a6aa23b9fabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9abba3b7-6331-4161-a674-39fa2e12a10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9abba3b7-6331-4161-a674-39fa2e12a10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f939d8ca-e3f2-4ba1-bd93-54041363a583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f939d8ca-e3f2-4ba1-bd93-54041363a583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_74750ee4-53c3-4ab5-976c-105980320d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_74750ee4-53c3-4ab5-976c-105980320d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7fa6f086-3f03-41aa-96b3-20000b493b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7fa6f086-3f03-41aa-96b3-20000b493b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d449cd2c-31e8-4bbf-bdef-8a396b354f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_d449cd2c-31e8-4bbf-bdef-8a396b354f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_43fa4421-32fc-4139-80b4-4137638ddcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_43fa4421-32fc-4139-80b4-4137638ddcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d0ed6cb2-0602-40f7-a7fe-54f8e7a066e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d0ed6cb2-0602-40f7-a7fe-54f8e7a066e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4b7455ec-961f-4ab7-8a2e-c304d7075eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b2ee490-5281-482e-ae58-947b5863e428" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4b7455ec-961f-4ab7-8a2e-c304d7075eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d4ac3dec-0d4c-4d1c-9ef1-a13f74fbfe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8cf54bc9-86ce-4db2-8054-67f58ec8a688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d4ac3dec-0d4c-4d1c-9ef1-a13f74fbfe6e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8cf54bc9-86ce-4db2-8054-67f58ec8a688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_77110f1e-65bd-4b9c-a519-d4a363a6df1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d4ac3dec-0d4c-4d1c-9ef1-a13f74fbfe6e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_77110f1e-65bd-4b9c-a519-d4a363a6df1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e5309a8-5b0b-49d4-ba0a-56f782e4ddbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d4ac3dec-0d4c-4d1c-9ef1-a13f74fbfe6e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e5309a8-5b0b-49d4-ba0a-56f782e4ddbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d7702716-c6ac-4673-98ee-3c6a4e9b698e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdbd6533-ad17-482e-8eb8-03bd00a3f293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d7702716-c6ac-4673-98ee-3c6a4e9b698e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdbd6533-ad17-482e-8eb8-03bd00a3f293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_710104a7-fc9c-4630-8d62-bfe193c8efde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdbd6533-ad17-482e-8eb8-03bd00a3f293" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_710104a7-fc9c-4630-8d62-bfe193c8efde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60f0aed5-8e99-4d73-9e10-08bc8c74a642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_710104a7-fc9c-4630-8d62-bfe193c8efde" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60f0aed5-8e99-4d73-9e10-08bc8c74a642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_LaboratoryEquipmentMember_434755c4-3f2f-4559-8ffb-f567e4fe10ec" xlink:href="nexi-20221231.xsd#nexi_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60f0aed5-8e99-4d73-9e10-08bc8c74a642" xlink:to="loc_nexi_LaboratoryEquipmentMember_434755c4-3f2f-4559-8ffb-f567e4fe10ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ComputerEquipmentAndSoftwareMember_60a20f58-c68c-44dc-ae6c-f5838631fdfc" xlink:href="nexi-20221231.xsd#nexi_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60f0aed5-8e99-4d73-9e10-08bc8c74a642" xlink:to="loc_nexi_ComputerEquipmentAndSoftwareMember_60a20f58-c68c-44dc-ae6c-f5838631fdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c0ef5236-10ee-4a90-b10c-5c53b1f329de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_60f0aed5-8e99-4d73-9e10-08bc8c74a642" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c0ef5236-10ee-4a90-b10c-5c53b1f329de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e422213-0208-44b7-a0eb-4ff283cfff41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bdbd6533-ad17-482e-8eb8-03bd00a3f293" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e422213-0208-44b7-a0eb-4ff283cfff41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_13add06d-67e7-44b2-90b5-d502640eba0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1e422213-0208-44b7-a0eb-4ff283cfff41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_13add06d-67e7-44b2-90b5-d502640eba0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_91a4fe00-d97e-438c-b32a-f1476c1b56e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0e09e97f-a252-4524-bbe8-17b601b4ba1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91a4fe00-d97e-438c-b32a-f1476c1b56e3" xlink:to="loc_us-gaap_NetIncomeLoss_0e09e97f-a252-4524-bbe8-17b601b4ba1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityDividendsAdjustment_d4d4cc89-14f0-45df-9e84-c9e821057584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDividendsAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91a4fe00-d97e-438c-b32a-f1476c1b56e3" xlink:to="loc_us-gaap_TemporaryEquityDividendsAdjustment_d4d4cc89-14f0-45df-9e84-c9e821057584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8fd4fe95-d79b-4589-a7f2-0608034ffa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91a4fe00-d97e-438c-b32a-f1476c1b56e3" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8fd4fe95-d79b-4589-a7f2-0608034ffa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d1944855-6ddd-4dbd-8819-8a00f585cf33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91a4fe00-d97e-438c-b32a-f1476c1b56e3" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d1944855-6ddd-4dbd-8819-8a00f585cf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_902ad1cc-b173-4f57-ba95-5660153a6406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91a4fe00-d97e-438c-b32a-f1476c1b56e3" xlink:to="loc_us-gaap_EarningsPerShareBasic_902ad1cc-b173-4f57-ba95-5660153a6406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9536dfdf-8a82-427d-90a4-25f6965faee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91a4fe00-d97e-438c-b32a-f1476c1b56e3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9536dfdf-8a82-427d-90a4-25f6965faee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2a17739-e8b6-43f3-801a-359c482664d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91a4fe00-d97e-438c-b32a-f1476c1b56e3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2a17739-e8b6-43f3-801a-359c482664d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_55f850bf-9c68-4bdb-84eb-65dd817143c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91a4fe00-d97e-438c-b32a-f1476c1b56e3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_55f850bf-9c68-4bdb-84eb-65dd817143c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3cbf12f2-19f3-4d0b-949f-013b630d8d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_904b7a97-74e1-408a-9968-71aa116c0144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3cbf12f2-19f3-4d0b-949f-013b630d8d01" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_904b7a97-74e1-408a-9968-71aa116c0144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e9d715c-e0bc-4590-9c2d-badda72695a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_904b7a97-74e1-408a-9968-71aa116c0144" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e9d715c-e0bc-4590-9c2d-badda72695a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e9d715c-e0bc-4590-9c2d-badda72695a5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_597395ed-482c-4fd4-8131-38d178759fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:to="loc_us-gaap_EmployeeStockOptionMember_597395ed-482c-4fd4-8131-38d178759fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_14fdaf6f-b4a4-4b50-8569-dcabf9ab9345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_14fdaf6f-b4a4-4b50-8569-dcabf9ab9345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_23132799-8e11-4462-9db2-2288077d6d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_23132799-8e11-4462-9db2-2288077d6d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_2b5aee4d-6018-4e06-ac43-ee14af5eb429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_2b5aee4d-6018-4e06-ac43-ee14af5eb429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_798c5db0-285a-4aeb-be22-a527bbd7e469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_51ff665b-8ac3-433d-adef-3bf46e84d278" xlink:to="loc_us-gaap_WarrantMember_798c5db0-285a-4aeb-be22-a527bbd7e469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3791867f-7ef6-460e-98c2-7541a29871d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_904b7a97-74e1-408a-9968-71aa116c0144" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3791867f-7ef6-460e-98c2-7541a29871d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_78d736ad-50bd-475d-b665-bd69f25ae49c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3791867f-7ef6-460e-98c2-7541a29871d2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_78d736ad-50bd-475d-b665-bd69f25ae49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_09874a95-c4da-463e-8e86-5727e5dc001c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4bb5e6c-d897-41fd-ba7f-dfd754ada8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_09874a95-c4da-463e-8e86-5727e5dc001c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4bb5e6c-d897-41fd-ba7f-dfd754ada8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a796ec13-39eb-4c50-9188-e4ee40678437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4bb5e6c-d897-41fd-ba7f-dfd754ada8f6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a796ec13-39eb-4c50-9188-e4ee40678437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfd7230e-ec10-434f-8a1b-e184153259cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a796ec13-39eb-4c50-9188-e4ee40678437" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfd7230e-ec10-434f-8a1b-e184153259cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_02ca74ca-ca50-4136-bcd1-99e0c06cf8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfd7230e-ec10-434f-8a1b-e184153259cc" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_02ca74ca-ca50-4136-bcd1-99e0c06cf8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_94f81486-b630-4313-b9e7-d45dd006f3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfd7230e-ec10-434f-8a1b-e184153259cc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_94f81486-b630-4313-b9e7-d45dd006f3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4b3cffa4-6d91-4fb7-abad-64746ef70cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dfd7230e-ec10-434f-8a1b-e184153259cc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4b3cffa4-6d91-4fb7-abad-64746ef70cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_caaae815-a2be-4fe7-9563-64885cc6e2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4bb5e6c-d897-41fd-ba7f-dfd754ada8f6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_caaae815-a2be-4fe7-9563-64885cc6e2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_77f30c1b-1ab3-4e46-a93b-e38ae8252c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_caaae815-a2be-4fe7-9563-64885cc6e2db" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_77f30c1b-1ab3-4e46-a93b-e38ae8252c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9dd8a12c-b3d0-4b65-a6aa-316df2c56421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_77f30c1b-1ab3-4e46-a93b-e38ae8252c1f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9dd8a12c-b3d0-4b65-a6aa-316df2c56421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e2bf35d8-5d6f-48c4-9f5f-d165632cec9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4bb5e6c-d897-41fd-ba7f-dfd754ada8f6" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e2bf35d8-5d6f-48c4-9f5f-d165632cec9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_69425cc9-e19e-44a0-b753-a5d7df14ca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e2bf35d8-5d6f-48c4-9f5f-d165632cec9c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_69425cc9-e19e-44a0-b753-a5d7df14ca3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d049fd73-b904-4807-8755-6a54a8c68725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_69425cc9-e19e-44a0-b753-a5d7df14ca3f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d049fd73-b904-4807-8755-6a54a8c68725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_d200ec64-8a2d-4957-9581-d1ff0bc80297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_69425cc9-e19e-44a0-b753-a5d7df14ca3f" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_d200ec64-8a2d-4957-9581-d1ff0bc80297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ef57d5-803d-4f72-9c2a-45bef555b6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d4bb5e6c-d897-41fd-ba7f-dfd754ada8f6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ef57d5-803d-4f72-9c2a-45bef555b6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_df3be17c-00f5-478e-818d-80b942026b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c7ef57d5-803d-4f72-9c2a-45bef555b6e1" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_df3be17c-00f5-478e-818d-80b942026b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bcbf5d0d-b876-47fa-8807-462bdb471cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_df3be17c-00f5-478e-818d-80b942026b72" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bcbf5d0d-b876-47fa-8807-462bdb471cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d07b5520-1c56-42d0-b681-e1e381062fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_df3be17c-00f5-478e-818d-80b942026b72" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d07b5520-1c56-42d0-b681-e1e381062fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5173332b-3051-49d6-9853-6476bb94e15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_df3be17c-00f5-478e-818d-80b942026b72" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5173332b-3051-49d6-9853-6476bb94e15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail"/>
  <link:presentationLink xlink:role="http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8bf3966a-45aa-47e3-b82b-f1f03918f94b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_PrepaidResearchAndDevelopmentExpenses_e76be22b-c9a0-486d-b559-d9e7f47f2dca" xlink:href="nexi-20221231.xsd#nexi_PrepaidResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8bf3966a-45aa-47e3-b82b-f1f03918f94b" xlink:to="loc_nexi_PrepaidResearchAndDevelopmentExpenses_e76be22b-c9a0-486d-b559-d9e7f47f2dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_PrepaidMaintenanceAgreements_8130960a-a369-4244-a1ed-bec15c10df23" xlink:href="nexi-20221231.xsd#nexi_PrepaidMaintenanceAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8bf3966a-45aa-47e3-b82b-f1f03918f94b" xlink:to="loc_nexi_PrepaidMaintenanceAgreements_8130960a-a369-4244-a1ed-bec15c10df23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_91d20153-6e32-4880-9d97-24ea51ee5265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8bf3966a-45aa-47e3-b82b-f1f03918f94b" xlink:to="loc_us-gaap_PrepaidInsurance_91d20153-6e32-4880-9d97-24ea51ee5265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_892397d8-be33-4f11-ba2d-d8ad0e2f2d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8bf3966a-45aa-47e3-b82b-f1f03918f94b" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_892397d8-be33-4f11-ba2d-d8ad0e2f2d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_f2be1b17-38db-4199-9712-07d044902560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8bf3966a-45aa-47e3-b82b-f1f03918f94b" xlink:to="loc_us-gaap_InterestReceivableCurrent_f2be1b17-38db-4199-9712-07d044902560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b55758dd-22f8-4dd8-9766-af0efeec99be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8bf3966a-45aa-47e3-b82b-f1f03918f94b" xlink:to="loc_us-gaap_OtherAssetsCurrent_b55758dd-22f8-4dd8-9766-af0efeec99be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa670f71-fd86-49e5-b2b8-af4ce6c02630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_8bf3966a-45aa-47e3-b82b-f1f03918f94b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa670f71-fd86-49e5-b2b8-af4ce6c02630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#PropertyandEquipmentSummaryofPropertyAndEquipmentDetail"/>
  <link:presentationLink xlink:role="http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b1ad5733-b2f1-44ee-800d-e6b2ea0d3c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_12e5205a-03b5-4356-9be6-3f2cd194f4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b1ad5733-b2f1-44ee-800d-e6b2ea0d3c67" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_12e5205a-03b5-4356-9be6-3f2cd194f4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cdbfbfe0-19a7-4657-a4e8-e25db4d2da3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_12e5205a-03b5-4356-9be6-3f2cd194f4a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cdbfbfe0-19a7-4657-a4e8-e25db4d2da3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cdbfbfe0-19a7-4657-a4e8-e25db4d2da3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_LaboratoryEquipmentMember_60382c00-dc84-410d-b926-f82f1c35e640" xlink:href="nexi-20221231.xsd#nexi_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:to="loc_nexi_LaboratoryEquipmentMember_60382c00-dc84-410d-b926-f82f1c35e640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ComputerEquipmentAndSoftwareMember_296631ea-cc56-42b9-b09d-02179f01906a" xlink:href="nexi-20221231.xsd#nexi_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:to="loc_nexi_ComputerEquipmentAndSoftwareMember_296631ea-cc56-42b9-b09d-02179f01906a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_17754905-430e-4df3-9cd4-fab3800b6dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_17754905-430e-4df3-9cd4-fab3800b6dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c790f114-f810-4bfc-b912-fa9c459905ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e231023-5fa7-4c4a-a380-ac34eda18f60" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c790f114-f810-4bfc-b912-fa9c459905ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40d30834-68b4-4107-ad50-9512b34b8a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_12e5205a-03b5-4356-9be6-3f2cd194f4a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40d30834-68b4-4107-ad50-9512b34b8a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f033a520-d19e-4804-bfac-2ffd41853d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40d30834-68b4-4107-ad50-9512b34b8a03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f033a520-d19e-4804-bfac-2ffd41853d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_855e6005-712e-4992-842d-390734182607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40d30834-68b4-4107-ad50-9512b34b8a03" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_855e6005-712e-4992-842d-390734182607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12dc357d-5b47-4fa7-a7dd-3a44f9e2a2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_40d30834-68b4-4107-ad50-9512b34b8a03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12dc357d-5b47-4fa7-a7dd-3a44f9e2a2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#PropertyandEquipmentAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://nex.com/role/PropertyandEquipmentAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_573233ea-d96a-46e5-a69f-e95fbaba5ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_03254748-f9e5-4f8f-9052-44ac05dbf4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_573233ea-d96a-46e5-a69f-e95fbaba5ea3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_03254748-f9e5-4f8f-9052-44ac05dbf4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/RestructuringActivitiesDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#RestructuringActivitiesDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/RestructuringActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5f61a74f-f77e-49e4-85d4-7e30720fe429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b2ee6440-491f-4bd2-9cf5-7fb159189026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5f61a74f-f77e-49e4-85d4-7e30720fe429" xlink:to="loc_us-gaap_RestructuringReserve_b2ee6440-491f-4bd2-9cf5-7fb159189026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b26974db-44c8-40c8-beb3-bce44c0af53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5f61a74f-f77e-49e4-85d4-7e30720fe429" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b26974db-44c8-40c8-beb3-bce44c0af53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_56f1733f-52d5-453d-b939-20a2b4465dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b26974db-44c8-40c8-beb3-bce44c0af53f" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_56f1733f-52d5-453d-b939-20a2b4465dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e017273e-1922-4668-8089-7261d2198dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_56f1733f-52d5-453d-b939-20a2b4465dc4" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e017273e-1922-4668-8089-7261d2198dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_2ad39a73-460a-4c0c-995b-d9e1fc1862bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e017273e-1922-4668-8089-7261d2198dea" xlink:to="loc_us-gaap_EmployeeSeveranceMember_2ad39a73-460a-4c0c-995b-d9e1fc1862bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b26974db-44c8-40c8-beb3-bce44c0af53f" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent_ccbdcb79-4893-4adf-9a57-c5885369016f" xlink:href="nexi-20221231.xsd#nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent_ccbdcb79-4893-4adf-9a57-c5885369016f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations_dba46f6e-6e41-4c3e-80aa-fbfe85ce5618" xlink:href="nexi-20221231.xsd#nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations_dba46f6e-6e41-4c3e-80aa-fbfe85ce5618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations_2310fbad-3323-4c17-a2ea-fdf30c9abb94" xlink:href="nexi-20221231.xsd#nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations_2310fbad-3323-4c17-a2ea-fdf30c9abb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_9018618a-2279-43b2-a98a-a0e62b2155d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_9018618a-2279-43b2-a98a-a0e62b2155d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_0b7ca0af-7583-464c-b2e1-9475b7c785c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_us-gaap_RestructuringReserve_0b7ca0af-7583-464c-b2e1-9475b7c785c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_29191fc0-36ac-4810-89ca-ad931fce1c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_29191fc0-36ac-4810-89ca-ad931fce1c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_05ed8e63-266c-40e2-b20f-9ff1e20a5146" xlink:href="nexi-20221231.xsd#nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a943106f-72cb-46df-91bd-e08d9439c711" xlink:to="loc_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag_05ed8e63-266c-40e2-b20f-9ff1e20a5146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_176826b5-0654-405e-8bde-054910b4cf96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3fa943c-1d70-4b1c-96b3-bcb9d20cd09c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_176826b5-0654-405e-8bde-054910b4cf96" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3fa943c-1d70-4b1c-96b3-bcb9d20cd09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2ace02cd-81d1-47ee-88ae-8e1f641e64b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3fa943c-1d70-4b1c-96b3-bcb9d20cd09c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2ace02cd-81d1-47ee-88ae-8e1f641e64b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a90f34a4-f6cf-44d6-bf86-0ed24b8a93e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2ace02cd-81d1-47ee-88ae-8e1f641e64b6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a90f34a4-f6cf-44d6-bf86-0ed24b8a93e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_a4ac3096-55fd-4059-a001-a6a998d0540d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_a90f34a4-f6cf-44d6-bf86-0ed24b8a93e4" xlink:to="loc_us-gaap_EmployeeSeveranceMember_a4ac3096-55fd-4059-a001-a6a998d0540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bd3fc8b1-570a-496b-b7a5-67a773dc05d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3fa943c-1d70-4b1c-96b3-bcb9d20cd09c" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_bd3fc8b1-570a-496b-b7a5-67a773dc05d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_31201539-8413-49d3-92f0-4b9b7b5de7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bd3fc8b1-570a-496b-b7a5-67a773dc05d8" xlink:to="loc_us-gaap_RestructuringReserveRollForward_31201539-8413-49d3-92f0-4b9b7b5de7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_729771c5-c65c-46a1-a992-83cc522824c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31201539-8413-49d3-92f0-4b9b7b5de7ef" xlink:to="loc_us-gaap_RestructuringReserve_729771c5-c65c-46a1-a992-83cc522824c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a9eaef6b-8e77-4511-a837-85ef65e143e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31201539-8413-49d3-92f0-4b9b7b5de7ef" xlink:to="loc_us-gaap_RestructuringCharges_a9eaef6b-8e77-4511-a837-85ef65e143e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_483bf03a-f802-4d7c-9d84-529a556eb77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31201539-8413-49d3-92f0-4b9b7b5de7ef" xlink:to="loc_us-gaap_PaymentsForRestructuring_483bf03a-f802-4d7c-9d84-529a556eb77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_1c19642e-7733-44f5-a74d-3f5a19e800d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_31201539-8413-49d3-92f0-4b9b7b5de7ef" xlink:to="loc_us-gaap_RestructuringReserve_1c19642e-7733-44f5-a74d-3f5a19e800d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#AccruedExpensesSummaryofComponentsofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2931e132-1242-4ecd-bf2c-2bd7b99976e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_AccruedResearchAndDevelopmentCostsCurrent_a22391a6-71e8-42b7-bdfd-a6e45f9d8212" xlink:href="nexi-20221231.xsd#nexi_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2931e132-1242-4ecd-bf2c-2bd7b99976e3" xlink:to="loc_nexi_AccruedResearchAndDevelopmentCostsCurrent_a22391a6-71e8-42b7-bdfd-a6e45f9d8212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_339c6d83-dc16-4a7c-8fac-dc9364afb66b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2931e132-1242-4ecd-bf2c-2bd7b99976e3" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_339c6d83-dc16-4a7c-8fac-dc9364afb66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_59bf4c85-c159-4469-8d3b-0c803a152a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2931e132-1242-4ecd-bf2c-2bd7b99976e3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_59bf4c85-c159-4469-8d3b-0c803a152a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3077177a-d3f7-4cc9-9f21-8b23d22c4a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2931e132-1242-4ecd-bf2c-2bd7b99976e3" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3077177a-d3f7-4cc9-9f21-8b23d22c4a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8a0dae52-a3b3-44a4-9269-8097bb4f2534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2931e132-1242-4ecd-bf2c-2bd7b99976e3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8a0dae52-a3b3-44a4-9269-8097bb4f2534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9c327983-5c6b-4c20-847f-e34bb8b8ec2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d96a4ae7-8975-47a9-8c00-e20b7ee25ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentTable_8181f5d5-02a6-4c28-a855-b820731d937a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d96a4ae7-8975-47a9-8c00-e20b7ee25ec9" xlink:to="loc_us-gaap_SupplyCommitmentTable_8181f5d5-02a6-4c28-a855-b820731d937a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_70cb74f6-a8db-420c-8c09-3ab5e973cae5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_8181f5d5-02a6-4c28-a855-b820731d937a" xlink:to="loc_srt_CounterpartyNameAxis_70cb74f6-a8db-420c-8c09-3ab5e973cae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd535406-89e7-4d43-8c53-8e53ff61329f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_70cb74f6-a8db-420c-8c09-3ab5e973cae5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd535406-89e7-4d43-8c53-8e53ff61329f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MarylandBiotechnologyCenterMember_9b51ff94-93dc-4f84-9b2a-174c09975726" xlink:href="nexi-20221231.xsd#nexi_MarylandBiotechnologyCenterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cd535406-89e7-4d43-8c53-8e53ff61329f" xlink:to="loc_nexi_MarylandBiotechnologyCenterMember_9b51ff94-93dc-4f84-9b2a-174c09975726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc9bac69-69df-4764-97db-1107d6c4ab01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_8181f5d5-02a6-4c28-a855-b820731d937a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc9bac69-69df-4764-97db-1107d6c4ab01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d0c57ed-bb3d-4b4b-86e4-34b2ded093ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc9bac69-69df-4764-97db-1107d6c4ab01" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d0c57ed-bb3d-4b4b-86e4-34b2ded093ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TranslationalResearchAwardAgreementMember_2cd76059-2819-4fa8-9261-993bb9a794ee" xlink:href="nexi-20221231.xsd#nexi_TranslationalResearchAwardAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d0c57ed-bb3d-4b4b-86e4-34b2ded093ed" xlink:to="loc_nexi_TranslationalResearchAwardAgreementMember_2cd76059-2819-4fa8-9261-993bb9a794ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_8181f5d5-02a6-4c28-a855-b820731d937a" xlink:to="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability_2eff3a27-92a6-43d2-8d5e-d96dc802c43d" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability_2eff3a27-92a6-43d2-8d5e-d96dc802c43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6c2a4cf3-9613-4699-bb89-418e1eb4cdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_6c2a4cf3-9613-4699-bb89-418e1eb4cdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage_ace3f885-48eb-4c8c-991f-41c8016b1a38" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage_ace3f885-48eb-4c8c-991f-41c8016b1a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod_2c86fb4a-9322-4674-a395-92f1a56ccbbf" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod_2c86fb4a-9322-4674-a395-92f1a56ccbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage_e80a4227-b421-43cd-97f2-189b87bcf32c" xlink:href="nexi-20221231.xsd#nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage_e80a4227-b421-43cd-97f2-189b87bcf32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6eb544ef-f6a7-41ae-8909-f0ca7576c31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_84f39f4b-bac2-4db1-8c3e-961dc85532d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6eb544ef-f6a7-41ae-8909-f0ca7576c31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d0760de-fb1d-4109-b8d0-ebb301073f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d0760de-fb1d-4109-b8d0-ebb301073f9a" xlink:to="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d8e473f9-004f-4e20-9a48-bf0533d6b012" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:to="loc_srt_CounterpartyNameAxis_d8e473f9-004f-4e20-9a48-bf0533d6b012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c073eac-2169-479e-b047-4a60cf6690d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d8e473f9-004f-4e20-9a48-bf0533d6b012" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c073eac-2169-479e-b047-4a60cf6690d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_JohnsHopkinsUniversityMember_9e768ef5-f054-4011-94db-fbfccb29619c" xlink:href="nexi-20221231.xsd#nexi_JohnsHopkinsUniversityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c073eac-2169-479e-b047-4a60cf6690d8" xlink:to="loc_nexi_JohnsHopkinsUniversityMember_9e768ef5-f054-4011-94db-fbfccb29619c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d017ef67-8bbf-4ed2-aea0-a4edfcfa8533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d017ef67-8bbf-4ed2-aea0-a4edfcfa8533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_537300b4-201a-48f3-860e-cd81597e8c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d017ef67-8bbf-4ed2-aea0-a4edfcfa8533" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_537300b4-201a-48f3-860e-cd81597e8c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ExclusiveLicenseAgreementMember_8175463b-9dc5-4bcb-b2e6-2fdebd3b5017" xlink:href="nexi-20221231.xsd#nexi_ExclusiveLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_537300b4-201a-48f3-860e-cd81597e8c24" xlink:to="loc_nexi_ExclusiveLicenseAgreementMember_8175463b-9dc5-4bcb-b2e6-2fdebd3b5017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MilestonesAxis_ec65a8d0-7c41-4d8b-ad8a-a064ed8d7be5" xlink:href="nexi-20221231.xsd#nexi_MilestonesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:to="loc_nexi_MilestonesAxis_ec65a8d0-7c41-4d8b-ad8a-a064ed8d7be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:href="nexi-20221231.xsd#nexi_MilestonesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_MilestonesAxis_ec65a8d0-7c41-4d8b-ad8a-a064ed8d7be5" xlink:to="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ClinicalTrialMilestonesMember_b9bc72f1-8269-424b-8e7b-e2f9f7006676" xlink:href="nexi-20221231.xsd#nexi_ClinicalTrialMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:to="loc_nexi_ClinicalTrialMilestonesMember_b9bc72f1-8269-424b-8e7b-e2f9f7006676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TherapeuticFieldMember_aad770c0-dd17-47c0-ad53-338af27562ed" xlink:href="nexi-20221231.xsd#nexi_TherapeuticFieldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:to="loc_nexi_TherapeuticFieldMember_aad770c0-dd17-47c0-ad53-338af27562ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RegulatoryAndCommercialMilestonesMember_f57368c1-2a00-4a1e-b6a0-6f5274fdfa0f" xlink:href="nexi-20221231.xsd#nexi_RegulatoryAndCommercialMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:to="loc_nexi_RegulatoryAndCommercialMilestonesMember_f57368c1-2a00-4a1e-b6a0-6f5274fdfa0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_NonclinicalFieldMember_a30b6edf-a318-4c0b-928e-05332079d1a5" xlink:href="nexi-20221231.xsd#nexi_NonclinicalFieldMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_MilestonesDomain_e685abc6-cf63-414f-a7e1-ba26a03b6d37" xlink:to="loc_nexi_NonclinicalFieldMember_a30b6edf-a318-4c0b-928e-05332079d1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28de1ac5-f790-4fca-b168-6756a3a44beb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:to="loc_srt_RangeAxis_28de1ac5-f790-4fca-b168-6756a3a44beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7464b4f9-9123-4ade-97ec-73679e83ddbc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_28de1ac5-f790-4fca-b168-6756a3a44beb" xlink:to="loc_srt_RangeMember_7464b4f9-9123-4ade-97ec-73679e83ddbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7ac151ec-da44-48ab-914a-5e6c1af84091" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7464b4f9-9123-4ade-97ec-73679e83ddbc" xlink:to="loc_srt_MinimumMember_7ac151ec-da44-48ab-914a-5e6c1af84091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8e631d2f-c20e-4d40-a958-49269206b91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8e631d2f-c20e-4d40-a958-49269206b91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b1fa3e17-e290-407b-a77c-5fe5e2089687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8e631d2f-c20e-4d40-a958-49269206b91e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b1fa3e17-e290-407b-a77c-5fe5e2089687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a062573-af96-4d8a-a275-44e1f3ad49ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b1fa3e17-e290-407b-a77c-5fe5e2089687" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a062573-af96-4d8a-a275-44e1f3ad49ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_19a16d2d-b15b-42bc-a0c8-e22426debf99" xlink:to="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MilestoneFees_2eaa5989-33a9-4b08-a443-7b70fd556d53" xlink:href="nexi-20221231.xsd#nexi_MilestoneFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_nexi_MilestoneFees_2eaa5989-33a9-4b08-a443-7b70fd556d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_MinimumAnnualRoyaltyPayments_63110329-2a9d-44f5-ae2e-def0897937d6" xlink:href="nexi-20221231.xsd#nexi_MinimumAnnualRoyaltyPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_nexi_MinimumAnnualRoyaltyPayments_63110329-2a9d-44f5-ae2e-def0897937d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SublicenseConsiderationPaymentPercentMaximum_fe02b7a4-8b25-49a3-abe0-124cdd82cac5" xlink:href="nexi-20221231.xsd#nexi_SublicenseConsiderationPaymentPercentMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_nexi_SublicenseConsiderationPaymentPercentMaximum_fe02b7a4-8b25-49a3-abe0-124cdd82cac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_CumulativeMinimumRoyalties_3850e115-fa4a-4702-a65d-6df71c249431" xlink:href="nexi-20221231.xsd#nexi_CumulativeMinimumRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_nexi_CumulativeMinimumRoyalties_3850e115-fa4a-4702-a65d-6df71c249431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_0014c3e6-4d9c-4055-9672-596488777f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_us-gaap_RoyaltyExpense_0014c3e6-4d9c-4055-9672-596488777f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_9b027a21-84fc-4ebc-ba03-fb6a5350dab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_b01f39bd-04f8-4184-99e4-00a762a6752f" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_9b027a21-84fc-4ebc-ba03-fb6a5350dab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e254b784-83e1-4dc8-a2a5-6ece327782a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_a1a8b38c-5ab9-4299-b02f-777aae1ee8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e254b784-83e1-4dc8-a2a5-6ece327782a8" xlink:to="loc_us-gaap_OtherCommitmentsTable_a1a8b38c-5ab9-4299-b02f-777aae1ee8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c7f8bac2-ec55-4064-bece-53cbd30e6b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_a1a8b38c-5ab9-4299-b02f-777aae1ee8dc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c7f8bac2-ec55-4064-bece-53cbd30e6b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1279e012-ae19-495c-aa63-d7d669f47f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c7f8bac2-ec55-4064-bece-53cbd30e6b6f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1279e012-ae19-495c-aa63-d7d669f47f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_PaycheckProtectionProgramLoanMember_f6baa3a5-c67a-4a85-8a45-3ca21883293f" xlink:href="nexi-20221231.xsd#nexi_PaycheckProtectionProgramLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1279e012-ae19-495c-aa63-d7d669f47f9d" xlink:to="loc_nexi_PaycheckProtectionProgramLoanMember_f6baa3a5-c67a-4a85-8a45-3ca21883293f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1c00f2cf-6239-4526-b429-ef246d7a4bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_a1a8b38c-5ab9-4299-b02f-777aae1ee8dc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1c00f2cf-6239-4526-b429-ef246d7a4bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e7a26984-dfe2-4894-8f43-bd3d0dcf3e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c00f2cf-6239-4526-b429-ef246d7a4bdf" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e7a26984-dfe2-4894-8f43-bd3d0dcf3e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_c13cdcd4-246b-403e-9851-832e378e0b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e7a26984-dfe2-4894-8f43-bd3d0dcf3e42" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_c13cdcd4-246b-403e-9851-832e378e0b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_5839df64-b793-423a-81bf-8a3a02289f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_a1a8b38c-5ab9-4299-b02f-777aae1ee8dc" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_5839df64-b793-423a-81bf-8a3a02289f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1b0f9c37-7181-4387-bca7-e00f69ada9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5839df64-b793-423a-81bf-8a3a02289f16" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1b0f9c37-7181-4387-bca7-e00f69ada9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_bbf74b9a-d8ce-4570-b49b-638432bf3baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5839df64-b793-423a-81bf-8a3a02289f16" xlink:to="loc_us-gaap_NotesPayableCurrent_bbf74b9a-d8ce-4570-b49b-638432bf3baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_132d0539-9ecd-477c-9342-457c13db0d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5839df64-b793-423a-81bf-8a3a02289f16" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_132d0539-9ecd-477c-9342-457c13db0d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/ConvertibleNotesAdditionalInformationDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#ConvertibleNotesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://nex.com/role/ConvertibleNotesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cdd0e641-17a8-40e3-8e71-feadb99eb172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_36b497a0-4abf-4640-98ea-dceea90de49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cdd0e641-17a8-40e3-8e71-feadb99eb172" xlink:to="loc_us-gaap_DebtInstrumentTable_36b497a0-4abf-4640-98ea-dceea90de49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_30cfcff8-451b-448f-a79f-c004fdf87ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_36b497a0-4abf-4640-98ea-dceea90de49d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_30cfcff8-451b-448f-a79f-c004fdf87ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d29c23a1-ac45-4bb3-a80d-7141a0dbb5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_30cfcff8-451b-448f-a79f-c004fdf87ea5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d29c23a1-ac45-4bb3-a80d-7141a0dbb5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_ebfe5c04-d174-483c-b08e-b23616fb3400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d29c23a1-ac45-4bb3-a80d-7141a0dbb5da" xlink:to="loc_us-gaap_ConvertibleDebtMember_ebfe5c04-d174-483c-b08e-b23616fb3400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_408a10e5-5241-4aca-9126-aa5e2f53b116" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_36b497a0-4abf-4640-98ea-dceea90de49d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_408a10e5-5241-4aca-9126-aa5e2f53b116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_78720c29-3aa6-495d-bb7d-ee41d8d733f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_408a10e5-5241-4aca-9126-aa5e2f53b116" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_78720c29-3aa6-495d-bb7d-ee41d8d733f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fde60de2-8d22-44ed-b73f-b2e3dfab468a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_78720c29-3aa6-495d-bb7d-ee41d8d733f8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_fde60de2-8d22-44ed-b73f-b2e3dfab468a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_370fd730-2d06-4c5a-8f09-fc0534a2023e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_36b497a0-4abf-4640-98ea-dceea90de49d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_370fd730-2d06-4c5a-8f09-fc0534a2023e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_85868a74-e956-4657-b885-0bdd4da6e6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_370fd730-2d06-4c5a-8f09-fc0534a2023e" xlink:to="loc_us-gaap_EquityComponentDomain_85868a74-e956-4657-b885-0bdd4da6e6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2d9caafd-4600-42ac-94d2-49f64de4bcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_85868a74-e956-4657-b885-0bdd4da6e6d6" xlink:to="loc_us-gaap_RetainedEarningsMember_2d9caafd-4600-42ac-94d2-49f64de4bcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_be18cf3e-ab3f-4a14-b78a-9c17a084e852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_85868a74-e956-4657-b885-0bdd4da6e6d6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_be18cf3e-ab3f-4a14-b78a-9c17a084e852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_36b497a0-4abf-4640-98ea-dceea90de49d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8013a1e4-598b-4fc5-83af-841e7a9a9ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8013a1e4-598b-4fc5-83af-841e7a9a9ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd485f5a-e9a0-4abd-b3d2-74b8ab4cf358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dd485f5a-e9a0-4abd-b3d2-74b8ab4cf358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentAdditionalClosingLockInPeriod_a39fb58d-e855-4ae4-8a23-c913b5eb3e02" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentAdditionalClosingLockInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtInstrumentAdditionalClosingLockInPeriod_a39fb58d-e855-4ae4-8a23-c913b5eb3e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentConvertiblePricePercentage_c457f318-9aa3-45a8-86ae-6e68fe23be3c" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentConvertiblePricePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtInstrumentConvertiblePricePercentage_c457f318-9aa3-45a8-86ae-6e68fe23be3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentFullyDilutedCapitalization_33c87b2b-c604-4000-852c-adcaac118626" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentFullyDilutedCapitalization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtInstrumentFullyDilutedCapitalization_33c87b2b-c604-4000-852c-adcaac118626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_1f5fdc8a-2e9f-4e10-9ea8-34b74c6fb2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_1f5fdc8a-2e9f-4e10-9ea8-34b74c6fb2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtInstrumentRedemptionAmount_99d2fb2c-2a6a-4050-b5a3-e39431403c3a" xlink:href="nexi-20221231.xsd#nexi_DebtInstrumentRedemptionAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtInstrumentRedemptionAmount_99d2fb2c-2a6a-4050-b5a3-e39431403c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0665a9ed-7769-48ac-9c3d-32d03c7bbc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0665a9ed-7769-48ac-9c3d-32d03c7bbc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance_d647efe3-a6e0-4a29-abac-3ce01f6492fa" xlink:href="nexi-20221231.xsd#nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance_d647efe3-a6e0-4a29-abac-3ce01f6492fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes_3b358edf-4c2a-477c-a84c-bef96e44a34d" xlink:href="nexi-20221231.xsd#nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes_3b358edf-4c2a-477c-a84c-bef96e44a34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtDiscount_3fda7515-f574-4983-97c2-fee404e8cef0" xlink:href="nexi-20221231.xsd#nexi_DebtDiscount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtDiscount_3fda7515-f574-4983-97c2-fee404e8cef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtIssuanceCosts_849a9cd5-ae4a-470d-a394-c04e027813ae" xlink:href="nexi-20221231.xsd#nexi_DebtIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtIssuanceCosts_849a9cd5-ae4a-470d-a394-c04e027813ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_99c10262-8c7b-4052-8c52-205b303358f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_99c10262-8c7b-4052-8c52-205b303358f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_af71fd45-7802-445c-8ded-f0bd99a68398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_StockholdersEquity_af71fd45-7802-445c-8ded-f0bd99a68398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_920d5800-0685-4fb2-b196-b34fc3bd5326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_ConvertibleNotesPayable_920d5800-0685-4fb2-b196-b34fc3bd5326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_667a5d56-4538-4d3b-b0d7-5bbcbc379476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_667a5d56-4538-4d3b-b0d7-5bbcbc379476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3885c5f8-b347-4564-b9ec-5502aab9f337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_InterestExpenseDebt_3885c5f8-b347-4564-b9ec-5502aab9f337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_d0bf0601-131a-4ec5-9c8b-576fd6634f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_d0bf0601-131a-4ec5-9c8b-576fd6634f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts_9060af63-5cb3-40ef-9c38-1fb479b992d4" xlink:href="nexi-20221231.xsd#nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d221e5dd-976c-4e38-9a01-500b36355bd9" xlink:to="loc_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts_9060af63-5cb3-40ef-9c38-1fb479b992d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract_07bcc6fd-4283-4b44-b8cd-f15b3c7f6b5f" xlink:href="nexi-20221231.xsd#nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c3b63d8f-fbe7-4c6f-886f-87090a1b9664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract_07bcc6fd-4283-4b44-b8cd-f15b3c7f6b5f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c3b63d8f-fbe7-4c6f-886f-87090a1b9664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_66b1bc58-5739-44ca-b1db-b0d117733965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c3b63d8f-fbe7-4c6f-886f-87090a1b9664" xlink:to="loc_us-gaap_StatementClassOfStockAxis_66b1bc58-5739-44ca-b1db-b0d117733965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_781285aa-cd8f-4338-8516-bdc230681680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_66b1bc58-5739-44ca-b1db-b0d117733965" xlink:to="loc_us-gaap_ClassOfStockDomain_781285aa-cd8f-4338-8516-bdc230681680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_a08e0d57-cbff-476c-9fac-a33e1470e77d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_781285aa-cd8f-4338-8516-bdc230681680" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_a08e0d57-cbff-476c-9fac-a33e1470e77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_5ca21416-257b-4927-8c60-7c4e1bb3a91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_781285aa-cd8f-4338-8516-bdc230681680" xlink:to="loc_us-gaap_CommonClassAMember_5ca21416-257b-4927-8c60-7c4e1bb3a91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SeriesARedeemableConvertiblePreferredStockMember_ef8ceb6b-5981-496b-80ce-1a02ccf6e9ec" xlink:href="nexi-20221231.xsd#nexi_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_781285aa-cd8f-4338-8516-bdc230681680" xlink:to="loc_nexi_SeriesARedeemableConvertiblePreferredStockMember_ef8ceb6b-5981-496b-80ce-1a02ccf6e9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_872d8e22-5dd0-49c3-b3ae-d970360c33ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c3b63d8f-fbe7-4c6f-886f-87090a1b9664" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_872d8e22-5dd0-49c3-b3ae-d970360c33ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97680404-1099-43c2-97ef-80a089b6ce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_872d8e22-5dd0-49c3-b3ae-d970360c33ec" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97680404-1099-43c2-97ef-80a089b6ce7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_8a02c538-39a5-44b2-82c3-3fb98e059853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97680404-1099-43c2-97ef-80a089b6ce7c" xlink:to="loc_us-gaap_IPOMember_8a02c538-39a5-44b2-82c3-3fb98e059853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_AtTheMarketOfferingMember_33618cab-97f6-46d3-abc5-a2b7d3146fd7" xlink:href="nexi-20221231.xsd#nexi_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_97680404-1099-43c2-97ef-80a089b6ce7c" xlink:to="loc_nexi_AtTheMarketOfferingMember_33618cab-97f6-46d3-abc5-a2b7d3146fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a385143f-8825-4738-82f1-7ff8c1fbab2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c3b63d8f-fbe7-4c6f-886f-87090a1b9664" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a385143f-8825-4738-82f1-7ff8c1fbab2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01b0e82a-dc49-4726-b6b7-43718d379210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a385143f-8825-4738-82f1-7ff8c1fbab2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01b0e82a-dc49-4726-b6b7-43718d379210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_eeb1f58b-d11f-4bac-a24d-452263e4c197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_01b0e82a-dc49-4726-b6b7-43718d379210" xlink:to="loc_us-gaap_ConvertibleDebtMember_eeb1f58b-d11f-4bac-a24d-452263e4c197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c3b63d8f-fbe7-4c6f-886f-87090a1b9664" xlink:to="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fe61b0d4-1a4d-47cb-a28b-b0f17c0f4bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fe61b0d4-1a4d-47cb-a28b-b0f17c0f4bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_717ba982-5444-4d95-9686-3fc45c857bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_717ba982-5444-4d95-9686-3fc45c857bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_875d6eca-f280-4775-a224-0376762740cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_875d6eca-f280-4775-a224-0376762740cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_321b50ec-b21a-46e2-bb26-b664a8ca3167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_321b50ec-b21a-46e2-bb26-b664a8ca3167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_79fdbcbb-593c-4e21-a8bf-60f306a46829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_79fdbcbb-593c-4e21-a8bf-60f306a46829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_9ce35eaf-2e63-4585-adec-7edf43507430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_9ce35eaf-2e63-4585-adec-7edf43507430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c359457d-ad83-4ca4-9040-bf1746b4d35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_c359457d-ad83-4ca4-9040-bf1746b4d35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_dc280747-0f63-4459-9656-e54ab405642d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_dc280747-0f63-4459-9656-e54ab405642d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_53f9459b-c9bd-47e2-a969-cf91e592cf17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_53f9459b-c9bd-47e2-a969-cf91e592cf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7df38cc4-f401-457f-ad10-b9b639083183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7df38cc4-f401-457f-ad10-b9b639083183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7331cb77-5959-4d0c-b600-2ae53926e00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7331cb77-5959-4d0c-b600-2ae53926e00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3bfb4022-d8bc-41c9-818b-d82d7bb9a369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3bfb4022-d8bc-41c9-818b-d82d7bb9a369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0d7a9b6e-56dc-4d50-8b63-57e601754a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0d7a9b6e-56dc-4d50-8b63-57e601754a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_212de097-5b66-4a80-9b29-0c1e5cadfd61" xlink:href="nexi-20221231.xsd#nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_212de097-5b66-4a80-9b29-0c1e5cadfd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_StockIssuedDuringPeriodSharesWarrantsExercised_08a24253-fe61-46f8-8881-4f232c71060c" xlink:href="nexi-20221231.xsd#nexi_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_nexi_StockIssuedDuringPeriodSharesWarrantsExercised_08a24253-fe61-46f8-8881-4f232c71060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SaleOfStockAggregateOfferingApproval_cc4393be-55a2-493e-8670-7d11592a1fa4" xlink:href="nexi-20221231.xsd#nexi_SaleOfStockAggregateOfferingApproval"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_nexi_SaleOfStockAggregateOfferingApproval_cc4393be-55a2-493e-8670-7d11592a1fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_SaleOfStockCommissionPercentage_b23a23ea-4757-402b-bd5c-9a24c0479b01" xlink:href="nexi-20221231.xsd#nexi_SaleOfStockCommissionPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_nexi_SaleOfStockCommissionPercentage_b23a23ea-4757-402b-bd5c-9a24c0479b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbfa3ffd-47c1-43f6-8df4-dd5d541c7a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbfa3ffd-47c1-43f6-8df4-dd5d541c7a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9e272d2b-8810-4355-9c08-874b1eedf2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fcf19ded-6b2f-4e09-be3e-5387c51150ce" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9e272d2b-8810-4355-9c08-874b1eedf2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://nex.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b2853319-0901-46c8-9e0a-1c72b928a7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b2853319-0901-46c8-9e0a-1c72b928a7d0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5ad7aca5-97c7-492c-a1c5-e80f96792f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:to="loc_us-gaap_PlanNameAxis_5ad7aca5-97c7-492c-a1c5-e80f96792f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7d5256c4-5907-4158-aa29-759db5878bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5ad7aca5-97c7-492c-a1c5-e80f96792f59" xlink:to="loc_us-gaap_PlanNameDomain_7d5256c4-5907-4158-aa29-759db5878bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TwoThousandSeventeenEquityIncentivePlanMember_52a0aaa8-934b-4428-ae70-c600ba959937" xlink:href="nexi-20221231.xsd#nexi_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7d5256c4-5907-4158-aa29-759db5878bb3" xlink:to="loc_nexi_TwoThousandSeventeenEquityIncentivePlanMember_52a0aaa8-934b-4428-ae70-c600ba959937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_TwoThousandEighteenEquityIncentivePlanMember_052908c1-1698-43a3-be37-4822ad4acd63" xlink:href="nexi-20221231.xsd#nexi_TwoThousandEighteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7d5256c4-5907-4158-aa29-759db5878bb3" xlink:to="loc_nexi_TwoThousandEighteenEquityIncentivePlanMember_052908c1-1698-43a3-be37-4822ad4acd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_The2021PlanMember_7c08681e-c865-4efc-b53a-c46cfe918135" xlink:href="nexi-20221231.xsd#nexi_The2021PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7d5256c4-5907-4158-aa29-759db5878bb3" xlink:to="loc_nexi_The2021PlanMember_7c08681e-c865-4efc-b53a-c46cfe918135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f8d45e16-39c6-41d1-b7e9-dd9a6ea45832" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:to="loc_srt_RangeAxis_f8d45e16-39c6-41d1-b7e9-dd9a6ea45832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b6394e98-358a-405b-92f6-faad4562b72e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f8d45e16-39c6-41d1-b7e9-dd9a6ea45832" xlink:to="loc_srt_RangeMember_b6394e98-358a-405b-92f6-faad4562b72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e3809c5b-2f2b-4c2f-ad53-50773b8760da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b6394e98-358a-405b-92f6-faad4562b72e" xlink:to="loc_srt_MinimumMember_e3809c5b-2f2b-4c2f-ad53-50773b8760da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_623e2aca-f299-477e-a2ad-7f38281ecc4b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b6394e98-358a-405b-92f6-faad4562b72e" xlink:to="loc_srt_MaximumMember_623e2aca-f299-477e-a2ad-7f38281ecc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e1f96841-cade-4efb-9b1d-cdea2704fd52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:to="loc_us-gaap_AwardTypeAxis_e1f96841-cade-4efb-9b1d-cdea2704fd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82761907-72f1-43e4-8426-3981153ad270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e1f96841-cade-4efb-9b1d-cdea2704fd52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82761907-72f1-43e4-8426-3981153ad270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0c5097b1-67bb-4c37-b225-e9ab84677182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82761907-72f1-43e4-8426-3981153ad270" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0c5097b1-67bb-4c37-b225-e9ab84677182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9b11a2c8-3607-4465-86a7-f9c1fd366dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_82761907-72f1-43e4-8426-3981153ad270" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9b11a2c8-3607-4465-86a7-f9c1fd366dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_36d27554-ac4c-4664-a79a-f07b5eadf0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_36d27554-ac4c-4664-a79a-f07b5eadf0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f273733c-185d-48cb-829e-9ad9109f9a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_36d27554-ac4c-4664-a79a-f07b5eadf0cf" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f273733c-185d-48cb-829e-9ad9109f9a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d3940426-8a11-4a87-9363-1e30aac9d043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f273733c-185d-48cb-829e-9ad9109f9a1e" xlink:to="loc_us-gaap_SubsequentEventMember_d3940426-8a11-4a87-9363-1e30aac9d043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9c72e1e-4d54-4ada-b96d-9f12a513a4bb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_047f2a5d-4600-4ebd-8f33-8a2231353420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_047f2a5d-4600-4ebd-8f33-8a2231353420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock_0e1d918e-8fdb-4fdd-b66f-e6422b1f118f" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock_0e1d918e-8fdb-4fdd-b66f-e6422b1f118f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f14e6512-edbc-400a-a2e3-413f5a1a2fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f14e6512-edbc-400a-a2e3-413f5a1a2fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d9f27f96-1a08-46b8-8d4e-0734ea22508e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d9f27f96-1a08-46b8-8d4e-0734ea22508e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5a8f22e6-90c3-4def-b8ac-e7a81996527f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5a8f22e6-90c3-4def-b8ac-e7a81996527f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0551b2eb-c89e-4c07-9b94-c412c8e2f21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0551b2eb-c89e-4c07-9b94-c412c8e2f21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_201a0c68-422a-4d40-8d86-180f9b886004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_201a0c68-422a-4d40-8d86-180f9b886004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b19f8618-aff1-4122-ab0a-65b3fd9f345d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b19f8618-aff1-4122-ab0a-65b3fd9f345d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c5de40da-0c87-405e-9148-e8ae2cdad34e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c5de40da-0c87-405e-9148-e8ae2cdad34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c27d4d03-d60f-408e-a0f6-989ef08471c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_98488153-7caf-4d22-9b00-f1b8f892aeed" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c27d4d03-d60f-408e-a0f6-989ef08471c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f3df7926-039c-48c3-923a-fef13d003cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7fffbb9e-c754-4242-a02c-cb87a8e9eef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f3df7926-039c-48c3-923a-fef13d003cda" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7fffbb9e-c754-4242-a02c-cb87a8e9eef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d66c15d3-12b2-41f1-9ac5-7531d4db40ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7fffbb9e-c754-4242-a02c-cb87a8e9eef0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d66c15d3-12b2-41f1-9ac5-7531d4db40ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3234386f-9fc0-46a3-9f83-e2885233cf31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d66c15d3-12b2-41f1-9ac5-7531d4db40ea" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3234386f-9fc0-46a3-9f83-e2885233cf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8dba6c02-12a1-4702-9a27-492ea78982e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3234386f-9fc0-46a3-9f83-e2885233cf31" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8dba6c02-12a1-4702-9a27-492ea78982e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8998f295-24c3-47a9-a59f-f07e98072d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3234386f-9fc0-46a3-9f83-e2885233cf31" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8998f295-24c3-47a9-a59f-f07e98072d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5c81f676-9c7f-4b02-b5e9-f4fa964ad76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7fffbb9e-c754-4242-a02c-cb87a8e9eef0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5c81f676-9c7f-4b02-b5e9-f4fa964ad76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b8474357-337d-4242-99fb-ca8fb6473e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5c81f676-9c7f-4b02-b5e9-f4fa964ad76f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b8474357-337d-4242-99fb-ca8fb6473e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#StockBasedCompensationSummaryofOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e5f87a-ba17-489e-8d50-175697d19b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3c85593b-f217-4d67-984b-83f713c15f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e5f87a-ba17-489e-8d50-175697d19b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3c85593b-f217-4d67-984b-83f713c15f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_53efc647-20c4-41c4-808a-7b1d22fbefb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3c85593b-f217-4d67-984b-83f713c15f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_53efc647-20c4-41c4-808a-7b1d22fbefb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b791ea1c-3b1d-4c8f-8e16-b4c06c225e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3c85593b-f217-4d67-984b-83f713c15f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b791ea1c-3b1d-4c8f-8e16-b4c06c225e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a18633ee-6aeb-4efd-85c9-e95490707350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3c85593b-f217-4d67-984b-83f713c15f96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a18633ee-6aeb-4efd-85c9-e95490707350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_b086bdb1-549b-4d45-a671-cc9237f2256a" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3c85593b-f217-4d67-984b-83f713c15f96" xlink:to="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod_b086bdb1-549b-4d45-a671-cc9237f2256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b9d1c8e8-1254-450c-88d4-ed46c9686e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3c85593b-f217-4d67-984b-83f713c15f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b9d1c8e8-1254-450c-88d4-ed46c9686e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6b01962b-78d3-4a16-9442-df860aa71aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3c85593b-f217-4d67-984b-83f713c15f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6b01962b-78d3-4a16-9442-df860aa71aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f1ebd3cd-aec0-47b0-83ae-24a5df8ab20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e5f87a-ba17-489e-8d50-175697d19b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f1ebd3cd-aec0-47b0-83ae-24a5df8ab20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a751edf4-b033-4d8c-95ce-5aa02f33bb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e5f87a-ba17-489e-8d50-175697d19b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a751edf4-b033-4d8c-95ce-5aa02f33bb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_fee2fcbf-f98b-468e-ba16-90f3dd3ac465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e5f87a-ba17-489e-8d50-175697d19b59" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_fee2fcbf-f98b-468e-ba16-90f3dd3ac465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0e4f0e37-23e4-4af5-8373-67ae46aa2154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e5f87a-ba17-489e-8d50-175697d19b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0e4f0e37-23e4-4af5-8373-67ae46aa2154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ac99b7ba-7915-492b-ab0b-78656abc8698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0e4f0e37-23e4-4af5-8373-67ae46aa2154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ac99b7ba-7915-492b-ab0b-78656abc8698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_06f49d92-013d-49a4-bb0f-a91d5326ec2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0e4f0e37-23e4-4af5-8373-67ae46aa2154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_06f49d92-013d-49a4-bb0f-a91d5326ec2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5a3d019e-c6d9-43c0-a263-072f8829d23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0e4f0e37-23e4-4af5-8373-67ae46aa2154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5a3d019e-c6d9-43c0-a263-072f8829d23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_0cc91246-cf48-42c8-b580-3cfa686b0720" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0e4f0e37-23e4-4af5-8373-67ae46aa2154" xlink:to="loc_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice_0cc91246-cf48-42c8-b580-3cfa686b0720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a18f222a-c866-4eba-89c3-4a5da1b361cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0e4f0e37-23e4-4af5-8373-67ae46aa2154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_a18f222a-c866-4eba-89c3-4a5da1b361cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_04eeeead-eefe-4733-b881-e835d7167f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0e4f0e37-23e4-4af5-8373-67ae46aa2154" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_04eeeead-eefe-4733-b881-e835d7167f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c5f30e4a-5c74-4797-99e1-7f49b725d798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e5f87a-ba17-489e-8d50-175697d19b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c5f30e4a-5c74-4797-99e1-7f49b725d798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cb3a34f9-a5f0-49c8-866d-7add77af598d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e5f87a-ba17-489e-8d50-175697d19b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cb3a34f9-a5f0-49c8-866d-7add77af598d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_d93510e0-b769-418b-bcf5-61d36fa109d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e5f87a-ba17-489e-8d50-175697d19b59" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_d93510e0-b769-418b-bcf5-61d36fa109d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_WeightedAverageRemainingContractualTermInYearsAbstract_115b0a4b-96cc-4fcb-ac5d-426b274787f9" xlink:href="nexi-20221231.xsd#nexi_WeightedAverageRemainingContractualTermInYearsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e5f87a-ba17-489e-8d50-175697d19b59" xlink:to="loc_nexi_WeightedAverageRemainingContractualTermInYearsAbstract_115b0a4b-96cc-4fcb-ac5d-426b274787f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f407af19-38d1-465c-a190-3fd97a7104da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_WeightedAverageRemainingContractualTermInYearsAbstract_115b0a4b-96cc-4fcb-ac5d-426b274787f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f407af19-38d1-465c-a190-3fd97a7104da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_82814311-e4a1-4662-acd7-0f1c10f568ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_WeightedAverageRemainingContractualTermInYearsAbstract_115b0a4b-96cc-4fcb-ac5d-426b274787f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_82814311-e4a1-4662-acd7-0f1c10f568ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dea54612-249d-4aa1-8f9b-6abf171a41ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_WeightedAverageRemainingContractualTermInYearsAbstract_115b0a4b-96cc-4fcb-ac5d-426b274787f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dea54612-249d-4aa1-8f9b-6abf171a41ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1_e3f3ee74-41c6-4ef5-afa8-746dd4deddc2" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nexi_WeightedAverageRemainingContractualTermInYearsAbstract_115b0a4b-96cc-4fcb-ac5d-426b274787f9" xlink:to="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1_e3f3ee74-41c6-4ef5-afa8-746dd4deddc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_94adf359-dcd5-493e-ad34-b1ebaf8cccd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9e5f87a-ba17-489e-8d50-175697d19b59" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_94adf359-dcd5-493e-ad34-b1ebaf8cccd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3cd44940-1345-4a1f-a135-1287a7a1890a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_94adf359-dcd5-493e-ad34-b1ebaf8cccd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3cd44940-1345-4a1f-a135-1287a7a1890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5dbe933e-7c01-46ad-8711-98dfa9476bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_94adf359-dcd5-493e-ad34-b1ebaf8cccd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5dbe933e-7c01-46ad-8711-98dfa9476bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4726c937-945a-4d52-9e88-ae13144ec9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_94adf359-dcd5-493e-ad34-b1ebaf8cccd0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4726c937-945a-4d52-9e88-ae13144ec9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue_27237ca1-0dfb-482c-9be7-721a74280225" xlink:href="nexi-20221231.xsd#nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_94adf359-dcd5-493e-ad34-b1ebaf8cccd0" xlink:to="loc_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue_27237ca1-0dfb-482c-9be7-721a74280225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail" xlink:type="simple" xlink:href="nexi-20221231.xsd#StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail"/>
  <link:presentationLink xlink:role="http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58976a80-2deb-42cc-a8cf-1a866755ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fb8e7f01-7053-4187-b777-3ee70812b949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58976a80-2deb-42cc-a8cf-1a866755ce09" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fb8e7f01-7053-4187-b777-3ee70812b949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_53f58bf2-259a-4bb9-82ea-bb22b376f857" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fb8e7f01-7053-4187-b777-3ee70812b949" xlink:to="loc_srt_RangeAxis_53f58bf2-259a-4bb9-82ea-bb22b376f857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e840582-02a3-4667-a33d-72ede81d8424" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_53f58bf2-259a-4bb9-82ea-bb22b376f857" xlink:to="loc_srt_RangeMember_3e840582-02a3-4667-a33d-72ede81d8424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7db2ef40-21f4-49ef-b2cf-90d302a754a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3e840582-02a3-4667-a33d-72ede81d8424" xlink:to="loc_srt_MinimumMember_7db2ef40-21f4-49ef-b2cf-90d302a754a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1a655a8-f69d-47aa-898b-760b34c1ca5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3e840582-02a3-4667-a33d-72ede81d8424" xlink:to="loc_srt_MaximumMember_b1a655a8-f69d-47aa-898b-760b34c1ca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_fb8e7f01-7053-4187-b777-3ee70812b949" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d1e8bb9b-7c32-4252-a33d-344d238d1d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d1e8bb9b-7c32-4252-a33d-344d238d1d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_423d6d0d-4d74-4ff4-9ee9-b7fc6a018408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_423d6d0d-4d74-4ff4-9ee9-b7fc6a018408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bcca9e0d-2762-46c0-bd8e-18ebb62c554e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_bcca9e0d-2762-46c0-bd8e-18ebb62c554e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13aa9f47-223b-4739-8770-f6e58754794a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_13aa9f47-223b-4739-8770-f6e58754794a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cae9a199-a786-45da-916e-f2faabf824e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cae9a199-a786-45da-916e-f2faabf824e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_748abde2-d912-4779-a60f-b0db515520d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e6deb92-8199-43f9-9d94-2329f3c9f585" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_748abde2-d912-4779-a60f-b0db515520d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#StockBasedCompensationSummaryofRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55ad077a-5353-43e8-812f-950264873892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4872a8b-531b-453f-8a03-25dcc3797a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55ad077a-5353-43e8-812f-950264873892" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4872a8b-531b-453f-8a03-25dcc3797a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a14fac0a-3bff-447e-9716-b8b74cb8071e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4872a8b-531b-453f-8a03-25dcc3797a5a" xlink:to="loc_us-gaap_AwardTypeAxis_a14fac0a-3bff-447e-9716-b8b74cb8071e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b029718-51f9-4d1d-973a-bc7ebb7ab633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a14fac0a-3bff-447e-9716-b8b74cb8071e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b029718-51f9-4d1d-973a-bc7ebb7ab633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8a901f7b-e9a2-4e66-8ee2-9330a962b3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b029718-51f9-4d1d-973a-bc7ebb7ab633" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8a901f7b-e9a2-4e66-8ee2-9330a962b3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a4872a8b-531b-453f-8a03-25dcc3797a5a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8fa291e3-2100-41cd-96fa-b1f4f645e387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8fa291e3-2100-41cd-96fa-b1f4f645e387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85dd64eb-70fc-457a-b5df-a1ec2151275b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85dd64eb-70fc-457a-b5df-a1ec2151275b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a1c8d6c8-196d-467d-a3cd-eb3df224c619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a1c8d6c8-196d-467d-a3cd-eb3df224c619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a2c130fc-cdfb-41af-96ea-45ee740733ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a2c130fc-cdfb-41af-96ea-45ee740733ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8cacad2d-bd8e-4222-a4f5-b83f172c1a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_88d789da-60b4-4149-8ffb-a9dd4c9885fa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8cacad2d-bd8e-4222-a4f5-b83f172c1a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3a883ffd-0020-405a-b0e6-30f3b67e2e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3a883ffd-0020-405a-b0e6-30f3b67e2e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eb55b00d-2196-44fa-8e8a-dda6dc47e494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eb55b00d-2196-44fa-8e8a-dda6dc47e494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5d062f15-8a2e-4e04-9b5b-f639fa3511e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5d062f15-8a2e-4e04-9b5b-f639fa3511e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_343c113d-98db-409b-9c08-54fe44b41ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_343c113d-98db-409b-9c08-54fe44b41ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_46c0ecf7-17ca-4462-bf00-25569e8b82e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1efc2842-dadc-4ef1-b815-e6d3f58d73f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_46c0ecf7-17ca-4462-bf00-25569e8b82e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2bebfd9c-91dc-4a61-bc65-ca9262996045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2bebfd9c-91dc-4a61-bc65-ca9262996045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32200123-e29e-4530-a13e-47ef8b97ddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0913ad7e-d36a-4da5-8554-8545752e0b17" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32200123-e29e-4530-a13e-47ef8b97ddf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1dd182c7-7ecd-4279-8f9b-1304ef522456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_75952d0b-6be9-4b06-8cd9-9377b6f60950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dd182c7-7ecd-4279-8f9b-1304ef522456" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_75952d0b-6be9-4b06-8cd9-9377b6f60950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cee915f8-0586-488b-a606-da8c0256be7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_75952d0b-6be9-4b06-8cd9-9377b6f60950" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cee915f8-0586-488b-a606-da8c0256be7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5b71b435-2f23-45e0-9f5e-1ab05adcdfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_75952d0b-6be9-4b06-8cd9-9377b6f60950" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5b71b435-2f23-45e0-9f5e-1ab05adcdfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bc42eff8-926b-472f-9816-6dda9034e7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_75952d0b-6be9-4b06-8cd9-9377b6f60950" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bc42eff8-926b-472f-9816-6dda9034e7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_69e73485-6986-4742-8d9a-9ed39119a636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dd182c7-7ecd-4279-8f9b-1304ef522456" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_69e73485-6986-4742-8d9a-9ed39119a636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5c73ecb6-bb1c-4a88-9886-f1cac43d558d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_69e73485-6986-4742-8d9a-9ed39119a636" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5c73ecb6-bb1c-4a88-9886-f1cac43d558d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_604e73ef-54d3-401e-b12b-748ddbaf946a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_69e73485-6986-4742-8d9a-9ed39119a636" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_604e73ef-54d3-401e-b12b-748ddbaf946a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_66862f46-ec6b-4eaa-b18c-3113a7fd7967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_69e73485-6986-4742-8d9a-9ed39119a636" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_66862f46-ec6b-4eaa-b18c-3113a7fd7967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_a4fe4d1f-c21c-4af0-b23e-4548a76932cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dd182c7-7ecd-4279-8f9b-1304ef522456" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_a4fe4d1f-c21c-4af0-b23e-4548a76932cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d1a7a880-c911-4acb-a5f0-1db6025c446f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dd182c7-7ecd-4279-8f9b-1304ef522456" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d1a7a880-c911-4acb-a5f0-1db6025c446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cb646199-7be3-4f2a-aefe-b0bf67183629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a38e75ac-910c-4184-95a4-583021dbbd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cb646199-7be3-4f2a-aefe-b0bf67183629" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a38e75ac-910c-4184-95a4-583021dbbd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa8edfef-0939-41f1-892b-2d2ea5beaf26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cb646199-7be3-4f2a-aefe-b0bf67183629" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa8edfef-0939-41f1-892b-2d2ea5beaf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1ba2dd65-62a4-4a06-b598-554bb8877487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cb646199-7be3-4f2a-aefe-b0bf67183629" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1ba2dd65-62a4-4a06-b598-554bb8877487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_37b3015c-e9c2-43fc-982c-a299bbefa2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cb646199-7be3-4f2a-aefe-b0bf67183629" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_37b3015c-e9c2-43fc-982c-a299bbefa2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_c264e16b-703e-4836-8341-32ee3c1cb41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cb646199-7be3-4f2a-aefe-b0bf67183629" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_c264e16b-703e-4836-8341-32ee3c1cb41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0829e7fd-c6d9-4364-af2b-8fc930a1d584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cb646199-7be3-4f2a-aefe-b0bf67183629" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0829e7fd-c6d9-4364-af2b-8fc930a1d584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b864e3b9-3216-4e5c-8ad6-9e5f14fcc5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cb646199-7be3-4f2a-aefe-b0bf67183629" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b864e3b9-3216-4e5c-8ad6-9e5f14fcc5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b1563ed0-beb5-4642-a262-2ce552193993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1563ed0-beb5-4642-a262-2ce552193993" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a696d0af-3933-4b2b-a0a9-270e6017ce14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a696d0af-3933-4b2b-a0a9-270e6017ce14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_b7cb9dcb-4a8b-470d-90f1-888d4990b5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_b7cb9dcb-4a8b-470d-90f1-888d4990b5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9dbbda5f-4a40-4191-8cae-7a7456a7121c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9dbbda5f-4a40-4191-8cae-7a7456a7121c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3bd23553-0bf4-4eb6-a72d-03f5a85397a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3bd23553-0bf4-4eb6-a72d-03f5a85397a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8f89d7f0-e09d-4b5e-b8bb-057760d6c567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8f89d7f0-e09d-4b5e-b8bb-057760d6c567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DeferredTaxAssetsOperatingLeases_25bfdb4a-12b2-422e-b30e-e7a4ac2f1808" xlink:href="nexi-20221231.xsd#nexi_DeferredTaxAssetsOperatingLeases"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:to="loc_nexi_DeferredTaxAssetsOperatingLeases_25bfdb4a-12b2-422e-b30e-e7a4ac2f1808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_62f22cab-36ec-41be-b994-b276382172dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_62f22cab-36ec-41be-b994-b276382172dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a76d50dd-51fb-426c-937a-b8d0c14f983c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a76d50dd-51fb-426c-937a-b8d0c14f983c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_224e1aa3-d8f8-4a18-abef-989959e4ade6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_224e1aa3-d8f8-4a18-abef-989959e4ade6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_27f959ed-212b-4d16-959e-01ce9ad84b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_72b9b353-b9ec-429e-b56f-affc69ff33b8" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_27f959ed-212b-4d16-959e-01ce9ad84b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_098d8a7d-e325-4719-a011-8a4c15a24a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1563ed0-beb5-4642-a262-2ce552193993" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_098d8a7d-e325-4719-a011-8a4c15a24a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_d6b9a488-1bda-422d-83ef-d98eb77f4a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_098d8a7d-e325-4719-a011-8a4c15a24a38" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_d6b9a488-1bda-422d-83ef-d98eb77f4a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b66033de-31fa-4c99-84d3-18e17acff1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_098d8a7d-e325-4719-a011-8a4c15a24a38" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b66033de-31fa-4c99-84d3-18e17acff1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_89ecb89d-983e-49fc-8ce8-5f42e77e7219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_098d8a7d-e325-4719-a011-8a4c15a24a38" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_89ecb89d-983e-49fc-8ce8-5f42e77e7219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_cb9e512f-8927-43ee-a7a1-17805d17acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1563ed0-beb5-4642-a262-2ce552193993" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_cb9e512f-8927-43ee-a7a1-17805d17acfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_43363f6c-8780-4323-9ebf-1cb18a2cb7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_dd147b91-4342-4530-a7e9-fa081e5d48ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43363f6c-8780-4323-9ebf-1cb18a2cb7c3" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_dd147b91-4342-4530-a7e9-fa081e5d48ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3caf0db8-97d7-44cc-98c2-ac52293d9897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_dd147b91-4342-4530-a7e9-fa081e5d48ac" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3caf0db8-97d7-44cc-98c2-ac52293d9897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_aab31f7a-8dd8-4200-a35d-f8b49399436c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3caf0db8-97d7-44cc-98c2-ac52293d9897" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_aab31f7a-8dd8-4200-a35d-f8b49399436c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_490ff7cc-24ba-4b0e-ad5f-c1a70821fe79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aab31f7a-8dd8-4200-a35d-f8b49399436c" xlink:to="loc_us-gaap_DomesticCountryMember_490ff7cc-24ba-4b0e-ad5f-c1a70821fe79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_dd147b91-4342-4530-a7e9-fa081e5d48ac" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_20c5d160-e822-4aa2-a4db-a4ee59a1ca04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_20c5d160-e822-4aa2-a4db-a4ee59a1ca04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_bad90bc9-0388-4cc9-88fb-2b313be21ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_bad90bc9-0388-4cc9-88fb-2b313be21ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_56c714e1-0002-43ff-97a4-78070335b84f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_56c714e1-0002-43ff-97a4-78070335b84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_27ee94f5-d7e4-4f52-b43e-c646a3680f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_27ee94f5-d7e4-4f52-b43e-c646a3680f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_972106b7-9953-4f9b-a0c9-60f8f771e4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_972106b7-9953-4f9b-a0c9-60f8f771e4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_DeferredTaxAssetValuationAllowancePercent_fe069082-7a9d-4b32-a385-4d966f267a24" xlink:href="nexi-20221231.xsd#nexi_DeferredTaxAssetValuationAllowancePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5e559aa9-e6ff-4465-9562-a873d9b7786e" xlink:to="loc_nexi_DeferredTaxAssetValuationAllowancePercent_fe069082-7a9d-4b32-a385-4d966f267a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/LeasesComponentsofLeaseCostDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#LeasesComponentsofLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/LeasesComponentsofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1e0c3ad8-070c-4af3-ace9-215bc2904654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ab17fdff-1de8-46c7-9def-9498dc93282d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1e0c3ad8-070c-4af3-ace9-215bc2904654" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ab17fdff-1de8-46c7-9def-9498dc93282d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3b207f76-1818-4362-87b0-f4cc666db5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ab17fdff-1de8-46c7-9def-9498dc93282d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3b207f76-1818-4362-87b0-f4cc666db5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_91756aa6-229e-4c65-9e39-a4d647b133c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3b207f76-1818-4362-87b0-f4cc666db5d4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_91756aa6-229e-4c65-9e39-a4d647b133c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_868f6866-f8d4-4e8d-855d-e14fedcfdcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_91756aa6-229e-4c65-9e39-a4d647b133c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_868f6866-f8d4-4e8d-855d-e14fedcfdcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9bfb3fbd-758f-4a4c-92be-c8436322b0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_91756aa6-229e-4c65-9e39-a4d647b133c4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9bfb3fbd-758f-4a4c-92be-c8436322b0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_196a60eb-b199-4704-971b-1b93baf1a034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ab17fdff-1de8-46c7-9def-9498dc93282d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_196a60eb-b199-4704-971b-1b93baf1a034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cab5dba9-6088-43ef-b50a-e9b0b1168323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_196a60eb-b199-4704-971b-1b93baf1a034" xlink:to="loc_us-gaap_OperatingLeaseCost_cab5dba9-6088-43ef-b50a-e9b0b1168323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/LeasesScheduleofCashFlowSupplementalDisclosuresDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#LeasesScheduleofCashFlowSupplementalDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/LeasesScheduleofCashFlowSupplementalDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e2aa7af-13ec-4f96-b03c-30125d82e129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0c73462d-0606-462c-abe9-60808c7e08ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e2aa7af-13ec-4f96-b03c-30125d82e129" xlink:to="loc_us-gaap_OperatingLeasePayments_0c73462d-0606-462c-abe9-60808c7e08ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e0f79e92-31dd-457b-af3f-ea19e88dfb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e2aa7af-13ec-4f96-b03c-30125d82e129" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e0f79e92-31dd-457b-af3f-ea19e88dfb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_80e21527-b48a-4c82-95c2-8400bf1433a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e2aa7af-13ec-4f96-b03c-30125d82e129" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_80e21527-b48a-4c82-95c2-8400bf1433a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#LeasesFutureFixedLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d9f31af-31bc-41bf-bec3-891a50aa3512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c79b9110-749d-47ed-8e1a-6c46d56e5d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d9f31af-31bc-41bf-bec3-891a50aa3512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c79b9110-749d-47ed-8e1a-6c46d56e5d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_256c9a62-6161-426c-8c6b-48cf08792a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d9f31af-31bc-41bf-bec3-891a50aa3512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_256c9a62-6161-426c-8c6b-48cf08792a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1a2ffa70-9c86-4174-b701-b20b6876eefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d9f31af-31bc-41bf-bec3-891a50aa3512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1a2ffa70-9c86-4174-b701-b20b6876eefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7fc417c2-e404-4f27-a099-80daa1b0794f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d9f31af-31bc-41bf-bec3-891a50aa3512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7fc417c2-e404-4f27-a099-80daa1b0794f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_80b20a82-480a-4c0f-8472-c862b509eeba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d9f31af-31bc-41bf-bec3-891a50aa3512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_80b20a82-480a-4c0f-8472-c862b509eeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ee28ba0c-ff62-4c09-81ed-7e0d47e1006e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d9f31af-31bc-41bf-bec3-891a50aa3512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ee28ba0c-ff62-4c09-81ed-7e0d47e1006e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9548526b-f654-40b1-9e05-cae6436c933a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d9f31af-31bc-41bf-bec3-891a50aa3512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9548526b-f654-40b1-9e05-cae6436c933a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_38a5bf02-b4a9-4e62-a645-b425f3f6941c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d9f31af-31bc-41bf-bec3-891a50aa3512" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_38a5bf02-b4a9-4e62-a645-b425f3f6941c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e1045d69-e2d0-41b3-a877-dd7a14c15391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d9f31af-31bc-41bf-bec3-891a50aa3512" xlink:to="loc_us-gaap_OperatingLeaseLiability_e1045d69-e2d0-41b3-a877-dd7a14c15391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_98240a11-4290-4237-8ccb-f330073beda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0d9f31af-31bc-41bf-bec3-891a50aa3512" xlink:to="loc_us-gaap_LeaseAndRentalExpense_98240a11-4290-4237-8ccb-f330073beda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://nex.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="nexi-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://nex.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_565ac3ce-9905-4f30-af46-30904b1cfc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_565ac3ce-9905-4f30-af46-30904b1cfc2a" xlink:to="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b73c615c-2426-4791-9013-0b235cd3f015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b73c615c-2426-4791-9013-0b235cd3f015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_abe25de6-97e2-4983-932d-6a7799e5e392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b73c615c-2426-4791-9013-0b235cd3f015" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_abe25de6-97e2-4983-932d-6a7799e5e392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_13c92121-49c4-4a13-bf75-52018a4070c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_abe25de6-97e2-4983-932d-6a7799e5e392" xlink:to="loc_us-gaap_SubsequentEventMember_13c92121-49c4-4a13-bf75-52018a4070c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7f46a0c0-ddd6-4c58-9648-3a540b8b5c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:to="loc_us-gaap_VestingAxis_7f46a0c0-ddd6-4c58-9648-3a540b8b5c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e13130b6-ed91-4a56-bb76-3563642f5c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_7f46a0c0-ddd6-4c58-9648-3a540b8b5c0e" xlink:to="loc_us-gaap_VestingDomain_e13130b6-ed91-4a56-bb76-3563642f5c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_482e847a-1f74-497d-a39d-329c0f5749b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e13130b6-ed91-4a56-bb76-3563642f5c36" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_482e847a-1f74-497d-a39d-329c0f5749b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_689add63-cf1d-49dc-9247-50fcdaa22bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e13130b6-ed91-4a56-bb76-3563642f5c36" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_689add63-cf1d-49dc-9247-50fcdaa22bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8c27546b-0041-4e16-987a-dffcafd11641" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:to="loc_srt_TitleOfIndividualAxis_8c27546b-0041-4e16-987a-dffcafd11641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53183332-dbfc-4a53-b58c-acea5e90540d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_8c27546b-0041-4e16-987a-dffcafd11641" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53183332-dbfc-4a53-b58c-acea5e90540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_29c6db41-5298-4768-95dc-4e94954bcf80" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53183332-dbfc-4a53-b58c-acea5e90540d" xlink:to="loc_srt_ExecutiveOfficerMember_29c6db41-5298-4768-95dc-4e94954bcf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_968c801a-a695-4c84-984b-a37cf899dcbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53183332-dbfc-4a53-b58c-acea5e90540d" xlink:to="loc_srt_DirectorMember_968c801a-a695-4c84-984b-a37cf899dcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_EmployeesExcludingExecutiveOfficerMember_a03e8b62-d071-49ff-b5ec-d39a87f210fa" xlink:href="nexi-20221231.xsd#nexi_EmployeesExcludingExecutiveOfficerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_53183332-dbfc-4a53-b58c-acea5e90540d" xlink:to="loc_nexi_EmployeesExcludingExecutiveOfficerMember_a03e8b62-d071-49ff-b5ec-d39a87f210fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c8b43d6-84b9-48c4-b2bc-6578d516febf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c8b43d6-84b9-48c4-b2bc-6578d516febf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9dde9121-2310-4c99-bce9-933876daf89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c8b43d6-84b9-48c4-b2bc-6578d516febf" xlink:to="loc_us-gaap_RelatedPartyDomain_9dde9121-2310-4c99-bce9-933876daf89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_2d6bb2c3-0b2b-4ace-9acd-7a182bb11930" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9dde9121-2310-4c99-bce9-933876daf89f" xlink:to="loc_srt_AffiliatedEntityMember_2d6bb2c3-0b2b-4ace-9acd-7a182bb11930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3862c97d-55fc-4f15-b714-9afc3ce11115" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:to="loc_srt_CounterpartyNameAxis_3862c97d-55fc-4f15-b714-9afc3ce11115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1e59ab99-3634-4748-9306-47c300d6a548" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3862c97d-55fc-4f15-b714-9afc3ce11115" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1e59ab99-3634-4748-9306-47c300d6a548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_JeromeZeldisMember_c2c2e49f-3e5f-4ce0-accf-e2d2d3945ca9" xlink:href="nexi-20221231.xsd#nexi_JeromeZeldisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1e59ab99-3634-4748-9306-47c300d6a548" xlink:to="loc_nexi_JeromeZeldisMember_c2c2e49f-3e5f-4ce0-accf-e2d2d3945ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0d42c622-44ac-4f4f-8c25-878203b76096" xlink:to="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold_159ed597-5859-4f61-83cf-862a632a7b5d" xlink:href="nexi-20221231.xsd#nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:to="loc_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold_159ed597-5859-4f61-83cf-862a632a7b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple_6fb07ef4-446d-4c13-b449-afb6f9f94893" xlink:href="nexi-20221231.xsd#nexi_ShareBasedPaymentArrangementOptionRepricingMultiple"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:to="loc_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple_6fb07ef4-446d-4c13-b449-afb6f9f94893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nexi_RelatedPartyTransactionHourlyRate_29a9f128-353c-4bad-a7a6-5d6b12d64105" xlink:href="nexi-20221231.xsd#nexi_RelatedPartyTransactionHourlyRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:to="loc_nexi_RelatedPartyTransactionHourlyRate_29a9f128-353c-4bad-a7a6-5d6b12d64105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bb73230f-e5c0-489d-9d19-ef783c6704a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_fc58e445-294a-4f4f-91be-c6e7d92c2212" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bb73230f-e5c0-489d-9d19-ef783c6704a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>nexi-20221231_g1.jpg
<TEXT>
begin 644 nexi-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %1I;2!3=&]V
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,U-0  DI(
M @    ,U-0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( H\$Q@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M@ HHHH **** "BL#6_''AWPYJD&G:UJ2VMU<('CC,3ME2Q4'*J0.0>I[5OT
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MCI*]#^-G_)+[S_KM#_Z&* +NG^,Y=<^$EWXEM%6WO(K"XD*@;ECFC5N@/49
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M+8202$&0M$BNJ$XWHT?RMCGUSC'%=G\4?B%=^%(+"QT&..;4=1R8Y&&Y47(
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M UKQM\5H+ ^(7LSIFD$@JGV>-@JDX&X,"X!R.3@'-5_V@O\ D<--_P"O ?\
MHQZ[;QS\1/"^H_#2_P#L.J07$U] 8HK93^]#'^\G5<=<GCCB@#8\&>.9_%O@
M&YU:"U4ZG:)(DEN@)5Y53<N!UPV1Q]17!?VK\;-1C:ZMK-[6+&[R_L]NA ]
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M*^I+]6?3KE$!9FB8 #N<&OGSX':WIFBZ_J;ZO?V]DDEJ C7$@0,0V2 3W]J
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MROV@O^1PTW_KP'_HQZ[CX\*3\.D(&0M]&3[?*] '.?!W_A._^)/_ -"C^_\
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MXNT^Y<73[V3W   !]\9J7QE\.](\<36DNK3WD+6JLJ?9I%7(;&<[E/I75T4
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M:74+:2XD:5UMYEVEF.3@,IQR:Z7PKX*T3P=;R1Z+;%7FQYLTK;I'QT!/I[#
MK?HH \(_:"N+*;6](LX(]^HQPLTC*<_(Q^1<>N0Q_'WKUGP3H(\->#--TO:!
M+%"&FP.LC?,WZDCZ 5?N=!TB\U!;Z[TJQGO$QMN);9&D7'3#$9XJ_0!Q\?PS
MT6+QT?%8FO3?&4R^49%\K<5QTVY[^M6_&?@32_'-O:Q:M-=0BU9FC:V=5)W
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MY581L.A 55&1[YKO** "N>\5^!]#\901IK5NQEBR(IXFV2(#VSW'L0170T4
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M48/KZ5H4 %%%% !116!/KUS%\0;70ECB-M-8-<LY!WA@^, YQC'M0!OT444
M%%9V@:W;>(]#M]5L4E2"XW;%F ##:Q4Y )'53WK1H ***SK+6[:_US4]*A24
M3Z9Y7G,P&UO,7<NTYR>!SD"@#1HHHH **** "BBLS4=>M=+U73-/N$E:74I'
MCA**"JE1D[LGCKVS0!IT4V0LL;&-=[ $JN<9/IFN)O?&WB/3]0L;*Z\((D]^
M[);J-50[BHR>0G'XT =Q16?HUWJ5Y9O)K&F+IDXD*K"MR)MRX'S;@!CDD8]J
MT* "BBB@ HK@G\=:DOPVU/Q"(+7[5:71A1-K>65\U4Y&[.<,>_6N]H ****
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M89QVR* +]%4](NY+_1+&\F"K)<6\<KA!P"R@G'MS5R@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH YKXB_\ )/-8_P"N'_LPJ_:2
MV\'@Z"6^*BV2P5IMW38(QG]*L:UI,&NZ-<Z9=M(D-RFQVB(# 9SQD$=O2N>'
MPYL)8HX-1U?6M1M(\8M;J\S$<= 0JB@#B;>YU*U^%7A?3HTF==3OC&\<,HB=
MXB[$1ASTW>OI70:/HFJ:?XNTZYTCPS-HEC\Z7ZF^CE252ORG:')W ]Z[+5O#
MVG:SHZZ;=P[;>,J8?*.QH2OW2A'0BJVF^%UT^_CNYM8U;4'B!$:7ESN1<C&=
MH !..YS0!Q'_ #+/Q&_Z_9_Y5=N,Z+<>"_$0.(9+6'3;LY_@= 4)]@V373_\
M(?I_V'6K3S;GR]:E>6X.]<J6&#LXX'US5B_\-6.I>%AH%R9?L@A2(.K#S $Q
MM(.,9X':@#A-0U&[-EXR\7V3L'CVZ;82*?NQJZJ[+]6.0?:H$\/:M%:6%WX>
M\*W5EJ<;QR'47U*)C,/XMXW_ #!AVKT2P\-Z;8>&5T%8C-8B,QLLV"9 2222
M,<DDG(Q6=:^![>T,,:ZSK4EI RE+1[S]V #D+P Q'L30!@:AH=KXA^+UW9ZD
M9'M$TR.5X%<JLI#X ;'.!G./7%>@6MM%96<-K;+LA@C6.-2Q.%48 R>3P.]4
M8]!M8O$\VNJ\OVJ:V%LR%ALVALY QG/XUIT >(:1I5CX,\40R_$GP]-/J5QJ
MA-GXLCG:6.9W<F)9 &#18!"[2"G'I6MI3'_A9_QBY/%GI^.>G^AO711?"ZR:
M\LY=6\0^(=:M[*=;B"SU&^$D0D4Y5CA SD'D;F-:UOX+TVVUWQ)JR2W)N/$D
M<,=XK.NU!%&8UV#&1\K'.2>: /$$\"Z?'^SE;>,UNK[_ (2.ST^.ZM+_ .U.
M&M@C +'&H.U4VC&,=\]:Z+Q7X1LO!:>$?%6DW-\^O3:U:07NH3W3N][',2)$
MD!.W![   =J]&_X0'2_^%:_\(1Y]W_9GV3[)YN]?.V>N=NW/_ ?PJWXA\(V'
MB73=.LK^6X2+3KR"\B,+*"SQ'*AL@\'OC'U% '*V1_XR8U09Z^&83C_MX-9@
M8-XB^,Q4@C[);CC_ +!]==XH^'FF>)];M=9^WZII&JVT1@%[I5SY,CQ$Y\MB
M005R2>F<U'H?PQT+P]9Z_;:=)?>5K\82[\Z?S&SY90NK,"=S;BQ+$_,>PXH
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M$_J:XGPWX6T3_A97B5?[.BQITEE+:#G]TQC+$CG^\ :]%1%C14C4*JC"JHP
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MTLY$\;DY+!_4DU/I/AU=+O&NI-4U/4)C&8P;VXWJBD@G"@  \#G&: /-9/\
MDA.O_P#81;_THCKV*N;/@;3&\)W?A\S77V2[F,TC[U\P,7#\';C&5';I724
M>:>&_">F>);OQ+)K7G7*1:U=116_G,J1?,"7 !'S'.,GT%9T.L:C_P *S@L5
MOYD$FMC2_MH8[U@)/S;NOMGTK6T+P1_:%WXAN;R?5M)FFUBY :UF,/VB D%<
M@@AER6P1ZGFNL/A'1CX7'A\V@_L]5P$R=P.<[MW7=GG- ''^*/#>G>"X-,U?
MPVLEG>+?10OB9V%RK$@JP)YSU_.I?["M/$'Q5\06VJ--):1P6SM;+*425MF
M6Q@G&3CZUO6/@.PM=0M;R[U#5-4>S.ZV2_NO,2%NQ P.1[UC2>%)-7^)FMW=
MPVHV""&#[-?6CF(D[,,H;&#[CGI0!1L4_LW2/B%H5M*\FGZ?;,;568MY>^!R
MR GL" *MZ^P_X4#"2PYTRT'7J?W==5H_A;3-%TJXL($DGCNRS7,EP^]YRPP2
MS=^*PY/A9H\VGFQGU#5I;1<^1 ]WE+<YSE%VX]1SGJ: ':U_R5SPS_UZW/\
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MK6+=R2V_P\\::1]HDN+73;L16S2-N94+K\F>^*[G4?!%C?:M+J5K?:EI5S<
M"=M.N/*$V.A88//N,5(?!6DCPE/X=A$T5I<'=+(K@RNV02Q8@Y)P.U '(>(/
M#]IX<TO1_$5C+<G5?MD!N+J29F:X#GY@P)Q@^@%>FRN8X7=4+E5)"CJWM67K
M'ARTUO28-/NI)DA@DCD4Q, Q*=,Y!XK6H \U\*^%-,\8^&!KWB%Y;O4KYY&,
M_GLIML.0%0 X &/3]*RKF_OM5^$^@27%W+]H&L1PI=*?G(5W"N#ZC Y]J[*?
MX=:8\MS]DU#5;"VNF+S6=I=;(7)Z_+@XS[&M*]\)Z9>:/8:6JR6UK83QS0I
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MBYNMUC#-=*[&WR"8C(I.!U&?PZ5TVI>$+2_U9M3M[V_TV]D0)+-8S!#*!TW
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MKEKIL<,<-J+M(4BWKN+D,PW$]CV Y[5WVL:);:W]@^UO*OV&\CO(O+(&73.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[45X3_PN_P 2?\^6E?\ ?J3_ ..4?\+O\2?\^6E?]^I/_CE 'NU%>$_\+O\
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MEI7_ 'ZD_P#CE'_"[_$G_/EI7_?J3_XY0![M17A/_"[_ !)_SY:5_P!^I/\
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M;?%7P7=L%A\16RDG'[U'B_5E%1[2%[71U+!8IQYE3E;T9V-%9-SXCTZTTO\
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M_"U?!G_09_\ )6;_ .(H Z^BN0_X6KX,_P"@S_Y*S?\ Q%'_  M7P9_T&?\
MR5F_^(H Z^BN0_X6KX,_Z#/_ )*S?_$4?\+5\&?]!G_R5F_^(H Z^BN0_P"%
MJ^#/^@S_ .2LW_Q%'_"U?!G_ $&?_)6;_P"(H Z^BN0_X6KX,_Z#/_DK-_\
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M/_DK-_\ $4?\+5\&?]!G_P E9O\ XB@#KZ*Y#_A:O@S_ *#/_DK-_P#$4?\
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M^#/^@S_Y*S?_ !%'_"U?!G_09_\ )6;_ .(H Z^BN0_X6KX,_P"@S_Y*S?\
MQ%'_  M7P9_T&?\ R5F_^(H Z^BN0_X6KX,_Z#/_ )*S?_$4?\+5\&?]!G_R
M5F_^(H Z^BN0_P"%J^#/^@S_ .2LW_Q%'_"U?!G_ $&?_)6;_P"(H Z^BH;.
M[AO[&"[M'\R"XC66)\$;E89!P>1P>]% &+XT\767@SP[-J5Z0TGW+>#.#-)V
M4>W<GL*^4_$GB?5?%>K-J&M7)FE/"*.$B7^ZH[#_ ":Z_P"-?B:37/'DU@CY
ML]*_<1J#P7X,C?7/R_\  17G5>-BJSG+E6R/TO(LMAAJ"K27OR5_1=%_F%%%
M%<9]&%=!X3\8:AX4O6-OMN+&XPMW8S#=%<)W!'8XZ'M^E<_151DXNZ,JM*%:
M#IU%=,]'\4Z+9V\=KK?A^3SM$U/+0'^*!Q]Z)O0C_/3-<Y6_\-+DZSINL>#K
MGYTNX&O+$$\I<QC/'^\H(/TK KW:-3VD%(_*,SP3P6)E2Z;KT_K0<B/+(L<:
ML[L0JJHR23V KJ-0\*:9H-Q;67B'6Y+;4)%5KB"ULQ.MH&P0';S%R<')"@_C
MQG$T*ZALO$6FW5T<007<4DAQG"JX)_05T?Q*TR\7X@74HADFCU!T>TD1=PG!
M50 N.O/&![>HK8\TP!H=U>:A<V^@QSZQ%">)K2VD.Y3T)7&5_'OGKUJ Z1J0
MU!K Z?="\49:V,+>8!C=DKC/3GZ5W&J6EU8_!.UMXX)K>1-28:G%L*,IY*>8
M.N,>61G_ &?:NOT0R?V]X%75-W]KBPN3,)/]8(]OR;\\]CU[[J /'I?#VM07
M,%O-I%_'-<9\F)[9PTN!D[1C)P.N*@O]*U'2V1=3L+JS:0$H+B%H]V.N,@9K
MT+P/>/>R>,[N=I[K57MBR&&0+<,F6WA&P2/X!P#CY?:L#4-=$OP\CTJVT2_C
MT];SS(+V[N/-5'P<QJ1&HYY.,]R: .1HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "M?PY8_;-45G&8X?G;W/8?G_*LB
MNS\)VWEZ49CUF<G/L./YYKS,TKNAA9-;O3[_ /@'3AH<]1)G0Q+DU<B2H(5Z
M5>A6OA8H]B3/-O"WC#4[:PT?3TM&U>^U:]O4CDNKPH(Q$X/+%6. I/3^[@ Y
MK<;X@W\.BWVM_P#"/QR:5IUR+>YE2^_>G:561XT,8#*K$@;F4L!G"YP-/2?A
M]I>FWVDW4$]XSZ5+<RP!W4AC.,/NPO(';&/?-32?#33+E;RV.H:E'I=]=?:[
MG3(Y4$$CY!89V;U5B,E0P'IBO8<\+*=[?GW?GVM8X?WB5KF/-\3;B&UU?4DT
M!'T?1[];.YNS?8=LR!=R1[.<!D)!*_>P"<$UU7B77VT*73+2SL?MVH:I<BWM
MH6E\I!@99W?!PJJ,\ D]A4,_PST>\\.ZYHSSWB6VN7OVVX*.@:-]R-A/EP%R
M@X()Z\UM>(/"=IXC6R>>>YM+JPN!<6MU:LJR1./3<"I!'!!!!%2_J[DK+37O
MV5OQO>Q/-,X>Y^);:5?:C!X@T1K1-)E1-0FM[CSUB61=T+K\BEE8_*>!M)7K
MGC.N?B"NFWUS?ZWHEU93PZ(M_P"2-1=UVO,(TC,6 BN25);!(SCG%==_PJS1
M9+Z:[U6>\U:2YF\ZZ%ZT;+<N$*(7544812P4# &<X)QBC_PJ;0U@GAN+O4;J
M*73?[,"SS(?+A$GF)M(4'*G&,D\ #!K5/"+==K[_ #Z_GY>8KU&<1KGB6ZT+
MXA#6O$FEK:&UT)F$%O<^=OW3(%&XJN#N;:>,#&<FN@T'QM%K>O/I$T=D)_LH
MN4>PU!;N,C.&1F"KM89''(.3SZZ-Y\,],OKB2?6=1U/5))+0V9:ZF3A-RL"-
MB+A@R@@]2>3FKMCH,FG7;W$^L:GJ+F%856[E38B@DY"HJJ6/=B"W'6L:T\/*
MG:WO)6Z_A^.YK3YU+R%E2MSP3JAL=:^RR-B*Z^3D]'_A/]/QK*F6J@=X)TEB
M.UT8,I'8CI7GT*SH5HU(]#KE%5(.+/:J*BM+@7=E#<)PLT:N/Q&:EK]'335T
M?/O30****8!114%[=PV%C/=W<@C@MXVEE<_PJHR3^0H&DV[(P?&OCC3/!&DB
M[U(M)-*2MO;1GYYF'\@.Y_\ U5\U>+?B%K_C&=O[2NVCM-V4LX3MB4=LC^(^
MYS57QGXKN_&/B:YU2[9A&S%;>%CQ#$#\J_U/J2:P:\6OB)5'9;'Z;E.3TL'3
M4ZBO4?7MY+_,****Y#Z TM#\1:MX;OA>:)?2VDW?8?E<>C*>&'L17?VTVF?$
MJ!OL<$6F>*HXR[6\2A8-1P,DJ/X9/;O^H\NJ6TNY[&\BNK.5X9X7#QR(<,K
MY!!KHHUY4GIL>3F.5T,=!\RM+H_\^Z-[YE=DD5D="596&"I'4$4M=+XLDB\0
MZ'IOC6T14>[;[)J<:C 2Z5<[L#^^O/\ ^NN94Y%>W&2DKH_+*M*=&HZ<UJM!
M:***HR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6HM;+5KZWMP21#%<NB#/)X!Q3)-8U.5;E9=1NW%V0;@-.Q\['3?S\V/>J5%
M%RPU;4=*+G3-0NK,R8WFWF:/=CIG!&>II)]5U"Y2)+F_N9EA8O$LDS,(V)R2
M,G@D\Y%5** -*Y\1ZW>*BW>L:A.L;B1!+=.P5AT89/!'K4::UJD6H/?QZE>)
M>2##W*SL)&'H6SD]!^54:* +5]J=_JDJRZG>W%Y(J[5>XE:0@>@))XK=T/Q)
M:6?@W6] U..=X[T++;&%5.R9><MDC@[5SC/0US%% %B\OKO4;CS]0NIKJ; 7
MS)Y"[8'09-3PZ[J]ND2P:K>Q+"C1Q!+AP(U;&Y1@\ X&0.N!5"B@"P]]=O8I
M9/=3-:QL72 R$QJQ[A>@/)YI\VJ7]Q=0W5Q?7,MQ %$4KS,SQA3E=I)R,'D8
MZ54HH EN;JXO;E[B\GDN)Y#EY97+,WU)Y-/:_NWL4LGNIVM(VWI;F0F-6]0O
M0'D\^]5Z* .N\(>,VT?79+[7)[Z\46+VL.'\QH\D8 W,,*,=JP+W6]4U1$BU
M35+V[B5MP6>=I I]0&/6J%% '3>-?$=GK]W81:1%/#IVGVB6T$<X ;CJ3@GK
MP.O:N9HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#ZF\(_\ (DZ'_P!@ZW_]
M%K11X1_Y$G0_^P=;_P#HM:* -B@@$$$9!Z@T44 <9KWPL\&ZPLEQ<:/';R@%
MC)9DPD^O ^4_B*Y,?!KP4LF\MJ[#_GF9TV_^@YKUJZ_X\YO^N;?RKFZE4*4M
M7$[HYGC:4>6%5V]3,T3P9X/T!=VG:.([I?N74@$TB'^\"^0I^@JAJ?P^T+6;
MQKK5-5UZZG;^.2:(X]@-F /85T5%:QIQBK)''5KU:TN:I)M^>IR7_"J/"?\
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M*H\)_P#/UK/_ '\B_P#B*ZVBCE0<S.2_X51X3_Y^M9_[^1?_ !%'_"J/"?\
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MOS 9QD<C(]Z /&?^%(>)/^?W2O\ O[)_\;H_X4AXD_Y_=*_[^R?_ !NO=J*
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MW149A\N\$A>F[')XJ32O#;Z7+!NUS5;V"V39!;7,D>Q!C R416DP./G9O7J
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M1K+7?21I+&4E174]0PR#6/=>&;68EK=V@/H/F7\O_KU\IBLAJQ?-AW==GO\
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M\2W>D:AK$%QI%Y-::=IEEX?EN[:Z> \B>40L<R."OR2)M7:>N36RNJ^)-?\
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M:MN;J<G'H!71Z;X-BM-9M]5U/5]2UR\LXFBM'U Q8M@PPY411H"S# +,"<#
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M!O $0))Y)#$KR< <8[">^\0ZO\4+G0+37Y=,TZ+1+>\)M[:%Y?-:2125:1&
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M+3RJ8B=TFXM]XGE2,<A2 <47"QZA69XBUVV\,^'KS6;])I+>S3?(L(!<C('
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M!4GE@6&1@X4 ;KQS^([WQE/>:K?V9TJ4VMG'!<M%' JP*Y=HP=LFXN<[PPP
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MIT\TLS;FWHX*E0.,BM>U.J>*O'/]C^)+R^TW[!H-K<R6FGWKVVZZF+"1R\3
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M:KM8.F3^3>*#]U_E/]*WJRDK,T6P4445(PHHHH **** "BBB@ HHHH ****
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M6N'M]*U:QO9HXTE>.VN4D94<!D8A22 P((/0@C%%SX@T:RU:#2KS5K&WU&X
M:"SEN46:4$D JA.3D@C@=C0!GZ=X'T#2]4DU.VM9Y+^2W>U>ZNKV>XE:)BI*
M%Y'8D912/3G&,G.9XG\"1WO@?3O#N@06JV.G7-O*-.O7=H;J&)MWD._S, <
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M>3++O+^9)%OV2,&/#."0 H'"J!<OO!6@ZCJ9OKVTEE=I5G>$W<PMY)%QM=H
MWELPVKR5)^4>@K>HH P=0\%:'J6J3:C<6]Q'<W*JMR;6]GMUN0HPOFI&ZK)@
M';\X/''3BG:KX.T/6+B"XO+1XYK> VR26ES+;-Y)()B8Q,I:/('R'*^U;E%
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MC<W!*PPB[3?(0Q4A5SDX96''<$=JFL-8TS5)+B/3-1M+Q[9MDZV\ZR&)N>&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M29OD\LH-NW[3SG?UR.E7/[:US4?$%QH6D2V$<^F0Q-J&H7%J[QF61<B..$2
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MM<\/+:S1Z3%,MWIDFP^4L<HR\*MC VR!B%ZX85U]%%@"BBBF(**** "BBB@
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M)KQ'6=)O/#^LSZ9J2;)X3U'W77LRGN"*IUW\S/E+(]Z_X3OP9_T,'_DE-_\
M$T?\)WX,_P"A@_\ )*;_ .)KP6M&;P]K5M9&\N-(OXK4*&,[VSJ@!Z'<1C'(
MHYF%D>T_\)WX,_Z&#_R2F_\ B:/^$[\&?]#!_P"24W_Q->+:CH6HZ3:65SJ%
MOY,-_%YULV]6\Q, YP"2.HZXK.HYF%D>]?\ "=^#/^A@_P#)*;_XFC_A._!G
M_0P?^24W_P 37@M%',PLCWK_ (3OP9_T,'_DE-_\31_PG?@S_H8/_)*;_P")
MKQ73]$U#5+.]NK"W\V&PC\VY;>J[%YYP2">AZ9K/HYF%D>]?\)WX,_Z&#_R2
MF_\ B:/^$[\&?]#!_P"24W_Q->'WFF7^G+$=0L;FU$PW1F>%DWCU&1SU%5:.
M9A9'O7_"=^#/^A@_\DIO_B:/^$[\&?\ 0P?^24W_ ,37@M%',PLCWK_A._!G
M_0P?^24W_P 31_PG?@S_ *&#_P DIO\ XFO"(HWFE2*%&DD=@J(@R6)Z #N:
MT;#PWK&I:T=(M;"7^T%!9K>7$3* ,\[R,<4<S"R/9O\ A._!G_0P?^24W_Q-
M'_"=^#/^A@_\DIO_ (FO")8GAF>*4;71BK#.<$<&F4<S"R/>O^$[\&?]#!_Y
M)3?_ !-'_"=^#/\ H8/_ "2F_P#B:\%HHYF%D>]?\)WX,_Z&#_R2F_\ B:/^
M$[\&?]#!_P"24W_Q->"T4<S"R/>O^$[\&?\ 0P?^24W_ ,31_P )WX,_Z&#_
M ,DIO_B:\%HHYF%D>]?\)WX,_P"A@_\ )*;_ .)H_P"$[\&?]#!_Y)3?_$UX
M+11S,+(]Z_X3OP9_T,'_ ))3?_$T?\)WX,_Z&#_R2F_^)KP6G(CRR+'&K.[$
M*JJ,DD]@*.9A9'O'_"=^#/\ H8/_ "2F_P#B:/\ A._!G_0P?^24W_Q->%W5
MI<V-T]M>V\MM.F-\4R%&7(R,@\C@U&JL[JB*69C@*!DD^E',PLCWC_A._!G_
M $,'_DE-_P#$T?\ "=^#/^A@_P#)*;_XFO%[3P]JU[KJ:-#8RKJ+YQ;3#RFX
M7?SOQCY1GFJ5Q!):W4MO.NR6)RCKD'# X(XHYF%D>Z_\)WX,_P"A@_\ )*;_
M .)H_P"$[\&?]#!_Y)3?_$UX+11S,+(]Z_X3OP9_T,'_ ))3?_$T?\)WX,_Z
M&#_R2F_^)KPVSL;O4;@6^GVLUU,02(X(R[$#J<#FJ]',PLCWK_A._!G_ $,'
M_DE-_P#$T?\ "=^#/^A@_P#)*;_XFO!:TK3PYK=_:I<V.CZA<P/G;+#:NZM@
MX."!@\@BCF861[1_PG?@S_H8/_)*;_XFC_A._!G_ $,'_DE-_P#$UXI?:'JV
MF0K-J6EWMG$S;5>XMWC4GKC)'7@_E5"CF861[U_PG?@S_H8/_)*;_P")H_X3
MOP9_T,'_ ))3?_$UX+5_1]$U#7[_ .Q:3;_:+C87V;U7@=3EB!1S,+(]K_X3
MOP9_T,'_ ))3?_$T?\)WX,_Z&#_R2F_^)KQ6;1-0M]#M]8FM]MA=2&.&;>IW
M,,Y&,Y'0]16?1S,+(]Z_X3OP9_T,'_DE-_\ $T?\)WX,_P"A@_\ )*;_ .)K
MP6BCF861[U_PG?@S_H8/_)*;_P")H_X3OP9_T,'_ ))3?_$UX+11S,+(]Z_X
M3OP9_P!#!_Y)3?\ Q-'_  G?@S_H8/\ R2F_^)KP6BCF861[U_PG?@S_ *&#
M_P DIO\ XFC_ (3OP9_T,'_DE-_\37@M%',PLCWK_A._!G_0P?\ DE-_\31_
MPG?@S_H8/_)*;_XFO!:*.9A9'O7_  G?@S_H8/\ R2F_^)H_X3OP9_T,'_DE
M-_\ $UX+6SX3T%_$OBBRTM<B.5\S,/X8QRQ^N!@>Y%";8G9*Y[SX=M(];O%U
MUSYMC&2--5T*[NS3%3R">0N>@R?XN.GNK@6MG-<,"PAC9R!WP,TZ&&.W@2&!
M%CCC4(B*,!0!@ 56UC_D!W__ %[2?^@FIG)V;$ERHY/QMXDNK?2K>*RW6YNB
M2\BMR% ' /;K^E<!9ZG>:?>+<VEQ)'*ISD-U^OK7=>)K:.XT%/,&2BAE/<'%
M8.D>&H)]1MQ=2M)&Z&0H!C..V:[<)C\-3I>SJ?%Z;GE8BG5G5NG_ , ]!T?Q
M#_:EQ' UOY3O;"?(;(_AR,8_VJVJY315"^+Y%4  6C  =OG2NKKS:<W--^9Z
ME-MK4K7]X+"R:X9"X4J-H.,Y8#^M>7^/=1N+SQ 89"RP0HOEIGCD9)^N>/PK
MT;Q%_P @.7_KI%_Z,6N.\8VD,\44CI^\7"AQUQGI6]'%1PU;FGM8YL7&4X<J
M.:\*W]Q8>([1K8MB201R(#PRD\Y_G^%>KZ7K U*YNH?),9M]N3NSNW9_PKC/
M#>E6MGJ4S(I=UB!5GY(SUQ6_X6_Y"VJ_2+_V>C%8R.(K1=/;8C"PE35F]S;U
M33+;5].DL[Q28WP0RG#(PY5E/8@X(-<K837"R3V.H[?MUFP24J,"13RL@]F'
M;L01VKM:YGQ;;_99;36XQC[.P@N<?Q0N0,_\!;:WTW>M.+Z'9-?:&4445H(*
MTM'GVR-"3PW*_7_/\JS:?#(89ED7JIS2:NAHZ:BD1@Z*R\AAD4M8F@4444 %
M%%% !1110 4444 %%&11D4 %%&11D4 %%&11D4 %%&11D>M !11D>M&1ZT %
M%&1ZT9'K0!YGX/\ ^2V^+_\ KFG_ ++7?ZU+-!H-_+:9$\=M(T6/[P4D?K6?
MIOA2PTOQ1J6O6\UPUUJ( E1V4HN,?=  /;N36[D>M7)INYE3BXQ:?F<+\((;
M=OA=8X5':=YS<9YWMYC#YO\ @(7\,5C:C;S6_P <=.M=-L+-H[/2BUE:RR?9
MXDR6R5VHW/7H.WM73IX T^UCO+;3-5U/3K*\D,DUG:SHL>3UVY0LH/<*PJQ>
M>!M%N;73HK83:?+I@VV=S:2[98AW&XYR#Z'/ZFJYES-]S/DERJ/:QER>&=?O
MOB-I?B6>+3+&.TA:&=(+J29YE(;'6)!QNKAM/_Y(?XS_ .PM)_.&O6;'0&M-
M2%]<ZWJE_(H(5+B=5B&?^F<:JI_$&LR'X?:3!X5U/0$N;PVNIW!N)G,B>8K$
MJ<*=N /D'4'O0II;^02I-ZKS_$U_#'_(HZ/_ ->,'_HL5J57L+2+3M-MK*%F
M:.VB6)"Y!)"@ 9]^*L9'K63W.A*RL%%&11D4#"BC(HR* "BC(HR* "BC(HR*
M "BC(HR* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /#/CSXTD6:/PKI\
MS*NT2W^T_>SRD9_#YC]5KQ"MCQ;JDFL^,-5U"4Y,]U(P]ESA1^  %8]>!6J.
MI-L_7<MPD<)A84UO:[]7N%%:.NZ!J7AK5&T[6[;[-=JH<Q^8KX!Y'*DBMRR\
M&62^#K+Q'KVLR6%K?79M85M[/[0PQG<[_.N -IX&X^U0H2;L=,\32A",V[I[
M6UOZ6N<E17:>%O %KXI\0S6-OXFL8[993%;S;29;D[2V5@8JP  Y)P!V+5RN
MIV?]G:M>6/F>9]FG>'?MQNVL1G';I0X22NPAB*52HZ<7JDGL^IWVGW;^-?AS
M/;7#^9K/AI//AD;[TUGT92>^PX//; KF(GWJ#5_X5WOV3XC:="X#07Q:SG0]
M'212N/SP?PJA) ;'4KNR))-O,\63U.UB/Z5Z^$J.=/7H?G/$&$CAL8W#:2O_
M )ES3KO[!JEK>&,2BWF27RR<!]K X_'%=YK*3>,+W5==\':Q.TLUONO=)=FB
MG6( *5&#ME7@G / (&"3BO/[:6.&ZBDG@6XB1P7A9BH<=QD$$9]JZBQ\8:;H
M<E_<^&]#DLKR[A,,<D]]YZ6ZGKM78"3QU8GH/<'K/GSJ-/\  V@WM]X422!D
M6\TQKNYC65LW,BJAV\GC.2?EQP#6?+I.BS^!;?53X=ATZ[FU46>UYYSN3/)4
M%_O#[ISGE6X';3\$>*/[=U*SLEMU@FTW1)K6*,7)5[QL)PC  H?ESD$D<^F:
MIZBDUUX.FUGQ78W.FZC87<?V!;BZN";CE2Z!)W<XQSN&.@]#0!=N/#_A*3XF
M'P?!H31*\+ W@NI2Z2&+S%*@L5P!QR#D^PYY[1M 5+-/M7AN"ZC&H?9Y=0OM
M2^SQR $@I$N].>#SE^0>.PK_ /">?\7-_P"$N_LW_MT\_P#Z8^5]_;^/3V]Z
M</'5K<:9:V>JZ*;H65Y+=VQ2[,8&]BVUQM.X!FSD%>@]\@'6QZ';>'9/B%IU
MAN%LFGH\2LV2H9&;;GV)('MBO*=/O[C2]0AO;)D6X@;=&SQK(%/8X8$9'4<<
M'GK787WQ(^V7GB&?^RMG]M6J6^W[3GR=JE=WW?FZ].*XRT:V2Z1KZ*6: 9W)
M#*(V/'&&*L!SCL?ZT =[\2IY;KPUX.GN)&EFEL"\CL<EF(0DD^N:X[5_[$VV
MO]@_VAGR_P#2?MNS[_\ L;>W7KS6SXA\6:;KVC:=8G2;J!M,M_(MI/MRL,8
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M\F1 225.48$'/H* -RTT#1Y_"=UXD@TBWS=W?D65E>ZGY<4"@99C(6C+G(;
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MFY%LTD%N)))'+LJ_(64 81B26] ,YH YZBNCLH)8=(\2C2]4#V4,47F8M_\
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MTGF83=EGP1C@!4 P%]\FNM%;)II-'.U9V"BBBF(**** "BBB@ HHHH ****
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MM9M]G)>B59-I&5R.<$9_2KW_  JKQG_T!O\ R:A_^+H_X55XS_Z W_DU#_\
M%TR"==:TNX\7>+)GOXX+;5+:>*VN)(Y"I+2HPR%4L.%/:L_1Y;#PU=W&I1ZO
M:7MW%:N+-;>*4XF;"@D21JN K,><]*L_\*J\9_\ 0&_\FH?_ (NC_A57C/\
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MZ7X=M]4EM]6AU.:ZM9+.WC@AE3"OPSN750,+T W9)Z@#)L_\*J\9_P#0&_\
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M/HKL/^%5>,_^@-_Y-0__ !='_"JO&?\ T!O_ ":A_P#BZ ./HKL/^%5>,_\
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MY*G"\9ZBK%OK]I82^(;G5->6>VT^Y57C:U\O[%E%(B! S*6+ C&22P4<\47
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M9Q@@]#76Q)+IOQ9O[FXM;MK;4]/MHH)XK:22,.CR;E=E!"<,IRV!SUKL:*+
M>-7<%WI/@SPZ;K3+EYH_&;3+:F/;(ZF:9E*AL#)&".@/'/>MC7K:[\1WGBK5
M]-TZ_6V_X1>;381/:20R74S;WPD3J'(&0 <<EB!GFO0=1TFRU4VAOX?--G<K
M=0?.R[)5R%;@C.,G@\5<HL%SS"73-2T[Q!I.JSW.M6%H^@P61DTNQ6YDBE0E
MBCQF*1@"".0HY7!/2NQ\':9#IFA,+<Z@5N;F:Z9M11$F=I'+%BBJH0-G<%*J
M0#@@'(&]118#R+Q!+XCUJR>#4$UQKU-8A)TVWTU?L<<"7*[9/.,>7^4!CMD)
MRQ^4*&QU6D:?<Q^,/'<TMI*L5V]MY$C1$+,!:JIVG'S8.1QWXKLZ*+!<\MT>
MTO=&A^'FHW^GZAY5EI,UI=+%9RRR6[LD>T-&BEP/D89QP<9ZU3\2VE_;KXE9
M+6:.>\\2Z>U@S0Y,S*(3F-6*K)C8V06 P&R1BO7JI:MH]CKED+74X/.C6194
M(=D>-U.5='4AE8'H00:5@N>8:AI^HZ[:^*=+O(KF+Q5JEA#-'!)!%#%);0R8
MV1[9I5R6+ EW_P"6B\8%;^E6D>L:Y9:C+>^*+VXLK>8HNIZ;':1P^8@4J?W$
M9<GT4L 5Y[9ZG2_#FF:/=2W5G%,]S,@1[BZN9;B4H#D+OD9F"Y).T'&3FM2G
M8#RZRTC48_@YX1L_[/NEN[:^L))8/(821!;A2S,N,K@9))Z5M_%DLO@4%(3.
MPU"S(B! \P_:$^7GCGISQ7;53U32;+6K,6NIP^="LJ3!=[+\Z,&4Y!!X(!HL
M!Q=]!=^+_%\=UI=K?6$-KH]U;/<WMK);YFGVA4 < MMV%B1E>1@DUG>&]'>Y
MT_P[I>K7/B@7.E20.UA)I\,=M!+",?Z\0!7CR#C;(Q8$=>:]1HHL%SR;2]3,
M.G^/M,31[^[GO=7O([<V]JTL<[NBIL9U!$>,C)DVC#<$X.-:UTV[\->*/"<U
M]!=7$-MH)TR:>VMY+C;,##C=L!(!VM\Q&..37;Z=I-EI1NS80^4;RY:ZG^=F
MWRM@,W).,X' XJY18#RS4]#U:>P\8/;Z=<2D:_;7T<!CP;N*(0,P3/#?<;&.
MI&*TYI;G7OB=IM[I^FZC;6<.EW<'V^YLY(!YC&,@;7 88[;@ ><9P:] HHL%
MSR?PYH$K:#HOA[6[KQ0MQ830[[&/3XEM4>)PP<7'D!2GR[O]:6(XY;BM:07N
MG>-(CX7CUF(WFJ9U2PN;,FS,>&#W"3%=JD@*P"2')(!3.X#T*BBP7.3^)5G<
MW_@QH+&WFN9?MMHWEPH7;"W$9)P.P )/L*KM))X<^(^K:EJ%E>SV6JV=N(+F
MSLY;GRFB+AHV6-69<[PP. #SSD5VE% 'E4'A_4Q;>')KG2YD$_BN;5&MO+WF
MSBD$K)YF,A2,J3V!..M>F:C;R7>EW5O!)Y4LT+HCG^%BI /X&K-%%@/*_#6B
MR3:3X>T?6+GQ0+K2I;=WL3I\*6T4D!'/GB *T>5SQ*68'N<U6\7R^(]:TO7+
M"\CUS[2+_9;:=9Z8K6LELDB,DAF,9+$@;B%D!SQM&#7KM%%@N<3'<OX9\<>(
M[O4+#4;B#5!;S6LMG92W(/EQ"-HSY8.PY&1NP#NZ\&K&BVETOQ0\17TUG/#!
M/8V2QR2)\K,/-W*&'!(R,X)[5UU% '+_  XM+BQ^'VF6U[;RVTT8D#13(491
MYKXX/(XQ^%<+IU[)/X$\8Z%;:-?W-YJ.IZC;VK0VK/%*TDC(&:0#;'M)R=Y7
MA<C->Q53TS2;+1X9HM.A\E)YY+B0;V;=([;F;DGJ3TZ46 Y71-'NK'XG2S3V
M\CQQ>'K6U%X8SM=UD?<H<CD_=)'TK(@-WH_@[Q#X9N-%U"[U*[N+Q;<16<CP
MW@N&8HYFQY:##@-O8$;3[9]-HHL!YYIMI>>#?%,4^J6MY?P2:#:V27-E:R7&
M)H"P9"%!9=V\,&;"\')&*R=.TO5+?P5I]U/HUY#)8>*)+^>R$.Z583+("55<
M[\!P?ESD#C->LT46 \MU33M3\5ZSXQ-AIM[:Q7^@1VME+=P-"+APTO&&P5Y.
M,-@XY(P1GK++6%UW17TVUTS4[29[!E<7=E) D#;0HCW. '.2?N;A\IYZ9Z:B
MBP',?#N5E\"Z587%K=VMUI]I%;7$=U:R0X=4 .TL '''5<CWKIZ**8!1110(
M**** "BBB@ HHHH **** *UYI]K?HJW<(<H<HX)5HSZJPY4^X(I8+G7=.P+6
M^CU"$=(K\8<?251G_OI6/O5BB@5NI(GBV:,8O]"O8SW>V>.9/_0@W_CM3?\
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M0$7T^517=5+5BXRYD%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH BNO\
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M/^$86_!,C>3M\XGS=O3.SOC.*U=.\96U]?65M<:;J&G#459K&:\C14N=HW$
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MB>5<*#C<NURRYZC>JDBMRF 4444""BBB@ HHHH **** "BBB@ HHHH ****
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M6UTJ_%I-Y^1L=G\R,E-NX8#=<$@XKKZ9+-';PO-/(L44:EG=V 55 R22>@H
M\ST/PKKVAV>A:B^EFXNM+O[]I;%+M9)'AN'.&260@,P^4_.5)!.<'BMO7K?6
M=5?P_K4>ASK+IFI-,^G_ &B'SVB,;Q[L[O+W98';O/'?/ [&">*YMXY[:5)H
M95#QR1L&5U(R""."".]/HL!P[>%+G6-<\9?VG:M;V&N:?:00NSH6#*DH;A2<
M%2Z^Q[9K/M]$\8R>$]:U*6,6GBB^2W@5$G0L(80H8))RJLY,S GH77.,9'I%
M%%@/.=,\+ZC/XIU*Z_LS4-/L;K17L4;4]4-W+YA?/.9)-HP> &(XYP3BJ_\
MPC.LW?A;PDMSI%]%<^&PD$]I%?I!)=)Y'E,\,L4@P1U 9DR,@XSSZ=118+G-
M^%-'AL9[^^32+[3IKORT=M1U%KN>4)NQN)DD"@;CC#'.>0.*37=)O;SQUX6U
M"VAWVNGM=&YDWJ/+WP[5X)R<GCC-=+4=Q<P6=K)<W<T<$$2EY)96"JBCDDD\
M #UH Q_&>B3>(_!NHZ5:/&EQ<1#RC+]S>K!E#8[$J ?:L7Q#::WXV\)WFER:
M'<:-(4BF5KJ\CQ)*DBOY:F%F(7Y"-YVD94@'G':1R)+&LD3*Z. RLIR"#T(-
M.H X.S\/&ZDFN3X=U>TNX[&>**;5M::Z(:10-D:^=(N#CEFV=%P#D[:F@^&-
M;TZZ\/33Z9')]@\+/8S12SH$-QF,B)B-W!VD%@&'UZ5Z%;W5O>1M):3Q3HKM
M&S1.& 93AER.X((([$5+18#B?!^C7^E^(KEK/3[[1O#QM%1-.OKM)L3[R=T2
MK)((TVG! 8 DCY>,U5\3Z1X@O]=U9'L]2U"QGM8X],^Q:K]CAMV*L)//"R(S
M?-@YVR<< #D'T"BBP'CMCHWB$Z_I^F:3.UE?Z9X6L;2^5;R.W*,2^5W&";?@
MKPR@!><-\U7=*^VZKIVD2:-I&IMX;M;.6S6PTO5! R744NS>9O,C,D1"L P)
MY!)7)X]$U/P]HNMO&^LZ18:@T0(C:[MDE* ]0-P.*GT^:PDM!'I4ENUO;DVX
M6V92D13Y2F%X&W&,=L8I6"YY]X;\(ZWIR^"1=V7EG2KW4I;S_25D\I9?.\L[
MB<OG>O/7GD#FI%\*:T/@Y>Z&;/\ XF,MW+(D'FIRK79D!W9V_<YZ^W6O1Z*=
M@N<%KVB:E<>+$OM T>ZT[4FNH//U:&]1;:YMT/(FBW[G;:649C)!VX; K2\+
MZ?J&B^(?$-O<Z?,;74-2>_@OEDC,>&CC785W;PP*'^''O75U%=74-E9S75U(
M(H((VDDD;HJJ,DGZ 46 Y^/2;U?BK<:P8?\ 0'T6*U6;>O,HGD8KC.>C YQC
MFN<?PIK1^$D>BBS_ .)@NJ?:##YJ?ZO[>9<[LX^YSC.>W7BO0;*\@U'3[>]M
M'+V]S$LL3%2I96&0<$ C@]",U/18#SZ_TGQ#8MXQL-,T?[<FNEIK2[^TQI%&
MSP+&RR G>""F1M5@=PR5Y(=HGA;58-:TN2\MO*@B\)IIDTGF*=D^Y<I@$D\
M\CCWKNKBZM[.-9+N>*!&=8U:5PH+,<*N3W)( '<FI:+ >:V^@:]+X%\+:-+H
M\T%SHFIV#3L\\)22.)QOD0AR2,#." W/2H='N]9BU+QU:Z5HC:B+G5)4BE2X
MC012&",?O0[ [,$'*;CPW XSZA4,%G;6KS/:V\,+7$GFS-&@4R/@#<V.IP ,
MGT%%@N>;/\.=1*OI2NJVW_"(KI O=PVFX#DGY<[L=^G0XZUJ:!X>+:EIDFH^
M'=6@N+#+FYO]=>Y@CDV%"8D\Y]V<D#<B?*2>#A3W=%%@N<MXOTV_FU;P[JVF
MV4E^=*O'DFMHI$21D>%TRN]E4D%AP2*Y?Q9H/B;6H?$<$NFZG>R7L)32S#JP
MMK6",Q_<EC64;GW;NJ.K$J"P7D>HT46 Y'1-%U"R\=7>I7-OLM'T>TMED#J<
MR(SEEP#GC<.<8/:N T)KNP\*Z5XBU16U#P^FH_:;:UCOT!$DD[*CK +<$D%]
MPC,QQZ9&![;67%X7T"#53J<.AZ;'?EVD-VEI&)2[9W-OQG)R<G/.:+!<X5/!
M<]H=6TV]T35=6@O[R>:*:#7'M[5HYG+;9HQ,I7&XABL;Y'(!)VUT$.EW^D?$
M6YO[339;G3[[3[>V66.6,"W:)G^^&8-M(8<J&/!XKKJ*+ <)X=T34;'Q=%/I
MND7>@:48IC?VDUZDMO-,Q!5H(U=MG.XDXCR"/EZUW=%0_;+;[=]B^T1?:_+\
MWR-X\S9G&[;UQGC/3- $U%075[:V0B-Y<PVXFE6&(RR!=\C<*@SU8]@.34],
M045#]LMOMWV+[1%]K\OS?(WCS-F<;MO7&>,],U-0 4444 %%%% !15.36-,A
M6<RZC:1BVD6*<M.H\IVQM5N>"=PP#R<CUJY0,****!!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% #D0R2*B]6.!72HNR-5SG: ,GO6/I,&
M^X,I'$8X^M;59R>I<0HHHJ"@HHHH K7MPEO:N[D# [UYIJE^L]\[VDJN,\C/
M/XBNG\8ZM+!:FV@@,DC' 4#+-]*\_M]+\Z&._B@8.S-F/:26([DGI29Z>%IJ
M,>>1JV?VBZE2XDPR1R!B/[V!UJG>F>Y8M Y\O=@GDDGV ZTV$.\GV=KDVL<?
MS;9UP0Y7!48Z@U!I=T^G:I-;RS;W"8BV+]WODGW%9QJ4W4=)/WD=,9:EVSN[
M31XIHY5DWR#YI&7J?3VKFSJUQ::P[:3(PC?@+MY;GG/O[^E=#)?79MG,-N9K
MN;)"JNYF4=/H*P]-TRYO)Y6U-UT]\X^;JWL *SK3IP@W4V*:CO(SM6^V6=PD
MS']\QRTH(;GTSVJWIMM+-"%G(=FC,Q7H#GH/PJKJ;7-G+) \JML<  #J.N>>
M]/CDDNP2)RDBQ@+BN.K[UN7:VGH:1LXI(H:G-M9-\4<<R-RRJ!D?A4MAK=SI
MQ\RWG6%@F 0N=_U]Z8+E[2>2.]0,S9R^,[NV"*NKX9N?[.:_-O$8&&](2^&Q
M4KDC&TWH_P 12LM&5+@"[BCOM0F)NG)<$J".O -5;;6A&S-(GF(Z\[>"#27L
M<<T9_>+"=N=B-E&K.B@::',!0 #G<V/PJ6NDNA*6FAUOABRMM8:5;Z&5U0AD
MA#!2<_Q<D5G:AI$$6OSV]O-*L>-Q<8;8,<@^IK$@GDM)G+^8DNS:"&((K4L+
MR:VMXI(WSN!WY[DGG-#3C)RYKIK;L9\KOH&I:=#:6D=Q:3%QT(<<@^OTI8YE
M>V5Y6!*CO4>H';<I"DF],;@I[9I!'LC95 + 9P1UK'=:FAIZ7H2:S.UU<W26
MJJ=J[QDN1[53\B33=8DANIED>)CC;D$@\YJ73=7U#3Y)'M9_*W)PJKU-.$D]
MI+]LF*273$AY"O(S6SE*\N9WB]C.SN6[+5+BP>:>SG$*XQ]?<^]4I1=S*+^:
M)V+YW2XS6;K$LD\\<]O%F(C,BQ@X##J<>];6C^(A'$%:=4VX(5N_M25]TM67
M:VI!;V]Q<L9,$@8&6.,_G4EW:7,2D_,"C\QKZ=?QS6U!;G7@T]U?+&%)$:R#
M))SGH/3BJ#I.6GB:93- K @<?*!Z]^.:2Y7)J+NUN$:FNIS]T<2B2)N#^E5G
MN7:4B1L\]STIV[S%XZ\DU4F;S)MIQCO5*-V:F[;:1]MEB*3(LN,A>N>*:E[-
M;P&#&W))'/W>U4+2\>!@4SN7H0:TQ8SZG%Y]OAB1\V?6JM;<O0RHYF67 R.>
M36U;7,>UBSG>1UK(G@EMI1%)&RL.JD=JW=-DLUMS"\0(;.<FEL&B1FWJDSK)
M$,[AS3X9]A##)8?I6C;_ &&ZC>V4%'VD(Q;H?2LM8VC?)' ;I1>[*B[NQJ64
M\UM=PS;P4!R>>N3S5Z)93.\,:&1V;=A#]P5C3_N713T8X_\ KU%9ZI-'?LT#
ML&R 2?KS6BC=E.'5&G/J$UC?I%M:/"\ENHYZ5TVBZI*)PR-G/\JI7,.G>([4
M^;\MS#PLH/+8[&J\'AS6)+@#3;B**(@?ZQ\?E7=3M:QC)Q:L]#JKY&#>8L?[
MDG*D<@>QK$LKN[CU:=KD*Y5@(_D& OI6CITUYIFH/I^H<[<!AU5E/<>HJ75A
M#:V\;JOR\A6'>M68Q=M!7@A-ZMU#&$$C#>BCC=2:U:-.\3("2IVD^U1:)=-?
M@"!=P1BVWU-7?MJO,5D^7GD$8Q29+O%E&TB1)BC2*OEGD'C!K;M[S.J0^4<P
MQK@,#U/>H+C1TOIH)XR&)^5_P[UOV?ACR'1_,#+U/%".>K4A;4Z*%MT0;UJ2
MFHFQ OI3JH\Q[GGG_"+G_A7V_P K5/M^[=]G^UW&W/G9_P!3NVXQSC;CO6Y;
M:@FE^*M;%Y;:ABYFA:&2'3YY48"%%/S(A7J".M=(TT23)$\B+))G8A8 MCK@
M=\4^JYK[F7L^6S1P2Z7X@2PCU^1XFE6\_M-K$63_ &G:R[3%O\SDB+Y<;.J@
M=:W/&(>33K:(V274$EQB8R6DEVD8"L06@C(,@W #'0$AOX170T4<VH<B2L>=
M:1H4E_!HMMJNFN]G'?WCF%[5X8EC.XQ@QDG:AR,(Q(Z#MBGWN@VXTV);S1//
ML]/UQS'#]B,WEVS9SL0*24R1PHQP..*]"HI\[N3[)6/.]?BDMUU%H[+=:W&I
M67EVTT3JES&(5S'L5&9A\N"JHV,'(P#BG%I2-HC?V?:6L,+:H9M1L(]+FD6)
M2G[M6@(BDE0':WW<9.0I"\>BZCIEKJMNL-XCD(XD1HI6B=&&1E70AE."1P>A
M(Z&DT[2[32XY%M%DS(VZ22:9Y9'.,#<[DL<  #)X%/GT$Z5V<79^'_M<>D07
M=HT^GG5)IO(%@]K#%']G<8\IF8JA<$X; )8C;@C/2>&+,Z?'J=HEL;:UBOW^
MRQ!"J+&55OD'3;N+=..M;E%2Y-EQIJ.IYKH=K9SPV9L=)N1K*ZJSF_-L^!"+
MAC)^_P ;=IC#)LW=3]VKS^')/^$;UNXM+ Q:K<:A<9F,1,S0&YRRKRK%6C!(
M564-G@@G-=K965OI]J+>SC\N(,S!=Q/+,6/)]R34]-SU)5)6U/.[/2D&FZMM
MADCL)D@5X+#0);6/>')W>1(Q:08P'"K\RD#G!Q%/87,VF:9OTR*'2X);E6@?
M1YYX78LOER?8PX=!_K, Y"YSCD$>DT4<[#V2.#LO#OVN3P_;ZI:O>V,27C>7
M-:-%&B%T,2-&S-A0!\J.<@!> 5P()M"M$M])?5-"^T6EAJEY$4-@UPR6Q\[R
MAL"LQ3)3& 0/E/O7H=%'.Q^R1YYJ-M=R^,XKB'3/*N8M4BS,NFS/*8,@%_M>
M[8$*L<Q@< D'H2$DT2VL[#Q+:66B&&^DN@\3P6! DA+1$!9%7:1G)V@Y&#QQ
M7HE%'.+V2.!UJPAFNM934='N[S697_XE=Y%:._EKM'E>7.!MAVODG++@Y;G.
M2NI>&_MB>*;R^T\W6HI;J;*;RB3YJVR_-#Z-O4<KR2 .P%=[11SL?LT]QD3,
M\*,XVL5!88Z&GT45!J%%%% !1110!%=?\><W_7-OY5S==)=?\><W_7-OY5S=
M:0(D%%%%62%%%% !1110 5R/B[Q3<Z'K6GV(O=.TBVNXI&_M+4X7D@\Q<8AX
M= K$;FRS?PX )KKJQ/$>D:KJ]K-:Z=JEK:V]S;O;W$-W8?:5(8$;EPZ8."00
MVX'C@<Y0SG=6\2W6E:YXAE33]-%YI_AD:@)UC+,\@\T^6S\%HP4X& >3TS3?
M^$G\7)=>'4:'1G_X2*)Q&@65?L3B(2AF;<?.&T/\H6/)P-PZU:/PXACMKZVM
M=1D2"Y\/)H48EBWM&JAP)"00&.'Z #IU]-5O"VZZ\,S?;/\ D AN/*_U^8&B
M]?E^]GOZ>]+4# ?QQJ]G#>VMW%927^GZW::=++'&ZQ2Q3M&0X0L2K;7QC<PR
M,^U6?%NNW(U/6/#^R+[(?#-S>[\'S-X8IC.<8P?3.>]37_@(7QU]QJ30S:K>
M6][;R+"#]EE@5 AP3\XS&"1QP2/>FOX'O[W6K_5=5UQ9[F]TB32S'#9^7%"K
M-D,BEV/KD%B23U P :AH<WH<WB'^WO!MGI^KV]O:2^&EE$$MK)(GRK"#N E4
M,V2<-@;02,'.:V?$OCBY\.ZH1)JWA^39>0POHRN3>>7(ZJ'W>8/FPP?;Y> ,
MC)^]6BG@VYM)/#USIFIQ17>C6'V!GGM#(EQ$0@/RAU*G,8(.XXR>#6?/\.KV
M33+K28->CATNXU'^T"GV#=.S^<)2KR;\,NX=E#<+R0"":C'2^(_%-[K/BBUT
M@:3##H;+Y3W,4DC3DP+)L(5U"\D_/SP1\IQFH+OXDQW$FBP6NH:3H;:CIB:I
M+<:P^Y(T?A8E7?'O8MGG<  AX.1CH[+PS]CU'Q%=?:]_]MR*^WRL>3B$1XSG
MYNF>WI6;9>![K1X='FT35HH=0T_34TV6:XLS+%<PKR,QB12I#<@A^,D'.>#4
M1GZ?\0+W6[+2K+24L7U:^O+BT>Z!,MFJV_,DZ!6!=6&W:NX??Y;Y<E=5\:ZS
MH-KK]I?QV,^I:7%;7,$\4+I#/%+)LYC+DJRD,/O'/!]16UJ/AB^OUTN]_M=5
MUO3)GEAO&M08B) 5>,Q!@?+*G &_<-JG<2#FK-X#&IV6M?VYJ)N=0UB%(9+F
MWA\E($C),8C0LV,,2QRQ))], &H:%K6_$=[IGB_3-+M;:.XBN[*[N&3!\QGB
M"%54YP,[B.0>U<K=^);KQ+\*?$UQ<:CI-T?['E::ULXGBFL)2C@Q2J[L3R&
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MA=6TT=IH]DMK9O*A"RRS'?*Z$]0%6-<CON'T?016^+"+'\(]>1%"JMJ J@8
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MFA(-/TG6H8=%29I(K=K'=<1*S;C&LN_;MW$XS&2%.,Y :EJ!PGB'_CT\<_\
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MK5\S7MSY+)C?*W)8^V/:DETUK+4I0]TORX*$(<$8ZGT^E4[ :]9W[W-J[01
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MUPXPTL2.0>Q(!JQ3$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"/J.![9/\5>BUA23J2]K+Y>G_!/2QTXX2E]0I.]M9OO+MZ1_%W?8****Z3Q
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"*Z_X\YO^N;?RKFZZ2Z_X\YO^N;?RKFZT@1(****LD**** "BBB@ KCO$
MWAF]UKQ[X?OX'N+:WL;>Z#WEM*BO#(_E[,*V0V0&&"K+ZCI78T4#.9_X0/3&
MTF:UEN+R6ZFO!?OJ32+]I^T#[L@(4*"H 4*%VXXQR<U-8\&L?#OB*2*YN]8U
MK4-*FLXI[QHE8*8V"Q*$5$52QR3@9)Y/ QV-%*P'(Z!X'BLH-$EU*]O[DZ7
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M"I$?0>@K/VD;V.U8*JZ?.].RZOY?UY#O$&BRV]RVM:-'NGP/MEJH_P"/I!W
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MY5I.AYD8KC/U]Z=;V5Q#/*;:9H[5P4VM_$OOZ_X53C4G%\KLS.:=DD<4CO*
M7ZG]*G2(RDB+G9W%:UW'ILNDR"Q1X9H5W,I.=X[X-9-A<>2_W"P8XQZU"L]C
MK@TT3PVZ$@-NW$\Y'6K4UPT(,4> S#! '05M6NA&:$SI*I=$W!"O4GMFL>$Q
MRW)CN(B)2^"2,8I$\\7L-LB6D:5VPV>/;FMU],BN8P]K=*G/S!B2#[US8FA6
M[=)-XP2,CO6[I6S^S69Y64LQP'XJHIMD3O\ $BVWA+[3:LAN(A<G_5MGO52Q
MCNM.U1[>Z0Q,& 90>O'7Z&M>TLY69)9<';]T@U9UHI+;6DS!?-C?8S=V7']*
MZ84UU,N>5[,G?3;+5%+0J$N5&0P7[V.QJK!-';0;IL<?YQ4NGW:+(IB)+GIQ
M@9JCK]M-9:>+U3Y\6_;(%ZIGN?:M=B%\7*S1CNH]3M/)4^6>H/H:R;^RGTVV
M:>6(A,@!E&5)/OVJ#2KE+E&:T+9 VL.ZUMWDES%X=GV1B13M$F?X5SR:8VG"
M6A2TVXAD"[)1N;C&:ZVPG:%5D=@JIU+=/SKF?#XWL"RJ<^@ZBM77?#<>IP&W
MANWA1F#!%&X*0.AYZ4XJ/,E)V1RXJ3C%M*Y;N+N"XU8S6<3 ,</\O&?[PJKX
M8TI_"FIW=V9Y9HFP6^7@KD\'GEN>M6M*MA:6,4!RP@ B8DCJ._M6G</'#<V4
M=R&07,I@WLI* XSM8CIG!Q[^E0JDVG&F]'OYI'D59*M&,^J.L@-O.%NX CF6
M, 2@<LO4#/IR>/>IJ@L[2&QM5M[9=L:=!G/O4]6*[>YG:GHEIJC*9UP?NOC^
M-?0_T/:N5UVZMO#_ (RT=+7SE'SRS(@#_(590H!YY;GK_#[UW=>4^([T3?$"
M_NB<IIT("GUV(7Q_WT2*GE2=[&RK5>7DYG8Z&W\5WGBB[:/PY$R6JVPD8RXC
MD,A<J5SD@ #!XY.>#P15)'O+#7E6:1I+N-P6M[92[-_O'J00>I(]Q4_PNLO)
MTJXN".6*H#]!D_S%=T%4,2% +=2!UJ)PYVG<Z:&+5%2CRW3_ *_KKYB@Y'I1
M116IP!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R
M/Q%\<0>"/#ANL"2^N,QV<)Z,^.6/^RN03^ [U\JZGJ=[K.HRWVJ7,EU=3'+R
MR')/^ ]AP*Z_XO\ B)]?^(=ZBR;K73V^R0*#P-OWS^+;N?3'I7#5XF)K.I.W
M1'ZAD>7PPF&4VO?DKO\ 1?UU"BBBN4]X*U/#WB+4O#&K1ZAI,YBE4X=>JRKW
M5AW!K+HIIM.Z(G"-2+C-73/1O%-A876G6OBWPXICTS4)#'/;8_X\[@#+1_[I
MZC_]5<Z#D5L_#"?^TY-6\(W!#0ZQ:.;=6_@N8QNC8>G0_7BL"W8E=K@AAP0>
MH->[0J>TAS'Y1FN"^I8J5)?#NO1_U8OZ=9_VAJEK9"01FXF2+>1D+N8#/ZUT
MWB;1_#/A_5-1T=AJ_P!LM8U$5P7C:.20J&^9-H*J<]0Q/?!KE;:VDO+J*W@"
MF25PB!G" D].20!^->GZ58ZQ/I^J6/Q*M'&EV-HWE7]XH\V"3=E1%-U?)[ L
M#A1TX.YY9RM_X=N[R+0+;2_#;VES?6VY9%N_.^V\+^\P3B,=\' &?:JMUX(U
MZSL5O+BVMUMVD\I9!?0,&?)&T8?DY!X'/!]*]7T0E;KPDR@OM\.RGRUQNDXC
M^522 #[DXX[=:Y2ZA_L_P79:=HUM-=Z>-72:YOGG@E$;$@*F(I'V\8R21S_O
M8H YJ?X=>*;<LLNEXD6-I?*%S$TC*OWBJ!MS#D= >HJAI_A36-4LHKNUMD%O
M-+Y,4D]Q'")7_NIO8;C],UZ499&_:7"EV*JNT G@#[)G'TSS]:SK7PQ9_P!F
MVVI:5I$>K7LNKRQW+23.$LD1VQD(R[?E"MECCGW% &)X>\*P_P!E^+4U^P9;
M_2;7=$KNRF)\-SP<,. >X(Z=:Y;2AIIU!/[;:[6S )?[(JF0^@&X@#Z\_2O9
M=; &L?$,@ $Z7"3[_NFKR'P[H%YXFUN'3=/4&23EW/W8T'5C[#_ZU &S<>'=
M*O? 4WB/1C>6[VER(+BWNY5E# XP5957^\.H]?3GF[O3K[3Q$;^SN+83+OC,
MT3)O7U&1R*[CQI;WVGZ)'H&BZ-J,.B6#^;<7LMHZ"ZEQ@R,2,!>P_#T%<SXB
ML/$-DEB?$CW#++#NM/.N1+B/CI\QVCIQQ0!#IOAK5=5L9+VTME%I&XC:>>>.
M&/<>BAG8 GV'J/459_X0GQ"+J\@DTXPM8@&X>:5(XX\XQF1F"]QT-=+-97.O
M?!S1K?0XGO9["[E^UVUNN^1"S.58J.<8/Z^U6)-$OW^%MQX?LX<ZOI^I>??6
M4$BR2.A7 .$)W8W+QVVGTH X75]"U+0I8DU2V,/GH)(G#JZ2*>ZLI(/X&DTG
M0M1UMIQIMOYHMXS+,[R+&D:CNS,0!^)['TKMO$=U%H/@7P]HNL6=M?:I 99)
M+:>1S]G1CE0VQU8$@CC..#[50\,:EJLD>HMH7AFTN=/DA2'4;"V>5FE0M@$!
MI&D!Y897(&<D<4 .\-_#J>^U&^M]>_T40V#7,/E7D.7/RE6ZG,9!/S#C/&0>
M*S!HKVW@_4YIM%AN9()T4ZK#J2.L&=OR;$8A\YQGMN]J[S1-!T[0?'U_IVE2
M,LU[H,K&SEE#O!,S*WE9'4A1GGG'/O6#8V5UI_P9\26]_;36LZWL):*:,HPR
M8R.#S0!A3?#OQ3;EEDTH^8$:01+/$TCJH&2J!MS8W#[H/)QUJIJ7@[7=(L)+
MR_L?+@A=8Y669',3, 0'56)7((Z@=1ZBO3[YW_X:&TD;FQ]DVXSV\J0X_.N>
MT,E]#^(Y<[B<$D\Y.^7F@#C+KPMK-EK-II5S9[+V\5&@B\U#O#$A>0<#)!ZF
MM^'PK!;_  \U^YU&R(UC3[Z.W5A(3LRR KA3M/4^M=A>Z9=^(?B!X4U[2XQ-
MI:VD#/=!AL0I(VY">S98#'7.1V.(=2BBG\,^-8KB7R8I-?17D/\  IDC!/X"
M@#S]O WB%(9G-@-T$(GFA%Q&9HT(R"T6[>.#T(S6IJ'@5;7P+INKQ7,)O+B2
M03J]_!Y6U2V-AS\QP!D!B<YXKT'P[X=AT'QE?0Z=H:P:='IWEQZG),[O=,P5
MN,ML.<'(5>,=@0*XR]L[G5?@MH0TRWEO&M+N?[0L"%S%R[?,!TX(//J/6@#(
MUOPW>W7B&QT[2?#4FG7$]HDBVR7?VCS 2?WI8G"@],' &/>LR_\ "NL:;IQO
M[FV1K19/*::"XCF5'_NL48[3]:]=O)8F\4SZ?'*D&H:AX72"RD=@N7)?Y0W4
M$G!X_N^U<=I%G=>%_AUXD_X2.%[3^T52&SM9_E>212<L$/.!N4Y]OI0!AM\.
M?%*2K$^F*LLBLT<9NH=T@4 DJN_+8!'3/6N9961V1U*LIP5(P0?2O9-88_\
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MR27%PL:RV]VD80,0/NF-LGDGJ*[CQ%HLVM:+J^M>+=+;0]8L54"Y23]U?OC
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MP>?>+G[J_,:11L6</V>U1#UQEOK4]%%8F@4444 %%%% !1110 4444 %%%%
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MT4[4?U%,AU4X-2+/B"P>"PFOY"6MF$:Y52_E,"-K$#G:#U]JV]"UC1O*!%[
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M1X^Q=$3RNJ[<DC*[6QU'-:ODR-XVUZ>W:.&>#0H3!<R.L:P2&"!00Y("L02
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M^'\_]OLW_P 54G_"">#/^A?_ /)V;_XJMNBGRHF[,3_A!/!G_0O_ /D[-_\
M%4?\()X,_P"A?_\ )V;_ .*K;HHY4%V8G_"">#/^A?\ _)V;_P"*H_X03P9_
MT+__ ).S?_%5MU#)>6T-W#:RW$27%P&,,+. \@7&XJO4XR,XZ9%'*@NS*_X0
M3P9_T+__ ).S?_%4?\()X,_Z%_\ \G9O_BJU3>6RWRV;7$(NGC,JP%QO9 0"
MP7K@$@9]ZFHY4%V8G_"">#/^A?\ _)V;_P"*H_X03P9_T+__ ).S?_%5>T[6
M+'59KV*PG\U[&X-M<#8R[)  2O(&>&'(R*NT<J"[,3_A!/!G_0O_ /D[-_\
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M?_\ )V;_ .*H_P"$$\&?]"__ .3LW_Q57[?5K*ZU:]TR";?>6*QO<1[&&P2
ME.2,'.T]"<8YJU(ZQ1L[G"J"2?0"CE079C?\()X,_P"A?_\ )V;_ .*H_P"$
M$\&?]"__ .3LW_Q5/L_%>BW\FEI:7OF-J\#W%D/*<>;&@!8\CY<;AP<&MBCE
M079B?\()X,_Z%_\ \G9O_BJ/^$$\&?\ 0O\ _D[-_P#%5MT4<J"[,3_A!/!G
M_0O_ /D[-_\ %4?\()X,_P"A?_\ )V;_ .*K;HHY4%V8G_"">#/^A?\ _)V;
M_P"*H_X03P9_T+__ ).S?_%5MU2&L6)U]M%$_P#Q,%MA=F'8W^J+% V[&/O
MC&<^U'*@NRC_ ,()X,_Z%_\ \G9O_BJ/^$$\&?\ 0O\ _D[-_P#%5MT4<J"[
M,3_A!/!G_0O_ /D[-_\ %4?\()X,_P"A?_\ )V;_ .*J_J^K66A:3<:GJLWD
M6=LN^638S;1G'102>O85;5@ZAEY!&11RH+LQ?^$$\&?]"_\ ^3LW_P 51_P@
MG@S_ *%__P G9O\ XJMNBCE079B?\()X,_Z%_P#\G9O_ (JC_A!/!G_0O_\
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MK]:UJAM(?L]JD?<#)^M35BW=FBV"BBBD,**** "BBB@ HHHH **** "BBB@
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MO!%<*OWLA2S8;+!=Y4'H.!A:@5X+[Q/K$?BVY@\0&R31K^X@LHHK6)M^R-'
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M>H6^$N+=?O$[=P8#KA@01^5:VEZI!JMKYUOD8.&5NHJ!].L]0L_/MXXTG=5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 9(XW8K&I  PH P,=.*+;P7H-K]I)LY+IKJW^RRM?74MTQAZF,&5F*J2<D#
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M20A464KY;$_>&Q0V<\[A3[GQY9>'M-2?Q1J6EM)<:D]I"-/G4A5$@7+[V'*
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M4-)6&&]6"#R)\-&&"[4EW' D+-P!U!7UJYIVL6.JS7L5A/YKV-P;:X&QEV2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6;YA\HY/8<&@9KT5BQ^+=%FTC^TH;IY(//:V\M;>0S><I(:/R=OF;Q@DKMR
M"<8YK+U+Q+:WUC'J.F>(VTNVM[A[.ZCDTYFD,TB[(E9'4/&5=T;D<CKP<T@.
MNHK"M/$NF0^$Y-6N]4$]MIZO'>79@:,^9$=LA,>,@[@> /IGBDN_&N@V-X]M
M=7DB-$4$\@MI6BMR_P!T2R!2D1Y'#D$ @GK0!;UC0;;6Y].>]DF":?=K>1Q(
M0%DD4$+OR,D G( (Y /:M.J]_?VVF6,EW?2^5#'C)P6)). H R68D@!0"22
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M70& 1"Q7$S991L0LQ)QBKL/BW0YM%N]6^WK%9V3M'<M/&\30N,?*R. RMR,
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MU:^7;-=,\!@MXUY6*,+*S;??&2>32:6I2<O=.RHHHK,W"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH BNO\ CSF_ZYM_*N;KI+K_ (\YO^N;
M?RKFZT@1(****LD**** "BBB@ KD]8LKF7XI^&KN.VE>W@LKU9)EC)2-F\K:
M"W0$X./7!KK**!GF4C^(-(O-<-C;WUI:7GB,-<7=M9&>:.W-O'F2*,JV_+J%
M+;6P-W&1D9$VE:K=6/B.5;36+K[5KFFS0RWMF(YIXT,0:38B* !M/\(( ^8
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MM/!!7/H5%% !1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5W2X/-N]Q'RQ\_CVJ
ME6]ID'DV8)'S/\Q_I4R=D4MRW1116184444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45EWUY/\
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MC90OR!\A3DX(8$8SZ=0:+,%),T**S#XBTQ=22Q::03/)Y0;[/)Y6_&=ADV[
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M/_'/_KUJ44<S"R,O^Q?^GC_QS_Z]']B_]/'_ (Y_]>M2BCF861E_V+_T\?\
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MU**.9A9&7_8O_3Q_XY_]>C^Q?^GC_P <_P#KUJ44<S"R,O\ L7_IX_\ '/\
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M11S,+(R_[%_Z>/\ QS_Z]']B_P#3Q_XY_P#7K4HHYF%D9?\ 8O\ T\?^.?\
MUZ/[%_Z>/_'/_KUJ44<S"R,O^Q?^GC_QS_Z]']B_]/'_ (Y_]>M2BCF861E_
MV+_T\?\ CG_UZ/[%_P"GC_QS_P"O6I11S,+(R_[%_P"GC_QS_P"O1_8O_3Q_
MXY_]>M2BCF861EKHH# F?(SR-G7]:U ,# X%%%)ML+6"BBBD,**** "BBB@
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JHTC)_P"^U<?A6Y12N"BD%%%%(L**** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>nexi-20221231_g10.jpg
<TEXT>
begin 644 nexi-20221231_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %1I;2!3=&]V
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,X.0  DI(
M @    ,X.0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( I(%!P,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MWY3_  H_X6QXT_Z#+?\ ?E/\*XVBCDCV#VM3^9G9?\+8\:?]!EO^_*?X4?\
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MJ?S,[+_A;'C3_H,M_P!^4_PH_P"%L>-/^@RW_?E/\*XVBCDCV#VM3^9G9?\
M"V/&G_09;_ORG^%'_"V/&G_09;_ORG^%<;11R1[![6I_,SLO^%L>-/\ H,M_
MWY3_  H_X6QXT_Z#+?\ ?E/\*XVBCDCV#VM3^9G9?\+8\:?]!EO^_*?X4?\
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M.OW^AZW>36UB)+"W26(*C8),BJ<\^A-8_P#PO;Q-_P ^FG?]^V_^*KF?#?\
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M^_;?_%5S*_\ )*)?^PU'_P"B7KF:2A'L5*O45M3TS_A>WB;_ )]-._[]M_\
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M (JO,Z*/9P[![>K_ #'IG_"]O$W_ #Z:=_W[;_XJC_A>WB;_ )]-._[]M_\
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MV::2T%JT68UCW%0=N..,?-4N3O9&L8+DYF>?5?31-1?07UI+5CIT<WD-/N7
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MT34IRINS"BBBJ,PHHHH **** -+P[_R-&F?]?<?_ *$*F\7?\CMKG_81N/\
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MLYAVA1M&1S]WJ3WKE***:26QG*3EN:_A/_D<M'_Z_8O_ $(57UW_ )&+4?\
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MCVTP^J4O,\2_X4QXR_Y\K?\ \"4_QH_X4QXR_P"?*W_\"4_QKVW^V[W^^O\
MWS1_;=[_ 'U_[YH]M,/JE+S/$O\ A3'C+_GRM_\ P)3_ !H_X4QXR_Y\K?\
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M3[L^>?\ A6GC'_H W7Z?XT?\*T\8_P#0!NOT_P :^AO[?N/^><?ZT?V_<?\
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MU1"%QU^@-0_V_<?\\X_UI*M)(<L)!MN[/GG_ (5IXQ_Z -U^G^-'_"M/&/\
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MT-_;]Q_SSC_6C^W[C_GG'^M'MI=@^IT^[/GG_A6GC'_H W7Z?XT?\*T\8_\
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M"7_@/_H(JK0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@.DH;:,\'!S\N01G% '1T5F^'-83Q#X9T[5X@JB\MTE*J>%8CYE_!LC\*TJ
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M* "BBB@ HHHH *4=124HZB@"SJ/_ "$)?^ _^@BJM6M1_P"0A+_P'_T$55H
M**** "BBB@ HJMJ!OA8O_92P-=' 0W!.Q>>I Y./0$9]17+)XUN]+'B.+Q!!
M;S3Z'''+YED&C2<2#Y%PQ8JV2!U/7- '945QLOB3Q!I%U#;ZU;Z?<27]E//9
MBR1U*S1)O,3!F;=D'AACH>.E9^D>+]0^QW4$=^FO7<L5J+"54C4-<3*Q:([
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MH **** "BBB@ HHHH **** "BBB@ JWIO_'TW_7)_P"55*MZ;_Q]-_UR?^5
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M<-@CR0.!EG'%=;5=;"U34Y-06(?:Y(EA:7)R44DA<=!R2>.O&>@JQ0 4444
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MBD A1QP#6+J]C8:AXZN-2UOPWJU_8W&DP)!Y=C,Q5P\A96"_=.&7@^M>D44
M>:V=IK.E6G@RYU;3]0N/L+W'FQV\!GEMXF5A$KA!U"E0?3'M5OQ/+=7-PFK^
M'=-URWUAK<10[K%C!<KN/[JX1A\@RV<MC YKOZ* $CW>6OF !]HW =,TM%%
M!1110 4444 ;7AW[UQ]%_K11X=^]<?1?ZT4F4MAGB#_CYB_W/ZUD5K^(/^/F
M+_<_K613)>X4444 %%%% !1110 4444 %%%% !1110 5;TW_ (^F_P"N3_RJ
MI5O3?^/IO^N3_P J *@Z"B@=!10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!+;?\?47^^/YTMY_Q_3_]=&_G26W_ !]1?[X_G2WG_']/
M_P!=&_G0!#1110 4444 %%%% %IO^02G_78_RJK5IO\ D$I_UV/\JJT %%%%
M !1110 4444 %%%% $UI_P ?L/\ OC^=-G_X^9/]\_SIUI_Q^P_[X_G39_\
MCYD_WS_.@".BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M6W_'I=
M_P"X/_0A56K5M_QZ7?\ N#_T(55H **** "BBB@ HHHH **** "BBB@ HHHH
M **** +0_P"02?\ KN/_ $$U5JT/^02?^NX_]!-5: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *4=124HZB@"SJ/_ "$)
M?^ _^@BJM6M1_P"0A+_P'_T$55H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** -KP[]ZX^B_UHH\._>N/HO\ 6BDREL,\0?\
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MJ-7M)_X_Q_N-_*@"_1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEEC@A>6>18XXU+.[L%50.I)/0>]*CK)&KQLKHP!5E.00>A!H 6BBB@ HHHH
M**** "BHY;B&%HUFFCC:5]D8=PI=O[HSU/L*(;B&Y5FMIHYE5BC&-PP##@@X
M[CTH DHH) !). .I-1P7$-U;I/:S1SPR#<DL3AE8>H(X- $E%%.V-MSM;'KB
M@!M%+@[<X./6@ D$@$@=: $HHHH ***CDN(89(HYIHXWF8K&KN 9#C.%!ZG
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M96 "RJA."!DD9[5;\1>,9]!U[2],CT>XNTN[F*WGOC^Z@B,F[ 4G.]OD)P.
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M6\L81HHD4*3TSAFR1GL >] &%K'C77+2\\2G3],L)+/PZJRSO/*X>=/*$A5
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MZ7-';1ZA-!8K<M$BJSDJYE78<$G&UL=>]>O XZ5SFH>!],U"_O;K[5J5I_:
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MR[DY0'> -N>F:2#Q%K_B7Q%:6.AWEMIEO=:)#J.Z6V$SH[G&T9(!'.#GTXH
M[RBO-)/'.M77A3P_JQE72;.[C<:CJ267VE+:4,J*&4\(C$D[STQ7H=A<?:M-
MMKCS89O-B5_,@.8WR <J>ZGM[4 6**** "BBB@ HHHH **** "BBB@ HHHH
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MM]S]B>?SRWF#S-WG>=UQC&[VZ?G6^!A0!V&*** "KVD_\?X_W&_E5&KVD_\
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MYH]TJ.<D-NC9>YP5 //6N@TZPMM*TRUT^PC\JUM85AAC!)VHHP!D\G@59HH
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M/\JCP?2J;7]U_9J/Y[;C*03GMBJ_]I7G_/P_YT@N:F#Z48/I67_:5Y_S\/\
MG1_:5Y_S\/\ G3"YJ8/I1@^E9?\ :5Y_S\/^=']I7G_/P_YT!<U,'THP?2LO
M^TKS_GX?\Z/[2O/^?A_SH"YJ8/I1@^E9?]I7G_/P_P"=']I7G_/P_P"= 7-:
M('SDX_B%(X/F-QWK/MM0NWNXE:=R"X!&>M-FU"[6>0"=P Q YI!<T<'THP?2
MLO\ M*\_Y^'_ #H_M*\_Y^'_ #IA<U,'THP?2LO^TKS_ )^'_.C^TKS_ )^'
M_.@+FI@^E&#Z5E_VE>?\_#_G1_:5Y_S\/^= 7-3!]*,'TK+_ +2O/^?A_P Z
M/[2O/^?A_P Z N:F#Z48/I67_:5Y_P _#_G1_:5Y_P _#_G0%S4P?2C!]*R_
M[2O/^?A_SH_M*\_Y^'_.@+FI@^E&#Z5E_P!I7G_/P_YT?VE>?\_#_G0%S4P?
M2C!]*R_[2O/^?A_SH_M*\_Y^'_.@+FQ&#Y4O'\(_G4>#Z53M[^Z:VN6:=B50
M$'/3D57_ +2O/^?A_P Z07-3!]*,'TK+_M*\_P"?A_SH_M*\_P"?A_SIA<U,
M'THP?2LO^TKS_GX?\Z/[2O/^?A_SH"YJ8/I1@^E9?]I7G_/P_P"=']I7G_/P
M_P"= 7-3!]*,'TK+_M*\_P"?A_SH_M*\_P"?A_SH"YJ8/I1@^E9?]I7G_/P_
MYT?VE>?\_#_G0%S4P?2C!]*R_P"TKS_GX?\ .C^TKS_GX?\ .@+FI@^E&#Z5
ME_VE>?\ /P_YT?VE>?\ /P_YT!<V,'[*>/X_Z5'@^E4_MUU_9I?SGW>:!G/;
M!JO_ &E>?\_#_G2"YJ8/I1@^E9?]I7G_ #\/^=']I7G_ #\/^=,+FI@^E&#Z
M5E_VE>?\_#_G1_:5Y_S\/^= 7-3!]*,'TK+_ +2O/^?A_P Z/[2O/^?A_P Z
M N:F#Z48/I67_:5Y_P _#_G1_:5Y_P _#_G0%S4P?2C!]*R_[2O/^?A_SH_M
M*\_Y^'_.@+FI@^E&#Z5E_P!I7G_/P_YT?VE>?\_#_G0%S4P?2C!]*R_[2O/^
M?A_SH_M*\_Y^'_.@+FI@^E&#Z5E_VE>?\_#_ )T?VE>?\_#_ )T!<U,'THP?
M2LO^TKS_ )^'_.C^TKS_ )^'_.@+FI@^E&#Z5E_VE>?\_#_G1_:5Y_S\/^=
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MZ/[2O/\ GX?\Z N:F#Z48/I67_:5Y_S\/^=']I7G_/P_YT!<U,'THP?2LO\
MM*\_Y^'_ #H_M*\_Y^'_ #H"YJ8/I1@^E9?]I7G_ #\/^=']I7G_ #\/^= 7
M-3!]*,'TK+_M*\_Y^'_.C^TKS_GX?\Z N:F#Z48/I67_ &E>?\_#_G1_:5Y_
MS\/^= 7-3!]*,'TK+_M*\_Y^'_.C^TKS_GX?\Z N:F#Z48/I67_:5Y_S\/\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"6V_X^HO\
M?'\Z6\_X_I_^NC?SI+;_ (^HO]\?SI;S_C^G_P"NC?SH AHHHH **** "BBB
M@"TW_()3_KL?Y55JTW_()3_KL?Y55H **** "BBB@ HHHH **** )K3_ (_8
M?]\?SIL__'S)_OG^=.M/^/V'_?'\Z;/_ ,?,G^^?YT 1T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %JV_X]+O\ W!_Z$*JU:MO^/2[_ -P?^A"J
MM !1110 4444 %%%% !1110 4444 %%%% !1110!:'_()/\ UW'_ *":JU:'
M_()/_7<?^@FJM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %*.HI*4=10!9U'_ )"$O_ ?_0156K6H_P#(0E_X#_Z"*JT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &UX
M=^]<?1?ZT4>'?O7'T7^M%)E+89X@_P"/F+_<_K616OX@_P"/F+_<_K613)>X
M4444 %%%% !1110 4444 %%%% !1110 5;TW_CZ;_KD_\JJ5;TW_ (^F_P"N
M3_RH J#H**!T%% !1110 4444 %%%% !17-:AXCU)O$UQHN@V=C+-:6JW-Q)
M?W#1*0Q(4)M5B?NG). .*JP^.7U'2=#?2;!7U#6E=H8)Y=L<2IC>SLN3MY&,
M YS0!U]%<;<^.+O3M'\1-J.FPIJFA1B1X(IBT4Z,,JRL0&P<$<@&M;PSXFBU
MWPT=4NXULI+=I([V$MN^SO&2'&?3 S]"* -RBN4\#^,KCQ=_:1N--%@+21!$
M-Y9I$9=RL1C@X[5U= !1110 4444 %%%% $MM_Q]1?[X_G2WG_']/_UT;^=)
M;?\ 'U%_OC^=+>?\?T__ %T;^= $-%%173SQV<KV<*SW"H3'&S;0S=@3V% $
MM%<M;^*+^QUZ]TOQ);V:M;:=_:(GL&<KY88JRL&Y#=".QYJ'3O%>KM<Z)+K&
MGVD%AKP_T4P.S2P,5WHLF>#E>Z]Z .OHHHH M-_R"4_Z['^55:M-_P @E/\
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MB_V7?6T^EW$4U^]Q;-''$(4*X5R K[B1C83QUKT6DHH **** "BBB@ HHHH
MM6W_ !Z7?^X/_0A56K5M_P >EW_N#_T(55H *\]\4>%[[6?B$VHZ>'@N[#2X
MIK"Z="8?M"S.=C=CE3@]P&R*]"HH SM+U"35M 2[FLKBRGDB(DMIXRKQN!@K
MSU&>A'!&#7!:+87MA:^%)KNRGA2RTJ^^TF9&C6$G:0'8CY,@'K7IU-DC2:)X
MID62.12KHPR&!&"".XH \L\$F]M5\*MXABO(;>.T:UTIS;0QH6DC!VN4F=SE
M4XRB<]><5;L]'O(/AUX=B33IX[N'6Q<2(("'3_27S(PQD?)CD]L=JZ[3O!VC
MZ7<VTUNEU(;1=MLES>RSI;\8_=H[%4..,@# )'0UN4 <OX7,MEXC\265U;W<
M;7&I/=PR- _E21L%P1)C;GVSGVJM>3/H/Q U'4K_ $^^N[34-.AAMY;2SDN=
MAC9]\3! 2N[>IYPIP>>#78T4 <9;Z9(?%GB>=]->*.?2(((<PC!^63=&I'!Q
M\N0I(Z>U8EN-8M-)T&UN4UBQ@71O++Z;8^9<239QY,C,C;%QC&X*,DY85Z=1
M0!YQX6TS48)? YN;*ZB^RZ/=13^9$P\ECY6U6X^4G!P#Z&F:7H]Y;^!O T*Z
M=-%/:ZI#+/&("K1 NP=F&..#R3V->E44 %%%% %H?\@D_P#7<?\ H)JK5H?\
M@D_]=Q_Z":JT %%%% !1110 M>8WNAW4O@3Q3 =+E>:[UTRB/[.2TT8:/#8Q
MEEQNP>G6O3:* .$\1:'J%_X@\00Z7;O%]K\."U@E5=D;2;GPF[H#@@>P-)$[
MZYJGA./3M)OK(:.S2W+7-D]NMNGD&/RE+ !LE@,)D87.<8KO** /-(]'O(_A
MO;0IITZ78\0?:6C6 B3'VICYA&,XVXY],=JEO8Y['2_&.BW&D7UW>ZQ<3FU:
M&T>2*Y$J[8RTH&Q-IZ[R,;?I7HU% 'G.KVVH:/?PR:1%J$VLR6]I;7,#6+3V
M6HHN1EI ,1E2['<S#[OW3D$NN5FTVW\8:5=Z1?7EUK%P\EL\-F\L=S&\2HBM
M( 57:588<C'7H:]$HH XK1M&N[/QI:->V[2_9_#T5JUR8]R^8&PRA\=<=NXK
M)TC1;NU\%^!85TV:&:VU5);F,6Y5H@8Y@S.,9 )(R3ZBO2Z* /-=!TRX3X@/
MX>DC/]FZ%<RZK;O_  _OQ^[CQ_LLTQ_X"*[+Q5>):>&KY&ANIGN;:6&-+6UD
MG8LR$#(120,GJ>*N6FE6=C?WU[;1%;B_=7N'+EMY5=J]>@ [#CK5R@#C=)O[
M8_#FQ@U#3=8:****UNHH[.XBFC(4$L% 61E!P,IGKZ X7P+:2VM_K?V.UNK7
M0I)D>Q2\A:.5I"I,S8<"0@G'+\\'' %=C10 4444 %%%% !2CJ*2E'44 6=1
M_P"0A+_P'_T$55JUJ/\ R$)?^ _^@BJM !1110 4444 %%%% !1110 4444
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M)_Z[C_T$U5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I1U%)2CJ* +.H_P#(0E_X#_Z"*JU:U'_D(2_\!_\ 0156@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH VO#OW
MKCZ+_6BCP[]ZX^B_UHI,I;#/$'_'S%_N?UK)Q74WLC)(H4]O2JWGR>H_[Y%
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MY\GJ/^^10%CG\48KH//D]1_WR*//D]1_WR* L<_BC%=!Y\GJ/^^11Y\GJ/\
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M]\T!8A\/*RM<;E(X7J,>M%:%E(SE]QSC%%2-#+__ %B_2JE6[_\ UB_2JE,
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M4_[_ /2HJE_Y=3_O_P!*BH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ H'6B@=: );C_CX;\/Y5%4MQ_Q\-^'\JBH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(%V(3D<,P/(]10!M45E/XFT>/7?[':]'V[<%,8B<JK$9"EPNP-C^$G/M6K0
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MU?PG;:]\4H[K6=)%YIT>C"))95.Q9?/8[<@]=IS7;44 1P016MM%;VZ".&)
MD:+T50, ?E4E%% !1110 ^+_ %R?[PI)/]8WUI8O]<G^\*23_6-]: &T444
M%%%% !1110 5Q_BZSL?[6AO5TWQ%+J2VYB2?1 Z;T)SY<DB\ 9&>>G6NPHH
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MZ;10 4444 2_\NI_W_Z5%4O_ "ZG_?\ Z5%0 4444 %<[\0+&ZU+X=Z]9:?
M]Q=7%C)'%#&,L[$< #UKHJ* /+?&7A75UU[1]0T*SDN+>_N;)=5@C&3&T$BN
MDY'LH="?=:NW,.I:.WC+3VT&^U)]<F:2SFMX=\4@>(1A9'Z)M(SSVKT6B@#G
M3I^K:5\-?[.TTQ7&KVNF>3#Y@#(\JI@ @\$9XYZUQFCZ7JD_BX7JV?B1X/[
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MBBB@ HHHH DC_P!5+_NC^=1U)'_JI?\ ='\ZCH **** "BBB@ HHHH ****
M"BBB@ HHHH **** )?\ EU/^_P#TJ*I?^74_[_\ 2HJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *!UHH'6@"6X_X^&_#
M^515+<?\?#?A_*HJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0N_^?F3_ +Z- 7-7:W]T_E1M;^Z?RK*_M"[_ .?F3_OHT?VA=_\ /S)_WT:
MN:NUO[I_*C:W]T_E65_:%W_S\R?]]&C^T+O_ )^9/^^C0%S5VM_=/Y4;6_NG
M\JRO[0N_^?F3_OHT?VA=_P#/S)_WT: N:NUO[I_*C:W]T_E65_:%W_S\R?\
M?1H_M"[_ .?F3_OHT!<U=K?W3^5&UO[I_*LK^T+O_GYD_P"^C1_:%W_S\R?]
M]&@+FKM;^Z?RHVM_=/Y5E?VA=_\ /S)_WT:/[0N_^?F3_OHT!<U=K?W3^5&U
MO[I_*LK^T+O_ )^9/^^C1_:%W_S\R?\ ?1H"YJ[6_NG\J-K?W3^597]H7?\
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M10 4444 %%%% %IO^02G_78_RJK5IO\ D$I_UV/\JJT %%%% !1110 4444
M%%%% $UI_P ?L/\ OC^=-G_X^9/]\_SIUI_Q^P_[X_G39_\ CYD_WS_.@".B
MBB@ HI0"3@#)HH 2BJ[:A9(Q#WENI$HA(,JC$A&0G7[V"..O-6* "BBHX[B&
M666.*:.22$A945P3&2,@,.QQSS0!)114;W$,<\<,DT:2RY\N-G 9\=<#J<9&
M<=* )**** "BE"EN@)^@HH 2BBB@"U;?\>EW_N#_ -"%5:M6W_'I=_[@_P#0
MA56@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M#_D$G_KN/_0356K0_
MY!)_Z[C_ -!-5: "BBEVG;G!QZXH 2BBB@ HHHH **CBN(9S(()HY3$YCD".
M&V,.JG'0^QJ2@ HHHH **CCN(9I)8X9HY'A;;*J."8SC.& Z'!!Y]:DH ***
M* "BBB@ HHJN^HV,?F>9>VR>5(L4FZ91L=L;5//#'(P.IR* +%%([K&C/(P1
M$!9F8X"@=23VIL,T5Q"DUO(DL4@W))&P96'J"."* 'T444 %*.HI*4=10!9U
M'_D(2_\  ?\ T$55JUJ/_(0E_P" _P#H(JK0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ;7AW[UQ]%_K11X=^]<?1?ZT4F4
MMB]?_P"L7Z54JW?_ .L7Z54H **** "BBB@ HHHH **** "BBB@ HHHH *?'
M_P M/^N;?RIE/C_Y:?\ 7-OY4 <^.@HH'044R0HHHH **** "BBB@ HK"U'Q
M0;76I-*TW2;S5KN& 3W"6SQH(58D+DR,H).&X&3Q41\:V$FDZ9>6$%S>3:J2
MMI9QJ%ED*_>!W$!=O<D@4 =%17,/XYLX-%UF^O+&[MI]%&;RQ?89%&,@J02K
M C.""1Q6IH&O6GB+0H=5M0\,4FX.DV T3*2K*WH00: -.BN=\)^-+'QA]N.G
M6]Q"EG*(RTX $H(R&7!Z$>M=%0 4444 %%%% !1110!+;?\ 'U%_OC^=+>?\
M?T__ %T;^=);?\?47^^/YTMY_P ?T_\ UT;^= $-%%9_B#5#H?AO4=56$3FR
MMGG$1;:'VC.,]J -"BL?1[[6;B$W.LVVFV]L81(IM+J25AW^8-&H Q[FJ^A:
MWJVO"&_@L+.#1[CYH7EN6^TO'V?RPA49Z@;LXQG'2@#H**** +3?\@E/^NQ_
ME56K3?\ ()3_ *['^55: "BBB@ HHKG=3UW5D\6)H>BV-C,YL1>/+>7+Q #S
M"FT!4;/3- '145';F<VT9NUC2<J/,6)BR!NX!(!(]R!4E !1110!-:?\?L/^
M^/YTV?\ X^9/]\_SIUI_Q^P_[X_G39_^/F3_ 'S_ #H CHHHH \Z^)FI1ZC8
M:IH<=[';Q6.GR7EY^]"-(^PF&(<Y/(WG'HM=IHMPDGANRFBD651;*=R,&!(7
MGD>XJ#7_  OIGB#3+VWN;.T%Q=0/"+MK5'DCRN P)&<CMSVJ]IVG0:9I4&GV
MR1QPPQA (XP@/J<#@9.3^- '!:/>10^ _#VH7-E;WTNK:NL[-.N?+>65L.O^
MTJ[0/I5ZY\::W#!K&HI86']FZ/?FUF#._G2H'52R\X! ;//7%2:)X9FN/#-E
MI%\TMJVB:J7B8Q9$\:2%X\9QP5<#(S@@U?G\&1SZ#KFF?;G5=8NGN6D\H9B+
M,K;0,\_=Z\4 $NO:Q?Z[J-EX>M;&2/2Q&)S=LP::1T#[$(.%PI7YFR,GVK#.
MM2Z!K7BV\MX8YF?5[&#;(2!AXT4GCN,UOS^%[Q-8O+[1M:;3AJ"1K>)]F$I9
MD78'C8L-C;0!DAAP#BF7_@J&_CUT->R1MJUQ#<HRQC_1GB4!2.?FY7/:@!-7
M\7G1M7UN"XME>VTO3$O04)WR,S%=GIU _.L:XNM:_P"$]\+3>(8+&-?LUY*K
M6;-A<QH60AB3D8'(X.?:M4>"&O+G5Y]>U9]0DU6R6SE$=N(5C56)!0;CCKW)
MY'X4^V\(7C:UINHZSKK:@^G0RP1Q+:B)&210I+?,?FXY/0\<#N 8VC_$MM5U
M#2MBV<MMJDXB2V@27[1;!L[7D8C81TSCIGVK8\,>*+S7M2N8IDL84ADD1K0,
MRW4&TX4N&X8,!G*CBK.A^'=1T.&WL(M?DETBTRL%J;8"0)_"C2[CN Z?=!P!
M3;7PM<#Q/!K6J:HM[-:Q216^VT6)PKGI(X8E\ 8' 'M0 WQA8Z9<6\<^JZ%>
M:X8T=8K>WC,@0XSDC("DX W4OP_DDD\ :09KY+^00;6G1RX)#$;<GKMQM_"M
M#5+'5KBYCFTC64L $*R1368N$;G(8#<I!ZCJ<\4>'=#@\.:'!IMO+).(RSR3
M2XW2R,Q9V..!EB3CM0!IT444 6K;_CTN_P#<'_H0JK5JV_X]+O\ W!_Z$*JT
M %%%% !1110 45D^*-;;P[X:N]52 7#6X4B)GVALL!UP?6I=4\1Z)HDZPZQK
M%C8R.,HMS<+&6'J 30!HT5SUUXFFN=533/#%O;ZC<^0MS+-+<%+>*-L[<LH8
MDMC@ 'CDXI-0N_$J^&;ZX6.QT[4;,-(O/VF"X54W8!)1ER>"2,C!X(P: .BH
MJAH6K1:]X?L-5MQMCO+=)@N<[21DKGV.1^%7Z "BBB@ HHHH M#_ )!)_P"N
MX_\ 0356K0_Y!)_Z[C_T$U5H IZQ>MINAW]^B[VM;:28+_>*J6Q^E<WX5\*Z
M==:%I>LZ@C7&LW,,5W-J.\B8NRAB PZ+_#CIMXKKI(TFB>*50Z.I5E/0@\$5
MSNE>&=2T>."QL_$#C2+=AY-LUH#,D8Z1^=N^Z.GW,XX]Z ,Z;QEJW]E7?B&V
MLK)M#L[EHGC9G^TR(C['=3G:.>@(Z"G:IXMUJ/4=>CTFSL'MM%MH[IY+EGW3
M*T(D*@ \'KR>.E32^!I'MKC3(]8>/0KJY-Q-8BV!D.YM[()=W"%N<;2>HS5^
M;PK'+<>(9!=,@UNV6W*B/_4!8O+R.?FXYQQ0!1TWQ3JLVKZ5%J=E:0VNLVTL
M]H(79I(=BJVV0G@Y4]5 P:I6?C769-%L->O;"QCTJZN_LKI&[F9<R-&) <[<
M9'W<9K<'AA$NM#N!=,3HUM) J^7_ *[=&$R>>.F>]<UX4\(:C<^%M+@UJ_GB
MLH;J2Z;3);79('$SE07)R$Z-MVYYZX- $,'B5/#"^(7/E":[\2S6\33;O+0D
M9+/MY( !X')XJ[;^/;^;2-5NH;:TO3H\D4EQ+;+(D4]LPRYCW\AU ;@Y''O6
MG-X)6074L&I207DFK'5;:X6('R)",%2N?G4@D'D9SVJQ?>'=0UC2'L-:UQKE
M)YD-SY5L(EDA'6(#<2N[NV3QD8% R?PSKDOB*SGU%(HTTZ28K82#.Z>->#(>
MP!8''L.:PM;\>2:/X@6U>72WA^V16S6H:1KG#D+OW#Y!R0=IYQ70:#H2Z ;V
M*UN-UE/<&>"U\O:+4MRZJ<\J6Y P,9-8EWX"GG%Q:PZXT&FSZBNHM;"T!8RA
MPY!DW<J2.F,CCGC!!&9;WVMZ?X@\:W6CVUC+#;7:S2_:6;=+BVC.Q-O0X'4Y
M'(]#6H?%>K:IJT=IX=M+(Q2Z3%J:37K/P'Z(54CKQSVJ2\\%WDM[K$MCK\EI
M#K,F;J'[*KX7RU3"-N&UL*?F.>HXXYTK'PS;Z=K7VZUE98ETV/3H[?;PB(<@
M[L\\<8Q0!DVWC*]UFUT.'1+2V34-3MWN9/M98Q6Z(=K_ '<%B6X'MUJ&X\;Z
ME!I+!=.MI-5@UF/29HA(1$SOC#J>H&&4\].:M6W@A].L]*_LK5C;W^F))$EU
M);"1)(Y&+,K1[AWQ@[NU2+X)C^PPQRZA))=?VK'JMS<F(#SY4(.-N?E&  .3
M@#O0&A'<ZYXCB\06NA06^E27DEA)=RW#>8(D*N  %SN((8#KUYZ<52T[QOJ]
MS;:1J5YIUG#IVHW8L2B2,TRR?,-X/W=NY3QC..]=*^B*_BR/7//(9+)[3R=G
M!#.K;LY_V<8QWK,A\%1PZ%I6FB_<C3;_ .VB3RAF0[F;;C/'W^OM0!GZIX\D
MTOQ-%923:6\#7\=FULC2-<J'(42%A^[')#%>H!QUK,N+R&PN?%D\]C;WR_\
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MZ3$S @$*<\D$@<>M &M15#4=>TC2)H8=5U.SLI9_]4EQ.L9DYQP">>:O]>E
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M)+/]VPC-O(=ZA6QM^5F9<9R,=.]=52YI* "BBB@ HHHH M#_ )!)_P"NX_\
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M[EDD9&QMZ8RO4\DUU5]9:AJ'PKFLK(.NH3:3Y4:D[6WF/&WGH>W-=/DCH:*
M//-4EA\2_#^\T[PWIMU'?1:8L6R2S,!C7Y<P N "2%(P,K\O)Z9+*UM-2>]U
M*UU+7-1N8M(G@5;S3TMEC5DXC(6*,LV1P!N Q7H9)/4YH))ZF@#S+3=.=GTN
M/4+&[:U/A%K>X6.(AN6(9!G&'P3QUK9\#7%RU_?6@9[[3K:"&.UU&XL6MIV
M+_N7!"[]@(PP4#YCU.37:9-!)/4YH \S\46%U.WCP):3R"XM+-8PL3-YN-V0
MO'S8[XKH%LVM_B1I<EO;-';C17B=DCP@(<;5)' (YP*ZS-% ' ^,(K/_ (6!
MI-QJYU**Q73KA#-8?:5(<R1D*6@^;D!N#QQ]*R]-L+S^R=!M_L5Q_9L/B0FR
M22$AQ:')#2#&0"Q?EOF(.3R:]2!(Z'%&30!Y9IVC:H;O4-(OK:5K#PY;7?V"
M0H<7!F4^7M]2BDCOUKH]#N-/L=+\&66J6+-J<]J4M'> %K=EAS)DGE,KQQUR
M :[#-5&TVV?6$U-T+74<!@1BV0B%@S8'8D@9/L* ,#Q99&\\2^$R;8SQ0ZB\
MCGR]RQXA?#'L.<8)[XKFM1TAQX>^(+0Z<_GW&I*T)2W.^4 QD%>,L <GCWKT
M^C)H X.YNFT3QAJ\UW:7DJZIIELEI]GMVD\R1 ZLA(&%.67EB!SUXJCX5L+R
M.Y\&B6UGC\KPY-%(7C(\MSY6%;/0\'@^E>E9(Z&C)H \NMQ+-\-=%TR.UN_M
MFG:M ES$UM(I3$SG/(PRXYR"1[U%=75FC_$/3VTVXN+[4KF2W@,-H9!.S1!4
M0N =NUFSEL 9R#UKU;)]:I6&E6NFW%]-:!U>_G^T3[G)!?:%X]!@#B@#SS5M
M#UFY3Q+9P1S/=R>'[*$.!@3.IDWJK'@D^GN,]:V?#%O9W_B*#58=3UN]FM[,
MPA;VPCM4A1L?(=L,>XC' &0,5V]!)/4YH XW7;Z+2?B7IE_?)<"T&ES1&6*U
MEF <R*0#L5L< UB:P='O?'UU>ZN=82PNM'@6"2T2\C$A\R4E6$0!S@CY7]>E
M>F@D=#BC<?4_G0!Y=8R7NEV?@>[UVVN8H[1KE24M&=XH2C"'>D2G:VW;G ^O
M.:M^*M0A>\&M>'_MDFH36@@2SGTN22WU&/<P\I@5!C.YNI*CUW"O1@2.AHW'
MU- #(]WE)O4*VT94=CZ4ZBB@ HHHH **** -KP[]ZX^B_P!:*/#OWKCZ+_6B
MDREL7K__ %B_2JE6[_\ UB_2JE !1110 4444 %%%% !1110 4444 %%%% !
M3X_^6G_7-OY4RGQ_\M/^N;?RH Y\=!10.@HIDA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% $MM_P ?47^^/YTMY_Q_3_\ 71OYTEM_Q]1?
M[X_G2WG_ !_3_P#71OYT 0T444 %%%% !1110!:;_D$I_P!=C_*JM6F_Y!*?
M]=C_ "JK0 4444 %%%% !1110 4444 36G_'[#_OC^=-G_X^9/\ ?/\ .G6G
M_'[#_OC^=-G_ ./F3_?/\Z (Z*** .:\;Z'<Z_9:3;6J2%8=4BGF:.41M'&$
MD!<$GJ"PX&?H>:5_ ^G3Z?J5M>W5]=RZF8_M-W-*OG,$QL4$*% &.@7N>YKI
M** *-[H]M?ZQ8ZE.9//L?,\I5(VG>NUMPQSQ63;^!].MYH%%U?R6-M/]HM]-
MDE4V\+YR"!MW8!.0"Q KI** *.FZ1;:7<:A-;&0MJ%T;J;>P(#E%7CC@80>O
M>B+2;>+Q!-K*M*;N6W6VY;Y40-NPHQQD]>>PJ]10!AS^%+22^OKRWO+^SN+Z
M9)WDMI@NV15V[@"I!R."&!'L*2+P=I?]FWUG>^?J!U!P]U<74@,LK#&TY4*%
MVX&-H&,5NT4 9.E:"=-F6675]3U%D39&+V5"$'L$1<GW;--C\,VL-E?V]K<W
MEN;ZZ-V\T4H#QR''*G&,<="#6Q10!R&K^#V/ARYTJP>XO)-7OHWU*\NI%,C1
M[E+L<!1]Q @"CN/<UU]%% !1110!:MO^/2[_ -P?^A"JM6K;_CTN_P#<'_H0
MJK0 4444 %%%% !1110 4444 %%%% !1110 4444 6A_R"3_ -=Q_P"@FJM6
MA_R"3_UW'_H)JK0 4444 %%%% !1110 4444 ><:AX:U4ZAKS0Z3?27U_=>=
M9ZA:ZGY%O"-B*I>/S021M.?D;/%;U[X"LM26Y%YJ&H*E\T<MY;V\RI#-,H&9
M,%2P)*YQG'M74T4 8.H^#M,U1=76Y>Y U>"*"YV2 86,$+MXX/)SG-:$ND6T
MWB&#66,GVJ"W>W0!ALVN03D8ZY4=ZO44 8WB/PU'XFLS:76I:A:VS "2&T>-
M1)A@P)W(QX('0BH[OPK#>VU@)M4U+[9I[LUOJ"R1B==PPRGY-A!&!C;V'<9K
M=HH YGP;H-QH,^NI.LGE7.H>=!++*'>53$@+DCH2P;CCV &*Z:BB@ HHHH *
M*** "BBB@ I1U%)2CJ* +.H_\A"7_@/_ *"*JU:U'_D(2_\  ?\ T$55H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -KP[]
MZX^B_P!:*/#OWKCZ+_6BDREL7K__ %B_2JE6[_\ UB_2JE !1110 4444 %%
M%% !1110 4444 %%%% !3X_^6G_7-OY4RI;;_6GO\IZ_2@#G1T%%;^Y/^>$/
M_?L4;D_YX0_]^Q3%8P**W]R?\\(?^_8HW)_SPA_[]B@+&!16_N3_ )X0_P#?
ML4;D_P">$/\ W[% 6,"BM_<G_/"'_OV*-R?\\(?^_8H"Q@45O[D_YX0_]^Q1
MN3_GA#_W[% 6,"BM_<G_ #PA_P"_8HW)_P \(?\ OV* L8%%;^Y/^>$/_?L4
M;D_YX0_]^Q0%C HK?W)_SPA_[]BC<G_/"'_OV* L8%%;^Y/^>$/_ '[%&Y/^
M>$/_ '[% 6,"BM_<G_/"'_OV*-R?\\(?^_8H"QBVW_'U%_OC^=/NT8WLY"DC
MS&Z#W-;,93S%_<PCD=(Q3I)G65PC%1N/ X[T@L<_Y;_W&_*CRW_N-^5;WGR_
M\]&_.CSY?^>C?G3"Q@^6_P#<;\J/+?\ N-^5;WGR_P#/1OSH\^7_ )Z-^= 6
M,'RW_N-^5'EO_<;\JWO/E_YZ-^='GR_\]&_.@+&4R/\ V4@VMGSCV]JK>6_]
MQORKHC-)]F!WMG=C.?:H_/E_YZ-^=(+&#Y;_ -QORH\M_P"XWY5O>?+_ ,]&
M_.CSY?\ GHWYTPL8/EO_ '&_*CRW_N-^5;WGR_\ /1OSH\^7_GHWYT!8P?+?
M^XWY4>6_]QORK>\^7_GHWYT>?+_ST;\Z L8/EO\ W&_*CRW_ +C?E6]Y\O\
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MO^Z/YU'4D?\ JI?]T?SJ.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
ME_Y=3_O_ -*BJ7_EU/\ O_TJ*@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "@=:*!UH EN/^/AOP_E452W'_'PWX?RJ*@
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M6,X,QDQN!V[7R3@[L"O3.E "@D="129/K110 9HHHH DC_U4O^Z/YU'4D?\
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M&KZE#:33 M&CY)(!QG@' R>IH U:*R-3\5:%HMU';:KJMO;32 %48D\$X!)
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M,JI/T%>-&U74/A'?^/)I)?\ A(E:>^AO!,08O+F94B SC8$4+C'<UTOCC3M
MG\&W/B/7DE>Z>Q1;8^<P:.0J-JQ*#]XL<]\F@#OZ*R?"T>IP^$=*CU]F?4UM
M8Q=%OO>9CG/OZ^]:U #H_P#6K]12S?ZY_P#>/\Z2/_6K]12S?ZY_]X_SH 94
M5S<P65K+<WDT<$$*EY)9&"JBCJ23P!4M9OB/2#X@\,:EI"S>0;ZUDMQ+LW;-
MRD9QD9Q]: &:5XHT'7IWAT36M/U&6-=[I:W*2%5SC)"DX&:?9^(M%U#4IM.L
M-6L;F]@SYMM#<*TD>#@Y4'(P:XW4M;\1:#'>>']2DL;IY-"N+FPN["%X61X0
M%971G?.0Z$,".01CO4$]O!9>&_AD^G1HKI<V:1%%ZK)#F3\\DF@#TNBBB@"4
M_P#'JO\ OG^515*?^/5?]\_RJ*@ HHHH 1F5$9W(55!)). !ZU6T[4['5[-;
MO2KVWO;9B5$UO()$)!P1D<<&EU'_ )!-Y_U[R?\ H)KQSP3K8\ >%5#(7AU3
M0X=4L(L<27858I(A[LQA./\ ;)H ]AL]6T[4;BZ@T^^MKJ:S?R[F.&57:%N?
ME8#[IX/!]*MUYS\,-%/A_P 0^)M.E?S;A([%[F;O+.\<C2/^+LQKT:@ HHHH
M ?%_KD_WA22?ZQOK2Q?ZY/\ >%))_K&^M #:*** "BBB@#C?$NG:UK?CC2(=
M+F^P6VEQ/>M>3V9FB>8_(B ;E!(!8]>.*R]$LKSPU#XET;Q!IEQK>ERW2W*O
M:Z>3'(DXS(%B!8MM<<JI9AD''&:]&HH \C7PKJ5WHVN0^&+.^@TF"ZLKS1]/
MU/?$6EA8/*BK+AT0A550V!D9Z<UZ#I'B=-:N(HH-)UBV+1[YFOK"2W6'C[I+
M@!SGCY-WKTYK;HH Y?PC9W-KK7BN2YMY84N-6:2%I$*B1-BC<N>H]Q72S"0P
MN(2HDVG86Z XXS3Z* /#8-(U_3M+@G\,Z5K*>,;B"2VUS[5 _DW?WMTGVAR(
MR0<%-C="!CT]?\.$'PQIJJMVOEVR1D7L;)-E5 .\-SG(/U[$]:TZ* "BBB@
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M\/SW&GZ#::/ TD5AJMM.X>8L4B1LL2SMEL#W)KJJ "BBB@ HHHH DC_U4O\
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M&:VJ "BBB@"2/_52_P"Z/YU'4D?^JE_W1_.HZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"7_EU/^__ $J*I?\ EU/^_P#TJ*@ HHHH **** "BBB@
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ML^-+>/4Y-+T_4[[RY4DL=YEB,8#-"Y9=I(RNXAQ[5MWOP^L+^?4UFGD6RO\
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M%%% !1110 4444 %%%% %H?\@D_]=Q_Z":JU:'_()/\ UW'_ *":JT %%%%
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MW6/,6&-I,*?O #/%<OHGQ"LM;\%7OB"*RFA:RB,LUD[C>!MWKSC&&4@@X[T
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MW'B"R\;:3I U_P#M!9U>XO(WL(H]D*C'WEY!+$ 4 =E1110!:;_D$I_UV/\
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M)C+^7"A=FQV '6@"S17!R>,[S6O .G7=I;7.FW^JS6]NC-$453(?F:-C]X
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M]LFX-LMH_N\@D?,Q+8Z]*Z*B@ HHHH M-_R"4_Z['^55:M-_R"4_Z['^55:
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M=]*\I>TN(O@SX;TN6"6WO9[VVB2!T*NC>9GH>F!7J['+$CUH ;1110 4444
M%%%% $MM_P ?47^^/YTMY_Q_3_\ 71OYTEM_Q]1?[X_G2WG_ !_3_P#71OYT
M 0T444 %%%% !1110!:;_D$I_P!=C_*JM6F_Y!*?]=C_ "JK0 4444 %%%%
M!1110 4444 36G_'[#_OC^=-G_X^9/\ ?/\ .G6G_'[#_OC^=-G_ ./F3_?/
M\Z (Z*** "BBB@ J"*PM8+VXO(8$2YN0HFE ^:3:,+GZ"IZ* ,N[\,Z)??:#
M=Z;!(;F199B<@NX7:&R#G....U36^B:7:Z2=+M["!+%@P:WVY5MQR<YZYSU-
M7J* ,[2O#VDZ&7.DV$=J7 #%2Q)'IDDXJ5-/CL=/N8='AAMI)3)*N0=IE?)+
M-]6.35RB@#.\/:0F@>';'2XW\S[+"$:3_GH_5F_%B3^-:-%% !1110 4444
M6K;_ (]+O_<'_H0JK5JV_P"/2[_W!_Z$*JT %%%% !1110 4444 %%%% !11
M10 4444 %%%% %H?\@D_]=Q_Z":JU:'_ ""3_P!=Q_Z":JT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4HZBDI1U% %G4
M?^0A+_P'_P!!%5:M:C_R$)?^ _\ H(JK0 4444 %%%% !1110 4444 %%%%
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M]QORH 913_*D_N-^5'E2?W&_*@">V_X]+O\ W!_Z$*JU<MHW%K=91N4&./\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>nexi-20221231_g11.jpg
<TEXT>
begin 644 nexi-20221231_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %1I;2!3=&]V
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,X,0  DI(
M @    ,X,0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( H $VP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
M 0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q0083
M46$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#
M1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7
MF)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7F
MY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&!P@)
M"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@4
M0I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I3
M5%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2E
MIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U
M]O?X^?K_V@ , P$  A$#$0 _ /I&BBB@#PS7_CCKVD>+=1T^'3M->UL[R2 ;
MUD\QE1RN=V[&3CTKV71=6M]=T.TU2R.8+J(2+ZC/4'W!R/PKYXM= C\4?%?Q
M;I#8$MQ)?&W8C[LJS;E^G3!]B:ZWX%>)9(9+WPEJ6Y)86::W5^JD'$B?@><?
M[U &WX,^)>K>(_B/J&@7EK9QVEOYWEO$KB3Y'VC)+$'CV%9OC[XL>(/#7CB;
M0]'L+&X1%C">;%(\CLZ@X&UQW. ,5S_PM_Y+CJ__ &]_^C!69\4KM+#XV->3
M!FCMY+65PHY(54)Q[\4 =+_PLOXI_P#0E?\ E*NO_BJZ/X@^.O%/A+1-'U.S
MTZR,5W$HNUN(I"8)BH.WAA@=1SG[II+'XZ^&;_4+>SAL=662XE6)2\,> 6(
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M^R\"Z9')+%]JO;C(M[8-MW8ZLQ[ 9'U_EY1\?;5;7QM87D(V23V8+,O4LKD
M_7&!^%4_B==MXA^)^EV\S9C>WM(@O0 288_^AT ;)^-OC&UCBO[_ ,-6RZ;*
MWR2&":,2#T60DJ3^%>J:-XWTS6?!$OB: 2"VMX9)+B+ +QF-=S+Z$XZ>N147
MQ#TZ&[^&FM6_E)LALGE1<8"^6-PQZ8VUY]^S\Z7>C^(=.N466#?$7BD7<K!U
M=2"#P00N"* (;[XU>*[BWDU#0_"RIID?6XN(995 ]2ZE5%=-\./BRGC+4&TK
M4K-+/4-A>-HF)CE Z@ \@]^IX!KM=>U"PT'PQ>7=\L:65M;L#'C"L,8" >_
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MI"BO"->\;_$'2_ VBZQ)>R6DLTTUO=B2RC5MZL=F0R<94'ICI7JFB^+;>_\
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MVY&2C1_*2,CCG\* /=:*9%*D\*30L'CD4,K#H01D&GT %%%% !1110 4444
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MT!/4BKE9OB#0K/Q+H-SI&I>9]FN0 YC;:PPP8$'V(% &1KOA_P (>-=*:\U
M6=S#LR+^&50R#U\P?R/'M7BGPB,EG\8(K739VFM#]HCDD7I)$%8JQ]BP0_E7
M62_L[VYGS!XDE2+^X]F&;\PX_E7?>"OA[H_@B&0Z?YD]W,NV6ZF(W,.NT <
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH Y[5/'GAW1]4FTZ_O9$NX55I(X[2:78&&1DHA'2M/
M2-;TW7K(7>CWL-W 3@M&V=I]".H/L:Y30?\ DLWBS_KTM/\ T"F6<::;\:M4
M@T[9#!=Z(MW<KT03B7:K$#H=O)[G)- '>5"EY;27DEI'<1-<Q*'DA5P713T)
M7J <5Y5-X]GT[6-.$/C:TUR6:]C@N=/AL52,([8)CD S\O;+'-:&FZ7JS_&+
M7?*\03Q;(;>5\6L1\R,LQ$1RO  XW#DT >ET5Y3XO\:W&B3ZA+;>.K+[;;R,
M8=)CL5=" >(WDY.['4Y'->GV-S]MTZVNMNWSXEDV^F0#C]: )Z*X+PY<>*_%
MFEQ>(K?78K"WN)F:WT[[&CIY*N5 =S\VX@'D'C/3M6GX8UJ_U'QCXJL;R?S+
M;3[B%+9-BCRPR$D9 R>?7- '275Y;6,'G7MQ%;1;@N^9PBY)P!D]R>*FKQS7
M[[5_$/PMAOKO575X]7,+JL$>) +@*A/'&W';KWS76ZQ>>(-+N-#\.6FL"XU+
M5IIBVI7%M&##%&H9L1J I;D 9_&@#MJY^U\965[K-Y8V]G?-#92217&H>2/L
MT;H,NI;.<CZ8SWK'MK[Q!I/C*/PWJFL#4(]3LI9;2]-LD<MO(G4%5&UA@YY'
M6N2\,:9K$G@/Q;-%XBGBC2YOE>(6L1\QU +/N(R"P!&!P,Y'- 'I/ASQ3!XG
MB:>ST_4+>VVAHKBZA").I)&4.23T[XK<KC_A?:WEOX"TR2ZU%[N*:VC:&)HD
M06ZX^Z"HRWU/-1W-]KWB#QMJFC:-JBZ/::1'#YTRVZ32322+N  ?("@>V<_H
M =7J%_;Z7IMS?WLGEV]M$TLC8SA0,GZ_2J7A_7E\069N8].O[&/@I]MB"&12
M,AEP3D5YUXCU76=4^'GBS2]3OU%YHDPCFN((5 O(6&5!4YVDYR=OH/>O0/"%
MK>6GA>S6_P!1>_=XD='>)(_+0HN$PH&0/4\\T -\1>-?#WA66"+7=22WGN 3
M#;I&\LL@'<1H"Q'OC%2>'/%VA>+()I?#^HQW?V=MDT>UDDB/HR, R]#U':N0
M^'<:7_Q&\?:M>H&U&+4UL(V?EHK=(U**O]U6)+$#J:9KGEZ7^T)H%Y9J$>^T
M:[34=G5XHMK1EAZAN 3]* /2Z@BO[2>]N+."Z@DNK8(9X$D!>(-DJ64<KG!Q
MGK@UYYX.G\;>,-'T_P 6'Q)#I]M>R^='HPL(Y(A;[R K2?ZS>5&=P( )Z5F>
M%]%UMOCEXS9?%5TJ6[:=+<(+.#_2HRLA6)CL^4* 5RN"0<DYYH ]=K(UKQ)9
MZ%?:1:7D<SOJ]Y]C@,2@A7V,^6R1@84],]N*X30[WQQX^T>\\2:+XDAT6V:X
MGCTS3A81RI(D3L@,SO\ -EBI^Z1@>M8NM>)=2\;^$_ACKFF?9K+4K_5Q@S(S
MQ12"*9'.T$$C*L0,^G- 'ME%>;V>N>(O"?Q!&A^)M9&NZ=>Z9-?07+6D<$L+
MPD;T(C #*0<@]>U</#\4O%6H: GB2QU#4I+N0^=%H$'AR22UDCW<1_:=FXMM
M_C#8SVH ^@*"0JDL< <DGM7G&N:OXIU7XH6'ASP_JXT:SN=#_M"=WM$EEB(F
M"_(''WCN5?FR ,G&<5Z#;PR+8Q0WDHN9!&$ED*!?-.,$[1P,^E ',V?Q1\&7
M^L0:9::["]S<N8X"8I%BF8'!5)2NQCGC 8UH>(O&6@^%#;KKNH"WEN<^3 D3
MS2R8ZE8T#,0.YQ@5Q?Q&A@\2:UX=\":#!$;FWOH-1NVB4!-.MHCD'C[K-PJC
MOSVJYH>;O]H/Q5)=)N>QTJRAM68<K&Y=WV_5NN/2@#J+7QIX<O/"S^([?6+4
MZ1&"9+MFVK'@X(8'!4Y(&",\CCFH?#_C[PUXHU":PT74Q->0IO>WEADADV_W
M@LBJ67D<C(KF/!%I;GXG_$C3?LT4FGI?V-TL;!63SG@#NVW'!WJK9]0.XJ.T
M*^,?CK%K.DA6TOPQ9RV4UZOW;FYDZQ*?X@@Y)[,<4 =IJOB[0=$UC3]*U34H
M8-0U*016MM@L\C$X'"@X&>-QP/>MFO,/B-H6F:=KOA/4;.TCCO=0\7V;W-QU
M>3$,H )/8 < <?F:]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !13$?>\@(^XV![\ _P!:?0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M4POB=8\<,I;/T(_QI] !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !13)7\M 0,Y95_,@?UI] !1110 4444 %%%%
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MB@"*'_6W'_70?^@K4M10_P"MN/\ KH/_ $%:EH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH B;_C\C_ZYM_-:EJ)O
M^/R/_KFW\UJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"*Y_P!4O_71/_0A4M17/^J7_KHG_H0J6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*U_X
M\X?^N:_RJ6HK7_CSA_ZYK_*@"6BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "HH?]9/_P!=/_95J6HH?]9/_P!=/_95
MH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ J)O\ C\C_ .N;_P UJ6HF_P"/R/\ ZYO_ #6@"6BBB@ HHHH *XW5
M;F"U^+.ER7,T<*?V7,-TC!1G>.YKLJI7VBZ5JDBR:GIEG>.@VJUQ;K(5'H"0
M: .2UR_B\0>-]%M-!FCNI--\ZYN)8B'2+*;44GIDGM6%9_\ ".?\*AN?[2^R
M_P!I^5+Y^_'VG[3N..OS;MVW_P#57IUEIMCIL1CTZSM[2,G)2")4!/T J-M%
MTM]0%\VFV;7@.1<&!?,!]=V,T <#>6\QUO3YI;_3TUD:/"EU::W"3$X_B*OZ
M[LYQGW]*R'O7O;?PH;>UT_3]/CDN8T2]+S6GG*< YR"0>2N3@<^E>KWVE:=J
M@0:E86MX$^X+B%9-OTR.*=+IUE/9"SGL[>2U P('B4IC_=(Q0!QO@Z*0>--5
MD%YIDN;:,7$.E0NL(?)VL221NVYZ&K?C*<:5XF\-:Y=*186DL\-Q*!GRO-0*
MK'VR.3746=A9Z=!Y.GVD%K%G/EP1A%S]!4TD:2QM'*BNC##*PR"/0B@#G]7\
M9Z=8K;1Z;)#JM[=RK'#:VTP9F!/+9&< #)S6-8_V9_PG_B/_ (27[+]H_<_9
M?MFW'D;/X-W&-W7'?K76V6B:5ITS2Z?IEG:2-P7@MU0G\0*=?:1INIE#J6GV
MMX8_N?:(5DV_3(XH \O%M!>>$;&V"%])F\6+'9JW1K8N1@?[.=]:/BZT:P\6
M2KX?MUMIY= N0%MD"%B#QP.I]/PKT22QM)HX8Y;6%T@=7A5HP1&R_=*CL1V(
MZ4K6ELUXMVUO$;E$*+,4&]5/4!NH'M0!YIJW_"/_ /"N=+_L#[)_:NZV^P_9
MMOG>?N7/3YL_>SFMO3=*L=0^*'B::_M(;E[>*T$7FH'";D)) /?Y1S74P:+I
M=M>M>6VFV<-TV<SQP*KG/7Y@,U8CM;>*YFN(H(DGGVB654 :3;PNX]3C/&>E
M '(>"OLT7B7Q3"/*28:B2B# ;9M7H.N.E=IC.,]NE5ETVQ34&OTLK=;QUVM<
M")1(P]"V,XX%6: .:^'O_(DVO_7>Y_\ 2B2NEJ*WMH+2 0VD,<$2DD1Q(%4$
MG)X'J23^-2T %%%% $4/^MN/^N@_]!6I:BA_UMQ_UT'_ *"M2T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1-_Q^
M1_\ 7-OYK4M1-_Q^1_\ 7-OYK4M !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% $5S_ *I?^NB?^A"I:BN?]4O_ %T3
M_P!"%2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %16O_'G#_P!<U_E4M16O_'G#_P!<U_E0!+1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !44/^LG_P"N
MG_LJU+44/^LG_P"NG_LJT 2T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5$W_'Y'_US?\ FM2U$W_'Y'_US?\ FM $
MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 10_ZVX_ZZ#_T%:EJ*'_6W'_70?\ H*U+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!$W_'Y'_P!<V_FM2U$W
M_'Y'_P!<V_FM2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 17/\ JE_ZZ)_Z$*EJ*Y_U2_\ 71/_ $(5+0 4444
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M .@YJ7_@7)_C1]878/\ 6.E_(_P/H^BOG#_A*-?_ .@YJ7_@7)_C1_PE&O\
M_0<U+_P+D_QH^L+L'^L=+^1_@?1]%?.'_"4:_P#]!S4O_ N3_&C_ (2C7_\
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M_P "Y/\ &CZPNP?ZQTOY'^!]'T5\X?\ "4:__P!!S4O_  +D_P :/^$HU_\
MZ#FI?^!<G^-'UA=@_P!8Z7\C_ ^CZ*^</^$HU_\ Z#FI?^!<G^-'_"4:_P#]
M!S4O_ N3_&CZPNP?ZQTOY'^!]'T5\X?\)1K_ /T'-2_\"Y/\:/\ A*-?_P"@
MYJ7_ (%R?XT?6%V#_6.E_(_P/HIO^/R/_KFW\UJ6OF__ (2;7MP/]MZCD# /
MVN3_ !I?^$HU_P#Z#FI?^!<G^-'UA=@_UCI?R/\  ^CZ*^</^$HU_P#Z#FI?
M^!<G^-'_  E&O_\ 0<U+_P "Y/\ &CZPNP?ZQTOY'^!]'T5\X?\ "4:__P!!
MS4O_  +D_P :/^$HU_\ Z#FI?^!<G^-'UA=@_P!8Z7\C_ ^CZ*^</^$HU_\
MZ#FI?^!<G^-'_"4:_P#]!S4O_ N3_&CZPNP?ZQTOY'^!]'T5\X?\)1K_ /T'
M-2_\"Y/\:/\ A*-?_P"@YJ7_ (%R?XT?6%V#_6.E_(_P/H^BOG#_ (2C7_\
MH.:E_P"!<G^-'_"4:_\ ]!S4O_ N3_&CZPNP?ZQTOY'^!]'T5\X?\)1K_P#T
M'-2_\"Y/\:/^$HU__H.:E_X%R?XT?6%V#_6.E_(_P/H^BOG#_A*-?_Z#FI?^
M!<G^-'_"4:__ -!S4O\ P+D_QH^L+L'^L=+^1_@?1]%?.'_"4:__ -!S4O\
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M:,8\8Z ?G0\:I#_>'^U5[3_&OA75[^.QTKQ+H]]=RY\NWMK^*21\ DX56).
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M #[_ !7^9Y=17J/_  I?_J/?^2?_ -G1_P *7_ZCW_DG_P#9T>QGV#^Q<?\
M\^_Q7^9Y=17J/_"E_P#J/?\ DG_]G1_PI?\ ZCW_ ))__9T>QGV#^Q<?_P ^
M_P 5_F>745ZC_P *7_ZCW_DG_P#9T?\ "E_^H]_Y)_\ V='L9]@_L7'_ //O
M\5_F>745ZC_PI?\ ZCW_ ))__9T?\*7_ .H]_P"2?_V='L9]@_L7'_\ /O\
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M_P#-:EJ)O^/R/_KF_P#-: ):*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH BA_UMQ_UT'_H*U+44/^MN/^N@_P#05J6@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@")O^/R/_ *YM_-:EJ)O^/R/_ *YM_-:EH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN?]4O_71/_0A4M17/
M^J7_ *Z)_P"A"I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "HK7_CSA_P"N:_RJ6HK7_CSA_P"N:_RH EHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*
M'_63_P#73_V5:EJ*'_63_P#73_V5: ):*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *B;_C\C_ZYO\ S6I:B;_C\C_Z
MYO\ S6@"6BBB@ HHHH **** "BBB@ HHHH **** "BLOQ-J<VC>&-0U&U6-Y
MK:!I$60$J2/7!!_6N:O-?\7:1H*:[?1:/=V*QI+-#;K+'*$;'0LQ&1F@#N:*
MSYM>TJUMX)KW4;6T2X0/%]HF6,L",C&35#6_&.EZ'<:;%/<0,;^4*&,ZJL<9
MS^\))^[QC/3WH WZ*S+:^GFUV[@:ZT][2.&-XXXI"9USU+CH%/8U-9ZSI>H3
MO#8:E:74J#+1P3J[+]0#Q0!=HK./B'15>-&UBP#2DB-3=)ER#@XYYY!'U%4K
M_P 7Z;I_BBST2>>%9KA69W>=5$1P-JD'G+9X'% &]15'6M1?2=%NKZ*UEO)(
M(RRP0J2SGL./U]!7/G7/$FD7VECQ#!IKVVI7"VN+/>'@D8$J#N)##@@D8H Z
MZBBB@"*'_6W'_70?^@K4M>0?$[6=3T[Q<(M/U&[M8VMD8I!.R G)&< ]>!^5
M<?\ \)1K_P#T'-2_\"Y/\:PE647:Q\_B<\IX>M*DX-V/H^BOG#_A*-?_ .@Y
MJ7_@7)_C1_PE&O\ _0<U+_P+D_QJ?K"['/\ ZQTOY'^!]'T5\X?\)1K_ /T'
M-2_\"Y/\:/\ A*-?_P"@YJ7_ (%R?XT?6%V#_6.E_(_P/H^BOG#_ (2C7_\
MH.:E_P"!<G^-'_"4:_\ ]!S4O_ N3_&CZPNP?ZQTOY'^!]'T5\X?\)1K_P#T
M'-2_\"Y/\:/^$HU__H.:E_X%R?XT?6%V#_6.E_(_P/H^BOG#_A*-?_Z#FI?^
M!<G^-'_"4:__ -!S4O\ P+D_QH^L+L'^L=+^1_@?1]%?.'_"4:__ -!S4O\
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M&O\ _0<U+_P+D_QH_P"$HU__ *#FI?\ @7)_C1]878/]8Z7\C_ ^CZ*^</\
MA*-?_P"@YJ7_ (%R?XT?\)1K_P#T'-2_\"Y/\:/K"[!_K'2_D?X'T?17SA_P
ME&O_ /0<U+_P+D_QH_X2C7_^@YJ7_@7)_C1]878/]8Z7\C_ ^BKG_5+_ -=$
M_P#0A4M?-Y\3:\W76]1/.>;N3_&E_P"$HU__ *#FI?\ @7)_C1]878/]8Z7\
MC_ ^CZ*^</\ A*-?_P"@YJ7_ (%R?XT?\)1K_P#T'-2_\"Y/\:/K"[!_K'2_
MD?X'T?17SA_PE&O_ /0<U+_P+D_QH_X2C7_^@YJ7_@7)_C1]878/]8Z7\C_
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M44 %%%% !1110 4444 %%%% !1110 4444 %10_ZR?\ ZZ?^RK4M10_ZR?\
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M7!5SC!ZC&*V9# GC;PC/>&-1)IDF9)<#>^U,<GJ>E=LNF6"6+V:V5NMK)G?
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MI?\ ZCW_ ))__9T?\*7_ .H]_P"2?_V='L9]@_L7'_\ /O\ %?YGEU%>H_\
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M_P!G1_PI?_J/?^2?_P!G1[&?8/[%Q_\ S[_%?YGEU%>H_P#"E_\ J/?^2?\
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ME_8E]VUV[_YYCY5_U7I_O_[?7V]=FBI<4W<WA7J0CRJWW+_(QO[$ONVNW?\
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M* "BBB@ HHHH **** (F_P"/R/\ ZYM_-:EJ)O\ C\C_ .N;?S6I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (K
MG_5+_P!=$_\ 0A4M17/^J7_KHG_H0J6@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*U_P"/.'_KFO\ *I:BM?\
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MC6$JRB[6/G\3GE/#UI4G!NQ]'T5\X?\ "4:__P!!S4O_  +D_P :/^$HU_\
MZ#FI?^!<G^-3]878Y_\ 6.E_(_P/H^BOG#_A*-?_ .@YJ7_@7)_C1_PE&O\
M_0<U+_P+D_QH^L+L'^L=+^1_@?1]%?.'_"4:_P#]!S4O_ N3_&C_ (2C7_\
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M_P "Y/\ &CZPNP?ZQTOY'^!]'T5\X?\ "4:__P!!S4O_  +D_P :/^$HU_\
MZ#FI?^!<G^-'UA=@_P!8Z7\C_ ^CZ*^</^$HU_\ Z#FI?^!<G^-'_"4:_P#]
M!S4O_ N3_&CZPNP?ZQTOY'^!]'T5\X?\)1K_ /T'-2_\"Y/\:/\ A*-?_P"@
MYJ7_ (%R?XT?6%V#_6.E_(_P/H^BOG#_ (2C7_\ H.:E_P"!<G^-'_"4:_\
M]!S4O_ N3_&CZPNP?ZQTOY'^!]%-_P ?D?\ US;^:U+7S?\ \)-KVX'^V]1R
M!@'[7)_C2_\ "4:__P!!S4O_  +D_P :/K"[!_K'2_D?X'T?17SA_P )1K__
M $'-2_\  N3_ !H_X2C7_P#H.:E_X%R?XT?6%V#_ %CI?R/\#Z/HKYP_X2C7
M_P#H.:E_X%R?XT?\)1K_ /T'-2_\"Y/\:/K"[!_K'2_D?X'T?17SA_PE&O\
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M7_@7)_C1_P )1K__ $'-2_\  N3_ !H^L+L'^L=+^1_@?1]%?.'_  E&O_\
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M[WR8^7ZXYKW'0]:LO$6B6VK:6[O:72;XF="A(]P>10!?HHHH **** "BBB@
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MQ7!2WNAZEXKTB\\%A_[5GO%?4#"CJ/(.3()ATSTQGO7I5% !1110!XI\6O\
MD=%_Z]$_FU</7M?BKX??\)7KCWW]I_9/+18=GV??G SG.X?WOTK%_P"%+_\
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M7_ZCW_DG_P#9T>QGV#^Q<?\ \^_Q7^9Y=17J/_"E_P#J/?\ DG_]G1_PI?\
MZCW_ ))__9T>QGV#^Q<?_P ^_P 5_F>745ZC_P *7_ZCW_DG_P#9T?\ "E_^
MH]_Y)_\ V='L9]@_L7'_ //O\5_F>745ZC_PI?\ ZCW_ ))__9T?\*7_ .H]
M_P"2?_V='L9]@_L7'_\ /O\ %?YGEU%>H_\ "E_^H]_Y)_\ V='_  I?_J/?
M^2?_ -G1[&?8/[%Q_P#S[_%?YGEU%>H_\*7_ .H]_P"2?_V='_"E_P#J/?\
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MVJ:HK7_CSA_ZYK_*@#D-(\&WEC\6=>\33M;-8ZC9P00QJ275DZDC& /QKLP
MHPH 'H*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "HH?]9/_P!=/_95J6HH?]9/_P!=/_95H EHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J)O\ C\C_ .N;
M_P UJ6HF_P"/R/\ ZYO_ #6@"6BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** (H?];<?]=!_Z"M2U%#_ *VX_P"N@_\
M05J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@")O^/R/_KFW\UJ6HF_X_(_^N;?S6I: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KG_ %2_]=$_]"%2
MU%<_ZI?^NB?^A"I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (F_X_(_\
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M6HH?]9/_ -=/_95H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ J)O^/R/_KF_P#-:EJ)O^/R/_KF_P#-: ):***
M"O+]2_X1+_A9'B'_ (3'[-_J[7[-Y^[_ )YG=C'_  &O4** //-5U#PQ<>"6
MT3PM%;WIOIOLUI;1$@+,?FWY/("_>)_QJ'3G73_ ?BK0+U-FK6=K=27,A))N
MPZ,1,">3D8'MBO2:IZO8?VKHE]I_F>5]KMY(/,V[MFY2N<<9QGI0!YQ?:WIF
MM?#BP\/:2C-J\D=M'#:B$AX'4J3(>.  "=W<'WJ;5=:>'7O$%H+R#1&+!5@C
MLC-<:AE.&!/'/08!QFO1--L_[/TFTLM_F?9H$BWXQNVJ!G';I5F@#RWPTJ2R
M_#G> ^VVOB,\X(5?Y5I74,$VO>/H[JTGNX6M;/?#;<2./+?[ON.OX=^E>@44
M >;>&]5:3Q3I5KI^KKX@M?+D5VGL@L^GJ$XS( .IPI!K+\+S1Z19^$-;U,,N
MF165S ;C:66"1I&()QTR.,UZ[10!YK>3Q:S<>,-;TI6.FMH3VYN-I"W,H1SN
M7(YVKA:MZK&D?@WP.J*%4:CIV !TXKOZ* ,WQ'IKZQX9U'3HFVR7-N\:$]-Q
M''ZUS6D>/])T_0K>TUQIK'4[2)89;)X6,C.HQ\H ^8'''UKMZ* //=6NM4N;
M#PWK_B"P^SP6M^9[F&)&8P1D$1NR\G(X)QTS5/Q+J%IXEO[O4- )GMK'0[U+
MN\12$??&=D>2.2#EOQKTZB@#@-5C2/P;X'5%"J-1T[  Z<4^PUBQ\*>*_$0\
M1R_8WOKE)[:9T8B>/;@ $ Y*G(Q[UWE% 'E4=@R>'/#_ -JM&@M[OQ4MQ!:R
MKS'"WF%5(/Y_C72>,;VWTOQ=X5U'4)!!9P2W*R3,#M0M#A<_4UV-% !1110!
M%#_K;C_KH/\ T%:EJ*'_ %MQ_P!=!_Z"M2T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 1-_Q^1_]<V_FM2U$W_'Y
M'_US;^:U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!%<_ZI?^NB?^A"I:BN?]4O_71/_0A4M !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45K_QYP_]
M<U_E4M16O_'G#_US7^5 $M%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %10_P"LG_ZZ?^RK4M10_P"LG_ZZ?^RK0!+1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !43?\ 'Y'_ -<W_FM2U$W_ !^1_P#7-_YK0!+1110 4444 %%%% !1110
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M-5\6>'-!NEM=<U_2]-N'02+%>7L<+LI) 8!B#C((S[&J7_"Q_!'_ $.7A_\
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M^2:^MOV5/^26:E_V&I?_ $1!49_97\$BX1/[4U_#*Q/^D0]B/^F/O7I'P_\
MA_I7PXT"?2-#N+R>WFNFNF:\=6<,552 551C"#MZU9V'4T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<_ZI?^NB?^
MA"I:BN?]4O\ UT3_ -"%2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %16O_ !YP_P#7-?Y5+45K_P ></\ US7^
M5 $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %10_ZR?\ ZZ?^RK4M10_ZR?\ ZZ?^RK0!+1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !43?\?D?_7-_YK4M
M1-_Q^1_]<W_FM $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 10_ZVX_ZZ#_T%:EJ*'_6W'_70?^@K4M !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $3?\
M'Y'_ -<V_FM2U$W_ !^1_P#7-OYK4M !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% $5S_JE_ZZ)_Z$*EJ*Y_U2_P#7
M1/\ T(5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5%:_\ 'G#_ -<U_E4M16O_ !YP_P#7-?Y4 2T444 %%%%
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MHH^L>0?ZR?\ 3K_R;_@'T\W_ !^1_P#7-OYK4M?+E%'UCR#_ %D_Z=?^3?\
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M.O\ R;_@'U'17RY11]8\@_UD_P"G7_DW_ /J.BOERBCZQY!_K)_TZ_\ )O\
M@'U'17RY11]8\@_UD_Z=?^3?\ ^HZ*^7**/K'D'^LG_3K_R;_@'U'17RY11]
M8\@_UD_Z=?\ DW_ /J.BOERBCZQY!_K)_P!.O_)O^ ?4=%?+E%'UCR#_ %D_
MZ=?^3?\  /J.BOERBCZQY!_K)_TZ_P#)O^ ?4=%?+E%'UCR#_63_ *=?^3?\
M ^HZBM?^/.'_ *YK_*OF&BCZQY!_K)_TZ_\ )O\ @'U'17RY11]8\@_UD_Z=
M?^3?\ ^HZ*^7**/K'D'^LG_3K_R;_@'U'17RY11]8\@_UD_Z=?\ DW_ /J.B
MOERBCZQY!_K)_P!.O_)O^ ?4=%?+E%'UCR#_ %D_Z=?^3?\  /J.BOERN?\
M'/\ R)=]_P!L_P#T8M.->[2L;4.(/;58T_9VYFEOW?H?8=%?FY172?4'Z1T5
M\2_L^?\ )=O#W_;S_P"DTM?;5 !1110 4444 %%%% !1110 5%#_ *R?_KI_
M[*M2U%#_ *R?_KI_[*M $M%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %1-_P ?D?\ US?^:U+43?\ 'Y'_ -<W_FM
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M%>S?\*?T#_G\U+_O['_\11_PI_0/^?S4O^_L?_Q%'L)A_8.-[+[SQFBO9O\
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M\U+_ +^Q_P#Q%'_"G] _Y_-2_P"_L?\ \11["8?V#C>R^\\9HKV;_A3^@?\
M/YJ7_?V/_P"(H_X4_H'_ #^:E_W]C_\ B*/83#^P<;V7WGC-%>S?\*?T#_G\
MU+_O['_\11_PI_0/^?S4O^_L?_Q%'L)A_8.-[+[SQFBO9O\ A3^@?\_FI?\
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MV_FM2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 17/\ JE_ZZ)_Z$*EJ*Y_U2_\ 71/_ $(5+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%:_\></_
M %S7^52U%:_\></_ %S7^5 $M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %10_ZR?_ *Z?^RK4M10_ZR?_ *Z?^RK0
M!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !43?\?D?_7-_P":U+43?\?D?_7-_P":T 2T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%#_K;C_KH/_05J6HH
M?];<?]=!_P"@K4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% $3?\?D?_ %S;^:U+43?\?D?_ %S;^:U+0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<
M_P"J7_KHG_H0J6HKG_5+_P!=$_\ 0A4M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !45K_QYP_\ 7-?Y5+45K_QY
MP_\ 7-?Y4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5%#_K)_\ KI_[*M2U%#_K)_\ KI_[*M $M%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1-_Q^1_
M]<W_ )K4M1-_Q^1_]<W_ )K0!+1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% $4/^MN/^N@_]!6I:BA_UMQ_UT'_ *"M
M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 1-_Q^1_\ 7-OYK4M1-_Q^1_\ 7-OYK4M !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5S_ *I?^NB?^A"I
M:BN?]4O_ %T3_P!"%2T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %16O_'G#_P!<U_E4M16O_'G#_P!<U_E0!+11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !44/^LG_P"NG_LJU+44/^LG_P"NG_LJT 2T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5$W_'Y'_US?\ FM2U$W_'
MY'_US?\ FM $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 10_ZVX_ZZ#_T%:EHQCIWZT4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1-_Q^1_]<V_FM2T8
MYSWHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH BN?]4O_71/_0A4M!&>M% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !45K_ ,></_7-?Y5+0!@8' H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *BA_UD__ %T_]E6I:,4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %1-_Q^1_]<W_ )K4M&.<]Z "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Q_%NI7&
MD>$M1OK(A;B&$F-B,[6)P#COC.: -BBN5@@FT'QCIEC!?7=S;W]G-YR7=P\W
M[R+81(I<G:3O((&!TXX%=50 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 45RT/]H0_$XQW6I23VT^FRRQVRC9%$!+
M&!\N3N;ELL?7 P.*ZF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HKF?&<"1:3<WOVW4(KLQ"&RAM;IX]TY)VX12
M-[$D9#9&%Z#G/06?GBQ@^V$&X\M?-(Z%\<_K0!-1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16=K<#3V*A8[^8+(&
M:&PN!#)(,$8WEEP 2#PP/ ZC(.?X,N)YM)NDNII'D@O9HO*F=GDMQG(B9SRY
M (^;)!!&"1S0!T-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%5[^]@TW3Y[V[?9!!&9';V _G[5ROA.XU63Q;JHUB
M>;?+:6]S]E9R4MMY?"*O0$*%!(ZD$]Z .RHHHH **** "BBB@ HHHH ****
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M_P!#9K'_ 'ZL_P#XQ6W10!B?V#J/_0V:Q_WZL_\ XQ1_8.H_]#9K'_?JS_\
MC%;=% &)_8.H_P#0V:Q_WZL__C%']@ZC_P!#9K'_ 'ZL_P#XQ6W10!B?V#J/
M_0V:Q_WZL_\ XQ1_8.H_]#9K'_?JS_\ C%;=% &)_8.H_P#0V:Q_WZL__C%'
M]@ZC_P!#9K'_ 'ZL_P#XQ6W10!B?V#J/_0V:Q_WZL_\ XQ1_8.H_]#9K'_?J
MS_\ C%;=% &)_8.H_P#0V:Q_WZL__C%']@ZC_P!#9K'_ 'ZL_P#XQ6W10!B?
MV#J/_0V:Q_WZL_\ XQ1_8.H_]#9K'_?JS_\ C%;=% &)_8.H_P#0V:Q_WZL_
M_C%']@ZC_P!#9K'_ 'ZL_P#XQ6W10!B?V#J/_0V:Q_WZL_\ XQ1_8.H_]#9K
M'_?JS_\ C%;=% &)_8.H_P#0V:Q_WZL__C%']@ZC_P!#9K'_ 'ZL_P#XQ6W1
M0!B?V#J/_0V:Q_WZL_\ XQ1_8.H_]#9K'_?JS_\ C%;=% &)_8.H_P#0V:Q_
MWZL__C%']@ZC_P!#9K'_ 'ZL_P#XQ6W10!B?V#J/_0V:Q_WZL_\ XQ1_8.H_
M]#9K'_?JS_\ C%;=% &)_8.H_P#0V:Q_WZL__C%']@ZC_P!#9K'_ 'ZL_P#X
MQ6W10!B?V#J/_0V:Q_WZL_\ XQ1_8.H_]#9K'_?JS_\ C%;=% &)_8.H_P#0
MV:Q_WZL__C%']@ZC_P!#9K'_ 'ZL_P#XQ6W10!B?V#J/_0V:Q_WZL_\ XQ1_
M8.H_]#9K'_?JS_\ C%;=% &)_8.H_P#0V:Q_WZL__C%']@ZC_P!#9K'_ 'ZL
M_P#XQ6W10!B?V#J/_0V:Q_WZL_\ XQ1_8.H_]#9K'_?JS_\ C%;=% &)_8.H
M_P#0V:Q_WZL__C%']@ZC_P!#9K'_ 'ZL_P#XQ6W10!B?V#J/_0V:Q_WZL_\
MXQ1_8.H_]#9K'_?JS_\ C%;=% &)_8.H_P#0V:Q_WZL__C%']@ZC_P!#9K'_
M 'ZL_P#XQ6W10!B?V#J/_0V:Q_WZL_\ XQ1_8.H_]#9K'_?JS_\ C%;=% &)
M_8.H_P#0V:Q_WZL__C%']@ZC_P!#9K'_ 'ZL_P#XQ6W10!B?V#J/_0V:Q_WZ
ML_\ XQ1_8.H_]#9K'_?JS_\ C%;=% &)_8.H_P#0V:Q_WZL__C%']@ZC_P!#
M9K'_ 'ZL_P#XQ6W10!B?V#J/_0V:Q_WZL_\ XQ1_8.H_]#9K'_?JS_\ C%;=
M<WXI\7IX7OM-BFLS/!>%S-,)=OD(K("V,'</WF>HX% %G^P=1_Z&S6/^_5G_
M /&*/[!U'_H;-8_[]6?_ ,8J/Q?XH7PKI2W*VIO)Y&(2W$FS(52SMG!P H)Z
M>E:#ZW86NG6UYJ=W;6"7"*R_:)E09(S@$XS0!3_L'4?^ALUC_OU9_P#QBC^P
M=1_Z&S6/^_5G_P#&*T7U2PCM(KJ2^MEMYL>5,TRA),@D8;.#P">.PJE>^*M&
ML]!N-7%_;W-I!D%K>9'W,!G8IS@L?3- $?\ 8.H_]#9K'_?JS_\ C%']@ZC_
M -#9K'_?JS_^,53OO&-LIT6?3;FSELKZX:.XF:0,(5$9<\AL*1@9SG%;D.K:
M=<6#WT%_:RVD>2]PDRF-<=<L#@8H S_[!U'_ *&S6/\ OU9__&*/[!U'_H;-
M8_[]6?\ \8K4L[ZTU&W%QI]U#=0DD"2"0.I(ZC(XJ*76=,@U!;";4;2.\<@+
M;O.HD;/3"YSS0!0_L'4?^ALUC_OU9_\ QBC^P=1_Z&S6/^_5G_\ &*SY?&$)
M\97&EC5-+M+6RB5YVN'!>5LMN13O 7:%YR#CTK3T7Q5I.O:0VHV=W$L4:%YU
MDE0-;KSS( 3MX4GGL* &?V#J/_0V:Q_WZL__ (Q1_8.H_P#0V:Q_WZL__C%7
MH-:TNZLI;RUU*SFMH<^;/'.K)'@9.Y@<#CUJ2TU&ROVE%C>6]R86V2B&57V-
MZ'!X/L: ,W^P=1_Z&S6/^_5G_P#&*/[!U'_H;-8_[]6?_P 8K)A\7RZGJFM0
M:7J>C11Z>A$*W+$F4A-S2,ROQ&K'!PIZ'D5T#:WI]G;P?VIJ=A!,\2.<W"JK
M;NA7<<E20<'OB@"K_8.H_P#0V:Q_WZL__C%']@ZC_P!#9K'_ 'ZL_P#XQ5UM
M;TI+J:V;4[-9[="\T1N$W1J!DEAG( '.35?0/$VE^);/S],N49AG? 74R1@,
M5RR@G .,CU&* (O[!U'_ *&S6/\ OU9__&*/[!U'_H;-8_[]6?\ \8JWJ>M6
M&F Q7%]:PW3H3#!-,JM(>@ 4G)R>.*IZ/XCAG\(Z=K&MW-I8_:HE9F>01QAB
M.@+'VZ9H 7^P=1_Z&S6/^_5G_P#&*/[!U'_H;-8_[]6?_P 8K1.JZ>--_M$W
MUL++&?M)F7R\9Q][..O%!U73QIO]HF^MA98S]I,R^7C./O9QUXH SO[!U'_H
M;-8_[]6?_P 8H_L'4?\ H;-8_P"_5G_\8K4L[ZTU"W%Q87,-U"20)() ZDCK
MR.*GH Q/[!U'_H;-8_[]6?\ \8H_L'4?^ALUC_OU9_\ QBMNB@#$_L'4?^AL
MUC_OU9__ !BC^P=1_P"ALUC_ +]6?_QBMNB@#$_L'4?^ALUC_OU9_P#QBC^P
M=1_Z&S6/^_5G_P#&*VZ* ,3^P=1_Z&S6/^_5G_\ &*/[!U'_ *&S6/\ OU9_
M_&*VZ* ,3^P=1_Z&S6/^_5G_ /&*/[!U'_H;-8_[]6?_ ,8K;HH Q/[!U'_H
M;-8_[]6?_P 8H_L'4?\ H;-8_P"_5G_\8K;HH Q/[!U'_H;-8_[]6?\ \8H_
ML'4?^ALUC_OU9_\ QBMNB@#$_L'4?^ALUC_OU9__ !BC^P=1_P"ALUC_ +]6
M?_QBMNB@#$_L'4?^ALUC_OU9_P#QBC^P=1_Z&S6/^_5G_P#&*VZ* ,3^P=1_
MZ&S6/^_5G_\ &*/[!U'_ *&S6/\ OU9__&*VZ* ,3^P=1_Z&S6/^_5G_ /&*
M/[!U'_H;-8_[]6?_ ,8K;HH Q/[!U'_H;-8_[]6?_P 8H_L'4?\ H;-8_P"_
M5G_\8K;HH Q/[!U'_H;-8_[]6?\ \8H_L'4?^ALUC_OU9_\ QBMNB@#$_L'4
M?^ALUC_OU9__ !BC^P=1_P"ALUC_ +]6?_QBMNB@#$_L'4?^ALUC_OU9_P#Q
MBC^P=1_Z&S6/^_5G_P#&*VZ* ,3^P=1_Z&S6/^_5G_\ &*/[!U'_ *&S6/\
MOU9__&*VZ* ,3^P=1_Z&S6/^_5G_ /&*/[!U'_H;-8_[]6?_ ,8K;HH Q/[!
MU'_H;-8_[]6?_P 8H_L'4?\ H;-8_P"_5G_\8K;HH Q/[!U'_H;-8_[]6?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5"YT'2+VX:XO-*LKB9\;I);
M=&9L# R2,]!5^BBUR90C-6DKF7_PB^@?] /3?_ 2/_"K]M:V]E;K;V<$=O"F
M=L<2!57)R< <=34M%*R1,:<(.\4D%%%%,T"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBOEOXQ?&+QWX5^+&LZ-H.N_9-/MO(\J'[' ^W=!&Y^9D
M)/S,3R>] 'U)17Q+_P -!_$[_H9O_)"V_P#C=?4GP=\0ZIXJ^$^C:SKUS]KU
M"Y\_S9O+5-VV>1!\J@ ?*H' [4 =M17'>/\ Q'K>AR^'[/PV-/%UJ^HBS+W\
M3R1H/+=LX1E.?E]:SAXYU?PMXB.F_$,Z7]FDTZ;4([_2XI0L:PE=ZO&Q9NC
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M"RI.WD2&.W9L8660+LC)R.&(-=!=W=O86<UW>S1P6\"&2661@JHH&223T %
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M<)_M*%<!Q[ 9'H>WRI\2?BUKGQ+2PAUFUM;..P9RL=J' 9FP,MN)Y&W ^IH
M^YD=9$5XV#*PRK*<@CUI:^5O /QU^(>I1Z9X6\.^'].U6YM[=($=TDW%$ 7>
M[;P!P!D\5],Z(-7_ +(A/B-K(ZB1F46*,(E/H-Q)./7C/H* -"BO*M0\)Z%X
MK^/>JP^(]+M]1C@T*U>)9UR$)ED!(JK_ &T?ACXE\1Z)HT$MY8"WLKC3;":=
MBD%Q<3&#RU9LE8RVUB.V#@<T >OT5P-QXK\5>&]4CL/$=EI^J2WEA=7-C_9*
M21,\T"!S 5=FSN!X<'J,;>:R=#^*MS+INHZGJ5]H.IVUEILE[/;Z:7ANK5T&
M?*>*1B6SR-^%P1R.: /5**\FT'XNR7.N:);:EJOAN^369A;_ &329F:>QD92
MR;R6(D7(VD@+@D=17:>+_$.H:5<:/I>@PVTFJ:S=-;P/=[O)A5(VD=V"D%L*
MAPH(R3U% '2T5X_XL\4:\--\6Z'XKL-'O(]-L[&XC,"S(ESYL^"6 DW* 4X4
M-U7.2#BN@OO'^HZ=HOB>*>WM6UW2]06RL8 C".X,Y7[*Q&[)!W@-@CE'QB@#
MT"BO'=3^,ES;7NM>5J?AFU719Y+9K"^F=;F_DBXD*?-B(%@P7(?..<5T$'C+
MQ%XE\1M8^$5TJ&S?1[/5(KG4(I'8"?S,(41USD*O.1MP?O9& #T*BL+P5X@E
M\4^#-.UFX@2WFN4/FQHQ*JZL5;!/.,J<>U;M !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3(-^].4&2!GCK5;Q7\/+#3/A_P"*)M)AU+5M:N]*FMDN+NYEO+EU*DB--Q)
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M<?>QU[5M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>nexi-20221231_g2.jpg
<TEXT>
begin 644 nexi-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" :U#10# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH1+W9Q#(Y51W)&!7W59_'']F3]E^^UE?"<UN=3O-@NX?#PFO?,V9VJ)&8Q*
M6/RJX]Q7EGQ<_P""F-AXC\.ZOH?A;P5.T.H6LMJ;S6KA5*JZE2?)CW9X/_/2
ML9-*'[I:_@:Q3<OWFWXGSQ^R[^T;XC^!_C[2HX-0FF\+7ETD6HZ5+(3"8V8!
MI%7HKJ#D,.N,'(K[B_X*+^#?$'CGX0Z!:>&]"U+Q!=QZRDSP:7:27,BIY,HW
M%4!(&2!GIR*_+*'_ %R?[P_G7[Z6/_'E;_\ 7-?Y5O4C[2C%OO\ E9F,)>SJ
MZ=4_\OU_ _!'4M-N]'U"YL;^UFL;ZVD:&>VN8S')$ZG#*RD J0000>179>#O
M@[X^\2+INJZ1X'\2:II<TJM'?66DW$T#@/@D.J%2 01U[&K/[1G_ "7WXC?]
MC!??^CWK]0?V&?\ DUOP1_USN/\ TIEI8>7-3C7ZZ/[]1UURU'2]49W[>@*_
MLI^)P1@[K/\ ]*(Z_-W]EK_DXSX<_P#8;MO_ $,5^DO[?G_)K?BO_KI:?^E,
M=?FU^RU_R<9\.?\ L-VW_H8J,+_O'_;R_0K$+EPJ7DS]G=>URQ\,Z)?ZOJ=P
MEIIUC ]S<3R'Y8XT4LQ/X"OR$_:6_:N\3_'_ ,074(N[C2_!T<A%EHT3E490
M?EDFQ]]SUYR%Z#N3]W_\%$?%D_AK]FZ_MK=S&VL7]OI[LO782TK#\1%C\:_.
MK]F?3_#FI?';P?'XLO;'3_#T=Y]HNIM2F2*WQ&C2*KLY"@,RJO)YSCO6=./M
MJKBWHO\ AV_N-)R]E2YEN]?D:&C_ +(_Q?U[PFOB2Q\"ZA-I31^<C%XDFD3&
M0R0,XE8$=,*<]LU7^!O[0OC+]GCQ4D^E74YTY9L:AH5TS""< X8%#]R08X8#
M(([C(/ZT?\-"?"S_ **7X/\ _!]:_P#QROS)_;M7PC=?'BXU?P;JVE:O8:M9
M17ES+H]U'<1+<Y9'R8R0&(16(ZY;/>K]HZ=1<NS_ *U\B%!3@^;='ZI_#OQY
MI7Q/\$Z/XIT64RZ;J< GCW?>0]&1AV96!4^X-?FY_P %-/\ DOVF?]@*#_T;
M-7O/_!,'Q=+JOPG\2:!-)O&DZF)85/\ #',F<#VW(Y_$UX-_P4T_Y+]IG_8"
M@_\ 1LU+$14:D+;7O]\6RL/)RISOV_*21Y5\,OCMXV\*_#6\^&_@6.Z@U+7]
M3,\MUIRLUY*IC1%AA"C*DE221ST QSF#QK^RG\7/ WAJ;Q+X@\&WUMI:CS9[
ME9X9WC!Y+2)&[.@]2P&.]?0__!+GP99:EXP\9>);FW26[TRV@M;21P"8S,7+
ME?0XC SZ,1W-?HGJ%C!J>GW-G<Q+/;7$312QN,AU8$$$>A!K2M%Q7,M9-?IH
MON,J<KMQ?PI_\%O\3\2?@K\;?$OP,\96NN:!>RQQ"1?MFGESY%Y$#RCKT/&<
M-U4\BOU5_:,:?XD_LK^)IO#ME=:M+K&D17%G:V<+332AVC=0J*"2<'H/2OQW
MUJS&FZS?V@! M[B2(!NHVL1_2OVE_9EF>X_9Z^'3N=S?V%:+GV$2@?H*&E7P
MS^2^33_R'K1Q"MTO^#1^,7B3PKK?@W4CIVOZ/?Z'J 02&TU*U>WEVGHVQP#@
M^N*T/"OPS\8>.K6:Y\-^%-<\06\+^7+-I6G37*1MC.UBBD XYP:]^_X*/_\
M)REQ_P!@JT_DU?07_!+7_DFGC/\ ["Z?^B5J:/[R$I/I?_TJPZG[N48KK_E<
M^B_V9-(O]!^ '@33M3LKC3M0MM+BCGM+N)HI8F&<JR, 5/L17IU%%7.7/)R[
MDQCRQ4>P4445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*6,XPRMN26-OXE. 0>XK*ERPJM3V>OX6_"US2IS3I)QW6GZK\S[0_P"'4O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'QJ_:*U7P!XR.B:':Z?=""%&N7O(Y&(D;Y@HVNO&TJ?QK@?^&O?&/_0-T/\
M[\3?_':^&Q7&>482O/#U)/FBVG975UN>S3RG%58*<4K/7<^O:*Y_P#XLB\<>
M#]+UJ(*INH0TB+T20<.OX,#705]O"4:D5.+NGJCQY1<6XO=!1115""BJ]]?V
MVEV<UW>3QVMK"I>2:9@J(H[DGI7S_P".OVN+*PFDM?"VG#464X^W7NY(B?\
M9089A]2OTKQ<RSG Y1!2QE11OLMV_1+7Y['9A\)6Q3M2C?\ (^B**^)K_P#:
M<^(%Y,SQ:I!8J3Q';V<14?\ ?:L?UIVG_M/>/[*8/-J5O?J#_J[BSC /_? 4
M_K7QZ\0,H<^7EG;ORJW_ *5?\#U?[#Q5KW7WO_(^UZ*\$^'O[5VEZY<167B6
MT71KASM%Y$Q:W)_VL\I^H]2*]YCD2:-9(V62-@&5E.00>A!K[C 9EA,TI>VP
M=12C^*]4]5\SQZ^'JX:7)5C9CJ*YGXE>)KKP;X%UC6K*.&6ZLX?,C2<$H3N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!A>-I/+\.SC&=[(OT^8'^E>:5Z-X[4G02<XQ*I^O6O.::
M)9WFFQB+3[90,?NU/XXYJS4=OQ;Q <#:/Y5)7Q<W>39ZRV"BBBI&%%%% !11
M10!'<?ZEO\]ZIU<N/]2W^>]4Z^AR[^$_7]$<]3<****]0R"BBB@ HHHH Q?$
MB_+ V.Y!/Y5!X7D,7B"R8''S[?S!']:N>(E'V.,]_,Q^AJCX;7?KUB#_ ,]0
M?RYJNAA+XCU:BBBI$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 445\"?\ !0K]H/7_  [X
MYT3P?X2\1:EH4EA;&[U&;2;R2W=Y)<>7&Q0@_*B[L=/W@I7U4>YV87#2Q=3V
M<7;J??=%?B?_ ,- ?%'_ **1XN_\'MU_\<K]&OV"_C1>?%;X1RV.M:C/J?B'
M0KDV]Q<7<IDFFB?+Q2,Q)+'[RY/]RM_9OE;['3B\OGA(*;=U>Q]+4445B>4%
M%>=?M%ZI>Z'\"?'>H:=>7&GW]MI%Q+!=6LK1RQ.$)#*RD%2/45^2G_#0'Q1_
MZ*1XN_\ ![=?_'*(^])Q['K83+IXNFZD96UM^7^9^V%%?-_[ OBO6_&7P';4
M-?UC4-<O_P"UKB/[5J5T]Q+M"QX7<Y)P,GCWK<_;7\1:MX5_9S\2:GHFIWFC
MZC%+:B.\L+AX)DS<1@X="",@D'GH:=1>S=GY?C;_ #..&'<\1]7OK>WXV/=*
M*_$__AH#XH_]%(\7?^#VZ_\ CE*O[07Q15@?^%D>+C@YYURZ/_M2M/9^9[/]
MBU/YT?M?17*_"OQ@GQ ^&OAGQ&AS_:>GPW+^SL@WC\&R/PKJJB47"3B^A\VM
MM0HKX[_X*,?&#6O 'AGPGHOAS6]0T/4]0NI;J6XTRZ>WE\F)0H4LA!PS29QG
M'R5\)_\ #0'Q1_Z*1XN_\'MU_P#'*4/?NT>YA\JJ5Z4:O-:Y^V%<Y\2/&'_"
MO_ /B'Q-]D^W_P!D6,U[]E\SR_-\M"VW=@[<XZX/TK\E/AS\=OB5??$+PO;7
M/Q#\5W%O-JEK')#+K=RR.IF4%6!?!!!Q@U^N?C;PG:>//"&L^'-0DFAL=5M)
M+.>2V8+(J.I4E200#@\9!^E54IRC3YHO5W_K\3GK858.O"-9W6C?I?4^(_\
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MJO\ G_D<^(HO#U72;O;_ "N+17XN:U\?/B=#K-^B?$;Q:B+<2*JKKET  &.
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M]K%2757_  N>S6RR=&BZSDM#](J***@\8**** "BBB@ HHHH **** "BBB@
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M/B5J<\<F^SLV^QV^#D;4)!(^K;C^-?7/Q>\8CP+\/=6U-7V77E^1;<X/FO\
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M*>M?]>4__HMJ_.BOPOQ&_P!YP_\ A?YGV>0_PY^I]4_L<_\ (M^(O^ON/_T
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M'\Z_26#_ %,?^Z/Y5^H^''^[8G_%'\F?.<0?'2])?^VDE?)G[8/_ "/&B_\
M8._]JO7UG7R9^V#_ ,CQHO\ V#O_ &J]>WQ[_P B=_XH_J<62_[VO1G9_L=_
M\BEKW_7\O_HL5] 5\_\ ['?_ "*6O?\ 7\O_ *+%?0%?0\-_\B?"_P"!'%F/
M^]U/4^1OVOO^2@:5_P!@Q?\ T;)7GNH>'A_PJ;1];1.5U2XM96^L<;)_Z"]>
MA?M??\E TK_L&+_Z-DJ?PQX=.N?LJZZ0N^2UOVO(_;9LW'_ODO7XMB\)]<S3
M-H):J$I+_MV<'^2L?6T:OLL-AGW:7WIH]-_96\1?VQ\-?L+N6ETVX>'![(WS
MK_-ORKYY^+&I/X[^,FJK"=XEOEL8=O/"D1@CZD9_&N@_9U\?KX+F\5+*^(VT
MR2ZC4]#+$"5'XAC6-^S]HS>)/BYI#2'<+=WO9"1G.P$C_P >(KT\3C?[<PV4
M9=>_,US_ /;KY+_<I,QIT?J=7%8CMM\]?SL<Y\3+&/2_B!X@LXAB*WO)(E^B
MG _E7VS\)/\ DF/AC_KPB_\ 017QG\9D$?Q5\4@=/MTA_,YK[,^$G_),?#'_
M %X1?^@BO7X%36.QZ?=?G(X\Y_W>C_71'74445^QGR852UK5K?0='O=2NFV6
MUI"\\C?[*@D_RJ[7A_[5WC+^Q?!-OHD+XN=6EPX!Y$*$,WYMM'YUXV<Y@LKP
M%7%O>*T]7HOQL=>$H/$UXTN[_#J?*7B+7+CQ+KVH:K='-Q>3O._L6.<#V'3\
M*SJDAA>XFCBC4O)(P55'4DG %>E_&_X6?\*VE\/-$I\J\L569O\ IX0 2?GE
M3^=?RK#!8C$86KC]XP:4GYRO^JU]4?I;K0IU(T>KO;Y'I7[(?C3<FJ^&)Y.1
M_IEL"?HL@'_CI_.OI6OSV^''BR3P/XVTG6%+".WF'G*I^]&>''Y$U^@MO/'=
M01S1,'BD4.C#H01D&OZ#X)S+Z]E4:4G[U+W7Z?9_#3_MT^&SC#^QQ/.MI:_/
MK_G\R2D9@JDDX Y)-+7FO[0WBN3PG\+M2>!S'<WQ6QB8=1OSN_\ ' U?89AC
M(9?A*F*GM!-^O9?-Z'DT*3KU8TEU9\Z_'OXR3_$+7)--T^9D\.V<A6-5.!<N
M#CS6]1_='8<]37FFAZ%J'B35(-.TRTDO;V8X2&(9)]_8>YX%4*^Q/V7? ,'A
M_P $IKTL2G4=5RPD(Y2$'"J/3)&X_AZ5_.F48#$<79I.>*F[?%)^6R2[=EV5
MWK8^^Q5:GE>&2IKR2_5GGN@_L>ZQ>6RR:MKMKIDK#/DV\!N"OL3N49^F:S/&
M7[*/B3P_9R76D7D&OQ1C<T,:&&<C_90D@_0-GT!KZ_HK]<J\#Y+4I.G"FXR_
MF4I7^YMK\#Y:.<XN,N9R37:R_P"'/S3DC:*1D=2CJ<,K#!!'4$5]'?LL_%6=
M;W_A#]3G:2"12^GO(<[&'+1_0C) [8/K5WXY?L^ZOXJ\<)JOAFRA,-['NO"\
MR1JLP.-V"<_,,$X!Y!/>J'@G]E?Q/H>O:?JMQKNGV4MI.DZ_9E>9LJ<X.0HY
MZ=>]? 9'DV=9+G"=*DY4U+ED]$I1[ZM=-5YJQ[N,Q6$Q>%M.23:NNK3^1[U\
M2O#-UXR\"ZQHME)#%=7D/EQO.2$!W \D GMZ5\T?\,A>,?\ H):'_P!_YO\
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MH<\OB.]HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M -?C!7[/_M/_ /)O'Q$_[ ES_P"@&OQ@J*7\27HOU/L\F_W9_P")_DC]2?\
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M2=BRA2P_ .OYUK^._%$WC?QMKWB"X+&;5+Z:\;<<D;W+ ?@#C\*]#^*W@O\
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M6W_HI:YZ?^[1_P"W?R9CGOQTO^WO_;3H****S/F0K\4?V@_^2\?$7_L8;_\
M]*'K]KJ_%']H/_DO'Q%_[&&__P#2AZF/\9>C_-'T^2;U/E^I[M_P3/\ ^2\Z
MQ_V+\_\ Z/MZ_39_NM]*_,G_ ()G_P#)>=8_[%^?_P!'V]?IL_W6^E=.*^"/
M^%_FSS,R_P!\G\OR1^$6O?\ (<U'_KYD_P#0C5"K^O?\AS4?^OF3_P!"-(VB
MWRZ(FKFV?^S7N&M!<X^7S556*'T.U@>>O..AHI_ O1'WTVN9GZ??L'?M ?\
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MJ=4H^UI.^Z_K\':Q^Q]O<17EO%/"ZRPRJ'1U.0RD9!'MBOQ]_;F_Y.D\;_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#E_$GC+^R[@VMK&LDR_?:3.U?;'>N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***X?XV?$:'X3?"OQ)XJE*[["T9K=
M&/WYV^6)?Q=EJ92Y8MFE.$JLU".[T/S6_;R^*7_"Q?CQJ%C;3>9I?AU/[,@"
MG*F0',S?7>2O_ !6!^QO\,Q\4/C]X=M)XO,T[37.JW@(XV0D%0?8R&-?H37B
M]Y>3:A>3W5S(TUQ/(TLDCG)=F.23[DFOIK]C7]H[P%^SO:^(KOQ%IFN7^MZF
M\<4<FF6\,D<=N@)QEY4.2Q.>,?*O-=E"/LHZ[K\_^'U/N<7"=/".E05W:WRV
M;^[\3]+OB!X.M/B%X'UWPU?C-KJEG):N<?=W*0&'N#@CW%?B#X@T.[\,:]J6
MCW\?E7VGW,EK.G]V1&*L/S!K])?^'FWPN_Z /B[_ , [7_Y)KX=_:6^(/A;X
MJ?%O5/%?A*SU&PL=32.6X@U**.-Q<!=KD!'<8.U6SG.2W%<T8RC4O;1K_AOU
M.+*J=:CS4ZL6ENOZ_K8^G?\ @F7\4_*N_$7P^NY?EE']JV 9OXAM291]1L;'
MLQK[^K\1?@U\1+CX4_%#PYXJ@+$:==J\R*>9(3\LJ?BA8?C7[9:?J$&K:?;7
MMK()K6YB6:*1>C(P!4CZ@BNFLN9*?R^[;\/R/&S2A['$N2VEK\^O^?S/./VG
M_P#DWCXB?]@2Y_\ 0#7XP5^S_P"T_P#\F\?$3_L"7/\ Z :_&"N6E_$EZ+]3
MW,F_W9_XG^2/U)_X)P_\FZM_V&;K_P!!CKH?V]O^37_%/_76S_\ 2F.N>_X)
MP_\ )NK?]AFZ_P#08ZZ']O;_ )-?\4_]=;/_ -*8ZK%?$O\ MW]#Q*'_ ",O
M^WW^;/R5K[=_:$\&_P!M?L(_"7Q!&@:;18K=7;'(AF0HW_CZQ5\15^JNC^!V
M\<?L"66@^6))Y_"B30*!G,J)YL?_ (\JUM7TP\I=FG]UV?08RI[+$4)>;7WV
M7ZGYU_L_>-C\._C5X.U\MLAM=1C6<YQ^Y<^7)_XX[5^H/[97C<>!_P!G'Q==
M1R;+B_MQIL&#R3.0C8^B%S^%?C]7U_\ M??&W_A8'P!^#=A'-OGU"T.HWZJV
M?WL*_9^?J_G?E2KKGI*/G;Y/?\$S/$X;VF.HU.G7_MW5??<^2--T^;5M2M;&
MV7?<74J0QKZLQ  _,U]E_P#!1?PS;^#]%^$.BVR*L6FZ9<62;?[L8@4?RKQ+
M]COP7_PG'[1G@ZT>+S;:TN3J,P/0+"ID&?\ @2J/QKZ'_P""I7_(1^'?_7*^
M_G!3K/E5-=VW^#M^IK*IS9C"GVB_Q_X9'QQ\+_\ DIGA+_L+VG_HY*_<>OPX
M^%__ "4SPE_V%[3_ -')7[CU=7^%'U?Z'C9U_'CZ?JPK\K_^"BO_ "<A<?\
M8+M?Y-7ZH5\K_M%?L-_\+^^)$GBO_A-?["WVL5M]C_LK[1C9GYM_GIUSTQ7%
M]J+[/]&<V68BGAZSE5=E;]47/^"=G_)MUI_V$[O_ -"6OIRO,?V=?@K_ ,*#
M^&\/A/\ MG^W?+NI;G[9]E^SYWD';LWOTQUS7IU;U9*4KKR_(\ZM)2JSDMFV
M_O;/RO\ ^"BO_)R%Q_V"[7^35]?_ +(?AB+Q+^QGHVA7@!M]4L]0MG[_ "2S
MSK_)JR/VBOV&_P#A?WQ(D\5_\)K_ &%OM8K;['_97VC&S/S;_/3KGIBO;O@C
M\,?^%-_##1/!_P#:7]K_ -FK(OVSR/(\S=(S_<W-C&['WCTJ(V^KRI2W;_S_
M ,SUL9BH3H4(TI>]"S]+1L?BKJFG3Z/J5W87*[+BUF>"53V96*D?F*_2/_@F
M?X..D?"/7/$,B 2ZQJ1C1L<F*%0H_P#'WD_*L[XE?\$W;?Q[X_\ $'B2U\>?
MV/#JU[)>_8?[&\[R6=MS#?\ :%R-Q/8=:^G/@O\ #&W^#?PST/PA;77V]--B
M97N_*\KSG9V=GV;FVY+'C)^M:PJ?NGS?$TO\W^1T9ICJ6(I1A1=];O?^MS\@
M_CY"MM\<?B#$N2J>(+]1GK_Q\/7[)?#W_D0?#/\ V#+;_P!%+7R1\0O^";?_
M  GGCSQ%XD_X6)]A_M?4;B_^R_V)YGE>;(S[-WV@;L;L9P,XZ"OL?P[I/]@^
M'],TSS?/^Q6L5MYNW;OV(%W8R<9QTS6=-\M!0>^GY'/FF)I8F5-TG>U[_.W^
M1H4445!X85^*/[0?_)>/B+_V,-__ .E#U^UU?BC^T'_R7CXB_P#8PW__ *4/
M4Q_C+T?YH^GR3>I\OU/=O^"9_P#R7G6/^Q?G_P#1]O7Z;/\ =;Z5^9/_  3/
M_P"2\ZQ_V+\__H^WK]-G^ZWTKIQ7P1_PO\V>9F7^^3^7Y(_"+7O^0YJ/_7S)
M_P"A&OM#]C/X1Z=\;OV:?B-X6O\ ;')/JBR6=TRY-M<+ ICD'X\'U4L.]?%^
MO?\ (<U'_KYD_P#0C7Z'_P#!+_\ Y)GXP_["Z?\ HE:<(\V'DGV7YH^FS>I*
ME34X/52_S/SU\3>&]1\'^(M1T/5K9K34M/G>WN(7ZJZG!^H]#W&#7V=_P3G_
M &@/[)U6;X8ZU<8L[YFN-'DD/"3=9(<^C ;A_M!N[5T/_!1G]G[[99P_%#1+
M;,UN$MM:CC'+1_=BG/TX1CZ%/0U\#:7J=UHNI6FH6,[VM[:2K/!/&<-'(I#*
MP]P0#10J<R:GZ/\ S_7\!U(PS/"WCN]O)_U^!^@O_!4;_D4/ ?\ U_7/_HM*
M^#O /_(]>'/^PE;?^C5KZ<_:P^-MK\=_V??AEKRLB:M#?7-KJ=LO_+*X6)-Q
M [*PPP]FQVKYC\ _\CUX<_["5M_Z-6GAHN%9Q?\ ,OR1GAHN.7\LE9I2_-G[
MH4445S'Q 4444 ?C/^U5_P G&?$+_L+S?S%>F?\ !.7_ ).,7_L$77\XZ\S_
M &JO^3C/B%_V%YOYBO3/^"<O_)QB_P#8(NOYQUT83^%'_#_[:?=8[_<9>B_-
M'ZF4445SGPH4R;_5/_NFGTR;_5/_ +IK*M_#EZ,:W/P/N(7N=4DAB4O)),45
M1U)+8 K]IOV>?@IH_P #/AKI>AZ?:11ZBT*2ZG>!1YES<%<NS-U(!)"CL *_
M'KP"BR?%;PXCC<K:U; @]QYZU^Z5=4?=H)KJ_P DO\Q5O>Q,K]/U;_R"ORS_
M ."CWPSTWP/\9K'6-*MDM(O$5F;JXBC&%-PKE9' [%@4)]3D]Z_4ROSN_P""
MJ?\ R,7P\_Z]+S_T.*N.I\<'Y_HS:G\,_3]4>S_\$V]<GU;]G4VDTF]=-U>Y
MMHANSM0A)<>WS2,?QKO?VO/A?XR^,7PDD\+>#;BQMY[J[C>]^W3O$)($RVQ2
MJG)+A#S@8!KRG_@E_P#\D-\0_P#8PR_^D]O7V"S+&I9B%51DL3@ 5V8F*D[/
MM%_@F<N'DXJZ[R_-GPO^Q?\ L7>(_AG\2]0\3?$+1[:-]-A5=(VW,5PC3,3N
ME 4D@HHP-P'+Y'3C[JKY9^+7_!0_X;_#N_N-,T9+KQIJ4)*NVFLJ6BL/X3.W
MWOJBL/>O!_$'_!4[Q1<9_L/P-I&G>G]H7<MW_P"@"*LO:<Z26R-.3E;;ZGZ,
M7EG;ZC9S6MW!'<VLZ&.6&90R.I&"K \$$=J_$'XY>$;;X>_&3QCX?L,I9:;J
MD\-L,\K&')09]@0/PKV/5_V\OCI\0;Y+#1;Z'3IY_D6S\/Z6KR/[+O$CY_W3
MFOGSQH=?;Q5J;>*?MW_"1-,6OO[2W?:?-/)\S=\P;V-9<K]HIK31_I^7ZFG,
MN1Q\_P#,_</X=ZE)K/P_\,:A*S/+=:7:SNS=26B5B3^=?!__  53_P"1B^'G
M_7I>?^AQ5]Q_"'_DDW@K_L"67_HA*^'/^"J?_(Q?#S_KTO/_ $.*M<5_'7^)
M_DS/"_P/^W5^:.=_X)P_ W2O'WB[6?&6O64=_9Z 8XK*WG4-&;I\MYA4\$HH
M&,]V!Z@5^F=?'7_!+^-5^"/B)PH#MX@D!;U MX,?S-?8M;UM&HK9)?BKF-/6
M\O-_@['CG[6OPSTWXG? ?Q5:WMK'->:=92ZC83,/GAGB0N"I[;@"I]0QK\S_
M -C'7)]!_::\"2P2>7]HO3:2<X#)+&R$'\Q^(%?K;\3O^2:^+/\ L$7?_HEZ
M_'G]EK_DXSX<_P#8;MO_ $,5SX;_ 'JW?E_%M/\  VQ'^[7]?R1^TUY=Q:?9
MSW4[B."&-I)'/1549)_(5^)7Q4\<:M\?/C+J>L8DN+S6K\06-N3]R,L$@B'I
M@;1]<GO7Z^?M 7\VE_ WQ_=6[;)H]"O"C>A\EAFOR=_9'T^+4OVE/A[#.H>,
M:HDN",_,BLZ_JHI4HJIB5&6VGXO7\BZC=/#N2\_P7_!/U6_9_P#@;HGP%^']
MEH.EP1M?,BR:CJ&T>9=SX^9B>NT'(5>P_$GTNBBM)2<G=F48J*LCX[_X*$?L
M[:9XN^']Y\0])LX[?Q)HBB2]DB4 WEKD!M_JR##!NNT,/3'SQ_P3E^+%SX.^
M,Q\)SSM_9'B6)H_*8_*MS&I>-QZ$J'7WR/2OTF^)FGPZM\./%5E<*'@N-*NH
MG4]U,3 U^-/[.][+I_QZ^'DT+;9/[>LDS[-,BG]":G"Z5W36SM^-U_P?4K$:
MT.?JK_A9K_+T/V5^)W_)-?%G_8(N_P#T2]?AUX9\/7GBWQ'I>B:?'YM]J-S'
M:0)ZN[!1^IK]Q?B=_P DU\6?]@B[_P#1+U^37[$6E1ZO^U%X&BE3>D5Q-<=,
MX:."1U/_ 'T!4T(J6):>UE]WO7'6DXX>Z\_R1^J?P9^$>B?!/P#IWAC0X%2.
M! US<[?GNIR!OE<]R3^0P!P*[BBBM)2<GS,B,5%61^7_ /P46^!>G_#GQYIO
MB[0[5;33/$GF?:K>(82.[3!9@.P<,&QZJQ[U]&?\$W_BC/XT^#-WX<OIC-=^
M&;D6\18Y/V:0%HA^!$BCV J+_@III\5S\ M,N77][;:Y 4;_ 'HI@1_GTKQ;
M_@EGJ$D?Q&\:V()\F;2HYF&>-R3 #CZ2&IPO_+RET6WR2E_FO0K$_8J==/Q=
MO^#ZGTQ^VM\%_'7QT\!Z1H'@Z?3X[:*[-W?PWMRT+3;5Q$JX4@@%F)W$<A:\
M\_8;_9%UKX/Z]KOB;QWI$%OKD>VUTK$\4X2,@F252C':6X49P<;O6OLBZNX+
M&UFN;F:.WMX4,DDTK!410,EF)X  [FODWXH?\%)/AYX+OI[#PW87OC2ZA.TS
MV["VLR0<$"5@6;ZJA4]B:F$E2D[;O_AO^ .474BD]E_PY];UG>(O#^G^*]#O
M]'U6UCO=-OH6@GMYE#*Z,,$$&OSM\0?\%2_%]RQ_L3P7HFG+V^WSS71_\<,5
M>>ZC^VU\?/BC?_V9H6H26\UP-HL/#>EJTK?[IVO*/P:AKF7+;<:?*[W/#=6L
MV\ _$N]M;:5]^BZN\4<H^]F&8@-]?EK]T[>3SK>-S_$H;\Q7X*ZLNH+X@O5U
M;S_[5%TXN_M1)E\[>=^\GG=NSG/.<U^\]C_QY6__ %S7^0K:*?U>-W?7]$8U
M&O;NRM=/\_\ @GY@?\%-/^2_:9_V H/_ $;-79?\$V?@/HWBEM9^(.O6$.HG
M3[E;+2X;F,/'',%#O-@\%@&0*>Q)/7&.-_X*:?\ )?M,_P"P%!_Z-FKZN_X)
MWV,=I^S'I$B !KF^O)7XZMYI3^2"HPNE.<NU_P#TK_*YKBM9PCT=O_23Z,U;
M1[#7].GL-3L;?4;&==LMK=Q++%(/1E8$$?6DU15CT>[55"JL#@*!@ ;3Q5VJ
MFK_\@F]_ZX/_ .@FL*W\*7HRZ?QQ]3\3/@7_ ,EY\ _]C'8_^E*5^WU?B#\"
M_P#DO/@'_L8['_TI2OV^KM_Y<1]7^43"7\>?R_-GS'_P46_Y-EU+_L(V?_HR
MOF/_ ()?_P#):O$7_8"?_P!'PU].?\%%O^39=2_["-G_ .C*^8_^"7__ "6K
MQ%_V G_]'PUCA?XM3Y_^D#Q/\.'R_P#2C]#OBGXWA^&_PX\2>*)@&72K"6Y5
M6Z.ZJ=B_BVT?C7XW?#/P?JO[0/QJTK1[J[DEO_$&HM+>WC<L%),DTGU"AC^5
M?IE^W[J$UC^RWXI$3;?/EM(7_P!TW$>1^E?&W_!-?35OOVC'N&3<;/1KF93_
M '26CCS^3D?C4X>//7E)]%^2YOQT^XNLW&BDMW^KLONU/TU\$^"=%^'?ABP\
M/^'K"+3=*LHQ'%#$,?5F/\3$\ECR2<UN,H=2K ,I&"#T-+152;D[LE)15D?E
MU^U3^QOXHL?C=>CX=^$-0U+P_JL2WT8L8#]GM9&)$D6\X5?F&X*3P&'85][_
M +-=CXNTGX)^&-,\<6$FG>(]/M_LDT<L\<S-&C%8F+(S#)0+GG.0<UZ=12A^
M[I^SZ?U;_(<_?GSO?^O^'/P[^.7_ "6WQW_V'KW_ -'O7[9^&_\ D7=+_P"O
M6+_T 5^)GQR_Y+;X[_[#U[_Z/>OVS\-_\B[I?_7K%_Z *=#_ '2/R_(K$?[U
M+_M[\T?FI_P4F^+5QXG^*]KX)MYR-*\.PH\T2M\KW4JABQ]=J% /3+>M>Y_\
M$\?V>=.\+> ;;XC:K:)/XBUH,;%Y5!^R6N2H*>C/@DM_=*CC)S\)_M):L^M?
M'[XA7<C%BVN74:D_W4D9%'Y**]=\&?\ !13XC>!?".C>'--T'PF;#2K2*S@:
M:TN2Y1%"@L1< %CC)( YJ,-)*CS?:E^NK_1>@8B+=7EZ1_3^F_4_5BO+_P!H
MGX&Z/\>?ASJ&AW]O%_:<<;RZ9?%1YEM< ?*0>NTD ,.X^@Q\(?\ #T#XI_\
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MT$RADD0C!5@>"".U?GZW_!,;Q#_PG&H7UCXRTS1-'2^>?3?*AEN+B*,/NC#
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M2@IRYI)/117=/3:T5=;V/I\70PV%P7+4BG967>__  ^I]4TM%%?T6? C)?\
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M\^[X5^+XL?<UE6SGU@3_  KV3]MC_DUWQY_U[1?^CXZVQ_POTC^2,\)\<?\
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M^TNXM;%I./WY*-@'U*)(/?.*BA%5:LN;I_E?\=BJTG3I+EZ_YV_#<]5\%?\
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M(KNWCG@D2:&10Z21L&5E(R"".H(IMY>6^G6<UU=3QVUK"ADEFF8*B*!DLQ/
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MH-^S_P#%_3/C9\+]&\0V%U'-=M D6H0 _/;W*J!(C#MSDCU!!J(156G[1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX)P_\FZM_P!AFZ_]!CKH?V]O^37_ !3_ -=;/_TICKGO^"</_)NK?]AFZ_\
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M5U?\N(>K_*(JO^\U/ZZL*_.[_@JG_P C%\//^O2\_P#0XJ_1&OSN_P""J?\
MR,7P\_Z]+S_T.*N2I\4/7]&;4_AGZ?JCT[_@E_\ \D-\0_\ 8PR_^D]O5?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF'6?VBM-\,MX=O-,L=4TF68.^IR21H\,@7(!2-SD,B]1W/-?+?\ P[)^*/\
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M?=W,(1Y(J/8****S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!A>.]-N=9\#^(=/LX_.N[O3KB"&/<%W.T3*HR2 ,DCD\5^;?P#_8Q^,?@
MKXT>"]>UGP?]CTK3M4@N;JX_M.SD\N-6!9MJS%CQV )K]0:*(?NZGM5OI^ 3
M]^G[-[:_B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M45YO\3/VC/AQ\(9##XI\5V-A>@9^PQEKBYYZ9BC#,H/J0![UXEJ'_!33X3V5
MPT<.G>*+] <":WL8 I]QOG4_I233V'9K<^M:*^8?"_\ P48^#GB&98KN\U?P
M\6. VJ:>2OYPM)C\:^A_"WB[0_'&D1:KX?U>RUK3I.%NK&=98\]QE2<$=P>1
M56=KDW5[&O1112&%%>$:E^W)\$M'U*ZL+OQKY-W:RO!-'_95\VUU)5AD08."
M#TJM_P -Z? G_H>?_*1?_P#QBDFFKH;33LSZ HKY_P#^&]/@3_T//_E(O_\
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M5\__ /#>GP)_Z'G_ ,I%_P#_ !BC_AO3X$_]#S_Y2+__ .,4Q'T!17S_ /\
M#>GP)_Z'G_RD7_\ \8H_X;T^!/\ T//_ )2+_P#^,4 ?0%%?/_\ PWI\"?\
MH>?_ "D7_P#\8KU?X;_$[PU\7/#2^(/">I?VKI#2O +CR)8?G7&X;9%5N,CM
M3LV*Z.IHKQ#Q'^VI\&?"?B#4=$U7QE]EU/3KB2UNH/[+O7\N5&*LNY82IP0>
M02*SO^&]/@3_ -#S_P"4B_\ _C%2FI*Z*::=F?0%%?/_ /PWI\"?^AY_\I%_
M_P#&*/\ AO3X$_\ 0\_^4B__ /C%,1] 45\__P##>GP)_P"AY_\ *1?_ /QB
MNL^&G[4'PR^,'B)M"\(^)O[7U58&N3;_ &"ZA_=J0&;=)$J]6'&<\TTF]A72
MW/5****0PHHHH ***@AOK:YGN((;B*6:W8+-&C@M&2 0& Z$@@\]C0!/117E
M'Q(_:F^%_P (_$K:!XL\3_V3JZQ).;?^S[J;Y&SM.Z.)EYP>]*Z6X[,]7HKQ
M[P)^UU\)OB9XJL?#?AOQ7_:6M7I<6]K_ &==Q;]J,[?,\2J,*K'DCI7L-59K
M4FZO8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HKRCXD?M3?"_X1^)6T#Q9XG_LG5UB
M2<V_]GW4WR-G:=T<3+S@]ZJ^!/VNOA-\3/%5CX;\-^*_[2UJ]+BWM?[.NXM^
MU&=OF>)5&%5CR1THC[WPZA+W=]#V&BBB@ HHHH **** "BBB@ HHHH ****
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MJ6H6]LO_ "T< G&<#N?RS7KBJL:A54*JC 4#  ILY_,=1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M38Y0YP2O;-;M4TXNS)335T%%%%(84444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !45U;I>6\D$HW1R*58>QJ6B@#R36-+
MDT>_DMI,D#E&Q]Y>QJWH>MFQ803'-N3P?[G_ -:M/X@*1JD&1\C0_KDY/UQC
M\A7*LNT]<BLZE.-:+A-!&3B[H]#5@RAE.0>012UQFEZY-IQVG,L/_/,GI]/2
MNHL=5M]07]T^'[HW#"OFZ^%J4'?==ST(5(S]2W1117$:D=Q_J6_SWJG6BO6G
M5])EL>:B_7]$<5>IRRM8S**TB0H))P*Q]1\306H*08N)?4'Y1^/?\*];DMU.
M?VOD-O+V.QAWOR?X5[DUR]U</=3-*_WC^0]J6ZO);V8R3.7;]!["H@*C8')R
M.V\!Z*8T;495&7&V'Z9Y/Z8_/UKL:H:#&(=$L548'DJWXD9/ZFK]2(****!A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 445%=745C:S7-Q(L4$*-))(QP%4#))/H *3:2NQ[Z(^ _\ @J!\5-TG
MAKX>V<W"@ZMJ"JWU2%3_ .1&Q[J:^ J[[X[_ !*E^+OQ<\3>*I&8PWUVWV96
M/*6Z_)$OX(J_CFNL^#'[.][\5OA5\2_%D*R;O#EFDEDB@XFF#"25??$*MQZN
MM94DU3=27J_+_AM$:U/C5->B_KUNSG?V=_BA)\'?C)X9\3B1DM+>Y$5Z%_BM
MI/DE&.^%)(]U%?ME;SQW4$<T+K+%(H='4Y#*1D$'TQ7X"U^O'["OQ8_X6A\
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M$_\  17KGP:_X*7>'_%&I6VE^/=&_P"$7FF(1=5M)3-:;C_ST4C?&/?+CGG
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MV!_^35O!W^]>?^E<U=D?X4O5?J<T_CAZ_HSZ$HKQ']J;]I7_ (9I\.:)JO\
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MO+T,>5<W-U/T _X>@?"S_H >,/\ P#M?_DFC_AZ!\+/^@!XP_P# .U_^2:^
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MD0>P4(W_ &SKP?\ X)C_  Q_MSXA:[XVNH=UMHEM]DM68<?:)@=Q'NL88?\
M;05^C>N:/:^(M%O]*OHA-97T$EM/&>C1NI5A^1-=.(B_8J$=]_GT_KLSGHR7
MM7-[;?Y_UY'X'U^RG['OQ6_X6Y\!?#VI3R^;JEA'_9E^6.6,T0 W'W9"C?\
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MJ@) !(&>G(K+"R<:4&OY?T-,3%2J23[_ *GZ3_\ #T#X6?\ 0 \8?^ =K_\
M)-'_  ] ^%G_ $ /&'_@':__ "37P!_PSW\4_P#HFGC#_P $-U_\;H_X9[^*
M?_1-/&'_ ((;K_XW6IF??_\ P] ^%G_0 \8?^ =K_P#)->]? OXZ:#^T#X0G
M\1^';34;.QANWLVCU.*..3>JJQ(".XQAQW]>*_(;_AGOXI_]$T\8?^"&Z_\
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M/DV<6>(T'Y9;JQY-?>W_  4Z\83:/\(- T&%R@UC4]TP'\4<*%L?]]LA_P"
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MY'_%CZ/]#J7\*7JOU/KC_@E?_P CEX]_Z\+;_P!&/7Z,5^<__!*__D<O'O\
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MC3P+XA^'6N2Z-XFT>[T34XQN-O>1E"5R0&4]&4X.&!(..M?4'[!O[4E_\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MG+]O3XJ?\*V^ .J6EM-Y>J>(F_LJWVGD1L"9F^GEAE^KBOHVORM_X*,?%/\
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MU^4U<D?>J-OII^OZFS]V"7<]P_9U_9)\7_M%/<7FG20:-X>M9/*FU:]5BI?
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M)X?TOQ!!!IL<D46JV45RL;&4 LH=2 <=Q7S%\2O^2C>*O^PK=?\ HYZ^N/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/9J*YGP_XQ@O(4AO9%@N5X\QN$?WSV/^1Z5TU(04444 %%%% !1110 4444
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M$;+XR\!2$?(UA<J#[B1,_P Q6%3XH>OZ,UA\,_3]4?*WP#_Y+E\/?^QAL/\
MTH2OW"K\,?@[J]IX?^+?@K4[^5;>RL]:L[B>5C@)&DZ,S'V !K]NKOQ1HVGK
M8M=:O86RWSI':&:Y11<,QPBQY/S$DC &<YKO?\&/J_R1R+^++T7ZGEO[8_\
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MSZYXCUBTTK384+^=<2@;^,A4'5V/95R3VKKK*,&VOAZ'-3O))/<_.+_AU_\
M%/\ Z#_@_P#\#+K_ .1J]<_99_8;\>? _P",NE^+==U;P[=Z;:P7$3Q:=<SO
M,3)$R# >!1C)&>:\+\2?\%$_BM-XRU>]T35;>VT"6Y=K'3;K3X'\F'=\BLP4
M,3M'.6/)/M7U3^Q+^T1\2/V@KCQ!=^)[32(O#^F(D,=U9VDD4LMRQSMW&0KA
M4!R-N?F3\52YFN9=OZ_KN%1)>Z^_Z_U\CZNHHHJ"PKY/_P""EG_)N]O_ -AN
MV_\ 1<M?6%?)_P#P4L_Y-WM_^PW;?^BY:YZ_P+UC_P"E(VI?$_1_DS\L:_='
MX1ZA#JWPI\&WMNP>&?1K.12#G@PI7X75^BW[!/[6.@+X,L_AQXNU.'2-1TXL
MFEWEY((X;F%F)$1<\*ZDD 'J, <BN^/O0E%;Z/\ /_,XY:34NFJ_+_(^Z*_.
M?_@JA?12>,O 5F&S-#87,K+Z*\B!?U1J^^?%WCSP[X#T&76?$&M66DZ9&F_[
M1=3*JL,=%[L3V"Y)[5^/W[4WQN'Q[^+VH^(K9)(M(A1;+38Y1AA;H20S#L69
MF;';=CM7#/WIQ2Z:_@U^IV1TA)OK_FCF?@;92ZC\:/ EM",R2:Y9 ?\ ?].:
M_:KQU_R)'B'_ +!UQ_Z*:ORR_P""?OPWN/'/[0FF:H86;3?#L;:C<28^4/@K
M"OU+G=]$-?J;XZ_Y$CQ#_P!@ZX_]%-71BM,+ROM)_A;]###ZXB_HOU_5'X.U
M^F/_  2[L_+^#_BFYP/WNN&/J<_+!$?_ &:OS.K]._\ @E__ ,D-\0_]C#+_
M .D]O6]/X*GI^J,JGQ0]?T9]AU\Q?\%%K&2\_9GU&1 2MKJ-I,^!_#O*?S<5
M].UQ'QM^'J_%;X3^*/"A*K)J5D\<+-T68?-$Q^CJI_"N&LFX-KIK]SN==)KG
M5^NGWZ'X<5^W?[.^I0ZM\!_A_=0,&C;0[->.S+$JL/P((_"OQ.U32[O1-3N]
M.OX'M;VTE:">"08:-U)#*1Z@@U]V?L$?M;Z'X7\/1_#CQKJ,6DPP2L^DZI=O
MM@"N2S02.>$PQ)5CQ\Q'&!GLIM3IN*ZV?W7_ ,SEJ1<9J3Z77Y?Y'Z$5\\?M
M]:E%I_[+?BN.0@-=26D$8SU;[3&W\E->ZWGB32--T@ZK=ZI96NEA-YOIKA$@
M"_WMY.W'OFOS._;R_:GTSXR:E8^$/"=Q]K\,Z3.;B>_7(2\N<%04]40%L-_$
M6)' !/%5]ZT%O=?F==+W7S]OSZ'R)7[+_L?:?+I_[,/@&&52';3C* 1V>1W7
M]&%?DE\+?AWJ?Q6\?:+X5TB-GO-2N%BW 9$4?5Y&]E4%C]*_</P[H=KX7\/Z
M;H]BGEV6GVT=K OHB*%7] *[)1O0<7]I_DG_ )G'O5371?G;_(_![6+=[/5K
MZ"4;9(IW1AZ$,0:_0C_@E??0MX6\?V8;]_'>VLQ7_99' /YJ:^4/VO/AK/\
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MXG;UZX4<G''<C]A_A%\*]%^#'@'3/"FA1D6=FN7FDQYEQ*>7E?\ VF/Y# '
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M6YC,<D;#J&4\@UZCX)_:W^+OP\T.+1]#\;7D&FPKLB@NH8;L1*.BH9D<JH[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M I:* /Q=_:L^*9^+WQT\2ZW%+YNFPS?8;#T^SQ952/\ >.Y_^!5O_L1?"_\
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MT,A SL; Y'*D \\@_D[\0/AKXG^%FORZ-XIT:ZT>_C)PMPGR2 ?Q1N/E=?\
M:4D5^[%9^N>']+\36+6.L:;9ZM9-]ZWOH$FC/U5@16/+RN\3;FNK,_!( L0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?BW^UE_R
M<E\1/^PO+_2O;/\ @E__ ,EJ\1?]@)__ $?#7TU\0_\ @GO\._B5XVUGQ3J>
MM>)X-0U6X:YGCM+JV6)6;J%#6[$#ZDUU/P'_ &._!G[//BB]U[PYJ>NWMY=V
MALW35+B&2,(75L@)"ASE!W]>*,+^ZC%2Z*WX6%B/WC;CW3_&Y[K1110,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD9@JEF.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_17#:5X]FBPE_'YR_P#/6, -WZCH>WI^-=?8ZE:ZE'YEK,LRCKCJ/J.HZ=Z
M+5%%% !1110 4444 %%-DD6-0794&0N6..2< ?B2!3J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB]_Z_'0]HHHHKYL]<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+*ALHY%));'.YVXKUOQ-XFTWP?HMSJVK7*VME;KEW;J?10.Y)X %?,/[&/\
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MK@[Y[2X!$,K]V# $JQ[\$$^E>F^)/&-VWPMNO$_AU(KFX-@+ZW292ZE<!B"
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M[*ZB6:&3[9;KN1AD'!D!'![BKG_#-'Q)_P"A<_\ )ZV_^.5]?_"/_DEOA/\
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M2_\ HMZYC]BS_C[\6_[EK_.6NG_;&_Y)_I/_ &$E_P#1;US'[%G_ !]^+?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS[R;B/PKR6BOD\1Q1G.)^/$R7I[O_I-CTZ>6X2GM37SU_,Z36/B1XJ\0,_\
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M.E!)=U^3-*Q_X6]]BM_L?_";?9/+7R?(^V>7LQ\NW'&,8QCC%3_\7G_ZGO\
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M.][M(P=A 5/S50?QKZ2LG1RF,)[O_._Y'EW53,+QZ?I&WYGR7\6/^2G>*_\
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M35-/8****YC<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445F^(/$FF>%=-
M?4-7OH=/LT.#+,V 3V '4G@\#GBHG.-.+G-V2W;V&DY.R6II5Y;\4?V@-!^'
M)DLX<:QK2G:;.!P%B./^6C\[?H,GZ5XU\5OVGM0\2";3/#'F:5IC H]VW%Q,
M,_PX^X/IS[CI7A3,TC%F)9F.22<DFOQ[/N.XT[X?*M7_ #O;_MU=?5Z>3W/J
M\%DKE:>)T7;_ #.M\?\ Q4\1?$B\,FJWK"U!S%8P_)!&,\87N?\ :;)]ZY"B
MBOQ;$8BMBJCK5YN4GNWJ?74Z<*45""L@HHHKG+"BBND\&_#OQ#X^N_(T339;
MM5.)+C&V&/\ WG/ ..<=3V!K:C1JXB:I48N4GLDKLF4XTX\TW9'-UO>$_ VN
M^.+[[+HFFS7S@X=U&(X_=G/"_B:^FO O[*&@Z+Y-SXBN9-;NUY-NA,=L#]!\
MS8]R >XKVS3=+L]'M$M;"T@L;5/NPVT:QHOT4  5^IY5X?XFO:IF$_9Q_E6L
MOOV7X^A\UB<\IP]V@N9]^G^?Y'@/@7]D>PM85G\57SWMP1G['8L4B7V+XW-^
M&W\:]U\/^&=*\*:>MEI%A!I]JO\ RS@3&3ZD]6/N>:TZ*_8<NR7 95&V$I)/
MOO)_-Z_H?*XC&5\2_P![*_ET^X****]LXPHHHH **** "BBB@ HHHH ****
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M*** "BBB@ HHHH **** "BBB@"O?Z?:ZI:O:WMM#>6TF-\-Q&'1L$$94\'D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M",9F%JV-O2I_^3/Y=/5_<SY_&9Q2H7A1]Z7X?\$\2^'_ .R;I^G^5=^*[O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P PHHHK[D\8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!'<?ZEO\]ZIU<N/]2W^>]4Z^AR[^$_7]$<]3<****]0R"BBB@ HHHH ****
M"BBB@ HHHH *Y"XD$L\CC@,Q;\S75W$AAMY) ,E5+?D*Y"@SF%%%%!F=7I\Q
MN+*%R<DK@GU(X-6*R?#TNZ"6/^ZV[\Q_]:M:@WCL%%%% PHHHH P/$$96Z1\
M8#)CIW!/_P!:LNMSQ%&3'"_921^?_P"JL.@QEN%>O:?(9+"V<G<6B4YSG/ K
MR&O6=%_Y ]A_UPC_ /01007:***!A1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRS,>PKY%0DY<B6NUCU+JU^A%:VLU[<1P6\,D\\AVI'$I9F/H .IKZ\^ _P
MX?!-O%KFO0QS^() &BA8!ELQZ#UD]6[=!W)T?@;\#;?X<6:ZGJ:QW/B2=/F;
MAEM5(Y1#W;U;\!QDGUROWOA7A!8+EQV8*]3>,?Y?-_WOR]=OB<SS1UKT:#]W
MJ^__  /S"BBBOU@^9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^ _X5O\ 7D4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN/\ 4M_GO5.KEQ_J6_SWJG7T.7?PGZ_HCGJ;A1117J&04444 %%%% !1110
M4444 %8>O76Z18%Z+\S?7M^G\ZU[JX%K;O*W(49QZ^@KDY':1V=CEF.2:")/
MH-HHHH,C0T'3O[4U:WMV!,9.Y\#^$<GZ9Z?C7J%[;_:[.>#./,C9,_48KEOA
M_I^V&XO6!!8^6F1V')/YX_*NOI@>-=.*V/#K\SIGT('YY_I5?Q!;FUUN]C(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P =?Z>_M0!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK$"JS:Q8+]Z]MU^LJ_XT 7**I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^-
M%VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO
M_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U
M_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_
M -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__
M )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*
MI?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :
M/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^-
M%VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO
M_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U
M_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_
M -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__
M )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*
MI?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :
M/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^-
M%VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO
M_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U
M_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_
M -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__
M )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*
MI?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :
M/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^-
M%VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO
M_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U
M_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_
M -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__
M )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*
MI?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :
M/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^-
M%VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VUI_\ S_VO
M_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U
M_P"_R_XT 7:*I?VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^- %VBJ7]M:?_S_
M -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XT 7:*I?VWIW_/_:_]_E_QJ-M>TX?\
MO]K_ -_E_P : +S-4$DP7O6=-XCTY?\ E_MO^_R_XU2CUB#4K@6]I<13RGG;
M'("<>O!Z4 :,EPTCA(QN8] *M1QQV$)FG8;NY]/84P>3H]J9)&W2'J>['T%<
M]?:A+J$FYSA1]U!T% $VIZM)?DH,I#V7U^M9VVEHH ;MHIU% #**?2;: &T4
MN#24 %&VBB@!NVBG44 -HI=M)0 4F*6B@"*61((R\CJB#JS' %<.-3TGQZDT
M+JT-W&3');7"[9(S_=*GH:N>.M%@\<:2]BLRS6Z,=Z(V0S#U^E>+:EINJ^#[
MQ#>"YO+2-MPOK?!OHE PJ!V.)(Q_<?I_"RU]'E^$C*+ES6GV/*Q-9I\MO=.B
MO/">N?#S5'U/PW<-$K'=-9ODP3_[R9Z_[0P1ZUW_ (#^*5AXRD^P31-IFMQI
MNDLIN0V.K1M_$/R([BN8\*_$R*\LXHM6>&[MF"C[?;9:-6/1)<C,<G^RWX$C
MFK'C#X9V'B2V^T6NTO\ ?22,X*GJ"".AKKKTX5_<Q*M+I)?KW_,PIRE3]ZD[
MKL>JXIN*\@\+_$;7/#&I6^D>)XGU&UFE$<>J* )(L\*)% ^89_BZ^N>M>PU\
MYB,+4PLDI[/9K9GJTJT:RO$913MM)7(;B5S_ (F\:6'AMD@(>\U*0?NK&W^:
M1O<_W5]S^&>E8-_XNU7Q5<26'AN)K2V4E)=5N(R""#@B)#_Z$P^@/6G6>FZ1
MX'MY;B1_M%](=\US.VZ1V]23R:]:C@[6=;?MU^?;\_0XJF(Z0^\KKX?U#Q1(
ME]XHF6.U4AXM+A8^2A'0M_?;W/X 5/<?$32= U*RT\%$CFE2 *O8L0H/YFO.
M_%7Q.O->DGM])*B*,A9;N4E88B>@) )+$ D(H+'!PIQ4_@WX<WFJ2B]D::T1
M@-]]/Q<R=R$ )$*_[I+''+8)6O=EA8JG^_T71+I_7WGFJLW/]WJ^Y[Q2$5CZ
M3?V-DUOI,=QND1-L8=LE@!T]\#]!6S7R-2FZ<N5GN1DI*Z&44ZDQBLBQ*0BE
MHH 913B,TE "4A6EHH ;12D4E "4VGTE #:*** $(I*=2,* .ET'Q48]MO>M
MN3HLQZCZ_P"-=<K!E!!R#R"*\JK<T'Q))IK+#-F2US^*?3V]J .ZHID4J3QK
M)&P=&&0PZ&JS:Q8(Q5KZV5@<$&5<C]: +E%4O[:T_P#Y_P"U_P"_R_XT?VUI
M_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4
MO[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_
MXT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_
ME_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U
M_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_V
MO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK
M3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +-Q.MK;RS/G9&I<XZX S7D$TK3S/
M(YW.[%F/J3S7>>+M;MFT5XK:YAF>5@A$<@8A>I/!]L?C7 4 %=WIUO\ 9+&&
M(C!5>1[GD_K7(Z/;BZU*!#]W=N/&1@<X_I^-=M7AYC4UC3^9UT([R"BBBO&.
MH**** ./\12%M6E!.0H4#VX!_K2^&;?[3KUDF<8??_WR-W]*K:M(9-2N23D^
M81^7%:O@J2W@U9IKB6.%4B.UI&"C<2!W]LU]=17+2BO)'F2=Y-GHU%4O[:T_
M_G_M?^_R_P"-']M:?_S_ -K_ -_E_P :W)+%U +JUFA;A9$*'\1BO'V4JQ4C
M!!P17K']M:?_ ,_]K_W^7_&O-==V?VQ>-'(LJ-*SAD8$')SU'UH H4444 =)
MX3D)CN4_A4J1^.?\*WZY?PJW^F3+ZQY_(C_&NHKY?&JU>1WT7[@4445Q&P44
M44 %%%% !1110 4444 1W'^I;_/>J=7+C_4M_GO5.OH<N_A/U_1'/4W"BBBO
M4,@HHHH **** "BBB@ J*[8I:S,IPP1B#^%2U3UAMNG3?@/U% GL<Q11108!
M75_#ZU\S4+F?/^KC"X_WC_\ 8_K7*5W'@FYM;#3)&N+F&&260D"215)4 #O[
MYH ZZBJ7]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\ C0!G^-+?[1H$S8R8F5QQ
M[X/Z$UYM7I^J:GI]UIMW"+ZU+/$R@>:IYP<=_6O,* .NM7,EK"QZLBD_E4M5
M-)<R:?"3Z$?D2*MT&ZV"BBB@85S&K0>1?2>C_./QZ_KFNGK)\00[HHI1_"=I
M_'_]7ZT$2V,*NR^'MX UW:ENN)57]#_[+7&UI>';[^SM9MIB<)NV/_NGC].O
MX4&1ZI15+^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?Y?\ &@"[15+^VM/_ .?^
MU_[_ "_XT?VUI_\ S_VO_?Y?\: +M%4O[:T__G_M?^_R_P"-']M:?_S_ -K_
M -_E_P : +M%4O[:T_\ Y_[7_O\ +_C1_;6G_P#/_:_]_E_QH NT52_MK3_^
M?^U_[_+_ (T?VUI__/\ VO\ W^7_ !H NT52_MK3_P#G_M?^_P O^-']M:?_
M ,_]K_W^7_&@"[15+^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?Y?\ &@"[15+^
MVM/_ .?^U_[_ "_XT?VUI_\ S_VO_?Y?\: +M%4O[:T__G_M?^_R_P"-']M:
M?_S_ -K_ -_E_P : +M%4O[:T_\ Y_[7_O\ +_C1_;6G?\_]K_W^7_&@"[36
M:J3:YIW_ #_VO_?Y?\:K3>(=.7_E_MO^_P O^- &C)*%JE<78'>LJX\26+,$
M2]MW=C@*LJDD^G6M>RLQ;J;BY(# 9P>B_P#UZ '6MJ6_>S\ <A3_ #-9^J:Z
M7W0VQPO0R#O]*KZIK#WA,<>4@_5OK690 F*-M+10 W!I*?10 RBG;:3;0 E%
M%% !BDVTM% #:*=2;: $HHHH 2DVTZL/Q)%%K5A=Z4LJAY$VRIGG:>WXUK3A
M[22B1*7*KF+>>)])US6+O1+IA%<P$%4D/#J1E77U!'>N'\1?#>[T75%UKP_<
M/8:A'G;-#_$.ZL.C*<#@\<5S>M>#=2\&XCMX#J&CQRM/_9YD,95R,;XI "T9
M^F5/\2FM_P &_$YX;1TNI7U*PMXU-U))'Y<]F2<8D3/*C_GHF5]=IXK["%%T
M()T'>/;O_P /V?R;/"E4525JBLSH_!OQCBNKF/2?$\4>CZIC:MRQVVUP?8G[
MC'^Z3SV)/%>FUYQKO@_1_&^FF:W\N=)%SE<&N5TOQ/XD^%MP+:]6;7- #$E7
M8O<PC' C9FP5']UOP(KRZV!IU[RP^DOY7^G^1V4\1*GI5U7?_,]OVTE1:??1
M:I86UY;DM!<1+-&Q&"58 CCZ&I\5\^TT[,]3?4;12UQWB/QI=KJ,NC:#9F[U
M-1B6XE!$%N2 1G^^V#T''J>U:TJ,ZTN6!$YQIJ\C<\0>)-.\,V@GOYQ'O.V*
M)1NDE;^ZBCDG^7?%<?)!K/CX%M0W:+H1Y%DK?O9A_P!-&';_ &1QZYJ:Q\-V
MNBS/JVM73:EJSC+3SD?+_LJ.BCV'%<AXQ^*SS3OI^D1_:;@*6*HP544<%G8D
M*BC(RS$ 9Y->_A<(HO\ =J[[O9>G^;_ \RM7NO?T7;_/_(ZW4O%VB^ [)8X%
MCBBC'*K@<"NWL;N/4+."ZBW>5-&LB;A@X(R,C\:^?O#7@S4/%=ZMVS?:GRK&
M^N(SY$1SG]S&P^8]/GD'KA.C5[%HOV'PG;QV<M]+,\KC?-=3%V9SQDLQSSQ4
MX_"PLN1WFMQX:M*_O*T3I:3%.HKYP]4912D4E !BFTZB@!E%+C%)0 $4VG4$
M9H ;1110 TBDI]-(H 2D(S2T4 ,K7T3Q%-I+!&S+;$\IGE?<5E$4V@#U"UNX
MKZ!9H7#QMW'\JFKS?2M8GTF;?$=R'[T9Z-_]>N]TW4H=4MQ-"WLRGJI]#0!;
MHJM<:E:6LFR:ZAA?&=LD@4_D34?]M:?_ ,_]K_W^7_&@"[15+^VM/_Y_[7_O
M\O\ C1_;6G_\_P#:_P#?Y?\ &@"[15+^VM/_ .?^U_[_ "_XT?VUI_\ S_VO
M_?Y?\: +M%4O[:T__G_M?^_R_P"-']M:?_S_ -K_ -_E_P : +M%4O[:T_\
MY_[7_O\ +_C1_;6G_P#/_:_]_E_QH NT52_MK3_^?^U_[_+_ (T?VUI__/\
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M_;6G_P#/_:_]_E_QH NT52_MK3_^?^U_[_+_ (T?VUI__/\ VO\ W^7_ !H
MNT52_MK3_P#G_M?^_P O^-']M:?_ ,_]K_W^7_&@"[15+^VM/_Y_[7_O\O\
MC1_;6G_\_P#:_P#?Y?\ &@"[15+^VM/_ .?^U_[_ "_XT?VUI_\ S_VO_?Y?
M\: +M%4O[:T__G_M?^_R_P"-']M:?_S_ -K_ -_E_P : +M%4O[:T_\ Y_[7
M_O\ +_C1_;6G_P#/_:_]_E_QH NT52_MK3_^?^U_[_+_ (T?VUI__/\ VO\
MW^7_ !H NT5475K%_NWMNWTE7_&K*2+(N48,/53F@!U%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %-9EC4LQ"J.22< 55U35+?2;4SW#8'
M15'5CZ"N"U#5K_Q1=&*,%( <B('Y1[L>YH Z+5/'5K:Y2T7[5)_>Z(/\:Y^3
M6M;UICY;R(A[0_(OY_\ UZOV'AVWM<-*//E_VONC\*U1QP.!0!RZ^&;R9MTL
MJ GKDEC4P\)'O= ?]L__ *]=%10!SW_"(_\ 3W_Y#_\ KT?\(C_T]_\ D/\
M^O70T4 <]_PB/_3W_P"0_P#Z]'_"(_\ 3W_Y#_\ KUT-% '/?\(C_P!/?_D/
M_P"O1_PB/_3W_P"0_P#Z]=#10!SW_"(_]/?_ )#_ /KT?\(C_P!/?_D/_P"O
M70T4 <]_PB/_ $]_^0__ *]'_"(_]/?_ )#_ /KUT-% '/?\(C_T]_\ D/\
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M=C_='M65>7DE[,9'/T7L!0 EY=R7TQDD/T7L*@VTM% #=M&#3J* &44ZC;0
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M /7H_P"$1_Z>_P#R'_\ 7KH:* .>_P"$1_Z>_P#R'_\ 7H_X1'_I[_\ (?\
M]>NAHH Y[_A$?^GO_P A_P#UZ/\ A$?^GO\ \A__ %ZZ&B@#GO\ A$?^GO\
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MB/\ T]_^0_\ Z]'_  B/_3W_ .0__KUT-% '/?\ "(_]/?\ Y#_^O1_PB/\
MT]_^0_\ Z]=#10!SW_"(_P#3W_Y#_P#KT?\ "(_]/?\ Y#_^O70T4 <]_P (
MC_T]_P#D/_Z]'_"(_P#3W_Y#_P#KUT-% '/?\(C_ -/?_D/_ .O1_P (C_T]
M_P#D/_Z]=#10!SW_  B/_3W_ .0__KT?\(C_ -/?_D/_ .O70T4 <]_PB/\
MT]_^0_\ Z]'_  B/_3W_ .0__KUT-% '/?\ "(_]/?\ Y#_^O1_PB/\ T]_^
M0_\ Z]=#10!SW_"(_P#3W_Y#_P#KT?\ "(_]/?\ Y#_^O70T4 <]_P (C_T]
M_P#D/_Z]'_"(_P#3W_Y#_P#KUT-% '/?\(C_ -/?_D/_ .O1_P (C_T]_P#D
M/_Z]=#10!SW_  B/_3W_ .0__KT?\(C_ -/?_D/_ .O70T4 <]_PB/\ T]_^
M0_\ Z]'_  B/_3W_ .0__KUT-% '/?\ "(_]/?\ Y#_^O1_PB/\ T]_^0_\
MZ]=#10!SW_"(_P#3W_Y#_P#KT?\ "(_]/?\ Y#_^O70T4 <]_P (C_T]_P#D
M/_Z]'_"(_P#3W_Y#_P#KUT-% '/?\(C_ -/?_D/_ .O1_P (C_T]_P#D/_Z]
M=#10!SW_  B/_3W_ .0__KT?\(C_ -/?_D/_ .O70T4 <]_PB/\ T]_^0_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-P_#FN6H,9;EG3[K['?0S9P%;YN,_*>#^F:[JO/*[30[K[5IL)S\R#8WX?\
MUL'\:"2_1110 4444 %%%% !1110 4444 %%%% !1110 9J*23%$C[:HW-SM
M!YH +FY"@\U@ZAJ.T'!I-1U#;D TSPQH;^*-2/F;A90D&5O[WHH^O\J -OP7
MX=.H2#4KQ<PJ?W,;#AC_ 'C[5MZQJ?VIC#$?W0/)_O'_  JQK%\MO$+2WPH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!S&O0MI^I17<)VECN!'9A7H6GWBZA8P7"])$#8]#W'YUR7
MB"W^T:9(<9:/#C\.OZ9J]X!N_.TN6 GF&3CZ'G^>: .GHHHH **** "BBB@
MHHHH **** //?&#?:?$RQ'H B?GS_6M^N>\0<^,B#_SUB_\ 05KH: "BBB@
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MP%;K39.F#U9/1O;H?8X([KX@6^F6?AW4==OV>U_LFTEO#>0+F6)(T+M@?Q#
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MM/">I"]LFLY3EXA@9[I_];_"@!**DN(3;S,A[=#[5'0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $=S'YM
MO*A_B0C\Q6;\/92MY=Q]FC#?D?\ Z]:U8?P__P"0Q-_UP/\ Z$M '?T444 %
M%%% !1110 4444 %%%% 'G?B#_D=&_ZZQ?\ H*UT-<]X@_Y'1O\ KK%_Z"M=
M#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKH]3@\N;>/NO_.N #%2"#@CH:]!T^Z&M:.DAYDQAO]X?Y_6@"A1110 4444
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M)#="VU:YBELA>9#/M5@\@4]%.4 /0[.*\[T'3;+PK'%JMZMHEM8LL[/>HK1
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MART7*Y[J?\#_ #J6XB,,S(>QXH CHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "L+X?_ /(9F_Z]V_\ 0EK=
MK"^'_P#R&9O^O=O_ $): /0**** "BBB@ HHHH **** "BBB@#SOQ!_R.C?]
M=8O_ $%:Z&N>\0?\CHW_ %UB_P#05KH: "BBB@ HHHH **** "BBB@ HHHH
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M=?-LY"3#<*/E8>GUJIX#^(OB'X9ZP^I^'=2FTVZDB:"4QD8DC;JI!X/J#U!
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MC3K>=K6XCE3AXV##\* .YU"'R;@D?=;D55K3O"MY81W$?(P''T-9E !1110
M4444 %%%% !1110 4$A023@45!?-ML;@],1L?T- '"5H:!#YVJ0Y7<J9<^V!
MP?SQ6=6]X3AW37$N>54+^9S_ $KEQ4N2C)ETU>21TM%%%?*'I!1110 4444
M9GB*80Z7(.<R$*,?7/\ (&N5LX1<74,1X#N%/XFMOQ9<?-!"">[D=O0?UJEX
M;A,FJ(V 1&K,<_3'\R*^DP,>6C?N<%9WD=?1117HF(444R>400R2$9"*6Q]!
M0!PU[*)KR>1?NL[$?3-04M)0 ^*-II$C499B% ]S7?1QK%&J*,*HP!["N0\/
MV_VC5(LKE8\N>?3I^N*[&O S&=YQAV.R@M&PHHHKR3I"BBB@ HHHH **** "
MBBB@ HHHH CN/]2W^>]4ZN7'^I;_ #WJG7T.7?PGZ_HCGJ;A1117J&04444
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MC(SE74_==&Z,I'((KVSX4_&.Y\*LL$I-WIDAR]ONY4G^)#V/MT/ZU1CE\/\
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M"K1005)!ZT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !6%\/\ _D,S?]>[?^A+6[6%\/\ _D,S?]>[?^A+0!Z!
M1110 4444 %%%% !1110 4444 >=^(/^1T;_ *ZQ?^@K70USWB#_ )'1O^NL
M7_H*UT- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM#X]?\*O\%_\(YI%SL\3:Y$R!D/S6ML<J\GLS<JO_ C_  U^;J(TCJBC<S'
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M*XWP^2-7@QWW9_[Y-=E09A1110 4444 %%%% #)&K/O)< U<F;"UBZC/M4T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %87P_P#^0S-_U[M_Z$M;
MM87P_P#^0S-_U[M_Z$M 'H%%%% !1110 4444 %%%% !1110!YWX@_Y'1O\
MKK%_Z"M=#7/>(/\ D=&_ZZQ?^@K70T %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K"^'_ /R&9O\ KW;_ -"6MVL+X?\ _(9F_P"O=O\ T):
M/0**** "BBB@ HHHH **** "BBB@#SOQ!_R.C?\ 76+_ -!6NAKGO$'_ ".C
M?]=8O_05KH: "BBB@ HHHH **** "BBB@ HKC/B9\8/"7PATD:AXHU>*P5\^
M3;J#)/.<'A(UR3TQG[HSR17PO\:OV^/%7C&:YT[P2C^%=%;Y5NF -_*OJ6!*
MQ?1,D?WJ\K&9EA\%I-WEV6__  #II8>I6V6A^C=%%%>J<P4444 %%%% !111
M0 4444 %%%9GB+Q+IOA/2I-2U:Z%I91E5:0JS<DX  4$G\!6=2I"C!U*DE&*
MW;T2]65&,I-1BKMFG17GJ_'[P$S!1KPR3CFTG'_M.O0(Y%EC5T8,C#(8="/6
MN?#8W"XQ-X:K&=M^5IV];&E2C4HV]I%J_=6'4445V&(4444 %%8GBKQIHW@F
MSANM:O/L4$TGE(_E/)EL$XPBD] :RO#OQ<\)>+-5BTW2M6^U7L@8I%]FF3(
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M)-MTW^T :Y70)?)UBT;U?;^?']:Z_5E_>1MZC'^?SH H4444 %%%% !1110
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MLESS#9[2G6PT9)1=O>27GT;-\9@JF"DHU&G?L?GYJ'_(0N?^NK?S-?;?PO\
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M..X7[T:(\A7V.T'!]C5+_A;WA+_H+C_P'E_^(KY0]LZZBN0_X6YX1_Z"X_\
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M,,JRL$P00<@CK5#7_AOXM\*6YN-;\+ZUH\ .#+J&GS0+GTRZ@=Q6W(ENSO\
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MFCMW)DG=>HC49./<]/QKV;]K*%VTWPY*,^6LLRGTR50C^1KBOV994C^)!5B
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MFKO_  J3X3?]!/QK_P!_;3_XBN-:JYE-<DG'>W8XS_A,8_\ GI^M'_"8Q_\
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M+I/^%N?"_P#Z!GC#_OU:_P#Q=?HIYQPO_"$I_<_2C_A"4_N?I7=?\+<^%_\
MT#/&'_?JU_\ BZ/^%N?"_P#Z!GC#_OU:_P#Q= '"_P#"$I_<_2JMS^SS\0/$
MDB^(?!$Z0B$?962&^-K<;U^;(/ QAQ_%U!XK2\:?&*QCU!%\):#=3V)@&Z36
MI5CD$V6SA8PP*XV]P<Y]C7MG[*/Q-N_'-OXETRYT:#2%TQK:96AF:0S&;S02
M<@8QY(Z#UJL/CGA:ZY5J[K5:;7/1JY//$8*6)4XN,4FTIKF2;4?AWW:]-SS/
MX _LJ^,+/XD)XM^(+>2;8O*(9;M;F>[E=67+NK-P,Y))R3@>M?6/AWPKI7A2
MWFATJS6T29_,D.YF9V]2S$D_GQ6NU)7?B<;6Q3O-V79;:>1X-'#TZ*]U:]^H
MAIM/IK5P'2)2-2T4 ,HI:2@!&I*<:;0 E6]%.W5K3_KJO\ZJU9TKC5;,_P#3
M9/YB@#M-7^]%]#6?6CK'_++\?Z5G4 %%%% !1110 4444 %<7KL@DU:X(Z9
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M<;S[YZ?IBK]?)XF?/6DST::M%(****YC0**** "BBB@ HHHH **** "BBB@
MHHHH CN/]2W^>]4ZN7'^I;_/>J=?0Y=_"?K^B.>IN%%%%>H9!1110 4444 %
M%%% !1110 4444 %174/GVTL>,EE('U[5+10!QE/BD:&5)%^\C!AGU%27T7D
MWDR8QAB1]#R/TJ"@YST)6#J&4Y4C(-+5#0Y_M&EP$]5&P_AP/TQ5^@ HHHH
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M,>+:STV!HU^AE1V_-J\7\5^)M3\?>+=1UO4I&NM3U.Y::0\G+,>%'L. !V
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MC,)*M2ARM7^]=#]A-5NGL=+O+F,*7AA>10W3(4D9_*OSJ_X>0?$O_H!^%/\
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M<=237B'[9W[)GAWP_P"#KGQUX+T]-(>Q93J.G6^1 \3,%\Q%_@*DKD+A<9.
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M_P";_P!"-?3/P9^%=W\,K74!=ZA#>27A0F.&,A8RN>C$\YSZ#I7+>*OV9O\
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MQ#A1R6/=F/<GUKV<CRW/,3F+S+-)NG'^12:3TLO=3:27GJWOW.7&8C!T\/\
M5\,N9][;?/OZ'#_M%?\ )*M2_P"NL/\ Z,6OFWX2?\E,\-_]?J?SKZX^(O@S
M_A/O"MSHOVS[!YSHWG^5YF-K!ONY'IZUYMX1_9I_X17Q-INK_P#"1_:OL<RS
M>3]AV;\=L^8<?E49UDF88OB'#8ZC3O2@Z=W>*M:5WHW?1>16"QE"C@9T9RM)
MWZ/JCV#7/^0)J'_7O)_Z":^ J_02^MOMMC<6^[9YT;1[L9QD$9Q7@/\ PR3_
M -35_P"4[_[;4\:Y'F&;U:$L%3YE%.^L5O;NT&48RAA835:5KOL_T/=/#?\
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M_P ?:M:L/X.R>=X%5!_!-(GZY_K6[MH 2BEVT;30 E%&#10 4444 )1MI:*
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MX;LN?];=Q)_Z$W]*^8=(@^U:M90XSYDZ)^; 5]!?M2:D8M!T33Q_RWN7G/\
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MTA"Y>/YU_#K^F:XV@$=G16?H]X+BU",?WD?!]QV-:%!NG<*I:Q_R#9O^ _\
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M>2,8!SSCGZ$A^!_@S[5;W-]HMOK-Q;[A"^IHLXCW8SA"-N?E'.,\=:X/1O[
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M&DVD8"].(5'%<Y^TLTJ_ 'Q\8?O_ -D3_P#?.WYOTS76^ ?^1%\.?]@VV_\
M12U/XO\ #L'C#PIK.A7)Q;ZE9S6CG&<!T*Y_#-/%7DZB7F?+X6:IU*<Y;)IG
MXJ:<URNH6K6:L]X)5,*QIN8OD;0!CDYQQ7U'_P +E_:U_P"@?XK_ /"/C_\
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M0*S$I&B/E0 "!P.U9Q3E+EL>+A\OK8B+DM+=S]9Z_%WXK?\ )4/&'_89O/\
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M$Y#'G/WOL9QTK\@5SD8ZU^T?A33X=6^&>CV-PN^WN=(AAD7U5H0"/R-?C_\
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MI^K7*VX23'.QW(5U)Y&#G'4 UX=^V=^UGX>\1>#[GP+X+U!=7:^=1J.I6^3
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M-9;5O>#8]VH2OV6/'YD?_7H VM5;-R!Z+5.K&H-NNW]N/TJO0 4444 %%%%
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MJ?PH,I#K>8V]Q%*.J,&_(UW]>>5W&DS?:--MW']P*?J.#_*@@MT444 %%%%
M!7#:G:?8;Z6$?=!ROT/(KN:P/%5KNCAN .5.QOH>1_7\Z ,*SNFL[A95YQP1
MZCTKJHY%FC5T.Y6&0:XZM?1-0\MA;/\ =8_(?0^E!<78W*S/$#8LT&>2XX_
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MC-S6[=SCI8NK1H/#Q^%W_%6"OG?]HG]C;P]\;+J37-.N1X=\5,,2721[X;O
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MKY:7]J;Q6S ?V?HW)Q_J9?\ X[7L'Q=^(NI> ?!VG:MI\%K-<W%Q'$ZW*,R
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MJY<?ZEO\]ZIU]#EW\)^OZ(YZFX4445ZAD%%%% !1110 4444 %%%% !1110
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M=Q%LU'Q$_P#:$A(Y$.,0K]-N7_[:&OH.HK.SAT^T@M;>-8;>!%BCC48"JHP
M/8 5+7,W=W/SJM5=:I*H^HTT4YJ;2,0IE/IK4 <[X\\&V_CKPW<:9,WDS9$M
MM<;<F"9<[7'YD'U!(R,UYA\,?%=U8W4^C:JAM]0M)#!-"_9AZ>H/4'H001UK
MW"N2USX9Z3KGBBWUZ1I[>]C01RBW8*MPH^[O&,Y'3((...PQZ^#Q<:=.5&M\
M+U7D_P#@G#7H2E)5*>_Z'/\ BCX:IXFU9'A 6QOE\N]VD!@H^970X.'5L8.#
MU(/!-=AX4\+0>%=+CM8YI+J11AIY?O-^ Z"MF.-845$7:JC  I:YJV,JUH^S
MO[IK3H0@^:VHC4E.--KA.D2FT^FM0 E(U+10 RBBB@#5\+P^9K,9[1JS?IC^
MM=%JC;KD#^ZN*S?!D/[RYF(Z (/YG^0JY=OYES(?]K% $-%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAKI'AR':UQ$GFWDR_P#+6X;F1OIG@>RBNY-.I#7V"2BK(YAM%%%,!M%*U)0
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M=*+/38X%[!4'X5F4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6%\/_ /D,S?\ 7NW_ *$M;M87P_\ ^0S-_P!>
M[?\ H2T >@4444 %%%% !1110 4444 %%%% 'G?B#_D=&_ZZQ?\ H*UT-<]X
M@_Y'1O\ KK%_Z"M=#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:* .F\&VN$GN2.I\M?YG^E3W,GG7#OV)XJY;P_V7HZ1='V\_[QZUG4 %%%%
M!2,P52S$  9)/:EK \3:CM46B'EL,_T["@#-UG5GU"8JIQ;J?E [^YJUHV@&
MZ59[D%8CRJ=V]_84WP_H_P!J?[1.F85^ZIZ,?\*ZFO'QF+<?W=/?JSII4K^]
M(15"J%4 *!@ =!2T45X1V!1110 4444 %5M2M_M5C/%C)9>/J.1^M6:*<9.+
M370'JK'&^'_^0O;_ / O_03795R6D0^3X@$?]QG'Y BNMK[*+NKH\H****H
MHHHH P?%DA%O;Q]F8M^0_P#KUS5=%XN_Y=/^!_\ LM<[0!M>%5_TZ4_],R/U
M%=37.^$@,W1QS\O]:Z*OF,<[UW\COH_ %%%%<)L%%%% !1110 4444 %%%%
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M)<MP9#Q_NC_Z^: +&JR;IE0=%'ZFJ5/FD,LC.?XCFF4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%\/\ _D,S
M?]>[?^A+6[6%\/\ _D,S?]>[?^A+0!Z!1110 4444 %%%% !1110 4444 >=
M^(/^1T;_ *ZQ?^@K70USWB#_ )'1O^NL7_H*UT- !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXY(#XVEL<[<YP"<<&L+QUXWNK'P;J>HZ#:O?7EBX%Q;[#YL4>?F<)U.%R1[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /&OVA_A_K_ (Z;03H=A]M^RB?SOWT<>W=Y>W[[#/W3T]*R/@'\
M+_$W@KQ9>7NM:9]CMI+-HE?SXI,L70XPK$] :]\HKY3_ %;PG]J_VQS2]IO:
MZY?AY=K7V\]ST_[0J_5OJEER_CO?N%%%%?5GF!7R1\8/AYXBN/B+K=S9:%J-
MY:7$PECFMK5Y5;*@GE0>^:^MZ*^9S[(J.?4(4:LW'E=TUZ6/1P6-E@IN<5>Y
M\:^%_@7XN\27<:2:7-I5MGY[B_4Q;1[*?F)^@_*OK/PGX8L_!WA^STBQ'[BW
M3&XCEVZEC[DUKT5.1\.X/(8R^KW<I;R>_HNR_IWLBL9F%7&V4]$NB"BBBOJ#
MS HHHH 1NE5+F/(-7*BE7B@#EM6M]RDXKB]6M^IQ7HU_!N4UQ^K6OWN* .$N
MH\$U2:MF^@VL>*RI5P: (@2#D<&OI#P#XC'BSPO!,[9NHQY,_KO'?\1@_B:^
M;Z[;X3^*AX?\1+;SOML[[$3Y/"O_  -^9Q^- 'MYXX-%6+J/:V\=#UJO0 8I
M-M+10 VDI])MH ;7,>+/B5X=\%MY6J:BD5S@$6T:F27!Z?*.GU.!63\:/'DO
M@/PD9+0E=1O'\BW?&?+X)9^1C@=!ZD>]?(UQ<2W<SS3RO-,YW-)(Q9F/J2>M
M>U@<O^LQ]I-VB?(9SGO]GS]A1C>?6^R_X)].K^TMX3:8H;?5%7_GH8$VG_Q_
M/Z=JJ:+\2M2\>>)%N-)NEL],M6XL_E,DJYQNE'49'8<#U)YKYIJQI^I76DWD
M5W9SO;7$9W+)&<$?Y]*Z\7D=.M!*E-Q:^Y^O4^7I<38KF7MDG'RT9[?_ ,(9
MX9^$=K//;@+9HX6*/&75FY6/W/8'OCUS4<FFGS8-?\=0?NF^;2?">,O.< B2
MX'0 9^Z1@=\G"UD>#OB1=65Y!=6D#:IJ-V0;R.9CL #'&,<#'45W.A^$Y[[4
M)M:UN?[3>3'<\K= .P4=E'85\/5S*M[U!1M43:?96_4^^I8F->FITNI7T_0]
M1\9ZN=9UU]S?\L8,GRX%_NJ/P&3U.*H_%SXIS_#'P/J^I:!I]Q?S:?%\\UO#
MYD<#'A3(<8"YQGVKL(4N_%\CV6D/]CTR-MD^H8ZX/*1^K8[]!W]#W6C:+::#
MI\=E9Q^7"G.2<LS=V8]R?6N?!T/?4WJKW;ZOT_S^XWA2E)/E=O,_/[X3Z;X]
M_:V^,U]XLU.>;2=!B@:"6YBBS!%&-QBMHP2-Y#,6)ZC+$XW 'A->\,^*KCQ]
M=^%I]-:SO[!Q]N-V&\F%.H)9<;@P^[M/S#D'&2/U(KY0_:V^/G@/PW<-X=\F
M;4O%T#Q^;+9!56U4\E97/WCM.0@[XR5[_3XI5LTJ*.&CRV5K+>R\_P!?U/:R
MW$87*^:KBX>U?V;NT>;NU]I+?ENKNU[JZ?'^+O'!FM;>U18;+3K.,16UC:KL
MA@0= J_U.2>YKC_"/@_Q)\9M?.F:##BVC8"ZU"4$06RG)!8]R<'"CD^PR1I?
M"GX4ZY\>M22X@=[#PM'(HN=3(P6!&=D0/WGQCV7<">P/W#X/\&Z3X"\/VNBZ
M+:K:6%NN HY9V[NQ_B8]2:XW%Q=F9<R>J,CX7_"W1/A/X>&F:1#F63#W5[)S
M+<R 8W,>PZX4<#)QU)/7D4M%! VO/_BY\"_"'QLTI;3Q)IWF7,2E;;4;<B.Y
MM\\_(^.1_LL"OM7H+"DI-*2LP/S(^-7[$?C3X9?:-1T1&\6Z F6,UG&?M,*\
MG]Y",D@#^)<CN=M?.@+1MD95E/T(-?N%7DOQ6_9=^'OQ<\Z?5=%2QU63)_M3
M3,07&[U; VN?]\&N&IA>L">7L?FWX/\ CMXG\*[(I;G^U[)>/)O268#_ &7^
M\/QR/:O9?#/[2/AG6-D>H"?1ISQ^^7S(\^S+_4"F?$S_ ()^>-O#,DMQX3NK
M?Q98<L(<K;72CT*L=K?@V3C[HZ5\X>)O!VN^"[\V6OZ/?:-=]HKZW:(GW&X#
M(]QQ7R^,R/#5W><.5]UI_P  [J./Q%'2]UYGV_I>MV.M6XN-/O(+V _\M+>0
M./S%7UE/K7Y_V=]<:?,)K6>6VE'22%RC#\17::+\;?&>B;0FLRW<8_@O%$V?
M^!,-WZU\O6X;JQUHU$_73_,]:GFT'_$C;T/L\34[SA7R[I_[4FO0X%YI6GW(
M]8B\9/YEJZ*T_:LLV4?:?#\\3=_*N5<?JHKRYY)CX?8OZ-'9',,-+[5ODSZ!
M\[WH\[WKPV']J;0#_K=*U)?]T1M_[,*?+^U-X<'^KTS5&_WDB7_V<UA_9.._
MY],T^NX;^='MQF'K2&:O!9OVJM,53Y.A7<A[;YE7^6:P;_\ :IU.3/V+0K2#
MT^T3-+_(+6L,EQ\_^7=O5K_,B688:/VOP9]*F8U#<74=O$TLLBQQJ,L[L  /
M<U\C:Q^T%XSU92J7T.GH>JV<(7]6W$?@:X;5/$&IZY)OU'4;J^;.<W$S/CZ9
M->G1X;KR_BS4?37_ ".2>;4H_!%O\#ZQ\3?'CPCX=WH-0_M.X7_EE8+YG_CW
M"_K7D'C#]I/7-8#P:- FC6YX\W(DF/XD87\!GWKR6QL+G5+N.UL[::[N9#M2
M&!"[N?0*.37N7P]_8K^)GCB2&6\TM?"^GOR;C5V\N0#VA&7S_O!1[U])A,AP
MM%WY>=^?^6WWGE5<QQ%71.R\CPZ^U"ZU2Z>YO+B6ZN'.6EF<NQ^I->C_  A_
M9R\:_&:=)-&TXVVD;MLFK7N8[9<'D*<9<CT4'WQ7V_\ "W]B/P!\/_)NM5A;
MQ=JJ8/FZD@%NK?[, RN/]\M7T#!;Q6MND,$:0PQJ%2.-0JJ!T  Z"OK*>%M\
M6B/.LWJSP[X(?LD>$/@ZT&I2*?$/B6/##4KQ %A;N88^0GU)+>XZ5[E117H1
MBHJT2AM8GBSPE8>,=+>ROHP>"8I@/GB;U!_F.];;4E4!\:?$;X:7?AJ^DM;R
M'*')CF4?)(OJ#_,=JX7POXNUSX2ZI//IRI?:7=#9>Z3<DF"X7Z#[K@=''(]Q
MD'[UUW0;'Q)I\EEJ$"SP.._WE/JI[&OE?XJ_"R?PC<2F4>9IS9,=T1A<=<,>
MQ _EF@#@/"_CO3OB+J<FEM:KI6M33E+;3WDW"96;""-CC<V" 1UX)QCI2^((
M\9?LK_%S0?$0M8[C2Y(,#RB1%<JP'G6[O@X<$ @X[*P!Y%=S^R=-\,]8\=7%
MR]^LOB^W+1Z?;7T:QQXYW26[;CYCD?1@-V 1DU]>:OH]AKUB]GJ=C;:C:,06
MM[N%98SCIE6!!KJPGM,!5:Q4.9>>CL_U_K<ZLSJ83&QA/ ^XVES).\5)/[-]
M;6L[-NSNDVDCQ7X._M#)\2]*@U"[2.V>9F1K>,$)&0>4!/WL C)[]<#I7HFI
MZ/B.>_TJ**YBN$*W>G3 &&Z0C!5A@\X.,X^H(XK6U#P;H^H:+'I)L8;:RA_U
M$=J@B\@]BFT87K]/4$5Q5KJ6H> -4CT_4W\^TE.+>\ PL@]#Z,/2OF<8I4:T
MJFO(W=/K'R?]>3/!E&=*SF[^9Y9KFCW'PQF;Q!X86XG\*AL7NGMN:;2FQD[N
MI,7^USCU(YKO=-FTOXK:5"\,YM[Z("6&\@<I)"P_B##D5W%_IJ7V=6TEXXKL
M(1(KC,<R=U<=Q_*O-]6L;:QDN$\+6,>B31R>?=6$:E1,Q')&?X0<X   R3@$
MD#M>:^RHWJ*\UM;J#J*"NSU*_P!8O-#GADNU2XTPH%DN84.]&QRQ )RI] ./
M>MN.5)HTDC=9(W 964Y!!Z$'TKSWP/\ $"'6(#9WHVRCY'CDZ@UL-:7'A&<W
M5@&N=%D8M-:+R8B>KI_5>A^M<F'QW-[S=XO\/^!^1K3Q%]=U^1UE-IMM<1WE
MO'/"XDBD4,K#N#3SUKV=]4=XE(U+2'I3 ;1110 VBE:DH M:78G4;Z.+^'.7
M/HHZ_P"?>NMU.81QK"G [@>G856\.V(L+%KB48>0;OHO:H9I3-*SGN: &444
M4 -DD6*-G<X5023["N7GN7\1:E'"I\N $X'?'<GWKH=2M3?64L"ML+#@_0YK
MEX=)U*WN%:.%ED4Y# C'Y]*B=^5\KLP5KZG4226^E6>3B.)!@*._L/4U@0K/
MXDO29"8[9.<#H/8>_O5N/1+F_=)=0G)Q_P LUQ_^H?A6U#"EO&L<:A$48"BN
M'#X7V7O2UD;5*G-HM@AA2WC6.-0B*,!161?1B_UZW@/SQ0IYCKQQ_GY:VJR]
M+_TC4+^Y(!^?RE8>@_R*WQ4_9T9-$4US22-2L+4O$3V]P\5M&KB/_6,P..N/
MYUI:I>?8;&64$!\87/J?\Y_"L."W\GPS<RD?-,0<Y[!@!_7\Z\C!8>-6\YK0
MZ:U1QT1T=O,+B".4# =0P'U&:DJ&Q0QV=NC##+&H(/TIFH7#6]J3&,S.0D8_
MVCP/\?PKSN7FGRQ-[VC=EFBLC0[=K*YO;8R&18RA!(QU!)_I5O5K[[!8O(/O
MGY4^I_SG\*TG1<:OLEJQ*=X\S+22))NVLK;3M.TYP?2JVK70M-/F?.&V[5YP
M<GCC^?X5E^$V.RZ!]5/\Z/%DQ$=O$#PQ+$?3I_,UO&A;$*EO_5R'.]/F+'A=
M"NFDD8#2$CWX _I6O5+18S%I=LK==N[\R3_6KM?3+8X HHHI@%%%% '/>+?^
M77_@?]*YVNC\6+\MJ<=V'\JYR@1TWA/_ (]Y_P#>'\JW:P?";?N;A>X8']#6
M]7RN+_CR/1I? @HHHKD-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH CN
M/]2W^>]4ZN7'^I;_ #WJG7T.7?PGZ_HCGJ;A1117J&04444 %%%% !1110 4
M444 %%%% !1110 5'<?\>\O^Z?Y5)45TVVUF)[(3^E GL<C111UXH,#T0YR<
M]:2BB@ HHHH **** .3LV%GK4T6"%9F0?GQ_GWK<K!\11FWU8R*0"P60>QZ?
MS%:]XW^A3D'_ )9L01]*9<'H2I(LBAD8.IZ,IR*=6%H%P5F:$GY7&1]1_P#6
M_E6O>,4LYV4X(C8@CZ4BU*ZN345GZ':M'9B8/NCDSE?[I!Q^HK0H&G=&3?:O
M-;W;PQ1JP4#J"2>,UH6ERMW;K*O&>H]#Z50A&WQ0A.,'U_W"*?:C[#JUS:\"
M-CO0?K@?A_*F9J3YK,-=@\RS$@'S1G/X'@_T_*MC3)_M.GV\A.XE "3W(X/Z
MU5N(_.@DCZ;E*_F*C\+S^9IYC)YC<@#'8\_SS0$MR36-(^V#SX/DNEZ$'&[V
M^OO5/3=2^TYAF&RX7@@C&<?U]JZ"L_4=&BOV\P$PW QB5?;U%!*=F<[K]CY+
M+=1?(2?FV\'=ZTEO>#4K4AO]>@^<8Z^]3:AI.J,H23]_&O0H1_\ 6)-0Z7H]
MQ;W#S2IY:%"N">3R.WX4"T;.=U>UZ\5R=Y%@FO0]7M?O<5QFI6^UCQ2 YZ08
MIE6)X]I-5S0![+\$?$WVBRGT2=LO!F6#/="?F7\"<_\  C7H<T?ER$=NU?-'
MA[6IO#NM6FH0??A?<5_O+T9?Q&17TQ!=0:OIT%[;-YD,J"1&]01_.@".BBB@
M!-M)BG44 ,HIV*YGXC>+AX&\(WVJ[/-F0".!.QD8X7/L.I]A5PBZDE".[,JM
M6-&G*K-V25V3^*/'.A^#(5?6-0CM"XRD6"TC]N% )//?I7"2?M+>$UF\L0:F
MZ_\ /58$V_J^?T[U\SZIJUYK=_->W]Q)=74S%GED.23_ $'L.!56OJJ>44HQ
M_>-MGYEB.*<5.;]A%1CYZOYGT=??%FY\?:Q'IWAFZ;3[2,[I)6PL\_?"@_=4
M=\<GV'!@U#X<Z1HVLZGXGN&03W'^EW@<Y*MP&<9_A)Q],@=,5\]PSR6TR2PR
M-%*ARKH2&!]017I6A_$B\94U"::2^UL9@2%A\A7 R2HX(.><U\UF6$ED]\7&
M3E!NS3Z>G_#'JY7GKQ<W3Q"][\/N_JYTD,:^.M/;5]9EET7P'"<1HI:.?53@
MD+&00P0_WARPSMQ]X:5I;WWCC[+;_9%TCPY9@+9Z5 -J(H  +8X8\?09X]3<
MM=+U3QUJD>JZVV(UY@M%/[N 8&0/<XY)Y/Z5O27DTUT-%\/PK+=8_>W!_P!7
M;K_>8_R'4_G7S&(Q,\8]=(=%U?\ 7_#^7U$FZGI^93UW7X?!&ERQZ;87.JZE
M%"TJV>GP--,0HYPB@D]OQ(KXOO/&GQ._:_\ BAHND6=NNE#0W<LRQLD5HN\A
MIK@$D&3;A-H R00 ,FOT/\.>&;7PW:LD1:>YD.Z>ZEP9)3[GL!V X'UR3K$8
MKZ++:GU&,I2@G)K3M'Y=35X:4[7E9=D?FO\ &[P7XD\%_$1_"<=E/<27+-)I
M]P5Q'/!GB0MT&WHPZ@^Q!/HUOXFN/#OP^TCPRHM+2"SB#7(L4*+<W'\4KEB2
MS'CJ>PP , >X?M2?&+P1\-_#/V#Q&DE_K-Y"S6-C9@>>O./,W'A$W*,YZXQ@
MX./E'X?Z=K?QYU2VL?#MM(L<A'VJZE4^5:+W+L._H.K=JA83$1C]8G?D>BZ+
M_@OS^[J?0UL=A)TH8:A349K63;NV_+1<L;?9U=]6W[MI(3JWCWQ%;:#H%LU[
MJ-TV%5>BCN['^%1U)-?87P3_ &?](^$MH+V9EU3Q-.@%QJ#J"(N.8X01E4]3
MU;O@84=!\*_A#H7PET-;/2XO.OI57[9J4B_OKEADY/HH).%' 'J<D]M0<#84
MVG4$4$F'XP\%Z'X_T&XT7Q%IEOJVF3_?M[A<C(Z,#U5AV8$$=C7PU\;?^">>
MI:3]HU7X<WC:M:#+G1;YPMP@Y.(Y.%<>@;!]V-??]%4I-;'9A\75PKO3>G;H
M?A]K&BZAX=U.XT[5+*XT[4+=MDUK=1&.2-O0J1D50:)9.HY]:_9[XC?!_P '
M?%>P^S>*- M-4PNV.X9=D\7^Y*N&7Z X]:^/?BI_P3CN[<S7OP_UQ;N/)8:7
MJY"2#V291M;Z,J]/O&M5-=3ZC#YM1JZ5/=?X'PZULR_=.?8U&RLO4$5W_CSX
M->-_AC*R^)O#.H:5&#M^TO%OMV/H)5RA_ UQE6>Q%QFKQ=T4]U+NJRT2-U44
MPVZ]B13'9D.11FI#;'LWZ4GV=O44!J,S1FG_ &=O44?9V]10&HS<*3=4WV;U
M;]*<+=.^3^- 696W>]*L;-T6K:QJO10*=0/E*ZVO]XY]A4RJ%X Q7JWP_P#V
M7_B7\2/+ETSPQ=6UD_(OM2'V6'']X%\%Q_N U]7_  L_X)Z^'-!,-YXWU.3Q
M%=K\QL+,M!:*?0M]]_\ QSZ5+DD<-;'8?#_%*[[+5GQ'\/\ X9^)_BAK(TSP
MQH]QJMSP9&C7$<()QND<_*@]R17V]\$_V!]#\+M;ZKX\N(_$6I+AQID.191G
MT<G#2D'UPOJ#7U)X=\+Z1X0TN/3=$TRTTFPC^[;V<*QI]< <GW/)K1K)S;V/
MFL3FM6M[M/W5^)';V\5K!'!!&D,,:A$CC4*JJ!@  = !VIS4ZD:LSQ"AK&C6
M>OZ?+97\"W%M)U5NWH0>Q]Z^9?BK\';CPNS3Q9N],D.$GV\J3_"X['WZ']*^
MIZAO+.#4+66VN8EG@E7:\;C(84 ?GDL>J>!]>@UO1)VM;ZW)P<95U/WD=>C*
M1P0:U)_C5I7B'Q//;:GI,?AJ"<*8)O.W0!]OSJQ(&P%LE>V#C/'/MGQ6^"\N
MA++?Z>K76EGDCJ\/^]ZK[_GZGQSX3R?"_4/BM#9>*]35+FTN$^RVL\ :SN9\
M_*KRY(&UL?*P"D@#<>5,RH5Z\7]7W6NU_O\ +T/2P&)P6'K6Q\.:G)6WM)=;
MQZ<VFTDT[M.U[J/XY_#7QI\*-*\/>-M.4016]TLTS0J3+:2!@8C)_LL<@]LX
M!ZXKU_X/_M9-\4KFX%W8)I4EL4#01%G7!4#<7/JX? XP,=>I^E;BWCNH)(9H
MUEAD4H\<BAE92,$$'J#659>$=#TW2Y].LM'L;&PG_P!9;6MND4;>Y"@<^]=6
M(J0K8+ZNHVFMI+]>_P#7S^?J4*DJCG&=D^ADWFFQZ]Y6J:5.+75(@=DJ]&!Z
MJP[@^G]17C_B+X:W=IJ5WX@\'QFSU=&\W4?#0P$EY&Z6W.1C/4KT.>,'ANYN
M[/4OAK?>8K27F@NWR3<LT'HLGMV#=^_.,]/-#:^+K2*YM9S:ZA'\T5Q"V&4_
MU'L>#WKYC#XFIAZC5K2ZKOYHPBVFTUKV_P CS?PIXJTGXI:*VEW\*S/(#&\,
MB_,K=""#T(KT#3;74_!OA;3K:VD_MN&SW+*TK$S-'N)4*V>2JD*,]=HY'6N,
MUS3;>WO+U[>QAT?Q9?+BYOX59!<!3_#DX!8*-V.2,C)%6O!'Q!EM;C^S=4'E
M7"<%6Z-[CVK?%9I"<E2IW2[^?8'72ERI_,],TK5;;6K%+JU??$W!!&&4]U8=
MB/2KE<S<:?)93-JVB;6,F#<6A.$E']&]#_.MC1M7AUNQ6YB5XSG:\4@PT;#J
MI]Z[*&(]I[LOB_/S1W4ZG-H]RX:2E:DKL-Q&IM/IE !36ZTZD:@!*58VD944
M;F8X ]325O>%M.\Z<W3CY(^%]V_^M0!LPPKH^EI$OWP,9]6/4UFU:U"X\Z;:
M#\J\55H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K"^'_ /R&9O\ KW;_ -"6MVL+X?\ _(9F_P"O=O\
MT): /0**** "BBB@ HHHH **** "BBB@#SSQ,/*\7;SP"T;?H/\ "N@K&^(%
MN8]2MIQP'CVY]P?_ *XK5MYA/!'(.CJ&_,4 24444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !36%.HH H74>X&N:U:UR#Q772IN%8
M]_;[E/% 'FVJVNTDXKGKF/!KO-6L^O%<E?6^UB,4 8C#%)4TJ8-0T ?0_P ,
M_%0\5>&U2=]U]:XBFSU;^Z_XC]0:Z%H]K$'K7SKX)\42^$M>AO%RT!^2>,?Q
M(>OXCJ/I7T>)8KZUBNK=UEBD4.CKT92,@T 0;:2GTE #:*7;24 >(?M2:7/<
M:%HFH(&,%K/)%(!V+JI4D?\  ",^_O7SC7WAK6CVGB#2[G3K^(3VEPA22,G&
M1]>Q[Y]J^:_&G[.>NZ+</+H>-9L2>%W!)T'NIP&_X"<^PKZC+<93C3]C4=FM
MC\WXBRG$5*[Q="/,G:Z6ZMIMV/(Z*Z6/X9^+9)O*'AO4PWJUJX7_ +Z(Q^M=
M5I/P+U>TC_M#Q,%TG3(B"Z*ZR2R#T&TD+GIDG/M7KU<70H0<ZDTDCX^EE^+K
M2Y84G]UE\V=/\&_#,-CX7&KWZB-9I&D1I./E' _#@UZ'H]B_CR&9I$EMM!QM
MB>-RDD[ C)'^Q@$9[YXZ9IOA[PI)XFC@N-4MC9Z+$NVUTIEV[U PID'9<=%[
M\9XX/H2J%4*H 4#  Z"OS&4?KE:=>2M&3;MW]?+\S]AP.$]A0A2>R7WD%G9P
M:?:QVUM"D%O&-J1QJ JCV%34I%5K^_M]+LYKN[F6WMH5+R2.<!17=I%=DCUM
M$B661(HV>1E1%!9F8X  ZDFOBCPS\";+4/VC-:\:R26WB#19]8EO8K:[M?,B
MD24EG)#8Y5F.T]/D!Y!KW'6/$.I_$^\:UMEEL?#H(_=D;9+C'=_1?]GVR?0;
M?^A^#[6&WMX#<7\OR0VT*Y=VQT KS%FE>+?U:7+![OOY+R_%GEUI*NT^B/2(
M=@B01@", !0HP *?7*^"M2B:?4-.N=8L[W6X666ZL+>97:R# ;48 Y![Y..H
M]B>JKT8-RBG)69Z<7S*XVDIYIE64%--.H- #:2EHH 95'6="TWQ'8/8ZMI]K
MJ=E)]^VO(5EC;ZJP(-:#4V@#P3Q=^Q#\)_%7F/%HMQH-P_672;IH\?1'W(/P
M6O%_%7_!-M]S/X;\9J5[6^JVF"/^VB'G_OBON.FM6,J-.6Z%9'YC^-/V&?B1
MX+TVXU!VT?4[2'&YK.\8'E@HXD1.Y%>1WWPM\5::S"XT>9<=2K(X_-2:_6/X
MN_\ ).]6^D7_ *-2OCGQ-_JWK!X:'0:@F?*^F^ /$NM7%Q!I^A:A?SV\+7$L
M=K;M(R1J0&<A0<*"1S[TUO ?B1/OZ%J,?_72V=?YBOK3]FG_ )'KQE_V*M[_
M .C(:;XG^[)2^JQ[AR'R]X4^$OB_QQJSZ9H>@W.H7Z1&=H4VJ50,JECN(&,L
MH_&O5-%_85^+6J[3<:58:0&[WNH1G'X1ES7L_P"Q[_R6C5_^P'-_Z46]?9]4
ML+#JQ.*/@OPY_P $X-?GD0Z]XOTVRCZLNG6\EP3[ OY?YX_"O8/"?[ _PST'
M8^IC5/$<PY87EUY4>?98@IQ[%C7TI36K6-"G'H%D<[X/^'?ACX?VIM_#F@Z?
MHT9&&-I J._^\V-S?B370-2T5MML,;1113 ::2G-3: $--I]-H 2JNI:=::K
M9RVE];0WEI*,207$8>-QUP5(P:M5S_C>UU2\T<)H\JB]202^0S!3.@X* GIR
M5.3QP <9S45)NG%SBKM=B)/EBW:Y\G_%;]E%]-^+FA:[X2CLM$T'[;:F2(,R
M);!"I:7<2>I'08YP>YQ]FUPGAOQ5;>(+62PU"/9,I,<L,HPRL.""#T-6K6:Y
M\$SK%*[W6@.?DD/S-:Y_FG\NW'%<W]K5<4HJN[Q6SZKU_P _O//H.%-N2V?X
M'7U2UC1[/7K"2SOH%GMY!RK=0>Q![$=B*MQR)-&DD;K)&X#*ZG(8'H0?2G5U
M-*2L]4STFE)69YK<)<_#6ZMU:::\TJ8[5N90,QGLC$=_? S6OK&AV?C*UCO+
M200:A&-T<R=<^A]1767UC!J5G+:W,2SV\J[7C<9!%>:7>EZC\-[K[1 \EYH3
M-]XDM);^S\<KZ-^!]3X&)P_L+V5Z?Y?\#\CSJM+V?2\?R/.?'%]_8^H*K0/:
M:['P[Q, A'&&([YYX[?SY&^\0:GJG%W?W-PO]V24E1]!G JWXVU&35O%FJW<
MC[S).Q5O]@<*/^^0*Q:_3<IRW#X+#QE3BG*23;ZNY^0YCC:N(KSC>T4VDOZZ
ME[3=<U'1Y%DL;ZXM&4\>3(5_0=1[5[/\,?B_/K]_'I.MF(74@Q!=*NSS&_NL
M.@)[8P.V,UX55C3I)8=0M9( 6G656C"]2P(Q^M>EB<+3Q$&I+7N++\RQ&!JQ
ME"3Y>JZ,^Q:***^!/W$912MUI* $:M#0]-.HW@##]S'\S_X?C5)8VD8(HW,Q
MP .]=E9VR:+IP7@R'ECZM0 :I<=(5Z=6_P *SJ5F+L68Y)Y-)0 4444 %%%%
M !1110 R>400R2$9"*6_(52T&'RM+ARNUGRY]\G@_EBC7IO)TN;!PS80>^3R
M/RS5V"(00QQ@Y"*%S]!BO(S&5H1CW.B@O>;,+Q1,TCV]JF2S'<5 Z]A_6I]:
MA"V-G9JW+2)&,]P!C/\ *JG_ "$/$Y^\4B;\MO\ 3=_.M&X!N-=MH_E*0QF4
MY]3Q_@:WI?N,-?RN1+WZEC3JF^9M3C7G9 A<X/&YN "/IG\ZN5G07 2QN[T%
M6+EW4D8X7A1^GZUY6!AS5>;L=-:5HV(=#_>76HS [D>7"MZXS_B*;JC?:M8L
MK3@JI\Q@3D'V(^@_6I?#<7EZ6C9R9&+'\\?TJIIK?:O$5W*0"%!"D=!@@ _E
MFNJC'VF+E+M_PQE+W:27<N:*F)-0?/6Y88^G_P"NL?Q1(&U%5!R5C /L<D_X
M5K>&\FQD<G.^5F_E6-?[;SQ"5Y*-*J'\, _UIT?>Q<Y=KA+^$D=5;PFWMXHC
MR44+^0Q4E%%>T<P4444 %%%% &)XK3-G"^>DF/S!_P *Y>NL\4*6TU3_ '9
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M4C4[,Y,7AUBL/.@W;F31\#45[;X]_9OU"RN)+KPPRWUHQ)^Q2N%ECR>BD\,
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MYL/\*OZM-]GTVX;_ &"H_'C^M-^'ML5AO+@CAF5!^ )/\Q0!V%%%% !1110
M4444 %%%% !1110!S_C:P^V:.95&7MVW_AT/^/X5B^&;OSK$Q$_/$<?@>G]:
M[B2-98V1QN5A@@]Q7FLL;^&-=>-LF+/!_O(>A_SZ4 =312*P=0RG*D9!%+0
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M9VOH=BVU$--I]-:D,2D:EHH ;10:* &M24ZFT %--.I&H ^&O$O\=9G[/O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***CN)TMH7ED.$49- &'XJN\)%;*>3\[?T_K77^&K#^SM&MXR,.P
MWO\ 4\__ %OPKC=!LW\1:\9I5S#&?,?TQV7_ #[UZ-0 4444 %%%% !1110
M4444 %%%% !6+XHT$:U9YCXN8LE#_>]5K:HH \XT'5C:L;.Y)0 X4MQM/H:Z
M2F^*/"HU/==6H"W0'S+T$G_UZYO3M<ET^3[->JP5/ERP^9/8T =-13(9DGC#
MQN'0]"II] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCOB]_P D[U?Z1?\ HU*^-_$W^K>OM3XD:3=:YX)U.RLHO.N9%0I&" 6VR*Q
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M17 ,'MIB.CQM^H->B9=3KZ* 0P!!R**1T!1110 4444 %%%% !1110 4444
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M1BVES<J;2<FM-%ONO4^I/BG_ ,C9KO\ U^S_ /HQJ\I\+_\ )7_!7_8=L?\
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M4EB8JRGU!'(J*BOT??<_.4^75'OOPA^*=QXCG.C:O(KWP3=;W&,&4 <J1_>
M!.>XSZ<^JU\H?#GSO^$[T+R#A_M<>><?+GYO_'<U]7U\9F="%&LN31-'Z[P[
MC*N+PK59W<7:_=!33UIU(U>0?5"4AZ4M% #*='&TTBHBEF8X %( 6( &2>,5
MU6BZ4--A-Q/@3$=_X!_C0!+IMC'HUF6?!E;EV_H*I33-/(7;J?TJ2[NFNI,]
M$'05!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"0?_LJ +']I6G_ #]0_P#?P?XT?VE:?\_4/_?P?XU7_P"%=_\ 40_\@_\
MV5'_  KO_J(?^0?_ +*@"Q_:5I_S]0_]_!_C1_:5I_S]0_\ ?P?XU7_X5W_U
M$/\ R#_]E1_PKO\ ZB'_ )!_^RH L?VE:?\ /U#_ -_!_C1_:5I_S]0_]_!_
MC5?_ (5W_P!1#_R#_P#94?\ "N_^HA_Y!_\ LJ +']I6G_/U#_W\'^-']I6G
M_/U#_P!_!_C5?_A7?_40_P#(/_V5'_"N_P#J(?\ D'_[*@"Q_:5I_P _4/\
MW\'^-']I6G_/U#_W\'^-5_\ A7?_ %$/_(/_ -E1_P *[_ZB'_D'_P"RH L?
MVE:?\_4/_?P?XT?VE:?\_4/_ '\'^-5_^%=_]1#_ ,@__94?\*[_ .HA_P"0
M?_LJ +']I6G_ #]0_P#?P?XT?VE:?\_4/_?P?XU7_P"%=_\ 40_\@_\ V5'_
M  KO_J(?^0?_ +*@"Q_:5I_S]0_]_!_C1_:5I_S]0_\ ?P?XU7_X5W_U$/\
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M +*@"Q_:5I_S]0_]_!_C1_:5I_S]0_\ ?P?XU7_X5W_U$/\ R#_]E1_PKO\
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MM[NV_P"?B+_OL4S[;;_\]XO^^Q5FY^'Y4G_3/_(7_P!E5-O ^/\ E\_\A?\
MV5 ';?#OXGIX1NA;W-PLNE2M\Z;P3&?[Z_U'>O?X9H-2M8KNTE2>"50Z21G*
MNIZ$&OD?_A"O^GS_ ,A?_95Z%\+O$UWX$E-G<W;7>CR-DQ;.86/\2\]/4?CU
MZ@'NE(14L<D-_;QW-M(LL4@W*ZG(85'0 VB@BB@#"\6>"=&\:6/V;5[)+E5^
MY)RLD9]58<CZ=#W%>2ZA^RO8R2$V/B"XMX\\+<6ZRG\PR_RKW>FFNNEBJU!6
MIRLCS,5EF#QCYJ]--]]G]ZL>0^'?V:_#VE7"3ZA<W.KLIR(GQ'$><\J.3^>/
M:O26\,Z7]KM+G[! );5=L&$PL0_V5Z ^^,BM2BLJU:>(_BNYKAL#AL)'EH02
M_KN,HI:2L3N$:DIQIM !3*?36H 2D:EHH 912TE '-^.?'VC_#[35O-5F8-*
M2L%K N^:=@,[47\N20!D9(S7A^K:IXI^,EQY=\&TCP^2"NEV[D^9CG,S\;^>
M<<*,#C(S7M/CCP+8^*VM+R:+==V6[RV/]TXW#'X#\J\ZU[QSI_AF&6TTQ8Y[
MF%=TDA8+%"O3<['A1^IZ $\5]%E_LXQ4J4;U.[Z>G^9Y>*YG*TW:/YES2].T
MCX;6*WDTD=L81N!) K2\3_';1]%TNV^Q02ZEK=U")(M-4%3'GH921\@[^I'(
M&.:\3^W:SXWU(263R2-NR-2D0J$]H8V^[_UT;YNX"5Z+X1^&EAX;MS<W6W?R
M[R2')8GDDD]37?6PM%-3Q+O+M_7_  _H<U.M-WC15EW+/@CQ%XUNM8N=:U6=
MKN&1&VZ3"%2)1C*JF>AR!\S'N<FOC7P'K3>(/VT=.U/P[I5Y8"[\0-*]A-''
MYT"MG[2&4?* H\TG'( [D5]JPZOJ7BZX?3O"=LHMHV\N?59@1!#Z@'^-L?PK
MZC)4'-=GX+^&.@>!WFO++3K7^V[I,7VK+;JEQ=,6W,68<X+<XSV'7%<\\53P
MJFW!*4E:RZ+S_JYI&C*MRVEHG>_^1U5>6?M2-J"_L_>-AI<<DMTUCL*Q#+>4
M742_AY9?/MFO4Z.O!KYNE/V=2,[7LTSUIQYXN/<^#_V /%5GIDGB?28-)GDU
M>Z"S/JOR>3#$JXCC.3NR79S@=<>U?4MGX_U7PO=_9_$\/VJP=PL6J6<6-F3U
MF7/3_:4?4=ZYOQI\([SPGJ\VN>!=+L8;>X*M>:386Z6[,PSF4'(#$_W< \<9
M)Q3/"/Q+L/$EN;:ZV[^4>.08*D<$$'H:^GJQI8R^(A&Z=K]U_E^3/'@YX>U*
M3LUMV?\ 7WG5^-OBMI>CWFEV4-S%<1ZA$9UN(W#1N@; VL#@\@Y_#UK)U#0+
M#Q3LU#3+J33-50?N[NTD*./;(Z@]P>#WK$\4?#>.ZLYGTJ.&\M7#'^S[K+1H
MS=9(L',4G^VOXAAQ7#Z=?ZIX1O)/[/:ZO;2-]IL+C!U"%0,LY11B2,?\]$Z?
MQ*M:8?#4U37L)6DN_7U_JQ-2K/F_>+0]HT7XE3Z3=)IOBV%;*9F"1:G&,6\O
M^_\ \\S_ ..^XZ5WZL'4,I#*1D,.017E/A3Q-IOQ$M4M&1+KS5Y&,X'<UZ;I
M.EV^B:9:V%JFRWMHUBC7T &*\+&TH4Y6MRRZKI_P#TL/.4UO=%JD:EH/2O,.
ML;1110 RBE;K24 (U-IQZ4V@ J"ZM8KZUFMIXQ+!,C1R1MT92,$'\*GIIZT;
M":35F?+_ (^^%6J>#[J>>&%[S2-Q9+B-2WEKZ./X<=,]#^E</7VQ65<^%=%N
MY/-GT>PFESG?);(S9]<D5]%1S>48VJQN^Y\%BN%83FY8:IRI]&KV]&?)FA^'
M]0\27R6FG6LES,Q .T?*ONQZ ?6OI;X:> T\"Z&89&674+@A[F5.F1T4>PR?
MS-=5;6L-G"(K>&.")>B1J%4?@*EKCQ>83Q2Y$K1/6RK(J672]K*7-/OLEZ?Y
MC**4]:2O)/J!&I*5JDMK62\F$<2[F/Z>YH 2WMY+J58HUW.U=/;PVGAVSW32
MHKMP78@;CZ#-6--TR/38<+\TC?>?U_\ K5CZOX1GUFZ,TVHX X2,0\*/0?-0
M VXUBVN)"S74/L/,''ZU'_:5I_S]0_\ ?P?XU7_X5W_U$/\ R#_]E1_PKO\
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MM;VL,DLL\*/(<!68 @#\>_\ 2G>)9H+FUB:*>*1E?[JL"<$?_JK0_P"%=_\
M40_\@_\ V5'_  KO_J(?^0?_ +*M"3FM'BBDOHS-(D<<?SG>P&<=!S[UUO\
M:5I_S]0_]_!_C5?_ (5W_P!1#_R#_P#94?\ "N_^HA_Y!_\ LJ0RQ_:5I_S]
M0_\ ?P?XT?VE:?\ /U#_ -_!_C5?_A7?_40_\@__ &5'_"N_^HA_Y!_^RI@6
M/[2M/^?J'_OX/\:/[2M/^?J'_OX/\:K_ /"N_P#J(?\ D'_[*C_A7?\ U$/_
M "#_ /94 6/[2M/^?J'_ +^#_&C^TK3_ )^H?^_@_P :K_\ "N_^HA_Y!_\
MLJ/^%=_]1#_R#_\ 94 6/[2M/^?J'_OX/\:X_5=G]HW!C=9$9MP93D<\_P!:
MZC_A7?\ U$/_ "#_ /95@>(-&_L.\CM_-\[=&'W;=O4D=,GTI 9==AX=F$NE
MQC.2A*G\\_R(KCZZ/PG.=EQ"3P"' ^O!_D*\_'QYJ-^QM1=IG04445\V=X44
M44 %%%% !1110 4444 %%%% !1110!R/B28R:HRX_P!6JK_7^M;&BW=O;Z7
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MV%G;_P"K@\L;!^'?\:U*?337G=7+JSVXQC%6BK"4C4M%,H;1110 TTE.:FT
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M_P"HA_Y!_P#LJ/\ A7?_ %$/_(/_ -E0!8_M*T_Y^H?^_@_QH_M*T_Y^H?\
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M_94 6/[2M/\ GZA_[^#_ !H_M*T_Y^H?^_@_QJO_ ,*[_P"HA_Y!_P#LJ/\
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MY!_^RH_X5W_U$/\ R#_]E0!8_M*T_P"?J'_OX/\ &C^TK3_GZA_[^#_&J_\
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M4 6/[2M/^?J'_OX/\:/[2M/^?J'_ +^#_&J__"N_^HA_Y!_^RH_X5W_U$/\
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MW)_*I;#PKJ6M2":[9H(S_%+]['LO_P"JNVLM(LM._P"/>VCB/]X#+?F>:N4
M4-*T6UT>'9;QX8_>D;EF^IJ_110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTW38-)M5@MTVH.23U8^I/K5NBEY@%%%%, HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 -9:AEB#58I"N: ,6\L@V>*Y[4
M-+W9XKM9(@U9]U9AL\4 >9ZAI9&>*P+JQ*D\5Z=?:9NSQ7-ZAI/7B@#@Y(2O
M:H&6NBO-.*YXK*FM2N>* (=-U*ZT>\CNK29H)TZ,O\CZCVKU_P (?$BTU\):
MWVVTOCP,G$<A]CV/L:\<:,CM416@#Z3EMRO*\BH:\K\)_%"ZTC9;:CNO+,<"
M3/[R,?\ LP^OYUZII^H66O6BW5E.LT;?Q+U'L1V/UH 0TVI7C:/J*C/6@!*:
MU.I#TH ;1110 VBE:DH :U)3CTIM !3*?33UH 2D:EH/2@!M%%% #**4]:2@
M!&IM.;I3: "FTZFGK0 4UJ=2-0 VBBB@!E%+24 (U)2M24 (:;3Z90 4UNM.
MIK4 )0W2B@]* &T444 -/6ECC:5PB*68] !5ZQT>>]8,1Y<7]YN_T%=%9Z?#
M8IB->>['J: ,[3?#ZQXDN0'?M'V'U]:V>G I:* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K,\36_VG0;U,XQ'O_[Y^;^E:=-DC66-D895A@CV- 'C=%.D0QR,C<,I
MP:;0!W&DS?:--MW_ -@ _4<'^56ZQO"T_F6+QDY,;\#T!_\ KYK9KY"O'DJR
MCYGI0=XIA1116)84444 %%%% !1110 4444 %4=<D,>E7!'7 'YD#^M7JR?$
MTACTPJ/XW"G^?]*VH+FJQ7FB)NT68.@J7UJQ &?WR'\B#7J]>8^$5#>(K,$9
M&6//LI->G5]<>:%<Q\0%!T>%L<B<<_\  6KIZP?&T7F>'Y6X_=NK<_7']:8'
M$Z"P6^;)ZH0/S%=#7,Z.3_:4./?/Y&NFH-8;!11106%%%% !1110 4444 %%
M%% !1102%!).!0!S&K3>=J$I!)"G:,]L=?US5.G22&21G;[S$D_C3:#G-[P5
M;FXU^)NT2M(?RQ_,BO2*XCX>VX:XO)R#E45!^))/_H(KMZ "BBB@ HHHH **
M** "BBB@ HHHH **** "BH;R\M]/M9+FZGCMK>,;GEE8*JCU)/2OG_Q9^V9X
M=CU271O >B:I\2=9B8JZ:+%_HT9']Z<C;V/3- 'T-17R]#^V#XA\'ZYI\/Q-
M^&UYX-T6_E\F+5DNEN(HV/02;>G;OW_"OIFPO[?5+.&[M)DN;:9!)'+&P964
MC(((H L4444 %%%% !1110 4444 %(1FEHH ADCW50NK0,#Q6IBHWCS0!R.H
M:;NSQ7,:AI?7BO2+BU##I6-?::&SQ0!Y=>:>5SQ65-;E>U>A:AI/7BN=O=-*
MYXH Y9DQ359HV#*2K*<A@<$&M*XLRI/%4I(2O:@#T;P?\5"NRSUHEA]U;P#G
M_@8_K^?K7H^V.YC66!U=&&0RD%2/4&OFUEKH/"WC?4/"T@2)O/LR<M;2'CZ@
M]C0![805.",&BJ7A_P 5:;XK@S;2;9U'SP2<.O\ B/<5HR0M'SU'K0!!12M2
M4 (U-I],H *:W6G4C4 )2'I2T4 ,HHHH :>M)3FIM  >E-IU-H *:W6G4UJ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0B)??DUIV^DVUO@E?,;U?G]*MY)IP6@ ^E%+10 4444 %%%% !1110 4444
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MWB]%4''O0!8^#?P;A^&EK=ZGJ=XVO>--5/FZIK5P=TDCGDHA/1!_GW])HHH
M*KZQJ0T/3#<@,]R^1$O0#_:/T_PJ[-Y6GVHNKIMB'[D>/F?Z>WO7BOCC7KSX
MC>(I_"^DRM!&J@:M?Q=+2$\^2I_YZN.W\(.3U (!Y&GBK0?BK^TGX6T'Q-=&
MR\'V4CWEI)<+B#5[Y&P%#]"JMGIP2/Q'W\,  #@=J^<O%WP'\._$KP.F@W=M
M]A@M(PNFW,'$MHZCY74]>PSZUC? SXYZW\/?%,7PI^*TOEZJGR:-K\AQ%J,0
MX52Q_CQ0!]3T444 %%%% !1110 4444 %%%% !1110 4444 )BHVCS4M% %&
M:V#=JSKC3PV>*W66HGB#4 <?>:2#GY:P[S1^O%>AS6H;M6?<:<&SQ0!YE=:2
M1GBLN?3RO:O2[K20V?EK'NM&Z_+0!Y_):%>U5VA*]J[&YT@\_+69/I9':@#+
MTO6+_0Y_-L;F2W;N%/RM]0>#7H&A_&!6"Q:M:[3T\^WZ?BI_H?PKA9+$KVJL
M]J1VH ][T[4],UZ+S+&YCFXR1&<,/JO4?C4TEFZ_=^85\]Q^;:RK)"[Q2+R'
M1BI'T(KJM(^)VM:;A)V34(AVF&&_[Z']<T >HLI5B",&DK#TOXI:-J*A+M9+
M&0]I5W)^8_J!726S66I1^;:7$<R?WH7#"@"LU-JW)8./ND-^E5WA>/[R$?A0
M RF4^FT )2-2TC4 )24M% #**** &M24K4E  W2FTXTV@ IE/IK=: $I&I:1
MNE #:**?'#),<(C/_NC- $5%7X]%N9/O!8Q_M&KL.A1)S*[/].!0!A$%B !D
MU;M]'N9\$IY:^K\?I6_##!;_ .K15]P.?SJ3<3[4 9]OH<$.#*3*WOP*T$58
MU"HH5?0# I=OK3J $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** $Q363-/HH KO"&JK+9ANU:.*0IF@#
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MK<O_ )$]FGD--?Q)M^FG^9]A:#^U=H'B#Q99:3%IEU9V=T_E"^O)$0*Y^[E
M3P3QG=QFO:=TC]3CZ5^:X6OL/]G'XP_\)KI/]@ZO,#KEC&/+D;@W4(XS[LO
M/J,'GYL>[PKQ=4S#$2P>827/+X79)?X?U7?5=CCS/*XT(*K06BW_ ,SV=8_Q
MJ0+3J*_6CY<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O(M2M?L.H7%OSB.1E!/< \'\J]=KSSQW:^3K0E'2:,,?J./Y 4
M<Y76^&9O,TW8?^6;D?AU_J:Y*N@\)R_-<QD\D*P'YY_F*\_'1YJ+?8VHNTSH
MZ***^:.\**** "BBB@ HHHH **** "N,UY@VK7!'(R!^2BNSKAM3;=J-T?\
MIHP_6O5RY?O&_(YJ^R1U?P[4^7?-V)0?^A5V-<M\/T TNX?'S&;!/T4?XUU-
M>^<84444P/'[R/R;R=,%=LC+@]L&NDTU_,L8#_LXX]N*PM:_Y#-__P!=Y/\
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MO_+//T(IAMI1_P LV_(URT/Q$U1?];:V\@_V0RG^9J['\2)?X],!]UF_^QH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>E?LZ^-O"_Q&\%P-HL*:;)8_N;K1B-LMM*/O;QU))R<]Z^EX84MXDBB18XT
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M>E*+(>E '*+HH_NU,NCC^[73BS'I3Q:CTH YM-'']VK$>E#TK>%L/2GB >E
M&-'IH':K$>G@=JTQ"*=Y= %)+,#M4RVX':K.T4N* (EA%/"4^B@!-M+110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^4?Q8KL?@K\:M%^-'AD:AIY-KJ,!\J_TV;B6VE'56'IG/->\5\H?M&? K4_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^E$<4:@X4=W8_P **,DL>  37ZZ?LV_L\Z1^SOX'.EVCK?:S>E9M4U+;@SR
M$*J]Q&F6V@_WF/5C42E8\O'8U86%E\3V_P SJ?A#\*]%^#'@'3/"NAQXM;1<
MRW# "2YF;EY7/=F/Y !1P *[*BBN<^%E)S;E)W;"BBB@D**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME+E//QF,AA(7>LGLB_\ LG_LMZ?^SSX;DN;N1-0\8:E$HU"\0GRXESD01?[
M/5CRQ&>  ![Y117.W<^$JU9UIN<W=L****1D%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR%=!KT_EVJQCK(>?H/\ Z^*Y^@REN=;\/80UY=S=TC"?F<_^RUW-<9\.UXU
MX_YYC_T*NSH("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]"FH:7(/W=Y'WX[..QKQOP;XTU+]E76AK.C_ &G6?A+J4^+S3SDS:1*3SQV
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MED48#=?K1&5W9A4I**NC/HHHK4Y@HHHH **** "BBB@ HHHH **** "BBB@
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M!'RPQCLV.I'TK ^&\-Q^T?\ $>7XL:\''AK2YI;/PMI4@!3"DJ]T_JQ.0/\
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M [7_ .2:ZKX7?M]?#[XM>/-(\):/H_B6VU+4Y&CAEOK6W2%2J,YW%9V(X4]
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MC#_P#M?_ ))H_P"'H'PL_P"@!XP_\ [7_P"2:8'U_17R!_P] ^%G_0 \8?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_ XA*&.BZ4N^\?PU7W/U/F,1DE:GK1?,ON9]645Y]X/^/'@SQH?+MM56PNL
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M+R"?&?*D5_R.:]?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#R/\ :(_9\TSXY^'80)FTKQ/II,VE:Q!Q);R#D#/=20,B
MOF:S\;_&:WD_X0_5?A]J>L>.(6^S0ZJ5QITB=!.[^@')^GX5]ZT4 >!? _\
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MXI_P5 _Y+CX>_P"Q?B_]*)ZZ<9_%I_+_ -(,L-_#J?/_ -*1X/\ L[?&B^^
M_P 4M+\36Q>2R#?9]1M5/^OMF(WK]1@,/]I17[1Z#KECXFT6QU?3+E+S3KZ!
M+BWN(SE9(V *D?@:_%'7?@_J.E_!OPS\18-]QI&J75Q87/R_\>T\;G8"?[KJ
M./=6]17V)_P3=_:$\Z&?X6:W<_/&'NM$DD;JOWI;<?3EU'^_Z"ME[\7#JORW
MM^J^?<PE[DE/H_\ AK_H_P#@'GW_  5 _P"2X^'O^Q?B_P#2B>OJ'_@G;_R;
M'I/_ %_WG_HTU\O?\%0/^2X^'O\ L7XO_2B>OJ'_ ()V_P#)L>D_]?\ >?\
MHTUAA/X53Y_^EF^)_B0^7_I)],T444"/PO\ C!_R5KQM_P!AR^_]*'K]HOA#
M_P DF\%?]@2R_P#1"5^+OQ@_Y*UXV_[#E]_Z4/7[1?"'_DDW@K_L"67_ *(2
MC#_[JO\ MW\F&(_WI_\ ;WYH_'/]HS_DOOQ&_P"Q@OO_ $>]?3/PY_X)I_\
M"?\ @'PYXF_X6-]@_MC3X+_[+_8?F>5YD8?9N^TC=C.,X&<=*^9OVC/^2^_$
M;_L8+[_T>]?:'PI_X*+?#?P+\,?"?AR_T3Q5-?:3I=M8SR6UI;-&SQQ*C%2;
M@$C(.,@'VJ,-R_5HWW]W\G?]"\1S?6)=M?S_ .',K_AU+_U5'_RWO_NJNX^"
M?_!/'_A3OQ1T'QC_ ,)__:_]ERO)]B_L;R/-W1LF-_VAL?>S]T]*L?\ #T#X
M6?\ 0 \8?^ =K_\ )->G? 3]KSP=^T3XBU'1O#>FZY975C:_:Y'U2"&-"F]4
MPI25SG+#J!6T')2O'<QERVM+9G?_ !A^)EA\'_AKKWB[4!YD.FVY>.'.#-*2
M%CC'^\Y4>V<U^-VJ:KXR_:,^*@EF:;7?%.NW0CAB!P!D_*BY.$C4?@ "3W-?
M>_\ P5 \13:?\(_#6D1.534=7WR@?Q+%$QP?^!.I_"O#?^"9/A>VU;XV:SJT
MZ!Y-)TEV@R!\LDDBIN'OMWC\:RHQ52M)RZ?Y7_'8UK2=.DN7=_YV_#<]:\"_
M\$N?#<>BPMXR\6:M<ZLZAI(]$\J"")L<J#)&Y<#^]A<^@KP;]JS]B34/@#I:
M>)=$U.77_"C2B&9YXPEQ9LQPOF;>&4GC< .2 1R"?U=K&\8>$-'\?>&M0\/Z
M_9+J.CW\?E7-L[,H=<@]5((.0#D$'BBI>6L=&$++26I^>W_!-OX[7FD>,9_A
MKJEV\NDZG')<:8LC$B"X0%G1?174,V/[R_[1KZ0_:F_8Y_X:6\2Z+JW_  E_
M_".?V;:-:^3_ &9]J\S+EMV?.3'7&,&O2?!?[-WPP^'M];7V@>"=)L;^U;=!
M>-#YL\38QE9)"S X[@UZ36M3EJ<K>Z_K\M#.%X<R6S/SB\??\$S?^$'\#^(?
M$7_"R/MO]DZ?<7_V;^PO+\WRHV?9N^TG;G;C.#C/0U\>> ?"_P#PG'CGP]X=
M^T_8O[6U"WL/M/E^9Y7FR*F_;D;L;LXR,XZBOVD^/7_)#OB%_P!B_?\ _I.]
M?CS\ _\ DN7P]_[&&P_]*$J*'OXE4Y;>[^+95;W<.YK?7\$C[#_X=2_]51_\
MM[_[JKZN_9P^"/\ PS[\-8_"7]M?V]LNY;K[9]E^S9WX^79O?ICKFO4:K:EJ
M%OI&GW5]>2K!:6L3332L<!$4$LQ]@ :.?D3=].HN7F:[GY^_\%/OBK]HU+PW
M\/;.;*6Z_P!JWZJ?XVRD*GZ+O;_@2U\))]HL9()U\R!^)89.5/#$!E/L0>1W
M%=Q\4/&.H_'/XRZQK<<;S7FNZEY=G!CD(6$<$?U"A!7U+^W3^SC;?#OX/_#?
M5M*A#?V!:IH>H2H/]9N!=9#_ -M?-_&05E3O3IJJ]&W^?^7NHVG:=3V2V2_+
M_/5GVC^SE\44^,7P9\,^)C(KWL]L(;T+_#<Q_))],L-P]F%>E5^=7_!,/XL#
M3_$/B#X?7L^(M03^TM/5CQYR#;*H]V3:W_;,U^BM==5+FYEL]?\ /\3DI;<K
MZ:?Y?@?DW_P44_Y.<U7_ +!]G_Z+%;/[.O[!O_"_/AC:>+_^$Y_L+[1<30?8
M_P"R/M&WRVVYW^>F<_2L;_@HI_R<YJO_ &#[/_T6*]%_93_;@\"_ SX.V/A3
M7M)\17>HP74\S2Z=;0/"5=]P +S(<XZ\5S8;E]G._G;_ ,"_RN=->_/&WE_Z
M2;-[_P $I[F.UD:S^)D4]R!\D<VAF-&/H6%PQ ]\&OC/Q-X?\1?!/XDW>EW$
MIT[Q)H%Z,3VLA^21"&21&XX(PPXZ$<5^A.I?\%1/AQ%92MI_AGQ3<W84^7%<
MPVT,;'' +B9R![[37Q++8^,OVO/CEJ-[IFE--JVM70EE6$$P6,/"@N_9$4 9
M/7'')Q51YW52A_3Z?J3+D]F^8_7#X,^-IOB/\*?"?B:YC$5UJFFPW,RJ, 2%
M1OQ[;LXK\N/V^/\ DZCQA_N6?_I)#7ZL_#WP;:_#SP+H/AFR8O;:3916B2$8
M+[% +'W)R?QK\IOV^/\ DZCQA_N6?_I)#4UW%XE..WO?H5A[JBU+>R_-'WM^
MP/\ \FK>#O\ >O/_ $KFKZ$KY[_8'_Y-6\'?[UY_Z5S5]"5UXC^++U.:C\'S
M?YL*_.[_ (*I_P#(Q?#S_KTO/_0XJ_1&OSN_X*I_\C%\//\ KTO/_0XJX:GQ
M0]?T9V4_AGZ?JCQO]E7]D7_AIK3?$-W_ ,)7_P (W_9$T,6S^SOM7F^8KG.?
M-3;C9[]:]V_X=2_]51_\M[_[JKRO]BO]JSPE^SCI/BJU\2Z=K5])JL]O+ =*
M@AD"A%<'=YDJ8/S#&,]Z^E/^'H'PL_Z 'C#_ , [7_Y)KJGRW]WLORU_$Y8<
MUO>[O\]/P//_ /AU+_U5'_RWO_NJON+P+X9_X0KP5H/A_P"T_;/[*L(++[1Y
M?E^;Y<83=MR<9QG&3CUKYKT'_@I1\,O$6N:=I5MH7BQ+B^N8[6-I;2U"!G8*
M"Q%P3C)[ U]8TO>4/)_I_P ..T7*_5?K_P ,%%%%06%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A>.H?M'
M@_5XQ_%;M_*O(M%;S-)LF]84/Z"O:/$@!\/:GNZ"VD)_!2:\2\.,3H5AGJ(5
M'Y"O7P?\-^I\[F/\:+\OU/+/B@NV[\'MZ7]RGYBJU7/BLNW_ (19_P"[J\R_
MF#_A5.O7J[K^NI\2OB?R_)&WX2CW:DS_ -R,G\\"NOKFO!L?_'U)_NK_ #KI
M3T-<KW/0I?">HZ NW1;(?],A6A5+1AMTFS'_ $R7^56V;;7CRW9]A#X4#-MK
MB_B),JPV9_VF_D*Z:\NQ$IYKS7XCZMFWMOFZ.W\JQ]LJ<D;RPLJU-I&'/J03
MO5";6O\ :KG;K5"Q/-9TE\S=ZXJN8:Z'9A\G5O>.K;6%/4@TG]I1/U1#]5%<
MB;QO6E^UMZUR_P!H2.]Y/"VQVD-U;/UAB/U05=ABLI!S:VY'_7)?\*X6'4&4
M]:U+/5CD9-=U',+[GE8G)TE>*.PCT^Q/(L[?_OTO^%.:QM!R+6 ?]LU_PK-L
M=2#XYK0:8-'UKW(5E.-TSY:IA73E9HR=2\F%3MBC7Z*!7):A,&8X 'X5OZS-
MUKE+J3YB2<#N:^7Q]5N5C[O*<.HQN<]XFUR2SVVEJV+N4;B^,^4G3=]3T'XG
MM7+QQK"I"Y))R68Y+'N2>YH6X:_FGO7Y:X<N/9!P@_(#\2:=7IX6@J$%W>YP
M8S$O$5'_ "K8*9-/';KF61(AZNP'\ZY;QMXP.AJ+2TP;UQDL1D1CU^M>8W5Y
M/?2F6XF>>0]6D;-=39Q*-SW:&ZAN/]5-'+_N.#_*BXMTN(]CY'.0R\%3Z@]C
M7@T4KV[AXG:-QR&0X(KT+P3XWEO+A-/U!]\C<13GJ3_=;_&B]]&/E:U1Z#I=
MZ\V^"<C[1%C<0,!U/1A]?Y@UNV,Q5AS7*S-]GN[6X' #^4_NK<?^A;?UKHK=
ML,*^?K4_J];W=F?04Y_6L/[VZT-:^DW76@C_ *BEO_Z&*^A]*.9K\^MRW_H*
MU\X3-NU#P^/^HG!_Z%7T9HIYOC_T]-_):^QPL^:B?GE>GR8E^OZ'5_"GYO&'
MB ^D,(KU:O*OA+SXM\2'_IG /T->JUYF+_BOY?D?29=_NZ]7^;"BBBN,],**
M** "BBB@ HHHH **** "BBB@ KB_B!\(_#?Q&MI?[2L8X]0*;8]1A&V9#C )
M(^^!_=;(^E=I17-B,-1QE-T<1!2B^C5S2G4G2ESP=F?%?Q(_9Q\2>"6DNM/A
MDUW21N;SK5,R1#)P'0<_=P2P&!STKR6OTNKB/&WP;\*>/ED?4M-6.\88%[:G
MRIEY)SD<$Y8_>!Z_2OR3-O#Z$VZN65.7^[+;Y/?[[^I]1A<\<4HXB-_-?Y'P
M117M/C[]EOQ+X99[C1"/$-AG.V(;+A![IGYO3*DD]<"O&[FUFLYFAN(9()E^
M]'(I5AD9Y!]J_(<?EF,RRI[/%TW%^>S]'L_D?4T<12Q$>:E*Y%1117F'0%%%
M% !76^$_BMXK\%L@TK6KF*!2#]EE;S(3@8QL;( QQQCH/08Y*BNBAB*V%FJE
M";C)=4VG^!$Z<*BY9JZ\SZ/\*_M@W,(BA\1:(EPH #W6GOL;KR?+;@G&/X@,
M@^O'KOA?X^>"/%4D<4&LQV=RY"B"_4P-D]!D_*3QV)[>HKX3HK[O \<YMA+1
MJM58_P!Y:_>K?C<\6MDV%JZQ7*_+_(_2N*5)XTDC=9(W 974Y# ]"#W%/K\[
MM \<^(?"V!I.M7VGH/\ EE#.PC/7JF=IZGJ.IS7IGA_]J_QCI8VZBEEK2X^]
M-#Y3YR>\>!W_ +O8>^?OL'XA9?6LL53E3?\ X$OT?X'B5<BKQUIR4OP_K[S[
M%HKPKP[^UQX9U !=6T^]TB3&=RXN(^O3(PW_ ([VKT?0OBYX-\2$+8>([!Y&
M&1'-+Y+G@GA7P3P#VXK[?"9[EF.M[#$1;?2]G]SL_P #QZN#Q%'XX/\ KS.N
MHIJLLBAE(96&0P.013J]TX@JO?W'V.QN)\J/*C9\MTX!//M5BL?QC-]F\(ZY
M-MW>78SOMSC.(V-95I>SIRGV3*BN:21^=-%%%?Q>?K9TG@WXB>(? -WY^B:E
M+:*QS);YW0R?[R'@G'&>H[$5]/?#C]J#0/$T<5IX@9-!U0G!D?\ X]7YXPY)
MV<==^![U\>T5]1D_$F89,[4)WA_*]5\NS]/G<\[%9?0Q:]]6?=;GZ5Q2I/&D
MD;K)&X#*ZG(8'H0>XI]?"?P_^.GBKX>^7!;7GV_3%X_L^]R\:CT0YW)WX!QG
MJ#7U1\/?CIX7^(0C@@NQIVJ,<?V?>$(['/&P]'SZ Y]0*_=\EXMR_-[4[^SJ
M?RRZ_P"%]?P?D?%XO*Z^%]ZW-'NOU/1****^V/'"BBB@ HHHH *X7XA7!:]M
M(,<)&7S_ +QQ_P"RUW5>;>-9C)X@F4](U51^0/\ 6@#"HHHH **** "BBB@
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M7%K)Q) XZJPKB_VC_P!G!OB,UOXO\(7']A?$/2?WEI?1?*+@#_EG)Z@].?\
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M\//^O2\_]#BKCJ)J4'Y_HSKIM<LUY?JCQO\ 95_9%_X::TWQ#=_\)7_PC?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$OD7@LH/4'G!Z@^U ]SZB1]W!ZTYEW#!KG?"?BRT\6:=]HM]T,\9V7%K)Q)
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MGB.PUOPM#8ZMJES?01W-W<K(J22LZA@+<@'!&<$CWKE/^'7_ ,4_^@_X/_\
M RZ_^1J_3^BLHQ4(J*V1I*3E)R?4_,#_ (=?_%/_ *#_ (/_ / RZ_\ D:NF
M^&7_  3E^)/@OXC^%O$%[K?A66STK5+6^FCM[NY,C)'*KL%!MP"<*<9('O7Z
M,T5I&3A)26Z,Y14HN+ZA7AO[0G[(7@K]H3%]?K+HGB6--D>LV"KO< <+,AXD
M4?@PZ!@.*]RHK-Q4MRU)K8_-#6_^"7/CZWOG71_%GAN^L\_++?&XMI#]46.0
M#_OHUUGP[_X);SK>PS^.O&$+6R-E['08F)D'IYT@&W_OV?J*_0.BKB^4EZF'
MX*\$Z'\._#-EX?\ #FG0Z5I%FNV&WA!P.Y))Y9B>2Q)))YK<HHH;<G=@DDK(
MYKXF>&KKQI\./%/A^RDABO-5TNZL89+@D1J\D3(I8@$@989P"?:O@OX9?\$Y
M?B3X+^(_A;Q!>ZWX5EL]*U2UOIH[>[N3(R1RJ[!0;< G"G&2![U^C-%*'[NI
M[1;Z?@.7OP]F]M?Q*6M"_.CWPTKR/[3\A_LOVIBL7F[3LWD D+NQG )QV-?F
MW-_P3/\ BIJ^MO>ZKXF\*RFZN#-=SI=W32-N;+L ;< MR3R1S7Z8T4DDI\_4
M;;<>4H:#HMIX:T/3](L(Q#8V%O':P1C^&-%"J/R J_115-N3NR4E%61X#^V+
M^S;=_M&^!M+LM&N+&R\0Z7>>=;7&H,Z1&)EVRH61&(SA#T/*"O)OV3?V._B=
M^SS\4EU[4-8\-7>AW5K):7]M97=RTK*<,C*K0*I(=5ZD<%J^UZ*5/]VW*/7_
M "L.?[Q*+Z?YW/B#]JS]A_QU\=/C#>^*]!U;P]::=/:P0+%J-S.DP9$VDD)"
MXQGIS7C_ /PZ_P#BG_T'_!__ (&77_R-7Z?T5,8J*LOZOJ5*3D[L_,)/^"7_
M ,42PW^(/"*KW*W=T3^7V:O0_AA_P2]%GJEO>>/?%,-[:1/N?3-%C<";'9IG
MP0/4!,XZ$=:^^J*T3Y7=$-7*FDZ39Z#I=IIVG6T5E86D2PP6\*A4C11A5 '0
M "OA[]IO]A+Q]\:/C5KWB_1-7\-VNFWZVXBBU"YN$F&R!(SN"0,.J'&">,5]
MV45G)<TN=[E1?*G%;'Y@?\.O_BG_ -!_P?\ ^!EU_P#(U'_#K_XI_P#0?\'_
M /@9=?\ R-7Z?T50CX4_9C_83\>_!;XS:)XNUO5_#EUIMBDZR1:?<W#S'?"Z
M# >!1U8=2.*] _;4_94\6_M':MX5NO#6HZ+8QZ5!<1SC59YHRQD9"-OEQ/D?
M*<YQVKZKHHE[_+?[.WX_YA'W7)KJ?F!_PZ_^*?\ T'_!_P#X&77_ ,C4?\.O
M_BG_ -!_P?\ ^!EU_P#(U?I_10!^8'_#K_XI_P#0?\'_ /@9=?\ R-7WW^SU
M\.]2^$WP:\,>$M7GM;G4M+@>*:6R=FA8F5W&TLJDC##J!7HE%5S/E<2>5<RD
M%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'D?[3'[0NE_LZ_#]]9N8EOM8NV-OI
MFG%L>?+C)9CU"*.6/T'4BORD\9?$3XB_M(^,XEU&ZU+Q/JMS(?LFE6:.\<7'
MW88%X4 =2!G R2>37J__  4/^($_B[]H6]TGS6:Q\/6T5E%'GY0[*))&QZDN
M ?\ <%?4W_!./X0Z?X5^$ \:36L;:YXAEDVW+*"\=JCE%C4]@65F..ORYZ"H
MHQ51.K+;I^GW[^A5:7LVJ<=W_3^[;U/BC4OV*_C7I>CMJ<_@&]:V5=Y2WN+>
M:;'_ %Q20R9]MN:R_@?^T9XV_9Y\2))I5Y/)IBRXOM O';[/,,X8;#_JY./O
M@9!'.1D']I:^-/VH_P!@V^^-'Q0B\4^%=1TG08[R #5%NA)NDG4D"551""2N
M V2.5SSDU2E.,UR[?U^ N6,HOF/J7X;?$#2OBEX&T?Q5HLGF:?J4 F0-]Z-N
MC(W^TK J?<5^8/\ P44_Y.<U7_L'V?\ Z+%??_[+7P(U/]GGP#=>&K_Q(GB*
M*2\:[@\NU,(M]RJ&09=L@E=W;DGUKX _X**?\G.:K_V#[/\ ]%BHQ'+[2'+M
M?_VU_D51YN27-O;]4>)>'?A'XZ\8:6FI:#X+\1:WISLR+>:=I4]Q"S X(#HA
M!(/7FM/_ (9[^*?_ $33QA_X(;K_ .-U^DO_  3M_P"38])_Z_[S_P!&FOIF
MNBI'D=O)?BKF,)<ROZ_F?BUX+^ 7Q/M?&.A33?#CQ;##'?P.\DFAW2JJB122
M28^ !7ZZ_&3_ ))'XW_[ E[_ .B'KL*X_P",G_)(_&__ &!+W_T0]<V)E_L\
MH^3_ "_X!O0C^_C+S7YGXP_!O_DKG@C_ +#=E_Z/2OW.K\,?@W_R5SP1_P!A
MNR_]'I7[G5VR_@Q]7^43F7\1^B_4****YS4_#KXZ?\EJ\>_]AV^_]'O7[&?
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M (-2+72S_!,Y5^]@T_-?BT?ES_P4T_Y+]IG_ & H/_1LU?1W_!,O_D@.I_\
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MHM]?P_0_;^JVI:C;:/IUU?WDJP6EK$T\TKG 1%!+,?8 &K-?,/\ P4(^*O\
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MFT*Z 'X^77??L)_\G4^"/]Z[_P#22:OV"KKE'EC%]_\ ,YE*\W'M8_#?P?\
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MFD>(5MBHG;2KZ*Z$1;.W=Y;';G!QGK@T;[!MN;]%%,DD2&-Y)'6.- 69F.
M.I)]* 'T5Y__ ,-"?"S_ **7X/\ _!]:_P#QRC_AH3X6?]%+\'_^#ZU_^.4
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M1]-U[2+[1-115=K/4;9[>8*1D$HX!P1TXK]ZJ_)O_@HI_P G.:K_ -@^S_\
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M6;'[1J%RO_+"U0C>WU.0H_VF%?M)H.A6'A?1+#2-+MDL].L84M[>WC&%CC4
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M_EG)Z@].?_U>*^'_ (N7_BFVN;I-*;2OB;X?=5US03E/MD*Y#2(O\7J.XY%
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M+H_AT72V/D?VM?Q6OF[3/NV>8PW8W#..F1ZU]Q?\-"?"S_HI?@__ ,'UK_\
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M ()Z_M/:SXTN[GX<^*[Z74[NWMC<Z5?W+[IFC3 >%V/+8!#*3S@,,X KN?\
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M9G/4\\9+'!P#BM/]JKQI-X\_:$\<:E*Y>./49+* $\+% ?*4#\$S]2:_3O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >??''X)Z!\>O ESX:UY&CR?-M+V(
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M3*/[VG'_ -#%>P5X.,_B_)'VV6_P'ZL****X3U0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MYX_;&D4>'_#D9/SM=2L![!!G^8KZ'KYI_;,G.WPE"&&";IV7C/\ RQ /\Z^-
MXPER9'B'_A_&43ULJ5\93^?Y,^9Z**] \$_ SQ?XXDB>VTR2QL7Y^VWX,4>W
MU&1N8<_P@U_,^%P>(QM3V6&IN<NR5S]"J5848\U25D>?UO\ A/P'K_CB[%OH
MNF3WISM:15Q&G^\Y^4=>YKZF\%_LK^%_#S07.K23:_>(,LDV$M]WJ$')_P"!
M,0?2O9+6UALK>."WAC@@C&U(HE"JH] !P!7ZCE?A]B*UIYC4Y%_+'5_?LOQ/
MG,1GE..E"-_-[?Y_D?.G@G]D.&%XKGQ1JGVC')L; %5^AD/)'7@ ?6O>/#O@
M_1/"-OY.C:5:Z:A 5C;Q!6?'3<W5C[DFMBBOUO+<CR_*5_LM))]WJ_O>OW:'
MR^(QE?%/][*Z[= HHHKWCB"BBB@ HHHH YOQ[_R!4_Z[+_(UY[7H7CW_ ) J
M?]=E_D:\]H$:/A__ )"]O_P+_P!!-=E7&^'_ /D+V_\ P+_T$UV5?.YA_%7I
M_F=U#X6%%%%>8= 4444 %%%% !1110!Q_B*V%OJ3D8 D ? _(_J#^=;_ ,.V
M&Z_7//[L@?\ ?7_UJI>*X=T$$W=6*_F,_P!*D^'\A&J7"=C#G\F'^-?4X6?/
M1B^VAYU1<LF=[111789A1110 5XTS;F)/?FO7=0E,-A<R#JD3,,''0&O(:8C
MH=!@$=H9.\AZ^PX_GFM*H[>$00QQCG:H&<8S[U)2.A:(****!A1110 4444
M%4M:_P"0;-_P'_T(5=JEK7_(-F_X#_Z$*!2V9S-7M#.-:L/^NZ?^A"J-7M#&
M[6K#_KNG_H0H.=['K%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&R\O[3P7HO\ ;-Q81K+<)]J@@V*Q(4YE=0>0>F:^W_\ @JA_R)G@+_L(7/\
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MS2JU+$-KS_%HN5^3?_!13_DYS5?^P?9_^BQ7ZR5^3?\ P44_Y.<U7_L'V?\
MZ+%<U3XH>OZ,WA\,_3]4?9?_  3M_P"38])_Z_[S_P!&FOIFOF;_ ()V_P#)
ML>D_]?\ >?\ HTU],UW5OB7I'\D<E+X?F_S9^0O[?'_)U'C#_<L__22&OO;]
M@?\ Y-6\'?[UY_Z5S5\$_M\?\G4>,/\ <L__ $DAK[V_8'_Y-6\'?[UY_P"E
M<U887_=?N_4UQ/\ %A\O_23\K?BG;R6GQ.\70RKLDCU>[5E/8B9Z_:+X)WD6
MH?!SP+<0G=%)H=D5/_;!*_,3]O3X47/PY^/6JZFL!72/$C'4K68#Y3(V/.3Z
MA\GZ.M?2_P"P7^U5X=O/ .G_  \\4:I!I&N:5F'3YKV01Q7D!8E$5R<>8N=N
MT]0%QGG!A?>P_)U5OPNF&(5J_/TU_&S1]L45B>*O&V@>!]$EU?Q!K%GI&F1K
MO:YNYE12/09/S$]@,D]J_);]HK]I_6OB1\;M0\5^$]9U30+"WC6PTV2SN9+:
M4P(2=S;2"-S,S8/0,!VJ.;WE'^D7R^ZY'["45X_^R<WC*Y^!?AV_\=:I<ZIK
MNH(UV&O%421P.?W2,0 2=F&RV3\W7BO8*VG'DDXOH8QES1YD%%%%06%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 17(S;R
MC_8/\J\"\-_\@O\ [:R_^AM7T XW(P]J^??"[;]++8QF:0X_X&:]7!?#+Y?J
M>!F?QT_1_H<U\55W>$_%"^NEY_)S7!Z6V_3+0^L*']!7HOQ(C\SP[XA7^]I+
M_HU>:Z"V[0]/;UMXS_XZ*]F7P+^NA\75_BO^NK/3=%;=I-J?]@5<8XK.\/-N
MT>W/H"/UJW-)M!-<<G8]&FN9(]!\)W0CT"+GHS?SIU]K"QYYKE=%U;R]%*[N
MDC"LG4M99F/S5\IB\4H2:1^CY;@'4IQ;[&Y?:_U ;-<1XTU;SK.(9_Y:?TI)
M[YGSS7#>+O&FDPHL O5N)T?YH[<&5E]CM!Q^->(J]2K.T5<^HGA:5"DW-I>H
M^2ZW5"9,UR[>-(/X;*\8>N$'Z%P:?#XRL&;$OGVI]9HCC\QD?K6\J5?=P9PP
MJX;937WG602+Q6O:R(!S7+6M]%=0B6"9)HVZ/&P8'\15M=0,?>BG64-R:V%=
M5>ZSHKBX15XK#N[CGBJDNJ;N,YJE>:E':VLMQ*V$C4L:FKB%4=HE8?!.BN:0
M:IK$&EP^9.^,_=11EF/H!7,W7B;4+ECY*1V<?;</,?\ P'ZUFR7$M]<-=7',
MK_=7M&O9117LX? PBN:KJSP\5F524G&B[+\29M1U%CDZE.#_ +*H!^6VIHO$
M&J6YR+B.Y']V9,?JN/Y53IK&NV6'HM:P1PPQ6(3TF_O.EL?%D%PPBF4VDQ.%
M#'*M]&_I6;JE\1?2G/?^E8%RP92K#<IX*GH:I+>212"*1S(C'".QY'L?7ZU\
MGCX*A[U)Z'W.6R>*2C66O<Z2/4CGK5J.\+8YKF#=>6RJ SR,?E1>IJU'#<2+
MF:8Q _\ +.$XQ]6ZG\,5&!IXG%+FC\/=AFDL'@7RRUEV6YT/G^^*7SCZU@+8
M6ZYS'O)ZLY+$_B30MC#&<QJ8F]48BO=_L^=OC/E_[1IW^#0Z2.Y*XYJ];Z@1
MC)KDH[J[M3\S?:XO< 2#\N#^5:EI>)<QB2)MRG]#Z'T-<\O;85^]L;<E#&1?
M)N=3HEWO^(7A0D_=FE/_ (Y7NWAV8-I<?^])_P"AM7S?H5SCQYX=8G[KR'_Q
MVO>O"=[NTV(9[M_Z$:^DPN+]I32?];GR>(R_V-1R2[_^VG=_#_\ Y*,Q[FPQ
M_P"/'_"O8*\:\ 2?\7%B/]ZR8?J:]EJ,9_$7H=>6Z4FO-A1117">J%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>2?&GX+WWQ8US0GCO[?3]/LXY%GD8,\I+%3\J8P?N]2PZ]
M*];HKS\?@*&94'AL2KP=KK;9W_0WHUIX>:J4W9H\[\%_ 7P=X):">WTT7VH1
MC_C\OF\UL^H7[JGW !]Z]$HHK3"X/#X&G[+#4U"/9*W_  Y-2K4K2YJDFWYA
M111789!1110 4444 %%%% !1110!@^-D+>'Y2!D*ZD_GC^M>;UZ=XN4OX=O
M!GA3^3 UYC0!=T:3R]4MCG'S8_/C^M=M7":>P2^MV)P!(I/YBN[KP,Q7OQ?D
M=E#9A1117DG2%%%% !1110 4444 4-=C,NE3@#) #=/0@G]*SO <@CUQE/\
M'"RC\P?Z5M7D9FM)T'5D9>/<5S?@]@OB*TR<#YA_XX:][+I7A*/F<=?=,]-H
MHHKUSF"BBB@"CKC!=%OR3@>0XY_W37E^GQF2^@ Z[P?RY/\ *O1O%S%/#MX1
MP<*/S8"N!T./?J"G^XI;^G]: 6YT=%%%!T!1110 4444 %%%% !5'6G"Z>X/
M5B /SS_2KU9GB#_CS3_KH/Y&@F6QS]:/AU/,URQ&<?O0?RYK.K:\'?\ (QVG
M_ __ $!J#$],HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF_R0ZBBBN8[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH HZY&)='OE(S^Y<_B 2*\GKV1T$B,C#*L,$5X[)&8I&1OO*2#^%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y5_P""D7BAM#_9
MW_LZ.0H^L:I;VK 'JB[I3^L:UX;_ ,$L] 2X\;^.-:9 7L]/@M$;T\V1F/\
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M^)'_ "4CQ1_V%KK_ -'-7[ ?LG?\FV_#O_L$0_UK\?\ XD?\E(\4?]A:Z_\
M1S5I5_WWYR_-"H_[LO\ MW\F?N1X;_Y%W2_^O6+_ - %?F!_P4K_ .3BX/\
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MQ^)?P>U;PSX)NK.SU/462&XDO9FB!MN3(BLJMRV N#@8+<U^3/\ PSW\4_\
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MEQ^Q[XF2)2[_ /",JV!Z")2?T!KCBVL!)KLO_26=DTI8U)]W^:/RGT'3-?\
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MG&3Z5^8=C;7MUX@M[>P++J,ETL<!601L)2X"X8D;3NQR2,5]7?\ "C_VR?\
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MD?F6#ID^J_X5[<CYZ+/.J*EN+6:UD*31/"XZJZD&I;'2[O4Y1':V\DS'^ZO
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M$'_%OF/ZF@S-*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6_(5/]W5]H]M/U_S/QF_97^-&G_ 7XO67BG5K*[OM-6VFM9XK':9MKKP5#$
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M-8LO:J]G5PTKPT$J]#&0Y:FIY=<QS6>1=6TMN<XW%=R_]]#BJCWUJ<XN8?\
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M6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*H"JHP .U>8^%;<76OV:G.%;S./]D$C]0*]0H)"BBB@ HHHH **** "BBB@
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MX[^*TD7VJST33;QGN+6Y^WZGJ-N@5'NB0X;&,9W!< \A5'W<XKM/$GCZ]O\
MS[+1+V?4K^<"&]\17'S!5'\$7; [*O&<LV>!7-_V?8:3H\L4I"6B R32RG)8
M]2[$]2357<E[Q^=YMFBK3Y,/HM/PV^[I_5_K;]F']I*/XH6(\.^(72U\86<>
M6[)>QC@2I_4=C7T#7Y#_ &#5M.U:'Q!I]Q/I-_"V_2IP2KQ '/S#_:[CT_*O
MO_\ 9;_::LOCAH<FG:BJZ=XPTQ0E]9,<>9V\Q/53^F:\NM1Y'S1V/T?A[/HY
MA#ZO7?[V/XGO-%%%<A]L%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'A7[;WB)_#7[,7C66,E9+J&*Q!'I+*B-_XZ6KXB_P"";.AK
MJG[13WC(&&FZ/<W"DCHS-''^>)#^M?7_ /P4,M9+G]F#76C)Q#>6<C@=U\Y5
MY_%A^5?*_P#P3!F1?C?K\9.'?09"H]<3PY_G3PNM6;?9_P#I-_U88C2E!+NO
M_2DOT/T[K\'/&W/C37A_U$+C_P!&-7[QU^#WC#_D>-;_ .PC/_Z-:LHQY\1"
M/=/\XFO_ "ZEZK]3]6O@7^Q[\-_!OPSTBVUCPGI/B+6;NTCFO[_5;1+ES*Z@
ML(]X/EJ,X&W'3)YR:_-#]H[P)8?#/XX>,?#6E(T>FV-\1;1LQ8I&ZJZKD\G
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M_P %(?\ DVV7_L+VO_L]+&Z-Q6W,OS0L+K=O^]^I\P_\$QO^2^ZQ_P!B]/\
M^C[>OTB\5?$3PIX$:V7Q+XFT?P\UR&, U6_BM3+MQNV^8PW8R,XZ9%?F[_P3
M&_Y+[K'_ &+T_P#Z/MZ]^_;_ /@#X]^-MWX+?P7H7]LKIR70NC]LMX/++F+;
M_K9%SG:W3/2M:S:C2LNGZR(HI.52[Z_HCZ%_X:$^%G_12_!__@^M?_CE0>/K
M&U^/GPAU[2/!OC'3TAU:%K+^VM-=;Z)!D>:@,<@!)7*GYN-U?F1_PP5\=O\
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MN7H96[?OWKZ!TK_@FC\3-:TNSU"V\0^$&MKN%)XF^V77*,H8'_CV]"*RP_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBHI170****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHKD-0HHHH **** ,+Q9-MMH(L?><MGZ#_P"O6K\/;<+874^>7D"8_P!T9_\
M9JYOQ/,)-1"#/[M #]3S_45VO@^W^S^'[;*;&DW.>.N2<'\L5]1@X\M&/F>=
M5=YLVJ***[3,**** "O(M0A%IJ-S$AXCE91^!(KUVO,_&$/D^(+G PK[7'XJ
M,_KF@1KQR"2-77HPR*=5/29?.T^+)R5&W\NGZ8JY0="V"BBB@84444 %%%,F
MD\F%Y",A5+8^@H YG5)?.OYCC&&V_EQ56E^O)I*#G.L^'MONO+N?/W(PF/\
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MHETMW87*Y5EX*D<%6'4,#D$'D$5Y%6FX/R/WS)\TAF-!>][ZW_S-VBBBL#Z
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M\O='MYII"  "SLA). !R>U9RC>HI^OXV_P A4_<I>S]/P3.8_9._Y-M^'?\
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M:3"(9L?*7C9U=<^HRI_X$*_2OPOX)\.^![.6T\.:#IGA^UF?S9(-+LX[9'?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*]TY"2BHOM4/_/:/_OH4AO(%Y,T8'^^* )J*@^W6W_/Q%_WV*/MUM_S\1?\
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M=>L?_?1_PH'AVZ_O1C_@1_PH S**U?\ A'+G^_%^9_PI/^$<N?[\7YG_  H
MRZ*T_P#A'KKUC_[Z/^%'_"/77K'_ -]?_6H Y;7E^6 ^FX?RJ+P__P ?K_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!NO\XGJU%%%>(?;A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(4$>0<Y/)/\ /'X5Z/7CUS.UU<2S/]^1RY^I.: .D\*P;+.24@@R/C/J!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5;JWQA4<[><_*>1^A%>LUY_X_55UB$@88P GW^9J *GA6<I>2Q9X=,_B#_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6/XBNS'&D"M@MRV/3_/\JV*Y#4I
MC<7TSYR-V!]!Q0!6K7T'3Q,YGD4&-3A0>Y]:RHHVFD2->68X%=E;PK;0)$O1
M1B@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JZEJ$.EV
M<EQ,V%4<#NQ[ >]6J\W\5^(/[8NA'"S?9(ONC^^W][_#_P"O0!E7EU-JE]),
M^7EE;.T9/7H!_*NKT?31IMM@\S. 7_P_"J/AW2?)5;N7[[#Y%] >_P!36[7S
M^-Q/M'[.&R.RC3M[S"BBBO*.D**** "H;U@MG.2,@1L<?A4U8?B35/)C-I&?
MG<?.0>@]/Q_E]:VHTW4FHQ(G)1BVRY\.O^8A_P!L_P#V:NSKDOA[;LMK=SG&
MV1U0>OR@D_\ H5=;7UYYH4444 %%%% !1110!Y-H_P#R$H?^!?\ H)KIJY:X
MB?3-1DC_ (H)"!GO@_RKI+6X6ZA61.A'(]#Z4S2#):***1H%%%% !7/ZUIXM
MY/.C&(W/(]#_ (5T%-DC6:-D==RMP0:"6KH?X&US</[-F;D9:$_J5_J/Q]J[
M*O([NUETVY&"PP=R2#CIW^HKT3PUKJZW8Y;Y;B+"RKZ_[0]C08FQ1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %5[VS2^@,;_4-Z&K%% '$R
M1M#(R.,,IP13[2X:UN$E7^$\CU'<5J^([7#1SJ.ORM_2L6@#MHY%EC5U.589
M!IU9GA^?S;'83DQMC\.M:= !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R9MD,C9QA2?
MTKBJ[*\7=:3CU1A^E<;0!H:%&)-10G^$%O\ /YUU%<UX=;%\P]4(_45TM !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 445D^(]<71+'</FN),K$
MOOZGV% &/XV\0>2AT^W9EE;F5E/12/N_CQ^'UK!\/Z3]JD%Q,F8%^Z#_ !'_
M  J#3=-FUBX:65F\O=F20\ECZ?6NNC18T5%&%48 ]!7DXS%<B]G!Z]3HI4[^
M\QU%%%> =H4444 %%%% %/5K[^S[)Y1]_P"ZGU/^?TKF-)TJXUZ^\I&Y/S22
MMSM'<^YK:\5?\@^/_KJ/Y&NB\)Z>ECHL#!5$LRB1V'4YY'Z8_6OH,O@E3YNK
M.*LWS6-*PL8M-LXK:$$1QC R<D]R?SJQ117JG.%%%% !1110 4444 <KXO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!&7<I!Z'BN*FC,,KQMU4D&NVKFM>M?)O/, ^2
M09_'O0!4TZX%K>12$X4'!^AXKL*X>NHT>^^V6P5O]9'PWOZ&@#0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ KAO'6GO;7\.H1C*OA6..C#I^8_E7<U%<VT5Y
M\,R"2)QAE;O0!P]CJ$5Y&N& EQ\R=\^WK5H@,"",BJ^I^ KB)F:RD6>/M'(<
M/U]>A_2J \(:RV%-MA?]J5<#]:9?.:O@6\,6H7EBF7@.9%;=P,'&??((_*KW
MB[P[)?;;ZS7_ $F,?,JCEP.A'N/U_"K?AGPV-#C=Y'66YD&"RCA1Z#_/I6Y0
M9GF)UJYYMS;D77*]\@_[N.M:&F^!9[RS6:>?[([<B,Q[CCWY&/I7?44#U>YR
M=G\/[>.0-<W+3J/X%79GZG)KJ+>WCM84BA01QH,*JC@5)12 **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHJC?:O#9Y7/F2C^!?ZT 7'=8U+,0JCDDU@:EKC3
MQV^53H7[GZ>E4;S4)KYLR-A>R+T%5J "I;>VDNI1'&N6/Y#ZU+8Z=-?/A!M3
MNYZ"NGL[..QA"1CZMW- #-/T^.PAVKRY^\WK5JBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *I:AI<5\,GY)<8#C^M7:* ./O-/FL6Q(ORGHP
MZ&J]=M)&LB%' 96&"#6->^'ARUL<'_GFQX_ T 8]O=2VL@>)RI[^A^M;EGX@
MCDPLZ^4W]X<K_P#6K EA>%RDB%&'9A3: .V5UD4,I#*>A!R*=7&6]U-:MF*0
MH?TK8M/$0(VW"8/]Y/\ "@#;HJ*"ZBN5W12*X]CS^52T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)5&ZUFVM1P_FO
M_=0Y_6@"_52\U."SR'?+_P!Q>36'=ZY<7&54^2GHO7\ZSJ -&\UR>ZRJ?N8_
M1>I_&LZBKMEI,]YA@/+C_O-_3UH I %B !DUL:?H+28>YRB_\\^Y^M:MEID%
MB,HNY_[[=:MT -CC6) B*%4< "G444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% $4]O%=)ME0.OO6->>'67+6S;A_<;K^!K
M>HH XJ:&2W;;(C(?<4RNUDB29"DBAU/9AFLJZ\.QODP.8V_NMR* ,!7:-@RL
M58="#@UI6_B"XAXD F'OP?SJK=:;<6G^LC.W^\O(JM0!U%MKEM<<,WE-Z/T_
M.KZL&&0<CU%<14D-S+;G,<C)]#0!VE%<[;^(IDP)460>HX-:5OKEK-C+^4WH
MX_K0!H44U)%D7<C!AZJ<TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJO<7UO
M:_ZR55/]WJ?RH L45C7'B.-<B&,N?[S<"LVXUBZN,YDV+_=CX_\ KT =)<7D
M-J,RR*I],\_E69<^(U4D01[O]I^!^58-% %FYU&XNR?,D.T_PKP/RJM3HXWE
M8*BEF/91FM.U\/SR\RL(1Z=30!E5=M-'N+O#!?+3^\_%;]KI-M:X*Q[W_O/R
M:N4 9]GHMO:X9AYTG]YAQ^ K0HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M WU453:&1>L;#ZJ:90!IKXBNEZB-OJI_QJ1?$DW>)#],BLBB@#;'B8][?/\
MP/\ ^M4@\2Q]X6'XBL"B@#H5\20=XY!],?XU(OB&U;J)%^J__7KFJ* .G&O6
MA_C8?\!-.&N61_Y:X_X"?\*Y:B@#JQK%F>?/'Y'_  IPU:T/_+=:Y*B@#K?[
M4M/^>Z?G2C5+0_\ +=/SKD:* .O_ +2M?^?B/_OH4HU"U/\ R\1_]]"N/HH
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MNO2PMH_NP1C_ ("*G50HP!@>U '(1Z?<R?=@D_%<58CT&[?JJI_O-_A7444
M8$?AN0_ZR95_W1FK,?AVW7[[R.?P K6HH IQZ3:1=(5/^]S_ #JTD:1\(JJ/
M]D8IU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !3616^\H/U%%% $;6=NWW
MH(S]4%1G2[0_\L$_*BB@"-M%LV_Y8X^C'_&F'0;0_P ##_@1HHH 8WAVU/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>nexi-20221231_g3.jpg
<TEXT>
begin 644 nexi-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %1I;2!3=&]V
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,U,@  DI(
M @    ,U,@  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( F $B ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M6^M$,;PE@ID3.X;2>X)/'?-<W!X[^+5K;BR?PS+/*HV_:)--E+'CKN!"G\J
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M-Y<2"1D\PY>)X^K+GH1[="* /*_B#XU\.^,#9R:!X)M/"]Q 6\Q[.=2DRG&
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M_9;T.TFT#5&UFTN8HIK,VC^>4BWH'V8W$%=ISCO^- '2_!3_ )-K'_7&]_\
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M.I:1?6EN()E\Z>W9$)+# #$8/X4 9FE_\G*/_P!A6?\ D]=A^T'_ ,BKI?\
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MH8KNP<9)8].]4?%7C'P]K^CK:Z;X+M-&N8V4I=6\XS@=0P$:[LCN37H?Q,\
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M_9DJD_BQV_I7?WFAZQXH^$SZ5KS!-8NK4&0L% $H;<N=O Y"YQTH Y[]G_\
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M8.2%.WY1E3^?7O7GOA_4?BCH.B?\(SI/A^XB1681W#V3;H]Q).)"=G4]3F@
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M1110 5X[/X!\1O\ '0>(5L5.E_:TF^T>>GW0@!^7.[K[5[%10 4444 %%%%
M!7DWQ.^&>M:_XDA\0>&YXVN$1%,+OL960Y#*3QZ<'%>LT4 >$7N@?&7Q!9-I
M>K2[+.0;)-\UNH8?[1C^8C\Z]+^'?@A/ WAUK-YUN+N>3S;B51A<XP%7V']3
M]*ZRB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4W;ZAK-]IN3'NFN;6;_1B?568]/K5G3]6T[5HFDTJ_M;V-3AGMIED /H2I-
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ME\(SAS;3K)M^NTG%,AUW2;BZAMK?5+*6><,8HDN$9I I(;: <G!5@<=,'TH
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M=L;C3;VWO( <&6WE610?3(.* +5%4;'7-)U.XD@TW5+*\FC&7CM[A)&09QR
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M,>!U]*>UA9O=0W+6L#7%NI6&4QC=&#P0IZ@'VH \P\0?:U;XH_V<'$PBL_\
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M^I6SWFDW=M$5#S0/&I;H"5(&?SH \7D_X19O@3;"Q^QG62L0B\G'VG[5O'_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_3+!)6BN+QS)+&4D51ESS_'@CID<8KWF@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZC?/"JZI&TL$ 8F01@X#L,8 .>.35+4]2NM8U2YU'4)6FN;F0R2.3U)_D!T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#00T;_ +_2_P#QNOHVBCZG2#_63']U]Q\Y?\,]>*_^@AHW_?Z7_P"-T?\
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M7T;11]3I!_K)C^Z^X^<O^&>O%?\ T$-&_P"_TO\ \;H_X9Z\5_\ 00T;_O\
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MYR_X9Z\5_P#00T;_ +_2_P#QNC_AGKQ7_P!!#1O^_P!+_P#&Z^C:*/J=(/\
M63']U]Q\Y?\ #/7BO_H(:-_W^E_^-T?\,]>*_P#H(:-_W^E_^-U]&T4?4Z0?
MZR8_NON/G+_AGKQ7_P!!#1O^_P!+_P#&Z/\ AGKQ7_T$-&_[_2__ !NOHVBC
MZG2#_63']U]Q\Y?\,]>*_P#H(:-_W^E_^-T?\,]>*_\ H(:-_P!_I?\ XW7T
M;11]3I!_K)C^Z^X^<O\ AGKQ7_T$-&_[_2__ !NC_AGKQ7_T$-&_[_2__&Z^
MC:*/J=(/]9,?W7W'SE_PSUXK_P"@AHW_ '^E_P#C='_#/7BO_H(:-_W^E_\
MC=?1M%'U.D'^LF/[K[CYR_X9Z\5_]!#1O^_TO_QNC_AGKQ7_ -!#1O\ O]+_
M /&Z^C:*/J=(/]9,?W7W'SE_PSUXK_Z"&C?]_I?_ (W1_P ,]>*_^@AHW_?Z
M7_XW7T;11]3I!_K)C^Z^X^<O^&>O%?\ T$-&_P"_TO\ \;H_X9Z\5_\ 00T;
M_O\ 2_\ QNOHVBCZG2#_ %DQ_=?<?.7_  SUXK_Z"&C?]_I?_C='_#/7BO\
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M@^S>=?6T?VM@EOOF4><QZ!.?F/TIZ7UI)?26274+742AY(!("Z*>A*]0#ZT
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MBLI])OH[N;_50/;.))/]U2,G\*/90#ZU6/<O^%]>%_\ GPU?_OS%_P#'*/\
MA?7A?_GPU?\ [\Q?_'*\%@T^]N;_ .PVUI/+=[BOV>.(M)D=1M SD8/Y4Z;3
M+^VLTN[BRN8K:1S&DSQ,J,PR"H8C!(P>/8T>Q@+ZU5/>/^%]>%_^?#5_^_,7
M_P <H_X7UX7_ .?#5_\ OS%_\<KPN?1-5M5G:ZTR\A6V"-.9+=U$0<X0MD?+
MD],]:=#H&L7%@;ZWTF^EM "3<);.T>!U.X#%'LH#^M5CW+_A?7A?_GPU?_OS
M%_\ '*/^%]>%_P#GPU?_ +\Q?_'*\&LM.O=1D=-/L[B[>-#(ZP1,Y51U8X'
M]Z;%974]K/=0VTTEO;;?/E2,E(MQPNX]!D\#/6CV,!?6JI[W_P +Z\+_ //A
MJ_\ WYB_^.4?\+Z\+_\ /AJ__?F+_P".5\^T4_8P%];JGT%_POKPO_SX:O\
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M8P#ZW5/H+_A?7A?_ )\-7_[\Q?\ QRC_ (7UX7_Y\-7_ ._,7_QROGVBCV,
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M_CE'_"^O"_\ SX:O_P!^8O\ XY7S[13]C GZW5/H+_A?7A?_ )\-7_[\Q?\
MQRC_ (7UX7_Y\-7_ ._,7_QROGVBCV, ^MU3Z"_X7UX7_P"?#5_^_,7_ ,<H
M_P"%]>%_^?#5_P#OS%_\<KY]HH]C /K=4^@O^%]>%_\ GPU?_OS%_P#'*/\
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MG<Y+'U)/6F5K%65CFG+FDY!1113)"BBB@ HHHH E1L6LJ[B,LOR[\ ]>W?\
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MK-CCKC%96@>/O#_BB[^SZ)/>3O\ ."TFFW,* H<,-[QA<@Y&,YR* .DHHHH
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M1_PH7PO_ ,_^K_\ ?Z+_ .-UQ?\ POKQ1_SX:1_WYE_^.4?\+Z\4?\^&D?\
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MDA!6.7_8.XG#>G.#TX.,IJJE>Y498:3LD._X4+X7_P"?_5_^_P!%_P#&Z/\
MA0OA?_G_ -7_ ._T7_QNO3J*R]I/N=/L*7\IYC_PH7PO_P _^K_]_HO_ (W1
M_P *%\+_ //_ *O_ -_HO_C=>G44>TGW#V%+^4\Q_P"%"^%_^?\ U?\ [_1?
M_&Z/^%"^%_\ G_U?_O\ 1?\ QNO3J*/:3[A["E_*>8_\*%\+_P#/_J__ '^B
M_P#C='_"A?"__/\ ZO\ ]_HO_C=>G44>TGW#V%+^4\Q_X4+X7_Y_]7_[_1?_
M !NC_A0OA?\ Y_\ 5_\ O]%_\;KTZBCVD^X>PI?RGF/_  H7PO\ \_\ J_\
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MZ5=H]I/N'L*7\IYC_P *%\+_ //_ *O_ -_HO_C='_"A?"__ #_ZO_W^B_\
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M_O\ 1?\ QNO3J*/:3[A["E_*>8_\*%\+_P#/_J__ '^B_P#C='_"A?"__/\
MZO\ ]_HO_C=>G44>TGW#V%+^4\Q_X4+X7_Y_]7_[_1?_ !NC_A0OA?\ Y_\
M5_\ O]%_\;KTZBCVD^X>PI?RGF/_  H7PO\ \_\ J_\ W^B_^-T?\*%\+_\
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MG9&#W W-A>V3CK0!X^+F/1?ARE]H6KZ?KGA>)PR>'M8M5%RA$F?(1U;/FJ_
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M$_\ )N?_ .+H]O$/J=3NCYCHKZ<_X5%X'_Z G_DW/_\ %T?\*B\#_P#0$_\
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M%X'_ .@)_P"3<_\ \71_PJ+P/_T!/_)N?_XNCV\0^IU.Z/F.BOIS_A47@?\
MZ G_ )-S_P#Q='_"HO __0$_\FY__BZ/;Q#ZG4[H^8Z*^G/^%1>!_P#H"?\
MDW/_ /%T?\*B\#_] 3_R;G_^+H]O$/J=3NCYCHKZ<_X5%X'_ .@)_P"3<_\
M\71_PJ+P/_T!/_)N?_XNCV\0^IU.Z/F.BOIS_A47@?\ Z G_ )-S_P#Q='_"
MHO __0$_\FY__BZ/;Q#ZG4[H^8Z*^G/^%1>!_P#H"?\ DW/_ /%T?\*B\#_]
M 3_R;G_^+H]O$/J=3NCYCHKZ<_X5%X'_ .@)_P"3<_\ \71_PJ+P/_T!/_)N
M?_XNCV\0^IU.Z/F.BOIS_A47@?\ Z G_ )-S_P#Q=,A^$7@DP1F30SOVC=FZ
MF!SCV>CV\0^IU.Z/F:BOIS_A47@?_H"?^3<__P 71_PJ+P/_ - 3_P FY_\
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M'_#0G_4L?^5#_P"UUXO11[*'8/K5;O\ D>T?\-"?]2Q_Y4/_ +71_P -"?\
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M*[:B@#D$^&VD/9W\>HWFHZC>:A)#++J-Q.!<*\)S"49%4)L))&T#J<YR:/\
MA7&FW$%\NMZEJNLRWMN+8W%[<@/#&&W 1^6J*IW -G&25&2<5U]% '.:'X-M
M]'UI]7N-4U/5]0:W^RI<:A*C&*'<&**$51R0"202<#FNCHHH **** "HK8 6
MR <#']TK^AY%2U%;?\>Z=?QS_7F@#XTHHHKTCYT**** "BBB@ HHHH ****
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M0KCQI=1I))_PD0<JVU4CFM^>6YXB;' 7C/\ %[59T[QW?/DB[CNMN=RXBG(
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M&.5H7\R,NH.QL$;AGH<$C/N:SK;PKX>L]7?5K30=,@U&1F=[R*SC69F;EB7
MW$G)R<\UJT5B64]+TR'2+'[-;M(^Z1Y9))6R\CNQ9F)]22>F .    *N444
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M?_G_ -7_ ._T7_QNC_A0OA?_ )_]7_[_ $7_ ,;K:_X6[X'_ .@W_P"2D_\
M\11_PMWP/_T&_P#R4G_^(HO5\PY<-Y&%)\"/#";<7VK<L!S-'_\ &Z?_ ,*%
M\+_\_P#J_P#W^B_^-UKR_%OP2VW;K?1@3_H\Z\?@G/TI_P#PMWP/_P!!O_R4
MG_\ B*+U?,.7#>1B_P#"A?"__/\ ZO\ ]_HO_C='_"A?"_\ S_ZO_P!_HO\
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M:=?U"<?6E7XN^" B@ZWSCG_19S^NRB]7S#EPWD8W_"A?"_\ S_ZO_P!_HO\
MXW1_PH7PO_S_ .K_ /?Z+_XW6U_PMWP/_P!!O_R4G_\ B*/^%N^!_P#H-_\
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MX']1Q0!\:4445Z1\Z%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8\2%LG'%@./?F6G?\,]_]3/_ .4__P"V4>UAW#ZK6[?D>+T5[1_PSW_U,_\
MY3__ +91_P ,]_\ 4S_^4_\ ^V4>UAW#ZK6[?D>+T5[1_P ,]_\ 4S_^4_\
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MGKS1';1Q*BIO 0 */,8\ 8'?FI:* (EMT4+@R?*% S*QZ=,\\]>3W[YH%N@
MP9.BCF5OX3D=_P _7H<U+10!%]G3UD[?\M6['/KZ_F.#Q2^0GK)US_K&]<^O
MK^G'3BI** (OLZ$8S)_%_P M6[G)[_EZ#@8%!MT.<F3D,.)6'WCD]_R/;MBI
M:* (FMT;=DR?,"#B5AUZXYXZ<8Z=J5H$8L29/FSG$C#J,<<\?X\]:DHH C,"
MDDYDY;=_K&Z[=OKTQVZ9YZ\T"!5((,GRG(S(Q[8]>>.WKSUYJ2B@"-8$3;@R
M?+C&9&/08YR>?QZ]:1;=%"X,GRA0,RL>G3///7D]^^:EHH B%N@ P9.BCF5O
MX3D=_P _7H<T?9T]9.W_ "U;L<^OK^8X/%2T4 1^0GK)US_K&]<^OK^G'3BG
MHBQQJD:A44855& !Z4M% !3)H8KB)HIXTEC;[R.H(/X&GT4!L<[XFT;3(_"6
MKNFFVBLMC,0P@4$'RSSTKX_K[-\4_P#(GZS_ ->$_P#Z+:OC*O*QR2DC[[A:
M3E2JW?5!7U-\*]*TZX^%^BRSV%K+(T3[G>%23^\;N17RS7UC\)?^25:)_P!<
MG_\ 1C5."UJ/T-N)Y..$A9_:_1G66]M!:1^7:P1P)G.V- HSZX%2T45ZY^>-
MMN["BBB@04444 %%%% !7A&@Z_J'PNL=?\-S:5>2W\EPTFF2QP[XY20%4^XX
M!XSW'%>[UY/JGAWXTRZO>2:7XLT6&R>=VMXY%^9(RQV@_N#R!CN:TA-1335T
MRHRMN9'B;7?%+ZAI-AXAM[RV:?36>632;,&:61\_N@QSM PH8#W]L<_H=A.]
ME\/XY;.5A'J\_FJ\1(4&2$\\=,>M=9_PC/QU_P"AQT+_ +X_^YZ/^$9^.O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!E>*?\ D3]9_P"O"?\ ]%M7QE7V;XI_Y$_6?^O"?_T6U?&5
M>7COBB?><*_PJOJ@KZQ^$O\ R2K1/^N3_P#HQJ^3J^L?A+_R2K1/^N3_ /HQ
MJG _Q'Z&_%/^Z0_Q?HSL:***]8_/ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BL#5/''AS1KYK/4=32*X3[R+&[[?KM!P
M?:J?_"S?"/\ T%Q_X#R__$T =717*?\ "S?"/_07'_@/+_\ $T?\+-\(_P#0
M7'_@/+_\30!U=%<I_P +-\(?]!<?^ \O_P 35V[\;>'K&SLKNZU$1V]\";>7
MRG*OC@\A>,>AQ346W9(3:2NS>HID$\5S D]O(LL4BAD=#D,#W!I](84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>5>,_C9_PB/BZ]T/^P/MGV7R_P!]]M\O=NC5_N^6<8W8Z]J]5KY5^,O_
M "5S6?\ MA_Z(CKEQ525."<7U/?R'!T,7B94Z\;I1;W:UNNQW/\ PTA_U*O_
M )4?_M5'_#2'_4J_^5'_ .U5X=17G?6JW?\ (^S_ + RW_GW^,O\SW'_ (:0
M_P"I5_\ *C_]JH_X:0_ZE7_RH_\ VJO#J*/K5;O^0?V!EO\ S[_&7^9[C_PT
MA_U*O_E1_P#M5'_#2'_4J_\ E1_^U5X=6QX2T-_$OB[3=(3I=3A9"#C"#YG/
MX*"::Q-=NR?Y$5,CRRG!SE3T6N\O\SUG_AI#_J5?_*C_ /:J/^&D/^I5_P#*
MC_\ :JP_BUH>C3Z79^(O"UE!:6D5U-IMU';QJBAXW8*V%&.0#R><%:Z'Q%>:
M+I/Q.TGPNWA'09=.U%((Y'%BJ3*TK;=P=<8P<'IGK6_M*R;3GVZ=SREA<LE"
M,HX=MOFNN9W7+:_7S(O^&D/^I5_\J/\ ]JH_X:0_ZE7_ ,J/_P!JK,O- T7X
M=^']:UJ32[;6;HZP^G6,5\GF10H 6!93]XX!&?ITYJUINE:%XGM_"'B<:'96
M,UQJXT^]LX(A]FG&UVW>6<@?=Z>_.<"CGKWMS:^@/"Y5R^T5!\FU^9[VOM>_
ME?N6?^&D/^I5_P#*C_\ :J/^&D/^I5_\J/\ ]JJWK^CP66C>*+KQ)X3T'2[:
MQE+Z)<0P1QM<D.=BL%.6! 3(.,ACQZ8=SXBM(?A+:>)E\)>&/MTVJ&T93I2>
M6$V,W ZYRH[TW.LGK/\  FGA<NJ).&'O=I?&[7:OO?[^S-'_ (:0_P"I5_\
M*C_]JH_X:0_ZE7_RH_\ VJHK*UT#3IOAR+_1M-D@U>QD@NFDM4)=V$>QR<<L
M&P-QZ GUK,L_"MGX-\-ZW)K=A!=75UK":58&[@5\(&RTBY!QN4GGCH*7/7_F
M_#RN4L+E3T]B[O;WGK[SB^O2UWY&Q_PTA_U*O_E1_P#M5'_#2'_4J_\ E1_^
MU4?$>VM-*FUFUTZW\ VULEOA+=[<+J"[HQG: N ^22O_  &N%^&.BZ9?ZAJV
MJ:Y;?;+31=/DO?LO:9EY /J.#QTZ9XS4RJ5U/DYOP1I1P65U,,\0Z-EIIS2O
MKMU.Z_X:0_ZE7_RH_P#VJC_AI#_J5?\ RH__ &JO/]9\8:+KWANXMKGPMI^G
M:HLJM:76EPB%%3/*N,_,<9&??VY])^(MK9:)<:A%IEGX"MH([7<+:ZME6])V
M\[ %QD_PT*K5:;4]O(*F R^G.,)X=IRO]I]+=F^Y6_X:0_ZE7_RH_P#VJC_A
MI#_J5?\ RH__ &JN-^(NG6-CX4\$S65G;V\MSI8DG>*)4:5MJ?,Q ^8\GDTS
MQMIUE:?#GP-<VMG;P3W5O<F>6.)5:8AH\%B!EL9/7UI.M75_>V\D:T\MRN:I
MM4?C;7Q2Z7\_([7_ (:0_P"I5_\ *C_]JH_X:0_ZE7_RH_\ VJO']#UDZ'J/
MVL:?8:A\A3R=0MQ-'SCG:>_'6O6/&%UI]KXM\+Z';>&M!AM]5BL;F>2/3D60
M,T_S*K#HI"X(P<@D=Z(5ZLHWYOP#$97E]&K&'L+WN[\SZ;]2Q_PTA_U*O_E1
M_P#M5'_#2'_4J_\ E1_^U5>TWP#HX^--Y+)-X<GL2K;=&7:TD?R#K#LVC!Y_
M'-9?A_3[*#X2>'KZ&V\'PW=P]P)KCQ# O[T"5P K8R2 !U[8K3FK]9=^BZ6_
MS.)T<I:3C1;OR_:E]I2??IRDW_#2'_4J_P#E1_\ M5'_  TA_P!2K_Y4?_M5
M0>$--;4_"?B>^TWPYX=U76(]4$=NAM8S;;?E#>67(PF,D<BLWQOX5L]1\6^%
M=%L[*QT_6[V,+JMMIRA8X"2#NV@X&%WGU( ]JESK\O,I?@:QPN5.LZ4J-K7O
M[STLKW:O>W2_<V?^&D/^I5_\J/\ ]JH_X:0_ZE7_ ,J/_P!JK(^+.@Z)/H<&
MM^$[.WMX-/O9=+ODMH@@WJ?E9L >G4]=R^U=[>^%[)?$@M[OPAH$/A4V&^XU
M$P1PRQ2;3G##!].PQDG/&*I2KN37-^'<QE2RF-*-1T'K?3F::Y;:;ZMWT74Y
MG_AI#_J5?_*C_P#:J/\ AI#_ *E7_P J/_VJLSPOHWACQSX=LI[F.UT^3PY,
M6U-XX1%]KM I*NVWJQV $YS]X]Q7$3:E9^(OB5:W-MIMK9V$]_$D=G% B((M
MX #*!@DCKUY)[5G*M623YM_0[:66Y;4G.'L&G'?67RZ]5KZ'I7_#2'_4J_\
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M^I5_\J/_ -JH_P"&D/\ J5?_ "H__:J\XL+.V?XP6UD]O$UJVNK$8"@*%/M
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M1_\ M5>'45G]:K=_R.[^P,M_Y]_C+_,]Q_X:0_ZE7_RH_P#VJC_AI#_J5?\
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M'_4J_P#E1_\ M5>'44?6JW?\@_L#+?\ GW^,O\SW'_AI#_J5?_*C_P#:J/\
MAI#_ *E7_P J/_VJO#J*/K5;O^0?V!EO_/O\9?YGN/\ PTA_U*O_ )4?_M5'
M_#2'_4J_^5'_ .U5X=11]:K=_P @_L#+?^??XR_S/<?^&D/^I5_\J/\ ]JH_
MX:0_ZE7_ ,J/_P!JKPZBCZU6[_D']@9;_P ^_P 9?YGN/_#2'_4J_P#E1_\
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M6G77C'1K67:UP\BA$DDEAA>2.)7^ZS,H(4'WH W**J:AJEGI=@;R]F"0Y !
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MR&PL?S<[>..G7FM:]\1:E>Z]!KLOPDU635[6-4M[B5KAD0KG:?+$0!P23_\
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M3^T<D<WI15E07;=]DOT7Y[GSAJ%SKT?AN]T7PE\-=3T&'4"/MDHBN+B251_
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M;N&/O^7SCZ5]'T4OJSO?F_!&G]MKE<72O=6UE)Z/IJSY%TCPOXKTK7+'4?\
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MR_\ Q-'_  A'BO\ Z%C6?_!?+_\ $U]C44?48]P_UJK?\^U][/CG_A"/%?\
MT+&L_P#@OE_^)H_X0CQ7_P!"QK/_ (+Y?_B:^QJ*/J,>X?ZU5O\ GVOO9\<_
M\(1XK_Z%C6?_  7R_P#Q-'_"$>*_^A8UG_P7R_\ Q-?8U%'U&/</]:JW_/M?
M>SXY_P"$(\5_]"QK/_@OE_\ B:/^$(\5_P#0L:S_ ."^7_XFOL:BCZC'N'^M
M5;_GVOO9\<_\(1XK_P"A8UG_ ,%\O_Q-'_"$>*_^A8UG_P %\O\ \37V-11]
M1CW#_6JM_P ^U][/CG_A"/%?_0L:S_X+Y?\ XFC_ (0CQ7_T+&L_^"^7_P")
MK[&HH^HQ[A_K56_Y]K[V?'/_  A'BO\ Z%C6?_!?+_\ $T?\(1XK_P"A8UG_
M ,%\O_Q-?8U%'U&/</\ 6JM_S[7WL^.?^$(\5_\ 0L:S_P""^7_XFC_A"/%?
M_0L:S_X+Y?\ XFOL:BCZC'N'^M5;_GVOO9\<_P#"$>*_^A8UG_P7R_\ Q-'_
M  A'BO\ Z%C6?_!?+_\ $U]C44?48]P_UJK?\^U][/CG_A"/%?\ T+&L_P#@
MOE_^)H_X0CQ7_P!"QK/_ (+Y?_B:^QJ*/J,>X?ZU5O\ GVOO9\<_\(1XK_Z%
MC6?_  7R_P#Q-'_"$>*_^A8UG_P7R_\ Q-?8U%'U&/</]:JW_/M?>SXY_P"$
M(\5_]"QK/_@OE_\ B:/^$(\5_P#0L:S_ ."^7_XFOL:BCZC'N'^M5;_GVOO9
M\<_\(1XK_P"A8UG_ ,%\O_Q-'_"$>*_^A8UG_P %\O\ \37V-11]1CW#_6JM
M_P ^U][/CG_A"/%?_0L:S_X+Y?\ XFOI7X36-WIOPOTFUU&UFM+F/SM\,\91
MUS,Y&5/(X(/XUV-%;4<,J4N9,\W,LZJ9A15*4$K._P"#7ZA11174>"%%%% !
M1110 4444 %%%>>_$B#QN]U:3^%68V<)#M';']X7']X'[R^PKIPN'6(JJFY*
M-^KV,ZM3V<>:U_0O?%J\^R?#F^4'!N&2$?BP/]*X_P !:=;_ /"FM>GO=XAG
M:5FV,5)"*,#([9%9VH:;\1O'S6]EJ]BUK;1ON+2Q>2@/3<1U)^E=]KGAJ?2/
MA+/H&@P/=S^2(@%'S2%F&]OYU]*E3P>%IX3VB<Y33=GHEIU/-]ZM5E6Y791L
MK]3E_@-98M]7O2N"S1Q _0$G^8KO/B!<VEKX"U9KXKY;V[(JM_$Y&% ]\XKR
MGP[;_$KPM8/9Z/HSI%)(9&\R%6); '7/M6@?!'COQQ>1/XNN_L=HASL8K\O^
MZB\9]S6F,PU.ICWBZM:*A=/1W>ENB)HU)1H*E&#OZ:',^&#/8_#;Q7><B&=8
M;5?]IBW./H#^M=+\/]5N/"/PTOM>@T\WJO>[95#[2J  ;NG3)K>\?>$9[;X?
MV.@>%-.EG1+@/((^6. <LQ[DDUO^!/#S6'PYMM*U>V*O,C_:(9!R-Y.0?PJL
M7F%"KA956KJ<U>-]>5*W3T%2P]2%5172._FSR_5M7U_XO:E;66FZ<MO:VK98
M[LK&6XW.WT' %0_%.S33M2T/P_:9D6PL5C7'5F9OZX_6M?P[X;\3^!?B!(UA
MIMS>:4TGE2/& 1)$3P>O4?T-6?$7A/7=;^,$5^=-F_LU;B$>><;=B $GKZBN
MVGB*-'$P5.451C%RCKU??7?4QE3G.F^9/G;2?H5[?6/BS;6L4$&ER+'$@1!]
MD3@ 8'>O1? MSXCN]#DF\71^5>&8A$,80A !C@>^:Z:BODL5F$<1#D5&,7W2
MU/5I8=TY7YV_4****\LZ@HHHH \$L?\ DMC_ /88D_\ 1AK1CUZ'3/B7KFG:
MI\VE:G</!<JQX7)(#^V,]?0^U<EXFFD@\<:Q+!(T<B:A.5=&(*GS&Z$5DRRR
M3S-+-(TDCG+.[9)/J35"/9]:LAIWC?P39*_F+;QF(.1]X* ,_I5/3KB:UOOB
M+<6TC131!G1U."I'F8(KRMM3OWEBD>]N&DA&(G,K$Q_[ISQ^%(-0O1Y^+N<?
M:/\ 7?O3^]_WN>>IZT =KX%\5Z[J'C?3K6]U6ZG@D=@\;R$AOD)Z5S?B6&2X
M\<:G! A>62_D1%4<L2Y %9,$\UM,LUM*\4J_=>-BK#Z$5U_A!5TRTU#QEJO[
MT6>4M1(23-<MT^N,Y/Y]J:3;LA-I*[%\61O;1:5X"T?$T\;K)=E/^6ER_;/H
MH/\ G%>P:=X=CT?P7_8ECAF6V>/<>-[L#EC]2:\^^$/A^;4-1N_%FJYDD9V6
M!GZLY^^_ZX_$^E>M3"0P.('5)2IV,Z[@#V)&1G\ZZ,0U&U*/3\S"BG*]1]?R
M.#U;P-?W7AK2H[)XX]0M[:*VNU+?+-&I#8S[,N1]33=:\-^(M0:^1H5NBUX)
M[>9K]D01AP0@B V[L#&3]:T],\57*:<;O5VBG$EM)<Q+;0F/"+)L7.6.2^X8
MZ8YJ9_&JJI==,N&B"M('\Q!E%D$>[&>Y/ ZFL?9RN:\\2A-X;U=[F]C$,/DS
MZM#J*2>=S@%=RD8ZC;U[TT^&]9_L=_#8@M_[/:[\W[?YWSB/S?,QLQ]_/&<X
MJ\OC>&-7EGM9FMED(:X4* H(=E&W)).Q,GV(/M5J3Q/(-(U:X:PDMI["(,(Y
M65@SLNY5^4^ZY'O2]G+L/GB9[>&=0/AZYLP(_-DU@W@^?CR_.#]?7 K.N_#G
MB.XN8WGMUN9+?45NA.U^P22,2;@JQ8VJ<=SZ=ZTY?%%_IFJ2:=?K%>S1HLN;
M.$@L"CL8]I8_-\JX.3]X<5:A\9PS0O.ME*8+=-]U*LJ$0CYL=\MPI) Y'IGB
MG[.0<\2;0]'NM/\ "]S8W 3SY)+AEVMD8=F(Y_$50\-^&[_2[ZTENA%MBT=;
M-MKY/F"0M^6#UJP?&D,,IAN["XAFXVQ[E8L67<BC!^\W3'8^W-,A\<0W$BQV
M^FW4CS.$MP, 2G)!Y/ ^Z3].?:E[.?8.>/<PT\(ZQ:Z581)8PR7,-GY(N+:^
M>WEA?<QY8<.G(.,>M7+_ ,-:[*M[&?(NVOM)CM9;@R;")4!YVXY!)]JUT\6Q
MW.AW]]:VSJUG;EV$F"!-@_NN.I! S_O"JDGC.<PI';::TEQ(0L1:10DA$PB8
MXSD#)R,]0#Z4_9S#GB5-2\+:K=-K4$*P>5J=E BRM+CRY(A]TC'(/KVI;S0M
M=UNZU"YN[6VLC<:0UE'&+CS/GW[LDX'%;FG>)H=0D?=;2V\?V;[7%(Y!$D62
M-V ?EZ9P>WXUB0>.KA8].^V6$J23VWFR(8MN]F91&$Y/'+$D]EH5.;!SBB"X
M\-ZPUY]O^PB62YM(X)8(]2>$0NF0"64#>I!SCJ.:9=^$=5MPD>F6=NDRVT<4
M5Y:WLD!B8#G>ISYB@],\XXK3F\>VR1(RV<P+1N6+$?NW5';:1]$_)@>]0)XR
MU*)LWFFKY<(E,_EN,E8RB$C)_P">C. .<X'O1[*8O:1-;7](OK[3=.>V>*:^
MTZXCN0LGRI.R@@@X^[G)(]#6+J/AS6=9CU.\N((+6YNS;1Q6RS;PJ12!RS-C
M!)Y[5W%%9&AB>*])GUK1X[6V6-R+F*1ED/!56!/Z5G:UX02\UJPETZVMK2W6
M"ZAN'B0(W[R/:IP!S@YKK** //K3PEK*Q01^1%;SV-NZ0W<E_+.K2;"BLD9X
M0>N0?0"H)O"NOW3%VLE5Y-.GLY&FU)IF+NHP_(P!D=!ZUZ113 X74/"^KR)J
M4-O% Z:AID-OO,V#')&",8QR#GK6_%I5RGBZWU$A/L\>F&U;YN=YD5NGI@&M
MNBD 4444 %%%% !116!XD\9:7X4N]-AU?S4&HRF*.55!2,C'+DD$#YAR : -
M^BLFT\16EYXFU'0XTF6YT^..25W "$.,C!SGZY JCX;\=:1XIM]2FTL3XTY]
MLJRJ 6&"0RX)RIP<9QTH Z2BN-TSXGZ%JOA+4?$$$=XEMIS!9H9(U$I)QMP
MQ!R3@<]0:B7XIZ7-9:3<66DZQ>-JR2O;P6\"/(!&Y5LC?[$\9XH [>BJ&C:J
M=8T\73:??:>2Q7R+Z(1R<=\ GC\:OT %%%% !1110 4444 %%%% !117&7'Q
M2T*UT>WU.YBO8[6>_>QW&-<HZ]6;YON^XR?:@#LZ*YG5O'NE:/>W]M/%=2M8
M6"W\CPJK*\;,% 4EADY/L,=Z@TSXB:?J&I6=E=:9JVE/?_\ 'H^H6HC2<XSA
M6#$9Q0!UM%<D/B1HG_"+PZVR78CN+AK6WMA$&GFD#$;552<]/7^=7?#_ (QL
M?$%_<:>MK?:??VR"22TOX/*DV'@, "01^- '045S>B>.M)\0WFK6NF+<23:4
M2)%*#]\ 6&8^?F&5(YQV]:S;?XG6]SJ[:8GACQ&+M K21M9IF-6. S#S,@>]
M ';45RI^(NB)H=SJDWVF**"^>P6)HP9)IE/W452<Y[=/PHT_X@Z;>W5Q:7-E
MJ6F7L-NUR+74+<122QJ,DIR0>GK0!U5%<A!\2]"NO"</B"W6Z>VDNEM&B"+Y
ML<C' ##=@=CP3P:Z^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SO$
M.H2Z3X8U34;94::SLYIXUD!*ED0L <$'&1ZUHUB>-?\ D0?$'_8,N?\ T4U
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MVE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY:5NF<XZ^V.]<]\2%%]9WMS#<^"C"MX9D;2I$^VS*6(&['WN&W-[C/:O,:*
M/0?AEXB:UN-0LM4U46]@FDW*V\,\X2/S&*\ $X+'GWI+:RTS6;/PEX;N=:L[
M*TCAFOM0N3<(JHTC_<R3CS J*,'IN^M>?T4 >@_$]HMFFVNE7NC-HMB'ALK3
M3KT3N@)RTDF!]YN.YY_$GSZBB@ HHHH **** "BBB@ HHHH *^IOA#_R2G1O
M]V7L!_RV?TKY9KZF^$(Q\*=&Z_=EZKC_ );/0!VE%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_ "+_P")H_X0KPM_T+6C_P#@!%_\36W10!B?\(5X6_Z%K1__   B_P#B:/\
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M]Y$';\#4Q\+?&T_O/^%A:2&Z^3_9D>WZ9\O->KDPVEJ2QC@@A3))PJHH'Y
M5X1<_M+6<7Q,6SAM/,\*J#%)?!#O+;L></\ 8!XQWZ^U &O<>.OB9\/_ -_X
M_P##]KK6CJ?WNHZ/D/$/[S)Z?@![UZCX=\1:7XJT.#5]"NTNK.<95UZJ>ZD=
MB.X-789K?4+))H'CN+:X0,CJ0RR*1U]P17C4%I_PJ+XVVEM89B\+>+F*"#/R
M6UV.FWT!R/P;_9% 'M=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% $-[>6^G6%Q>WLJPVUM$TTTC=$11EB?H :
MH1>)](F\*/XDBN]VDQV[W+W'EN-L: ER4QNR-IR,9R,8S7._$R:[O-/T[PUI
M5M'=W>LW($EO+-Y2O;18DF#.%;:& 6/.T_ZP5RMY=:CIWA'XC:!KEA!ITMQI
M%YJ]G!;W1N$$<L3B4!RB=)06(V\>:.M 'I4?BK19O"1\3QWRG1Q;-=&Z*, (
MP"2=I&[/!XQG/&,TNF>*-'UA]/73KSSFU*R:_M1Y3KYD * OR!CF1.#@\].#
M7EVW8)_AVH_=37JZML'06#(;AACT-RK1X'&'JU\.IHH+GP T\B1J?!LP!=@!
MGS;3UH ]=JK::E:7US>06DOF26,P@N %(".45]N2,'Y74\9QG'6I'O+9+22Z
M:=/(B4N\@;(4 9)XK!\ P2+X/MKZYC:.YU5WU*97^\K3L9 I_P!U65/^ T 7
MM!\4:/XF%]_8EX+K[!=/:7(\MT,<J_>7# 9^HR#V-9R_$;PM)H]UJD.I-/:6
MM^=-E>&TFD/V@8_=JJH6;[PY4$'/6O,=(U*?PA97%_IXQ-XC;4K&V&>#?IJ,
MZP<?[0F.2.T0J;0=-MO#^DWFFVY"VUCX\M(59N.%AMAD^YQDT >IZ'XST+Q%
M>RV>EWCF[A02/;7-M+;RA"<;MDJJQ7/<#%5+7XC>%;W4HK*VU7<\TIAAE-O*
ML$TG3:DQ7RV.01@,<UC>)+NSU#XJ>%(M.=+NYLHKV:^2W(=TMF@V@-CIND,>
M >I''2N7@N5T7P'IMWH^LZ;XA\+K+;BVT75+95NXOWB[(DD5N94;HK(3E<9[
MT >F6>LW\WC:_P!(N;6&&UM[.*X@D60M))N=U)8=%'R<#D]\\X&Y59=/MEU1
M]16+%W)"L#2;CRBLS 8SCJS<]>:LT %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6)JFJS:5:V8MXXL2*<AHRH&,=%SQUZ5MURWB88M=/ Z!&'W"O9>Q
MY'T- $7_  E=]_SRM_\ OEO\:/\ A*[[_GE;_P#?+?XUB44 ;?\ PE=]_P \
MK?\ [Y;_ !H_X2N^_P">5O\ ]\M_C6)10!M_\)7??\\K?_OEO\:/^$KOO^>5
MO_WRW^-8E% &W_PE=]_SRM_^^6_QH_X2N^_YY6__ 'RW^-8E% &W_P )7??\
M\K?_ +Y;_&C_ (2N^_YY6_\ WRW^-8E% &W_ ,)7??\ /*W_ .^6_P :/^$K
MOO\ GE;_ /?+?XUB44 ;?_"5WW_/*W_[Y;_&C_A*[[_GE;_]\M_C6)10!M-X
MHNV96:"V+*<J2AX[>M+_ ,)7??\ /*W_ .^6_P :Q** -O\ X2N^_P">5O\
M]\M_C1_PE=]_SRM_^^6_QK$HH V_^$KOO^>5O_WRW^-'_"5WW_/*W_[Y;_&L
M2B@#;_X2N^_YY6__ 'RW^-'_  E=]_SRM_\ OEO\:Q** -O_ (2N^_YY6_\
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M/A-=QWOA*:6'Q?-XM7[6P^W31-&4^5?W>#SQU_&J7Q\95^">N[^ZQ ?7S5H
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M'Q%_T!+[_OPU?381TY4(*<EIT^9X&(YU6DXHZ#3M3\KQ)X+&>+>V13[%G?\
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MZ?X1N+MEB@C $DC\*N8"!D]N:EUZ6;2]2>2PR?[9@%O&5Y"SCA6_[Y)_[YH
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MW.>,U.QT\SW_ /PBAC/AC_A(M#^R?9C_ *-]H^U+Y_DX^7;CRL[?EW;L<YH
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M[+;2P'>K%FWN&X)8G"X &<G'>MO^SK'_ )\[?_OTO^%']G6/_/G;_P#?I?\
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M4YW,>% )8@ FJ=_XNL;72XM1T^&?6+*2&2?[3IS1R1+''C<QD9U3O@ $DX.
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M$>IQB>'_ (:ZKI*6,%X]I=1C^SI;B7[?<J(Y+:"&-@L*X23+0!E=L$%LD':
M?3J* .1\$>&-3\.R3I>O;):BVAM[>WMYGF5!&7Y4R*'1,, L19PO.&]<6\\
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M_#5[IMKKE^MG-JDWD6@=&(D?CC< 0OWARQ YH V:*PK_ ,:^']+U>^TR^O\
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MJ#C)T+K7-=\)^)FL]<\117EM<Z)=:@9;FT2..REA*<KY8#-&?,/RG<WRC!H
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M+<VTKZ[&%'VHM&<1D)\GR<CY<=^*]/AT/2;?2#I5OI=G%IQ4J;-+=%A(/4;
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M* ,2BMO_ (12^_YZV_\ WTW^%'_"*7W_ #UM_P#OIO\ "@#$HK;_ .$4OO\
MGK;_ /?3?X4?\(I??\];?_OIO\* ,2BMO_A%+[_GK;_]]-_A1_PBE]_SUM_^
M^F_PH Q**V_^$4OO^>MO_P!]-_A1_P (I??\];?_ +Z;_"@#$HK;_P"$4OO^
M>MO_ -]-_A1_PBE]_P ];?\ [Z;_  H Q**VF\+WBLJM/; L<*"S<]_2E_X1
M2^_YZV__ 'TW^% &)16W_P (I??\];?_ +Z;_"C_ (12^_YZV_\ WTW^% &)
M16W_ ,(I??\ /6W_ .^F_P */^$4OO\ GK;_ /?3?X4 8E.CC>618XU+.QP
M.];/_"*7W_/6W_[Z;_"MK1]%334WRE9+ANK#HH]!0 FC:,FG1^9+AKAAR?[O
ML*U:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HH/^
M6N/^>A_C+?SZ?0<5+44!SYO(/[PCB0MC\^GTH EHHHH **** "BBB@ HHHH
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M\\KC_OE?\: -NBL3_A*['_GE<?\ ?*_XT?\ "5V/_/*X_P"^5_QH VZ*Q/\
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MVZ023MOR^4(R 0<8XYK*N["/1=3O?$'B"&ZU6R75#(GB72-6)>U3S JPO#G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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5'#"@CC1>BJ!@#\JEHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>nexi-20221231_g4.jpg
<TEXT>
begin 644 nexi-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $W .D# 2(  A$! Q$!_\0
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M#4NT444 %%%% !1110 4444 %9^N:W;>']/:[N=S<A(X8QF2:0\*B#NQ/^<
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M+6SLGXN[.>!G*9(\R2-3A5Y49!&W@XZUQ>M:3IVCR7$\$D$MO<2^5#Y1DE>
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MS<C!5/=8^&/JVT?PFM'KR:K:;I\.DV$%G;AO)A7:"QRS'J68]V)))/<DU9H
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M%)9*@2%H&#)M P ".. * +%%%% !7R)^T];7^C:M/<6UCH,:F59+DV+R?:)
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M^U^)M/O?-MM0OQ'+,H$81621>N%^7/)XZFO4M5<6>J:#?GI#>B%SZ+,IC_\
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M[L*[.N4U+38=4L9K.Y#".08+(=KH0<JRGLRD @]B!5KPGKLU\DNFZB5&L68
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M?2)B2?<F.MZ-2-.?-)7.+&49XBDZ<':Y1^#_ (@%[I,NEROF:T.Z/)Y,9/\
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L?D[&BB@#1L?#>D:8P:STNSM7 P&AMT4_F!6E110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>nexi-20221231_g5.jpg
<TEXT>
begin 644 nexi-20221231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %1I;2!3=&]V
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,W,@  DI(
M @    ,W,@  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    ,C R,SHP,SHP.2 Q-3HU-#HR,0 R,#(S.C S.C Y
M(#$U.C4T.C(Q    5 !I &T ( !3 '0 ;P!V &4 <@   /_A"QUH='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG[[N_)R!I
M9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X;6QN<SIR9&8](FAT
M=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M
M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R
M9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M/CQX;7 Z0W)E871E1&%T93XR,#(S+3 S+3 Y5#$U.C4T.C(Q+C<Q.3PO>&UP
M.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D
M9CIL:3Y4:6T@4W1O=F5R/"]R9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC
M<F5A=&]R/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T
M83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_
M/O_; $, !P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;
M'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*O_  !$( E0$] ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M10 445Y6VA_$0_%L7WVNX&@"[W8%X/*\G^[Y6[.<<?=Z\YH ]4HHHH ****
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MOIWH ]0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYH]^^*]&^*WB>V\3_"G[=X;N)9K(:FD%Q($9 RA6/(.#C<4_'%<-H\GPRMO
MADU:&ZN]?:-P8LRKM?G:05(3;TZDGVH Z+X67FH^-/"GB#PEJ.I2>6T"&WGD
MS(T()(88)!(X'&>.?6N'T[P/_:'Q.?PA_:'E[9YH?M?D9SY:LV=F[OM]>,UV
M7[/7_(Q:O_UZ+_Z'67_:]OX6_:%N]2U??%;PW\YD(4DJLB, V!R1AP?I0!V'
MC/PL?!?P)N=(6^:\VW2.9?+\O.Z0'&W)X_&M;X#L3\.G!)(6^D R>@VI2?$'
M5+/QI\'-3O\ P_(]S;PRJVXQLI8(Z[C@X. .?H*Y+X4?$GP_X5\'W6GZW+-%
M.EPTT:I$7\X%5&!C@'*GK@=.: *WAUV_X:<G^8\WUX#SU'E2<?H*@^*.L7NL
M?%"30=5U632M(A9(U)#-&BL@)D91C=DG\!5;P!JG]M_'ZWU00F 7EQ=3"-CD
MJ&AD(&?H:[SQQKOPWUC7+G2?%Z7%M>V)$8NUA;(X#85DR2.>C#K0!'\._AU/
MX?\ $EOJ^D>*+;5M(,;K(L!*[R5XX#,IP>>O:O6:^:OA[/\ V=\8+>T\(WUS
M=:9-*49G0J98=N3O7V]>.F>,XKZ5H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#\0^#-
M \52P2:_IXNWMP1$3*Z;0>OW6&>G>MRB@!$18XU1 %51@ =A7+ZC\-?".K:N
M^IZAHL<MW(X=W\V10[>I4,%/OQSWKJ:* ,W7?#^E^)M-^P:W:BZMMXDV%V3#
M#H<J0>YKF_\ A3O@3_H!?^3D_P#\77;44 <S:?#OPM8:+?:3::7Y=E?E3<Q?
M:)3YFTY7YBV1SZ$5?\/>%=%\*VTMOH%BMI',^^0!V<L<8Y+$FM>B@#'\0^$]
M$\5PPQ:_8K=K Q:+]XZ%2>O*D'G X]JAG\$>'KGPQ!X>GT_?I=NV^* S2?*<
MDYW;MW5CW[UO44 4-&T33_#VEQZ=H]L+:TC)*QAF;!)R>6))J_110!0U?1-,
MU^R-IK-E#>09R%E7.T^H/4'W%8>G?##P;I5XMU9:%")D.5,LCRA3Z@.Q&:ZN
MB@ KE-1^&'@W5;QKJ]T*$S.<L8I'B#'U(1@,UU=% %#2-$TS0+(6FC64-G!G
M)6)<;CZD]2?<UE:]\/O#'B;4A?ZWIGVFYV"/S/M$J?*,X&%8#N:Z2B@#B?\
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M;3=<LS:ZO90WD!YV3(&P?4>A]Q7-1_"7P/%/YJZ#&6SG#3RLO_?);'Z5V5%
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MBJL+-K%@%G&8B;I,2<X^7GGGTJW<7=M:>5]JN(H/.D$4?F.%WN>BC/4GTZT
M345#->6UM+#'<7$44D[;(DD<*9&]%!ZGZ5GV=W=MXDU."XO=/DLX4C,4$3YG
MARN29!V!/(]J -:BLYO$6BJL+-K%@%G&8B;I,2<X^7GGGTJY<W5O9V[3WD\=
MO"OWI)7"J/J3Q0!+16;:>(]$O[I+:QUC3[F=\[8H;I'9L#)P <G@$U=NKNWL
M;9[B]N(K:!,;I9G"*N3@9)X') H EHJF-8TQM0-@NHVAO <&W$Z^9_WSG-.N
M=4L+*0QWE];6[B,RE99E4A <%L$],]Z +5%4WU?38]/6_?4+5;-_NW)G41M]
M&SCL:DLM0LM2A,NG7<%W&#@O!*'&?J#0!8HK-NO$>B6-PT%[K&GV\R_>CFND
M1A^!.:E76=,>."1=1M&2X5VA83KB4(,L5.>0!UQTH NT54CU?39M/:^AU"UD
MLUX:X693&.WWLXI;'4[#4XVDTV]MKQ%.&:WE60 ^Y!H M451DUS28KX64NJ6
M279(46[7""0D]MN<TM[K.F:9(D>I:C:6CN,HL\ZQEA[ GF@"[161J%[=+K.C
MI97VG1VMP9#-%/)^]G&T%?) ZXY)]L5;OM7TW2]O]IZA:V>_[OVB98]WTR10
M!<HJ#[=:?83>_:H?L@4N9_,'EA1U.[ICWJ :YI)NHK8:G9F>8 QQ"X3<X/0@
M9R<T 7J**Q]-OKEM0U?^T+_39+:VD'E+;R?/;I@D^=G[I[_G0!L45G_V_HXD
MAC.K6.^<!H5^TIF0'H5&>?PK,\0^,[#P]J^FV%Q);EKR79*7N50VZ8X=@>WU
MQ]: .CHJJ-4L#IXOQ?6QLR,BY$R^61G'WLXZT6.J:?J:LVFWUM>*OWC;S+(!
M]<&@"U16/XLO[C2_".IWMB_EW$%NSQOM!VMC@X/!J+0?$5I<Z-I"ZAJ=K_:=
MU9PR/"TJ+([,@)(3W)["@#=HK)O;J\C\3:9;PWFGQ6LJRF:WF?%Q,0O'ECN
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M)G"*/Q- $U%5[+4;+4H3+IUY!=Q@X+P2JZY^H-5F\0Z*D<,CZQ8*D^?*8W2
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MT74[,W+@%(1<+O;/3"YR:FO=1LM-B$NHWEO:1DX#SRJ@/XDT 6**S[G4X9M
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M-1TO3].V/;6NG7$=Q EN0N&0$ '(.1R<]_>K&J:#:ZO?Z;=W+S+)ITQFA$;
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MB>-+;55#GR;%2MJ)"21MQ\FWIW]:[S3O#EQJ%KX>U'Q-+(=7TM'8^6RA69P
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M>Z??QIY?VJPF\MV3^Z>""/PIRZ/;:#X5U"W47VII)'+)*LKF::X8K@C..2<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "L3Q'_ ,NW_ OZ5MUB>(_^7;_@7]* ,.BBB@84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6YX<_Y>?\ @/\ 6L.M
MSPY_R\_\!_K0!MT444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *Q/$?_ "[?\"_I6W6)XC_Y=O\ @7]* ,.I;>VENI"D";V R1D#C\:BK5\/
M_P#(0?\ ZY'^8H&0?V-?_P#/#_Q]?\:/[&O_ /GA_P"/K_C74T4".6_L:_\
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M87O^=6-)^(E]JLWAE19V\0U2>X@NNK8,87!0YZ'=WS0!L_V-?_\ /#_Q]?\
M&C^QK_\ YX?^/K_C5#Q?XOU71_%=GI&F3:-;1SVIG:?57=$!#$8W CT]*J:_
MXF\9Z)9Z==C_ (1VXM[^:*WC>'SF!=U)# Y V<=>3TH VO[&O_\ GA_X^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %8GB/\ Y=O^!?TK;K$\1_\ +M_P+^E &'6KX?\ ^0@__7(_S%95
M:OA__D(/_P!<C_,4#.BHHHH$%%9FNZ]9^'[$3WK%G<[88$&7F;^ZH[T:*=5F
MB>ZUDI"TV#'9Q@$0#W;JS'OVI75[&7MH^T]FM7U\O4TZ***9J%%%% !1110
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M^(/^0@G_ %R'\S0!E5N>'/\ EY_X#_6L.MSPY_R\_P# ?ZT#-NBBB@04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !6)XC_Y=O\ @7]*VZQ/$?\
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MF@#*K<\.?\O/_ ?ZUAUN>'/^7G_@/]:!FW1110(*BN?^/2;_ '&_E4M17/\
MQZ3?[C?RIK<3V.=HHHKI/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %8GB/_EV_P"!?TK;K$\1_P#+M_P+^E &'5O3[W[!<-+Y
M?F97;C=CN/\ "JE% S<_X2/_ *=?_(G_ -:C_A(_^G7_ ,B?_6K#HH W/^$C
M_P"G7_R)_P#6H_X2/_IU_P#(G_UJPZ* -S_A(_\ IU_\B?\ UJ/^$C_Z=?\
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MU4HH *W/#G_+S_P'^M8=;GAS_EY_X#_6@#;HHHH$%17/_'I-_N-_*I:BN?\
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MA"/\?Y&JM6M._P"0A'^/\C2ELRH?$C=HHHKF/1"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$\1_P#+
MM_P+^E;=8GB/_EV_X%_2@##HHHH&%%%% !1110 4444 %%%% !1110 4444
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M2_9I_P#GA)_WP:/LT_\ SPD_[X-%T'*R*BI?LT__ #PD_P"^#1]FG_YX2?\
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M:H/RG=C_ 'AR>V=J]C?6FCZ-<ZKY7V35&FO[HW@F\CS9"-N_ROGSM"X^I]Z
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M &56YX<_Y>?^ _UK#K<\.?\ +S_P'^M S;HHHH$%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK"\8?\@.W_["FG?^EL-;M87C#_D!V_\ V%-._P#2V&FMR9;,W:***104444
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M!&R,>(I#PKCTYP#[?050\>Z5JJ/#KOB7%MJFISRQM8K#M6)(0J @[CD'@#U
MSDUR-OYGVJ+R,^;O&S'KGBC2<=0NZ52Z/LRBBBN ]T**** "BBB@ HHHH **
M** "BJFH2:C'&ATJUM;ER?G%S<M" /8K&^?TJA]J\4?] ?2/_!K+_P#(].Q+
MDD;5%8OVKQ1_T!](_P#!K+_\CT?:O%'_ $!](_\ !K+_ /(]%@YD;5%>3_%'
M6?%VGKHTEE#'8W+7#K%_9UX]PTIVCY60Q*"/;GZ5VG@J^\3W^CB3Q=IT%G/@
M;#&^'<>K)SM/X_@*IQ:C<B-5.;A8GM/^2AZO_P!@NQ_]&W=;M85I_P E#U?_
M +!=C_Z-NZW:EEQV"BBJ\]_9VTZ0W-U!#+(K,D<D@5F"C+$ ]0!R?2D4>??$
M'3(;KQII=QJ>@ZEK&FQVCK(EA"[D/NXY4C'YUFZ?H.K_ -D^'H+O3;P6T>O&
M6*WF4R-;VI P'QT'WNN.M>K6UU;WMLEQ9SQW$,@RDL3AE;Z$<&I: /&[7PIK
M7F:SI]W:7#V&B6-ZFEYB/[YIE;;M_O'!/3.#BH[K0\2>'&U[PUJVI6D.C"*2
M&TMY"\<NXD!L$8(]">_2O:*1W6.-GD8(B@EF8X 'J: /(;;0=>U;PYI?A.]L
MKNUM9KI[F2>="WV6V7[D>[&-Y.[CJ..QKK? ]G<2>%GT'Q%IC(^FR-;JSPE4
MF3G:Z-W."1D<]^]=;;75O>VR7%G/'<02#*2Q.&5OH1P:EH KV-A:Z;:I;V,"
MPQ(  %[X 4$GJ3@ 9//%6**AM;RVO8V>SN(;A$<HS1.&"L.H)'<>E $U%%%
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M?_QQO\*/[9L/^>__ (XW^% %ZBJ/]LV'_/?_ ,<;_"C^V;#_ )[_ /CC?X4
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MV'_/?_QQO\* +U%4?[9L/^>__CC?X4?VS8?\]_\ QQO\* +U%4?[9L/^>_\
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MR [?_L*:=_Z6PUNUA>,/^0';_P#84T[_ -+8::W)ELS=HHHI%!1110 4444
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M%% &9/\ \C98?]>5S_Z'!6G69/\ \C98?]>5S_Z'!6G3?0F.["BBBD4%%%%
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M+/N<Y/XLN[::VBG\)ZTKW4IBA'F69W,$9\<7''RHQY]*F_X2#4O^A0UK_O\
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M?8K7_GVA_P"_8H X^BNP^Q6O_/M#_P!^Q1]BM?\ GVA_[]B@#CZ*[#[%:_\
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M:O9:;;VTUQ)<R11JKS2MEI"!RQ/N:R_[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\
M"J<6TD91G",G+74W:*PO[1NO^>O_ (Z/\*/[1NO^>O\ XZ/\*GV;-?;Q-VBL
M+^T;K_GK_P".C_"C^T;K_GK_ ..C_"CV;#V\3=HK"_M&Z_YZ_P#CH_PH_M&Z
M_P">O_CH_P */9L/;Q-VBL+^T;K_ )Z_^.C_  H_M&Z_YZ_^.C_"CV;#V\3=
MHK"_M&Z_YZ_^.C_"K^FW,MQYOG-NVXQP!ZTG!I7*C5C)V1>HHHJ#4**** "B
MBB@ HK)O;VXAO'2.3"C&!M'I4']HW7_/7_QT?X5:@V8NM%.QNT5A?VC=?\]?
M_'1_A1_:-U_SU_\ '1_A3]FQ>WB;M%87]HW7_/7_ ,='^%']HW7_ #U_\='^
M%'LV'MXF[16%_:-U_P ]?_'1_A1_:-U_SU_\='^%'LV'MXF[16%_:-U_SU_\
M='^%']HW7_/7_P ='^%'LV'MXF[7*_$:UU:;P;<W'AZ]N+2]L_WX\ARIE0#Y
MEXZ\<CW ]:N_VC=?\]?_ !T?X4?VC='_ ):_^.C_  IJ#3N3*M&2:U.8^#5K
MJW_")"_U>]N)HI@([."1R5BA3@$#MG^0%>B5ST%U+:V\<%MLBAB4(D:1J%51
MP !C@5)_:-U_SU_\='^%$HMNXH58PBHF[16%_:-U_P ]?_'1_A1_:-U_SU_\
M='^%+V;+]O$W:*PO[1NO^>O_ (Z/\*/[1NO^>O\ XZ/\*/9L/;Q-VBL+^T;K
M_GK_ ..C_"C^T;K_ )Z_^.C_  H]FP]O$W:*PO[1NO\ GK_XZ/\ "C^T;K_G
MK_XZ/\*/9L/;Q-VBL+^T;K_GK_XZ/\*GLKVXFO$223*G.1M'I2<&AJM%NQK4
M445!L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !6)XC_ .7;_@7]*VZQ/$?_ "[?\"_I0!AUN>'/^7G_
M (#_ %K#K<\.?\O/_ ?ZT#-NBBB@0444V66.&)I9G6.-!EG<X"CU)H#8=15+
M2]5@U>!Y[-)?LX;:DSIM67W7/)'OCGM5VC<F,E-<T=@HHHH*"BBB@ K-\2?\
MBKJW_7E-_P"@&M*H+VT2_P!/N+.8L([B)HG*G! 88./?F@#QS^Q;30?AGIGB
MS2));+5T*,S)*V+C+X*E<XZ<X&. :ZO4_&7B-KC6Y]#L-/;3]$<I<&Z9_-E*
MC+;<$ 8&>O\ ]:KUA\,M'LYK5I[S4M0ALV#06UY<AXHR/10 /PZ5+J?PZTG4
M]1NKIKK4;9;Q@UU;6USLBG([LN.?SH R7^(.I/XFTZV6UL[/3KQ+:1'N]X>9
M954MY;_<RNXC!ZD<5FWOQ<N;?7IXXXK'['!=^0;=Q+]HD4-@N& V#Z'FNKN_
MA_I-YJ27,EQ?I K1/]ACN,6[&-0JDICL% ZT/X"LEU2:\L-5UC3A/-Y\EO9W
M?EQ,Y.22N#UH H_%7_D6]/\ ^PI!_P"S5)X\\;2^%IK"UM/LJ37>YFGO%D:*
M-5QU$8+$DGM6YXD\.6GBC3$L;Z:XA1)EF5[=PK!@#CD@^M9<OP^LI[6%)]8U
MJ6YMY6DAOGO,W$>X % ^/N_+G&.I/K0!BZ-\1[R_FT66[@M$LKVYELYY8PW$
MJ@%&7<1A6W#@C/6L^Z^*NI1VMO((=/M1>SS-;SW22F-8%;:I8)EBQ(;D #CI
M787G@>RU'PT-&U'4=3NXUG$ZW,]P'F5AZ,5Z<GMWI+SP'I=S9:=!!/>V,FFQ
M>5;W-G/Y<H7N"<<YZ].YH X]/$;>*=?\#ZA+$D4HNKN*01D[255.1GG!R.M=
M1\0-&DU:PMFBT:;6?)W@VR7OV=5R!AR.KD$< 'N:N1>#+1+C2;BXU'4KR;2I
M)9(9+J<2,Y?&0Y*Y(&!C&*GU[PO;:_+#-)>W]C/"K(LUC<&)BIZJ>""* ,;X
M9WD:?#R)IKB:3[&TBSF53F(J<E0.> "*WM"\3Z1XE29]$N_M*P$"0^4Z;2<X
M^\!Z&I="T*Q\.:6MAIB,L2L7)=MS.QZDGUK1H \P\->';+QV^KZOXAEGFNUO
MI((1',R?957&W: >O/?/2I--T&T\:^*_$(\1R3W<>FS+:6L/G,HC4 C?P1EC
MC.?7-;]]\.M*O-2NKR&[U*Q^V'=<PV=SY<<Q[[A@]?ZT_4?A]I=]J37UM=:A
MID\D8CE-A<>7YH Q\W!SQ0!YS<0RZEX97P_-=R7%M!XJ2QMYW;<?+(=1SZ=_
MQJ?4-;NM=\#Z?X:9V6]MO/&H#/*I;*2 ?K\OXBO1H_!&D0:7IMA;+-!#I]ZE
M]'L<;I)5SRY(.0<\XQVQBA/ ^DQZOJVI)YPGU:%H9OF&$##YBG'!/7G- 'E!
MBM+F7PO'J6F7NJPG1VQ;V08R%O,DP1@@X'^0:W--L=4T[4? 4&M>8L_VB[*1
MRMN:-"$VJ3_2N[TSP3INE:AIUY;S732:=:FUB#NI#*222V%&3\QZ8^E2>(_"
M5KXEN+&>XO;ZSFL2YAELI1&P+8SR0?[HZ8[T <5\0+'^TOB7IEO_ &-_;6=/
M8_9/M7V?=AFYW]L5#XW\'Z-9:+H-U'I/V*ZN+VVMIXOM+R;$*-NCSNP<$8W#
MTKK+OX>VEY-9W#ZWK:75G"8$NH[L"5U+%OF?;DGYL?3%:%[X2M=1T?3]/O;V
M^G6PN$N4GDE#2R.N<;V(Y'S'TH \^\6^&;&R\9:'I&E:#_:-M]EE9=/^V-%O
M.6)/F,<C'7KVQ7IGAZR33_#]G:QV']G!(^;3SO-\HDY*[_XN2>:H:_X-M/$&
MJ6VHR:AJ-C=6T9CCDL9Q&<'KSM)[UKZ98_V;IL-I]JN;OR@1Y]U)OD?))^9N
M_7% %JBBB@ HHHH **** "BBB@ HHHH *Q/$?_+M_P "_I6W6)XC_P"7;_@7
M]* ,.MSPY_R\_P# ?ZUAUN>'/^7G_@/]:!FW1110(*BN?^/2;_<;^52U%<_\
M>DW^XW\J:W$]CG:***Z3S0HHKF/B%=W-EX/GFLYY;>42(!)$Y5A\WJ*&[*XX
MJ[L=/17%2I>^%/$FF(-7O+ZPOW:.2.]D\QD(&=P;_/ZU+%X\D?[/=OHL\>DW
M,_DQ7IE&2<XR4QD#CUI<RZE<CZ'845QEUX_EMGOG&B2R6FGW36]Q<+.,+AMH
M(&,DGT[<<U;U+QA-!J%Y;Z3H\NI)8('NIEF"! 1GC(.[CTHYD+DD=117)Q^-
MY+S4;>TTG2);PS6R7.?.";$)PV<CM^IJ;QA?WL<NEZ7IUP;5]2N/+>X7[R*,
M9Q[\T<R#D=[,Z:BN7F=_!6GR337U_K'VF6.&V@N'W/YASP&]#].,=\U"_CB:
MUMM2&I:,]K>V$2S&W-P&$BLP7(<#W'8T774.1O8ZZBN2B\<LL\R:AI$]H!9M
M>09D5C-&/8?=/YTEOX\5O#]SJEWIQA6)D6)$N%D$I;H-PX4CN#THYD')(ZZB
MN,C^(:'2]0N)M/59[)8W,45VDJNKN%R'4$9&>E+-XSU!X;^W71I+2]CLC=VP
MDG0[X\XW], @$MMYSM(HYD/V<CLJ*P_"&I:CJOA^"YU6W\N1E&V7>I\\8^_A
M0-OTJD?^)Q\1P <V^BV^3W'G2#_XG]11<7+JT=31113)"M31O^6W_ ?ZUEUJ
M:-_RV_X#_6IG\)I1^-&G1117.=X4444 %%%% &%J/_(0D_#^0JK5K4?^0A)^
M'\A56NF.R/.G\3"BBBF2%%%% !161XKU6;1?"][?VP!FB4!,C(!9@N?PSFLW
M3-+N='M$UF_UZ_NECMVFNH97WQL-F?E'\./UI7U*4=+G4T5P]OX\CUA9;*2R
M6W^U6LK0.ETDI.$)PRKRAP.]9/A4_P#$X\)?]>5Q_P"A/2YET*]F[:GIU%<5
M\0;:XM;%=4L]5U&VD,D</DPW)2/!)R<#O^-4=5MKCP_XQT%;-K[69@LY1+FX
M!=B4QC<1@ =?SHYK"4+K<]#HKCG^(,2:-#=&P*W<ER]M]FDN%15=<%LR'@#D
M<GUI!\0D?38)XM-:6XDN_LC6\<ZMA\9&U@,,#P.U/F0>SD=E17&ZGXZO-)(%
M[HB1%4#2J^H1AAGLJ]7_  J>\\:3IJ$EII>C27[);)=!A.$_=L,DG(XQD=,Y
MS1S(.21U=%<MI_CFVO;B(26K06\UDUW',SYSL)#IC'4;6YSV[5LZ%J<FL:);
MZA+;?93<*6$6_=@9X.<#J.?QH33)<6MS0HHHIB"BBB@ JUIW_(0C_'^1JK5K
M3O\ D(1_C_(TI;,J'Q(W:***YCT0HHHH **** "BBB@ HHHH **** "BBB@
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MQ)%(NUD5U*@,.QSQ]10!W-%%% !1110 4444 %8GB/\ Y=O^!?TK;K$\1_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*FNHAIMKJUM;I)]ATW68)50$MY:?-GK]!7K-%'*'M?(\NU*:RU^X\57D2O)
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M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?WK_ ".6NO!WC&[\3VVN2Z!:_:;=-H43)M8]F(\SJ,G]/2MC[+\0?^@%9_\
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M5Q>V-LMS;WL<2J2"5'*XQ_%Z>O7BI--\:WT7@G59M3D$NJV+B)#L WF3_5G
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MCG-4]&U=_@;U6J=25/VE1N*N[.&WSL_P*'V7X@_] *S_ ._R?_':/LOQ!_Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME=M6+X<\/?V"M^\MS]KN;^[>YFF\O9DMT4#)X%;5 !1110 4444 %>:>+_\
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M:2/1HU=G#Y$LG!!R,?-QSV'%:_\ 8&F?VE>7_P!F_P!*OH1#<2;V^= ,8QG
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M>\S@^1G*Y'8#!X[5V-8</@W0(+6PMHM/"Q:=/]HM5\U_W<F<[LYR>>QR*W*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8GB/\
MY=O^!?TK;K$\1_\ +M_P+^E &'7.:I#K5KXPL]9T2SCN&MH"@\U@%R=X((W
M]&KHZ*F4>96.?$X>.(@H2;5FGIO=?>9?_"7^//\ H"Z;^?\ ]MH_X2_QY_T!
M=-_/_P"VUJ45/(^[.?ZC+_G]/[U_D9?_  E_CS_H"Z;^?_VVC_A+_'G_ $!=
M-_/_ .VUJ44<C[L/J,O^?T_O7^1E_P#"7^//^@+IOY__ &VC_A+_ !Y_T!=-
M_/\ ^VUJ44<C[L/J,O\ G]/[U_D9?_"7^//^@+IOY_\ VVC_ (2_QY_T!=-_
M/_[;6I11R/NP^HR_Y_3^]?Y&7_PE_CS_ * NF_G_ /;:/^$O\>?] 73?S_\
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M/_[;6I11R/NP^HR_Y_3^]?Y&7_PE_CS_ * NF_G_ /;:/^$O\>?] 73?S_\
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M6&$$*"0268]%51RS'L "37-M')XC\8Z/=6EE<VVF:,)9#+<V[V_FR.FQ41'
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M/<H(0EG7EL#C.>#5>QT*^\-S>%)M5MIKFVM1=270M('N##<RY<$H@+$ %E#
M$ ^F:.5![27]>IV</BC2)K"_NQ<O''IJEKM9H)(I(1MWY:-E#<KR..>V:33_
M !7HVJ7T=I97;/++&TD.Z"1%F52 Q1V4*^,C.TG'X5Q6L:5J>KV6O7XTZZB.
MOW%G8V\+1GS([=6 :611R@(+'G! QG%;UY:2Q_$"UN(]/N9+#1M'D,"PQX5I
M78+Y:$X!.Q.F>XHY4-3E_7]=C:LO$VDZC?FSL[EI),N%?R7$<A0X8)(5V.1W
M"DG@^AJ*/Q=HDNH)9QWC,\D_V=)1!)Y+2X)V";;Y9;@C&[.1CKQ7+:98ZG;1
MZQIWA0ZA_8S:9,;2/4+=H#!>.S%4C,BJY3!SSD#CYN32^$]'M)K?0[.[_M^?
M^SX5F2UO;+[/;VLJ@<EO+3S&!) ^9^Y]Z.5"4Y.R/0J***S-PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L3Q'_P NW_ O
MZ5MUB>(_^7;_ (%_2@##HHI\<4DS;8D9SC.%&:!C**G^Q77_ #[3?]^S1]BN
MO^?:;_OV: (**G^Q77_/M-_W[-'V*Z_Y]IO^_9H @HJ?[%=?\^TW_?LT?8KK
M_GVF_P"_9H @HJ?[%=?\^TW_ '[-'V*Z_P"?:;_OV: (**G^Q77_ #[3?]^S
M1]BNO^?:;_OV: (**G^Q77_/M-_W[-'V*Z_Y]IO^_9H @HJ?[%=?\^TW_?LT
M?8KK_GVF_P"_9H @HJ?[%=?\^TW_ '[-'V*Z_P"?:;_OV: (**G^Q77_ #[3
M?]^S1]BNO^?:;_OV: (**G^Q77_/M-_W[-'V*Z_Y]IO^_9H @HJ?[%=?\^TW
M_?LT?8KK_GVF_P"_9H X^\\4Z)#XJMC+J,*""VN(I=V1L<O#A3[_ "M^5=0K
M!T#+T89'%<AJGPXN+[X@6VIBSD^Q./.N5\L\R+C QC^+@_@WK7;_ &*Z_P"?
M:;_OV:N7+96,:?/>7,045/\ 8KK_ )]IO^_9H^Q77_/M-_W[-0;$%%3_ &*Z
M_P"?:;_OV:/L5U_S[3?]^S0!!14_V*Z_Y]IO^_9H^Q77_/M-_P!^S0!!14_V
M*Z_Y]IO^_9H^Q77_ #[3?]^S0!!14_V*Z_Y]IO\ OV:/L5U_S[3?]^S0!!14
M_P!BNO\ GVF_[]FC[%=?\^TW_?LT 045/]BNO^?:;_OV:/L5U_S[3?\ ?LT
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M-8XT!^ZJC 'Y"I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<$+S3R+'%&I9W<X50.223T%+%*DT22PNLD;J&1T.0P/0@]Q7$:UJ^L:OX?\
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M_D(/_P!<C_,5E5J^'_\ D(/_ -<C_,4#.BHHHH$%%%% !1110 4444 %%%%
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M1C,<.NYIS(A!).1CEB>A]*Z.B@##NM!NTUV?5=%OXK.:[A6*Y2>V,R2%?N.
M'4A@"1U((QQQSS6M^$X;*+0K1X[JYLHY[B:]NX[1;J0RNF0QB*.,,V>=AVX
MXSFO0:* .&LM%O-;\/ZIHA:6TTH3PG3Y[BQ6"0A65W!B4( NY>#M4_,>M='K
M.BOJ-W8WUG="TOK!F,,KQ>8A5P ZLN02" .A!! K6HH S!9:O]C<-J\?VQI
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M ,A!_P#KD?YBLJM7P_\ \A!_^N1_F*!G14444""BBB@ HHHH **** "BBB@
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M"9 9AP<X!)QWQUK15E=0R$,K#((.010 M%%% !6)XC_Y=O\ @7]*VZQ/$?\
MR[?\"_I0!AUJ^'_^0@__ %R/\Q655W2[R.RNFDE#$%"ORCW'^% SJJ*R_P#A
M(+7_ )YS?]\C_&C_ (2"U_YYS?\ ?(_QH$:E%9?_  D%K_SSF_[Y'^-'_"06
MO_/.;_OD?XT :E%9?_"06O\ SSF_[Y'^-'_"06O_ #SF_P"^1_C0!J45E_\
M"06O_/.;_OD?XT?\)!:_\\YO^^1_C0!J45E_\)!:_P#/.;_OD?XT?\)!:_\
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M_C1_PD%K_P \YO\ OD?XT :E%9?_  D%K_SSF_[Y'^-'_"06O_/.;_OD?XT
M:E%9?_"06O\ SSF_[Y'^-'_"06O_ #SF_P"^1_C0!J45E_\ "06O_/.;_OD?
MXT?\)!:_\\YO^^1_C0!J5SOB#_D()_UR'\S5[_A(+7_GG-_WR/\ &LG5+R.]
MNEDB# ! OS#W/^- RE6YX<_Y>?\ @/\ 6L.MSPY_R\_\!_K0!MT444""BBB@
M KA?#G@;5='^(&I:[=:HLUK=&0K&K,7?<<@.",#'MGIVKNJ* "BBB@#E]?\
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M3U&1P<5%_9=A]CEM/L-M]FF):2'R5V.2<DE<8.3S0!4\4_\ (G:S_P!>$_\
MZ+:N0M].M=(C\$7NG0B&ZN7CAN)AR\Z/ 20[=6&0, ],#&,"O098HYX7AGC6
M2*12KHZY5@>""#U%1FQM&6W5K6$K;$& &,8B(& 5_N\<<4 >:>);NUN]-O\
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MCD_G4JV%FDL,J6D"R6\?EPN(P#&G]U3V' X% 'G7BV2PN]-\0R6.CV2'246
MWUS<^7+ ZJ-BP+L;:H^7 #("Q/&22=/S'F\9I)(Q9W\+EF)[DR"NLN=#TF\N
MC<WFEV4]PR[#++;HSE<8QDC.,$C'I4XL;03"46L/F"+R _EC/E]=F?[OMTH
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M<_X1S_IZ_P#(?_UZ/^$<_P"GK_R'_P#7H PZ*W/^$<_Z>O\ R'_]>C_A'/\
MIZ_\A_\ UZ ,.BMS_A'/^GK_ ,A__7H_X1S_ *>O_(?_ ->@##HK<_X1S_IZ
M_P#(?_UZ/^$<_P"GK_R'_P#7H PZ*W/^$<_Z>O\ R'_]>C_A'/\ IZ_\A_\
MUZ ,.BMS_A'/^GK_ ,A__7H_X1S_ *>O_(?_ ->@##HK<_X1S_IZ_P#(?_UZ
M/^$<_P"GK_R'_P#7H PZ*W/^$<_Z>O\ R'_]>C_A'/\ IZ_\A_\ UZ ,.BMS
M_A'/^GK_ ,A__7H_X1S_ *>O_(?_ ->@##HK<_X1S_IZ_P#(?_UZ/^$<_P"G
MK_R'_P#7H PZ*W/^$<_Z>O\ R'_]>C_A'/\ IZ_\A_\ UZ ,.BMS_A'/^GK_
M ,A__7H_X1S_ *>O_(?_ ->@##HK<_X1S_IZ_P#(?_UZ/^$<_P"GK_R'_P#7
MH PZ*W/^$<_Z>O\ R'_]>C_A'/\ IZ_\A_\ UZ ,.BMS_A'/^GK_ ,A__7H_
MX1S_ *>O_(?_ ->@##HK<_X1S_IZ_P#(?_UZ/^$<_P"GK_R'_P#7H PZ*W/^
M$<_Z>O\ R'_]>C_A'/\ IZ_\A_\ UZ ,.MSPY_R\_P# ?ZT?\(Y_T]?^0_\
MZ]7=.T[^S_,_>^9YF/X<8QGW]Z +U%%% @HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>nexi-20221231_g6.jpg
<TEXT>
begin 644 nexi-20221231_g6.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '.!#,# 2(  A$! Q$!_\0
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MY11[.'\J^X/K%;^=_>SV/_AL3XT?]% U#_OQ;_\ QNC_ (;$^-'_ $4#4/\
MOQ;_ /QNO'**/9P_E7W!]8K?SO[V>Q_\-B?&C_HH&H?]^+?_ .-T?\-B?&C_
M **!J'_?BW_^-UXY11[.'\J^X/K%;^=_>SV/_AL3XT?]% U#_OQ;_P#QNC_A
ML3XT?]% U#_OQ;__ !NO'**/9P_E7W!]8K?SO[V>Q_\ #8GQH_Z*!J'_ 'XM
M_P#XW1_PV)\:/^B@:A_WXM__ (W7CE%'LX?RK[@^L5OYW][/8_\ AL3XT?\
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M$^-'_10-0_[\6_\ \;KQRBCV</Y5]P?6*W\[^]GL?_#8GQH_Z*!J'_?BW_\
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M]XM_[%#6/_28U$Z<.5^ZC6CB*SJ).;^]FLO[8GQHVC_BX&H?]^+?_P"-T?\
M#8GQH_Z*!J'_ 'XM_P#XW7C:_='TI:OV</Y5]QE]8K?SO[V>Q_\ #8GQH_Z*
M!J'_ 'XM_P#XW1_PV)\:/^B@:A_WXM__ (W7CE%'LX?RK[@^L5OYW][/8_\
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M[.'\J^X/K%;^=_>SV/\ X;$^-'_10-0_[\6__P ;H_X;$^-'_10-0_[\6_\
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M ,>D'^XO\J*^8/T<_'3]JK_DX_XB?]A:3_T%:\JKU7]JK_DX_P"(G_86D_\
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MB/\ DIS?]@;2/_3=;UYK6=/X$;5OXLO5A1116AB%%%% !1110 4444 %>B?
MO2?"6L>,+J'Q?)8BV2PEDLH-4OGLK2XN@R!4EF3#(-I<C!&651GFO.ZV/"/B
M:;P;XCL=;MK2SO+NR?S8([Z+S8ED .QRF1N*G# 'C*C(/2IDKII&E.2C--['
MM7QL_9^A^'/AK6+W0M(NM7M!J<D[ZLTXVZ58APL,!CW!GD;>ADD*D)NC7(8M
M76_L_P#P5\#>-/AOX-O-?TC3KF[US5M1T^YNKC6I;2]VQ1@PK90APDTNX@;2
MIZC->)-\=/$\W@.]\+7!L[N.[$\<NK7$)>_,,TZW$T7F[L%7E16.5W<8R!Q5
M[P3^T%K7@7PSHFC6NA>']0.AWTVIZ5?ZE:R2W%E<R8S(F) A(VC&Y3C%<[C4
M<+7U.Z-3#JKS6TMM;K<[2;X'V7B3P#\*K.QM'T;7M2DUM=1NDT^>ZNY_LUP%
M1&AB!)=1D8X YR:@OOV0M9TO4O%MM>>(;9(O#]M:W1:WTZXGFF2XC9T9H$!>
M)5VD.S A3ZUS6B?M,>+]&M-.M7BTS4[:UM]2M9X[Z!F^W1W\@DN1,5=2<L 0
M5*D5<M?VIO$]EXP?Q1!H?AN'74M(;*SNTL74V,<431*(0).FQN5?<N0#CBBU
M5;?UJ'-A7:Z[?E_F4_C-\,O"W@+P7\.]5T37)K_4=?T9-0N[6:WD4,2[@RHQ
MX505V[#SQNS@UT&G_LLW"^$M#\6:AKQBT*XO=/AOM^DW4!2.ZD"!H'=0)\$A
M25 P3GD=?,_%7Q)U'QIX1\.Z!JEG82_V%$UM::DD3+=F LS>2[;MI4,Q(^4'
MWKK_ !!^TUXK\2>&[C2;BQT6":Z6P6YU6WM76[G-DP-L68N5^7;T"@')XR<U
M5JEDDS-2H<S<EI96];?YF'\>/ ^B?#?XL>(_#?A_4I=2T[3[IX!Y\3)) P)!
MB9F_UA''SC .:X"NG^(_CZ[^)OBV\\1ZAI^GZ?J5Z=]U_9L31I/+_%*P9F^=
MN^,#CH*YBMHW45?<Y:CBYMPV"BBBJ,PHHHH **** "BBB@ KTWX!_P#(>\6_
M]BAK'_I,:\RKTWX!_P#(>\6_]BAK'_I,:B?PLVH_Q(GF*_='TI:1?NCZ4M68
MA1110 4444 6=-TVYUK4K/3K*,RWMY,EM!&!DM([!5'YD5])_&#]G70KJ?PK
M9?#>TD2Z7Q _@O5I;J=VCEU!$1EN,L3L1OWO X^3@5X#X#\8W?P]\8Z3XEL+
M:UN[_2YQ<6\=]&7A\P [69003@G(YZ@5WEA^U/\ $BUL+RVO-?EUQIKZVU*W
MN-79KB2QN()/,1X,MA,DE6&""O%8S4VTXG91E14&JF[_ $_S/26_9JT'7?AS
MX?T?P[XCTG5/$MQX@U:U_MR.SFB^TM:VV_[%M?!!W*^UN0<@]\5R'A/]DKQ%
MXHM=.N/[2CMA-H<6O7EO%8RW-S9Q32M';Q^2GS2/(%9L#&U1DUC:M^TSXGU"
MZT">STO0=!&B:XWB&UCTFR:%#=N/WA<%SN#G)(]\ @8 ;>?M+>*=5\8^)M>U
M*QT;4X/$=I#8ZCHMU:L;!X80/)54#ADV$9!#9!)]:S2JKJ;N>%DTVOZM_G^#
M-7Q)^R[=>"=.\77WB/Q=IFE6_A^^@L ?LTTIO7G@$L&P#E"P(!#?<PQ/3G0N
MOV//$$?C_3O"=OK4%Y=S6$NI75RFG7 AA@C1&+P-C%T"7"J8SRPQ@5YSJWQ<
MU35/"NK^'4TS2-.T?4M4@U9[:QM3&L4D,?EHB L1LV]=V23R3R:ZF/\ :C\5
MV<FC1:?IF@Z9I&FPW< T6VLW^Q7,=R +A94:1CM8*/E4J%QP!3M5[D*6%OJM
M/GW_ ,CF_C'\(-2^#/B*QTS4+E+R._LDO[:80/;R&-B5*R0O\T;AE(*GVK@J
MV_%GB9?%6I1W4>C:5H,,<2PQV6CP-%"H!)R=S,S,23RS$]!T%8E;QO;7<XZG
M+S/DV"BBBJ,PHHHH *]'\9?\D.^%_P#U\ZS_ .CH:\XKT?QE_P D.^%__7SK
M/_HZ&HENOZZ,VA\,_3]4><44459B%%%% !1110 444-]TT %%?6^H_L^>"['
MX2VNNWOAZ?3=./@A-=G\7?VN[,FIL<1V_P!E)(97.!PHQGKQ7G.M?LB>,- \
M!'Q+>7%NCPVEM?75B;6X40PSLJJ1<%/*D==ZEHU8L ?:L%6@SLEA*L>E]+GA
MU%>_:M^R2^A76K17WQ'\-PC1]5AT?4W^SW;?9KB89@7 C^??D9V\+SD\54\,
M_LC^)O$VK>)M(CU6SAU?0[RYLI(!9W4L+O"F\EKA8_*B#C[N]LD\$"G[6%KW
M)^JUKVY?R/#**^D/A%^SOI</C;X?CQ-J>F:^OBK2)]4M_#<<4_G^4;69D=W
M"@K(B@#=ECTX!KQOXE?#NY^%NOQ:#J.HVMYK4=M'-J%K:JW^@2NH;[.[$89U
M4J3MR!G&:I5(R?*B94)PASR6G_#?YG)T445H<X4444 %%%% !4MI_P ?EO\
M]=5_]"%15+:?\?EO_P!=5_\ 0A0!^[=G_P >D'^XO\J*+/\ X](/]Q?Y45\H
M?IZV/QT_:J_Y./\ B)_V%I/_ $%:\JKU7]JK_DX_XB?]A:3_ -!6O*J^GI_
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M3:I8>#M T:\\2:;>:=J;V9N#YYN65I)OGD.U@5X484;FXKF2J(]&4L/)IO\
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M_P#P/Z^XAT']E3Q%XD\0^(=/LM6LY+'0V@BO-16PO6*S2DA8?LPA,X88)8E
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M(\SHHHKH. **** "BBB@ KTWX!_\A[Q;_P!BAK'_ *3&O,J]-^ ?_(>\6_\
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M?X_U^!V?AW]G'PI-KWPAMSK*Z_+XNTV:ZO-),\UHV]5E.^.40G8B-&%(.6+
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MR 9*.' /L<U^A_\ P[Q^$_\ T.NM_P#@3;__ !NC_AWC\)_^AUUO_P ";?\
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M>>(KN+3+*TN=9TC3M(:2-W/V=;)D:*5,]6)C7(/%?6W_  [Q^$__ $.NM_\
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M]C+JW_HBTKS.OTSOOV&_AI>> ='\.2>+=773K#4+J^AN!<0[WDF2)74GR\8
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M;I!_96)[+[S\[:*_1+_AWC\)_P#H==;_ / FW_\ C='_  [Q^$__ $.NM_\
M@3;_ /QNCZW2#^RL3V7WGYVT5^B7_#O'X3_]#KK?_@3;_P#QNC_AWC\)_P#H
M==;_ / FW_\ C='UND']E8GLOO/SMHK]$O\ AWC\)_\ H==;_P# FW_^-T?\
M.\?A/_T.NM_^!-O_ /&Z/K=(/[*Q/9?>?G;17Z)?\.\?A/\ ]#KK?_@3;_\
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MV_\ \;H^MT@_LK$]E]Y^=M%?HE_P[Q^$_P#T.NM_^!-O_P#&Z/\ AWC\)_\
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MMT@_LK$]E]Y^=M%?HE_P[Q^$_P#T.NM_^!-O_P#&Z/\ AWC\)_\ H==;_P#
MFW_^-T?6Z0?V5B>R^\_.VBOT2_X=X_"?_H==;_\  FW_ /C='_#O'X3_ /0Z
MZW_X$V__ ,;H^MT@_LK$]E]Y^=M%?HE_P[Q^$_\ T.NM_P#@3;__ !NC_AWC
M\)_^AUUO_P ";?\ ^-T?6Z0?V5B>R^\_.VBOT2_X=X_"?_H==;_\";?_ .-T
M?\.\?A/_ -#KK?\ X$V__P ;H^MT@_LK$]E]Y^=M%?HE_P .\?A/_P!#KK?_
M ($V_P#\;H_X=X_"?_H==;_\";?_ .-T?6Z0?V5B>R^\_.VBOT2_X=X_"?\
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M#M_@4H_X7=\/^!_R'['_ -'I7Z;77_'U/_UT;^9K\RO@7_R6WX?_ /8?L?\
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M[P_G0![TGW5^E%"?=7Z45D=!^.'[57_)Q_Q$_P"PM)_Z"M>55ZK^U5_R<?\
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M.8[CX%_\EM^'_P#V'['_ -'I7Z:W7_'U/_UT;^9K\RO@7_R6WX?_ /8?L?\
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M+:]A))*2KM)Y!*DH5)4X)KK;:VAL[:&WMXE@MX46***,85$4850.P  %244
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M^$]K8^,)?$%EK^N6,EU-#<ZA8P31?9K^>.-8Q+(#&6#,J+O\ME#;1D50\+_
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M_P"?>;_OVW^%'V.X_P"?>;_OVW^% B&BIOL=Q_S[S?\ ?MO\*/L=Q_S[S?\
M?MO\* (:*F^QW'_/O-_W[;_"C['<?\^\W_?MO\* (:*F^QW'_/O-_P!^V_PH
M^QW'_/O-_P!^V_PH AHJ;['<?\^\W_?MO\*/L=Q_S[S?]^V_PH AHJ;['<?\
M^\W_ '[;_"C['<?\^\W_ '[;_"@"&BIOL=Q_S[S?]^V_PH^QW'_/O-_W[;_"
M@"&BIOL=Q_S[S?\ ?MO\*/L=Q_S[S?\ ?MO\* (:*F^QW'_/O-_W[;_"C['<
M?\^\W_?MO\* (:*F^QW'_/O-_P!^V_PH^QW'_/O-_P!^V_PH AHJ;['<?\^\
MW_?MO\*/L=Q_S[S?]^V_PH AHJ;['<?\^\W_ '[;_"C['<?\^\W_ '[;_"@"
M&BIOL=Q_S[S?]^V_PH^QW'_/O-_W[;_"@"&M3P__ ,?%Y_UYS?\ H-4?L=Q_
MS[S?]^V_PK3T&UG6XN\P2C_1)ARA'\- T8U%3?8[C_GWF_[]M_A1]CN/^?>;
M_OVW^% B&BIOL=Q_S[S?]^V_PH^QW'_/O-_W[;_"@"&BIOL=Q_S[S?\ ?MO\
M*/L=Q_S[S?\ ?MO\* (:*F^QW'_/O-_W[;_"C['<?\^\W_?MO\* (:*F^QW'
M_/O-_P!^V_PH^QW'_/O-_P!^V_PH AHJ;['<?\^\W_?MO\*/L=Q_S[S?]^V_
MPH AHJ;['<?\^\W_ '[;_"C['<?\^\W_ '[;_"@"&BIOL=Q_S[S?]^V_PH^Q
MW'_/O-_W[;_"@"&BIOL=Q_S[S?\ ?MO\*/L=Q_S[S?\ ?MO\* (:T[[_ ) .
ME?[TW_H2U2^QW'_/O-_W[;_"M*]M9SH>E@02DAILC8<CYE]J!F/14WV.X_Y]
MYO\ OVW^%'V.X_Y]YO\ OVW^% B&BIOL=Q_S[S?]^V_PH^QW'_/O-_W[;_"@
M"&BIOL=Q_P ^\W_?MO\ "C['<?\ /O-_W[;_  H AHJ;['<?\^\W_?MO\*/L
M=Q_S[S?]^V_PH AHJ;['<?\ /O-_W[;_  H^QW'_ #[S?]^V_P * (:*F^QW
M'_/O-_W[;_"C['<?\^\W_?MO\* (:*F^QW'_ #[S?]^V_P */L=Q_P ^\W_?
MMO\ "@"&BIOL=Q_S[S?]^V_PH^QW'_/O-_W[;_"@"&BIOL=Q_P ^\W_?MO\
M"C['<?\ /O-_W[;_  H AHJ;['<?\^\W_?MO\*/L=Q_S[S?]^V_PH AIT?\
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M!@CN6>^MT F*C<R@%L)D*2WS X%>E^,[?2[[1M9L=6U$Z98"!Y+R:&]-I)!
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MTG_H*UY57T]/X%Z'YM7_ (L_5_F%%%%:& 4444 %%%% !1110 4444 %%%%
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M&])\1WOB6R\.:79Z]? K<ZM!91I<SYQD-(!N.<+GGG S6Y0(****8!5G4O\
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M463UV[KJ0=_D4U[;0(*5/OK]124J??7ZBF!W*_=%%"_=%%06?C?^U5_R<?\
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M#)-(B%CHWARZO=473_WDTEU?3Q&(7$DSL79E5Y>6))+CGY:]$6)V8J$8L.H
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M2BH.F%+,5R#M).,5#J7P.^'NL0:E#>^#M)N(=2O/[1O$:(@37.&!F.",,0S
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M%,059U+_ (_Y_P#>JM5G4O\ C_G_ -ZD!6HHHI@%%%% !1110 4444 %%%%
M%F3_ )!T/_71_P"0JM5F3_D'0_\ 71_Y"JU(84444Q!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% %G4/\ CY_X G_H(JM5G4/^/G_@"?\
MH(JM2 *XWXO>#[[Q]\/]2\/6-GX?U ZALCGM/$\<\EC+"&W,K"!E?.0I&#CC
MFNRHI@?/=_\ "3XHZKXP'BJ]TSX-77B(::^CG4)M-U5I&LVR&@;,N&0@D8(/
M!(K%\-_LX>-?"&@Z[HND>&?@I9Z7KD/V;4K8:;JSK=0X($3%IB?+&3A 0!V
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MT31+#++C.-SQHBDXY"COS70T4 %%%% !5G3_ /62_P#7%_Y56JSI_P#K)?\
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M?]^3_C1_PFE[_P ^UE_WY/\ C18.9'245S?_  FE[_S[67_?D_XT?\)I>_\
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MASSF21VX P-H[5=_X32]_P"?:R_[\G_&C_A-+W_GVLO^_)_QHL',CI**YO\
MX32]_P"?:R_[\G_&C_A-+W_GVLO^_)_QHL',CI**YO\ X32]_P"?:R_[\G_&
MC_A-+W_GVLO^_)_QHL',CI**YO\ X32]_P"?:R_[\G_&C_A-+W_GVLO^_)_Q
MHL',CI**YO\ X32]_P"?:R_[\G_&C_A-+W_GVLO^_)_QHL',CI**YO\ X32]
M_P"?:R_[\G_&C_A-+W_GVLO^_)_QHL',CI*LZ?\ ZR7_ *XO_*N2_P"$TO?^
M?:R_[\G_ !J_H_BR[N)KD-;VBA;:5QMB(Y"Y]>E%@NC5HKF_^$TO?^?:R_[\
MG_&C_A-+W_GVLO\ OR?\:+!S(Z2BN;_X32]_Y]K+_OR?\:/^$TO?^?:R_P"_
M)_QHL',CI**YO_A-+W_GVLO^_)_QH_X32]_Y]K+_ +\G_&BP<R.DHKF_^$TO
M?^?:R_[\G_&C_A-+W_GVLO\ OR?\:+!S(Z2BN;_X32]_Y]K+_OR?\:/^$TO?
M^?:R_P"_)_QHL',CI**YO_A-+W_GVLO^_)_QH_X32]_Y]K+_ +\G_&BP<R.D
MHKF_^$TO?^?:R_[\G_&C_A-+W_GVLO\ OR?\:+!S(Z2BN;_X32]_Y]K+_OR?
M\:/^$TO?^?:R_P"_)_QHL',CI**YO_A-+W_GVLO^_)_QH_X32]_Y]K+_ +\G
M_&BP<R.DJS-_QXVOU?\ F*Y+_A-+W_GVLO\ OR?\:O77BR[CTG3Y1;VA:1I0
M08N!@CIS18+HUJ*YO_A-+W_GVLO^_)_QH_X32]_Y]K+_ +\G_&BP<R.DHKF_
M^$TO?^?:R_[\G_&C_A-+W_GVLO\ OR?\:+!S(Z2BN;_X32]_Y]K+_OR?\:/^
M$TO?^?:R_P"_)_QHL',CI**YO_A-+W_GVLO^_)_QH_X32]_Y]K+_ +\G_&BP
M<R.DHKF_^$TO?^?:R_[\G_&C_A-+W_GVLO\ OR?\:+!S(Z2BN;_X32]_Y]K+
M_OR?\:/^$TO?^?:R_P"_)_QHL',CI**YO_A-+W_GVLO^_)_QH_X32]_Y]K+_
M +\G_&BP<R.DHKF_^$TO?^?:R_[\G_&C_A-+W_GVLO\ OR?\:+!S(Z2BN;_X
M32]_Y]K+_OR?\:/^$TO?^?:R_P"_)_QHL',CI**YO_A-+W_GVLO^_)_QH_X3
M2]_Y]K+_ +\G_&BP<R.DI4^^OU%<U_PFE[_S[67_ 'Y/^-.3QG>F11]FLNH_
MY8G_ !HL%T>N+]T44+]T?2BH-#\;_P!JK_DX_P"(G_86D_\ 05KRJO5?VJO^
M3C_B)_V%I/\ T%:\JKZ>G\"]#\VK_P 6?J_S"BBBM# ***^D(?A3X1\<Z7^S
MZNGZ+_PC9\7ZG>66J207<DTDL<4Z(&W.<!BN[H ,MTXJ)24=S:G2=6_+T_S2
M_4^;Z*^P/!_P7^'_ ,5(H-=B\,1^'+'1/$.K:9>:98WLQ&I6UK:O/%N:1F82
M$H%=EQD$X KR[QEX-\-:OH_P8\6:9H5OX>@\7SR6VHZ/9SRO &BNUB+QF1F<
M!D;GYNHXK-54W:W]?TC:6%G&/-=?U;_,\0HK[4\;_LX^ [7XNQ>(-.T;[)\,
M](M]176M/6>1D%Y9R^4L&\MN'G&6 @9Z;L5\_?%ZQT3X6_M">+K"Q\-Z?J.A
MZ9J$MO!HU^\QM]A08!9)%D.TG(^;J.<TX55/1!5PLZ*O-K>W_!]#RRBO;OVJ
MM!\/^%_BU<>#O"OA+3=!M[/[*8YK22=YKEIX(GVR&21EP&<XV@>^:E'[,*WG
MQ2M_AWIOC&UO_%5N9/[9@_L^6.*P6.$2NT<A/[_&=F %RQ';FFJD>52>ER'A
MY\[A'6SM\_F>&45]-:?^SU9_#]_',>KM:^(8)? 5_J^G-=VHAN;*XCDC7+Q;
MW\N1<Y!#'(;ZBK7Q _9OT[Q3XIU^[T6XBT&QT70=(N'TO2M-:[GEDFM [SF%
M&#+'N'SR ,06Z&I]M&YI]4JVOU[??_D?+=% Z"BMSB"BBB@#N/@7_P EM^'_
M /V'['_T>E?IK=?\?4__ %T;^9K\RO@7_P EM^'_ /V'['_T>E?IK=?\?4__
M %T;^9KR<9\2/J,G_AS]2*BBBO//H HHKRSQ]XE\<>&O&_A>PTS5- NK7Q!J
MZ6EOI<VES?:8[5$,EU*TPGV_)&I.=F,L@QS0!ZG17FG_  F7BW1_C)H?AG5#
MHE]I.NVM_=Q0Z=#,EUIT5N4V22NS%9%<N$.%3#G R,UZ70 4444 *OWA]:TO
M$W_(P7__ %U_H*S5^\/K6EXF_P"1@O\ _KK_ $% ^AF4444""BBB@ HHHH *
M*** "BBB@#4N/^1:L?\ KZF_]!2LNM2X_P"1:L?^OJ;_ -!2LN@84444""BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1ONGZ4M(WW3]* -7Q)_
MR%#_ -<8?_1:UEUJ>)/^0H?^N,/_ *+6LNA;#>X4444""BBB@ HHHH ****
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M:A#%!M#7"LK83GY4)1"5YSMZUQ_C?QAJ/Q"\7:MXDU<PG4]4G-Q<&W39'O(
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M459D=Q\"_P#DMOP__P"P_8_^CTK]-;K_ (^I_P#KHW\S7YE? O\ Y+;\/_\
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ME?[TW_H2T#,RN.^(_@S7/&VG3Z;IWB>/1-+OK26QU"TGTF*^6>-Q@LA=AL<
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M\KR1YV>NRM9OC!KGB&XALO#\7A[37L]%T_5]:U;Q)<21V5JUW'OAMXPA!9B
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MCFL#4O@NMQ\/W\-6>OW%A,->_P"$@AU(VJ2M%-]M-V$\LD*RACMY.2*])HH
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M,CMY@9V10PVDD]!0!S>C_ /5_"L6C:KH7B6QMO%UCJ>I:E+//IA.FRB^V^?
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M.RJ 9 ""#G';->HTQ79P?@/P-XCT/QEK/B?Q-XAL=;U+4;"TL?+T_3VM(81
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M3]* -7Q)_P A0_\ 7&'_ -%K676IXD_Y"A_ZXP_^BUK+H6PWN%%%% @HHHH
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MFG_?AO\ &MRB@+(P_P#A"T_Z":?]^&_QH_X0M/\ H)I_WX;_ !K<HH"R,/\
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M^_#?XT?\(6G_ $$T_P"_#?XUN44!9&'_ ,(6G_033_OPW^-'_"%I_P!!-/\
MOPW^-;E% 61A_P#"%I_T$T_[\-_C1_PA:?\ 033_ +\-_C6Y10%D8?\ PA:?
M]!-/^_#?XT?\(6G_ $$T_P"_#?XUN44!9&'_ ,(6G_033_OPW^-+'X,02*?[
M33J/^6#?XUMTJ??7ZB@+([E>%'THH7[HHJ#0_&_]JK_DX_XB?]A:3_T%:\JK
MU7]JK_DX_P"(G_86D_\ 05KRJOIZ?P+T/S:O_%GZO\PHHHK0P"BBB@ HHHH
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MW)YBW[50X!)5\]J .]HHHIB+.H?\?/\ P!/_ $$56JSJ'_'S_P  3_T$56I
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M,_#&0QXRJC;QFD,[#X8_%:W\>?#=_%VI6D?AZ"VFNX+O==+/;+]GE:-YHIP
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MS:\97!#<'CGWSP#X7@\$>!] \/6UNEI;Z78Q6B6\<[SK$%4#:LC_ #.!T#,
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M,OCK_P $5G_\E4<R[![)]U]Z/.**]'_LOX/_ /0R^.O_  16?_R51_9?P?\
M^AE\=?\ @BL__DJCF78/9/NOO10^!?\ R6SX?_\ 8?L?_1Z5^N]Q_P ?$O\
MOG^=?F/\'--^%2?%WP0UAXA\9S7PUJS-O'<Z-:)$TGG+M#L+DD*3C) )'I7Z
M37'BC2A<2@B\SO.<1KZ_[U>5C'S21]1E$>6G.[ZEZBL[_A*-)]+S_OVG_P 5
M1_PE&D^EY_W[3_XJO//?NCRSXJ?!'5_'/B'Q-K>E:M9Z7JD^CZ;%H=U*C,UC
MJ5E=S7,4[X',9,@4@9)!<8YK*3]F$/H.MZ#)K"QZ?JG@F+PS)=HA:X^V_:)K
MB:[8' (:28MC.2<CBO:/^$HTGTO/^_:?_%4?\)1I/I>?]^T_^*HL%T>7Q?#/
MQMXLUJ;6/&=]X?M[NT\-W^@:=;Z")VCDDNU02W,S2@%?]4@$:@XRQW'BJW@/
MX2^,6NOAR?&UWX?CL/ 5J$TZTT SRM>77V3[+Y\TDJKM58VDQ&JG)?);C%>L
M_P#"4:3Z7G_?M/\ XJC_ (2C2?2\_P"_:?\ Q5*P7-&BL[_A*-)]+S_OVG_Q
M5'_"4:3Z7G_?M/\ XJF%T:-6=2_X_P"?_>K%_P"$HTK(XO.O_/-/_BJMZOXB
MTVWU2YBD%WYBOAML:D?A\U 7)J*SO^$HTGTO/^_:?_%4?\)1I/I>?]^T_P#B
MJ NC1HK._P"$HTGTO/\ OVG_ ,51_P )1I/I>?\ ?M/_ (J@+HT:*SO^$HTG
MTO/^_:?_ !5'_"4:3Z7G_?M/_BJ NC1HK._X2C2?2\_[]I_\51_PE&D^EY_W
M[3_XJ@+HT:*SO^$HTGTO/^_:?_%4?\)1I/I>?]^T_P#BJ NC:D_Y!T/_ %T?
M^0JM4,OB+35TFWE/VORVFD4?NUSD!<_Q>XJI_P )1I/I>?\ ?M/_ (JD%T:-
M%9W_  E&D^EY_P!^T_\ BJ/^$HTGTO/^_:?_ !5,+HT:*SO^$HTGTO/^_:?_
M !5'_"4:3Z7G_?M/_BJ NC25BK J2".A%)6=_P )1I/I>?\ ?M/_ (JC_A*-
M)]+S_OVG_P 50%T:-%9W_"4:3Z7G_?M/_BJ/^$HTGTO/^_:?_%4!=&C16=_P
ME&D^EY_W[3_XJC_A*-)]+S_OVG_Q5 71HTK.TC;F8LWJ3DUF_P#"4:3Z7G_?
MM/\ XJC_ (2C2?2\_P"_:?\ Q5 71HT5G?\ "4:3Z7G_ '[3_P"*H_X2C2?2
M\_[]I_\ %4!=&C16=_PE&D^EY_W[3_XJC_A*-)]+S_OVG_Q5 71HT5G?\)1I
M/I>?]^T_^*H_X2C2?2\_[]I_\50%T:-%9W_"4:3Z7G_?M/\ XJD/BC2<'B\_
M[]I_\50%T;>H?\?/_ $_]!%5JAU;Q%IMO>;)/M>[RXS\L:D8* C^+TJI_P )
M1I/I>?\ ?M/_ (J@+FC16=_PE&D^EY_W[3_XJC_A*-)]+S_OVG_Q5 71H.BR
M*5=%=#U5@"#^!J'^S[/_ )\[7_OPG^%5?^$HTGTO/^_:?_%4?\)1I/I>?]^T
M_P#BJ NBU_9]G_SYVO\ WX3_  H_L^S_ .?.U_[\)_A57_A*-)]+S_OVG_Q5
M'_"4:3Z7G_?M/_BJ NB^D:QJ%1%C0=%10 /P%.K._P"$HTGTO/\ OVG_ ,51
M_P )1I/I>?\ ?M/_ (J@+HT:*SO^$HTGTO/^_:?_ !5'_"4:3Z7G_?M/_BJ
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MG_?M/_BJ/^$HTGTO/^_:?_%4!=&C16=_PE&D^EY_W[3_ .*H_P"$HTGTO/\
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M-_R,%_\ ]=?Z"@?0S****!!1110 4444 %%%% !1110!J7'_ "+5C_U]3?\
MH*5EUJ7'_(M6/_7U-_Z"E9= PHHHH$%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4C?=/TI:1ONGZ4 :OB3_D*'_KC#_P"BUK+K4\2?\A0_]<8?
M_1:UET+8;W"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5J>'_P#CXO/^O.;_ -!K+K4\/_\ 'Q>?]><W_H-
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M/'AKQBO@WX>^._#>@Z5X;MO$UJ]AI%GJG@W T[4KN\3RK>4*.(YHQEY$RV
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M#]HP,#S./GP!CYL\4ZZTVSOM_P!IL[>YWQ- _G0J^Z-OO1G(Y4X&5Z'%6**
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M^8^M2QZ790W1NH[.WCN3 MJ9EB4.85)*Q9Q]P$G"]!DUVO\ PA]E_P _\_\
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M#[+_ )_Y_P#OP/\ XJBX<K.4HKJ_^$/LO^?^?_OP/_BJ/^$/LO\ G_G_ ._
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M/_BJ+ARLY2BNK_X0^R_Y_P"?_OP/_BJ/^$/LO^?^?_OP/_BJ+ARLY2M3P_\
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M_P (?9?\_P#/_P!^!_\ %4?\(?9?\_\ /_WX'_Q5%PY6<I175_\ "'V7_/\
MS_\ ?@?_ !5'_"'V7_/_ #_]^!_\51<.5G*4Z/\ UB?[P_G74_\ "'V7_/\
MS_\ ?@?_ !5.C\'V7F+_ *?/U'_+ ?\ Q5%PY6>GI]U?I12KPHHK,V/QO_:J
M_P"3C_B)_P!A:3_T%:\JKU7]JK_DX_XB?]A:3_T%:\JKZ>G\"]#\VK_Q9^K_
M #"O9/V0;&&]_:'\+-+&)6M%NKV",C.Z:*VE>/\ \>4?E7C==!\/_&VH_#;Q
MMHOBC2?+;4-*N5N(DFSY;XR"C8(.U@2#CL:<TY1:1-&2A4C*6R:/HOX5? GP
MKXYT'P3?^(-%UO7=1\76NLZO?ZY:WKQ06$ENS[8'4*02S<L6(;+#''%>D1^
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M_CQM?J_\Q2&5J***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH *LZ?_ *R7_KB_\JK59T__ %DO_7%_Y4AE:BBBF(**** "BBB@#/\
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M_DX_XB?]A:3_ -!6O*J^GI_ O0_-J_\ %GZO\PHHHK0P"BBB@ HHHH ****
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MY=XW&WYD9V9BIX)8D\FM>B@"GJ&BZ=K&E2Z7?Z?:7^F2H(I+*Z@26!T'12C
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M_P">[?D*/^$93_GNWY"@+'/T5T'_  C*?\]V_(4?\(RG_/=OR% 6.?HKH/\
MA&4_Y[M^0H_X1E/^>[?D* L<_170?\(RG_/=OR%'_",I_P ]V_(4!8Y^BN@_
MX1E/^>[?D*/^$93_ )[M^0H"QS]%=!_PC*?\]V_(4?\ ",I_SW;\A0%CGZ*Z
M#_A&4_Y[M^0H_P"$93_GNWY"@+'/T5T'_",I_P ]V_(4?\(RG_/=OR% 6.?H
MKH/^$93_ )[M^0H_X1E/^>[?D* L<_170?\ ",I_SW;\A1_PC*?\]V_(4!8Y
M^BN@_P"$93_GNWY"C_A&4_Y[M^0H"QS]%=!_PC*?\]V_(4?\(RG_ #W;\A0%
MCGZ*Z#_A&4_Y[M^0H_X1E/\ GNWY"@+'/U9T_P#UDO\ UQ?^5:__  C*?\]V
M_(5)!X?2!G/G,=R%.@[B@#FZ*Z#_ (1E/^>[?D*/^$93_GNWY"@+'/T5T'_"
M,I_SW;\A1_PC*?\ /=OR% 6.?HKH/^$93_GNWY"C_A&4_P">[?D* L<_170?
M\(RG_/=OR%'_  C*?\]V_(4!8Y^BN@_X1E/^>[?D*/\ A&4_Y[M^0H"QS]%=
M!_PC*?\ /=OR%'_",I_SW;\A0%CGZ*Z#_A&4_P">[?D*/^$93_GNWY"@+'/T
M5T'_  C*?\]V_(4?\(RG_/=OR% 6.?HKH/\ A&4_Y[M^0H_X1E/^>[?D* L<
M_5F;_CQM?J_\Q6O_ ,(RG_/=OR%2/X>1X8H_.8;"QS@<YQ0!S=%=!_PC*?\
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C]]?J*W_^$93_ )[M^0H7PRBL#Y[<'/04!8VE^Z****DH_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>nexi-20221231_g7.jpg
<TEXT>
begin 644 nexi-20221231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %1I;2!3=&]V
M97(    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,Q,0  DI(
M @    ,Q,0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( JD%# ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M;4/CAK.HZQ)9^"M 6\12=ADBDEDD _BV(1@?G7L=_:+?Z;<V<C%4N(FB8CJ
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M^I[^E %;Q!\3=6TGXM6GA>WM+)[&:XMH7D=7,F)-N2"&QQN].U>H5\^^-/\
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M=S)\Y)&05 [^M6?BI\.M5\<W>G3:3<V</V5'1Q<NZYW$$8VJ?2@"YJUO##\
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M.*Y3X3[F^"/B51DGS+H ?]NZ5Z+X\\/W/BGP3J&C6,L45Q<B/8\Q(4%9%?G
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MN?'"_BU7X?>']1MPRQ7<R3H&ZA6B+#/X&JR?!;Q5K-]"?%_B=;JWC/:XEN'
M[A?,  JY\=K.'3O NAV5JNR"VN%BC7/15B( _(4 =A\*C:#X7Z3]F\G;Y3>=
MLQC?N.[=[^N:\C^%>QOC8YL/^/7==%=G3R\-M_#[M6]#^%7B'4_"%E?^&?$
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MZ]JU?BGX&U'QQI=A!I5Q:PR6TS.WVEF4$$8X*J>: .:U4D_LMQY.?]&@'/\
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M+7-,\0VF4,R^3(Z]I$Y4_7!_\=K)^)'B1_'VL>&=.TT[C+;1,4 ^[/,1E3]
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M'B\*:+#XGE\0I8@ZK*NUKEI'8@;0O )PO QP!Q6Q110 4444 %%%% !1110
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MJF?04 >E45POB&7Q1I]M>WY\4Z?:2PJ\T.G+;H5D1>0I9_FW$#MWKJM!U/\
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M4 5V@621W[YW_*!TQCGK0!T5%>=P>+M6?X>^(;B6ZA?5-(G>W6[A12LH!&)
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M;\+Z+I\5SK/FFZO/+N-6>S4?9HST^1?E_$UT7AY+G[$\EQKJ:W'(V8ITBC3
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M2\^TB\%RJ^3D?,"AY/X5V=% 'E<7A'5XM.U.RNO"UEJ6HW3RD:Q<SQOD-G#
M-\X8 \#CG'-=YX2L+G2_".F65]'Y5Q!;JDB;@=I';(X-;%% '.?V5>_\+1_M
M?R?]!_L;[+YN\?ZSSMVW&<].<XQ4/AO1;_3_ !GXHO[N$);7\D#6S[P=X56W
M< Y&,CKBNIHH X@Z=X@\,>*=5O=#TJ/5[#5769XA<K#)#( <\MP02<_YY;;>
M&=8GTKQ1J.J1Q#5];M7ACM8G!6%1&RHF[H2<C)Z?K7<T4 </>^'=4E^#:Z%'
M;9U(6D<9@\Q?O!E)&[.WL>]7/&&B:AJGA.PLK"#S;B&XMW=-ZKA5^\<D@<5U
ME% !7FT'A+6D^%^NZ0UH/MUW>/+#%YJ?.I="#G.!PIZFO2:* ./\6:%J.I_#
MVVTRRM_-O(_L^Z/>HQM(W<DXXQZU/>Z+?S?%+3M8CAS8PV#PR2[UX<EL#&<]
M_2NIHH XW3-/US0O&VJO!I:WFFZM<QS?:A<JAM^,-E3RW7C'I[\44\*ZY_9_
MC2&#%I-JET9+.3S1\ZYR>0<KD<<^M>@44 >5W/A+4KJSTJ"P\&V6E-9W4,D]
MQY\32R!3SAASCJ3DYX'%=5!HU^GQ7N=9:#%A)I8MUFWKS)YBG&W.>@/.,5U5
M% '/^-M!G\1>&);.RD6.Z1TF@+?=+J<@'Z\BN9\0VOC/Q3IEM;SZ%!8+;W$4
MLJ_:TD:=@PY7G"J!D\G/05Z-10!QNK:5K6E>-6\1>'[&/4DN[86]W:-,L3Y4
M\.K'CH .?_U.TG2-<O?$UUXEUFW@L;E;0VEC9>;Y@C&=VYV7@\^G8GT%=A10
M!YU>:-X@\1:UI4UWX=M=(NK.Z2:?58KI6,BKU50OS8/HW3\ZO)I_B'POXDU6
MYT?2TUG3]4E%P4%RL,D,G\7WN"#_ (5V]% '/M=^*&T![G^RK(:AYV18FX)!
MA_N^9TW]>>E8_AK0=17QK<:Y/H\/A^V>U\EK.&=9#.^[.]@GRC'Y_K7<44 8
M7C;19_$/@W4-,LRHGF13'N. 2KA@,^^W%8NK:9X@\4^&X)+G3HM*UC3;N.ZM
M5DG65970<Y*_=!)/'L,UV]% '!ZG9>)_&26>FZMHT6C6"3I-=S&[69I=O.U
MO3)[G^G/=2QK-"\3\JZE6^AIU% 'GNCZ=XQT/0W\,6VF6LT"EX[?57N5")&Q
M)RT?WB1D\?3TY@?PEK9^&^@Z8]FLTMC<^;>:<;A4%PF]CLW@X[@]<?E7I-%
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M=+.\TJ_=QMX '/6B2P\1>'_&6KZAHFDQZI9ZLL;D&Z6(PR*N.=W4'D\5V]%
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M\C&03Z'OW9 T?@YK?5]4\"?8(HV6,W,>I_:#!NX^6-NGX5Z5?6%KJ=E)::A
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4DY:/Z'N/;\J+C/0:*;'(DT2R1,'1AE6'0BG4QA1110 4444 %%%% !1110
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M .UT?\+X_P"I<_\ )[_[77D%% 'K_P#POC_J7/\ R>_^UT?\+X_ZES_R>_\
MM=>044 >O_\ "^/^I<_\GO\ [71_POC_ *ES_P GO_M=>044 >O_ /"^/^I<
M_P#)[_[71_POC_J7/_)[_P"UUY!10!Z__P +X_ZES_R>_P#M='_"^/\ J7/_
M ">_^UUY!10!Z_\ \+X_ZES_ ,GO_M='_"^/^I<_\GO_ +77D%% 'K__  OC
M_J7/_)[_ .UT?\+X_P"I<_\ )[_[77D%% 'K_P#POC_J7/\ R>_^UT?\+X_Z
MES_R>_\ M=>044 >O_\ "^/^I<_\GO\ [71_POC_ *ES_P GO_M=>044 >O_
M /"^/^I<_P#)[_[71_POC_J7/_)[_P"UUY!10!Z__P +X_ZES_R>_P#M='_"
M^/\ J7/_ ">_^UUY!10!Z_\ \+X_ZES_ ,GO_M='_"^/^I<_\GO_ +77D%%
M'K__  OC_J7/_)[_ .UT?\+X_P"I<_\ )[_[77D%% 'K_P#POC_J7/\ R>_^
MUT?\+X_ZES_R>_\ M=>044 >O_\ "^/^I<_\GO\ [71_POC_ *ES_P GO_M=
M>044 >O_ /"^/^I<_P#)[_[71_POC_J7/_)[_P"UUY!10!Z__P +X_ZES_R>
M_P#M='_"^/\ J7/_ ">_^UUY!10!Z_\ \+X_ZES_ ,GO_M='_"^/^I<_\GO_
M +77D%% 'K__  OC_J7/_)[_ .UT?\+X_P"I<_\ )[_[77D%% 'K_P#POC_J
M7/\ R>_^UT?\+X_ZES_R>_\ M=>044 >O_\ "^/^I<_\GO\ [71_POC_ *ES
M_P GO_M=>044 >O_ /"^/^I<_P#)[_[71_POC_J7/_)[_P"UUY!10!Z__P +
MX_ZES_R>_P#M='_"^/\ J7/_ ">_^UUY!10!Z_\ \+X_ZES_ ,GO_M='_"^/
M^I<_\GO_ +77D%% 'K__  OC_J7/_)[_ .UT?\+X_P"I<_\ )[_[77D%% 'K
M_P#POC_J7/\ R>_^UT?\+X_ZES_R>_\ M=>044 >O_\ "^/^I<_\GO\ [71_
MPOC_ *ES_P GO_M=>044 >O_ /"^/^I<_P#)[_[71_POC_J7/_)[_P"UUY!1
M0!Z__P +X_ZES_R>_P#M='_"^/\ J7/_ ">_^UUY!10!Z_\ \+X_ZES_ ,GO
M_M='_"^/^I<_\GO_ +77D%% 'K__  OC_J7/_)[_ .UT?\+X_P"I<_\ )[_[
M77D%% 'K_P#POC_J7/\ R>_^UT?\+X_ZES_R>_\ M=>044 >O_\ "^/^I<_\
MGO\ [77K]?(-?7U !1110 4444 9NKZM!IR(DSE&FR P'W?<UQ.K74;;IY)E
M8+U,9SD>U;6J6AU&XFGO9TAMS\H!&XXS@>W/]:X;7H((K/&FA[A#,0Q/&0N1
MG\]WY5S5I-1N;48J4DBNWBD6-VXGM$,$AX)7!'_ QR#]>*UK2::^TV5M)5<%
M]TA9?WD?ID9YXZ'I7#A#<R,B$RQC[T+??7_$?YXJ/2;_ %/0O&5H+6VGFT^8
MB/?#N/E<?,K?[/?':N:E*5[;G75I0<;['<6Z*L?DGE=N.>]41I+/JYU"5W+>
M3Y"*?NK_ 'G'N5VC\#3X[C=(!'G+9(R>@]:UF8A%CS\JCBN]'G,K+&JQK&HQ
MN;'X5;MX@9"Q["JSW#K,BDYC7M@<9JXTR!&\O&.@IHEDL_C67PGH\DWV,7T:
MN,1F;R]N>I!P?;BLC_A?'_4N?^3W_P!KJ#Q#I>I7EC;_ &>V#+).A D8+O&X
M9P#UXKS#4+5K+4)[9U*F-RN&'(JM!JYZM_POC_J7/_)[_P"UT?\ "^/^I<_\
MGO\ [77D%% SU_\ X7Q_U+G_ )/?_:Z/^%\?]2Y_Y/?_ &NO(** /7_^%\?]
M2Y_Y/?\ VNC_ (7Q_P!2Y_Y/?_:Z\@HH ]?_ .%\?]2Y_P"3W_VNC_A?'_4N
M?^3W_P!KKR"B@#U__A?'_4N?^3W_ -KH_P"%\?\ 4N?^3W_VNO(** /7_P#A
M?'_4N?\ D]_]KH_X7Q_U+G_D]_\ :Z\@HH ]?_X7Q_U+G_D]_P#:Z/\ A?'_
M %+G_D]_]KKR"B@#U_\ X7Q_U+G_ )/?_:Z/^%\?]2Y_Y/?_ &NO(** /7_^
M%\?]2Y_Y/?\ VNC_ (7Q_P!2Y_Y/?_:Z\@HH ]?_ .%\?]2Y_P"3W_VNC_A?
M'_4N?^3W_P!KKR"B@#U__A?'_4N?^3W_ -KH_P"%\?\ 4N?^3W_VNO(** /7
M_P#A?'_4N?\ D]_]KH_X7Q_U+G_D]_\ :Z\@HH ]?_X7Q_U+G_D]_P#:Z/\
MA?'_ %+G_D]_]KKR"B@#U_\ X7Q_U+G_ )/?_:Z/^%\?]2Y_Y/?_ &NO(**
M/7_^%\?]2Y_Y/?\ VNC_ (7Q_P!2Y_Y/?_:Z\@HH ]?_ .%\?]2Y_P"3W_VN
MC_A?'_4N?^3W_P!KKR"B@#U__A?'_4N?^3W_ -KH_P"%\?\ 4N?^3W_VNO(*
M* /7_P#A?'_4N?\ D]_]KH_X7Q_U+G_D]_\ :Z\@HH ]?_X7Q_U+G_D]_P#:
MZ/\ A?'_ %+G_D]_]KKR"B@#U_\ X7Q_U+G_ )/?_:Z/^%\?]2Y_Y/?_ &NO
M(** /7_^%\?]2Y_Y/?\ VNC_ (7Q_P!2Y_Y/?_:Z\@HH ]?_ .%\?]2Y_P"3
MW_VNC_A?'_4N?^3W_P!KKR"B@#U__A?'_4N?^3W_ -KH_P"%\?\ 4N?^3W_V
MNO(** /7_P#A?'_4N?\ D]_]KH_X7Q_U+G_D]_\ :Z\@HH ]?_X7Q_U+G_D]
M_P#:Z/\ A?'_ %+G_D]_]KKR"B@#U_\ X7Q_U+G_ )/?_:Z/^%\?]2Y_Y/?_
M &NO(** /7_^%\?]2Y_Y/?\ VNC_ (7Q_P!2Y_Y/?_:Z\@HH ]?_ .%\?]2Y
M_P"3W_VNC_A?'_4N?^3W_P!KKR"B@#U__A?'_4N?^3W_ -KH_P"%\?\ 4N?^
M3W_VNO(** /7_P#A?'_4N?\ D]_]KH_X7Q_U+G_D]_\ :Z\@HH ]?_X7Q_U+
MG_D]_P#:Z/\ A?'_ %+G_D]_]KKR"B@#U_\ X7Q_U+G_ )/?_:Z/^%\?]2Y_
MY/?_ &NO(** /7_^%\?]2Y_Y/?\ VNNP\!^//^$W^W_\2W[#]C\O_EOYF_?N
M_P!D8QM_6OG"O7_@/_S'O^W?_P!JT >OT444 9=^_P TA/\ "*I^;N;CGWJ_
M<QQ.\GG<*>">>:I/:.OS6^77Z<BKOH!760^9(,]&INF;WN)RW";_ ,ZAC9EN
M9@ZD'=G!&*IP:I+I]Y.DL321X+J%&3TS0W9#2N['71CO3Y!E#GD=Z\_O?B=8
MVMK#@&$S';F0XVDG )ST'>M42W=M'<SC5I?,^64^:V^)5] N.%.#6"JQ;T-G
M0G%79IFU$<Y(X&3@5'.<*U4KB^NO[>$;1$0\?O!]TG'05;N3B-JLR:LS'E;Y
M:\_^*X$FAZ=.?O177ECZ,I/_ +**]!D&8@:\Y^*L@31+*'N]V&'X(P_]FH\P
M.$MV VLR[@""5)Z^U>D^*?!6F#QAX;A\/V_EZ;K*1D*LC-QN!=@6)/W&!KS.
M#_5BO>_ T]GJ?@71]9OG0R^'1.I.<;5"$8/_   K^5,DY3Q_X$T[3O$NA6^@
MP-!;:G)]G95=G"N' )RQ)Z-T_P!FL[Q5X.%WX\NM'\$Z3(R6<2"91(2H8C))
M9VXZ@=>QKO/ %VGBGPO8WVI2_O\ 1M1FFD9OXMR.WX#]Y_XY65X%U>TU_2_%
M,#VZ76H:A=-<"SDNC T\;=$#CD <CCCG'0T <=HOA+4-(\?:+8^)=,\N.XG&
M(Y=KI*!U&02#VR/>NMDT32A=_$8#3;3%G;QFV'D+^X)B<DIQ\O('3TJ_<7$]
MIJ'A#2;K1[?2%AU -#!_:7VJ5%PPP<CA26X^8] ,4DA'VSXH<_\ +M'_ .B9
M* /&;.2&&^@ENX/M,"2*TL&\IYB@\KN'(R.,CI7J,5CX,E^'4_BG_A$<>3,(
MOLO]I3<_,JYW_P# O2N)FUCPX^@BTB\+>7J'DJAO_P"T)#EP!E_+QCGGCH,U
MUMH1_P ,[7W/_+X!_P"1$H YU/!>M^)7DU/PWX=DMM.E.88FN5(4 <X9R"W.
M>:U_AGX?0>-]2TWQ#IL;R6]A(S0740?8V^/!P<CH>#Z&NBU_1M2\8Z9X8O/!
MUQ&MI:0JK!9PGV1@!R1GMC''/'O6M8ZG9:E\:-2:PF258=%:&1T((+B12>>^
M 0/PH \?T/P?KWB2&2;1=.>YBC;:TF]47/IEB 3]/:EA\':_/KDNCQZ;)]OA
MC,KPLRKA..020".1T->E^&Q9ZY\*=/L;'1TUF>TF)GL!J)M65MS'?D=>N<'C
MTZ5K:3J,U[\6XDO+2VM+B#1F1T@N_M!'[Q2%9MHY'ISUSGF@#R9OA_XI2^@L
MSI$OGW$9E1 Z'Y1C))SA>HZXZT]OA[XCMM8L+&_TR2%KV39&1(A!P,M\P) .
MT$X)YQ6Y\-K2/Q)JVKR:O>75Q<F NMJEV83=EB2P)!&1D+WQR/2NB\;1Q:7\
M.-#B:P72UMM6C+VBW1N?(^61B"_<X.<=LT <EX]^'LWAC4(6TJ&YN-/G9(8I
M)'1W>9L_(%4 ]!Z5E:CX \4:5IKW]_I,D=M&-SNLB.5'J0I) _"O3O$<"V/Q
M7T3Q1>M"-&=4MUN3(I7S&23:<=<#@YZ=.:M:BT^A2>(-2C\,VR6US#(TU_-K
M19;I<' $94X8] N .< XH \CTOP/XCUG3/[0TS2Y)[7G#[U7=CKM!(+?@*W/
MB]IUEIGC*&#3;2"TB-FC&.",(I.Y^<#OP*Z74-,U#Q1X&\)3>&;Z*&+3H@MT
M_P!H$?V=PJ@R'GL0WO\ -QP:POC2ZOXWMV0@JUA&01W&]Z //**** "BBB@
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MM))5CE*$+)DHP)P?N]#Z5T]GKJCXGV%KJ]M:Z=<KI3PQA+S[059G4JC-M'S
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M8E7"EPV!N&0C X'0FM >(-,L_C!9:3*\<-GIE@;*V9\!4E8*>#V^4!?KQWH
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M _Q)C_C]TK_O[)_\;I?^%(>)/^?W2O\ O[)_\;IDGF]%>D?\*0\2?\_NE?\
M?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0
M\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/
M_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\
M*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\
M?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0
M\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/
M_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\
M*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\
M?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0
M\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/
M_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\
M*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\
M?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0
M\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/
M_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\
M*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\
M?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0
M\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/
M_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\
M*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\
M?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0
M\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/
M_C= 'F]%>D?\*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\
M*0\2?\_NE?\ ?V3_ .-T?\*0\2?\_NE?]_9/_C= 'F]%>D?\*0\2?\_NE?\
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M_P!_9/\ XW0!YO72^%/%Y\*6FJ"WLA-=WT'DQW)EV^1P>0-ISR0>H^Z*Z/\
MX4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[
M^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'
MB3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R
M?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_
MX4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[
M^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'
MB3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R
M?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_
MX4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[
M^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'
MB3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R
M?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_
MX4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[
M^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'
MB3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R
M?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_
MX4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[
M^R?_ !NC_A2'B3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'
MB3_G]TK_ +^R?_&Z /-Z*](_X4AXD_Y_=*_[^R?_ !NC_A2'B3_G]TK_ +^R
M?_&Z /-Z]?\ @/\ \Q[_ +=__:M9'_"D/$G_ #^Z5_W]D_\ C==W\-/ ^I>#
M?[3_ +4GM9?M?E>7]G=FQMWYSN4?WA0!W=%%% "$9&#6%JVFY?SHUR1U'K6]
M370.N#0!Q7F)YR*RE>>A%7HE90;HC@G"YJ_?Z/O)>'Y6Z].M9UU=7$=OY,]M
M]WHT?^%%[)V& "R/N95)7D$CI]*LV@^<YK,CU*!,^:73ZH3_ "I%UFVC)*F1
MO98S_6L8IIZFC:L=+!A<\9K"O[F&VA=YVVC)P.Y]A59]=O904L+4IGC?(<G\
MJ99Z!<7D_G7SM(Y[M6[9D4+&RGU6[5Y%*Q@_*OI7>Z?9K:P*H&.*;8Z=':Q@
M*HJ]2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ****  @$8(R#7D'C[X?75A/)J_AV'SK,@M/:(N6C]2
MH[K[=1].GK]%3**DM3HH8B="7- ^21KEK:3;HY#M/5!U%=[\/YE\2NK"-A%&
MW[QB/O =L^]=_P"+_A%X8\73/=2P/I]^_+7-H0I<_P"TOW6^N,^]6M \#)X7
MTB'3]-=9(XQR[<,Y[DUA*A%VN=E;,)5(62-="HC 084#  [4%J$LKM5P8_\
MQX5(EA<,?FVJ/<UTGCZD(CB#[Q&@?^\%&?SJ:.T%UQ)&K)W++FK45@B<R$N?
M3H*M@ # &!0-1(K>VAM(1%;1)%&.0J* /TJ6L35/%VE:1JITVY&H37:PI.T=
MEI=S=;$=F52QBC8+DQO@$Y^4U6_X3S2/^?/Q!_X3FH?_ !B@LZ2BN;_X3S2/
M^?/Q!_X3FH?_ !BC_A/-(_Y\_$'_ (3FH?\ QB@#I**YO_A/-(_Y\_$'_A.:
MA_\ &*/^$\TC_GS\0?\ A.:A_P#&* .DHKF_^$\TC_GS\0?^$YJ'_P 8H_X3
MS2/^?/Q!_P"$YJ'_ ,8H Z2BN;_X3S2/^?/Q!_X3FH?_ !BC_A/-(_Y\_$'_
M (3FH?\ QB@#I**YO_A/-(_Y\_$'_A.:A_\ &*/^$\TC_GS\0?\ A.:A_P#&
M* .DHKF_^$\TC_GS\0?^$YJ'_P 8H_X3S2/^?/Q!_P"$YJ'_ ,8H Z2BN;_X
M3S2/^?/Q!_X3FH?_ !BC_A/-(_Y\_$'_ (3FH?\ QB@#I**YO_A/-(_Y\_$'
M_A.:A_\ &*/^$\TC_GS\0?\ A.:A_P#&* .DHKF_^$\TC_GS\0?^$YJ'_P 8
MH_X3S2/^?/Q!_P"$YJ'_ ,8H Z2BN;_X3S2/^?/Q!_X3FH?_ !BC_A/-(_Y\
M_$'_ (3FH?\ QB@#I**YO_A/-(_Y\_$'_A.:A_\ &*/^$\TC_GS\0?\ A.:A
M_P#&* .DHKF_^$\TC_GS\0?^$YJ'_P 8H_X3S2/^?/Q!_P"$YJ'_ ,8H Z2B
MN;_X3S2/^?/Q!_X3FH?_ !BC_A/-(_Y\_$'_ (3FH?\ QB@#I**YO_A/-(_Y
M\_$'_A.:A_\ &*/^$\TC_GS\0?\ A.:A_P#&* .DHKF_^$\TC_GS\0?^$YJ'
M_P 8H_X3S2/^?/Q!_P"$YJ'_ ,8H Z2BN;_X3S2/^?/Q!_X3FH?_ !BC_A/-
M(_Y\_$'_ (3FH?\ QB@#I**YO_A/-(_Y\_$'_A.:A_\ &*/^$\TC_GS\0?\
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MIM3=126]P9D95;# DHA!&0>A!!ZUGVGA74;?X?W>AI>QV][,TS)/"S;1ND+
M9P#R#@X]3UJ#2_!TT'B-;Z73])TVT^PR6CV^GEBS[BOS%BBYZ'MD<<G/ !E^
M*=?O-;\)V=XNE^3IMU?0&"?[1NDP)1M+Q[1M# '&&;MGK747?B.\.I7]IHVF
M)>_V;&&N7EN?*&XKN")A6W-CUV@9'-8<_A+Q!)X9L= 6;3A;6$T;+<%WWSHD
MF5!7;A#MZ\MDCMG-6[WP>5\0ZAJ$&D:-JL=_M<KJ7RM X7:=K>6^5.,XXP:
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M$UA'&(\>1";E%9HD^_A1@$J!7O\ 5>_OK?2]-N;^^D\JVM87FFDVEMJ*"S'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSP$4@?B?\*DJ)?\ C\D_W$_FU $M%%% !1110 4444 %%%% $=LQ>UB9CDE
M2?7BI*BM/^/.'_KFO\JEH *YN^_Y*GH7_8%U+_T?8UTE<W??\E3T+_L"ZE_Z
M/L: .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_@?.'_"+Z_\ ] /4O_ 23_"D'AG7CG&B:B<'!_T23C]*^D*BA_UD_P#UT_\
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M7_PKW^U_X\X?^N:_RJ6J]BNYI_J_2_G9\]_\(UKO_0%U#_P%?_"C_A&M=_Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEAZ9 SC\:CE,OK#['645RB>)(;><PEQ %&=K9)QZ@8Z5L:;KUEJ2_N)0W^T
M<4G%FL*T9:&G1114FX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-V/
M_)4]=_[ NF_^C[ZNDKF['_DJ>N_]@73?_1]]70SR^3;R2XW;$+8SC.!F@!]8
M'B?PJ?$_V0/K>I:=':S1W"1V:P8:5&#(Y\R)SD$#@$ ]P:=_PDO_ $Z?^1/_
M *U'_"2_].G_ )$_^M0!3U#P%9ZE=SRSZIJ2Q7T<*:E;1M$L>H>6, R?N\J2
M,*WEE,@ =!3_ /A!K'^V#=B_OQ:-??VB=+WI]F^T]?,^YYGWAOV[]N[G%6?^
M$E_Z=/\ R)_]:C_A)?\ IT_\B?\ UJ (['P7IUA_9/DS73?V3=7-U!O=?F>?
MS-X;Y>0/-;&,=!G/=P\'V2>#YO#<=U>1V<[RM)(DBB5EDE,DB;MN IW,O SM
M/!!YIW_"2_\ 3I_Y$_\ K4?\)+_TZ?\ D3_ZU %"^^'MC<^'=1T&QU*_TK2]
M1DD>6ULA %19%Q)&F^)MJ,27XY#,<$#BNBTRSDT_38;6>^N+]XP0;FY6,2/R
M2,B-57@<<*.!SDY-9G_"2_\ 3I_Y$_\ K4?\)+_TZ?\ D3_ZU &[16%_PDO_
M $Z?^1/_ *U'_"2_].G_ )$_^M0!NT5A?\)+_P!.G_D3_P"M1_PDO_3I_P"1
M/_K4 ;-Q$9[66%9I(&D0J)8L;DR,;AD$9'49!K"\*^$SX4M1:P:YJ5_:JI"P
M7B6^ Q;<SEHXD=G)R2S,2223D\U)_P )+_TZ?^1/_K4?\)+_ -.G_D3_ .M0
M!NT5A?\ "2_].G_D3_ZU'_"2_P#3I_Y$_P#K4 ;M%87_  DO_3I_Y$_^M4]E
MKGVR\2#[/LWY^;?G&!GT]J (_%'AZT\36-O8W\DT<0N!)F%@&R$;U!]:YS_A
M3^@?\_FI?]_8_P#XBNXF_P!;;_\ 70_^@M4M0X1;NT<=; X:O+GJ039P7_"G
M] _Y_-2_[^Q__$4?\*?T#_G\U+_O['_\17>T4O9P[&7]EX+_ )]HX+_A3^@?
M\_FI?]_8_P#XBC_A3^@?\_FI?]_8_P#XBN]HH]G#L']EX+_GVC@O^%/Z!_S^
M:E_W]C_^(H_X4_H'_/YJ7_?V/_XBN]HH]G#L']EX+_GVC@O^%/Z!_P _FI?]
M_8__ (BHX_A%H+O*#=ZC\C8'[V/T!_N>]>@U%#_K)_\ KI_[*M'LX=@_LO!?
M\^T</_PI_0/^?S4O^_L?_P 11_PI_0/^?S4O^_L?_P 17>T4>SAV#^R\%_S[
M1P7_  I_0/\ G\U+_O['_P#$4?\ "G] _P"?S4O^_L?_ ,17>T4>SAV#^R\%
M_P ^T<%_PI_0/^?S4O\ O['_ /$4?\*?T#_G\U+_ +^Q_P#Q%=[11[.'8/[+
MP7_/M'!?\*?T#_G\U+_O['_\16-XD_9\\,>(K$1RWVI0SQY,,X>-MA/J-@R/
M;(^M>K4'I35.*=TC2GE^%I34X02:/$O '[-VB^&-;MM;U?59-:F@*S6T)MQ#
M&C]0S#<Q8CMR![5[;45K_P ></\ US7^52U9VA1110 4444 %%%% $4W^N@_
MWS_Z"U2U%-_KH/\ ?/\ Z"U2T %%%% !1110 4444 %1+_Q^2?[B?S:I:B7_
M (_)/]Q/YM0!+1110 4444 %%%% !1110!%:?\></_7-?Y5+45I_QYP_]<U_
ME4M !7-WW_)4]"_[ NI?^C[&NDKF[[_DJ>A?]@74O_1]C0!TE%%% !7%^-#J
M6JVLMGI]S%#9E=KM&Q+2-_=) P%'YFMWQ+JT6E:9^\D:.2X/E1E 2P)')&*\
MJUO49&N99$!>&%EC66084$\G/OQU[Y[5UX:DZDKIVL<M>I]E&3_PC-W%N\EU
M=@=I"*SC] >*[/0]+NIM)=;ZWAAR<F1XUE\P#^$ ]/J:P-!O8;J:*,WKM(\F
M(U2, ;1RP!R?7N.U=;<7LKQ8C<+'&,XC0_,HZ'Z<8P*X<YQ]3#VIIW;*PF%5
M5WEL7E1$M\1+&RK_ 'X,].^00156\OX-/4,8GEA0;FCBE##&,G*D%B/U%4I-
M3"0L&19$W_O-P 9N.R@]:S]1FCB5;^W#-L4,&F8 +R,KG\>M>%@LQJ.M&%5W
MB]+]CMQ&"AR-Q5F;D7B.TUB,17&ESK;_ //7=C''&,@9_6K,EGI]]:[[629H
M=N%B$0('TQC^=<*OCJXD*Q- HW,6&UOD9?0$9!&,<]O6N@T7Q';SPQS2[0#G
M<'?&WDX.<^GU-?7RP[C#G3NCQFNYVV@2F&T2TDFFEVCY&G&& ]":V:XWS].O
M[=PLB20R@J7CF#CD<J>HQ]>*\*\3Z.-"\175C&^^)&W1-G.4/(S[CH?<5QR7
M4ZZ%3F7*SZGHKY!HJ#I/KZBOD&B@#Z^HKY!HH ^OJ*^0:* /KZBOD&B@#Z^H
MKY!HH ^OJ*^0:* /KZBOD&B@#Z^HKY!HH ^OJ*^0:* /KZBOD&B@#Z^HKY!H
MH ^OJ*^0:* /KZBOD&B@#Z^HKY!HH ^OJ*^0:* /KZBOD&B@#Z^HKY!HH ^O
MJ*^0:* /KZBOD&B@#Z^HKY!HH ^OJ*^0:* /KZBOD&B@#Z^HKY!HH ^OJ*^0
M:* /KZBOD&B@#Z^HKY!HH ^OJ*^0:* /KZBOD&B@#Z^HKY!HH ^OJ*^0:* /
MKZBOD&B@#Z^HKY!HH ^OJ*^0:* /KZBOD&OKZ@ HHHH **** "BBB@ HHHH
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M -'V-=)7-WW_ "5/0O\ L"ZE_P"C[&@#I**** /)_BI)J4OB"V^Q7\=O#;0
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M JI;ZM=1SQ+:7-O'YL85&"B,*PZ$89CGZ_E4JZ5J$^K7$(?[#<0#$J2H&1F
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MZ[_V!=-_]'WU=&RAE*L 5(P01UH X:BNS^PVG_/K#_W[%'V&T_Y]8?\ OV*
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MJ)?^/R3_ '$_FU $M%%% !1110 4444 %%%% $5I_P ></\ US7^52U%:?\
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M-9_X2'Q'>:KY'V?[2X;RM^[;@ =<#/3TK+HHH *^OJ^0:^OJ "BBB@ HHHH
M**** "BBB@ HHHH **** .;L?^2IZ[_V!=-_]'WU=)7-V/\ R5/7?^P+IO\
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M*U_X\X?^N:_RJ6@ HHHH **** "BBB@"*;_70?[Y_P#06J6HIO\ 70?[Y_\
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M+=SUZ5-4H\J"BBBD:A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M /GSTW_OU)_\71_PN#7_ /GSTW_OU)_\71[> ?V]@N[^X]FHKQG_ (7!K_\
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M@#M;S5+#3R!?WUM:DJ7'G3*F5&,GD]!D<^]"ZG8/IO\ :"7ULUE@M]I$RF/
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M=?6M"BB@ HHHH **** "BBB@ HHHH **** "BBHKJZALK62YNI5BAB7<[L<
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M,7P%<!MH!QDC'S'K7=T4 </*\^NV?AS3[33+VVFLKJWN;DW%J\26ZQ?> =@
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M O+C<I\W$+$$* P#/ACYAX%=A_PD.B_]!>P_\"4_QH_X2'1?^@O8?^!*?XT
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M88=*U[W>[^YK\CP35/ FNZIJ6_2])N267+B5/) _%\#\*J_\*M\8_P#0'_\
M)J'_ .+KZ)HKJ5"*22;T_KL>/B<LH8FM*M*Z<G>RV_&Y\[?\*M\8_P#0'_\
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MXQ_Z!'_DU#_\77T311[&(_[%P_=_A_D?.W_"K?&/_0(_\FH?_BZ/^%6^,?\
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M '/?\*_\&_\ 0I:%_P""V'_XFC_A7_@W_H4M"_\ !;#_ /$UT-% '/?\*_\
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M@[5+9QAL8;[IZ$]* -.BBB@ HHHH **** "BBJ&L:WIV@6'VS6+I;6WW! [
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYE\/O$&AR?$#Q#!I\Z+'J+P_8(TA95=8T<M@8&W ]<>U>H44 %%%% !1110
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M_;5__P!"SJO_ ']M?_CU']M7_P#T+.J_]_;7_P"/4 ;%%8_]M7__ $+.J_\
M?VU_^/4?VU?_ /0LZK_W]M?_ (]0!L45C_VU?_\ 0LZK_P!_;7_X]1_;5_\
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M '-V/_)4]=_[ NF_^C[ZMZ\NXK&SENKAML4*%V/L/ZU@V/\ R5/7?^P+IO\
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M/">CII<VG+;2?8IG5VMS<RE%*OO&T%OD&[G"X!K$U'PC=3ZOJUV^F:-JYO\
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M6I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-V/_)4]=_[
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M&]5"@J,8P<_UJ+[-/_SQD_[X--=&C.'5E/H1B@#K-#UP7:BVNVQ./NL?X_\
MZ]2ZIXGTK1=0M[+49IHYK@ J4M99$0;@NYW52L8R0,N0*R-"T1KIUNKD%85.
M4'0N?\*T-3\*6>K^([75+^29UMH?+6V2:1$<[PX+A6 < J/E8$=Z $E\=>%(
MFB5_$>EDRW7V-=EVC 38)V$@_*>#UQS@=2*L0>*-&EE@MYM2L[:\G@-PEI+=
MQ>:8QG+X5CE1M;D$C@\\&N:T[X?:G8ZFVHS>(_M=V+J"9'N()I!MC$RD$/.V
M"PN&^X412 0F,@PK\+G344F762]OY)62%UN/]9L= ZJLZQ<!AP\;G@_,,C:
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M/B'2A;6\I@FF^VQ[(Y "2C-NP&P"<'G@U6'A1?[7:]:[)#7<USL$>"/,A6+
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M\C(N7!VE8SGYR"0,#/-/_P"$ATR2UFGL;RVOE@N$MIA;W,1\MV95VL2P (W
MX)R>P)(!YG5/AR]_X@.I1ZL422Y,L]LPN%1TRAVCRIXP3E"<N''(^7@YVAX7
M \+0Z,+K'EW,=QYHBZ[;@38VY[XQG/?/M0!=L_$>B:A<M;V&L:?=3I((FB@N
MD=E<JS!2 <YVHYQUPI/8TS_A*?#_ )D\?]NZ9OMK<74Z_;(\Q0D B1AGA"&4
M[CQ@CUKGY_AX7TU+>UU8VEQ%;K%%<Q6XW1L)6D+@;NI#NO\ P(G-5G^&1BU"
M^ET_4(4M9HRMK;7"73BT8A1E0ETB# 7Y2B(X.T[\C) .@MO&WAW4+_[%I6KV
M5_<JT0>.WNHR560 J_+#<I!'W<GD<40^.O"5PL;6_BG191)*(4*:A$VZ0]$&
M&Y8^G6L=O!.HQV;"35EU!A%;NZR0$23S0IMSYC.V%88'S!B.I9JYK2/ 'B75
M?"IT[4KR;0U65MXD:9Y+K,<:[WV7TF=NS:H9V4C(,8PIH [VS\;>'M0,K6&J
MV<]O;BX-S<+<QA+?R2 ^\%@P'.=V"N!DD KFPOBSPZZ63IK^ELNH/LLV%Y&1
M<MNVXCY^<[AC SSQ6#<> KF<OC5XD$4]U<6G^AD^6TUS'<@29DQ(!(A! VY5
ML<$;B\> Y)1=37FI0O>WD3K--#:>6@=I5?<JER5'R*,%B<C.: -A/%FBW%U#
M;Z?J%OJ$DEY]B<6<R2^1+L=\28/R\1L,=<]JFD\2Z%%J$]C+K6GI>6\9EFMV
MND$D2#JS+G('(Y/'-<WH_P /[RP\0MJNH:_)?O\ :8IE5TE)VHEPN,R3. 3]
MIS\@1!LX09J"Z\"ZCK6HZO\ VA>P6VGS7DL]K$MH&D+/;K#O:3?@I@O\FT'(
M!W8 % '56WB?0;RZCMK36]-GGE@^T1Q17<;,\7_/0 ')7_:Z56TSQIX?UAKP
MZ=JUG/#:9+7"7,;1NJHK.RL&(*J' 8]CUK,U;P+)K&H7PN=30:;>2R7#0+:X
MG69[4VV1-NQM"'(&S=G'S8^6L^\^'FLWQO+B7Q#8I?7T4MO<21Z4PC\F2*.-
M@B>=D.!$I#%B,Y^7&  #H[[QQX5TRZ-M?^(M+@G69('B:[3<CL"5##.5R 3S
MBMVN1C\(ZI;V_P!FM]9M/L\&H&_M!)I[%T9Y7DD5R)0'!\Q@N I'&=W.>NH
M**** "BBB@ KF[[_ )*GH7_8%U+_ -'V-=)7-WW_ "5/0O\ L"ZE_P"C[&@#
MI**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G?%>E2:M)IJ0O93/
M#.93I]\Q$5V@&&R #RN[(.U@#C(K L]1M+R;P1>VUJ;"U^U74(A9]ZQ/Y<B;
M%;H1N!"XXQ@ #H.XOM.LM3@$.I6=O>1*V\1W$2R*&P1G!'7!/YTDVF6%Q8+8
MW%C;2VB!56W>%6C4+T 4C'':@#SK6[B*YB^([V\BR*L=O&2IR RQ[6'U!!'X
M5=%GIMKJ7A)]"6%I+\.MTR'<;N$Q9<RGJ^"!RV<&NU71M,2WE@33K189D5)8
MQ H5U4852,8( X /2G6VDZ=974MS9V%K;W$V?,EBA57?G/) R>: .'T#PIIN
MIZ#XGLX[*U@GDU*[MXIDB56B4,"@! R%!"G'M1H&I2>+=5MKZ=3_ ,273&2;
M/&+R3*O]<*A_[ZKNH],L8=0DOH;*WCO)5VR7"Q*)'''!;&2.!^0K/T/P^NCZ
M=>0M.)[B^N);FXG$6P,[GLN3@ 8'7M[T >>:;:Z=%\+M&U73MC:VMW D%P#N
ME,OFA3%GKMV9^3ICMZZUQ97&N^*/$L5YIVG7CV^V* WUVT;6L1CR'C C;&3E
MMP(.1[5U/AWPGI^@Z?91FWMKB]M(_+%]]F59&'/?DC@XZUH7VBZ7J<B2:EIM
MG>.@PC7$"R%1Z D<4 <5J>FW3:98:AJ#Z5XB:PTHF[M+B?*R*1D3QL00&.S&
MXJ,@'D5UPU.T_P"$1&JXN/L?V'[3@L?-\OR]W7.=V.^<Y[U8OM'TS5&C;4].
MM+QH\[#<0+(4SUQD''2KE 'FU@D*>+_#+V^E:?ID6I6TS/%;7/F27$31;AYR
M[%SR!SELG//>H[/0M+;P=XU==+LS+%=7Z0L+=-R!5R@4XX ." .E=]::#H^G
MRK+8:58VTBG*O#;(A!P1G('H2/QJS#:6UNLJP6\40F<R2!$ WL>K''4GN: /
M/KZTCMM$\(V>GV-FMCJ$D;749;R(;F3R<HLC*K9W,.A!W$ &H];TVXTSP?XN
MC=;"UMI(8GBT^RN#(MLW\1P47:&^4X [&N]CT/28=/DL(=,LX[.5MTENMN@C
M<\<E<8)X'Y"G1Z-ID.GO80Z=:1V<AR]NL"B-OJN,'H* (M$TJRTO3XULK=(V
MD16ED"C?,V/O.W5F/J:T:0 *H"@  8 ':EH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#E_ W^HUW_ +#EY_Z'4?B:**]\7^']/U-4DTV83NT,
MG*32JJ[%8=#C)(!KIX+6WM1(+:".$22&1_+0+O<]6..I/<TV]L+/4;?R-0M8
M+N'(;RYXPZY'?!XH XCQ!;6\>L:%H^EVME/I<DUP9+.6Z,=NTRX(C("L!@EB
M$QC/;BJ>MV%SIO@CQ!;RFRBM_MMJ\-C:7!E6TW2Q%DY5=H).X+C W5WS:/IC
MZ:NGOIUHUDOW;8P*8QSG[N,=>:5-)TV/3_L":?:K9YS]F$*B/.=V=N,=>?K0
M!QUU;"\\7>+[4WPL//T^VC%R6QY98, <Y'<XZ]ZT/",D-GJE_HSZ19Z;?6L,
M#3G3W)MY@0<, 0"K9SG(SC')P*Z1K"S>2=WM(&>Y3RYV,8)E7&-K'N,$\'UI
M+'3+'2XFBTVRM[.-FW,EO$L8)]2 !S0!R4^E6.K?%:\BU.V2ZA32HF$4HW(3
MYC#)7H2,G&>F:YV"RAL_ASH^LPACJ4.HQI'=NQ>14$YC$88\A-G&P?+UXY->
MIBUMUNVNE@B%PR"-I@@WE0<A2W7&>U1?V78&S6T-C;?9D;>L/DKL5L[LA<8S
MGG/K0!P7C">RU*W\22P:5:/+ID(234+VZ*2Q2A<J(1L;'.W !3<Q/KDW[:1Y
MO&UE+*Q=W\+LS,>I)D3)KJKG0])O;HW-YI=E<7!7:99;=&?;C&,D9Q@D5.MC
M:+,LJVL(D6+R%<1C<(^NP'^[P..E 'F&EZ?:Z?\ #_POK%K"J:B;ZWW763YC
M*SE"F[KL*G&WI[5OZ1IFE6OQ!\3W#Z?:AK9+:>(B!=T>8V+LO&021R1U-=:-
M,L!9Q6HLK<6\+!HH?*78A!R"%Q@$'GBB73+">_BO9[*WDNX1B.X>)3(@YX#$
M9'4_G0!YTDUN^H^%]6TW3+335O\ 4"(YENR]W<Q,&W>:-GS9^4DEVP2!WS46
MJKO\)>*5RRY\3 94X(^:'H>U>B0Z!H]O<>?!I-C%-O$GF);(K;N?FR!G/)Y]
MS4S:7I[Q2Q/8VS1S2^=*AA4AY./G(QRW Y// H YFUL;71/B3;6FE0):V]SI
M3F:.,861DD7:[>K?,PW').:K^/SJ:ZYX>.@^5_:(-V8/-&03Y![>N,XSQG&>
M*[,VMNUVMTT$9N$0HLQ0;U4G) /7' XHDM;>:XAGE@C>: DQ2,@+1Y&#M/;(
MXXH \W<V-Q;>&;318([K3[Z>>2]AU"X,?VBZ50<7#;6+/NW':1@E1C@"K-YH
M=];:#K#6_P!A@?3KJ+4;"PL[@RK:2(NYUY1=H<9(7&/G/KSV\FC:9-#/%-IU
MI)'<OYDZ- I$K?WF&.3[FE33H+32Y+/28;>Q4HPC$4"[$8C[VP8!YYQWH YW
MPG<Q^(O$&J>)8LFV94LK-B?X%&YSCW=O_':@\32V.IZQ?6#Z/97TMC8>;//J
M-SY<<"-DYC&Q\-P26 7HN2<#'2>']&B\/>'[/2K=MZ6T>TOC&]B<LV.V22<>
M]2W>D:;?W$5Q?:?:W,T/^KDFA5V3G/!(R.: //;&)=:A^'R:J6N5EAN#*)&/
M[S;%P&_O#@9!X/0Y!-)K.G6T6@^.M-AMH_LEB\<]K#L!6!FA5F*#^'DGITR:
M]&CTVQA^S>396\?V4$6^V)1Y((P=O'RY'I3Q9VH>=Q;0[KG'GGRQF7 VC=_>
MXXY[4 <3J=E9V,W@M-/MH+>)[Y9"L$816)A.6XZD^M==:3:L]TRWUE9PV^#M
MDAO'D<GME3$H'YTL&BZ7:QQ);:;9PI#(98EC@51&Y&-P '!QW%7: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YNQ_Y*GK
MO_8%TW_T??5TE<_J7A:2\U^75[#Q!JFDW$UK%:S+9I;,DBQM(R$B6%R"#,_0
MCMZ5'_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB
M^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@
M_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__
M "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%
M<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_
M /0]^(/^_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^
M_&G_ /R+1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+
M1_PB^K_]#WX@_P"_&G__ "+0!TE%<W_PB^K_ /0]^(/^_&G_ /R+1_PB^K_]
M#WX@_P"_&G__ "+0!TE9=YHZW^L)<7',$<8&W^\<D_ES6?\ \(OJ_P#T/?B#
M_OQI_P#\BT?\(OJ__0]^(/\ OQI__P BT =( %4!1@#@ =J*YO\ X1?5_P#H
M>_$'_?C3_P#Y%H_X1?5_^A[\0?\ ?C3_ /Y%H Z2BN;_ .$7U?\ Z'OQ!_WX
MT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^1: .DHKF_P#A%]7_ .A[\0?]^-/_ /D6
MC_A%]7_Z'OQ!_P!^-/\ _D6@#I**YO\ X1?5_P#H>_$'_?C3_P#Y%H_X1?5_
M^A[\0?\ ?C3_ /Y%H Z2BN;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_
M 'XT_P#^1: .DHKF_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\
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M 'XT_P#^1: .DHKF_P#A%]7_ .A[\0?]^-/_ /D6C_A%]7_Z'OQ!_P!^-/\
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M^A[\0?\ ?C3_ /Y%H Z2N;OO^2IZ%_V!=2_]'V-'_"+ZO_T/?B#_ +\:?_\
M(M2:;X6DL]?BU>_\0:IJUQ#:RVL*WB6RI&LC1LY BA0DDPIU)[^M '04444
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M@<"7>.J9?/#8R?TT9RUOK_BBWU?5=+TW[<X"_P!H6ID:> QX7RSYBA@/F&T
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M %%%% !1110 4444 %%%% !1110 4444 %4M8U>ST+29]0U"58X84+8+ %R
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MV5U5HA!=-,2",G.8UQVZ9[_CD>.Y4G^'&JRQ-NCDM-RL.X."#6]IW_(+M?\
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MI.O1:S<7 L[2Y^SP2/%]K<((Y'4X(4;MW7/)4#@\UJ4 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,TKPQKN/E;%V _>YD('' )Z4#\9OA\MY!:GQ+;^?/,8$3RI/OAMIS\ORC/\
M$< ]0<4 =Q167XE\1:=X3\.7>MZU-Y%E:*#(X1FY9@JC"@GEF Z=ZXOPI\;O
M#.O> I?$VJRC25M95AO+?;+/Y#NY$:AA&-Y8 'Y0<9YH ](HK(N?%6BV?B5=
M N;T)J;6;7P@\MSB!207+ ;0,@]3GBN=MOC1\/+NZMK>'Q1:"2YC,D?F))&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAVYSA4 ! Z5W*(L:*D:A54855& !Z4M% !1110 4444 %%%% !1110 4444
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M*VELMXUVMO$+ET"-,$&]E'0%NI'M19W*WEC!<H,+-&L@&<X!&?ZU-0 4444
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M KCK?X?ZC;?"7P)X<CT2[6[U76XK[691:MNAC#,293CY"%91\V/ND>M?15%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M55%RL0,VY"Q^15#L S#@_>(/=_$'4;+2M;\&7NJ7D%E:1:RYDGN95CC3-G<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>nexi-20221231_g8.jpg
<TEXT>
begin 644 nexi-20221231_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $X .L# 2(  A$! Q$!_\0
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M(SUH EHH&3P.36'I?COPUKFJR:9IOB+2=0U*/=OL[6^BEF7:<-E%8D8[\<4
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M/&54\8(QP:?IG@_1M(E\ZVT^'[3G)N9099B?>1LM^M '.IXJL[D9LH;[4O\
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MCL[O3K^:^DM(8I?)>, E)C+A%#>GSE<'\.]:U0;!1110 5X3^TQ,(UT]<_\
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MEF_L7Q98WF=MMJ*_8+CT$@RT#?\ HQ/^!+7:5R&L:;_:VEW%H'\J21<Q2_\
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M97]-^<F$_P"]E?1NU:RL&564AE89# Y!'J#0 M9>H0?VQK6EZ1UBW_;KH?\
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F% &KI?AW2]%_X\-.M;,XP6AA56/U(&36C110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>nexi-20221231_g9.jpg
<TEXT>
begin 644 nexi-20221231_g9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %F JP# 2(  A$! Q$!_\0
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M%_'5VE[K5G=B"?3D\R':R+C+EV.P@= Q- 'Z:W%U#;>6)IHXC(P1/,8+N8]
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M+]C'XB>)/&GQ*GA\/>%/$W_"27DM[IWBG6+Z47NG1G)6WBCQA6Z(&Z#Z<#]
M:* /E/3_ -GWQG;_ !"_9WUA[6S%EX+T5['66^U M'*8 @"#'SC=W%?5E%%
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M.&!;*RMY7D+"'.U\M(S/D_-D !0!0!W.@?&S1]>U)=-;3]2L-42.^:ZL[J-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXV]Q7U/(GF1LO3<,5PFE?"FTTGX-CX>QW\SV@TE])^W%%$NUHRF_'3/S9]*
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M5S7BWX(^(KG5-#U6'Q+>:IXCDURSFN]9$$$0L[2WM[H1JD'W2N^<[AR6\T]
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MTVVU&XO;RVTYYX+IK6]EM0 IG3R(V\K<[EGV;U&#UH ^G:*\&\._&_Q#J'Q
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MP# @C(K'C\)Z+#ING:?'I-FECILB2V5LL"B.V=,[&C7&%(R<$=,UKLP52QX
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M/?:V/7:?2OFR3]FW5(?"MMI^FZ+I>F7TMGXFM+J:-D0%;MV-HKE1EDQLXYV
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MAU#X*R3Z?J?V;6!;:G)XG'B>QN6M=\<$P5%$<B;AYBE58'!4_-Q@@4 76_:
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MFI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1O\ OHT>8_\ ST;_ +Z-'U=]P^O?W?Q/5N/6CCUKRGS'_P">C?\ ?1H\Q_\
MGHW_ 'T:/J[[C^O?W?Q/5^M+VK.T!BVC6>3D^4O\JT?6N5Z.QZ<9<R3%HHHI
M%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<OXV\1W?AZWM'
MM1&3*Y5O,4GH,^HH ZBBO*O^%E:O_<M?^_9_^*H_X65J_P#<M?\ OV?_ (J@
M=CU6BO*O^%E:O_<M?^_9_P#BJ/\ A96K_P!RU_[]G_XJ@+'JM%>5?\+*U?\
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M(]>[,VYB3U-5%M[HSG%1M9W$HHHJB#TG0/\ D"V7_7)?Y5H#M6?H'_(%L?\
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MG'>M+QU9>,+'QQX;@T*'5$\*V]ND:0Z*]M&J7 F4$7/FC/D"$$ ("<@]]IH
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M=QB48,:RBXV8'J8^F?K7H?@W^T?^$1T/^U]W]K?88/MF[KYWEKYF??=FMJ@
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M_P#(K6W^_)_Z$:Z:@D:WW37EVH?\A"Z_ZZO_ .A&O46Z&O+M0_Y"%U_UU?\
M]"-=6'W9Y6.VB5Z=&VUU)Z YIM%=QXYX;;? O5-/\/W=W!,9/$[W=RL4?VWR
MH(K2:[\V0(R*IWL@7[Y8 Y'2HM-^$/B^W:UN+B2*;5&L+"VGOWU)W96M[UI6
M!!&'!A*@'CE2.Y->[T5G[-&WMIGAN@_"7QMYB0ZYK,UU:R:C;RW@CU20?:(U
M\WS)%QADW;XQL!&<=!BM_P"'/P[USPWJU_>ZP([JZO=!MK&2]^W/*WGQ"12K
M*>H(9#O_ -D^IKU.BFH) ZTG='A_A'X4^*+/PKH&@:DLUM;65S;&\>'5TQ+
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M^2__ "13HJY_PHWQS_T/^G_^$^O_ ,>H_P"%&^.?^A_T_P#\)]?_ (]1SO\
ME?X!]=J_] \O_)?_ )(IT5<_X4;XY_Z'_3__  GU_P#CU'_"C?'/_0_Z?_X3
MZ_\ QZCG?\K_  #Z[5_Z!Y?^2_\ R13HJY_PHWQS_P!#_I__ (3Z_P#QZC_A
M1OCG_H?]/_\ "?7_ ./4<[_E?X"^NU?^@>7_ )+_ /)'(_$+7-/\/^"=9N]3
MO(K&U^RR1>=,<+O9"JKGU)( ^M:FAZM9Z[H]GJ&GW,=Y8W$8>&XB.4D7ID'N
M*G\3?LV^*?%WA_4-%U7QSI]SIU]"T$\?]@*"5/H?.X(X(/8BK=C\ ?&6EV-K
M96GCO38+6VB6&*-?#R@*B@  ?OO057M/=^%W^7^9G]<K\]_J\K6_NWO_ .!$
M=%7/^%&^.?\ H?\ 3_\ PGU_^/4?\*-\<_\ 0_Z?_P"$^O\ \>J>=_RO\#3Z
M[5_Z!Y?^2_\ R13HJY_PHWQS_P!#_I__ (3Z_P#QZC_A1OCG_H?]/_\ "?7_
M ./4<[_E?X#^NU?^@>7_ )+_ /)%.BKG_"C?'/\ T/\ I_\ X3Z__'J/^%&^
M.?\ H?\ 3_\ PGU_^/4<[_E?X"^NU?\ H'E_Y+_\D4Z*N?\ "C?'/_0_Z?\
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MQ;9OQ\P&<8(/]*Y__A U_P"?QO\ OV/\:ZZ-2,8V9Y6*HU*LTX+H<E177?\
M" K_ ,_C?]^Q_C1_P@*_\_C?]^Q_C6_MH=SC^J5>WY'FWC+PK!XTT,Z7<RM#
M UQ!.Q50V[RY%?:0>S;<'V->>:?^SG9:7I\MM:^(;Y6E$8DEDA5O-"3/(%<9
M&Y<.J8R.(U]Q7T9_P@*_\_C?]^Q_C2?\($O_ #^-_P!^Q_C4.I3>K+CAZ\59
M+\CP+1_@'INDV-K:G4Y[A8&L3N:!%9EMDE0+D=-PF.<=-HQ2>'_@5#H<EG))
MX@NKQ[22S,3&UCC*I;0RQ1KQWVRY+>JCCFO?_P#A 5_Y_&_[]C_&D_X0)?\
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M - RU_[]"C_A%='_ .@9:_\ ?H4#T/%:*]J_X171_P#H&6O_ 'Z%'_"*Z/\
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M\(KH_P#T#+7_ +]"@-#Q6BO:O^$5T?\ Z!EK_P!^A1_PBNC_ /0,M?\ OT*
MT,_X=_\ (K6W^_)_Z$:Z:J]I9P6,(AMXEAB&2$08'-6*!!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228640896560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEXIMMUNE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-2518457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9119 Gaither Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">825-9810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NEXI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,078,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">None.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001538210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228642902032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tysons, Virginia<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641712096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,642,340<span></span>
</td>
<td class="nump">$ 30,326,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Available-for-sale&#160;marketable&#160;securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">51,491,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,671,411<span></span>
</td>
<td class="nump">4,394,916<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">37,368,751<span></span>
</td>
<td class="nump">86,280,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,459,071<span></span>
</td>
<td class="nump">4,427,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">967,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other&#160;non-current&#160;assets</a></td>
<td class="nump">264,970<span></span>
</td>
<td class="nump">324,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,059,824<span></span>
</td>
<td class="nump">91,032,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,377,374<span></span>
</td>
<td class="nump">1,045,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,357,153<span></span>
</td>
<td class="nump">6,170,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">599,047<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,333,574<span></span>
</td>
<td class="nump">7,215,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">425,766<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,759,340<span></span>
</td>
<td class="nump">7,271,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.0001 par value, 250,000,000 shares authorized as of December&#160;31, 2022 and 2021, 26,078,451 and 22,828,904 issued and outstanding as of December&#160;31, 2022 and 2021</a></td>
<td class="nump">2,608<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in-capital</a></td>
<td class="nump">222,547,530<span></span>
</td>
<td class="nump">211,498,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(190,249,654)<span></span>
</td>
<td class="num">(127,743,455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,012<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">32,300,484<span></span>
</td>
<td class="nump">83,760,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 43,059,824<span></span>
</td>
<td class="nump">$ 91,032,116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228644997888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized common stock (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">26,078,451<span></span>
</td>
<td class="nump">22,828,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">26,078,451<span></span>
</td>
<td class="nump">22,828,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641689440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements Of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 47,148,450<span></span>
</td>
<td class="nump">$ 37,456,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,934,439<span></span>
</td>
<td class="nump">15,799,432<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">63,082,889<span></span>
</td>
<td class="nump">53,255,782<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(63,082,889)<span></span>
</td>
<td class="num">(53,255,782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">664,372<span></span>
</td>
<td class="nump">52,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,424,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">843,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(905,326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(87,682)<span></span>
</td>
<td class="num">(61,407)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">576,690<span></span>
</td>
<td class="nump">2,354,274<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(62,506,199)<span></span>
</td>
<td class="num">(50,901,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Accumulated dividends on Redeemable Convertible Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(377,562)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders&#8217;</a></td>
<td class="num">$ (62,506,199)<span></span>
</td>
<td class="num">$ (51,279,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss attributable to common stockholders per common share (in dollars per share)</a></td>
<td class="num">$ (2.60)<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss attributable to common stockholders per common share (in dollars per share)</a></td>
<td class="num">$ (2.60)<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">24,059,104<span></span>
</td>
<td class="nump">20,186,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average number of common shares outstanding (in shares)</a></td>
<td class="nump">24,059,104<span></span>
</td>
<td class="nump">20,186,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228640860512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements Of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (62,506,199)<span></span>
</td>
<td class="num">$ (50,901,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on&#160;available-for-sale&#160;marketable securities, net of tax</a></td>
<td class="num">(3,012)<span></span>
</td>
<td class="nump">3,012<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (62,509,211)<span></span>
</td>
<td class="num">$ (50,898,496)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228635874544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect of adoption of accounting standard</div></th>
<th class="th"><div>Series A</div></th>
<th class="th"><div>Series&#160;A-2</div></th>
<th class="th"><div>Series&#160;A-3</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative effect of adoption of accounting standard</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative effect of adoption of accounting standard</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income/ (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,735,303<span></span>
</td>
<td class="nump">22,047,361<span></span>
</td>
<td class="nump">31,209,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,047,435<span></span>
</td>
<td class="nump">$ 7,685,865<span></span>
</td>
<td class="nump">$ 10,887,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A redeemable preferred stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A redeemable preferred stock upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_TemporaryEquityStockConvertedDuringPeriodShares', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121,880,303)<span></span>
</td>
<td class="num">(22,047,361)<span></span>
</td>
<td class="num">(31,209,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_TemporaryEquityStockConvertedDuringPeriodValue', window );">Conversion of preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35,048,885)<span></span>
</td>
<td class="num">$ (7,685,865)<span></span>
</td>
<td class="num">$ (10,887,449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,256,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">$ (69,374,941)<span></span>
</td>
<td class="num">$ (1,537,274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">$ 8,206,938<span></span>
</td>
<td class="num">$ (2,277,332)<span></span>
</td>
<td class="num">$ (77,582,005)<span></span>
</td>
<td class="nump">$ 740,058<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,144,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock</a></td>
<td class="nump">53,622,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,014<span></span>
</td>
<td class="nump">53,621,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt', window );">Conversion of convertible debt into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,669,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt', window );">Conversion of convertible debt into common stock</a></td>
<td class="nump">30,252,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">30,251,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of transaction costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,441,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of transaction costs</a></td>
<td class="nump">114,551,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744<span></span>
</td>
<td class="nump">114,550,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,166,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">1,165,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_NumberOfWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,979,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,979,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable available-for-sale securities</a></td>
<td class="nump">3,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(50,901,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,901,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,828,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">83,760,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,283<span></span>
</td>
<td class="nump">211,498,827<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="num">(127,743,455)<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">3,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of transaction costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,184,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of transaction costs</a></td>
<td class="nump">$ 5,145,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">5,145,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">362,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 33,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">33,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod', window );">Cashless exercise of options for common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised', window );">Cashless exercise of options for common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,870,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,870,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable available-for-sale securities</a></td>
<td class="num">(3,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,012)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(62,506,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,506,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,078,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 32,300,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,608<span></span>
</td>
<td class="nump">$ 222,547,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (190,249,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Common Stock, Cashless, Exercised in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Cashless, Common Stock Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_TemporaryEquityStockConvertedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock converted during period shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_TemporaryEquityStockConvertedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_TemporaryEquityStockConvertedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock converted during period value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_TemporaryEquityStockConvertedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228639783344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements Of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (62,506,199)<span></span>
</td>
<td class="num">$ (50,901,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">994,792<span></span>
</td>
<td class="nump">870,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Accretion income on available-for-sale marketable securities, net</a></td>
<td class="num">(1,131)<span></span>
</td>
<td class="num">(32,065)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on asset disposal</a></td>
<td class="nump">21,264<span></span>
</td>
<td class="nump">8,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,870,364<span></span>
</td>
<td class="nump">5,979,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_LeaseExpenseNoncash', window );">Non-cash lease expense</a></td>
<td class="nump">500,553<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash&#160;interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">903,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,424,877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(843,619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,723,506<span></span>
</td>
<td class="num">(2,053,690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">59,129<span></span>
</td>
<td class="num">(300,726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,387,057<span></span>
</td>
<td class="num">(1,002,896)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other</a></td>
<td class="nump">1,258,098<span></span>
</td>
<td class="nump">4,011,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(498,353)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(51,190,920)<span></span>
</td>
<td class="num">(45,785,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,255,116)<span></span>
</td>
<td class="num">(2,350,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from disposal of equipment</a></td>
<td class="nump">80,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases&#160;of&#160;available-for-sale&#160;marketable&#160;securities</a></td>
<td class="num">(21,509,940)<span></span>
</td>
<td class="num">(90,456,865)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities&#160;of&#160;available-for-sale&#160;marketable&#160;securities</a></td>
<td class="nump">71,500,000<span></span>
</td>
<td class="nump">39,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from redemption of available-for-sale marketable securities</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">50,315,744<span></span>
</td>
<td class="num">(53,807,281)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial offering, net of transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">114,721,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from "at-the-market" offering facility, net of transaction costs</a></td>
<td class="nump">5,145,409<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">33,255<span></span>
</td>
<td class="nump">1,166,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities', window );">Principal payments on capital leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,260)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from the issuance of convertible notes from related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from the issuance of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,974,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs associated with convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,137)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,178,664<span></span>
</td>
<td class="nump">124,887,625<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">4,303,488<span></span>
</td>
<td class="nump">25,295,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Net cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">30,393,852<span></span>
</td>
<td class="nump">5,098,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Net cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">34,697,340<span></span>
</td>
<td class="nump">30,393,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the year for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Gain on extinguishment of debt from forgiveness of PPP Loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">843,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 5,370<span></span>
</td>
<td class="nump">$ 131,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_LeaseExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Expense, Noncash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_LeaseExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a),(b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228731678560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of the Business</a></td>
<td class="text">Description of the Business<div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NexImmune, Inc. (the &#8220;Company&#8221; or &#8220;NexImmune&#8221;), a Delaware corporation headquartered in Gaithersburg, Maryland, was incorporated on June&#160;7, 2011. The Company is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The AIM nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body&#8217;s own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are artificial AIM nanoparticles, which act as synthetic dendritic cells. These AIM nanoparticles can be programmed to present specific antigens to specific T cells orchestrating a highly targeted immune response. These AIM nanoparticles can be rapidly engineered to elicit an immune attack that can be directed toward any foreign substance or cell type in a patient&#8217;s body. The Company&#8217;s first two products, both for the treatment of different types of cancer, entered clinical trials in 2020. Following a strategic review of the Company's corporate strategy, including with respect to its adoptive cell therapy programs, the Company paused investments in its cell therapy studies, NEXI-001, NEXI-002, and NEXI-003 which is designed to reduce costs and reallocate resources towards our AIM INJ preclinical development programs. As part of this strategy, we will focus on developing AIM INJ nanoparticle constructs and modalities for potential clinical evaluation in oncology and autoimmune disorders. The Company is exploring several external opportunities to continue to advance these programs. As a result, the Company will focus its existing resources on its injectable platform in oncology and autoimmune diseases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements - Going Concern ("ASC 205-40"), requires management to assess the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements are issued. Under ASC 205-40, management has the responsibility to evaluate whether conditions and/or events raise substantial doubt about the Company&#8217;s ability to meet future financial obligations as they become due within one year after the date that the financial statements are issued. As required by this standard, management&#8217;s evaluation shall initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring operating losses and negative cash flows from operations. The financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had an accumulated deficit of $190.2 million, negative cash flows from operating activities for the period ended December&#160;31, 2022, and significant ongoing research and development expenses. While we have no outstanding debt and $34.6 million in cash and cash equivalents as of December&#160;31, 2022, the Company expects its negative cash flows from operating activities to continue and thus has determined that its losses and negative cash flows from operations and uncertainty in generating sufficient cash to meet our obligations and sustain our operations raise substantial doubt about the Company&#8217;s ability to continue as a going concern for at least one year from the issuance date of these financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s research and development activities mature and develop over the next year, the Company will likely require substantial funds to continue such activities, depending upon events that are difficult to predict at this time. In this regard, management plans to raise additional capital through financing activities that may include public offerings and private placements of its common stock, preferred stock offerings, collaborations and licensing arrangements and issuances of debt and convertible debt instruments. In the absence of additional capital, the Company plans to strategically manage its uncommitted spend, execute its priorities and implement cost saving measures to reduce research and development and general and administrative expenditures which could include minimizing staff costs and delaying or terminating manufacturing and clinical trial costs.</span></div>There are inherent uncertainties associated with fundraising activities and activities to manage the Company&#8217;s uncommitted spending and the successful execution of these activities may not be within the Company&#8217;s control. There are no assurances that such additional funding will be obtained and that the Company will succeed in its future operations. If the Company cannot successfully raise additional capital, its liquidity, financial condition and business prospects will be materially and adversely affected. The Company is continually looking into further capital planning and the evaluation of strategic alternatives. There is substantial doubt about the Company&#8217;s ability to continue as a going concern.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228728277888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation and Liquidity</a></td>
<td class="text">Basis of Presentation and Liquidity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Updates (&#8220;ASU&#8221;) of the FASB.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228728277888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the recoverability of long-lived assets, stock-based compensation, the valuation of financial instruments, and the valuation of deferred tax assets and liabilities. The Company&#8217;s estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Although actual results could differ from those estimates, management does not believe that such differences would be material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to credit risk consist principally of cash and marketable debt securities. All cash is held in United States financial institutions that are federally insured. At times, the Company may maintain cash balances in excess of the federally insured amount. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk. The Company&#8217;s investments in marketable debt securities have been issued by corporate entities and government-sponsored enterprises with high credit ratings. The Company mitigates investment risks by investing in highly-rated securities with relatively short maturities that the Company believes do not subject it to undue investment or credit risk. If any of these financial institutions fail to perform their obligations under the terms of these financial instruments, the Company&#8217;s maximum exposure to potential losses would be equal to the amounts reported on the balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographic Information</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities with maturities greater than three months from the date of purchase that include commercial paper and corporate notes. Classification of marketable securities between current and&#160;non-current&#160;is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. There were no outstanding marketable securities as of December&#160;31, 2022. As of December&#160;31, 2021, all marketable securities were classified as current.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and dividend income are recorded when earned and included in interest income in the statement of operations. Premiums and discounts, if any, on marketable securities are amortized or accreted to maturity and included in interest income in the statement of operations. The specific identification method is used in computing realized gains and losses on the sale of the Company&#8217;s marketable securities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its marketable securities as&#160;available-for-sale.&#160;The Company determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date.&#160;Marketable securities that are classified as&#160;available-for-sale&#160;are measured at fair value on the balance sheet, and unrealized gains and losses on marketable securities are reported as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity (deficit) until realized. Marketable securities are evaluated periodically to determine whether the carrying value of a marketable security exceeds its fair value and the decline in value is determined to be other-than-temporary. Management reviews criteria, such as the general market conditions, magnitude and duration in which the fair value has been less than the carrying value, the investment issuer&#8217;s financial condition and business outlook, as well as the Company&#8217;s ability to hold the securities until the recovery of its amortized cost basis, to determine whether the decline in value is other-than-temporary. If a decline in value is determined to be other-than-temporary, the value of the marketable security is reduced, and the impairment is recorded as other expense in the statement of operations. As of December&#160;31, 2021, any decline in value of marketable securities was concluded not to be other-than-temporary. As of December&#160;31, 2022, no assessment was required. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted cash</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,642,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,326,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,697,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,393,852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent amounts required as collateral on corporate credit cards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, marketable securities, accounts payable, accrued expenses, convertible notes and derivative liabilities. The fair values of the cash and cash equivalents, accounts payable and accrued expenses approximated their carrying values as of December&#160;31, 2022 and 2021, due to their short-term maturities. For a description of the fair value of marketable securities, refer to Note 4. The Convertible Notes as discussed in Note 10 contained embedded derivative features that were required to be bifurcated and remeasured to fair value at each reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, Fair Value Measurements (&#8220;ASC 820&#8221;). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt">Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt">Fair value is determined by using inputs, other than Level&#160;1 quoted prices that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt">Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant judgments to be made by a reporting entity.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation and amortization. Major replacements and improvements that extend the useful lives of assets are capitalized, while general repairs and maintenance are charged to expense as incurred. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the related lease term, whichever is shorter. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property, plant and equipment by major category are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of its long-lived asset group for potential impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoverability is determined by comparing future undiscounted cash flows associated with such assets to the related carrying value. An impairment loss may be recognized when the estimated undiscounted future cash flow is less than the carrying amount of the asset. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured as the amount by </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which the carrying value of the asset group exceeds the fair value of the asset group. No impairments were recognized for the years ended December&#160;31, 2022 or 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable convertible preferred stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s redeemable convertible preferred stock was classified outside of stockholders&#8217; equity because the shares contained deemed liquidation rights that represented a contingent redemption feature not solely within the control of the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible instruments and embedded derivatives</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that contain conversion options and other embedded features. The Company bifurcates embedded features from their host instruments and accounts for them as free-standing derivative financial instruments according to certain criteria.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any change to the Company&#8217;s debt arrangements, the Company evaluates the amendment to determine whether a debt modification or extinguishment has occurred, including whether the amendment should be accounted for as a troubled debt restructuring.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s derivative instrument related to certain features embedded within the Company&#8217;s Convertible Notes as discussed in Note 10. The derivative was accounted for as a derivative liability and remeasured to fair value as of each balance sheet date. The related remeasurement adjustments are recognized in the accompanying statements of operations and were settled upon the conversion of the Convertible Notes during the year ended December 31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including share-based compensation, as well as costs for third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, based on its estimates of services performed and costs incurred. These estimates include the level of services performed by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial and contract development and manufacturing organization expenses </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes payments in connection with clinical trials and contract development and manufacturing organizations (&#8220;CDMO&#8221;) under contracts with contract research organizations that support conducting and managing clinical trials and the manufacturing of materials utilized in clinical and preclinical activities. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of the obligation to make payments under these contracts depends on factors such as the successful enrollment, treatment of patients, the completion of other clinical trial milestones, or completion of manufacturing milestones. Termination clauses within the agreements require notification for a certain number of days prior to completing work, payments for costs incurred through the termination date, and termination penalty, if applicable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Expenses related to development and manufacturing are accrued based on estimates and/or representations from service providers regarding work performed, including progress in the development of processes through technology transfers to manufacture the Company&#8217;s clinical material and completion of the manufactured clinical material. Other incidental costs related to patient enrollment or </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment are accrued when reasonably certain. If the amounts the Company is obligated to pay under clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records compensation expense associated with stock options and other forms of equity compensation based on the estimated fair value at the grant date. Compensation expense related to awards to employees and non-employees with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the requisite service period of the award, which is generally the vesting term. The Company&#8217;s policy is to account for forfeitures as they occur. The Company uses the Black-Scholes-Merton option pricing (Black-Scholes) model to estimate the fair value of stock options. The Black-Scholes model requires input-based assumptions that are highly subjective, judgmental and sensitive in the determination of stock-based compensation cost.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted after the Company&#8217;s IPO are issued at the fair market value of the Company&#8217;s common stock at the date the grant is approved by the Board.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected volatility was based on the historical volatility of comparable public companies from a representative peer group selected based on industry and market capitalization data. The historical volatility is calculated based on a period of time commensurate with the expected term assumption.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate was based on the continuous rates provided by the U.S. Treasury with a term approximating the expected term of the option.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected dividend yield was 0% because the Company has not historically paid and does not expect to pay any dividends for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based-Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12 for a further discussion on stock-based compensation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes it is&#160;more-likely-than-not&#160;that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results,&#160;on-going&#160;tax planning and forecasts of future taxable income on a&#160;jurisdiction-by-jurisdiction&#160;basis. The Company recorded a valuation allowance against all estimated net deferred tax assets as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered&#160;more-likely-than-not&#160;to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Recognized income tax positions are measured at the largest amount that is greater than&#160;more-likely-than-not&#160;of being realized. Changes in the recognition or measurement are reflected in the period in </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which the change in estimate occurs. Interest and penalties related to uncertain tax positions are recorded in the provision of income taxes. There were no uncertain tax positions nor income tax related interest and penalties recorded as of or for the years ended December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share Attributable to Common Stockholders</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock and common stock equivalents outstanding for the period. The Company adjusts net loss to arrive at the net loss attributable to common stockholders to reflect the amount of dividends accumulated during the period on the Company&#8217;s redeemable convertible preferred stock. Such dividends are only payable if and when declared by the Board of Directors (Note 11). The treasury stock method is used to determine the dilutive effect of the Company&#8217;s stock option grants and warrants and the&#160;if-converted&#160;method is used to determine the dilutive effect of the Company&#8217;s redeemable convertible preferred stock and Convertible Notes. For the years ended December&#160;31, 2022 and 2021, the Company had a net loss attributable to common stockholders, and as such, all outstanding stock options, shares of redeemable convertible preferred stock, and warrants were excluded from the calculation of diluted loss per share. Under the if-converted method, convertible instruments that are in the money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of bifurcated derivatives is added back to the numerator of the diluted net loss per share calculation if the conversion of the Convertible Notes is dilutive.&#160;The following table sets forth the computation of basic and diluted earnings per share for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,506,199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,901,508)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated dividends on Redeemable Convertible Preferred Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(377,562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,506,199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,279,070)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.60)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.54)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,059,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,186,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following potentially dilutive securities have been excluded from the computation of diluted weighted average common shares outstanding at December&#160;31, 2022 and 2021, as the effect would be anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,523,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,976,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of redeemable convertible preferred stock also participate in dividends with shares of common stock (if and when declared) and therefore are deemed participating securities. The holders of redeemable convertible preferred stock do not contractually share in losses and therefore no additional net loss per share has been disclosed under the&#160;two-class&#160;method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging growth company status</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an &#8220;emerging growth company&#8221; (EGC), as defined in the Jumpstart Our Business Startups Act (JOBS Act), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section&#160;107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transition period for complying with new or revised accounting standards, and as a result of this election, the financial statements may not be comparable to companies that comply with public company FASB standards&#8217; effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an IPO offering or such earlier time that it is no longer an EGC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting standards and pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as subsequently amended (collectively &#8220;ASC 842&#8221;). The guidance amends the existing accounting standards for lease accounting, including requirements for lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expanding disclosure requirements regarding leasing arrangements. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting ASC 842 in which entities can elect to apply the new guidance using a modified retrospective approach at the beginning of the year in which the new lease standard is adopted. In November 2019, the FASB issued ASU 2019-10 deferring the effective date for private entities for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the FASB issued ASU 2020-05 which further defers the effective date for private entities for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As an EGC, the Company adopted the new leasing guidance on January 1, 2022. The Company combined lease and non-lease components as a single component for all underlying asset classes. ASC 842 provides a number of optional practical expedients in transition. The Company applied the &#8216;package of practical expedients&#8217; which allows the Company to not reassess i) whether existing or expired arrangements contain a lease, ii) the lease classification of existing or expired leases, or iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. The Company completed its evaluation and recognized $1.5 million in operating right-of-use assets and $0.6 million and $1.0 million in operating lease liabilities, current and non-current, respectively, on January 1, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU&#160;2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for&#160;available-for-sale&#160;debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for fiscal year beginning after December&#160;15, 2022, and interim periods beginning after December&#160;15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company&#8217;s investment portfolio, current market conditions and historical credit loss activity, the adoption of ASU&#160;2016-13&#160;is not expected to have a material impact on its financial position, results of operations or the related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641644384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,722,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,979,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,991,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,722,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,979,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,991,897&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the years ended December&#160;31, 2022 and 2021, the Company did not have any transfers between levels. There were no Level&#160;3 recurring fair value measurements as of December&#160;31, 2022 or 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641634800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid Expenses and Other Current Assets<div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following at December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid maintenance agreements</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,394,916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228645661744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following at December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,803,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,688,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,708,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,229,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,281,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,459,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $994,792 and $870,285 for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228645697024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Activities</a></td>
<td class="text">Restructuring Activities<div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company announced that, following a strategic review of its pipeline, indications, timelines and cash position, it implemented a strategic realignment initiative, which was designed to reduce costs and reallocate resources towards its AIM INJ preclinical development programs. As part of this strategy, the Company initiated a workforce reduction plan to reduce headcount by 30%, primarily affecting the clinical development, manufacturing and administrative staff that had been needed to support the AIM ACT adoptive cell therapy clinical programs. This plan will reduce the Company&#8217;s workforce from 74 full-time employees to approximately 50 full-time employees. The Company estimates that it will incur approximately $0.7 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. These one-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued salaries at December 31, 2022 includes $0.4 million in severance expenses related to the November 2022 restructuring. The Company communicated the workforce reduction on November 14, 2022 and recognized $0.5 million in costs associated with the restructuring during the year ended December 31, 2022. The Company expects to complete the restructuring in the second quarter of 2023. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges related to the restructuring activities as of December&#160;31, 2022. There were no restructuring expenses during the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:26.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued Restructuring Expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued Restructuring Expenses</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance, benefits and related costs due to workforce reduction</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,440)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Totals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,829&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,440)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641541904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the components of accrued expenses is as follows as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,210,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued salaries, benefits and related expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,855,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,357,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,170,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228645661744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a Translational Research Award Agreement effective May&#160;23, 2012 with the Department of Business&#160;&amp; Economic Development with the State of Maryland, Maryland Biotechnology Center (&#8220;MBC&#8221;). The mission of MBC is to integrate entrepreneurial strategies to stimulate the transformation of scientific discovery and intellectual assets into capital formation and business development. Under the agreement, MBC provided $200,000 to NexImmune for research on its artificial aAPC for cancer immunotherapy. In 2013, an amendment increased the amount by $125,000 for a total grant of $325,000. This grant was recorded as income in 2012 and 2013, as the Company incurred the expenses which qualified it for the grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must repay the funds through annual payments calculated at 3% of annual revenues for the preceding year. Payments shall continue for 10 years after the first payment date and may total up to 200% of the total grant amount. The end date of the agreement is defined as January&#160;31, 2024, or when any and all repayments due to MBC have been made. If the Company does not earn any revenue, the grant does not need to be repaid. Through December&#160;31, 2022, no revenue has been recorded, therefore, no payments to MBC are due.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Johns Hopkins University Exclusive License Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into an Exclusive License Agreement with Johns Hopkins University (&#8220;JHU&#8221;) effective June 2011, which was amended and restated in January 2017, referred to as the A&amp;R JHU License Agreement, under which there are license fees, royalties, and milestone payments. As part of the agreement, the Company acquired a perpetual, exclusive license from JHU covering its invention related to Antigen Specific T cells.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JHU was also entitled to milestone fees of $75,000 in connection with clinical trial milestones. For the first licensed product or licensed service in the therapeutic field, the Company may be required to pay JHU additional aggregate milestone fees of $1.6 million for clinical and regulatory milestone fees. The Company may be required to pay JHU reduced milestone fees for the second and third licensed products or licensed services in the therapeutic field in connection with clinical and </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory milestones. In the diagnostic field, the Company may be required to pay JHU aggregate milestone fees of $0.4 million for the first licensed product or licensed service and reduced milestone fees for the second and third licensed products or licensed services in connection with regulatory and commercial milestones. The Company may be required to pay JHU aggregate milestone fees of $100,000 for commercial milestones for the first licensed product or licensed service in the&#160;non-clinical&#160;field. In the aggregate, the Company may be required to pay JHU additional milestone fees of up to $4.2 million for all clinical, regulatory and commercial milestones for all licensed products or licensed services in the therapeutic field, the diagnostic field and the non-clinical field. The Company may also be required to pay royalties in the low to upper&#160;single&#160;digits on net sales of licensed services in therapeutic products, diagnostic products and&#160;non-clinical&#160;products. The Company is required to make minimum annual royalty payments of $100,000 to JHU under the A&amp;R JHU License Agreement, which started in the low five figures in the first year of the agreement and increased to $100,000 in the third year and for each subsequent year of the agreement. The Company may also be required to pay JHU a low double digit percentage, not to exceed 15%, of any&#160;non-royalty&#160;sublicense consideration the Company receives.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will record a liability when such events become probable. The Company has not reached any of the milestones or transacted its first commercial sale as of December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company must make minimum royalty payments, which began upon the fourth anniversary of the agreement and upon every anniversary thereafter during the term of the agreement, which offset future royalties per above owed to JHU. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred $525,000 in cumulative minimum royalties from inception. Future annual minimum royalties consist of $100,000 due each year during the remaining term of the agreement. The Company records milestones, royalties and minimum royalties at the time when payments become probable. The Company incurred $100,000 related to minimum royalties owed in the years ended December&#160;31, 2022 and 2021 and is included in research and development expenses on the accompanying statement of operations. The Company has accrued royalties of $50,000 as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;23, 2020, the Company applied for an unsecured $843,619 loan under the Paycheck Protection Program (the &#8220;PPP Loan&#8221;). The Paycheck Protection Program (or &#8220;PPP&#8221;) was established under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) and is administered by the U.S. Small Business Administration (&#8220;SBA&#8221;). On May&#160;1, 2020, the PPP loan was approved and funded. The Company entered into a promissory note of $843,619, which is recorded within other current liabilities in the accompanying balance sheet. The Company treats the PPP loan as debt under ASC 470. The use of loan proceeds must be for payroll costs, payment of interest on covered mortgage obligations, rent and utility costs over either an eight-week or&#160;24-week&#160;period, at the Company&#8217;s option.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company submitted the PPP Loan forgiveness application to the SBA in March 2021 and received full forgiveness of the $843,619 PPP Loan in July 2021. The Company did not carry a PPP loan balance as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. As of December&#160;31, 2022 and 2021, the Company was not involved in any material legal proceedings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641567760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text">Convertible NotesIn April 2020, the Company entered into Convertible Note Purchase Agreement (&#8220;Agreement&#8221;) for the sale of up to  $15,000,000 of convertible promissory notes with 6% interest rate (&#8220;Convertible Notes&#8221;). The Agreement specified an initial closing date of April&#160;23, 2020 and allowed additional closings within 90 days of the initial closing. The Convertible Notes were scheduled to mature on April&#160;23, 2021.<div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Convertible Notes required a mandatory conversion upon certain qualified financing events (&#8220;Mandatory Conversion&#8221;) and allowed for conversion at the option of the holder upon certain&#160;non-qualified&#160;financing events (&#8220;Optional Conversion 1&#8221;). Upon Mandatory Conversion and Optional Conversion 1, the outstanding principal amount and all accrued and unpaid interest would have automatically converted into the Company&#8217;s preferred stock of the same series issued in such equity financing and will be equal to the number of preferred stock obtained by dividing (a)&#160;all principal and accrued but unpaid interest under such Convertible Note by (b)&#160;the price per share paid by the other purchasers of the preferred stock sold in such equity financing multiplied by 80%.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Mandatory Conversion and Optional Conversion 1 did not occur by the maturity date, the outstanding principal amount plus all accrued and unpaid interest would be converted at the option of the holder into Company&#8217;s common stock at the price per share obtained by dividing $85 million by the Company&#8217;s fully-diluted capitalization (&#8220;Optional Conversion 2&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company (i)&#160;consummates a change in control or (ii)&#160;the Company&#8217;s common stock becomes publicly listed on a stock exchange, the outstanding principal amount plus all accrued and unpaid interest would be automatically converted into shares of the Company&#8217;s most senior series of capital stock outstanding at the time of such change in control or public listing, at a price equal to the lower of (a) 90% of the price per share paid by the purchasers of such stock in such a transaction and (b)&#160;the price per share obtained by dividing $125 million by the Company&#8217;s fully-diluted capitalization (&#8220;Change in Control&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement was amended in July 2020 to allow the sale of up to $50,000,000 convertible notes and to allow for additional closings within 150 days of the initial closing date. The Agreement was amended in September 2020 to allow for additional closings within 190 days of the initial closing date. In addition, the provisions of Mandatory Conversion and Optional Conversion 1 were amended to allow for conversion upon an equity financing at a price equal to the lower of (a) 80% of the price per share paid by the purchasers of such stock in such a transaction and (b)&#160;the price per share obtained by dividing $125,000,000 by the Company&#8217;s fully-diluted capitalization. The Company evaluated the amendments and concluded that the amendments represented a debt modification.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Agreement was further amended to allow additional closings through December&#160;31, 2020, and in January 2021 it was amended again to allow closings through January 31, 2021. In January 2021, the Company issued convertible notes with a principal amount of $9.0 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Convertible Notes and determined that the Mandatory Conversion feature, Optional Conversion 1 feature and Change in Control meet the definition of an embedded derivative liability that is required to be bifurcated from the host instrument and measured at fair value. The fair value of the derivative liability for the convertible notes issued in January 2021 was $0.7 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company amortized the debt issuance costs of $0.3 million and debt discount of $4.2 million, comprising of the initial value of the derivative liability of $2.0 million and the BCF of $2.2 million, prior to the adoption of ASU 2020-06, over the term of the Convertible Notes using the effective interest method. Upon adoption of this standard, the beneficial conversion feature was no longer separately accounted. As a result of applying the modified retrospective method, the Company recognized a transition adjustment of $0.7 million recorded in accumulated deficit, a reduction of additional paid-in capital of $2.3 million and an increase to the carrying value of the convertible notes of $1.5 million on January 1, 2021. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt issuance costs and debt discount amortization expense for the years ended December 31, 2021 was $0.6 million  and is included in interest expense in the accompanying statements of operations. The interest expense at 6% of the Convertible Notes&#8217; principal amount for the years ended December 31, 2021 was $0.2 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed an IPO on February 11, 2021, which triggered the mandatory conversion of all the outstanding Convertible Notes plus accrued interest into 3,669,010 shares of common stock (Note 11). Upon conversion of the Convertible Notes, the outstanding Convertible notes principal plus accrued interest thereon, net of unamortized debt discounts totaling $30.3 million was reclassified to stockholders&#8217; equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641611072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract', window );"><strong>Redeemable Convertible Preferred Stock And Stockholders Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock', window );">Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit</a></td>
<td class="text">Series A Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2021, the Company completed its IPO, pursuant to which it issued and sold 7,441,650 shares of its common stock at a public offering price of $17.00 per share, resulting in net proceeds of $114,551,315, after deducting underwriting discounts and commissions and other offering expenses. Upon the closing of the IPO, all of the &#8212; outstanding shares of the Company&#8217;s Redeemable Convertible Preferred Stock automatically converted into 10,144,041 shares of common stock after giving effect to the reverse stock split, and all of the outstanding convertible debt and accrued but unpaid interest thereon of $31,272,183 converted to 3,669,010 shares of common stock. Upon completion of the offering on February 11, 2021, the Company&#8217;s authorized capital stock consists of 250,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, 145,000 warrants were exercised at an exercise price of $0.01 and 145,000 shares of Series A redeemable convertible stock were issued and then converted into common stock upon the closing of the IPO. The remaining outstanding warrants outstanding as of December 31, 2020 were exercised and settled in January 2021 with 2,896 shares of common stock issued in a cashless exercise.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and BTIG, LLC (together, the &#8220;Agents&#8221;), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share, having an aggregate offering price of up to $50.0 million (the "Shares") from time to time through the Agents (the "Offering"). Subject to the terms and conditions of the Sales Agreement, any such sales made through the Agents can be made, based upon the Company's instructions, by methods deemed an &#8220;at-the-market" offering as defined in Rule 415(a)(4) promulgated under the Securities Act. The Company agreed to pay the Agents a commission of 3.0% of the gross proceeds of any sales of shares sold pursuant to the Sales Agreement. During the year ended December&#160;31, 2022, the Company sold an aggregate of 3,184,900 shares through our &#8220;at-the-market" offering facility resulting in net proceeds of $5.1 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable Convertible Preferred Stock and Stockholders Equity Disclosure [Abstract].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable Convertible Preferred Stock and Stockholders Equity Disclosure [Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228645636416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During January 2017, the Company adopted the 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;), which provides for granting of restricted stock, options to purchase shares of common stock and other awards to employees, directors and consultants. In March 2017, the Company amended the 2017 Plan to increase the number of available shares to 660,838. In September 2018, the Company adopted the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) which provides for granting of restricted stock, options to purchase shares of common stock, and other awards to employees, directors and consultants, and reserved 1,741,770 shares for this purpose. The 2018 Plan was amended in July 2018 to increase the number of available shares to 1,809,143. In February 2021, the Company adopted the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;) and reserved 2,757,556 shares under the plan. No further shares will be issued under the 2017 and 2018 plans. In addition, the 2021 Plan contains an &#8220;evergreen&#8221; provision, which allows for an annual increase in the number of shares of our common stock available for issuance under the 2021 Plan on the first day of each calendar year beginning in calendar year 2022. The annual increase in the number of shares shall be equal to the lower of (i) 5.0% of the number of shares of our common stock outstanding on the date of the applicable increase or (ii) a lesser amount determined by our board of directors. Following the annual increase in the number of shares of our common stock available for issuance under the 2021 Plan, there are 1,439,424 shares available for issuance under the 2021 plan as of  March 1, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of options to be granted under the 2021 Plan, the option exercise prices, and other terms of the options are determined by the Board of Directors in accordance with the terms of the 2021 Plan. Generally, stock options are granted at fair value, become exercisable over a period of <span style="-sec-ix-hidden:f-546">one</span> to four years, expire in ten years or less and are subject to the employee&#8217;s continued employment. Restricted stock units awarded in November 2022 vest after an 18-month service period. No restricted stock units were awarded in the year ended December 31, 2021.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was recorded in the following financial statement line items within the statement of operations for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,870,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,979,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of option activity under the Company&#8217;s Stock Option Plans:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January&#160;1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349,267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965,502&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965,502&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,852,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares unvested as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of the options granted during the years ended December&#160;31, 2022 and 2021 was $2.42 and $11.16, respectively. The options were valued using the Black-Scholes option-pricing model for the years ended December&#160;31, 2022 and 2021 with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.6% to 83.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7% to 81.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%&#160;to&#160;3.80%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5%&#160;to&#160;1.40%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;to&#160;6.1 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;to&#160;6.1 years</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of stock options vested during the years ended December&#160;31, 2022 and 2021 was $9.2 million, and $1.4 million, respectively. The intrinsic value of stock options exercised for the years ended December&#160;31, 2022 and 2021 was approximately $0.2 million and $2.1 million, respectively.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $8.0 million of total unrecognized compensation expense related to unvested options that will be recognized over a weighted average period of 2.4 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A restricted stock unit (&#8220;RSU&#8221;) represents the right to receive one of the Company&#8217;s common stock upon vesting of the RSU. The fair value of each RSU is based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the 2021 Plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.233%"><tr><td style="width:1.0%"/><td style="width:63.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.881%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of restricted units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding  as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $0.7 million of unrecognized compensation expense related to unvested RSUs, which are expected to be recognized over a weighted average period of 1.4 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228644878272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s provision for income taxes consists of the following for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax provision:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax benefit:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,339,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,606,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,370,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969,433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,898,469&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,969,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,898,469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision (benefit) for income taxes</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory U.S. income tax rate to the effective income tax rate as of December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal statutory rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,477,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,758,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,838,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,316,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,249,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,857,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,886,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458,533)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363,427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company had net operating loss (NOL) carryforwards for income tax purposes of approximately $135.2 million and $115.4 million, respectively, which are available to offset future federal taxable income, if any. Approximately $10.5 million of the federal NOL was generated prior to 2018 and will be expiring in increments through 2037 beginning in 2035, while the remaining $124.7 million will be carried forward indefinitely. The state NOL will expire in increments through 2037, beginning in 2035. The federal research and development tax credit carryforwards, if not utilized, will expire beginning in 2037.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Section&#160;382 of the Internal Revenue Code imposes substantial restrictions on the utilization of net operating losses and Section 383 of the Internal Revenue Code imposes restrictions on the utilization of tax credits in the event of a corporations&#8217; ownership change. The Company believes that the future use of net operating losses and tax credits presented above may be limited as a result of past ownership changes and a formal study has not yet been completed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions more likely than not of being sustained. At December&#160;31, 2022, the Company had no gross unrecognized tax benefits and did not recognize any interest or penalties related to uncertain tax positions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At December&#160;31, 2022, the Company provided a 100% valuation allowance on its net deferred tax assets because realization of any future tax benefit cannot be reasonably assured. The Company&#8217;s valuation allowance increased due to the pre-tax losses generated in the current year.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income taxation by both federal and state taxing authorities. Income tax returns for the years ended December 31, 2021, 2020, and 2019 are open to audit by federal and state taxing authorities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tax Cuts and Jobs Act of 2017, research and development costs are no longer fully deductible and are required to be capitalized and amortized for US Tax purposes over five or fifteen years effective January 1, 2022. The mandatory capitalization requirement increased our deferred tax assets as of December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641552672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space and laboratory space. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company does not recognize right-of-use assets or lease liabilities for leases determined to have a term of 12 months or less. Options to extend a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the operating lease liability is recorded at the present value of future lease payments over the expected remaining lease term using the discount rate implicit in the lease, if it is readily determinable, or the Company&#8217;s incremental borrowing rate. The right-of-use asset is measured as the lease liability and adjusted for prepaid rent, initial direct costs, and incentives. The Company's leases contain variable non-lease components such as maintenance, taxes, insurance, and similar costs for the spaces it occupies. For new and amended leases beginning in 2022 and after, the Company has elected the practical expedient not to separate these non-lease components of leases for classes of all underlying assets and instead account for them as a single lease component for all leases. The Company recognizes the net fixed payments of operating leases on a straight-line basis over the lease term. Variable executory costs, as it relates to net leases, are to be excluded from the calculation of the lease liability and the Company expenses the variable lease payments in the period in which it incurs the obligation to pay such variable amounts and will be included in variable lease costs in the leases footnote disclosure.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease payments are not included in the Company's calculation of its right-of-use assets or lease liabilities. Variable lease costs were immaterial for the year ended December&#160;31, 2022. The components of lease cost under ASC 842 for the year ended December&#160;31, 2022 are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:27.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline">Lease costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Statement of Operations Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses: research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses: general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">586,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information and weighted average remaining lease term and discount rate related to leases were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:69.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.433%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline">Other information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(584,429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term &#8212; operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate &#8212; operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future fixed lease payments for operating leases in effect as of December&#160;31, 2022, are payable as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:69.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.433%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Maturity of lease liabilities for the years ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the year ended December&#160;31, 2021 was $0.4 million in accordance with ASC 840.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228645771696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 16, 2022, the Company and Zephyr AI, Inc. (&#8220;Zephyr&#8221;) entered into a Joint Research Agreement (the &#8220;JRA&#8221;) focused on the joint collaboration, identification and validation of certain targets in order to facilitate further research, development and potential commercialization of immunotherapies. Zephyr is owned by a holding company with multiple Board members from the Company. The JRA term is two years unless mutually extended.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the JRA, Zephyr will identify suitable antigens or combinations thereof for validation and testing by NexImmune. The Joint Steering Committee (the &#8220;JSC&#8221;) provided for by the JRA will then determine which identified candidates shall be subject to further analysis. NexImmune will validate which, if any, of the identified antigens are suitable for T-cell engagement and killing function (the &#8220;Final Candidates&#8221;). The JSC will make a good-faith determination as to whether the data supports the further IND-targeted development by NexImmune of any of the Final Candidates. The Company and Zephyr will jointly own any Final Candidates, including the intellectual property related thereto. Each of the Company and Zephyr shall be responsible for payment of their own respective costs and expenses in connection with the performance of their respective obligations under the JRA. If a Final Candidate is to be further developed, then the Company and Zephyr shall engage in good-faith negotiations to agree on the terms and conditions of an agreement with respect to the further development and commercialization of such Final Candidate. If such an agreement is not executed within the prescribed negotiation period, then neither the Company nor Zephyr may further develop such Final Candidate. The expenses related to the JRA for the year ended December&#160;31, 2022 were not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641611072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn March 22, 2023, in order to retain and motivate employees and other key contributors of the Company, the board of directors approved a one-time stock option repricing (the &#8220;Option Repricing&#8221;). Pursuant to the Option Repricing, the exercise price of all of the below stock options to purchase shares of the Company&#8217;s common stock previously granted under our 2017 Equity Incentive Plan, 2018 Equity Incentive Plan and 2021 Equity Incentive Plan (the &#8220;Repriced Options&#8221;) will be amended as of April 4, 2023 (the &#8220;Effective Date&#8221;) to reduce the exercise prices of such options to a price equal to or greater than the closing price per share of the Company&#8217;s common stock on The Nasdaq Stock Market on the Effective Date (the &#8220;Nasdaq <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Market Price&#8221;), on the terms described below; provided, however, that if the closing price per share on the Effective Date is less than $0.40, the Nasdaq Market Price will be deemed to be $0.40 for purposes of the Option Repricing:</span></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.567%"><tr><td style="width:1.0%"/><td style="width:32.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.801%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Repriced Options</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Terms of Repriced Options vested or vesting within six months following the Effective Date </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Terms of Repriced Options vesting more than six months following the Effective Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All options held by employees other than our executive officers, in good standing on the Effective Date</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to 2.5 times the Nasdaq Market Price </span></div></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to the Nasdaq Market Price</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All options held by our current executive officers and 100,000 options held by Jerome Zeldis, our former EVP and Head of Research &amp; Development</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to 3.0 times the Nasdaq Market Price</span></div></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to 2.0 times the Nasdaq Market Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All options held by our directors</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to 4.0 times the Nasdaq Market Price</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Option Repricing exercise price will be equal to 3.0 times the Nasdaq Market Price</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On March 23, 2023, Jerome Zeldis, M.D., Ph.D., Executive Vice President of Research and Development, entered into a Consulting Agreement with the Company (the &#8220;Consulting Agreement&#8221;) effective as of March 31, 2023 (the &#8220;Transition Date&#8221;).  Pursuant to the Consulting Agreement and effective as of the Transition Date, the exiting Employment Agreement, dated January 4, 2021, by and between the Company and Dr. Zeldis is terminated, Dr. Zeldis will have resigned from the Company, and Dr. Zeldis will transition to providing consulting and advisory services to the Company for a period ending on March 31, 2024 (the &#8220;Consulting Period&#8221;).  Pursuant to the terms of the Consulting Agreement, in consideration for, among other things, his compliance with certain restrictive covenants, including customary non-compete and non-solicitation covenants, and a typical release of claims, Dr. Zeldis will be paid $200 per hour for services provided to the Company and vested options to purchase 100,000 shares of common stock of the Company held by Dr. Zeldis (a portion of the grant received by Dr. Zeldis on February 11, 2021) are eligible to participate in the Option Repricing (as defined above), with the exercise price for such options reduced to the level set for executive officers.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228642927536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements - Going Concern ("ASC 205-40"), requires management to assess the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements are issued. Under ASC 205-40, management has the responsibility to evaluate whether conditions and/or events raise substantial doubt about the Company&#8217;s ability to meet future financial obligations as they become due within one year after the date that the financial statements are issued. As required by this standard, management&#8217;s evaluation shall initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring operating losses and negative cash flows from operations. The financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had an accumulated deficit of $190.2 million, negative cash flows from operating activities for the period ended December&#160;31, 2022, and significant ongoing research and development expenses. While we have no outstanding debt and $34.6 million in cash and cash equivalents as of December&#160;31, 2022, the Company expects its negative cash flows from operating activities to continue and thus has determined that its losses and negative cash flows from operations and uncertainty in generating sufficient cash to meet our obligations and sustain our operations raise substantial doubt about the Company&#8217;s ability to continue as a going concern for at least one year from the issuance date of these financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s research and development activities mature and develop over the next year, the Company will likely require substantial funds to continue such activities, depending upon events that are difficult to predict at this time. In this regard, management plans to raise additional capital through financing activities that may include public offerings and private placements of its common stock, preferred stock offerings, collaborations and licensing arrangements and issuances of debt and convertible debt instruments. In the absence of additional capital, the Company plans to strategically manage its uncommitted spend, execute its priorities and implement cost saving measures to reduce research and development and general and administrative expenditures which could include minimizing staff costs and delaying or terminating manufacturing and clinical trial costs.</span></div>There are inherent uncertainties associated with fundraising activities and activities to manage the Company&#8217;s uncommitted spending and the successful execution of these activities may not be within the Company&#8217;s control. There are no assurances that such additional funding will be obtained and that the Company will succeed in its future operations. If the Company cannot successfully raise additional capital, its liquidity, financial condition and business prospects will be materially and adversely affected. The Company is continually looking into further capital planning and the evaluation of strategic alternatives. There is substantial doubt about the Company&#8217;s ability to continue as a going concern.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Updates (&#8220;ASU&#8221;) of the FASB.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the recoverability of long-lived assets, stock-based compensation, the valuation of financial instruments, and the valuation of deferred tax assets and liabilities. The Company&#8217;s estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Although actual results could differ from those estimates, management does not believe that such differences would be material.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to credit risk consist principally of cash and marketable debt securities. All cash is held in United States financial institutions that are federally insured. At times, the Company may maintain cash balances in excess of the federally insured amount. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk. The Company&#8217;s investments in marketable debt securities have been issued by corporate entities and government-sponsored enterprises with high credit ratings. The Company mitigates investment risks by investing in highly-rated securities with relatively short maturities that the Company believes do not subject it to undue investment or credit risk. If any of these financial institutions fail to perform their obligations under the terms of these financial instruments, the Company&#8217;s maximum exposure to potential losses would be equal to the amounts reported on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and geographic information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographic Information</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three </span></div>months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities with maturities greater than three months from the date of purchase that include commercial paper and corporate notes. Classification of marketable securities between current and&#160;non-current&#160;is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. There were no outstanding marketable securities as of December&#160;31, 2022. As of December&#160;31, 2021, all marketable securities were classified as current.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and dividend income are recorded when earned and included in interest income in the statement of operations. Premiums and discounts, if any, on marketable securities are amortized or accreted to maturity and included in interest income in the statement of operations. The specific identification method is used in computing realized gains and losses on the sale of the Company&#8217;s marketable securities.</span></div>The Company classifies its marketable securities as&#160;available-for-sale.&#160;The Company determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date.&#160;Marketable securities that are classified as&#160;available-for-sale&#160;are measured at fair value on the balance sheet, and unrealized gains and losses on marketable securities are reported as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity (deficit) until realized. Marketable securities are evaluated periodically to determine whether the carrying value of a marketable security exceeds its fair value and the decline in value is determined to be other-than-temporary. Management reviews criteria, such as the general market conditions, magnitude and duration in which the fair value has been less than the carrying value, the investment issuer&#8217;s financial condition and business outlook, as well as the Company&#8217;s ability to hold the securities until the recovery of its amortized cost basis, to determine whether the decline in value is other-than-temporary. If a decline in value is determined to be other-than-temporary, the value of the marketable security is reduced, and the impairment is recorded as other expense in the statement of operations. As of December&#160;31, 2021, any decline in value of marketable securities was concluded not to be other-than-temporary. As of December&#160;31, 2022, no assessment was required.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, marketable securities, accounts payable, accrued expenses, convertible notes and derivative liabilities. The fair values of the cash and cash equivalents, accounts payable and accrued expenses approximated their carrying values as of December&#160;31, 2022 and 2021, due to their short-term maturities. For a description of the fair value of marketable securities, refer to Note 4. The Convertible Notes as discussed in Note 10 contained embedded derivative features that were required to be bifurcated and remeasured to fair value at each reporting period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, Fair Value Measurements (&#8220;ASC 820&#8221;). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt">Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt">Fair value is determined by using inputs, other than Level&#160;1 quoted prices that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt">Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant judgments to be made by a reporting entity.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation and amortization. Major replacements and improvements that extend the useful lives of assets are capitalized, while general repairs and maintenance are charged to expense as incurred. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the related lease term, whichever is shorter. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property, plant and equipment by major category are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of its long-lived asset group for potential impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoverability is determined by comparing future undiscounted cash flows associated with such assets to the related carrying value. An impairment loss may be recognized when the estimated undiscounted future cash flow is less than the carrying amount of the asset. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured as the amount by </span></div>which the carrying value of the asset group exceeds the fair value of the asset group.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_TemporaryEquityPolicyPolicyTextBlock', window );">Redeemable convertible preferred stock</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable convertible preferred stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s redeemable convertible preferred stock was classified outside of stockholders&#8217; equity because the shares contained deemed liquidation rights that represented a contingent redemption feature not solely within the control of the Company.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Convertible instruments and embedded derivatives</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible instruments and embedded derivatives</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that contain conversion options and other embedded features. The Company bifurcates embedded features from their host instruments and accounts for them as free-standing derivative financial instruments according to certain criteria.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any change to the Company&#8217;s debt arrangements, the Company evaluates the amendment to determine whether a debt modification or extinguishment has occurred, including whether the amendment should be accounted for as a troubled debt restructuring.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s derivative instrument related to certain features embedded within the Company&#8217;s Convertible Notes as discussed in Note 10. The derivative was accounted for as a derivative liability and remeasured to fair value as of each balance sheet date. The related remeasurement adjustments are recognized in the accompanying statements of operations and were settled upon the conversion of the Convertible Notes during the year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including share-based compensation, as well as costs for third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, based on its estimates of services performed and costs incurred. These estimates include the level of services performed by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock', window );">Clinical trial and contract development and manufacturing organization expenses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial and contract development and manufacturing organization expenses </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes payments in connection with clinical trials and contract development and manufacturing organizations (&#8220;CDMO&#8221;) under contracts with contract research organizations that support conducting and managing clinical trials and the manufacturing of materials utilized in clinical and preclinical activities. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of the obligation to make payments under these contracts depends on factors such as the successful enrollment, treatment of patients, the completion of other clinical trial milestones, or completion of manufacturing milestones. Termination clauses within the agreements require notification for a certain number of days prior to completing work, payments for costs incurred through the termination date, and termination penalty, if applicable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Expenses related to development and manufacturing are accrued based on estimates and/or representations from service providers regarding work performed, including progress in the development of processes through technology transfers to manufacture the Company&#8217;s clinical material and completion of the manufactured clinical material. Other incidental costs related to patient enrollment or </span></div>treatment are accrued when reasonably certain. If the amounts the Company is obligated to pay under clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records compensation expense associated with stock options and other forms of equity compensation based on the estimated fair value at the grant date. Compensation expense related to awards to employees and non-employees with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the requisite service period of the award, which is generally the vesting term. The Company&#8217;s policy is to account for forfeitures as they occur. The Company uses the Black-Scholes-Merton option pricing (Black-Scholes) model to estimate the fair value of stock options. The Black-Scholes model requires input-based assumptions that are highly subjective, judgmental and sensitive in the determination of stock-based compensation cost.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted after the Company&#8217;s IPO are issued at the fair market value of the Company&#8217;s common stock at the date the grant is approved by the Board.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected volatility was based on the historical volatility of comparable public companies from a representative peer group selected based on industry and market capitalization data. The historical volatility is calculated based on a period of time commensurate with the expected term assumption.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate was based on the continuous rates provided by the U.S. Treasury with a term approximating the expected term of the option.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected dividend yield was 0% because the Company has not historically paid and does not expect to pay any dividends for the foreseeable future.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based-Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes it is&#160;more-likely-than-not&#160;that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results,&#160;on-going&#160;tax planning and forecasts of future taxable income on a&#160;jurisdiction-by-jurisdiction&#160;basis. The Company recorded a valuation allowance against all estimated net deferred tax assets as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered&#160;more-likely-than-not&#160;to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Recognized income tax positions are measured at the largest amount that is greater than&#160;more-likely-than-not&#160;of being realized. Changes in the recognition or measurement are reflected in the period in </span></div>which the change in estimate occurs. Interest and penalties related to uncertain tax positions are recorded in the provision of income taxes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share attributable to common stockholders</a></td>
<td class="text">Net Loss Per Share Attributable to Common StockholdersBasic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock and common stock equivalents outstanding for the period. The Company adjusts net loss to arrive at the net loss attributable to common stockholders to reflect the amount of dividends accumulated during the period on the Company&#8217;s redeemable convertible preferred stock. Such dividends are only payable if and when declared by the Board of Directors (Note 11). The treasury stock method is used to determine the dilutive effect of the Company&#8217;s stock option grants and warrants and the&#160;if-converted&#160;method is used to determine the dilutive effect of the Company&#8217;s redeemable convertible preferred stock and Convertible Notes. For the years ended December&#160;31, 2022 and 2021, the Company had a net loss attributable to common stockholders, and as such, all outstanding stock options, shares of redeemable convertible preferred stock, and warrants were excluded from the calculation of diluted loss per share. Under the if-converted method, convertible instruments that are in the money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of bifurcated derivatives is added back to the numerator of the diluted net loss per share calculation if the conversion of the Convertible Notes is dilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting standards and pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting standards and pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as subsequently amended (collectively &#8220;ASC 842&#8221;). The guidance amends the existing accounting standards for lease accounting, including requirements for lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expanding disclosure requirements regarding leasing arrangements. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting ASC 842 in which entities can elect to apply the new guidance using a modified retrospective approach at the beginning of the year in which the new lease standard is adopted. In November 2019, the FASB issued ASU 2019-10 deferring the effective date for private entities for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the FASB issued ASU 2020-05 which further defers the effective date for private entities for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As an EGC, the Company adopted the new leasing guidance on January 1, 2022. The Company combined lease and non-lease components as a single component for all underlying asset classes. ASC 842 provides a number of optional practical expedients in transition. The Company applied the &#8216;package of practical expedients&#8217; which allows the Company to not reassess i) whether existing or expired arrangements contain a lease, ii) the lease classification of existing or expired leases, or iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. The Company completed its evaluation and recognized $1.5 million in operating right-of-use assets and $0.6 million and $1.0 million in operating lease liabilities, current and non-current, respectively, on January 1, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU&#160;2016-13,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for&#160;available-for-sale&#160;debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for fiscal year beginning after December&#160;15, 2022, and interim periods beginning after December&#160;15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company&#8217;s investment portfolio, current market conditions and historical credit loss activity, the adoption of ASU&#160;2016-13&#160;is not expected to have a material impact on its financial position, results of operations or the related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial, Contract Development, and Manufacturing Organization Expenses, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_SubstantialDoubtForGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Substantial Doubt For Going Concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_SubstantialDoubtForGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_TemporaryEquityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_TemporaryEquityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228646253568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of cash, cash equivalents, and restricted cash</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,642,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,326,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,697,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,393,852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of estimated useful lives of property, plant and equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property, plant and equipment by major category are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following at December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,803,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,688,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,708,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,229,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,281,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,459,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of basic and diluted earnings per share</a></td>
<td class="text">The following table sets forth the computation of basic and diluted earnings per share for the years ended December&#160;31, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,506,199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,901,508)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated dividends on Redeemable Convertible Preferred Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(377,562)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,506,199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,279,070)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.60)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.54)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,059,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,186,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of antidilutive securities outstanding</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following potentially dilutive securities have been excluded from the computation of diluted weighted average common shares outstanding at December&#160;31, 2022 and 2021, as the effect would be anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,523,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,976,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641552672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value assets and liabilities measured on recurring basis</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,722,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,979,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,991,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,722,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,979,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124,003&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,991,897&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228640802528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of prepaid expenses and other current assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following at December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,375,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid maintenance agreements</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,394,916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641567760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated useful lives of property, plant and equipment by major category are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following at December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,803,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,943,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,688,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,708,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,229,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,281,041)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,459,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228644878272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Charges Related to Restructuring Activities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges related to the restructuring activities as of December&#160;31, 2022. There were no restructuring expenses during the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:26.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.485%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued Restructuring Expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accrued Restructuring Expenses</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less: Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance, benefits and related costs due to workforce reduction</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,440)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Totals</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531,829&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149,440)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,389&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641567760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of the components of accrued expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the components of accrued expenses is as follows as of December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,210,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued salaries, benefits and related expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,855,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,357,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,170,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228644974176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of stock-based compensation expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense was recorded in the following financial statement line items within the statement of operations for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,057,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,870,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,979,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of option activity under the Company&#8217;s Stock Option Plans:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value (millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January&#160;1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,305,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,701)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349,267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965,502&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested or expected to vest as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,965,502&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,852,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares unvested as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of black-scholes option pricing model</a></td>
<td class="text">The options were valued using the Black-Scholes option-pricing model for the years ended December&#160;31, 2022 and 2021 with the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.6% to 83.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7% to 81.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%&#160;to&#160;3.80%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5%&#160;to&#160;1.40%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;to&#160;6.1 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;to&#160;6.1 years</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Summary of RSU activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of RSU activity for the 2021 Plan for the year ended December&#160;31, 2022:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.233%"><tr><td style="width:1.0%"/><td style="width:63.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.881%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.486%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of restricted units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested and outstanding  as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641676192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision for income taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s provision for income taxes consists of the following for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax provision:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax benefit:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,339,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,606,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,370,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,969,433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,898,469&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,969,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,898,469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision (benefit) for income taxes</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory U.S. income tax rate to the effective income tax rate as of December&#160;31, 2022 and 2021 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal statutory rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company&#8217;s deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,477,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,758,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,838,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,316,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,249,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,857,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,886,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458,533)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363,427)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228640673600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Cost</a></td>
<td class="text">The components of lease cost under ASC 842 for the year ended December&#160;31, 2022 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:27.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline">Lease costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Statement of Operations Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses: research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses: general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">586,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Cash Flow, Supplemental Disclosures</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information and weighted average remaining lease term and discount rate related to leases were as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:69.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.433%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline">Other information</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;&#160;&#160;Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(584,429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average remaining lease term &#8212; operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted-average discount rate &#8212; operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Fixed Lease Payments</a></td>
<td class="text">Future fixed lease payments for operating leases in effect as of December&#160;31, 2022, are payable as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:69.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.433%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Maturity of lease liabilities for the years ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228639528432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the Business (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (190,249,654)<span></span>
</td>
<td class="num">$ (127,743,455)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,642,340<span></span>
</td>
<td class="nump">$ 30,326,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228640682000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Investment positions in marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accruals related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax penalties and interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">967,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease, liability, current</a></td>
<td class="num">(599,047)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, non-current</a></td>
<td class="num">$ (425,766)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative effect of adoption of accounting standard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease, liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228640919200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Restricted Cash and Cash Equivalents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,642,340<span></span>
</td>
<td class="nump">$ 30,326,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">$ 34,697,340<span></span>
</td>
<td class="nump">$ 30,393,852<span></span>
</td>
<td class="nump">$ 5,098,579<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228642929616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Useful Lives of Property Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228642818880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Basic and Diluted Earnings Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (62,506,199)<span></span>
</td>
<td class="num">$ (50,901,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDividendsAdjustment', window );">Accumulated dividends on Redeemable Convertible Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(377,562)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(62,506,199)<span></span>
</td>
<td class="num">(51,279,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (62,506,199)<span></span>
</td>
<td class="num">$ (51,279,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss attributable to common stockholders per common share (in dollars per share)</a></td>
<td class="num">$ (2.60)<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss attributable to common stockholders per common share (in dollars per share)</a></td>
<td class="num">$ (2.60)<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">24,059,104<span></span>
</td>
<td class="nump">20,186,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average number of common shares outstanding (in shares)</a></td>
<td class="nump">24,059,104<span></span>
</td>
<td class="nump">20,186,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDividendsAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDividendsAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228643240864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">5,523,502<span></span>
</td>
<td class="nump">4,976,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">3,965,502<span></span>
</td>
<td class="nump">3,305,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">1,558,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,164,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">506,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228642120016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) - Recurring basis - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 23,722,328<span></span>
</td>
<td class="nump">$ 22,124,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">23,722,328<span></span>
</td>
<td class="nump">22,124,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Fixed income debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fixed income debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">7,979,279<span></span>
</td>
<td class="nump">56,991,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Fixed income debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fixed income debt securities</a></td>
<td class="nump">7,979,279<span></span>
</td>
<td class="nump">56,991,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Fixed income debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fixed income debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_FixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228642119888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses And Other Current Assets - Summary of Prepaid Expenses And Other Current Assets (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="nump">$ 1,176,491<span></span>
</td>
<td class="nump">$ 3,375,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_PrepaidMaintenanceAgreements', window );">Prepaid maintenance agreements</a></td>
<td class="nump">369,606<span></span>
</td>
<td class="nump">132,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">403,653<span></span>
</td>
<td class="nump">479,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">245,278<span></span>
</td>
<td class="nump">308,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">74,467<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">401,916<span></span>
</td>
<td class="nump">99,189<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 2,671,411<span></span>
</td>
<td class="nump">$ 4,394,916<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_PrepaidMaintenanceAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid maintenance agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_PrepaidMaintenanceAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228640747616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property And Equipment (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">$ 7,688,663<span></span>
</td>
<td class="nump">$ 6,708,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(3,229,592)<span></span>
</td>
<td class="num">(2,281,041)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,459,071<span></span>
</td>
<td class="nump">4,427,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">6,803,996<span></span>
</td>
<td class="nump">5,943,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">516,974<span></span>
</td>
<td class="nump">486,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">47,877<span></span>
</td>
<td class="nump">47,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">$ 319,816<span></span>
</td>
<td class="nump">$ 230,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nexi_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228644794112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 994,792<span></span>
</td>
<td class="nump">$ 870,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228639905216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Activities (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,389<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in headcount, percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations', window );">Number of positions before eliminations | employee</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations', window );">Number of positions after eliminations | employee</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring, expected cost</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,389<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring, incurred cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag', window );">Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">costs associated with the restructuring<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,389<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,389<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Cost, Expected Number Of Positions Eliminated, Period Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Cost, Number Of Positions, After Eliminations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Cost, Number Of Positions, Before Eliminations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228643147296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Activities - Summary of Charges Related to Restructuring Activities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued Restructuring Expenses, beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses</a></td>
<td class="nump">531,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Less: Payments</a></td>
<td class="num">(149,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued Restructuring Expenses, ending balance</a></td>
<td class="nump">382,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued Restructuring Expenses, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expenses</a></td>
<td class="nump">531,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Less: Payments</a></td>
<td class="num">(149,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrued Restructuring Expenses, ending balance</a></td>
<td class="nump">$ 382,389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228642095920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Components of Accrued Expenses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">$ 3,210,794<span></span>
</td>
<td class="nump">$ 2,611,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">267,383<span></span>
</td>
<td class="nump">384,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued salaries, benefits and related expenses</a></td>
<td class="nump">3,855,797<span></span>
</td>
<td class="nump">3,143,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">23,179<span></span>
</td>
<td class="nump">31,473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 7,357,153<span></span>
</td>
<td class="nump">$ 6,170,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228639954304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information, Maryland Biotechnology Center Grant (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 23, 2013</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 23, 2012</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development arrangement contract to perform for others compensation earned</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nexi_MarylandBiotechnologyCenterMember', window );">Maryland Biotechnology Center | Translational Research Award Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability', window );">Research and development arrangement contract to perform for others liability</a></td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage', window );">Research and development arrangement annual payment percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod', window );">Research and development arrangement contractual payment period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage', window );">Research and development arrangement, contractual payment percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from contract with customer, including assessed tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement Annual Payment Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development arrangement contract to perform for others liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development arrangement contractual payment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development arrangement contractual payment period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nexi_MarylandBiotechnologyCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nexi_MarylandBiotechnologyCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nexi_TranslationalResearchAwardAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nexi_TranslationalResearchAwardAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228638681392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information, Johns Hopkins University Exclusive License Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nexi_JohnsHopkinsUniversityMember', window );">Johns Hopkins University | Exclusive License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_MilestoneFees', window );">Milestone fees</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_MinimumAnnualRoyaltyPayments', window );">Minimum annual royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_SublicenseConsiderationPaymentPercentMaximum', window );">Sublicense consideration payment, maximum percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_CumulativeMinimumRoyalties', window );">Cumulative minimum royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nexi_JohnsHopkinsUniversityMember', window );">Johns Hopkins University | Exclusive License Agreement | Clinical Trial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_MilestoneFees', window );">Milestone fees</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nexi_JohnsHopkinsUniversityMember', window );">Johns Hopkins University | Exclusive License Agreement | Therapeutic Field</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_MilestoneFees', window );">Milestone fees</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nexi_JohnsHopkinsUniversityMember', window );">Johns Hopkins University | Exclusive License Agreement | Regulatory and Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_MilestoneFees', window );">Milestone fees</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nexi_JohnsHopkinsUniversityMember', window );">Johns Hopkins University | Exclusive License Agreement | Non-clinical field</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_MilestoneFees', window );">Milestone fees</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_CumulativeMinimumRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative minimum royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_CumulativeMinimumRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_MilestoneFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_MilestoneFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_MinimumAnnualRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum annual royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_MinimumAnnualRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_SublicenseConsiderationPaymentPercentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicense Consideration Payment, Percent, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_SublicenseConsiderationPaymentPercentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nexi_JohnsHopkinsUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nexi_JohnsHopkinsUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nexi_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nexi_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_MilestonesAxis=nexi_ClinicalTrialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_MilestonesAxis=nexi_ClinicalTrialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_MilestonesAxis=nexi_TherapeuticFieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_MilestonesAxis=nexi_TherapeuticFieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_MilestonesAxis=nexi_RegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_MilestonesAxis=nexi_RegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_MilestonesAxis=nexi_NonclinicalFieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_MilestonesAxis=nexi_NonclinicalFieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228640033536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information, Paycheck Protection Program Loan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Apr. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Gain on extinguishment of debt from forgiveness of PPP Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 843,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 843,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=nexi_PaycheckProtectionProgramLoanMember', window );">Paycheck Protection Program Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 843,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Gain on extinguishment of debt from forgiveness of PPP Loan</a></td>
<td class="nump">$ 843,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=nexi_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=nexi_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228639007456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Transition adjustment recorded in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,300,484<span></span>
</td>
<td class="nump">$ 83,760,667<span></span>
</td>
<td class="num">$ (69,374,941)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Transition adjustment recorded in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190,249,654)<span></span>
</td>
<td class="num">(127,743,455)<span></span>
</td>
<td class="num">(77,582,005)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Transition adjustment recorded in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,547,530<span></span>
</td>
<td class="nump">211,498,827<span></span>
</td>
<td class="nump">8,206,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative effect of adoption of accounting standard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Transition adjustment recorded in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,537,274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative effect of adoption of accounting standard | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Transition adjustment recorded in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">740,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative effect of adoption of accounting standard | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Transition adjustment recorded in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="num">$ (2,277,332)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_DebtInstrumentAdditionalClosingLockInPeriod', window );">Additional closing period (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">190 days<span></span>
</td>
<td class="text">150 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_DebtInstrumentConvertiblePricePercentage', window );">Convertible note price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_DebtInstrumentFullyDilutedCapitalization', window );">Convertible note fully diluted capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Convertible note redemption price, percentage of principal amount redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_DebtInstrumentRedemptionAmount', window );">Convertible note redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance', window );">Fair value of derivative liability of convertible notes at issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes', window );">Fair value of derivative liability of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_DebtDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_DebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes outstanding converted into common stock (in shares)</a></td>
<td class="nump">3,669,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts', window );">Convertible notes outstanding, net of unamortized discounts, reclassified to stockholders' equity</a></td>
<td class="nump">$ 30,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt conversion converted instrument net of amortization of debt discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_DebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_DebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_DebtInstrumentAdditionalClosingLockInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, additional closing lock in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_DebtInstrumentAdditionalClosingLockInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_DebtInstrumentConvertiblePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, convertible, price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_DebtInstrumentConvertiblePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_DebtInstrumentFullyDilutedCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument fully diluted capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_DebtInstrumentFullyDilutedCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_DebtInstrumentRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, redemption amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_DebtInstrumentRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_DebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_DebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of derivative liability of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Derivative Liability Of Convertible Notes At Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228639600528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of transaction costs</a></td>
<td class="nump">$ 114,551,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,145,409<span></span>
</td>
<td class="nump">$ 114,551,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Authorized preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Beneficial conversion feature</a></td>
<td class="nump">$ 31,272,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes outstanding converted into common stock (in shares)</a></td>
<td class="nump">3,669,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nexi_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_SaleOfStockAggregateOfferingApproval', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_SaleOfStockCommissionPercentage', window );">Commission percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,184,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Redeemable convertible preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Converted common stock (in shares)</a></td>
<td class="nump">10,144,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of transaction costs (in shares)</a></td>
<td class="nump">7,441,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price (in dollars per share)</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nexi_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Converted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A redeemable preferred stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_SaleOfStockAggregateOfferingApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Aggregate Offering Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_SaleOfStockAggregateOfferingApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_SaleOfStockCommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Commission Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_SaleOfStockCommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nexi_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nexi_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nexi_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nexi_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228639014912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Mar. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,757,556<span></span>
</td>
<td class="nump">1,741,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of the options granted (in dollars per share)</a></td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="nump">$ 11.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of stock options vested</a></td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,439,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense period for recognition</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense period for recognition</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nexi_TwoThousandSeventeenEquityIncentivePlanMember', window );">The 2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nexi_TwoThousandEighteenEquityIncentivePlanMember', window );">The 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,809,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nexi_The2021PlanMember', window );">The 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock', window );">Percentage of outstanding stock maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Increase In Authorized Shares by Percentage of Outstanding Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nexi_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nexi_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nexi_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nexi_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nexi_The2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nexi_The2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228639974672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Based Compensation Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,870,364<span></span>
</td>
<td class="nump">$ 5,979,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">3,812,441<span></span>
</td>
<td class="nump">2,918,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,057,923<span></span>
</td>
<td class="nump">$ 3,061,474<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641982416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Option Activity (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of restricted units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of beginning of period (in shares)</a></td>
<td class="nump">3,305,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,628,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(362,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(255,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(349,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of end of period (in shares)</a></td>
<td class="nump">3,965,502<span></span>
</td>
<td class="nump">3,305,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest by period end (in shares)</a></td>
<td class="nump">3,965,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of period end (in shares)</a></td>
<td class="nump">1,852,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares unvested as of period end (in shares)</a></td>
<td class="nump">2,113,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of beginning of period (in dollars per share)</a></td>
<td class="nump">$ 9.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">3.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">8.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">15.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of end of period (in dollars per share)</a></td>
<td class="nump">7.38<span></span>
</td>
<td class="nump">$ 9.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest as of end of period (in dollars per share)</a></td>
<td class="nump">7.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of end of period (in dollars per share)</a></td>
<td class="nump">8.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Shares unvested as of end of period (in dollars per share)</a></td>
<td class="nump">$ 6.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_WeightedAverageRemainingContractualTermInYearsAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding as of end of period (in years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest as of end of period (in years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable as of end of period (in years)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1', window );">Shares unvested as of end of period (in years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding as of December&#160;31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested or expected to vest as of December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable as of December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue', window );">Shares unvested as of December&#160;31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Outstanding Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Options Non Vested Outstanding Weighted Average Remaining Contractual Term1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_WeightedAverageRemainingContractualTermInYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term (in years)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_WeightedAverageRemainingContractualTermInYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228639922592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility</a></td>
<td class="nump">78.60%<span></span>
</td>
<td class="nump">78.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility</a></td>
<td class="nump">83.20%<span></span>
</td>
<td class="nump">81.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228642093904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSU Activity (Details) - Restricted stock units<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of restricted units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">1,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (dollars per share) | $ / shares</a></td>
<td class="nump">0.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense | $</a></td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense period for recognition</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228639509248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision For Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current income tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred income tax benefit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">12,339,546<span></span>
</td>
<td class="nump">10,606,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(7,370,113)<span></span>
</td>
<td class="nump">3,291,842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">4,969,433<span></span>
</td>
<td class="nump">13,898,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Change in valuation allowance</a></td>
<td class="num">(4,969,433)<span></span>
</td>
<td class="num">(13,898,469)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641697200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.17%<span></span>
</td>
<td class="nump">6.52%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(0.58%)<span></span>
</td>
<td class="num">(0.13%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(0.02%)<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in state tax rate</a></td>
<td class="num">(12.61%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(7.96%)<span></span>
</td>
<td class="num">(27.41%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228636005520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 28,477,866<span></span>
</td>
<td class="nump">$ 31,758,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">575,883<span></span>
</td>
<td class="nump">701,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,913,771<span></span>
</td>
<td class="nump">1,445,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">291,022<span></span>
</td>
<td class="nump">291,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">7,838,512<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_DeferredTaxAssetsOperatingLeases', window );">Operating leases</a></td>
<td class="nump">216,925<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">52,751<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">39,316,001<span></span>
</td>
<td class="nump">34,249,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(38,857,468)<span></span>
</td>
<td class="num">(33,886,096)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income tax assets</a></td>
<td class="nump">458,533<span></span>
</td>
<td class="nump">363,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">ROU assets</a></td>
<td class="num">(204,694)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="num">(253,839)<span></span>
</td>
<td class="num">(363,427)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(458,533)<span></span>
</td>
<td class="num">(363,427)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_DeferredTaxAssetsOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_DeferredTaxAssetsOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228640019456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accruals related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_DeferredTaxAssetValuationAllowancePercent', window );">Valuation allowance</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 135,200,000<span></span>
</td>
<td class="nump">$ 115,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">$ 124,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_DeferredTaxAssetValuationAllowancePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Valuation Allowance, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_DeferredTaxAssetValuationAllowancePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228646255712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Cost (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 586,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">379,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 207,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228639960112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Cash Flow, Supplemental Disclosures (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="num">$ (584,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term &#8212; operating leases</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate &#8212; operating leases</a></td>
<td class="nump">6.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228635857712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Future Fixed Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 617,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, to be Paid, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,087,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,024,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228641980400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 22, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,965,502<span></span>
</td>
<td class="nump">3,305,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold', window );">Closing share price minimum threshold (dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Affiliated Entity | Jerome Zeldis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_RelatedPartyTransactionHourlyRate', window );">Severance cost, hourly rate (in dollars) | $</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Executive Officer | Jerome Zeldis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Share-Based Payment Arrangement, Tranche One | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple', window );">Repricing multiple</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Share-Based Payment Arrangement, Tranche One | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple', window );">Repricing multiple</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Share-Based Payment Arrangement, Tranche One | Employees, Excluding Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple', window );">Repricing multiple</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Share-Based Payment Arrangement, Tranche Two | Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple', window );">Repricing multiple</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Share-Based Payment Arrangement, Tranche Two | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple', window );">Repricing multiple</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_RelatedPartyTransactionHourlyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Hourly Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_RelatedPartyTransactionHourlyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Option, Repricing, Closing Share Price Minimum Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nexi_ShareBasedPaymentArrangementOptionRepricingMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Option, Repricing Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nexi_ShareBasedPaymentArrangementOptionRepricingMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nexi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nexi_JeromeZeldisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nexi_JeromeZeldisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nexi_EmployeesExcludingExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nexi_EmployeesExcludingExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228728316688">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>nexi-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nexi="http://nex.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nexi-20221231.xsd" xlink:type="simple"/>
    <context id="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i373e3231b3f840a68e2e1b764ca2c76a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ife75d305cc1f4ff48462a16aa940d5bb_I20230301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="ia325791ead244863998b1f8f312ad14c_I20210211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="i3cfc586d3ef2479899da6a9e51989ddb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea9cb688d3fe4d64b5fd77adc7e14243_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i37d7504e32234f1795742c55cbc6b155_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff21ea6215e44aaf8825b8629943e25d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesATwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied4b640b66f4431e8a9ab05b2c296a7c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesAThreeRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5ee39eb5c7c429d8d549dd5e1664fe4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7c755cb14bd427e8793ab33dac3fd7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie510bed0d8e14fc599909e739c5e7d89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6dca16917b304e32b75b202c42131f15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida3374a79ddc4d3cb5ad2f1dc1e8a42a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81a07e7e0c0f4c6086be99b99cd79cdc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b987d568d844b0b874f7c2bca5b1c71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02d7650fa3c34b7c9124b8138bfa5e7c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i323e4338ce04403fb958b956a6ebd5c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54f8c709c7614cd892e0ff95fd765294_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c885db91fa648a29884e7d59755d5ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesATwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i362e074aa71542d3be5f2ac89ce168f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesAThreeRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifcf18312a9b849779921e6320f8c96e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3d72f5c306cd45b3a45cc5043d61410b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i245c6670d41d42a9b3fa719e42f16d0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbbf1a64b75d4fce82cd179c3bd44da8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesATwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44b3409c2a62435692c6df71b1354eaa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesAThreeRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i736ffb84dab44fb0b3e163c0502409b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52a135ff906f46e9bab66d63a940f8e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia891e7526d504d8fadb55664f61f3e46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0445e2ff34a46f185f60587d785bf3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i79d26598eacc4a57ba2e44555e59db4b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i82f02bb4e976485b911d7b3e40c78b45_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i087599b8fe8e4804833ffb19d54c95d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc09a4b59e0b4de088c1ee9a6f9b937b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23dd0eac814249f3a9f87f2d470e24a0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2f44e04246d4f92ae9eaa55d8242626_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i87575f3a4a8d47e0b099f6f2d5697f3c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5ae3ce8c146e4b3a8647cdb069d847f0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib14beae652b44f86850981cbd7bea2fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9cf8573a7849487689779272da2d03b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic3ec5ac6a0fb4bc1994df10d0b09682c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieb99aa2cda304c0e9bea4f6fc09c71fa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i174925bbb76f4a498cf99885a1362415_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec5ab7a1dbd54ea8861c3ef82c751c0b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i791c94e47b51427dbee42f8cc8773959_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4a0838ebfff413db2e9ad8c231fef39_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia4f8973765ad4bc8be9332ad3594c082_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i074eae8be4554fceb16fac6998ae3c9a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4ba9051f6c594a37b6e8e5e56c95af66_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieca80fa7685c4607ad5fef70aa7ce16e_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i403fdc2b033c4c1b88c48004e7a37ed6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b550a9ae7a2446e8c50991ec5a09571_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic044d50d4b384932ab18201e6f0b8da8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie253db02491d4a9fb3f8cad4afeb89c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a167d620d684558850204ae675e061c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02e707e70eb144e8a9764dbe72b5e376_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9482c390e2874f69bdd95e842f27cb9a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i294000fb786942f083924e218896237f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia62f066291d846ab9d346921a55d6947_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i25ad398f6533421f95d670a14ced26ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4421505cb3f46938fada27cf31ab63a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i403ec125cb5f41cb813253079b7b88b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2e473ef2ced4a76af90569c4e60acd9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebce9dddcdbc4c0aa95432c1635a3c49_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib1965187e11b4cd7be206e7c49075e52_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24e448c466c94c3bbfea9fb4d64de651_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ffac7d5bf164513a7108afdd83a49dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c5920ce6d144e6ca4a4780bbb323bfb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4ed377902824f8ba0190be0190253f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i906f22664a64466f86557348630d1046_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d5098de97364db3825058bb650872b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icaa2d70a7c5a44e0b33c4306131e12a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nexi:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec4224fbcf36436d982945a277e0bbaf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16f5c36a4c3e45f1bbeaada8cda374f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8a0b0ffb5bd4c57ab7546cae1b3e6f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i53fe34a4932b4e8087a347be3b55c58e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c590145da4b44288c802fc50a344e72_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="ie321f805cc7f4133a42ae2ffef7ab78f_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="ie19a45c8600b4fbba9f92e595547ba14_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe540e5b2e574273bb15fd4fe0b096b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97ccdc3f285040bd876d4fa408564bf9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icbc1c26d23f6405c928044ee7980345e_I20120523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:MarylandBiotechnologyCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:TranslationalResearchAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-05-23</instant>
        </period>
    </context>
    <context id="i0dc71e39107c4d2e888729d888bb4e8b_D20130523-20130523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <startDate>2013-05-23</startDate>
            <endDate>2013-05-23</endDate>
        </period>
    </context>
    <context id="i69c37fb252ac488eb687ac1d9ffa59fe_I20130523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:MarylandBiotechnologyCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:TranslationalResearchAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-05-23</instant>
        </period>
    </context>
    <context id="ie5deb40f57714a11a917ea127c6f7c9f_D20130523-20130523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:MarylandBiotechnologyCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:TranslationalResearchAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-05-23</startDate>
            <endDate>2013-05-23</endDate>
        </period>
    </context>
    <context id="i64dedfdb14784525a0d5de1ec201e691_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:MarylandBiotechnologyCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:TranslationalResearchAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie3294ba19efb4f899898ab09f55e6853_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:MarylandBiotechnologyCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:TranslationalResearchAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6719abe720c5406d8c6c8df3e56df15a_D20170101-20170101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nexi:MilestonesAxis">nexi:ClinicalTrialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="id205558188da4f4faaf0ec195c63003f_D20170101-20170101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nexi:MilestonesAxis">nexi:TherapeuticFieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="i2c23fd7809674603b59c0f27fb6a073b_D20170101-20170101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nexi:MilestonesAxis">nexi:RegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="ia6fc5f4226364570a5d62f606626c0ab_D20170101-20170101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nexi:MilestonesAxis">nexi:NonclinicalFieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="i432594ce07a346698a0597e5adf392f0_D20170101-20170101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="i2735225fb3054df286cd15e9d84e3203_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib3562b2fa26c44aba06d2f7770d6feb4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nexi:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia0e4cc0109264b539acd8b2cbc12a65b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd3d3cf5f9f6420abe32fd8826ce546d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i073d07654a3240e784df7ae6097d2764_I20200423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nexi:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-23</instant>
        </period>
    </context>
    <context id="i6e206dd327124b4b8af59ef1f3ab5579_I20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="i64dc0ef29e704fa49df23a5b74b93453_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">nexi:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="ie2aff3fdd4ae40b29ed8bab59335a89b_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ifb6c8b0ddc244a308e9bd3ecbb524199_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i225885d205f04fb9b33ee53d4cfb8f44_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i8ff48a09a554472b8be106abefa1d461_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i873c597d2cf845d493f5de5873c03e05_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idf7c9ea8fe8d4438993e95ae15b3887d_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ic8342e5909c548198f1f8f812c6ccc2a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i54b8bf4223dd408ba5dfb81b3157f859_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i869076cb5c1441619748ef3b03caf454_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74ebc54878b1455ba9248d3203abce2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibee929c3ceb949d69a3628128e96a111_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i370d6d24e959405ba7d21d7a1ef23d52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic87f7845ea6d43edb990474d68bfd9b9_D20210211-20210211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="if353ba0711344094942f5e91286b8497_D20210211-20210211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="i26259b22e3b94e8c8e38c181c55cf7e8_I20210211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="i6ab94587a7134bc29507a4735e3b4bb5_D20210211-20210211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="i8f4fa39048644fd7896c3a33c09994df_I20210211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="i77a57977aaa446e78a28a3a70e9a899c_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i85c929ab7b9c4820bc56af8cd2f474ab_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i5835f11998cf40f68d148e445724cb8b_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nexi:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="id09449ea526a48e0b9e20fb9696883ab_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nexi:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia81c0f51abc5407c9f1bea1bc4bfb1a9_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nexi:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i606c2339afea414788b70bdaefc16503_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nexi:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie9d3dab50aea4a7f8d84d00874e49e4e_I20170301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nexi:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-01</instant>
        </period>
    </context>
    <context id="i275a48529a1a4c3885fad3563305e566_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i30203c7ac84149eda4226a53b00d5520_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nexi:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="i8ab04e02de714324a031d507a830df05_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="ibf9d66ae0c7a46f68c98ad662da4fd70_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nexi:The2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4928ff38b944471a2f040e95d09d31b_I20230301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="i8cde262665d140a4aa955aed31f5920a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ief18b08960f540d7b60fdafa452c819e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i02e219dda5744914b465aec9d485e6e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i28b3cec944184d4f8af71eef16bd69a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b304823751d4c239cbf3f21b62ab9a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idea423a341804ae2b054938793d90352_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3fa6115f303b4a3fbf9b708fedfe989b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idda403dc84674bf3b38163cc09604d2e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05746f41db1943c1bec2cd0749ac1f49_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0c755e4c19e14dd3b1b1970081b2809e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c1c88b03e284ba5a4f2d5abe7153e3f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff7fdf8fd69c490e8f4f46d8e7a75f7c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3333ea4033604cef87ae7f2a775a3bca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b6232ae6cb64482b9ec1943b0fe3126_I20230322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="ie2d06934bf864579a4979bf7aa1310c1_I20230322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nexi:EmployeesExcludingExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="i7c4097a670b849ad990fb5d2224c365b_I20230322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JeromeZeldisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="i3d28adc4141b4bbfb5dd66693b958745_I20230322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="id386af48387549ec98b66a7ea05efd78_I20230322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="i4ea14e11723c4f1f804456e484f29855_I20230322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="i0692d5e0603d41138cf06daaf012d2ef_I20230322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="ia3e2d6cfd7a944f3927adf427e2f02ea_I20230322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001538210</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nexi:JeromeZeldisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>nexi:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="employee">
        <measure>nexi:employee</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-32">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-33">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-34">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-35">0001538210</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i81a07e7e0c0f4c6086be99b99cd79cdc_D20200101-20201231"
      id="f-147">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8cde262665d140a4aa955aed31f5920a_D20220101-20221231"
      id="f-546">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-3">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-6">001-40045</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-7">NEXIMMUNE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-9">45-2518457</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-10">9119 Gaither Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-11">Gaithersburg</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-12">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-13">20877</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-14">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-15">825-9810</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-16">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-17">NEXI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-25">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-26">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i373e3231b3f840a68e2e1b764ca2c76a_I20220630"
      decimals="-5"
      id="f-29"
      unitRef="usd">28700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ife75d305cc1f4ff48462a16aa940d5bb_I20230301"
      decimals="0"
      id="f-30"
      unitRef="shares">26078451</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-31">None.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ife75d305cc1f4ff48462a16aa940d5bb_I20230301"
      decimals="0"
      id="f-36"
      unitRef="shares">26078451</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="ia325791ead244863998b1f8f312ad14c_I20210211"
      decimals="0"
      id="f-37"
      unitRef="shares">10144041</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <dei:AuditorFirmId
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-38">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-39">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-40">Tysons, Virginia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-41"
      unitRef="usd">34642340</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-42"
      unitRef="usd">30326352</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-43"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-44"
      unitRef="usd">51491942</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-45"
      unitRef="usd">55000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-46"
      unitRef="usd">67500</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-47"
      unitRef="usd">2671411</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-48"
      unitRef="usd">4394916</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-49"
      unitRef="usd">37368751</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-50"
      unitRef="usd">86280710</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-51"
      unitRef="usd">4459071</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-52"
      unitRef="usd">4427307</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-53"
      unitRef="usd">967032</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-54"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-55"
      unitRef="usd">264970</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-56"
      unitRef="usd">324099</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-57"
      unitRef="usd">43059824</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-58"
      unitRef="usd">91032116</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-59"
      unitRef="usd">2377374</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-60"
      unitRef="usd">1045159</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-61"
      unitRef="usd">7357153</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-62"
      unitRef="usd">6170709</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-63"
      unitRef="usd">599047</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-64"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-65"
      unitRef="usd">10333574</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-66"
      unitRef="usd">7215868</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-67"
      unitRef="usd">425766</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-68"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-69"
      unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-70"
      unitRef="usd">55581</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-71"
      unitRef="usd">10759340</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-72"
      unitRef="usd">7271449</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      id="f-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      id="f-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="4"
      id="f-75"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="4"
      id="f-76"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-77"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-78"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-79"
      unitRef="shares">26078451</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-80"
      unitRef="shares">26078451</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-81"
      unitRef="shares">22828904</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-82"
      unitRef="shares">22828904</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-83"
      unitRef="usd">2608</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-84"
      unitRef="usd">2283</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-85"
      unitRef="usd">222547530</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-86"
      unitRef="usd">211498827</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-87"
      unitRef="usd">-190249654</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-88"
      unitRef="usd">-127743455</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-89"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-90"
      unitRef="usd">3012</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-91"
      unitRef="usd">32300484</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-92"
      unitRef="usd">83760667</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-93"
      unitRef="usd">43059824</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-94"
      unitRef="usd">91032116</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-95"
      unitRef="usd">47148450</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-96"
      unitRef="usd">37456350</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-97"
      unitRef="usd">15934439</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-98"
      unitRef="usd">15799432</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-99"
      unitRef="usd">63082889</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-100"
      unitRef="usd">53255782</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-101"
      unitRef="usd">-63082889</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-102"
      unitRef="usd">-53255782</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-103"
      unitRef="usd">664372</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-104"
      unitRef="usd">52511</us-gaap:InvestmentIncomeInterest>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-105"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-106"
      unitRef="usd">2424877</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-107"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-108"
      unitRef="usd">843619</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpense
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-109"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-110"
      unitRef="usd">905326</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-111"
      unitRef="usd">-87682</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-112"
      unitRef="usd">-61407</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-113"
      unitRef="usd">576690</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-114"
      unitRef="usd">2354274</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="iea9cb688d3fe4d64b5fd77adc7e14243_D20220101-20221231"
      decimals="0"
      id="f-115"
      unitRef="usd">-62506199</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-116"
      unitRef="usd">-50901508</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-117"
      unitRef="usd">0</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-118"
      unitRef="usd">377562</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-119"
      unitRef="usd">-62506199</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-120"
      unitRef="usd">-51279070</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-121"
      unitRef="usdPerShare">-2.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-122"
      unitRef="usdPerShare">-2.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="2"
      id="f-123"
      unitRef="usdPerShare">-2.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="2"
      id="f-124"
      unitRef="usdPerShare">-2.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-125"
      unitRef="shares">24059104</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-126"
      unitRef="shares">24059104</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-127"
      unitRef="shares">20186127</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-128"
      unitRef="shares">20186127</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-129"
      unitRef="usd">-62506199</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-130"
      unitRef="usd">-50901508</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-131"
      unitRef="usd">-3012</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-132"
      unitRef="usd">3012</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-133"
      unitRef="usd">-62509211</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-134"
      unitRef="usd">-50898496</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i37d7504e32234f1795742c55cbc6b155_I20201231"
      decimals="0"
      id="f-135"
      unitRef="shares">121735303</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i37d7504e32234f1795742c55cbc6b155_I20201231"
      decimals="0"
      id="f-136"
      unitRef="usd">35047435</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="iff21ea6215e44aaf8825b8629943e25d_I20201231"
      decimals="0"
      id="f-137"
      unitRef="shares">22047361</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="iff21ea6215e44aaf8825b8629943e25d_I20201231"
      decimals="0"
      id="f-138"
      unitRef="usd">7685865</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ied4b640b66f4431e8a9ab05b2c296a7c_I20201231"
      decimals="0"
      id="f-139"
      unitRef="shares">31209734</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ied4b640b66f4431e8a9ab05b2c296a7c_I20201231"
      decimals="0"
      id="f-140"
      unitRef="usd">10887449</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="ic5ee39eb5c7c429d8d549dd5e1664fe4_I20201231"
      decimals="0"
      id="f-141"
      unitRef="shares">1256609</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic5ee39eb5c7c429d8d549dd5e1664fe4_I20201231"
      decimals="0"
      id="f-142"
      unitRef="usd">126</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic7c755cb14bd427e8793ab33dac3fd7b_I20201231"
      decimals="0"
      id="f-143"
      unitRef="usd">8206938</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie510bed0d8e14fc599909e739c5e7d89_I20201231"
      decimals="0"
      id="f-144"
      unitRef="usd">-77582005</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6dca16917b304e32b75b202c42131f15_I20201231"
      decimals="0"
      id="f-145"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida3374a79ddc4d3cb5ad2f1dc1e8a42a_I20201231"
      decimals="0"
      id="f-146"
      unitRef="usd">-69374941</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3b987d568d844b0b874f7c2bca5b1c71_I20201231"
      decimals="0"
      id="f-148"
      unitRef="usd">-2277332</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i02d7650fa3c34b7c9124b8138bfa5e7c_I20201231"
      decimals="0"
      id="f-149"
      unitRef="usd">740058</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i323e4338ce04403fb958b956a6ebd5c2_I20201231"
      decimals="0"
      id="f-150"
      unitRef="usd">-1537274</us-gaap:StockholdersEquity>
    <nexi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i54f8c709c7614cd892e0ff95fd765294_D20210101-20211231"
      decimals="0"
      id="f-151"
      unitRef="shares">145000</nexi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i54f8c709c7614cd892e0ff95fd765294_D20210101-20211231"
      decimals="0"
      id="f-152"
      unitRef="usd">1450</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <nexi:TemporaryEquityStockConvertedDuringPeriodShares
      contextRef="i54f8c709c7614cd892e0ff95fd765294_D20210101-20211231"
      decimals="0"
      id="f-153"
      unitRef="shares">121880303</nexi:TemporaryEquityStockConvertedDuringPeriodShares>
    <nexi:TemporaryEquityStockConvertedDuringPeriodValue
      contextRef="i54f8c709c7614cd892e0ff95fd765294_D20210101-20211231"
      decimals="0"
      id="f-154"
      unitRef="usd">35048885</nexi:TemporaryEquityStockConvertedDuringPeriodValue>
    <nexi:TemporaryEquityStockConvertedDuringPeriodShares
      contextRef="i2c885db91fa648a29884e7d59755d5ad_D20210101-20211231"
      decimals="0"
      id="f-155"
      unitRef="shares">22047361</nexi:TemporaryEquityStockConvertedDuringPeriodShares>
    <nexi:TemporaryEquityStockConvertedDuringPeriodValue
      contextRef="i2c885db91fa648a29884e7d59755d5ad_D20210101-20211231"
      decimals="0"
      id="f-156"
      unitRef="usd">7685865</nexi:TemporaryEquityStockConvertedDuringPeriodValue>
    <nexi:TemporaryEquityStockConvertedDuringPeriodShares
      contextRef="i362e074aa71542d3be5f2ac89ce168f3_D20210101-20211231"
      decimals="0"
      id="f-157"
      unitRef="shares">31209734</nexi:TemporaryEquityStockConvertedDuringPeriodShares>
    <nexi:TemporaryEquityStockConvertedDuringPeriodValue
      contextRef="i362e074aa71542d3be5f2ac89ce168f3_D20210101-20211231"
      decimals="0"
      id="f-158"
      unitRef="usd">10887449</nexi:TemporaryEquityStockConvertedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231"
      decimals="0"
      id="f-159"
      unitRef="shares">10144041</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231"
      decimals="0"
      id="f-160"
      unitRef="usd">1014</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231"
      decimals="0"
      id="f-161"
      unitRef="usd">53621185</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-162"
      unitRef="usd">53622199</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <nexi:StockIssuedDuringPeriodSharesConversionOfConvertibleDebt
      contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231"
      decimals="0"
      id="f-163"
      unitRef="shares">3669010</nexi:StockIssuedDuringPeriodSharesConversionOfConvertibleDebt>
    <nexi:StockIssuedDuringPeriodValueConversionOfConvertibleDebt
      contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231"
      decimals="0"
      id="f-164"
      unitRef="usd">367</nexi:StockIssuedDuringPeriodValueConversionOfConvertibleDebt>
    <nexi:StockIssuedDuringPeriodValueConversionOfConvertibleDebt
      contextRef="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231"
      decimals="0"
      id="f-165"
      unitRef="usd">30251689</nexi:StockIssuedDuringPeriodValueConversionOfConvertibleDebt>
    <nexi:StockIssuedDuringPeriodValueConversionOfConvertibleDebt
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-166"
      unitRef="usd">30252056</nexi:StockIssuedDuringPeriodValueConversionOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231"
      decimals="0"
      id="f-167"
      unitRef="shares">7441650</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231"
      decimals="0"
      id="f-168"
      unitRef="usd">744</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231"
      decimals="0"
      id="f-169"
      unitRef="usd">114550571</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-170"
      unitRef="usd">114551315</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231"
      decimals="0"
      id="f-171"
      unitRef="shares">314698</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231"
      decimals="0"
      id="f-172"
      unitRef="usd">32</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231"
      decimals="0"
      id="f-173"
      unitRef="usd">1165992</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-174"
      unitRef="usd">1166024</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <nexi:NumberOfWarrantsExercised
      contextRef="i8ac5a918158d426f8155aadfe39c6fd3_D20210101-20211231"
      decimals="0"
      id="f-175"
      unitRef="shares">2896</nexi:NumberOfWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i375e368460234d10b9a4f96599c3c1e6_D20210101-20211231"
      decimals="0"
      id="f-176"
      unitRef="usd">5979784</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-177"
      unitRef="usd">5979784</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifcf18312a9b849779921e6320f8c96e3_D20210101-20211231"
      decimals="0"
      id="f-178"
      unitRef="usd">3012</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-179"
      unitRef="usd">3012</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3d72f5c306cd45b3a45cc5043d61410b_D20210101-20211231"
      decimals="0"
      id="f-180"
      unitRef="usd">-50901508</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-181"
      unitRef="usd">-50901508</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i245c6670d41d42a9b3fa719e42f16d0f_I20211231"
      decimals="0"
      id="f-182"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i245c6670d41d42a9b3fa719e42f16d0f_I20211231"
      decimals="0"
      id="f-183"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="icbbf1a64b75d4fce82cd179c3bd44da8_I20211231"
      decimals="0"
      id="f-184"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="icbbf1a64b75d4fce82cd179c3bd44da8_I20211231"
      decimals="0"
      id="f-185"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i44b3409c2a62435692c6df71b1354eaa_I20211231"
      decimals="0"
      id="f-186"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i44b3409c2a62435692c6df71b1354eaa_I20211231"
      decimals="0"
      id="f-187"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i736ffb84dab44fb0b3e163c0502409b6_I20211231"
      decimals="0"
      id="f-188"
      unitRef="shares">22828904</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i736ffb84dab44fb0b3e163c0502409b6_I20211231"
      decimals="0"
      id="f-189"
      unitRef="usd">2283</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i52a135ff906f46e9bab66d63a940f8e2_I20211231"
      decimals="0"
      id="f-190"
      unitRef="usd">211498827</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia891e7526d504d8fadb55664f61f3e46_I20211231"
      decimals="0"
      id="f-191"
      unitRef="usd">-127743455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0445e2ff34a46f185f60587d785bf3c_I20211231"
      decimals="0"
      id="f-192"
      unitRef="usd">3012</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-193"
      unitRef="usd">83760667</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i245c6670d41d42a9b3fa719e42f16d0f_I20211231"
      decimals="0"
      id="f-194"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i245c6670d41d42a9b3fa719e42f16d0f_I20211231"
      decimals="0"
      id="f-195"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="icbbf1a64b75d4fce82cd179c3bd44da8_I20211231"
      decimals="0"
      id="f-196"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="icbbf1a64b75d4fce82cd179c3bd44da8_I20211231"
      decimals="0"
      id="f-197"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i44b3409c2a62435692c6df71b1354eaa_I20211231"
      decimals="0"
      id="f-198"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i44b3409c2a62435692c6df71b1354eaa_I20211231"
      decimals="0"
      id="f-199"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i736ffb84dab44fb0b3e163c0502409b6_I20211231"
      decimals="0"
      id="f-200"
      unitRef="shares">22828904</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i736ffb84dab44fb0b3e163c0502409b6_I20211231"
      decimals="0"
      id="f-201"
      unitRef="usd">2283</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i52a135ff906f46e9bab66d63a940f8e2_I20211231"
      decimals="0"
      id="f-202"
      unitRef="usd">211498827</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia891e7526d504d8fadb55664f61f3e46_I20211231"
      decimals="0"
      id="f-203"
      unitRef="usd">-127743455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0445e2ff34a46f185f60587d785bf3c_I20211231"
      decimals="0"
      id="f-204"
      unitRef="usd">3012</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-205"
      unitRef="usd">83760667</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231"
      decimals="0"
      id="f-206"
      unitRef="shares">3184900</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231"
      decimals="0"
      id="f-207"
      unitRef="usd">319</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i79d26598eacc4a57ba2e44555e59db4b_D20220101-20221231"
      decimals="0"
      id="f-208"
      unitRef="usd">5145090</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-209"
      unitRef="usd">5145409</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231"
      decimals="0"
      id="f-210"
      unitRef="shares">12890</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231"
      decimals="0"
      id="f-211"
      unitRef="usd">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i79d26598eacc4a57ba2e44555e59db4b_D20220101-20221231"
      decimals="0"
      id="f-212"
      unitRef="usd">33254</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-213"
      unitRef="usd">33255</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod
      contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231"
      decimals="0"
      id="f-214"
      unitRef="shares">51757</nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod>
    <nexi:StockIssuedDuringPeriodValueCashlessCommonStockExercised
      contextRef="i4db0a2af3bd045109daecbcc723174b6_D20220101-20221231"
      decimals="0"
      id="f-215"
      unitRef="usd">5</nexi:StockIssuedDuringPeriodValueCashlessCommonStockExercised>
    <nexi:StockIssuedDuringPeriodValueCashlessCommonStockExercised
      contextRef="i79d26598eacc4a57ba2e44555e59db4b_D20220101-20221231"
      decimals="0"
      id="f-216"
      unitRef="usd">-5</nexi:StockIssuedDuringPeriodValueCashlessCommonStockExercised>
    <nexi:StockIssuedDuringPeriodValueCashlessCommonStockExercised
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-217"
      unitRef="usd">0</nexi:StockIssuedDuringPeriodValueCashlessCommonStockExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i79d26598eacc4a57ba2e44555e59db4b_D20220101-20221231"
      decimals="0"
      id="f-218"
      unitRef="usd">5870364</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-219"
      unitRef="usd">5870364</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i82f02bb4e976485b911d7b3e40c78b45_D20220101-20221231"
      decimals="0"
      id="f-220"
      unitRef="usd">-3012</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-221"
      unitRef="usd">-3012</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="iea9cb688d3fe4d64b5fd77adc7e14243_D20220101-20221231"
      decimals="0"
      id="f-222"
      unitRef="usd">-62506199</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-223"
      unitRef="usd">-62506199</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i087599b8fe8e4804833ffb19d54c95d2_I20221231"
      decimals="0"
      id="f-224"
      unitRef="shares">26078451</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i087599b8fe8e4804833ffb19d54c95d2_I20221231"
      decimals="0"
      id="f-225"
      unitRef="usd">2608</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifc09a4b59e0b4de088c1ee9a6f9b937b_I20221231"
      decimals="0"
      id="f-226"
      unitRef="usd">222547530</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23dd0eac814249f3a9f87f2d470e24a0_I20221231"
      decimals="0"
      id="f-227"
      unitRef="usd">-190249654</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2f44e04246d4f92ae9eaa55d8242626_I20221231"
      decimals="0"
      id="f-228"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-229"
      unitRef="usd">32300484</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-230"
      unitRef="usd">-62506199</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-231"
      unitRef="usd">-50901508</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-232"
      unitRef="usd">994792</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-233"
      unitRef="usd">870285</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnInvestments
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-234"
      unitRef="usd">1131</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-235"
      unitRef="usd">32065</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-236"
      unitRef="usd">-21264</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-237"
      unitRef="usd">-8440</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ShareBasedCompensation
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-238"
      unitRef="usd">5870364</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-239"
      unitRef="usd">5979784</us-gaap:ShareBasedCompensation>
    <nexi:LeaseExpenseNoncash
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-240"
      unitRef="usd">500553</nexi:LeaseExpenseNoncash>
    <nexi:LeaseExpenseNoncash
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-241"
      unitRef="usd">0</nexi:LeaseExpenseNoncash>
    <us-gaap:PaidInKindInterest
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-242"
      unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-243"
      unitRef="usd">903919</us-gaap:PaidInKindInterest>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-244"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-245"
      unitRef="usd">-2424877</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-246"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-247"
      unitRef="usd">843619</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-248"
      unitRef="usd">-1723506</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-249"
      unitRef="usd">2053690</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-250"
      unitRef="usd">-59129</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-251"
      unitRef="usd">300726</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-252"
      unitRef="usd">1387057</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-253"
      unitRef="usd">-1002896</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-254"
      unitRef="usd">1258098</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-255"
      unitRef="usd">4011882</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-256"
      unitRef="usd">-498353</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-257"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-258"
      unitRef="usd">-51190920</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-259"
      unitRef="usd">-45785071</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-260"
      unitRef="usd">1255116</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-261"
      unitRef="usd">2350416</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-262"
      unitRef="usd">80800</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-263"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-264"
      unitRef="usd">21509940</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-265"
      unitRef="usd">90456865</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-266"
      unitRef="usd">71500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-267"
      unitRef="usd">39000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-268"
      unitRef="usd">1500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-269"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-270"
      unitRef="usd">50315744</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-271"
      unitRef="usd">-53807281</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-272"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-273"
      unitRef="usd">114721518</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-274"
      unitRef="usd">5145409</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-275"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-276"
      unitRef="usd">33255</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-277"
      unitRef="usd">1166024</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-278"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-279"
      unitRef="usd">12260</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-280"
      unitRef="usd">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-281"
      unitRef="usd">56500</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-282"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-283"
      unitRef="usd">8974980</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-284"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-285"
      unitRef="usd">19137</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-286"
      unitRef="usd">5178664</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-287"
      unitRef="usd">124887625</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-288"
      unitRef="usd">4303488</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-289"
      unitRef="usd">25295273</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-290"
      unitRef="usd">30393852</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ida3374a79ddc4d3cb5ad2f1dc1e8a42a_I20201231"
      decimals="0"
      id="f-291"
      unitRef="usd">5098579</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-292"
      unitRef="usd">34697340</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-293"
      unitRef="usd">30393852</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-294"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-295"
      unitRef="usd">457</us-gaap:InterestPaidNet>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-296"
      unitRef="usd">0</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-297"
      unitRef="usd">843619</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-298"
      unitRef="usd">5370</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-299"
      unitRef="usd">131866</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-300">Description of the Business&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;NexImmune, Inc. (the &#x201c;Company&#x201d; or &#x201c;NexImmune&#x201d;), a Delaware corporation headquartered in Gaithersburg, Maryland, was incorporated on June&#160;7, 2011. The Company is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The AIM nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body&#x2019;s own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are artificial AIM nanoparticles, which act as synthetic dendritic cells. These AIM nanoparticles can be programmed to present specific antigens to specific T cells orchestrating a highly targeted immune response. These AIM nanoparticles can be rapidly engineered to elicit an immune attack that can be directed toward any foreign substance or cell type in a patient&#x2019;s body. The Company&#x2019;s first two products, both for the treatment of different types of cancer, entered clinical trials in 2020. Following a strategic review of the Company's corporate strategy, including with respect to its adoptive cell therapy programs, the Company paused investments in its cell therapy studies, NEXI-001, NEXI-002, and NEXI-003 which is designed to reduce costs and reallocate resources towards our AIM INJ preclinical development programs. As part of this strategy, we will focus on developing AIM INJ nanoparticle constructs and modalities for potential clinical evaluation in oncology and autoimmune disorders. The Company is exploring several external opportunities to continue to advance these programs. As a result, the Company will focus its existing resources on its injectable platform in oncology and autoimmune diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements - Going Concern ("ASC 205-40"), requires management to assess the Company&#x2019;s ability to continue as a going concern for one year after the date the financial statements are issued. Under ASC 205-40, management has the responsibility to evaluate whether conditions and/or events raise substantial doubt about the Company&#x2019;s ability to meet future financial obligations as they become due within one year after the date that the financial statements are issued. As required by this standard, management&#x2019;s evaluation shall initially not take into consideration the potential mitigating effects of management&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring operating losses and negative cash flows from operations. The financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had an accumulated deficit of $190.2 million, negative cash flows from operating activities for the period ended December&#160;31, 2022, and significant ongoing research and development expenses. While we have no outstanding debt and $34.6 million in cash and cash equivalents as of December&#160;31, 2022, the Company expects its negative cash flows from operating activities to continue and thus has determined that its losses and negative cash flows from operations and uncertainty in generating sufficient cash to meet our obligations and sustain our operations raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for at least one year from the issuance date of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company&#x2019;s research and development activities mature and develop over the next year, the Company will likely require substantial funds to continue such activities, depending upon events that are difficult to predict at this time. In this regard, management plans to raise additional capital through financing activities that may include public offerings and private placements of its common stock, preferred stock offerings, collaborations and licensing arrangements and issuances of debt and convertible debt instruments. In the absence of additional capital, the Company plans to strategically manage its uncommitted spend, execute its priorities and implement cost saving measures to reduce research and development and general and administrative expenditures which could include minimizing staff costs and delaying or terminating manufacturing and clinical trial costs.&lt;/span&gt;&lt;/div&gt;There are inherent uncertainties associated with fundraising activities and activities to manage the Company&#x2019;s uncommitted spending and the successful execution of these activities may not be within the Company&#x2019;s control. There are no assurances that such additional funding will be obtained and that the Company will succeed in its future operations. If the Company cannot successfully raise additional capital, its liquidity, financial condition and business prospects will be materially and adversely affected. The Company is continually looking into further capital planning and the evaluation of strategic alternatives. There is substantial doubt about the Company&#x2019;s ability to continue as a going concern.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <nexi:SubstantialDoubtForGoingConcernPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-301">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements - Going Concern ("ASC 205-40"), requires management to assess the Company&#x2019;s ability to continue as a going concern for one year after the date the financial statements are issued. Under ASC 205-40, management has the responsibility to evaluate whether conditions and/or events raise substantial doubt about the Company&#x2019;s ability to meet future financial obligations as they become due within one year after the date that the financial statements are issued. As required by this standard, management&#x2019;s evaluation shall initially not take into consideration the potential mitigating effects of management&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring operating losses and negative cash flows from operations. The financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had an accumulated deficit of $190.2 million, negative cash flows from operating activities for the period ended December&#160;31, 2022, and significant ongoing research and development expenses. While we have no outstanding debt and $34.6 million in cash and cash equivalents as of December&#160;31, 2022, the Company expects its negative cash flows from operating activities to continue and thus has determined that its losses and negative cash flows from operations and uncertainty in generating sufficient cash to meet our obligations and sustain our operations raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for at least one year from the issuance date of these financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company&#x2019;s research and development activities mature and develop over the next year, the Company will likely require substantial funds to continue such activities, depending upon events that are difficult to predict at this time. In this regard, management plans to raise additional capital through financing activities that may include public offerings and private placements of its common stock, preferred stock offerings, collaborations and licensing arrangements and issuances of debt and convertible debt instruments. In the absence of additional capital, the Company plans to strategically manage its uncommitted spend, execute its priorities and implement cost saving measures to reduce research and development and general and administrative expenditures which could include minimizing staff costs and delaying or terminating manufacturing and clinical trial costs.&lt;/span&gt;&lt;/div&gt;There are inherent uncertainties associated with fundraising activities and activities to manage the Company&#x2019;s uncommitted spending and the successful execution of these activities may not be within the Company&#x2019;s control. There are no assurances that such additional funding will be obtained and that the Company will succeed in its future operations. If the Company cannot successfully raise additional capital, its liquidity, financial condition and business prospects will be materially and adversely affected. The Company is continually looking into further capital planning and the evaluation of strategic alternatives. There is substantial doubt about the Company&#x2019;s ability to continue as a going concern.</nexi:SubstantialDoubtForGoingConcernPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="-5"
      id="f-302"
      unitRef="usd">-190200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LongTermDebt
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="-3"
      id="f-303"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="-5"
      id="f-304"
      unitRef="usd">34600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfAccounting
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-305">Basis of Presentation and Liquidity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the FASB.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-306">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the FASB.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-307">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company evaluates its estimates, including those related to the recoverability of long-lived assets, stock-based compensation, the valuation of financial instruments, and the valuation of deferred tax assets and liabilities. The Company&#x2019;s estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Although actual results could differ from those estimates, management does not believe that such differences would be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments which potentially subject the Company to credit risk consist principally of cash and marketable debt securities. All cash is held in United States financial institutions that are federally insured. At times, the Company may maintain cash balances in excess of the federally insured amount. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk. The Company&#x2019;s investments in marketable debt securities have been issued by corporate entities and government-sponsored enterprises with high credit ratings. The Company mitigates investment risks by investing in highly-rated securities with relatively short maturities that the Company believes do not subject it to undue investment or credit risk. If any of these financial institutions fail to perform their obligations under the terms of these financial instruments, the Company&#x2019;s maximum exposure to potential losses would be equal to the amounts reported on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of debt securities with maturities greater than three months from the date of purchase that include commercial paper and corporate notes. Classification of marketable securities between current and&#160;non-current&#160;is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#x2019;s ability and intent to hold the investment to maturity. There were no outstanding marketable securities as of December&#160;31, 2022. As of December&#160;31, 2021, all marketable securities were classified as current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and dividend income are recorded when earned and included in interest income in the statement of operations. Premiums and discounts, if any, on marketable securities are amortized or accreted to maturity and included in interest income in the statement of operations. The specific identification method is used in computing realized gains and losses on the sale of the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its marketable securities as&#160;available-for-sale.&#160;The Company determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date.&#160;Marketable securities that are classified as&#160;available-for-sale&#160;are measured at fair value on the balance sheet, and unrealized gains and losses on marketable securities are reported as a component of accumulated other comprehensive income (loss) in stockholders&#x2019; equity (deficit) until realized. Marketable securities are evaluated periodically to determine whether the carrying value of a marketable security exceeds its fair value and the decline in value is determined to be other-than-temporary. Management reviews criteria, such as the general market conditions, magnitude and duration in which the fair value has been less than the carrying value, the investment issuer&#x2019;s financial condition and business outlook, as well as the Company&#x2019;s ability to hold the securities until the recovery of its amortized cost basis, to determine whether the decline in value is other-than-temporary. If a decline in value is determined to be other-than-temporary, the value of the marketable security is reduced, and the impairment is recorded as other expense in the statement of operations. As of December&#160;31, 2021, any decline in value of marketable securities was concluded not to be other-than-temporary. As of December&#160;31, 2022, no assessment was required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,642,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,326,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,697,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,393,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts included in restricted cash represent amounts required as collateral on corporate credit cards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, marketable securities, accounts payable, accrued expenses, convertible notes and derivative liabilities. The fair values of the cash and cash equivalents, accounts payable and accrued expenses approximated their carrying values as of December&#160;31, 2022 and 2021, due to their short-term maturities. For a description of the fair value of marketable securities, refer to Note 4. The Convertible Notes as discussed in Note 10 contained embedded derivative features that were required to be bifurcated and remeasured to fair value at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, Fair Value Measurements (&#x201c;ASC 820&#x201d;). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt"&gt;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt"&gt;Fair value is determined by using inputs, other than Level&#160;1 quoted prices that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt"&gt;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant judgments to be made by a reporting entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Major replacements and improvements that extend the useful lives of assets are capitalized, while general repairs and maintenance are charged to expense as incurred. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the related lease term, whichever is shorter. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated useful lives of property, plant and equipment by major category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of its long-lived asset group for potential impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recoverability is determined by comparing future undiscounted cash flows associated with such assets to the related carrying value. An impairment loss may be recognized when the estimated undiscounted future cash flow is less than the carrying amount of the asset. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured as the amount by &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which the carrying value of the asset group exceeds the fair value of the asset group. No impairments were recognized for the years ended December&#160;31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s redeemable convertible preferred stock was classified outside of stockholders&#x2019; equity because the shares contained deemed liquidation rights that represented a contingent redemption feature not solely within the control of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible instruments and embedded derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that contain conversion options and other embedded features. The Company bifurcates embedded features from their host instruments and accounts for them as free-standing derivative financial instruments according to certain criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon any change to the Company&#x2019;s debt arrangements, the Company evaluates the amendment to determine whether a debt modification or extinguishment has occurred, including whether the amendment should be accounted for as a troubled debt restructuring.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s derivative instrument related to certain features embedded within the Company&#x2019;s Convertible Notes as discussed in Note 10. The derivative was accounted for as a derivative liability and remeasured to fair value as of each balance sheet date. The related remeasurement adjustments are recognized in the accompanying statements of operations and were settled upon the conversion of the Convertible Notes during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including share-based compensation, as well as costs for third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, based on its estimates of services performed and costs incurred. These estimates include the level of services performed by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical trial and contract development and manufacturing organization expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company makes payments in connection with clinical trials and contract development and manufacturing organizations (&#x201c;CDMO&#x201d;) under contracts with contract research organizations that support conducting and managing clinical trials and the manufacturing of materials utilized in clinical and preclinical activities. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of the obligation to make payments under these contracts depends on factors such as the successful enrollment, treatment of patients, the completion of other clinical trial milestones, or completion of manufacturing milestones. Termination clauses within the agreements require notification for a certain number of days prior to completing work, payments for costs incurred through the termination date, and termination penalty, if applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Expenses related to development and manufacturing are accrued based on estimates and/or representations from service providers regarding work performed, including progress in the development of processes through technology transfers to manufacture the Company&#x2019;s clinical material and completion of the manufactured clinical material. Other incidental costs related to patient enrollment or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;treatment are accrued when reasonably certain. If the amounts the Company is obligated to pay under clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records compensation expense associated with stock options and other forms of equity compensation based on the estimated fair value at the grant date. Compensation expense related to awards to employees and non-employees with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the requisite service period of the award, which is generally the vesting term. The Company&#x2019;s policy is to account for forfeitures as they occur. The Company uses the Black-Scholes-Merton option pricing (Black-Scholes) model to estimate the fair value of stock options. The Black-Scholes model requires input-based assumptions that are highly subjective, judgmental and sensitive in the determination of stock-based compensation cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted after the Company&#x2019;s IPO are issued at the fair market value of the Company&#x2019;s common stock at the date the grant is approved by the Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected volatility was based on the historical volatility of comparable public companies from a representative peer group selected based on industry and market capitalization data. The historical volatility is calculated based on a period of time commensurate with the expected term assumption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate was based on the continuous rates provided by the U.S. Treasury with a term approximating the expected term of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected dividend yield was 0% because the Company has not historically paid and does not expect to pay any dividends for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based-Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 12 for a further discussion on stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes it is&#160;more-likely-than-not&#160;that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results,&#160;on-going&#160;tax planning and forecasts of future taxable income on a&#160;jurisdiction-by-jurisdiction&#160;basis. The Company recorded a valuation allowance against all estimated net deferred tax assets as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered&#160;more-likely-than-not&#160;to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Recognized income tax positions are measured at the largest amount that is greater than&#160;more-likely-than-not&#160;of being realized. Changes in the recognition or measurement are reflected in the period in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which the change in estimate occurs. Interest and penalties related to uncertain tax positions are recorded in the provision of income taxes. There were no uncertain tax positions nor income tax related interest and penalties recorded as of or for the years ended December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock and common stock equivalents outstanding for the period. The Company adjusts net loss to arrive at the net loss attributable to common stockholders to reflect the amount of dividends accumulated during the period on the Company&#x2019;s redeemable convertible preferred stock. Such dividends are only payable if and when declared by the Board of Directors (Note 11). The treasury stock method is used to determine the dilutive effect of the Company&#x2019;s stock option grants and warrants and the&#160;if-converted&#160;method is used to determine the dilutive effect of the Company&#x2019;s redeemable convertible preferred stock and Convertible Notes. For the years ended December&#160;31, 2022 and 2021, the Company had a net loss attributable to common stockholders, and as such, all outstanding stock options, shares of redeemable convertible preferred stock, and warrants were excluded from the calculation of diluted loss per share. Under the if-converted method, convertible instruments that are in the money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of bifurcated derivatives is added back to the numerator of the diluted net loss per share calculation if the conversion of the Convertible Notes is dilutive.&#160;The following table sets forth the computation of basic and diluted earnings per share for the years ended December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,506,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,901,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated dividends on Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(377,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,506,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,279,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,059,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,186,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted average common shares outstanding at December&#160;31, 2022 and 2021, as the effect would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,965,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,558,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,164,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,523,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,976,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of redeemable convertible preferred stock also participate in dividends with shares of common stock (if and when declared) and therefore are deemed participating securities. The holders of redeemable convertible preferred stock do not contractually share in losses and therefore no additional net loss per share has been disclosed under the&#160;two-class&#160;method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Emerging growth company status&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an &#x201c;emerging growth company&#x201d; (EGC), as defined in the Jumpstart Our Business Startups Act (JOBS Act), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section&#160;107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;transition period for complying with new or revised accounting standards, and as a result of this election, the financial statements may not be comparable to companies that comply with public company FASB standards&#x2019; effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an IPO offering or such earlier time that it is no longer an EGC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting standards and pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as subsequently amended (collectively &#x201c;ASC 842&#x201d;). The guidance amends the existing accounting standards for lease accounting, including requirements for lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expanding disclosure requirements regarding leasing arrangements. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting ASC 842 in which entities can elect to apply the new guidance using a modified retrospective approach at the beginning of the year in which the new lease standard is adopted. In November 2019, the FASB issued ASU 2019-10 deferring the effective date for private entities for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the FASB issued ASU 2020-05 which further defers the effective date for private entities for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As an EGC, the Company adopted the new leasing guidance on January 1, 2022. The Company combined lease and non-lease components as a single component for all underlying asset classes. ASC 842 provides a number of optional practical expedients in transition. The Company applied the &#x2018;package of practical expedients&#x2019; which allows the Company to not reassess i) whether existing or expired arrangements contain a lease, ii) the lease classification of existing or expired leases, or iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. The Company completed its evaluation and recognized $1.5 million in operating right-of-use assets and $0.6 million and $1.0 million in operating lease liabilities, current and non-current, respectively, on January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU&#160;2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for&#160;available-for-sale&#160;debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for fiscal year beginning after December&#160;15, 2022, and interim periods beginning after December&#160;15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company&#x2019;s investment portfolio, current market conditions and historical credit loss activity, the adoption of ASU&#160;2016-13&#160;is not expected to have a material impact on its financial position, results of operations or the related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-308">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company evaluates its estimates, including those related to the recoverability of long-lived assets, stock-based compensation, the valuation of financial instruments, and the valuation of deferred tax assets and liabilities. The Company&#x2019;s estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Although actual results could differ from those estimates, management does not believe that such differences would be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-309">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments which potentially subject the Company to credit risk consist principally of cash and marketable debt securities. All cash is held in United States financial institutions that are federally insured. At times, the Company may maintain cash balances in excess of the federally insured amount. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk. The Company&#x2019;s investments in marketable debt securities have been issued by corporate entities and government-sponsored enterprises with high credit ratings. The Company mitigates investment risks by investing in highly-rated securities with relatively short maturities that the Company believes do not subject it to undue investment or credit risk. If any of these financial institutions fail to perform their obligations under the terms of these financial instruments, the Company&#x2019;s maximum exposure to potential losses would be equal to the amounts reported on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-310">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations as and manages its business in one operating segment operating exclusively in the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-311"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-312">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three &lt;/span&gt;&lt;/div&gt;months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-313">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of debt securities with maturities greater than three months from the date of purchase that include commercial paper and corporate notes. Classification of marketable securities between current and&#160;non-current&#160;is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#x2019;s ability and intent to hold the investment to maturity. There were no outstanding marketable securities as of December&#160;31, 2022. As of December&#160;31, 2021, all marketable securities were classified as current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and dividend income are recorded when earned and included in interest income in the statement of operations. Premiums and discounts, if any, on marketable securities are amortized or accreted to maturity and included in interest income in the statement of operations. The specific identification method is used in computing realized gains and losses on the sale of the Company&#x2019;s marketable securities.&lt;/span&gt;&lt;/div&gt;The Company classifies its marketable securities as&#160;available-for-sale.&#160;The Company determines the appropriate classification of the securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date.&#160;Marketable securities that are classified as&#160;available-for-sale&#160;are measured at fair value on the balance sheet, and unrealized gains and losses on marketable securities are reported as a component of accumulated other comprehensive income (loss) in stockholders&#x2019; equity (deficit) until realized. Marketable securities are evaluated periodically to determine whether the carrying value of a marketable security exceeds its fair value and the decline in value is determined to be other-than-temporary. Management reviews criteria, such as the general market conditions, magnitude and duration in which the fair value has been less than the carrying value, the investment issuer&#x2019;s financial condition and business outlook, as well as the Company&#x2019;s ability to hold the securities until the recovery of its amortized cost basis, to determine whether the decline in value is other-than-temporary. If a decline in value is determined to be other-than-temporary, the value of the marketable security is reduced, and the impairment is recorded as other expense in the statement of operations. As of December&#160;31, 2021, any decline in value of marketable securities was concluded not to be other-than-temporary. As of December&#160;31, 2022, no assessment was required.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecurities
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-314"
      unitRef="usd">0</us-gaap:MarketableSecurities>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-315">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,642,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,326,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,697,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,393,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-316"
      unitRef="usd">34642340</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-317"
      unitRef="usd">30326352</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-318"
      unitRef="usd">55000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-319"
      unitRef="usd">67500</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-320"
      unitRef="usd">34697340</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-321"
      unitRef="usd">30393852</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-322">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, marketable securities, accounts payable, accrued expenses, convertible notes and derivative liabilities. The fair values of the cash and cash equivalents, accounts payable and accrued expenses approximated their carrying values as of December&#160;31, 2022 and 2021, due to their short-term maturities. For a description of the fair value of marketable securities, refer to Note 4. The Convertible Notes as discussed in Note 10 contained embedded derivative features that were required to be bifurcated and remeasured to fair value at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, Fair Value Measurements (&#x201c;ASC 820&#x201d;). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt"&gt;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt"&gt;Fair value is determined by using inputs, other than Level&#160;1 quoted prices that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.27pt"&gt;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant judgments to be made by a reporting entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-323">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Major replacements and improvements that extend the useful lives of assets are capitalized, while general repairs and maintenance are charged to expense as incurred. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the estimated useful lives of the assets or the related lease term, whichever is shorter. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated useful lives of property, plant and equipment by major category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-324">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated useful lives of property, plant and equipment by major category are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following at December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,803,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,688,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,708,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,229,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,281,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,459,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,427,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i87575f3a4a8d47e0b099f6f2d5697f3c_D20220101-20221231"
      id="f-325">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5ae3ce8c146e4b3a8647cdb069d847f0_D20220101-20221231"
      id="f-326">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib14beae652b44f86850981cbd7bea2fb_D20220101-20221231"
      id="f-327">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-328">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of its long-lived asset group for potential impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recoverability is determined by comparing future undiscounted cash flows associated with such assets to the related carrying value. An impairment loss may be recognized when the estimated undiscounted future cash flow is less than the carrying amount of the asset. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the underlying asset group. Any impairment loss to be recognized is measured as the amount by &lt;/span&gt;&lt;/div&gt;which the carrying value of the asset group exceeds the fair value of the asset group.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-329"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-330"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <nexi:TemporaryEquityPolicyPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-331">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s redeemable convertible preferred stock was classified outside of stockholders&#x2019; equity because the shares contained deemed liquidation rights that represented a contingent redemption feature not solely within the control of the Company.&lt;/span&gt;&lt;/div&gt;</nexi:TemporaryEquityPolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-332">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible instruments and embedded derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that contain conversion options and other embedded features. The Company bifurcates embedded features from their host instruments and accounts for them as free-standing derivative financial instruments according to certain criteria.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon any change to the Company&#x2019;s debt arrangements, the Company evaluates the amendment to determine whether a debt modification or extinguishment has occurred, including whether the amendment should be accounted for as a troubled debt restructuring.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s derivative instrument related to certain features embedded within the Company&#x2019;s Convertible Notes as discussed in Note 10. The derivative was accounted for as a derivative liability and remeasured to fair value as of each balance sheet date. The related remeasurement adjustments are recognized in the accompanying statements of operations and were settled upon the conversion of the Convertible Notes during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-333">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including share-based compensation, as well as costs for third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, based on its estimates of services performed and costs incurred. These estimates include the level of services performed by the third parties, and other indicators of the services completed. Based on the timing of amounts invoiced by service providers, the Company may also record payments made to those providers as prepaid expenses that will be recognized as expenses in future periods as the related services are rendered.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <nexi:ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-334">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical trial and contract development and manufacturing organization expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company makes payments in connection with clinical trials and contract development and manufacturing organizations (&#x201c;CDMO&#x201d;) under contracts with contract research organizations that support conducting and managing clinical trials and the manufacturing of materials utilized in clinical and preclinical activities. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a time and materials basis. A portion of the obligation to make payments under these contracts depends on factors such as the successful enrollment, treatment of patients, the completion of other clinical trial milestones, or completion of manufacturing milestones. Termination clauses within the agreements require notification for a certain number of days prior to completing work, payments for costs incurred through the termination date, and termination penalty, if applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Expenses related to development and manufacturing are accrued based on estimates and/or representations from service providers regarding work performed, including progress in the development of processes through technology transfers to manufacture the Company&#x2019;s clinical material and completion of the manufactured clinical material. Other incidental costs related to patient enrollment or &lt;/span&gt;&lt;/div&gt;treatment are accrued when reasonably certain. If the amounts the Company is obligated to pay under clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.</nexi:ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-335">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records compensation expense associated with stock options and other forms of equity compensation based on the estimated fair value at the grant date. Compensation expense related to awards to employees and non-employees with service based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the requisite service period of the award, which is generally the vesting term. The Company&#x2019;s policy is to account for forfeitures as they occur. The Company uses the Black-Scholes-Merton option pricing (Black-Scholes) model to estimate the fair value of stock options. The Black-Scholes model requires input-based assumptions that are highly subjective, judgmental and sensitive in the determination of stock-based compensation cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted after the Company&#x2019;s IPO are issued at the fair market value of the Company&#x2019;s common stock at the date the grant is approved by the Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected volatility was based on the historical volatility of comparable public companies from a representative peer group selected based on industry and market capitalization data. The historical volatility is calculated based on a period of time commensurate with the expected term assumption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate was based on the continuous rates provided by the U.S. Treasury with a term approximating the expected term of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected dividend yield was 0% because the Company has not historically paid and does not expect to pay any dividends for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based-Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-336"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-337">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes it is&#160;more-likely-than-not&#160;that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results,&#160;on-going&#160;tax planning and forecasts of future taxable income on a&#160;jurisdiction-by-jurisdiction&#160;basis. The Company recorded a valuation allowance against all estimated net deferred tax assets as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered&#160;more-likely-than-not&#160;to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Recognized income tax positions are measured at the largest amount that is greater than&#160;more-likely-than-not&#160;of being realized. Changes in the recognition or measurement are reflected in the period in &lt;/span&gt;&lt;/div&gt;which the change in estimate occurs. Interest and penalties related to uncertain tax positions are recorded in the provision of income taxes.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-338"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-339"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-340"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-341"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-342"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-343"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-344">Net Loss Per Share Attributable to Common StockholdersBasic net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock and common stock equivalents outstanding for the period. The Company adjusts net loss to arrive at the net loss attributable to common stockholders to reflect the amount of dividends accumulated during the period on the Company&#x2019;s redeemable convertible preferred stock. Such dividends are only payable if and when declared by the Board of Directors (Note 11). The treasury stock method is used to determine the dilutive effect of the Company&#x2019;s stock option grants and warrants and the&#160;if-converted&#160;method is used to determine the dilutive effect of the Company&#x2019;s redeemable convertible preferred stock and Convertible Notes. For the years ended December&#160;31, 2022 and 2021, the Company had a net loss attributable to common stockholders, and as such, all outstanding stock options, shares of redeemable convertible preferred stock, and warrants were excluded from the calculation of diluted loss per share. Under the if-converted method, convertible instruments that are in the money, are assumed to have been converted as of the beginning of the period or when issued, if later. Additionally, the effects of any interest expense and changes in fair value of bifurcated derivatives is added back to the numerator of the diluted net loss per share calculation if the conversion of the Convertible Notes is dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-345">The following table sets forth the computation of basic and diluted earnings per share for the years ended December&#160;31, 2022 and 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,506,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,901,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated dividends on Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(377,562)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,506,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,279,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,059,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,186,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-346"
      unitRef="usd">-62506199</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-347"
      unitRef="usd">-50901508</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-348"
      unitRef="usd">0</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:TemporaryEquityDividendsAdjustment
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-349"
      unitRef="usd">377562</us-gaap:TemporaryEquityDividendsAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-350"
      unitRef="usd">-62506199</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-351"
      unitRef="usd">-62506199</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-352"
      unitRef="usd">-51279070</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-353"
      unitRef="usd">-51279070</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-354"
      unitRef="usdPerShare">-2.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-355"
      unitRef="usdPerShare">-2.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="2"
      id="f-356"
      unitRef="usdPerShare">-2.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="2"
      id="f-357"
      unitRef="usdPerShare">-2.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-358"
      unitRef="shares">24059104</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-359"
      unitRef="shares">24059104</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-360"
      unitRef="shares">20186127</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-361"
      unitRef="shares">20186127</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-362">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted average common shares outstanding at December&#160;31, 2022 and 2021, as the effect would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,965,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,558,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,164,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,523,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,976,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9cf8573a7849487689779272da2d03b6_D20220101-20221231"
      decimals="0"
      id="f-363"
      unitRef="shares">3965502</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic3ec5ac6a0fb4bc1994df10d0b09682c_D20210101-20211231"
      decimals="0"
      id="f-364"
      unitRef="shares">3305291</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieb99aa2cda304c0e9bea4f6fc09c71fa_D20220101-20221231"
      decimals="0"
      id="f-365"
      unitRef="shares">1558000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i174925bbb76f4a498cf99885a1362415_D20210101-20211231"
      decimals="0"
      id="f-366"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec5ab7a1dbd54ea8861c3ef82c751c0b_D20220101-20221231"
      decimals="0"
      id="f-367"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i791c94e47b51427dbee42f8cc8773959_D20210101-20211231"
      decimals="0"
      id="f-368"
      unitRef="shares">1164080</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic4a0838ebfff413db2e9ad8c231fef39_D20220101-20221231"
      decimals="0"
      id="f-369"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia4f8973765ad4bc8be9332ad3594c082_D20210101-20211231"
      decimals="0"
      id="f-370"
      unitRef="shares">506768</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i074eae8be4554fceb16fac6998ae3c9a_D20220101-20221231"
      decimals="0"
      id="f-371"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4ba9051f6c594a37b6e8e5e56c95af66_D20210101-20211231"
      decimals="0"
      id="f-372"
      unitRef="shares">150</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-373"
      unitRef="shares">5523502</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-374"
      unitRef="shares">4976289</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-375">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting standards and pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as subsequently amended (collectively &#x201c;ASC 842&#x201d;). The guidance amends the existing accounting standards for lease accounting, including requirements for lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expanding disclosure requirements regarding leasing arrangements. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. In July 2018, the FASB issued additional guidance, which offers a transition option to entities adopting ASC 842 in which entities can elect to apply the new guidance using a modified retrospective approach at the beginning of the year in which the new lease standard is adopted. In November 2019, the FASB issued ASU 2019-10 deferring the effective date for private entities for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December 15, 2021. In June 2020, the FASB issued ASU 2020-05 which further defers the effective date for private entities for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As an EGC, the Company adopted the new leasing guidance on January 1, 2022. The Company combined lease and non-lease components as a single component for all underlying asset classes. ASC 842 provides a number of optional practical expedients in transition. The Company applied the &#x2018;package of practical expedients&#x2019; which allows the Company to not reassess i) whether existing or expired arrangements contain a lease, ii) the lease classification of existing or expired leases, or iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. The Company completed its evaluation and recognized $1.5 million in operating right-of-use assets and $0.6 million and $1.0 million in operating lease liabilities, current and non-current, respectively, on January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU&#160;2016-13,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for&#160;available-for-sale&#160;debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The standard is effective for fiscal year beginning after December&#160;15, 2022, and interim periods beginning after December&#160;15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company&#x2019;s investment portfolio, current market conditions and historical credit loss activity, the adoption of ASU&#160;2016-13&#160;is not expected to have a material impact on its financial position, results of operations or the related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ieca80fa7685c4607ad5fef70aa7ce16e_I20220101"
      decimals="-5"
      id="f-376"
      unitRef="usd">1500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ieca80fa7685c4607ad5fef70aa7ce16e_I20220101"
      decimals="-5"
      id="f-377"
      unitRef="usd">600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ieca80fa7685c4607ad5fef70aa7ce16e_I20220101"
      decimals="-5"
      id="f-378"
      unitRef="usd">1000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-379">Fair Value Measurements&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,722,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,979,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,991,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,722,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,979,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,991,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the years ended December&#160;31, 2022 and 2021, the Company did not have any transfers between levels. There were no Level&#160;3 recurring fair value measurements as of December&#160;31, 2022 or 2021.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-380">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,722,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,979,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,991,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,722,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,979,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,991,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i403fdc2b033c4c1b88c48004e7a37ed6_I20221231"
      decimals="0"
      id="f-381"
      unitRef="usd">23722328</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3b550a9ae7a2446e8c50991ec5a09571_I20221231"
      decimals="0"
      id="f-382"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic044d50d4b384932ab18201e6f0b8da8_I20221231"
      decimals="0"
      id="f-383"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie253db02491d4a9fb3f8cad4afeb89c0_I20211231"
      decimals="0"
      id="f-384"
      unitRef="usd">22124003</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5a167d620d684558850204ae675e061c_I20211231"
      decimals="0"
      id="f-385"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i02e707e70eb144e8a9764dbe72b5e376_I20211231"
      decimals="0"
      id="f-386"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9482c390e2874f69bdd95e842f27cb9a_I20221231"
      decimals="0"
      id="f-387"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i294000fb786942f083924e218896237f_I20221231"
      decimals="0"
      id="f-388"
      unitRef="usd">7979279</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia62f066291d846ab9d346921a55d6947_I20221231"
      decimals="0"
      id="f-389"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25ad398f6533421f95d670a14ced26ca_I20211231"
      decimals="0"
      id="f-390"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id4421505cb3f46938fada27cf31ab63a_I20211231"
      decimals="0"
      id="f-391"
      unitRef="usd">56991897</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i403ec125cb5f41cb813253079b7b88b1_I20211231"
      decimals="0"
      id="f-392"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib2e473ef2ced4a76af90569c4e60acd9_I20221231"
      decimals="0"
      id="f-393"
      unitRef="usd">23722328</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iebce9dddcdbc4c0aa95432c1635a3c49_I20221231"
      decimals="0"
      id="f-394"
      unitRef="usd">7979279</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib1965187e11b4cd7be206e7c49075e52_I20221231"
      decimals="0"
      id="f-395"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i24e448c466c94c3bbfea9fb4d64de651_I20211231"
      decimals="0"
      id="f-396"
      unitRef="usd">22124003</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5ffac7d5bf164513a7108afdd83a49dc_I20211231"
      decimals="0"
      id="f-397"
      unitRef="usd">56991897</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9c5920ce6d144e6ca4a4780bbb323bfb_I20211231"
      decimals="0"
      id="f-398"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <nexi:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-399">Prepaid Expenses and Other Current Assets&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following at December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,375,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,394,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nexi:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-400">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following at December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,375,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,394,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <nexi:PrepaidResearchAndDevelopmentExpenses
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-401"
      unitRef="usd">1176491</nexi:PrepaidResearchAndDevelopmentExpenses>
    <nexi:PrepaidResearchAndDevelopmentExpenses
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-402"
      unitRef="usd">3375388</nexi:PrepaidResearchAndDevelopmentExpenses>
    <nexi:PrepaidMaintenanceAgreements
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-403"
      unitRef="usd">369606</nexi:PrepaidMaintenanceAgreements>
    <nexi:PrepaidMaintenanceAgreements
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-404"
      unitRef="usd">132104</nexi:PrepaidMaintenanceAgreements>
    <us-gaap:PrepaidInsurance
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-405"
      unitRef="usd">403653</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-406"
      unitRef="usd">479393</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-407"
      unitRef="usd">245278</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-408"
      unitRef="usd">308842</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-409"
      unitRef="usd">74467</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-410"
      unitRef="usd">0</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-411"
      unitRef="usd">401916</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-412"
      unitRef="usd">99189</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-413"
      unitRef="usd">2671411</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-414"
      unitRef="usd">4394916</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-415">Property and Equipment&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following at December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,803,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,943,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,688,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,708,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,229,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,281,041)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,459,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,427,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was $994,792 and $870,285 for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id4ed377902824f8ba0190be0190253f8_I20221231"
      decimals="0"
      id="f-416"
      unitRef="usd">6803996</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i906f22664a64466f86557348630d1046_I20211231"
      decimals="0"
      id="f-417"
      unitRef="usd">5943501</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5d5098de97364db3825058bb650872b0_I20221231"
      decimals="0"
      id="f-418"
      unitRef="usd">516974</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icaa2d70a7c5a44e0b33c4306131e12a5_I20211231"
      decimals="0"
      id="f-419"
      unitRef="usd">486822</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iec4224fbcf36436d982945a277e0bbaf_I20221231"
      decimals="0"
      id="f-420"
      unitRef="usd">47877</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i16f5c36a4c3e45f1bbeaada8cda374f9_I20211231"
      decimals="0"
      id="f-421"
      unitRef="usd">47877</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic8a0b0ffb5bd4c57ab7546cae1b3e6f4_I20221231"
      decimals="0"
      id="f-422"
      unitRef="usd">319816</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i53fe34a4932b4e8087a347be3b55c58e_I20211231"
      decimals="0"
      id="f-423"
      unitRef="usd">230148</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-424"
      unitRef="usd">7688663</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-425"
      unitRef="usd">6708348</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-426"
      unitRef="usd">3229592</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-427"
      unitRef="usd">2281041</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-428"
      unitRef="usd">4459071</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-429"
      unitRef="usd">4427307</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-430"
      unitRef="usd">994792</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-431"
      unitRef="usd">870285</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-432">Restructuring Activities&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company announced that, following a strategic review of its pipeline, indications, timelines and cash position, it implemented a strategic realignment initiative, which was designed to reduce costs and reallocate resources towards its AIM INJ preclinical development programs. As part of this strategy, the Company initiated a workforce reduction plan to reduce headcount by 30%, primarily affecting the clinical development, manufacturing and administrative staff that had been needed to support the AIM ACT adoptive cell therapy clinical programs. This plan will reduce the Company&#x2019;s workforce from 74 full-time employees to approximately 50 full-time employees. The Company estimates that it will incur approximately $0.7 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. These one-time employee termination benefits are comprised of severance, benefits and related costs, all of which are expected to result in cash expenditures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued salaries at December 31, 2022 includes $0.4 million in severance expenses related to the November 2022 restructuring. The Company communicated the workforce reduction on November 14, 2022 and recognized $0.5 million in costs associated with the restructuring during the year ended December 31, 2022. The Company expects to complete the restructuring in the second quarter of 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges related to the restructuring activities as of December&#160;31, 2022. There were no restructuring expenses during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued Restructuring Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued Restructuring Expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less: Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance, benefits and related costs due to workforce reduction&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Totals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <nexi:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent
      contextRef="i7c590145da4b44288c802fc50a344e72_D20221101-20221130"
      decimals="2"
      id="f-433"
      unitRef="number">0.30</nexi:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent>
    <nexi:RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations
      contextRef="i7c590145da4b44288c802fc50a344e72_D20221101-20221130"
      decimals="INF"
      id="f-434"
      unitRef="employee">74</nexi:RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations>
    <nexi:RestructuringAndRelatedCostNumberOfPositionsAfterEliminations
      contextRef="i7c590145da4b44288c802fc50a344e72_D20221101-20221130"
      decimals="INF"
      id="f-435"
      unitRef="employee">50</nexi:RestructuringAndRelatedCostNumberOfPositionsAfterEliminations>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ie321f805cc7f4133a42ae2ffef7ab78f_I20221130"
      decimals="-5"
      id="f-436"
      unitRef="usd">700000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringReserve
      contextRef="ie19a45c8600b4fbba9f92e595547ba14_I20221231"
      decimals="-5"
      id="f-437"
      unitRef="usd">400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="-5"
      id="f-438"
      unitRef="usd">500000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <nexi:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-439">costs associated with the restructuring</nexi:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-440">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges related to the restructuring activities as of December&#160;31, 2022. There were no restructuring expenses during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.653%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.485%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.024%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.902%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued Restructuring Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accrued Restructuring Expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Less: Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance, benefits and related costs due to workforce reduction&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Totals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ibe540e5b2e574273bb15fd4fe0b096b5_I20211231"
      decimals="0"
      id="f-441"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i97ccdc3f285040bd876d4fa408564bf9_D20220101-20221231"
      decimals="0"
      id="f-442"
      unitRef="usd">531829</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i97ccdc3f285040bd876d4fa408564bf9_D20220101-20221231"
      decimals="0"
      id="f-443"
      unitRef="usd">149440</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="ie19a45c8600b4fbba9f92e595547ba14_I20221231"
      decimals="0"
      id="f-444"
      unitRef="usd">382389</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-445"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-446"
      unitRef="usd">531829</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-447"
      unitRef="usd">149440</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-448"
      unitRef="usd">382389</us-gaap:RestructuringReserve>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-449">Accrued Expenses&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the components of accrued expenses is as follows as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,210,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued salaries, benefits and related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,855,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,143,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,357,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,170,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-450">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the components of accrued expenses is as follows as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,210,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;384,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued salaries, benefits and related expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,855,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,143,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,357,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,170,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <nexi:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-451"
      unitRef="usd">3210794</nexi:AccruedResearchAndDevelopmentCostsCurrent>
    <nexi:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-452"
      unitRef="usd">2611380</nexi:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-453"
      unitRef="usd">267383</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-454"
      unitRef="usd">384254</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-455"
      unitRef="usd">3855797</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-456"
      unitRef="usd">3143602</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-457"
      unitRef="usd">23179</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-458"
      unitRef="usd">31473</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-459"
      unitRef="usd">7357153</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-460"
      unitRef="usd">6170709</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-461">Commitments and Contingencies&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a Translational Research Award Agreement effective May&#160;23, 2012 with the Department of Business&#160;&amp;amp; Economic Development with the State of Maryland, Maryland Biotechnology Center (&#x201c;MBC&#x201d;). The mission of MBC is to integrate entrepreneurial strategies to stimulate the transformation of scientific discovery and intellectual assets into capital formation and business development. Under the agreement, MBC provided $200,000 to NexImmune for research on its artificial aAPC for cancer immunotherapy. In 2013, an amendment increased the amount by $125,000 for a total grant of $325,000. This grant was recorded as income in 2012 and 2013, as the Company incurred the expenses which qualified it for the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company must repay the funds through annual payments calculated at 3% of annual revenues for the preceding year. Payments shall continue for 10 years after the first payment date and may total up to 200% of the total grant amount. The end date of the agreement is defined as January&#160;31, 2024, or when any and all repayments due to MBC have been made. If the Company does not earn any revenue, the grant does not need to be repaid. Through December&#160;31, 2022, no revenue has been recorded, therefore, no payments to MBC are due.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Johns Hopkins University Exclusive License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into an Exclusive License Agreement with Johns Hopkins University (&#x201c;JHU&#x201d;) effective June 2011, which was amended and restated in January 2017, referred to as the A&amp;amp;R JHU License Agreement, under which there are license fees, royalties, and milestone payments. As part of the agreement, the Company acquired a perpetual, exclusive license from JHU covering its invention related to Antigen Specific T cells.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;JHU was also entitled to milestone fees of $75,000 in connection with clinical trial milestones. For the first licensed product or licensed service in the therapeutic field, the Company may be required to pay JHU additional aggregate milestone fees of $1.6 million for clinical and regulatory milestone fees. The Company may be required to pay JHU reduced milestone fees for the second and third licensed products or licensed services in the therapeutic field in connection with clinical and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;regulatory milestones. In the diagnostic field, the Company may be required to pay JHU aggregate milestone fees of $0.4 million for the first licensed product or licensed service and reduced milestone fees for the second and third licensed products or licensed services in connection with regulatory and commercial milestones. The Company may be required to pay JHU aggregate milestone fees of $100,000 for commercial milestones for the first licensed product or licensed service in the&#160;non-clinical&#160;field. In the aggregate, the Company may be required to pay JHU additional milestone fees of up to $4.2 million for all clinical, regulatory and commercial milestones for all licensed products or licensed services in the therapeutic field, the diagnostic field and the non-clinical field. The Company may also be required to pay royalties in the low to upper&#160;single&#160;digits on net sales of licensed services in therapeutic products, diagnostic products and&#160;non-clinical&#160;products. The Company is required to make minimum annual royalty payments of $100,000 to JHU under the A&amp;amp;R JHU License Agreement, which started in the low five figures in the first year of the agreement and increased to $100,000 in the third year and for each subsequent year of the agreement. The Company may also be required to pay JHU a low double digit percentage, not to exceed 15%, of any&#160;non-royalty&#160;sublicense consideration the Company receives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will record a liability when such events become probable. The Company has not reached any of the milestones or transacted its first commercial sale as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company must make minimum royalty payments, which began upon the fourth anniversary of the agreement and upon every anniversary thereafter during the term of the agreement, which offset future royalties per above owed to JHU. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred $525,000 in cumulative minimum royalties from inception. Future annual minimum royalties consist of $100,000 due each year during the remaining term of the agreement. The Company records milestones, royalties and minimum royalties at the time when payments become probable. The Company incurred $100,000 related to minimum royalties owed in the years ended December&#160;31, 2022 and 2021 and is included in research and development expenses on the accompanying statement of operations. The Company has accrued royalties of $50,000 as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;23, 2020, the Company applied for an unsecured $843,619 loan under the Paycheck Protection Program (the &#x201c;PPP Loan&#x201d;). The Paycheck Protection Program (or &#x201c;PPP&#x201d;) was established under the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) and is administered by the U.S. Small Business Administration (&#x201c;SBA&#x201d;). On May&#160;1, 2020, the PPP loan was approved and funded. The Company entered into a promissory note of $843,619, which is recorded within other current liabilities in the accompanying balance sheet. The Company treats the PPP loan as debt under ASC 470. The use of loan proceeds must be for payroll costs, payment of interest on covered mortgage obligations, rent and utility costs over either an eight-week or&#160;24-week&#160;period, at the Company&#x2019;s option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company submitted the PPP Loan forgiveness application to the SBA in March 2021 and received full forgiveness of the $843,619 PPP Loan in July 2021. The Company did not carry a PPP loan balance as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. As of December&#160;31, 2022 and 2021, the Company was not involved in any material legal proceedings.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <nexi:ResearchAndDevelopmentArrangementContractToPerformForOthersLiability
      contextRef="icbc1c26d23f6405c928044ee7980345e_I20120523"
      decimals="0"
      id="f-462"
      unitRef="usd">200000</nexi:ResearchAndDevelopmentArrangementContractToPerformForOthersLiability>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i0dc71e39107c4d2e888729d888bb4e8b_D20130523-20130523"
      decimals="0"
      id="f-463"
      unitRef="usd">125000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <nexi:ResearchAndDevelopmentArrangementContractToPerformForOthersLiability
      contextRef="i69c37fb252ac488eb687ac1d9ffa59fe_I20130523"
      decimals="0"
      id="f-464"
      unitRef="usd">325000</nexi:ResearchAndDevelopmentArrangementContractToPerformForOthersLiability>
    <nexi:ResearchAndDevelopmentArrangementAnnualPaymentPercentage
      contextRef="ie5deb40f57714a11a917ea127c6f7c9f_D20130523-20130523"
      decimals="2"
      id="f-465"
      unitRef="number">0.03</nexi:ResearchAndDevelopmentArrangementAnnualPaymentPercentage>
    <nexi:ResearchAndDevelopmentArrangementContractualPaymentPeriod
      contextRef="ie5deb40f57714a11a917ea127c6f7c9f_D20130523-20130523"
      id="f-466">P10Y</nexi:ResearchAndDevelopmentArrangementContractualPaymentPeriod>
    <nexi:ResearchAndDevelopmentArrangementContractualPaymentPercentage
      contextRef="ie5deb40f57714a11a917ea127c6f7c9f_D20130523-20130523"
      decimals="2"
      id="f-467"
      unitRef="number">2</nexi:ResearchAndDevelopmentArrangementContractualPaymentPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i64dedfdb14784525a0d5de1ec201e691_D20220101-20221231"
      decimals="0"
      id="f-468"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <nexi:ResearchAndDevelopmentArrangementContractToPerformForOthersLiability
      contextRef="ie3294ba19efb4f899898ab09f55e6853_I20221231"
      decimals="0"
      id="f-469"
      unitRef="usd">0</nexi:ResearchAndDevelopmentArrangementContractToPerformForOthersLiability>
    <nexi:MilestoneFees
      contextRef="i6719abe720c5406d8c6c8df3e56df15a_D20170101-20170101"
      decimals="0"
      id="f-470"
      unitRef="usd">75000</nexi:MilestoneFees>
    <nexi:MilestoneFees
      contextRef="id205558188da4f4faaf0ec195c63003f_D20170101-20170101"
      decimals="-5"
      id="f-471"
      unitRef="usd">1600000</nexi:MilestoneFees>
    <nexi:MilestoneFees
      contextRef="i2c23fd7809674603b59c0f27fb6a073b_D20170101-20170101"
      decimals="-5"
      id="f-472"
      unitRef="usd">400000</nexi:MilestoneFees>
    <nexi:MilestoneFees
      contextRef="ia6fc5f4226364570a5d62f606626c0ab_D20170101-20170101"
      decimals="0"
      id="f-473"
      unitRef="usd">100000</nexi:MilestoneFees>
    <nexi:MilestoneFees
      contextRef="i432594ce07a346698a0597e5adf392f0_D20170101-20170101"
      decimals="-5"
      id="f-474"
      unitRef="usd">4200000</nexi:MilestoneFees>
    <nexi:MinimumAnnualRoyaltyPayments
      contextRef="i2735225fb3054df286cd15e9d84e3203_D20220101-20221231"
      decimals="0"
      id="f-475"
      unitRef="usd">100000</nexi:MinimumAnnualRoyaltyPayments>
    <nexi:MinimumAnnualRoyaltyPayments
      contextRef="i2735225fb3054df286cd15e9d84e3203_D20220101-20221231"
      decimals="0"
      id="f-476"
      unitRef="usd">100000</nexi:MinimumAnnualRoyaltyPayments>
    <nexi:SublicenseConsiderationPaymentPercentMaximum
      contextRef="i2735225fb3054df286cd15e9d84e3203_D20220101-20221231"
      decimals="2"
      id="f-477"
      unitRef="number">0.15</nexi:SublicenseConsiderationPaymentPercentMaximum>
    <nexi:CumulativeMinimumRoyalties
      contextRef="ib3562b2fa26c44aba06d2f7770d6feb4_I20221231"
      decimals="0"
      id="f-478"
      unitRef="usd">525000</nexi:CumulativeMinimumRoyalties>
    <nexi:MinimumAnnualRoyaltyPayments
      contextRef="i2735225fb3054df286cd15e9d84e3203_D20220101-20221231"
      decimals="0"
      id="f-479"
      unitRef="usd">100000</nexi:MinimumAnnualRoyaltyPayments>
    <us-gaap:RoyaltyExpense
      contextRef="ia0e4cc0109264b539acd8b2cbc12a65b_D20210101-20211231"
      decimals="0"
      id="f-480"
      unitRef="usd">100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="icd3d3cf5f9f6420abe32fd8826ce546d_D20220101-20221231"
      decimals="0"
      id="f-481"
      unitRef="usd">100000</us-gaap:RoyaltyExpense>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-482"
      unitRef="usd">50000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-483"
      unitRef="usd">50000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i073d07654a3240e784df7ae6097d2764_I20200423"
      decimals="0"
      id="f-484"
      unitRef="usd">843619</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NotesPayableCurrent
      contextRef="i6e206dd327124b4b8af59ef1f3ab5579_I20200501"
      decimals="0"
      id="f-485"
      unitRef="usd">843619</us-gaap:NotesPayableCurrent>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i64dc0ef29e704fa49df23a5b74b93453_D20210701-20210731"
      decimals="0"
      id="f-486"
      unitRef="usd">843619</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-487">Convertible NotesIn April 2020, the Company entered into Convertible Note Purchase Agreement (&#x201c;Agreement&#x201d;) for the sale of up to  $15,000,000 of convertible promissory notes with 6% interest rate (&#x201c;Convertible Notes&#x201d;). The Agreement specified an initial closing date of April&#160;23, 2020 and allowed additional closings within 90 days of the initial closing. The Convertible Notes were scheduled to mature on April&#160;23, 2021.&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the Convertible Notes required a mandatory conversion upon certain qualified financing events (&#x201c;Mandatory Conversion&#x201d;) and allowed for conversion at the option of the holder upon certain&#160;non-qualified&#160;financing events (&#x201c;Optional Conversion 1&#x201d;). Upon Mandatory Conversion and Optional Conversion 1, the outstanding principal amount and all accrued and unpaid interest would have automatically converted into the Company&#x2019;s preferred stock of the same series issued in such equity financing and will be equal to the number of preferred stock obtained by dividing (a)&#160;all principal and accrued but unpaid interest under such Convertible Note by (b)&#160;the price per share paid by the other purchasers of the preferred stock sold in such equity financing multiplied by 80%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Mandatory Conversion and Optional Conversion 1 did not occur by the maturity date, the outstanding principal amount plus all accrued and unpaid interest would be converted at the option of the holder into Company&#x2019;s common stock at the price per share obtained by dividing $85 million by the Company&#x2019;s fully-diluted capitalization (&#x201c;Optional Conversion 2&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company (i)&#160;consummates a change in control or (ii)&#160;the Company&#x2019;s common stock becomes publicly listed on a stock exchange, the outstanding principal amount plus all accrued and unpaid interest would be automatically converted into shares of the Company&#x2019;s most senior series of capital stock outstanding at the time of such change in control or public listing, at a price equal to the lower of (a) 90% of the price per share paid by the purchasers of such stock in such a transaction and (b)&#160;the price per share obtained by dividing $125 million by the Company&#x2019;s fully-diluted capitalization (&#x201c;Change in Control&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Agreement was amended in July 2020 to allow the sale of up to $50,000,000 convertible notes and to allow for additional closings within 150 days of the initial closing date. The Agreement was amended in September 2020 to allow for additional closings within 190 days of the initial closing date. In addition, the provisions of Mandatory Conversion and Optional Conversion 1 were amended to allow for conversion upon an equity financing at a price equal to the lower of (a) 80% of the price per share paid by the purchasers of such stock in such a transaction and (b)&#160;the price per share obtained by dividing $125,000,000 by the Company&#x2019;s fully-diluted capitalization. The Company evaluated the amendments and concluded that the amendments represented a debt modification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the Agreement was further amended to allow additional closings through December&#160;31, 2020, and in January 2021 it was amended again to allow closings through January 31, 2021. In January 2021, the Company issued convertible notes with a principal amount of $9.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Convertible Notes and determined that the Mandatory Conversion feature, Optional Conversion 1 feature and Change in Control meet the definition of an embedded derivative liability that is required to be bifurcated from the host instrument and measured at fair value. The fair value of the derivative liability for the convertible notes issued in January 2021 was $0.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company amortized the debt issuance costs of $0.3 million and debt discount of $4.2 million, comprising of the initial value of the derivative liability of $2.0 million and the BCF of $2.2 million, prior to the adoption of ASU 2020-06, over the term of the Convertible Notes using the effective interest method. Upon adoption of this standard, the beneficial conversion feature was no longer separately accounted. As a result of applying the modified retrospective method, the Company recognized a transition adjustment of $0.7 million recorded in accumulated deficit, a reduction of additional paid-in capital of $2.3 million and an increase to the carrying value of the convertible notes of $1.5 million on January 1, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The debt issuance costs and debt discount amortization expense for the years ended December 31, 2021 was $0.6 million  and is included in interest expense in the accompanying statements of operations. The interest expense at 6% of the Convertible Notes&#x2019; principal amount for the years ended December 31, 2021 was $0.2 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company completed an IPO on February 11, 2021, which triggered the mandatory conversion of all the outstanding Convertible Notes plus accrued interest into 3,669,010 shares of common stock (Note 11). Upon conversion of the Convertible Notes, the outstanding Convertible notes principal plus accrued interest thereon, net of unamortized debt discounts totaling $30.3 million was reclassified to stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie2aff3fdd4ae40b29ed8bab59335a89b_I20200430"
      decimals="0"
      id="f-488"
      unitRef="usd">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie2aff3fdd4ae40b29ed8bab59335a89b_I20200430"
      decimals="2"
      id="f-489"
      unitRef="number">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <nexi:DebtInstrumentAdditionalClosingLockInPeriod
      contextRef="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430"
      id="f-490">P90D</nexi:DebtInstrumentAdditionalClosingLockInPeriod>
    <nexi:DebtInstrumentConvertiblePricePercentage
      contextRef="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430"
      decimals="2"
      id="f-491"
      unitRef="number">0.80</nexi:DebtInstrumentConvertiblePricePercentage>
    <nexi:DebtInstrumentFullyDilutedCapitalization
      contextRef="ie2aff3fdd4ae40b29ed8bab59335a89b_I20200430"
      decimals="-6"
      id="f-492"
      unitRef="usd">85000000</nexi:DebtInstrumentFullyDilutedCapitalization>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430"
      decimals="2"
      id="f-493"
      unitRef="number">0.90</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <nexi:DebtInstrumentRedemptionAmount
      contextRef="ie2aff3fdd4ae40b29ed8bab59335a89b_I20200430"
      decimals="-6"
      id="f-494"
      unitRef="usd">125000000</nexi:DebtInstrumentRedemptionAmount>
    <nexi:DebtInstrumentRedemptionAmount
      contextRef="ifb6c8b0ddc244a308e9bd3ecbb524199_I20200731"
      decimals="0"
      id="f-495"
      unitRef="usd">50000000</nexi:DebtInstrumentRedemptionAmount>
    <nexi:DebtInstrumentAdditionalClosingLockInPeriod
      contextRef="i225885d205f04fb9b33ee53d4cfb8f44_D20200701-20200731"
      id="f-496">P150D</nexi:DebtInstrumentAdditionalClosingLockInPeriod>
    <nexi:DebtInstrumentAdditionalClosingLockInPeriod
      contextRef="i8ff48a09a554472b8be106abefa1d461_D20200901-20200930"
      id="f-497">P190D</nexi:DebtInstrumentAdditionalClosingLockInPeriod>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i8ff48a09a554472b8be106abefa1d461_D20200901-20200930"
      decimals="2"
      id="f-498"
      unitRef="number">0.80</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <nexi:DebtInstrumentRedemptionAmount
      contextRef="i873c597d2cf845d493f5de5873c03e05_I20200930"
      decimals="0"
      id="f-499"
      unitRef="usd">125000000</nexi:DebtInstrumentRedemptionAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="idf7c9ea8fe8d4438993e95ae15b3887d_D20210101-20210131"
      decimals="-5"
      id="f-500"
      unitRef="usd">9000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <nexi:FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance
      contextRef="ic8342e5909c548198f1f8f812c6ccc2a_D20220101-20221231"
      decimals="-5"
      id="f-501"
      unitRef="usd">700000</nexi:FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance>
    <nexi:DebtIssuanceCosts
      contextRef="ic8342e5909c548198f1f8f812c6ccc2a_D20220101-20221231"
      decimals="-5"
      id="f-502"
      unitRef="usd">300000</nexi:DebtIssuanceCosts>
    <nexi:DebtDiscount
      contextRef="ic8342e5909c548198f1f8f812c6ccc2a_D20220101-20221231"
      decimals="-5"
      id="f-503"
      unitRef="usd">4200000</nexi:DebtDiscount>
    <nexi:FairValueOfDerivativeLiabilityOfConvertibleNotes
      contextRef="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430"
      decimals="-5"
      id="f-504"
      unitRef="usd">2000000.0</nexi:FairValueOfDerivativeLiabilityOfConvertibleNotes>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature
      contextRef="i11e43cd0be044888b37cbc375f6f43a4_D20200401-20200430"
      decimals="-5"
      id="f-505"
      unitRef="usd">2200000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:StockholdersEquity
      contextRef="i54b8bf4223dd408ba5dfb81b3157f859_I20211231"
      decimals="-5"
      id="f-506"
      unitRef="usd">700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i869076cb5c1441619748ef3b03caf454_I20211231"
      decimals="-5"
      id="f-507"
      unitRef="usd">2300000</us-gaap:StockholdersEquity>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i74ebc54878b1455ba9248d3203abce2c_I20211231"
      decimals="-5"
      id="f-508"
      unitRef="usd">1500000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ibee929c3ceb949d69a3628128e96a111_D20210101-20211231"
      decimals="-5"
      id="f-509"
      unitRef="usd">600000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i370d6d24e959405ba7d21d7a1ef23d52_I20211231"
      decimals="2"
      id="f-510"
      unitRef="number">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="ibee929c3ceb949d69a3628128e96a111_D20210101-20211231"
      decimals="-5"
      id="f-511"
      unitRef="usd">200000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ic87f7845ea6d43edb990474d68bfd9b9_D20210211-20210211"
      decimals="0"
      id="f-512"
      unitRef="shares">3669010</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <nexi:DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts
      contextRef="ic87f7845ea6d43edb990474d68bfd9b9_D20210211-20210211"
      decimals="-5"
      id="f-513"
      unitRef="usd">30300000</nexi:DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts>
    <nexi:RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-514">Series A Redeemable Convertible Preferred Stock and Stockholders&#x2019; Deficit&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Issuances of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 11, 2021, the Company completed its IPO, pursuant to which it issued and sold 7,441,650 shares of its common stock at a public offering price of $17.00 per share, resulting in net proceeds of $114,551,315, after deducting underwriting discounts and commissions and other offering expenses. Upon the closing of the IPO, all of the &#x2014; outstanding shares of the Company&#x2019;s Redeemable Convertible Preferred Stock automatically converted into 10,144,041 shares of common stock after giving effect to the reverse stock split, and all of the outstanding convertible debt and accrued but unpaid interest thereon of $31,272,183 converted to 3,669,010 shares of common stock. Upon completion of the offering on February 11, 2021, the Company&#x2019;s authorized capital stock consists of 250,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, 145,000 warrants were exercised at an exercise price of $0.01 and 145,000 shares of Series A redeemable convertible stock were issued and then converted into common stock upon the closing of the IPO. The remaining outstanding warrants outstanding as of December 31, 2020 were exercised and settled in January 2021 with 2,896 shares of common stock issued in a cashless exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. and BTIG, LLC (together, the &#x201c;Agents&#x201d;), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share, having an aggregate offering price of up to $50.0 million (the "Shares") from time to time through the Agents (the "Offering"). Subject to the terms and conditions of the Sales Agreement, any such sales made through the Agents can be made, based upon the Company's instructions, by methods deemed an &#x201c;at-the-market" offering as defined in Rule 415(a)(4) promulgated under the Securities Act. The Company agreed to pay the Agents a commission of 3.0% of the gross proceeds of any sales of shares sold pursuant to the Sales Agreement. During the year ended December&#160;31, 2022, the Company sold an aggregate of 3,184,900 shares through our &#x201c;at-the-market" offering facility resulting in net proceeds of $5.1 million.&lt;/span&gt;&lt;/div&gt;</nexi:RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if353ba0711344094942f5e91286b8497_D20210211-20210211"
      decimals="0"
      id="f-515"
      unitRef="shares">7441650</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i26259b22e3b94e8c8e38c181c55cf7e8_I20210211"
      decimals="2"
      id="f-516"
      unitRef="usdPerShare">17.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6ab94587a7134bc29507a4735e3b4bb5_D20210211-20210211"
      decimals="0"
      id="f-517"
      unitRef="usd">114551315</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia325791ead244863998b1f8f312ad14c_I20210211"
      decimals="0"
      id="f-518"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="ia325791ead244863998b1f8f312ad14c_I20210211"
      decimals="0"
      id="f-519"
      unitRef="shares">10144041</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ic87f7845ea6d43edb990474d68bfd9b9_D20210211-20210211"
      decimals="0"
      id="f-520"
      unitRef="usd">31272183</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ic87f7845ea6d43edb990474d68bfd9b9_D20210211-20210211"
      decimals="0"
      id="f-521"
      unitRef="shares">3669010</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-522"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-523"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="4"
      id="f-524"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="4"
      id="f-525"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-526"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-527"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8f4fa39048644fd7896c3a33c09994df_I20210211"
      decimals="4"
      id="f-528"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i77a57977aaa446e78a28a3a70e9a899c_I20210131"
      decimals="0"
      id="f-529"
      unitRef="shares">145000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i85c929ab7b9c4820bc56af8cd2f474ab_I20210131"
      decimals="2"
      id="f-530"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nexi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i5835f11998cf40f68d148e445724cb8b_D20210101-20210131"
      decimals="0"
      id="f-531"
      unitRef="shares">145000</nexi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i77a57977aaa446e78a28a3a70e9a899c_I20210131"
      decimals="INF"
      id="f-532"
      unitRef="shares">145000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <nexi:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i85c929ab7b9c4820bc56af8cd2f474ab_I20210131"
      decimals="0"
      id="f-533"
      unitRef="shares">2896</nexi:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id09449ea526a48e0b9e20fb9696883ab_I20220630"
      decimals="INF"
      id="f-534"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <nexi:SaleOfStockAggregateOfferingApproval
      contextRef="ia81c0f51abc5407c9f1bea1bc4bfb1a9_D20220601-20220630"
      decimals="-5"
      id="f-535"
      unitRef="usd">50000000.0</nexi:SaleOfStockAggregateOfferingApproval>
    <nexi:SaleOfStockCommissionPercentage
      contextRef="id09449ea526a48e0b9e20fb9696883ab_I20220630"
      decimals="4"
      id="f-536"
      unitRef="number">0.030</nexi:SaleOfStockCommissionPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i606c2339afea414788b70bdaefc16503_D20220101-20221231"
      decimals="INF"
      id="f-537"
      unitRef="shares">3184900</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i606c2339afea414788b70bdaefc16503_D20220101-20221231"
      decimals="-5"
      id="f-538"
      unitRef="usd">5100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-539">Stock-Based Compensation&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During January 2017, the Company adopted the 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;), which provides for granting of restricted stock, options to purchase shares of common stock and other awards to employees, directors and consultants. In March 2017, the Company amended the 2017 Plan to increase the number of available shares to 660,838. In September 2018, the Company adopted the 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) which provides for granting of restricted stock, options to purchase shares of common stock, and other awards to employees, directors and consultants, and reserved 1,741,770 shares for this purpose. The 2018 Plan was amended in July 2018 to increase the number of available shares to 1,809,143. In February 2021, the Company adopted the 2021 Equity Incentive Plan (&#x201c;2021 Plan&#x201d;) and reserved 2,757,556 shares under the plan. No further shares will be issued under the 2017 and 2018 plans. In addition, the 2021 Plan contains an &#x201c;evergreen&#x201d; provision, which allows for an annual increase in the number of shares of our common stock available for issuance under the 2021 Plan on the first day of each calendar year beginning in calendar year 2022. The annual increase in the number of shares shall be equal to the lower of (i) 5.0% of the number of shares of our common stock outstanding on the date of the applicable increase or (ii) a lesser amount determined by our board of directors. Following the annual increase in the number of shares of our common stock available for issuance under the 2021 Plan, there are 1,439,424 shares available for issuance under the 2021 plan as of  March 1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of options to be granted under the 2021 Plan, the option exercise prices, and other terms of the options are determined by the Board of Directors in accordance with the terms of the 2021 Plan. Generally, stock options are granted at fair value, become exercisable over a period of &lt;span style="-sec-ix-hidden:f-546"&gt;one&lt;/span&gt; to four years, expire in ten years or less and are subject to the employee&#x2019;s continued employment. Restricted stock units awarded in November 2022 vest after an 18-month service period. No restricted stock units were awarded in the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was recorded in the following financial statement line items within the statement of operations for the years ended December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,812,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,918,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,057,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,979,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of option activity under the Company&#x2019;s Stock Option Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January&#160;1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,965,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested or expected to vest as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,965,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,852,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares unvested as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average fair value of the options granted during the years ended December&#160;31, 2022 and 2021 was $2.42 and $11.16, respectively. The options were valued using the Black-Scholes option-pricing model for the years ended December&#160;31, 2022 and 2021 with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.6% to 83.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.7% to 81.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5%&#160;to&#160;3.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5%&#160;to&#160;1.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;to&#160;6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;to&#160;6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of stock options vested during the years ended December&#160;31, 2022 and 2021 was $9.2 million, and $1.4 million, respectively. The intrinsic value of stock options exercised for the years ended December&#160;31, 2022 and 2021 was approximately $0.2 million and $2.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was $8.0 million of total unrecognized compensation expense related to unvested options that will be recognized over a weighted average period of 2.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A restricted stock unit (&#x201c;RSU&#x201d;) represents the right to receive one of the Company&#x2019;s common stock upon vesting of the RSU. The fair value of each RSU is based on the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the 2021 Plan for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.233%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of restricted units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,558,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding  as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,558,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was $0.7 million of unrecognized compensation expense related to unvested RSUs, which are expected to be recognized over a weighted average period of 1.4 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie9d3dab50aea4a7f8d84d00874e49e4e_I20170301"
      decimals="0"
      id="f-540"
      unitRef="shares">660838</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i275a48529a1a4c3885fad3563305e566_I20180930"
      decimals="INF"
      id="f-541"
      unitRef="shares">1741770</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i30203c7ac84149eda4226a53b00d5520_I20180731"
      decimals="0"
      id="f-542"
      unitRef="shares">1809143</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8ab04e02de714324a031d507a830df05_I20210228"
      decimals="0"
      id="f-543"
      unitRef="shares">2757556</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock
      contextRef="ibf9d66ae0c7a46f68c98ad662da4fd70_D20210101-20211231"
      decimals="2"
      id="f-544"
      unitRef="number">0.050</nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if4928ff38b944471a2f040e95d09d31b_I20230301"
      decimals="0"
      id="f-545"
      unitRef="shares">1439424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ief18b08960f540d7b60fdafa452c819e_D20220101-20221231"
      id="f-547">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-548">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231"
      id="f-549">P18M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-550">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense was recorded in the following financial statement line items within the statement of operations for the years ended December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,812,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,918,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,057,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,870,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,979,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i02e219dda5744914b465aec9d485e6e6_D20220101-20221231"
      decimals="0"
      id="f-551"
      unitRef="usd">3812441</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i28b3cec944184d4f8af71eef16bd69a0_D20210101-20211231"
      decimals="0"
      id="f-552"
      unitRef="usd">2918310</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7b304823751d4c239cbf3f21b62ab9a6_D20220101-20221231"
      decimals="0"
      id="f-553"
      unitRef="usd">2057923</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idea423a341804ae2b054938793d90352_D20210101-20211231"
      decimals="0"
      id="f-554"
      unitRef="usd">3061474</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-555"
      unitRef="usd">5870364</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-556"
      unitRef="usd">5979784</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-557">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of option activity under the Company&#x2019;s Stock Option Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January&#160;1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,305,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,965,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested or expected to vest as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,965,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,852,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares unvested as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-558"
      unitRef="shares">3305291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="2"
      id="f-559"
      unitRef="usdPerShare">9.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      id="f-560">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="-5"
      id="f-561"
      unitRef="usd">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-562"
      unitRef="shares">1628065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-563"
      unitRef="usdPerShare">3.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-564"
      unitRef="shares">362886</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-565"
      unitRef="usdPerShare">2.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-566"
      unitRef="shares">255701</nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod>
    <nexi:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-567"
      unitRef="usdPerShare">8.04</nexi:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-568"
      unitRef="shares">349267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-569"
      unitRef="usdPerShare">15.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-570"
      unitRef="shares">3965502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="2"
      id="f-571"
      unitRef="usdPerShare">7.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-572">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-573"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-574"
      unitRef="shares">3965502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="2"
      id="f-575"
      unitRef="usdPerShare">7.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-576">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-577"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-578"
      unitRef="shares">1852331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="2"
      id="f-579"
      unitRef="usdPerShare">8.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-580">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-581"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-582"
      unitRef="shares">2113171</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="2"
      id="f-583"
      unitRef="usdPerShare">6.28</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-584">P9Y</nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1>
    <nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-585"
      unitRef="usd">0</nexi:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-586"
      unitRef="usdPerShare">2.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="2"
      id="f-587"
      unitRef="usdPerShare">11.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-588">The options were valued using the Black-Scholes option-pricing model for the years ended December&#160;31, 2022 and 2021 with the following assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.6% to 83.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.7% to 81.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5%&#160;to&#160;3.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5%&#160;to&#160;1.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;to&#160;6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;to&#160;6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="4"
      id="f-589"
      unitRef="number">0.786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="4"
      id="f-590"
      unitRef="number">0.832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="3"
      id="f-591"
      unitRef="number">0.787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="3"
      id="f-592"
      unitRef="number">0.811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="3"
      id="f-593"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="3"
      id="f-594"
      unitRef="number">0.0380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="3"
      id="f-595"
      unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="4"
      id="f-596"
      unitRef="number">0.0140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-597"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="2"
      id="f-598"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8cde262665d140a4aa955aed31f5920a_D20220101-20221231"
      id="f-599">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ief18b08960f540d7b60fdafa452c819e_D20220101-20221231"
      id="f-600">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3fa6115f303b4a3fbf9b708fedfe989b_D20210101-20211231"
      id="f-601">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idda403dc84674bf3b38163cc09604d2e_D20210101-20211231"
      id="f-602">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="-5"
      id="f-603"
      unitRef="usd">9200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="-5"
      id="f-604"
      unitRef="usd">1400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="-5"
      id="f-605"
      unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="-5"
      id="f-606"
      unitRef="usd">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="-5"
      id="f-607"
      unitRef="usd">8000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i05746f41db1943c1bec2cd0749ac1f49_D20220101-20221231"
      id="f-608">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-609">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of RSU activity for the 2021 Plan for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.233%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.486%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of restricted units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,558,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested and outstanding  as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,558,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0c755e4c19e14dd3b1b1970081b2809e_I20211231"
      decimals="-3"
      id="f-610"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0c755e4c19e14dd3b1b1970081b2809e_I20211231"
      decimals="2"
      id="f-611"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231"
      decimals="-3"
      id="f-612"
      unitRef="shares">1558000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231"
      decimals="2"
      id="f-613"
      unitRef="usdPerShare">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231"
      decimals="-3"
      id="f-614"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231"
      decimals="2"
      id="f-615"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231"
      decimals="-3"
      id="f-616"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231"
      decimals="2"
      id="f-617"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2c1c88b03e284ba5a4f2d5abe7153e3f_I20221231"
      decimals="-3"
      id="f-618"
      unitRef="shares">1558000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2c1c88b03e284ba5a4f2d5abe7153e3f_I20221231"
      decimals="2"
      id="f-619"
      unitRef="usdPerShare">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2c1c88b03e284ba5a4f2d5abe7153e3f_I20221231"
      decimals="-5"
      id="f-620"
      unitRef="usd">700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iaba13b82d8fe4a61be88169bb59474c2_D20220101-20221231"
      id="f-621">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-622">Income Taxes&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s provision for income taxes consists of the following for the years ended December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income tax provision:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax benefit:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,339,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,606,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,370,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,291,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,969,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,898,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,969,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,898,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision (benefit) for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory U.S. income tax rate to the effective income tax rate as of December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Federal statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,477,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,758,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,838,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,316,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,249,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,857,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,886,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(458,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, the Company had net operating loss (NOL) carryforwards for income tax purposes of approximately $135.2 million and $115.4 million, respectively, which are available to offset future federal taxable income, if any. Approximately $10.5 million of the federal NOL was generated prior to 2018 and will be expiring in increments through 2037 beginning in 2035, while the remaining $124.7 million will be carried forward indefinitely. The state NOL will expire in increments through 2037, beginning in 2035. The federal research and development tax credit carryforwards, if not utilized, will expire beginning in 2037.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Section&#160;382 of the Internal Revenue Code imposes substantial restrictions on the utilization of net operating losses and Section 383 of the Internal Revenue Code imposes restrictions on the utilization of tax credits in the event of a corporations&#x2019; ownership change. The Company believes that the future use of net operating losses and tax credits presented above may be limited as a result of past ownership changes and a formal study has not yet been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the effect of income tax positions only if those positions more likely than not of being sustained. At December&#160;31, 2022, the Company had no gross unrecognized tax benefits and did not recognize any interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At December&#160;31, 2022, the Company provided a 100% valuation allowance on its net deferred tax assets because realization of any future tax benefit cannot be reasonably assured. The Company&#x2019;s valuation allowance increased due to the pre-tax losses generated in the current year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to income taxation by both federal and state taxing authorities. Income tax returns for the years ended December 31, 2021, 2020, and 2019 are open to audit by federal and state taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Tax Cuts and Jobs Act of 2017, research and development costs are no longer fully deductible and are required to be capitalized and amortized for US Tax purposes over five or fifteen years effective January 1, 2022. The mandatory capitalization requirement increased our deferred tax assets as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-623">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s provision for income taxes consists of the following for the years ended December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income tax provision:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax benefit:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,339,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,606,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,370,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,291,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,969,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,898,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,969,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,898,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision (benefit) for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-624"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-625"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-626"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-627"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-628"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-629"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-630"
      unitRef="usd">12339546</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-631"
      unitRef="usd">10606627</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-632"
      unitRef="usd">-7370113</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-633"
      unitRef="usd">3291842</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-634"
      unitRef="usd">4969433</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-635"
      unitRef="usd">13898469</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-636"
      unitRef="usd">-4969433</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-637"
      unitRef="usd">-13898469</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-638"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="0"
      id="f-639"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-640">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory U.S. income tax rate to the effective income tax rate as of December&#160;31, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Federal statutory rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="2"
      id="f-641"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="2"
      id="f-642"
      unitRef="number">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="4"
      id="f-643"
      unitRef="number">0.0017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="4"
      id="f-644"
      unitRef="number">0.0652</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="4"
      id="f-645"
      unitRef="number">-0.0058</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="4"
      id="f-646"
      unitRef="number">-0.0013</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="4"
      id="f-647"
      unitRef="number">-0.0002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="4"
      id="f-648"
      unitRef="number">0.0002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="4"
      id="f-649"
      unitRef="number">-0.1261</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="4"
      id="f-650"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="4"
      id="f-651"
      unitRef="number">-0.0796</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="4"
      id="f-652"
      unitRef="number">-0.2741</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="4"
      id="f-653"
      unitRef="number">-0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="4"
      id="f-654"
      unitRef="number">-0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-655">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company&#x2019;s deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,477,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,758,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,838,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,316,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,249,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,857,468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,886,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(458,533)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-656"
      unitRef="usd">28477866</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-657"
      unitRef="usd">31758878</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-658"
      unitRef="usd">575883</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-659"
      unitRef="usd">701576</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-660"
      unitRef="usd">1913771</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-661"
      unitRef="usd">1445296</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-662"
      unitRef="usd">291022</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-663"
      unitRef="usd">291022</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-664"
      unitRef="usd">7838512</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-665"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <nexi:DeferredTaxAssetsOperatingLeases
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-666"
      unitRef="usd">216925</nexi:DeferredTaxAssetsOperatingLeases>
    <nexi:DeferredTaxAssetsOperatingLeases
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-667"
      unitRef="usd">0</nexi:DeferredTaxAssetsOperatingLeases>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-668"
      unitRef="usd">2022</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-669"
      unitRef="usd">52751</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-670"
      unitRef="usd">39316001</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-671"
      unitRef="usd">34249523</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-672"
      unitRef="usd">38857468</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-673"
      unitRef="usd">33886096</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-674"
      unitRef="usd">458533</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-675"
      unitRef="usd">363427</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-676"
      unitRef="usd">204694</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-677"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-678"
      unitRef="usd">253839</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-679"
      unitRef="usd">363427</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-680"
      unitRef="usd">458533</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-681"
      unitRef="usd">363427</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-682"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231"
      decimals="0"
      id="f-683"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iff7fdf8fd69c490e8f4f46d8e7a75f7c_I20221231"
      decimals="-5"
      id="f-684"
      unitRef="usd">135200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i3333ea4033604cef87ae7f2a775a3bca_I20211231"
      decimals="-5"
      id="f-685"
      unitRef="usd">115400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="iff7fdf8fd69c490e8f4f46d8e7a75f7c_I20221231"
      decimals="-5"
      id="f-686"
      unitRef="usd">10500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="iff7fdf8fd69c490e8f4f46d8e7a75f7c_I20221231"
      decimals="-5"
      id="f-687"
      unitRef="usd">124700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-688"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-689"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <nexi:DeferredTaxAssetValuationAllowancePercent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="2"
      id="f-690"
      unitRef="number">1</nexi:DeferredTaxAssetValuationAllowancePercent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-691">Leases&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space and laboratory space. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company does not recognize right-of-use assets or lease liabilities for leases determined to have a term of 12 months or less. Options to extend a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the lease commencement date, the operating lease liability is recorded at the present value of future lease payments over the expected remaining lease term using the discount rate implicit in the lease, if it is readily determinable, or the Company&#x2019;s incremental borrowing rate. The right-of-use asset is measured as the lease liability and adjusted for prepaid rent, initial direct costs, and incentives. The Company's leases contain variable non-lease components such as maintenance, taxes, insurance, and similar costs for the spaces it occupies. For new and amended leases beginning in 2022 and after, the Company has elected the practical expedient not to separate these non-lease components of leases for classes of all underlying assets and instead account for them as a single lease component for all leases. The Company recognizes the net fixed payments of operating leases on a straight-line basis over the lease term. Variable executory costs, as it relates to net leases, are to be excluded from the calculation of the lease liability and the Company expenses the variable lease payments in the period in which it incurs the obligation to pay such variable amounts and will be included in variable lease costs in the leases footnote disclosure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease payments are not included in the Company's calculation of its right-of-use assets or lease liabilities. Variable lease costs were immaterial for the year ended December&#160;31, 2022. The components of lease cost under ASC 842 for the year ended December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating expenses: research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating expenses: general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;586,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental disclosure of cash flow information and weighted average remaining lease term and discount rate related to leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(584,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average remaining lease term &#x2014; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average discount rate &#x2014; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future fixed lease payments for operating leases in effect as of December&#160;31, 2022, are payable as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Maturity of lease liabilities for the years ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for the year ended December&#160;31, 2021 was $0.4 million in accordance with ASC 840.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-692">The components of lease cost under ASC 842 for the year ended December&#160;31, 2022 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"&gt;Lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating expenses: research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating expenses: general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;586,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i02e219dda5744914b465aec9d485e6e6_D20220101-20221231"
      decimals="0"
      id="f-693"
      unitRef="usd">379288</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7b304823751d4c239cbf3f21b62ab9a6_D20220101-20221231"
      decimals="0"
      id="f-694"
      unitRef="usd">207401</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-695"
      unitRef="usd">586689</us-gaap:OperatingLeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-696">&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental disclosure of cash flow information and weighted average remaining lease term and discount rate related to leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&#160;&#160;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(584,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average remaining lease term &#x2014; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted-average discount rate &#x2014; operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      decimals="0"
      id="f-697"
      unitRef="usd">584429</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      id="f-698">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="3"
      id="f-699"
      unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-700">Future fixed lease payments for operating leases in effect as of December&#160;31, 2022, are payable as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Maturity of lease liabilities for the years ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-701"
      unitRef="usd">617999</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-702"
      unitRef="usd">469939</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-703"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-704"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-705"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-706"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-707"
      unitRef="usd">1087938</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-708"
      unitRef="usd">63125</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3cfc586d3ef2479899da6a9e51989ddb_I20221231"
      decimals="0"
      id="f-709"
      unitRef="usd">1024813</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseAndRentalExpense
      contextRef="ia6e00fe622094987b8a7ead639c26abc_D20210101-20211231"
      decimals="-5"
      id="f-710"
      unitRef="usd">400000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-711">Related Party Transactions&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 16, 2022, the Company and Zephyr AI, Inc. (&#x201c;Zephyr&#x201d;) entered into a Joint Research Agreement (the &#x201c;JRA&#x201d;) focused on the joint collaboration, identification and validation of certain targets in order to facilitate further research, development and potential commercialization of immunotherapies. Zephyr is owned by a holding company with multiple Board members from the Company. The JRA term is two years unless mutually extended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the JRA, Zephyr will identify suitable antigens or combinations thereof for validation and testing by NexImmune. The Joint Steering Committee (the &#x201c;JSC&#x201d;) provided for by the JRA will then determine which identified candidates shall be subject to further analysis. NexImmune will validate which, if any, of the identified antigens are suitable for T-cell engagement and killing function (the &#x201c;Final Candidates&#x201d;). The JSC will make a good-faith determination as to whether the data supports the further IND-targeted development by NexImmune of any of the Final Candidates. The Company and Zephyr will jointly own any Final Candidates, including the intellectual property related thereto. Each of the Company and Zephyr shall be responsible for payment of their own respective costs and expenses in connection with the performance of their respective obligations under the JRA. If a Final Candidate is to be further developed, then the Company and Zephyr shall engage in good-faith negotiations to agree on the terms and conditions of an agreement with respect to the further development and commercialization of such Final Candidate. If such an agreement is not executed within the prescribed negotiation period, then neither the Company nor Zephyr may further develop such Final Candidate. The expenses related to the JRA for the year ended December&#160;31, 2022 were not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i97a90c417a404807b67812e3dc3d073d_D20220101-20221231"
      id="f-712">Subsequent EventsOn March 22, 2023, in order to retain and motivate employees and other key contributors of the Company, the board of directors approved a one-time stock option repricing (the &#x201c;Option Repricing&#x201d;). Pursuant to the Option Repricing, the exercise price of all of the below stock options to purchase shares of the Company&#x2019;s common stock previously granted under our 2017 Equity Incentive Plan, 2018 Equity Incentive Plan and 2021 Equity Incentive Plan (the &#x201c;Repriced Options&#x201d;) will be amended as of April 4, 2023 (the &#x201c;Effective Date&#x201d;) to reduce the exercise prices of such options to a price equal to or greater than the closing price per share of the Company&#x2019;s common stock on The Nasdaq Stock Market on the Effective Date (the &#x201c;Nasdaq &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Market Price&#x201d;), on the terms described below; provided, however, that if the closing price per share on the Effective Date is less than $0.40, the Nasdaq Market Price will be deemed to be $0.40 for purposes of the Option Repricing:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Repriced Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Terms of Repriced Options vested or vesting within six months following the Effective Date &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Terms of Repriced Options vesting more than six months following the Effective Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All options held by employees other than our executive officers, in good standing on the Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Option Repricing exercise price will be equal to 2.5 times the Nasdaq Market Price &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Option Repricing exercise price will be equal to the Nasdaq Market Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All options held by our current executive officers and 100,000 options held by Jerome Zeldis, our former EVP and Head of Research &amp;amp; Development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Option Repricing exercise price will be equal to 3.0 times the Nasdaq Market Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Option Repricing exercise price will be equal to 2.0 times the Nasdaq Market Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All options held by our directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Option Repricing exercise price will be equal to 4.0 times the Nasdaq Market Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The Option Repricing exercise price will be equal to 3.0 times the Nasdaq Market Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;On March 23, 2023, Jerome Zeldis, M.D., Ph.D., Executive Vice President of Research and Development, entered into a Consulting Agreement with the Company (the &#x201c;Consulting Agreement&#x201d;) effective as of March 31, 2023 (the &#x201c;Transition Date&#x201d;).  Pursuant to the Consulting Agreement and effective as of the Transition Date, the exiting Employment Agreement, dated January 4, 2021, by and between the Company and Dr. Zeldis is terminated, Dr. Zeldis will have resigned from the Company, and Dr. Zeldis will transition to providing consulting and advisory services to the Company for a period ending on March 31, 2024 (the &#x201c;Consulting Period&#x201d;).  Pursuant to the terms of the Consulting Agreement, in consideration for, among other things, his compliance with certain restrictive covenants, including customary non-compete and non-solicitation covenants, and a typical release of claims, Dr. Zeldis will be paid $200 per hour for services provided to the Company and vested options to purchase 100,000 shares of common stock of the Company held by Dr. Zeldis (a portion of the grant received by Dr. Zeldis on February 11, 2021) are eligible to participate in the Option Repricing (as defined above), with the exercise price for such options reduced to the level set for executive officers.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <nexi:ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold
      contextRef="i1b6232ae6cb64482b9ec1943b0fe3126_I20230322"
      decimals="2"
      id="f-713"
      unitRef="usdPerShare">0.40</nexi:ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold>
    <nexi:ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold
      contextRef="i1b6232ae6cb64482b9ec1943b0fe3126_I20230322"
      decimals="2"
      id="f-714"
      unitRef="usdPerShare">0.40</nexi:ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold>
    <nexi:ShareBasedPaymentArrangementOptionRepricingMultiple
      contextRef="ie2d06934bf864579a4979bf7aa1310c1_I20230322"
      decimals="2"
      id="f-715"
      unitRef="number">2.5</nexi:ShareBasedPaymentArrangementOptionRepricingMultiple>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7c4097a670b849ad990fb5d2224c365b_I20230322"
      decimals="0"
      id="f-716"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <nexi:ShareBasedPaymentArrangementOptionRepricingMultiple
      contextRef="i3d28adc4141b4bbfb5dd66693b958745_I20230322"
      decimals="2"
      id="f-717"
      unitRef="number">3.0</nexi:ShareBasedPaymentArrangementOptionRepricingMultiple>
    <nexi:ShareBasedPaymentArrangementOptionRepricingMultiple
      contextRef="id386af48387549ec98b66a7ea05efd78_I20230322"
      decimals="2"
      id="f-718"
      unitRef="number">2.0</nexi:ShareBasedPaymentArrangementOptionRepricingMultiple>
    <nexi:ShareBasedPaymentArrangementOptionRepricingMultiple
      contextRef="i4ea14e11723c4f1f804456e484f29855_I20230322"
      decimals="2"
      id="f-719"
      unitRef="number">4.0</nexi:ShareBasedPaymentArrangementOptionRepricingMultiple>
    <nexi:ShareBasedPaymentArrangementOptionRepricingMultiple
      contextRef="i0692d5e0603d41138cf06daaf012d2ef_I20230322"
      decimals="2"
      id="f-720"
      unitRef="number">3.0</nexi:ShareBasedPaymentArrangementOptionRepricingMultiple>
    <nexi:RelatedPartyTransactionHourlyRate
      contextRef="ia3e2d6cfd7a944f3927adf427e2f02ea_I20230322"
      decimals="2"
      id="f-721"
      unitRef="usd">200</nexi:RelatedPartyTransactionHourlyRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7c4097a670b849ad990fb5d2224c365b_I20230322"
      decimals="0"
      id="f-722"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>91
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M;_H-T3E)H(C.5:ES?*K&#9YO]\X/)%ME&Z!G3$H69V^7E 24ZQ/4]W/&Y.9
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M7)%1Q'N6W" 7_XB(0XB%T/KUU?$(';?K-+?&<P?PVFXJ=X@]0SXIIFYMO=2
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M!A<]K"=53*AB8>3*-?F9-#@RW&N&0QV4-<#SA91FM[ 75'\3DM]02P,$%
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M0VD^E!8TM,Z:!<>9FL24%0EU>T!I$9060VD)BM95;6OY($,\'Y=5JU1JW_K
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MUL; [F$ZH 0&!9\*SKO.%Q1R:(%EYX5"UV]>,5\''+-82 CZTQRI"X@5>):
MD_3M45H3X,$AE@X=" M;-L"X]?9W:0K_D,*>0R].-J[4-3(-KC$'6J@9DH7U
MM?>(;G7=)4$":@X*GG(;BW477:8S%,'Y$EKVB8S375M##>%/@&LL%G0'\D ;
ME6L1]=C9M#\PA'/(PH[X=Q)VXO $VL=",Z#HY?;#O(,#QY;N3)"4WH*?==_8
MO\ DO0 :O6!_Y6@L=MCZ5\?VT(H@!^Q.PW%1%%!MV0R]!^2;(WSI.(<?C%Y>
MO+L</3P\Y\J5K$6YRHPNWEUAYGM$KT :/7YT,AU_6YOSZ)YK8BJ;&*%V>_K0
M05P"VE&+_EW8Q1"'P!U"/* 4>F% B\U>4#0COY*-BKP1<\8!HPUIU*HEXBK6
M2B:]5+/!V[#UELN"":&C\@@5$*116V_'NRY6.CF7M==L?<JD!/E1,)"_[%!I
M&".A]01N@6R\F=<(7R^?PNS2=0LH\0+WGJ\=O>&[UK*+G=\]BEO49J7S9N+A
M!O*-A@0'[TCD2NCT.5AT_#9LP/0<N%(M-GWF)^[LXC1XOI.JH8+X@-6&CXQJ
MA$X!)>V&*T8*:3!EWR>Q,]O$;[!DE8HA0?]9*$"[ [LA=[BD\G$J#27F+19$
M($7'.YJFK64!-SZAU_QO9P;+B"YRF\?>'%PA.\NN4%&(7.KN[M,4;9\9N@WF
M,S6<^=33"Q+X<<@PSHJLCCP:,!"6NNB':Y,(PI)E$GB6+YW<DG8>7,.<16Z^
M]\6P2AUPY]E+:#Y^L)-H#7/S43M.2-G9TBJU?(4.*,^HI1!H[YI^-@*8C!]$
MI702C51"2:4^^:^NKWZ>ZK1A;MON <"O"NV]H,Z4HAU8<J.@&U:SY&M18VRK
M8_<P$H(T?./F'L<2A#APQQTJU]4E%S"\[JS(\9?51C("UG'3I&:!G.IOF_MU
MH-+<.C%WNK['Q=U?VB\L_G'V]^G1' [5M5PLOP8T=S#\.6);(R5=R!M7H@W"
MW?F0/PP+MP:""G=3-IV$Q5Q[;GEMN5?K4271H'*1^;,R0 *PY*1"JQ EZWE]
M22Q=6/OC\<G1D_X4S$-Q7Z+!/U@V$+F45-\"&N_/J<[U\?L@V8N9Y$P7A.HE
MVF??&&F/F -L^OL8+O,ZCGW$S2/*+:>_WW$_T2TYK R?V.@%FWNK/8WF8(#\
MFE69Q[8;_%_5X6N%$6>NT3G$;2F0\[%5%CGI;D0/4\Z%P\DLK#_DR6>YM!.<
M1DOMVIFAW&VN1A9]F+AUH(VJS0U!PW/YV0-HB?OI?M1#E^YP>=,QM@*9A:\=
MZG9?B84$K/!\KS %^K=\62L-W_]B*G"XF.*.=6W3DP=)]HM=7W9<CITN4]UG
M_<7-*_)=I/*N6U4]FO?H*G*D-X,XMAVH4B &N.M@;J)+ZY$^4?K#(FLJ?TW@
M*X-K&JZOT14W8_8>RUC/Y<76RA@3ZQHTVJ4R]N%OI.R0]]JN^JJ'H9X0LL^0
MY8 8T8J&M5%>&FG>,R^N4_71"S2(1=+H3\"X=Q/JL1NN9-(<)'3E>,@V'-!$
M5LW 4<1=[PZE*E+^9&*<3T"*UWV-EVL/2N4M'ZX!Z3N?I"'?BC[/53RGE*Y3
MWUU",4RZCD,;1!9Q)C'7EV\N&WWT>'9C/HH<1+U<[MR_2E0Y*6&LV:)$239P
MVH[K>2?5-Q6PW5ML,G%TZ!O?9.?K+7^:DF_4S G4PO0A=W@[? :_2%]_M]/3
M-_37FK]L01%IB:73HZ>/1\JG[]+I(;I6O@7C?AY=(S_Y6QMYGH#QI4/+EA]X
M@^$_!\[_"U!+ P04    " "D@7Q6B31&K]("  !7!@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6RE55%OVC 0_BNG5*HV:2(AT*YJ 2FTZS9IE5 9
MV\.T!Q-?$JN.G=JFE'^_LQ-2)M$^;"_$9]_WW7=GWS'9:O-@*T0'S[54=AI5
MSC67<6SS"FMF![I!12>%-C5S9)HRMHU!Q@.HEG&:).=QS82*9I.PMS"SB=XX
M*10N#-A-73.SFZ/4VVDTC/8;]Z*LG-^(9Y.&E;A$MVH6AJRX9^&B1F6%5F"P
MF$;9\'(^]O[!X8? K3U8@\]DK?6#-[[R:91X02@Q=YZ!T><)KU%*3T0R'CO.
MJ _I@8?K/?MMR)UR63.+UUK^%-Q5T^@B HX%VTAWK[=?L,OGS//E6MKP"]O6
M=W0>0;ZQ3M<=F!340K5?]MS5X0!PD;P"2#M &G2W@8+*&^;8;&+T%HSW)C:_
M"*D&-(D3RE_*TADZ%81SLSFSPH(N8&'0HG*LK97B\$T\;@07;C>)'07R[G'>
MD<Y;TO05TF$*=UJYRL(GQ9'_31"3PEYFNI<Y3]]DO,%\ */A!TB3-'V#;]2G
M/0I\HU?XLCS7&^6$*F&AI<@%6OB5K:TS]$Q^'\NXY1L?Y_.M<VD;EN,T:GPA
MS1-&L].3X7ER]8;:<:]V_!;[OU[2?Y/"<9_O%5(WY;INF-KY$A9",94+)L&2
M"U+/.@M;- A4C(89Y*%S.!#8M6"S(>\:7:6YYV<O]R%4L PG2J1N<!6L!LL!
ME*C0,"EW_A@;1W0'J,8(4M!(NL=WIR<7:9I<?<ZR15@.K]X/(%,[/T1(E*<5
M08A%4-H1Q&E@34/O@*TE0DG9A^"4>XU,.7\>L'X1$MB0<"-\/9X0?"!@%@H2
MPSMJR);7H9@'+VWI:(,9;F'5<.8.I&;+U5ZIKX;'WV;+^>#8VXD/FKU&4X:1
M9B%$:?N^W^VG9M8.BQ?W=N3>,5,*94%B0=!D\/$L M..L=9PN@FC8ZT=#:*P
MK&CRH_$.=%YH*E]G^ #]?\GL#U!+ P04    " "D@7Q6X'IL(1DB  #!;
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M<D@T(3%&PPI/\'\6/&B:=D\ZG%@S T:ZP*0[0X[T"BS7M[(ZS%'/6I6DIF3
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M0CF0O'<FWW3"?V&61=^*K].2^9.2KN80L"WL ]>\U7.!.5-;[)-7($K<;0B
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M@6X3J.?=%O(L[YEET[%6:Z)=-**YC9?JLY$<E^ZCO%B-IQSS[/2!<4U>F6B
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MJ(AVR(-7Z Z4Q2I)[T2LG0E[9"+5/V2W/$>Y)>Z!R5G>C^J@-2DOM5RA) (
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M^%_8==@T#2#?&JN:0S I:&K9??G^\ XG >/XE0!V"&!>=Y?(J[SEEL^G6NU
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M,G#VD*Y(=GP-Y]H?G8QG@WKCEY"AFK?2=I/:G_9[;M&-]V]XMR3ON=[4TH#
MDD+CJ]$@ -TMGLZQJO7#OE:65H<W*]K5J!V [DNE[-%Q"?KM/_\%4$L#!!0
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MG @/&".E]XXY9GOZK6V0I 6:U*(DS@7E8-BA5EXX608[/:1 $K[3=MR7/9F
MQ!^(WOTRE%Z[@="5_$S0J]&G5ZDY8R6VN_+?QR+ND,?;U%M_HRB&<H@B:V.5
M[:RRHBJUT@5&RF2M &-J[NYW7V$L2%VTV8F4_$QQS9?I+(%%2>+=+ATT)AH'
M*7^_=QGJ+'QNVF7G2:J_4-O+@KLF3Z=1AZDKFYW^/ Y=[Y9]TUD6(G7U&=G%
M81:Q89CIQQMUQ+#1GO\VFKM*:MA(%BV7NJ0^B#M/UT)?ZNX\=78\%@ %2PE9
MAU2H]2-1+5F(6Z%M9Y=>O%%RH9D-LSY/!BXZJ!>=A%YJCW#Y7K-Y8'08P&T?
M9QU8ED@^-4(FVF-E6NMYNN"FCSJT@^#@"RJ.D+NSW(F%22%ON0%BL"A;'>BP
M@@!FM<+$B>G&T[YC%],4PW*)/DJ834 %$''?L&G0>G(ZWS5#+4_"!/JA_D28
MFS1<4PVA .U0X!SC\?YY!HWS@\"D\8+QSB#OJ6H5[2#YVR&EA_('9+D>"GH]
M:VQ9]Z7!<,<FU8 ;PS ECD<QN#-3IT*O%[W/A4T>0SV,?Z&+OP>[. '/9R%E
ML#_*-@^WTUQ/O_6V!;N!.*).9EF0DPS',T*WB#%-C%9WW_6X95MPZHD-%YT&
M]1X(DR0O3[T(Q^RSN+:TH^&4@(\8^"KQNT%0_+,6B\;J,FZ+YM.]H:!I2AKB
MN5 BA* 0;$PF?GYR/'XZ^SN2%S_ODO=C#'^E W&ZNKZ^9@&&NZ%';T.$W>4T
MFM$402,7\I^CQ+,3Y<I8-!!WVK9.+#2*](V"+JLP)Z5MURTI1/EN@?:F+^'5
MXN;U+3U-K*+W94Y8<F'>7(:]Q:?)[43<5M1+I+7:(IZ+F;B;*V\O%SNE87Y:
MU<WZMB?3L%5Y0&IHMQ1G2]J.J+WF86]3B-.T8*.V!^F8=PZ=J[IDI'O;'NH_
M 6)>-@F.GMJG&M#K.@;@7<J2%E6"=^%#:3PRHW=#-21M.98^>F9Q>R5.GDW#
MM=:QA'P,DE.)<R&O+\-F!H%O#:]K'*7S;A^#.YKUII15ATF46G5C?8&J*0S0
M4(20HDZPR^<^5#8F)NB.4)HU!WM^J?#;1JG/5*7F)^$C(E,;0"=FI*@F^6_V
M["5HQ/3:-P%*<:6]CVNQ#N>D38%<S<C@J,IB@39AOWJY(%M_X%22<DVLV.3Y
MLAR0B$DWA6'B0VN'MMS&^.\+ENN<2W0F+56TG8,Z?WX[G0P7UF^HR'"2)B7P
M_V![#WO\@5"F,W<2UD0T$K:*W;*UR]*5A-EH"V>UX[U"P!Z0JFLJO!GJ=@!,
MMYX]7&IDV,>Z-!CL=S6:\(5<<$=+Y35\JWD7MT08I-(2?NA?3=NM5&>Z!C]N
M7S.R)95'Z9!XEG""HGTUZ8;DH(N:=B"T:?NCS8MN =AO"7-%!16:]44)S#M6
MB6):,2Z^X;6A4S:Q3]/UG2GO0@D+S@)KZK]*]$IE%XSP@IL<>H]RU'L/ALZM
MX+=]U$9 I/!*+#U-+Q07X3W:[GAX&PG(%[2"*]4*5Z>39Z<C8<,;OO#%FX;?
MJL$FWE3\<:TD<@D=P.\K@T07OQ"#])KUXG]02P,$%     @ I(%\5E[+(O]O
M"   $!D  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULS5E=<]NZ$?TK
M&-WDCCVC6)3\$2>Q/6,[-U-W)HWGIFD?.GV 2$A"0P(,"%KQ_?4]NP ITI04
MIW,?^A!%%('%V=VS7_#%VKJOU4HI+[X7N:DN1ROOR[>3296N5"&K(ULJ@S<+
MZPKI\>B6DZIT2F:\J<@GLR0YFQ12F]'5!?]V[ZXN;.US;=2]$U5=%-(]WJC<
MKB]'TU'SP^]ZN?+TP^3JHI1+]5GY+^6]P].DE9+I0IE*6R.<6ER.KJ=O;TYH
M/2_XAU;KJO-=D"9S:[_2PUUV.4H(D,I5ZDF"Q'\/ZE;E.0D"C&]1YJ@]DC9V
MOS?2/[#NT&4N*W5K\W_JS*\N1^<CD:F%K'/_NUW_145]3DE>:O.*/\4ZK)V]
M'HFTKKPMXF8@*+0)_\OOT0Z=#>?)C@VSN&'&N,-!C/*]]/+JPMFU<+0:TN@+
MJ\J[ 4X;<LIG[_!68Y^_NK7F03FOY[D2?[->51<3#['T<I)&$3=!Q&R'B.E,
M?+3&KRKQF\E4UA<P 9X6U*P!=3/;*_&]2H_$\70L9LELMD?><:OD,<L[WBEO
M[L5[7:6YK6JGQ+^NYY5W(,2_MVD;9)ULET5!\K8J9:HN1XB"2KD'-;KZ]9?I
M6?)N#]*3%NG)/NG/<\=/BK@SXKIT.B=K)F/A5TK<VJ*4YE$HXY53F=#&6_%T
MH[BO7;H"X\7UTBF%2/3BX-=?SF>SY%W["S]/WQT*Y <674ELMPM1EP(R7TQ/
MQTF2T#_Z,>T<43I;Z*JR[E$8@@GB^Y4X>TE@ *KRPDF :$X<J-6<?"3^ONI"
MK$J5ZH6&5M) EO9:YH(\K\U29"020*)!CIEB"59B=8X$1;NR3%/"V.P*T+01
M;Q((>*Q( *GZ1'@ ,L IUM!&4#;-ZASR814D$Z*A-7T<TR !VA?M&4-Q3GVK
M-3E-0HZ!0F3!8%C.E'6)CQ1[D)'%MUKFP1@+;:1)R0;J 6:J6L-^;(7<MD):
MKW8-0Q[NG",] [0E9]<(=V7S3+D^!F/-JV?@^%1&JV]@B.G&R5](Y#:LC''K
MYL!U5*+*8PT="6OC[!+K9&%KD"7JA^*0NIHIDXG:E%)G&QJN;9UG8B4?E) U
M\K'T.L6>QNB^B9].8!'LZ>MW%0Y4"^7(6\CDZ=?&3)4L\*&<AC\1 S6+0&%,
M5X*\ZQ\[9B)(:PV,<T4O@3V>9>IB#EM#Y."4.1D>C_-'D>D'S;H?R$-6M6,#
M4CXJ/J_]0/':D"\9U2 W0/+!_)!Q0&"*3UJZDJ U"\%[-CX^G"AC(G$MK9\B
MKL";W28H4&)UF>N@T7GR\DC<!3D_1P@8(Z-D(VR:UJ[!R-%(!U)R> 9GRKRN
MGDD:N&Q#DGT!$Q-PGSRI+0JL#!:*NY\:>ZNK7YR?HE?(<SHG*OE4]J(&@U]E
M.J\)6BI+[1&A?TC&MB\D9YN0O%OTBLF!/B1MN;VC1"4%G&Z6E"?I=^_0W""%
M'&A]N!523]VYPB.$E/4\URF"+=<5(27WQB7J>Y#_I[ML;Y2SV3OIN:]#82&H
M4D9#T1C?5/:">9OH[""-7O7H<VDATW^KU8(=V K8-Z:-,I*AEQ0H57-.H'!_
MD[S<!-SN(.V')V,(2)N E +=DJED;*1ANUVQOYV.T]F?P\?;UC*WP3*[>H"U
MA+OQ+0N)]:\U_,B%'E;B<K:M53E-VE:EVZ>$YH24;C=3)=S3)DQ/]_8)G&=^
M@/BS*KWB]-Z'_:.3]W<H\60TA(V,<?2B?= 4W;SQ)W,JMS<-]![0ITT)^K%A
M=7L.C\__?WC<4N1_X''3(,;>^T'FM:15)(<-6'!#1+A@NC2OV:*KF",Z*YSB
MT<-P5<$,BNFFL!GZJS2> P]_2KUM^!.\W"?;HG9<FP>>VT8OOW*V7JX$!K/
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M+MR_AP=O2[[SGEN/68Z_KI0$4%J ]PL+N\4'.J#](\C5?P%02P,$%     @
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M!/A_KI3=/9""[A/?^?\!4$L#!!0    ( *2!?%:P')I6Q 8  /80   9
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MH7:&69)82_MBR7_@AYW'7S+A.7A"(VW83-*C/MDT#4LZ<XAN!=*-:W'!W$@
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M[ISW$%O(EY_H]SXQYS3I!GP9J,QTLR?F\@=B'6F4CN69WJ.T!3*=@T'.BF3
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MP<4=G_*O\690#H0;SF7ZL=S'JSB6B^HS7(%(KTJ0%^+M4ZV>/%<0OTXC"4E
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MP0K2_])W>_JS9NNN[[L=_;C5"K0U/@#?UQU$??(++A#^T-V+_P502P,$%
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M!C@J&T#[I93FX-@"PU]"]AM02P,$%     @ I(%\5KB9)>,-!0  *@T  !D
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M'D,?3YK: 3D#;3,WM4%DNYD33R2+?:X?!=_O^N0'9F##-59G)A7F&HH:S$+
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MBC;@^DQ*TPW(0/]Y-/X/4$L#!!0    ( *2!?%:).I*("@4  ,L,   9
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M:#_RC.0NZV?OL2WN#R/KGL;]P*K>'+_E;A5C-9P@5-00*OHPH;+=/331,*4
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MS4:.\H(BG4V4K(FRUD;-#ERHSMO ,6&KLD1EGC+CA[-E4PTB4[)DF6 IBZE
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M\0B4-3#/4REQ/;$;= >NV5]02P,$%     @ I(%\5D8872&. P  P0L  !D
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M \S9NJD7FXY5.U]RK93% LXWMUAC@W8&.+]6RIXZ;H&V:I_^ U!+ P04
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M-#,N>&ULM5A=CYLX%/TK%EVM6FDZ8$/XF$TBM9E6K30K11VU?5CM@P=N$E3
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MS$/"?!!L).)-)^(-M C8(&6,A-E(F(.$423,1<(\),P'P48RUK7^A*[V8\H
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M@=)<*,V#TGPH+4#15-&V[HMYS@L<9TS$>HQ]^NT-?61OF4&-%"C-@])\*"U
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MJL4U9R'/Y0YB^V.6E2]?9 /[TJ_S?P%02P,$%     @ I(%\5M;.=:4K P
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M, ;Z_I)S]3HQ&S1M9_P=4$L#!!0    ( *2!?%:TDC^7B ,  "X,   9
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M6S!W];7"G=^AY+P"H;D41,%BZIV%I[,PL 9.XSN'C=Y9$QO*O90/=G.13[W
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MP3 !<ZX3(76MR.-DCH9QH4\GOB$>%LU/MC%G3<SHG9AA!/>R-+F&CV6*Z9\
M/@EH540[%;.H$W&.20_ZX1E$013!TV(.)Q]..W#[;7;Z#K?_#NXC&JZ<>IAA
MB1DW&K[?++51])I^'%+>X T.X]D.N](52W#J40MI5&OTXN.C<!1<=[ =M&P'
M7>CQUPH5,[Q<06(+F%$!-61*%B#;&^'J?8AY@WWAL&TKK^/SX7@PB"XG_OH
MJ6%+:MA)ZMGU!:;G;$T<5DB=;&=%RP4,J@*.C\91&%W_$]'N>"&\(5-P"47S
MQ,(QI.Q-=Z1WU"H9_9^2E-I!UO0VB#+^EX0F4-C?2W;0"T;COU+M[_5U@6KE
MII<&%[1I\?:T'9 WS5SX;=Y,UWNF5KS4Q"DCUZ!W05E4S<1J-D96;DHLI:&9
MXY8Y#7E4UH#N,RG-;F,#M'\;\2]02P,$%     @ I(%\5@E813)E P  J0P
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M.U.'I+!F5:;OQ/XC-(8F1F\E,F7?R;Y>.XD<LJJ4%GD3C 0Y+^I/]M!LQ$$
M#8\$^$V _VO ^$A T 38G7-K,FOKFFF6S*38$VE6HYJYL'MCH]$-+\PQWFN)
M=SG&Z>06< \4>4]N*EU)(#?\ 5)B9\F"/>*!:47>7H-F/%/O<-V7^VOR]L]W
M,U=C=J/AKII,EW4F_T@FZI-/HM!;1?XJ4DA_%G 1NV7WG]@O_5[%:UB=D8".
MB._YM /HZO7A?@].T&YE8/6"(WIWH+D$LV/D$@I8<]RY_RZ62DO\KG[KVK!:
M;]RM9W[ YZID*Y@[^ M5('?@)&_^H*'WH<OL;Q+[R?JXM3[N4T]P!X,N@[U1
M0PW68I$5,T^G71+2*([CF;OK0)^TZ)-3Z.,N]-ZHH>BU6'B /@[C.#B"'K;H
MX2GT21=Z;]10]/ %NM=-';74T2GJL(NZ-VHH=?1:ZFE+/3U%'751]T8-I9Z^
MECINJ>->ZL];P-J^UB"[V'MCA[+'KV6GWG-I\GKI;T$I@!'YIP3)-"\V=5T:
MD5O.ECSC^G%$M"!+4ZEX.B*?A6999V'JS3/4::-V:)5ZTR@.ID<,']1B>M+P
M.>%Y66DLPKS <P.E.QWU"@UV1%\X>A\&U#Q=.@WYSX;\7D,+DQSKX8YE%1"Q
M)IEM+++F_#BH3G.]HH/-^2_J!L5G_I0&1]P]UWO:6U.QX*,U>,".6D&GC^!%
MYK%G7FWBAO"WEF[WH!G,06YLCZS(2E2%KOO"=K;MPR]L]^D^+Z^;^$],;GBA
M\-36&.J=15C'9-T7UP,M2MM:+H7&1M5>;O&_!$BS .^OA=!/ Y.@_7>2_ ]0
M2P,$%     @ I(%\5L,.DQ#]!   $"4  !D   !X;"]W;W)K<VAE971S+W-H
M965T-C4N>&ULM9K_;^(V&,;_%2L[3:W4D<1\:SM :DE/NVFG5>W=)FW:#VYX
M@>B2F+,-%&E__.R0Y@M-7;*^Y0=(@OUQ_.#'\4,RVG+Q32X!%'E,XE2.G:52
MJTO7E>$2$B8[? 6I_F;.1<*4WA4+5ZX$L%E6*8E=ZGD#-V%1ZDQ&V;%;,1GQ
MM8JC%&X%D>LD86)W#3'?CAW?>3IP%RV6RAQP)Z,56\ ]J*^K6Z'WW((RBQ)(
M9<13(F ^=J[\RX .386LQ!\1;&5EFYBN/'#^S>Q\FHT=SYP1Q! J@V#Z8P-3
MB&-#TN?Q/8<Z19NF8G7[B?XQZ[SNS .3,.7QG]%,+<?.N4-F,&?K6-WQ[2^0
M=ZAO>"&/9?9.MGE9SR'A6BJ>Y)7U&211NO]DC[D0E0J]ERK0O (]J$#]%RIT
M\PK=8ROT\@J]3)E]5S(= J;89"3XE@A36M/,1B9F5EMW/TK-[WZOA/XVTO74
MY'[](.'[&E)%;C;Z79*3 !2+8GDZ<I5NP!1SPQQVO8?1%V"?F>@02L\(]6B7
M?+T/R,F'4_*!N$0NF0"9?S2 IW9P &&'=/T,3%^F!,=3_$:*J]4K)*2%A#3#
M=H^4D/S]FRY!/BE(Y#]-(NYQO6:<,?JE7+$0QHYVL@2Q 6?RXP_^P/NY23A,
M6( $J\G8+63LVNB3^_T0T7.35"R=1>F"G$1I_C,U#D8KKZV.>]@@@YG)<C/I
M7@SZ?8^.W$U5HH9R7:]/+_RB7*WWO:+W/7OO#P914W^MA+;]Q80%2+":<OU"
MN3ZN_?J8,F+" B183<9!(>/ .@"G,9?&<YG?R$I$(9CK392L$Z*6NKTECV?D
M9,;CF E)5B#V14_)OY49ODGO?;L7%<=XG5[=55/KN;65$0E6DW%8R#ALY6.M
MSM5\'L414S C-ZF*U$X?^Q4$3X#\!?$L:A3-VDK;08H)"Y!@-77/"W7/<;U^
MCBDC)BQ @M5DO"ADO+ /4MB 8*EV>,BE.B-+OA;QC@@]1K-K;F[RS-I-JN[I
MPXJC=<PX<+3U#-J*A02KB>5[Y1+9:^OIFT<(UR:QD-^UNT,]&1[A:7LS;4<C
M*BW HM4EKJ00']?8.0]+2TQ:@$6K:UG&$=^Z3/\?"^D<6%W4^IYY'7C:WG!K
MF=XC;?AEW/!?R1O/79TI]],UD_I2?<MVB3EZ)?1,N0"S?4:^F%ESJ4VOQV;#
M)-"H+6I*0:4%6+3Z+U!&'K^';'K4!(1*"[!H=2W+$.1;P\'D#LR2W7@]6<<J
M6L70*&#_>7H]]#AJHL&BU54I,XUO#S5O]W@0"0@5;[8V9FJ9HM("+%I=^#(%
M^4-D:Z,&'E1:@$6K:UEF'M^:!8ZU]ODS:Q^&;'L[K55YCP3CEQ'&?R7#O/WR
MG:QBO@.09_I*'L;K;*5TW#4=,]Q,46D!%JW^5WB9E:B'_&<X:BA"I058M+J6
M92BBUJ!PI/%SB.]7XWBG?^!]>U.MA7F/A$,K-UQ>23AO\/Z7+3]VZ6X_B]9#
M$_=.S7N$)UJ&)]I%MCEJ#$*E!5BTNI9E#*+V6S]'VKSW[/I.#SV.&FBP:'55
MRD!#[8'F[1ZW+=WMC;<>CJB9"8M6%[[,3'2 ;&W4&(1*"[!H=2W+&$3M=X..
MM/;PU51N;Z>U*JB!QJT\?6*>%?K,Q")*)8EAKO%>9ZC'L]@_?K/?47R5/9#R
MP)7B2;:Y!#8#80KH[^><JZ<=\XQ+\1#4Y#]02P,$%     @ I(%\5I]2 8GH
M 0  6@0  !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULG51=3]LP%/TK
M5M[!:4H90FDDZ(J8!%)%!7M :'*2F\3"'YE]LW3_?K:3AFYJ>=A+[&O?<\X]
M]G727IMWVP @V4FA[#)J$-MK2FW1@&3V7+>@W$ZEC63H0E-3VQI@90!)09,X
MOJ22<15E:5C;F"S5'0JN8&.([:1DYO<M"-TOHUFT7WCB=8-^@69IRVK8 CZW
M&^,B.K&47(*R7"MBH%I&-[/K5>+S0\(+A]X>S(EWDFO][H-OY3**?4$@H$#/
MP-SP"U8@A"=R9?P<.:-)T@,/YWOVN^#=><F9A946WWF)S3*ZBD@)%>L$/NG^
M'D8_"\]7:&'#E_1#[F(>D:*SJ.4(=A5(KH:1[<9S. !<7)T )",@^1>P. &8
MCX!Y,#I4%FQ]9<BRU.B>&)_MV/PDG$V0<6ZX\K>X1>-VN<-A]L!R$"E%1^47
M:#'";@?8[ 1L+<!=)1X!KC[7>V&B@[]AU)4\U9U,=2>!Y^($STU1Z$XA5S79
M(E,E,Z4ESVW)$,CK>H>^SW(!9*TZ"8;YEGD[9O-SE<Z>U8RU/S[4)K%!ZT/I
M@=NCQ_'_-I(XB<_B2_+Z"#('\W;LU.C!S?M7]\A,S94E BJG%Y]_<5UDADX>
M M1MN-5<HVNM,&W<XP?C$]Q^I37N ]]?T^\D^P-02P,$%     @ I(%\5BGO
M"FE' P  S!0   T   !X;"]S='EL97,N>&ULW5A=;]HP%/TK4;I.K30U0-I
M5D#:D"I-VJ9*[</>*D,<L.0XF6,ZV*^?KVW"1WT9Z\,&"RJQ[_$Y]]B^:=SV
M:[7D]&%&J0H6!1?U()PI5;V/HGHRHP6IK\J*"HWDI2R(TETYC>I*4I+50"IX
MU&FUDJ@@3(3#OI@7=X6J@TDY%VH0=IM08&^?LD'83J[#P,J-RHP.PJ>+M]_G
MI;I]$]C[V;NSL]95Z^GR=A>Y<-!E&'F%;PX01F4QT>0@M_K:8UA?F'SW,/E]
MXIAT;UO:##_70I9XCM%2#\ULQV^6O]OR$C=20L>0(U<HPWY>BG6]Q*$-:'52
MT."9\$$X(IR-)0-63@K&ES;<@<"DY*4,E"Y4G:X-D?JGA=NV!S7L= HF2FER
MVPSV>^R&[P"K'AADG#<&.Z$-#/L548I*<:<[9K )OH "UWY<5MKA5))ENW,3
MK@GFII.,2YE1V:1IAZO0L,]I#G8DF\[@KLHJ E"ILM"-C)%I*8CQL&*XAI:=
M4,X?X '_EF]I+_*-?3.[)IJF-N2:5L9V0']3S6IOREZ_2C>HV'.I/L[U=(3I
M0V73>TESMC#]1=X8P-3;N#JI*K[\P-E4%-1._N"$PSY9\8)9*=E/G0U*9:(#
M5(;!,Y6*338C/R2I'NE"K<IID>.>.R?H^>^N\Y0**@G?-*UK_YA7^=6.W1OQ
M7W@VOU9V'7M-QMWC]^A. ,=N,CD%DR>QW;U3,)D>O\GX!#RZ\^71F8S<26CC
MN+5UV&JB 1QJ!^%7."+S==)@/&=<,>%Z,Y9E5+PX<VEY1<;Z3[4M?3T^HSF9
M<_78@(-PW?Y",S8OTF;4/2R$&[5N?X;IM9/F1*US,9'1!<U&KBNG8],,=$-G
M=1<0=I$[<_D1C&,Q/P(8E@=S@'$L"\OS/\VGA\['8IBWGA?IH9P>RK$L'S(R
M'RR/GY/JRS_3-(WC),%6=#3R.AAAZY8D\.-7P[P! \L#F?YLK?'=QBMD?QU@
M>[JO0K"9XI6(S11?:T#\ZP:,-/7O-I8'&-@N8+4#^?UYH*;\G#B&7<6\84\P
MCJ0IAD M^FLT29#52>#CWQ_L*8GC-/4C@/D=Q#&&P-.((Y@#\( A<6S>@SOO
MHVCUGHK6_[\<_@)02P,$%     @ I(%\5I>*NQS     $P(   L   !?<F5L
M<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5Q
MD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC
M0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W
M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ
M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "D@7Q6(E"QMEH%  "F*P
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MBN]P"P_MN2SS:R>:/]VK+DG:;$;/Z[*<0MN5N;2R6+]FNGY%]O@_4$L#!!0
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M;_EL_"/:X@502P$"% ,4    " "D@7Q6!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *2!?%;=1?(5
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( *2!?%:97)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ I(%\5B<2:40\!P  @"\
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M965T-2YX;6Q02P$"% ,4    " "D@7Q6Y,&8Y.,"   R"   &
M    @(';'P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
MI(%\5AS95$@@#   .XL  !@              ("!]"(  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( *2!?%8JQ?A A @  +DE   8
M          " @4HO  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " "D@7Q6H&?VQ>4)   H&   &               @($$.   >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ I(%\5HDT1J_2 @  5P8
M !D              ("!'T(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " "D@7Q6X'IL(1DB  #!;   &0              @($H10
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( *2!?%8D],4V
MU (  +X&   9              " @7AG  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ I(%\5KA7173W @  J 8  !D
M ("!@VH  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "D
M@7Q6&4]%918#  #(!@  &0              @(&Q;0  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( *2!?%;]F2&,]P0  $$,   9
M          " @?YP  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#
M%     @ I(%\5HPRYGJT @  "08  !D              ("!+'8  'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "D@7Q6?[''+<\*  !R
M'0  &0              @($7>0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM
M;%!+ 0(4 Q0    ( *2!?%9>RR+_;P@  ! 9   9              " @1V$
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ I(%\5H6]
MTBK\!0  %@\  !D              ("!PXP  'AL+W=O<FMS:&5E=',O<VAE
M970Q.2YX;6Q02P$"% ,4    " "D@7Q6Z)P+"ED(   M%P  &0
M    @('VD@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M *2!?%:WN@IN^0<  .X3   9              " @8:;  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ I(%\5K <FE;$!@  ]A   !D
M             ("!MJ,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " "D@7Q6*P@N%2L%   6#   &0              @(&QJ@  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( *2!?%8UB@V15 8
M )\1   9              " @1.P  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ I(%\5G)?]N=:(0  ]&X  !D              ("!
MGK8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "D@7Q6
M=1>-)L$%  #"#@  &0              @($OV   >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( *2!?%8!]=!\Z (  .$&   9
M      " @2?>  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ I(%\5L&BTDH' P  D@8  !D              ("!1N$  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "D@7Q6 R1C!E0#  !Q!P
M&0              @(&$Y   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( *2!?%:<N'%]U0(  +H&   9              " @0_H  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ I(%\5KL81LC!
M @  '@8  !D              ("!&^L  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " "D@7Q6N)DEXPT%   J#0  &0
M@($3[@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( *2!
M?%:).I*("@4  ,L,   9              " @5?S  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ I(%\5ILUSFH?!   9@H  !D
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M=#,X+GAM;%!+ 0(4 Q0    ( *2!?%9&&%TAC@,  ,$+   9
M  " @8T* 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
MI(%\5FJ_GWC[ P  F10  !D              ("!4@X! 'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " "D@7Q6=]J98C $  !M&@  &0
M            @(&$$@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( *2!?%;LI]@W* ,  '()   9              " @>L6 0!X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ I(%\5H::P%:W P
M@Q$  !D              ("!2AH! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " "D@7Q6.<S.L&@"  #'!0  &0              @($X
M'@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( *2!?%9M
M.@9S5@0  )06   9              " @=<@ 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ I(%\5DM\IWOL @  ]@D  !D
M     ("!9"4! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *2!?%8["0:SUPD  )EK   9              "
M@?HX 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ I(%\
M5HO33Q9Q!P  RC\  !D              ("!"$,! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    " "D@7Q63(G(<Q@(   &5@  &0
M        @(&P2@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( *2!?%;6SG6E*P,  ,@+   9              " @?]2 0!X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ I(%\5HD(Z#)K!0  9!\
M !D              ("!858! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    " "D@7Q6, /&-I(#  ""#@  &0              @($#7 $
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( *2!?%:TDC^7
MB ,  "X,   9              " @<Q? 0!X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ I(%\5A5:M[,P P  \PH  !D
M ("!BV,! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "D
M@7Q6>$GT?4 #  !/"@  &0              @('R9@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( *2!?%:L RJ8#00  ,@.   9
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M970V-"YX;6Q02P$"% ,4    " "D@7Q6PPZ3$/T$   0)0  &0
M    @(%5>P$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    (
M *2!?%:?4@&)Z $  %H$   9              " @8F  0!X;"]W;W)K<VAE
M971S+W-H965T-C8N>&UL4$L! A0#%     @ I(%\5BGO"FE' P  S!0   T
M             ( !J((! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "D@7Q6
MEXJ[',     3 @  "P              @ $:A@$ 7W)E;',O+G)E;'-02P$"
M% ,4    " "D@7Q6(E"QMEH%  "F*P  #P              @ $#AP$ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ I(%\5A[?F5X< @  /2<  !H
M         ( !BHP! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ I(%\5J5_#G'N 0  D"8  !,              ( !WHX! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     $H 2@ ]%   _9 !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>156</ContextCount>
  <ElementCount>367</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>57</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Statements Of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/StatementsOfOperations</Role>
      <ShortName>Statements Of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Statements Of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Statements Of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Statements Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity</Role>
      <ShortName>Statements Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Statements Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements Of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Basis of Presentation and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/BasisofPresentationandLiquidity</Role>
      <ShortName>Basis of Presentation and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Restructuring Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/RestructuringActivities</Role>
      <ShortName>Restructuring Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://nex.com/role/ConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficit</Role>
      <ShortName>Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://nex.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nex.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nex.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nex.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nex.com/role/PropertyandEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Restructuring Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/RestructuringActivitiesTables</Role>
      <ShortName>Restructuring Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nex.com/role/RestructuringActivities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nex.com/role/AccruedExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nex.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nex.com/role/IncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nex.com/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Description of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/DescriptionoftheBusinessDetails</Role>
      <ShortName>Description of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nex.com/role/DescriptionoftheBusiness</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Restricted Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Restricted Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Lives of Property Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Useful Lives of Property Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Prepaid Expenses And Other Current Assets - Summary of Prepaid Expenses And Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid Expenses And Other Current Assets - Summary of Prepaid Expenses And Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Property and Equipment - Summary of Property And Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment - Summary of Property And Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/PropertyandEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Restructuring Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/RestructuringActivitiesDetails</Role>
      <ShortName>Restructuring Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nex.com/role/RestructuringActivitiesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Restructuring Activities - Summary of Charges Related to Restructuring Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails</Role>
      <ShortName>Restructuring Activities - Summary of Charges Related to Restructuring Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Accrued Expenses - Summary of Components of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Summary of Components of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Commitments and Contingencies - Additional Information, Maryland Biotechnology Center Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information, Maryland Biotechnology Center Grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Commitments and Contingencies - Additional Information, Johns Hopkins University Exclusive License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information, Johns Hopkins University Exclusive License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Commitments and Contingencies - Additional Information, Paycheck Protection Program Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information, Paycheck Protection Program Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Convertible Notes - Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://nex.com/role/ConvertibleNotesAdditionalInformationDetail</Role>
      <ShortName>Convertible Notes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail</Role>
      <ShortName>Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Income Taxes - Schedule of Provision For Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision For Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Leases - Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/LeasesComponentsofLeaseCostDetails</Role>
      <ShortName>Leases - Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Leases - Schedule of Cash Flow, Supplemental Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/LeasesScheduleofCashFlowSupplementalDisclosuresDetails</Role>
      <ShortName>Leases - Schedule of Cash Flow, Supplemental Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Leases - Future Fixed Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Fixed Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nex.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nex.com/role/SubsequentEvents</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="nexi-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - nexi-20221231.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - nexi-20221231.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  nexi-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="nexi-20221231.htm">nexi-20221231.htm</File>
    <File>nexi-20221231.xsd</File>
    <File>nexi-20221231_cal.xml</File>
    <File>nexi-20221231_def.xml</File>
    <File>nexi-20221231_lab.xml</File>
    <File>nexi-20221231_pre.xml</File>
    <File>nexi-20221231x10kxex231.htm</File>
    <File>nexi-20221231x10kxex311.htm</File>
    <File>nexi-20221231x10kxex312.htm</File>
    <File>nexi-20221231x10kxex321.htm</File>
    <File>nexi-20221231x10kxex322.htm</File>
    <File>nexi-20221231x10xkxex1072.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nexi-20221231_g1.jpg</File>
    <File>nexi-20221231_g10.jpg</File>
    <File>nexi-20221231_g11.jpg</File>
    <File>nexi-20221231_g2.jpg</File>
    <File>nexi-20221231_g3.jpg</File>
    <File>nexi-20221231_g4.jpg</File>
    <File>nexi-20221231_g5.jpg</File>
    <File>nexi-20221231_g6.jpg</File>
    <File>nexi-20221231_g7.jpg</File>
    <File>nexi-20221231_g8.jpg</File>
    <File>nexi-20221231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="601">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nexi-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 23,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 601,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 156,
   "dts": {
    "calculationLink": {
     "local": [
      "nexi-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nexi-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nexi-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nexi-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nexi-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nexi-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 547,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 6
   },
   "keyCustom": 51,
   "keyStandard": 316,
   "memberCustom": 20,
   "memberStandard": 34,
   "nsprefix": "nexi",
   "nsuri": "http://nex.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://nex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Basis of Presentation and Liquidity",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://nex.com/role/BasisofPresentationandLiquidity",
     "shortName": "Basis of Presentation and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://nex.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://nex.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nexi:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://nex.com/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nexi:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://nex.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Restructuring Activities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://nex.com/role/RestructuringActivities",
     "shortName": "Restructuring Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://nex.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://nex.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Convertible Notes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://nex.com/role/ConvertibleNotes",
     "shortName": "Convertible Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nexi:RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficit",
     "shortName": "Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nexi:RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://nex.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://nex.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://nex.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://nex.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://nex.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://nex.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nexi:SubstantialDoubtForGoingConcernPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nexi:SubstantialDoubtForGoingConcernPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://nex.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://nex.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://nex.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://nex.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://nex.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Restructuring Activities (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://nex.com/role/RestructuringActivitiesTables",
     "shortName": "Restructuring Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://nex.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://nex.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://nex.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://nex.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Description of the Business (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://nex.com/role/DescriptionoftheBusinessDetails",
     "shortName": "Description of the Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "nexi:SubstantialDoubtForGoingConcernPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Restricted Cash and Cash Equivalents (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Restricted Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i87575f3a4a8d47e0b099f6f2d5697f3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Lives of Property Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Useful Lives of Property Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i87575f3a4a8d47e0b099f6f2d5697f3c_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Summary of Significant Accounting Policies - Summary of Basic and Diluted Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Basic and Diluted Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://nex.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Outstanding (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "ib2e473ef2ced4a76af90569c4e60acd9_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "ib2e473ef2ced4a76af90569c4e60acd9_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "nexi:PrepaidResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Prepaid Expenses And Other Current Assets - Summary of Prepaid Expenses And Other Current Assets (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail",
     "shortName": "Prepaid Expenses And Other Current Assets - Summary of Prepaid Expenses And Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "nexi:PrepaidResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Property and Equipment - Summary of Property And Equipment (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail",
     "shortName": "Property and Equipment - Summary of Property And Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Property and Equipment - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://nex.com/role/PropertyandEquipmentAdditionalInformationDetail",
     "shortName": "Property and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Restructuring Activities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://nex.com/role/RestructuringActivitiesDetails",
     "shortName": "Restructuring Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i7c590145da4b44288c802fc50a344e72_D20221101-20221130",
      "decimals": "2",
      "lang": "en-US",
      "name": "nexi:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Restructuring Activities - Summary of Charges Related to Restructuring Activities (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails",
     "shortName": "Restructuring Activities - Summary of Charges Related to Restructuring Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "nexi:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Accrued Expenses - Summary of Components of Accrued Expenses (Detail)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail",
     "shortName": "Accrued Expenses - Summary of Components of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "nexi:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i0dc71e39107c4d2e888729d888bb4e8b_D20130523-20130523",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Commitments and Contingencies - Additional Information, Maryland Biotechnology Center Grant (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails",
     "shortName": "Commitments and Contingencies - Additional Information, Maryland Biotechnology Center Grant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i0dc71e39107c4d2e888729d888bb4e8b_D20130523-20130523",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Commitments and Contingencies - Additional Information, Johns Hopkins University Exclusive License Agreement (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
     "shortName": "Commitments and Contingencies - Additional Information, Johns Hopkins University Exclusive License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Statements Of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://nex.com/role/StatementsOfOperations",
     "shortName": "Statements Of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ExtinguishmentOfDebtAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Commitments and Contingencies - Additional Information, Paycheck Protection Program Loan (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails",
     "shortName": "Commitments and Contingencies - Additional Information, Paycheck Protection Program Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i6e206dd327124b4b8af59ef1f3ab5579_I20200501",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Convertible Notes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
     "shortName": "Convertible Notes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i74ebc54878b1455ba9248d3203abce2c_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ConvertibleNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i6ab94587a7134bc29507a4735e3b4bb5_D20210211-20210211",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail",
     "shortName": "Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i6ab94587a7134bc29507a4735e3b4bb5_D20210211-20210211",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i8ab04e02de714324a031d507a830df05_I20210228",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i8ab04e02de714324a031d507a830df05_I20210228",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense (Detail)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i7dbf4cfdf7364c51ae3569ac7348cb4b_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Stock-Based Compensation - Summary of Option Activity (Detail)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Summary of Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model (Detail)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail",
     "shortName": "Stock-Based Compensation - Summary of Black-Scholes Option Pricing Model (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i0c755e4c19e14dd3b1b1970081b2809e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i0c755e4c19e14dd3b1b1970081b2809e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Income Taxes - Schedule of Provision For Income Taxes (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Provision For Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Statements Of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://nex.com/role/StatementsOfComprehensiveLoss",
     "shortName": "Statements Of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
       "us-gaap:UnrecognizedTaxBenefits",
       "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
       "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://nex.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "nexi:DeferredTaxAssetValuationAllowancePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Leases - Components of Lease Cost (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://nex.com/role/LeasesComponentsofLeaseCostDetails",
     "shortName": "Leases - Components of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Leases - Schedule of Cash Flow, Supplemental Disclosures (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://nex.com/role/LeasesScheduleofCashFlowSupplementalDisclosuresDetails",
     "shortName": "Leases - Schedule of Cash Flow, Supplemental Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Leases - Future Fixed Lease Payments (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails",
     "shortName": "Leases - Future Fixed Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i3cfc586d3ef2479899da6a9e51989ddb_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://nex.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i1b6232ae6cb64482b9ec1943b0fe3126_I20230322",
      "decimals": "2",
      "lang": "en-US",
      "name": "nexi:ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i37d7504e32234f1795742c55cbc6b155_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Statements Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity",
     "shortName": "Statements Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i37d7504e32234f1795742c55cbc6b155_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Statements Of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://nex.com/role/StatementsOfCashFlows",
     "shortName": "Statements Of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Description of the Business",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://nex.com/role/DescriptionoftheBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nexi-20221231.htm",
      "contextRef": "i97a90c417a404807b67812e3dc3d073d_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": null,
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - nexi-20221231.htm",
     "menuCat": "Cover",
     "order": "66",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - nexi-20221231.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 57,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r588",
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://nex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nexi_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development Costs, Current",
        "label": "Accrued Research and Development Costs, Current",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market Offering",
        "label": "At-The-Market Offering [Member]",
        "terseLabel": "At-The-Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://nex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nexi_ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Trial, Contract Development, and Manufacturing Organization Expenses, Policy",
        "label": "Clinical Trial, Contract Development, and Manufacturing Organization Expenses, Policy [Policy Text Block]",
        "terseLabel": "Clinical trial and contract development and manufacturing organization expenses"
       }
      }
     },
     "localname": "ClinicalTrialContractDevelopmentAndManufacturingOrganizationExpensesPolicyPolicyTextBlock",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nexi_ClinicalTrialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "clinical Trial Milestones.",
        "label": "Clinical Trial Milestones [Member]",
        "terseLabel": "Clinical Trial Milestones"
       }
      }
     },
     "localname": "ClinicalTrialMilestonesMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_CumulativeMinimumRoyalties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative minimum royalties.",
        "label": "Cumulative Minimum Royalties",
        "terseLabel": "Cumulative minimum royalties"
       }
      }
     },
     "localname": "CumulativeMinimumRoyalties",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt conversion converted instrument net of amortization of debt discounts.",
        "label": "Debt Conversion Converted Instrument Net Of Amortization Of Debt Discounts",
        "terseLabel": "Convertible notes outstanding, net of unamortized discounts, reclassified to stockholders' equity"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentNetOfAmortizationOfDebtDiscounts",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_DebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt discount.",
        "label": "Debt Discount",
        "terseLabel": "Debt discount"
       }
      }
     },
     "localname": "DebtDiscount",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_DebtInstrumentAdditionalClosingLockInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, additional closing lock in period.",
        "label": "Debt Instrument Additional Closing Lock In Period",
        "terseLabel": "Additional closing period (in days)"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalClosingLockInPeriod",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nexi_DebtInstrumentConvertiblePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, convertible, price percentage.",
        "label": "Debt Instrument Convertible Price Percentage",
        "terseLabel": "Convertible note price percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertiblePricePercentage",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nexi_DebtInstrumentFullyDilutedCapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument fully diluted capitalization.",
        "label": "Debt Instrument Fully Diluted Capitalization",
        "terseLabel": "Convertible note fully diluted capitalization"
       }
      }
     },
     "localname": "DebtInstrumentFullyDilutedCapitalization",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_DebtInstrumentRedemptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, redemption amount.",
        "label": "Debt Instrument Redemption Amount",
        "terseLabel": "Convertible note redemption amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionAmount",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_DebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt issuance costs.",
        "label": "Debt Issuance Costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DebtIssuanceCosts",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_DeferredTaxAssetValuationAllowancePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Valuation Allowance, Percent",
        "label": "Deferred Tax Asset, Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetValuationAllowancePercent",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "nexi_DeferredTaxAssetsOperatingLeases": {
     "auth_ref": [],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Leases",
        "label": "Deferred Tax Assets, Operating Leases",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeases",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_EmployeesExcludingExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees, Excluding Executive Officer",
        "label": "Employees, Excluding Executive Officer [Member]",
        "terseLabel": "Employees, Excluding Executive Officer"
       }
      }
     },
     "localname": "EmployeesExcludingExecutiveOfficerMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_ExclusiveLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive License Agreement.",
        "label": "Exclusive License Agreement [Member]",
        "terseLabel": "Exclusive License Agreement"
       }
      }
     },
     "localname": "ExclusiveLicenseAgreementMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_FairValueOfDerivativeLiabilityOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of derivative liability of convertible notes.",
        "label": "Fair Value of Derivative Liability of Convertible Notes",
        "terseLabel": "Fair value of derivative liability of convertible notes"
       }
      }
     },
     "localname": "FairValueOfDerivativeLiabilityOfConvertibleNotes",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Derivative Liability Of Convertible Notes At Issuance",
        "label": "Fair Value Of Derivative Liability Of Convertible Notes At Issuance",
        "terseLabel": "Fair value of derivative liability of convertible notes at issuance"
       }
      }
     },
     "localname": "FairValueOfDerivativeLiabilityOfConvertibleNotesAtIssuance",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_JeromeZeldisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jerome Zeldis",
        "label": "Jerome Zeldis [Member]",
        "terseLabel": "Jerome Zeldis"
       }
      }
     },
     "localname": "JeromeZeldisMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_JohnsHopkinsUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Johns Hopkins University.",
        "label": "Johns Hopkins University [Member]",
        "terseLabel": "Johns Hopkins University"
       }
      }
     },
     "localname": "JohnsHopkinsUniversityMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_LeaseExpenseNoncash": {
     "auth_ref": [],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Expense, Noncash",
        "label": "Lease Expense, Noncash",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "LeaseExpenseNoncash",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_MarylandBiotechnologyCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maryland Biotechnology Center.",
        "label": "Maryland Biotechnology Center [Member]",
        "terseLabel": "Maryland Biotechnology Center"
       }
      }
     },
     "localname": "MarylandBiotechnologyCenterMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_MilestoneFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone fees.",
        "label": "Milestone Fees",
        "terseLabel": "Milestone fees"
       }
      }
     },
     "localname": "MilestoneFees",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_MilestonesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones.",
        "label": "Milestones [Axis]",
        "terseLabel": "Milestones [Axis]"
       }
      }
     },
     "localname": "MilestonesAxis",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nexi_MilestonesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones.",
        "label": "Milestones [Domain]",
        "terseLabel": "Milestones [Domain]"
       }
      }
     },
     "localname": "MilestonesDomain",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_MinimumAnnualRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum annual royalty payments.",
        "label": "Minimum Annual Royalty Payments",
        "terseLabel": "Minimum annual royalty payments"
       }
      }
     },
     "localname": "MinimumAnnualRoyaltyPayments",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_NonclinicalFieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "non-clinical field",
        "label": "Nonclinical Field [Member]",
        "terseLabel": "Non-clinical field"
       }
      }
     },
     "localname": "NonclinicalFieldMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Number Of Warrants Exercised",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "nexi_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program Loan.",
        "label": "Paycheck Protection Program Loan [Member]",
        "terseLabel": "Paycheck Protection Program Loan"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nexi_PrepaidMaintenanceAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid maintenance agreements.",
        "label": "Prepaid Maintenance Agreements",
        "terseLabel": "Prepaid maintenance agreements"
       }
      }
     },
     "localname": "PrepaidMaintenanceAgreements",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_PrepaidResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid research and development expenses.",
        "label": "Prepaid Research And Development Expenses",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentExpenses",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Convertible Preferred Stock and Stockholders Equity Disclosure [Abstract].",
        "label": "Redeemable Convertible Preferred Stock And Stockholders Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureAbstract",
     "nsuri": "http://nex.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nexi_RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Convertible Preferred Stock and Stockholders Equity Disclosure [Text Block].",
        "label": "Redeemable Convertible Preferred Stock And Stockholders Equity Disclosure [Text Block]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock and Stockholders' Deficit"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockAndStockholdersEquityDisclosureTextBlock",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nexi_RegulatoryAndCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory and commercial milestones.",
        "label": "Regulatory and Commercial Milestones [Member]",
        "terseLabel": "Regulatory and Commercial Milestones"
       }
      }
     },
     "localname": "RegulatoryAndCommercialMilestonesMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_RelatedPartyTransactionHourlyRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Hourly Rate",
        "label": "Related Party Transaction, Hourly Rate",
        "terseLabel": "Severance cost, hourly rate (in dollars)"
       }
      }
     },
     "localname": "RelatedPartyTransactionHourlyRate",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_ResearchAndDevelopmentArrangementAnnualPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement Annual Payment Percentage.",
        "label": "Research And Development Arrangement Annual Payment Percentage",
        "terseLabel": "Research and development arrangement annual payment percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementAnnualPaymentPercentage",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nexi_ResearchAndDevelopmentArrangementContractToPerformForOthersLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development arrangement contract to perform for others liability.",
        "label": "Research And Development Arrangement Contract To Perform For Others Liability",
        "terseLabel": "Research and development arrangement contract to perform for others liability"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLiability",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_ResearchAndDevelopmentArrangementContractualPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development arrangement contractual payment percentage.",
        "label": "Research And Development Arrangement Contractual Payment Percentage",
        "terseLabel": "Research and development arrangement, contractual payment percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractualPaymentPercentage",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nexi_ResearchAndDevelopmentArrangementContractualPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development arrangement contractual payment period.",
        "label": "Research And Development Arrangement Contractual Payment Period",
        "terseLabel": "Research and development arrangement contractual payment period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractualPaymentPeriod",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nexi_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Cost, Expected Number Of Positions Eliminated, Period Percent",
        "label": "Restructuring And Related Cost, Expected Number Of Positions Eliminated, Period Percent",
        "terseLabel": "Reduction in headcount, percentage"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nexi_RestructuringAndRelatedCostNumberOfPositionsAfterEliminations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Cost, Number Of Positions, After Eliminations",
        "label": "Restructuring And Related Cost, Number Of Positions, After Eliminations",
        "terseLabel": "Number of positions after eliminations"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsAfterEliminations",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nexi_RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Cost, Number Of Positions, Before Eliminations",
        "label": "Restructuring And Related Cost, Number Of Positions, Before Eliminations",
        "terseLabel": "Number of positions before eliminations"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nexi_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed",
        "label": "Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag",
        "terseLabel": "Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag"
       }
      }
     },
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nexi_SaleOfStockAggregateOfferingApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Aggregate Offering Approval",
        "label": "Sale of Stock, Aggregate Offering Approval",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingApproval",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_SaleOfStockCommissionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Commission Percentage",
        "label": "Sale of Stock, Commission Percentage",
        "terseLabel": "Commission percentage"
       }
      }
     },
     "localname": "SaleOfStockCommissionPercentage",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nexi_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Redeemable Convertible Preferred Stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_SeriesAThreeRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Three Redeemable Convertible Preferred Stock.",
        "label": "Series A Three Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series\u00a0A-3"
       }
      }
     },
     "localname": "SeriesAThreeRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_SeriesATwoRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Two Redeemable Convertible Preferred Stock.",
        "label": "Series A Two Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series\u00a0A-2"
       }
      }
     },
     "localname": "SeriesATwoRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Common Stock, Cashless, Exercised in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Common Stock, Cashless, Exercised in Period",
        "terseLabel": "Cashless exercise of options for common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockCashlessExercisedInPeriod",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Increase In Authorized Shares by Percentage of Outstanding Stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Increase In Authorized Shares by Percentage of Outstanding Stock",
        "terseLabel": "Percentage of outstanding stock maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInAuthorizedSharesByPercentageOfOutstandingStock",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period",
        "negatedTerseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Outstanding Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Shares unvested as of December\u00a031, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Options Non Vested Outstanding Weighted Average Remaining Contractual Term1",
        "label": "Share based Compensation Arrangement By Share based Payment Award Options Non Vested Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Shares unvested as of end of period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nexi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "nexi_ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Option, Repricing, Closing Share Price Minimum Threshold",
        "label": "Share-Based Payment Arrangement, Option, Repricing, Closing Share Price Minimum Threshold",
        "terseLabel": "Closing share price minimum threshold (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionRepricingClosingSharePriceMinimumThreshold",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nexi_ShareBasedPaymentArrangementOptionRepricingMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Option, Repricing Multiple",
        "label": "Share-Based Payment Arrangement, Option, Repricing Multiple",
        "terseLabel": "Repricing multiple"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionRepricingMultiple",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "nexi_StockIssuedDuringPeriodSharesConversionOfConvertibleDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares conversion of convertible debt.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Debt",
        "terseLabel": "Conversion of convertible debt into common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleDebt",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "nexi_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Common shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "nexi_StockIssuedDuringPeriodValueCashlessCommonStockExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Cashless, Common Stock Exercised",
        "label": "Stock Issued During Period, Value, Cashless, Common Stock Exercised",
        "terseLabel": "Cashless exercise of options for common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCashlessCommonStockExercised",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_StockIssuedDuringPeriodValueConversionOfConvertibleDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value conversion of convertible debt.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Debt",
        "terseLabel": "Conversion of convertible debt into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleDebt",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_SublicenseConsiderationPaymentPercentMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense Consideration Payment, Percent, Maximum",
        "label": "Sublicense Consideration Payment, Percent, Maximum",
        "terseLabel": "Sublicense consideration payment, maximum percent"
       }
      }
     },
     "localname": "SublicenseConsiderationPaymentPercentMaximum",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nexi_SubstantialDoubtForGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Substantial Doubt For Going Concern",
        "label": "Substantial Doubt For Going Concern [Policy Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "SubstantialDoubtForGoingConcernPolicyTextBlock",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nexi_TemporaryEquityPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Policy",
        "label": "Temporary Equity, Policy [Policy Text Block]",
        "terseLabel": "Redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityPolicyPolicyTextBlock",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nexi_TemporaryEquityStockConvertedDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock converted during period shares.",
        "label": "Temporary Equity Stock Converted During Period Shares",
        "negatedTerseLabel": "Conversion of preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockConvertedDuringPeriodShares",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "nexi_TemporaryEquityStockConvertedDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock converted during period value.",
        "label": "Temporary Equity Stock Converted During Period Value",
        "negatedTerseLabel": "Conversion of preferred stock into common stock"
       }
      }
     },
     "localname": "TemporaryEquityStockConvertedDuringPeriodValue",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nexi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series A redeemable preferred stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "nexi_The2021PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The 2021 Plan",
        "label": "The 2021 Plan [Member]",
        "terseLabel": "The 2021 Plan"
       }
      }
     },
     "localname": "The2021PlanMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_TherapeuticFieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Therapeutic field.",
        "label": "Therapeutic Field [Member]",
        "terseLabel": "Therapeutic Field"
       }
      }
     },
     "localname": "TherapeuticFieldMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_TranslationalResearchAwardAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Translational Research Award Agreement.",
        "label": "Translational Research Award Agreement [Member]",
        "terseLabel": "Translational Research Award Agreement"
       }
      }
     },
     "localname": "TranslationalResearchAwardAgreementMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_TwoThousandEighteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "The 2018 Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "The 2017 Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nexi_WeightedAverageRemainingContractualTermInYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term (in years)",
        "label": "Weighted Average Remaining Contractual Term (in years) [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermInYearsAbstract",
     "nsuri": "http://nex.com/20221231",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r556",
      "r631",
      "r673",
      "r674",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r319",
      "r347",
      "r562",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails",
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r167",
      "r215",
      "r221",
      "r227",
      "r283",
      "r402",
      "r403",
      "r404",
      "r426",
      "r427",
      "r448",
      "r451",
      "r453",
      "r454",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect of adoption of accounting standard"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r167",
      "r215",
      "r221",
      "r227",
      "r283",
      "r402",
      "r403",
      "r404",
      "r426",
      "r427",
      "r448",
      "r451",
      "r453",
      "r454",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r167",
      "r215",
      "r221",
      "r227",
      "r283",
      "r402",
      "r403",
      "r404",
      "r426",
      "r427",
      "r448",
      "r451",
      "r453",
      "r454",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r365",
      "r517",
      "r539",
      "r557",
      "r558",
      "r574",
      "r578",
      "r583",
      "r629",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r365",
      "r517",
      "r539",
      "r557",
      "r558",
      "r574",
      "r578",
      "r583",
      "r629",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r357",
      "r365",
      "r393",
      "r394",
      "r395",
      "r516",
      "r517",
      "r539",
      "r557",
      "r558",
      "r574",
      "r578",
      "r583",
      "r624",
      "r629",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r357",
      "r365",
      "r393",
      "r394",
      "r395",
      "r516",
      "r517",
      "r539",
      "r557",
      "r558",
      "r574",
      "r578",
      "r583",
      "r624",
      "r629",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r319",
      "r347",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails",
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r621",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r216",
      "r217",
      "r218",
      "r276",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r402",
      "r403",
      "r404",
      "r426",
      "r427",
      "r438",
      "r439",
      "r440",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r480",
      "r481",
      "r485",
      "r486",
      "r487",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r582"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://nex.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail",
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r142",
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r72",
      "r175"
     ],
     "calculation": {
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r181",
      "r535",
      "r547",
      "r551"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r26",
      "r29",
      "r120",
      "r503",
      "r542",
      "r543",
      "r602",
      "r603",
      "r604",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/ (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r582"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional\u00a0paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r614",
      "r615",
      "r616",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r107",
      "r108",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r338",
      "r483",
      "r572",
      "r573",
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and discounts"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r137",
      "r151",
      "r177",
      "r205",
      "r258",
      "r267",
      "r271",
      "r279",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r441",
      "r443",
      "r464",
      "r582",
      "r627",
      "r628",
      "r677"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r171",
      "r183",
      "r205",
      "r279",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r441",
      "r443",
      "r464",
      "r582",
      "r627",
      "r628",
      "r677"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r68",
      "r278",
      "r286",
      "r531"
     ],
     "calculation": {
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fixed income debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Basis of Presentation and Liquidity"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BasisofPresentationandLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r58",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "verboseLabel": "Description of the Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/DescriptionoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r52",
      "r173",
      "r560"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets",
      "http://nex.com/role/DescriptionoftheBusinessDetails",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r47",
      "r52",
      "r57"
     ],
     "calculation": {
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Net cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Net cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r47",
      "r131"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r205",
      "r231",
      "r232",
      "r239",
      "r241",
      "r245",
      "r246",
      "r279",
      "r307",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r345",
      "r346",
      "r348",
      "r349",
      "r352",
      "r464",
      "r559",
      "r596",
      "r610",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r143",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r301",
      "r302",
      "r552",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r614",
      "r615",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheetsParenthetical",
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Authorized common stock (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheetsParenthetical",
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r582"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common Stock, $0.0001 par value, 250,000,000 shares authorized as of December\u00a031, 2022 and 2021, 26,078,451 and 22,828,904 issued and outstanding as of December\u00a031, 2022 and 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r30",
      "r187",
      "r189",
      "r195",
      "r532",
      "r536"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r149",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r82",
      "r316",
      "r317",
      "r328",
      "r329",
      "r330",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r1",
      "r139",
      "r152",
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r6",
      "r7",
      "r90",
      "r93",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Converted common stock (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r605"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current income tax provision:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r613",
      "r662",
      "r664"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r119",
      "r422",
      "r431",
      "r613"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r613",
      "r662",
      "r664"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Beneficial conversion feature"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Convertible notes outstanding converted into common stock (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r204",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r332",
      "r339",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.",
        "label": "Debt Instrument, Convertible, Beneficial Conversion Feature",
        "terseLabel": "Beneficial conversion feature"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBeneficialConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r133",
      "r135",
      "r316",
      "r484",
      "r570",
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Convertible notes issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails",
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r20",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Convertible note redemption price, percentage of principal amount redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r21",
      "r90",
      "r94",
      "r95",
      "r96",
      "r132",
      "r133",
      "r135",
      "r148",
      "r211",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r341",
      "r484",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r613",
      "r663",
      "r664"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred income tax benefit:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r50",
      "r119",
      "r423",
      "r430",
      "r431",
      "r613"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r3",
      "r4",
      "r138",
      "r150",
      "r417"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r164",
      "r598",
      "r672"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r613",
      "r663",
      "r664"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r117",
      "r661"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r117",
      "r661"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforwards, not subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Operating loss carryforwards, subject to expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r117",
      "r661"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r115",
      "r117",
      "r661"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r117",
      "r661"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r117",
      "r661"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r117",
      "r661"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "ROU assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r117",
      "r661"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r50",
      "r256"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r127",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Convertible instruments and embedded derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r367",
      "r398",
      "r399",
      "r401",
      "r406",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r196",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r228",
      "r231",
      "r239",
      "r240",
      "r241",
      "r243",
      "r454",
      "r455",
      "r533",
      "r537",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss attributable to common stockholders per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r196",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r231",
      "r239",
      "r240",
      "r241",
      "r243",
      "r454",
      "r455",
      "r533",
      "r537",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss attributable to common stockholders per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r206",
      "r411",
      "r432"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r659",
      "r665"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r432",
      "r659"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in state tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r659",
      "r665"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r659",
      "r665"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r659",
      "r665"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued salaries, benefits and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r658"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails",
      "http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r89",
      "r167",
      "r191",
      "r192",
      "r193",
      "r212",
      "r213",
      "r214",
      "r217",
      "r224",
      "r226",
      "r244",
      "r283",
      "r354",
      "r402",
      "r403",
      "r404",
      "r426",
      "r427",
      "r453",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r503",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Gain on extinguishment of debt from forgiveness of PPP Loan"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails",
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r457",
      "r458",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r128",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r330",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r458",
      "r513",
      "r514",
      "r515",
      "r570",
      "r571",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r460",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r330",
      "r358",
      "r363",
      "r458",
      "r513",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r330",
      "r358",
      "r363",
      "r458",
      "r514",
      "r570",
      "r571",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r330",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r458",
      "r515",
      "r570",
      "r571",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r330",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r513",
      "r514",
      "r515",
      "r570",
      "r571",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r461",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FixedIncomeSecuritiesMember": {
     "auth_ref": [
      "r577",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.",
        "label": "Fixed Income Securities [Member]",
        "terseLabel": "Fixed income debt securities"
       }
      }
     },
     "localname": "FixedIncomeSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r608"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on asset disposal"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r36",
      "r67",
      "r595"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Accretion income on available-for-sale marketable securities, net"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r50",
      "r83",
      "r84"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://nex.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Gain on extinguishment of debt",
        "terseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows",
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesComponentsofLeaseCostDetails",
      "http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r50",
      "r70",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r287",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/LeasesComponentsofLeaseCostDetails",
      "http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/LeasesComponentsofLeaseCostDetails",
      "http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r412",
      "r415",
      "r421",
      "r428",
      "r433",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r207",
      "r225",
      "r226",
      "r257",
      "r410",
      "r429",
      "r434",
      "r538"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Total provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.",
        "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesScheduleofProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r190",
      "r408",
      "r409",
      "r415",
      "r416",
      "r420",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r607",
      "r669"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r134",
      "r146",
      "r194",
      "r255",
      "r482"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r38",
      "r336",
      "r344",
      "r572",
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r199",
      "r201",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the year for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r35",
      "r254"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Components of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesComponentsofLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesComponentsofLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Fixed Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Lessee, Operating Lease, Liability, to be Paid, Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r205",
      "r279",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r442",
      "r443",
      "r444",
      "r464",
      "r566",
      "r627",
      "r677",
      "r678"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r141",
      "r157",
      "r582",
      "r612",
      "r622",
      "r668"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r172",
      "r205",
      "r279",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r442",
      "r443",
      "r444",
      "r464",
      "r582",
      "r627",
      "r677",
      "r678"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r1",
      "r139",
      "r153",
      "r329",
      "r343",
      "r570",
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/DescriptionoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails",
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r21",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails",
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Investment positions in marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Available-for-sale\u00a0marketable\u00a0securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r47",
      "r48",
      "r51"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r51",
      "r145",
      "r161",
      "r170",
      "r186",
      "r188",
      "r193",
      "r205",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r237",
      "r258",
      "r266",
      "r270",
      "r272",
      "r279",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r455",
      "r464",
      "r567",
      "r627"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://nex.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://nex.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity",
      "http://nex.com/role/StatementsOfComprehensiveLoss",
      "http://nex.com/role/StatementsOfOperations",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r228",
      "r229",
      "r238",
      "r241",
      "r258",
      "r266",
      "r270",
      "r272",
      "r567"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net loss available to common stockholders\u2019"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r238",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting standards and pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r16"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Notes payable, current"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://nex.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r258",
      "r266",
      "r270",
      "r272",
      "r567"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r492",
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesComponentsofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r489"
     ],
     "calculation": {
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesFutureFixedLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r489"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Operating lease, liability, current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r489"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "negatedLabel": "Operating Lease, Liability, non-current",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r490",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesScheduleofCashFlowSupplementalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r488"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r495",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate \u2014 operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesScheduleofCashFlowSupplementalDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r494",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term \u2014 operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesScheduleofCashFlowSupplementalDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/AccruedExpensesSummaryofComponentsofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r182",
      "r582"
     ],
     "calculation": {
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other\u00a0non-current\u00a0assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on\u00a0available-for-sale\u00a0marketable securities, net of tax",
        "verboseLabel": "Unrealized loss on marketable available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity",
      "http://nex.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationPaycheckProtectionProgramLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r600",
      "r623"
     ],
     "calculation": {
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash\u00a0interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r290",
      "r606"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Less: Payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Issuance costs associated with convertible notes"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases\u00a0of\u00a0available-for-sale\u00a0marketable\u00a0securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Authorized preferred stock (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Redeemable convertible preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r601"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets",
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r561",
      "r568",
      "r623"
     ],
     "calculation": {
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PrepaidExpensesAndOtherCurrentAssetsSummaryofPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from the issuance of convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial offering, net of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from \"at-the-market\" offering facility, net of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of convertible debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r66",
      "r197",
      "r198"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities\u00a0of\u00a0available-for-sale\u00a0marketable\u00a0securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from the issuance of convertible notes from related parties"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r40",
      "r66",
      "r197"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from redemption of available-for-sale marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of machinery and equipment.",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Proceeds from disposal of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r105"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r553",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r71",
      "r174"
     ],
     "calculation": {
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Property plant and equipment gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r73",
      "r158",
      "r534",
      "r582"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets",
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of estimated useful lives of property, plant and equipment",
        "verboseLabel": "Summary of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentTables",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable convertible preferred stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r364",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r364",
      "r506",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r504",
      "r505",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.",
        "label": "Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security",
        "negatedTerseLabel": "Principal payments on capital leases"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Research and development arrangement contract to perform for others compensation earned"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r109",
      "r163",
      "r685"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/LeasesComponentsofLeaseCostDetails",
      "http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r52",
      "r57",
      "r136",
      "r155",
      "r173"
     ],
     "calculation": {
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofRestrictedCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r597",
      "r609"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r288",
      "r290",
      "r293",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Activities"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r289",
      "r292",
      "r296",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Restructuring, expected cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r289",
      "r292",
      "r296",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Restructuring, incurred cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r50",
      "r294",
      "r296",
      "r625"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r289",
      "r290",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails",
      "http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails",
      "http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r290",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Accrued Restructuring Expenses, ending balance",
        "periodStartLabel": "Accrued Restructuring Expenses, beginning balance",
        "terseLabel": "Restructuring reserve"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails",
      "http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r97",
      "r156",
      "r546",
      "r551",
      "r582"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets",
      "http://nex.com/role/DescriptionoftheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r167",
      "r212",
      "r213",
      "r214",
      "r217",
      "r224",
      "r226",
      "r283",
      "r402",
      "r403",
      "r404",
      "r426",
      "r427",
      "r453",
      "r542",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r252",
      "r253",
      "r265",
      "r268",
      "r269",
      "r273",
      "r274",
      "r275",
      "r355",
      "r356",
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue from contract with customer, including assessed tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of the components of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of antidilutive securities outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r103",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://nex.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value assets and liabilities measured on recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/PropertyandEquipmentSummaryofPropertyAndEquipmentDetail",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofUsefulLivesofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r57",
      "r136",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails",
      "http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Charges Related to Restructuring Activities"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of black-scholes option pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r90",
      "r91",
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r178",
      "r179",
      "r180",
      "r245",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r574",
      "r596",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "terseLabel": "Summary of RSU activity"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and geographic information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of restricted units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (dollars per share)",
        "periodStartLabel": "Beginning balance (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable as of period end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable as of end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of the options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding as of December\u00a031, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding as of end of period (in shares)",
        "periodStartLabel": "Outstanding as of beginning of period (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail",
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding as of end of period (in dollars per share)",
        "periodStartLabel": "Outstanding as of beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested or expected to vest as of December\u00a031, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested or expected to vest by period end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested or expected to vest as of end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r371",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (millions)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Award expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofBlackScholesOptionPricingModelDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable as of December\u00a031, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable as of end of period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Shares unvested as of period end (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "terseLabel": "Shares unvested as of end of period (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding as of end of period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested or expected to vest as of end of period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Public offering price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r58",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r205",
      "r231",
      "r232",
      "r239",
      "r241",
      "r245",
      "r246",
      "r279",
      "r307",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r345",
      "r346",
      "r348",
      "r349",
      "r352",
      "r464",
      "r559",
      "r596",
      "r610",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r25",
      "r89",
      "r167",
      "r191",
      "r192",
      "r193",
      "r212",
      "r213",
      "r214",
      "r217",
      "r224",
      "r226",
      "r244",
      "r283",
      "r354",
      "r402",
      "r403",
      "r404",
      "r426",
      "r427",
      "r453",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r503",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r244",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r24",
      "r89",
      "r90",
      "r97",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r89",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of transaction costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r89",
      "r97",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity",
      "http://nex.com/role/StockBasedCompensationSummaryofOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r25",
      "r89",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r89",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of transaction costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r89",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r65",
      "r582",
      "r612",
      "r622",
      "r668"
     ],
     "calculation": {
      "http://nex.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Transition adjustment recorded in accumulated deficit",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets",
      "http://nex.com/role/ConvertibleNotesAdditionalInformationDetail",
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r479",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r479",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r479",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r479",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r510",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SeriesARedeemableConvertiblePreferredStockandStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplyCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Supply Commitment [Line Items]",
        "terseLabel": "Supply Commitment [Line Items]"
       }
      }
     },
     "localname": "SupplyCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplyCommitmentTable": {
     "auth_ref": [
      "r2",
      "r140",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has committed resources to supply goods or services to a customer. May include identification of the goods or services to be furnished, identity of the purchasing party, pricing, effects on pricing for failing to deliver the [minimum] quantities required to be furnished, cancellation rights, and termination provisions.",
        "label": "Supply Commitment [Table]",
        "terseLabel": "Supply Commitment [Table]"
       }
      }
     },
     "localname": "SupplyCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r307",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDividendsAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://nex.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends).",
        "label": "Temporary Equity, Dividends, Adjustment",
        "negatedLabel": "Accumulated dividends on Redeemable Convertible Preferred Stock",
        "negatedTerseLabel": "Accumulated dividends on Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityDividendsAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series A redeemable preferred stock upon exercise of warrants"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfChangesInRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationJohnsHopkinsUniversityExclusiveLicenseAgreementDetails",
      "http://nex.com/role/CommitmentsandContingenciesAdditionalInformationMarylandBiotechnologyCenterGrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r289",
      "r290",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/RestructuringActivitiesDetails",
      "http://nex.com/role/RestructuringActivitiesSummaryofChargesRelatedtoRestructuringActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://nex.com/role/StatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "terseLabel": "Change in fair value of derivative liabilities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r407",
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accruals related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Income tax penalties and interest expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r247",
      "r248",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r230",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted-average number of common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r228",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted average number of common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://nex.com/role/StatementsOfOperations",
      "http://nex.com/role/SummaryofSignificantAccountingPoliciesSummaryofBasicandDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r585": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r586": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r587": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r588": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r589": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r591": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r592": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r593": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r594": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001538210-23-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001538210-23-000007-xbrl.zip
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MA#'@';$;D,3W8LIXE+@8[75IX"=;, X%P?,)\:&;>/$>E*G);/)8>I1N'-$
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MHCSL!*)'2_KP;-?V6$A9!$PG%IQB-3SUO<2VN>^[MCZ!#<Z,^S*2GF275^O
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M7VI1@;3Z+P$/>=JFEH^'<AYW(\H9<8B#]3B(;CP(@$,FL1^%Q-^CW%;QPV]
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MYEB5]1YKPJI:EH>I'KC6QUG%KFBM<A_5O;WNCWM)NQVTCUBRI_V=HWU/TWZ
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MI2,JL<>FGX[U5VSEB.;GWN+<$@I&4.\I>/<HN"V8<PY[9'O<:^6ZI] MH5
MI>/L#<Y=HU!3+N>XAR83<6Z=W10@5:^RJ>P^I=M3_B8* >(67;KJ=REUNT0,
MG5%Q9Q[DGM*WA-(!)1QWGUBQ8Y0>FR(\QSML:5J2*R8] :W7 P*6HS]4_]%Z
MI$- 2@.W3N'M4QS,LE>PMX:H$?IPQ9ZH=XRH3;:40[#</2M8-@7YW(O%OA5"
M9UN(ZAJ,Y;T8WA:*Q<PH-]@[D;?1B1RW]7S_V)/;=I ;IC2YT5Y [I: A <9
M">FC"^HJ2[(&%-H528G6.;L2?);O1>2VT*P$[IYH=Y!H3::2$QQ:;\MJHJ=
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M&XLJ^&9+4%!/4+^QLE2CN.![)'HV)$(=#B>?*K$!JBLH$J!KP(\U%HQG G.
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M?/GYEZ( /1-!#RO$9W12(*OZG M(HP9D$<7"QFK 3L0E+=1D7DN"&)IG*),
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MD'0G1(/(?8OB<<_HJZ:O/"-K3:2O7GZ&_-5TCLCJOJ"[5_L\N<E!;H%WC[2
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MENJ/"[<_KS)4FQ2#KE7:L 3BA.)$$]2\>E"3R4)"<./$ 3:G0HFF,>ENZ &
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M%/W2T8 9^Y7.-54\J\UNZS5D-_V*X$A*#.1AZSQ4ME %[N7FU3(M1#J3>@%
M=7N7Q2VF3<9![0:;&M\U$<U5R=6FM,/;),T-%.V%86S*J=AK>[#@CY*N#SC5
M*UGW.VE+&GKCXF2]M7'1M&T<U/UC,^$!EWATVM:J_)>87LVKD:S_5EV%A@Y1
M6/4UX(_L1F)6(FE4;67U8=&\+GLGIHFXI6O9*06!F*$V"XJT.JRA\-!'UX*(
M@^J;L<^ZW+D[IGXJY66)(RV27B,JR5-,5PDXG7.5!>>\^/W=$3:%$KE1P/4O
M;IMJ:AI28<^*KB.5<N#U6VZJQ#I9HWI53OJ9_AA A0=@H;Q"SQ9=&]E=D:-'
M+LV!4QC/'[J]NE2!7? 'GW5DO>0%E%Y&U:*H=PA9;0J5L1M8GZ.WQ]<G*VDC
MW90#/.@%/"2>(E V1EE4&=&WUG5V7:XU76=5F'[>L2-)9<HR&G>Y B-KD(DT
MVK!S!2Z#Y[K6],*+U0<*ZJ)LI*%^6IDD,>^RBU#0'1U?=-U>%2S&PZR-#A##
M.T\__.W0^@U5W\=*F;@C1:(+LA]^3ZK$IG K(\!T)HY,=1DFJRPTT]734HUJ
M A!K ?'*ZG)D,!N,S4!>3N8@$S-T,\P^BTE&56'A^W>C;A",CJE?*QUWBCQN
M*G-P0.L>JS"ZQ!A,'L(.^\U@]J^+[VIOK$1:R0A[/X:/2YBH-[]_/U(6DM06
M!E)_4EX+E98D:(4#KKL@_(M<AOA5 "N950"UGTSB'D89U--:%\WYV;'TEPEL
MOM8FV?4,-XVJRGNY>,!=*&]*)</'AC,R[4WU^]$V*+:JT0TR)'6I.8"YT.UY
M, "'M<A+'30_8GL@D-I8,/8&+EWHHMDJGB8O2SU&]66YD9MNFU+I?D,FXJBG
M?;=---1*:E2@='M#F=:D=DFK<B8K**S9E"DM GNY=<W#P)3P#JTC;*8C.\BU
MH6S99;7KXM9[M,JK.L6\JJ46T(-%ZUZ/G<KXQ^'YH?56<!GF?%/-0&,<9$V.
M3,_,MV^.1GK,0U-VT2^)4BW]2"2JQ&67=*DWW2]]1J,8V^=T.*C"J_ !(& >
MN#ST2JVWR-!8/&]D7R&,:8+.(+4[N5-<H"QVN)WFJ _JF<I#]Z'Q=YN,O_;(
M^IV^X<V#H2.C0:YJF^VGSK\7HP356*9IJ*ZX%5 S<HM]B,WXF\@^Q+8!:]F
M$-N:Y#[*;<VOED,[9JJY]>+WC_\82S+$I ^Y;NQO#1;D2*8'2+/WGJ+*S%L1
MP.%FM.F2YWHBV$S[0ZX!K[;T9)WY@M*!(]J-TK'E)N/ ^=S?EZKOQNR-L>Y^
M(9VIO>"//&=3_HTNG4':\U+*D%:X?]R\P=^$ZEJM\5#9%69P3UM&JGQ;8_1M
M 3X//31MW$PEK^NF):/^Y!^=#:1].*HS,.;/]RV7'Q<$@RQWU06Y[?<PFXY[
M\P31%B]OBOY7@T80+2@>4J*LILWDNKOE%=H8PZ!+%[OYEM+D'S= _:?1HV4:
M7"W[YO6\SSI O503N:HN<:2ZZ2'[:W.F!S)"=P!6;\.")VFPF#P$V<99YW_L
M$ZH?U.MI8/5C]Y55]H#IS]T+2:";WD"VLYAK ?98-I6AZW9"@[0A?Y(V:V>,
MM4:4M@_[J;"2T2[8<M\D\1\>VW+OCFVY*V-;GOM#QK94Y[/A_%^9+"I$M:);
MD-+DRH56*0H;=(X^*I4J^*X#3S*E?U#3M6+([*'LOS)\&96QD&*&11<SS,TU
M#3D*)=]'7;<-6K0]OV^DY2K;C^O@R3!>8J(=)O'7A&ZU3M!?@NJ9U&7C#"-H
M72O3.;!'K7*TN@4&;"9E+M@L%[HT;;@[T\VV'R&H,=U'Q0@&@0< :\F5;T>.
M'H&G%3(%O5@*ZYF@5^>'TI&T3!<#FO 8'ZF^TKB) WV2:A/ZCQ$6OE0E4\2-
M$0[Z&2LVD&TO;TANH<$5P3ZN@=+UZZ0KBW(=!M.5JN:P3?LVZZ2K^C1UJT)Z
M:<Q<A;;FU3A59)RD1 5D"DH %DP!Z]/5I^9B$T-4F1/R3C&(QN?89V+2$VJ=
MWFW.$[61278KLZ4-W&59A&&:^L!_TM$S/ : H7F37(H)U=ZAXJ^:N2S]8K+J
M0CDW52"U;3ZVF+@B)K60_;S[H299==L7!4U9ZM9Y2J1K5-"3()"*>::"I ;P
MNV"?8<G ; +KU;K^XOD-I.'0RY?,IU3/YEG,[U%3@)7R*U%*!J,_9])<N%O;
M-4JN8J2FZUJ2J6H^= 7"J:NNV*AAZP \K%9NF7\I)4EE)-WG6DGS_7U^K6M;
M+ZFH%DJ-6-#:V\#/XMUF,$D7 5<4*^6()M>%D/C]0S//WRE4!8D!BXQVM ,$
M(CN?&65/VP!U6QZ"+G&%K8F.>K2A(P3Y+GIT%L)J*[SX5S-XR7*8HA] :P-D
M,DQQ]/[=4MAK>,7[]\#?96"IG9/5GK_R>/0C)*;RW#HIJC+/E?&D(QG+]V?]
MJ*!V]J$<:#U]:IQ/VZ'"A%ATFN2*")6T!?9%-RW*^/N(P :L90,B IO"PX[J
M97:A[!D=S=2,7M(W\CE,?94*B P RZ ??M=V(>@](</X(Z:2T52 R6AB L L
MIE>J\ZA0<K\WVU!?JR:&8!&WMC?A\2W7!([4\L>VI85>42UPH,^=2Y(M_>H5
M2^@ZHJ32E]$M0ZU0FJMJ V*P.9&B]:7&7LN6-4N2P-*V"5=S_[@,&@,GMA8J
M0'O;7SRJ+@?13._A8#RW'%TJF:6RN=-.7GSYF8/CD6S^KMXGCY4-D/61YHKF
M*2Y!9@#L@#(@_1)8AOO%_+,.*[H W,BT[=;4M(0_73N<9A##TX;>Z8<W71DO
M]CZ8MM.L="J#2A_)ZC88^-"PWBX J$=!JF88C\<4%>J:0G1P?:'E$"JP8/N,
M6X4.B+_$4@#5 D@W,WIU_Y2Q+>EDIV:$/Y'O_.'#F!W5Q,XZZODB5:M6';X9
M 2DUHV5GC;&J); QWCV6\PY&>-]UACHO %=&&3 [S;!1Q>-4U\-:FN^=^VX8
MV#;-8X?+6'K]QN262KBN-[=4+N$!29;;1#'NYE',<E__K_0XEH9>9B*ZV/T0
MJ\IJZW.!TSNT,E#7)5.#.91=" \;JS1*,S13^7B7&S@,@[5M6@0ZMI$R=Q0Q
MO(U'C+'"BUZX';A@GJ6RJY*<Q)?J60(*SG6F>V9/L=]@_8!)*]L$-[)Q</N
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M"V\-0=(UC6PDVP810-V:9"9B-,@+'EEO*FS<D5L@.]70!US16.VD4CUR0%.
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M#7$#47.W !$&F\I!P2V80EK2R^G(MUC#DS-%@WOS,X<18*E 2<+F1_27^TR
M^?QV?64Y#-5OM-[A+G&7#42,%U1YNUUSN9"L73^BNQQEE]JNMR+']*H$\SPI
M-GRD!O-PDSKUY0]17/Y9TSZT+9?+"LS\ PWGN'OI#NJ61+9<Y(:5OZ/(N&P
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M;)D%'(\&G3J/)Z _Y,!3KG&YG-N;AG^<OAE#O#3R)"1)>=FTA%:AL<0$AZ)
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M.M12Q &*"<D0N6^SU,+'#1]7^R43ZJ1_^\V38'ZW6@6?W'1U<%X;\J/"0^X
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M/%V9_-?(ULF#PX\VD@+DGXM.E?.YNLD/)^=_.66O0W!NZ*-&8B \N%[)G&M
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M6Z(<QK 1A]*(X>4^PVY;:22G%2%&T(3GMF9Z*$(X\/#&#=H2SB(6Z597VYZ
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MREZI7EQLF0&0).V+E1K\L$E7=#QF'DJIO(1CSII714I[&,@=0S)1$@>21)K
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M9O;*%JZO.4RYD&!(0]"%O[382(0SK7U!V%]1.QTR4++43F476?&1!U'67[F
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M]7E'.',?;!S<@;:/S]#8S1[<^R5QB+1BWXEY! >R[68';ZMJE4OA%5*=5ZW
M&1A.';>.XV:T$&)E0A2^)!\<_QD\D)3"BA-8B0)J#/"(PD"2UHG^8CI$89!=
M+;;<KQ:^B[[46O5%&S ,?5WWPS=,:&Z3&2*TH6??8KO##/5ABXD^=R4_=]]0
M9,J0C0XF8OYXI3<]ZW/7S8BDJ"LRDA<RT!0=!^15,W[JH[<-7;REH%K:^?P
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MI*:PQ;.D&P_=4RVQ0\@K@\ZR ::9'7Y"F4ILJ&%DX5P0C[.)WX<<)$#"/M$
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MJNT8X+:N+CDOI2)9/7577)0=EPE;(T=7S?9Y-0,'0=:."V7O;\7]XH13TLG
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M) 2C/DOIQK+!T8_HMH;P.L4"O;5.#GONDEX[ X[48Q.<0V%]/Z3W4P42?Q\
M(>="*G*B,W3.%[#S(1^]^.5QB&(F7S[[ZB]'3YY^H;']134EZIR$[O[O(8R@
MVR?$.D<%A94]SR.!0R1L))J8<DDC&=RIN1<PNDC:44"@I1#648C0D=[ U/@E
M7-0OJ(&_$03+OG>6D %97\KDNB[I[PB## 4F,JIMW0ACA#"<O/AE0N4/VEW@
M-ODV?J2O6.?:*&&YGSELR>!L23-!Y"TQ_04WEG 0;BKR.7J=,Q(<B4A"UT,S
M'\ TE *%4_QA6!3TMB0:.',O:5\+/(?)/G@ES>&C>Z=0#JY.B>AO6J #J;6*
M0(*O #K$@V. &,]^YE\2GBW,YFN.CH6,/#R5OVF,E"LQ+@ K93-@EB1.\Z/T
M^23%11WOL\<ZYG30/:U5^$N6Y 4 T#\@?C[8*&Y2FU7EC':5I[ T.+Y?YV3"
MLX'[^>?&.8_8UL!8M38ZZ4-AE*'5X%URWDV )7E.SH]-RR8X++RWF#0]EYPC
M!!\)\NY8/"#F0G@U!3T-OD>[XX-==,1E\I3!WQI$/\Y)W*'PNCW<GWCMX"G'
M 39*@[ H;_3K;&GR7>7DFA3X:[C!8$MY\4R;.94;W6T7":ZH/2:.EB"],S?"
MH)9;-ET'WSPTUKASV;;#/CI"Q$]IPADP97-!R_+BEX.;>K;SQH_-Y;3C[@55
MXWF,+'8Z(@[8..Y823PJ) *['N-/*;)2KX^/BTE58QD8TV9Q<-\>$%!)"1BH
M/A5V'HQQZ]<L^8)HWS]WY_WIET2R<XZFRJ%&MZ["+_=@_ZFK_LN8TYS!2DLT
M4ZVA&K\=_7-2[0BS1MGG;H<S3RZN\*U&T&;*/;0CJ1.BY LM<00;2<](+C=4
M6GJ+E,=-4N(9GL S?/KLFR^":_CDKP4/'M=&<,HJ",[9^SH >4O7U'0R)6<G
M_S47%YB)LFK"+JC TATK M^//509"?&5=,'(97G1SH0M91$N:L[T\6=1#4!J
M976U7<"H<@M5>=FTY%"*:XNFSHC_Y8=1)/;3B__WU<&3)T\Q8/G'T5A\IG=+
M3)X'/X5GRD["0SD]EM.?/I33[\!8'LKI(S[&6/:.>P-QV;$3$&RK[T1!^;2/
M27FE*GH?/R.Z&>9?3+PO$=WF1-) O%=S<U[S51-FA/6,\=@7KX\M4VV!%CQ6
MQZ?$O61CNE%U/V2%EQ3L(+[NG:4K8DA2O2,"9O;0QILHK;M8U&I3;Q81]\8Z
M?K$$\7YB(8KJ'4KO]J14%8]-=9)'2.(H[BT4;]U4LN3[PKH(>\3HBJQRJ46T
MU+ S*BF#73L@7[\3"IU8,%4+SF'GU42XW;546HB]8>$J0=<>?SG'G[OF!V7B
MR#$7HK7%QCSF\'8\=+FIZ)EU&'"]V+HNLS#2DE='WM\]SP*^";O"'%'9#_%L
M=8K.<2?7TB=S<GS.,QO^0Q,H/7SX8.LG[:I&NDYZ#Z2CNQAML)19P:M;#@/O
M'0E#92U=DJ-7!JTY_#-/-#)\A]?FQYUZ=L$?-DL*,(AHY_]G[TV;V[B2;=&_
M@KAQW@TYHL@C>6R'XWV@);FM/BU;3W(?W_>Q !2(:A6JT#60QOGU=^?*8>>N
M*E"4!Y)FHS^T11*H80^Y<UBY%KW1]Z_?R"M]#Z^8:U]KDWT/UZWYOG*3F<G7
M)\S7S;['>*AD][)DC#8M\)F\BB;-?@%RAJ+>34O).Q/ 368^I]%09G6,7'B^
M3Y\]7:S# <M977!C[F4Q\U+D8.@7(W^KFM7[8*B;/3B-DXWG=Q@5Z84.'@3<
MX<_%+\1?%$=&TFBRH&5O1'8V[NBFY!?2!:"4+T4QH9<U%-;$?]HL/'>/1F&?
M4VF.0T/]GS.C0EA.$CX)Y]U!A9MU:%"V%1(:S#)IX] TL0]&@ =>N;SS@OV-
M-H)^H>LZ;2PEN+WD_U+FBP^ODUW^7C%'3"X 7!66JJV<<!6V2\?/(ZFE?_D5
M+P"AV)7IES=Q$J1^99\OB-FAJ(I6_%Y+^(S47#7?0L-6UO%DH/17CO8Y7D33
MJ(F6"!II_ZE0D$30%2E<^@#"4,*R#,NP<!0^"\$B$( J'WX6OTM?L>^[J"%\
M0240K0<93\Z* IV4Q1>)'&NRM.)NHET61R6&"L2]C)/XV1?RT2>SF^L34RPM
MP7HI !S%O>"QN(V0"%(CH3F#YYPT:]0<F3W-R@W=P^BZNW@+?]JC"J_%6<_D
MR500(NF$<9JNB<>0COK!*\&DT(/%$]Z5&AUWB[]2D7[Q;3!_N8#9?FB DJH7
MKRC"J]>?(*=-:'+SGM(OB9B%#OFR8$E<WE%^)H]L[K"LHF?I[EYV6\B,4HHY
MN]V%YA*W9 TNN08!+-SH[8AW=C9Q*MVYJZ%M:5O<XO[!O28O>.@YMP"JVO P
MM.AY'Z7C=O0M&JMB98MG5,AZ=K[XCG$VQJ)/A0]6\8"IT*K7LPR?Y^T>76[0
M^,#:*%:?W]$!$IQ7_OK[MT)/,%H].[N@!1?:(!Q>%30FT:@'PW^C%RFNTY0?
M]=CHB@LY:QM@0)L6JZAA\:7@I*_>5P<[6NC2MYH HB'5(DQB66AU$6>99/*5
M"-^"CD>1,7VN/#O.Z7P$1O&5"^!691N<&#I_5G2JOSP/\8I'OSZYH(,X'&'/
M/G_RU2=SZ<:O/J5"]-//L;%F_O[%TZ_H[U_2(O<#ZJ#JZ9:_C1/_"<%1ET#V
MJ>/9>513I$CR/(^3_'[9M/%;$?D5#H1B*_E=JQ6!7]AB:A4ZFB@5;8;JZ!W/
M%^^ =IU95MW8 W.JC3YYZ?3;H@5B83!-93;MGF!84S/^"7D-)D*'%$'9O3];
M%G6Q*4D]J=(>H]YU?]O-Q:.!ZYQ%@3EV=:KR/=F]L1?B?"A,2^0!;]393G,5
M1P:?BZPT!5D4JO-/&89]$VY$9 :[HC=.\KHHA*;NR>?N6_K*]!2)_RGO7NYV
MD-<JE%Y=J"I]=[VQOTP\X%CZ;(8>.U%$.XF:M:PI**DM2[+)5:5FS&6-D@/L
MJAG5Q<6M%C:#.>LT5>-1^.P-R)A%=__8]9AURU=/_,6$,Z/;N\X48150I&U]
MV0@9 1@KF'>;(?WSWZZJPD@7I5T@+);+DE<H#<]Y8DR.^@\TB!P0@]Q2E-8R
MP=0+;WEX* !"@M]0$>&=4.//[HZV(+"+WPFHI3'54SW"%: X7JBYB/,+4<0U
MU_P]EW@[.UT1P<G%\9LC@\A=EB\;%69!?7EVK*4@Z .^.03*K2SJG_W09Z&5
ML;#>(SCQWTQ/NN/Y!9<:=H<KBV2FZI]CFJ$<T4,.2MPD/9O7@C]_?7&FZ!;^
M31SM!+^Q>!-V&_>OO2*22@JB\*1$$T?J6%&_* HA1K40RL]7E.;6Q Z%;:;&
MJ(;ZS#;;=5["C24(4TZJ7_(S%OZ:M)5:P?=[25,[ &;>F/X0'EU@.+SE&/LY
M$@;)C[L+'F"&PZ! 5J '7G*N\/OUTV=PM5SJ%,)0K6J&\F/9@'GXS$_;R!+'
M3(]J-ZA6+=D>U;NX5G^+.(VFLG:C!B]0FU%ST;S:G<K3B3MC*?6\"A'*VFKF
M_T/GWT_)\\?$;\Q\2=/C\Q\Y&N.(1Z>0AQS\:>8]D1QRI<QP)NC1"%C<H9M'
M!SX\FM6VK-;A !%!R1X)1^H_JZ'>DM0NTKU#Y'8ISQFS)PLW5!@C8IJ3-PZO
M$[%"_$J\1&5F1D^9SS^C]&30@23<7J+I&!-#L85$..(*X'FYR$X(8]=_49!3
M0-4'VW:GJGFLFG]ZJIH_@&<Y5<UM17XKW.JWJ7-K=P&D6?D8I") R=U'QRX@
M7\IWT *.595QEIJ-K,@T#9(:C/1["!^)?F.]\ H]=LQ65%;'(0M L.%:Z;A]
M# [HJ O"81>< .,C<$H=5,\)J7;NO,<A%%?;D_*\.,\64P7W3[CHO#DPQ !-
M:L=EP!&O)070F$!&Y0K1O?_&L&]NR)#2"3VYB62GB?*2FPO#&=\RI,T+TD?_
M6NJX3#;,B89;]=#$S(B)4Y@#NJ;ZTTVZR>S6[87BF/VP^2?]8+"P6$NSNI>W
M=3-A53R6G];&@B//E:L NEL,$9PGY?/)/(T'G9A^5P1WV0S5AV9 Q >L<;C\
M'Q3P^RX6-NU5Q=D+8\?OAM@H.#-[T"+KBZK,S 3\//_.Z>M)KJJHG<CK\3<6
MRVLR[,!5*KZ )H*PI/JTY2;3R>("-(WS:--P;Z^]H1(TWY0>DMBRP]Y*&\]&
M<1/M]K1\:VITO"J2YYM'Q%CNMH?B0G)#1NMN@W^*1)<L2]\^9KM'LSO@7*8N
M[+*3"GL\[GK%PCS&TT62Q9I!+H7PXG&=- "%M24HMCBPT==E=I5C&?-C_0D(
MQL6 @&PE1/[EGHDV>.?,0?3.PX^T3[2B\AEMM'$8_^QSA/!/LUELA60L9_/]
M/K?/.7DPL"CH#*:7P=0E6MAA(P7R0\UX?8P>PU%:G/5;^F512^)VM07]#+RU
M=8&$>"XJ89(7_";6!*0)XTG^B?![Z&<D?@0L ;8 '>,;Z5=\]C0+KR[:30ZC
MR.?4#+AAEZ\9S_5D.:T),+*1 (DNY4_%DK:\4CLM8P=R%@*U@,.%8F*<%CDT
M2,%;S]VR)*WD'BM,MZQT4;BA(>1^/U^D: LV)GAKUD<*CB\Y="SIQC3-MYF:
M\6 >\Y1<"H\IO 4!(_?CITEU"+1,0W=QEM)52GAE\P3ZAL):F:T@G+%1!V2\
MLO_R.>J 3\\7/QXK4&%C%<&"E*(5!714#1Z/L,5H4 C!%87RG#33IA"9TJ*P
MW(CHZ63LP#F\YY&3+&.]H$HH[.W$G/<*7<LHM^O-GVE34"_.PZG=55QK;!84
M>H[QPD_G>L8;'17?5#D[Q^#$4=,7N$U *"61F<>V+D^CJ"< %.TA^8[_,($Y
M4=)2%ELI%S(%TPW/PN1G/"ZV@OR5C1P"*),#I*70X]/GEV1<F HW7+$74Q)<
M#/7(,G')7)/>M$M*D-./ 15U>_\RVCHKEAD2KBM_<1ZE3"0A-\7%W92;X$9Q
MN8T/)-^(:Y5B-4 1-44R<YRJ3@[MZ=I+(.51T=K+CZCQ9@WF8,F0XZ%UXHSW
M2-UL.@[GBPN+%ED1ZWCAU=7PX8:KHV"5:MEU'6$/HYF@ 43FF79"N3FQZ-\M
M*2QFA.B4ULYZ4EAE:U;J$C$@I,*!J+3+'&=8<_F&2D?P;B(;@[:%7U,?GH8?
M%?6X(H1K3Z3-=S_?;J*9$KB3'<OKX&A4X,Y%8O@]S=Q]SARI(O9,@G_0LMNQ
MF7L4 ?R;MZ]>O_2GX"-P2%[5! <,7OVG3Y]]&0L'53[4JRV@.9)-@RT-FU3T
M&"E &]4^9S!S9>U33,$1W) /V"(RV("5DC*1&^I'('Z_F/!1P#.M+ J9I!K[
M]E4#+M?7+Q6 ]T3H:# W0D430M_P[+LBB<1!++MJ@NL9G-(Q?1;*OL2@QR)'
M8QR;"@MSA\H\9G_$#DHTL!32!$?%,YC$?@GT<;0WN]YCV"\S90"XUV*['<4B
MG2]>:C!G#X4HIP\KL^@]]"G.P[76T/-Z;A">6(W]-P73T;$EW#9[CKAL)J"M
MZUA#YY=N%37S3W;@+-2S*.,3Y6L_\%OZ<C_WOJB6$B,G6D6HS+SFDGSO'H-&
M]^7G@?Y[;'XYB-H3+8GP&4M8-G41Y=4E\][M@KMQ)H6T=3GLL#_7BX+)6M'_
M0-YK4DC)VZID$=WV$'OXV0#)XD;^IJ+I;&-=#ZJ]AYAR"6NUY1X$)44ZLE.1
M>)T8. \\U-@2/3+84!F>\Z"[(U><C05S8354S>50Q.HB8"*B%=9#HVSH.FTW
M&%=6\!R=4Y'U.U:8_BG!+F(!B!G=WKS-KO+[%Y)P5KF94BB=+UY!^P,$PQG@
M23!MX5;<ML!EH!6+%H950A\NAC;6)1CCUW(C7HO#E)JJ:#%@(,/62*;8;"UG
MEE8MRS^BR([&)6$E/H$_#/SQV0G\\0">Y0& /^YI ?HT2 A:?4-HQ,R!7X8@
MY>_+U?NS9K-!XH4W.7PM[E %-[[0+F_+O32P,M212JQ]D:/&N!NJOB1;6@;#
M5N> *X38MC<% ?+H'.P_4H;S4:QD8-Z\CC6:<99>EH7V]B:%0G*K.DQA0DGJ
MP'!S*29.-S.^7]--F7;Y.IJ'Q"1*GD=)BQ\+\!E\P<B0IT<59B&X('GU&,#0
M%S<EF6.O (I2DM_T-3[5Y/E #M"Z"M 9X"XFRWV9=]PIG7/RM2W.8GF;?]7<
MT(:@S81A3Q&@X1BYHS$NZ#-RXQ"X"#IFX_N)O#I 5M>W*O/#M?6]._(,QQY
M>T?)\:M*ED*BZHP#0Q#,3'D#A 3B)A:)A,:KJD ^*_ !]9D).T85HQM?Z#IW
MNKI,245\,.4OB^"W]]O.UU^.8MX$((N&&BR>\\6/W">"^;]Y2),%AWA'_5H&
M=J0X]KG&T>/C3MVG:Q!XU)+HIFZ3RQ"RU>M.3#H+TTX:;#*QTZM"&2L)ON$
M4[2<67=#[ *S9(Z&5S'HY*]O&@)9.[X((/\6^RI?.5521,2-JSD@$?^$T!DY
MF_;9./,3I%?GFK..+?LH2- 6NC&EA^<#TXL =)94L!OJ#G3W^= 5GSR*(^';
M-@257O[<CF)0)UPW[?L1U$':HQ_!,?&J7OQM",L^IJ0@PJ-"<3,OO;AJ!)BZ
MR:\:P.Z"2;E2_V2$O'E"6#-@ZD<]&I)+XK'79!)23R%6H#6*!F_+EWV5J?>#
M,!T-!U19B*2RTWLW&Q0RD);2Y@03$]\'-VK(F?E&L2I?/-4=]?>R6X8O_$29
ME ,GQ$:C8$\0>1)&=X_,U)]QD_Y3<D/#OJZE.U1@;<OB,L?'ORN6K>OI?VI^
M']L88H%.6TZ(B)8[]2+_U5(!.N,GEN:7Z?TY9Q=^?E&LV'C$YWUGQ\OM=T7L
M8_H02=(1#;!LR@1]%,IP*PV4&[3&$IQ,&.$7I<@.=J-.[_ 08B=8 DFU#%-M
MA,W0CS0;2!\L^-+"H22-1GSP..;);4J+,)_>G1GJL)%&O_%M[75SC=S*)"VW
M)N3(96%O[;X$71-M_^03H:/4#"F;R  @4R@O?8SS]TACMZ2O4NV2] 7DMQ3"
MG!&BGG??+1@J-.N'-O;BBNB*/6O%%EB:E53)!ZW0KXL^)_Q_C-28O&P=['3+
M2[9IPP:U7EO*R^.8G^7AP)A;U7^ZV4K6]-+>-<TT#_NU MVF[^AHCJ+RABFO
MSD*,"HBJB'X8%=O)7Q-+_Q?/&#+G;H&W:9U0>QPAEV&)$@;#KL/T&Z&K+.*^
MB!@<QKLIBALC(P="##__^N+-VZ/*./-6[3$X(&^)/$I.GF!7*R_%]@A\C.^,
M+=[)**5*5&--#+&)(PT.A<3%RP1C\3(G_LE:+I$M_DX>_^)B1S#X'-S&'>4Z
M^ R[(R$D+.%$3@<XG/CS&&J#1SC"URZ/-L^,_-?G;]+7<L>)N@/';+1^%%3Y
ML!X2_4L'$S=# WD>3MS+TD"AP5&H<L.5+;XOJC J[\O' !I[M2'*5%)38O:P
MV+#E!G0DU38>6*-V3Z1QYKE&-]R<FZK7.YDP\-Y-Z%_=H@Q'6EA"= G55M\X
M1RKLB)8C8"*H:Q/Q+9/I;INN6 U_0FJ#>2G"Y\BQ7@93\,;MTK=^ESZ"A?H.
MWNX-SNU87X.$R>!NK N"I=)>]A!HXB(TAJZ$#H8L=-FNS^@3!W;NJ:X_-7V*
M^?,ZJO&+^_S0M$8?(.87W]LF/&70%)]G_U7[#]XD%/7 )D\_E&OHB>8DP:E7
MHMQ=BZU27I%G(NPW)9R6UA<[$P\/#B?U!4T?GBXLM4'BTH5\:%6!,/Y27KU<
M%=);DN\\VU+7GZ6-\*KGE\P9](;;*Y;:2 25_5P-M1 +]P?%W.>FU)+."6/^
MZ69U<5T=XJK83LGAV--6[F3N(.&>5@Y"F1\TY\'@M:094EL5J3JD&D'E5HL$
MF>XF7='WZ?A!HM6_16L<^/B0NW]^&"\[+B[; Y5Q)YB.<68X""J6#&%<B;MA
MWP3[PI>[89'/][S,+'1Z=^:XM*L!&B!D'#;G<'?BO%#?+U#<]$Q$#7HP8E4T
MKP%R+GO(,3#;]^VZ,A-&,9J ]7\N1."/\S'J_5 M2P0?)%MJVIO:I#PB>$ R
MTB =-*?:?#J_Y+T<:;9PU-B1%:GKC:)C+*SH',E9,5$]'D\4#;%*__FI2O\
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MMZ$!);A.>(7@:LJ2DO1@OQVZB)WC5BU;CL4F/-Y-.__?#YCRY0F8\@">Y0$
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M]!!(KV!Q9..EY0*UCK,X5TP&*[?+10T*C0W",I@?'S(,^<#>Q709*82CJ(A
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MZAG7!/AZA2,FU@1Q$WR7-7S?KAGY#^A5F4U<G);$'[<DP*-5V<:5;!S)M"!
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M':A8A!DSZYX2Z)@)<N4!<%9\)-PGU=%3AA<G.ZI2C4!)<S8]!M5DQ'N"Y=K
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M6-*4N&%2O+MR4321K K:=4TUD^IUCRM%04G^VK,2XPQQMJ!2TX*R7WCM#&H
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MPD<\!BV9'*>@<$6DZZ.(5LZX.GP>4&4B(#D%)V;&$J<0(J*9&'T6*$]Z1 :
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MRP%]E+'V#C3F=Z7J5[N&%M<:[F%$ET.(I<)\%!%%-([U].QR;3H=MA\IEDA
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M;7-)?PQN_KXIR2,%HJ!;F'K!81%Q!>K!VB/(L+ "9NU)]=(+BG2+!%%KXZ@
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M1)R+E!Q5#=H,'$OQ+)DB\F4!Y0?W1SP4O93Z!;U ]%X$#KP"S^AS,OFMFP.
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MMMOX?AT7H64>3LU)JA"7$F,C[S#GY"WC?C"1E>?L#VY0(A )O78&I/-7!Q\
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M->>2I]X<^<]"Q<P1:Q6*FBI6T^R:.\.R"G!\=_YB3ID?MTZ&>E%2NRWAATC
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M&!(#O"#5/LG6*PY2]M1X[J36.\FZERP'Q4['3]\N?CFJM4P*2/],A:\ >H-
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M/5R?O_WZ3]_P<6-[*P"JA$!W][!>P1#'V0I0O*^.5(@*R<0'_"[Z:@[HUKC
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M%91<%(' R;6#X4&"ZVC(2-$]6&_27F (8Q/QA@KZ-F7+Z9%O5G]LAR3/QT_
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M_,AE-;U2FE\I2>%52$PY-Y,*P"C:W3J-VI;*QWR2RTS[RPEDG+ML7%4)R'\
MEC'2KB))J:H;=CU@7-^5JW?+?/6.ZL!%M3E;AZOK"/!TT*X#*68DU763.+1.
MXJ:P_A<#+Z"V%#P6B.:T3'.ZB45.5S<:3H$?6R"EV(XHAQOK(3TC22F3FA*F
MZM@'D%8S!^35R?@:X=TY%1YUN:5"??;:C-\B#F23E><S7GKZ$SLB= NFS-*
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M#LN'C_@)-P66O?A[OPXW1ZK"T:67=1Z+F^.\AK;<].'Y*H$_-LV[!;2H^;S
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M6EEO3_UI>C@&:\?'#V$05(U&8%5:*.(S8FYL&*\PK@O=:I$IS&N_*M:D^L.
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M=>LW5HC!5@^VLW."T\UM[8H78@+X+V' <FXPH__ .!I3!N/BJNH,1? &CN1
M'Y5KS=MP.P+5JZ&9-9>QH3N9=O8G =]7*)NZ>FY<1;B4.742[U&/S G[:I#6
MQ<6>PV:0H@)55^X9(KZJR.FYO2[V(E3(YFY-$FSKF0-<CS[G05&X"KX#<C R
MCLCS-<%'41B/JJ&"7R@CWR0=:ERNX&\P6YM\#UPL3\ &O=HDZ69(&J2$Q$YF
M7>W%<*YU&P[R95V6YE7Y@$$/@4>"#.,R;*(TUK:Z"!$,27M,U..BW'UG=-U*
MF;?ZE\+GQY:1F$3/>/JW/?APDA;FD63V$6*H)["4/8A00881]DP>6%O*(H7]
M?_\Q;%H!';O/9H#GDGE(Z>3G(5 IEHCQ3T[<+(L-HRDV"='N"9QCX)R7)W#.
M(WB6IPS..;K^5,>\8+&M]R ,)/>W-N.S4&#+JCG3OYWS7Q*DNZ<G3PS7NNQV
M/=>I" 0I')OUIBJ98+)95@(89%;("+:T!V4D*'.(1J*Q>XB$_1(4I%/ &YME
M_V9:Z=@(*YY#1FHE74&1 ];C70X%*",P-^YV&41TU!%66_I2CM$Z:D-GC%7]
MN< 4["C<A_N"X.OX=;7KKA[0A+QG-?]],:3):+T'A+2;Q9#^VS@P_NW[>=KY
M>H.DQ1OE5>$(^]+5)*SH317:U[(9+FTS/,87?E]TX73]F]N]*&/.F2&7PUUS
MAZN7(0VQZ:@7G1-".37%E!A>>/GT531I[=PEA0=V>,4GX+,^XM%=F*9%1I0N
M9/!Q+&0,(Z? N.VIK(\TPEXJFLQFC)L)D(Z/+5SRK-\)HDH^(ZD.O'VI#<Y4
MOM)&\:XG\UR!GZ_N*-=(V0IE-Z0<),,4C(>@S6_-6'I!VAJ,K'V;,TPC-\(>
M*SO$NG9J-*V<!KL98O[VJFC/>'S<@*6#J2]G\-09# FW-J$$"@;V</ B. ":
M:=.T@\NN\EV^TKYZGH/-XJIIUJGE9^L=&R DC)\JL"+!6!_&S^8H=]YG[#1S
MX#Y5."/G@JQ,TRRH] V65R$D#*.^V^L%-'OC6&SCTPLU"C(U+IU>REEEJ(=_
M]'1F*27OMBCVDGMT&&6MQ\0US/J)!I",11Z]1ORJM8F%]V4!]/'0#/70^5FG
MGU+N.1JM3=,FA7"!9RH?3WH6*4&OD2RJCM,44+"^PZ7(IE3(LQED""W+J[:Y
MY:W/T(9'>>2_YPD82_2KO&VI(;O\1V\6MO8=ON58K08>G/(O.4R(+)[)H7P"
M!]L/UXDI-2:PS%-;90,+!["LZ.4M;=3!^U5!)R3EN+5QCYCM'^P /#Y+?$+9
M/08-Q#ES#0 J1_#=W:["^1+C&%<'M@,GA@6 *-"8=)F&0(JZQ";Q&'C?@4UQ
M8TM-J.D#R%?8E@9WN^X@1(&7XA(9;NQ.OA%1P"\9=)>J\@_)IQ8J\'MR31H%
M[!<_<],80PJY=5<KO?'G#MI..6;.[D^S^Y\OODN>U)XN+ 0<'U*>YF/965)
M._GQ_),QI1^W&-!CR>"5 K&Y*1)Q$>4.2@<+;$9\C8YJ"N1[T'JRXXSE!044
MQ!T0PN,KATUXM%W?[AJ)>KMF=TW-[RM\);P#\SC9D4O?T;]*R<=Z(*#.:5.&
MW#T]WZ95S1CAF!B>R4K>)P/-J/E=+V!,\!+1XU+2H"IO>)&46P;_D^3PWM9:
M)N^P+=S:B9P\$(7I#G48[3V/3=AI$2X?#41U,!-A%B)+GAGWH7V%\VD,PW!^
M%9]P$:#HI.$2@.._R00_FH-K)KB \)QJ/J.!"*$M*Q6J:VBP.2"XR]4B*?DD
M19NN:6I%X-$.7)64\WH*DF/_;NQB?EWD:T>M&(&+1Z0Y[P(S.O,Y!>SG:U^\
M^L[1Q)XQ'GD&YCX JNEIE #5"" RVI-*XC*[R,3[CI;(WSH824)P&T\*U=C#
MPKJ^S0]2H/[ET$G!6VA=FQ;N<DG8%OQ3[H+'B]7^(;)O#A\Y&@0#>R>0,J.M
MF$!=O#<P9-H>JE#8!/1R -5@J ]]&"*K*T(B3B!NW,4]6D-D>7.:(!$=(A1L
MEQR]Y$[L.4I412-EKL?'RDF4/.7YX@*4K[#/&5I&"-^T!>$B;'H6?RE!$<YY
MQI[)GC4GQA'Q*';5P ;B1]Y>%[73HNFZHI/%R\O?[B;H"''N^ #+U\TN?8$L
M)J7C]>Z;VKT+-+YI9B6[/W[+^U,Q20 SUXSCL";YU'IU2W3176,"X%-M#FJ#
M.%'SXN49;0C)40'9 E8GAW>)K3'PB^<W2;"_WS:W!3P:RZ9X F.X@O[2UNT<
M'I%:3<,+2=_N2GAF&$4L^79/<R& <$'[*?!%M"T8-C4W>&K5C[Q)8HO+?1?W
MKR?.2&%!L=U6/N4=([F,@0"62R*2TTIF6>OQQ)G9[D,TM^>Y$G^$IXAQ;6>-
M(*G>TT%9?!=BET8G2#4:PRLJ(>H4*!>M7KK@,I<VC&@B3:LY#MJ1D>?6W\C,
M20;2D,K03S/,N#A@=@<Y 2)X+,Z8)5=-(9!6P*$@R9BPKMD\XI&9!(!/I=A<
MS5@?4,?ZR),\FXWPK5CXQ_;<U0.C!K*BMG)GP,2W@0<@M4YW='(*E^.FF3..
M1G)$ZMN-#DNR 82/H_\?([;(_:D1-,[U!CCG!0]NF$,;?^N+FP:F^F-28+&,
M*PEW%#$"W1+!_:OV).##+7 WV*94=?7=R/Y0'M_#&9E<LAHD[*D70#^ET5@A
M'!-(BN/+13,<)2//["%.D!*#E'QZ@I0\@F?YS4)*>&^%W4O8 O09Z6XU)+'F
MGA:D]$>VH2X*ZF^>,B^1?T^3C9KI\29CRAQ"[TKI#S9GP0<JY+P)[QB.J&$W
MKC?Z0I K\F ->LJO.*SS@9<%6AJ!I7W(DT9:XDKI&$KAV&J'8]<0!SI"8(%#
MBZD$Z>T-1=WM>U9,K$?0:KRDL&H;$0>[^=[[,1\B-GH;,+T?G%><K5*QQX)E
M<?W@878B"I>>>.*LH>.NH>.\DZC&T/0??S00QIS5Q-E1,V5Q0F(P(Q%:5,#4
M7JS=6&FW8QYU7[7+;VHQ>3<WS&_!%5:F,-#F)':?J[P+;Z/[CMKZ"N3[A^M4
M5[0U&1I]SHYXNS=A?!"!#S9/5 ^6U>/<K)F]J<T-4=#>*%5F)9Y9"_0)K9-_
M(Y@]D8]PP\;Y-/%S?P6HN[C.X:'().R)L)^3\NP:3S94O!]"/A:P->F08.:Y
M[)'^.GDK&]-R2P=.>*9J("/>8T46.;0OUSYKQ5;Q2'8SY;K427H*V?A!,ED'
M<9 E/I;GR)+^HKE%YE7'2+O'9:B5AJ-LUV<L\]$6Y789K)YJ@%)J8<6<E]Y[
M$$IPD6@I;V*96]$$[7VE&3\:8_+#H' )@\JEVPDS0BD,'NR,N6-(J)A#:#_"
MM >("GO=]EQYG<JVW%"%F9C9JX,B=\FJ'WBYX#_/%Y<B%><*68ZQ'6M#B+LC
MI@1I7<_05SL2[U4BXYG'IO4(^>2JH7"5T)D3F0=U&(+Y$/RJG$-:<!TV&Z+D
M;-I2.8^(2,*4UC?+ TVYFE?*M1:%ZQF@HRL<C?B2LUN26(ZFM9WXNF^A'!T$
M9?0@T&9+:")Z%_XJ)A@>\HYIXH8U:WT.(N7K4JM/7/NDKYI6_K6:"RD;847"
M!JNFGFF0#!?'\OBQYMHG47TP,01=1EG8L#ADZD%O"D_,:/ECZ@? HVG$%,1S
MNN#P<M:.H-S[ZP-SJTG+(&>C%!I3)9S9\(1[JN6FUI*=L;W3 %?H0M(:7]N2
MYLUR(0>=SA+0&/)B.'7*6C.DCKH^'$--OY,N'])9PQ:F=>^$?*?,M,H*SIQS
MLY/V!*SF]^D0CD^WB?%(8 ! ,/@4I7 /:DEDF*6]P]C.EA?YZP+LIH3S-M)J
MI0Q8M-+BQDWQASM(.%DFKT24V?INNZ:]"I[\/YTLQ41)-GUN8CQ3O>-=?F#L
M(?Z#A#C\-SU/)T=%ZJ,)+"?X=:UB6RC]K=H0@]1 L#%;%CE-WX? 'M-:7$/$
ME$LBKPBWTL*@LP\>2> P65+S Q'I!LS>4T-"AHEAT*AB>@H9^E$Z8DX#Q()#
M.RC"]J?WVJ+_I)4EM5<*?S\2)N\"'%/5%;=:MP'<5AJZMZ Y_?/DBA 4=G2P
M,&W*O<<RK%Q*5.O/I^ORP#:)!</=BL;A;8*:0D+)8:8SYS$;GLR*W!S=+73U
M>&D'P.63MYDJ(@NA;!SYJNR(A(*VZ+N:TB8HN)%O2(]Q,%8L]+Y 6%S(."DG
MS49:NIB^NCC3JTK/.Y:+>XQ.C[#XFC&8.%^\CN\657'9EZC"45KKHB>>(&%Q
MSUU7/!I64,KP% .20 LK-4+]1D\AZ3=U5GIC);6L/YL06>R> *@Z)),"-(1;
M"\&7,!PORT,UG1,M\\F,I\9I_,J80R")--Y!'(;0.W-ED+P16K@Q52(I3IKS
MK78@%"8-O6: 68_=P\@V$DYK2Q4;0KEGT PL'X<_MU=B>.)6^\FKSW6,=<_=
M'ILX2N;P]@O501B>EVOD&NR2E-:+I)>W6N^M*#N$!HC$*LH## ^-@3P)P]?I
MV8Q53-WR;.9I$P39O#>CA&J*@J_*=P6#$;%GAHDHRW4DAMZNF]$56(4ZCH;,
M^7KB]*>Q4M(,[#%H'8*N#4!-BG>;UI?CM*<BB;*!ZQ]=&5PH-J]TB'7^WS6_
MIE&MTOS$3D/%Y8A/F[@_]W"8[CO\'[]18#2WTA^XB9L*0>^.NCV1EW@G+@*7
M>,0NXQTIG4A#- N"UX,IL9?((KG<NX=<30O]3C>V>&@"%P[8HQY[/B:U3M"D
M0P3+X$G4 GE7BTYBYBLG8T3G7VL&"._>27S785M:33\$G@71&LX"^(-!0BR6
MJS!ZN51N4M&X3I^<-T62$;',JB#$LZ@@.\GDS'O:'M= WAY]'(+-\(QPV5(S
MV%K.$?D6IF&77CB'#K=I56\LEHF*O9*C\PH0-%E'26%9/8;]FWSWO"(RF@,J
M#8B2F]N"W\6M3[E2F(DFK+D6 0O()IUHFO,*A?4^N/TELKE_*^R4HX_YNG)-
M):<-JY3. %Z&\9C$8ELR!Z_JMX>OWC>&T(.[QJ]H41K@NLI_-N00M.B$:"FL
M,<#6K1&"7*"6L=G\Y"X?AC8.6 B<'&HFF@HR13R6\N;8M]-AS'1 -N& <#]!
M2R<8"(:_@Z_8%M%B[)JP;@\2W##_OT\T0$MAK\"F$EPBPP0L7:%TCV713'@^
M[KR*.").972';D\MES'BW 8_BGH#V.\GA#&V2AK B)7D^>=1$IKI.M4A#0%+
M97FFQ,:&#S<EHV'T=7E/,2"9=#%CV'RVZ6L]IT_@$@.7?'8"ESR"9_G-@DL&
MIEKCDV$':M1ID[/_O?@II*F&?0CJM,E&B5;(PZ]"H+X7](KF2+PSG& ^<&%4
M\JNI'M4GX/Q^T[=DSA4\;+S&F7D%4E@099\LUG]N1NC-'5A5"8<@(2-R7WJ2
MH[<*6$EU3#A)-BG]$!R$EOM!PJ66;1.<+.,X3!KRA8W-Q*C$O]'O:K3%;@2=
MI ,0A/DWOJZ5EUN^LV9A<F'G%M* *;)_;<ND3_X]:JHO[S6C_Z:;WY,=[?+"
MO+[@452L21#^F\"^:V[<<)4J;2,7#S@>Y!DGN5EH*&IT,_/+FKW!).?M/),)
MKTJR7^1<X''0'L_>?+(V.!(8: X,[4B7^KH)^: 3*LX)-$X@!8+Y,/W" N2=
MG383PZ_!90=K,HY#IWF4IM.$B:3Q3(9K %46]H2Y>-U+"DR^:,28N,?[^.W<
M*RFSJK%Q!=Y$O9V6X;9 D:'C?2UK\^L?TU(P1,)F*[7#UN:IDJRZWUV1/(U<
MORZN&L @5#XJO8:O!D@5F]O7I3M:.]B5)23V7@'VLMM'(/Z1@JYE@\;-WJV)
MCRAZ7; @@@%*]/C\]@S#^JZX#O$3D@"U3XY.A:\^.Q"L*Q?I-N-(0^.1\\7K
MAKJE5[36@QM6-ULAI'8'E4LN2+LC'X.,V427].1$"*/MU!0E1R6/=OHZ1F\=
M1=??C.(L%691.:*O?QRL1@[[R"$IJB0!@K1JWB[+/4(GH4#GJ@=UKV"8I0I"
M%R$Z=_EC>HL,\ZH#(K928S?=1F[!1O"IA>]L;ADPZA >0_Y@3@91LJJPL_K,
MA)K00#W?C65M_:Y5RLHPI3+A1TQ>.AF<0%@-$LG]TIH?02&N*0KDU\:A>IOL
M0A\'Z^C9;HCK?)1;$V=(%.)X'!B(0R;&/9)CKXM%QU':>'@<H/,P22)KFI$R
M!2LJYM*+</%O%L!!6;V-#1G9-J*SII:W+CQ<QVT[AV$*>NE9:>XZ QDW&UP&
MS/KQ5CQK#YI.X@^A&>;+6V.^-<$]68$AJ6I'1MH"Q 8H<218I6A$7*L<N]5&
M:ZL7 R*T1N.^G1Q"[ %G:%4H<V+*2&0$5TZ';>H21#ZU5+(+JC'7C%>BY7/5
M%H6B)P!#]0RUH)Y@CG7/X# %FYDNCWBYOOM>*<7GMA$VI%]6?-$3\)]^*B:6
M R9M=CD1QZ.?3YPZXU6)XK[2Y8L%9+A5 JK;S/.W_."]D3&3V&TQ01TV.\/3
M0!2TP<)2Y'P*VO%R'^P1+SI2\ECV9<7]D'P2A^7=$HS\<+8\G-D_I,\T[P@L
M$"N3,MSIJ<\A$2=&]("(39M@7X@]F\/]M0VN6-BJI'UW=&^%R0(TE[U53?MG
MRKR0*$4D;* -DL>-S!$YWX(B;\&M8[0+8X8Q0"Q8"%8P-T<0R_(,J^N&XB3,
MBO):AQL6)4[-JZI9 G5!<WG_&<@FQX06%A8SYRF\">25[B6RDCTAJ71[++)M
M_16?W3VGZ]W%1H4N2\5SH:TJBUY'YKX_A8WN&DZ0R81Y,%RF:+A,DVLN^O4F
MN8Y"X&[$RYMBX?O)NBA:X=>?X,P3!G)I-ENPI 3)Q7BB8P>^[*3!R3GRPJ(U
M=TD?P/M2^- 4>"X%MB\?O_&>/)+C/'+F*K$"A-65#&E3)[2)K(S$15T2O?A%
M:(,[/#OIS)BBO.$PQTB81V:#GL4=+E+"5Z]7\9$QZ]DD<$_+/VO;>KKK4R=S
MN+T8Q^(QQ?H>'FB*JA[N&7-?>)?D5IYH=?9@8T5G96(<,8L^@87[P\STH,,3
MG4N-Q+UN:6=^;:=F:7S4#<XA-I]LV)SKD:*()E47:+>DKJZR#Y"_/'7=?9$+
M@LQ.:5ZZ^U)9VWK04J"]?M:M&OD@LX>D8XP4L3#DB#+@Y<_ SK[5A1U!<!X1
M@[XO/9[I/L7/T(:EL(X@$T7;18)NM\V<D1BJQH8)"!=:\8M0SG0E4*I[3L<3
M6.47!%H0OCKRH-'^(*O+'W#0HQMXW*,S/CUB]]<MQ$K<-B")++1HNO:"U,P!
MG\>_LP4L9B:;H[V;=^+F4M015>;IS/C-!FTHX]Y'-;-L]F@Y%:WW1LMZ1;Z-
M7[HQ$54U1)'T*./\]^.))R0%=2>'D7Z[;U;O'N,;W3]S\>*EN2K07<!J$.\2
M^%,IU$4F.WKQCEY<M133F(TY7H"A6O62I2M^YGXU%7,/5FXMO-ZCB_Y;DT3_
M\_\NV]_]SPFD8B"5ST\@E4?P+!\>I/((3F58HN_KQ?>K?4.%D9>?9XN7SU^^
MS)Q3OT:C!WLQQ/I4[,GGM(;!OXJQ^O]  &<$]%\5=,CB-']&7Q.%P6"P-AO1
M%?R$!I3JY'_+NW7^#[;L)/9-8>I?_WJY>"8_XL_M5\&Y"J/'122<L)G11U7$
M O'I<^[4$G_-4N'KL'_8&BY+ >E973LQA]<Y$96P:FY!M6WZS7^^.'_^G/)#
MB^X:!?2R+K?]UEW+M9 (+QL7R=9<V&,13+;P\L9_1J)F\;8@!1M]<\^:(=_3
M,7[3AU7X^6>?/W^6?_+LQ2?)R'XGS_-E>!XF\'P3GT?'[MR/]WA2J7)7.R*"
M 7WBD7,IL\K#X+2JJ@170TQLQ7U&(=*Z=(?MLJGT-?_V]?__RC2EA?2/O/J/
MVSMFCZ 6U#0"7QSTD_/_QQ?/GZT^>?;I)\\NTB5PB9HN?OV:&[?I!SKWV--1
MSCVV>BPB,^.+/X:]$SSO>IVWLE_"0F9VTXNPRJO%R\]@(3Z=N_%78=G$.S+7
M.6?-["M&KG%TR5+N+EL(_!Y]SB*WE#['O38T-C.P6KR+-1I@#(#N9,(_@.)\
MUG;D#KD=%^CTL/.#P=[Q-M!^JMN6!(9K-F-:\D03CX4+PMIQA>KY^P_=/?>B
M9U%B,7C9WG?N3NL=BJ\8XN,0$('@E61ERV[5%OIFR&JL9:\6]5D83%US=QJ[
MN-B__>0I['%X_>M&*,-^V=;0-IC!MLNFZ+$8@^J#PN$>]_?G60FG1*.$KKBH
M<&I)X@>2"1M9_,=BE?!==]Q<"AY5EY 9(%WU)BD3#TZ]^O!HE5PVR< 5$3U
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M310$/@(O#Y8\=1.SU#T491I17E/'8\"<)_E#@W1N8/+'AQ%W15+U9!%^EYM
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MK:@@"LO""FB95.$DTSH\;:,'=@C)$S?)20FB3!Z:M0QDF@Y1P'J2K%3Y/43
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ML7[Q]NR/4L$*X?K,5%@=#UJWM OX@*0Q"Q/[8O$U[YI7P*R33_2ZRFMI!2"
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M[#+*"4G0R@%2T<NR9?..R;E=T436V" 7Q=CZE7 J@UW?A?'PX1\J.NVBU^P
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MJV[_&E/3-N#^KS/UC"5 [\CB,6(B^,WI=Y4 74OFK"$!>IU#FZEYE!G?_,I
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MR]K99>WLLJ6[N'-V64_)XFX[NVSYV=1GE_&>_TZ3D1K^V XPV[*98%NUV':
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MG^%I#_("U0,&*."L*?ZH=4->XKOUNWQXPUQ<13(FX'U(.B(SCC0>14@[#%O
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MN+!8J'J(:+6!E03:&X--P*=#E2?HGQWU<$0[OX#B 68-F#F*1L+SG'<XLI*
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M/_#/21;,*(VY \&TCPD+ ,Y5] ^L^TZ1>T5D6%F9Y."-XV_BE-1)%K*72F&
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M!:M<[.D(7&-"V8IN+)_=6JW"DXM48PWR&9!:@0M3SD3:^<5$1S]@7Z !G*P
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M@6'$R1L$NEH <O=CD+UZN-6R_87I;</_A9@F"GFOEBVE.9*9LO9JUULWL5G
MRIP<EB@L>4 23%IHA,BT_GG_?EM]>)KD^*XTR7>]#LN8O]=WTR2O.AH^5\=2
MO\5+>X8+7N-TO4?OJ-/M@S6+_I?,@'L-HE%7W%Q(*Y&X5_E+[TTLXQ_LC[Y$
MA-L46$:Y6O7O7:A6&&RS/W?&V=8_OIGGN_(T]P8O//Z_CPDV$PRG7O^ W +X
MW]_##(M1_R>,1S@2[WWG=<?WKJ;T'^/?_A/' %QE84X#7?!<ED$\^Q[9]B1;
M2-F"8,:2"Y08YRI9:[QK!8.XAS^(P]GT#7$K7]3<'=Z/N#D'SG,^&S7_&B2)
M>D3'<U V>14-:Y01%L[;V#UU'NM+[S&/SWU#]6GT??TDG\)](^_W *0BL-@A
MK156/.":?+LNRP:-?)UUA"XH(?7@5)"9UE_(>I F,(G;:X29"]6A5WD:?<<R
M@J@/#B/[W%JFSX*[B01_PLPR2)V5$NB1MJ,8M")-7+H<+J,O-U:LH(P]P:.1
M3+[4YB%G"GP#K,C'QEE<B)3>\1QK5$W4A!F9*9JJ(U$//;ZQQB+;":$AW.&4
M6ID8A!!D1B'(OO!S3DU,8IA:WZ<C](K%G$K"P:VFGDHLDH^#:);728D#,W#<
MQ,]];./LXL%Z4\&K;1CY42$&384,J0@EE;Y+@BB3T4W@E_H@:[Q\&F1LX-JS
M@LTQ\\.D[]1>XAY0&G6KB5')&%XU4<+].!KVX2 CKN\Q*_1><,,(R,5((:CI
M"%NH$GX?Y\H[ II4C18T@Z+DA97W"+]BKPC-[Z5Y)90:1+C=N6J Y/Y(.2V>
M"B*QKGKB8]MS1"3TJ<PI!>^#!IY6V@:YWU@*Y.Z\8BA];!QG!7%)?44JOXPY
M.^PES,)BH:)^!,6-Y['Z C," 8;)BB+ (BNB,$%"@PJ:1H.H ,[MG'1ZOGJU
M4S3%_$!^FQJWOHU:.JQKZ;[2TFCD9R.>3)V% A2&D*D%@SU4RJ))ZGT))>\;
M#4HVFL:N5J"&NA0Q*> O(VU;44Z:9CC!_0VI&EK)A[GRN]6MM*1Z]<IJH;Y]
MI*@JH>K6_":A@YEOKE-GY'K,Y-O'YDIB(X$MDNCTF".5YX@FDI8Y>$$D;($R
MG+9 ^O6[O1/O#4/Q7"885T5!=A4'B<]#&1K_1ER"PGC)GVVZ\J[AI7P*N;;$
ME+J2>AJQD,[AT[&8.*XY]D;;4K8UQARM!]F[AVH2IM89!G+@F 6C(8,T##X,
M"KO('G.J,@&;)P7RB:]UX/ /E)X?@GP4_.E=T^^D!U?R)>Y6G%W*M^3S5_AZ
MM55??9TEKAE32LSR4BMU'VLQ0$5E4HT4C5=OJ7%-+B9$MW/89:YM6)^FI ,I
M3=\1<)D,NSLUMU:OPR]M;L'D%H[:W,(&K.4Y9R=K!BSHN9JI47^#WQ#'P3P/
M?U'_P#K)>1PL?HD2VA]]Z:4\7FX"$I\@S\&'D)?0^_C/PA?'IYVCXQ-DC2*#
M_Q^I%PO7=(AK_E:,ZG\[Z'=.N[VE?^YVEO_M.1X+?SP[7>NQ?Z.3X-. \T:"
M_O=/!S]52$+(C+UYX:$/-_*0:U_*GXB\[E\$S_&7_ORKUVLB?)523*2G#Q9V
M5U_6JEK7_"Z'VIZ7>UZ?E9=4/3CM;V?T+S4+.<*6[J_8T%Y,<VM*>(.J?I2C
MSW@7+5ELLN"!F[$2:]+#(<==(B08?IED*2QH7\YB. Q#T'F/?5?P0562S*+1
M* Z?WM+IZIY<.6H5*#)>J-7RZJ(0FS)IN" XEY3!!"5H> <Q6AJX-/C<%"FK
MN*7*MM?>4K]S1!7F^5)WX/N>^>,)JMV@QQ(J?)L4&M/_[?X-:))"U%[,*  -
M@H="'RH.7OUJ)1FFQL2!*'OSSROZYF]A,'+27_\KF,U?V@FP!]V>'X5>#[HA
M!YWN:HGU?8^\%5A5!7(?<GRC 24><//I[^X]62;7=)3^$73T#WJT#^+YP^\B
M@AZ''JU\^A9U0?+I;Q1UNV=WP4&/AWD\6WJWYO*J.EG*O6H/MTF.F%(>T[%2
MZV;Q5S;_:?PE<O62 #,'-7/K87T;^F2?-H)Z>M(Y.CEX2 3UN-OI':\7D[S?
MWPXYHONH =3>2:=[=KPMBSWM]+K]QXCVWE/N/6.\ZZ>_?PAF7&5Q)1FP-=2+
MVE\7=_?36A_=AN ?'$:)[4S4.,9)<YK2$B]0MCT@BKVSY_0O^@$!T&%5.'WH
MC5*45ZI H:8Q]GY^\9C6^K>;&T]T@LWFQC^R*"\B[_<T06B$M73DM]A]=W)B
M_[$.ONLU'#_9C1MU_L=G/;]W>,C5[=63?306I+/HKG\2CTG:[TC.C;M-/W\?
M"MZ#<L^QZZ/.47\3&?BA(>1MDM^_I],$R_/A#^"\+'%<OB58^$T2N^% MT0N
M]WM=OWMP?$^V;F:@[RI][R#3-Y-FXSA^?1G;M,7-YKKCSN'1\['<0RWAK9*7
M;KKK:5)=CVC\;J$H/3P $[=W7U':S%N;;,CNLBAMVN)F<UWOL'-\\'P\M\4Q
M=M4+I[$H<([*L#!S/VOI"=.0:8&0J^%JW"?ES)<V,.0M1H]51W^\O([^'GW\
M9[J/ORV^WYWB^Z?GTF8<DJOS3Y^]R\O+A\),G/:W 8V[U^T8. 6_'@+EDJH+
MU8_I_8IP'.ATKPVM_DQ;1## 5ZK_\76MLF([X. _.[E>3IA*(UE>P5A6(,+-
M%;D\=\-T@1IT!6$#;NE;WNQ5AT=YVO0MC6)F^7SO#IC3SM'I\C\_/"5Z</KX
M#3#]SM'!P9:L]>BP<]@_VIGT[>G:V=N=3$2NM_WSR=/M?M-(WYBO7Z\-[1%S
MIZO,T^^:@J[;!A5U\3@,<?>)W8.K'O]]WTF2/0%5[TZ+?P]R;HAT6S?!=[:#
MTFW-O>N2"!F/2"DV_F<S%K:RJN\C#[?N?KAIQ_>=5YWS3GM/#G_@>[).ZGGG
M;@$GD_;@O]GB11.@8'LG3OH_[IUX")CD3E^83^D EN3MO4H'+[Q_)/@7OB[M
M/?F1[PGKCO?AB! CGU!S/,=FWP?%- IR[V,8?PFK:N('9/RCHQ^=\:^'$0(X
MKF+\2E946H4>ZZ@VZZ/;J_26Q$;39/^-P(2PXZ@3+]\E5-22ZL'W\3J-O=]Q
MNEZ&;BV)YKW^B[V#%ZU]<O)#B^D@RF:!QA%>D4'=Q5MQCOBHUQUX%(Y34>$>
M_.]5Y[?.7J^]'7\_.OAQ;\</$?"$AWFO8%%9,%.*H?<"=$/+^L<G+>OO-.M?
M!67LO1;<Z/-D$J6^]XE$/ZJ Z\[O[5505^&PO0H[?17^9QHFDT&4>'NO8-TO
MO'\'J=(&K8\ 5E"K"G:;_W^ER3?_##-&,)VT7 ^'<M#:_CL;K'\7ADG@_0K,
M/HV:$[L_(,,?_<"IJN4,OW:SEVR7\>VPC-ZIJ]]_QL)Z*Y3S]*]WSZ5WU#DX
MQ(-X'RHH)(R\G9>CJ, .M5E4%.&*;HL-/N3^IA^R'@Z*/13;?=8'FW[6'U*:
M<!G)Z$G32+3.P3_[=-Y^<P7T=LP2I">N-8&;6F/MDF#OF;B*%H)CI7$JILP?
M6Q?:DN=RYMBBJSEPR3B\/$(&U&,L^]U^O].TXZ5H%$]U%-[U-'Q66KATX)/_
MR-W-<*/5R=-T6IEOB /JBM0]7!MU]%4)IX]3S)PO_UXF(0^^@^^:)_F&J#+#
MUIGP*]-J\0'7X;Q@LL/WCBHKZ)UT$# OI5F+_TFC!!=?(CP&?A7^?D @V/!%
ML('SCMP!L_=Z==M5FA7C-(Y2[[K #LG)P@L*[SR''_XG3,)AT/'>XK,_@+Q3
MJ^KA2WXOXP6_,8<MK'K%KW$Z"&+U_&@H>+<D20LL)KJ<S>#4K)UA [N] 4*'
MG>%PSGF,$U*#$<BN:33WLC0.<QZU"C<!Y[3C4^'E<QRZ.XABG!\(+_D5M@+6
M.1#CEN;4XY)O4UC%B(;(]8Z]11ADSDA=A3!"BP,FG?  VX_S*:PNGO%O9&M7
M63HJAX4^0M][%XV!KHLA+/<=/@B_^A9\\N$4,0_?!TG 8[P[]BX#V2GO*DJL
MYVEF<Z99H^9!&$6LQ=*=^KX\'N1+D(6^?=JPB.L GMVI,D>N!IS0NE69RU60
MA#$=T/4\@P>P 'J#;@[\C$/WQNFPS'&^$-[G("OVRSE-8@V2*,09?X3I>YO"
M:AF25^9(AW&,4PRS8+XPVI->1*9C+#.0J?AR J3+"$N Z\XBY!2S?#W<%X%^
MKZ9!-@N&"V\4X@17,VSZCP0^D^7(#?#0S^'7(,?3BV-X/-T"]45<)3[I5>>Z
M@Q1X%3&AZ4GT/?A?8"/SP([W+YJH&0%A&'E!+TXB\6H6[3#08R+IT-5Q-,AU
M!9:,2P$U"S8>[M_TQ5I70(82QTBXG F'WQ^!EL[,?KXDZ2V0@W=+RD08RD<X
MB(@F-^I)GG*9<4H43GH,<!QQ@E=3837D9KHQ4WNQ)5.)U[<D^M7F"1>AY#EL
MY+HYL0S^FLT"-=(=%%>WX[T*<>*RHS3>9QW>E6QQN12W(9>NX)[#A[5 46HC
M'1M9SO?%45RVSCBS9+W^SCW6XUL=_99 I!&O1G/Q(GCF:Z,N]?')MRB, L9C
MG[ X'QJQRA>-1)/U9#V:-4IH'E2:^%X2EEDJ%Y .9A+ %^"T"YKUA?#O)/%"
MN,%#'#,.[Q1S8Z$UMUELIWX:]1MJ"Y#<E2 XFU8N+SR3YC /HA15H"@S+:9M
MI0?'>A.-HD"D,ZT5/G"9##N^=P[&3 3B&(4BZ=)W$4CN4)1;^1\0<?',^\<B
MO0V\?T29EI[P"'@P/.!=,6HP7ZQS;6"!6[*9<L5DEO&$DC9-(MBM]RN8MG-?
M=/LT-!/H<VUSS.,@H=?!LJ9A$!?3(<ZG-1.I161&I!VKJS!:)LJEJH:)]UN0
MW:#TUOKY>CA-TYCE+GSV'#[K?E*TSLX)3+*RI<\&]KRBQ>8YS'\F9UV"/J3Q
MHRY>>QV0CL2JC07RC)9N/_H"5DB?4._PT=(IXP"X>>&+H38.V7B]3FE>5%JY
ME*L\2'Q%&*/II$S4WXCGK2]5UVA]10E7DFO7)=IGOO?A]XJ![BWEX!\0$>JD
MDEUK)RL_QUJ><[*RR.9G@H.;BOCA&ZSMDVNVV^NRK2: 2#(HF7 ^'@>1H.Z@
MS!R$Z, 56D!4PDZ]L[,3DH !^'$)ZMU767J;V%X7&E!P*J@.N1;)%V @=A'_
M#5YIP\??=ZZF4=QQM @J\/?@( ]!6F9H8<RGBQQ-#%PL_#B<AK.(?)^]B%QW
M_8L7'>^U4NRLGKR"]#NY.I<H/]!,4UZF)R!Z?UR\.X>=XY^UBRK2]%KY6Q01
M)GN//B?A O[^^R#/@^$4_.2BR"D2@4;9;VD^1[7*IK78!NK\V8C02N4\SZ.<
M;)ZK+!V#E9%F8FT["VU^BH]?3\&8+<+E7W?]XPMT5],LB< @>PW>(?K*BE_6
M>!BHCP2-:G<=H@2M[^AG5C<BS8?_P@FLZ(+E8.=6'@8$PYOS*BN3_#8:?O'I
M1S _\G!AZ2F,\4B<27C7K_& Q(%0T<(2T[_,E;A,X$H7H(!H[:#O<_"#F_X,
MJP'M-?6&:D>9?:MFLO21,2&(M/!N&04)%GTU%G#U^:*B[Z_3&*WOZ*N/,:ET
M5,:HGC^$7W\-8[8&D%<L)Z'Z2+@<U]&$XA?D Z"INVM6:-]J7FUJ6WT.ZV"9
M[=ELARTQ+NO.G_BL*V2[;;,">_\CPEO+D2YBJB!&,]+[-4(O5T5R?">.W>^2
MW^ZL1E\@/F /'I-2K(_B01BY V^*1&\A,3Z+\]$WFV3!;*EAB_MJ5EMV$**N
MOV35\<**OJO81R6P+,'RKL2Q)6#OUS:6S_&U*CAL*T#+0L;+;^)BL#0K$,UA
M,Y"JMH\]2_."'$JZ]^3>5C8*3ZSM#XZ]I)@+>I6@9<LL=*3:%!W?> Y4(&(B
M*49N9,2*UFG[X/)]])K.M8#K'A9,0R*9D,F)#F#@.QJE,UBE#Z])K)_P&? +
MVD TJ/,(+)KET!!+1,81Z]Q(Z=R9: #<QPR<(-2?OH2,A_13_9&.3T[Q6J(K
MJ#+<QS7"V(*OCBD 9-WS83 *9Z24_Q4" :XP,L-:X]^@ "106G7T7W=,#)F>
M6-&4^NNOP=XAY-R=DZC=XR6MT,^5SJ,%+9.F9)$A@PTK E5%UOI]XB3>"1FW
M,PR+TC1X$'9\TX&R6H,CIG+&43W@V$;QILSDP .5/-G70^/!NAQ^099*);[/
M%Y*$0%A,TU$NAFZ!BGT?Q,V05@[,,,-8 $H73%? I8GC7!F?.H8(%J4EVI!A
MX=+.4G;;G9Q<HSRE(5+:8KFL[4B+6K3E5!Z$>/ZK!'GY9#DKZ9YI4L[ "BYA
M12$. 075%:*E/R\'L4Z#X#LB3H@"S]^@(LC09K'H<>3- W+-Z,/\;R^8S\U#
M1F$^S*(!'JE>EY9N<!Q ]9#N?W!^=>&9\*?/&0RL^\ '890T9*(UO25"A%(@
M"*8+([ :B4.:6 'IH?0TT>"VDL>GZ9<!^"Z%]@_(P@5_8 Z6:EYU@K#*Q.OU
MF"^M4\9@9RK'Q_X-NE'DSL F?%>.:;_)R6:YDNQM%D:#,IM84=0QN(#PV'"(
M _](5(/@9,%-N@04&QN[*?O1PL=HJN1X">$PF7%)P<#US9!E2>X[9[;A53,K
MNL)W3=93**&AM?I9<U\-I3241+9:?5=6Q]B5"V>6&4$;]-P'5_N'?P,!C@5V
M(,;?P\)'$?Q)?'\K(O ZRH=X41?\8!Y%<IDDZ0W+<#'IQ= \;:KOH<787[_&
MBKZ 0@1H"'DH(?.";+EQF8SLS/N0/Q;]A3<.Y$2\0!4T <\/0XW%% 3Q9+H\
M^U.1XO;AD&7O%@C<E6LB"=^<7/H<W@05_P-.265=3#;)(@.#=R<@U][B8 /;
M[ YRMG359:PMOM%C<IZL=D!E'DD^AQ_?O^9LERZHZ4E!S8E5P6-_[WP6 2$:
M\F7:RSA33Z 'G(<38"18?\T1:WSML93?],Y.3^17/;_&PU@T<A-DN%N[-,"X
M)<93(&>RF>&5<\.>E';Y>HZ;U+-!UO6WG=*GBLN(7^&T@TW4)8D+*R/:/;;?
MV]71,(NNKMMK+[]W=G9@?$!PX<Q+EU1]P3<.S3>ZQS5^NA7!,TXIX*Q$A'NO
ML,ANKC0[K"A(0!<:)U55>E'^!!^8EX,\_+-D7S"?ETB(L6<BN:SRJ[>Q+@2K
M[/P&2ST<M[K*66>*GZO"]!R.%\.4X-D-36@.O_Y]%$!_O0+"9ZT>A//J\[DY
M 1"F2[.ME683D(!#MEPI1(V5!3HX3>3X5!831+>W3#&5.%8%2)5OO,K2]$N\
M2.SB)2(@?K?9-ZT7*+GKU^;RBC*E)0I6ERE%J&PG"7T;$Z3:"_.MHB7<&C_$
MDE&N>R47:NXJ"57-M'.^-?'6:M".S3"]-K*FV(C"AU1*BSXV#QFB#%SQ!+I_
MK^&N*V.2%'+%NOPMK%B4_%02M14WL.$5:(=\.!U@WSZ7W 3*H&JRWA;*=K-+
MAOO=E_=^YQ^?+]]=?OZW'5S(J5B'%K"B>DBO0!4ZX]O7>^>KJ.B .UI[3;Y(
MX$L%;[GI5>?E!&XT2>*7J_=89/#!,,RU,1_&:!^\+>.1+3X_E!D':QTK_9"J
M@.12BAM/FA\_:LFO(@QF:@',3Q1JN<%0R]RI)DEA@_!/E3.T2&Q.N"+XW)!\
M4P 7U\Q#OL32(1M&GU'OS/+G'3-1UCG3E<A2=:QKIV,NR!U3<6'H6Z/ :)]#
M78#GI+7>.@7T1^YBCB@D4C%CL+)X&,UAMV-=QTAD'0[AN,E.2TV)ROG7U#E%
MPS_ZGBP[0^:5=6@X)#O1+,=Z/TY(NYT"\X"*O<7,,1IPZ!=BV4YU<6+3ZQ"=
M8@'R _BSOLUEINY64<DH3Z*.DT9 RN$_;+,/6>0SR.2"2^*\=^\NZ&W\._$G
MZ;=5[^307[IM"M]@2J/,^!#^!^B]TN4YY8=VS_C4ZY>!G9\\#POY)EC?LI+N
M*;)LA*7Z5?LX&/Y9PF:I8D"25I6CM@Z3 K(.JSVG$EU3*KY);J(\P"SOL$%
M!)0Z(=I@."ZF?/ P; NQK$*LT[80:P/6\N,68FEULY$F<ZW#K-^K]K@=^$WQ
MR>4BZSJ=54)9WO7Y?<P:8Q_T[8B-[Z'VCTGCDN!G682R_WR6+0K1(=X\=N6^
M]L8#T\2CBK//1W"G(RH*QT?1ZW\-4TQ]5^K5E!O^_M4Y5\9=_29-1>((O)FE
MF>UQ:XOLUS3ZJPR+H+$D_!-8#ICED5^A)F2[A8/*#;U$>F/W<].59VY[Y:TG
M?H<G7H<.W SO^P&.KA5^E>2L;,PJ.9/ OJY:;VY$YE>8UUYEZ3^B48)E=M?B
M^ZD+:[_&#C&OW>6\7,I$"74"HEQ1*6M)<F"*D4I!'>]UJ%IJ39H$'XYF;*$*
M8H;3+,4(78:5+/"Z'$S<D&6)V@49D-&ZB_Q\BY4[*#[(LWUWX7.[+]8!%$XY
M#I4% HG&\ <NZ\'S0C,9?:[*I2,J2,N-::ZT$T!P!/N#(-?E.]3$4BEZFH9K
MT$1U7+Z'C]GV?2UKL*36@IHK$7@P<1V"0^5E>&1O\6ZQ+C-?L^5".[$#RF85
MZ,=E]8US8<2<VW%%4H]4=LY3J3#0'#DX^:9<TW%A;2Y&%R1*;M+XQN2]JW3,
MPHE1*; 'NKVZZ%.O!7R:.+0W'B@?W)++H-7&(!PR,?VO9U$Q_0<*!5@1D!]6
M5*_?2XA4>"^'>+2</OPUF*%1)?D&G3L)=/&!<G>+AO[82U12:90KG_F&="\R
M*5,\+]3W/@12/:%K8>DB*&WF\D(4DU:&TP3-CL()-C3')9]X@R#YDI7S8KCP
MYF$1J;HZ.]IVZ%+&";J_[ORS\[[#%<8J_GZAY,)54$RMLH=+;$^KU7*I\MF&
M(K5_AC@G/<$%FT?![WMGIX>-L76UQD<*K"]5T:.LG+C<6*@P""4=[FK["[!:
MB>M@*N\13H],"AO%99.@W3E#H+\>D.JF=0,_T##0C8[.9E?TW:JBL/>.\D*S
MX/6UZ@L53G.ZR&IJVZV@<ST"'3\\TR);ER-SGPFJ9?< 7%"+U^?50H-KUJ\Y
M!;_J87.=:*\%^,UB_(<?5Z5)N9:=-;&>I=Y2=7V]L[-3-[QZW%SUIPHD_&5E
M@*9#<,0*'$C()>DFY&ORZU9 ><+-,P:@8)BE>;X_+I.AJ 4*'>KG+95D@S**
M1ZJA/-7Y^4 U9%=.Q+6<*.I>SN<Q*12=>?V+5KZ4Q<FH8]4=8DA17D&ZC92Z
M75Q\/<15:I (S@25?Y9AGM2TR/OKW_'#OYD>XW?!K8)V*4"4_A;$L?TE_+-J
M^&EP_QH6_U@9VW) 74483ZP[?TL\/]]39:H!!L$Q0VVZY1W"^*R@Q "R%97O
M95'^Q<X]5)(+7.P4391U,0M0!6-H@0F]<UJ'7+WEF,6;UCG]#6XH; IL>-A?
M4^&U DRY5RA"/];II[IX\]&M.L+D499%_T1V T7%E[DA8;O"-?IG%,8!?MF(
MZXI6:TR2VJY:4!9IQ-73G"V\05D:)>,XF,VH^ULYH@K4R4Y9Z])!>U<8(%N6
MKK;._\Q69EC%0NKD(WQ8M%VWBH]QZNNCK6>F:B!,-I237V]R6:)[E-(!QV\>
M9=+^?JF.@TR'<W-DT?LWKPV]*XG$.][ !>[['Z6?Q* Q^178D$I-O>FU,>@F
ME,"S82LJYP2KT6@IG]^13V]@I&A_A!H"Q_A:$_N#A1_B2S=N$0Q2-.?E4P2F
MI9"LW%)SM8#;U=@MVK]&/1\DZ5?%R0-&AXFX*LU)M&GHK @O:M>ZQPV5H?5Z
M!CHQ//8E!L_*^@*[90(_H*(;=*1<@&^64^G=X=BO!=_%T>9D6D:ZZ<Y2P_!9
M^IN/$B )= 38-!U'8-ZHH@3\:_71#8XT^)K-+B*L]SO47=U';OK>'/.)U$;-
MBMR232*#?'T*UI.=$ ;GC$T$PTJ5JYQ\O-B'FX)=X8TDWDU=7L5??];<\S<K
M;U07&!8U^V'[^2+=?RO5L*H':GF1_B=$I,->(@&0RJMU[6SY#<N!9&?@FWQA
M,&T&GR8O08)2^1!Q[+C:W6/=:UAK'P--)E(J5Z&"^I,HXS('WL4>3?R'M7NC
M&='IK.R^6@OL5I+1SL'^P$V3E<S.@&4U((H1)JM0/V8@X.&95)G!:]32SY;#
MW-<HS0=<W>'@6W$EAS3 (L$V,@$IYE9#*7-#53EZRF 5E-2EC UBH(CW<0NA
M*G9&[Q-8R5(8Q##8@(NA2*H@"K/]/\ZOO7P!GMY,.LG2V]"I?:+R!I*^J%@T
MTJ33!$:G76LIZ?<KQ+^K.O[4QOF2;V-K689]<,Q/(^]ZOAAFP;A@L,4"O%KV
MFSB=H"Y+:/]1.5IX=1H,3Z=@A-(/JC,VM9 CX:K\?_:^_+EMY%CX7T'Y):_D
M5Q!-\*:5;)5\;.+-[MJ?Y60K[Y?4$!R*R(( @T.RWE__]3$##$"0(JF#((6M
MQ#9)8([NGKZG.UOG"M&7$:?D?N8#?@^+=ST_K^,(%(YRR:@8:=1,*%[+5!GZ
M7B'-KAAS^0LA-;)^$Z!U!M=H2FM.@EIHGN:6%2S)4Z/6^+[*NS.8)+P^O?%B
MU@/U[1;3LU#B*V#MRID,4&:B)@5""J@,B.=.L34#^G @*6-IE65F(0%C[@*(
MKS2ONL2AJ,0#/(IZ$%9A$_X=ZU:&E"6#84W>D'GSYY "JH2)4A69)KLISVX:
M-]E--5C+R\UNVECVMG"*'\FZ,92VK*9M;HOL',,R=$09(&*F6N52\??3"V@1
MWLSN.,=HBJA2+JIV ^^CTMQ84]GP5T ,5?PHWHE;L7.Z3^1JW?*.VR%1<S4O
M>T(_E!++C1O/[[GV@0%,\[ZS2@[X !K)^8\B0@2K%W+UKU1DB'/]3$Q<J"#V
MRB5>#FT;=2@KB\Z7W7VE6D@??<_ZV4/;;%4YUW6#;*-8O"YO5*JI UN6/L<R
MY;DN56-A C=E+6(X3->)2.Z6F)7SHSE=X8:K<K<JXBX2MHF*;W.02*Z^FXET
MGLV;Y 5I#$=4O@MM#\PI3U*[ @.UC=5\ DX\6F !^8A-HUCZ7/ 8^:N?8HD'
MWAZ7TS!\2CP9F1Z,BD(E'[W-4OGV0L&=]47IWDE8D2_5I0Y\-2_54P&!_+&\
M3-#J!']/!&CQ5R -K)_%[WRELK!6M*I\*I*$0X'ZF%Q'8IJB\U(7WB W\>9Z
M?^AH4U5'$/L;#PGFKL(TZ 4W^A;@S7>RA/+P@S636$R1]EG*\%%R,*.:C%I4
MA2=SB]L([2TJUJ]Q2;+#4*\XC_&%4:%,WI)K!.8!9*[.''.M,31[<<@$K4DB
M.KRQA,4!8)'9X E'"^E6=(FJZUYNA%O68^*6LD\>H) \^A;*<JQZ"U;IOT.F
MR5S&G*Z"G,ZQ58+[&ET#W7(>E;@QTOCP$%&R%*5KW\Z!=Z VJGZPEFD4IT8O
M%Y5 EJ./BY''.HL"IY;?L4$173G\CEQSP>8NYQU0%;$L!<U%[D+YKVZ>3M.R
M/E=O8"&X0KI'/DG,E10PI CXHB-&YO$I-I&Q/A4ON738B>MG?D*6<F L2G19
M\,4LG$:?]VG.9/E'T,*#$(1C ++55R4]8")@/J"N7TLNG1#E[M<P\H"*R9R8
M"V Q08B"9H&,@/TGD;R&C5($B'8\S4V0:C#H*#)I"2JTH^16-HA&'ZR65(9L
M_S@2L)>8FES,0V Q@/A9&E&->#8HN!!2ADW@S^[O\]!'PR/+5T)C)(RX?T>,
M_08]8-U3HQ98D<NY)%O@&7;SX3Q"=:]!MH8IQ-X$)0)3%3"S.XT].$B^F(2J
M10JR?@I7+L+R7NU-34#(N,T*EX5YM4#*QL2.(_!3[(*RIQ2P$H]FD!422>(2
MLP:RDS?JI.#D0%^W:'BITOZ,S9R6$:(JG*2T0RXA%:>N2R5D8Z87<O41=M41
M4N2,ISC*WZ10@9=Y$V&@J13HMD.E\3I0N$>U: %JK,^KV?-\LM.MZJW)W;DO
M;F/=H"!F!38L;!Q/UT3R0LC+ZM^I<"=6S\(J7T@=,PR/,,YOPB2K Z'I$.-O
M"9K#<6(-^W_4/^.C:E)B:&7RO0WQ<C3,CD<B\?GHNC@(JBWX/U#0?2M3 LUC
M9ZLZ7SAV<&?="-0,[];;^>9E5I$]#J!"[SM\1VH:S"D#'XM3:I5[W6 *;#,X
MKQIJ "L-&[ TQ;^9&Z@Q<H #8$B=96*KNWZ0F0*?@+RP:!V>M4=S6O1:_2?8
MV;UJ@RKQ<CA=@1;P-?6EU1^T^_JX_"KBJ?@/&(HLKO%W%)\4E(M+-"5 VI'N
M4+ZB7R&GX5!-F+UB4&3*#$1C,S$>1 47*1,L1$R0P@=]7DP+\)\9$O:]JU67
M0.)T\F^E*ZLT/LK?5#4$X!1)@?(]<\JLW93 ]JXV2PC=@)2BJL4NF==YETQ7
M]_G"Z$QANSG;H)ZQV8.9D.:@$XP:S^Z,-UVN08B9@2#?\4I(1'W@:.>6T[X\
M[[)<4_%%=TZ:T*6;M,#TP^\SA)^)UV>=U[89,B+!3VR$!<J="@LA"#KMBRI\
MT4_.A>7-;&UV8>J*8I3K&!=MG>6G-0TEJT\DVH12U0 S5*: BD81AR8E9(86
M8=:(2W['),Q8EHGIW^GT>J&J"KLBBNY(P*?LHBETRO/X\D8. Z(QT%=DE%$L
MZY:4"I9/07>64A!_,8^0P]\NN/A0@)107$%CQ,D!!K9JS$,9@MBU)U>I0 \!
M6S:YV^[^F-*GRC-')*9XCDQKYQ]MU,C@3-AJ$*SV0!V"U">;7E6]B"C5507L
MX!=TTM"8V=G I+Z9V8VNM%^]$D[ERPI*$#K48+>(V(DD"(*4\CW2)A31J(UO
M/>KCN;B?1EILQZS7F$#HPISBC9T%Y:9GJH[F)1L.(O-!RVP?:ULJ\K#*FTWU
MI7P Z&@1^R5_7<::KU#74@T9E6*H=.*9G*I&>Q3@I>Z)J"BJ"V:J&G#<(I>K
MI%6AH42 +7")6*G^"O=%3:=PV4RE:CV(' ZD UTEXOJ:V!!Y2VI.ST>B_:PY
M4,!U :+43<T+R.;$SIIQA@'7QSHNJQ5!\0S$6#D8C7W.T\J^"E(\C*IJO&"G
M 8P">&&+ _4=-01/IR9I69<)OZ ,D864B6&PFK8,9V?#:\65D5A' T=9C%2
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M*4*<E#25,3"F"0=G<(AW=UC&B9(45"C*SLK+;I(QNDQ-H>):)8=6W!=6?67
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M5L>:ES85=X#?<_B+/^?]>V_G'EX1UT[D\I)S@,*X</:FZY@3>E'PICBH!=C
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M@PU?@Z:3F9SY.HO<=FNI6&/!DN$R@U"E7%&JHV(SZ@S)&TX5@V_.G-?6QJ&
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ME]!V2+9.\!AD"OCS+Z$('1"7?83%;Q+(P/<!.7< >>+N)&E=1*8W28G_\0_
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M&$9! IEZ;H+[LW$%-Q[I#[1%^ YFAR7"\""^B&!2SP?HP(\!'$DRMM$FID.
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M>X'1P)B>K'QK<N>+VW@[*CA<OT1U\(K9S+[@?7TFO+Z3@9QY"7T='UDKQ<^
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MPED^(!O'-(A9Z/OA+1([7>K -!','XDM5T8):"^6N+Z.Y#62J)FD0"D%*CT
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M1!2*O8#EZ/6LL.< ;S8!5"/4M"(91M<B\/Y/F721Z8^KL,KZFJ,7\443KH%
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M=3UN*C?):F6P^XICO/"@C'^+!F 4LRLL>(JV+]B'[(O2"1!@?HDF8:T,6I<
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M"PTL-+#0P.+6)MQZ1!I8%ZZM(Q2K4*Q"L0K%*F[=]ZU'I5B%:[NN:RLTL-#
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MGR520#,_C;QIJ+>EAU6B+$A0CL*M?G\4P!-0&@5(POPR@\\ ::D0/!R@N'8
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MYTA,W3C OZXFE-3-+TB:8@+%WTA_!'XGQK9)#J_]F9_'H\%9D# /%9\*K ?
MH^S91:Q(;75T0[8,3=8-I8P2E9N:F_6^"1)1^E=$9ITZ2W#447*4'7BAX8=!
M:.N6X9LJH;IIN<2W=</Q/8-SE+H?CM* HQ19URQ9-[4&<=0>;*R&:>/N$XGZ
M&'(Y XR>98 WCHT!2;]3%HOA_YZD2[QBH&G5H+=4P!PR&]:DV+Z,X3])-"DL
MY5GF"Z.?-#C[#TV3)7RGMSKLG$C[L"W3+2?\G:JQ=4WQ4Z>XF@3_VA3WNKC'
MFGI5-EQ5=HVMQ7V-E"><KZ\TR].(Y72A^[6%+%_76#QDSJI)ED^ CE;5ACQE
M D^9,D"F0>93W4&T4Z>WFB1Y+?1FM3J6+9N-HC=AKM]AP4>$.79#&F=%[G'"
MLOO\F3BJL-+?0K(7Z+CBV "W^191T648V)#O[%9'DRT;S"=5;9#I)(SV1HKZ
M'1 @]A.6==>07=5J$ $VQ7;7=U -M=Y!V4.28^9\76)^[5/)H^2_FA3 5ISF
MMCJZ+>N6(]OFUK*^$CH/R. _4?JL23]L0Y\F]M2Q9,U19%NMRPW8+7T>7\[$
M*C< "Z7S9V;^XQ'ZD%>HQ#07AO_;&/X< 7=]$N=@=EV5.+BAE=D,NXO+ANG*
MBBTL_N.EO-HL_OHH3V.4IX$-HM@-HKRW-O7W0#?%5"1LDT$)JZF$:V=)>#;*
M:&':STKS P^5KMLR\<T%^1@1GQ$/7W$MM^$W<*41!U7Y26]U7,N6%;U).0XG
M'J2OG_)J$N05*.^E,W[3J.V,_[ C]?N1XQANXV &P)\5P1G^A0C$OZ$8GX0]
M;Y+8W\S?-5L=S3)DU][:V15F>&,)KB[I70?!6:V.KAFRXKH-(C@1:.>!]I?$
M]YI1KJ)\50=,8+>Z/N61KBU"FDWS8RJG7M<"F6.11;4>0E05/C8X_[JLF*[L
M:$:]T=VML-OPZ@C!VH*UW_K\IBIK.ZV.JV(80E:W/\-O &LO-4G4BI9L'3:)
M.S]'QMV7C?+YNOOQ^O/UP_75O=2]N93N'VXO_OK;[>?+JZ_W90/OJ__]=OWP
MS^KC=XZFMKPL+>Y'O MP1+>J+ZZQ%GQGSQ IDD6[66R:^8S5#!4M^'5]X,-5
MU\MV>"QJMRZ+NJ"A.TY"&^9/N)C*J=LV_+>U@=V\B)+@H*/DH+H,USHXR%):
M';!C#5-631$B:YB234=T4H<@"LG>2"TAU#]/S-D-^4IM=4 KF3;PE=Z@4\,3
M/ZINL"ROA^RT5L>255N1;65K<=Z\PVI./6ZSC9SYQ*,IUU@N:PLV2CIJX-GA
M@20=E7SUO"%7Z:V.Z;I@)C4IA^_$CZT/).OH9=)[*>W(JB_MZ @-\WV?7?N+
M@4]1*;9?F;^]]62",ZS(NJ[+YO;Q)%$N=E1$6I-VV)Y(+?0L-=64'<LY"!I]
MZP.3IMG\4VFKPN[?C]V_<0*AA3D\FBG;5I,J]87IWTSA7I'Z7K3^'6'][Z_H
MX+*<FIZ61;\X)J>T^=D$Q?E)N2(TNAN)7J+B*T#^ OZ.\HW8R6UB#8^(QC=2
MC*]/<J_:#[;"F@J:3EW=1P[1(&]J#*>>V$T!G!-UB^N/W53E,)4%;6S3K6.6
M0"5D'I#Y?J+467_0IBIU:BQ:@\T&C;KR:QH6K6F\B;\B<SD9#**\F&"/LW(2
M-L":QO[KZJ#6452[D;4_L^@\COI_;N4I#I.8FT QV3L.HIC>^9AP=22(.7K=
M6R+V+J!9139L#4UC)32/KXY_.;_=YXG_O9?T 8]963Z!?;7R9S&/[$U.3#5[
M#Z4URV=,(\< <S*2D*4_OL2T=S2][Y&4UJ+8C66LF\1L'7<DO4WO<Y+3@ W@
MF;QX0:>;+\N9%4O>S%*N:<E6J\-F]RZZH0M?2$.22D_X/%E:N<T,WY/M:#[2
M9(=L.UEWE/>2%,@KJ&I]V2]@:ND6ZAJ:5M\6G%9',Q4<2[!T-,$B^OB^)#)^
MHT0RC%Z6PW6YT:FK;/"]QFP?1$M59.\*4M=9-JH.);<IB+X=Y5D., 6Q6W$/
MCH+-463%=F1C2;/:140CYIK!H!OAS%&KXFQ7R]\"9^#>:9KL:([L*HL9(XLX
MBQBD^$R!R5O7XU!QWO F\RXGU+')(#Y'9],%E+I2,\0Q0_,HK7XYM!&E&4AI
MFM.D\I*FG"SLL6P+5H%(('V.!9P= 0[7F4^&44[ZHE?=FU1QC9%P!^"_CB\X
M\*LR&':K ^UN&K9LZJ)CW?&275U57/60'?CJ\#+9<!TP+)M4<=*42-9>BW)'
M@U$?(RY "&'D1]M, SA86^G=6XCT#';YY];9XNB]G,""@BN2Q@"U; HEEQPC
M5?G-;G545Y$UPY4M<]&)^T68[$= AAN+^#<C0P?(4+-EV]!EPS2;08;"GI^6
M^,44R&0P3&F/QEGT1*4HAG^OZ( D[*O:FS.4N&#-@2^F,7'-$/$YR;(;FM^&
M#^3G^MFA3GW9H<+*;RP5UM>K87,J?%4-N$JKH\N**H:Z-R]?--LTA4%45>Y8
M,TPGEUPQC%1E.Q4;Q<NZHLB&(TI_!9'N0'%L3Z1:J^/HLFTILF5M'1@ZRMK?
MIJJ.J5(#=IY;596LF1,L>J;O!C+'(LGJK];HQL'V<DVO<U!"C7AO>/]7P?2"
MZ?=2!%,+TQMUCE!H -,S4^=]CKUX2^T]98T,2/H8Q?S=VBRW^120E19DU/F3
ME[[OS!H!4X]9];,W3N!^Z%&)^!@))?$S)K#%28Z630I?QU($"WM,P>H9DI05
MSN<]FE$IC&(2^Q%SI$E.6<'$PD;7@D*Q%L.$Q0Z3C!VZGJ>T3_+HB7[X$05Y
MKV23J5\55*%,?D(\H(%1OOHG.P?WZZTL&+P_G>ES=N'4G[A>Y*G(5%P5U'J@
M@CUI.)00H&I'L1S3<XT@=.W?5=5IE;_JI1-#^9&>>2DEW\]("'L\)_T?Y#EK
MO9\E8*#>:;C/@VPE8,*P%L L6-< &,Y%(&(2;+L!" 6)0%.\"]9$&K,6J9>B
M(/[#ZPBR@;50@"#38"$19Q'268;\Y<)%?T&V[(YJEP&DU;FY^L?UER_?;JYD
MZ?KFHKV2G1NZ_/N'[L/5EZN;AWOI]I-T>W?UM?MP?7MSO^8^8-5,&4S$#],^
ML/H^&6;TO/SP(8BR89\\GT<Q6P/[T8?B687,0H:;4SX,2OSRA!>QQ /YL?"X
MBS<7E]OLTIPJY==LK>W8ULK+2EM=>>VEQZIJVU+=C1[[\C7=,7:R6&V]!;T2
MU7@UU.8NW+K$".>T_S8VI[-6*..?E*32%8BU8)RJ+NFJ/&.D;0N:*7=I76NM
MV4!#AWIEV[<JNSTID*E5B.H :M)?5SES?03+L0\U3-.JA[2:4=[=J*#R+K)2
MUNQM]Q4<*I+Z/19,#N@3[2?#P72#R4,=Q;7F_@]RDE#]?0M=F[B*;Z@V,13#
M46S/LAU5HWK@ZX%BZ\'OEZA^%%51S]8*[)9DU8V#RPE177%95#7 8[8ZABV#
MHR,;YA%FSPNF.E*F(A95E)!:P#BNX3JVYQ";DL#275^SB.<SIE)+IGH]<%HK
M4^% >QL8RI+U1C%54W*$]JB3?Z4QQ:@GJF02#*(XRO*4A22/JT:@^6JLP 0P
M7'<&#QOR'!8(F+*K&[*A-VFJTHD7"31?\M=,APZC0]MU@0ZWS@\]PBJ!723Y
MK$ED/,LG67#?3Z6O:/-UPCBT4C!?U4Z.KMOJ6+JL.)KL.(?1RE'T&3U8S;$M
MM<(&6AU3ES43%(935S%!PW)%#S7*B^4A4I@F@U)A)/&1C?==D\&J%'!NKP]6
M5'*.66U2NU.9V=07=8.H(#X*"MQ>QN^0 K47Q?VI% _OZ=2.U07S2F#I76'Z
M_[+-R=VZ%IGH:[O7B-\UGIS3+-^^"OQP)>@>7;KK^ F C\%T+CA+=%06GCJH
M;\N0=;M)416AP!ONH]5&?@;H;DTVU2.<$<2)R&WXP>=%C\2/V,M#"DE4-+_&
M%%QP=J,G%K%=.BOHP!LL-%_ ?XM3"A#X#PU^)5&,=O%M?#G&2;9^@P]5,46'
MCQ,@P+I%?"4"7$/28VL_V= ,V;&/L+'?80A[Q*0$9 1+A+6/HJR'*IR+>V^S
M"<TG83[5?D@/>,B0I2@PU=4,,F[#2T!%%?%NB_&>)T""M9_/5R/!-02\T^HX
MABY;:I/R1)IR/M^$2$T1G3NNAGW-%_8E_)=FOKPLVD5OOH,EN+<]7:E <:]+
M<E5I=5S%E'5ML3?!^J<IS;/1#UF(\W.6[27XX=I*S3@P1S3<)'$R>VRY*:.I
M8#+9LM644TMAM#=/LK\-(6JMCJ7*AK(8F3F5X_.F9=5.'ZR+3-JFV/+U<9S>
MZIBV)5MN795,(I_V2&BV;F^@/IIE4]=TTY UN^96A2*M=KLTK!N:2_TDJR&5
M]JBXKHJI1HGK>Y;C!'I(C< R/#,,;)L$ODU50S/TC7T&P,WFR8VJ"9:9)IN*
M):MN#>FUS= 2)]>7^Y!<B^WHU0*[1I%=106:71P$VS!Z/<(TW36&MT5/44#C
M(,.3X*\TH'3 >K5=)#%;-WZ^2VE(TQ3N9LU.Q9'!V[H9#W0P3%*2/O/VLI<E
MQKK!OT8\[:["*8):WP&Q.$4X:H6P'1&NH1P<[.!ARZ:U3<#SL \6]D-'I7\@
MD2<2]9FXSQ,<YS9(<"T+ QDJ]M+:WA9K7*K4^@V!JFW^>.3-S@Y99@S0;DFP
M#\G4T/B"6C^2+/(K2R'W!%TJP;J"==_:=ZR?=36L[%=ES79EQ5X,G#>,=4_&
MNV2XY.TX(YPI$$CQNO:&-.1C9=GW/9*N..NJ$$:>GWQQS/*KXNX/6(#=T?0>
MR:->&T1;*<C*V=;E>R\Y82^32>K+H8)]K[P0M(OKUEH=K6TM2M'M7;,UZ;'A
M34R%3#E-F;*E<50#9^H;290W6_<+LA!/B-OFXN%PXV7*R42"%FTU?CL-S@@L
MECQ2">QP'&^1A#.&628EHSS+X9>PWUK/F2M+U^;)F97LRD&WX^."OQ<8['($
MWC#\W8:,6;/;"=8V\[G,AFZO$$,+NZR\0:Q,-=@(3E590W1M/6MXGS;1;D[>
M3XZ#ZSYKV36)VPW=8$TBRL'!.;+J6#)L]4 Y>,4,S36G&S(O],7)FTYCQ\M=
MW'ZY^WKUV]7-_?7?KJ3/M_=KC9G#4:*P?#%G3LR96Z; #GG.'!5SYL2<N9V#
M[$3GS+V<*BW.2<4YZ5NG.%0V=T4"@V#,TV;,9B:_ZXI(?F]@R)N7T@)2ARGM
MT3AC/2T!O35TJ5XC)K#O!M95ERB:;70FK0^E1^R8]PZIY1<IB7G@:)S3<@;B
MX2P#(<"_'Y#T.RWB$=0?I:QCJLQR89)0RLE/T;=CKWT[+J8E )?R$TS_EO01
MLI->E_=C%';3*(-+E_#/^/$.H) $H"9NPP?RL[*&4%L=7594T?#C@"AXG[.0
MFD*WVBJZ/:G6?ON)6%PL6"Y;)4D6\>YY8^ T':@Z0=-L*=8(/;Q$E&TLDO0B
M"N+*VI+Q 9LF&&U% H>1T2@$@!  ^XJOU"D #!9M<5Q'-MP:.E7N4P"L./PO
MEKSJV+[S)R]]WUEY6%[SSVJC5_<U<F4Y @\]*A$?HS8D?@;X2G&2P\-)"E_'
M4@0+>\2)\T.2<O>Z1S,JA5%,8C^"[[.<Y!2+E+.%C:X%A6(M!J8%#),L0IHZ
M3VF?33^89 /\/[,1C()XE,E/B >D,LI7_^3M<S*6P_O3F3%G5D[]6243Q1AG
MHO32263GD9YYX+-\/R,A[/&<]'^0YZSU?C:[(XK/IN$^#[*5@ G#G26K<$8&
M*93P::7G(#AHBG?!FDACUB+U4A3<?W@=03:P%HM1 =-<H,QG+$(ZRY"_)#;'
MA-GYF=$VFYM/]%OWYM>K>^GZ1OIZ=7EU]:7[\?.5='%[\[>KKP_7^/GNZ]6G
MJZ]P4;I_N+WXJ]2]*3[]=OOY\NKK?5$%+UW][[?KAW_N3U*NN7U,&LFDJYFL
M$>Z7ZZHLH87.$KYGSOQWJ"S>-B7+==HZSZNJFI&E:FW7V2P]ZJ7'6FW%7'UU
M\X0LS=CLJ2^MU6Q;JEBK6.OAK-71F[36MX> T;8;!8&7UJJW[8.!J]EVQ5IW
ML%:K;1^,=$'-O5XJ]=8IN L)I87)T\R<4GNM<XJ*O017!SXKI#U4@?1! ?-^
ML2F7Q!NQ+4O;G8M::#JOC=@V=;[QR<YKPA)^!0_K[C9'_$C!QAW)[MF.,^R/
M''KZ&XN]HP,G[R"UM@K9KM8C37XL)+0<!QB[L%8,'9(^B^O<D2@XNX[9YPLR
MC'+X7@!W8^!.NBPSB%[2,/*CU7-U!42K0I3E0W%JG3Y(9-_PT\3WTCO,@UHX
M_1- 7QOH#TE>B(<E1BC[?FU#M"S2/?I"Q35M E;N+DH5J\F 03**UQ&BIP<:
M04^"G@0]'2\]\4*84P>PH,J&4.4;WMJ4*C2W?$84!X#C\S.W_JJT]1#ZD?1)
M[%.)Y-)?2#PBZ3./+?$,#W5Y24"5RIS#F*0U#ZPZNGGI=F";BD%U3=.-4+5=
MTS8TWS1]S[<\U31_OP8(*U4'IFS=M4LW6QU54V5;-V5=T>MO8R6J_1M JD=6
M[+\E?RZFHN^&.2](FF)6,5>3W3Q/(V^4\V$%=\"WU8<;Z5:K XRJ&+9LZ.8I
M,:M0,NLHF3#45$HL336I81 2.HYF>HZEN:ZA4\T,]J5D[%9'TQC9ZM9B&=41
MDZW0,4+'[)0W=Z!CG%;'EBW'E!U+J!BA8N9'6 >&9QF*9UFA8>@J=8A+/,7T
M-%]S+6+[^U(Q+EA&JJPI+K@R6P^./R2R%2I&J)B=\F;]*L906AU5D1T'W!AC
ML;G@$3-KE6=L$Y\7*NP%%>:;E.HN]4S?]@W-#9S --P@,*EJ649(C3799&N=
M9:C !K)F6K*EG!07")4E5%;-O#B51,2UUC)^TS#6O=C%07":X+03X#3;MS&B
MK1I>8&@V=6Q7)YZN!\37P\#VMN"TBFI/;W4<\-0LV=47&]@*9A3,>*#,6*7Y
M$355Q:.!$CA4-4+?=%U7<:FMNZ 0[<!Q5W+CBIY'-;"ET>K8MFPZFJPHBX&_
MAC66%BPI6+)>_6@%/E$M5[4]G9T$>[;I 0^"5:KJ:JBN>P;\&B.&T4\:G/V'
MILDR'C1;'98#KWT0BE%PX;%P817%&!!=MPUB@Q/H&X'N>R8)M% -? QG&AK9
M@V*T6AW+E6%5LFMLTP3TD"8NL'=KSA)FFL]4;!*AS;P3GN&?13_/>E$ BSU'
M3-JMS@6O]<(NQX ,ZK/&?B1(AHPP\;/O8YP;NP&RP!Y)@S&&5R2ZOA1M70+>
M?<=4YZ=W+8=EH8<JJIT7J&E/#6L%E@26!)8$E@26!)8$E@26=CX%J_8#>T$$
M32$"@26!I3UAJ4H,1?=<QPY,RPD<P_ 4S[&-T/8USR>FI_JVNH<8BM/J:+)F
MV[*N;S.73%#=VU)=!:)3M,"V3"4DNJ\;GNUCBWC/477'"XE)UTX^K('6W%;'
M-A19,;<^76XPN37E&4=)]I6$K:930]<=GRJ&H>BAYYH._&<1BWJ!Z6MO+VQ-
M3*^53=T&@;N8"K\785M3J?UA1J6OLVS$RNJ34"K;A$KII)'M<-R\-D/<2Z,A
M4!S]25,_RMB/?I T)=-39C9(]ST\)JR6U&L:H>/;BNO;EFKX@>-J5 E#UPQ1
M*VFNL>Y4S)C^C!:J4Q MB$4:3 ^ZY G L%EVJ?(D;Q/3?PU3!B V:.+E'HJI
MCH@T%]5#772YJG!J.6G^C?1'='/*Q$19V3 %71X876[FR@LL"2P)+ DL"2PU
M $O[+PP41+!W(A!8$E@26!)8$E@26!)8.G8LG73*-I_BEA7)U_.A\"C.$X )
M&\N3O3B6Y\3.H?83 R]&[BT+@U>.,>J\\:SC*$L;SXJ<@,,CRMU%OZM1)(M^
M5R9(H^BMZ@!-;E/_*NBQ*?2X5$AJ/J W\%PU));A$,UU'(/:@>G:IAF8)&B4
MD#1?;)PJ:/+P:')11NZ'(#>3D=9+O4$%.1X>.2Z?56"!FK8-0FS0BEJ@>]0,
M->([KD]5RPGU1HE(^\7&GX(F#X\FE^38[84@-Q.1SHN]+8^"'D4MS*ZSV1SB
MF\15'2"GP-"L$#Z8A 0AU5W?"H.U"7XFJ715!MLD!',;%HP0>7UZ3WVX-8\V
MD,DNXP'5,,!TW;K??X,9X;0H=5$NOQ&9,D%<.Y5:+$U:4;?N%BX(M+$$JMLF
MU2W'L!1--P)5\5QBA*YENJZO^RJUFDV@:JMCZK*EJ;*Z)"(EJ+315"K**@66
M!);>7.(3BRI*2"U-4US#=6S/(38E@046B681SV^VQ-<*B:_)JKMU2_@:J?2D
MZ[=FCZC]":*!;KR\IC-JD3XADEP$E@26!)8$E@26!)8$E@X32Z)^YU#.1MAA
MX"8'(Y=@]5?V[/16!QP[RY5A8:*L^DCH<W<G(B\1YTNQ!TZ;B^2'R8V6+0CO
M: FOKI..[0BOHE T@2H563-5V7+JFH HB%.8;@)+ DL'A:4]''"\J:"W"D&O
MR8I9UP!.47I78U^ZZ?,+*8J1Y&+*:?%'E/>DO$?AZRB/2%\:CKQ^Y,.O0HHD
MTY9BRJ:HY"FLI2!@/\DV[%=WL(>4XBA98$E@26!)8$E@26!)8.G$L22*1 [E
M(&2M(I&-F\E:-M:,&H8J6]LWE&TPO9\60>ZW%F2*&!?IS<'Q#Z*HXW@I[2V+
M.C87>U@#IQJR:2JR:8LBN ,CQZ,SQP26!)::+]K?LGIC8]%N*Z5H5V5=;5)A
M7DUE&@NG&*M>&D1/Y;.+1W!G3K.'BT<?^SGDN)J:H\-/-_BH]\GA!&SB5(X9
MQ6&PP)+ DL"2P)+ DL"2P-*)8TG4:AS5$06[>,NM^]+L#RH[=RKV$S1DR]UZ
M>G"#*?^T2'._AQ4KR'*1\C2@O,7AZ(+HCH7HWO+<HAY9B#WZ9=4R9=<5A'E@
MA'ETUIK DL!2\X7\6YY@U"/D#2[D+5G1MLZ:$*49]9]:_"!I2F)132&.=@66
M!)8$E@26!)8$E@263@I+HIKB4(XJ6%W]S6C@T?0V_'MANV_NG>$$.-EQMRZ:
M;S!M'R7Q'9T$$E@26!)8$E@26!)8$CGJM49[61S_S"-@'V(CGB&-,X(VGDA1
M%P=B DL"2P)+ DL"2P)+ DLGAR61HBZ(0&!)8*EQ9RB[3V_N!O\:9?D 7//L
M(>D"X' !I']'HN ZOB##*"=]5OC!'.>+*;_Y*_WW*,JBG-[3]"GR*4^9^TK]
MY#%F3V'9<Y6/8JQ6QY1=VY5MITF)<H*.A;016!)8:J).J#L;NG$ZP6ZF3J@I
M>?J8@NS?XI3"JO]# ^F11+$$A#L@Z7>:$YSD2YY(U,=/9T  9QF@6<K&8YRW
MB,.+<R)QFB>P)+ DL"2P)+ DL"2P=)A8$OG7@@@$E@26!)8$E@26#AM+%>*7
MH1^JCJYJQ/4<P[5MU]54:NF:$CJ^:]'*?:)N\QY-,2R9TAZ-L^B)7L=^,J"3
MX-1O21_!^2N)XL])EMW&]^,P5#>-,K@TW0;BAN:WX0/Y63ENZ> X>D7=NJN/
MH-W&TF[=L??&T*[;/-IM2E*[ZNPKO [8E/J =)&S+HXM!98$E@26!)8$E@26
M!)9.#DLB9UT0@<"2P)+ DL#2:BR]JU):$-A::/JZ8OF!87HZ,4S?-Q5##RS5
M4!7O]5!6!MO]<^ML/J9U0W,>Q,)X5=5 E*.T.J8BNXHJF\KBM(A?!.DUE/2$
M@#@$+%41$-O'NG<B(-3F"8BF9(:[>T@,MY?2V4?2)[%/)9)+E]2GV+A/TE59
M0D+9/O.[\'0X/,YUP%J0C##CG#D[Q=4\&:YR@PZ'7ZNU6]1 A5N6K02&&AAX
MOJJ'Q%9=:FBA:@5*^/OU6H=2#W0P3%*2/E_]>Q3ESWP0U.THSW(2(_QF63:,
M?M+@[#\T399QJS;6##6=+-6!^SV?INZ-O%\4*GN@[C_N _D5D-XDAE_4S[OA
M]@N2IL\ J^X X)]W\SR-O!&KYWE([D 0Q'D5]M<%^V^53"$TW7)-YWM>J!++
M\&PS,$*?.IH?J+;KZUY@& %Q]J#I#$'J0M,)3;<+3;<;;J]7TYF"_86FVX&F
M,PQ/-Q37UXBE&;IIN9IO!:&M>JIN&I20/6@Z2Y"Z(/6Z9?QNZ+Q>&6\+PF]R
M-9_@J^4JQ-:M,/0<L)0\PP@]Q=.I:NF^8BH:<)QGK<E:K^B,-4+W3JNC:;*C
M.;*K;-W9Y7A82'A)PDNJ08/6Q>;8.+^7] %T&5>BE?G<Q?E*FJ,+%A<L+EB\
M1A8W-0+F<!BZBA4:%G4]XEE68.G$-930H=J;L;BK (NKJFRX#NAS6S"Z8'3!
MZ+4FWSBN2FU3LP)3,0(G)(%GFI9EA)8:ZM18K<Q7Y-S4P/)JJZ-JMFP;NFR8
MYA:9-X+;!;<?/[=787;%,$RJA:%N$,,*5<<,+<5T[,!V3"_4_;=3ZUJ]9>""
MQ06+"Q9GSGG@A88?!B%XZ89OJH1BC)OXMFXXOF=X;\?B>JOCZ+)M*;)E'8/A
MSI)OW[.8?IE3.I4?._4LGP(^TH)2.G_RTO>=V534J9\-2/H8Q7S)VBQ?SCRF
M-H)S7R,X#0GNH4<EXN,X0Q+CL884)SD\G*3P=2Q%L+#'E/2E(4ES*0FEO$<S
M*H513&(_@N^SG.24-?K>>N.OP*]8M6'"(X9)QIJ!GZ>T3_+HB7[X$05YK^2A
MJ5\5]*-,?D(\H)91OOHG.T>,JJR%F4]GYEQ>\]2?O722KOU(S[R4DN]G)(35
MGI/^#_*<M=[/(@$P, W!^<VOW&(8UK+%A9QNV"*G!) K2<IZOY^#%* IW@5K
M(HU9B]1+4=[^(3(55]4,.U =334<2@B(&D>QP*!RC2!T[=]M8"?6IAP8Y0)%
M-6,+TEF&QGU*AK4@TNK</W0?KKY<W3S<2[>?I(O?NC>_7MU+US?2UZO+JZLO
MW8^?KZ2+VYN_77U]N,;/=U^O/EU]A8O2_</MQ5^E[DWQZ;?;SY=77^_90:?]
M0;KZWV_7#_]<R>A-V?X_*4DSZ0KH(!A7''!=5I0=:" A U9_(+U#=$?QB :_
M5-[7*W)OV<]X,_RQB&.Z$,#2)\.,GI<?/@11-NR3Y_,H9IMC/_I0$%LA%U$4
MS*E"]CY^N9 2KM-V%!<%15&04KRXD"%M)D/F]'IQS6C;CKKRLM)>?>VEQ^IM
MU=[LJ2]?TW1G!VMUM,V>NH^U"K@*N#8+KF\/ ;NMJL:!K-5L*[I^(&MUVAK7
M(@>Q5M>V#F2M=MLTM8-9J^VLM]97"F!?SQV;"M#-A!)>CA<L&M_[B0XMKX']
M2@-*!\SX X.3+0P_WX&#0M,4[%06S)D/M6P$OHT@?5# G Y\C5T3%@"; 6!!
MB'-A"'346AN#S)VGS=<#60V')?P*'M9=@_1>W_&I@8T[E=TS34!O"^CI;RSV
MC@Z<%\E@D,1KJY M*!$>DB8_%I*PCP.,W: <=\GB.CCS\NPZ9I^+R9<"N)L#
MU_='@U&?Y#1@$+VD8>1'N8!H;1!E[>,YM4[WD&??\!8[[Z5WV&5G(3E' 'UM
MH#\D>2$>EABA[/LW,D2KH.H@(,LK2G9.FL<%-%[*5J_]="2@$?0DZ$G0T_'2
MTT:%HT<'8$&5#:'*-[RU*;.0WJ+#Y'H(G>HP^1<2CTCZS&-+1;;']B.33K=>
MO'EM)-WZFFM5PNZN<\]?Z46\0Q(]W.SR:GL_3+8\R&:/;GTML Z)285..<R&
MC6Y];:P.B5R%3A$ZY7#:*KKUM=PZ)"85.N4P6R.ZCB!70:X'VM[0=4^;>/<_
M8O$D>*/)+0HU1:FS1>$AL8'P"X1?T+!&@IJBUM1(4#"B8,2F;/H V_W!6VIM
M]R?84;!C4S9]T$WY-$6OJRF?X$G!DTW9] &VSM,4HZ;6>8(1!2,V9=,'V.!.
M4\PZ&]R]"3?6-#^:O5MSEO#1?,I>DVCL.LM&+),O"6'SK*HQ0R*0PC092"V2
MG^4]>C8@Z7>:M^"F$-X2/THA\:,^D(<LQ90WNTMA#06=^DF6K\Z076.4S.'%
M6XO(_6;]&QO4;U5@26!)8$E@26!)8$E@26#I8*<1'AX15,R^"CR%:"34O4 Q
M3%5Q T)]S_=M</%LP[-^O\0Z'$555#P_T-;S_- 9H,'E"$W\.]A$$O C?=@@
MNY15]@8M#,NHCB&[BE)3M_,FTOMI$>22_*JWH<:_D?Z(3A'C(KW90&^J*RCM
M:"G-=@/-,EV'$M\WB&E[1*.&89HF-=T  UV[H;2*8L]I=4Q9-4Q9<878.S!B
M/#IC3&!)8*GY@MVUB:OXAFH30S$<Q?8LVU$UJ@>^'BBV'C1#L+NE8#>4)ED9
M36E0H-E[Z%"PG/2N?M+4CS)VL,%/-)(A8FEN^,XFB>*'QX>;2<OE1-*(:@&!
M)8$E@26!)8$E@26!)8&E0ZLU/#PB:/#Q!+MXRZW[TNP/JKIVJH*YW+*S?<"N
MP81_6I2YWW.*%52Y2'@J$)Z@N:.EN;<\L:A'$N(8>EW6S+HJL 55"D--8$E@
MZ:"PU-"CBWHDO%Y(^,62Q?U1Y4F785R0K->G62;1J6.+XL "D3M3F[%.\_%=
MINZ)9XAGG,HS1)IJ(^) ,?T9\?Y2'PDH/)RW1>.,X JZ:4KB1SH L?[Q>7++
M'7G&K[H_2!KP<7U,=9:"=JP[KV.N72OK4*/5,579-K<N<A1)*0VAX-W%BSCY
MOF#6E60Y1:DOQHQ,(#Y!=X=%=U5ZG6P?-)IK>E([!5K+*'#]AB>"^ XAZ""P
M)+ DL-2 T-"6XGO=+L2:6E_'=Y'>NDL:9!@^\]#3P=C0V!L2V:TBH"ZP)+ D
ML"2P)+ DL"2P=')8$MFM@@@$E@26#B \4G=N9#?XURC+\=PO>TBZ #A< .G?
MD2BXCB_(,,I)GQT1>O.GB%_IOT=1%N7TGJ9/D4]Y:.4K]9/'F#V%15DJ'Q*R
M1A".K<BZ);(I#XR.A;016!)8.MB0>6-U@MM,G5!3_N5A!-GMM:CV6YQ26/5_
M:"#UDRR3@'!Y)VR<\2B1)Q+U\=,9$,!9!FB6,NJ/4B -NDV7B8,]%Q.GEP)+
M DL"2P)+ DL"2P)+)XXE45T@B$!@26!)8$E@26#IL+%4I7;#T4)%\SR#NK9E
M.*;GJFI@>SHU%-]V/,.L7+M11C)O\QY-,4"9TAZ-L^B)7L=^,J"3,-5O21\!
M^RN)XL])EMW&]^. 5#>-,K@TG3A\0_/;\('\K!K!U)15PS9%_<<Q$/#V$?BF
M$[#:* )N2GJ[ZNPKFQT0R2+L(GM='& *+ DL"2P)+ DL"2P)+)T<ED3VNB "
M@26!)8$E@:5ZPEF4N+YG.4Z@A]0(+,,SP\"V2>#;5#4T0]\XG'5#<QZ_PE!5
MY1B4UNI8FFPJEJRZB[/$U@]$"=(3 D)@J9'Q[NT$A-X\ =&4''%W#WU8[*5T
M]I'T2>Q3B>32)?7IP*.II*NRA(2R?0YXX>EP>)SK@+4@&6'N.7-VBJMY,ESE
M!AT.OVYU#%X'F/9\^K@W2GB1__9 "'_<!_(K(%WP1J-/YH7$/!6J$!)32$S!
M&T)B"JH0$E-(3,$;1U.U<SH"N=HL$<6Q3=?UG) ZU' 4P]'U,/14-S -WS4#
M[??K]:9KL6??CO(L)S$"K')@SFAU-$M6;$<VS*TG=QX/"PGU(M1+#?U?ZF)S
M;)#=2_H NNSJWZ,H?Z[,YR;PN6PICF!QP>*"Q6MD\=!77&)XIDL5SPBHXCB^
M2JE+K-#U7-WVWH[%+6!Q39--PY9-?>O)[X+1!:,?/Z-7.5K7]"!0*/$=S+1Q
M0YVXH6.'6F#8"M4,HJSD]!4GZC6PO-WJJ*XBPW)D:\F(\\H58(+;!;<?,;=7
M8'9?"PV#*L#I5F"$KD:H2PDQS<#1#,W2K)K4^HL#C#2G[@%&@K\%?PO^1O[6
M_= W'2O0::@9MNNX;D LXE)3A<]!\(9FN]OJZ)JL*XIL.%OW4&T G[.\NO>L
MK6B9+C:5^C;U+)\"/M*"4CI_\M+WG=DLLZF?#4CZ&,5\R=HL7\X\IC:"<U\C
M. T)[J%')>+CS#(2/P/@I#C)X>$DA:]C*8*%/::D+PU)FDM)*.4]FE$IC&(2
M^Q%\G^4D9\.>LZTW7A/\7GE,L7G#A$<,DXPU#CY/:9_DT1/]\",*\E[)BE._
M*LA0F?R$>$!THWSU3W:.7U59"\&?SJRYS,>I/W&]R,61J;@J2)% !5UM.& G
M !LYBH7]4HP@=.W?5;34BU_UTDD:Z",]\U)*OI^1$/9X3OH_R'/6>C^+.L#;
M--SG0;82,&%8"V 6<D4!,)Q^0*@E*>LN?0XBB*9X%ZR)-&8M4B]%8?^'UQ$$
MZ'E@C9"!2R]03S">))UER%_.5OI;2*6U -+JW%S]X_K+EV\W5[)T?7/17D<J
M-&GY]P_=AZLO5S</]]+M)^FB>_^;].GS[=_OU]P'K)HWM1Z+'Z;N8/5],LSH
M>?GA0Q!EPSYY/H]BM@;VHP_%LPJ9A0PWI^T8E/CE"2^V%<Z/13YY\>;B<IM=
MFM/=_)JMM1W;6GE9::LKK[WT6%5M6ZJ[T6-?OJ8[QDX6JZVWH%=R]E\]L787
M;MTBBW_G[+)>UOX_*4DE"C(O&&?M<Z-15^4E6?O;@G#*=5O7C%P4+/MQ&I;#
M;Z:Z89O=GA3(U!F0[:'KTYNK)K9S'$TMA?WD1R:%:3*0DB%%JP,L?_37GM89
ME[!^4X M:>T-VA:LN\(]U%J]N;^P1O.O*MO=<PQJS?U6#D(U(9BTYMX.O^Q2
M5VHJNUS.CDT. PM6:M+>JK 2L:BBA-0"=G$-U[$]A]B4!);N^II%/)^QDEJR
MDOI6K*2V.J8BNXH*[+28174JO3;W0SY38\^D/)%2"@3C1^#AQX6ZQ6_QLX_F
MV2@#5RB*E]IFY]L;9TTQP9IB:,UYCKMKO[HFL5S2(1!(Q&*!$HD#B0P26/Q_
MV!?'-<IL38CL<6#A-#+@<Y_BAVX<=*=P4ED4:ZV.ZQJR[2[V/!:MYX^&%+>W
M ]Z %/56!Z=?:H[9(%*LR2[@%.4VW&SN^G[*4 DJ'XT['&RY9)KEU*S+R6!+
M&8V&E;&_ ^LEU$BO=I8%)ZWPK^,G6EATE7G.:'546=47JY5$G[&CH+JZ!7\]
M5&>R-!W%6A3T)]V]:H^&_N=BC#'),G#]\# W 5$O+/P]12HG;';)4,$R?6[#
M+F(G4ROS&U:SJ+*V_5AQ8>,WEQAW%NNKF1AM,/-EPZBKJ*I!1OXA*P"6?'OF
M$8SW80XFC;-M@SR':V'MT:QG70@^(AHNIK!0F<F<5L>4T9O6MQ?ZPL!O+OG5
M;=_71'XNDI]KN[*]?1I^\PS]PPCFW"3Q&3O#Z5/ IT1_(CKI1A&:D["?ZI+D
M,?T9G7]&F%]QD ,B$ ]5F<A0\)14D4U3;Y"I),SVADKP]<CNQ1I)0ZV[1E(8
MY[6*<HX$+(5*:98OB'1AHK^)B7Y'HN Z_FL4PY\<$U5X3*N-QX1=WER:J]LN
M?XWFUC G]%;'573951>3%P_>(C]DX7[1(_$CQ22KD$2I]$3Z(U8Z%\#CGE@Q
MJ-2/B!?UH_Q9!.3?5M1?QWZ*)M4EY7]?QY=CK'PND!+1K(K\-YIH8PFKOGD'
MKRNB\1N1Y!KJ@34U-#1#=FS[J%)R#R-:@X<L>  +2X2UCZ*LAT?K7 ]XIY97
ML^>TF@Q/NVAV&U_-(.,VO 145)'UEK#U#Y4$]YUD4X$&UQ#N>.9JZ+*UQ/87
M&3?[-/NSN>(*=J;.,NW[$UV^3:'%NA;;/I_1E B?;NV-&NY2.@07OPSI<1)(
M\AY-"YH00;X]I6(MVML%KBYI2-.4!D6XO1L'MX@OGA9364([F(AK:SH6F IC
MX<#H=)_&PAO1IXONH6*"#>$N9FX=L@W!WJW;#7</&>JD&,^!1H!4\ SGU,)I
M1&":J1 8<O"XE:-F,PXS\;C?E55MZ_"\B N>M/BOAQK55@?;J-K:HC5RR,'
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M-@0_"MX-0,PCH(L,+XZ_Y+O+IC;/B:@'# 18&T.A@%T)A5?7@I06P -H# 1
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MGRV(<?IS"-H.UY/!TE!8@'*D:8SS!H> ]1S#,A$#S5@MXV<NV&GA>,_ @B!
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MFM19:4VL31E'(" 68M=+]\Q@Q^ &%@88 -SSF6<T#SW\TA)G:FR 6I&6# (
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MUL1RT["UI=)>K),#ZNCWX8/\*M7/9 2/'3I>'OYB;)4[-[@=1J?H^\6<MM!
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M#,]0%=_U7<NV#<_1"0V(;QRB#+LH+3KV80HLAR:Z+E9F]Y:V+.;U34P#-*>
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M!R\?DN#R)H)77NI949B*"'UA:>R&CF=Y81S[GA4&3FP]CR0,@=QLWXR"?:K
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MQ47J>I&7V1GGR\6$G=<;S5OO44ZX^=7=I3(N;/@?%Y$=,]>W..-^G#AI9H>
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MO,AXKYKZ4VV7 0H"P\.JR;RBS%[)F(&-YU/TKB7%HI3<5%>L#AO^7):H5G4
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M1111ZJ8\]BP.7)<'69B&++6L,& "U <F4$^P \O=,*&NI8NK'I12='T3@"'
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MM^929_83+^Z+T.5CER>^:WH--_%Q0BND@QK[-^_I%6[?[FQ_ QK$//GKJBQ
M<SQ6*TP2(4!I7;/KB<AZE%[O>9U>_EA\FG:.81%RN<DFF[=B4LR(F^K"]B7)
MW:6?E7!0')$8YFR.B5IY:N!N.A"RC+%P>@X0_=<R8>QH\^U-E_B^O=KUB)0O
MRQ&.':4I]P+&(IO%S/>X2**4A9[PA;\AY:OGXU8ZD@IH]%0HU<YRK,?:H])E
M4.^P64C/8RU5@L<Y:?QIY(FO8:P;><\R<S[0ZH%6FV21,'83H$V@@9"E+ MY
M%M@ "=N/L>/LINCE4]&J@S'VR Y-=Z#-P#[2ZFB%(:/_>WD*@XH!2:]\>I-/
M\VI>RO$3ZU6&&BK..*@,,IX738-![%HL=-S LU.6.&Z4Q)F;.7;L.SR.^+[(
M2\ISL;S C)Q^)M%(&AS&]D>5BDNO7&FRO'ET3 5GCLM=D @6X\*)+8]%;AA$
M;AI9KN?LB4A@J+Y9OFVRH)]P\'SH^&8LQ>]%W6QGC5_O0>:B<HFY<!1IL4 '
M&\GG@X+Z4-"\&EYU+X?]T_,J+,<TP\ R7?_!O&J'>/ R#-$#%SAP@0TUU[ZP
MK$SX0.D1B\(@#GD@>.J#)NWX/$[V1&/QD0M$060&X6O@ J3I_)UB6.U4GG;I
MW%.%6H?/B6*.<H9K=89CXO+Y'65I#,14@Q<84_W>"9'F6%M>+6YNL)2C3BTU
MN-IX*ZETN8>B;*TJ 469G=6KC'PR_\3QPT/D\[#81XLINX>8\NJ@JNS''Y=_
M/U4\^0T'F/^'_A I@>,,%L:O!'W6#9[H#VK7=H!2'TK?=$,P^HOZ,X&<6_ )
M_?U=E#=2G7I'V3Z_O&$0UEV#"#*? 5#YM,H3^HMZ*AGO5-^+)3"]&3_61:][
MG.I?(%%()84]((;Q\+#J"S+.'K.Q[[VK(Y2\:9WT%U7).=*""]'G[%J>Z42'
ME(%#RL ;21G8:2?UX>DVNZ%JK2\H5:'3]7:(G*.CTPBT]K=$R6.>L?6&7@1J
M#]?LW<=SN*,2R8WX6VNY+047=5MGL+0/5=T:M7WKZ#0X"5;VLCK(AH-L>)14
MEGO)A($F?[L3"K7-0^;.0$- WSXZ=0;F&^^C%'@[:66R>\ A=6RC<;7K$/A#
M28].KOJLZO[_@8UAQ]I9/C6M\IW0M/S^N+Y#JMD+1=_5IL0#<7B\35&-0N*1
M=@7.7G=/6/2*,?>E/^/->#?K@1$/=V"^0%;T[IE%Z;J1'NWLA'N/]? Q"]9W
MS##LMQ[LA3U&(O=>N"E>)UZ^!A&I<?;>4M)#L\O;E?=M'Y'WI3_CS5B;Y]CO
M#@?\O$E[\YFDY,,:GBHN5)_<YZ%&<]M(4!_GTGIF,# Y:'L)NL>J^NO$V6>4
MH-OA[2;QV4/<L>(S.#K]O^U=>W/;2'+_*B@EF]A5$ _OAWU1E=:6$V]Y;9<E
M;RKY)S4 !A9N28 +@))YGS[=,P,0!$&*#Y $2=Q5:641! 8]_9[N_CD#I4NM
M3UT)[KIRCXL),C\D:4BCW=*UI^O,'SO(W-&"BLV;I#-/?F,;BG4QABMKEMU'
MH:?#N.<0A39P[Z:&%(?@F@.EK0/ +O+OJ=_C8@+1Q6+4YAF%N\>I%UR.JONA
M;SI6H--0,VS7<=V 6,2EI@J_!X$ T>Q^.:JM8#FJ:YFRJ>R<1MN(+8X<(>R1
MMT^XY&BSES]1@5[NFFPGU1TJ1[55K-EK ,([8TG>Y!X74(YZ3,2.?9:CVAI+
M5K52CMK;AMXVK%N.VCU/KUZ-6O7XPN@G#:[_2=.DH4K5UJ]N6,>^]O8D#,3%
M)#\1=8<&B$Z$(Z\8.$Z>"-B@_41PBY7&]<$??0AW&,'F>W\;(]P5V_J'!/^T
M>V1GM!C9;<8NI]-IN#'3G[#]WO#M3U34.Q_<O2SOF\9\9CLQWTG)^";W6/^-
M3H+GNQKU;<S8RX+!9MC!^6#0:B\8[*U);TU.+AQ\6=C*J2W;AXMV:^'B86S+
MQ1SQW560C_=[Q-='@8>1Y\J.;AGN.=COZ)B:K.L[SY7I7D'?SGQZPJ:VZ15/
M5 0['YU5Y'#3,,Q%EW3WV=S=D[V63&EGV;2K =5R7MPA<G*4JQNKI:DNO<Z^
M$)V]1Y^I'?F8CW'4#8(<1VW[3*P_^=J ZW@?,S#;$S\"V^]Q5Q_-'$8R/R=B
M/WDL(X;K;SS#Q6&0?:JJRZK=UJS,#N6P=^;6$[:/3:]XHH)XF)BF#6FL>9%L
M0,U[DM,/)$KG)YM59%!'?U%KZW2I0^+7DEWM+*>V'=:TTFL-O,A3UWLY%G(,
MG,;:B6.A7GEWZ=T.%]SL34IV/\]QS+;/<PX$ 74:,$K/0HU)A.LQ*02S*CTQ
M@ 2(:1 UB>,I9=(//IE2"MA$)_810YF0*+Q)L"3\8?#(./I4>H8HZ5]/H?-R
MEPEYZWDG.'EC8"S6MS%B;4.C'7'@ND@C^^I&50?JXG0O68*@#(^/HR<ZG ZD
M(V"M5=^X.LT,7X93*LLF(_ZW);AKCL.W,(HG0!A4A)Y.B*V"YO84RP@-A02Z
M&02:;_@V@?_[=9RVAXIH/M.4<J$-I$E62.>O0U"!U_ "R1"4!K_V>@Q$P@M&
M24"'J(8W%^0H?V1?FD&PD=G[OEGJQ[R,J 9?%#3A4+I(JY?I<G-@)#;7'3BF
MO@T0FPT?.MMA=ZU$X-(&IFKM!2[,W,]BUP.CNU"XL+FLX>4!-Z&.N4Q IJ(J
M2GI*AJ  AU$^?2%[O"\LBY?H4SQU@9&Z%BG%HBRE38_2:,U;*AV@BK]0,,$?
M)0]\ U?I]RB.1I-1Z2A=:S-/PKVZL9W!HJ/T"[;CG#]ER,]EE'&5JQM''RSZ
MV;_L+E9'@YDY;]'<,9#1NR6:KLI$<W$VU!:B>8J462&:V!<-X=U:HGDQ%;+?
MHNS/ZS"E5(I08K&3,D4$R^VUU>Z4.&U]LJ-!VZ_4X'9_@-W^*#;[)6VB7]VH
M@T58D%]XH)XG(AUZY@1:H52P>73@**W:^\.4&9ZW%';:=FTJA>;5C=*V%.Y(
MH/WZW9M*H85JREA/"B\OMH<51 &- VD:T>%+<V-WH\0A<SM=M-[M'6NL\GG?
MBPU%L6B4!QL4Q@IAZ%YQR,GS36>.PW;B&^=EOKF8R*A4G\"8HSX>6K-NRO$#
MJEF:99F!:BC$(,0U34(#70TA E?(/MM!5K'^FH51KGMU8\Y<K>) L='1:GQ_
M&JJ.ISBNI82FH01@/Y0P("$Q3,UW5)=V^_TMA76]J/7WYX>U?4AS0$'20V*I
MJAGJBNX91 ^]T/5LQ0EI$%+7<;U]HF6WP4@J"I*QO2 % 7A@X'8YAF4;7JA[
MNJ-:NN\K(%I&H-&NO[^VF2#-5W?5JA)>KF3H4GU7GN1D6"OJRK!DI:P=$3TL
M^ZKJ:M>E7P*8O?, F*)4J60V=;VV#VO&8SI6\3;4=,'&#N$7^>7BKG:]V Z3
MRF 9@A6DFJ_P0CZ.BOK196Q,"R3)[6J:@(W)>)PF/V'-.3RU TR]>T/X#!KB
M =7 2X#PEL)R6\MYN",L? 3"L(K-Q=.J)1R[;LE;5PS%[8K^11EE*:4;*_KM
M*M(7=_QN-!XF4TKO:?H4^;29 <IF(;;7&=O4ZN?ODBS_G.3_0V%Q?O(C!MK,
M%6XV;;D]-ZQK41:P.IH9UTF<EC<%&LR>RN:BQAD%YA@2,1ZU[!DM]%;^2'+I
M&>XI>7AA>:,$7&>)+-9GCQG;XM-7.6R*:1M6:*B!I[J&[JL>]34?=)'A$E\-
M#7>-R&=OA!?F(TG%G_"Z=9PXAU5--SMQ&XH<#S?^,<GR*)SN3^C8'=]$0)/(
M7UWYQL3P&U 27@EWFS&G]!V(D^WP9IW1+Z@>BU?C9ALUA_0*&SLTY>VW^^_L
M-_7M:[AR#!<C !(SXJP7 P4'1(."=I62N&Q,0$8C\91UA]AO,Y2]41(7#QC#
MK\B;Z-6*+\!SN#<Q[P]3XC_B9U*42<SW@8>PZ_UAPHJIL69ZO:>*+P8@[G@]
M:YFH\>9B/%'94T$V PN1Q_!PO. -4Q_P[J+^6(2KE6^)ZF5E]A7B9<EPDB__
M2@>B;L8:'ZXKU9Z</I6?C^FLA/4'O?922OZ\)B$L]PT9/I-I=O6W>9$ >2B#
M>GV 5*P38.EKAF$KK]DDVEP.P<HE*=OR-Q,0R12O@C61SJQ%>DS1>/Q+9"JN
M"D8[4('%#8<20H+ 42S']%PC"%W[_\ VLKX&Y'%L>$1Q_?O?R/):_\.S6[.*
M_4Q_?AR-)C&5I8^QOY;5L)H.1XZU_"\/=_?2PQ?IP\?/MY_??;S])-T_W#[<
M_7[W^>&^\\3_L'E@MD'SR#'>2-4&W%1?,\](JKH^TJNRO^=UDX9K;'9Q3"5P
MJ&K9MA\:OF,Y@1K:H>9H@>*Z&K'V/_ZI;'?Z+CR[F5?"WI3Y)-^2X1!V$WV^
MYOXF2W'K_4JGZ;H\S/4Y@8, ZGHR@O5/4?>ATX!QP5.43\N\ TLH?!W"6JN9
MB)7\_F8W]_6P_4^..=#TK?J?+'W@*NOU_FS44F0.G"W;JE9_9CC;=56M7*PU
MT+3UVJHNM/^)C]]!\:I$#9.Y4.CRNJ+^NYX'8*$%#S1FT<QE]DU]+^=P@=>0
M5(%$\U+?2D+5UH.-W>!G+@U 5/%MTZ2&K[I4-8) ]U1/=8%A'=73',6E+*FW
MF,9MKX#S[J\)F-J/,>B%"4-)_H+9R8='$C</\7IQT$39<6ZIRAX'AQ\1B+ ]
MI( +@HW;[.5/5,27SY/83L[;JYM;7\S7F"VQO@9H;ZKF033 $:K_:K[3-5[_
M1G6.$9XQWOY//I.FAPQXT703CZBZYVB!$U*#6*I'(6:R7,\S7<,V?.VE,^H#
MVO#YZ3$;SM^T5 TQ!4S3D8'\'9J.VW9UWH4Q]8KA1[MQ]@&MULYCD2Q5QPH-
M8[']Z**F/G?-"O'"J'[2\SD9H?EBMTV\2*.+ PO;[C"Z,&X^!^LSS]&M!D[=
MG=%YV>'1AR0-:=0'2&=FF\IMW<8\65V$#NF#HXLW3X*I)R"9K=JF]O! 3SMH
MZMC9W)Y!<T3F5=0UU'%;+_@(3_-5WW$\1:>:8WC$)$:H!2;QJ*V:.M7#)77Y
M73G"6R/_Y[28_VN1FT[CG*]]@3F;4\#=2'.B.F2Y9[&=(NGH&>&B%G';2;1V
M0(&T@%6QHC13PRK[,^I;V](^'JYOK:%735.061?'C%9[U;;K4OMV_SV3I>?'
MR'^4X 78M;ZXJ,U^M:W"E&[WJVGJ7)?SRGZUYIX@5A'^8B\&D.FJNP7R^MX!
M.C[&P,WT@?Q\'V78L 4!Y&(YNJ;5X39\SW%<XAA*X!(#[NPHOJK;.OQPK8 H
M6KU\G3]&@N?0;#7$16-A_\N/FU\>==W \Q33])W04"S?,17#"D/?H(:NJ(9Y
MP$8 E(\D9A8V+(E]QY7&KS2F890O:0+0](V; +I1\5_O\1NGR5.4X69B27_$
M62%'5D"Z9U&69T5[X*Q98(LY!&OW 1R\Z!_<Q('"7<6-44^T@6/OH9!>'8"7
MMA?4$V,OB]766]"%5OWWJ"<7BGKR;I*FL!T5K3I3MV]>2 2V K+0QA3-_<)
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MSA<B=:RA%=-\(IHM:<TVS1-LS4:<<W2EHA \B3@'HA8P[T63=AT%/2@P'_!
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MAU0KX/,/"$DXZ'S!N$"^1C'!P5A)&'"AR'HH@NZ2.5@H>Y0E@Z0Q6OD]XHE
M_NK+7V^> [>W9U]K&/2G&"\:U9REB6J/GS21(&.'@T^?/NT]2\,JEZ#49%3Y
MOORS/QCV#P8-JJVR/?NZX5<_H=N&#*M.U4R&A&Y#&4K[4Y4MF"C5[\!2C/+^
M::F$A$"V_EV3"@/BO)FRQSV74!O#+Q:7?Y28.O9])A2]?!(_6RRH/V'1 W@D
M 3M,4+LED\1K:4ZWI&NH_PXQ=SCS#/UH;\'9@G!!29!UV(K!C)/)44^Z[7[B
MI?[KX?$;D"0IHE60-SWY>@](B'>Y:DE"*]$_Z@4 @$<BW;2YX0M.FC8<2 (8
M&130WWW['>PU;3^0.*'WUVB^2R9-FP\DU*=KM%Y2W\-[1-VCW@F#:+.'Y+.O
MMQ=:^*!JBLHD3!(VJ_H_[ZM_ ]1?Q:-]I*A^WBN6+7 ) ^)>^Y_5WT6#CHGC
M(C6$!4NPILNKL)0L?ICHK$:3H]"EX@)\+)\K20Q*U8H;]3O,ZU<Q0!D.'=+U
M,?9DQ',W(T0$!D7GRQJU? "JO0.]D%C-,3F*Z+NJXQO,H24S(BC(UD3A>4*C
M]M_6:A_]F&/WCPZAD2HEN)Y<P\BBQ#&9?@61$85W!116?-#U!*TX=53_)VP.
MC9D1/Z"/Y)(%36#0:8UHO*]%(\<028Y=166&_2D)+OQ;XA*80XT]<L+\1QF$
MP9\W$'01SHE[)YCS,/*C_V?,<PD/SOX,J5@V07'CNHRH?ZA'/1( AG^T$@%E
M9$"I$$C5CD ,E)7C[RB2I*O6@H/9N<>>&O7=E,:(WL=Z]( 14IPZI/U3$CB<
M+B0W-H$A_#@,J$^,SK.2S(C!)QDOT\#Q6!!R(G^L6"$V0< ,)=PZA,,Q#FC
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M9U..YY<,[VA8LZK2:%I:BG-=TTK$02MY4"P0DA)UU(SRQ]373TDTX60$74M
M:F?A7S,16SPMOS[JNZS9:"5:2G)K9^Q?K<NXFWD#FVG,SV@)^HG0JGW/K\":
M@%TMDI>^CM,%&R#=J (C]/H1TVKHLXONR@&4E(JK?[4'#:YKM:4WSA(NMV$
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MKCATZ5RFG:/<R;H7;Z22G2I3,;<@*?=-K5;=:!; +'B./__P?U!+ P04
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M:S9[O6#Z^?SJ5][">?W62142_?KI9"G'%S#[-,+9U9)>C9>+'E@3;"A:,E[
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M,M5)!YIYH013/@M'/GPHN?5,T[5@CL5YVE9OMS-[FPB]!T?G'<[FTV%MEK:
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MJ-/=?SH8<S91Q[Z\\,N]^,(HRYG.;IE85)G.\FC-8J@]4\+F(I.Q6O:61?$
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MJ8PO*9 %90.S(1>FG250CK@O!'?9)@V1MVY4=R^0IV\]M)-S#PFTU^#,EC.
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MH(LDXZ6$K"%EJS:EP:-/?18L:"O;YIO!)R0=B6MH7.+>>C)6DK>&:2R)1:.
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M3GD#\D.=5L8QI1SM(U)+%D*)+($OT6JGT+>N@N^&[.F7D6S"P3N!__;:ZR'
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M%;"M2'OP95=05N3M J:GT_X&D,.<\%NKY7[U[B#3'G;PFZ!0**%XM QSK=L
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M(;LEC=_CU_+ZE_2*02]H.9ZP\;>DP@XD0,H=.HYXO ;-'+\#<'<189<J/^^
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MA_8-W+]LGI# WW1157R#D1%?JO_X9DG'])S7Y-*%GN(DVTS?*.@.V-YV Z$
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M[4@0.\U'_A:#@3Y*\<QMPZ)7J6;<N(_U!&/5GIKN7'R2X&O:_D8;UZ!T<0W
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M5$UH=V2NP-.!\'PXA4)<9-W718L;(6CV#:QC1<YB]!WW-<-!SP\TWMK@:,M
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M?VD#=_UA%PIX"EI[ <A2Z(N1[]?M[W_FJZQ2L"9 ):/9>QT:DM0 >10<0Q*
M_N&EU/=5Q6T=YUS\ULCW*RA\M*0^F2OGF1>I!W3#UTDQ5Y@RD/6QSGC8)P,X
MDYK+:&578$=5^AU]D'B?](:DM20VS3N45;2] "VNE0\W(*/JG_^;:8*K2M!H
M(UC!$*SUHSRF:2B!FSG(\?OZ*[T$8."X/5_Y"R!PYM8$:ZK@SGWQ8EQ@CK#?
M)$Y^63QCRFYM>1/E_.X>KE]TQZDZ:;#-7NU04M<L%[M_.=JZ@IS3.#.(&!95
MA:J;AK>JQ;'GJ\V63"?=<N3<AB[%N\0UC_$L\2)-V)"ZF-Z!/[6WO ",G4"O
MZYP2,A.)[K,V?/D1$*)G$MTHW0<A-M"4OI*-X-,TV0BAX/,9:@<Q@;F,_,S[
MLMZ*6( H*^9F+U^*9_:#,^72@U(:5^9F8[Z%!Z78GE.\+"I7TD^ X^*6@54M
M29//=QNA\.JSAI\P??O^+VA&.1^QL"O.NZG;IJ_#F^?:6=9E6EHSF=I:HAAS
M*?%^$3/2&GE4?S>-:+6+<T\R/4B[\4CF3=&7=&DDL3IPBKW<S]$>OY.^^AMM
M]AKS(&.C)-IIRR=&M>H#I^E)5S\!SIULT[P.V(/?0-$4TU(M'5Z<W_1S8S,D
M@[W8=(/:J#P.M7FQV+E'#,XY(T4X+4I5&VI'<Y8,01FR2B@K,]XW^X9Y(G6M
MS7,-2@EU!]QZAN2?ZD%TV1D+7P%(M!\TUVCR%1/Z/APDWV4^!D%ST9>(<X%3
M2B*A9_C\H[%NX]1^9<AI/R;=V'5[:TT7[FQO_*P0*)-@TT6GRDR>Q&Y2%-SY
MGQ#/4FE8Q[E<R)I^7=3):0S3G?B #G S)!8Y+W5B<)U2V-6&#0;Y,C6<D5\K
MZ=7(A+(5-+ N&@2E]NB],;@BB>*%Z]0MB#WXQ.B[*Y /"##2M/MK(95:6SN4
M+OP$61/^1'E/(@ O3%#<:C=] 3",AP0<'@0\ 73U+<$WK&20T&G5[;>F?!ZK
MIR>#+17>:2'@"MM6JV^.EVRM=@F,]&3_?.E#<Y<3%?X2R'LX#G&-$:?P7.MG
MZ%>\_0"JDW, VUA:RO=H**T3# ^:UL"\B5U::X*/8**?K^4=8-3<%Q\)1MG#
M!K]:JD_PHXD_V0)VVDT=^/*=$#58\Y)>?I^%?T\9QA0D..+;$V22)7RU_B82
M*#R;CVUS7YVY<9TV+I'^<7*[R;(YJ(8A%3MP6^_M%\ECPULQG&F.!D-1T=5]
M__YGRXZIL8_G+8)LM#,IFOMBU,8<Y]7%LT!1*7/R6,JEN(-H>19, .!,<, &
M>=3B!9!,5/,"F)?INBH4NGF_,Q[4,'"6NQ;Q&VYJT98QRG!J^H'+\9&Z>4#+
M?=^8">!5&O[(\MTS[;2_#FSB]DL&:BQ#W)7S*\FW.QU <$FUR3*AXRHT4/0"
MP!S#(N[*1,F:GWI>)#O5PQ#G.^E<N()"L'IH%TG]Z5O:\W6FK++U6I"@5A^>
M"E])&@6C6P[;$1QX5?^XDY,5(Z6AY0MY$-5%XO9 SCE9@;M[C0*<GM^>K>:N
M-_..FO:!F7(WUF2P-JP_.U?)O^_.<X%?E@?\@(I(GNOVDRP6*3,5.QH*&[*5
M$.HL!!J2L9 +W,]=)P0>L;MA&8YT2&O-TOP^:51ZJ.&BM^_'QI7K,%= *  #
MHK)65OIL^=#I0X[@<_%?&(_ZWMJ9/<1[J_U#^?IY=$J,WD9GJCW+/]]N8%8_
MQLMGW7D(XPC]%?3P2!PAT:N$ZSHB"2]_6G$S$ ]K&"55;/X1Q)@G7#?JPM1W
MZC6"33BZ%MV7@K!*X,NSLYX!@B"D8A_Q/+XV"8ZINV_.N.1]#Z2&!@P;G8T_
M>2^_ /: HX=)H*Q^@Y63S((#BK;>:9)9RS:"2&IG)WPV[LI!@/NI291;P>+*
M7?2@?M(V*1_7,)5M%1_^)AH#^9.,^<C9K7)2]13KD\;JV(5L,O@MAWOO[Q45
MKCP_GFC UG4V)03<ZX\Z Y37V3G9N1^; QGE3GU<:GIW?POM(MR?RU*!K;>Q
M\_W3U!BC[I=4*C,T_*0 '<E'W8>;D#1,%*?MF]6]G;LL#K**2RE"12;?NBG-
MQU@<:I5;='"HMICZ#BI,\PIICW6Y'::*]S$O*,"UZI.K/Z^):9=Z9M3G*)P^
MD8'!BA1_);VE#0#$J_[]^@SJF+GU[X0'A=X;*0#3LM] :S*VHUF=-<5"B)<.
M_#%K_PX74-AG14ZI/5-JE"/?:=NKVW6E9WPNGS:X(<.7W:V@EUG)ISUS!R_3
MXHLDFUY(RF )P,G@-*+J41PARM/?J/%W1,'%C1<*[M-<(.FD%ODQOLMIZDKK
M 0-@?R>CLJ;Z%".\P0)V,5JL@3A><U<*'5I+&JS9-F:&(K)%S?O.;6XU5-+.
MO3QMYM&$N>+E&9I*Y"KNK!]TSG>?E^;8YF0P)Q:7PV+C<S%S_,D*L,2H6J8=
M1 0MQ<)5YRE$I,B2M9!CJ2X3)6G#G/A,2"8YQ-AMSY1+/Y[+@(E[WXV/T-NE
M'<*!:R!OR^JXDI[2_?,_[C>',%+!6Q:QXF0PI\99V/>B&N;J]-:PN/E8.?KZ
M_!&BMX)(S8)/;Y&SIQJ4."GN8OKYQ9@(3; H;^H;82!CC=>F&TCRVQW^L&]G
MU]M-Z2938I-,/ZNS_2<->:$MJ>ACOV]_FL[X$IC[52J5&ZS9&FB/=K]RGZX6
M^<8G1$(F\A"KDQ?Q;?[.1YE$R,ZN]H3C]W%+L?ELQBUSX =?V8"-'4^>Y[6N
M*_DJ4<K>>X\H$?V-;U51U73A+P ,>R9+Y=_MM8#8/ !-ZHK)7AK\?B>SXO=%
MU-4X_[ V ]@K!M:$;7$FT/-ZA5,2-N5PS=IFG5H\8T7TB=%,JI'K8AT;K]H&
M>4Q3KVOZ&>] 7=*#,Q-<UA%LQ.,[3',F](0K6@&/\24M]O10G3IQ31(A#+!9
M&GS+4X\5V[1JIL)O8<U ?5C;=.:>CAI2!B+$L&<'8JQZA5;QM$2*X*-^D'A3
MC]:GS/4\>@-5TFWGJTZPM^<(^2,L+ZP%Z48#N(X)3R!#\!Y-<B4"9JC%K\PJ
M(&5*I;8O /S3JF<0%!$T$>_8NU:S[OW$^FWND=X2>N!HRWQPTWM/]EMJ9\"!
M?0'O+"5DD#G]XYE_>L$+P :+BS>J[!^BX@L'G#"ZG#Q_NV1G598F14#?64VP
MJY=K'(-!:C7S+*-\]>J=D=BN2_A[KQZ3^4'%'H)ESY2?!H]9"1$<P*V&=K >
MZ7$YIF'%>6\:55Y+=6,?XCF_U$@"<LUN>-1XB5%8"^XUTT%CV!Z0'_]B.WH;
M N%PTX=1LAY+*[4T U3FB$*)S+^929+?%J#>4<#U:L]V%]SVMN+U2MV"+%,M
MG? HD2Q9!+;\B5,WQH]&Y?HG]R] _*U/1SJ(Y]Z4R&.$QN"N72(_#9K@.F[J
M',C;SD Y>K&/[1+P,\LPZE/\5DZRWIQ])8)2656/HEBWZ=[M-'6KO9$'A9O9
M)7Q(L  72W4.2$V)6(L)JQBUN2']3NEI8LH%U<[4*K/+;TL9NH<;%_N*3=AM
M-K0%68'S.6^;WB#&%Z4Y*/U5T 6OB#V4SDQ22_9;XX*];OGN4TB:#3/YDQ77
M+V,OX:(N:OO^J/53U<??E35U6J(G=E;G-DY=U<^#P@"NX^2C )=GI+/5Q#QZ
M^*XA>FBK?]GY8I=@E-.$CG%U+M^WLTWCK(E\V/[]\NW<[F01W0N ?7:E!X$E
M;$JH7&5@<D!R+))G-U>K&LGD:^["P>WG/3M*)-$P ;&''%/H$^[L*$5<1HKS
M7",#G/XF4OF+7'?3 S34AN;9PL+J%6,%9XSV#)HGN*J[1JLM-+EE-D)YT"(;
M@[C3-&.X<=X9*ROR;2()2MF  '7EI C7^C%/K]3I ]OO@?T^P<P08F0!]4 !
M<F#."P"GH1'67)>@-OMY>M?*W)QZ"+_<0;))A,91@9P:YZ]][Z:KKCT?\;S*
MEHIO2>L-I9T8K+GIC7^J-NKE#\!$)#]#2CQK>OB\?5G_:=?E1V(PB?F*=I^U
M-M/.\KG"QEW(8FJYOQ&5K[$Y7*)>=N@#&1]7CH^:+ZOMI<VED8G)LG)Q6SNW
M\ENKQ"[CK7B_VFC #B^4<&2@\\TYSGC4Q_3@@:>J8ZB!KE88Z5V@AJ"#*?3+
MRC![5]\X!8C6)GD#KMQ&8,@;UY**53.<=U>]JWXF$W<#Y2@!^Y6#=/D!&$LJ
MS1>A\WMZ9I<G7!JT_X 8>C7OW EX==+17.M80U@;_^7!DQV%U=#H-_#P%CU=
ME"8?9<S9AV?]%Y":6Y.MK)IQ_<VZ<\SND4RR63,0'EH<V@J80DTPRT,:JH:Y
MJPS>AW)F>;-DP=?]W5SOI@71HN<*\(!G-6&\XV1W9N!5>B_[:];=I-AGGW>-
M?8G$  & ^?15567VP[$N0BR(Z>=REPU%OV/)5'Y.F ?F^GTLKE]E73YB+N-B
M^2E%;=:.O3JC?<X]W9#>V?NQ66"\%LJZAK&?GB4:GE;)!(.&GH]B2G0[9W8+
MHM%M[;9<%V!<B>."\JB:DMF942,5I15'&03=D2GC%7;WC?)CKKP"$,P00]W)
M+7B#NCV^-':SCY2@-492FUA1UA5FSZPO&Q#<\AWBH >+M\2\N8'3FS.0K1,S
M6G>B%^ Z:+3^:)MK1Q*+[Y]O2*XB9Z'_: 9P&9/E&K4U2?I+XP,^D>\^O+<7
M7_]28WK'JM YR=;PD\A@L#1QKFY)H5%>_H1L-^54?=\$??HJU\G-\^3TQ"%4
MF6C$33S# HVJB;IVX(-H&7+&V5KHU3CAREV:,GBL11Y665;8=)FIP9E!N/Y*
MS#S'XAYSJ*6C-7]]MM]YN?W[N#;)V=@@F[H%I8K/IGB)O8T)^O-$VSG.Z-9]
M8PKOXL\A'#!7Q#$^(>86OC2'DEF"YJC1>4UX\C2B;F\1)[1N\/4D))R)H]_A
MGZA!EA;F0)Y';<02)]I@"5B(89FY&(A>F 9BL?:!^9[@I0P+'*%Y)^Z1^+^Y
MJ]S @NB.IDT)L!?SC=!K)35^5C(+=DI)@#KHWR%_:IB!VA>WS]20##<M&AH;
MD[]I$HV.M8Y?8"F &AJCSDWWZR[^=GC7TADOL*7S^0<*&1G9^($-\KAUL+'#
M0-8H=#RB%,YVU?5^<7'IN/*U^V'3Z><,>ZM!@XF&"1%U_D 8A'&0*28;.O=A
MU+5Z8(TN(S9:!4T]OZ_$=3$]E)WSVFKF^-3A:FD!G[%>[S?^+S3E[F!<L52Z
ML]^@(KY\DO(*V5'.'#C8]=/1ZI$LUW2L>32@^ZQWW_8^+[4$1'CG8@26,B&G
M^C%(;Z&#$HX4N1NB)<("*;WS,?A1![\2M ,.(S,:).18QI_77E(O'$CNR9%7
M5_3UDC1RFZ@X7%-6+@WAM)F,.V46J7ZD S2+G E-L[53@ATJ#-=6;0WR2H'5
M_F.<U<A5'V,) >IC_RITDRU"5Y/6'2B-]81EQ!\9^0FBTJLDLX#LQSV'A]'U
M&UWH('_BL]"LU1C&"=LT64&2V_$OT[5N:.XJN,Z>U;^6>EOM*/PK+=]T_.RL
M=&.?[?TD^:=X0**;#!F9>A!J)7EV^"E>R<FMS+;IIK&*AE*X#7KVC5K,"'MS
M>0)5#%;*W'4NK03K!!4%0\C:S_JW17IVK,T)QI8WQ15;$,+R#;2TAUDD.1;*
M(I(XO]5XTO0RSN;'179:0?]9+4*R8''I+NW04"YC>47J1RL)Y:N:3]C6XG$
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M.?855]+5X+L-=C%EEO[%U-!*&/2D.(&F)UY<<>FL)KJ*342XXLZA7\U(N?A
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MW##ZHE;,OZ!3HN()DIOW4/-(T!BBA<.6RN:4C$G5,JF1*^5LC\A5I="I<?&
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MRSP"F>B-.29FTIA?9<E4P]V;NQ*GROW-)S2#R;P+YJ6$S&A[LNLQC!> =Z
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M?(YA-A,2*?,L8K4V(Z(Q"?(>FOD"3(-P*',)-JLH]*OS1[T_C7/ER ("B&!
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MD)3,U'PWM,RZV9"TY;*GT1&3WSRYO+CZ:Y3,'$QK)EO-6.7<P0@"3A+VBOV
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M*.R+M1 6-S8 K/?X!I<@:/(T]8_K6OT&;'L$]21>,#X^'9K=W:H]"9B>R +
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M7YT70UJA_3O>=RE%8^E<,ATZ>"+ECY^^F(=,(1^IN-V)O[HP1'"870 -#PA
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M&OE39+\X7?OY9"3UNK:",Q]5X-8 :&V)TD=I-IA_ RLX)FR0UD9TO^Q\][:
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M8M7=L*DC_NT<L//\L4G#8*@N72]N#'^3+$2EVO@2MB\$;T"X%O1Z5J[8D9#
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M9R\$'J/77TK\L*G]#9CZ<8"\<E##?P&\@Y/$_0E(^#DV#\]WH,J8)_R/E?S
MQ,J4Y0BD7@55X\)L01KV:1.SV!L1,9;>EXJEQFM=*8J4&+Q7,5$Y*ZC1/(^L
M^[NKJ71>,F^0@M%NB+:'RX]:/=9$9_--W-\U-Y_O+Y^8SWLBN8L2I&8J%^:#
M%- M$@7.I6BQKMS5C'[A^8O.HS67KZT<:])WY#>G)P#U,.DKAO.8<C[I)+FH
MOZ$3B;%*1CH(_)\U0=LONU_TR? !8HCVQV>[\L;/)"?GHCNQ*D3Q1X+#DV0
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MFVD7O#UB;A1>\\ .C?>OL\(C%&2;(=S!7+&<D<#JD[[=B<%P#TQMQ.RV<H*
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M3!+O,!=W^CJ37-GV=-?]>8CIY9-?<31/W$B$GF/PIAL)&?S;!!H-R4</!8\
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M-8@#7#LME0UN\$7YFBM68'8K+$JB!]%T\0?..*)9<OW1Z3NY 'RM.]/*&:3
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M^0G2KDS*UL405K/7])CS]<"^NFA=[:A4#R$)00S+#_O]Z!Y88):MQ2EQ@N1
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M>^6765 P3#JTBL!N+I5"])K[%Q<Y/Z0(\S#Z@>O%5Q.9CD1<;KG-2DJ9>F#
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MQ<C*OU =.L$Q$] JA/$&T/[20]X'VQJI^OT;IS:\S?H#]]]& EWQ36WOR=?
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MYH8D#-SD[="K%-XU*N;<0UU&-. RP1VHBH=B*_0M(__P4;KQR"2^-/(X([7
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M%'+)PX<4G>9TX%+6/-[X?6_?S$$G<<29C)[C6;6%7*7VY70;_YC>1K 6I96
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M<5BYA&@U#J\;>E#%V*Y=<O#Z8:&D36C:0\C56)*YH,=RWU'+0FV=7?SXW:3
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M^U4*"+I?_NV5;I1.-A!-)5>LT]H>BZV0P/Q@:V9%]>TC?U:AI1Q2IF?\4,)
MW:>1@PVNNLQ@C(]H0H$"PN(8)&5T+6)D\U"V[=ILAN+YQN)6JD(U/IE.]\B0
M&'VPNQ%<(K@X9#/:2:7U_'KV,'[X%@-%-&I:40B>GRCJ9VKT"EDA/DS88I$O
M7L=\QXX#;>&%2@24A$>%$%$SU"AF(_C=B;2B=.#65XH"T\-O'UKL1,6>9,XO
M&K24A1ZA='U/PZO8E0GO9H$],($TL2E1\Z8XA^2478L>%GZBBFJUV0L"UY.U
MMEWFH:L1-8F3*!^XO_X17*8G!0@B33'D=WM#8Z*W<*H/'ZT2A?5-#[/Q:QLZ
MM=MC5@JP'XP'WC=M5*/F(NRC76FO,D-;J[(*Y0N Q!G>C@L3AKPU,S>2<+1S
M&B=K5E?47)\^UJ"^W\'6I8_]-/<LFG_L1'(L)!V:.PU+;==F\2M75&(%G<E?
MS.X]*[RO5C+4R5&YV=!*(Q[W0<',F\0ERG. 48_-YR[TF1IT.+H1[_5_L?>6
M07%%09OP$ @2+! TN#L$=P@0/+@/[CJX:X @P25 @@SN##ZXNQ,<9G"'X.YL
MWJW=^M[:K:UZM^K[N3_Z7]?I[GO./?V<>_KV8[F3Q7RKGGKY3&=QD6HL/"K\
M8W3/]W(!_'FWP/B=O=3ZSDFXPRM@TYQMN9:6W,X5XFF!XNGY/.'[Z%$EFY<5
MLO>VRB8]93 :]_'SU$G]L7QESN6UC9,:J!+TYX(^.G /5/C3BDL"'MX%X4 _
M> B/WJ1X#U\^N"0QE%+WN^-(E1OSMMDR#/-RPGA'L3'8[N&!/S?+I^UF:"A'
M'8(*DZ=UC"KCDG] D/ZVMS7MI+,)&:@V?05\#B!@T<KPO60$R[#$[.4C9IJG
M[U'TI$_=R9-'L?[SU:2E&(8A9A=4_NB3)EP7WSS!#5[QKI*H;0M5FSD^!9&V
MMX\ILG[5++4T37#^3!/Z)V;V2A=;K'/:7\ILE;-ZAB>HD;X%:*_863^0*#/Y
M9F"4DL&;LDAFSL0+(V4[P@9,,&<R7]_,P=960GV6;ILLO\NT)+8S8H*K K@0
MN*T\W#Q<G>!-.O'.D?&(!>J\0^?LJ51QE0-XT1?F=?E .H*K%->-T6VF]R\E
MW/+L/#&%1<Y^)@ED.B6BNLIU3:!B3BI$R+;.F\VV>=@7VL261&>I:T9I-L4B
MJ1/14+1C=1UUHS UG2UC<1_B8Q!XSE=QP^"]Z ;RNV-3.1HTZYCC<<4 C&P)
MZ9"]#/'>K"_E!PJ'#6MGD94)'%Z81>N"##L31UX'?[8@=C;DY&REMDEV_]ZE
MG*;JT8R,9X\3DSBE,+0?(GLKF0G\U/X%8"R\6_=_N\6H=Z=29X;VV0FD:$D^
MT+U\,,G>IN!+8N*&^\BII;J$:3=U<Q"!C1C]?.XY*>Y!2]916O7/Z3&AZ@9H
M"#?%<BKO3\< >$M^.6Y.M9%LR93TMVUW)4+5VO.YU4(WI]JI*S]%RP2AS*&8
MG33 7FQOILE-):*D?2OVNP,CZCE\*#9V4?Y-AKWNZ1\<VN3:_(HWR[@2 3W<
MG(-%,B@-\P9&A'\HYY2+L2**!@,-"_AM;8E^MEJ[.0VXNKJZ3=A4&VQH=+O!
MR/25VJ=X#8'HC\.[43:\@XU0FUU7N%7,UT*7IG 6DFU7! :0^_L#KP?9/OV,
M1R4^_2RQ1Y7&!CWSU$]L,/J@#N)0$%4$,]&9=V5+%"L*VL;*![6:<W>-@Q;I
MU>!"HB+^FV2C@H;+KWWX-C0ZH,P3VDV1$#$CZ,J4ZG,M_'C-[/&+L?W%TQJ-
M]R6?-4G#]8#WY-<_2+.:A#H-#9(T/FZ83>E:X32LP5Y#R\P8U^:+6$HJ7R6D
MI6Y&G1H#HH]Q JI&+_UCM\:6,AWA"\1;HMP:_^E*3R-9=X9*;ZPEML ,)AWE
M.E-RD54#U0>C+7_"9J"9KU3]]+_4K_X?95N*-BIZ+NZM>TDKC=:$YS<NOWFQ
M9.3'4"92&8&'^3EKAE*7?U D)^??>&^@QSWZL-9F1,1VGZ+2P+HU89A")??0
MI'AD9?: 4'TU,,.&DDMN$.'S*/]TV\N:XF5NW LCD3"WE6A!*DTS0R&]KS?0
MCG,OL=SZ)KI4??,KERREF7A[\'SIZN\3W7HL__9%AB3Y&T0(W_M3AB78-FR0
M8KS!HQM+YZV,4*BJK9=*L5VR_BC?+5ID \?*:5) O_7'GRNR\N(^9)RIA7#A
M5B5RIOP4BS7*^P++PP#1\@PA:']1]7'!4 __.ONJ/MCM]/3 $"-MP6IIC&_7
MOKE6LNS$2FUFGP5;:8;=B2$%RF\H>AF?4>X'8!&:*4;EUS!+C[O@ACHUZ"W3
MC@7Y#[(Q4C5?3=HU%L$5>:BLJ9;RN?'WL7RQ>\H.06[6K DB97!2 .!0: ]\
M=;>==(3+P$0]\&:SZ?!Q?@<&\_TH,\%$'5[,-Z]T+DLZM%Q;0DP1IF@*63X8
M'&O,,C7YA<3N]1QP$+)SS) D/(LQGMG!W=J 6EZ^D9%]M-O)=TY$Y"2GN%&C
MWDQ#HK3_"L!1&)71;'ISPG@*1?O1XFJ FQ/7AJ@%@N:2<,N!S80N&T,PZ8Y<
MQHF?-WL\]\SXU,J%&#_:N"%\!NRYF9^5VA>TX*:FDSF%LT*@X2E.N2ESJ!;?
M/ZF[/1DDZL'"$Y& 3S<WEPHU6RXNX8N<0V)%-91@1?G,SE])1S!4,U2((OHP
M!+*9Q#^Q[K77S)#Y9R8FL[DR'5Z3S=(17&K[!P:4=;'E=/D301KZ]ZHPSM+/
MTD<7-[]=MH2LD>F=?#MG$]-QN@3YT)+FFRYK)(\*+V#Z1U^C[^ECQQYN[JEE
MQ7:GQ.RR4(T+VAF/'U0MORV\?VTY2E!>IJ<IS5UCBLF3SP>QN#J7M2L)R(L6
M=#K\*DC[*N?S[H);7U#A8M<K>G%B8J>537VS>Q<\X?)NB\+8[52SD-"-L3.=
MP>Q^A9U;KZ6O5D7$#=[_*W(LFD@ 0RC3;WX^?I.*5 +HH=1$I=\)I0N8GDNS
MMY-P<G)Q'?B*BXRLNR6>)>]EZX:;?/DF?LS^8.%\'"3AZ+$^LV+,:BJ/4Q%*
MF[F7<[59(J0,]$ZWY/Y<@4KJG^-[NY6NF#)<T@IMDBEJR7R>ZLN3RPA]T+)N
M]OSY@T3D5I0)WM:_544[)Y\QEF$[(#S'N)*>T0"3A5M&%@S5;E'Y[D79&8T[
M(822N,J3/J_.24Z?KYMH"*?E(M?WQSQD&@5T$"5>6L^7S2^W8Y3L6J8ATH"5
M0/H&@]!HP559X! 8#52((T_"@E4F:[<R8U&G[X;>A^JP1Y_:G2<#.DP6&GX_
ML3$N1GSSOI<NX@#(]PHP;8D]_HD74$!#L!_ PF9NLT;K3%)(V,K,?C)0^/-2
MW["7[TR5%.R[?:F3I_?U%,/&PA.T*'7[UESE,4U:E&CK%5"EIG>8+!LXCECM
M\$W^X1+(N/)S8^ZCV^$'W;4"?: (!UU+G*^.4MYATH]>&FOQD5*#WF+ON-G[
M3K8Q$=:<B\4CNS9RTGG:)D2EIBC&2(J_%!0I7AK0"G,&@HHKH?)MDU6SP<<D
MUP)7E)H*19;6IFM;V#9+B@G-/?*;!^VX+-[=WR5BV25NC0@16I:B@R6E'J:8
MD#;'\HL+_ C?N5_]< DC5*7#%2DB"1K,_?S8V?2Y?.5SKC<*606/FD"Z&>-O
ME(;=1 UK&CJ!L"I./3$C'R1SO-_LYY8D<HGTC-/,]]8)WMV05K^QPX1[V4\#
M31C8&JLY35/3#S8,,>$,.T&][4Y+=^9#[D&?N*Y%5.-\H50@Y2B"E?=.P*3T
M'S5O'C3*XCE/?/:>J/=>\&]> 2R:CX'':]:/A@/+]TNO (U61\X)OJUV1WT[
MM,*[<GW"5%@XNU58;A*9F(_:MS"\IZ$PWQ"A!;F9+\FT*M2L2=9F!( &H76O
M?K'R],???F+Z/,Z*A7?!K#0+V][I6FTO,_8X%J\ 6]AH?7_GV'9DAX'#88X'
M9)(H(EFY(7*);A;7P,R<KB#-ENA='T$(%T:H,R(9 E7G=QTI:5)8!+7"8);M
M1[RT,YL&6&7ZJ379\]8OH[F-'^;",28#\K (&M2^N- &IML6S*89,_WQ#Y-U
M,]>#G+TW-/QI#DL3?>_DOR;VQ#@+;+:_B_(_V7ZD,Y^XOBMH-)3.KUVQ=RG5
M\_&<^7*8QAFIPWFD:65ZL5Z6;XY" ]C,!*KS1:XMW:16]\!R,]2JXQ73I7\H
M!!X#WU G::+8!RQ;;#.A#^8="EE6ECM6K](DQ-'*1&G_F J7T?H3KA$BBY)+
MDULP4]^JQ"Y(,&4Q%MLB3_][)W'B$[]PTB  P.6-=W_UH=#3Q3.0XM' ]PNA
M9ZP8V$.^Z.)M**P7+\C:)9[I=U2NLS()()7&$752?B.:NWBP%$97TP"->GX9
M?2]94I.B?8^BU!KMO@5Q5%/?7G(IRB_=;2&#9)XM99#1;]NSE-5E7#K<O8\.
MYPI\!9!X_NJE'U]162F?W!@6WR"9/V%CQ0!"!G)=?L=\&?M#DEE;Q=P/_"2G
M98D)1F7@A2WIZ1_<Y*U.B+-3CG5[?1CE-!^^I9V]6KZF4]>>O6P594+.* >%
MRQW1R^&O5_^A@\9[NWKYX'+:(G\B97X:^;R'@J-BZL;WN\AIACI",40_Q89"
M%NQM&,V1QK#8&R'Q4@?89G>+DR!/EB8]$DT2$.; >JY4P88?IE;YF>,:\:?Q
MYDM_I'+GI)$96U1%&8ES!1@A&*#2_X'@KLD':$@^2A>&E_K@2)DL8*0.3ER$
M=U7T<VD0(6'_?%S(G9(5IJB5!=OQ+;C>3;!$ND\R[[*ILXZU.$PRA5(2/AH=
M![^K&3-Q1D/)I:*=8JLX$E&TM<PC<BIHP?[0;?(Y"7?J/8&T88$U@XT@D8B+
MT0]ITLT;N76/<E2KEGD-M:F34][?QB]T7HE X7O[>A\C@W50A/UV9NWZ3O.$
MPJ$1R:.9=]'%HPH_,$J_M#9CA/:^W*&31RRV799EF!*K2\?O7[B!XZ(#7\;.
M\@5@_1*F<>'9TOC(N?]W1,$(!O'1;1INN7^! 9'M,_71]DT%3L=LRH1)V)PN
MD=[N[_H<'>J"L #T+8=]Y^2)98<W=< #6"$$TC[>"E^6\C*]2:$*)DG#^B5
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M//[=& 1M"E<5Z7B#L><TG3_'FL@S@PH/ZZ9]>)B/XM.V,'082=7YLR9<>(:
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M]C4Q#K^(LF_O^3?*Z!TIA5VG(4^-K @;WGE%8E,O30E51"X*Q'6A@ZQYZM;
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M44X!@#^X_O[[7+Q6IJ&=U]^" ]=[]11L#U?DP'&<$W&XP_O\1?"BJ&-6,?!
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M/A3$:6FHA^JXQ0]IO;M");B0G C9VB)%%"*3O?;YD-AT%D__"=I=D\7BV*1
M=:\:!Q#9V@0MVR0TA3R*=KIINT79<J]D<KND[MSO!B@18;TII(R].8^,DQ(]
M-?;G+WDA\2A<JADNV)"(*K@(&I&G8GS>*"9R1I?Z[!F>4W2GHCG#G-L,J1>S
MYVK[IJSH2$RI\7)@;]3PS*F?8!;;;N50,%]:\>?]&D:-!=FWR^OR0P-4K5>
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MSR)??OMH/*7M<X9S'V?F%5S:?WJ@S4#"F^9[.YK+#5G?Y<>__INFG^S];%O
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M\U89'30EWGSIIC.P/63VX3Y:[%,DP:>(C(W^=>&28*8LV?O%2ZWV?#HAY:3
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MSR^1V0=5)5H$OM*.Y>G&DI7QX6_']")U@F2E$\KGGFM"A3D'3/Q'T>@F4TW
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M9PA[)+&WY\N]!;<DXBAY^9(-7G1MH795+BD6'?@([A:55[51>5LL=J+OY],
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M23O^N6H?Z,**J.D9@H6E[MN@O7(BB:,)*W2%([N_6COB/[+PR)A]*INLR7Y
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M6)1;NS_\(*6 @$A**2$-TLU8@(!TMTB+=.<@2@TEK2B@= V(=(Y("4@W2)>
MQ- U,]_@=N^M^\U]SGO.>=_O[]K7NES/L-9]_^Y<]UK/LU$CJ&F 6%Y&3@;
MP,  [J'_ U SQ%^D/:PM $!1$6 ' . L@(4A#IQ!C_#1#_+!U@ 6>HR!'FN]
M3#[]%R ' .*N%1H %_T; ?I9"MT!FI6O:W^VG^UG^]E^MI_M9_M_M&E8VUY6
M=[%W,W="/V _Q?Q:39"BJX:,IUB_C2MCHK^.,45$ 2 FYO?Q[Y7%V6>GU'Y6
M%C_;S_:S_6P_V\_V_W;CN\;'+W:-7XR7_S(OKYB@H!B?R%_]#5V# -: +7 9
M4 =< 'O #3 '3HL1U P^K96+BX,8#X^=,[>)F?U]<VY3>UL>#Q,''E[N:SR
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MM.+69NT/=_IA&^-@N ;X_1Y<^.3(>FI_#7:0MRW&=BSBQC(^B#3M!\UX>[Q
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M.]I"6THVTUD@7F3BLT'^P-N!?P9>:DGP_?]$%?WK$P(]I>OV=/ @LM-T+W"
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M[C!2CT2%F*$O"FF?EK6%/[9=L.<WB;(A%'8Q?;>[?)W6G*Q5SZ-KO,F/ZNU
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M!%[57F&S0 $&*&"#?NDZP?<EE3H*H,M''B(UR>3!<X/@*5![VE]<@.(V(ZM
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MT> 11!<V##IN/>S!9$TKD9#-3\9\?Y10>(4"IV5((8JU?.)8XZ4E+JW8K+_
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MM@<45/[U@7-<_QCM*\. V;:(NCU2#CF<34$"?K()J_+I>@;I8>!"HL+8,X?
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MA!Y-RU$#;+$+$<3JYFX4R8@E>4%L(1]-0F\68[7CS& _K6HG5E!?5\\.+B<
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M@C% J1$6:$OFRF]M*:8'UU-JE1X(0\WQLR:8Z,)ZZ-X/=5_%NZ/%/CCFNMD
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M;*FHE]@SUNX9"8(9G#5TGS6N0?+'8J[B\[;OV(2."A>N/6AT#O]-"G@KY70
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M*CM66<>SR>,K-[7KN_GH4J)TQ!&-]V13NS^[:Q@4Y8%H\L*?LK&K[;/I'FD
M3S4=,VS*?;01S=IN,)86 7&I?891\(1W7.INN7:Z@1^ EIU;#/%%AT(F=E?
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MB;#U.B5=#L+8L_62O4RRH,UNGBU9F#(0,%ZR_SK!JT TATI][&"&LM.2NK=
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MF]UM_H9R?LP1[XK;=3<L_&4/*/'-HCGMB'GZA;AA5P+?2@ZH;G:WZ'Z)$1"
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M#+]O7)3%;SL#FM<)2'=J)EE^VJX</E2*[L_,P9=$)%:%Q'>TYW8N5M-J$T8
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MOMM[1>UEYT^UV+N^9@I2C17.6I3A7N;<GB5"B.R@3*:OG7%YV]TV)?^!XQ8
M0TS273K@^A0H\"&W?4Y7A%$8&V[RNU;03_[VU!)^DH-_*-TIZG0,3/33VPRV
M]%23?*%2)]D[;!VOF?/A.XN6C#B8>UX#QH&G!'4D#.X/A\4!+[.]^<P9 L^\
MEBSU6ISCF\UOM%[X/=A.U_A:9M-%\H%UQ\E7*,2I[)\%LT(L)MO7+37UA+;G
M;LDX8U>XM9:7?T0WY*3TI56F>E-AR?1$USM"5<612KUX5  H4S'VY"W#PO8'
M;0E[?'4&_Q"?IQ=&#JFHUJ2S'\]L"[1!N*3&13B?5'P-D"3Y0]%$;7-GP0W4
M@T<)/"\T20A=95]AKR[??[Q.L$P;&E5;! Z FN%-6?C#;R&%";X+15\/S'J5
M%K TS%(>&[@57<%D<J-=K?T,[L+&OHSX)/412&SL^.SH%G#??"JZ:#P/VA%]
MBMMH&H+!]6*G*$O=:3N'Q^"1/  ?P;09C["M(67:SKP?IU2G%W_X)4;L.TD8
M&5/EZ\.R"F?#Y%BH9!U+MFC.)JX4<;)X&(6,&:H_?5>P#VTC*CAZ#FO8XEB\
MOL*]JEG>2BY_AFOR:GCTJB&.-J7X.5R'"Y=R;5G%'C08<[NB/D'A<-B,KTM0
M/8*--7((VK^D\RKZH(^AF-[U2MJAP/4JBV:*J;83$(P)_XGHS4KP6@W2GDGD
M=8RI(?H4=*S-.7G*A?FA'%:%\ZN+A1U^SZ?A9T2B_A(I<H$$$0^*?"=M^5P#
MGK51J6VA(Z1  ;:G-=$9BRR/7?)A.Z%YSK@))I]D&*4+G:7(B;["E$1H4Q7$
M!3JG/M7L?[3;>MP.SM-FF="!K8T]J0B(7G$0)K? $5SVF:L@WY,/N-]X:! /
M*Z=30VFOC>T:SH\0,7 /F>A/)8UB*O8MA$*S?7<<44H8!<4O:RNB,N2;'ES6
M'1YCP\DTQ1>.#\Y.ZYGC1<Z#HB[%H->%-KT6[91DM7 $#Y14@D]7CD@$C#=)
M24L'3:J3'S 7,5M5!!19T[)+-HGC.),M$B^XQX_\(E/\&5##K_M%4.>T,\%+
MQ>$XM;7'62BI^FP+I.@EF>/\IEEF7'BL.A*>0I.*1E40&;4X?35NG16'/NY4
MM"V&CPG:(QQ0-QWVE]4Z]"A\+CO,N\SDJ%M&]PI?$;UIITK^6%.H?@O8\S.W
MTW&)9-/*C&S*G0A'89[H)-77^^AM_V7!F[T7X*BB)O'NN/A,LHXRV[SW#?5H
M35DJ*N('FV623U_&ZG]#E_QMCS5Z)WF11]X-\/:;M^9_"S"I6D[4OWW-N;3;
M&>U%PW:C3:>30.)-8@;?B]/4N<S7"_G"ZSB;5=Z7X)7?:VT5/(BMRD86EV%X
MZ@TXU")].L8!H]4:'&IBRAC*KO<; V?QK<9667@+O0-D1';2!@*^T14!VR_Z
M&M/!9)"!C')) _IQ//:K%I.7"H%)G:BN_*ANXR*Y6V,UQJ/!>+I6EY=OK!]U
M=*.M8!UB#-B.#"!V,7PD[*MKQ(26U79 H4<%09ISV*(-4JC&-MOSS4GS#F[V
MJAZV2_4R,A]!&TCD8V'6U%>?R6T"&+L)Q>%N:&9ZM['=!I A8O:G7*><>AB,
M%G.F[@+R70KA6 ?MC"\YA6\!8,W2FXVBM_^B_\6E.HFE>NGYEC%<-];WFF)>
M:$E716\JZ]Z$13?XOEA).2D!UHP>SRJMMV!N. ],-J5+ZTMF5FH*CM*W47GV
MN*J>OPUI6//FHZ>/#LAC+E^\1%-Z3A<3/=B'=UG[D?@U0:OM=QN%L4I7S"W=
MI^]TRX;\A@1;PDM4#0"SIS7Z \CN8C9X@G3C9,TU84&,.XMRO&UKJG+<TWF'
M:8%RH6W .OS%]PBA4:AS5,G=;5ARSKFS]*UN-\9QM)VX%#///K+(QO3WCO,K
MX K@!K;NM<3$<-KK;JGSY=1&]N(F-.&"PZ+Y'X6$ JM/<LR3GPX?)2R;,CH[
M8V7J.A2 K8;.,6X!GONG$L@'S^%*Q S,!9F'GT]FA[ZLK<(=+(QATYI^GF=1
MR(;ZSG/&&SB@+K!$8G<BH-XB-'GQ[NT<"]IUT43+W;)3;1B -X]_UP!=#)3B
M8ZDU$$N.E?#=L:]$><Y/F]0[D)WMHSC";@$/R$<]Y!8UCPKR_!)R19UV@A\&
M<)(W&9_P?#? ;B_=E_-=*T![V^J*&L/7T,MXTDNL3N2V;=]LVVNX1<HZ5!Z&
M:FZO,;<5S3FVG\*N7%DN5&UL<U_)A2F9=4,.X(2MSH07W']%HSY%N>D,PX'6
M*06]A\5]UFB0VL9;Q1?H\V201L?>5.?4$AO!X@^',&+V8R26D"=+["TC\VP*
M$QZI/N6 2)97'<611&^!G*J%U5?I<I#7CI&)W4<9]' WN6JL4CRMJ:"/,AQ/
M9&P,G@1[?R(OUN?D!*;V BP5M2G/.AU [O?*;X;&E0[5X\>DDF?CEIH_=*0Z
MTHMC.\-G1K;.3R9SC0X=F;--2>1,STB T6HE!X)9G>D$=^7-$"K3T\MK_$[Z
M&&IY<,UH@J6P\A9'@M\RQ.R-51;KN"2 2O<)M;Y4?!+EYSRY!7!%%#<^23D+
MZTR1=TE]5!&X@-5RL;!W'1-$5>.]6:D.(1BN>W,@?.!J/F<Z-YN(R:ONSE\R
M#:H[K K%'ZFM)4948),2D@8XXC2!29^/K(YR%$#5GH?)^<O(R??-2%2(A<1]
MW1&0TG]3,NW$IS( >4U><@MX]_H6H%Q;65,YCD^IQ0B'6%J#%P8)U7"ZZ[FY
MP$,2K%;G$PAE_>Q8EB-'HN3).*,M:>H0]T&,D.V+D![DAP7Q1VBX!$Q'[F9%
M' BY/067T^E-=>VTC.*\J!& ;0!)+OPQ3I_,<B_FTZ+'"14RFC?]CFP@UM#9
M \#<+#;QGCF*I26L[M72*W=[AHG)5K.!EM2*H?TC,1(95F)G*@5D5;%7$LMH
M3PN/48)2RC5N 2;Y]2/J%6M/,33N9IL#D2:$$9^7-ZQ#VT?^(X[WZCX'T$J2
M\B6H2>&D[*SR+EP,(,%PNCOW4<2"8'1[6R^6!F5C<!M?>7'2?=TY)'"GX1M+
M6G^_#7OR5C*]KA$/PW40ZELKZ]$@:(<LMF*_^QVPQQWMQ;CR,/D(8Q:FUHPX
M=:A\G!+[F9JQ?Y!#O;C!)Y1,?TB-3K=5Y[W\%)=,_[>( ,M!#:>[4>9(5&5I
M(--!N,49,01*, GERU*,,#0\K2*_YBG2:[[8R>)U82HZ?I!DU;M?PWPG7KYP
M37!V6T8X2$5_F?[9P0M3XUOPZV:2H32Y?1F.ZI=)=N(;$]>+X6/E/VY#$2#-
MC6[+&XUC@?Q\IT6"0==FF5T@O.)?K#-4:W\!N?GX#]W[_G;NPI9"=E5VMR^W
MO,I%2+G;:SUZ&VCD:\>KSWJE,ZYFW<@<9[Y/=H+0<?^JX^I;43[6QH#<$HJ.
M/G_XS+0H%=D3(N.0#FK0.*)*F*TPL47RTP&]96Q,-'N@T4WGI>!N^1-2Z\3Y
MVK[7IY2AY3G+,KGENR@N*<)#<6LCL.W^.*O<+U=?/L"U/>"&Z3ABPZVY,5[(
MM0=<<;"\M:9.6E'G_4P]W).'$294KT8E/J>OC?KT<D:?V%ZQ,ZOQ[;&9\3ZC
MCZ*<_)KD<R%!3LU$66F$^Z2&5M^:U:L&A0G4[?J%?+*B3UAHUN3XRP;1STW6
M^#_?(%/4%:N6IHB=@;)<(H$!R42-Z**&^>(^^;'>H7KYD94;8NYRV'"K-645
M3A?C;^85QU)>O@,K(3A%9KXD8W*960A]'56Z1&((K-G3UN(,SY588@@QGFJ;
MDJ*6JHRPVUD%X(?([R ;'Q>M!0(.F3#9%_L?GH4U54[+P:+**EEGO"6F#6QL
MG_2]UG?A'Q=;G-8QL+Y_YGHTJS;7AS@,/6UE\D_L<4)=K&MM)VVKJ:%#Z-EV
M#")[9"9(/^BH.<8DM;-+.#=R"X#68N&RQHX7^-0Y;/9GL3>_5G]S)6;AH6B+
MFX+6YVL-#[29IL1LDS([)45X5>.NGC,H3&J9[1(__9448]3Q6@2?IJ10CC/A
M7DX7N__7-BGKJD(\IV5O[/6JOG%OI(03]\W%L:-K/?6&&)A6<#1[86"PR\,J
MVH?(" *0XG_Z]">U(7YMKDVST+)AU,;G*7KLXT9^[W9OVT13! ');\J#PL30
MI.BL I<=DM>7LI'2?D-M,F*@ $/7'.:MF7.++Q2P95H>PW:WDL59YF..:WO0
MV).#(A8:W)/.*LYNLYM=\O!#5J;0>H;T7\K%Q'7U5OFFEFQ5U7S8JX-:Z%O)
MC>HOV&\4=2%9)56AK#$N22IN$9D/#S6OT(LX?18+W%4>2U_8@7FGS@L.IE<U
MWY,O?&HN)K@%:,)T4\0 ]A<TD?:&2[N/=3H!H4,P2[5)'_18BF=6<!UM$EH;
M?Q$_:.Y&3MB$UUUK) A=>73>G-\X? .>7?M_WR&6W@+:>U)V4]:%,0;_,NK4
M7E<6;<X1#Z4HCED)]D,(X%(,N6@G16@/H ^7^$$N+!Z&.6"F;%WSZ.CH(1V=
M5E-"'C1RUK;[)HH#G><#R,JYW]0(U9)C*DMA?N(J0=WBX5DFE_F!J:58&W <
MQ+I/AE:'3$;BUSO**PU*.7HL45Y^02B/^F+,3>XM+B_.>R< "1ES!5RAO,KJ
M]62.*=K@RF9P#E?IB'Q1B&6'*;K&A>@O !380M/3J1M)+ZO<O^>T%2\10%XY
M8E+9/[FJC23>1$O\^6ZO3GH$-]&^3$*C,1GN2-*5]HXI:R9 ![C/:"+0TY )
MC^QF'!;B4*]J?-/MKU1M]BZ.;+*T+2N2+](]/=<B6#^\'Z=!YUXW$6\ OI4J
M(UOSR*/EN6IK_UO  >)(XS:+^RT@8\J;EX1=H7*TK$!'O+-R>O9KJ3A0IY"-
M?;=7LTA]L5IHS_>ES[6*>HSM5Z\)/$RX&S)?1Y5?_9#_"0"=-\M);+N:>SK7
M?@EX2?;/A .JF&T6DJ404HO8=<KK&_>!05:P)#VYLL?0Z^K&2[8>7+9+Z7-F
M('*N49_MMS"EPNY=-#.WI(.Y+2V!D-DA *XK;'!6F ??@+T58)]GZ12?X.(C
M._0H+^M;]+.@).XR"*.Q^BJ?T1,"Z87'H TT$XE%.24=^ILV-!H!MG;0F&'\
MTJ@N-6=%8"[QXW=%VNW!3_F%!+X-@>D0DO;:4CPS]+[A8H$P<CI=3IW4X<;!
MF*^2!:IG[GNV9S]S.RD*_$EKYD_"Y&0#R9*L&?7F7S3&?I\:(-39:9DN6,V4
M:I\BAH#H>E,!<5D24@HD?F+T[:LK9 G(4Y7\UJ105\$XI+@TG7GJY RTY7[B
M 8K/N?HJR.'RN[%.[?6.]M/-CE9[VBV1HN3-[11^:J3O2,N.X53H@P'/ -MT
M".'[0^93C>^F@<,.1)WKM1JSWO&S+Q%U- JB/Q@MD-56N8^%S <P6^XXR'AM
MQV54C5K%$S"M1G%-M^5K9O*A/ 7 #9SBU"HFN&AM,FM1L:=C:TJ'=.7<\_9\
MA+PJ3!R:[NA_YI]CKG!F=P'B8W"%)1LG3UBSX333L?F4Z:^3DYD7+/7#S<QN
M:D6:U23GCN.=#LS*0-:^4E+)$1A&RU[E5RO6G@FOI^W2I3Z2/D&*6>+R@ZEI
M6H'D2ZNKXL'W9T04,:._(%"5\ .X.<9&();PLP)#S?A5X3BD"AGV]!'"M'F
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M@T?2C46*[.5XJN+=V$D[L]8&8KC8'2H.[>*NM8%!2B/,'!CT,^Q/B3*">>"
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MF3=[GW//WN?<>]=[GO=?[Y[_O1;4HOKKGJJNZNKN7_<W"_0X>AZX<5]931G
MPL("GF!^ /3"C6TEJ/U3 -#0 +@! , '<+#N %<P$B&F<#_4'L#!R%@86>]]
MZF]_ 2H N/%CDP' PSPCPI3E, PP;/[^V5_TBW[1+_I%O^@7_0\E'7M'EL?N
M$$\;5TP!]S7V[VB" H,:LE[C_$VNCHO]7<:6% * N+@_Y#^0!?[;W[3]0A:_
MZ!?]HE_TBW[1_VP2%A06D1;$_$JQ"(E+"PI*"XK^A\\P& 2P!QP!%N QX Y
M $_ !O@-C* 7"!GMW-V=I04$G-SX+:PAEC;\5A!' :B%LX 0OZ  ( .".EM8
M@6W<62QM;.V=9#GWZIHX6>RM93GUQ30$-9P5;>SL5;U=;1Y[:^I8>8.MI*PY
M07+7K\E I:&.SHXV[A8L4,=G3F[24%G6W[5+8^3?'@NPRLFX6C^5?G1/^:\M
M,"59UK_VY?GSY_S/1?@AKK8"0E)24@*"P@+"PGR8%GQN7D[N%E ^)S>VORJX
M9^-FY6KO[&X/<6+YK6QA"?%PEV7U\+"WEGYJ\53,TMI:C,_20L2:3TC(VH+/
MPEI$B,]:1,1:0DQ(4OBID"7K7\U;6_W-NK.'Z[/?;5M;"=@\LW&T<7)WPT1#
M2(!5X/];FY@0_<WH?QA^C(^8-M**KC86[C;W,"SWV^#R"6)^I73^;7#Y)07%
M903^H9V,P#]T]+\@6G(RUE;25K_U">+Z%_./;5S^[T;[F;W<'V#Z+SYB'OU%
MP"C'9!X! 8&,P)_M_OM "/PU\3#2W](4\TF6_P?TR\@O([^,_#+RR\@O([^,
M_&L9^0/JVCAA\.US#)!%3P&* !XN[E5<'+RKN%?Q\?#PKY$28C#&-4J2&T2D
M-)1TM#24--3T3)PWZ1EO,5+3L/*SWN*ZS</+0\<B("+ +<S)S</]FQ(L/'S\
M:P37* @)*;@9:!BX?YK0S0 I_I4 G"EL+%;@"BD6-BD6^BO # !8N%B_T[^=
M"+"N8./@7L7#)[A&B&E0<0.X@H6-?04'&Q<7!P=3ZX>I!W!(<<EN"BE<)7]H
M@<?J0B$<&/L!G^UN:0OEHX%]=A%+UR"":U34-+1TMS@XN6YSBXJ)2TA*22O>
M4U)6456[_UA'5T_?P-#(RMKFJ:V=O8.;NX?G<ZB7=_"+ER&AK\+"X^+?)"0F
MO7V7_#$S*_M33F[>YR]EY1655=4UM:UM7]L[.KNZOPT.#8^,CHU/3"XL+BVO
MK*ZM;VS"#PZ/CD].$6?GO_F%!6!C_1O]AWZ18ORZ@H.#C8/WFU]85Y[_UH 4
M!_>FT%4RA8=X%B[DK,*!^!1W8S^4MA"PB3S:I[1T';A&Q2ZZ< O^FVN_>_9_
MYEC0/^79WQS[PZ])@ @;"S-XV*0 "#A7#N?*("$:0TEN3:I$>##*,=[1\#&^
MT\U"/ZHEE,!0]-RI0U.69\+=U&C.M']'3)WM+?]',H'</FV_EBXDSUJ$Z140
MA:\^W.GU.-FTFJ_C>$P==V^-?ZJ@7UA1U;Q^F'6(^AR!@W&<@>&G*OW-+ ;5
M], UYCWMJW/!<K<V9]D0,;EVU(F5+I/&9[/&7XO8SYCMNGD5EL;U(#&-O-#@
M-C/)%,6!;5XG4BK!M&>/9*)_9,P[NDS/$^F#]JM0ZM'%:  ".Q?4LVWG*2]!
MC(_%7[7;6:Y(:(U6U;WKLM<.N#?M?T'=1@/]"6C@37XQBKL6]$I.&J[UHER#
M^7'94$&DO@M7G?&K+ Z"\."J$!I&%:F+3W&=2\4AD&-"'\EG'C9QB[IAZFU,
M6); #_:-7L]9CG['>HV%GEZ._>M)I*^+8ZJ7$BR.)$6Q'K<T\E3";5\4'K^\
M3>[(X_IN\3;U'E':#.J%/LE">KCW6D0C*R.G:ND75*>^K7V:Q.$]GH[%YT_(
M7*+OC+UN*=HR(ZD:0XK'>5FNIX 3\':%*VF*AVVT<N5&=F%7Z]D;F?:]':BO
MR4U]_ORCLV@<_L:\:PU^DD$T1^G[:%14(&P ZCDZV*$NGHAC&\O0?=%;TT*$
M!_?6_SSV(YT4MMRHB ;,Q6'=/.NU $\G4@G^^6CKP%X.?Y#Z$70Z)QE>GV;/
MZ,GZ9&E.YEP_$]%Z7+Z'LR7A$O=%R4KD)F.*1>=6^ %L8K%#O'I,8$8A42R$
M9JH:SP72YX#2P<I;$(BBUD]CC5&"^R<QI<L,XB<:M"FSN0V8,L2)Q/Z 'AUM
MR\"6+@2N;,1V\YH[-%1W555>K_*4+F-JMO:#);WQ]:LP-J<W,+LKKB;[EK=G
M^$L-<.D2B- %A8TY+C*'G9O6][Z=G1UD:0#(+&)0H?+TG$N02$>K<!0::-/K
M^?1MCCV$().,1.EU7!:*<C-9(NJHU[:%#)&,Q5)9%:+&S]HL0!OU7/B</#JM
MAI+ZJZPT?5-(\DC3FY2;7[P>N@0T&DP+;415K,V5'6;/QBPR2J]0&4A\-;M-
M[5KBX<$2W(+#CY^!#VD4@Q8MSFHH*NY_^?2.V3CBE4V"_#%_MHZ^QO[2XC=H
MC[8CSZ,R=5E%"^@D!X>4_"8@$SR7-T^WX[%SMTUAOWUEYJ C46]TFPC:6M)Q
M!6NO&7NVT1]Q,VO:W%<I!"4JIYQ.$7?_,M#:^N'QG3#D=<"/1\G+O -$AXAI
M33(R\<9I>AKBX1D'N6D]VQP3OXI#++64!AX4C0C;/5*GCVB?<!&K=[U?W4&3
MRVY5)8KEFM'44#7D?A$Q-8&C=P(OCY/:SK >/@Y=TN!8,MG7S/\T\63:Q/A+
M!T'S4X9 Q!(%UDJ9KR.<HS2WFSJX7K1*B%,2:IUVMS%+67EN;,LTM"WF596_
M4&W#T+&IP#;UJ!WC21QEH&3'Z(K6FIGZ_MXB-E*JH7'HV$_8\&:RPAK7F<W+
M,;8/6V,?.D<;MMK,;NZ?AB=J/+X;1YLSR?:NOJ2,99.R;JGHCO;58\HE?R8X
M&@@30$GV+5SD'_OQFLVTEGB11O):WFT2-)UKOC.ZUJ%%!3:C&'2?<"?L^](M
ML_M%XDW,:VK)L\ ,$M6/]8<&<+U2Q_U;,BJX_1H/"QV71<[N^S^-I8P>%#_B
MK' ^5_FJ%<;$/<A6OC^2D^YA%PD1^/IPI=M2!VAF15;3 /&1_7@- ^9RZTWT
M,KI$S^D<C^,<O-^_4'KVP)C6^@>^M;:$WU5B>T@C&U)UW[_"R5>7[NTGIB<5
M<31!M<^O=7>QR79WNL@SRP^8X'WMHW:@4VFKTX"T)9D_C=NTNZ]JI7_&2%L:
M@N.M3^@(QUXT#SNRD AY]BJ\@X6_:)!FXI.SG"7V]:9]2MH,$J^/]=A*B)'%
MNBWL;(6<]MPMD2ZJ28\8!JOW&?.Q6\U;:6]*D5KPN1>^NI3I42/6+\/+2V2$
M\DCCH[H&(AG<IH_: 9]CR@Y?I5%?W>QQ@^*@HR4OV>^17[I*WLED &S1P7(Y
MT3P_Q+1(D9;[*X$C%>DSXQ]P3Y6>?:MA >[ZML7A CXCE)U0K0XW:,["]_.Y
M-Y6GKSNYNSX+?[QGLFQ;VB6)Y.D210.1<A)UI8[2@\J-PVM)0M\37_V(B*G-
MS0]2VU7((,GB*L8?JX? \=3WQ2,*U'QN995IB#6,QWT3<]SL?*K(2:OM;97M
M_2EB<<H'#80Z(Y(]Z:F^]TKB.'<1P\^"Y1D9*9?1 ![2?#&&>O,\ZWQDLS=G
MJN.*,LN]*39QY6L!FI3&1=[AQT'.PE *X*$9<SY2'ZX5YJO!$;M_,.)Y\TG<
MJU&5-\2$J7/<Q9_\5&06\[KA/(O401YO;\(+OTPK<7ZWBN,:KCT=AR-KF*,
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MC3V'M[$W-8 G!D@A. 63S"#$5W$QBGMQEZ<Z:XKO*,Y$E3380K%(K7E#!R6
MP3V6)6B@R'/NG+9HKA6$^PPI5#RY>0@F-]-R:(^E(B6+4V XZ&PJ-(4_;ZV
MZT<65BSEIYC?LGH,5,[56=GN.='\\+L.&"/:T0![NB$:J&0^EY->;<2'=?..
M@K9.8)>DC-XD$4AI&<,%]1G*(HW<6H*+^923! __=[07C14J?TW&R7]+QC,Y
M,^&_)6,\JF^HG3FL0B=.2<]'4$>H0]XB_5O#):.UDON3;VTW [O81NM#=3 [
MSD7#(_4H":.X;Y,J?">>E63/<([TIB6/NL0VDS73DI4C;#ZU;L,GICJOE'D\
M":<@/]/&(_SC9%W0%^Q/WW^L%=KMDK<^Z;>\NJITZ,3W2+FYXZHJ1QV$ ?H
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M'X8:9+'S^#:[JHS62N^C@<BYZ_.5^UJOZN5K40WL+[SFK'P&'<\L#K8[M1R
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MYE^.$R<JD%5@('VDS[Q?N;.+Q'/:R3$>9^V35N9C@RZDWHL*RU0Y2V#> _S
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M E IARN#SYT<E8*3/_=E=-A&[Y:LD@Z4SL6L><Y(>%$Q;$4O9XKLQJZRY"
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M5Q/ZU3;CVA_7$YSP'\'%;A:;%Z!'^[;N9_F??1I+4A(E\:9G$N3T?#4TIZS
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M"QRM)&2NG4'?P1((A89GV:0/=>I+)D-0>\G>6H<WOBN<2+(/OAU]"LGG"#U
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MKKM!-Q;;*,/._&N.?+P;);97.CD*FB7%@0*ZT]<7S)[,;(4V:.#/K]24Q,W
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MIKR>0%JW]HJ8-IP9K$O9OE9=?]E^D@%5+/=$;$\+^6IOT-ECGS'MX"ID<HD
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M/_RR$8PC>!A>B8T-IB59)C>-'4^<)?:H/_M8S>YDNE-7B_36,K;CF1^H,8R
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MMV*0@4Q:L^^I%? ' )V.(7L5:!?1((3V#"FY;H^<B;Z-:6V[A#!(FC\8D')
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MMR](!6NDE^43D8MT>VPS=ZVP6![X4TKJ4N+JZHOSXH]"3M?%M+/D9\;I7 (
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MJ1V:#:M->FU 28B6-L%M&%VD9C)DT)P:9Y,9QJ%OQQVD19].Z<K!^;=1>[\
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MU#7]^.#4;Z6ZI;P_@=^BEM1 +*0W5&YD%&+9>!2$MU8\BI_]PF6>AWK>>NW
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M>W5E\6E%C6;KOP)?JVG"VG&H<5FK0:<XQ!F;]H()SH3*:M^(N>#2Y]&[ORC
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M'WU1$T!]?&> W_:#DF&Y3XYL!ZEQ6L@SK[R.W?\]+R-M^'L;(D4#-)?"Q6F
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MI,Z8LEY%R5%S:%<E&$@4,B..O])5CM%]^:2\>V&J>T<7D:G6%.UZNB=11F<
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MM%X8A/:;#F!+GUONV#[C[S,O9ZGO+2,;?*(!HOZ)%#:Y_Q12593Y2#+V*A_
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MS;(M*YU[K]JN*LURO>W0(XVO)+L<!J=M^Y'@S?(V4]M5J8RZCQ:7N@9VD1-
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M[OO-]4>R8)?2O;N_KFA;[8N\/!/34GO8>._)&Y:#F"!P-XT#%U\^W\_Y^(7
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M &O@IPA.2*3ZI73_"".$?)MY2?3&Y:6";]/DR&GR&SL?0A:%4W<&0Q%!L?I
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M2^VL=E I(_BJ,$C"\>^(D09FVKN*@GNW/*-0#.&3<3GSC:F?/>I_6#"WXMR
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MH4=24XDY$7$_.C]&;2![/ 2#;A'$FGM\=E%<,.6 R>]-'E^]#T9J?=-VM#O
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MMR!AO&R(;/S^;;Q5F'=@R[)GUO+=FQ?I@%?"3/9N3V@\\9MX>;)^+;+^/#6
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M6T(:O_P8KE(J<=<,N7N^=$%K"WQ%\P2\*^4ZD9 [7A";T>.8JH $V]=$9I3
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M]QQLZ<NJQJ1^=^FT9WN(METJ3[ >/Z5-VT&)D^@ 4EY^^<!ZOMS#D+,,;+I
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MZC6-1R$'3^C]2$%-YWGX^\'UH"OE1&F>ZJA;?!..B2N7EI;[D:.-%?.8]U5
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M*'^>>@:_^OXE37_KJ&V\ZH8=F;.:1N"%)GTLZ!)Y%QP:D()C7DNB%$@YU<(
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MM_TJX*E[)?FX^,7*CT(E0/TTF=VRW/)$4JH0V;J1*DX:R NQ*4=NX:N1A5,
MU_+XE@OY.=*//1TF?C9MJ+LFDPAX1#,G56542<->L.,NNCRZ-SSXJM79#_K=
M37^?R\#&3UN_AOVJ&>.%"]Q\\/K3Y>;?%[^\?+J;6@;GL2!9:7><CFLQ*>'W
MKJ5'+4@EX:O$\N6>]A5I*P=0[I.@\X^J2A2%W+83 A9/^Q5WA:MJ2E_KPX(U
M&( 6IX ^^NLT#CKK;P:@HVB< 7#?(4NH@ X.V>AA$*:*>LH <*S#Q GM)2=+
MODYL?+B2T5ON\'>B5$TZ?^?94VS']W8>+>\S8V_Q.:A_I0*>H-3^H*#H=L9E
M"&HD&;Y0WN#* /S]FXT!8%EAJNUA^+^NMSY'LD0S)5.6_BT&H.DIB&H,Q!>%
M"#  M^/>,@!O.N&DM)[-6@XRWGJ$ -K#K\LN*4ZUKQ9=E11=;,C' G%L7T,4
M?+Y.WE:R#TQY43-7K<HB+'!J9^[94APV:J<!LGB5*C)/LWWH?.*Y1Z:E2=LK
MLC5!E0?O^G9?>B=JCM-#QE-.9+O**#EA96FW*3!0://5"Y*5@.=Y_E3#//";
M*[7?=EN&8JR^N]H7PH:1%W9*!>\J&86JG5X4@JBFZM.H5J"2YR0C8@W!)?'E
M6[NX*?M*R57:9--UX-9'%K@2M6@#<YHD>0>OERX2%YNOX\Q58.5[:\5@&S>"
M&&W 8'=^0N""ZZ!)!^&AOQ"M+^XJEFV%V66I>K1^J(^PRPP0SY2NYO]UPN";
M>?9'L#T(2/+YO$!00*@7HJ";5(09'AQ3B1$EP>8>#E[9*W&9+SJK^5P]YWPK
M_*#C9*W\)/OB* J?8SRP?3,:(AW1D'9WB:]@"V!YW F"*GD"ZP6RASCB1U<?
MV$.VRMU2XHO8 U;W)!Y]Q(^S>IY)X-!Z]P0V"=QEP??10IAA^E+B-=0R\) T
M&+WRUE6_J@#?ZV.5H.]$T:(ZC,)D;#<3W(FCRNUM"P_I;4*E_A&]N-ZY&1$%
MAT;P35@;DH!=G#M:AU#S4'F;9[LSKB[FGW'OLMW5?9PO]5'\FD8C7)EG;[4#
M-,G1"C[;\+Q..\4YK^^YAQ/2=\G\QO:3GS'%40H_<>!;8VUS51W4).9L+'L)
M.N(>67Z99<N596;_*"7J8Y:>>73%T)[^,/!4@U,P=B?BR*&^0/>XBK^#RWZU
MU</V"0$]5JX@EEET"$$2Y[9( [;:Y(6I>[[OGYPQ.G;SP[V'WW[<-[F\^=JA
MA\)4(5W\_2!<#3TNB(3I .]J!+RE-ZL CY2*AIL<GPVW6^6KSDA/[:A*C18*
M2US)+)U+U*:0 K$0T'L'SK+1+7RV;VNYZY5K^N<CUN#7;^V844T(NF-OJ&S%
MFWX*+;(S&6)W!Q<,;ONS=!X7I5?MIFSU$(SH%Q!,G_T4;%RA/Y+J=!G1<W:&
MD_::DK_!X7YDC=VAQN]<A(\Q,ZQ_M&'+BF.CMK9Y=M-]-F5\LWE1JTK6WS;3
M'Z]!#", 6_N$X4[NR39VO!B7! ]B_%W4#\-YYUS'N%#I?FWUD#O#:'Z2G!;8
MZ,WHXG(I]E7)XHTKHU82"X],8&:S:"\:T_@O%7,<X=/))<$J__2C?D[7]PNQ
MZ^8Q'GP>VJ[:O,6K$877M"P9@+\P%<PL/N>_6%W^;=)]-"VTP>^#3,'SG'B#
MR^6]JY[2HU3C10^5IB/9WI(BNY*2I+KEF3JD+NL/R5<G0EHH3)O<V;<H?[3'
M]-XZWS!5<['YPPWVD(7:7&G7_#L5AJ_P0ZJ=DFNY3C2L$>?K=_>"6H:LK.I%
MSNK$"8RDU]_"FD[N@8<]\Z);_#ZX\?Z]<*7VULTMK;L@*=IU6%7W)'V(F>"K
MCR1&%^O^]GZ2W W('\?]#;<YF)M S,\FH/EJ"%;ESCPT&O:&35XSVUWQXZ^:
M3(4BCZ^6M2O\#D:^;[B6&U!A''P.;%*#KG*>Y'IP'"7RX,!B6ZT$\L1+U:".
M,SO/0XCI;1B 5ZXFR>*<0#>I9'1'4H@ +?<Y7<Q!/P?".[ >A$7,\(^3^8Z?
M_?!CV1;8;-"K3D1!4'%R(.<=H76TPN?]F^'20K8HQ8[[M76ZEV]U*_/)G,+6
MN%..]>" 3F]Q3Q1\EU'IRUP6,&V/W-?M/G'2OW]=6\C&6IR3!9IT./!:5KUS
MKG' EI9FEU>E+?ISMIRY&8<;>' VD6S=.397+1^M/?6":'Q#ER+_:=8Z_7@;
MT75Y^DY.AE-5L#Q."0LDZ<+X9J9:*7('5KQF\WN5>W\Q .A;0/Q?8*40$9(5
M \#Y<H?7Y'[-^,T](C3XC?\E:GP$]92UBVU$SI9K9&M1FQLM="6@+DEM02]Q
MA $ KX0"*2"J>P,)=9+)%B<^E^:X=&Y4NW>CN(_="'=1.^[3]\(! SY![Z-?
MUV8GY>492Y/]:F*)0C%XY1\ [GV/?#RJ43I=J;GC''C:*OK/?J!CG_!*>5;G
MC#<0<B0:P<B29+TPH\P &-14U*:M;';Z-NH[LY>GBT/DU7B2F'CD,DJ7,2V]
M@H(X/I>QX@:.Y_CV[I)G?DQ1<KY*<Q"9IB%>4H>)( CZ8- JYDD?B4* 4I(Q
MO39K>1%Y,M6^&:'+8ROO458O6IM/K^'(%1OJ5[/1+P]N,S471U*(!\625-$"
M4QC=3[?7T$V8;"=" B:?79&SM"N0B/R[E^VQ-/>_U(0;P8ENZ/]GIY%K/O^1
M$U,#:/X =0_>MEQ\9O@VD9#LE*_#E!,9N$VPHY6JYA71CQOF]0G@!,W_* J]
M/XIBOHX-EUK4\3+'MO]YJ6QDBW)F'W?!]M_>/VF*VE7[*6^HD%P2Y7:$U4 I
M;  BV=VM)ZHL8M;Q!'2$O306'1)$0]X\@4^B-RY,G1A28K]XH^<$^HZ%GAHT
M,?N#8D"'CH,]198T"3T7HO_6*/!4V2C+F[M=\W=9%*JU?)+^]"[3Q(_;>8I:
MEI4O?_0'C\V[X2 +[GI*GQ?[\M$W2$Q&7QA[!57ZK2P4N+V0(/&@SNI9I^L9
M;Y[7:Z&051#I.91)Y/TWF,S^,Q!#.@BVQADQ405JP0"4$AF (R5($P/@;,]V
MC\"'V,$=V*L/6=38J\T\:7CM_/?L4Z=+U\55)9%!&75)'-\>H&R$ITOH=XM]
M#>-+3"XN0_+(E?\O@A;T?PI:5#Y\P8IT@_Y.A*D_3GQ@  @WX<TE>%?:&74.
M.CMSKB]"0*7SH-4FL#53Z/2UQ)&&"*!6IOX4RH%,ZGY%^HBT2-F73)M?O]WU
MPQ#G^[/3L3<HJHUT@D"Q(&6AW 6MJCP<(9I>IW&_$]0]6<KFM_WZ9LT5X@[6
MYBYJBF8JD/R+U^);ZY>JK\P\."L3N:?'EB_%A@5SAD@0C * BWJ1A7?;KSK5
M7IAVI0=B.LE'K,AF%&M$3DR+Y1L$NIJ,(ZV92.7=TUSO23?Y4RG*NB_54(]=
M;:M'A=&!94B3\$FL14/M-6%_]U]OE.SJ'1^9>#_PW7'(&HL'7Z2/:#,_$1:Q
M^#294WO3XPI/-?_Z"C"U;TQ"GGJR8;KF?+GJIV8CW2)ZH\FTL:FSGH7M/ID!
ML-8J(L));8O(:,', E\C6<6I>]\C?2YG*$I7%L/,DN/#K_-G:DE',NV9>0"J
M65MUM!*B!=)/&.U>SHI=#3=?UB_D>HW\PK,!JH RQ=L"%\DVOR'R^X[YE2.[
M&.'K0FPT/-^>TJYK>Q]9VD&* 4"109^#5=U5@TA''^[;%<*,17T-D]P6Q%5D
M;:DR?7__?X<WJP&('VKF<^ :N)+>7"=18>#$VI#@UE]Q@W\XP<#!0 G% )RI
M:4+N7UT#D6280!U9&O@$SYF(*!L?O/E",2JE<GH![HJ)L1EK0^#Z<,&V[- R
MLC;X#VC0_B_0D$K!L1#J[4D6Q6[*=<9?D2]$ICFDT\>7GIQZ_J)J+.J@D:_Y
M2#Z<NK,5*]9BN%>^$AHU\==<#-:O_T9,)KIJCP_WF0$0EX\ ;0Z:TLY::PO<
M;W-:S&&_M4^&IS::NNFS2UYS,$+]%NW#\RU:Y1.,FE5LOA:=R&MLM8[U+'*)
M*:P44[[KXI11ON.0Y,!-$65J$^5AT):D)#TZKG&RMGP?:\JM>NN1^#WA9?,P
M9TE_U$ISF:8'-E1R@?Y:&55LNC2EO_OM:D_W:O;5;5,&P(Y@>T"0Q]W"1C:8
M$@2Q]PPXB# $'2$<.-_UZBFT% 8FG=,\S[>9E*25O-,_Q/GH_E=F@G]U9WJH
M'P2'PI>;64V0;!O676[^S">@2=E=NA%Y#.1*,:7J5J<Z&+M+5[%]6OD>=HW)
M(/>!HXWU1!^29-XS.F\Y013ES$,LA[T)T&T^:?NL[UJEJ KGV_J"7BV?K;3#
M=_O(BVXXYR*WT4-BL3+9IUT(N)WY+;1#:6ND;=YKZ*6CKH'L'YK]L3*4\Q[%
M8VXIZ].I?8$^5*VMBGZK/U:2,Z@4&-?I_!Y9T3OST?6CTSC7K8/>$\&?0U@)
M.0MS5.8T$^G[.J49ZR16\CLC!@:526S2_G9+@/@[-!0OV3Y(VELH385[KQBM
M^4"\5XON9GAJ+QLB"TN?M[ 9WLR):@E17/,(1YD]>"GMB> AU."L%_O.D3IL
M!SU>XGB-($(3)5BW+Y]^,.UDPF5659%7Q:;_!KW _#8$^=JL-)-U\OKH,>X4
M'UV2T_QZ)80-?GK-$P<5</%0YC*04C28<GCW<![_*<BBT'#; '9WQ:31?2_,
M%:)"1H+<@-4.&)Y!$8O;0YX>F,CGOSY@AGE=@7FATO-083?PA0;0R?+<>T]K
M/N "II_<S?#5%WG?MW%J$>U'*]3F)ODWIXF$-V9/=.3U7>ZO3I[D2%9CL7K<
M%'1,F7CP%=:NGKM9&A#-A(&B*7TOZS)?CQ]4'=B;'YL+^-H,\=8%;/= KKMU
MEKUYP7;J(-63EJVICQ_K,']6YYR<HO5MJN-J<&VN:P]KII4N/U5:8\$:IX,B
MM72D64473[A9$:U+!P*3RPU+@6[7>NZV) ->[CC *=;,>6R'I#?,T_4:%GE^
MX./ROK@//%5[N+,@.?+4D>D%]2#]S?->!UX?O*-6$N9^K;8N2M]N^.@0#>ZA
M]@T<D:,7_7'&BQQG C:M!_:C1:0@0@(AKR\/FU>^>R6T:Z4+#!;/=S\2Q;;Z
ME9%LC(.]E(U<H#JNWY[/48OV^K;&'*ZFVX_8RO3G@$WF=GY%,R]W5[J]VZNL
MR-SS>UU<VB&4SC(74XPUT?Z]*4F#/3L*GO?'G5X$16:JTMM'9"IK96&_):9P
M8O%@[Z2?S'L2/K)V)5 6DXOPJ)8Z#WHBU/6%TN^Q#YM!<=U\3LIZHP[>TJMS
M$_)TPY],P#N-21LKH$^ =R76X$1.!F#2U%ZU6(G?Y>*ZGO9F-5+9^5V1VL*&
MB:DEO'.O[]\S"8@?G[W!5.,N3&Q]M0<G; S3XJFRV:1$.A<<%RK68KD+ZUNF
M54]<F4#>T/!GC9E_N8_*_C<!*I5*E;*Q6PXF"4U12YUNJT;A5RUE0I87F-]E
MJNVHNO'K^.^O:]$\OW_=KY?@/GFFET5<\: )E:LM$9"PV40_,5I5='4A>:-[
MND?0Y/3M6R)_7\(2LH'AF1>JT]2R\%\C+Y:7O8R_N:8CS?KA%GO3R>\P=7B7
M.,&4%EBSQX,=+8I F:?EF":!P5H(O5CU2G)C;FG G^Z!SV7]H!<>=I2N'ST(
MNI,05ILP*&!UQZ)](97_Q1C_$BO86D?1[G9"ZZ:$9U;2\-)US3<<>3"GL3'D
M=V2;/.GN315\:98R=']XYMFOP(2YKW/?1+7#@JPKTIS[W\E[W%:NIG_N4V&+
M3BSL,IME %('8/UP/E]$&#%(IDZW*K;%H4NJBS@^\^K,Q1@/7SJAB $ H"7=
MD3R:LO!"]U&BWUY3@,?(\X$1PS"]KNE?/LE:F[UP#WGR29(UO=X.OG;-%EB.
MH2;.@.G-L0Q =D[IB=M(HFOU\B$*\VOCLT'Q4[?\?.I)'R GR-V4AZ3?(3@:
MZYJ_MFLS85>IT(#OMBLX$+M_8__8C[E_QSO4(!2_TUSW>;K&.E-@8'O[J\>N
ML5:8R?9L7M02LB1DF6)'LM;%3VOSJ>LA'/,$TE9_47B^Z6".:7I.GGR1.#8\
M2E*OE1K*OS4PL@[79=Y4AJ[FG<!OU]8;8Q#_OI0?Z!3<S92;1%D\F9KESJM^
M3SG%P>6P.MSR@T?LI\>58;ZL5;<H5TB@6P3)=TH_JCRX348NQ^V+&02["?\J
M6G[[ZJ'PV3'T.OH8OC<Z6&0%N?#[2O.VYE9M=7F4&I\XV]EOI^;C+6,+WV9=
MZW_@:P1_X!P1+E8I;C'I1K\WFQTEO=SW_'_5(B#I%M!S#O(591#Q8O2?MNH.
MJPX"E,?P+H5R)A[G@H_D;'!-\(:A W!J+'3!=("NWP-C_\]#Y8H9XP6:#D7;
M*.E!4L.GI6D6"8[/?XIU&K]1_4GO%HVLO]<2S@VU79KL@ISUJF!MOR'X=K91
MA2C/ 'Q8C60 -B>!M--%&]U'(3#U.."%!2DI4^.7#,"5@$]V6H:5Y!RSO*DC
MUU80&QH R50=+?$\L!78G^-H7S3X^D-'R.3+ZM/'NSY#_K?Z8-(;R)BH<NH5
M@GG!F:)\0X (8,J^Y 52 +/TD82B-PW!UY3F%Q5&%*J^+&>;W@D:?W[3B^(^
M@3<-IZH5D&ILJ@=?IL.K-O@DWF?-%M:?>;C;RO)3R]@?@_\-Y(*OV3&!>!-*
M5[M/[P7OVF@JT:ES1V*&E&XT0O&7^_Q&^\5!MZ)-V,XO@E? PR<7,]+[J1N$
M_!8H)U43HDLX^9F6.78K!H2)LY]Z@:SM$-&W.=(A,@$J7H.IS%$'#,  Y"&H
M.H4:&F!-ZT&LBD!A[?!=2<C< 1US) L1UA-[6%PRDC;"= (\L3EZ-Q7*P_P8
M )S)(?$-(8+Z%X:]ZI%3:(I_$?&JEK^V#N>^?0<>E0YW1IUF )KU";?9)[A]
MJQ.Y[:N#H)0"[1\:F'FE?OJXZ'7Z ,'A\\(:^/IZ/WGH*FAWU.05[2('96TL
M@^0S#X[3M,V><I^T"O=\+L>B<,_S"\+K^!NO7H[[P6:O<@0?\JY>YK,HHJ1
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M\0VFA."V7Q1/I1)WPBL-OG>LKX?";I%8P#Y46;QZB 9>.34KXI'K._8^L?W
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MM0."RZ"P,S,5F^5PY2 A8J;\3NC%&$#48TH^&ST NB]PV^#JM8ML%\V!;3K
M\VN!TK9A(6T&3SN$D%APFP(MPU^BSH94D]\(;2I#?S:I'Z]PQ?M@\31#F)+Q
MZ\#AUYL8P*)TP\^:PYMN(I";"&^G_";&11G.\(_#/";<=;0/;OLH9\"+@IJR
MW>RXW<TTI ,FLJR;M H;];PB!T\(=DF^)$W.<K\V&-GOF,PBH-<2C9"6QA,J
MFJF!W6FK77%WO%#GXMEQ1'%D_>P:2JCB?F^1+[V,?9N3;/]6 OMWU^/(5L)U
M59:[.U(PW)U%+TS&6QKEAR\N27;%BK.V& XL%@Q&:IR'JS5/O6KS2!GD[Z%P
M_I;)!<#U&B&-4.H'_:)BQB+Z)_@B=A3/MITB'UAJ4=OTEN$OO'["-DYK]^4H
M&&R/W#W7+*U76#8 =GJ\KC6LR];=N7)J\I@Y?OS$O S@\6P(UT%4,\3&UE/(
MJS<+Z))3WT1Z9!9RS;<JB"3=.)3W.]1$>.8]S\"U&DVF4,;* U^^2C9 6TJ+
M-MOJ(0\L\BR<'@-HN\H:3,S[-6 $^; A7%AT/S.J>$]R33,OI^1TW)[LB.#T
MEV((ZT^1EW\EFDFLA_"^UO)21UB4=&2Z-9Y;,W+Z=.21N!+W2SZZ<X.C>ZA7
M1FW'\73*%[*42[S!:/@<;K77->">JM MX4>E-(76=4$V$J1G=? %%1$2ZZT&
M-=E?2\&GSJ,0=D>F*F+"*_ELA]I<3M?9SR\>E>!81+P@]&J_6R0MNQD%?0MK
MH3[_W9ZK8JH#&'@W:KN1,5%M++:*3E1G8!R/\<'MU88;PM=A#7([CCJUWI$/
M*M]<9'!C&1[?.7,(HFD9@B2K:[T:8X)%\(M"B0;U@+;%S#NS5)2<J>ZAOIYX
MVRD(H"Y"J1,-/%I(2 @.=LZGLQV(!0^45.N\P!.:]S]."J(4$E85\=<IG]P,
MU"/2(T;*3L^FA[#1_F_OO*>/ ;33Z,"\\%9$/=TR4U8,1)890I@X!SN9;[R@
MC5:RVF+-+G?%65'R Q'7JV4B->#[\Q=!%:&BLD5WHCU#[QB_IJ$T*=$GN+8-
MX1CN7&4*C_X66^!@!-^]EZ!X@5T$]:L%"):N)J)Z _?5R/M*=LLV5FY,3<FK
M<>(B9EIJ#/<E"?WP#\%.6R7ENN)^(M^<J\)XBUMP6;N?%(T8QG'0<6H(J=E7
ML?4HW<L;CWV-9AA$"WEQAZZX^F=5?5&W.O^1T*G6-1"A#)7& >K33QP/M=DP
M=&$ 1/7&Y@6S;C*&SE_JZSYK*2:2OE;J;W(]HE^BOOX94L]E)"8@K&*_$;J%
M 9!HM7;6J38DB,6<AXT=UFO PV/>C,'L;)E3%C0J0G[-O*OIZ7]GB^N*:P_F
ML%BXAXA:[@N&R@TCU;(&=TNRRLIK G\XW+NC?(<*)](*A9L.N_-#_H["J+*"
MH+<<+%!C+7/=+#8R  /XMTV2<DC')@:0=X@!L%@?]'+D7QNCD]K;=H"+9H+^
M/E,8 +Y/X#D&(+J_^,Y_Z%K::Y&OSV#V9'!O4WA38!5,@P&81:UR;)\=$HEI
MSI0W"70DY7QP)4*MVRT;'[:<;TJ@I-Q.2P18)\[+YZ%G:0O;TNJHI#.9%F4W
MAI4<O[6XR;:W1\]3*)&K\B=A6-UR\W,L*-D /K1WO7I(:V5HLY%LG]W%L&&]
MK_W-SK&BT044O,)Q$,(Q[3ZA9_CLC<$@\1["IG_/ 0.XYT._W40DQG<[,N<F
M0G2SVCXXY=5$Y#%.\<WZ_/-*^"1L18&BK2?34JLVH\.>0[92\Y#GA<9'665[
MPVLI=[(COAR#]TSY#8.;TA)#OYZ2P&^'+D=^6:#1B9<=]=++NO.9EY##.M=U
M56B^_.XJ"ZS0$@/XLS&;CG-8.]AF_LC9(*6C .7R&6J"EV  R\:O,( [@D@F
MT"^(6;SK>=6,5_@TC>.&5\UI0=-,<(O$DR.\]O;:T5,B-=7*:URY39U?/>RV
M=R]I8F6'&$Y@A5M%X'WF$D(22B93:SI"@E@V50=;+$,$=9_ ?EW(-XSX/-B*
M\PA,.J>POYS=/WAOL:;?NV:J?5/H$5K@.+L"OMI1YB7=5*-$N*OT8:8@FK,O
MIU\Y[_O7YOU.GD'K0P)V"S.^-%WG;[;K:%<R>%3RK9=7CV")("MN?ZV$B?FF
M$#%0SH"G._.CAHJRP,PHQ*4I06I,5R]D2>+L-)F\+:A=B5!#(VAK)U]!PS^@
M%LK@TR^!?P0,1K,0%JJ]F."?!9>\37&>3XIB7M'"<62E@NFB<D_%Y=N!1.\K
M1D^O"]^L@=LW:(1TM6;(CS^F)CF 1,ZN.(HJ)31*2-J%?G4N^M<$TO)F*:J/
M83EQ2,D)RU[\,IUKF\^3J:R)<@,9^0AY=77/69W'=UTW <54 @>+]\5PLI"R
M\+49Z=S@/N-&MIC#MD=;NVBZ#J=R3:$D_2/RAL:AONY:?G)*!]O(X'J=:V'$
M;@MU5*)">:)657C5*\^L:!/ZX'>BXRA>\5WFPY8F<C'#$5TK:O,0@5MJQUR9
M99=6/J5>Z8T7Z0U"FQK1^G"%HAS&TBO7"SW9R]4E\-Z$8*" D)CD"I3M#-_'
MVD#B^;WBJHOYX%O![WCQ]&/&?J*RLR</)(#A#*]&86?"9U03S-=$90.E3)<1
M^ZFKC*P7&PTN(2<YX7FZ]=83D_,B=.IP>)9"*S4X[SA^KPI>ICV&M'<LM$X0
M/_\>]WS=!CW_ 7X8A=8O6N(+G!^[;FTL3 \),V/7[DT9?3./%YQ&*^:NTN>E
M#$] S#:+3$:6\Y?-E@2'K6C\D;6 <P+[ZD.&<.QLO(7XE&&UV>IQ+'EWF8LG
M>Z!?X;@)?O4 0G"=$C)[)R+N(6E.G_,3>TKGS^NN93)!Z$D)N@DOF244-1W+
MV_H)Y@@,P+/+W/:$%Q;7QL@J1 5+X@<3(-_"9]\ZA0,[$E02;[XRM7:^AS2G
MJ?R49')V!ANFYO#B,N=\RFW<G7#RI)%<*R'1I02K3OXU+M. LP1"<C8A=&;,
MD8P0>"P&8/(A<0 ]?JT4!66K/%@\1NT9BQ^!-55TU0>\,YF(36+'I%6:CWOD
MD[>&5:3(EU)^P"/;AX(EL+?XLF*="";<U7H^9J5%3#N\?<(K\H,R")<+GZ$Z
M70C-*T6=SAT116:D(;4%N.=+<%T;<D6Y^2!<:,QIK+1D0_YFEJ  <Y$7G1'<
M<44ITOG1A8=FKJD0D6LA7U>YYP^)]^*^+#.-^0ANN,O0LD0HNWN^9X'!TKQ!
M8/-J.K,'Z^9<BM([<>J0]0XSYY)GYRXJD2:6,G@$JINVA_TGQ#.O9)JF),BL
MGGO8Q':FN8R]T"343M#!?W!35@,7SK&6#&R!DB!%'::H-0-7PGF7XXWES<T=
M26.[A9A>"'73>FIM/25[=T)EQ%;[ABW[$-:'#&DWTGRB$N-26K6RN/.[@B@%
M%)W3A$S.0'.#4$J02U&PBXH!9!9XNL$"&@<U]@-OH*K0]Y/QKF6&T,/7=T$6
MUYJ'@OW3@G;S?_+I>.V1OY4L4<%6.P[30!U^V8SD'Y4W?(OB0N#ZBZ!R7=&Y
MTS1ZV=R&#SXNP,!&?MQ(Q&OG1>3#@=\)6+/@6U[47H3P69DQT\\=;B.H]&WM
M=U_ &X^N/V&9C>^4HY1'=?]@-F]"]JII3<<K/ +23<5E,!$2C'!=:5!:<?UB
M6X#D*S"8&? XI!W6?K.UNT/)A7^E-?=-BXN8BI-V;@7F;)Q!(O7^<?=\10W<
MZ[Z7<460D%%D%\DKZ@#95;T.#>5G )S4FYD80.@0!J"VB%:<PJKB'!36'2NF
MV_^.HUY.G?\^V'""?F"CAWXPA)!M[#GG6<, /J R^A8;? Y_=-JG)*V4-5DK
MX>\V,A[=_L0<D[Y#G6D_TUV$);!OR>*WWOC[@Q5&],%@:[(2]CMZ.0H%3@6\
MY[SIZYX80#,&P+"D )1$Y"W/FE6-EA]26L;MS<[0"'&EOYS&863%$<*!6C7]
MVR3!ZEB+-I-J1&MEUW4\=-G*?N^[H$F'$'(5=@AYT/*3:Y;IKAA4V7DDM\_9
M=:,Y5:>'8\@I*!R,9R/!:6'Q>=NR8&9MQN#9:DHN8M,212R1>B5.OC[1T9OE
M;$@86]1E(T*0+*BHN'T! L'$N%>'_&O;]%'Q*B-%#)=2ZT5O%1L3I]C;<O".
MR)\7'D6N4$0\;2K=G#RT8_CVX?GYQP*;1Z!6KZQ;GTZ%88U;,*WK][SE/T=4
MHW=1+)=)8!5[-)UT_-F6ERL\^-QX4DPJ5S(7D3VIP"(3[H^*,ZI<606V5?WD
MSA.2\$^*+#8*$G4S#F'47@E_F?ZH6?DV *<X9\10DYM&BXICR+14]!G"PFBJ
MKDZ"!/$#OMD1CR5!8@J.ULO>5ALS-F^65Q/H),QDL-2L.; %UY7\XEXHC53&
M-$.>C)Y;&\?=^R_#_-CWR=V2/I3PI\GE.X2DT*GEL7\YP,HA]QR=8XI]@24(
MR>XBF5G=F!CHI]7S[%%RTAD=.783G*@:];"I>B\)>/T%&,=I'T^E,GIRQ?OI
M?I;?,H'(P[O/U(^)!;;*M;*T:-BKW8SV3>F;()=)PZEI!E.-,#3>)3"%!\ET
ME#%?@->:,+I^[AZLE&BQ234X9[S0V(.=_SRUI8B\M.W*TH4^H@!-N*0=E:MW
M(*#U4_1'/L-0*9N0_I_ODV@S;+4<V2EEAVUR:HX%]]J6(DD0D)6/M1/\1&H*
M%==D/9L&OWH>V#)]%.3]E' *F>EJJX5]1@(S7F5NQR=DCBP>NNT5+IAI'$^;
M!.+A"!RHJVOT,VF1TLI'E&QI</)FO5&/^0,_+S& = 1XQ>Z/8A ,'0E:R9%\
M>YI3RH>=]G465)U*8-WQ/U\P7F7Q+*YR?+&F.R)L9<L6D&5']Y$#[*K9M5U.
M0E716>^"0L\I/'):H?=G=/447-V?_E#W(^-FJ)2Y(<,X92/ECDARG62ZX\!Z
M?'Y)Q_]QH:.J?W[H*\0,@H.(E$1DV;GF(2#J8X52!;WF=:71C+B?/M5\NSLU
M%2U=VMF]0T=I%!LD21^4+&4:UM%'I:(>71$;VC:L[5:=XVWK)7,4O"11LPRE
M-F#^E&Y%G1WI>'WM4E+A'O BQ=@F=<E_3+S$</&:%7M_^.$G9WEO/87ZT4UO
MJ>3W]9^6S<#L/-6W 5%?W<]A-NFU[!L:'$9HF, L^!7KTC+UP@SW&OE)U[[C
MLK=Y^U>$OB6UU/E/(VLH=J2&GO=_/JJS$!HD!K\"OQK1I_08(M85B&YHZNTR
MD/64%9+("43W--)-U LN*]C2Z<G7CZY'GXK(>-K"R[CC;K]XQ\MGN"U%=B2P
MP%SPL\(Z2CHZ0T%-Z7=;Z>]S__A.A/^-K0#XT&WW)5P\<J:BX0T-&0-KF"-C
M2J]_'/*6U^81SGGIN #P^5AK'/17,;W$O!-.O_>$NP;2U8?\Y ?LONFE" 9@
MF7<(89\$NRHE1RT&-4]U@.:[%%'$66)2*PW UN<0JTEG#IOG.,F%]H]4U^Y^
MS<@'OKL#NWV4L^]NAZ-DLQS..I=DQ W[_G-S_+4PPT[;-OCY+O5DV@KA1OWX
MH:T 824EGW[OJ 2>9+2'IP8[TI5_=<Z%'=[";4I_W7?XRRL6.93?9O+-<E?G
M!%1#QQ(J\001T_7@X62%9V+W2;5>W"P!U**3C-YC56!@1,K'6K="__7\FU&'
MF)WYQ17ONT;4UG$$W=AA:$_]TQ[/7CT?'-))_]0$/31L6Y]-$W!Q9ZU=^L;U
MD*\#?J?(1BVK4?Y*3L_+>TJE"NC7BIEL^0._W)-LR$_!P1#COLOZ/($!'T*C
MI/J'/%1RAD(+LR_$(0%H@6TT'2K!BS#UYX_R;0'+<?^-Q;?]O#Q(PL!.F8\>
MJUG>C<2?3L(TR_RRF^HQ "G7B^FCG4U*70^6@6T, !=1VMNYJ5JM_?3I>FUR
MK0P!A?'IS;I"TB5@I,!H-C>QOFZG$K>7)E']/5D'FB8C9+AW6];6.3534U2.
M]JRV) 8@MF^D/76LS+[N74G15B#VX<AYKJDU&FF  ;SJRH.J0UK]#&LQ@*CC
MHB_7]-84-'J:4WM[P;B%F0K"AU%QTS>V=\>O'+=$0'O)2WWD:NY<&7D]D8G]
M2=(!U[B R/ZI\A$P.'"9-IZPXA8+:K</[N&#%ZO&WS&^X'(ZO%(.]5NX/?(F
MT>[N-!\;KD K5?<CCV[=VCZZYV,* 5+FUD29+]XQD@3H>P/R^;7&E%N-X+WC
M;)T27[B[3S8ULY0B%*Z*<P]8]/3<S;R^A<LG.3=3Y7$P=,0D0HCGO\[J^$H.
MZ7_%1Y89F,G\Z&%08.A>*ROAE!-F3# E4\93699M+DM06K%\#FTF/A*HTD93
M#)U;0Z9>(0,_:/6L)._*CY]:(O&Q,[_!_[=V8OF;NG/^U89Z6D1':DNP@$9>
M2]#[(ZYXVN/<FS0(#=4=P+V/T>^^$CMO>88<6*3F]BI[C;B8;U1UPJ8A'8M$
MQHEJPTQ87*EZ9=#?N? D7IE5M;T'^"@7A^9;$G29ZF:C#6RV]L@N'%H:[(?F
M>V7O,EFR)<'X]4%MQS<&1YY'!PG/U.7'J%A<B%5T\RXD_(D2*@ZFP'S'E2%G
MP% ,H P:BB8JT[>*.S+<ZE3B$E?MJ7HM-XB#$_3JC'((D'"\,W[%[OQ84VS8
M55**3(T?) E92I*X ;\(E:! U-JXOAX3*+?1,=*NH&'=), E4!3TGW)?15IO
M[9N?RR- ,,[TS>7S2(J$9XO&GV=6DX[6R6<1[^LCT7<2S=XAB O?COS\@902
MUEKE3%^8(^X.VCW<!>M-B276P+_O3#"$0#D3IFI.-!NPR^ ,(9C?N6N99>7Q
MV,AWDOI;F%8.P^ )GNWECG=^-U(#>T7MIWA($-*5T1RTXZQW_Q<5!I#RN8T2
MN'>R#W8;D?_QX]6S]K$9NTW8AH^R6QWZ#@9P%-S:QQAWI1#Y.2VR($%JIX0!
ML,:8+BB6]([+0<0XX0A$X25TI.7+=5>"";Z1ER:Q[[LX(T=0TT<<^]WHT\ST
MHZ\?[<$USG0=]5HNQRUB<OP/\N08HEYQY%$^\A\GF<E/3@D7VRCP$<I! /W*
MM?;L(D F=@&-H)-%9;AI>-;XP(; 9!Q14N)EG\^>KUS/X)*#N_ CK:$%(0S
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M[0V3U'$/7RT6W->4WOZE)_E[M.RMI^_M.)1B-F;T",11,NL)&];6[6J0O,]
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MT&CU3X7R&UO*NYI\WK.Y6-ZD4'4Y41YEHI]QF_ZGHZ&Q8H1,>!4#K^#/)&K
MZ0['T-+1[32[\"K.MA&TW::N)IHO^2/+)T;ZW#=0+"HXDX?:K<S>*::M)T+/
M'%V&3/AM<&3-W\UCO\K'>?%@Y!]]&NF?]K_0F"UN6&1N;FL<G!%ZDO>/WA*/
MSP,% G2RY?D_/G:G4_'67JGI&R*38];\)5:!/G& L'>FK,CG+'*4A^]T^HI8
MP\CT7D41E.]?$@^6%-5+N=M_+7H,ENT")9OM9Z;><J>6YMPS:-!>&[-(]R6U
M868;5\:QR+')7O$E>*/+>J/.DNWT&V"&S654^89"AT@(P)1L3U7YIC+6O6,O
M4Y--O1E#E97N"[1S%D^T#=+ZC&5STX6)($J#MD\BA:U7J$D4J+5X.U,93R9?
M%Z'5I;FRJ#=66%3=BBKBJ8',^^0C2-2][L#U6A>)*T(+M62JOLW-<;5;KI_@
MWIF3Z91VZV%,$3DK2*@R_6E@N7_]Y0?>A4<>DL,O&^>.9KD]7Q:%JNB;WMT-
M.^HS8SP%N>/&X$P5_4'H*J/7TS4?'>S2CCH&L6_9'*37AHGQ<G[9R1%8>"?_
M/Q(RT >WOZ8I  )Y[A$O5R$57&)[O%[B[+D$TUX&7RHS!!7""#" KM.FLWXL
M?FM75"R#$1A /+H&N,$10X&\0SV&B!H?D2(_SDG_(V;?Y>8'$56/WYC+O4G\
MP1F88EU2='/%V-Z>,_-=W4/D@,<O)SN5OE+A_(8'E#]U_#Y%*P+2ON7?E\9?
M\M?UH:RZUFPP"UCB^)VY)7VXK5EOFI4,TG)_@9KH-,%#P5: 4%"X9Q>5OQ29
M&D[U:%'CKYRVQ\(VU1_.NI<F:C?%.%R#XJ9/02(H-[PK'XV1J9[W;-?L12P9
MBOHCOSG YG]ZZ/WO.>"NU53]L+)4XN-T*\I3&4\\;^@\=%N;-E=41GB[Z_)J
M0I<U=9/@8WB8S2.U$EG5^4_"S2CB=86B5AO\63?& [RA.2X=I0]'D2U*FPFX
M]F>3OWHV=5^NK<522:!VHXLB7\5X^^I[=W*@((6WH^:&L0Q)X/?_9+,&'A,E
MHG$P@#2"#>OL2="_<X4QWKAEPS9KXE_[1I^=PLD]C%,[W,X\!9[\C^VUO1U)
M )P<1@!Q3XDCZ6_7P ^J4]2ANYP5^,/\E8XNSD,JO^+#VQ@B\)&],>?,B/+%
M^]S(I];+-5P^/8_PM.88BMV&.)[T3N,Q)&=PBI /^-0,B+EL-^J04TQ$<#RX
MZ&"MT3-9@#0BB7OSY#)&6U=WEM^OTJD=>/G#<]!WTM*V.<@/VY]Z*)C9GSQ/
MS(RY57Q&Q$8SY[QU?VK<\#X<\JF1[!<-B&"+VB<ZTP92_ *G!XV$NE\YO_=0
M<<W5!P,7W_2#ZH9]-/1LF&?G6BO9*QD0T4UK'PS<TC<^?-9X!P;76[-;YQ7I
M\7:/ L\CK,2HW\@\4JD,P;H&BQR5$( -69TE*R![/T?EQ=UTJ,+LBSO8A7+3
M)GMLJP/ &Z*O^B]NX_]A[[VCFNJZ=?&-("@JB(#200$ID=YK5*2+2.^@@%3I
MTDM E!)*I$OOO41Z+TH51'J1WJ1*;R$)R0V^W_G.>^JXY]P[?N?<WWG_6&.$
ME?VL[,U>:\[YS#7G7'84N=;L>!SJ\N\#F?EYUWL=<=)&Z#5:"V+K_YU-59$(
MG*X_6[G_/K>+8'-\>]/O%;H;H7-;.]I?2IIZN2Y<4OU!""3TF:RBL9F#JU!.
M\F)4EH.6:"F*E%J9X?8.'R<6\!5UZ,L\9\>'9Q7I;L8W0%>O:L%<U]OWBM_\
M-Q#@?[7_*TU1H?_A-07][#G=!6=KO6BJOM[/FJYLN8#HJY:X&V-'MT$-UI?2
M^D;3OY17D]Z*B:VB8CP<"CZ@#&:) "6X<7<7FL4\I*G%L*3YE-8=:*#F.R!?
MRA,3/U;>^N85,YXJBYNM;E,J54 L3C3?YQ >*<@@5%/-F7YXXX)W=8I0;++C
M5:GC-.:E&(JJY_CL^2-N@Y<N;FNV*A;YN JG(G'SFWA8HZ#+"J\*-X1@*:OT
M!]R\5\9-V)2W"N96\V,JLK* J[Y#>/!5KX]8(*\<M@K^TJ#L'5*6?4OF7D\P
M(G:UJ2N_LK5NY.<AUPI?VG(Y$@H<]8+2AWT,+J].[CRLC=UO1) BM+& L2S
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MHW9T\9#)!UF(ZCNFM&]J&=\T$(O7->R^=THY9>5W/TQM^CH"NH8%Z"'YK=6
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MOPK& C,T?Q3^&;D?+<ILS>(:06%>28=W+ BH&::>=L*N;!Q0)!@&]"R?$A_
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MRL+51G_J/;O"7)>3U9*#'D72+B1TA*63RTO#BI0L6VM5A3FF=Q49'MZ%N1'
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M@>S>LFKM>(-$"%_?W/LJA@!3DV[V(6+L(/3-<8EC>ETI.OB;Y=&OH[()/*H
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M*RKNVTP9I"=5Q=M6XI3VZ/I,&50\;'?23+28?J$=0F:=)S1BG0IFFI;G:WQ
MSC*E>-<(O!B_3Q"<]%1'C-Z;HWC*$MKJ.YN8P%V;B[;5\%<;*2D6V$;3.$&$
M?E*NO-J1\78\@)ZB&\I@WCQ+3\L:JQ?O59I2DN0TE#VDF2DFNGP&6UJI>;_8
M9 0FD?EJJJRDL.>(:!OIX-2$KOD,N,';=:$A B'>&G+-U6,5VP&SY!WE0;)
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M=#?IOBIH1L,/1H[:*>RG)UL^ 7W,<(V)U.%9K/=[ER"".9\+Y+Z/1(>-OAU
MJCA=I6BZGY8<[+<G/S\(I:<8XC:;Y#K4IY/4^\ O[Y)]=@UP CBXW?+YY*UT
M4'#J=)#3<H $!R-=H>9A9K4U5.:1TC/+T97:"[MTO&-(ZX5K ,XF%K^<=ZHD
MT6Z91+^&)G'"@\AJ0T6"7L9IK$CLFVU^]=Z?;=*.),Z'/JUM*1A< R);MINX
M&Y \;V/3.M9G3*(>DO!N=97>O#6UVK;T-%VC5\]06\D,,R9-R"SE@\EWBU$,
MLE0U3$/ QA_6)3+C#30PY\7M?HZ61*7P3=_8W7"$?60-*3*6\@+R UW2Z0%J
MHV.VK")^1D3/*&\"_5;] D ;G3R^OG# KC2%\!JY(@[ZN>(U,G\Q4=>?X<57
M6E,7!Z^PTB#EZECIKU.@/6$>QU"T)W2U1SS0F=N\ 0*30(B%5W>+#%OF+4:B
M)75)<?_IA%4)X(&_&JKQ<#M9(BQJ<#5J^A6WM,W"C,D!9AYS,@N;,0X4=U-G
MBS3^0L;!""!_L0 0Q]OM&,TQI._';" GCPJ43"C:?,@J#F9LAN.2#U4EMO.D
MCE)L]R*,+A#C7$^-WOZP['B)U_V7CA/L+Y^>I%R$AV>YE"3_/WPOD#(+LZ^Z
M&SS!(.8V3NS!-6 ;SK$>)C;G4ED3KKFX_*[M(/7ANFI0=PVS-V)%2W>T@=/=
MB*[=*Q07^$HGYI\JU:KRJ@HB9)H4_56="\?M'^"O7M ^M;!X=#Z5*6K0\]UQ
MU[?E"J4SWK@HXJILS^VNA7_^XQJ@N-JA%!7ZW6E\)7)D6(;\,"CSOW**9F[!
M1@_C&=;Y'F4 ]:\!#+#8\D_Z!J^(%\0#0%^*FA_K>PV]?+"WXG(,1.2YV9"R
MY(9]?&W5YWC<=<38%(U#KRN\9P=VC43>=+KQ+8!,@S5&FB"*^&NP'E#Z!:W@
M3CJL>P5:-]#NS:^J/J**LQ26'<FD%F=,1N1H<&Q?J);/UIK[B[ZUEHAH&I.A
M&<(9&\'M?KQYL51/?<!/-6<?9/+3;[CTC^>1V,M_X?_POV?3\U<Q^^]5FP#
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M4F>[N(F514R]T<@M>70LJ_:V@V4* 'LN\ZR=PS=*11H:"04V,8,Z;$,,GZ
M_P]S[QG55-2UBT9144$0D%ZBTD% J@A(1*6+]%ZB(C4BO9>@"-(1$%%00N\A
M4D*'T(LTJ9'>03H!$@*DW/A^[W?/>=_O._>,>\<==]P?^;'6R,K>V6NM^3S/
MGG/-Z8$S>/:\@CN\$<H'??JV]JP<,0*;,NR:WP\ET&/>%"?Y^XK93WQ>\6;L
M?Z*E7CO?0*(")Z6L+^55:21N02M1[[O*ER+&\G5^F5];YHV;;S\]) /.R6(O
M^I,!+60 75G8@J*Z<'5@A1W4RHOJ!(9G#KA*BPR1_?XRI#PVR5)=]6 >HXR6
MR-EVVVH8RY M<4>HZ#UI'*_]W/C$5R.-TH:K7J4H4F14C$"<R)B3?A?261:N
M__XKGY,)K]9KB$E./%*CM]PVOO2.5V'*2_FM)['I;.5C)4"D5J)1'[=U[$ST
MG+%$BDF'5[.U<=2:4)4QI[K%->XGPT:_G=4"U?4TN1V5O&TT-CEDG@XD*2!N
MF\0FCINS9.48]9\P%O<@LVZ/:[)4.$[<&4IT+BVQ8(0;)4($7)F4C8N3X.#$
M@'%-DW+[PIR;[:9?@T+V800^FTN?=_EF??-KIFZ\[7T6#Q*'+LAN,L)-,MAV
M7R2QZRD9"*N;_%%ANUW3AO[,4B6JGG-U;-S9(/\4=FEJ5L?6^]I 8QSM?GTO
M5[2;\=L>WAD&,!QVN=$?V#$4,0?$\ 4^GK<4_FZ:_;3.W/0/M^5^9X@!ON&Q
MZS5\CM$H&Y?%C)*SKO?03RA#&/@UM%4YR(Z8M0"[CK<W[:]WF9IMHP>+V[52
M_99Y19F8K6,E;E6!M,F<PS/YWDZ8F:P<3$=VZP8_KP&%!9>!NS/NN-)M8"S-
M%['I!\/F3TS=>KK60=N%-\^2J ,VKWFF\C!%->H+-,@D*%XVD5_RT(CA]HF?
MW(24T!:=/=G<1@%Y.68(&6MK-A_R6A>@=(O3WGUA?!4U<SY*2;I%@K*MCB@&
MA&DG:VJOJ%S"FR>,TV^3/15+_/4+N!BJRA^$KL-!2[[194CMWU76$J]3T4]R
MG0>9U<[=Z==5O7I%\,>E*F4NO,G<DJ-];,^I>'JSHEIB)>Z#>.>N!M;#[T@O
MN[EDLDLF3V%S%YR*K1DX4GICOY:C:T>$MI,!K0],NO;G+#I%NY[[LRI;<B4:
MIAWH1BO+?)Y1MRTH&0B4CLR,EF@<? ;@.4%H[\_<V_<+U$DP_JA=!&]\N=IU
M6<J%LX[;?^C!UKJ[F>Z+RV.HSE]8(30NR6UG#$6A$VG><3*&<7*AC.FZ^4@
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MZ7N-BJ"DNOL"<T^K'/9OJYZ*H$>Z4/?(@!<@#FB;+ 8I4_=JVJ7,O-<I;'1
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M>)LB'>?@,,;-B>;KOU0;56W-1KG<IRH(@B6.'&KPI0=28C:4FV;X/;#FK'_
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MI;C@/=NX2=>XVT!LI.TV"^G\F+D4:=\MG?E!\=31V7I1;[E".W% .M>+X_[
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M77IE4G$H4AI(UU _SK,[]@XKL&'#BE6JZT!)Y["\_5!J#[]_W#*+U:7S&WJ
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MWX4]&<R-TE! 2BAIO>+>+44SA43Y4D;,]P"MR\.(2J73\$[7/!%Q6KY&W"8
MS<('B=PEN[&\RRYL?>B$V9HQ#?4[,)S2,W]VPF8B/1WU$.>/2DFFW SD\JR"
MS*?5C%]^XBRMS.$IOEU#9$&VD4T8@"UC!N */(X!@#( %(.B\2UWV_+JR.EI
ML?"3'Z^ >5N^QKYD(R#_)75Z:/G072KG[?KLFFMVXHS_8AIBM/=N7\N\6.3W
M'!-K1#=*V3GX1U\$)DI3[T>5U41/>0?D05@_A9^<IDW+I8J$YN:2W^RZC&7!
M0XQ8NI.V,1]/@X<C\<C7_)K)[[0N3;B0W]99F_=Q](I"^I%2=/!O;TD<07RS
M*(38&<IJ6NUFHGK&52#N0["'L3JVA@=OI;*[R65#4+4RUO/Q((3D%Y<FCJY/
M*E<5W9WXKI5G49[WWD-.'R$S!5$GU1*$L**DCS9@=LM?E@4)[N<CEB?3DYY[
MQ8>J/>4*'D/#>[&GDR&#?ISP.;;0ZM.3?[;YTRM"V9EAY\A7.!<MJ;UD,4!8
M=#B[]CT7O--!P(T!:-@\TOD-&!.R5%*LI$2PG&S[UGSVS?T%7F/#)H#I*+Z/
M>Z%PH2#]6=V3@/+!@Y!J]PNI8H=FN_(<?A=OV]Z8X88FWVW'N=98-XCE]+!V
M)>?I'MRL L6A!4FR\U.@9K@&9M@/[%S<4'@EB(?]^6\5%<$XE!YYJ&.:NXPP
M%N&A$$7K/?_)(1[4*! ;#>J[X[8R.<-TZYM3<A.N$P[$PT.'3]T"<7^R>+E_
MUJA$7/OAO.+UHYQL,^2T.HA)K?.'0X.J6"Z&)W'.N?4F(]H.^DY0;PTT!%:C
M<PS$VI1*O^QH.!X1/7N#6[/^%?02]7_+L=[K:T:]#4!PE/@="?AR-TAL[HY]
MN-P%N=K5MMUT,E=B;V 1\1D#\":M+36IA $X)3Z.'7^Q>PBRG:GP^BF_S$$W
M'F]+L?',6/H%_8UV+5U,B-3?3E[__H(W6H;[C-',@4+%&+1I'>2$/!0+=J+]
M_>M!AW\O0CN.C_>$":]$\!FKF58<D\"V')^S=!?80GGLF$_V[30T_+&#_X&@
M2WPQY(<G/GZ9_3+P!1-])7774#?SQ!4]OP*5S4G$>_Q8FR<[Z'6#6^':4[GV
M\_6SGF:3RW=162SKG"9X:$0^ 1GENR6M+V_]\%BT]WV;TD[\"6PVJ03_D/M]
M:F+BSCIB/.#&/5M_"BAM6<8;UU;3++TQ-O&99(V_RAW!OSB1FXHFYFZ=BKQ,
M])3L[5ZD$7_>:H=?UW_MY?7S;"*(:*P^O3$W/=JX3_+?_45>27],+AG&!7GT
M(7J_[U'< C>WYE_SG#I__\QY7[83 +0*[;.&D&R4!JM44EF*I^\*Y8ESCMC'
MHT+@61^F3:+ULW$NWU\\V942>R!FG5^R-D[-+.BRW=#G-E&TK]/B(P4LF#>P
MS!=9VURC[CW([5\16-#4"0U!>D'U="FZ@=*^.;[5RA"?ZBN=F]]%Q8?\E1 +
M(VD+V^/5^@3IS8EPI!\MQN^ZM.@)3;RZ\.Q1-J=)D8F_'5/XH.W"ST"5E4A9
M4,CW9%!R,LUMAT,8&!GH?[;9UD7B@_OXMMN^17ZC: DB9=_/U;&&^'4X69*"
M@W0M_,'>(+7L6M355XUNE]"'Y-4L<O,&-3+//%E\ZB0DN0$]TEI\=TY3G1*\
M5(IQ0L(VN[X^R;PS=TN0@[NE!AH!K)A.G*WOVA?26:#8/T8N(WU#[-XWWEE<
MI*!Z&I]AQ]Z6I[?*%JC5)II>[W7>5<J9*2FE5EG[.<6EV'TQ=>4-S$VVM&
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M%S8F1##%7H,!R@CMU-32#-\ZF\)+M%6'J?.=PZ]ZJ@OY^O*#T*H86B+LW@'
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MF%X=+1LNZY*4BHAJD)]OM/@YZJG%RP#,\3K[8P=KO[^XKG&N6:7T@"A$<EI
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MT'LW?N)B@)!ADA.=S86? 6AO@,%6MM8AWR@@4NH";C:- 6 &=J86>FK"/&W
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M92^^E&:NK4=&IUO/;_:E4A$4J=\MY5.!C[>W=,<H6H37W7NZ*JRKO]:&QW[
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M'#41?>C-JU-,%^CT$^8$44'\FVY5M&F/XA5SN^Z^7^; '&*YH\JBVN,PU:C
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M?;TU!O)-*>ZB2'DXV%4B(5BV3!QYI";7^\H!#[A%=?F2Y=YH_SM=TG]/A&?
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M8_GBNZ],63M]K_IN1V?OM"LB"7<?UPRZ)TE^U:OF8>.8))@W+;E SD/8_=2
ME.71TZNGEIVPEOH42:V5$CX]MC.]E/NE6"&PM7/! Z,7T.B!S8)9.I-!'>KB
M3(?+%$.@NJT49JP^"S]__3K4)#]\=W/_CWCPK\Y!*GWW32N%AA>2M1L_A0ZV
MS+&!TOP;-!&D>1&69<_):.Z+AW.$H)*SG8?J^ $\T"R)>[AU&B,:6N8@R?OJ
MYVGV'Y/B<%A%>6QZ2E0F8DB<6T\K>SC1.33>H:1^VR7]-H["TV.^/XAY "IF
MN_SK[MDN6ZO:A\=/S!4ZV8\(_6^P=\!NS$'EK[J]D-I63#7#"B>0]8)F0CPJ
M;9&&1;%$ W0['"5K%[V';I)?1^+?%EGH[AU").M%+Q_3?71$-OJ+:E.*,>JG
MG+T;U6[YC&DB5]F#CRDN?V[X!0_*F^8MQ[[]&Z[V0C>^R"GJ&\P!--':UE1%
M@=;U=+]0J<#UB)K#3KX-=?[\?5"],T&_AC7ZXS)B +E@P_4P\:%)ETIUC,>/
M&>\?C&UIV#]7$_%*;4TFKY!K"WR@,]M8EA7/NE&LV+_/N\35$] *"<&1XH$G
MEU19_>'_TE/<PC_)6WXAA]'Z'YJ@N#?=:K+Y;%6+S6Y\W$KBR#/DB=!Y'@GF
M^=UQH D0%CXN8L__B$YN:169'!Q>J!OE9ZZLJ($?[+XE;[]11Q.K($6M^U[C
M.Z(09HT'T.Q$D8VL9\;I$?5[!.OL)-^GV^YF/EU[^$QCM\XMCBCZ&;E%EL5-
M//"V*62.8#L1<L=&0,[/P*$..;Z'L#K^G?..[-3 [D+OT'"O,")(ZGX)VG*>
M#$/IW#;[Y(*O?/_1"H8[6RE ?JATPD0KGN$>Z&')P\"!E>;KU#H6&2!B'#&:
M?WXL#IN^0'IM7$E!D^V'_)R+M$0WMU7*NCK12^Y+S.A8V5'ZN=!D\6IDHM+J
MOQ+WEBO=PYS<M#73=,16.OEO#C/(_K,&XH1_,+*7F"X;-F[8=$1=%ER[=P_6
MM3YW/,:/O6&?^1\#3S^<PRQN0%GVOZC>]V,;ROX1(W)F, @D:?I/3,8N,6N(
MF8=("06:]5&GJKPKIKD3MI% ^_1G>Q"5EC'%_ZJOS?\G,8B#.J,KBS'@NJ'7
MP[PE^295,>D[-ML*0QF6]HA"A, ESB_8M\82'CE?[//C 4;$ETX7=X.DU]9!
M92M]C-N(H36$(G?;>%Z1+#=$:-.;>R4*;1=U'S8 4< #311X8'\2LE D:80'
M9+#T.(SJ57)L(-:GNPEN@;Y=<\+'7W'17[B.2$PZR=LW>0*:.!=E!VU:X8$E
MY#:(QN_1ICD!RCVUV!9EW/?!Q85!O8;CM[^P0R>!(<.*HO?Q]VFMI-??D>7Q
M4\NY3HX2.Y;P/)//N=I4.0DK/O9_CXRY?^%H,-!]LHAZQ_SUTS%O!_UQIK=K
M-6$R2W9"))3,C(JY/BO>9V]M0_HND;)12TVO.U)_E.''-_ +7@UK'1_3J^SR
M2,W_G?A+T2G(=30LX-7! )%$,?]5U11-J4==%B;X1^IKZ2J"KAG?S;P9.^S?
M9K!L 6$3FMV;%_,2%=?>7IG!-!^,DQFOF..;"MP5LI! TVCB?N\'QX@]M:CB
M$C@B/4@?@)^+:ELDTZ,R[NB^#N,@$ D3&1J4(9VTR=>2(2G8Y<WZ&=XI>)M2
MK+EP7[DZ;3)#\LMBTL?CIX[.;COBMLYECLSM0=^TYINYG^B(B9V%VZER=,X"
M:0E_H/PH8YN3:XO0JI U+U:QMU+*K,?@O>,_Z)06.>.AM9KR6CK= Y+;B0\W
MI7J6K0^IM[5^LVUCPV=3,9%WONKU[;"<,OED_Q5MZZ>%-C<M, SFDK)PDU9.
M%^H;?M[-8.S# P2@=O/VZHIZ[H5BR*UU]SJS6-PN]=GR2]'?>*"=Q;)88'D,
MZ?*ZF&NXRH^ZY@SS)TP8^\UM9E<DS.WQY)(HQ>66N9F Z':>C%M(QW U11B?
M))&8ZZ>XL9\$^1,2=L?'4OEP.VN@;_@AQWLL4)IDGZ(6]T+&_)X,+\S!%E9?
MO:>"]MLL.TE?/" \LI8J3B&_:V-1SF^YPC^1W@Y[-8X0YDR_-\>><@MR.$KT
MT-< <MJ%R F"@G(VD^B8"NT+C"%)'QP?]=+[!*;W-$Z@TD-Y,68+4XS&XUBS
MWZ_"UB3HLSG/[RDN6,3NWR<?+BH7,%95W&SJ\U,<L0*?%=;QNYTQ7G?47[+K
M#RV:5IMLE&>:CK@U6=HQFDY_%3_X(F S$%$T[6@TV& <L:7[>C#SJG2I!+U<
M+-!M_/CU8#9#@KBR4?=C+M?$JA?=V?)O"O6-^XVXY.-FRY:%S2FUSV:/-?J$
MO49V^;0'$[-MI38)V1L4AK1_;*L,Z5(HO["UN\U:6&M+S)I@K)@Y6]S-]G8B
M2^Z-=S&+SK)W*6M"BD@82TQ13JEVUZBV0DF*B%*80E$L4HW%K2@6_*9/BR0$
M?@B)FN7^QR2X#U//+YR.12ZX+,M:A)C/'<]@\\\:.-*.]_% AP4#K,5QB7,Y
M0.W<+<UQY[OG2[++E46Q] _<.14TI6]_'0<C<8-EMGXU.*&B,^G5.!0C!2G7
MC2/M>05[6, [RQO.URV+N[:I%1>5$..P$#_2:K3/O"]EJ_O7)QO5A3=1 JM/
M:3W.*^\[=S328#_AJ+H7^S\/H2MV>3;\0*9MABYLPP'WR$YU*WT8TY#GU!:5
M"Z_>+)^GT][+&RZD^ZERQ?0S;AJD0U^B>!K9!Y=&JD;838>%6 F WQL8+1!"
M:U>JSYL\IW1=/XTIJYAT,%7%I9CFMD,_)]IB20FY(_ HID)ILF?&+SBK 2W$
MA%CDG,FU=X3@I)GACT3;!:Q(J&!N(PQK=85EU9T+?A%Y:/B>437E\W'>5:FL
M[_?.0A*AEF)2+M^L)3^86:C?\!ZMO$%;^\JU:?[=<$NMPBBRW.#%,/.0PU*U
MOX#\@^DU'M_N8JI-!02%]GL/G[0P96YF3KK$L)CPJQD,I<KJ=HX ]0B:C_'[
MC"IV]0Z$('W+%.G>"(K:KKO3]&PJ'0.)SKC%[GBH-%NB)OAO]%+_&/CY<&D7
MD=#W,YKAZ4O5A##%YNLD793CMJVG$%OP/[F%S$CX_")'FL:I+ERMH/C[HU)Z
M1O?-#GY>]Z[43_[??,5RZ&Y< '[]>" *@1[1L?5P/YMS?@B\B18D6N1.T\[4
M>]^=?\C+J:@KY^+&.QVL_.WG>?J*EI:\*VM6R6=QT)U+X/OCU?"RSGGZQMFX
MO-$LZ+-B[C.99FBES[>E,P)CX6QDQZ4UTOQ')<\/,Q7G*HMIY9_O^-[YUI$-
M_?1:N=?*^NG-H\3. 0,"F=MF?Q(>A*A5:V%_P2B[<6YM"L'*U%167^?O' '7
M_(%?U$MOM8<$Q MX3>Z'<2!(MOXK__R5L/Q+25%QTC][^8_$/%#IB/5([Y1+
MDVN>&?U?5289\!8IKMA1WFVO\8..ZQ@R/30U9W'I@>G(4OSM+4.T'-(*GSQ[
M;_D>.")*7X.O<'NT?'"L3>/Q728]8X!MC] R@O_%LV\PPMLX824L->%Y?@PJ
M-<SRESP(JRQ47-ZDN1U.P&*Y 2^5H5D8*WL5]58/#TR^4\:YR7_]>=\RD9UU
M.#MHU;$\6PP/O'E;<OEB?N_6)SPP)X>Q82K)ES=,;%EDV OZ1<CZ,>8L#"$3
MV=I:8V$SK*=\EB5!-ERS@2E6_]%'HTWG-FLAK1J!B)P-0>'R?K*]>A2L3:O4
MQ1)M0V"3%0:$J0>7(ZG/C*MSUNT?8_WT,^Z"C"P:3(/V=,S*RD&S92)G[SK\
M!=.J)$6]A??(;9.>+[RJC9A:?V!]5$2APT&XV:#LI^L,U:-S3_#!EBY\(?Z]
MDAL@1C;R,7U<>!+@% DSOK1C0XZ7%HRTG4WZ\G*&L38]2E\>B>J]BH;=69#T
M16&1O6ZQG,DEI8$:CY,9O$2M%%8^B7B2*)#1-O_J>"^!K?I:6JB?2OM!-OG/
M-SMNI;/BA?Z@/3<U]26C,5V1['?->=B_,C\(GMW W2O*E-D&J$>WLF"T]B>S
M%,.L L\54WS?^^-6[WFM7?2=*M;V6YI7%ML,;FKVE@<U]/*-?N-3.@\_-/(C
M0KU@(BZOE94PGS/K>5M;[WIG2.0)P+ @LR[H'3<]7BG9(M1@EE-MUK00>6O!
MU/%NJL7Q]-3PT93CXX[9GC_4-<@:60:MA[_T"($[::GRGKS5N_T:KZJT=W)R
M")3T$\, S%6N1D D5 #7MR\2LO33L/QF+NC$;8MCJ3^<DA[D'L6R00TU<0$E
MTS)V/FJR;(1@^#3"+6X?[Y$"62<V]5N<H"Q3YAF0U$<66^EP^_W=@S^^T@<^
MJE_AQ%]9;7+#9(,5= )RO -(G8E<?<OT+"8'3IP]<68D+MJ%68L0/G5Q)GFP
MFHUW&_(1/-2VQX:3<N1[=_G' JKAD0&C)DN7@=6:[;+R2/MPY(^_?Z6XG?[L
MY0N3L[J?&)B)E?:J_ODV3F[M%?[!1*2F06PQYE.6^UC-CTYPL;/OGJD9\E3=
M7H5XSUM!G=WZ;N:>?IPF$[)+L<!G-&%$:H/V(%7CQ/^X(&=$:BL5-W!:,*=Y
MFB&F5HB\6S_FV'YJ;B]BCP>\,Z5.S6WCLTSJZK?B#,>34KT*RA!UAX:G!@WO
M;>$=S#YNX_#FAKK-#]KFYM:28XPK8Q_ZA#RS&HX[S>W94L \!\D/SG6IZ#[;
M/18^L0LMH+PWXF"[?7E &U#H?D=B+,R_"%CG0N;XFF)O>-,T:P1[6-!(L]G,
MTM>0,/](^OTS&;:24'?(XNORZYCU[M'';ITOWZH59]/+:5HMT+)^)%-V'N0.
M(]#GEQN3@D+LWM(]Q+"3!6Z2[OQN5F5EB$95P-@L.'CVNF%VA,*UHG! RI^:
M]X.HQX?#HE$SN]B"\PAA'7B*4AMG_+F])I'$4O_-*?16JP?=F[[EOAA>9,?T
MU\>F.RYGT;ZR+"S@51 )U,#-TDTZHBBS9H27]8D:\<FKC4TR3>][LHSVT]RQ
MX]*T&^)K8;S'&W0^/G\'%#EJ7A:_R][=>_!'\47 W:?; EOS^R[YZKKV4'Z]
M93PP_PV\KJ*MQ[EWSH 'PJ3I\D.1;SQE3.A7#O;<HQ]PG"4,S"^,E@<&C@0V
M@_]ZZK0,>!JH1HZ)Y=3%*-!Y^1WZ$6:4?ETRU-*BL2OX=2VQMMB2:RRJLJG.
M7OW3P[/2@@AE=>')!?'G><,;I3+_;PQ[%%4O_;:2=H>NTN\K#CEH%U&W3+9;
MQBW:'(T[6'TM#@2>I2]SK4R=)0F"3LIE[@W^UU6A_SM"<.CQI>FE<W :WS@_
MV*!V_&@JI3MMT:JRX5G)=OM7W(FH9*S/N OJRXD%BJC9'E%C8_RFAJYQ*'W2
M.[S1=4%#L_[&B_.B $7C8SAG^X]BEJ(\K@;# W7'C*PP3H;,_^Z$)G.S^:B)
M](4U_WK[4G1+ITS85KMX8Z9+H4:Q':@)+O8X)N?5?85'FH8?JP@C<\8+!F55
MU!Q:+JWF?\@2*^$/P0,'M"FXABD\\,QXYM\= T?_F3V4W&L#'8B+8MV^X %9
MXW7[M'TB3&0$'C"[&NVI7T?WK\6@_S=DL9$9^GA(FDW-BB__@P^A,3>7;\R@
M[+2LV'3$.G?T)2\U0.5CKX/3+[ T>( .\2:KGD1!-F%QLZ?!FSP^;2=U9/\O
M7$OSTZ026J(#SL/$L.^$R)T2CG*V=F,5J,JAX<H'8@%:#/=H(QF&;*#QH:>,
M75W$;#9IYR03;W6%0F%0Q],W[)+GX]_^0S,TC>U+6L/Z&S:^W=1MOR]-T?O]
MZ_9B XD:F(.C.P>33WTFM"W$=6RSP"S^OM+13UX>FPCE*"$[":[LA&QE75);
M/;(=V5LU:(_<Y[5<\$]V0N.?<ZAWP$L62 CFL[@']E,<'I!7MLA=.W,BX^W:
MM[^M)JO,/54*KUF%[A*3&Y"'Y^Y8^4 &]J]<U3B5QHBCJ_GQ4KZRBQJAC32H
MB,Z8HBV1DW'"$BXZ99K-@MN@SX@O4$BI!1JF&WGX(B:S\<Y@YR.2[[.YZG-0
MRK C5=!$9P>\(;0I9=O]4$FR_]&N^^'7-*^6Z-NG++.-1"%"]:W$B5@#GE;Q
M2FW'!B^]':O<LIF?B'2-#T^:!XH_Z[E0B^G%FLWB@55?VH7^,&GJ?:M?-4/'
MQ5Z[9#-!K<]WC@R JUEE:"*MX3THI$C-VH,A,6FLPM&5G22<[#7D*P*!(T+W
M+'6D$5;_:/C NU.)K!IB*C.X+G#Z,*JC\3#X:9;1J/*"B_ 95[N%ZD3QQ/JQ
MFDC53PP9C4"O/@57J9@YS]Y6\CY[&X+$4\7R;G')U)2Z>$M.]R.L%@'+/G6K
MWP"(:E>2)E\N>T/[3+ST@,8V:4_VODO,^F]9X*1Y+^QLN$6:>*SQX6:_?=XS
MI\=XP$AXJ)J< .+U]3R];8QV_+Y>RQ*D\GV/]%B-V:2&CY'==LTHV^GD=R]3
MNZ'SCD>FY=+(H49A3VZC'X:\];).K);^?-3SU\^M1N[L4 <66#''AP>(TZ&;
M.F$WH8JH\SY^_J6:N@I6;M.)6C<%*<)K!"!3R]F?&A-[B\BQI!(33VOMY+SA
MLI1>I.W=%Q3N6KCNC<A.IN-$O?8?H4N)9BF#)WIL678;9MLE>TV*'H6>W\K@
M6?L/C [E02^F3>7MK\?U/Y(CL3.[:OQ<0,L:-T!@&(.1154-\;B@DQ0]7E/K
M.2]>G:U+ZIP[>(0.P36?@LYYBQ=2Z//*ZP-6 .M@^1@Y5U:&PS,#:_)]^1=?
M:%0"\G)IN6M*QZH'.OE[LR/R.6N-LG?P !54"34>L*KD%F%,KSS]YAEU3AQ3
MKB8%42WUAU8_P4%)"T+5[$U-"R[L2L3W+=S!MR<8>:@>6_YGJ$N!^>87*]_B
M::55U=",C\M NEG&O&7-*_/#"P%/7]>HNUMTQY-GCVTEH_L[_B[16IZE8]Q_
M'$AS=JR>?<GFNB/LL)Q64['EFU;*;F]\D6(IV//4%"*>NI9UUM1V4JJC7S'H
M2+>E61_0,>$I.*U$[I<,;N_;W_KE?D#EZ$M,MFOR8NGPECRT>9^[<[SI7KV:
MU/(0Y.]@C[&)]4JDY'[G:=3U=(N,LGQ%+!QC4;Q1;E;^_?LAE6"SA]#M)PH*
MSS()U]6\#I9(^I^4/GWSP]Q3L5@-<V0WOEXV4=?S_>AA&E]NRM$ED/.ES(3J
MHY)"^>X3D[J/*?]=>!W]-3DJXRX!^X:9%91Q<>[69AK1&+W:Z,L#/CVY0GV2
MLORG5BP%\SB]HZ;MA27N?DJTPNH0[NV/=+7XY[&UO0^Z>@)\EJ[["ICWW]W7
M,QVFEKPIDE193'724#5CM D_AJUU1_5:AN04#R8)&VV(UWP^2B7LP8V,\AS-
MB4I;3.Y2\*([7'Z$+[$<Y@Q!E7/L^QX.@TUXGW<0N-B^B]WI?['#3KU@@<R?
M134-K>$!6X,(SP]M\,842]\<6])'JL7"+LK+UK_=:,]H& Y,OGE;UI:]@-'V
M\O?9O;336@UW1YZEN*CQI[@?@3/C2Q3N@[,E1$^=K=$@TRV+!QCZA8L.9,-X
M!F5A*\^M0T?I3UG19.6E,%+TU+/]3PZ3TH7.4%VK&/J[V2.%K01H@]^#N#YI
M05_^'1\>?<>?02FF((F-4_<UW US#WNW(D]%4XKGP[9UJ=\^,16M_SJXA4M8
M'5GB&>='T,!?GG'V.@Y?3%7:(Y.ZUB-U@A%$Q]XUL4?EIZ7M;?K?E84/6)]T
MY,XJ/^ J^ABK+ 50!^$!8OJ6]".A]3GTDTMK%W;)H(+]P"&+BH',#8G"E-&.
MNPL[]7<]CQZN[2-B)#T6\E&P+T@UMH]3S@+D<1BM-$T<E[POB-R%S2$OB$3_
M_IU<\52W';=31-<A2@SJ(I3*5>$2KU&7E? X@C5B3&GZIH%.]*^CA^?:E=>U
M?S^[W)RH&UYS5W,46I11J[\D=G^4/QYZ\2T]:3?]8CFJIPQCN\^.88'<!7N-
MGO2[@"9>'\^P][CLTKA@N#>YWNJ^2I)LAS)\PP/<9OSF:?G?OA]X1A4?-S11
M6N#NBP9!UJT'FU"O+JTBM4GU*;F9+,. 4IS<HQ!EEI<]/5[7R4<,6LQ)4)@T
MKGW]Y%P%R-*JFX+TE]&H>0+$3\=Y51//A5!W>;I/>HS^#Z[52S_XLR^V<^=K
MV,C(H]0$1#%R;L;5_>U3<4].A7L)4^/G&&4N3F_=JF[N[?Z';2.47/9?QE@N
M1F?F'NN.,Y;(GQ80!C>84AHA3.@^>5H:"4:J 8)B=*(&.LCX9?*_XR/N'KVE
M-B(>O4,VL>82;TBBQAI-$%"T1!&I:K.]0U\R+ZNGTEX5YFI@)0LJX^X71WK;
M-D=6IDLTZ0Y7\;V:BCKBF'%S4+4Z]I^2M E=E#5RV@&1,%-M30*U=O$PP-%@
MA(?W6)4^A?N'_N+0JDBPS1M: X7K@NFO;U._*64#_&2@4+2&&\IZT;UT84);
M[C5B;>/PQR7@<6B+%]M5Y()-ZI@T5<ZU:2U@3==IAAR_-T%;=H;$Z@B.G(A&
MR+PO6D^JT+=!'?TA%5*?N/' ;858NB6-.)!P*ZWG[:-W-Z4>\#N,KX3'=-L+
M*3ZJTE%H-S*DMGKI==W]X7C?Z@,.@WPNH0D<"-4^6,PC):\M1=:H.S_Z>;(^
M?SZ_G0/CF,.7ZOL8_%.8X)3)Z=X[5B:LT%Z_G]0SD4YJ]!@+F0ZQWE !4G%F
MN) .I<=<*6SI74D_YNJLG^W=3J@0[JQO&5N9'5N2/5:8+&S3R688J?(G4B65
MM?B?'(F)*OU&7'JQ52_ZLF6M\DM&Y:WR0^7UNLM]_IQF_SDM\K-BLI((:Z\4
M;5 8UH,]\1XFJ2ICR-EA>S:DJ\;>\'QH9!I)H1A;W,T&7BY@C<VL?!Z@S%45
MI;+WCXSE0>8**;V8P@,IO5B-/Q57"<Q(O9B?.LMVJQC[)6XRPG6AS:2=!(M$
M#EW,4.UZ-@8E:/.)3=_NGH'#8/<S/FUWI06<%%2!B7I /<;J,5A-]DYL_M=7
M8B2S;0=$BSX&O^'FR1ZE=OIUOA$_9\QG5+XW7[?D92DGT"735BHV9]]G7/L"
M[FW0/SN=-I7>OONY(=Z'X*/%*[^6)H)J!(;'UVDJKHZ7B=8 Y1.U6HP'KDD'
M-YGWO%_YE%/('[HY=_P7#35G7BRJ=5WWY4<I+D34M(""ZQ1#F"?'R=E3O 3Q
M0*])\*K"N?7'[:R?<>HYX)/;',4L7QVIM%[<'%09B0<BU/*'.8 \N!N+)N&5
M_\21JE19AM1.Q4W$_XZC>$P! ;7J$TU!Y5]E)QLWTE(8B/]R^5G@BI:KB"V0
M=@-\@D4>Z:WI:V&;;K9"C]@SNC/N_&N81N=Q,N^2+>O+S]EL$>\GJQO8%@2>
MO7CG*HTX/CG)(.75:=.:"H[\&\JZT80VP-A?(_9)-5X/^ATKRK/MR;0\FLK]
M/$F3:^?KSF&O!T1COZQL;$SBZ7,7#CT0HA8A2AD>P>].5VGG^@WI0\4#E7)T
MR.AJA*;VNF)NV/I3 3>!W*SZVR.IBEX_4\O#(IOEJ?2M:.%I(:0'E1GD&A/^
MO]CG,/:Q</8 A8B.<9T [@'NM'VUZ"G&H7 1=PBC+]G9"<+DQN?8V'SV;+&B
M8?W5Y[/WZP2-NPG$!*H5!TXPAV=C,^_]:.,5"QTA'4&*Z[!<MX0]EO!+!O#R
MZI]KC^4\V? @@?RL.7R*0[:-FRS:DGB_'1R<YL3!AFJY@-J<CK<CI0G>(:1G
M'[#<-660UIBD4<N'[S)#,>58^^^(M-]LWH5>C%72]R^_S<M:YO],JZ%KY9CG
MGW+(_E) )&%!#OI.]4$ELKBMP'-RK,UC$X9C6_3[9_ J.Z$0DOR#_J.2'F1N
MN9G*2-399O;ATXRV79M_93U%FQ6W7*<2(=,L^Y)D:S(,5BO-=76)KP4:0CMS
M+8:%854<B=#/_3/F00VX!(6>N1T#K?8!RNZ3/3/C CV A.#7M62MB&8M2\VB
M3%U7X*7VH#S+RZ+3^_?,"%<51$&+#*)K^AP9=S]H#KVI.AL6;)]>2K@D-1%T
MYN4B\+]XP(0,<V@Y/.UMH&A$%QP&6JLF,*GWFL=*<28_/1'=WLMLBH+R_QSU
M09074_]JE1S[X!0!YZ0)G$*!1VW%%^T@/]\]2K^H76A,7U *5%%/2/9NXBQ5
MV-#E&W\X0$13HGA:_&6$<A4\9T]^7,:N&T5B0YB>5%A0Y)5T,R.#S!<-*;Q4
M^IQ.G?SV+"V^[_Q>X8%,2U39YS+NW](W[+(8#32')[ZS?U;QQP->ZF3K<[G>
MI4,.R0UDP@0W)T7@;E3 ;SK.(TU"CGS'G"F9VU=,.LQITNW*1!Q-:UZ[6N 4
M6\Z13YK7#-9 &"K"^6)/2&<T>DZMFCO'?N=+Q9>#=D\BL:-#*J=3KN-S,=/^
MMJB0<X-V_NN;C;1CKP]Y$%F</VEMTHN4&L-+ Z33$K3<K=W)*%#(^'.W(PCU
MXZC?+SQV=+WTFQ=_IH>FDX$M@OQ$1Z$")9T5!QW: 3*WE*,/8OE@04G7?5U&
M#$!N=_W<MF;KR!KKX-J1;2JVQW>02GE?0_6*9.P .WD[XN=%H^YCZX4 /%-=
M/R,[#UG?(6AO/GF:#VYO=K6<'\MM.'U!=\M%0M5G]]O8)_&0PC(1XCWO!E(\
MT'#3B=V2*7-/IRQSSS3>.Z1!O2ZDX9&8>O:%W.S7R9"&#[!)T(X._3_\;!MN
M9-ZY8#Q@;L^D)C=;V ?;>Y%+J;)X,5M1AA _U-WEKYL?LVH_-;<1UF*OJ]_J
M>V-J2DL_F2*\*C=^+?-QH.SMO/+<Q]EO,YX)Z9#R"D1<+W\P;!G>,^_G&L+S
M3@SL?@N:BP=LCC.436-TN?S%[V"IL)]PI#4!4$+^+V[<'^XC%@$2[D<+695$
MG'C -SU]V@&1!'FSY[^WG[YX3:W@66?+N1S/Z?:OG>3*>'_027E_5N!T&%8F
M3#A8.%+8<$F&6DOAVL<!@@TC=3.RU+Y]?0N#D'Y,D)VC=(IA.A>;\*51]*>(
M30P#K*X4\*V125]!_SNV^=I@@(UY0U4>$+P**R+9Q HB2"(+LGDZK_E+\).V
MGDC1]+$D\3+CY,[TG)#YKEG]:I$WMJF)%HSB_SL<4?^_B#[-)7PZ(^F[7.E+
MWI;)ZS3V[TX WO_9=',FCW]3G@GN]_PW UW^^_,0_A<"E=K7P:DHAL*V<,[8
M6^.#D$I13)P 'K"HP -LB-1&+EBWTCX_%G;YMS+ISMFOVM''OH5LG5@L(]'\
MA'B@ZY021XL'-ERDIT3P@$M($29YB_K?N5S,>\W!%SJ7[PW,A_U5AASI)IP[
MWX=UQ5&N-PE#5XUP9QKC1Y*J\VDI3(7[<L^"K?3E$_(F6Q_&*[PZ_VAA:] )
MJL0#F 1?^@U17)CW!5.].A 6J3YI\L<B7FLF3?0XIZFN203Z\4+^V2-T<>$3
MP"OFV31L' P::I [T7D-92\IE"0>C+J8-TC&#8$.=!&0K5D0]F8#_\GE3XJY
MZF6.&+Q<BSMGZHRF]29AJ@T66(ZC_;D#[OP-4->!1A1=W*8%%3*K+^%C['7:
M/]<RNBXMZ[@/BF91]),DZ8+$5S<SU6WOA/9>R2\G7J;QP(T5W2AS[%8_3MQV
M+Q^J/4Z=1"Q4LNDR(LC9OY;>4[<7"+M9+[I/WW(P9SYG1VXA)R'/JE_14723
M0"?XF1?1.-+S[/DAQ_Y-+L,''7K.$H>S<W0-2&-<DGBYZEV4\.C;$:F9!C*E
M?8..J!#<0]2?PKS&*C8:_:'G5!/]IV&I^5_/ P,M./_.- 3M-/RV=HCNJN \
M>K@,XSHWT,>F0"DS-VK$@TX0)2834YFQ1L8VD:-,+3SI&67VZFA[5(BNJY*D
ME2=M)/7;VK!'&IB[Y.9Y;DG67FE\"2\,*H(,>7FY11!NV8Y[Y7V!B$^MP[&Y
M?1P-1TW+4<[[O@.-:.>2:8*/(@G"@?N?X>BWC6O[046&&+&QTFR>P=;</KK$
M39G/']-[&NFBL*^QMIZA3 XM 6:6>*#F21<L$&(Q<)&^L!M(%%Q/DV-HDB&3
MN/Y'IF/M)3'EKC)X((AXP++!8/BF\)3,3:+X]/-;)0@F^_X%V,TMNA(Y(1,3
MH<Z8F*8'%B-AV);ZC9<V*NY5G/D'6A;+45%A"=ZA;G$8HUZHS'ZG/Y3=K=*H
MNK)I9(FYO4H_5+C'.T#Y@<Y<+.D[NO$=<S_7(6$2T#S\!+8:!CFQ0]GH+YF.
MQICK\,XLS]-:.21Z.)7XY35FH/:V>Q=\11ZDZ/J4&J^!ZDDYPW@N;K1:;HZB
M=\G BTRLJ<I6W^)M\]\>8<Q2G/M8?<T<1(@('I2HK5X^:')K%@R>6[KHCR5\
MV45?H<OAST.O.3S75/ZUZ1TW C]IFI# 24+E+VD2,T[-%+1S.\,&1[OO&YF>
M;2QG=<>P6)F!!?VEB<<[+MSMI.SP1!T/1('(8>-*L#B#A%;=8LW%T*$VC33[
M5-&9*9WL)_'LB1]DC22,H#US_X,7@O="R :U:7'O36VR7E]"L>J#5^G?HC-P
M 'P39J_1L #+[<<-E:F>V(\_&O)[1.SU[=&<2?TMDXLS$J*EJK!9)_@2;';G
M=R-.OA<]V=::<@&:V<;M6L-^G0\UZF,+A#\[0#WLO2B"[*?DO5QF1L/6#HC/
M#$;!!TT[\L7R/DO%JD^_"AE-%'5'_OYM HK108__W3^MQ'6=GJY%-+AA^;QH
MV47'JK;_!)YHC+ >0N6LTF=><_H?09Y A@\*\(!=U)TS#V.+SZ_4V6X.S7_$
MR/%\PBHLX $":M'M]/S&O7MS3"QMFF0?#@5PZ:G>>VU[Q&2TGO1ZP\^<4K,$
M93NE[3"]484/SBE-A04W5J$@]4\)JUDK(#W.I]C]X557W38>:4?.TK*XL]SS
M34^+[9I%Y^]H^*4"B]EG/))VL,<#:I08W?2>*IA=$X57DK=T(#VFO-C\1<9^
M7()&&X '3D<]QP./-R2Y%TN%=$T#[=^5M8Y^" 8EVN&!MCW*J >>6P8C2[XG
M!VH5A%.]6DB-Q9LP.O1MZ^EI 88Z'!Z \&-K]RWVA@>9YD::%A2W[@^-G^V<
M,25=\* M=KQ7<\MZDB.'()5M&J=SL; ;(/2Q+[^I:#.,& ^T<*/V7M2X3KB\
M:[)+D?* //0CKO*CGA[?3;YI@4U*U&H%V[)YX-B++U)JNM"_?6$EKZVU'"N.
M+$9;8NJTAY@2CH@(TMWK#;A+Y,9^$B?TP-? -N_S_"4/=;Z0V-^Q:J7;1'IZ
M@?O,^'_;7$OU%FTFM=[V>_1C>.9[4HR5XH5M%Q[H5/736U,S<)725B,SK&R*
M2JQ)>--90!2##H_J\)?^6A_ET#E86V W'=OI8TWZF[=15'.SM2XFV@X)_",=
MZ:J)]9 F@?(E@!!UO(I76U'M5$T"G'>&!F5(LM+5,JYG7.&*\9;T&O[M'KA7
M/3IIX:M(*TOP6$DV [= YZ2N-X7"_J:'A]V%<YOTHV$,?UXWK-"4M_Z6Q,%O
M7RH/\(%%.R*<QD\8;ICCS*)B^GG[,(%EM'-?!,(W<YBJQ!5323F"EG@^AI"4
M*)JR$X?V.7LX70S)8V6/K[]3?&>_U1_<1%'B]\CVFDU8<T$+4%O5SP&K;RSR
M ?T:[S,706G5-#;4#SKFI:M_]JHL43(U+GS:>^_IBV@"Z1]E'UH;'S6ARDIO
MYN;]<=S-%+ON^FK&T(-HJ%%(I"<[/"(MS@0R/'P@\<ZS^Q5[6;E/]N[Z;$DG
MN]UA>C",VG7NLSY74:]]<4=M6E^4]'9:\7DD-G0O.[:)JU0ACRD[7\\H>SOS
MJ5[8-\9A8<O8$D4V:T4V0V4I.TI*A3!E'9Z$M K=;EZ;9%*ZVU?5T=[=VCQ(
MCT<= =WJE'K4B6F/3_/?BZDVNC$YZAP6'!9.F^8VB<.'X"5O3_.$&X],H;G!
ML=FV=C<3LVVYG+1#N54UA>,[8C.\N.AYF0^N:JCA![H4RD;5-M$5RGIF&V]B
MOT/U%ON$6L1-X<&%[ZM1_'<:S!5PFY&KGSOT6#-ON/<.<</5NY+:I!^6H_XD
M2.=>KD]##@M/WTC:K[O+)]0'H+;^S^/IY.#6#P]M>)A[)B?7)&AJI4M\<(1(
MR*)!6Y_<XN/"5;447_'[D+=5.BU1>Z+%Y','18V$:%@!^E!38(I%T9I,E$;>
MS[ SX]CR+TP%R\W>C2NT2Z#>A+3BR-RAB1(,^V03PVB8T  >L,(#$YM+2R%?
M2&IZV9J"7,?T&W^8!@JYW6/&[>_"/GT8"<>E&-J>3*JG.UI977>O=A\L>=)*
ML6,XJ$ MLPT !BWIQ)A719AKH]FX/B.^*IJ'9ALE>("G@2#&Y_83\=,.,D;I
M210LO"J*R>:)/1WOT,R$:L*?)X/?-R,;]$(RCXDR;S:>1X#5I:V3>RU?AW&4
M_K+-R0>+^!.JY>NH 51C^=K_[.=@$RNL L B5UT5X;8C$3*D.5*<-AEW4YJK
M?RCO*FU"D3CK<]U30:_QN]C0Q3*35FQ2=HX9R!FRQX1,_2?0R?)$CZ<-N*DL
M56A/V#89.7K_LY>#$%;B#M WYF8]\I@K__ZFGZ;$!1R9;7-S0]\G6I^E)]_]
M](1JCFS]4N/"JM23@_PVT\)A+77P_?VO-:"9X;EB<5OMI@9FZF>7Y)CC >!*
M5:5E3O[W7\= FFC77.B%[UNR)445+/LAWX:YQ'U1<R4J*N] PW#/3O  BA][
M?=S*-#&&+&Z1 '1*V[E\JZRZL8=O<_T@((RCZ!_9OT3ML>3.SJ"WK^>B\<#6
M.-B,YDO3RC"." ]4C$O(T)M36QQM:&"%6(ZI1\8E%AX*N;KT]V+MLQ!?.R7&
M82R-4;\N?\J[E/\,@O^+D$_#"IT/9PM'>Z..>7$^H^+G##_1EU!444JM)8P#
MH=GU7P50N=*^YU9-^)] "HH3;IQ(M[K$I,^48SDH_RYO],R:W&3474V1OTF4
M.:@X7OK/7 'V&;),?C4 "P\,!-GHD7JIVHH"WH3G8==/!"2ER/J$<Y@^RNYL
MPG(=]9W\?SI\/:^%9)1RD2Y]O_PTU;_<5\T1X:KZWC(*!]_=SBW3"Y[$X9>[
MD;J09Z1NQXJZP^W;)O$$@D?2V4,!;$P%R"R[N<E[\=$?Q>_")IF0;U?>Y_V8
M\EJNJ%6F"8FH XW0;5NF\O/&VOS1"X:=C] R["+NZHZ3%[=V(^1&LJ;S?I2^
M9JHBZ)CA>S JLF5L$#,/[W>1H</='8-\AZKE6]R?8GC_D1D/O,24GE-:*,_E
M/?MQ;M#C=A3B[X9 *TO26PN);"QI/+(PV^J D0>B!VX&46UR$%3I5(>I50'Q
M6F$<0,[4E:ZGBC^_/#')D>5_+TSE'TX%I9R,:RGJ!?R(TJ,IL;*R7$/>!>T]
MEF\W"!L 3[(=MPN128PC*L5N\EWD5/OD"YZQ2H$[-0(DY1_[5W73/J5]C/ S
MZ2-)/)34SE;D<= ;#+X3_4Z6"7ENL1^XE&T_J)IG*U]:5;^P+"F)EL+2Y#/Z
M^G(O:80VDN"!3YWFD68WATQ*G59:Z"4,>QMZW;FR8^?ZJ4NL!M/E$I>P2;MV
M#>+2<R@RTA^!O1))NWB *\*XZDU$9LQ2#"VCLK[^@X>1&6'YX%J-9#'SQ6KI
M\K("&5O9@H3"A0)R0:0D7:#PL=V=6CZ[Y]$(.<W@W(PLC$&[]^A?)-E),:7;
M4]$%&48J[X_'A4F:IV6V;U\-%EYN/9?9CX:76["*L[3 9QQR4I.7$G*<H2^R
M/$)6JINBR83\.A0W,BRJ*7$_I_[MAMY$]^9[V^2</L+[<.,8^-<^F:"W>5IJ
M;S.BWQ9,%"JS?^PNOF>R?9:2B-,E?E<3:/U[SN?,P!+5N]!1OF_1X0T+/E*J
MF9D1[><FK+C5.1O3M5X$D0:6P]H&CKCW*.RB;2?=?IK._'Y7T%3(_IVQSY<9
M-:XVYG=M\Y[=)%N7KZ*-2</6US+*AU^[<'N,GE+H@OA:=1(GP:>&1E -YT/I
M%;0&JD8!#9E/X2==+X!^]?,J8_ [6'U]<P,T/>_R%R"Z5G>^X$>)>3V(X['E
M!:>?WR\$0/;#; [=MS>BWXD6;O_RE9$T<!_] V7-Y>SN4=\)O4I]4>JY?'#H
MY;FU-:_1.4HGR]P %UXIR*NDSBIM)!L +N0<F02X55OUFVQ'LUFM7I_U+PP?
MM[\=-UE0E76V9.M]]T825@<Y/\L@IBM)R=-EI/++*]19C>YE$<.QP*W^KU/Q
M_R[Y/S%7]G^B1O]/"(@,^C]-#JFO0_$'(\JL?M2B3A)<7+AI8HT<LJS=I939
MWJO9;,#5(K_8GSB*]\RVS+DX/QYCBQ#T_L9!"#X;DVTYKH!VE(GDRK,)C\;Z
MODE?]T%/]SPHD;0IF"CVNU7S[_T4VTA5O4%7K/O,RY$27K=;U#4E'IHE1?37
MW]PD^D;9W^#[]H-_HK5_<>"GDM4:O\(T<XJ*UO$(?83ELL6_S2&),IR$!6 @
M.3.YHY%!>1.F>>Y]SM8,3K4/GKZL9=#O>X?:U9*,(SQ6B=/V<-KZTW$6S/6T
M9W:,:Y+M# \D'[#O7.I:-I5#7,,EUQFP'[I$+Y S:B3B' LZ!Q!&(_6@C"U1
MA37-0>&IK42 MLR1)::+\:;2XY(-\?LI&6W[MG"WLE3ZZC55I?L/._.4- 7M
M.WH][:J)Q$OA*EDN*8F)'J>I?^H5+._\55J(=],?'SA(GZ19<.S_4O)R[*C@
MQ7E"[(.5&ME$.,_:RK$5Z_XTY?H-Z.$\'F"P-R<82=M2KA4Y$.WE$>1;CK[[
M.Q\/C''O%JU"Y5'C+3CNY+Q181.3T*F]%T66,8UE.91H^,H?3Y4R=GIL;J+^
MB9[YQ>2%^9:>7U$?I/'\Y:'2<.XQ]+E7%K1\*2HBC77_!"Y\,59=5<$J'#W1
M\?\P]]Y!37YMNV@0%!4PHB =E"+2%>DM(M*E]ZX"4D*1W@E(4UKH* A!>@\(
M(?1>1'IHTGMO"1 ($,+F]YYYYWS?F6^?,N?LO<\?]Q_KF35KS3RK7=>]UGW=
MOSD>KSKQ=OY@GNIRPM_$F7@L0^^;@+UJ=M.$$[]2Y](^_ V\VYS%K'S2Y=<,
M0\NUGENW#P C%FW,/R\K/[6X6/L+1378OE?U1HG%6\;<&G]#"_ E,CUSOKUL
M+B$>[F(Q/2ABQX/P0%R?3$T)"YA1RK1173-R=G$=0DO^!^\+PAN+^U> OS(K
MUP.*\.=B.>\ZC[R\68N,W+[S.%,HC8XJIX<U7%_[N2QI(6M%RY(93H<0%L-P
M!;B)@6"$%SI_O#"1ZM+NU"G,SBHK#MA_G_KQ>=MKK21G-TNU*T"<!_S2U6*5
M.R):Z"9&(PRKQEXAY^4TPL,<V>E?@!8K\]",I'ZE1PP@"N("'U12_?Q:(*%'
MT\ ^>FP3H:[^(RFG7N;&>'7)PKWMT;_S[2>I-4.(D5INQ4\!DI]Y1LH@=@)T
MQEL\ULU_C*@]R7H?/W6&ST]KC(.WX ^]:5YA/A=.")7XK6N%Q0<;4?F2FCYG
MGBJ-85L<^GPLF5>+&.;#KXGK9\R_ Q;>ZS18P052#!R>HV*)Z7I53)IT&ZM5
M)LWVFQ7'AT3:)S][;)FKHA8F?Y_Q=*:!OK#_"NFL1[WM*U:YX.>7P><"W&([
M2&-G75KAQI=)'E90K4GWB7?L*6(;LCO5<9#C)Q:R]FG,&>4FN?0I,'#AJY@F
MR_HP:ST'R\?/I19A@\5;S<!A=Y.?;@6;:1XQOV^^F9B([UYDSN$F@EOR+MW]
MK@YF]*"?'5;5)7!Z3S6<[^ 8:Z,GQ$I?YH@9-<_8[D.!EV4RIV&$5-"%2J.D
MW A66EOU>W6M=0J8MGF,H+$@KT_\J4?J 9!)X@3N\K]7K8!8P\Y8A($7I"V$
M:!6<:1\QXU"4_7L.3F:;^CEA]:W+S9/GV$P6GAA=N#-!:0!YF2=E?2OU!"3X
MQ^CU'DV"[/>(%K/<2_U&POR,'B:E::VSRMXX;_6[M-$<5%L#N\FSJP9>W CQ
ME_6>-*@GO^4I_C%XGJEG+/3=G5/ARJ46DDWS^S&)BJB]755RH2]UGLQA@X;0
M(GA>45M=^7MS'J%N-U3L#/)4V&K!K^5[&^,,Q6N*I2UC#52W<_L5@+B@XPIP
M>WHKM&2.L<^-]=@.:.IWCW3)S)'ZH=FKRMXG:2\8?>:[PFF87/T,=I**=#I0
M,=SV(Y'*_+VV_M5KW EN*64P>KP#&HYGA5 */[-42T&JG=0^?R[2K$S\5V0)
MIV_084$.H_%>41[U3 E7#AG8H\</G),'"J/P@9AKLHVWOQD:)1T3:F$3:R5N
MQ,!>13QKM1CP<KX!.F717N!9M$R7&$VFZLFV.:A(D !)$%S[?DW313R4$(/X
M1G]<6^NC\?,5M84_#;AT>+-IO>TAE*CLOX!UV[2^7@D*5.0 2>T1>8@R+#/L
M^K"XWU]GW#GV<S8?F4M7.O/[D +PB;ZK9;Y<Y5 Z=S(+_.@*X!>Y(DPK4IE%
M?N=1NDY_K?WG(.F#14*M,/3.9:Q"_PG?&HM91!*H'](*+K3F[F3.;A18<O[2
MLL2",;VA,./H18 ^]26')1%(68*%#Y#Q^+:>0 J 7G:J77;0/V%4Q%3_*.?<
M&E'_YX;L'Q^&4)G/4*= ++U $+;$C/I]NM'$T\=]-E:ZZ;:#][;N@+@>HYLT
MS$F%?^,M<%MN)U/^G(M&^BO&[!SS9;1 BCAI/8GPU&/3H\36-3S-]=&M@59/
M?UI4HFYN^?UC79WKX-Y8BF6OS'I]$0IU^")9/5XFN:HQ2A,1N7YK@:J83J.R
MJ*07#USQFU%EN 3K![O#[_YZ-CKA<)F]-7C;'<KB$;PR2=<M7G[1WOPLHLL8
M,JU]QY&1D?9C]Z(DLUBYN#IET2Z\2"779&W;@=+T($;*(P]'HR9J'%H7'WSH
M&$<XU)8F+9!*&\0E8R0ZEO9A$3,N1?UA68BA9E%0]@;(]+YD/&82&OC$#)P6
MUG5YV9NR+)?@ULH4Q!1T7"PD(O/47[L9\S'KU&OT/0TK+14^GM^7"#^D8TH:
MAN<I]S>>8$>,O@#GF]R?/*]>.7WD\B.CWZ\2L*3(?DX>[]?:<D\8&*DF4U)H
M)A*Q1*9(YE(D\6!4Q"><".\<?33B"Y/;9'Z,\<A/_=F6M5G!G[IT <**?'$U
M:^CE@3!&U('"GN2YJ@ZH*J MPO+1+1%/#H^_ZY+M% W[G">^^XR"[1]^R@#
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MJH&^MW3.RXLVUXM'1G-WYF0O>FB[P5PUC,]L>F# _6J3J5+X7K^.@,S/B ]
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M2_?"T*ER)M+\ A+G>A8U]MH"!^6&5JOGS]B7% &^/Q)G-#^)4$U[D&@J1ZP
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M$^:+@1C,@1&$*X" '*KUPR=#WXF>CK0?R<CJ5).> I%T9:']4<1^#F[C>D'
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MX[]*=4=2IL:5</W$GM7>V7+;3<VXN]31?.)=U"1.24:;2IC3MN=4NPB;X==
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MPX-<%R$1B3B KXMM/]@#FF\WG]$E&6G/F0H7#!IA(ZSYTEWG%ICKY17>1JJ
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M%+7O.=EL/I6HL?9Y%DGS5;.HHQ\_)UJN54M?O9,<Q)>FF..'=\63#[C]3*'
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M]FZE0YT]VB!<R(E_=E-&OL?R)P8P<!XYF9@KC4[[9>:@.-EB0Y-R-\&*[L-
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M.]^K/X(Y0)$W:AZMTW(9;")WV@+I=S*SHDL=E5RD[_%-T&( .PR0"'Z$(M!
M&_P11RJ!KF* H67TB\L;Q5U+(CA)4MC-#(M&W@,'5ZZ6W_>MRGT+YXCD$[98
M"KZ:(%E?V3BM:;"EWMAC-8 *9T\YK3RCF4YPITZQ0'HP#T6MC5PD<AZG68N)
MW@N55GC'\L$LCQD'S-E,0SDDI *KB<HUH=XLAA)XA6Y=7U0H?XA,(!F.UQL:
MCI'@] ^('!(25+^(.JCRC4%LFJ]UW&@/<HIZ77UPE71^764EJ?BVKPE'1_::
MHW:(P:D)Q;>[Y=L=D%#238+'X+KUD[B/^XFT[7N+(M"W\/VR*5=RT([O2A=L
M0HN08TQK @/D>G51XL].[^;+N'.-)HQTY0J7MSY3]_L1$2@KSN']1S;V)20I
M2:<[=];E%>O3#;D]3N_*-A\-_:DE?IP>SL3T0Y'?6#CBBL(;;7O?>:(;/T^Z
M)'G(LLO!OJG66^V<7J?$$(K!)+I8-1&:4EK=27BT;7.UV"ZXN8Z$T8(:3S"8
M:.6)J-E^Z=:,8Q?1H<4&C(FJ](;VZ$Z=IQW\VNHZ5R/?_6?Q\3=K<BPH##XI
M:K40C7/3O)AXR3%IS]1_>V$'G[$Z36M7/6->=I^P7$Y\WY-LN<@?ZP?SHOG1
M)_#"#+EA'P;2#H7]?>AHRJR\#'MLVE+H%J\!!8(0U"2=-25+7]2IQ\KZEC*S
M:MRF O_8-K1\QHC&(J@?93T/O>\41OBJ<M5%U?K[0?OPTW>KOE0!A6V9P(;@
M"!$^BO6NC#VALGIEU7NR6-OPMN<;^*_Y<#_I/?E%R^I\X3_KRKXI+&7HRG17
M]+:'&2@UB*BB%6#R6SSB<Y&7B7!.4C^2/5L_I725*2Z.*]HH,VD!(40*;?+0
MP^N.:2N.X\;E[._[M3I#BWOL\G(I6_$[.V<D)+8JEJGQ5Q-L] E/# Q3S6_!
MUY!'VC#_!QP)&AN=-"1T-*KO/5ZG);HD]/13W1ZOSO-@(1T1L$.&J-=!3_"M
M* *R]^45M,P9/(S1O96(<85-Z:,>Z,OJX1*?Z@HBXJPI2QNZD'WIJM1DLQO"
M+H:Q%QSPIR<9.YEZKLIENR#OF:%\(>F;")4>>I8P_9<.LQ2*544\!+AM0O.?
MP6S-+\(36&(?YQJ48H 8OASEI"?SU2[W])WJFFG(1Q@KJ[Y8"-#WWAX#I"W)
MA"(!CQW#PH9YN'G57+#?N$3TK*"><>_\IOIH]!4DOYK,M^FK"3.>JH$P+Z\P
M<"^*:9<_:O6@YNV-)_!408;2"N4\V(JKZP%W88$3S:BVW]J^>)2@3EQ6=?8\
M,YRTD<9!(/2S\%E0LE>/8]<-&6ZZS31KN5AT95HB]S)SK22TYWY!OAWD6ZR+
M[V?R<J-(>7+-C]>%OPFO_4J:MS1H^)@!][U[R,K^R' DY54'!58!J(&<H(CJ
M,R]DM2]7CTJ30+V_E+>L#BS<W/1C>R_YBP7$O8K3NO4X-_37]9H=Z^8NT#VQ
M(UE/BE>GE@1>2X3]GX5MQRMSWT0S3O:C-& '0_M/83J_-MD;+H/<C2B!KZ79
M)H13\;M3VMU5:;&,!'G"STF%C9T<FTIK*8;&QP>?$4O3O>JLX>7A#&Y73W +
M&%:-]>H_IG,%;^%G\"3(93$_SI=/-P<L\3,NDR12_0"S=7WJ7>M9AL76#)O\
ME2BL2RI=S-"2)\:!O]4)\1>6HEI>;ZO@9K!_LWNO22$1/RZX7JG;])RECFF$
M<\Z7SC3=R)YY[4-GT]6[8T.;FXO5,6\^,\6J\VG.*W=[>&J,57I[99KWQ$T)
M#.X<]#3?Q #=RF.K/ +:D45%90C\SP]]54YO'D-+U6H)W17\=!G8W"U<:V/1
M)C$HT(F6S6Q7\&:"/K?L7)7EYG[X';HHIO-FXF=C)J/!:L)FPTCXE1KG.<8U
M!=NM#YH"FC=9 DE3408.#'1V&<D'!;;EE@#Q!SPYEFQCX(KT#(X>CW_J+46F
M>&.KKHMI= W *3VHHA P-14IB0MY5O]\S7V-<LH%.5N:/TS[;.C8*\FCQ$2_
M?WF4U)"LSJ2,ZGNSUJ2[='N>P?^YS;OV_XYI_9O,WV3^)O,WF;_)_$WF;S)_
MD_G_#YFK/3E:<)WO=?AXN3USE ]\B,F)4A]GDUWFTY&>@](UT24?I^NUW8S(
MZ6,-5S1QSHC61:DV^_SH0S9+_:V<"":3.C-^[!1DY$LQ5AE_YD0I7VRXLF.
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M7ZSR8H!I ][#O,HUCX?:WP^9F7!O/7'UR%" I)!V*>(M?S6>L.?22^ \\<(
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M2._V:RK-,N F)/U/L<;41VYS^>2"#8&NUKCHK:^>OSK.?UZHE\!%'D:6Y3R
MGN^[6 P6.C%JQ_A23"F/+T$"T#[)C0%Z^' <H\[8/G^IX]FCB1;A[17S%\.6
MT-;93=?FXQU[2G7LXNSYIYACQAE[&&-2(*9<1/RK^]G9MC<AE1"5(E4L/*#
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M8(AV%1'01<L:,A  7Z75]8*3I$_IM3#DB.:5LNN3,+YTA[^?74]'7]Y;VV5
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MEHR"7[L,_I_VC:=#YO7+V.8=);MTB:M+K\#9HDOJU ^(TYH^K)&WZO:&3\@
M][! 7%&^T:K8Y1F+)^4'N(@X2]1O'Z3=;A[B0_*U2GW#E.(2ZC2_H;N''6>J
M3C(J1X7T5W1KXK6^/C'H13,21SAHLI\MP?W'&73O!36X%?XY5O,^WU;&6)F_
M@G$R-^U,Y<Z\<VUQ=O/*+!DHT+=)K;/@\9+<.O4O*<\5F=46],-$G049F4]Z
MSI]OV!:7>YJZ5'SYDV7-G<X;"NQ2/QYIQ_1X,4=[YTI'<KB$&O3.\[T UR>N
M0M_[)I@(FIQJL!ZVP;,?0 3_Q^ERX)/PT?XZCX2KP8YN=X?X[<,[H6-FZMT5
M/_:XFC_E*L4GWKJ;!.<[!1O4OB6M.E:QIWO9PM0_U 19,HY,)%%?7T1FV)&!
M9E#Z9D>\S/:V?^9C,B YFUKYROB-9]6J4I!$'H\+6T>@D".WR&\UU.JW1/O
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M9=]F*#5,L$GJ;[7-1023V/0#T+8*]:K&F^R:I*<7%Q>8A[Q^FI5CE8DK=XY
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MME(6SM-+?8M1W3?FRP>%)ZD^C?TV/7DZD=_]=Q/E/^Q_CH&$\*V)[OVTZF1
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M@0QHDP%_:I*DX.!W B_10_J;,FZ!Z!8MTP]MA7&&L ?.\G.O@D2W1N>-.5[
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M8"]F7<H1B\P,%^M2^E- P-S[$\-9:X#%VU$Z!ZTVI7<?3]K?YZ$<U^\<3Q3
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MBG5!-?8>7U'C+GF*']--,'EWB4NR^-;UP/9V$G0G]=_OK^O#^4Y/.6#ZR^.
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M^Y,495^J)=.KLL/M "_P9[%9N8IZ&7W\G&ENOAJ$]:-1ZF+.%JHIM@@EU!Y
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MG9JPJS^ M'W9W4*.+<T(Z1QZW3D>?4UO3L+8,@AO?7Y-^R*)%@NH6-5;?U(
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M'W$?TOB>"Y8;[ZY89X:+32D$U699OV\OA+ -]]@<\B*T]_UQ55SM@E(+Q=V
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M@%A>A<^+QVE6G8,]N;'7-A@"A#DL^Y/;LXR_Y]*8BY;:_\T[^_[?<#$F4(9
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M>D>*?::4%AR,<-4$CUX8.H*MG[@)F^__L\%$0'A^]C7T%C8B)3TE; Y]QBG
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MP%6R8[KD2V;0QNU^VW&*]T!DT=JPP67WE;AXEB;V9@^N 6Z8SW/01_!HX]%
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M?KQK&URB+7PZ^ZI,$^G+T7TMH<B+WRX9Q.J<7HNXT6'!8%Q0H.]MEVWEM3X
M65X=>-R:^\X[:<")#$LUS,;#L4K-JNRU<4%:WG;NA1,E%6HO+G%Q,75>O1%R
M;+<W-P/Z]%-8EGOZKO1K-#>4'>\RIAU5B=ARMN[Y)NC$%>"7>(=XAO^LL?1%
M2_$B)$MYYYOC1>)P1*4*YVK'K=<U"H9:WM[NEQ+-\CSZ!9,2M903]0+6O9$1
M9]=Q4 <#5<NE?61D2F!<DF?>^6RT-'A=0*++)'F*,W)"]2KV]2B*.=4,T^Z3
M=:DN1;-T*]3ZWELMH:222[&Q&[D2UX7ONCCGF5Z]723 BBT]3+/]A&]=U*G!
MQK4[23QVN&P:Q?B.N_#YMY-,L(7UFC%$O.K)J4DSDA%F-*,X]S#@0:K'[6K'
MKB>)7KOQIFX,W$<V8V][:B]%<N#RDK/@<U2 6S(KXV,_?_^;QLF&XDUC0_K[
M]%$<$.EW]-<F"AI\_6/=?NB0'YK%QJMFI,<7'9H>S1+V5<3EFNH-S2WN>[_3
MMR1WM;.SF5E:W_4N6\?![04[%.MJ'R?S7Y+YUO ^1/O>R=AC/4C)5];O;,6"
MQ%<]'5R\SIN (X(@.7X]HQNK]X8O#Y>6NN1^37EQXY'V:\9'XVU/,I\]"\1:
MG-?^1X7Z.5VK/WO4_GN[8.AVD0OH+1UL?COZO+)5\3KJ)/$A E9L93G91RY\
MUK#H;Y;\9>CX#::Y$*<NE!CE!^PTA66]VI0B@Z&!Z+RMSTQ"1.=&XA1;^U,Q
M[G@5)]PH2H@*A'Z&=2MB3,GA=C0\=^4+K"Y4?]T.G^M,,JO3*9W="!+!?)U#
MQE+D'!6J!4X.H*M=MK+/]8,F/H4]/5?)U[/!KIJ\[DYI@?&;J(LT3QUG)X5O
M@?'D@#'2V7Z*MD@<>HN#BQ+/05"W0K>YI1^0($=\Y4E)B<'@;A +%6C1U\_!
M<+4-VT18_&H1H!B8"M*\$Y(*)/1VH0_FG6DQ1* !C!>/)$5E_=E)']Y/B='>
MI0+X*_UP9;DY"*??J.M9?(P69M^4TV3]/R=]F+G?YHT_"PDTN6E*G(C[LYC%
M8 R7%'>WDJ1Q;=#GJJ,]*L!@1 7@.Y'@@Q_$HS:([;_(UN&=*"S&6+I6BE(C
MYMQ_SG!-*+4H#B(7ZL^X7-N>7BZ?S.2S+V.S-?0+H,2NY^&:3M50F$UI6 ]\
M!K:9!]]-IY$M!A/:_\ B9G<V0#TS-$I&3V-P<- ;],%@UY'NGQX_Q; N=)OK
MX0'[LJO%4\HMF#19J(V9!GZV=[[A=^;UFF'\02[.6D$<GZB ,[_L?1?TX%Q8
M[VR#/6',<M76JU]['X1_@HR?W1>$+5NWT9X]5@9KD:5<\K-H]B3=5A7&2L'G
M![RJ535P5203E,N0ZG:6+=OXE$Q\FD#5(1=)5J2UGR &9:=-Q %-ZGREXNKJ
MQ3[WW9-<M/;M5]A)UTR[7 EGT+M(&QKRWSQ@G0-'>$N?".+!/ \OF0R&&P_M
MUTJ6E9(Z8%+JMWE\Q<3= D/5Y:4GZ.:#!H7<29J8V$1%EH+Z[<*K>K<9TT8;
M-BS[U+IRR-(4VXH5M#$9&CD/ZV0_DK"F\=0ORX>4=RH!\G#BZ2"GL<H,R8=M
M+=#@N"UF3WKT1+4.2N%1S[C,'\V.'<LD/:$"B56+KL13$-CZW;%-C=99./CD
M/A6(4#U=58^/FE=R*I -O)D7X>SR2T#A\:,;%:G?+H8RJ2;',2&+.ZV\2''%
MW>2G^NO(%:@C/@DGB1^:U[VR:#BLS.KE?-%@]X)2@U,^RZT/"9K?8<<>TV#/
MSC;#@EZ(JNS7X<K)WBA9^S18967H:G=]S$W7=Q@^]OII-8$TQ@.]#E"5?2N8
M95V!:PQT6O;"2!2K/Z_=OF^2XE91 J<0HG>, [^X8*469+S(9D+H[/MDI4TQ
M^U@9YV&D=4F"FV[(C<_XCD><43:2[+SJ8<?4D^%*V#L"-028Y+F6.O@$A.<<
M5=>XY6+0APGO;B"^15=9]K?QGUIM [&1)')F8%W3$<E.3@I?<[5+P-><4LAY
M4%%D"TV_4%>PE[N79S5<G+?\EZ:Z=S7@GY10T0YCCDFI4H7.JY,[5\(W1&=]
M;?>D<9/X4BK :KB(JQ-NG'%)S@%M9:CDAPJ*?+<Y>(M6?5^*'F=<Z"))P.&<
MYG;?&V319_-QS^J4K[:OG"#L',&V/Y6QXR!X:ZALD!?F=[@O3_W0A&=@H8M0
M1 U\U:V+G'V<;%T.O8$_NS>'Z+2"M6&5W^KD0G8JWC]32$T0.L5>-ABY^3"N
MX*;8 9K$M=?P91-*_-"5AYX+'C4] M6,9"Q CKB\(83]5"IP6ZZ;Q(1/8^_8
M>8WBQ1J]_.RTJ4XTN#0OQ;6<#&,T(5VWLH^"+5F-P#8'(61@]/'[VCONP>=D
MVW32W1)_PUMB+/REI9[6A/OV2;P9\#CQ./-8?U/@&.D:I OR7W6]G21#!02O
M_*G?<(>M/44';'[J\!#S=:5IF<P'K;W:(^DQ$KQ-^@V"B>2 "=,/'>M @9I^
MVF>LA&J%7.^.M7\6K5W.P].R>!FU0IN% ,K01'^<U&\H'[Z,8/7P]\SXU+KI
MH73]\[AK ERVO4].]^C=/"D3(O&G_";!J9X!T7PN;^/&G8F191+[YSN:-T[<
M_YYX;%CT3H\>\8DO,HX*/%&R*(9/)+66NISZ]K0A,<@'OC5X"C:G[F"SM"IV
MQ\+IR++DGI$@#VU"YR9F9=9!?W&A^+!Y2 N(E_2R$5V)L8XA?W6WX>UU0SB&
MLD6WARLF#PNHK:<38106FM>Y;!^"WKKD27..@XUH"O/7Q7XV/ZZ.++F,=M3E
MP2 5CH[D^KM7B@,Y*KZUWA<2\^&Y*# 2+R!N+"Y"#BP8_.K^FI?2M.)?\\^>
M9(UFJBSX;2IP1X%B_"=:0!'_P@/_(STMP-B.9*3-@LTFA*)HHF6*<\9 D7.@
M5UFG,+@F!QR;K5[%KHLSJ3VIUWG+O8[9L(6?&?F-"OSS<4G;/5_L3N9?W&5"
MMO_S04JCQD++;PR"C="R#@_%9?E,NI'=B++9KTC26^E(,$Z:9OQKKY'WD$KD
M#["E5W\2A.4!77\ZD08(^RR X\"F1YGOP.'LZD>@U^BSZ*4<OV)*:PV$H+B)
M8U]0B) #\T*_UZ/"<BR"OQH/!RG@G"Q@UVWWA%X QE/MHMV_-3GP1U@)BK9"
M-'I+PIL6ZK+0;LI<-(F[A%$!:TX:H9)T2HDUPE@BD=)+/](3W3H\I5)) W^*
MDTYR8"<IKUU)Q>,P+&'7]0V:+4@#@VC?Q0=VF/OB3,K/.TA,^F/[PMV3E7*>
M6VLT03?'_G;ZR[FDF&@KR-KLFM'3W%RB](@ #+.#,\3G86W;3N,C6U%<E)&!
MY80%'<0VZV./;VYM+Q.+W8*+UY"_V'$Z>"0&O3@;2=)8@-&"^/,7HX5N5^HH
M Y6I#B_X39?C36P3;\_Y(C_"YCZ@=U\&Z)%A,["U(<B#L6=H3[!O!<F4="X5
M7^YP2$H[8B4&P;J'_=K(O6"R4 0*1WY%!99&&ODI!ZN4Y#X(/646M.O]YW01
MCWXJH'4)V81^ CN2<V6$-?G3HKFG"3?D$-)P(-].!3A!M-BY@G8!350LSOE$
M.L\C3VK'++*9"XI,,+'A6(,25IY@K-Y<\FR>T%J3.9K%K,Z#X>@7_9PS&I_,
MIIT(20H?@@NM=7<U:LE'SSV']SIU^/CHHH?(18T."G#P"ST^1X,ZO\7A9Q4A
MYUH[CNV^8V^1.;B"?D@%;!&1\@@V*F"/9IYL81%>R7=,SUL*81O4N1&Y=#B1
MQ[56==.OT- [CPRQ.Y0,ZBD5X2FZ3BE%+Y9C4J/!<YD@KB"E[.X"BS\J/GB_
M(;U+I\E356E.AU=,M25*Y:NU+@:RZ!L#LX?PL]W52GG!(;Q;)2FPZM'A4>0V
M\"TRYY3;M!'E(F5\K ?,BYY#S(#P75C:H#K9%G3B3DCLQTZ-F_V2X$J[SZMV
M*>AX\\FX)C5%Q7R>A^=TG<G0X^ZQV4-3!(UFU(TAU"4_)0VL5))(1KYC2K<G
ML\IMF\3\*;ZPWVPN8\P8TWD!! ;<S D].WAP@?RP=51+*-Y*/2'7:KNV8+SH
M^%)2K*_RF*^Y7FK:[I:]@(MQ7ZV^.@=#^/\9#:#_/W()!&.[YK)>83>;4U5Y
MQQ)RNO><I9\"O0[7Z*_&; Z'WCJM>8CLF8U!5(#;9T,))7WNGZPV)HRDS/F=
M-*(^ORY0EG%FR%;]P:C"O FI\#+RF+ <^(ER*I;!C.XMY+?KG7G\@66G4T!D
M>&M)0'_H^?#O*W&1NBBSI^Q#')M4 (#9H 6"'H^6NGB3I?9:K3E,V=S]"]IM
MLI[-)4=<N1 EF//VO'=W)_NF%4>)>4Q3U8U$9W,"CS47YD?:'/K4^@1GG&.*
MN37B^.3D9/X]=6Z0X8:>4*+3;MO?,M#D9]D5F99+N3,_J$ 8I#"7][6EP;KK
M-Y(49J=CEM\/K*.KH(;-?U.IJ\CSX>7^MDF@GW%4]Z4SS?19C28(&MCL -/
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MA%W;M8@B0L02\O5O6:*7B-AMI>=#UVZBP3MDD P62A1F/WBC<B*7B&R#W2#
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MFR0YHH'NR&Y7-U _M(0\H7IO:C9594JGQ>,V@PU=<=P3G5PMU*\P#XC[\W[
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MS 8SVX<O[SP>R*UY^PW!P'1?X.K>,OKQC2);/CNDV[;SGEQTK8%%;R;\&0W
M@E5CI63L=BM8#KA5/-*0=,THVN.VKTXQ_/E B.?X,=[;J,]Y657IM5,4$*/U
M[8Y$$W(%I:KI')'4!J_(C:Q49?M.%1R1'4L:[&P8W$V+F LT;<UUSCK_\BX3
M4Y[<?L?&H[DILQ_(<FBH;*/;PX;^O1NF6]WE0^+3I[.[AXH4!%YKWF6P\>)O
M[(F,A-?G;F"29XW T]K:NS2 * ]K.RJXB9N(FZTE*\_?OM*!E![9YCE=+-3.
M\ X,:^4[-8M91K2!1CGF42T3V+"!713QH5>H8(=?]ON!Q-YCGX1]7W@S7PE(
MI;S(RDXVRSJL* ==K* !QE#S[3FODOK("@2=!QW'2F13YL!M4_<0K9AA=#F8
MS(8RK,(4-6@1M,5Q.'%S7=;PYXEVCND\"-6A#Z?[</H3=1>5@'V1H@Y=R4:U
M'[*[LT?_2E20=^._XG3)_]N&Z!QJPG._DR#<@N1^ZBLY-YV7"LNQR[+0)[A\
MKE&>#'S/&&=R_-B9QS([-S:<Z1LT(O-V)=&9;L):^6XT<A?O%BI*1-ISCT&6
M[FYVOR%BEH ;Z+EZ- )9J1GG4R+5Z.B6@Y$3=D5\2WD9%+5A[L_U4=+YJ4%C
M_# -  TX9!?>6%-*JA^#0ST.D06@4U<)*L"S*JHTP.G,K/'<2,&*IZ@5!^NH
MB^C?!B^<"N07)4]DU):TYV''6]7X^O9XC9=L @*X_21L3%Y+&%TJ93Y]XC;O
M3U2Z&AWI-=^E\@3J$+XFSQ6>%6U-4O!_&QWAF6<VH>7&=ZG4WDKY/,"@YZS#
M8L&C'+2;@1S'J>O4G;5QT05$) AOP'K2%V2:]AA?$N*] +JVKQVP_]G^1:OW
M]FAV.2+H$U]KK',!\00IP%=Y ?).G*P<E&ONJ]O*H>52H2 C-G)PEM+Z@?&P
M]UFG3-]%WWP$&A]KN=(:I*P1F$.HIS)SSR)#4Y=ZPC^O#1('C2H]>;O,S,4N
MQ]7<OKGB\ORW,DY?V5Z1'8D/H3*KSVZ]4^.OZ _4^CSI*S^_??<2!]BKVK@^
MXD=X@M.E7PO*#WA_9@$;B-X\-( / 6C9KPT5QL+Q^H@PTW/5\)Q)!TNQ@"C1
M"/$O#ALXG<N:(@^NS_+8^.N3=%1--G">6"X1%NXOZ/+@Y5L_%+.?7E)X<NIG
M[XKE!4++_B!>Z[LDEV28BGH.,7B;4FS=<-$Q":]BQO/MA*0T#SFW.D<QH*37
M76L:8L9'@2+A56C<(X+Z'+!]K8+U-!%)$GY@H3;M[D9!.BOT-%?S#MSO[F'R
M)XG.=K2?Y5Y OG$A0SY-0$T=![L%12]G<PDVQU7%WU..ML^5.VRD 1B!-$#"
MAQH:X)M1[K93#TK6EH%$C4DUJ,@67CK*WJ0!1K'SDN]@(H$G^P,UYF/4209/
M:S*7A&JWK<-?:J<8NL08:0)X&3UI@ I67/,LXDVU3ZJ8J&1$PU.FSB.7SV,\
M9S3OI.K?0FN<F?X$82.)D@T'8"RPEB.WJ,KZ@(EB^?;-.9LH\'V_6%)9R+&Q
M?_03;#I&W%O @>:3VUDO$5$Z8<LSCX<ER,3G#49/C5[EM3#: 0BCJ1,7R*X/
M5NLH7>3?:Y)3.[KUU=.]8XC0:;$:PDJ+&XMO_/H5W*:WB_3TT0.KGE9' 8A(
M[0H@<V]G!G=(J&]',Y!EYD31C%CH*(8#D]#VDFYC@H/6\[Z<T8EF$MQMLX%U
MH:NJ@^6*)>=F6J[(HLY+-%5='G]:$S]]S'FYX]29B;=M5>1P)E=_=\O/=&AE
M2'3$5VOTN:H)$D%THZA;'R%0'D62'C_X]?)3^?-73VH9SL3ZYD1$UK]\A9!'
M^@\>;3XZN?&A\A5F4Z6%>IH&(.QT(+F_$NJ(& OJ.)?36!IT]_;5;7++'^XI
MO1+/4O^5G*!0J!JU$\E!92<;)K1FS^4&P^?..U]P=4/L/\I!C"L<9D*/PETF
M7J&GVQ7<AS!]1CF/1I+ZV7B7BO<HY_4TM-S=V8LN/I*-.B.5[Q.OR5SPR28>
M?(?1QD%;(]"/H$QEMIB%GUK'<,'#9'5GKC2<TT-=]JZH] "MI"6^LLHD 50C
M>##7OOPY@>"U5M+O#0KG,$ZJ/?Q2,3SB<V+,]!(3]>A2UF$53[+$RK0AA!'O
MN0!_VZ3L:X.UO(1V?K?P+%D^ 97L[K1H_R(B ?'\M$%(L/M3*!#D@#I+[:F3
M2"[PC>\R;*P><N4:%QK(BM4T9JE)8N4_8]V7ZG&@=DUKF@C6SVH*PB-P;?C!
M-CCKWLR5KNLYG]:4[J\YK16T<'6[B^;;/M!7!/I=!3[T5CGNW+H')HID)I[+
MZU]#G]N2V,6-FD45&UW]B,J/>?Z2M8H&:$=4=@TIF$^QUA>RM<-D^]7XB*X'
M4,+E[,N)7Y[F.99\[>$0!   \=I7 <<$4W=F7H,J#D+0#C%J2Q6GA<N&7PS)
MC20$?K:/T6[?:[XVJ.+*%"M]4B.00M]- ,J7!AE@:* >_OWH^@P^_G;Y1XM3
MSTE\"AT*TSL**PX=D]C#(2/7C&1C"PE3!"1K<A?Z%EK5GDCH6O#P56CADNU?
M=;17[5JO7GE1+NT"$%3?1"EV\2 WBX-DH#&@,DA[#-NL9%L% ?Q.W)NE6\6D
MVWEIK32[JW9_=F[JY&U5[!YD%M[>S;JP%3S12@56#(EM7%[75>?+Y7&4V&76
M_J$<'=B"+G:=KX5(U#D?H(DG5:9WT$%J6T3/G81Y+5PC 767&#&?(=W2GJD1
MDU3H[<( '3-^5":;D@BY?O$Q@"<AE:*-;UP<1X15I-6'[T@(5X0]!0)<[>YH
M?Y_U"("T6=ZB%*#M8H!M=5-AA7@XKBZG>!=O,4D#_)#ZJKWRL$RZ?M/11]Z$
M+>%7K]S^=)2W6T"VB;FIQJ+I(S>>]VT5$JTBS"5,)TZ<.%Z>0SY'<MZ&I^1
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M_DK[)Q/G[W=J<S:+/7Z@<B[QL&L!>,@GUTLZU4LWAZ;H5UY[%];V.S^)%.D
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M'1L4B]M!-XB1>0C>A/I(0X3U'G16PN]C)6QD.L:,,\N'#L#JD\WH +3LAH5
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MUY=1^%E0=>GK10>4%RIM*%;:+7BG";Z2&B*-VO^Y27Q0)VU$#55E<9HH)^3
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M7V6ZK.'J@*5M_]B6=,:MF-<K+=@8$K<?Y@,=8 MAT!!.*'\^R4H;-R61XTC
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M+]05)J(E,Q+7Z("AT]V<_3F;YBXZ$A5O<[N>=G+F[=??WDR"6<C9<,&HY'O
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M/(00%[,0%(K;"367A+ZV$S3];=%V]WS.@4!4 !/D,QWP:J0,:P(\ZT#D6E?
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MT)"6#&-6(GM!F08:F"E/2US9FT>3+U:_P3P;CS-V7C*8O'95&;MLQ#3D)@!
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MH8[?)&D<I!5CCF%=CL.O1YQ7-W<]"/*E<41""NZX)K_[;%F.G7D!5PGE%D=
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M"TQ^$XIW%W78T\0_34B7^W#?8G\3$'!Y1M*Q[^ZDRSV)^/T<R5H%Q_7O&G2
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MG* :<PH&O"#-NC9S:XA?%U,6(>#ZU)9C-#GJM]E#H\N!SYMX@8_$:;LIKT=
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ME/ P(DG@]EI,4MNR\DF<:,6TC+>3*[5U ]CE1(,V688K ^F9/TW*&E_S<VY
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M"28A[3'_*]SZ 2@$<:'4.CB1RD*Z5-M2"]#JQ4CTT3A>/-$Z7&<AG,?O5AQ
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M#O!"&K$K*<EVT+^7X3%[*26ZV7=E&+&8ZPS#UEE"#F^I64-&R/(%]?IW#G%
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M+?MZQ5! DK.+T32G"87EF>7!;_@2>?27V$*,;R966EG@B"U7=K):@U:8LFK
M-T[(%LJ2%Q*QH@]#[&N@F7# VQHXAJ1J2AK[XCT*HC6&24W<!P?JW>)]^HJG
M[=BR];832^54WSWJ^<("=ZECJ><:9LDVO8_UD9C.DVSQP[DU5,EL47CYP^(*
M?4S9#<3_RA/JK2V"G?#.[%41/BB K^& 9N0 #BC>08?1$0K9@;$AKO'ORD"Q
MZ)@,F9T@'%"AOW)K9#4%NMM7]>\ZE65C+4BIH H7D\_.FX"1OXQ_'7S_Z 4)
M@,Q:2N2[PR7P3]0@-]AJW=T+JX6ZU[:AHADS\4@:I&1*F!;7?'M@\>&:_#D#
MX5'>6:V8X![U(\,#GD@Q0);GJ*75O2/ATU8BF,TOS6]<VR=@P03/"U17W<$.
MS#,3-_#C+F*_$L2)V=\XM:)LBV'@QP$FG]3?#6[=/__."MZR0Z\21H90/>1[
M;0+>#!JI+)6N<MD_)CL.8<\&6'[<I2@E\ 'YP;%:<JD_Q<TG/4%E\G7U\MEM
M^_D"+!=*72WS^"8N>#(P'^4"AEZ<K*;_!L\9J.2EM7Y'H7 J1$WT]"8[TJ+[
MA>9E_^8[GUQOTAPHR*^;DC__/'-'.?-%AD<E&..ZEANY6XC^S(@#"B3.H.NY
MRS8S;2;)$K/X1:V\YEU5PX(NO-N*.)QQ6ND[*@C_'N,.NZO%#]J@(\-V8=B'
MNI;,\UUHC[ TB9_$*-0':$7_EAB#_SF"ZZ_HP/WML*%N[HC1:CC]4]UK(GQ3
M7#YGMS#L"?TJ^1$W.:DZ0*$4;72_GGT-J_Q5>MM:8O5.WBYV"TNO'5E6"V>X
MOOYM9Q]O)9LC3853E*O8RQ4W5LDK^0\2XL_M*O !,\..YE!1[+[OW[DN3MYA
M33&SP:". YP)58T&/BSB0YFV_#DCM$X,,)2>JYP0UNE&[)".2+D+VL)MPN7;
MB*K?L!#"XN2J_'=^S+I^"D.INFZS\5O.P[_\,8BQ%U\U>V:<:&ET2JD))@++
M(VY]K7*9-;(N_IW7TU'QX.(\%90/M.9ZF1,9NG1:B-8XAC?"B4Q#TS_G )V3
MRJKLS>EQ#;!JFL>3PJC^L&U_<'+^50^ET87M3KR].E3R="C^$9:_Z\E;8'/4
M1-?P1CA8L4<;^(G;?.&\JR'INC<TU3I/:_+M%=[G)T;S!3YA8>U)E_X,%U<H
M<-JS^Z1)GX:;X7V^R(!N:^;F^&?0HWZXX:2;>LJ "/V5\Q>GRO/RC0EJ*PW"
M3&$O).:DG65BC6M!-\639E^NN_1EGJK7#?SUMPQ^XR\"4K>S:_VI7(J7L'KU
M[IV 6F8/M_?"P2XN!%51&E9Y*5QIT&X-$UJ?OE>*., ('[H."480NU=P0&-]
M7DIDX+))IX_$:)J@X>YQ/D-BX+&X#I89>HSPUB,;=J>9/;LW0OZNMKHZ?"M9
M;6K)KY4"KL?>SY(DIX[W6C',RR=;)GL;S0+1;73B39*1]J:USQ&R(:8C>E)2
M2V/;%PD2O4CVJ82?.>^KL&!9J]E<86Q/L ]*$:8[9WS@ /UCR@B4>J+ZYBGI
M=9KUTAU9H3NOSMJXV^83!2IV0,TH=$@N]G9;,&35J JLD8(#YBVV^L;NS)>=
M!-7>RG$V5/ &/Q,)O5N0NM C)?V\6_"&W2!"V&*S[_3A#/KS"S>\/I[IR.WI
M^_[U_J>O"Q=CRZ<SBQK'NE^72+Y4MN0>0J3CX^7V&Y84!!O8\=\>_K*6*T.F
MG-ZL^V!216XJ/;ND)/6#3BI/&D%NR&X5@P,L\8M:_/AQ1K7E8+O.^2$ZBS"I
M&ID_UPY[]CQE%RS0685\;,5%69M^*(=(,!D0(>G6_/).2D@J+3=J7+9GE*2M
M2'X/?*%T"\U//=MSWPXS,JM =$G'7[(&?O&UBBN"<DC[9P/>/3')N]N=#0\3
M?"'V^[%L9H?M)-O0NF&F5HX#')D,UR=C*\0 )HY_1XI%SVUAK-%"LNET3@G"
M!4YWI?P(O@%>Y"#&? 2A;BE<(B/! >TOY5&+D&\%.54P$G'9X4$(2<;0*1Q;
M9G]TP+=R?NPT<(H/C06$;_."Q86JCR.>YW5FPL1!\Q9ZQ>YO\H\IPCP/;8EZ
M!1Q ?91(WV@.TQA5=1_!6#8:Z4].%J2SEC=3*NECJ+)SUV$O_K;>9@E[CX]:
MY@K\6^]ED)CU'F5D>NN[H=F+*^PU!RNH$7C '2*IS?P;-\<>BPLLSD(8I*@O
M#RB*4XH#2976-L.*8D3)OT+D782]>HZS+8%ULD86/]$]''""[,%8=&7 NF)?
M8S<HT<&NY8$XX)X;J?WY"PCJ<H;='=,4Z*O_S^0HQ,*Y@(@Q6!\SIZ0H0A7A
M[#DN\W6*'+_O%CW+$I[[_VH"I-;%@@ZV_ZI ?(>GM'SEIGC'$26=XV:RW^7V
M0YZ7"Z_+X(S,7Z>SV]9$:.MD+RT>(];3C>AC%O;SK\*N=\<\%6@7(B,J>>@G
M2?,AH!TR?C?IFAOD)N>\<PEV$.)KH:W?X 1C$^D)VEJ%L"VL7LR^^-&4L#*E
MRDW6=GZ" !:?&(P\R(_3-1_?(-'NA&PC3OLOH?[JXNW?^(>!,"<F&6PPY=8Z
M<X-'GO+TE6H1>+S8Y42-.N+%>\8V)EKV"V3)K>QS&*7><XF1PL.- ,-SL<CF
MJ,&M"/:ZN]D-;0P/$!8;>X5M,_L*M=HXP" 0@:$>0<E?-\R==\E2<5)\T[80
MKQ\Y]]&],O9I:<;4.;7^9>%;I[ %$^AC[FL$'U+JO(>G:O3D%"\0J:Y3Q"_Y
MFV-(,9$XP'BM'EBMSEW72G--+,NIYFG[^37@@>K%2S+[4RZ,9.GN"!QP<0\'
MA,_EXX Q?& \M'= <>CIDQOFGIL9/-DV==-AB)SS+*1U@^T\1AYZ0UD*H6"I
MO[\>:4F7LI83!>VG&#[K*VM6^]6&OK]W04K "DN.Y?&QL>,8CENR79E)0BD0
ME:T$?.F<>$R,/K1">.6Y&+O$UP;IPASY,X;+CXNG>,="*[(WP=0 %$YZ4T=X
MK+_&C62R9'=?PJ_2<N4\=[ L]<M]W:*4%!1+"V P?FHS$;,X#JZ.A_>6Y9>>
MNXF\J&R=0TM$G(W$_@EDE6^O;'[*(B37^[XHO6BO/%[,O/"D7#U:0#XK&VDN
M <^$=<&S^9.N1S1^_U 2KG292_C9.C$.T(D=SRN\ULTX1$E,Q,L&N17_1RNO
MCGEMAW3/E73Y.37\@E4%DB07/,8\G+6?!;7[J&\(-M^Z7%HERO?$EQZ- _PL
MM)X?AU78RV!O6S@_W-BB)K7H-7 ,"G<]@"]*+&F/]#I?OQ/XZE'3!:D8Y.1;
MLN5K]@['Q-_^EB:Y]!:Q(/;LXZ3&PR_1(,9HL4FC"7:HSW[(9B<YV\HJ6T]?
MV&&!=TP:+WXN84F_I%&W>><=Q6\$GT(AHGJPN3A8Z2JO?- [(?A)'UZ0]92Q
M1KFMZ5Y7YR-&$E)..A.)>U".A+R4Z4SM-Y _8#[(L*OK#8>RI/V'#CUDG4?%
MQM?ONG+V"$"!KNK^>]]ND7,BEMD?;$A4E3%N'MPZ[^A;T]6E(&@:T'T_'6GM
M$F4TC@.F]<@6-C20L:3'9Z8(]\09M_VDRX^.+ )?7++$6[E-%<@_W6ILX\:T
M 62D$^);@[EFVTS)2.XC!CA1J#\US)<U?]DN,X"ZU8ZV2"ZKA>X]?SWG;S.I
M<''XK^:YO_'_>U">(A=VSECT.'# ]Y89;+ YYFMAB# [I '<]Z76('LC\?8>
MHX"]0&33E*Q!ULO>(LF51XK(^)OR%VTV]%6;3M?OL@TY3$5(--GH:4*[LY0U
M- [X*APVUEW\T;?:L-)^%3C@+3,.&!A KI8Y/]D<.6?30!-6#O-8!*N6%=[0
M?\DQ_3ZPR^]N!=%88+B<))7A6K]ZG3J1#30]J/5-_AWG5==X0>_\Z*6]5%TM
M=:L&,0KU  ^6__/)N6K],,-WF-U^VW;6NND%[<!O6X9/V"_IKQP6V"F.,M8R
MW7K:A)E>V5 M?,)8]ZWC/HIEE8T$8-UM/+EY,5BZ:)-M.R&UP\7?O8WLI :>
M;J]6;J/95LYX==T-G@^\'SOU4">S=0*=+=>!;VF3MQ:QJ"CD" "_E-Z?%K3W
M+<W;S@55JRM:*6FW5L"LBYZ?U?.0\%.,JD. Y%U#@'EFV1S(GM/LU).^[6S?
M-T^&=^9(11U_OP63D1LA 7F_'MPIJ*^WH _/3YZ2F,./67OPL0#2$DY.5VRR
MQ/0%) /Y4N!=M7,[>\+<S;WI3-V8['0/6TVE>DHU[NQYJ6+@49@=C%5C93@(
M/CSJJS0@9V]!AIH#8;W9MCQ$5WPI%&7^)=]&]F)OJ;HIGUBON#EO1C$,[94;
M-4B5/V\W$OH4+::Z=PA%#9NGW?R>]8'>_]%'R 6P0&(;]@5>D&W$XH#[,I56
M\F(42CPD(?.OKM46$X3G:)B,J412SD>7Q:B\AW(2[B9=%Z]C:%"S-$M.Y16-
MZ:Z1;"4&/-\2GB+CD$7::383S:$+G:H$G';["R&>7VD7O_Z)FT*E;LB@7C_>
MTK.WSN+"N41L%P>V&+S#LG94D ,%YM9VNX_WB8.AG-OL2</<?-O/&/E"Y-(<
MK7<+/$V-*D+3H(K^AB)TU^/RF489HLF[QE;\\+]Y-/WC45GZAJ>&AA49W6UY
M^7S 6E%*^C^W0>1O_ :%LN9G\^XVDE3&_HO/D5\,K0:?,Y^J#R.9;6R8AENE
MKFM@$T=XT]V1R$N(3\Z*6ZJF % $D,9.#1X*548MV;H&]!WA ))HB4&QZKS]
MH$YQ54@-#D#FFP-OM/[,(D&6)**2///N9K:LCG<?@:-"UM$RLBU9I?E%4O:*
M3O!/0L*]'P5MK:CVDN)SB@^O#X+*GS4ZK4P&>3S3D8._0_D.-M82=O$^^[2A
MS,J2R?KAD_FFM;->5]>G;0T[YDZ$*/((JUHE&\+CQ_/ZKBJ!R#'%^AGU")UF
M57UFYMW]7/PZ:5)0ALT'=*TU>)V'7.';:L>FE*UGY-^(DZU2QC3.1(,'RU,?
MORF*CKFE'B@.][&ZU.8_2]4EKDEST(ZYG%^]@*7K[KEV^!H-;6]:%R4^(]ED
MW^CC_MN$R7[AC<FRY2H79N(37Z+IST\ZP:*Z)%G!JBH&*F])E@X/GYG?")K=
MF3JSP[!G9^C@ER/MCPN#MM7!%3^M&44X$2[.FY!>,,E.+4W.5<S]!X;G$Q_$
M)<[!C9#'8)(5GL!G#I95XD:P4&*((M:#7;!IO&' @?';8F.3$50P>^>(SNR;
ME&9BIA@O_VV-D0$?!E(_Y5")?(%0[S_SW#IW6J/%C4J3PH26EY_R'118?&)_
M]L&HV8?-E7/5O,PQ^@93MRQM8)6L;;5OH(;\]WW_2&M%D3N'NBJMC=/&9P(,
M]-,S;V8*Z*MU[R@\__AMD3\*/.S:3Y3PEV^@W_B'AN$I=+.-6B3?>[)<"-RW
MGP]=Y&$-;CGLBP\> XFV &KY'L3RM_@3Q8AX^!3<X%J=4-[8U\$NQGR4/[4;
MR_L9I0?$62Z\^;,S-[G9YC?6'&UU9,94::]ONA'LJ.7VH-7GR;8"DVD?S1@%
M;L-V*DX033B@4(1*/5K9/'I0YLSE_8<M*B%7 G1N[L#A0,;$VX-G7OIH,$GJ
MW!1SAVI-],[WLSO]]#A 6;OLX'12OM2SEX:A.%C0[5?[[/V0/]XSS++6X(A?
M#/I$0^M)R6-P&J&R;\@;!D]HZQ5=%0*#EH[RLX8<'J;>9&:Z6]X%OXY8OH\#
M/N" 8_/-C?!3-ZLN"R?^UI]T"J[HI @<D*RNK:_GDORWAZ(1ICA@_Z8_]A(.
M2(I=RXVJ_'+8(RZ) Z!7+E/M^*!ST\HJM;/47J]*,/2CE+E]F%*@K-1__(_L
M4*.)'(L'J7>#^QCZ?]5A4?QDT$PU<IC,;R#RUJH&S5K:?<3VQ%11F<JOJZ-@
M;>,U;/N"-9KV$V'>3<2VDGQK,^OL R]X"@HJ#*/.K!XT=M8CML@,1;\4_=DU
MD:H['P91A#285Z[416* #9=X?WO[ FGF1>6MQ]2C<TSZ<R]@BI-JA0%;'P=Z
M4PL[9P:+3 G+0\2B>!SXU:B($C030?">HC$Y&4M84[Y9_U]=WOD;_[@@?&@9
MVOZSE0(^6)FS67C'(6UAY*YG9&L_D9_OW0C%EY#/MW$ .,&!LL?9H<B]:>0R
M1LR^]$^N<3<ZA>GHWFS[>%; V-E<C\T<4R "!]>*+B8/;?V,4EM64QZ0/$?
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M@2K2?RTNSS/44USK/R\NK["  (COOVD'XOMO!OK_P6Q)@\S-),S^&I.]T[_
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M(=]I7PSP&.L"6(5QWR=KOF"L'/-;)5+W!]*KQU,]HN:=JRWZN>3"T[;]\/C
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MQ,75WT:&H+@XT,S;G?6DS)5.2[GR+O-B**GA+'KKP8L]$5TH+HPBI35$L3_
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M%DW'+C4NU$W1"=QPK75A4M5R#Z \0^$QRC.P)LV.Z7W) _]#1]+U\\C>8^1
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MO;__.M/Y0)2 \:A@3?!-6[8E15Q+PB%FK6U#>AX:T1KZS9(X*RH% =[E_#
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MLZ!,(55[']?+EPQKJ:<>JI,@C>_<2D.%P9/K(XKA']ZO?'#4$,(%*?;69':
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MF+A7W)BTG3GXP,K0%O V$JBJ2_;BLTA"?ZGX&A7"LF%S95_=G)_:7:2<A^/
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MA\Y"I+.+QD83D7V72OGN1342H#7%%-V(!!PO34]9N2!89D:5Z\9G5;S6:BW
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ML$XH&WE :Y!<1>11;,]O]F@Y^5T/E&2_^Y"<W2KZY+Q$,^_C<#H]W9Q@_^"
M;H 7.$X7X=.>3CH1[UJ.K\@[U&_FY;W _@+Z<8M)L$U8:Z?7MG/-3!'NTS.C
MD[8<9^'@\HE 3S%G0!IL6ESHJ$MJ!!2M-LAWR=VYK&6U\#*Q<[*NZR+H* FB
M$E/G_$>_<BSB?FV6JM9/^GV<??P-[0CA9T'*="%G2]11'MUYU[!Z7U$KA^SE
M%9P7FE539S\^Q#U]32Q-UD[_<G4U6AS71&%\5@/A9TW3Y4]5\8ZUNCGOU=I/
M/F5#?_A-<_TH$=S;/2S7B@()J'(=%*;A/KQ+7C)9.H>B6X5T7G-.B2V[ACWS
M:O2 ^@^EFS^(8\%,S$.3B+.4;X=,^&_'N ;YW.THO&PO>@VM3T?_"66B$9-3
M"7;^U2# ,M#Y/&#W29&.?W#.#I=(LD&BF>D)MK"N;HY92+TJMP2UUMKI&A#Q
MMDG[KN8"U?/5P>T:WPJ_/:S:WFMOT@'D7>R8G-*Y^J1&N%A7KJ7M-_WT<RXI
MQC8H*0$Z_&>/RIY!P%HK*M3JP@7'O5>YI9Y_<K&358J>L[AE%<6L3UQAIYS-
MCI?"Q*% I],-U2W4L[/P%DB(\CLBU^"CI0%W_21OJ=#%KL]CK@4KO"L;_$X<
M!+:$<5:#2X]-X5'K[?,,HS%056NUV.S& T!MY[?L3R+O,_C<#Y8R>I-WV5P7
MJ%X!F=Y50:K#!$_@ZQ]GQ24>2UIE6EZ0V+F9Y,PMZ/%Y*.%4T644/TCO$ZQM
MX[A5V[+C;"&;5T2A@5K\(K ]_>56!YSR+A4T:3MLQQZ&E@Z9+ DD0%8TV'5+
M9@+:-4_%-P8E.<6I#_"MFE]JM.=,/<W02?^?9MP81C*"#:'?Q.[K^^$""%>!
MC-YE7\#3'9(VJ9K][5.<(J^ZO7$?),>+@UPDP"#VH8E"C_5#E:UO)9D54@J?
M-4'3D[>-H.U5^1D^=1U?O6S%[SY.!.0!DB=L8ZJC@X0 QU[B:\0. 7P=O?L6
MVJQX8?V]4/_I)E!;]9W0 [_QWNGUK^\5/W$MQ\7:TV5./KC1CV9VHTTK - '
MC#CUJ$PTE&,AI 9EQL$US145B1^J:^72CY^K7ZE%4GZ>*[6!DRA,;47:*;ZK
M;DS@.'=PLJ_B\EB-Z09XGC>P'[93,4)A-AUN4R&VMNY?^'$ZTNLV'H0*$H '
M'F9Z-P$F(^B9@,Y0.8\-:1)]^'CYJ;KW'0 XIF5Q%Y-WE_108ZKAOL&)HQ^;
M@J'T(_!5$XKJ$>_-O,;JVM8:'YL]SS*CZ$_K2:C%?I*K8Q@8, I15O59$1(;
M2LU9<M?$4^ K-M*4)_*DE/@Q?=>;L3[B^ZW?O1?%: +L<NJ.9M,K)1K?*-.[
MR;0=MA$M=.=85?1:1^]<5.8F,<ZK/W[TR/L'[/>(BHI.RGY"!V+9+YVCAO0V
M6ZR]*<\%XJ%GND7U '^*7,N](E^Q&N"Z..X<(]'\\B2)XQ %$T>K^]WRXE;H
MX2O71E%9F#&.\C)K:S7"CPJM,!ZXU7  ]1S!O-TK$:,9C\RZ.,WYF#*\T#)Y
M87K*O==(-JQSPU#1PO_7CXLRXLRC%0XO4^%+LV2"O>_&,/ K31"YY3G61"02
MWU@*VE!=G/12DU^E.-P(]A9*FF%[]!-ZL+KB>05*,J- W'9Z)T,O."J@?D6*
M&56=%]]-\/LY$O@;<$-5U 5%-"P4)E/>W0_;8+TW)N28?\?ZVX@RH)JTQ^M!
M$-JLEQJ/OD/D>[##@R-SLA5#GQ-G>>#4A2>:G) IDU(C-GQF]8_V%/1IVBXT
MUW6UT\+Z#BW78(]3H[-"EJ%/]$XG)XDRBCUU=9& +PTW'R=?C+N1'KX(Y20N
M*4_Q"R*5*EHD</;<TVEY>C350CIA_ZD^%B/]Y$2QGF!&-+I+#Z42XU)F7(**
MZ(_38/^R_X)&%+R> 5Q!A$*79WJ[M*"4K,]M0B8[ON?I.6;-4:6>1N-X;@6=
MM^(C="]B4]H<UD7?=)'SQ%2R%[ZS2*!9]"I2I/Y"R4&*QO\.!J"14#,@^J54
M=FMRW!K&N3YLV'FM'"(^S_9\@NE$L5;/*Q9_$!@G,.K[B%/KGA 1TK4L?H1>
MF66M<ULK-!/GSVXZ3?O=0#-,4-1ST;WAH#=K8PRC6LU0"!%[V96!=<_K::(X
M<6M8LI>@,Q2#N7]NDP&F%&G1[@4P"PZL8N,O:DD6['J/=H$BR?.#2D7>%&P+
M,09;T\>?)34E'3 (BT=A $AZA'R;!?L %T6L??Y 1(J>(1FBN*V%?FIC.N-M
MHEO:QA97DV[E:?HMH<A&H%S_>K/WWQYX^S?&*FPX>5BCA+L^J#!M.O$J%TI\
MP9P@$X[^N((B//ZQRX(@W  3)EQ.</L2D;_FXT?7(S0#L2ON"W,R*]:[NKI;
M50>T/:7P( 4$"B4#KKE"C_T\M&9$0,?0O39W\ONL+"MRT2BH?>[$[Q.+M-'$
MMKA4E,V"'F%^O7#^M9'&];?'Y>$M%-9BM.D',!6(%<^PYF^T:JD< -GI?36U
MJ5W0(GXJ-4"T*/1J</U6C!&AAAM5OKTL/EM^8/_JW?L%:Y)'<H98C:QX*%+'
M@:_]CS:T*FS2J:9N34SR^D04BSS]YTLO%Q=VS(P39(UR_,\"-3B&7F,(7F3B
MUH8>.7PQH#^FRN\!X2,HU&?M:^ZXVADLRS@H^]G,Z#^0N8P>KT8F41HW;_ZO
M!?._D FHA($([.XI$-)E4_0-N<O;);3VX:O.6W?Q?4RSM!YE'*L)*6O-+];U
M'?2/[2.*$*,&M@.5NZ_[Z7TB#]FE(&S*6"9C*&U;LS4@W.T6VH^)!N/[O+Q?
MXO"::^2;FF "B[C< 9,3A=H(D@XAMPTM;U P6%?WIZZKBV3^V\B0J==Z01+4
MO$<I!A,MU)XKZ^@Q,"HI'$8'"-8W'7B7L>>EG'/2KIP9+78L16C4&G6KW:K#
MUWOVXPL(8:7VKG>8Z _V3CT3][%636/N^W[1XB5>%>QMG<7QX5++9/=L-L/=
MY8-Q!M-K8@PB]HOON=;)UCO7Z4D67J9U+Z#K2_3A)OD#DI2J&)]OV3+>S(IH
M<W1%?;MG&YO5KC/FN1-2DB&Z>>&,PJQ+&]!1KC9UVQN!0Z%:=<0!EUTO%'GO
M1IQB53SO59OHH4P7^N[G D445:J?UJ)6"3#$ %/SL2]5YB-!-"O'8R0@<B:O
M.-/R^DR>NCYG;E>MQ_F[EVW<8['VAV[!$PEH!Y,C 3U :L^>-FXK_F=^"3,P
M&K8M1_KRU5#0JE1S1Q:XNK:B1M&&PK,T,_S3B^!'+%%& D2\ $(UZ7_:C!&-
MW3J@P%L.K[+= ^GF(M,7=SND1P4M&\<&SXYF3J6.5<)_(^*/6;N%Z$E^]TV<
MU=>0:NU_PP14):"9I&6>3D?1DU]3J$^<W9EWEYS[4-C<:-&"251+"KK^\8H0
M\FXD(-AI->KZV5^_&P;6B2,>U*R/S8(*FO^,SG+6NF*!+<^=@R(2\+:ISHGR
MG1.FN."JR[-(E?R"'(1?X4=]7W-$\#&I"J2SMK9GS@"V$4>M;9S?BK<5=<A1
M4&X_S<-.IP=1]+-1J)KZ%/Z;KA$B_T&EPD@B_U5$;EDL5'VGUD39E'G&^/&)
M0GK1>]+>6F;4+2HL[7%_=E\Y$(FOQ.Q9*;?41.Y\KN5EXK',@0SNEB;MZBJQ
M>)>C$+NW> ]-F.8]\"@7;$#9"*F;/B_HG6.4)\J.Y$8"V"_])@2OY 68TC_/
M?D("GL+::<X8$2 DX+$CZ)C7^K2]A73J4VV8ZM%FG!M5CC&%:WH/$U[F=L'3
MV^)]@4R@*((IVU.QHY8=C?KE^'DYX>Y*<[./G=3+'&,4XV^H!!(;<8L;Z:\Q
MRC09TU9;L2PO^WUR$#9RE8U1SYEJ*T(%2>@PL(N>]-%K+OTO[?1_M!&=E/<8
M7K$FC]X]-.CC^+/3'_[X I<?83-UG4Z"!/@E(@RWGH7\"F7M$Y?^]WB&OC:@
MK.P7)/SS29TT^QB!T["'DR_E,>$][92KI;WK5L/D:J07)RO<<17^U-T-UH+1
M[)0L?AO"!MK;%+][HC6NDW9[K15^ZU6@'5T-W:Y0(J.C<RZ.R1AH*)@,G_Y]
M9SD*Y.[1ZNR7B:A1\;\=-RQ<T_$(/!>5[4SNJ8I P]O>)]XD&V2K/\."D%%O
M:!C0',5??N>!&YSTZ'K")MB5IM;-C;0E3(+;!,5?[H5>"L(F;F6/>@UFSF1#
MISP#7MQ(R3E&*Y/2)0BL.F,*;)5[;]YRKBX9MHO1'-^23TF:V%'%LOX8C>?D
M;'TJ1[8!R]>!A,B7S2 !W F"3;G*N7?SA?1Q*_N%',)\(T(<P5I;LI/GK"OX
MGAY*(6H!%@$.Y<F,9K34P4+AX:O)6=F^PM/G=];WO0IU%>E4(NM^DO;BXQ+[
M;V#TE-1!-=[VD,?@9<"1%K0)QV>]Q"JLIM0B6;SZ-N;(MT9PZ? ..CCFNE"J
MN^80+B*:O7-J!2V8"AZ;R#4GR&WT,C,9-$I]3,=43@T6>KT).:_(^KE.Q<0'
M+RV#F]:7^E&=Z4_(,A3XLLSPK%0J\65GMZ1Y,27P"AR<VN&WT_G 5RF-*$U$
M/(CL58(NQW;&=I]Y%G>,SRMW&]?;27]QQH^6JAUZUKZS;?TU>[7\F:48P.Z-
M5H,=WX!N-(EBNKE6TC<:@:@\S\.@X&O- P@:Q+ :"0ABAX_U\S2$]Y-S:)K0
M9Z(@I@ID=7MS1[ZOLT(IX^.4]4IS-U96\K.&K,2!O,T6[8DMC& \+%;1FYCY
M+[%H@$I)"!KV=>37J*>(1TA =[+^0;9=@54M<2T;L17'EF6\,W=J,!V-GA9X
MP=#3H_T:$G+++?[=N-8'R\3&+>\N4O[Q5%RPH!7&0 8?1>J1#ZIV.N71W-%(
M"&R)VN^%G<$RZQ?.CUT'I2[/</I0F=E3\5,MHFU4BGOVCL\K>TZ]1Y[9*()A
MN<VSK&Y5WMK+%[,N0^?B7\E'4ABC-2_?-==.'\1.+)^,K/8_B8E$5UZ$E=-2
M?ZT_Q-OV$".?/0"';84JAFD^A6,R8-)28P(NS\H=DOO-CWJ#S$/DZXZ:FS.^
ME0;ND,@ZQ2>KG7YUR!"!Z#DU1GZMHPGUIY@U1P25[7):-@3-A1!0Y-:XX*F1
M_X; 2$D%Q:;3=%@XF[0<^O;:-KF+=6-+$B;@#;&*Q;IB$5F0UB<<9_WJ[.^[
MQ4@JD\;D*O5V<2B(1'')A!Q!+!MG*L#%O7O&H#>5R2OP9WWC.65;@_2/7*(Q
M>ZGCX2L$['"&8Z)BO5N!*9%W2,"G<+]:Z.8ZKUK"%2=Y3,SL[&8Y!T(7NQ8)
M( 9[VM-YYD:NC</<6 ;:2?$DMR7AT@I.'PBU0)R?.*=W5[=T'#Y0E(=4[R_<
M3#R?:J'8\[:(V&]B9X7V^WD7'<L_JXRR8HI5" JHJ>ZU/[N370OY9BMBYK#V
M0]=G\.;;V]4%8=)Q3#H7;N8V"C]1H;C0BT]>5FY6+C#6P"BW-1!<6.GG1IVO
M[$/1=4("4'_9%"RLLV^F40TL6#=$!<-">];Z^N*X'+FG-K[VWJ#77#>)T[2M
M:O>P5DV\NO;+N3R3S_/BRSH"=?%Y^TU/Y\XD%J5PIGSCN8FCKUPU_:T0Z;10
M*IM_RS)5#J82UTS4&W-%\.*GN+4T6B:-.(7;MHNU)>_>/_-4-#S*#RL[=\"#
MRN=:U;I7L0]!L(DHLMJV-BDMZ"*%)A"#\JW'P [0DRC@CH>6M6G\%_<CXI.I
M.(BP,Z%__-,?7EZE)S>12>9$TV;2'Y3T??I9K7/@S0T<3:<.SQ!OM(X2*AK<
M2Y]>53%[&CQK9L0(+SP<)>VQW@KWI[$1PX@<4#)::#! 9[:;__F<=*!6P^CT
M<+DYX%8$HM/[>9\W08TIA*>W>>H-GV_F+TY28X&;/O\LG<(]G%Q?R2.5;R6N
MY7@1'JJ0.CO-:;%N>AS[["AF^QL8Q5>_CTX3*9T]HT>$W-YE&H='=WEQM:4Y
MAU4+*091;WIO)==8#W%VH-*_SVI/9(NA805H;%U%T?DXT:_]/TWRND^V:5T:
M4$_4%+I1<8T,OJ^WL=QH2,O&YSKL=X$ ?$/J=UFK$-\S=Z][@VZ?0&7B??PK
MM\=#^&H/F:5,HLB@N"SYWU839B\\C\Y(.$6XI8O?Q<J^B#<UFGST1"00:#T\
MH: ^^;:U;^^K4*Z"1BG#\$N>.]&##'JUN-6[,R%7H2_++$=@]_>5'\MTU3Y1
M?C'%*ZU&._+V)F^?;L(ILO+FBRG*28 &YY6Y+S3'<:_=T#W*QIDR2=>XUE);
MY[CB!SU! F;/D \-C?4L@JYDP'780:7Q^ZM25\377#O*;#&]XD5O"\ -_H%U
M<RH# TY9ZVJ2B %+/.8ZA?KO.,V:LCBGFPN+5$1UAX<_[A3L@?4;!0^2G]/U
M6N\O*WNC,TB,5HSNLE!I=7HT\$7D[O*//BTKI%!$0_D>+8.+6M$#$(3%:=2(
M*NQ]G'[E1B6EF;RY^88^4D4=%$T%V&>=N]5>RUH'15P3)U0&?:).0XL%B'T(
MP"(0"SE  MJ*F=N5;ULTA:W7K3\U)Y=<R_<_R#3;%H<CD<,N0R!O*[:G@\K,
M.2?&?/D%7&X^/(98OTV Y;53^I>S0K@8V1Y_+13M6&\N>#8I88HGZ@<+IO"]
M@9#[L/?OX<U@&.)6)7-GF2%*(_T.[4+3>$(NN+@K$UO.TTC.(/W.Y0/XK>59
M>7#_BQ]NZ8X#G6@T[ C>\?WGPWDK1[9>--"Y>(4)S63[:]Y\NMCQ!?/2+9,!
M-XZOU\M),!\.+(6+*D.#HB;UM_LF4/F-V,Q5.]OCA6;5XY O'+?/2AF3BH;M
M>$:?#I'/)R5:T8,(@C)^7)1[DB0D:B:*<=4Q7QJ0W$^"YR,50[I B"V:(Z%3
MCDBT##*KKM2X',E8T+)W*/@3J2#'#A4IY2"^(?[3]] 1)&#=,+?DWERZM9/*
M?/.TL[;?Q9BFZ[5H=R&7&+ZFZ(9X?WL[/-V:77RM!5+@.8 $= J7EA[N&UN9
M<C>BF3WV4B>,BVZ+Q*".WR/7N@VGP03MDSQ03\ZOFJ9GA1\]&Z[][+XI.2@$
MVO'!9<3]R(S41N^.0 3+TSF.1_8K,X.W(PKU+2RI>B7)U3O56[&&'.[+^:-B
M9$?G*Z&WTC;95A-OJ(9'[B*$\8*L201IGXVK6%<6(F20 ,5QB@^QNE[P[);8
M#D.&GV#U?',TW"=D&)-E0EI9M[P(4.FVO_C19O4+:8^\19U^EXM&XW=.K%)M
MK 3H%)L&HG<1&A7)PJ./;I5.%WFCFT-M/&A<^\SM)0]3F;8./Q:)'3:WM ;6
M[TP-Z99;*PF4*5X/*'-L58L4A3*7O5_\S^Y7_U_;#44[S8E*DR@28-3H<$=8
M<SSL%[$:=<6T3(T$5.A#[D-USEZ+/Q,3#VT-4IF^E_E-J&90>/3<@!7V(%32
M:8\-(]UP+)2;)DUJZT\NV$[Z*.V^JVZ@T16EG\,U--U>]OP"1RY2\]4^S2Z4
M=2^]\^L=,3P:-6!% C*_1B !H%PD .8*ZA3U++\/).>_NT]$ B)FQ\&:-.]S
MO%OW&,4;;J)26]?2F[20 $D<BON'+7YH"[>1@*_>QX9W:#P.-W<<2 !%>;9E
M]JYKT)UI[Z6ATVGB+?=L*!*P_3P;M+(#0BS1_#FAVYD=H9]R-*CDY_W>@9CS
MGZ-EWY/M=8/.\,9;#\]:;^U;(GY%%4X S^-HEO[)IU<[%Y*\KS*Y*:^[&ORW
M8T4A+,J)D("Q-P]@;9U  HX;KOE"Q?+EQ&?>@=PN:03S]V_6YS:THM0G\*=^
M:UO\P/.3/=B3,@QJQ<^+_;UY+ V.\B -7<M0K6,TI7SL4KU)F8[C\YO03SWY
MX%U=" 6[(<>B[PU&.Y!:U^KTHZ[-!=[\B MODT=UB3/-Q0_9H#&WL\*R%EQ?
MF99*8JT6YIJ'AK;KF34)[E]_H_TL]_V5,6UU%78#(EVZ6W@@16HBAZ/\]>#<
M)O>+%LY(4F/5F%[J0N>B4"' (R.@=9$8EJ^DOEH-PS'#SU90LRM'F<@,C+)E
MZ RUU?KRFOFZ5%R\25&LNQB<77ZI=GJ1?23;V] 4QEBZCD6Q)1ELDS*_P2(:
M)F/U?C4_"E9; XGJTI1_G)IN!U;T<R3&Z!>.]O)\'ZLL6^J'(DVCD=^2C01\
MY$Q0N[1MBCGM7FD#D>^2.+B!2G82M0@HFR;UWQTLFL2:]*]J)M^R(7)BP<4P
M7FU*P BO8DD%%8JP8(_*EL&.-,V'O-K6Y9<6B'[ZY##(I=JJAR&&V(L5O78G
MGW4?W23X3Q&"X0(]X;?S&"P*II0!?6>%6X@/QS*[RW*O?$WCWK 0Q@KR*N9I
MJ;^6?/Q:DJIXZ0%RX-O[8Y#]^MF$$,B-FER,U/<#  5FBS*&H[.'!'PKF6M!
M]]S$D;V1PG%1CKSTBH._]!"(<]I=^.+5W[^UW/+E5U31I,_*(:7+OI[#P*_R
MNRG?^Q6T6_^91+[2==9G#AY,*4Z8+1FFH]$> B='O;24Z9YY2[YXQ[_/%[6T
M&NZ"N[N>:PKF-:<M 00!SZAE@ K73T/%"E6&;+YQ%G\8O*1KYVC!O969@@>W
MY*Z'V?2A/PF%J=;%R @YOB=B*.\ ?9_AJUS0]FQAM:0CE<N:.E!3]08\>]2\
M'"I6K'PY>\ATXT,R.&BY<,M\A']DN$Y0,V](H!WDVVC_K;4."9#3,P&>^':B
M1;K,9%4@*&"E+*NCN7L-?C^Z%<C8RYDB0M.S64D%5IT,I=1DIU]>Q=]7F+#-
M-I;'BK  @PT)[>Q@@0L]\MB<M'*P*(V&#]*H , S  JT2-^7\/CNO'R^O$G:
MS 4C>=+KO:'RWB8G0P:ZB#W#=Z;"_O/R3.;_%G>V&^*TB:C[1U'I&P_S%X*W
M7:]JEL04F4G!FL->@I%<SO(?3HZ 3/F%N54(*E@S__#]R"SX1D50I-XWK']R
MR/"@EF[#A_P:-]10(W]3Z[HSHJ9YP9M&\,]L?E]PRW?\^R M)[<V/_^C-;E?
M5E7L]8)J&ODF]F_\S]]H$G==TN/W?[S_J&-CS&(Q-Q A.+_0=[4YNBH; =X#
M-TR>EW+-K(OL)V,5QLS286#3]:W&(*9[$.+'S],Q'(AT$VK=/4EW^06_IQQR
MW:8^BXL5VFS>?=@!)3OGW"[2?N$6K1/94?B12B_<RL5Z^44EWZ6S%P0O9>?B
MW16&2Q0'MC-*_U9HY,VJ1:2;8(*=HMYD.<-;_.)%_5$ZELA0S*A\IM!K@G^L
MD+>+=.J@WA_6%K>ZTB6W 8X14;$N-PYF_VA- E@H)'V.._H#OP==H&"_!=/S
M1JDN :9\C!.1,_F(/A9K?CSU62PF_L:IH<2XRD/LN^]:PVN:5VX?4V, VT>_
MU4*]*B#'TB6:ID1\X[LD6-1 -3"C8''O&DU8]A'IT7 JE >3?;ZAL>Y&+V=$
M H6$6FL '6776<:SW/XOQOG%D+Z^,>G;N&+?//K/47WA=1J=P_\6.OYCK'$D
M /M\O?7ZB>7*Y;7A/;^AS+CLU [&=7_400MLB^-_&$S\S]7L;4.9K]-HD0!M
MSKO91=_??XPG^T?A\J.0?JB#-/__*X/_BON_XOZON/\K[O^*^[_B_O_YN/NL
MA+CNN$9A[>C8#=(I65C@-$60,2B^>$QOBAH>I3#QJR9?BC!MW='$Y9VR$ MO
M\F0?\Z_0N=-'H<R9CT++?4 6>="4-)D#+#G"SV;I$J&8VUR>6>7[$P<46HT!
M]J\(P:^3 %Z C7B#'* UH%):2TEJ0%]*E_1@U:=/0R1ACYGK1?J7,F<,NF2S
MVM)\ P,5*RN0C>AP?==8-U=UETM4DF3?ULQG]G%MDZYK5.U^]X;-9+M?3I1Q
M6'47=-2AN@(8T-S)FB4F+0M])HVJ%LNV5^QE!%*99R,33G_=\_Z[V[>9C2W@
MR36"E:4W-A2O)4[E\(A%T55<=B2>C7_(GMHWKZN#?+U8EB]UNO@V\X$=5T9F
M+;4<IK%YK!52NO95^WR)B_F $/SJ,B8X&C50(ZZOKY<0I5A:_1XZ<=^+LW(1
MGS&?[T3YWFNO2D:42%> _OJIXIV+_$2N7(VH^LB /+K:JU<$7"L2<G_=>L^L
M;P%75]D,-A88U:B2Y2=(%*!L*U(+AP:>ZDVX[EG:\^*HC\R0]1@G^'R1C@N_
MS4FE%ES_S*&FC>]9W5DM<_*F?,>9WG.YWXL,*RX@+IW+LUCG:TWN#@-Z<:'V
M/)G8:GV:R=+9HHSE(SB1IOY[E:#]9;=S,,C&*.%F4VV+<_M9QL^[ESM^5@QG
M"?)N6/IOLS8^RV']2O]2K@HL!:C\\>XAC+1=$/FM8*[UK+=;=T+!I([RD=QX
M-YGZ0+<\6;13S ?0FI^GX;TO+^CFE 0)H"PG.4Z\C4I& NZ^E(F?V6BRN[-P
M5FX,$JGQ166V_EO7['N2V6 D8*OS <VMG*#C@:N+4/\>M#O[PC.26XYR+"1@
M]&LY$N!O_)#./T =UT>MMPAK).!RD^->T%!L7+;RL]]_$=>9M/ROY\-2X_8E
M//I2NTO5M99V^F.KJZL!D;\2*S_/L!3/72 !"$.#AZADX!C>WW8C ;W,2$#P
M^1KHZF@:"3@<,KQU;I*:[=2!WRJQ1X85+/:4J3;Q1:Z^WN7"4-N1=UA;LC]8
M]V3G\;G:K*55H=0L&\87Y0=P<0?-3D29H=R90\ZB'/\<+^J/"5D[&<;.+7E)
MSZ[.&N<.S2BR:WT\" 2VHG-,S\1C<A,E9HQ:0@?\&*^%ZUNG)2Y&Z./NINF8
MCK+G)<1J/EYR_.W3$^.(76PB ?M\,W&#'G7E\[!OX"0JF3'NF*"K]WF3'/"2
MB8/U@4U6*\J>.)%W!4-<3[_2H853BT90]SRZGGZ_+/XWV#FJ/U/2G+:P*>4Z
M(:I],IG$OO16<@2O5G8P;E+4:FR;O+L[H 4RX9 +!L0Y)HR,K[H)?^ZF'D"]
MGC99_#M8'MFP"UVJQ4RJ5-<U>H[U[:&]^ZWA9A+0=IG7;>8F6G*INJ#$T%R[
M(J81_B/,J>/@@5)012TO7I/,%*5?(@%8>QU(P.E:,1*P\K,5\9OFJ*7I@:/%
MR%OOKL*0@$BM4?#[OWQW,R3_@(WLG[B*/X43^I!B_!=W57:(HB9^FJ.]6UIG
M&H -XA %'HI3B]IL-<1J+E'2N<,+P^V9'(:411NVHG0,>E"OE]ZO_%.\\>C!
M<_MO8=CB]RO*!/ ?[UJL26YV7^PX9N6N15+-<LBYT#7Q6B\@E5G$--)OQX<4
MN.>F??CGUJO]#^#P]/%TT5,\J[*C4-6%J._9VQD.F5')Z9F&OO(5+IV7Q_9(
M%KUK7!2()$J8GNKK_55 %[?/?*%*,V,#DKL$_CU_G';J'*19SPI]#2N +N3Q
M*XIF_RI31I<GW?O OL_Q:BW=1E%^*W3)8^A81MO84),N\Y+'AQECII@=Z/VW
MW-&Q\G;:I#6T1XGKV'Y+]5BWIO$[_?M4(CW32*"*0CH0RS-P]QE[67"A$JFY
M^O%\7R>+HXS$[A/:NX?'!Y;,W,? 6_\^.&B5\FBCA,=@Y^<L?7N!^6-!$TDJ
M<VV&ND5^C_^9-%/;-^(HG18+_-NU;$&9+UX#_]=<O]!0B[PR,;^A+GE":W=B
MTH\$]/W,0P+^+?0-T"+"K+3<N33@BUY["UD%A?\ ALH_5Q?_<_']G^Y:S"?D
M=E#H=.''-[)^8I?;U.B9+--V^!FSF\,$Y<Z^6'3KSZ#]43#*@7&=R1O\%?.#
MV=;X2\J8H>@UCB=&IG ]TU5GIP\OJAK29WP*[/)BEQ<<,EAD%*3KUCRH@Y@"
MTL'_2 'J?X+(@ZB$SJPZ5?D\'O6U)KSRS3L9!'FX<V98)T]*3A_"R7=[%9KK
M(7H'R106KJ27J(3_;=RMOQ\W9 [AH3L%;QG/V[X.7B1CW5R -H7%3)EB?Q N
M5@RCR*]M#M3U@@EXYDF%YR]22U,/H)P7S=0?9OQ]0HDDVYTQSBF9.9$UJL[<
M_/JTA3J63_-:;%K$@'HF3WZ9ZL6]=*V[_#Q[ZK<D[V*GDYA%<M$?&.=%O75_
M OO?I?^[<,S_*N#ZW^O*.@Z^F7,3Y9NYGXI[//62Q^PKIB8@/"JK/&)OK_QI
M+1* OEW:Z+_W!!?>M75I,Z+"=%QBW2YMZ;96K)QM+5-#J/:1*NLO88YY'(/6
MBFL1T2 Z]-3ID+9,7+ZI:=R?V1(J_BTU;NU&MP)B-Z'KP.HL/L5,>\<ZS_'7
M#2D7]"P;G"GZKYRCI&Y]@A@8D3C27MD[R5\Z;.Z$)G;5R+Z)'+%6O)EVEGV3
M+@WPM(\HT__H^:NW)['!/M^^(>(L\&+7DM/6S@Q:^=CW%&(I*BX4>:I>=P0)
M\U4JAWX'0CD.P3,+Z?2F0."]2%[SNAU7!TSI?K2N"I(P:)T_G\Y@>5'&%Y%C
M@HJ*6OM8RA6'*MM42.F[[$_E ;LX'-KM#9-#G_-,()H=VW8ZUBRX\S=&S8QM
MM@G'RSJF(=T%P6'OPX C\OUW]R16W]2S)?3S'017^D6=HGH@^6,\/C^W%-,8
M>TSKHQ6%^FW#&9S&4^CB#JQ<X1BR$_1>/&DL/=T;%/JEI;%<G6/QJ#PH_O_H
M9_\?K,XA#'3"# 7-*2\@ 6_*-C,;*\%3S_$-H9UNY!6.<3*4Z%2X0*<]"6K6
M0I"EE9C8,>@[>.FD^Y.(HZ'NRX?.WH'>DTUTZK,U!R;(W*^QG68AP_2&Z4)I
MQG\>,CB:BKA9-&^NX5D@W6APK8)H-2$!40GXS-S'41E1*9&"12Z>6IVS>)V$
MU[A);.Z[FH0^ @,]F/U/GZR:;H4"CL.R,* U#OL@UAN*>X(48-45S2YD[7:X
M#D;CD4_%FC,IOD9F2(H80VSM&]K<J!P@ 6"GC"KXE6_S\LK2UL&-5BX28+P#
M,ODZ><,WNC\F$,OL&SQ/@1M>'/Y(5)KA_GNN=9SLJ_P\[65YFD6?,-?H?'],
M#$*4W_[T4^#F-YTMQ$=;(> [Y4/Y!QIXES[Q9/X !VSW^75O-K\O["DG%"Q"
MP2/4VJDD*SNS_V9Y&W\0$'F!LBF3@AE1X0*&PZ(.9G-E\[6EO1U>5$,4L_&^
MC%0R^P5%IU2FM2R]1$\R>F7_ZG%\7?J.E)[B[U<[/[ !O62?(E];HO8ZV+*M
MWF7P+!2PTT:NFT-.&>7:/.XNG05YJ_,?Z$C\@=WHNC..4ORBX+K9-QP7Z4NM
MY@\;QW9Y?-Z+F,WFB\H32T[VV9F),*/FTR4E[*D3)-4S,CJ5+[!L,"A1W6VP
M2]N).J#X2:S4JM2V_EF$<,?91D<F)E][F*$EQ6F=%3S!8'L@YQ[QQ:+"84\_
MI--/\^8#(KZDI1(S1 TRN5[;\'[YK5UN2.4>8C9?+,7D92V7MFX]6+AT\&U^
MORA7JF]K,)NW7ZK6R8JTU2/]H2RSNH^?8R6$'LWUHU)M/^K^XS(,#3UB\%YV
M&'3?H45SS5M,7-MDA@30;;8B 9]8H^[(I\,,0N>NKF[?,?\*-0W^\R*-#VY4
MZ0X4V-&*96"=J-/U-#&NBO'G;HN5MOP"XSI7RS1LVEAQK][V5W7"KD7-EX10
M].@?X>FY6IFC->^RAZR4?1,M:D$=BKF[R\ 0C;_>34\]JSJ;]N%L+^ 9HQ;J
MD,/!JBFL6;>^KB%%\WAUBMV-5"1W$A9U0_2]/O;U:,WTMXW4TUY4NEJ;#O)K
M> EQ=UD>W[=[XX4D8$+II*-!TF5Q)2*_"V]@XDW9KEI?7V6";C\*2SVT?E2R
M;M6]_[SD+L/$[=OAG:6W>\!%>8UG\0V#6^X,[H^,>21@@8D_A9\_J7I!H$<8
MUBR]QGQKRNN U;_^W>P&>!$>N"R\@KA:^LVG,L0/WYNZIV(=8IQU\XF08KTZ
M5YQW>*Y?N=C<F83GTF;LC,%TRE.U=]UU.6XP6FPH[P&\+ES^/11S1YH:U9%!
MQZ"IL+!S;^&WID2G7H58>3R]F>'FX,"8Y4Q@960F.R G0QI.&9"\4PJJ=KBG
MWEFFF>'K):[T\<(FP;C_.,)H0N'OZ[-%->R%G<YZ3#CZ3*G<.I:'HX5K-I8@
M(I!+<'4U)D/*.K4A[?;B6'?4QXG^=7VLP+(F2[BR(DKJ(Q7ZL=4Y&;!QLN+U
MV 6(YJ62>&^1=VG9#^#=+2_)]V<])[=OP=0XL9YG<79D%9[5%YPTB2/WA;.B
MH/E>ZQ.*"!?-1MT C\)EY5>!F%T0W&7+-_$X<:=&9Z,*KD+WE0Y&MG;GNMNE
M3V@7<@=+/$5EQIRD\L:67%?.EY" I#T#P&>$X=L4S2DW',:1RP]3[M7ZBT]B
M%2TS"$B/7LL;.T4E4JC4J#4>E?;$9=^^G7!=L&+2UNFPD5N5^KUNE?1UC$L9
M7?86;39^T9HDT5$29VGQM-NVD392&XM-<3OSC!(WWIV#$!&(OH3>6/C6G<U+
ML1^CKQ[:]*"P4&N5*",O26HC8B%G,[FL@Q3-0B ZU9KD&3W[DZWP;)-9].+I
M%+C,I4;=C4RNEY,7WUB+65<IG9%[OV"W9JFRA<WVOWO@G:WTYQK%=^@7HQ;W
MV][/PMZP%=%=EH3W/]?V.JC+*!!1#FO7-.7>@-#_.^,WKGR9Z$8O7"<KHZ\+
M)3VC2(A55$<KR(J._7)F).2S7L>2#KW8'1V^H1H:\QHG-3O)8=U\OAL16>34
M)Z(>VU"IFL@6)YK?0<TQ>3Y*], J27>Y3L09=JYPK\*&FJ[@'J=H%=1KH(*B
MGP)K!@["[$RP_)R5(@-?-ZSP7#=*:'U&.L8Q%1O@E+K5JI(215K=TCA9)G(G
MMFNC7:$U%"@5$31EZJ)2,UU#08K-IW6I>4Q&_)Z2F^NE&VVQ$77F9TEXZ/#D
M[)LL8ZH2)* T2O'XUDG%"T18Y=D"19]R7U3QQIJ3)4M\'"_1K^JHX<<BCOMQ
M1P<4XFM%'/+@;ZM;&UTR>1>?"9UWU+)Q]@1LK4#K*$:?V4"#BZ$K>]X1TTT_
M5PAGG87X<&4D!40^@Y[F.X"\K+"/H/JC:%I85::A4L4LUZ^I9"OS^^#&^A]&
MATUV4._2BA&3\M6)^-;);_$-=%MO+X*GLO-7'4$<WNM-LG</9/9$+.7A8_0B
M*NVNU&_3+\C?::N%&U+K9S,0"2FJS:*ZFCK$V5"L$@YRO#=^]:3-=@.;0)P\
M'?B HYEG1&6-A6_(S(UCEN6RV9R547;EZ>^L/_"%)3R7%Q4OQ<V&T<0@ 9A;
M!Q=^V?N.=^7VW)NK6P*'$#M'C2NS6*]T[0TK>F?MM!%%&G45'3,;(C.39.?-
MN&@U:<+^__.<&8-,=TEQ77C5;>,1T. A1_)A:AH%73H#7([:SOP!Z<V-2(!*
MSZ__N7YHQECMQX+9!/Z.E\G@9! *.#F[+!<K)O:X3';ML1,[\-'65B )E K7
M.">C:BZ4U__8X/P[-F8_G> X/:484=PI1/T#6C.QL*BG)[I<^@*<SW?R.=M*
MQ'<EUV@^/\0<8;B.N&6@+AOIZ3;3/:4@9@3]H)4\'_$K'F$[M ??Y#14U"?_
M=8PC@>RIT(;1:J0L6E1/FDVAX<=>>G<M"'$_*YU<Q4 ?9=;BE\]>+%[4(;FR
MU?LV\+*26=! ;Q/5TS&$)0+K1E:1_2X9 +E1N99="#CUL.U=^C_(>\NH.)=M
M4?0C$$B"!7<)$@@:W"T$#Q DN$MP"=I8L"#!G6"-2X"&X.X6/#@TWC@$:;3Q
ME^Q]9)^UWSEKG??&'??<<7_4'ZBN;UI53:UY.,._'Y:_6CB9W'5'\JVU<IK%
M#,B'G$>LPL1U,ZNE)=Y*"!^@M2F)PQWV%26O%:YE]F?$[!>;]@V</1IZN=H$
M1IA PG)ENG1?[4IW<5A&#-Y%[4P*4>:M'"M__7INWW,-6CH7"696,UZQ";=)
M.9MOH)FQ)R@X.L#5%%[_AHSD([[]P4#E@R?4(F*SJ;42?#*0\45WCTE'1L\;
M;'G@J)YY5%QK0#M].N]+JS3MBB[K3GB\TNBB!RX$UGB4#HXW[W8.',KH&^KC
MR392!JN,3.,\A)_4]\ZG3!;E)392]I7(W=; 1I%W4^.RHEB9K^77LZ"AM&H,
M*YQ \1UJ"YQLIZM'L/2BRBJI<F3:TRZ"+JT_C\7PF0P3,5B77X1C>6"DZFNU
M=6318H(69N77C&\T(J;DM\OGGN_"'7Y)[, <Z\^S1?FE1[VXC.5T[U2V 7X"
MX:CI%QIZ,W>-^ X&<J[H(:G/,"*9B4+9%C^!I85,"YB>N,0)CS=7"<G15KQW
M$V!15E5V5H0H&?UG[0G*RVZ8YILI<CE,+K_Y'5@L*1_,Q"W>M>RMRU\==A:*
M8HU][A_^1)Z,Y3M5#L?"GG0M\[RF;7L(Y]+XG0XZ\9=2+YGRKC(R:@NM"D=Y
MYTMZ8K.BK80Z =V8EQSUK@4]I5K#97J6<.7&NVGBK52*"-[<I"?.$>0)]DBC
MOU]J_;TMF"!W^38%,NA+@QN?MZ*6A%^8C L]5/'#=I[)(F$ \,0)B\K>LX>V
M$J2IZSXZT_M^XI/QG/<XE%)OS61$<Y 5_)),H"S5[PGS\[T>4I'$]>ED/B^&
M8!M+.L,7(Y2KM:\X447?KXF@>;]K45.K&JON/\.4=W@^_7"1+DW!CJ1/_+&(
MY8-% DGMZ=)3,ASWHMO<?C:\6\IIW>#^T:/>TMFU,@YM';3H9C%8>%O5=OR2
MTCW S_H\S?G)@Q ,OF9C)RQIKO0P8.<_"RZ]B.G?["P_=K[M71 3?7%&4&5?
M^XJ8OV\)NYZJKP5P),WL4,:R;JQ9ROW@5<PRX]Q\S.+4B\_%88)J*FPV98AX
MV_K;0KPUO+L'I'X'",-_FY.PZ,NC<;'#H;:_>YX8?]N0M'<W@[]MR,*D<N>1
M\R\6/_;%5E\A#.]\SWRO;XG^%B;%9__M"+D'?GM"QGSAC;![8-4'E'OGS1U]
M?<+^+PZF,+&M+ME?$SCO ?B @/4%ME703[?,HVSO7Q/$KMIN[\+_'NA\0O3;
M9W /_'8:;+<A%C_X'K4VJ_SV*\C<7B;_JU^AA^ID-<]W.<47L4%>XQ52W7DN
MI/Q'G+9_H83^RT*^!WZ;R*>&-_;U;7_ BO$/6$?IM'1!C;TH"F\8#7_[%^[*
M[P'?G+]%=SN#CMIN[H'=>^#BBOV.3\_PAKT<WW<T^->Q_]'\7X(P<)D;A!75
MQ:;AG8 ,J\'J_LN6J%YE?U%BQ;:=J\*ACH\VH2%W$WO[RO\,6 $"#G/KNR),
M>.G<K?J;0H9_A'2C9$&D@*@"^D= 9/X(JFO/;V_)/X+R1TB=I@XH)]!G_V]@
M9$(FTLW+V"KT6UVFQY>%H=BC@_G*?G=$H*F@NU(GKD0PC9@86WWM;^*KMAF/
M2TMSTB3@W .Q+V3Z,O$?(O\4E.MSQOA?(A<3_T3L/W"CC/V/M!;[ R^2RAW/
MOQCT6?TSJ:G^P(T9HC^0FNJ/K!C4K/=ZPVY:_4^4COYOGQ3_-TOJ3H4W^M'0
M^8\F:]+L2U3AIM 4CZW #8PHSQFR/RQ!XPV"OY(N.6=]41MAGIW,< _0_)T)
M?*8U_WN9H)_<=1@^"!,1WP'31"T-'&O< ])Q3S4$?&>%/G=Y.@=.!$84%.=[
M)9(8Y_V,.?SSO=HB&#8(56Z8^/G"]\6FV)]3W],5WTON MM8X5*9XR]08J(H
M%ZI<[_7$<, C^D]WIT&&%.6X3]>LZIW:D.^?R=3I+N-Y_ %E9_(QV/0O[+%"
M%9GJ3,=S_+:$$ZJ_1!61O.N0;_DWA5]^,>#/F+0SJ;+/L" 2Q+XAW/=G)T>Y
M4DZTE>CJW^AMNB(3_ J?-+B\)I3.8\SM'JAU6?XG$H[5H%_;,2LT3KH^]DY3
MD#7P6*?.""W6CD)C "@3HRW6RC&7$3PWFG;%TBZR4W-E2WSB#S(*-XS(!(A[
M.97?;/[]8VX"?P'KIE%L1. ;N%((:D6V'L]P4.\ADRE>7QN&^M$*9=8YA.E_
M%4G*NGHH^8Z6 UG''?!VS\\?*)]97EI1318SLLC\4#? A_\"],:^B@I]%VY8
M#9 \I>W=?MPK7X]&B?A7V7+Z"\>&IZL3F!$1D@=2Z(:BAGSM EWHG,+0-0-X
MS*39BOCBVOV3*9#^=3WGO[">BZ=AMPBM!B*R&,0$)>N9/*T7OLR+XWE:>9/I
M$DR7N<3^5FA&\[\C<XUB1#>OQX4)2BT%[2&8Z_$V=:A+<Y U#76C[WFM6D^Y
M:$[16EQ=_H=L/I(:"-NR9J!\_60I;-(>SYO70;!TO%RX&*\^.N$8S71'T_+_
M^,WY?^EAN#=6?4TWX3*H2ZR])&2IBF_1"R,01UE! @LA:3#FK6\TJ!0^\F;\
M9>/$BY>)P1RBDU?;/DWH^O#O,LW(V1OC>;Q&Q7"WL!KA/;VU^5;.CYC/6]JC
MQ!VW.]U##S_7MY^6HPD@3 CML!L21]L@63_-PL2#,XWX$H#$%,;WI38*P^RV
MZH,O1N;72S\X="@6TIW2TJ)-5WB3P,5Z6GDG;&OT^=J?EB4Z\R7-L)8]7W][
MK5]+[,_?L=;*'#=^@UP&4CX//3IKR<@8NL.M]9HO(1DGM/SYZ4AT6SOD";)_
M-653B*JBV<WS,1=V[)U4243\:ET867?2A50/8MQB-F1(B#C=#R >I2A"'J_)
MC-!H)9GTEBL$1<O;""T^IP=WTF4.W4U&CDPRND50]$@0\_>OKTQGM$67RX0W
M\ZSN:TH0:J8N1M0Y^;NW_0Q"]:[DQ>R;A ?N&;BN96*#JF!H$0XWBOD[E7,R
M*\=ML],7M>:ZZBGDPA'(@+RQ8\OG^0CSDNSW4\**<)L.RF?14I.G"*58MSK4
MS1&I:_+2/%N?=L!Y@G^Q@\(2>>Q& D;!U7G%W5C0X,0*,:4FA&I543XHCHB3
M6T'2\XGNF2=I)=BEY&N;8*BLJP;+$@[56YF9Q] $MG?A2LL(>>R%+1^5!<$H
MV,B"X.YA1-TC(^7V^P4]-NNF JN/^P7(P5_*V0T?V5R%_+P'RG:2H+8[Q9CO
M;;ZSLM%R5 _4T2@AFQ8'R)135B/-0&]T"-VNCD&#$FD2D]RZ]&UQ/_3R^S+0
M'?/) 3[[SABOV&'=(]]N78AOM^&LSCT0DO_#E<262*4ZLBQIU:*.M4XH ;/T
M,8G.R;Y[E^=%=],A\5ZM#F%N/GVO/V&:N4.QU+K"!Z:!JI>SRLC,U1QKF1 7
M49QH3;AFCPT[GKXE:5*X:;XE34=P/E+01KW%((K:10S&S;(\<)JAW*W#]IF%
MPT:P)SB3;NMI_N+X:[-[P(6#Y(9Q2E@BUS( #V)]3NJ8#F.O6<@S,#[5[[8X
M*J="=*SNOUKKA13OD+I!Z"=3-><2<\9I)R'V1QN?V$*^R#$D"YO&CM@P=%.2
MP?$_TBDJ=PNRY?U81'@N33-RL[*A3P:\,P3/VX;>J1[0!1.3G_%G8;M,"BMD
M6_'?34U7[['TTE-9-<G>O7(DVZ0- (W*Y^<CLAUJ[-R6=H6$;!3I<^==&B-4
M+T/[FZMR3K#$H+L"Y)I?+#.Q8F^\5ID5W<4;FL=/[P&,?A+2= 7'6'ES(5,W
MY$$6@E#D6OZ=U.Q?.O8C4+1Z,HS&*M5\-<Q'5ZE>:QH0G4?Y<+-'":\Y<OSP
M?6 -ZB=2V_4+ZA)CUO/DDED#J&0F+VQI@R[R):?3@"Q5I)C\#'>&V^+6CS,%
M5GE\.PA]1N>;8I_'JHXVW;;-E-""Z#6AZC%O%1;W1F^W5OUA2&T&_9P&YI=5
MV8E-)0_C$RQ49]U[ /4GSR"%E_:UZZ="11N0!JOTM90^[ZZFGC^)U/5NR8U,
M"^"YCZ\B3LX723UYX.VU*GNJ<.V%7LZ$^%S&JMCI7RL<Z3]Q,OS!<^/PLS=/
M&6CS6%$>>O$N_/7$N;XN-,T\F!?\S@*J\\96=;\)G,&_-<>&VVV@,^Q2>P]8
M88S-RU'KKU1N)#[>HE>/0WO;.MDV=^YKD[KW,\8G!]2M.KP1>4P]0A#%*;X
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M2WSCI37W .:.Y$B#+R[+J*DPD@YK16\EH8D6.8%Q!'*F];J=J,#L+D<SU#!
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MHPR8U=508T&>JX+-(^B>+.C0]E,7W:!M<=/\DPW>(LR^[*\K<,-(O&N=/NE
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MSC^/4\FU7C)K."'[>:5DR%+FY':2],[>JTA$RMW0(FJWE[\\&X\-)X6-0.L
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M/KAS.TH2+QS+K[Z3^<K@KZK) )>YDW,(%=L;;OM24DCI473!Q'0LNT-X-ZZ
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M+7)&.>+-D)YBK1Q%QP&5HZ&XHEOBL(&U(GTE3R%A4K84OJ9 T6\U4'7\'VP
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M5)B2H-C2@\['0WN/S>DVM!,_?S_@FM547+FEF>F@(JG>Q^XJT#K=5^LR.3A
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M!OD^/?#^<)M-L7\>[DI?%.%?F'<DFX+FU,P9$8$3V1$J.HFTG?!K\VBFWHU
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M]PATT#:.+W7"P$ZX!]8*4;Q:=7PZC_E87+_P/ [3E100'R5)R)JEP"*1&Y%
MBU;"PE2OF92&E%LWVDUGVDM_&?N4N/SQ>*?>47-C+:H@:Z):J,0!K[:@HL^L
M,B\<%#.@S39/.QAO(>6(-.BZ17XDR2K,U]3CN9E;;'6N^72)6+&)'VO-Q(XZ
MH-GLI(.'-ZHU<#+^-=QHJG0,/)QT()U&6'O\^)'LNN5@TC/QAPEK(K[(00ZD
M.Y)D&AMP\G%90DKC8UG<8 H)_<%> 31:GMA50_3=);*&:\UX6YC6TF-(;EJ0
MH:B<J1F]^(K\@&:47R T/[!C!A,FT](JFU?7<JUF(!W_$FK^M#BKG2QX5GJM
M5X&20V--.>6<7D";["6HH'??\&?%PAN-%=WB7K\4XN+6C:W$)P,*+L#$<WAP
MBDU+6?>1%,7%+%WJZTM</>1^M*!U[T6!TA)#3.O&]RU>)3OA#^1X5NX!::O0
M*%W]T/I>41G5%!0LY\#]]YA/KD<;=$MTK>P.7#4;_A_VWC,JJF9=%YT( BI!
M29)1 4%)2LY)R9(S""A!DH#D)K9DR0H"DB7'IDE-3I*#Y!Q;<H9N8I.Z#ZX]
M]KYK?6M_W]IGC+W'/?>.\V/VCUG5;YYO/>^LFE4NUDX$',3Q4C<]Q.>?+R2P
MXWE05PL?PTKR3O""W6I,,_FT*;^6UP/9*2Z1@X*;1Y ['D$=#<XX+B2L=N6<
M$Z]/&,M*Q!H>.E._GII[:I-DZ&$ZI, CYVA#ZF%4[MI;\89?:L9K.2U/R7]K
M4KXR0*WF0GE,+5.97V)"$*"X5'[Y56/X:_*684YV3G'O?\R!_4"Z![*+6N;.
M3-O$ONZ@@ZSH?K*;U@[O5,&:RXORV-\W'%/#>^*.6']1CTHP6TX_^N3J)9C$
M_K*7\1N9>9]_=@QY-\Z](4O!8C'L7_UYP7:[NRX.5*"JA8$%U>=V).B']\ZJ
M[VJ]%&2!3C32AP%+HXN6(3,2))&2\S8:J.M S!T$;0T4BB_)2G\LS+L)ZG[@
M].'YXT0$7'F4SX%X2TYC;)_3Y8X"^Z[QFMZLMSW^&2* B0B+<H,G:8?U.X$)
M.4I7&1D?.*-36OZIH2/^R9M8\U+Y/+9' N_H80$6B-BV^'/ZZCR3QI.2F1/X
M[IU^V>6?-0F6<V<? 3M!1NS2HY*E:Y$JTX,\B5+-BJ1\Q+,@/<62'"5[,*5T
M?LM @J>XP!NB!H+U%,13,/ZEP(CWPP*E_!]>!3;N@_95H<X%<V>#!+>='DD#
MK>MXB&TC5S*L'E#6XFITF$-V7;+.!.])315_@OJ4$4[4&N.XD;Z>E\4'QX4"
M&X9;O#1Y?D=]_;K2H&)2%;>1DD!9+U=*+9_>Z:[38)J%^D)6[*0RQ./87%2L
MZ@2$?O/=Z-%H;ANI4B.!3+6]:4O9^ZCZPE0,T(H!B+<<EBB:!9PP@,,@83L&
M:+S])H:YE5=&\JF<L<)E34EG&+!L)TZU^7FS#@9#%T%L8K:ZR^:,%DQ(N0N7
MK:3]I-]\!-&>]ALB!C_NB/(5S6_!'<9@1BI[3/Y*\XH6,5+4!W?MM '+W\A@
M=/AOK_>HJ-.#BX]-2*R2QMMC(0-AAV)UC$"4143G[ ^<-&)*QG2# 0P0B*=T
M_<.(ON<@?K@C87.AF]CH/8\!;"Y4>*HIX5VJ]?O]KF1J>'R.O\3H]^CLV;(<
M'VWK6GL\/W2KY,[,S'K9BZ4A"GNPDK)>34[8W+8KVCB[[1F< VT<S])_/K:F
M<^N.SZJVC#8.,KYS#X]O?%B2MB3NUQT.$8W*AOIQ/B.]*3:."(.([4<&P4;9
M^;?OT&67K+-_4!4=HQ9H,^*2C98-$[F2W2(DL<XN#UY=MH@T#\U\3ON W4_O
M2VS*,9.C42095N?T)?>('5/EIRUJ2&>"&?>@=;;R!^H)/,VXEADZ_S3IBKO/
M!']I47>U0KCTC(SQ)OB*E C?SMC6WS',T3/0P>8FR'BC@L7H-AJE->DL SC6
M1;>)":C%'STN*IHVL%&\KU8.J]4.1N#@N]_(27B:H=):2V?K98"X2JM>-&PF
M'C#W[]T:AQAV/^!^:-3\Y$&$WQ:AC;HD+2_#'7;%6:EB4$@[]7QD!:/<6[!;
MFM03_^1X7N66NT247[H4A\>]L;*WSH,+O)SYME[;/!I+?/CM8;67Z=H3Q@?F
MSSBO4WO+<HEG&"OV9]7@F5?Q,V%;DTE1$-?\3X'5D\Y^W!ZO##B"^=22]6)N
M^PV^'C5<+$GTN'E@.Y,&@<!VL_2IN/;N/VOO8GH@HXWW@*Z=XI=SV([5=R(N
M-'E4LG-^AU?QUGEG&;>ALI7O[(<@8RI=VX=:,MB33HOEN HM!977]8NP*V2.
M9\L@ON":7F5\U="6,WLHCA.K+O"T9"=_-H'=<:%NBQ7[RRB:3F]J7J^RKJG,
MQS+OF2V'^-Z&Z-V[_ 6++\2'1[WXGR2!VY1Y5.O*&#7&2]AYI]'#9KFJ3A '
M^V41^;,7J?51V,]OU%/_XW1Z_FX/_Y:"J:H;6RP&\$9J_..W3H"WI8R7W"4/
M_.H5!CA3Q0"[7\%M8AA@;! #7&<I]+31P@3=X/TM6+VO7/BP\>^#*$^O2S<)
MM"8&N+!@0 R"CWDPP*H$!JA2WWT[)UYD6+T":B3?_<>6?_P7_01=V_\8P9_P
MBLW79NU!Y8X='Y?AB=;P__-$_*\2W-F]$-^5?;ND,4754KI]UJ<H8?DSGZ4]
MVXN&*/V,(MJ6:/'88+Z9L6,#:H4!@KTP0$$Z!GB" :[*HU&6S>>)&.#@^L8L
MZTGI'H,V9/9 U#CLY!];_OBW?R?9XV)'?6$R_G:TLH;:*S&*7$Y2),8+:]OD
M%>I^2]7OY6@U58/@9PS6=8SQ$O,F,O3IH3D(.3_>?9S-?O*""^65YNV]>?Z*
M<X#;#5IEFU_B&2=4:4B'\A;.VU?Z<%VTDA;__4;&3T6<E"M?QK.\Z?&I%76?
M[?1-\=2*HZMAL[MK8?$0>/@1QQ'NP)! AL5,IN5^_^[,W_;9D"%0-%IQ:RV,
M4F I_4[B\/+^?]8 319_<JF9W%%-G&,U@+0J$V#),GJ&9MQH"D"*??R+ID/%
M T?!- <G&H;O*XDLI56,=QOWPJLO&?K&=M&TWG(-"/Z<U;ZF=?F:]W.&V+WI
M^WE97BZ, 5/1^2[]*H/ZHV_&>/L":V$U1L/=(?X2&3M2*]2HM'IP",.]?5'"
M @^G_=H13AH!BI:#O(O-C85Y_%\G#]^6B:;M5/$-E&N'JS3>W$>#$:J%&X5U
M[_(LBS=+;:@M6E_/S'%NK+SXP3!T\N" T !JXGQ8(-,QO7==>]_X#T"#V);
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M?<;\!VC<=!FLL@%4LNPH(R*^9#-WAHTCHOV9GQ1>G^@1-'I[!TZ& ;K3BS'
M9" &..<H6GYZ4-;SA'&_QD!%JW#^6,I$TYMMI'([.NB<O6+*H(_QY47JHH;J
M/DTM^4&_CQDB :V@$XH!7E]7G;)\*G<,HH=F0U>6 X/29ZZH)@QGI:P9$FQQ
M/CQVKN*]S;/MIS$LX[F^'EFU]_O;?JE_GZ\UOO=]^SRD=9L.W.9LK1L#[_DP
M8AW3181:9;JIN2>(%W%*JUL_&;N51H<:Y81Z/$Y8ZJ>@84F=61"ZOR;?1_<=
M_>L 5R1IA%1=F<^E-P)2^V7)SKV#*]^:G_YA=4.5]=&$A_G(^Q])^@P2=03.
ME02L;\2NR@8WW$@;$]I0JQ5Q@9X-:)N&ET&X\JJB+ET0UW1$Q*4K!LCHDL8
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M /IE27E<U/0(J5P29.O\<=2HS?8D+E"VG7Q@2 ';+[WWHX!5,04R.)$0TI"
M^TNT]*R?VE"^G\2%O86@<(5>U<!U,L+%5M\-UM:=0:+ ''P_1C .O<W#^E#J
M]#MA[]/<C$+]33?<@Y,WGU< 27:]M(]8/2Q#NF(0T-;$:-NI@*>- O,<-Y/L
MK=T53=+GE)PUW90]](TW =>OUWUL)X7E@CGX* Y>Q2C<5AR1'<XGDC2K3($:
M7XF,LB#M*E#IBJ-'L_5L^9SQ[VI JT1F4\DA#WY9IC5]Q1I1UZMJXAS>6V5-
MX* \F-&*L4KBC;N_S_T<>$8_KK+=6:6:;:*:>Y9N%3R@E$^Q-K^L'R?KSBDY
M)^QR_)TH*6QQS]OGJ50ADTYZ<T5YU")5ID_$3^Z6<^(7:5ZZ,MFHF#:=6OZJ
M_0>U>H&S3$%9"R&1VS4$):#N[X0V_[X<X RZ-!C4(%7@K39>4KE[1[.^*K9G
MFI?"29C_H>2'EC<'^)=LFXILU&-Q>@=5GOKV;]F;*HHH%[;@8> ,Y.#E0_KK
M,BC#[!IK_O!NOE1F0 2"H.B@2$L,</,  R#Y3OC(^XXI3\7VCPNK+R],O,2%
M?B]Y[@ ?L=M*H+@2,$!H%OIN-#D&&"HKQ@"_FDS0CYLZ,Z/SNVK $.WF]9F+
MZ7]FXK)P*Z##]TYC8W/ #X.._IT)R,U*B/532+T <G?*W876W/T8FL]:&$4H
M,R_?"R49J*03_AJKVI\NU _UEAYOX"K<:'J"J((5Y6RQ?'E2!E*N*.A^SPX6
M$ $MYQG;&IRV&\3M->+6<[4JZR@;3_ I>84:+'ZYO6Y]T"Y)2Z** ?)UZ]4-
M?(Q-^L]H'01R3[['7P@Q0V*'>6'EM8>^L?FH3C8?G;[VIIOC?/TB6C6V!9"%
M$:NP5RI*C$',OFGPU],)^D@#&VJ233"QJYB$[+#EQ4L#%[?1YU_.SI*D$UEB
M!T12UII",A/&DTSN.0@'Q-J'7<Q7P79ANSF[SBL^#FW&;!/>4OE;8$3H]K.K
MJBW#:+8=[JK^/4.J&9Z(94'R(K&\L#64L]VB*DKZ..Z #]OK!%JN=.A=7._V
M'@/8EGBY0/,W\L^3=+UG4XD_K3-3UBG-C]N<,SP#^4O<M_7D"F%_BW"#63\.
MP@JU--37Z_9]_8P&=\[NF*]@6=FDT_=YP_!J[ _JCDSK_C516SNV6RN]J\WC
M$3YS1#4]T,R-PO.BR07XT7/]'<WPDZ?(1AC8%MR,ICQ;;W>6"(7=:93% (L4
M5:YWLH&Y.^%?*@-OYUE](@)HW3N<FX@KD=4!QUD^MHMB&FM/3)^]GE7*ZZNR
M&N#.6UW.,UD?:<K/# EJJ*V%';T(]NI1&-9*8!L9T/#T,*KWCDYV]>"K]7[N
MFH&R7$S+R9B%RY<;U?A[+"CG/< UIY&K%KM2MD)%G9B0;7%O45>WTMDK33/>
M6@L/C^O$Q>M]A!UVCAL&U@'WHQ@E=O-SDW(*FQI&FJH:Y_=.#$_$/=+V#C6'
M*GTD3%#JD"W"' -(I4:H_:-NX,:',O>6/6O+^MHQ7CH>Q7$TR;;[YTU3F:I'
MMI].BJKDESA!MX6.3J$95EE;^V?-.%R[WS9M#$6@OIX"7K-& EX,#XQ1 NVQ
M)G-*EHN$[R;F5]^%85ORG,FK2.^QQ;<LBVWG3ZP@C2N6('C7@1_(H!]R07\'
MY)U>H;C@_G6UHKZ/QCG%1? 4FK.1K\=;]65<G/'KC%-V:DFUC[NX2]G8I:X%
M4G&[4P+AM\UU\K%MQ_=EEKT:%_S@;#/M:[S&%LL/ Y,05PP0=#Y10)\TTN 4
MG$:0X&;6VH6>$$Z+.[(@_S=[I.F/&34[5<(@3SABE2RGFYLUUQ(EJI<14;#%
M*Z[%$YB%;8&1G..]@[7/LT'3!X?TALS"*ZXGD&0)$E3AG2)"E>W%!:@S9&IS
MT+1ZER#KYP!_=]\JB1X #D_MW^YJ&I9N@U4VXSRQ5$NJS,^[QHE*A1435QIC
M9Y-H$H9/GM$A,#O&#G&*"==O#HNW2/G"I>U2:$-H3,]J?_Q [QMT(<>KPRZM
MEW#&KH/JSL3[*L-L>I-IBU@1YP$W8N-OT/S\'':VF(I8SC0O:LV3KQLR$H]W
M(=#<^?LO5N$$AB!HFZ=X\V^4:ESA?%5F95=]%:]U 'I;3T.TWS@:%1>>"]+M
M\'2#6/I<=RFI8)G.4ZCR"5:OM\6.V%W.\?&041T;CUF;FG9D&OT:Q^SA4+3K
MT(U0&J0 #:P-MI\@47?T0EV7X\1?9<^2DK3##W[:=ZMO1GL6"7SRMEEX9O2.
M^,:6_XS2S=*ZTJ0)?<::"$LA$5SA<UKG,5(3Z>'K[**Z2_NE?U-&7\VHVB?F
MZOYZ[6%PAC-4;K%^_GZK":&K&"Z=9'25XJ.:FAAMAA:JSW>;%M;')K+/QZ]6
M]Q+S;1AN\7E!Y%Y5A^&SN-?<%FV(8\;1$XWQ@'I=IQ7XH2^^@U" P<@^E!=:
M$K5WZLF9-_@,E+Q$EY9<2,-URV;B?*  Q&DYIM,Q, [<C#1[G@+@8C$=B]<6
M\:/9D,4Q&[J><#_72"6-X?5X*8\3CT?<V9]ZU?+#L0L/T=W+*9--PZI;!V@W
MEN01\"$Q0R/<UN!B9L;0;)W-3VCBS?C1=2R?S^=FD%^Z0Y['+TFNFA/U57;Y
MU>-85GEJNM1C /+-9M*22Y-KJS^NX)HA"-E)NX[<Q>CFU</H'!\&&:XB$7@R
M0C9]UC:N8Z1Q'/8U+3JW^.R^/*(Y[ CBU'5=+05JZB?L)#P?7+T*UH;# LQ$
M5'BB8,X=21)AE^I+1;N6Z+M7[R9W[6EZ+FBA%;?Q%J9X1D>:2C(KSI.JN9Z/
MHLO'3M(FISEM#=W+#A>2L[<P .*C%?<"2%.KMAXQD#]RA\5?/FF)BNBR1&V=
M"%<2+_K5>+ZH*U+,6^5TTI=R?(\WSUUB&OS&52WP[OV?!Z>.GYWA=$)0STS8
M>;VA8A?IP$,!+FL9Q=/Y1JZB:CO7NK&SM39=)&<R<<@;&,H+PDY-/M_1;F7V
M-9%"QXE47)?FQ;+H.AVNS3ND0,1LVX&U"<+?%HM!6V"QG001#);H[4JXVE^Z
M8MNX_<3'" H[(UPG6]G;8%NXZ/.JAM=;]M7!$D+YHC\I+QDV8]L^OE^KL-"W
M,Y+Z0_),Z<R'"+YW6I(CZH$4!15OD8 L]7S8NU5/=*=H.5N?74M>;=GDXV46
M=IK$JO<N=2Q1<R!#XRE/!D5,>;TG%Y>$V.5@RD[)<5G68*:M"0%,657FOH.S
MA8UI&DOE7/L.R5/S*!\\S2.J-"832E"X26DC_:VQ8@CO:I2((2L[<^LC6K]Z
M!Y8(2[H0\J,KLC2*K0&3+VJ#6BR#U$_/CQ.,CAI+SANG#]^?LX2*.B*="(U/
M6\_C8^U<G;%_<CZ(-5>@SG]?*]6#[]BRXJ=/SS<LJKZD2KV55"E..>%=%-H3
MCF8^=/IX4_,47'?31U.&)5!9OW&^-Z^=-$^PEW<\BUZKY,ADQ,3QOP9>&-2C
MG8NN;"#7)?_DPF 4>!$?:7)UAWH0?6<5 RQ9_1',0,ORL[:>[S%L:SN<G32=
M>#M?A[%<& ;8T)L (TS^;9+W#UQ](F6NF7S   9%X$'8:<5R.DI:]+J^ENZL
MP #^9V!4DL0_,K7=L6$]C_ *.1\W1/M &]-I,4#KO:7F<PJ^],O[?1B@??B?
MF)J8J<N-F<U)3!3"#W=]=E#K?\1<T7_D>4$=)IY%OXB&Z6" =-M]RRZ)/QB'
M%_R/3">GQM2O@1[Q?R/.^T_\0>8C*];V?]WQ_PUWV&Z:!$X(>#JT7CV>5(<E
MC:Q)B'CS=*I/\@A1:7;_"D!-FLG8R1$4*"7R]/^L*$P,(E=44QS   $F^>HR
MY&.@A_]P/BWY>C/) V3]O('JHHZ9Y2VBX5F&A?L,"WC[7*4E*9QTID\+[14%
MMDYXBC2GNY(FC[B\#1HN6-J25_%P%V/NH4HE1FHP );UQ'4VSX5M[KM_LK36
MKWJN(<W:TKW[17\F.!E)T]7O8%$T!8-4.M14EGFP$BNWN[)L&IW4+A8<10=6
M;% 3$+M+Q#S"DNM_^(YF]FQR)$<5+R@O\"1T0%-Y>B,^555@ :*C76OT]3UT
M;!6-K6\*UVUD\^^GE;S"8CD+VQ=_\'K& '5'QW:IR7"V_&DU4HA23>PP[""=
M:/92$0$+F-XXY\G6D#=WX"8W-01<!V%6##B@_:[[7R3"2]!=5B$BE- ^]!87
MU2E?+@^A2J[8TM9$6-#H\/RF_:<D/F;JVU_?[&]F_$2]&31#S':XIWRRU+/3
MO<KE&!#_B(:-7$J,VXLR(D8NC -4!0I/ZRW4+A2_ _:;HX^K&WP6J7:;&*8V
MZ,E&<U))?HGZB^O]HJV@7XDU1.,@#O6\A:I&8%ZF4&Z)F8>?G01B/X-O%QN_
ME2ZAT#:H2QE?]O'0J%:5TF@;"](F'Q$YJ^@[MC,Q0346&.I;USG-SLQ4Z>WU
M=AI&#L"E6LB).T1X1V$<Q&TGB5_>L^OP=>F\<]B.GH!=BBPVDZ+N+^%$OLV=
M6[!69HEC[,0B>:F*!U6_(M1'W@\\GG=8QM%=5TZ^X+-_2._1.?\)BP6:7S(#
M"N-U?*:U2B[[W"FJT<3'?:Q3:UW8(5'<;<0WR,O';*D?5JPFE=-=UNYWU^>+
M(/#&'2J#X!C\M'<D]!CIXJN]^"WP!:7T7:PHO";;W,PF)?)O<O>(9&2?^XR,
M'5N_G1<R26U6RPQCZQ/^O6L*,4X9!HB9P@ GE+$80)9Z.-HXY!4JH<1Z)J\_
MQ\:=^&9OV:*3//%NQ/&1^'@/*,GZ ;*SC)V$U^EQAI"N[(."0YH,\ECV<E4>
M)=Y(IBBG@=T8U0(^:;%T@W)J]\A+4G/H&D?#NP<K/K^^$Z#C5%5JDB8NEC@Z
M*B/)AG%=7 6?RB7ZL_7.:C9[F'[9MZ>6EWWDS$;*<)$GZDL6H-9([\NYSG"=
M_(PN1B_@I[7K!=N2=% _;]V2+7J!48B#JV'!KR]3H@X/'S9)>^H*+.F9UR [
M\W#PC?6Y5EYJTY9Q2I+'XAP:OJHP5$0J-KLNFQ:+!^J:+-XTXAY50\8770Q;
M?H61D+R:Y!C=CEA!^Q1DSY:36K.5>>O3S,KD@.[(M8]V;C-/JYY9.UU5;'S'
M "FZI=8+=-%R"),3YBBJ^.GE.=#"#I'>E0)4'/5B\0Q&*+O?D51B_B4U'M>W
M>'V_>3NZ_5P7\HKIF:#?./-3-YZ27\2FLK)@X8UV/AJ-:-6?K6%.C7*3!X)B
MABV3I\;4(UGEH.4QCMW,JGH-./MP 6'$!?>*C[*  0+^"8;;)!MD'VY\:W?-
M]N3EO1"<!Y\(ZTN?QQY#Q'@Z=)_DT30:9:8HV#'_5+*[%8U?_O[U:I32'N5F
ME(TELK PP8A[,?/V"-[A70L**?H=RUI1HMRR$Z=:J*@B*<A!URMYJOW9&<_6
MT-83EM0!+*->6>'(1J]1U>#C]!UWQ)0__$*LY!)>?087C.X_?%[! !:U%"SJ
M6P:9Z<9[Z2=-FS\L(6.]C>^F7LT46\;M\TE\W$:5M)LWTF"QF*DJK?5!JY"^
M'D_YGO:9:MV*U\B)TXXX*'%W,542Y;GV$_]RFB\ ).XKVBPH8?+Z]D ]8OW3
M'J>9Q^[$FI*/C'W@KN\/I@B%FJ<=D86.<^?N$"%O=7"N38SUY#;YSG!F7[*@
M//MM$<J3> F!WAHA"9"C3@8RA4?Z$/(U]XX+W/5I;Z"T^'OWO@_9GX7H$Y?2
M*SX[MR>_&-ZKQ !WYJ;F< Y78A83;,W?3G]:1Y*_:/.E:1[9AS#7W;,+ES/D
MGSD3?_.Y>C5@HIB!^@5!+DW]G4_OEM][Q853&'5GX>T+O'(3GQM]B&P7(&%W
M.[<;B^8)K,8&%)VD5A#BFQ(J/@5>0B=$H--GHZW"'25Q;TGTVIA_\OO*UU0U
M>7F\]?GI\;8M[\$R/<P) [09[!1Y41UPSEPH1$T8!CQN99;TF(V28IF!C7:4
MS6VXGTY4#4 L[8T"OSU0#K@H$?XL.7C16JBP+/3S"5U5TLAK>>EV YE;#TGQ
MORT+8;,PBDF*?[U*:4MC5E9JG8&,VJI)EWH8I'[%+Z^L.5CYY#/RO%N\L<"!
ME\/=L&Z,TW[7KCBR\_.$>B>GZ&"Z[TZL7X>]]<+C$+4OIX9*#@S339-D45(D
M,C$";Q@2<C]X^?*%XD654(B)[,:39,?.>I0_#+<_>:=.J:)*6\9T8D N5.H<
M]J &L5 ZF>YP@1^OE"S_*Q[_F"50>O/S+0MLS\_.45E)%O! 5\,/7S;CW3:Y
M9^7(=..KRR5-WP@MY(F;!HR*+H>-)G=5]9!P3_^\([L:?N^B6LMM1FY8XC%>
MHV0:]UCF^P7KHM569IXS>VX=[D_R/1@@+>(7D;/?OESYM\9L93NP?%/3J,MZ
M%2BW:;2$L?8.2V]LN3^^X$5M#^/0!&?68K^E?K1F0XW_'</D"CM:G3Y^1 &9
M7Q^/&4Z:EZZCC+F5*0BJD&XPO RKTIL+_Y9M\1FAK4=ZKN,&6\1IF"AF'H5
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M_KGV&X7-9-O7<UJPTU%BT[6@X&GCVQ3C8?2";5^>X08I+_:T1/?-0R)",<A
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M K /]\D/-E[<C?9JI[G-C_7#?YHVQ73/QVB#:TQYA\GIH^#]N:/KLQH$T*P
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M,U7304]4A2W472R5:"VS"U=*.P./&7IB&,IQP<HJOR"WG'"Y0*>KJ[46K6Q
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MNRX-R*RHK!XK_EA1$?8)6AWU.9R7ZKF_'_J*ZK\>>/J@BS]9CO\*5?JQ(P*
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MFWJ#&OJ9$A:C NQ]HLPL?7F.X?&YEM65EM#8TC@L>3<BGJQ>,O+K=UO!]#;
M&E,X,/^SG/[$--$&-_+F2Y'I['B3^D]Y-C,G#^NU30V65UBM* ':,@[24:OW
M3_3&?&?,\G7SM5 [1N2$,=B'(S<ER0[NS)%MP_O$68Y/9]\XSQY^9]^*ZPLW
M\J#II;TMG&D5C48O0>\4IU6O-9UR'H9&DJPG]YQ@L/]"W]I@:#+P.IGTXS,O
M=/7L^I'_6"$XR\*9"7?$@Z?HVO\QKB9Z:K:?PW!,4L3[*3:(5<1WZ^PSG)JH
MJT?D)M%2\['/4(+?G $^ZHW,R-+_"#A_B<IT!=I<-4]R+';Y[L"/:!.)F]5L
M>:?+SK=M#@6ZGN!\F<W&YYJC:[8$5IA+Z^$$\K37>PX/3C '[ ,">)P#OKNH
M00!-?V"<F)]U1S I-M!62??]'Y#B[GF"Q-GD&OS&\#@#5SI\KWF%Z %PI%73
M7OT+/CH.UT( 0[K@VQU0FY\0!6OIP]-7Z89[SH.6Y.%$H+87#UI S%;BZ%\
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M7;B*)C:O7_](,=^72%5AC&F$?YBO ZWJ-BE) ]8CYG."A,"7E$L78,$3;?K
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M=T^&/B."YY9L)&2WW*JAT0S[[".3JZI>%$4\&M@*\ZRO!LU6]&4KA35Q$Q,
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M.\Y?R_"YV1ZM 69:J?^LQ@'Q7Z,CNLV&KS20A)L*0!=5/)] ^'BT?;)V*U]
M" R/I>=LUB=3.JKG\0[=97,ND0BU$"+WHS!TDG-:NN#A7_,]D$$J'T=ZU#1
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MR[^WD]-<Y@N\LQEO/@_G[^><E.BTZ%517\)9.<2;EL6"ZR\5[C_J-C@Y=AM
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M#WS5.FHF1R4\.''\D4[T(_IY1+B?:?%0Z>1/_?\#G6\L,["#Z8XP?$,<5 %
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MP-L-LQ@[2NJF#LLB$1+KG.^ 3AB3\JB%Y.VWA,*, 0<>KT^34"&KR("+^.8
M7)Y7_-XE(O\_2P^0Q/D<@:]XS[]TQ^W&"<= VS^@D@F(R+,U0G&AFDRAJ@ X
M -I\O9H$ L[_!L<GUW? *J1RL7FMMQNR_.2%M,D3\M8J,/5<EEIXA:SJ0XXZ
M'#7;FZ[.6M&DEL_1&-OY$@X7B"\@&JD?K>(CS_*-#QTG32&(TH: "P0'@!78
M0@+4_"?]-:'RGUM<>N*K%!UHB LA^JFMF&QV[?=;8B^5^P)!-2B=6/9A^-3$
M:"G%U_V1E7X 50PYENIZ4VZ)$A5YXVM!1=IXLZOI]-7T']$A!4A,BF7I2%0Q
M4PHD[K"W[H3([3X:I\D[A"V=)?D3O&70U\ 21<RD7UE9WQ(Z'ZN$-GL?\*(L
MTE"GAZRLXFQHKU\:1I"I[R;W$9WC!CL0-?6H Z7%5^OGXU5M6#-HY1%.?E&J
MKZ3OTR?I*P-03Z3M'U6D_>Q LD;S6% 1YNU3G7:W9B=GASU"MC+GMGESPBD4
MS@GOM;62OW'*UN9C]4:0M!H[U_F,@QE*["EK1MUY$*$OHT#/5@RL!&\Y79(K
MQI3+@8)(FLU.@\V>SIBUF8,] DFPUP@!X8 ;Z[82^P">BNDV;=J924"AGKXQ
M#G[3%YC<NL&^?6E!M+,54#N*68?'O<LCOL].)9VHNI'[]:2PA:YYZF^+MCEV
M2K_AQ/(0DAEG917"8PVF**:S5E=+0>?\4Q7X94-;8]1I^ZH<>3;6,]/(\5!%
M6 P4K'8L(0NW >,%7B"(##YI^T=];"V#V>?K\7? NC1)S9N1,H)DZ<F0?-@B
MA <DJ]5,S H-0IKC@'.I.8H0JG,E[!ZA( U \_QF6WG_?*S]#M!+Y1MQBV%B
M-V&C?8-_5>:2Y]T5.UQBQ8T9 Z.<D%&16=5"BY?YE=@@*ME#KWRIWN^ YA]D
MA>45=75-<]#\IH9@8:#G(!9# E/)+<"UM*2 X_>O]L[&N>T;ARJJQFA*C_%M
M?/I?(Q=:-(LD4UX(';'S-P9%6_K<),Z<1V70'K'=( DBK?X7]<OVC/MDE/M$
MK_3&2=BR.PLS&/*@GA=45W';!=*SG[]K&V+#'/*3M#U,)+X#T.??-#<?,QHZ
MAO&?O">G?A 8<&H:WIH>^ Z1]I KS&:M"S*RA>&6#';P*QMP@=&/KHZ(>"N_
M^T9HH&QN.!2\T?/FZYV^%MXORZ5-0$4J%& Y$D;BRIPE#'>#N2]4WP%V=GAI
M\JP'*;-?+99GCJ\C@ZNM_P9CB0;2Y371NP,)2J1EA*GUHXK!Y2OK)H9ZTHZQ
M'N 0%L&^$E$T=+!_JG.BY/^^?:3)"S5CA9-OZ?I)IA4J0QU/7& FH4EXKALH
MUN#?(HZKP(L:(#\G-(0&E7%ZVU[%>#%J"E@5 M2!=R?XQW5Y,?DBG8=LXM54
M6'6?6 )3P#VQ8@\]WD:W@^?S\D5&(R.M<[FCUA=IY&[O@"V)>6>J,6)9JHK$
M/WW4**5DW\D:DLG#MFM 3TH3@Q'_OHZZ;Z;BNKHX+X%BMS BC?Z4,S<'4F@=
M]N+[A8T4+>2:YC5='TP*\83NXO(<04GFN%NGUHY%C$,O,']4YBU\YA,]0XSG
MN-A9OBU2D%^OJH"9P(/T O1'[X!094AQF*]-ODJ[KF4S(M68:L2 4*Z6#DS=
MV^R;*PPK8H(D(:Z^R2<[(KM#N7F(7+BBJ.K/Y*/:=T"%27_3;,G(SH?99;HF
M4[&$@,/M+C^[ &A9?/K;![Q IA,3]!?1"B">=^%B.ICV+KL-LCJLBDEBCZ9)
MOW[B,E?I29?[3'>BC]CW#L#17P:BTG65?JDQ6.5I ^F,N7.>"QS?.# !X..D
M_7AQ(D7D691K^W>9:>P)=;V#!7A.9GEI2>.\IHO5-A2?K../<O_U)^0V%BBY
MA+4AYQ8KM"-\3!-T&2_47](C>YEGN5[O1M>AHC6?+M^D+:<T,#ZU;P 9")R3
M\T(2150W^ 5(GJWB1E ?[]&24>3L!KC10\H]Q<9/'NC[/9 ^CX:)"M$17$-'
MIG[(6B7#=*10W)6F9#59)103!2#5]'B6:[]U&Y0S5&E?&+6KML8^N<;Z& R\
MSA,>W]$G 5L?37;0H=6H!5Q\IYDBG_^>Z#RJ[ ]M:]^!P_71JB:O]3Y:N32/
M.0Q\$NO,+52_W.R[V6:U65^Q0Z>MB%#7I3.6._E(W2RV/N'>HI9*)ITO\F-N
MH \?:EEAG.$J:S:.*T\/<):O*'&S=0NMRY6_IO^3N#K1DE+[\FOWP9R<3T5F
MDH-["F=5]W"QH+[KA]'QU1?#RF@.$WX1YF%$4:[/V(->A"3 0!S !P1'LIF1
M==L+*SV+YHP+^P.MI*-(0A,2W%WDH#D;\LER>=I_CBQV1TR^(7EE]C"(+8CM
M+:7ARHI;2/CS)^&+#$F6*@(C-9?%%H;HDZ;,&B%^#'HE:%VWL-T<+-Q<AHHV
MH+/:(S !T$E:3T\9-GDXF>B 3K0FT#L-/=1IJ-C,#->\ WP(> *LRS:8L%O0
M!"< _%#N$U71PCG6<6Y80EKE_#EJW";4PKOH50(K+-TA< W4 F&?!1'!PFKD
M5KCNCO1(3X_ #;:-GTU@ROO8!K8JT[\U-<L#&67Q.9QC34;]BV //+G3K6@D
MKEW)ABV'D;&4-P;K:VMM'Y_N-XY]75A^-D='GT#O.9X.!?GO[DT'&ZAZ9C>T
MC6%&NPX[;4L4I 5QNS%;TQ]B_V>L=M+F(I4R7@)/,1Y6I@B>)51/O ,2R51&
MVY#+2\Z@5LTIT"@<6](. "%OGZ>#[NT[ /58W#Y#@+Z][^VN-SW#S&*9>R'2
M?$@C"K#ZNX9=Q&V[0VQ4>*P:XUC[WAG_DQ/K&9 8!Q0'A]<#V62\%2%JL-P1
MI5>?V=2N7V"I<BW0MNJ,VB9"T'KN;Q:6(/V[$\ACU_&6"RPS^(O?.+W>MT(G
ML>43<RNND*UGH65)F1I(&31,<4N5%LB5-POFJ45++#?4_W4,],@L$0ODW,A_
M71IJ,(P?@(3&CY4?78OXH2ZF*?7Z))/!1S]^>%K(8( 3FI.YO(AH'ZM&MQ-?
M>3"R '%)-(O?SF(A';[N3W5@254?;;U6S8I:K0?L[RJ3&2[?V>ANO0.Z#=[@
M5.;KA5'UI=-.%FBRQ?9[]^E4"J*DT+OG'0>J;'6?T2K8\\BO+\K9=A^_!G*\
M X(^_$+YVX ,)M@P.')/XBZHL)C/=[79BT(85%L(9+*P9V^]&%*XE58M Q#
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M5]0)]788F= 96"KVLK\[C4;R91W^JL"I2_^:Z#];#G3:;ZCM<_^5LCK,4GR
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MIA=-O%96G$!J#OC3S[2'WGY^EC,3S9"BWRK73P'HC)(WB4?F;,K77+YDK/:
M/2^-Z%)??_0KJ"WCX>MU4VR=#7J2<IOH+(6^+6X@7%GWJ\#;/IF$G775LRYN
MK1GU80U:(0 85.M0@IV1XMJ]OT&E"WE=DO$)%6)2/,00ZFK"@-LN 1[WPEI1
M%EBI5NN4,I!\F[^9+NR(3UH^C$KS5]U0%.?AWPN6]5*4#OGPERYM-H#G^TJ/
MF2K7YG/[;8D'E!ZB#6G,=F<,.&8\0.EADA.D&AV^^Z$<B#,= E]6:XR<M2,9
MIQD4C P7<AP'7&ZY]JTXO!75UWU1A%6BT0<.GP*=_PS$,\)"$X,HRI)D:6"5
ME9D;XK;K)U@+XN1YO=@($_!:; ZN9;8(?\3\M< .=O0\)!AP,R9\-$7HCT?A
MUU!Q+F Z4:?$=(8Q,R$71EW>)?4ZLGM]Z,NL<W.R+NM+^\DG/DK [?*GA$D3
MSS1H>(J>-S.II=UVA'J]RT))2BW4K8/M^K_5;>;A4#=:'/])442F3!E$9DA9
M0R/[5F1RF<10QE*1+%FS]U+6(O,*&5FR9=)BB8QA!H,)1:5F$+(,8VPUEBPQ
MBWG=>Y_[Q_L^S_WC\_?YYYSG.9]SGN]61:V/ OD-04(Q!-H$M2B(F6QXJ4>1
M,X>V8FI,-E4G,R<G]G5=)S:2WC;*>0G:O[4.4N@;QXQ%9>KM03<N1L'GX$Q'
M/X< >?O[#Y,5\S*G]HGG#[I0;T84:&Q9\ $PB5N7T7:-#[">5#,O:R?\^\?J
MRNC*ZOH O8^)=W*::TN7N"N"W.5*] V==VC@8#20=8O&[FI"R62IGL1%Z3H#
M<6S:?Y7_;[SRR[=]3O!4PJV)A@3R4"30EP3]W7+FLHG4JJ]FLL;4!3E))_2J
M!JY<X->""JXB/E;YHLE5T]FR/R=.;:OT9K2-A'?'AV&$!MGT*T/J]5B#)'&,
M2K.:]$GS=BM]^WZ):*F:?U6[<-J]/_MJK.W+M2NRTE0J>.F/&%I7$A[UY$UW
M-_H!JZ2^>\3CN-?(E^X+TLDL5K^7&S)8(?IX=D]4$NECM 5XTU$A#L5(S%L+
M2G#1O5\S'X-OV2ZY06-&/\.D7S74L7ZGDR3NH*WK8&@GF9GI]H?!K_-A6)?"
M ^4>Y'W@=B%])$\[=Y%,2UFW=[D/2VPO$9&>*6.[YQJ_4YUQY=:BNWE;A<F8
MNTMEIOL'JLR1"<WBV(: 5A8,C8XP]FH,E=1BDP)-,8Z$)'\3#?P][B#[4FRU
M_=!'>N7990\M,ABNT:*\4?%0C77^E&^(3).QT>P>F/S%5O\X5;,#M)]0ZAK'
M_T1TVC@\%;$0K)6]&+,-O_Z?4/$4=.5YRTM_Z;>^1,LD]N&<ET<UF,])/DM*
MF2C1Y@O.W@*9%J]/:28F:)\0S-ALXAC-QZFE3/&!<[0J=3PDW[^@TSXU'')9
MK/1I@5\Z5K%P)=Y=K&SS#ZY>?TW)2D31+7?;*_1ZK-2C\XHJNU)WW2;M-YOE
M# OC8RUQ7)^O^!]SZJ<QADX#TU&79I"UWTM_>:I"K@^'K"KGQS^^$:\(!/MG
M93,.)TYAX![O6J4"D#]UC*>#1SH(HH''+B[I0"#G>Z0DA!#35_/G,-XY1=UB
MKFK>6XQG^AX@W1JZJ424#9+00&-^K6&D6;.@J=-:S)YKDA*W4ZP^N%= IHBL
M(Y/(!^L9TDJSJ6+E<A!"SDP&$O]TT)=Y:;>MG@SV'"S"D6#D)4W=?+82U+$-
M<3OD>/;9C]\7QWOV8R+RWJ; Q<(60N_&O'( %2&@1*\=:\IEL&S.-N-3* @\
MM:Q_<F"&Z$808&HMMX!CKM9^,*Y-[WW!*@VAO%Y8,YBVQ(!!*) 9"B4%B ."
M;W"OR".#A@,F8P$M>2#GSZ[8D,? S=?B9HOZ8+]:@XZW+D$_@R1]?_/4E\QH
MU;&"!UV$3)>A\WP@8(\ORM;#ULW3IJGNYB_N=,=[@R[&XY#%2@'N"<'JLKIF
MS4K=IM*1L0MEAH52BS#Y=NV#=9KTMFVI*A?@GXO#_ZAYX;M!K"K'$K K;FCK
M4\L?XW-:2[[!-9."ZK-D+,G:Z!=\X%%$69?U=JJF1O&?DRRW $F!ODT/N]RS
MU,! O(ZL,T&[96S8>31S0T1&4 &$NITQV1?3N4PQGBEB5Y9L$2NK[O3Y# D<
MW 8E<1'5S,?:.5?WPG;+K7_JHQ_5OU).4VS\,A.(H$W<\N*\,T_G Q/ZOTN$
M[1VGJ5R$9X]N<:65<.Q@73%/#,&51'E_4\+OM*/5@-J#A8X)UEY3NOUAQL(>
MP.^;8>3R*H4P?FS[>ZX-!H_44E[]HWN(=NQ=:#VZN2&\C:*==4J?COI^][ /
MP;86CC97YJYB[65VJJDGLIW*;QUW^YH)Y0/1XI-;:<"JND/'Q $3^3EBF(DR
MJ3[QS)DCHG=B%0AG=&Q/8 ,ZC$XZA1:38$$B6IUATAZ48N$)WYDI"H*0_YD]
M;KD*\Q7IE>P!<]9N '%@'"/CP%A4-J7.=X.J>! _4,[!O7>UO"U;J7?4VD*X
M"9RZ(MH>.:ZR(I3S DVIF/@^TJEF]<TAWX<*D;8>#G3H93ZUT&:HQ 5*W7XD
MA@FE45QD)T;8'9>'3S?T7=MXV*Q2?PXB9R2G+W)Y)>M(=KR]:Y0@(N"TI>=>
MVNA\[7SP:,GJA9&3H[77/NPGNT?_<#_+!_8O35U1#]];/DAORHI6](1W4MXT
M>ML\.AX&$JOAK,OFZNT.;-M%X@/)9/'P8L$?)L>*-NY$WZI)JT=(9JBEF"UV
M#N<YQN/[]RB][Q[O @!"*5?AZQHD_8V;AZL^L;YE+!+:XV03=@*'@+CU!(=\
M 82$P:,HFT^>2%K[&>>-AHGUD7 '=CY./JVRFLSH,/QT<59^SJGZ!Q^(?72(
M#\B5B*4)(06S'0^:@CQ6A'*#GE=PU_HUSA!XG(<P/B /OF%T2&G'W5,;:B)C
M*I;0W^7K.LX_/S0+6YBYI[(9P3YJV)6?DI\-$]UL'6.J)ES/T2TON!] Z849
M6_O]7"C*?38TU[!MF5RH&Q)YV5/D0%.WPZ(?\V\Q[?^'>;AG0*Q<;T%4]2%.
M7<DU]N#I;8%E)B70 %Z.Y,W!0/*?0BPE!>2YJCRHUH.XL: E\=)@,L=8DWL,
M:[K*><T'Z(,,/O!P9]Y,)W?19'A>[$(*U=:.GL$33]Z,G&0-9]NA,_SSO)[$
MV77M"+E5-R7&ZDE[Y1K)T%E0H)1@:?H$C/O'K8\__!=02P,$%     @ I(%\
M5LK2!_"/"0$ T%X! !0   !N97AI+3(P,C(Q,C,Q7V<U+FIP9^R[!52<S=8F
M^N($#<&=((&$ ,$#-)8$"\'=@[N[-A(@$)Q $A+<@TO3N&L([JY! W2CC75?
MOO/+.?>?_\S,E;DSZTXVO1=5]5;54WO74U6[>KV-FD6M O=?RRK( FAH:,#;
MNS\ M7;_MXR/K14 *"D!3P  P 4PT<0 ]+L4_EWF=:0M@'F71KM+:W]+_^L_
M0 $ ]X?WZ "<NS*"N[S$G0)T>W]K^T?^R!_Y(W_DC_R1_TU%T]:12</#V<O2
M[2Z#E8#QMVB"["YJR$O _/=T?5+BW](8PGP D)3T]_3?(PO<SW_U]B>R^"-_
MY(_\D3_R1_[W%KYG?/RBS^X^(DR\@J*" J)\O/]IV5T, M@"C@ 3H %X ,Z
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M8J!7+LMFRMFZ]FUCBYWN2M/O(@0DN.Z?WS!]6G1HK08=(H)7T8=P2$O&WK$
MBY#SY82 $H=MH]$W%[T8Y*9ER(CAMLA(R]OX\ P\RA5[9#OTA+_)Z>(8!1S%
M+H )= QD@+<=JYE$"SX?[<^OS.2*BSI_5C\''.8ZK6TN?7:USC(CC<G@6"?+
M>XT@#<-^:5]MN9@J#+H#T[3=HBP"1YQ.?>((<A106=OO2",-67(;[AJM>>"*
MF!XB4T63^5]5R7\B(KLOO-*FZL+6KN6/!.W?_RP<=JN2ID*RLV2V@R.D1.TX
M,\<K0"H4WU,S'E95)]U3K3:V_76>2[SF&23K3])CLVC?*)._,N=T9L#!+;D=
M \6MN"1- ]ID7HHO02K?+R[*X*9)D\G*X;>,R%#OJ;Q]0FMDKM3:X._/)3N^
M;H.\41TN'SP#-E6Q?G!^^M#7^-+G^Y%<VN$/JK)U;8/"9JEJD><<.$572/)<
M1V^O #4PYDRCOUX/GH 7O.WJU:LXO3Y+T'JPX$[I%IPBN@1?J.HMA>OGJ,8W
M"L,2QK[;XV6+1@OZOB9V]='$HM)D0>;AR]LY,6?L$V6 DLQ+P5^0VLH^5U<R
M=>4%9@6ZQXDM9 R%NWKGWMZ.ZTK*^!^6)!2?J_.3D4A81W(F6="'@.+M@.F<
MFJ_=^D]*G\[W!.OUFCW:Y65_?NF[G?FZP=W3V=II8EF%OIGS(B^EL^@JN0=0
ME+&:]XE_U=:H:$]OKM*0?E+'X90X5\GG@C:P2JKC5'[PVS%C_7R=TX:4-O]+
MYY/-58L,'%8\(#6Z0#"6%X+QMC$VNQD'>U&YU?KVY-M$N:<B_F,"[T_3TX<L
M?"FIENKWZ2@ZQ/F7@[G4-%=T)LPGIF_/\+5JP$UNUFJT@;3/?]LI<KT85'\W
M6&C4X4WUG <SNS<H:Q0KFE-HO]N/+;9+VK_4]OR$9SG./D^6,42D6$=O@N$Y
MJY'L6-*:4;:IZ+IJV%/-[00<0X\L_%HM^;- (4?QBNQ)+HL:8YHU*PVJ@XN:
M: -ZY2Z-V+P)9\<*$F7JLE]Z@,0F#0"144LV'#=KI5#?2U7PDE=SFL%E93U?
M^#:^O"]J]859KMA.*#5N@Z-FN"J5H3W#!OV /+'(>(F[)C<_Y3R=OJPC88CL
M..C<M9;\6&H_3N&\QZ!UZG2)Q_D\(]O>NNWP-L<RWGN"]8XP3XBA^H'OEF^_
M,U9C<5N?X*22>8HUFB]GT6PE.>74T:1_R7A+X(K_;G'UE,F:70#-+YJ3\8YY
MCB]UD*-M$Q9U=0F^BL[L(TZ?62_GK@O;MJ5HR;3!Y\@XU@C^$MVC;]CA0>-?
M$AC"97UO./F[)?@K8><5!;.&"D[ZQT9)GQHTA7;CZ$,.SOJF@T5%GQ1-/27*
MX.DYJZIA8=Y\TZI'W;<\+#IF_MWV*JW&%CH]$]WFL_"S&NVL(PM?4UOR \^A
M0!ONGG<=SZ]%::<1V@,<>_.PL(ZB6D82?<.=^1=[-.D5Y^E3W_A 7$^>QOT,
M3B)=S.@,%K8I_;I0TG^C5&#0Y5O88__DAQ7T"]R5%[\O52S85V)*_+ I;[<&
M%T*O_F/\!=\#_W<OY$;_6HBNK?QP#7V$U_AUEWY*<XZ2+*=W&K;")QRQ3Z"8
MTXORM#ON.!TN3\^H0C+6)=L(W$M$;S7IHH$&&:W6J:<"M3J3%66E4\/DY8]T
MNP+Y;/M4JRFP$4OM7.B'P@PVQ_#]IN<]@&[.=X.]QL"E!?WYE04EEZB6[#A+
M:ZV-)+1A$;KKZ S?-4C(5D/*PRAL?06J)T47[/F @HR;*#1:&)'<I6KCE]+2
MDW[07;5X29!4$BXEM<@?IV+&F=LZY7'+I07AO#9XA@(\%M]4'5Y91 -0&1FL
M24KM??%2^! ^012+RP\P28]V[?1IR74$M'+R]Z&56FH<[3LOQF"1+/Q)+=HR
MY]=5C0;V2\K#RU[758HN[_M@[()66X?+PW/EW(?,H5C4MI8NWR7RX%(/QK1*
M/3GIE5FXO_HZ>]-\HX2F6 !7%C2!4[\@[[#]]]\[YM!1/W*)EB25(E73^@VA
MY7I-RIWNB[7X=K7Y04EY4-:4%9PH.K&+99\"+WG[A[E'L$)86.UVAC2=-QE:
MK@R?@GDT1:H>.8M:0_I7@%C=/FGF1E-B*8LG\DS1=JUQ<GQY<Z'Q-5[BA<(V
M8P0AX$6FIJG<D%=V,?M5LYK2=V&3]MT)_R[T+Z,T*;WK&@,;,I!;M#;2=P$]
M.L>-"OE0/(FB)YRFM[/SBC.6.U!PFYFYO'2MO]]T1"5 %4='1B-3=X*K0GUX
M6ZTV8A=>=X]=RVLD)SG9,#5RG=!<%6$O5' 5&R,:.KP#U4'$D:,;!BS(XM 1
MWS5UEW'7SXQU$ #?M_73^M7SV1Z2L#CLE$(Q8X>MWGYNYL(GMZ&]-5GPU7A<
M-K/8-K9PL8\%Y,AM5=_YZXWN6C HTPZ8SRE>L:=Q^OQ#\&[/_]FV1$E:ZM_Z
M19#39"X_JL6_B&*4>T,D ;?];&F"#$V<7,:SY7'%@S%/,7ZW5;)WAMSG(V^X
MW>SLEV0'E=XK%BT;S,LJ8XP\R9*,$D SBQYIF%S[*M78.GZ8G:Z.X_,KO*O\
M19((-7:1#ZU&TW0 ::')'M_E##\+-:.-4;<843#:J"KV+;G^A7K5!/.#/9VZ
M\\2J=M]?NAV2ZK:)>U<.94[,DUR&2Q04:]8:VX[[T,RO]/#Q8&XUU2%?>T?0
MLT7#+C(H9BG',98M[AX90UNX3J;AN*,S5OYTL27AP"[!)]QR\"KK5C"/FF$M
MS=3UC7;#6)KI.>YIMDN5 YW"%L?2-^MLD#4YU+5L5]O;;/I(HR9T=>/^H$OT
MMKB$NKL495&14P57J>/\'=?*LDU:6(=)Y-9]"N;L*/0_/G(4/<2O#^GP8=,Q
MO.,D4/4_/7+X;Z@A=\:^,[Q)6S$^Y;!V9W[%&\ZQ4$_<S2 >ZZWU89T8;[>5
MY9CA8CAB:W:+ML06U&!^)0@83540IGYR?_JFS4:7U4?M_6!U\7.,MM<;()*U
M6'P-A"_6<+ZULZ?@%>B3L :'+3Z%0_IV8DQ0RIBM!$G-^!GCP3UGGC/.*?7$
M$;#KEL!KOW JP'I7KP(V\_KVQ@MZ59:>TD61VCM_Y$"8D>O$'^\PBD/H=KPG
MB7O#0[[1''5;E\#ZY6':,TNUD<H-6'EAM[Y0>HY/6^>#G7.7.9$F&ZKV$.&"
MY4AZ_[,SP?$]B0<3@O0\*A-UXI#R=%?Z[GM.+]82[J/UB]!]N[@HH2D(LR]9
MV85Z\_ -%+ZQ>B?;CNU@3IC@)O$YBTBY2V'"$M%2VL457M);QRM?-%J,%D7M
M8%[1(K2"?%WX0?(W-2,R&#)FMWR_9DJPZ,RR9?(I#P4/VV9UYN")ALC\(@/_
M;G058T1I[LP9H2&H=T,UY&V*(F&(5!\&-4Z\/G"" O 0UG(-"![70'=3@AEW
M_<4F%>9#3PY#[G%?0T?Z)T,'79+! 1CB/\/K]NK8EN*E, B2C>J^KGWEXND$
MP^(-!L3T?=5E6F:IG_V*V@3X3QBF")#$$]S-;,213J!=+B89W4UNS&B=7'1L
M?H0JMD[L>Q3PKJ1C X0";(09822:I9*;!8@59/,J"AACAC@B&78K][3]WEU<
MI1_\^I:]D;&W*M\-N*3S0K_!PX[T$Q!V/PC=-:>TMOCW$O/<BTTA+\K':LU9
MXM5M,$9N.-?2&;976WK.AM[Q&PW9NQV /C1,9KLT*?QRK?7(:ZFW;199)89T
M"1447B3-]F:8#Q=37=:A (JQV;,A/^S_FDW]B)*NY#F>B(.G&Y._Q@7:U[8G
MVNV['>O5<:G[RL=N.="W(SP@C?"S\R;LB"O+^#EUCO"ARO!YP^,UOXK!Q Q^
M;>03%## -P4^B$?&O1Z&_=2OASL0FO*\5XY["(:@ *=MMJICW(N N1$3NQE$
MBK4[&':B45<%3=WR/J[KP:.TZBY2!C9A][*(G'L;L>/S;GBC48 R)&+Y:K:#
MJ^4'VE9M^ QKFW8_Z]G!@;9@BP2AR?IY)%&)4_7#"8)X#+?\,%X@;I7!]4 _
M59+HM+V.S\AP3T/:L4ZW]O)0T:#[UN>-==B"8)-PY $[7*:U^>A9$Q1J[Z':
M9:JN,$ U["N^@Y&4_*9R4H+KT2=_:Z!RHG9$='SD+0FE]>57:^5MJ,-DXOR\
MC0G5PT@%^0.N(X&9I$.J8$U:W;5^.J+TH%;(Z/XR:>7,H6/Y5NK>^/D,,V>3
M2$"#)D/N<Q%&M?T].W'^SM1Y,N\9[0<J_L6+O9I+*X-;\IO$*0H;^-]<)/,!
MW[IT=#LPD?7$0]C2K_,2?\Y:OX3:G^ZD#YE-!&X7B7@/C@R07&..7[N-,<>=
MUF,ZOHSKKM-JP:I25\U#W3,-TWHG! :')%]<@Z(V%!VU7F8^ZGD]'W6/U;%O
M %H(UC\2."(RM*-H99@,4'H:J3,^-GOID*WW#?!V'0"(/F\+H(T@?@Q:?P )
MYMIJB]H9R$\L<I7NF4%357-I0^/D?_,.@*;C$M=BG59Z*^V%[]N<W\=EH'U?
MNYU\T7Z<%QIL0>=N1-2V-DA,,M]#CDAAP#EYF($SQZJT5S9?LLM %O9Z4F+A
M4>%W.V$T IN+"UFEX(WG -I\L B^O?NJ @WC YNZ^8ATP5V/:1*M35FO'U_(
M8C895I&>SOH3S@'BZ^(&)IFRT)G3P6ZYST(3@M]S5E>?=?$$$._J)]Z(C(^M
M*3A#%#]PL#Z0*1SRTL=DVC1U_4;\9K(Q/OBW)VU3,;@68F#C3.LY5-:R/&O)
M7JX9-M.*FT6@Y'8XC@)ZVHC+:T>Q\@J\WF'-H_]^0^#5]T;CAJM0S[Z5&ZYU
M"+$G_/63LG>:K5Z:*8YM>!&C?>3RR$@ 23YAU3+F=%^!^)S#U)[L#;KI1VY:
MIN3@W/KOC9FA3P4)C964YR_4QH\>J=8H%"[Z&MO0"Q/0C>)0C/85[H))/)HP
M8D7GU%9C F?G1C^I[88"-X_GH9$"7U5">4TZ+!\LWR8M[Q_HWAY][KDG=G7!
M0L]9'];1J%41X70J3Z$9"M=5$;H99!'6?BK'#BNN /%;^J]AP3:KE9].+XNY
M['7]G/_<,<R;^=$KBY"6W5;@VML]U>9CU1FK3OHN&'X&9T=BH8"<S0KY"+90
MW/47KWNSI<5=L#D9B/%T#0;*&A5$1*>#)E(9N34K!OL8?<Z& !<A)-TX<?L<
M3UHG1;,_OTB#Y<^0C_ (4#" @1&C=> T/7]H HQX.Q.,+S8K\@]0F7,<?UR+
MVN/SH_FMT7FNA@ A'!0D9V_"L(_OAN:_334B\7%(I5.;IB#*O&"(:_*E"N]7
M^_<6]YXZA*&%F5/W00#W5J;*VF9$[-H2WM8\VW@N-&V-2^M%[S$!3-/%-69C
M\7I\;SXP(PHNUJ5NDR!CSP7+X"QZ*U7":A<<JNGG.5)Y6K;TLB.5)B/%VM;?
M,Y!U^HTQ_H8K,B%&A3U((KV)^+57[.HU/:-ZH$PYCR#MN<I3(Y.AK4:>'!C
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MG8V0_IAD)L+*T$QPH@(=]SA@W]"\ER]-WSB4WYS40XE'&\0/K9,B']M;)IJ
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MZN^^$Y%(0?7@KCVN=O7+>W^[%>7ODD,3#0((]P%//+[I<U3KO_"%OT)'>J^
M8RZ4:)UD"@00FW*!>UHH,'.P?M.  +Z#BU!Y-G[S:O^%,.3_5B+\ P),_X'
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M^>UKH0/[O4&J5)X9;POPA30"V)Q  $_ IP4X$ GRE(,(!#!2 G^-1%=*2 !
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M9V%_+2#-=KF+FT5AYTHXM]Y?6'2WFAB;+\2P9]6(GZ1[F9^6TH.L9&&?FIK
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M(39" !DVV\YQSW5__!]TPU\'E$5.X(V65Z;E>+Q\=#K80E?W^\BG,VB N<K
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M?F9P2GM4$-.$4CYRRETWXF3]OI^PAIC:T.>8:&>Z7.RM/:Y=\M=]#!#Q6?Q
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M_&^KJQY-?>_@Q?%$U1X(!:.]V;8=VBCD1U"UQ7'Q2C9!9V/8S,],6/'Q-:U
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M#2RKC^S2!C)!WPT0TP$Z(C_D:5!\?>!<* <ZK$C/VIJGAGEA*,LR#O OLA8
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M%)E0Y'O$'NH_=1D9^E=#Z?^OM3^ZSJ(MNHDF)T74:]_K*]$5V[B3""!6R!U
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M;X&(@BNS^0D*W7I5[K,,SNQ9[LVOF=35Q[(,BW;_5![_S<I=2V*[ T3",NX
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M&DU?+GO)D+%*6D<D-!)<U*F;Q*EO?.LS&%\+T*GV&EZ?1EN=$U4D]@HE_+9
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MCX91BH*?F>5KLSB76H]@-R_+_&#&U58'9=#][SR]Q!KVSD"P;D-KM.K!#\<
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MI0=XS(OL9Y<:7P!F[)>&T-"M5OO^E</]GA(@D8)G=<7"._]92]1@H+\?CY_
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M3;^+V5$[#;':SIJGS #C%A7-#0?48]F:];,B>Q( <:%]]9/W_:OAPG(W8@^
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MP%I2WMFRN[^N[=&Y5;RG,GC#,W_87Y265M&W_FH]^4Y.Y5O?3?V1>[ONXY^
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MZ^H;6MO:.SJ[NGMZ1T;'QB<FIZ9GEN$K/U?7UC<VMY 'AT?')Z>HL_-??!$
MB C^?OQ#OFCP?!$2$Q,1D_[BBX#0\]<$&F*2&R*7:!5U29^]HKLI^O8R_?VX
MS/+O9)QB>@B&YZ^'R1FYQ)>YD;]8^XVSO\98X/\19__!V'_R-0.@("+ *X^(
M!@ "C&&R0 ["X0NTJ-45)R959.EN<+)E09/D1'D;F='0[27"1^F8?N]%M"1O
M9\PY'TL(!E6+ ZRXJYX4X0 ),:@P'."9/>B( 7H;FO->^C74_46 KRF-L7[J
M8]\6:/T.!#&5P0+:^.( /(4OX@!1PS@ 91@R&QM^*1,'"!#$ 5#S7JL, 0/
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M*SFXL/1ZQCA 5PYP3_@@J^4IYCK:#5,$^[F"O0F9,M'!D#CV%H]#'*!GTCA
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MSFU=8I8@>\FN5JH167_0_6+5Y\U=>*7J3CE\D::G&+PA>1)GO^M;T)5C9#:
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M6PNB)="U>;0\,CH!;GK%T;01(_3JE0O;D?7R(4#6^ .U-EGW>@'#@E' & Y
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M'SY_>CWG!T(BF2ZVT1T^4KNW\&9UV 4YH06=$QI^;L,[,@VD!=9GF!TPDG$
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MP->6PO3?B[U,GS14C!Y3*MUK&3NF3W^Z-*_EWSAP2/@5(+12)21K*Q%4XN<
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M[I-CZ/Z<.,]LX8>1AAL9?R0'M+P (L/OZ(Z/S B>7WV=X_[.R:Z@WRF\@]9
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MX1OW",,1.G6@ZR"'7"!B!$@CC0-\K,HX)Y],=&(/;#;]\W]*R<]'""L=.N
M'1G%Z/89>1)6U2^Y655WZ.R.Z/&7)(4#M+*'=*M\R$WX""1C%%6&-V[9?2'^
M^[PW_^VTJXM+>C$H\T4J%/  B$^'AS?!>9-@Y#$(X^:RYGC(OP1&)RWBJ]"3
MOY^L_8^3/9U^:N>1&2C7XYM9X?R#"F_XLIIX7"*9F,",Q[ZRNQ!]Q'Z(N/_K
M1:4H07&:5];NLES6[^=7;M"X>#^PHRZ3YEI]3R0_$X[,(/:"M9M V@O%H:P.
M%ARCZV/0X\OB3@K[FM5:HEM\\^DW&-J?=IO=)W**#9QRKH/:?%%4IG]$"%T
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M,D">8++D+$MZBINW-Y.O%&OE]WO2)UU&=K](?G&E/(SU51OAU:WU  X_C8D
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M%T[3I)V'-Q[W)RL '^^2QMG4-(U+A1I'CEO'$Y0FB:[#9>GNN@Z;K+*',FR
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M2%[<'W:WT L<))#5E;=$Z[XWFT9 ]TNJR9K-]*<XT:?>59#IOO$$0BEEX /
MZLE:,VFW)?.$ L0) BXU2YOS V](W<\]Y"":[T"AW__DEC<F#NDM90T+@X?B
MS5ZCAQZBT2/:5"@6R*WZ<?R#6F+6$*7]>PIOLE=F@P<"=N<IA?+*S%0P<=DO
ML63=&?RMT^LMVB]%(+N2;8,B.SFAE&9./"P6L]%WB8-RRZ4F)WC^3UH'GDM
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M(N3\,SX K</F;-BS;MZ"A8:O8\[3CZ:+X'ED5!5;;C0MT[S&*W2\'<;+''7
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MMW9B=>+6,6_)M*%6DPG_$"#F>OM"H?^G;_C_=7FN:FN;NL',)7MBV]&>Q0W
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M=-/7%/ISF[<Z;Q$LTS#MX%0^<:RAQ/0VXNI[MK"RT&01\1-A 7',$2Z1SAL
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M;&_VG;..U#V_^TM@;JA;*$$Q0::%&5S4C=Q"/G*MGB)VH?G#,SR& T7-'RP
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ML6BF5:8 <;=;U(CTB@F\0S; L_4<7SFSSA,4:8QO5W7U L5-;HG9\YR@>FU
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M#45C2,Q"31CC.$L&&]'"JT?"JU(IG\P0><<K/]MBL!>R,/\0GIXF#H%_PO=
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M8#/[M//'ZF*0%!PO3C ,LH3;8<O<5<\%'5^J+XP+,=FPIDV,]'PU,U#1"5.
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M;QO"7LY0:]MG9ZK!G1Z-HH''/II3\Z[C1;5W &BF[V9?^V)B[\GV1#8JNYN
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MAY0"DW6(?LCM9>3\N"@!&+R91 !([ @ !C2#XHT)NYM*HR_2?CLS,R,#_I8
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MT;\&(0*1DU-24#)243&*<K)RBOX/ _\-H"<G+KM"34+$!Q#3$Y'0$^%[ !X
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M*]B7#LKJ[A-P;;1#CP8KVJO X8MK]L,G5K>\U5J+H/(F4\%O5+]2-J+(5(U
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MY8UD-,'=V^90J@@.MR70M.1!@V6Y2,8:/3N5<R _3=[[07 EX-/"26\5,<F
M4'/G@[HL*LRRL3U.C\*2@U!5F6>Q1O[63%\5J>(!I76:(JR8GBZ!JOS VN?T
M9EJ;RR=:&<KT5>&\!+2,I&$\O;MS#1$B&(Z'Z+X<.[(L7W?J[$E9V)SYZZM:
M2J*EN<!F@['A'HS; #I>R$FX]"Y3Q=C$ZKW9ZC?'!?5?E4Z^FU_*6I\>1C50
MI4:+K;(>B,>@8N6.S=\-#@Y6!??Y1J5D*4:&T2C&A5'YK5Z&5U;U3M6RF9+9
MQW#=1@J0C!&$L?2%^F4.CC[<[)G&[%GGYOG>#X6(UMUFM$:STVHRR&*ZXD-#
M-FZ.,;C("F1O\./[FRW./.>O2M4R[U;BXN62376QU]?D&N.;S(*+7QBUO^RC
MA3XX-S-?A<;HED"<+29/A^\='L@WF#2GW_JC<##W.%_W2EWF?B\0C(L"]8R^
M&M,O^X&)WQ>?><1]V-#6<@!P7DERCNS^7$&(JP/JL+XG*\WO1M[J#^KSVB\Y
M7/'(RS?0&7&/X'D1(?DUN%)N]-HMVO?2ERNZGY+ZP7-)U#PCC7!Z5)PQ*B?U
MXW0^;F:MBS3@ 3-#C>/\X/ZW]?S-2.54=NA _S8>("@J.RRRNK!\"'L+-60V
MW2YN ?FXM//7P_W&MT5!4$7Z_7Y 0GE^U^:#)K<S>M)&Q?D%_Z2]AU[9=P(7
MFY7K5MS]&B&_A:-&2Z;"15;7:\?@_(*]Q2->I$>N,%K'!3*.YVGDWU@1;@<X
M_C"YV3#OM5:])N^*CY.\\0X_^9O2(^RM(AE?&')=4)[\LD]9(HUEHN!T8V+T
M-R(#"NERPGB^+$$>K964+%4ZGMOE/L]A/KH[_@J9D]JR$,-&&JXZ>P=-H'"]
MX9_B8<$DAK=]"=+!<40=G3K1:I@ IJK&NE;,N:G(G1G=3_LCFYCMM$ TF-Y@
M$)(^VN *J5MMA0QUM3BROU_PV0V4$@W_(F7.]96$F):"-&GK,R&.U8F5-B:1
M)/J5LH)H05D;#NV0^82CT=189M2S),_[K#1CTF_0]=79ODF^2:;6L$Y;EF%*
MUY:"!#Y]0</S-Z6YFJ!ZQRN7[F-8NQ4JZ#4,W_RMA)5O9WS@VI'=UBLLWL,I
M/=?R0KFGB(2ZB>FZQ>E X%\8Y"721L\=#PC)+9_19^*!>[F[822HT5X;%C33
M^[[2JMX;;UT<Q9RN]%0DF;/Y?8TLRJ"+R)+CH0Z X*1XF!H6<WYH3$V^ZNYX
M]Z+8X:]$- :21Q]KN8O[/4#3?#+ZWOX@I:W8X/&E#Q0]-X!)7]-&G]6LOE?5
M5TUJ')?6U-@[IL\":[(<R^]S@U$?T#DOG2?6,I2J%"N^ZMX(+"\[3,J_98>9
MO4*8[Y6ETM4.%LN=\_WI)/1<.6L1+,C>*HDX2'C%L:!*F/BP+Y3<O_KEC )S
M>2.'Y1N^6RF#2> 2ES 5@L2F EV&V$!_#;A;KMF^/ QS7KTW*3=0N?K>R]AS
MEL LB:+8@'Q<EG>G!MN[[G;BNC%YK=@UG0R3-SVZ6K1[/]B $P__0CKQRWQR
MW,Q,7_ 1GQ(>B)+WY^&&JY\=4LV[&WURFBSY*4*",]< _9J'RC[11X%[YFPJ
M;^:SH:D59B:<[N;[?QWZB@<H?I"#"^1W,UUJK"!ROUKRVCV>]5OJRP9U>4J.
M;FGRJ&/^$S4-ZCQGQ_AUGGME,X)>$&VN!*0=;>'.;[0'8"Q7-V9P@N9=]X<]
M[3=WM*FRG.X<H4*9YV=GVHL+:1^MQ23EIG:+NY$_;GU%VL3EDU(%O5>M=IE_
M:NFHTI[%'].<5HP6 8=K7J\Y01Y7>SJ9&5>1B%%?U;K%A,R_CF'8_]* !Z)/
M[WU=Z)VA@!'1XP&G60$Z#]\=%Y(I^)U*2TQH]^_<DO6$]/F>[XH\\!]_'H=F
M1MFPH4#ZN5#6I1V _DKE!RT/W^8?3R/N(U"56AA))(W;FO1:*B/"EY*;(M\]
M^^$>)P!6.4VE@ECJHV(3<KTRV2AIMP4C;$P/OD-'A$EZU,3.O#$NNZ.-P9;0
M^L/ X*:^RU$8VV&>PU++X1S=WC(J?CNTZ[)ZOZ-5_<S#$P_$!D9D&1RNQ.#*
MU]J"C#NF*E=BC\Q+:UW8<G7678,D3D7)% Y H#(F?0T0)L=DVA[*"$D1>^>"
M:NV9&);HQ/)#B*"RJ7<TV2T4HSI6E3 L'RQT?3RKQ>?,/==]L_" !9):G1*Y
MC9AH7M[' Z]L*=J'7,LK@G)- V_7T@LXTJV:\<B@QW@,WE1KHQ'=N^^#NL\-
M"E9;IR9ILWUI]>AR7&SA\&@$TLH8RX+VJ@F@Q%3W4OEZLB%9&!:DN+KB $K@
M [K5#+<P&2929EE>4K)87Z>5I"+],RT<P7BIP9.4P\W3&&WX.%Q&STG')**W
MX:-8I/(6A_LD5@^UJXNF>RGNS]GPY<F7RN(=1;DGK%M3]%-!U2K1JZ#4^BF%
M%K-$_A>CG_H/A5XY=/27I\Y$*N!H()(]-M?@T[8V=1<"9M)]]&$GX7LES7^>
MG(Q"+9 :5-MG.7C@FG?[O"<7XN>^4^YUO@/RM<=$D>HHQ'&U.29@I7R4;/MW
M6=G.;=SFT4/^)A!55$IIYKDIJ!L::]$1#;<+_[)C9FK<J=[:S3[?FCVD4YF9
M!?BTEU8" >U*J+T(7I1!>>D]RC^36DZ);D<3U6*8#&"T! )]H>9Y&8.:[55Q
MN&_Z/&J?Z#23OETCCV>D/;.: @WZEOSL=T_0K(7ZP3NFY)Y] =]A@81^UBTO
M8GK$3*2<!LU/R;@(;O<(L7P>Z9\"_C8Q13&ZO#R!"V B*UQB,)I_+6!CL2^G
MBH/\N@^KX) E@OOY[<C(FNVIK5V;Q4\0KXGNSJ^8 ,1;C\:"9SF<WE=\MM #
MX.1@2:R()).KV7%U+%R/JRUO64RQX*:,3(B4YIT(?Z(!C/VLT:2&TI,Y-QC4
MO3T6#PSE^_+K;BJ0"_D]A[(O7!9VK/M,0G>_07\A*D?IPIBF_>DXMEN^[ 3F
M,&=7U0Y:/N\?3GUSI9-U]/GT!-8 XX)39H99A$\%SIY]<>#V416X[?="2Z=S
MU&%J#%0H1F8T>,M8AES=?>OPYV^<-HT>#DZ'2[I_ H[CID3SQ!QX/4/?J)>_
M C%EO:Z[GN4 ;"6O./RZXOR?/K71Y!3JYJ?"^C1YZI'YB0\D#<P.#YP>)D__
MLN6*&, #E'OA1=X%9TVXT3SG(&4$%B2OA^ AL[2:+9Z!*WX6C%D8W=1C;'WQ
M%MQ> 2]3-P3ENW,3J(+@C.1'*"ODK1=O:J2QJW-8" DO$=0"*'>LI?OI;"1#
M4K] P@UM/7MS'J%<5;HB("T4Z77CR92NX'&<#_PK91/IA2/N60N8$2/G!J9Q
M1C5&7F_@MGK8N9E!?UNG<@#(#\SW"99;CLUG:$,YOYQ_,+4)RPUL#H99UC$!
M,8!C9"B!8J6[ MH7NDU)'CQS,$Y)KCN;K9(\8>+3AW#CL(<K%].QEPFM7:,U
MT9_[UKWR(F7H.M36BNLPEA666!LH8]MB_%?%#"MR0GZ+!25Y(A[M/L24KJ8F
M>H=90RLP#CVN]K 4SM(YP<CJ03*9R*T2P(00^Y?IM9'"6!&DY=-9"9Q.SE-=
M_C!'+Y*-IUK*W(7'-@@;\Y74EXHJBO'7;-%:GUMB3K3]W3ED:3!]FX$;-3_L
MVPPB*84__B\MLJ>+"M8.FNV3A2T*W@%4=X4HFCZMOO!-SU?O]>.AT^"PQ) O
MW9<<ONP=,Y%A#6M+D/$A0TX5V'2UA@B3<$M2NGS%Y-M>+7FE4E'>4&6A;4\V
M!B?V@5/[@)AJ[C$"#_\'BYD0X>[N1H3H-Z1/T43!"H;IUO^\:S>63NZ>G6D9
M%":1[+801FW%5OC'Y"U0Z6 [Y*H6%[:4!A 64__)S]O_,T4,;#WI-"-'M:]"
M5?3LMU'];9]W"5ZL0FQLR 73&$:BGC UC*?W"G^P<(?B;Y9;C_OMCLZ$![YQ
MI!J'AU+N__I_:=7*ONPTADB\E?A0-KQNT9TJHU]2DP&L$(>DF^ZF80@B2V#(
M! \T@L^5A8F'83VVE(L+Q?1N_1DZ/OG^,G<ISFNCK.4=%G^=A1S&,'0;Q7.+
M>+XF<QKIAL5ROPRH<N[,:5FJ1G7H*[!\M;#2VJ>&!0D[_J1D9C/Y]00HRDPB
MT>0ZO7-EHV'R>S;LZO<Q<(YHWVJ2Y^4,XLZ>>\)$P'L;.E8NXET;V/1::VVP
MYR%?K+R+(^?3+ZCPX+,OW,23 :D8G8!9W+*WQ+))0$OJ7CH>*%$,%/KB/&8$
M*GEH)?G*":U5X!D:$?:H=$Z/$CZV/>05XWAO7<3Y#^RJ:E!5^:TI@F=AZG:?
ML\AG3;?%A']5:/-&*!=2JBPG5ISH&W,I_5Q>7AJF?W/+ ?1F\&W?FHQ2OWPS
MQY\:@2CS.\(>4IULIUS)P<-].96ZZ(S'T3V2U,DE;!FWG#D\XO8Y[T1W(JP7
MW7K8XQ(:#MEWYPS>E_>6_MP^TKK;-RWHOP#G!7T68- =0"89@0H?6MW>X>9%
M"\4'<*EJ33M,WCS)2!MZ+FYJ+O0Z]5WL"G +#ZCSUZ,EZCP_8<KUIY\EGUHS
M3Y?&'BAUQ3_N^YX,*^0G284Z:'(M,FTRN$?(P%#R'8G%TY462LCX94/F\GBC
MM)+$4VK=$3)@WRR QK(WA)'=IKG,S?388G$!P=7WGNLK%:7NI$<!)$T]= ST
MP30BM?*G^TSM@FO5*.<C.6IS2NS0;/5,O=AP(=JK'@]0G2Y:5R'F*R6YA9V.
M,M>-?@%]4A"'*2-0\4Q8R^)K%2R[7$K7&>3!KW>TE-'1HP;3/6XAL,1Z?09$
M3TYN9?V8GH!-8&[V(--#=)+N[T2_D\KA.T^F'##O[#YV^FW\7' ]NC^P4?:G
M\RF'@',2K6P"L/T4WMB<[5)9=3U;A\.Q[*^'"D5$8Y=N5>\J?[K!S&;.#(8%
M7R[=7?G 83FO[AZ-,GA+D)U=EM4%&!T>S_;"#C?;&@0N!P$]\$4,64;PS 14
MFA[W!J)'J3.?+,DIW/;OTE+^YEDDX'M:2-M7.]G#G &I,J3[HG_6M!\Q-5SO
M\;-)0C9O2R 0ZY[6/B._3.,6X@C+OU$WO=H$3YG9&?=$)G^@P^K5'R"7YRKG
MH0/^<#SPE1</C)=I<O4^<Y\[K8ZKX&]MT[51OJ&C&7]+]<U* ']"&5(_PIL6
M\LQ]7J<']F"7IN7K'[V:;Z-?UV>O(4/IKOUT"=2OV#5R"SRRZ=PL;'R2R[*8
M_K5ZR:8HGY"%OCRTBJ@N=U<I31J-4U,/YLYKG.E:.T!_8/@Z\.?A8_18]"@>
MJ)0+=["8A)O[K2Z&^$_ES7$,J1:_NCL!^#R,7.'$ Y*^?_U+OQ,"-I]6TT$O
MCJZY?&@V?[>O(E6?Q/I:FD,F(B+ZT$1?KZ]OJV<N*QTMQ\W=^#6S_\'\S5H#
MY*'T CDE'0F7"\F$<+4R#+U9JMB]:&D$N[IDZSI+MKPOK14&>Y"Z?.6<$WEN
MIKOJ*B&1584'5D52K1O\OU%XLWMXG X^5T5IN9 \WSF8ZYL^\*[B:XR2;C?/
MXZLR(--=>:Y95AZ+:;TRE4_4FDW534W/>+QRE 7'#D9%. RN'",LWEE,!710
M8,*-]1\&O']DU)HR,U "TWDA>_XE@ 2$YHM451%[,5T=]FCEU[Z\NJ%%XI.:
MX FQ)IK<NPXT?>M.ZROG%V9! HF,A@)QY GF*2I$FA1RY:0,]__,LV<KG9#(
MZ]V>\<3>^FCIEJW+=\N'XMYKH)LT15,@\+1*M.^X%R>(VD"\\FS0<]=SO1N[
M_"#4R0F2P[^9>4BFI ZN9H:SY^854)R\'/>JW+]Q';9@==V7W3LLK8UB>S:E
MGFAQ2LK&TFI(SG3VZI  3>WCY&[6^?'(7Q$-/=NY(]7.2!TYU;:(97-81V/Z
M6E,*Z_A*NI;/;1\M=>AE,(YB4KX HQ=P3!!_)/NP*99]O3.">IS '%Z.*/UQ
M(9D4KKYIRZU;KAOL2^@14/6R3%:P\IW%S9@L",UUWO2"6Q.MWF3NAVNVE!8[
MCSX6CS8+4OS6$^%-W_/-!18_?E6[Q=P@."B?W^;^\<E-!_]JX@'^?EWDUI_;
M2.X_PW[9-C>GWW5&W'!/;'HVY1\(0<)C6#R*V,SF![>J&X 0)J8NUY;J5Q[P
M&V%FU6Z^0UX>82>3'QN-*$05I-/\,J=2HH,:_(XAYT>S.OHF8=8.01#B@1MI
MC5$.O/D/;3EJB78,W8#3%E$QRYC6NMA5(BHYMQ7N0OK<8VWTY$[.["'!'Z?&
M:,9K]0HS?>-.KL1X@",;Q*8>JU1(9_01/O,;D5N\3+5_VGHC10P-:3RJ%1:Y
MP1J=_&U%"C$I'W+TNS>"<UI.+]G,!-;>.%5=5)<_H6IR+Z9XA%)QB??IZ<GO
M0MJC!*2WO+J?#3KK++'0C7X[<,[*]]V[ZNO/@M+[3#2] ,21/'=-.23U7NW$
MB5^0:T"E6Y ^M5F$P?23/HKG[Q4!;2YADL:/3<&'<.U5?3]=?5L3?6?#J2K3
MX3=S%82<\%MGOI/']HZ%#>?T8376;,U2M1D^%,JVIN?_H^BIJ.XZ=;YVV!A(
M_YXO<S[?M,!$F*?JPJ:^J'M6G88%;D_ \?/V"/EA+C3&$?VL\J/EKIE%0XWL
M',^-GGDB#HT%L=;4-TZQ.IQ^49I<)4Q;(54UU1C[S<&=PYZ9D"_J"S[6/\3A
MOF^Z.1F*N19"9]X??*C8Y5:"CYVTZ?N_\?#,,$WWG#![6S &)M(^O@14/!\9
M-XZ?-)]2;8IX>[6N.QGWT!6657HYP.MB=X@?/-*JO<[/9BRCA'4?D3N\"HG1
MX,8DFK7.1,P&N(IU>JW-R3\6_B$A)=4)HRU*,ED,Z@DY4<#1Z=]88VJ>SKS&
M5G2%+<GM.:0?J%%B/2FDQ26L503077594JT=#WAOK&ZZ_!"6H;/./$1UMU]&
MB^7S^?F%"86\-_VN@@;?]$WYG@F[B=)<ULJ((8[,#>K-V_^%G;<,BNM[UP6;
M8$FP0' /'C2X:X*%H EN(1"@<:=Q#>X$".Y.0P@T[N[60 >'QIW&M1G^,U.G
MSCE34_?.K;IU[YSZ?7B_['K>VGNM]:SW>=;:>^W5.-7ZCX#SCVQ8G2DDL#:"
MZM89+KU3KY*>WGG&6$N3*X<6Q_WE/-C:[$;+DC6<0IF@4PW=+< L?J7-_3['
MI4]X7XJ*B&C; =2LY1?:]J8A>8]DAB]\><EN39:-!>V;E+"1DQ75>VU$2.(:
MFQ_1XE[=5!>:AE(1N.P'=Z.:I,=5O7>W4,?VO+\X:TU[W6'[&@NR<XYKOJW_
M<O2:0L!^+FI;>+Q^7<?WS8QK9#:)+LBZ^^JM"?T"Q7!Z7]A'C7<+4IIB9MG&
MZKJ>E"*0]CXR$YA=;DLJ'P]=0XPDUVCL."E[OO_<HM!Z@!1UD.S7:ZA.ZT0+
MLT<),"Z<D_XE"EN#W M (]4)KI4DEJ*C"]C]:8)\\CPL+P(H@:"F%I6?XU<"
M>?_5O$&0JL$TO^0/Q-Y5S4W]*'IWJAO+IF'7"8;02U$MQJM(_K\2E-?6FI &
M^6FNJF\1I@Q6Q&KN]P4H':+R]!C^XG01JT]\55Y3UE9HF'4%\;/AR.S:,H?I
M5<@LK>3*"/^?DR<7PO7::N459!3OT\R;ZII:'2IS:]=X.,8[!360Z*^-Y#'N
MWG\=X$ OONY6F^+P5@+"A4U;6B:2#)D^O+C\X3IDAHLRMKA^MSQ#&;L>UL+I
M+>?:[!;_]4X?F/W-F)U)D&CEJB;6$W!.'K)U.C^(?\SYIE[;D;RVDI"7.H)W
M.OOC&N010&QUUKTF["W,X"  :>#Y%/"3H#PJ@?<TF3FFX<D&4 -%+MJB"WW:
M>Z)!*L4O8\])U[L)W.IIEK9C0L4F,(LG#23#^<7MNVXYLXG&:K;2R\<YU[6\
M^&G,H\YO2#;OE5V,J)6RJ\52R/>L'0?F(EPB^#J.>#+( ;-Y#<>4UGJSZ14@
MWW'I--*-:>8$9MTX0CL2-$0<BO Z60F).@(SY-ZD4,?:L\(3G QNX_>K8>=
MB^ -J"\11LW>'<!TE/4X3'H$1-Q+PUN]5*IG3:%@OKO,<JXY#6TR&E: 8S]:
M@L>N%OCX_CU\R5J3G+.*.KYH%X8QR:"OF;D=[XL0;4"-AS[9+D=9!P$DWXQ-
M"Q><ODR6\+8H&*D+F@[^);CH[79!/Z$IKK'>F\RQ=BJFWWSWS2R\Q^U5//7F
MV.; IGS[4_76).HTV)-@G)&@VTO#32KK-P':HVG<C-HE\'FHQ^7$*!$?@5 C
M@G01WI=()I^7ZST.EKLF]C3S7.1S1DJINM(W7P++WDE+&JAAYJD;^>2#%M0:
M)\3DOB93F>_+JTT8=.-K-FJA!7YQIU"1.@=+8BP;64U*^RZS1VJ&PT=F(VW)
M23-B4HU3'7R<TP#[Y1(X=D/KADV3<#?!Y.J*A%P9@-;N^/O91KP7^WI5X9P?
MKJ@9(L;V1$->[V1_CV6)6'%GWA96OVJVF*^U;9%URWX%N:,8/"O:O50?BP\V
M3MQ$CW%,7"G-P6V*6.4K];: ^^#=N8WKU4.3?<:MBR,_N+*^ /!F.3DN//DE
MS0L:*JN::RR96;YJ2A*8WD^WFI[]GZ9G(4;2M 0Y&TXH^U+4L<KQLRSS\D*:
MZ.%]#NB.>#YP>]SK?-D@[9G<&0Y^77*2<-MDKC>(N"\Q"K<P"P_Z]Z9BI=T,
M-MU[Z #M28B7LI=BJ 8T,VO>9X'L9ZG0M^*@(QRC*FX_TOW!D_P/L_E-VM-V
M5<$:HG+^"FUF04#2C@$U'@QK%?A=+S4E B/R 5RNOR<P7SA0EXP&T>EAET<G
M=9*'09?]1=4];&!@\WI\BD)5[AQ<P1]C@K;[45>EY2/I2K/%UZVE\D X,^37
MWQ=:)A84AV&#I[U!_93>2RILYCZJA@B22 @.L]2TZ=3!^>](\8%ZW2Q=4@M+
MG Y4S-,G:9SZ<W'\2@_DAJ5HGV"AWUP 47TK_69!B)G!L;,B%LM:)!=VH8H'
M"M0YLCO09(PX$KI\D6^R) ^($?%3<6YC3Y4+S:?X6F1_^$OL]_8F!P21;3.!
MZ?&% ]+,UFIWI1@H)^C&&LWSDQ:P3H^9"V_4Y;I76ELAM)RPNJT0R2PJIY=!
M</SIW9#@>1D_2&/\L=H>KG2.*(XX-/<3&5>"1%B#G@&DN3%,XGB<?)R?_.SW
M43B6@IBZ;4[3)[LC6NO@K_E?U10VMH57+RM1U6:]M=HP:Q%BO@P*;3!6OSQ9
M"_POVC:V6E\5Z5<F9J(]5[0? 3\*<Q> 5Y,^[7<,!2F)'[@[;<=_.R:.87Y*
M YPWL<6>;!6#]:^'U4Z.&KW34A)MZM66GFLQS:N\3#(212:-]*_ONH+L[%-Z
M9].XE^&S'?/LJ6J^G^GQ,^I$3<ER\+3R6E;4$6T0US4NK#T]H0B*5HT3_<'7
M)2R'R9^<!S2ZQ9QC+N9WW/3 2;618*ONSTF_>!KJ=#Z84E:2E(P[CP* LV;D
M%^#^<,[:#XJRHQ5LO-7JO\M=.L><K[6(JTKW]8JC_=:H)K@2/\7,3QLL&=9B
ML1&H$!'IQZKXMF5L7INMS'E_@OG5'YED6?)=#R]^2">:H QA^[M>0OT39>>G
M-FJ! :B]MTG).IE\6N3+:UZ?F!$]AH D14"S(&V"J*97++45[S6)RK0:4S8?
M+&\,>3QT1@Q%"W%HO7-=M2!$V9G69IION<4,YJ>R6C=0?25+:;+Z5"I1F@ ?
M':09O1P-HI 23=#S 8@T?%]<;H,0>%Y8^S*80)!5B.(/[W36-,K^%VV<JNN8
M,R3!OO);U^"3AY^SWT"5&P&4XV^$YE)NM%$1][UNY"[N^,")PDWX\@C)5H-.
MUPOAU4-*7.XI?_;)_X'=H?_N723A]0>F,X,3@=QB8+P'[+.'KX%7X%%/1'^"
MU Z.BXL:)KYX?S0_%250JXTF\B.0[E7K8>^I KYCH$R1B@\KAW.GNP"2Y,EQ
MT>$=4B@+.%P)V+-$'IHF>(CYP%7PP.X_U3"S=Y!4TZ_[9T7^7#N-?_@=,Z^0
M)NH>50<7XJH)5 'U>3I9'46:5.Y(<,[$\T&:H*Y*X[61G4[E&QO>';D;2**Y
M22EJ;9)@5U#MH<K0?M>L7G*^RVE\A<$XQ8: 0X?@&"EJQWJ&L^%V< 6G2_OS
MW63MR1OM5_IE"ND!\_(V,3@VZE*4VY>:Q_<<-(=^S ^8=Q0';78(9,W84CW9
MN(ISU!<)BDG[\T< V74>\NA5,NQ4:G:\A6I-L]X!5XY'!-Z4QH(:)N(>)L8-
MS]2Z>C^5/W/ KZV;]<;I]R"V/^7IXBO%\9O-NF6R6>:I%O62O?@>?A^[F;68
M669T$W4*5J:CX(RHK&RP.Y\:)I[7VI*&<9!UKKQMIH*>/%G0B'$+F2)%37WU
ML;:829X5>7'P 7L%[9G=FX9Z=^6]!LV[?H: 7M>?:BA&MIC!D()KX\I='$N)
M)7?0:3=)6K9(B@RN<T!75E$K4P1@_5XWUTHDNWO!EF=H9;0E]N N?SF?0F%I
M4&B=&B)^%.DGV,LAJA-#^;?[Z\D@Y\7:H VVA?@#6VF>O] 2KRJ,CXO"J@HC
MN3[-#NQ,N6)%PAJR$B7PY70)U%_<3OBYJVG[TB_Z31!QHE6*G)*PV.19I9,'
M)EM\OP1DAU -,VGQ6DFCJ68JY_>);?+/67>U0?'^[-=*M)_'2)UC"C:VG]J@
M9@G;11AMZUIRFS E<\S:[H]D?<NP'?-$'>,VU"1$&;]>D,[N,2)-'AN2C=FE
M8O*O7^(LIJ6IHFO,?C5_/=XK\AW2<DM(C&7O2/BG:GY*+C,(5SN#-2!Q<%S:
M*%H6X-A4EP0&&CV9:9!OG[@BY^&/UJ7\3]427T[V^F/\<?T>5*9<HIVN>F!&
MC+.VJ]6-^N^!IM^W;@*Y,Q<R4X+&B[_YH+L]M2/3R'*9%D$,*51V7ULPI-L;
MVV7*UHS8U1DHG_G"-1JTLR0ITI+F%^;-!5?6VI:?@NI"+Q1E.Z7_183LWJL&
MVJ<"ZW:NABD!\V6Q13GR^U,1DKMMII,>*!UZUV:A_."QJX,DGW E0H#[&B5B
M\4(/LV"#UD(6NMC'S:)_F8>X;Y"0174I4B.!20L$7I K#L](29;99^IU_X\-
M7WF/ZXDBRX%9M C5D-6$;97(C[-\"PU'8"W%6<VD">>$=A<"5>IN_H5)*4KJ
MXN]P/S+&K/1RRTG+V1<BRN[<S;IIABV'4JT\7MF[XZ[LUGQ<KT\K"_5W@$_>
M*FOGUCW*11SGGMNV2&_T64K,BJ97TO/X:F8.FF4&,\3Y^1;F27*=+\6.B.E<
MQ=3?Q9OZ-,>&+R0O6F-&5]<;Q!UOM N>IJ=7$<A9C5ITRM6RA=\B3V>AE\^)
M@4#.F/$=V>6)DPH&;Q3E!1CGO\$SJB1"E,Z=2U_F$ZLE8)IO.'5-,:1[U%9D
MF8$](,;MM_T6VQ\H]:VR ,E,7@A%']H@);NN=A: N8KTWFJ&$*4+%-1]=09:
MW*NQ5 >%]"RPJRT,B[#4>Y^ZM6-*0.153Y)K\$):#*UNO[=6S*>,6MO;TH4A
MCY>,?G6N9_AJ[CY-3Y$VZH2[M5IR]-U39A$;MR-IS.%X-=PE*9,%\/==6)O@
M[ZE5*$5W\I_Q9^QLWK ]NJ\8J(0T@BHKR++#DIQG#<H\PSW+N WM?Z!\9K,N
MNT=&\&5I4%R+?E,YQOX%S8/)TM/8:$?69GKU&*'7UWNQR!79)>C2AJA#"+F1
M3/0,G+S'&5HI42[E2]IW6 >O;MK-9FV/BFZZ#J/=[>P4QGB$*&'R3TQWU[-K
MS@%!U69=. 3$-:!?8K@=[3B)26(^D&)C.<@;CTQ[]B7"E<VA'V?;>H&V%;ON
MRNQ:<K9#" $4C0=!1UBA^Q//\3EBPUHT*X$:UB)ZEO.^J0[UYKPN-2U354M]
MRP#*BSPE/'R07Y]>6VX>D'LOV?-/WP9%85@W7:7PTC2U*M&_.(8;NS;J1H-S
MW8:C\KQMJ2QU_@U6= )OCSR9&$X_C0";RHK,#,F:@2>[\J7R)YWG;8^ )6\G
M0;QANJ8F%M3!HWN:,D/+.@$W"9P_T")(,E/:SOCK8<XI7DBHD%ABPV4?J[+6
MZ$5VV.U<W82^L3YH-3K2F$+U3V8Q:P6N#K7B>J4?S9<*9:7.6V*P-RRE3KCQ
M*ZH2X?CK=]2%I!:('%Q#,^3*B4#K6B;]>^1(6[5F\-]P]11V=VQ)P#:F<'D*
MDFJ&*;N3@^BW2:'MG<D9H8<?'9Z1QV<H__2N"&=F[GRZ#^L,1YXY9Z>3DF I
M<X(OQ--?./.S0EO#=7BN55QWT]CLBRF@8,E?78<6"V:)K@8JDD\^QH>WP;ZO
M;7W)[ M-/#@++\U_V8V1LZ]5+XAI_]$6=5REP3%85.)+LYM-C52H5F6PZKE@
MU Q$_D2Q[FHZK _SEL0YS*S1ZWL1UM'A>U!%2KI._:O2WN $F8,4ROZ2+17:
MHZ6A7^"&4!)AJ:,_]J[J1#N+PW&;=7.[]<G0JE,K>/6A64.H[UE$FK_8U'B7
MR+01%D(S<G?V\DHD:DO)VLOCE7P@X9I'!VK\F(@6+-R%2DGM6ODA$FB_947S
MO2YV<#E_2TZFVU%H'7AL&$V(,@ *59H%>YM^ARL_F^3'T/]LX6P)?9Z:OZA#
M9+Y>^H NFP=LHTN'4Z9=-EK@5!#L1MM2.GZLVD!>Z-#3P.U;G#"$>]U^JF'X
MUG.6XF:837)\;6[41NL4/2!@=J#(D31B2SF9#2JIBK;C'SP'>4O:7+8IZ7:+
M#%CXS"UW2JC'CE]4PB, 9]%<2HB0\+6%;*QYH!94_RB)XX*,,\6J;R/QKKU%
M/W&'QUJT9]X6F732W97\.D_:#[?XV:$;=MEU(AFKBKQ*TCZ1TI?) _Y?.;&?
M@\:5/&;A;UI3;"(SJ)^/?^[_"-BP>Q+[UZ JK:EOL^=A+L,X(IMV6R8N?Q[R
M9'<(<:4V+@ZL!43!YN/PJ_"B29?KBU?T=:_U:[N8Z8<,B$S[,4LD(+N0CROR
MOR$S1Q<*M',>H)*:X=:8DWRL3B%2ZD!_H3L:C#WRNFRX4C8^NUO][8FF3GQP
MX)*:"0I]T!AO[$=3KAA.;QXQD5O&6MP)G_@+R;JWL<-]4YV8HQG:.4]61:5P
M3;3$WIL"-Y4FTSI?X<-I\DN90_5FM+,$/%3^_/56XCN]DWO%0KI!=VM7HFG'
M9G0"0DEWYH#9)CT6U-3F:3$EB12T_&[BTV,+);"(?@^[-BH0[TK<"0^B?2(0
MY%.P:'7EGLP-=%@9B<7(Q,Z3#;**4Y$G^^;EZ<-6F><O=@>7;C$F "GL1KXV
MC&S$5GK[1O=W"Z6;..NTGGV8F"+\@5<#5MMP7B[.(-I/,J]EGB8'L&";P,9M
MR[IWU9X7#RGT^.[NA9DN'IG*L>*%$^69@1H$;;,Z!#@M$S^9K)77UVE'ES2<
M6'<%"4OUI<LY BHH _O+-8<V8O)K5!::Y *QQ-5%>R0<[N3@*:D)A14/E:/G
MJRX'F%/-3RYLA!_,>B9[[057EC?(>%]JK9$OYM;M5#SRK#?CE#M.-?=X*8[/
M%]?:Q_C+"?-?NNAD7F?JXLL@C",)G87B-:,D'Q/KTCE%8(E4"O%IE)@3=I#.
M;!O:R5+A].?>8CN0#I^OR^G'$GD9HE\!-VKH/H*R[?77J15[T/=U0WNS+/ 4
MS\P1P$"?DX@[D=Z=,JQ6DMQH/PTGPJIN/D,=/%K:H&-(S0W1(5Z-\N,U?!*R
M /3M"$X^K^%POG)1I0GY.0ZSAC,>H:76E*@LQ]B^WWP/KW5:$*UU#?/H]:&]
M+3P5G79:[]U&&@P[A3K$-L[ZIYKW6%#'7,4I>GP9IOG6/=86E'E.9S<9$K5#
M=A596V4"SLYVEMB,5KI3G+RE$.B'&Z105RS2PRFI_>0;*9.8_'9U0Q]"E.W;
M3[[\)\LA?!3*!//7^D<Q"^HDEF&$"=)FD@)RGGC(5EZU$_&'XL![R0+@JI&J
M19FLJRO324YL1C-.C]FS#L_LC^<B3Z1"R,7[E.PO4S;6A(Y$#)T/.RQ,VQBX
M=HHAB2:,Y* ZXP1.XQ0LM_&?U:6HS;S?@!\!7>43YW[5L?7SQN%%D:.J26*#
M%,)C>-@BY+OW^@7&5IXIH875H:-*'(K,&<>:?_V=/,0>,/FA3]RW Q?O>]K'
MRK7G 2/+WCM^XS /7JQ@$L"+F[/[V_\I"T+99->ZUDZRIU<45-1?KFN52VTI
M,?%[D##B^0!')Z;PO4_CDQ3CZG?=<A:E;17"J7SHZUO;7Y#K]=SUX%=)Z3=*
MK,""$4?1?N"_N]R[<1ZC]D\W85DNK^/'21PDVWN26$U9@+,$RQ07A,JK.T7
MX29>URC5CL(S.C*F@3F[ZX^]R_XHLQ&BLM&C;;9OKQ.-A#O)?*BW-JYQ3)H*
M8;C)8_FM,6"M(=HL0I9U9_U-P-[S'+PWDX>XX6O[''9G'9$, K\9MG:L4L=1
MK_*(!] N+BH[=):L5E[5&A/H2?5_LF4/8N,)+#P=>KDMW/VRH1W/FS/J^=1I
MF1.==;@>]\H1\<*MMD(9D4P) ,4?L"M%.=,6[T/3<S>JN]8;U60EE7!L9"#$
M8"J\NT):$4T ZS7"J4F4K9ZDG[4Q39J?VK37("CI%]75SRHXK[Q\6C!XR^;O
M>PZ!]#PX3 0%/']J"T9B!]DHX"JBAS&C3C6SLN3@"FI!^5O9^C%[1' "K>(-
M]2*]TC^+] Q]V>"I<=R]G=;##:]46J?2_H(@*GC77:+++OTF[EULAH?9!0/7
MYR@SA&$K(4J'Y02HOROMO:66'F-;,38V?.SN$$C^PYS!_OT@O7A;UH6SZJ1K
MU<MKE:EAU3]ULYL>5!?/S7[*F7$-_M7?[-@=-[8ZV,G!$X'>X_GX%(.219L5
M:H5<7:71@WG"B8F-W#/;N1AP,=LAP-W;T&CP@>WYC;>@C46X%KTW;'_S':7=
M7PF[S/8'S;DG:E6%M]<59^G+GO1FM18-DYY>+;+;4JQC.OA-5-%5@MCD6B;$
M&"V*]WC"F:.XOU;HR&$1O'H]#7#4GU9#D27\)_Z)_\)!1 E]GC)]20C8=HUV
M%T6G+BH;+4$+3R/D>25$Q6MPT3IZ?M44[%XX1[Q!2AJ%\T,>=4<:K)/NDHOY
MU5ES"%WX7E9D?3B&&WG"E("'O]B\!H^*>@3@RI)# @_O9+Q;UOKMP=\7 "DZ
M:-]J/$7Q2Z&]9>4H6V\-D/QNHL$_O8OYQX96:%]*2>KY^*=6DMIWH):41F4>
M?# _-G?YJ4G*.9 XE!Y");YW(KRK1X%.J"[UOU]H<=:#'V(?J)?\DT*4//&L
ME LJ^Y*&YT/*+8H^&!VIM45@Z"")NJ^SX:F3ZZ%WHI_.1J#/@Y29%BW^XNWK
M#HL:+!J$NKDMOV!WLD;5AQ9.:^&_3+[CGW:J(TR,^45ZY*SK_*=10S1HW4=+
M6;PH<!XV>CJH^?V;H"G]=7D M-URX=>R-'B'NT']-%WQ8^:BPWN+&Y@L6B2E
MY4IWA[V])\+0M-M9L <KDVZ91V+2/6Q,Z/F*@!_ [^,L^=%W@=G^J2SRZY2U
M8X)YG8$4'!/QF^_U=:U=8H4@40<%B<4S0U>0C=[W&H.."9G ^4ZQ<B?M+ P>
M<5&8:0XH;U_%\O"X?E&_7D-%3S+W2+R=E9-WPK*HGTZ98/ UIAR9%M7SXL^D
M_[.V+?^_QARE/)GY#KJ%XIO$Q.F+XKVHD4CR#+.--'_'J)E>UV?IWQF2"BC^
M= -1*>0O;J&Y/SFFHSK\*5"7BWZ6>[?*64OT4E5Q;KC=>"_2WJ._XU]D[,&A
MS';L>WYL !D-KM..IE!0V(M]6#,T>!>=&\MQ_,7[/9"Q+[F/DR%V"W.A];O0
M$OK*^XPTBTBR%+%5K8>?@5B.;S;B1YWK1,P21LF:OET+5\9($=/E1[T<2P-:
MO7SXT-!R)YL_: LIEOIDDF[)L:."BW)+?G:-%!FV.T8?#QD:?DWH:KU(]-5!
M^F$%[+*G1X:+AP9+N%>&DJ@@S-SC670@SZ\RL'T1('LH\#91[XBWX1'P _$(
MT-A&JOI=-DFN>?M--SX"$E<>*EO\*2-8\/<? 2=MDGL&CX#!8R1,_IXK]C9%
M\M3K$0"!Q3TYN_9' -8ZLG#\/NL1<.CBUW7]""AU?@0PM]\9>J 3HOR3_4_V
M/]G_5;)=]R].<7Q\_DWBR)K:P!@988G"<NFT[VC<%V&ORPWE%HH3OG]M_60A
M3#T#*=.CDH,#CRT4;,>'4"AB> ,.QR\J*8P"GU<@BD(;WG-CJY)AQ6>/NV\:
MS!1,V]G*L6HH5"Z_)1:T8ZY]CQ8:J(WFU]%/^P "6RL6M4&_VS)JHU\IZ/IY
MT!3)>:SG[AH(O7>FIWO-;GHLL^+CU^.7Q2K.] CX/-'RW9+#MCA=]5?857?#
MC8'WT,K!5;_55N%;HX5,5Z!TWQU5;Q-K_T:6MIWP\1>YA/'R3!EMIV75N C?
MO4> 1W^C8?X)W_61H *:Q[!95%;0+"0U3#96DC6&K97:F8W=JKK"BKNQ^EJS
M&1005WW 6K,H,A*A8FKTE]*\DF\ OZ7%-*<HW*SF>M;XQ<ZI\B6W#WE#C[D]
MEYUGG(-/0T7LM3'-!:??QM4CP+I$['WAGG:RP"/ H@[[CTKP"U).1(,%X +>
MTJT&L>:0\;+0*!)D"Z&, &-4>M;_NY&9_ ^#LD&HQ@M[!/R[ROWO;U)%F^<O
M[H<DZ7]0RKX1?P3,[_R'@G_ZD@7UG^1_DO])_E^8O/_[A"96<DWPSN]>R;?[
M4I(+J7^3?G7T"# SI?#3N^EJ]5N5O.]O/UQY!%A-8%9-RA*BI/@^ OB"'P'/
MRWSMMM:S/=N=*55./1;?KF9YE*E:[I_I;\)V!\K;_+5U\5)IQ^6*=M.7X4Z+
M3^5Q+#<ZU<X<MX!JKI.TS,$J8?<JL:":+WZUZ0>9..][M_<?C_H-28]5X[[C
M>E#MCQ_[,NO,SW?[F_!2-<:M YD!&>=4^U^4W&VI1M:U4D9NODM8VX=K3W *
M?0[28:VV?V\AXZAMG@K!'U-8-5O]XIS!ILD6N5]UN$;QX8.8[XG/E..$9G-B
MV'S%8#DOM=:-]3B2+8 IM%C%]US;2.>6)_$1\"?BG SC&T;+-KPB@$^)Q:OU
MK\DU/=Y#6NP[(24W5&N>(T#@EZRVF5V)MR=:O\1,UAJ\)>TW=YN&Y&0JHA;M
MT/\2,SST8;2,X5U\:SWN@,[M^:)/7J1OO^<*_;"GX@B1P0]Z! #8;CXS;(KY
MK2J+JB X?]CG=$SH6SGY9"899K"% C*JF?-='@'F-2V:JVONZ\-@FDZ13U')
MCK2I'X)+OO$H6MB)!,"J*\\Z2(#P;*R_*U8:R$> W+1YFIP]?#%FQ?]A&RFL
M:X0^<\C_P-7[3KS)T(K\!]0 2Y@S"D?,=A(U1HHR1FB;"@?@.,\5#,&A[Y_G
MB UW&><4#>^C3[$NR'$E0PM:H%]NFN-39C&\ET-5KNW-;#'_ZX%U%_C-Z:/C
MZ2FFZL=V1T?QHMPU'*9]^?HI8BHIOG=^0)^R+P;O.@?6%.TD3">P-13D%R18
MGE2>\TDJ=E)94/ML-D(H=AB;@P[?,41,=;84_\HY;0ZEIX^*2=KCUKGF,0[]
M?%V,Q*?TX'W>-OQ0*"C)4^G^".AH90M/USE9WZ&;XL+R\ Q-*+%_!-0R"#M@
M& _W"6_'!/'/SN,_ K /?<;OVU > ?$$_L+3)T;U<.W$SR<KH69UT$+A$*9&
M#4*4,;(!CC$/L%^(+XWTNH^2,@(WG6+0WH2>CT0=\^_">F?GP Y((J2)PT]N
MNL6T"/3MK!.&#RXL8*T@=L@V^XK)8%''W2_F-0N)*?Y>ZFTYG=9EEF0RJ4=&
M]9RV(5YQNPT%]20'CV;BGJ8*E$#&-.FRW1@A,#]E_\7@]GL8VH-XJ<F)6[M$
M(V<L=3KSPEK4T$D-ZYK0!H$4??P$K/#:1G<_^Z7+'045%7_J(1.3%TI)NI;6
M8K^OO%%CYSJTT!HH$@5K)X8K#2M9*X7QF<LK<"(GY(\)?YC/"U-G7(QYY. Q
MV8<BWRKML(_%<V4[DB6]$J'Y:<J0L>89T["O:A_:1E\WR\YN?S[XQGI.0.Y#
MF'3'L'=''.Z$RHMMHL:3^2E) JOYEK36S9G>0?^F^<*YX*5DAM\,^/%QK8B!
M\\K(OLG>PGNA";@U^M3L@E94:]X213;]9GP8U^+J-E6-%&5*K"_UZ%JT#/%4
M;F,#=-LLY"V#B[M'NB2M)N"<.BFIY!JUEUPK[>KJ]E/\@IR@:$78IGSI2T74
MDRH5!"66*<+X T)V7X;/XDN]?B)=TAD9P[PC##4H*U.X7"]2-5<1CO-1$GN!
M$3+"PP<[LY9-WG5P0/NN0GJ.Y2_<(92#1S]UCP<7M_B$G(#R-3)#MO%:M=U$
M#M$"5_S!XY'SKLFIZRQ?H;:TM6%S^:2K472)C3<=QQV5*6I0?CQ"$$779Y#Y
M+<LW:![6TXRSQ'_(["KAH?9ZM?P($*0D[[J>VD,*UIO1ENO(25/U7>7@B>5%
ML #^9T=55?D&^>WM_W5&S*;8AE/^.U.F<IRY '7.!&:JMUR6M?%S17=\^W.E
ML"('O)-MH&3( 9)H6\\OXLC=)VT0YV^R%-U+N2_58]#K[;0+>PKK)K^0<V&F
M-H5MWB!*MZI' (?S-(V-:]5+*(2L:(8"^>J!7%07QNP"J/F YW.D,GG<Z_QE
MTY-7C]6KY\+#1?]SH33_-&O*IX!,_X4SS]B/_4WM:4RN]5CVU,]2,;4NMENM
MKV6.>^:#: Z'TX5KKQ-QQ#XEV$D$W\;J#<!J;3\>Z[E 5Y/A@_)'11\8A/94
MMS]X4)?JE'HIE'_4IBI2^=/T@]*,T\?:8 2+VFL&ATMZNN)T2J]Z_0>\HC4D
MMS'V[^9^'*$+F,N4 XTG]%?67*_0V\PZ.1I'L5>L6/H44&%! ?>7^0EB-:/6
M2J6R^7EBE_5O#!W$2D*'5*>G&T_+_^1C,IM]F88:9]VIUDZ9* 5K+?:Y,L@O
MN#GW.DKB'S!6([RS?*?.>A(26E\(HR&_PBR;#H_G"YH#]XZP2*5X^7L"9/"^
M.J>MMMB#NZNN(P_=IEZ\^D"_6$P?J'I1L0-QMAJ<\Z#<]"0J#N7#PP$1PXP1
MRAE-F6-Y*SMU0.YP30<%QI_;\8-B%ZA4UN/6LYSLL3UX(>3\E0'LJB6[M/+\
MZ0/X,21V<J!M0!"TRC%B7UBA!=-^S="O_ROP]DW$RIWXO+52%W.TV7(#JS[#
MB6?:-HG<'[\0[I6B<!?7%W8]BB4>PYOUH]'-@ML+1Z['AA;=QMC+UZ;]751:
M2B:. IGTO^A^B?:>%>/$8*ZJOM<\F)/OQ&%/!N#H.B="KXK\A1U/^OO0"XP/
M='E)EA_.O1%9N,?I)Z.2W4T<!4A"!%%??N[2XI)N$7V#K@Q'^=>'3<Z"4Q&3
M)I<JZ5E.\T= B/]D+J_DS[H>M$6WJ(+4]1744R*9@=@#FG#_IY),DXBX;@4X
MD%OXMRA7 (?]BG=YE&S663<G!?'42 /]7MK%K]H36->-.A8!-89?5LL<[9,R
M.$@MRCF X*VO>](DBN%+S-W:RSB-,:*B^@[!'!V1!]'^/"K.':3K\;&>8EQK
M"V_OZ8N6P\P0.#WN45-',^2D%0/.J8#Q.D\"YZP0_W<2%" '^?7HITI/G4HQ
MB)%U]+4IW(#-/A:;-WXB W_?R-58NOSM]8RW-!H5:HFX'PBRMDP]E6Z H I)
M2WT$**:JAXF3")M>8Z<!SK-QKU%E6D^2,NMR,5R75(:LFX$ML)ZOMG.G@2AK
MTZNQ>F?B@K+3$!_5.U&5FF2O-N=7I&PQC>.?O&"5UM2L)TFQ/>7 (\:9A&.E
M9Z/>V6P'9>^DQU0.</HEC^XTTY4E<"C@@N&UUYQT-2VS%2T/$EI(8MN%ZJP[
MI(TG%P3@H"?8S6%N3*R[FW81-?O[4RQ[+.5D KW!,^E!,O0XT\3QCU#(M7>3
M:@]]\9XGQW)QT:<$2!YCCS5#1+/O-_<B[@97^JJ/H>\G(?8O0"O=03U7;['M
MG;F24 UNLM1IG_4\DSEB;[GJ%V<#3];J+_&NNVYNPEG?E\B*)6\(,4[;#';L
MPMIS<_!89NY%_4S,^4V_30#=!?&H:FI+>K[6#TDQ! IDM25-7*MV?NZ%/Z=#
M"(8>V7]MJ@&NUH>LX0^@^SK?]7905 =*;Q<335USLOF1[(BL_*A:08I?H#CC
M,Q>8?_IM])".O -S8.D9FJYG%6Z^.V4_H)YE]_N]V_P(H.:X5L.D*?#F3=<_
MX5^NMD#O7RA(%_%ISR95I%O,21Z7P4 6N.SN#UDA26;YV)2\,K5&.G$&Z9@)
MV$+H2VX4^]<-ZP,/F&!M^-=!LE!L)RL"PWZZKC'") S>++]%^R%(&XU^-UP5
M9W M4Z<T^_VT!N@1$&:#E_#DB*-\2-4P4ZSU, K7]DL.+R+M:Y39OVFJ<NLD
M,?C[:CA.7%2VJYXL!^6 "%9ZLEAKL]72;B[GYQB*&/L9"(;':5]GRPB-?KT^
MTT>N("ISW6+;T!,'_8/BJX70O*A5UPWS]>IC?0EW]7Q#V;E*@79H=;&T6E^)
M?N)G&ST_A&6QH'(^ KJS:!!X_G;>\FM>PK5S!S0D K'<23I?7X?8@3"%+^F)
MRM>Y4 SWDO5>G!1%DA!+5Y+C4^J'8P7VQ#=<7/ -OGD$!*.NF><76IW)N-KJ
MQBSPQ?'*%: SK$^@CG]:U7X/QWFM/;O0A9>WE!,S)E24B;;V\2U6N,#V%JD6
MS<8$9OP<Z+W1M*M7-"?T4^HQ1SM,SJ'->#H!4[QQ&R*PWI6V6=E*'2F1R3+-
M""AX^9X84RP0E[MS6XB4?_^SE;OV(^"5F)28Z/?OY0L/:136"]H-^)#.;K-\
M:MR)CQG0VH:G4NFMHB_$&=%R:YQ$R&M(0CS>0,/"S4Q&&;!0KP<XC;;N]'US
M<E&VN$]NDWS"O;"%J:WF\T+#\7JF_]H6_G<R\SSDBUI!=1:[,S3S7Q^YW2M=
M1N-UD+=&99'538'MS S(^(,<IAI-SO*2&,['&5Q&OWN;MS4:$P#K=AWINM(\
M%4K _F29G9(:A+Y?4/H&U\3MN/"+@AB#. MIAZ2WN$8$CL8.#OM0CN>+H?<X
M<'&MO:/E[D_ K+'/V!L? ]3[-1?U@?1_TRZQO!8HHJEA<(9"<B^?-_!X$;N?
M^/T/%T]+)9EJ;VYV:KIK0Z(TX&#EBJS;Z=(<Q9G5T<A!YR"-5\DJHK\D!X\K
MI>MV6N1TYP\0RIGW"'##QOZ]'^>)_]2-JS#W'!#UL=Q);"1-SRV?HL@<9FV"
M9HQ&,'LJ2T<&3?/$K;:J167)=;:)=?F"WBZ,K5",.[CE3EK+0J-DM-:[@]YQ
MS!W7HV*)1F963'PUF[2S:JDB8=R6(;Y[^R;TJ&V7.TLP07Q,. >/K,K0/M23
M^?[-G[_@9IK7O47@LW=)X0P);H=C*VMLT G8BU5E0NME?FC%AN%$N-A< !G%
MZRW:!\?8OE96:.\RD7U$@B%#4^<T)\V=& D^A8W=2^Z@9B MY=V6OS#-BWO!
MQ!Y?G+8974X):"#?>8S.C#D][=$X?7R,0B7UT:PUQ=PA9^)PUK)<Q(<!45V5
MYP.KIVQSM:,H%:N(E1";9Q2I[1Y #!F[Z.DD5#''S/8U(T7<:&>N\-<?WFCM
M+/G\7#U"N;(5B\GG0]E!8IT(AE9Y<YL^ EZ@Z4Y?!/'J)K*]^:"Y1TA)G=Z(
M65(1^^.6HV69?X:=OYR%$P?\LS,OZ]T:@RZ^<]"B$Z^A9+CW^S5QO#YR&Q*<
M"H[^T'6%7"7^L"Z,R3AWJGXV?\?[?;UQ!4/)==Q<'UR)\=*=8Y%W?8+V48*G
M.(^ 9SFX+VUY.GW1.TNPA-#WC9($)73.GB]V4S2M4Y6E=#U@?D+@A=L=0LJ-
M(=)$D2.E6SS>G1.H2;3G3)!B>B39WDKVC1_]DUI:1:Z6<*QC;5*II-/27)V*
M !*EIEIHUL=K@4UVB1)!I15R"E1V\R[>GD>W,>^$C@UBDE8/_?0;&H(^0<TR
M#PWZN1?+2KKKMF@M$)5GG1(D32=,N9)AWD8GNR>=J QJJ4D;2;$Y&LY]H'V5
MZM?7XVN&,Z&ARPPSN#E7)%J!4F#6FAI3AAAA(]4K;BEJ/Y\U*B_E&?#Y\"B/
M67/C(^ S^5K+>"Y:4,P]8CD3?"UI=+*!KURQ>VA+.5I-,2*/7IWA7;"*,,HM
M,5C:K5I=(J8H%[Z7-3=<&4]GR1_^JO[+"0LUX B=MT? T_S7K40C6"^3_%)9
M3[BR=LUCJY\)C]<6DPP5DQ:W0=P2=?S[M3N\@0_JPQG-TU':<K]C@&WQ<^QX
MJKK6"W0$&:;P@+E\-NB+:>S[\AM-NW4QM:)%W;$2>(M><3(*6"H?!O\,S^]8
M+2+%S0R@.ANLPIHLT!73-Z'+B=:[%7@NPG*&28A2A:"7_3TA]IT_)A$SWJ9:
MKDO\X"^#\S"!%19>*))E^GRZ_<\48\*\[&*4(>'OBY<*#)Z.HVZ21&)4E7O4
MC$_Z?. ]*D&AZ9X^)NT?F2RJ9!'EJ6WJN5NZ)R+7F&/Y;@\A^_S4KJ_"=A96
M^:4_R@?$7$WY$G"R*\9;(9O;5LV8R!'E],M(9NBED!"KMFBHF!.KW$E60]W\
MT^IC[FBP-$,/W=4\)>HD9P/;.0'=4S[T&(XP!Z]SX1A@@?QJR;;\Y9 VWS2[
M4G "&LSH40,FTB:H::'LR'>Z0)X6A[G=9(RAN6P4#:V7(/$V-9+]?D_ Z:%I
M!Y)^PD9BH6PW%OTW+1E:V)HS5%2QOYA_!G37#:0'&8UWSQO([!V-,W+ -8$*
M+YUZ7(^<K'-F9[>E3]K#?E[;K:C4M\KA.0K40GUR8Z1<Y#3<G3.\&]>G*O9J
MK+A!D5VO+:.M8&Q%HL\KS?[65$X/H>YYQA8"/)B:UY3MNV5>@__R_QF-I[#7
M1HO)9U48YX\U2D4(*M;\F;#AO ^=@E"4AWB<M]=Y#!0$-4GQ^CMATJ.FG8G\
MO__' X9$?02,>"&7'@&78 ]TST= A]]-K-]".W(F!\_X:?F$*G"3]G:ZPLC\
M*/4 2.!4GFKL3#.@F7[]J>ZP/@0U8EMBWE24628*3U1ESYVL%MI-N\!NU;UK
MH-(*U^=K:ZJM54>5ZR)C8HN?(!#9;G5Q-)#:3OVYZ@ ^330PR\(.4H=Q'IEG
M;>)TDSGDV%+GIPV5)4;GV<IV\;2,]$-;)%W(E17Z/8B?6W[?5)"8*4G1,.2+
M+"R3-^-8KU,^DE)[,;;H1"9OE5MZK:H\%>6DZNHJ<#E?78*2?@H6.C_4NR6$
MU-82NPWE:GL%!%P[&UBG78ICLO"/^K4<U#8<VIR?6PXKLY>1;<4=N9T/EM@U
M1N],N32"V7/J$M:8+%/L3@O4G1PI8)YZU :9F\[L40NPF'OU::WCGME9_(Q(
MH5/DV+70?2#2==]=4-("NAF';@$XT!+"7@JQ'K7U?0W*-FA+0WJ-"@T[;,ES
M, 0E^"WNROS]M$Y/*JU2)4^#>J\8>_TPU7Y\D'UOEX(D# V7W+[Z^ AH_^.'
M:#++LI?UE+]_BT?@-WZ4] CXUT]=UUW\NN(0S/?(7>.K2U6DH!3U/YA_,/]@
M_L'\+\,8&VL'/P+^PU6CPW][E4S#=*_>-F-Z'5"VL,^3XN41T='>54V3^DYR
MB7;6+VAJ3USB]L"03\FEB#!80JQS,7Y1&^)M<6W9]E;?QVU,E0D^B>VNK\VD
MT!1R6SJ^ZE,>,O7ZP\2!2>1!]=A$=!&01_$1\'*S/.^/.#O'RR1MGCEB;U[1
MO\ $W6&:5*!3\_>H!![1\\I);TWQO#X;=OKOFE@U0C<^F(4FE;F%1KKXEN44
MZT>/@!\:L2- 0NQ7>*3[!IP: 3.L@KZWXH&SILY PI%T[##2TFVR0XU5=W4#
M\:I(?@ZZ:7T#2_+"H\Y39:)FGM_]I/1\>!%UKQ9>\"NC&E?[P779%5_ZYL#
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MXD_TR7#KO(@Y-;F)5PF>&PZ8E&<1HY/>Q"X%D-H4N9/[75O:1T!X9'?J$LH
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MO1Q;P4<4W^*O65X37/W@6VY$2SC10&5B>?!<)T=26WVDLY(?_#"N%PJZ7#U
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M'VFU5HT?'YFXD92N1JUFI;B\-;^,_J&_%Y?0Q@X<P.HS((O)>>76\^PAMC/
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M1X\<_;B4^F(+D1 W'5B*I5>\G5F/XK;YVT<S\K92M"2(!6;[I4=LR?ONC8G
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MQ-BM@+;)KB10D$60RC#V'H4:K)A0=(8_&$&6MU&>RL78EU19D;GU*/&=2%S
ML4;6)O8.AF6"N23^'C3.\:^2I[$!CO0_9#  9R'W(@BI(W,_0M]0LT.KKC)5
MY/X=^\M7A*QT&YYBZ^+EW_Q)//?6EVD[ZMQ4Y=2-9WY-I#R+J#8<XYPE?%O,
MR?K5)9K;S3]_](6+4]-X%G8(/O6 :L@)MO\K].5HW=^2&\2A"D1F(0JY[F&
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MY+_T89SSZZF"M"\.@=<'-3% *Q8H#ES_*+O!'VKLKH%FIN:W]Z33T+0$@1A
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M9OF$)X:R$7_6\NV2V9SZ)WO8G=KT=@-9*DM;LW3OP.BDBJ_;$WKQZ&7UA5W
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M1ARD\8&!/GD/N#K?]/"'/<D4JA6'/_0:A@I:#3XT1L1"VM7YGN*Q6$<:$%+
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M9TI["IHF>41:7I&Y;(F2/;YST9LIL/^-=KUG/^HA;"'43NI)7C^$=X7SIN#
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M()P8?)QVJ4<$/_6O=IHO=A7O6"+^TK0#[A9;7<$.^^.:H7"Q>7D*/BM#"O=
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M4)PR\-P^.B\*:LOJ/V8-SE2,8_<)QW&:'WEA<L:%4.U=N.-A^IDL)U]'NR&
MOAJ[T"RHA"[1>S/?.#>2]1 "D559&TQ096"/Z=WFX+\HXNTD6HK/ ]6!1)*^
M191F;NXN9"<I+Q8"H0]5Q#; (4BIR!ICQN%;.D<(-9)?BL)'68Z3V8*%>(5O
MMQ$; ^\&5]NA)?JMS-]&ERQD$2(0\^?Y6EIA!<]$<:7=U]"8>>5KRAM*4R>U
M#2ST9"0RE'W['(9/.]_KA*KP1*PZR23*\WF)Q>AWA"2WWU1%+CN3#JV"- 2A
MG,J7]6:..;*X+7>#L68U 9NRC\Q:%OG>(NR_X4 &7.)Y)^,\?::<T8D#.*[*
MD'N4:S\-I2.EB<N:Y6GO*A&>[M6PK&!4]")E3(DDH!1S]UR>R_-5'J+UYV<V
M9KN^;TB*>9_W=,N!S/=$T8ASMLSY5<TD?E>\ ='  &2@L4$<VFI6 Y>R=4LB
M&D](<TD=@X%3-%*3UQ-$DF-P#M@50=S9L$?Y^G00M5O.U.,\BO-+D'IIU(=W
M*@7O/WP@U2T6#QB2VW1RM/E^&2/?6#5U6E]N;D=%0V060W>0((4GL<G3\@CI
M!6*D@YH7;ZYEN1<IVV+_.3W+HE3JBJ:@[A #:;V1C5Y,"V(RI@5B0=-D5I)8
MZHW8^&D^NFT>"PL+0K5J[7O"+T?V;A=41?-6=<XYZQKQFN<E>@,1#(3/U=TY
M['GR^86..]TWR[\/Y%W2=40-GKLVOXL;P5<KB[#2AY^*[A1E%ZT4MMVX6:OR
M-4XV[Z]/VDY&#S9W(*MU(RR9"[2#CS^RN])A;/>G++2VH$B"5F_Q#@WK1M::
M/NCKEK$.<+S5L(;E_S0+7D,R"0ANX@YCKZ3.9<FRL O251:X:N2\<$Q-OF5,
M*:T-[EY]TXCQXUA<^*PQHT(VR2ZETA3%K@@KQY&(Z>%>NX8']WEM[HQAIUM9
MKQ63WF+AJOY<33Q-Z@$VL:SP0PO$D:(S*%6;M#Q4HV]FQ+]LP/Z36E3D([H
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M[9>Q!-!17V&RA01(IGDTOU;Z<YDNW$$!OQA?G]Q=*[G_G/80\R\%!#2@%["
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M./QY%#;A0NDX#QL6A=+#%-P0DU4HMG)-=>#@46W=4.0F(1Z_#"&E7IY*>UU
M5 \UQ61#63<2*]<)DX-43LK\BAJF+,TI#G#-^!P+>T<33Q/?4B@?HX+<,G+
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MN/_)U9HD><T6V6;XORU+JNU#4S,.$>+U% E"2?,F<0\6KO^\;NHW[Q>-\AZ
MR-$C?ABCK*\Y[H@WJP3U.V3U W7-94\>W+TE_8YDX>T1H8<=H XY[3^]-%FI
M-S:SKU8RF!.*<G]-QO:\E\:$&C%Y*A,N$#3Z]^;"7DXF;LYN]8UG58'<HQ<6
M.4NUM3CS*!5OIO?T<BJ(4@)C5A[90')"5,-/KE]]7$8^WWR]0;I&+%>R7K);
MLV>0J^;,3-:O;D%TSLNA6VIA%JP9+--+P.=$Z4N=-X@!V#MJ*[AG&>K.A2Q!
M=87?,LNK^$H01 :VDJD<./&)/5+Y(2N1^H912XMY9<)N-4FWJ?:N/V["X'K
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M83)OXIEMP.[%0:WUIW^KF+OEE^RHG?@MQ7TU3%6G=LSFP&;%&[>0*GH3WW>
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MMB8-HQ%@O47>%SVB%>WRY;(H/+R4<3*\1IL&+\N!P\B/(K>;3_%+X +JEWN
M"*Z EC>O4(Z MUF-X7K^BU\1^+]-"8*7^+>FTI44Q=?!XCCQ5>_G"H,NT3*4
MP.A3I,NB: ,YH*@ER96O#>Q('CJS^KH=Q@].UMZG\3XI1:)'1Q0AN KRTP_Z
M,SP1?X8%L!C17OH='M'?8$'(DC3_'1XKD+ZF8M.73C,PR(&".%B"HQ9Q"K@9
M1N$]II-JGO(2M+',$=\:9,4]MU-?IE[?^$2Z-_#KYJ#\CYL#?+@890"EPHNF
M$F!<OP>6:, ZT66Q]+T+J2*L]!DA!5 K7C C.&JY^0C2H/T/XWO(/XWW(:)_
MV.[9P<?JAVIJW@9TK-?U'^\LO?=@$<B_;.^K0W_8W@W_8;G_4^=BC\R(@@[1
MB7G6G_*'ANMNK#!&.SSP'X;[M_\RW/]79\\)'&\#RKNB%7"BH<<]0-W&!,.'
M[$PM[Q*I#ZJ[LL:2)V*M)I!_M,;@5>+O2O*RMP>/T*R=%AOFK;TL?B%,>")*
M(9KC^)9CEB P>;YB?^J*7#%VPET=RSA(;JIQ\?  ="*$K7;TO/Z[E>YIX_/U
M.+V:6*%(4?P6&$,QC&&) $YF<CA<&;^<J;<3&?.5@F6?G][5DXG0,65\AC",
MUKUW+9L[KOU9_9>7?SD"ZZZ17R/> ^OCHC!];VQ)41/LM!M\K(4[\G4O*%Q/
MK>X2/46Y!WKSP)=UHBL:E]UWOO? %3?6/8!O^&I$NO03^.W*37,[+"*E^?>G
MTG\'C/Z<'6M?3]3U$ASU\SN,]3@@LVR'4(,0!<KVRU>X^:C "WY(B8%AB4&_
M:A1DI$N0-E@LJ .BL2(1)D_N.MLOP$%7Y(+@-LAQQ"W"/7!B1?[+3UJ]B1V^
M7T7O%"3N@<ZI$2[E_;?DTS4^AT?P:=BR^_WQR%\PNGX>+!PJ\7\/7\6V>X"
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MUL' C^V_,K=63'KQKCIMXRQY6DDFT+Q.71:7@(YZ!J#U!;/.M-N#XX/'<\6
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M'7E+/#3Z1WYR***EA RH2['V=E\IY>ZW&),)?<#G_<#9T%-+H1/A*Z)9',&
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MNZ,"JZMG#M^^%5SQ8*5W8F^B7:3^%<V"DO0N42;IG6"!/:F\>S FAIX)[Y2
MKX! )%FR#)VO-ZT&=4CL9NEA-%0.(.UO#2Y95+8-Q%%WYD4F"U'@L7V5I)I>
MC]A@<+K&=B6/_M@PP;B=:(N;09XH(HXS^R.8K_X!J#[SV@"<;)/T?$2^J3G-
MG?(LL74!"403AKGP36I[/5).@RUF\J'U"YGF-O6TEM]9?M)=BE]*N!O6_[/;
M:'PT,#K0?;YH.K!C-!XA\MR5ZNNIO )]<=DUE!>.^)-HH.ZWB#8<DB@TOVO]
MLA*@C,Z#,!I 9V\4GJ7G^CLN0,7Z>CNC73((=?X!4X%KRC=AB+LM>_>M/Z3!
M2/%,9,XFB;/>1)X_8AU9E*8;S.$4B4? Q+AV#9A# FP_VHE^RO.!N@]P>+-%
MO!6%;RC2I(O QZA8S9.Z1 :$#]5,"-64*IB4=>1GPG!-"D+(K>%+:&%)AYF=
M!I\8YH+67T[:S+8EU/NJ4_[QO[(-B,YQ\7.:4)M%X;-K<6^_4[*/]Z3I="!0
MQG;)DY=><P%LY,W<"Q7NIRN[@_$J>16V%1BOB54LU8^KKL049DC2,E?A;1]*
M]IX MHM7+#]2QE=S[BY@/#"> P?=8!:XW9P@9?@8LL!-CG.&+./=R78=M75;
M&Q+/*UYJ8L>!O5>2,O"YZNSG$2>H7]SL//$7[/,95S%M8I0NVF6EJOAHP'8
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MR7 1C%M=V8SWUP ^+UTT6!A;JY]!YD*C3M)D?LH3Z7]3,XHON)TW 0E67*M
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M<]W-O_',V4SG\(*Z^8U?)_?29?;SS^ C#C@K3+4%#@SRXU+1)(PI.)[,G94
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M_\"X_D=:4O2!ZY+B'P,>'KC\1D+#VLK/,JBG98Z\$3J#;66P3CA;ZQ] 5,C
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MZ,M^Q3J5CC)(J-J\8RY\=#/3.N8]T1;D=E =M71#N%9QS2@N^X(-525ZZ,M
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MR'AL362TIU.X^JBI__0L/Y#87NMPQ.>6B]';[ZL<SJ\:%I=Z^=B'KH;LOW/
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MC6CYJ*NL2+P>N0;*R!XN\=L!CV9-S)QF<J]O!-5^W'0I7OBEI11,O)^.<:6
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M!D.Z,EHD4IR0W(<4-W_'59KN"J5!_D.>3B-LSJ(^USF-O_^2@U3D9^M*_S8
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MO-1N"7VY?#\OU?(&%@BIIW>-AL$\21/O7$(<6:WQ=H>FF&RS-PC*!*.[R>;
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MCXN&.CN9^^$\Q#0#9DTXJ2M2:C\0M+_VX]XH;W/BJ=QPTZF]FG<L:9S;;H?
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MP>[B]CQUCERY3.$,J<[KG #QG)+6,Q/S+1"WX<-&73#XQ(^]YG>:ZASX;;/
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MUOWQ)1DQFOCOEMVFYIP;#ATJCH.$829C);MEW]3X=&>AQKRU1WTF3/X!NVD
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MJEY/?^[E-U)_3WFFC!_HEAE'DP @!LFX-P5(L0I>O;3.OHXX?8]>3;%A(M0
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M,XJP(O_# 84<L.>WZS-&W[IR"JB>*9S'_0^#3O_#?\?ETZG_ E!+ P04
M" "D@7Q60<#=1$)*  !B2P  %    &YE>&DM,C R,C$R,S%?9S@N:G!GG+IE
M7!W!TRXX!/?@#DEP=Y>#! \:W-U.<+?@$H)K@KM+<'>'X'YP"0XY$.3@E_^[
MNW?WO;L?=K>FZU/7]*^?J9ZJI[K[9?EE"WBK(",O \#!P0$FKP_PL@I( ?!O
MWORGO0K":T-$041$0$!$0T9&0L% P\! 1T-'Q\3"?8N)A8.%COZ6\"T.'CX!
M 0$&-A$Q(3XQ+CX!_G\&@8-_?0<!$141$14?$QT3__^SO/0 ."AP L )/-P'
MX T.'#P.W,L 0 4 <(AP_R7 _RYP;U[GB(2,@HJ&_FK0^!9X P</_P8!_C^S
M?NWU?^T'$' 0<=]S2B#AJ9DB?W#&YPI*R$.AEJSM)5"?@=)PF[D$HZ(1$A&3
MD-+2T3,P,O'P\O$+" I)?926D9635_BLH:FEK:.K9VYA:65M8VOGZN;NX>GE
M[1,2&A8>$?DM*C$I.24U[<?/]/R"PJ+BDM*R\KKZAL:FYI;6MK[^@<&AX9'1
ML=FY^87%I>45R/;.[MZ?_8/#H^.+RW]7US>WL+O[_^"" ^#A_@_Y?\2%\XKK
M#0("/ +R?W#!O?'\CP$. N)[3B1<"35D4V>\#UQ!*/B2"7FUO:C4W.I0 C.7
M&31"&IYMVHO_0/LO9/_O@ 7__T+V/X']G[@@  8\W*OSX'$ $/#T.3^* ?B_
M:TU J=Z11YW!AH$TV)%X7)$[5.V:+I!%S6 _8_>[Z&>MYH8HR+F @]I$Y]Z%
MM_/D&!Q37N27,]H@)C@T)V6F\-: \G6O='M:]A>@[HQPQ8':UTM*22B5Z040
M_J-MNSHC?]<[DHM5?7F_JA0XX>E,4$E=F20@3?6M$OGB.G3-=G&I;5A@W1KN
M\@7XNWNF,EHAM-HO9-_1Y]G\8#G] J15'/#C/F/L[4('[5)9Y_<#F<2Z=YAK
MKDGM8[.[-SI:;8V?[V*<7X"X>5;*;J?5X@OD>%"KI44D2! ]W:.S:@5F+37O
M'B,I\UUE[JRPO37A;3N+<YGU>_'QMW!;+N"L9EC[-G/%V8=%"ATY=QO6:E9Z
MG9P1MQ9<8M0D,HW6*'$XZGW _9TJTJJ-RV]7L=;*3_[5H<:%=@T!?;QVFR=L
M[HS=)\4ESD_D6K2;@P'8D,-[NA*JF]0\^ZH)&B$7VWNW)=RU9&TKRQAMCXG2
MWV3$U CN^(=B3# /?].&7=X]W"&_UI*6VG1A+]JW=T,D5LQU@A\#.&7>!?T=
M!+X$]+&7W&\&;$V>O "Q,R\ RGK;!<%^A8,H]?S!<S68O1^$YX9-N$%F**8_
MV (V;I:@^!.Z.'2^^<Y[VCM*9'[42/MA_)C1[_T%E<)%YWZ!?0D$3'AI>V[6
M:J^HF#Z#*X[_XU8NEQ N><M#,!=38Y:=]:[I JL*YP4HKB'OOW2CORXC5,&%
MU)PW^@K/'7F;:;P FVHM+\"T;>HSX_3Y;E,BIJ-BNG!9UQ3\L"^.;M$+D&TC
MY3?Q/+)?]RAZP=U/R=#S:V%K8Y9&GF+TDE+;$J,\"L;F)-&W'\B?-$BZ7O/H
M?\CH4E!QM!0U\ +T6* ^3NA^WT&*:56_M.7YJ0_C9=##?O0.GX/A26/^8Y0A
MB[_^/ (* ]S>3E ,@&F4ZV3ZF0Y=4*Z1<@PP)T-*;)VG_,$T$*KD*IZZHZD_
MC&BHM 6],KNB6FUQJ!,!SMN=0O9J(<:C:!TM2IG9XN_<WKW%$@X1)YU7DP;P
M_U?5Q 0;U$.?<B".EI?3OSY*(V9KB^+@N_SV1W1IQC&&5;!6(-7-?1NSY>QF
M$R99<W\!JNT\[E-ST6^SN9)4$\X>06^,ZK)J2C_)-40?(+P13(G(OSCN*],_
MQ&D<,[+C%JLI91Q;,X1KXGX!/NU2,6&7B!4N)CM7JA7:5)#;O"EG !@H /C<
M$E4DSTB6@\ZY<8AKJ;[0NEZBSUC$>Y5ZC+P;<\4=Q4-W=NPC(\:Z\6';[ZD]
M=S'UT9]*UAC7XW0&;339,?#K%MR5T"RT&EHP_>VBN8K(=VR>.,@/*!.C@/9A
M52FL 3>Q*RV5"()*^W.>;SH-$(UN*\181:G Z>8GJ/A]A58C8.'5+R'&!$UM
MSD>/JZ-0& -S.C=[INV_-UP>F>3.M.J84GO*.'78A@798E7\L<UFFC.MBQI2
M-)DYJJ,>I1ZE^LU511,NGFEOMBQR<>JFBISZ* >CHHJIOJK(L)?@T]D@2YGC
M+4S]JZ+Y(-R'RZ N]UL<>6IL^<Y'4^GS%ADLQ(!?+[S*EJ 2^H/M-::<DBX>
MZRBU!E7YS="1KNW]PJ5NV7+<(KUZ\M5KA.Y_]RTW&HN'0 9FVT6B K?P&@C?
M6>S"TY?58%^D#<;H[V#W5\GX$TDNN&480G,V)?5VO%2X[%$\ @5&,93A=JHY
M7#C+M'ANUZX",&#P.HT72"EE)_=70O/IK*'I7S-3FZ@L^T:H<17Y)U?WF''9
MB.QBY<@O')\)'EULNOCFZ+J2QBYX!W]/T3 WGBW:X.(BT]-\F?0ZB=:.\9HS
M6!!QA#;WWZBM'Y/R7I=_7 ([TZ=:I],-#3F0@1B^X#0<(//\17R>2^/[^G[A
MRA%/LG[EJ%[VS7'"^>^$2MKT3PAW>U9H?,[C/EK90UIMG/?S^%6L;&YZ4Z>[
M[)'5IP[7F.9*\MLAIR[])4=QM@XFO^F9:G^CIMW"[[OTQP-PTA+6#UR*)2>D
M7_.0OU'+GUD%_=XT%7,8@? QE?R&2'G[16C!"P(<2)UM0T?LI_;5NUHZYQ]T
M$RR(32KA@-CA]/1?PHCFK=^&!(_DI?'ADJJEGLJ<2VSZ$_SYCH:?A(<CDJ#T
M9@$])ZW5*GU.F+(&"^ZNOYVI3D_,G\?(Q_I/WJ^^ %\&W9,!-6G\_Z9:])%^
M2H11,WK].%T+#G <NC++-)Z>H)Z0=JK<T9YB6-) 3!&/%A\GZWZ]"VKP6B83
MP];X>RIWY'T5^"2#Q23O0MN,;$.'R7]JG;A3O&MI*)2[H\*63-P#SE3)I=O"
ME_+OB+ZXI>GWE]EQL]Y4CVE/HGUT8GP!4IW*'BJ.O_[S% U/,5E^%(=VE56P
MI5CO&%+^U?@29([XJ"+8,WH'[W TI; 2>XE:;=T<ZU78$F*;3N!D)-K/W.I3
M+4LM:O-&CX%$!$O)].BK,'2QM7RTV+;KPZP[IH+HZNF98WZJ)<1I1=I,1OAB
M$'#04HEL7NEWK)0,.^=I%9MIE%'LDZ&3N/Z4</Y=GU(?RL<_,;);I1'RN;YU
MGJ8VZGP#O/RO:X%&*\&Y6?#3GKF/-34LHC07Y5$2=\Y@MK'40+3HDC7TM(3)
MDV(:]'2EZ_H"*$D;5F:1*2LI2BZ*4#L]8)8.UM_J4+'"Q[F9:)^\+;MBE53Z
MK!#L/2_KP4WPVSS_4VAER%$+N:]9(/N,-)GB8^Z9U19_WG4N=D:7V*-,75=W
MG$J<1GTZNBXG6YS(ES0< YGQ=_\^)*$<K[I4^L GG!A@Y5PD333ZRJ\G7FIA
M4_29:DEE>Y)O:XML409:4#8>&.-V:);!^@<X?S>SEA^W?;E<-3#P'OK0KF_7
MSFV_IBM^AT0@WXNA#(Z^D+[R\)$I(<C.GQ%MFDB]E,FV2!3LQ]OT-$ DH4;8
M"F9>B.&UB/M9%IF4D2C\ A#YJ8/+**K=4W-47P!MBLZH2M4&B91 -!D4,^2)
MS?0M=^RWQ M8)Q'=V0<^0TN*=>MO'E>BW4<MT:<Q^/5V/UBU-;4WMPUTF2*A
MC^::N)+YC7".(#O1BP*\8M_MJ2 'MM4.E2(5WE;RA+2F]*DES)1R0W^_<@A4
MA^''DF@D;Y0T^+U_*KBF"A-*.1\@/25-#K)JZ$KIIXD")/!BED?-4X:X5(K\
MGPJ.J2#WHC$O0.+-"V 7+-CQ$[^"[@^R+0)\0J8+XE=EO776R3)'OV:ZWN<9
MC!PPFL5EI'M_Z"C-GL.PH(CV,:B?0N]$#\J6XNY?P=;N6UN0HZI(WX G5(MP
MI_*/\1"[;/2O@4!ID2TU9+Q\3#O$A_UD_I@IMKE4+*5P;6T@V[*O>IGZ^;%2
M<JC[.P&!3WU,]\UPU-6J6-,-FCOJL-EC(5, %6?WUIL6;)O#1U!!<5"^KNWA
MZF-D7T/6>EL]E<M SE"#37X@&L/_14<NZ".))!NC98D@C>BIEU6L&EMCL"GZ
MNJ!Q?A-1)\P);8WF&;>3[R?-EV?;AK_%1\4"L?8R >%$1)=TPZJ)P7E(5V$&
M+UG8\B_K#[/D>Q^Q:SQ$5U>D ?E"6_N2RCD#I9M.A:/0-&V=H1L* EEH_I7F
MV5(9#4SV^PM@_0+@G)#>1M;PW%6:1AF*TR7K&581YGBW'(_U.V(,:3,)_YCM
M"L\/% !/P1^KP4XT%J[DKYYP!1O&R9A]T^KT4S]CU-?7I*7T,'X 5CN]=NI,
MH1Y56\9O_<27&M#)WKFW-JSL*%513QXEMUJI2JQ)0>6IX:?-&AHW*0/Z9+>,
M\::V3N9).Z-XF%G[0M_**2.$BN'7J&,K,_>)?+ZHV;&..+T*;\W>X.3_:>VG
MIBYH2H\DV'N7#!?,/?]O6$IO*+/097Y ,B<G[U3/.+;#T'?GA$RM1)XOC/5Q
M6G3.-G%UK+0R"I[9J6*\Q>]QK*#L#EP!/0@SEKNXC;HN8SU+7/I,^&&] #[@
M/-\RR6F8/.&ZYH?L6<(..N^ 5E/;=Z72NSJ>O=S8Y;=5^'[F),@8KC$#!T4^
MH+YN2!O5MTV<*C]VJHB8;RUARQQMN".5!;1Q@+<7<K'\UBY2V4RFYNE'YV2K
M^<\+"794J'Z^KGFLY8HTGO(>=<?\J#4*9U6[DW=]780 ^L"J"W>]H[3!="<,
M;S?5=S7$]V9\-.]CXKFHG+2S4R^+E*-]( <=Y%-(LP?RN_3[3\$E"":S6LBV
M8T><QY1$LWZL9793>':$6C,ZQU,(T1?)3N6_22Y_XXI7I1X@3OE VB(>R(:(
MWNX20AH"[.*F58C1/[R2OR3S@![2:@/]06]'UHZC?0DN'A?Z\H1@$+5._YE/
M28@12\/]WXAJ)-1)*YLAC8>[7TUBU?X,\![)[@2816M"895$6G_W]:=(Q\GN
M*S!"[DA3 \5HG@K]!,L.0;A_YAV?)VA(8SK"-Q5G62QS3I\T#"X)"";%OM3N
M61/L.BDA9LVMBB^E5]>RJ!?TWW@MWG"XK([G#LVE;B5*D)N0Q\T8?]N@FN]0
MVLK25Y[1(^8%CV 6>JK'=VDXB"=A!GL;7&QTJ2R*D.V 0H4^>^$IM-3G# E5
M50TN-)X%!][P.0>O,>6^V^*?_.U-#>QT,FFRD[F+!>!%.&<DKKP 6F(!%T@9
MSMO^SJ=DG]#!&&03W9F3M2*1R#\SS\A3Z).6,F_*(9A_LM,7[V,:9[IC;K@4
M!*)8+$,$!0XRX3*M*1<.(;%YI5XU_?<+#S1+I$U)IJC=EU>1]GL//+4 1:$'
MBZQ(L.#Z$%-3TI:ANPBO:%<)OKE*DZ*AG!UMNLUC1B(N(]Q=<'[F.>,_C-M!
M=U=/D4UKS^*A@-YN./F=&A+;"LSLO%)=B$,GY]%W\K2WD3]U.73"0-P8-?X#
MVD=9G3-=S>%[@S1(%KHB96G@8AF/7Z<R3K)5WA$]W<%@:(E"ZL'G3B7S@=O
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M] IQ9:*$@#)ZE;Z.?ZH7LM_<VD^^RU^#:WFPU+H"E%^ &%_^D"K'J@X0^*G
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MICHPLM>+TJ,^Y&B@5=E(_7N_]#MGH(N@X2*93W+'EG"#D"LL-*B;&CY'H;D
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M \P> A=HJU=E6S^;9!'4W""LN!\WFOIQ8/H%F!+42'%[).9X9%+D^>^WPJ,
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M[_)QLW7?%?6@)/]?A3(G_P-02P,$%     @ I(%\5NL@KMNRI   0K0  !0
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MPR?\CPL'U_^_ =3X! \E'M \,R9\ZT7[2#*"B$XMK:AQD)A;R@1-;^<]3\+
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M.-Q5%LGDK =\RW#]<4IRO$.Z$%)_D65=>.ZR$.:(O>Q.A*EQ4JD[US0V9BV
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M)Y/)_*:4ZMD\N%V55HV,LB1J/K"U"3&K.K&Z0FP]:]OC]&!]]:ZU%7GE0]?
M'2*E@I:"ST_5WB4F=W>E#0+KU](587+#7:_ZN%U]IA\I^AKSY9%:E6B(Y_1M
M[9ZM-Z-AR6MX20YSA)WS&G0 X_\?NYD,!F\<3CGT%T!TI,*/$44OMN@KXVU8
MTSG#20D 0I$Z(D\'V(_+JEG&H&_K#YL/_Y0E]Y55;(A-P#R0%G9I(<SF5%HK
MX>2,9LV8!U#[:M=%V'+T)?%[3X4#&LTC9G/G1GR6BS FT+WD4I_H>H#A<-!,
M7C&0G/B7!5_?(@NF--6**-)+)-B,4'DZ*+JWQR]UG,RXUFBLB.;)DE!U1#B
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M#8R+[E*NM1'37!LMG#ET!(M*(LF%]6^D!1_S3:!*VN7,::29W'][:&]&&@
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MG%..$9Z#ZYXQ9F;MH$#R']/?)-9/VQ=%:XWMU;0GAZ*"TS<:E7;>D'QKQN*
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MVS#*22-ICI=.-J](SJ[T-SXAJ(QWX;F+^\MAZ]U?CCLX["C)IIU^1/BPF2=
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M^X_SS[&#\V8$JGL1S4.%]<>N3K>O]&/=VO#9*@I+Y7LBC30!<X<8C?A[W)B
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MZ!KG5NB&U@9;F':4H:7$##-EU+I.^#;0L9/Q&O,KG6T;(Q?7+()9O&%] 52
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M!9.\J U02_ YU@S<9*[+5/C NA=QJM*:8(MUSZ_ZW5SG-VV*,8L@L(S:Y&2
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MK$$)[;I^9$OL:7M(#'9_ A#:UGLSB: =72_@?IHGBJ7!H+%(<L8/J=+>)>-
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M<U:#T-7[=<T:>+KX!("6/0'"OU4^ 5P7'A_R'IF"Z@X@VM\"NX?GG@"MH"=
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MJ>:9^L-]_P'$_SSQW/B-;E_IH5?:)-N?@E2[<L'?OT_%*;_!3A^E0$[7VT^
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M8$3+!+:GV?P;"327-R4/=L0ZMT\2>E-]MX EI;GSFT$:,LFG25"R;RYIXWP
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M0<21__AW^?]O7.!_VR^-AC+\7U!+ P04    " "D@7Q6'3]@,%W\  "$J H
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MYL6,2&W'21'")#5[7($9) 0E4"1!BH6*0Z2P-0_OMSTUQMU)!WXQ\KGX(;Y
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MG0Q8'"1!&C*88I/I'%$)21(S2##CAGK2A%M=S_H6;&JDU-:K%=P$&LV ^6!
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M@VK"@SRT96;4@J5>H*T\:&L/V#-H/U@C $H(C)=U"<(5:,&@C>4ZI]\5:*
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M()0PHXCB,) D#JWLUXX^ID8C]157+><5,)*:M'U&5M?KOT- ;6\ +X)IG$M
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MS/4HE]F\4XY5@'  (VP"IR66QMN&0L72*$8QYG%H%9?QHMVI+<6U:([YS]M
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M[Y=\]2#OZ+?/="VK .O-?/FU#LXPJ3TY(3'.*(<QC@5$81A BJ2$ 6$9BU5
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M1E.&(,PYD)07 !:< ,*UB^ 8ICG6_Y\KJP._(2%3<PR[]D=[1=N&:N[MH8X
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MEN__E>&M8BNSD?==]MD^;I?B@[;TS#_7W8O,><)JN:G)KV>%0!7E10FJLF(
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MWZ[0?\KYUV];*6Z_R[6>+3X\FF=^5*_GBT?]VZ-.Y+.LJLI*8 E2)2" /">
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MC+L'%P*VH[VZ( _U*(MZ+_4:KBWW_* !T$^>I5 OEE+*@.05 ;"D&. RSX&
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MD_7V(&*J@AFM@$!%8;IM<T"SBH""4)+FJ7:]I9OS/2UG:@ZU4S/9Z>GH1\_
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M2S'_/A>/=/&?\^VWSW)1Q[Z;;_.'NU632?AZ9>+4694+7%9Z3<CS2@<X&''
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M(EA"*'*G1=^QB,DYQEI#GX/+ ^!<SBM]X1CGF+)I.7P;@7KMO/5!3R4/!+S
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M7[G=='1 _RGG7[^9KJ/:^]*O\LT/N>;SC?;!<RYGE'-<0B1!)G*S.D<9H%1
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M5#NQ<R.4:S4#6J<*QZ ].^CM""<\H"/SSLV,#"]O8.H>X^<$4:B8/SNAT\8
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M?%'G<9&.6XB!G62YW9@.^K&W)OV9I?2>1"L=55J'W)B$P2_4)F:@-M-N>,)
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MC#P[..I[UB>^ZZQ&]'&=4_M,?I!?MTN^7'_^=;_:+;^NY$)_#W$2*P@2E2B
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M+@U')Y:H!.*36](F)11+TY\RBNUKGHN3JA[#(7<.*F""8,8!9KD"*-'K$%9
M!7*:4\83HE+FY'AQVOS<"./^X\>7GSXZKC1. ;-<67C#,/9*HJ[6,L9-TF6;
M0RT43AN?=F%PT;"SA<#EIWQO$3HW(2:$;+>L';.\"Q0YM#BCS_6H9O2+ID6U
M'.G;]4 GV+&WO>2)C\&=(3D_%G=OPF^\O-FL/^L)Y/&%9+M/NHDV>$HP3%*6
M XY38;R8,2!,2)#G4*92<H68T_'X93%SF^6,EL"H&1D][R*CJ6>DU!5<[2AG
M.%HCLTL%U"=7H)S)I1^'0#QR1<BDE-%OZ%-VN/'T@/LRDQ!Z6<5-E&^6:_EZ
M)Q_+A<C3(F4* 0$+6-?:Q@QQ4&"*- _0-,=.E^]7)<V-#NH[GXZFT6]&UZA2
MUI$/KL/K<%$V%+1)[LB<\?*['^O#(N35V$4YT]^*]9E[\4*L]X6)*X0]]2JJ
MZY6]4]73Y0(2+ F'!,B4IP#%2 "2( 0RDWH&TSC)"9ND_E>_GG.CIUJK:-\H
M&]'*.^AKG2]+KH?6O!ZAH^VH;@;=-S)1!G"5O>0,6]MK/H+:XAF4WK+KDN<N
MK'5#RS]'V2P[J(,5Q;(4YSG3[.BNDJ[;,]5)OFQ6^N6R]EMU+0EHT]:<R*'5
MMQK('8W_;^L?/XHWNPM*H<:KE<QI1Y\+#&=CR>EESY&Q9^52+.GVQT=J<F95
M@JHX:$(HH3E6((\)!XAF!6!IC &),9&*8)2+W&D5=4W2[-9!M,Y771>E\@DS
MOPZJ)<6$@&IL6G%!R9T^;B$0BC*NRIF6)FZ9>T8--U\8<&K3%(YOKCE;3QZ$
M*2)%3 &%"00H80R03.FM52&0RGD":>J4_^JZJ+D10J-DM#$:>QS37,;3X9QF
M,$J3'-2T,!T"O<=Q9.X%(^1)S65!TQ_5]!I\\:RF_PT_9GB_W7 I1?E**_DK
MW34YL2I)U2*^O%^+![I:E>_4_3>Z7)D4JJ\V6T-/QQ1:BYQ12%21 4X4 HC1
M#!#*8H#C-)&%)"S!3HN*(%K-CV]JHR+S042/![/^^2]Q#O^Z4?5_:6L/4)LM
M*+5%]>\?Z?9WN3/_4/]<'NQTHZXP'6['<I-WX\B$>-J#1XONHHY-E==79959
M1YG+EY.$@/<G_6M,#4>D0?$.Q+EA=)J4GH/"^)3)PS;N43/Q5[VZU%^U^&6Y
MV4G^9;U9;3Y725?E]E=I#F<6,4GT"I"DNC.E7A(6:0IHG B ,JPDRK)"8"L'
M>CMQ<Z/I5N'H1..H5MFAV-YMG/M)-#QZ([-C+W#1;[6^+N4*;R/H4)DP*)(3
M%2'L1?1? A4;M :FMZ[@[5:F*R%H;=%)M4#[M_Q6VF_ESM3TT/S_;2FD^.7'
MWTM3$/?5<DW7W&2R/Y2!.#H/0ZEWYBD""3+IBTR":H89!XG2.W9)8H%CY;*L
M=E=A;N1<%?Y1J\T?S1I,M:I'U+.*AD>WV"U^QP5[9"XWY;@JK%OUS3WC3\:"
M:+G^.3H8T2E>,LI]@S^(@9:O'@I,NE;U!^CIPG1 2\./'EZ7Y5Z+D:_76@)=
MO=^SU9*_4TJ:&A\+*##!(LM!SK&YL\ )8'D* 4Q2(>*,*59(W^.%7LESH[_3
M#>BR5EEO,VMM[Z*UK*X#=>^L2T.(FW7$35D4_R."_HYQ/P8(!O>D6_U6ZZA1
M.ZKUCEK%Q]G"6V$UPC:]7^ZS;<6MX.C;;MLUX$=F+Z1N9MM4(7J@7Y<[NEK^
MCXE;K<YL]::^SC]1!;$<W?./U;D8Q7&6HP0(I)D-<:( SC$$:5*H B*D>.(4
M*#94H;E17Z>BVM?F1J)-2%.=N%6W.!&O#\4C6IGE1GN#N]".#:?LF)%)LC6E
M+K!F"GD>K+EK[XWJVIU-7IPZ..YHU*@UV4(!'8AA!ZLS*?&& N\I'P=K=W!I
MADK$PTHS1>T7PP0N"AX#J%>3 $%1 (P(-22,L$))HMSVVE<ES8U8*^VB2KVA
MQ1>>0&K'AT& &IGH'# :4E[ALOWABRH\D?-<I10NF]M30.'*"WY4\))NUWK=
M9RKK5LZH=9;'SH),I1F35"_(."&:$#($,&.Y_C%!BE 4<TI=".&&O+G1@CD!
MTMQ;FDB!.CP@HKO==LGVU26T*6/+-X^/>H=9=IP8W:CC5A?8$4A 8$>FD593
M4ZV\=KZ?)LFH)4*!B.:6M$GIQM+TIZ1C^YIG]@%:?GFUVOSQ5MN@_UJ7H:J+
MV5XX;KN0DD#JO:*B'()$2LU-(D6 $I:"7& 94T:RK' *A1JJT-S(Z^/^Z]=5
MY6--5Y$X;C?TYG%=FQ@M6QNK_<FE>X1_=4R;/+13[=ANRJX:F0ZK"P9C2Q6>
M5/7*ZY->N7C-T-T]CI&I(A"^H=)7#%5GVIP6@< [2W01JMV096T6&<H%%X@#
MR@MS/2L%8(GD@'',8BES(9%3=KC+8F;'K6:Y!ZI +[,"/.@9HJS+H.HJ,V*V
MBQ&9QV"Y(]\%3P?7#\VH53_F4'SC&H'<>'KB:E=-4&15)J-\O7Y?Q6+?K*&Q
MR&G&(8$2H"1F .$\!01! ?16E,>%81VW#!L3ZS\W(CNK5G4L455=HG[1_ZD-
MK>M8R3I47FQ6*[KM[(M]HN8G_&J&4.HLOH4)N7IHE'V-@MY;1#4.MI6G9E!N
M:E@_/G<Y*4_M9S!CC=XUP<I!#53#]UZ=[8X5J!Y,&H'M;LE6LDY7R)=T5?_2
MI(9^)8U#O5P4(DDYRRE("XD!2CD!6/, B+FB,4TA23+'NW1W)>8VVQU5U:OV
M5M=(U<JZ7I1[](GMY?BX2(]^(<YVG;J$=U''@KNHTP5'(Z)7-[K X][;'\-@
M=]T>*DQ\O^T/TOF=]H"V/'TGFV"A3YM[_M_[Y5:^WV[T@G3WX[W^'G?WZZIV
M7U7>=X'C-)8XA:!0U5FQN<=2@H!<"L&+% N(Y6(M/VO2%G9T:"_<:FB2>FAV
M51C1KT\W]$7/;+4?4:UV==8H6YT=?27M.\*. 0.#.Y&W9!O[N-M$C=I1J_==
M5&E>^P&]O(FRN\>D,V"A7";M!4_K,^D,R)G3I'L+?C366Y&\B?$B,5)0(0@2
MEN8 2<0 C3,%9,(SR+*<H#QU6<Q9R)S;VJU5N1I"XJBT9TD^&]3MR"HPEB.S
MU F,'7W;4]C;,8K.Y.0 4"!6LI$X*1TY0/"4AUQ>]8B$-NNVX\*L6;>9F)=V
M*?=6[MZI^\>-7LW]3[5+?J?,.^9^:;/7_&CR7A2)[@*0*Q.84E (B*(,Q K2
M6,5,4H=(Z<'JS(VV.BOA:+W9R3+:['?E3H^^;K#*7C=1F21%=55?F7(7;24W
MCEY+M=2_U\N*\B3%G:R2I3G$$@_OZWY&G+X'I]C*=K:I!VLZ^]O(.(F]4U'7
M(O-S]>[!J$E[R2$B?-+>FBABO$*^<[[##[VV//9:,_!HM]?TS\*\>QB!H<++
M@Z'<&WX^7,ITX>G!$#D)7P_7JN=E*/\BQ=XDK7OJ._<++9?<3.'+U5YK5$5\
M''T\"8=2)A"#0B:)23&2 0P1!0I37A#."Y2Z9?7VTV-N<V<GW(D9O>NE?ZUY
M)%L_TL,=I.,5I&=?65XECM\#8U\)-A88]"_Y[/YRZ)'&DE'CF ;B&>IJSE.+
M::_8AD%U=E4VL+GA<?$?Y,H<BKZGV]T/P]8+65!$H"EN'.<Y0#E, 4VY! E2
MB!:Y2C%VHLL^87/CQ-.8;..?L6SCLO5 Y6>[C>JQ;6U4]%5;-2A9WEE76)[G
M!@)X[!/<$VP;1:-*TVHY/TZ$^S5 1@AJ/Q/U;''LUXSN"UV_^HX?Q?RR+Y=K
M698O9,FWRZ]-_3A#:N4[]5Y_5^U.Y3CWIRDL<)Q*(& L ))* <(2 J0L1)IC
M3BA,%WH LHTM];@KX3)>NJJ,N=\ZZ-[ZC+5FN3&-1X_8\<^X*(_,2JWR41?G
M*B&:T=\@WK5 K\+&6'_Y(QB(QCP4F)3<_ %Z2GD#6O*]@!)2/IK56^>P4@NJ
M@]0K5_?F0B1%4&*%8D"5<;[-"LU_,)< 9HI0 5$BH).SO[7DN:W"CHJ?++F^
MMJK7)[6N-U*VW6![+S4"N*/?3AUP[1Z<'[1N2S*,<$?E"%:PFRI;N1/?5SG"
M<7YKY=J 9Z5Y7AW<Z6WI1W.G0K>B_/M7H9>)+[_OY+HT4M\L2^, Q 040@(%
M]481T20#.!,(0*8R M,<9L*IPH.EW+GQUE'MZ*!W5"L>_794/3*Z.Z; L.T)
M._(: =^1J<L6VI?K_:/<5A-X0/YRQ"L0>]E*G92['*%XRERNKP?F+8TQA+G3
M1&_5UI]DI!B5 <Q'F.&=4!I[?)S(G,?HN 2#]=BX^/*UD='MTS?Z;__V3^UO
M]!\FIO;?_NG_ U!+ P04    " "D@7Q6/)LZFU"8  #[Z@8 %0   &YE>&DM
M,C R,C$R,S%?<')E+GAM;.2]V9*;27(F>J^GJ-/G]GA7[(M,TEARDVAB%6DD
M2SUS;F"Q>)"81@(4@&21>OKQ )#[0B00?_Y!C5EW,9G,1/CRA8>[AX?[/_V/
M;Z>S7[[B<C5=S/_Y+_RO["^_X#PM\G3^Z9__\L?'5^#^\C_^Y1_^X9_^'X#_
M^>S]FU]>+-+9*<[7OSQ?8EAC_N7/Z?KS+W_+N/K[+V6Y./WE;XOEWZ=? \"_
M;'[I^>++]^7TT^?U+X()>?-?E__(,^,QR0B<^0!*LPP>T4!Q"J/3AF>1_K]/
M_XB62:>8@\RM &5]A,@X AJ!+"66A=2;#YU-YW__Q_J?&%;X"S$W7VW^^L]_
M^;Q>?_G'7W_]\\\___HM+F=_72P__2H8D[^>__1?=C_^[=;/_RDW/\V]][]N
M_O7B1U?3NWZ0/I;_^C]_>_,A?<;3 -/Y:AWFJ2ZPFO[C:O/--XL4UAN9_Y"N
M7^[]B?HW./\QJ-\"+D#ROWY;Y;_\RS_\\LM6',O%#-]C^:7^^<?[UQ=+SO';
M7]/B]-?Z_5^?+P@%1.'F-];?O^ __V4U/?TRP_/O?5YB^>>_T.],:24AN-BN
M\_]N?_'7R^6^+'%%"-FP]X:^L?O]NLK>2^.W-<XS;KDX_^#9(EW[H5F5X>+B
M-V<AXFSSW4G&Z63SJ2=QM5Z&M)XDSF,H7D(03H%"62"@MN!#0EK'8\DW.*V4
MKHC4C<A7F/[Z:?'U5_K@7ROW]8N-&#8BN+7<5AR'T7V^PS[2STZ<SZEPA<"8
MT:""5N ]-T1[SB7P4I@K1Y%]=;7K5%]5X\DR_;)89ER2B3A?+BS3-97>AN?N
M)W[]$I;T09 ^3V?Y_+>KK6BAJ_6B@>2V:B%R__(+<5UPN<3\9JN5>YG;<+8F
MPXF;GVRA\9/Y_"S,WN.7Q7(]$=+RDI. G!,91IN)?JD#B"*U%U($HW(3S5]=
M=2\$B/X1<+ D.T'".UQ.%_GE/+^@,W;"4$=T,@$=0(:@K!+XA!R*]-::5,^^
MV 0*UY;="PNR?RP<+LN1P?#\;%DE]6JZ2F'VOS LSWG07"AFK(22@@7EF8)@
MD(%WEH6<E"T\'7>6W;/R7I!0_4*BB40[,1$?EV&^FE;9[\P<&I,+81A$2 E4
MXA9<+!&R$4%%)T7D;0Z,FROOA0K=+RJ:2'1D5+R<KZ?K[Z^F,_S][#3B<H+.
MF*1, 1\M'7K&(1UZV8(6CJ&+*=ERG.-X<\6]4&#Z1<%1$NQ"^^_QT[0*8;[^
M/9SBQ%IOA:=X$-%&4$*3.1-2 5J=E=)6!MT" ==7W0L%MG<4'"')+I#P>IX6
M2S)A&\%_(/GC\\79?+W\_GR1<2*LR$XH#<P&<H&82^!,(*?82A36(S)_G#NY
M!Q%[X<3UCI-V<NX"-A_#M]>9Q#<MTVUR:F<)BRBJ6!< ,Z-ST&""B(R!S<D9
M[A6+EC< S#W+[P45WSM46LBV"Y"<Y$PJ6.W^>#.=(Y\DZ[+GO !JHI^0SB Z
MQX%"+"N-P:)S"XMRQ]+[I:Q8[^@X5J@](>,Y??EV^7'QYWS""L;,N %6@@:5
MF0>ON0+FM B,<Z:];H>+RX7W0T7'F<P6 NT)$YNS\>WRW7+Q=3I/.%%*1L:8
MH\C*"U \!PC..,A2&VF-C>S(6/6AU?=#1\=9SF:B[0DB[Q:K=9C]_],O&]])
M%9F8X@&*2(6.Q>0@%HT0HU<89.7MN.N:^]?>#QX=)SX;B77L[&?E88EA0W<.
M#+WV!7B.EN@.'&+*&K16UK"H=0K'Q;)75]L/ #VG.0\5W<@JKW?BLW>?%_/S
M%$PJW#H*O4'2X08J>0^.(87@&%3$4BSQ<)3:;ZZXG^H[SF4>)<*1U?\!T]F2
MH,M%_#A=SW"".808I(&BD+P=+HEV2]Y.<8A!NZRT/"ZLN+GB?NKO.(EYE A'
M5O_'9:A51Q^^G\;%;&)9$5F+!,P;.JE"D> *KVD4+AR70:5BCM+]M>7V4WS'
M><O#A=?)IG_Y+7T.\T^X2;@FY3&XE !5O;$7F8%+G(%D217FN?#Q.+M_UZK[
M8:#CG.31HNPB'/@;SF;_/J=@]P.&%9UC^?5J=48'&2O:!4<"H5^J<8VH51PA
M@=-<<"Z",EX>A8D'E]\/'-UG(5L(MPN4_,=B=D8*6&XN[):K22P&?2'G)C#)
MR,YY@GET!B0/(EL;DI,M+KMN++M?N53WV<=CA-D%&G9U'=MK^WH,DA+.5A-4
M)5#D0V8O*I(*J[EU[V.]R\TZ.Y%4.,Z'>&CU_;#1?0ZR@6B[@,CK.7T:B6/Z
M%5^$==BQ-0G<<A^=!1,U4:^L!.]B H\F"*U=%*(%1.Y>?3^(=)^(;"#:+B"R
ML7[/PQH_+9;?)XI%;IATP%EPH&2D(Y%Y!*.+R3%JK_ X'_2.1?<#1/>IQ\,%
MV04./IR&V>S9V6HZQ]5JPA7/DDL!L01)#K2,X$PRX- +([))K+2XV[RVZ'XX
MZ#@#>:P@N\#!RU-<?J(C[U^7BS_7GY\O3K^$^?<)<J>LI6"ZR!I;>T?"0;)R
M+B>>-6,DFA9VX<[%]\-%Q^G)5H+M Q_?+BM&MT7F$ZEUD H5&%G(UCD6(6AK
MZ:OL,[<.>6EQKWE[Y?V0T7'FLHE(1X;%ZU26)V=Y2C]QLE[C:JN 5[/P:9(\
M4T+;""(93\Z00X@R)]#<JB!DH&/PN!*J^]?>#QH=YS8;B;4+F_'A,\YFYQ;/
M668B.420K*,X.]0@RG$-+!ACE4TR-"G$O+KF?F#H.,EYI!B[ ,&[LSB;IE>S
M15A/8B))9$ERT(%./8J?P7-&09/7RFDI24:^ 0:N++D?!+I/91XJQ"X00- ]
MK17#B_3W#Y]);*NW9^OZ1KS>X4RD]2+8F"%:18%SK&G9),AEMDEGQKDVJ04D
M'J)AO[=_W2<VFXFYDS=?J\N"<\S/OK^OE. \X4?\MGY&/_QW"K*R\AXM2"<0
M5"D,/$H.V8HHK.)2XW$5EWN3LA^$.LY_#B/T3I!T^03R%7UG-6'%I1BSA\AJ
M<*Z-!)]X(HXD;1+OA<^B"6YN++P?2CI.@;80:%>8V(9=6R8(TSI*S""+H-B+
MJ4#RH"C,V(B,,ZF25PU1<67I_7#1<2:TC5!'1L8)<9 W7-1@2Y0<7/09,LL"
ME$ -SF^>JF@T1#G3^K@;^&O+[8> CG.@APNO#Q>5*%^&V>MYQF__CM\G1D5N
M)%&,,9 8ZL.4@+6:4%DTAAPG'UO<L-]8=C\4=)_Q/$:8S=#P3[_>$N(;^L8C
M^T1M,C&OYV6Q/-U\Q'4R]VL9=>LSCND>]3!!1S:2JK1/=LFG*VM<P"*2)I/G
M$1RK"2@6&40DVYZE"T6@<LC8CZ3Q@S6.,N#;3WTU79Z^SI,H:MDG>A!N$R9[
M"Z[FVDNT7#"C2DS'!0?7EANGFU1+A5VSY@=+<NPS?$OXIA@P:+)A/$202>J:
M)Q$0>'U#QG(TV3&=PG&9A2N+C=-*:F#U/UJ*?2C_S:[9X(2.&V9DS7F4^MI8
M>@17; ".UA,W*AEU7)AW8\%Q>D@-#(*#I-G9*?XLS&I'R@^?$=>K0X[PZQ]P
MS/G] "E''MYG*_@4PI?)YHED]<3?EE?3.2TVI8ALL;UEO "%S<A"T(:46>O8
M"J?0/5# ;HR)9-J=D_&A&[H25G&CN=VBV_V!L_7J_#N7&^4Q=!VZ^\_7.%FM
M2*R7T"].A=IIE?Y?DYY%$)=& D-!<6DR,K&'+J@/X?(Z!>-X!8,AX=P\-!#W
MB$?%=>IW!7P73!A?5/&9@;2<@PHB 8FG@#,24U#.!1T&P<P-0L:%SC&:O1,D
MQXBY ZP\#ZO/)_-<_WCYGV?3KV%6<^4GZ^=AN?P^G7_ZCS [PXGT-AO2+B"O
M75B9CN"=)%^I!*X#.N;D0^^X#\'.7H3U@*6C + 86AL=0.RWL/P[KD.<X>YI
MTQ3/A3;),?%2B@6E8\V@)%_O7!!\C<B2B,GA0Z',(<!Z@)QQ@IWAX-1*\AV
MZ#V2/*9IC9O-<5&<;D*Q7!K0+-8 /FF@J(!#H. M9Q69Y0^5WAP"GSL)&2=
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M$Z(VH'?D)&YF75B6:O[;0HJZ6*><-V; ]NM;(L:%3 /%WM].Y@ I=P"3>UJ
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M*11*8ON>E:V*8X:<'C,V^H[04[_@VVZIS3^^W3QC6;W\ALLT76&>.*.5<$E
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ML;S?@A;:&P&E!,Y+KI<>)"QC B&!)&C098:M'Y?L1=BX(V8&0E=[E72 L]V
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M$-&58)25V;4NH=F-LI?5V+(7>.[/W6FOR?-*I6Y>:5Y%NK2FJQ^#Y4X?_,R
MR=+GV>HC.XH^ZT+V%@+R.DB6S+&K6R^YU<;;Q'UH/HA^Y.SHH>_Y5V-YB8S+
M-47O5E_RXM,7G&T?&J\?3C[,+R[>SA?U/YK(Z+3V,D 15;[)6/!.!7"R6"XI
M?"W>-);O:3D\ZWSJ/NAO5A@R/) Z\%".+9NYU7ZV:;&9:)E+I*N. !]571>M
MP#&'8 -/0I202VAMJ9HST?EHK!$1V[CJZCCX''Q^OFTVM:YPL>KB%-VMB_['
M8KY<3H+U/"./(.OH/15= 5=G#P<5F8E"Z,R:#QMIST;GX[U>SDDZ%D(]W$5/
M+52^72IVLU09N3-2Y@P&<ZB3*A,X'3UDKY5GEEFIF[]V[TWER#-LS^@,# N
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MEQ.Z'VLOOB!A./@/E^%HAL7SJ6-X=!W6+@/>[@J(F:)\\@(8EXD$A.2Y!U8
M/4]:"I.C.'GRHQU[+[[NH9\#.Q(FS^%>?4XT/PV]>E(Z&F5BO#:"F.1!R<@
MA9' K"C."9^$'&0P[LDX?/&%&N=S:(=#9O=+1)X3S4]/_D^;M!@]%\I +*I.
MA(P.@G8,9"QHG DDHGL54H<6B#2E^\57CPQ^%'L'VTNX/Q\H&7@Z*.!UE+A
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M0]*X7N)XZ&NAH0[\Q$?8>#V?K::SR^GL\[MO)-CU6_&K]-^7RU5]1GY7KJ1
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MB^9II"'XZ*.JKBO(-U)ZI\!_3?\^7=VYMCZ0THG.+Q,9DI":Y$U!I:+H+QA
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M1_KCJ\DMQD7'. (:KVN[G**3I0*Y>I:(]G[7L4W/X.7N5\?Q<$Z)DR.D//;
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MDDDVEBG<*9%T?/71X4QTE0<_#K9]*'KXCL7M']1_!&+A__U__G]02P,$%
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MB"1W?B0<H(RD,*EK[IIE($='D.Z="1-+94KT<[2IE0Q *;2*.4.Q(?O !>,
M6G#^U5V<TGS,R1LPTDTIN:G"8H\V.H-]?A!>(:0J'[!0OJB && Y#Z!U8Q)'
M94M8#MAR^CUM\.21P9/YX,X>#U$/?5P"\.7YU6'O(9)[A\^&Y'UZL"M0[O:;
M)QUGB$MNL#. !WW<^SSDZBXDQ[0TVW=QL3'B@$HU4HBVJM00  Z;"..9$:UX
M[N6XE'K!J<N\K+FD'GM5N%U@I5YQMJL4X%?H8I04S&].31D9P035PDU A*3
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MA0MBPW#2/N%KEZ86:/9!M+WH0B- NK3K73YSSZKZ#5>^_.6S\[\ 4$L#!!0
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M7PC<^EL'M^M[OGFU<]CMO#ZV%:"JO( (0L>QPJOWVI!Q(ST^X&\U2B7YD4F
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M(!N$H_B)7+E5M8"[C[+M11,^ N9+M]KD"Q>QJM]P)\S?3CO]'U!+ P04
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MU6XGD,.A# MU*P.1!^DP.)MD*@YZ'=Z:[9W&"SON<U T[9A+$$;:UJ#W!K-
M)/"/+*92)O"HSY?C<9G(3G"9A-U.(()S&8NIR&00IMDDS03JWV"JBE&@BCR
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M"':,8::20L8QK)WVUV$1BEE D <4"O+4P;V6=!,X1).TP*_!'!1D_'%,'4S
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M9D$"FI/L6PF',]_2GL"(2\8GD3L[M GSV0[(\"[>;SH"T80'#6!G)M>Y1<>
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M%LK(S?=ZIZT]#OIM!M"LWM=89%G-2G&6H\I@48?K.*<-O*#T5IJ<*NUQC.B
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M#Z^:EFOM&;_D2<LR#AM[&K>.K&\Y,LV0P)D*ABNO G^]I_-F1UM:(R4:O++
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MF/I1675[-GH:YKC@.(@[C,WQ:1O244(DN[6WI .Z>=CP>I_\O(K!I5[+!$O
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M^E>9J3Q2H7/]L9Z ;\K"88C\.L$HG:)N[@0U2GF*7F5\TIK>,.1GC"<R7M#
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MP*76MHNZT0P)/64L9VKZ-A>,Q(8Y U07=*!0"TLXN&5C,VAN6V>7<GX7^GK
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M0?>P78GI=N6\MDG%1Q[RVI.*Q]ND8E-2\?D@C6;PSZ@8QS_]?U!+ 0(4 Q0
M   ( *2!?%8C3:5!]RT$ $QE(@ 1              "  0    !N97AI+3(P
M,C(Q,C,Q+FAT;5!+ 0(4 Q0    ( *2!?%:DUDYHQQ(  -K,   1
M      "  28N! !N97AI+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( *2!?%;J
M^IDAD!T  #\? 0 5              "  1Q!! !N97AI+3(P,C(Q,C,Q7V-A
M;"YX;6Q02P$"% ,4    " "D@7Q6F[/Y;RE2  !1C , %0
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M2P$"% ,4    " "D@7Q6ATNSCZ=(  #320  %               @ '5OPX
M;F5X:2TR,#(R,3(S,5]G-"YJ<&=02P$"% ,4    " "D@7Q6RM('\(\) 0#0
M7@$ %               @ &N" \ ;F5X:2TR,#(R,3(S,5]G-2YJ<&=02P$"
M% ,4    " "D@7Q6DD)N$7XA 0"6;0$ %               @ %O$A  ;F5X
M:2TR,#(R,3(S,5]G-BYJ<&=02P$"% ,4    " "D@7Q6GG.,9F^6 0#]] $
M%               @ $?-!$ ;F5X:2TR,#(R,3(S,5]G-RYJ<&=02P$"% ,4
M    " "D@7Q60<#=1$)*  !B2P  %               @ ' RA( ;F5X:2TR
M,#(R,3(S,5]G."YJ<&=02P$"% ,4    " "D@7Q6ZR"NV[*D  !"M   %
M            @ $T%1, ;F5X:2TR,#(R,3(S,5]G.2YJ<&=02P$"% ,4
M" "D@7Q6'3]@,%W\  "$J H %0              @ $8NA, ;F5X:2TR,#(R
M,3(S,5]L86(N>&UL4$L! A0#%     @ I(%\5CR;.IM0F   ^^H& !4
M         ( !J+84 &YE>&DM,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    (
M *2!?%;:N3,U?P,  %(.   ;              "  2M/%0!N97AI+3(P,C(Q
M,C,Q>#$P:WAE>#(S,2YH=&U02P$"% ,4    " "D@7Q63#%1\@0(  #7)@
M&P              @ 'C4A4 ;F5X:2TR,#(R,3(S,7@Q,&MX97@S,3$N:'1M
M4$L! A0#%     @ I(%\5CCOQ;<("   ^"8  !L              ( !(%L5
M &YE>&DM,C R,C$R,S%X,3!K>&5X,S$R+FAT;5!+ 0(4 Q0    ( *2!?%8F
MX>4WD@0  / .   ;              "  6%C%0!N97AI+3(P,C(Q,C,Q>#$P
M:WAE>#,R,2YH=&U02P$"% ,4    " "D@7Q65%:\Z9P$   =#P  &P
M        @ $L:!4 ;F5X:2TR,#(R,3(S,7@Q,&MX97@S,C(N:'1M4$L! A0#
M%     @ I(%\5L7TBW?B1P  S4 " !T              ( ! 6T5 &YE>&DM
M,C R,C$R,S%X,3!X:WAE>#$P-S(N:'1M4$L%!@     7 !< &@8  !ZU%0
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
